PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Noto, A; De Vitis, C; Pisanu, ME; Roscilli, G; Ricci, G; Catizone, A; Sorrentino, G; Chianese, G; Taglialatela-Scafati, O; Trisciuoglio, D; Del Bufalo, D; Di Martile, M; Di Napoli, A; Ruco, L; Costantini, S; Jakopin, Z; Budillon, A; Melino, G; Del Sal, G; Ciliberto, G; Mancini, R				Noto, A.; De Vitis, C.; Pisanu, M. E.; Roscilli, G.; Ricci, G.; Catizone, A.; Sorrentino, G.; Chianese, G.; Taglialatela-Scafati, O.; Trisciuoglio, D.; Del Bufalo, D.; Di Martile, M.; Di Napoli, A.; Ruco, L.; Costantini, S.; Jakopin, Z.; Budillon, A.; Melino, G.; Del Sal, G.; Ciliberto, G.; Mancini, R.			Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ	ONCOGENE			English	Article							CELL-DEATH; HEPATOCELLULAR-CARCINOMA; CENTER STAGE; FATTY-ACIDS; TAZ; EXPRESSION; YAP; PROGRESSION; METABOLISM; EXTRACTION	Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/ TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.	[Noto, A.; De Vitis, C.; Roscilli, G.; Di Napoli, A.; Ruco, L.; Mancini, R.] Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy; [Pisanu, M. E.; Costantini, S.; Budillon, A.; Ciliberto, G.] Fdn G Pascale, Natl Canc Inst, IRCCS, Naples, Italy; [Ricci, G.] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy; [Catizone, A.] Sapienza Univ Rome, Fac Pharm & Med, Dept Anat Histol Forens Med & Orthoped, Sect Histol & Embryol, Rome, Italy; [Sorrentino, G.] Lab Nazl CIB LNCIB, Area Sci Pk, Trieste, Italy; [Chianese, G.; Taglialatela-Scafati, O.] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Trisciuoglio, D.; Del Bufalo, D.; Di Martile, M.] IRCSS Natl Canc Inst Regina Elena, Res Adv Diagnost & Technol Innovat Dept, Preclin Models & New Therapeut Agents Units, Rome, Italy; [Jakopin, Z.] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia; [Melino, G.] Univ Leicester, Toxicol Unit, Med Res Council, Leicester, Leics, England; [Del Sal, G.] Univ Trieste, Dept Sci Vita, Trieste, Italy; [Ciliberto, G.] IRCSS Natl Canc Inst Regina Elena, Via Elio Chianesi 53, I-00144 Rome, Italy	Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Fondazione Pascale; Universita della Campania Vanvitelli; Sapienza University Rome; University of Naples Federico II; University of Ljubljana; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; University of Trieste	Ciliberto, G (corresponding author), IRCSS Natl Canc Inst Regina Elena, Via Elio Chianesi 53, I-00144 Rome, Italy.	gennaro.ciliberto@ifo.gov.it	Pisanu, Maria Elena/AAC-9143-2019; Jakopin, Žiga/B-7089-2019; Di Napoli, Arianna/AAB-3210-2022; trisciuoglio, daniela/AAL-4002-2021; Budillon, Alfredo/K-4763-2016; Di Martile, Marta/K-3348-2018; Del Bufalo, Donatella/AAC-1594-2021; Ciliberto, Gennaro/J-4131-2017; De Vitis, Claudia/K-4726-2016; Del Bufalo, Donatella/K-8673-2016; Trisciuoglio, Daniela/H-2131-2016	Jakopin, Žiga/0000-0001-9384-0858; Di Napoli, Arianna/0000-0002-3159-5380; Budillon, Alfredo/0000-0002-6330-6053; Di Martile, Marta/0000-0001-9924-9022; Del Bufalo, Donatella/0000-0002-3148-6096; Ciliberto, Gennaro/0000-0003-2851-8605; De Vitis, Claudia/0000-0001-8899-2347; Del Bufalo, Donatella/0000-0002-3148-6096; pisanu, maria elena/0000-0002-0029-3523; Sorrentino, Giovanni/0000-0001-8628-8778; Costantini, Susan/0000-0002-7538-4657; Trisciuoglio, Daniela/0000-0002-7007-7914	Italian Association for Cancer Research (AIRC) grant [IG17009, IG15216]; Fondo di Ricerca di Ateneo [C26A142LZ8]; POR FESR Lazio; Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille' [10016]; AIRC IG [17659]; Italian Ministry of Health [RF-2011-02346976]	Italian Association for Cancer Research (AIRC) grant(Fondazione AIRC per la ricerca sul cancro); Fondo di Ricerca di Ateneo; POR FESR Lazio; Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille'(Fondazione AIRC per la ricerca sul cancro); AIRC IG(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	The work was supported by Italian Association for Cancer Research (AIRC) grant IG17009 to RM, and grant IG15216 to GC. Fondo di Ricerca di Ateneo 2014 (C26A142LZ8) and by POR FESR Lazio 2007/2013 to RM. We are grateful to Stefano Piccolo for kindly providing TOP-FLASH reporter plasmid. We acknowledge Claudia Cippittelli for technical support on immunohistochemistry. We acknowledge Italian Association for Cancer Research (AIRC) Special Program Molecular Clinical Oncology '5 per mille' (grant no. 10016), AIRC IG (grant no. 17659) and the Italian Ministry of Health (RF-2011-02346976), to GDS.	Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Belkaid A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1452-1; Byagowi S, 2015, CAN J DIABETES, V39, P123, DOI 10.1016/j.jcjd.2014.09.006; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castro LFC, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-132; Chen LiPing, 2016, Journal of Zhejiang A&F University, V33, P1; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Leger S, 2010, BIOORG MED CHEM LETT, V20, P499, DOI 10.1016/j.bmcl.2009.11.111; LEPAGE G, 1984, J LIPID RES, V25, P1391; Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004; Mancini R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021320; Mason P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033823; Mauvoisin D, 2013, CANCER SCI, V104, P36, DOI 10.1111/cas.12032; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Noguchi S, 2014, CLIN CANCER RES, V20, P4660, DOI 10.1158/1078-0432.CCR-13-3328; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Ntambi JM, 1999, J LIPID RES, V40, P1549; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Piccolo S, 2013, CLIN CANCER RES, V19, P4925, DOI 10.1158/1078-0432.CCR-12-3172; Potze L, 2016, ONCOGENE, V35, P427, DOI 10.1038/onc.2015.102; Rappa G, 2013, EXP CELL RES, V319, P810, DOI 10.1016/j.yexcr.2013.01.003; Rios-Esteves J, 2014, J BIOL CHEM, V289, P17009, DOI 10.1074/jbc.M114.561209; Rios-Esteves J, 2013, CELL REP, V4, P1072, DOI 10.1016/j.celrep.2013.08.027; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Roscilli G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0816-x; Santinon G, 2016, TRENDS CELL BIOL, V26, P289, DOI 10.1016/j.tcb.2015.11.004; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Southam AD, 2015, CANCER RES, V75, P2530, DOI 10.1158/0008-5472.CAN-15-0202; Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837; von Roemeling CA, 2015, J CLIN ENDOCR METAB, V100, pE697, DOI 10.1210/jc.2014-2764; von Roemeling CA, 2013, CLIN CANCER RES, V19, P2368, DOI 10.1158/1078-0432.CCR-12-3249; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Yeung B, 2016, INT J CANCER, V138, P533, DOI 10.1002/ijc.29457; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	48	91	95	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4573	4584		10.1038/onc.2017.75	http://dx.doi.org/10.1038/onc.2017.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368399				2022-12-28	WOS:000407246200005
J	Boussiotis, VA; Charest, A				Boussiotis, Vassiliki A.; Charest, Alain			Immunotherapies for malignant glioma	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; CANCER STEM-CELLS; NEWLY-DIAGNOSED GLIOBLASTOMA; CHIMERIC ANTIGEN RECEPTOR; BLOOD-BRAIN-BARRIER; TUMOR-ASSOCIATED MACROPHAGES; IMMUNE CHECKPOINT BLOCKADE; GROWTH-FACTOR RECEPTOR; MICROGLIAL CELLS	Glioblastoma multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells, and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.	[Boussiotis, Vassiliki A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA; [Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA.	acharest@bidmc.harvard.edu; vboussio@bidmc.harvard.edu			NIH/NCI [CA183605, CA183605S1, CA212605, CA185137, CA179563, CA069246]; DoD [PC140571]; NATIONAL CANCER INSTITUTE [R01CA212605, R01CA183605, R01CA185137, P01CA069246, U19CA179563] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI grants CA183605, CA183605S1, and CA212605 and the DoD grant PC140571 (to V.A.B.) and NIH/NCI grants CA185137, CA179563, and CA069246 (to A.C.)	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alexiou GA, 2013, ACTA NEUROL BELG, V113, P7, DOI 10.1007/s13760-012-0097-y; Alizadeh D, 2010, CLIN CANCER RES, V16, P3399, DOI 10.1158/1078-0432.CCR-09-3087; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Ardon H, 2010, J NEURO-ONCOL, V99, P261, DOI 10.1007/s11060-010-0131-y; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bardella C, 2016, CANCER CELL, V30, P578, DOI 10.1016/j.ccell.2016.08.017; Bauer M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039956; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Belcaid Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101764; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2009, CANCER RES, V69, P8886, DOI 10.1158/0008-5472.CAN-09-2687; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Campanella M, 2014, PEERJ, V2, DOI 10.7717/peerj.497; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; da Fonseca ACC, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/264124; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Charles N, 2010, CELL CYCLE, V9, P3012, DOI 10.4161/cc.9.15.12710; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen WL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0487-0; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010; Danaila L., 1993, Romanian Journal of Neurology and Psychiatry, V31, P195; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Ellsworth S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27357; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Fadul CE, 2011, J IMMUNOTHER, V34, P382, DOI 10.1097/CJI.0b013e318215e300; Fadul CE, 2011, NEURO-ONCOLOGY, V13, P393, DOI 10.1093/neuonc/noq204; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Fleurence J, 2016, ONCOTARGET, V7, P41172, DOI 10.18632/oncotarget.9226; FORD AL, 1995, J IMMUNOL, V154, P4309; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Galarneau H, 2007, CANCER RES, V67, P8874, DOI 10.1158/0008-5472.CAN-07-0177; Geranmayeh F, 2007, NEUROSURGERY, V60, P159, DOI 10.1227/01.NEU.0000249192.30786.67; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gielen PR, 2015, J NEUROPATH EXP NEUR, V74, P390, DOI 10.1097/NEN.0000000000000183; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hodges TR, 2017, NEURO-ONCOLOGY, V19, P1047, DOI 10.1093/neuonc/nox026; Hou Y, 2016, BLOOD, V127, P1587, DOI 10.1182/blood-2015-10-674531; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Huang JY, 2010, J IMMUNOL, V185, P1450, DOI 10.4049/jimmunol.0901352; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Jacobs JFM, 2010, J NEUROIMMUNOL, V225, P195, DOI 10.1016/j.jneuroim.2010.05.020; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028; Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Jun HJ, 2012, ONCOGENE, V31, P3039, DOI 10.1038/onc.2011.474; Kabba JA, 2017, CELL MOL NEUROBIOL, V22; Kakarla S, 2014, CANCER J, V20, P151, DOI 10.1097/PPO.0000000000000032; Kaminska B, 2016, BBA-MOL BASIS DIS, V1862, P339, DOI 10.1016/j.bbadis.2015.10.026; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim JE, 2017, CLIN CANCER RES, V23, P124, DOI 10.1158/1078-0432.CCR-15-1535; Kim TG, 2010, CLIN VACCINE IMMUNOL, V17, P143, DOI 10.1128/CVI.00292-09; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; LAFFERTY KJ, 1978, BLOOD CELLS, V4, P395; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LeBlanc AK, 2016, NEURO-ONCOLOGY, V18, P1209, DOI 10.1093/neuonc/now051; Leung W, 2014, CLIN CANCER RES, V20, P3390, DOI 10.1158/1078-0432.CCR-13-1766; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Ling Y, 2007, EUR J HAEMATOL, V79, P310, DOI 10.1111/j.1600-0609.2007.00917.x; Litterman AJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26294; Llaguno SRA, 2015, CANCER CELL, V28, P429, DOI 10.1016/j.ccell.2015.09.007; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Louis DN, 2016, HO CLASSIFICATION TU, V1; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; LOWE J, 1989, J PATHOL, V159, P143, DOI 10.1002/path.1711590209; Maes W, 2011, CANCER IMMUNOL IMMUN, V60, P153, DOI 10.1007/s00262-010-0946-6; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mathios D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2942; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Maxwell R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0754-x; Mendez JS, 2016, J NEURO-ONCOL, V127, P329, DOI 10.1007/s11060-015-2037-1; Mieczkowski J, 2015, ONCOTARGET, V6, P33077, DOI 10.18632/oncotarget.5310; Mineo JF, 2004, BRIT J CANCER, V91, P1195, DOI 10.1038/sj.bjc.6602089; Molofsky AV, 2015, GLIA, V63, P1320, DOI 10.1002/glia.22836; MORRIS CS, 1991, J NEUROL SCI, V101, P47, DOI 10.1016/0022-510X(91)90017-2; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Oh T, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-107; Olson JJ, 2014, J NEURO-ONCOL, V118, P557, DOI 10.1007/s11060-013-1339-4; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Paff M, 2014, HUM VACC IMMUNOTHER, V10, P3322, DOI 10.4161/21645515.2014.983002; Pallud J, 2015, NEURO-ONCOLOGY, V17, P1609, DOI 10.1093/neuonc/nov126; Parada LF, 2005, COLD SH Q B, V70, P173, DOI 10.1101/sqb.2005.70.025; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Patsoukis N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00330; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Perng P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00153; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pitter KL, 2016, BRAIN, V139, P1458, DOI 10.1093/brain/aww046; Placone AL, 2016, TUMOR BIOL, V37, P61, DOI 10.1007/s13277-015-4242-0; Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291; Prados MD, 2015, NEURO-ONCOLOGY, V17, P1051, DOI 10.1093/neuonc/nov031; Priceman SJ, 2015, CURR OPIN ONCOL, V27, P466, DOI 10.1097/CCO.0000000000000232; Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2017, SEMIN IMMUNOPATHOL, V39, P225, DOI 10.1007/s00281-016-0616-7; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135; Roth P, 2015, NEURO-ONCOL PRACT, V2, P6, DOI 10.1093/nop/npu029; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Sampson JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031046; Sampson JH, 2011, NEURO-ONCOLOGY, V13, P324, DOI 10.1093/neuonc/noq157; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schultze SM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002109; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; Varga G, 2008, J LEUKOCYTE BIOL, V84, P644, DOI 10.1189/jlb.1107768; Vauleon E, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-41; Vecht CJ, 2014, ONCOLOGIST, V19, P751, DOI 10.1634/theoncologist.2014-0060; Venkatesh HS, 2015, CELL, V161, P803, DOI 10.1016/j.cell.2015.04.012; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wainwright DA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00116; Wainwright DA, 2011, NEURO-ONCOLOGY, V13, P1308, DOI 10.1093/neuonc/nor134; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Wei J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016195, 10.1371/journal.pone.0017868]; Wei J, 2010, MOL CANCER THER, V9, P67, DOI 10.1158/1535-7163.MCT-09-0734; Weiss T, 2016, EXPERT REV ANTICANC, V16, P1087, DOI 10.1080/14737140.2016.1229600; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772; Wierzba-Bobrowicz T, 1994, Folia Neuropathol, V32, P251; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wintterle S, 2003, CANCER RES, V63, P7462; Wong ET, 2015, BRIT J CANCER, V113, P232, DOI 10.1038/bjc.2015.238; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xia M, 1999, CELL MOL LIFE SCI, V55, P1649, DOI 10.1007/s000180050403; Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2; Yan D, 2017, ONCOGENE, V36, P6049, DOI 10.1038/onc.2017.261; Yeo AT, 2017, J CELL BIOCHEM, V118, P2516, DOI 10.1002/jcb.25948; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117; Zhang CF, 2016, J SENSORS, V2016, DOI 10.1155/2016/9307560; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	202	77	81	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1121	1141		10.1038/s41388-017-0024-z	http://dx.doi.org/10.1038/s41388-017-0024-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242608	Green Accepted, Green Submitted			2022-12-28	WOS:000426505400001
J	di Martino, S; Amoreo, CA; Nuvoli, B; Galati, R; Strano, S; Facciolo, F; Alessandrini, G; Pass, HI; Ciliberto, G; Blandino, G; De Maria, R; Cioce, M				di Martino, Simona; Amoreo, Carla Azzurra; Nuvoli, Barbara; Galati, Rossella; Strano, Sabrina; Facciolo, Francesco; Alessandrini, Gabriele; Pass, Harvey I.; Ciliberto, Gennaro; Blandino, Giovanni; De Maria, Ruggero; Cioce, Mario			HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; CELL LUNG-CANCER; POTENT ANTITUMOR-ACTIVITY; ADVANCED SOLID TUMORS; IN-VITRO; SENESCENT CELLS; STEM-CELLS; INTRATUMORAL HETEROGENEITY; ACQUIRED-RESISTANCE; DRUG-RESISTANCE	Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDH(bright) cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.	[di Martino, Simona; Blandino, Giovanni; Cioce, Mario] Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy; [Amoreo, Carla Azzurra] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Nuvoli, Barbara; Galati, Rossella] Regina Elena Inst Canc Res, Preclin Models & New Therapeut Agents Unit, Rome, Italy; [Strano, Sabrina] Regina Elena Inst Canc Res, Mol Chemoprevent Unit, Rome, Italy; [Facciolo, Francesco; Alessandrini, Gabriele] Regina Elena Inst Canc Res, Dept Thorac Surg, Rome, Italy; [Pass, Harvey I.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA; [Ciliberto, Gennaro; De Maria, Ruggero] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy; [De Maria, Ruggero] Catholic Univ, Inst Gen Pathol, Rome, Italy; [De Maria, Ruggero] Gemelli Polyclin, Rome, Italy; [Strano, Sabrina; Blandino, Giovanni] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; New York University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; McMaster University	Cioce, M (corresponding author), Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy.; De Maria, R (corresponding author), Regina Elena Inst Canc Res, Sci Direct, Rome, Italy.; De Maria, R (corresponding author), Catholic Univ, Inst Gen Pathol, Rome, Italy.; De Maria, R (corresponding author), Gemelli Polyclin, Rome, Italy.	demariaruggero@gmail.com; mariocioce@gmail.com	AMOREO, CARLA AZZURRA/K-5375-2018; Galati, Rossella Maria/H-8867-2017; De Maria, Ruggero/S-6385-2019; Cioce, Mario/R-9734-2017; di Martino, Simona SdM/K-9304-2016; Ciliberto, Gennaro/J-4131-2017; Galati, Rossella/ABH-6437-2020; Strano, Sabrina/K-9654-2016	AMOREO, CARLA AZZURRA/0000-0003-3817-1967; Galati, Rossella Maria/0000-0003-2646-8384; De Maria, Ruggero/0000-0003-2255-0583; Cioce, Mario/0000-0001-8129-6664; di Martino, Simona SdM/0000-0003-4533-3776; Ciliberto, Gennaro/0000-0003-2851-8605; Galati, Rossella/0000-0003-2646-8384; strano, sabrina/0000-0002-6341-4230; Alessandrini, Gabriele/0000-0002-4380-7627; Facciolo, Francesco/0000-0002-7137-8946; Pass, Harvey/0000-0003-3222-3471	Fundacio' La Marato' de TV3 [432/C/2013]; AIRC; Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	Fundacio' La Marato' de TV3; AIRC(Fondazione AIRC per la ricerca sul cancro); Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	The funding for this study was provided by the Fundacio' La Marato' de TV3 (grant 432/C/2013) to RDM. M.C. was supported by an AIRC and Marie Curie Actions-People-COFUND fellowship. We thankfully acknowledge the support of the Italian Ministry of Health (Progetto Nazionale Amianto) to R.D.M. We thankfully acknowledge the helpful advice of Dr. Paola Nistico, Dr. Maria Lucia Dell' Anna, and Dr. Valeria Catena (Regina Elena National Cancer Institute, Rome, Italy).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aird Katherine M, 2013, Methods Mol Biol, V965, P185, DOI 10.1007/978-1-62703-239-1_12; Alimbetov D, 2016, BIOGERONTOLOGY, V17, P305, DOI 10.1007/s10522-015-9610-z; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Basu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052188; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Busacca S, 2016, ONCOGENE, V35, P1483, DOI 10.1038/onc.2015.213; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Campisi J, 2011, SEMIN CANCER BIOL, V21, P354, DOI 10.1016/j.semcancer.2011.09.001; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Canino C, 2016, METHODS MOL BIOL, V1379, P139, DOI 10.1007/978-1-4939-3191-0_13; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Chatterjee S, 2017, MOL CANCER THER, V16, P793, DOI 10.1158/1535-7163.MCT-16-0677; Chernova T, 2016, CELL DEATH DIFFER, V23, P1152, DOI 10.1038/cdd.2015.165; Cioce M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.136; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corpet A, 2014, CHROMOSOMA, V123, P423, DOI 10.1007/s00412-014-0469-6; Cortes-Dericks L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-304; Cortes-Dericks L, 2010, INT J ONCOL, V37, P437, DOI 10.3892/ijo_00000692; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Galffy G, 1999, CANCER RES, V59, P367; Galffy G, 1999, ONCOL RES, V11, P187; Garon EB, 2013, MOL CANCER THER, V12, P890, DOI 10.1158/1535-7163.MCT-12-0998; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gomez-Casal R, 2015, CANCERS, V7, P876, DOI 10.3390/cancers7020814; He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Jones SF, 2015, INVEST NEW DRUG, V33, P1100, DOI 10.1007/s10637-015-0282-y; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lai CH, 2014, ONCOGENE, V33, P4867, DOI 10.1038/onc.2013.439; Liu X, 2016, ANTI-CANCER DRUG, V27, P417, DOI 10.1097/CAD.0000000000000347; Lundgren K, 2009, MOL CANCER THER, V8, P921, DOI 10.1158/1535-7163.MCT-08-0758; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Mathias RA, 2009, J PROTEOME RES, V8, P2827, DOI 10.1021/pr8010974; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219; Park SY, 2014, EUR J CANCER, V50, P341, DOI 10.1016/j.ejca.2013.09.021; Patel S, 2014, ADV EXP MED BIOL, V806, P409, DOI 10.1007/978-3-319-06068-2_20; Piper PW, 2011, PHARMACEUTICALS, V4, P1400, DOI 10.3390/ph4111400; Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213; Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078-0432.CCR-14-0947; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Shimamura T, 2012, CLIN CANCER RES, V18, P4973, DOI 10.1158/1078-0432.CCR-11-2967; Shimizu T, 2016, CANCER CHEMOTH PHARM, V77, P997, DOI 10.1007/s00280-016-3010-1; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Socinski MA, 2013, CLIN CANCER RES, V19, P3068, DOI 10.1158/1078-0432.CCR-12-3381; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Thakur MK, 2016, INVEST NEW DRUG, V34, P112, DOI 10.1007/s10637-015-0307-6; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang Y, 2011, CYTOKINE, V56, P365, DOI 10.1016/j.cyto.2011.06.005; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755	65	16	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1369	1385		10.1038/s41388-017-0044-8	http://dx.doi.org/10.1038/s41388-017-0044-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29311642				2022-12-28	WOS:000427279300008
J	Welcker, D; Jain, M; Khurshid, S; Jokic, M; Hohne, M; Schmitt, A; Frommolt, P; Niessen, CM; Spiro, J; Persigehl, T; Wittersheim, M; Buttner, R; Fanciulli, M; Schermer, B; Reinhardt, HC; Benzing, T; Hopker, K				Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Jokic, Mladen; Hoehne, Martin; Schmitt, Anna; Frommolt, Peter; Niessen, Carien M.; Spiro, Judith; Persigehl, Thorsten; Wittersheim, Maike; Buettner, Reinhard; Fanciulli, Maurizio; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas; Hoepker, Katja			AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE; RAS ONCOGENES; P53 TRANSCRIPTION; CHK2 KINASES; CHECKPOINT; CHE-1; ATM; PATHWAY; GROWTH	A fundamental principle in malignant tranformation is the ability of cancer cells to escape the naturally occurring cellintrinsic responses to DNA damage. Tumors progress despite the accumulation of DNA lesions. However, the underlying mechanisms of this tolerance to genotoxic stress are still poorly characterized. Here, we show that replication stress occurs in Kras-driven murine lung adenocarcinomas, as well as in proliferating murine embryonic and adult tissues. We identify the transcriptional regulator AATF/CHE-1 as a key molecule to sustain proliferative tissues and tumor progression in parts by inhibiting p53-driven apoptosis in vivo. In an autochthonous Kras-driven lung adenocarcinoma model, deletion of Aatf delayed lung cancer formation predominantly in a p53-dependent manner. Moreover, targeting Aatf in existing tumors through a dual recombinase strategy caused a halt in tumor progression. Taken together, these data suggest that AATF may serve as a drug target to treat KRAS-driven malignancies.	[Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Hoehne, Martin; Schmitt, Anna; Schermer, Bernhard; Benzing, Thomas; Hoepker, Katja] Univ Cologne, Dept Internal Med 2, Cologne, Germany; [Welcker, Daniela; Jain, Manaswita; Khurshid, Safiya; Jokic, Mladen; Hoehne, Martin; Frommolt, Peter; Niessen, Carien M.; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas; Hoepker, Katja] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Khurshid, Safiya] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Jokic, Mladen; Reinhardt, Hans Christian] Univ Cologne, Dept Internal Med 1, Cologne, Germany; [Jokic, Mladen; Hoehne, Martin; Niessen, Carien M.; Schermer, Bernhard; Reinhardt, Hans Christian; Benzing, Thomas] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Hoehne, Martin; Schermer, Bernhard; Benzing, Thomas] Univ Cologne, Syst Biol Ageing Cologne Sybacol, Cologne, Germany; [Niessen, Carien M.] Univ Cologne, Dept Dermatol, Cologne, Germany; [Spiro, Judith; Persigehl, Thorsten] Univ Cologne, Dept Radiol, Cologne, Germany; [Wittersheim, Maike; Buettner, Reinhard] Univ Cologne, Dept Pathol, Cologne, Germany; [Fanciulli, Maurizio] Regina Elena Inst Canc Res, Translat Res Area, SAFU Lab, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy	University of Cologne; University of Cologne; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Benzing, T (corresponding author), Univ Cologne, Dept Internal Med 2, Cologne, Germany.; Reinhardt, HC; Benzing, T (corresponding author), Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.; Reinhardt, HC (corresponding author), Univ Cologne, Dept Internal Med 1, Cologne, Germany.; Reinhardt, HC; Benzing, T (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany.; Benzing, T (corresponding author), Univ Cologne, Syst Biol Ageing Cologne Sybacol, Cologne, Germany.	christian.reinhardt@uk-koeln.de; thomas.benzing@uk-koeln.de	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014; fanciulli, maurizio/ABH-6745-2020; Frommolt, Peter/L-9656-2016	Schermer, Bernhard/0000-0002-5194-9000; Frommolt, Peter/0000-0002-1966-8014; Khurshid, Safiya/0000-0003-1620-3091; Niessen, Carien M./0000-0002-4892-9391; Hohne, Martin/0000-0001-8698-5389; Jain, Manaswita/0000-0002-5107-7505	Volkswagenstiftung; Deutsche Forschungsgemeinschaft [KFO-286, SFB-829, SCHE1562/2, BE2212]; Bundesministerium fur Bildung und Forschung; German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative [LS-1-1-030a]; Else Kroner-Fresenius Stiftung [EKFS-2014-A06]; Deutsche Krebshilfe [111724]; University of Cologne (Koln Fortune Program); Cologne Cardiovascular Research Center (Graduate Program); Cologne Graduate School of Ageing Research; CECAD Research Center Cologne Maternity Leave Fellowship	Volkswagenstiftung(Volkswagen); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative; Else Kroner-Fresenius Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); University of Cologne (Koln Fortune Program); Cologne Cardiovascular Research Center (Graduate Program); Cologne Graduate School of Ageing Research; CECAD Research Center Cologne Maternity Leave Fellowship	This work was supported by Volkswagenstiftung (Lichtenberg Program to HCR), Deutsche Forschungsgemeinschaft (KFO-286 to HCR, SFB-829 to HCR, CN and TB, SCHE1562/2 to BS, BE2212 to TB), Bundesministerium fur Bildung und Forschung (SMOOSE to HCR, SYBACOL to TB), German federal state North Rhine Westphalia (NRW) as part of the EFRE initiative (grant LS-1-1-030a to HCR), Else Kroner-Fresenius Stiftung (EKFS-2014-A06 to HCR), Deutsche Krebshilfe (111724, HCR), University of Cologne (Koln Fortune Program to KH), Cologne Cardiovascular Research Center (Graduate Program to MJ), Cologne Graduate School of Ageing Research (to SK), CECAD Research Center Cologne Maternity Leave Fellowship to DW.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahuja AK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10660; Bacalini MG, 2012, EXP HEMATOL, V40, P197, DOI 10.1016/j.exphem.2011.11.005; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Bruno T, 2008, CELL DEATH DIFFER, V15, P515, DOI 10.1038/sj.cdd.4402284; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Bruno T, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00034; Bruno T, 2010, CANCER CELL, V18, P122, DOI 10.1016/j.ccr.2010.05.027; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; De Nicola F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.381; Desantis A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.117; Desantis A, 2015, EMBO J, V34, P1214, DOI 10.15252/embj.201489920; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Durkin M.E., 2013, BIOPROTOC, V3, pE908, DOI DOI 10.21769/BioProtoc.908; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Grabocka E, 2015, CLIN CANCER RES, V21, P1243, DOI 10.1158/1078-0432.CCR-14-0650; Guo Q, 2004, J BIOL CHEM, V279, P4596, DOI 10.1074/jbc.M309811200; Hafner M, 2004, GENESIS, V38, P176, DOI 10.1002/gene.20016; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hopker K, 2012, CELL CYCLE, V11, P4122, DOI 10.4161/cc.21997; Hopker K, 2012, EMBO J, V31, P3961, DOI 10.1038/emboj.2012.236; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jokic M, 2016, MOL CANCER RES, V14, P1110, DOI 10.1158/1541-7786.MCR-16-0094; Justilien V, 2017, CANCER CELL, V31, P256, DOI 10.1016/j.ccell.2016.12.010; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kaul D, 2007, INDIAN J BIOCHEM BIO, V44, P276; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marino S, 2000, GENE DEV, V14, P994; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Ollion J, 2013, BIOINFORMATICS, V29, P1840, DOI 10.1093/bioinformatics/btt276; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tubbs A, 2017, CELL; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Xie J, 2004, NEUROBIOL DIS, V16, P150, DOI 10.1016/j.nbd.2004.02.003	65	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1503	1518		10.1038/s41388-017-0054-6	http://dx.doi.org/10.1038/s41388-017-0054-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321668				2022-12-28	WOS:000427459500008
J	Bonnin, DAA; Havrda, MC; Lee, MC; Liu, H; Zhang, Z; Nguyen, LN; Harrington, LX; Hassanpour, S; Cheng, C; Israel, MA				Bonnin, D. A. Almiron; Havrda, M. C.; Lee, M. C.; Liu, H.; Zhang, Z.; Nguyen, L. N.; Harrington, L. X.; Hassanpour, S.; Cheng, C.; Israel, M. A.			Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; INDUCIBLE FACTOR-1-ALPHA; INSULIN-SECRETION; IL-6 SECRETION; NERVOUS-SYSTEM; TUMOR HYPOXIA; CANCER-CELLS; MOUSE MODEL; RAC1; GLIOBLASTOMA	High-grade gliomas (HGGs) include the most common and the most aggressive primary brain tumor of adults and children. Despite multimodality treatment, most high-grade gliomas eventually recur and are ultimately incurable. Several studies suggest that the initiation, progression, and recurrence of gliomas are driven, at least partly, by cancer stem-like cells. A defining characteristic of these cancer stem-like cells is their capacity to self-renew. We have identified a hypoxia-induced pathway that utilizes the Hypoxia Inducible Factor 1 alpha (HIF-1 alpha) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 -Signal Transducer and Activator of Transcription 3) axis to enhance the self-renewal of glioma stem-like cells. Hypoxia is a commonly found pathologic feature of HGGs. Under hypoxic conditions, HIF-1 alpha levels are greatly increased in glioma stem-like cells. Increased HIF-1 alpha activates the JAK1/2-STAT3 axis and enhances tumor stem-like cell self-renewal. Our data further demonstrate the importance of Vascular Endothelial Growth Factor (VEGF) secretion for this pathway of hypoxia-mediated self-renewal. Brefeldin A and EHT-1864, agents that significantly inhibit VEGF secretion, decreased stem cell self-renewal, inhibited tumor growth, and increased the survival of mice allografted with S100 beta-v-erbB/p53(-/-) glioma stem-like cells. These agents also inhibit the expression of a hypoxia gene expression signature that is associated with decreased survival of HGG patients. These findings suggest that targeting the secretion of extracellular, autocrine/paracrine mediators of glioma stem-like cell self-renewal could potentially contribute to the treatment of HGGs.	[Bonnin, D. A. Almiron; Havrda, M. C.; Liu, H.; Zhang, Z.; Cheng, C.; Israel, M. A.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Hanover, NH USA; [Bonnin, D. A. Almiron; Havrda, M. C.; Liu, H.; Zhang, Z.; Hassanpour, S.; Cheng, C.; Israel, M. A.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Hanover, NH USA; [Lee, M. C.] Dartmouth Coll, Dept Biol, Hanover, NH 03755 USA; [Nguyen, L. N.] Geisel Sch Med Dartmouth, Dept Pathol & Lab Med, Hanover, NH USA; [Nguyen, L. N.; Harrington, L. X.; Hassanpour, S.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College	Israel, MA (corresponding author), Norris Cotton Canc Ctr Dartmouth, One Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@Dartmouth.edu		Lee, Myung Chang/0000-0002-7051-5822	NIH; NSF; Cancer Center Core Grant from the National Cancer Institute [P30CA023108]; COBRE Grant from the National Institute of General Medical Sciences [P30GM10315-15]; Theodora B. Betz Foundation; Jordan and Kyra Memorial Foundation; Andrea Clark Nelson Medical Research Endowment; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Cancer Center Core Grant from the National Cancer Institute; COBRE Grant from the National Institute of General Medical Sciences; Theodora B. Betz Foundation; Jordan and Kyra Memorial Foundation; Andrea Clark Nelson Medical Research Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tor Tosteson and Dr Jiang Gui from the Biostatistics Shared Resource at Norris Cotton Cancer Center at Dartmouth for their consultation regarding statistical analysis, and Tabatha Richardson for her administrative support. Microarray processing and data normalization was carried out at Norris Cotton Cancer Center in the Genomics Shared Resource, which was established by equipment grants from the NIH and NSF and is supported in part by a Cancer Center Core Grant (P30CA023108) from the National Cancer Institute. Multiplex Luminex Cytokine Assay was performed in DartLab, the Immune Monitoring and Flow Cytometry Shared Resource at Norris Cotton Cancer Center, supported by a Cancer Center Core Grant (P30CA023108) from the National Cancer Institute and an Immunology COBRE Grant (P30GM10315-15) from the National Institute of General Medical Sciences. Financial support was generously provided by the Theodora B. Betz Foundation, the Jordan and Kyra Memorial Foundation and the Andrea Clark Nelson Medical Research Endowment. Support was generously provided by the Theodora B. Betz Foundation (M.A. Israel), the Jordan and Kyra Memorial Foundation (M.A. Israel), and the Andrea Clark Nelson Medical Research Endowment (M. A. Israel).	Agro L, 2015, BIO-PROTOCOL, V5, pe1659; Akbar H, 2007, J THROMB HAEMOST, V5, P1747, DOI 10.1111/j.1538-7836.2007.02646.x; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asahara S, 2013, DIABETOLOGIA, V56, P1088, DOI 10.1007/s00125-013-2849-5; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bonnin DAA, 2017, MOL CANCER THER, V16, P705, DOI 10.1158/1535-7163.MCT-16-0616; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Davila J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005458; Desire L, 2005, J BIOL CHEM, V280, P37516, DOI 10.1074/jbc.M507913200; Dwivedi S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-128; Dzaye ODA, 2016, J NEUROPATH EXP NEUR, V75, P429, DOI 10.1093/jnen/nlw016; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Finucane Mariel M, 2007, Epidemiol Perspect Innov, V4, P8, DOI 10.1186/1742-5573-4-8; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; Garabed RB, 2008, J R STAT SOC A STAT, V171, P699, DOI 10.1111/j.1467-985X.2008.00534.x; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goyal P, 2013, MOL HUM REPROD, V19, P528, DOI 10.1093/molehr/gat023; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Hamer PCDW, 2008, ONCOGENE, V27, P2091, DOI 10.1038/sj.onc.1210850; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harris MA, 2008, CANCER RES, V68, P10051, DOI 10.1158/0008-5472.CAN-08-0786; Havrda MC, 2006, THROMB HAEMOSTASIS, V96, P361, DOI 10.1160/TH06-04-0224; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hjelmeland AB, 2011, CELL DEATH DIFFER, V18, P829, DOI 10.1038/cdd.2010.150; Huang Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-304; Hwaiz R, 2015, BRIT J PHARMACOL, V172, P5347, DOI 10.1111/bph.13325; Hwaiz R, 2015, J LEUKOCYTE BIOL, V97, P975, DOI 10.1189/jlb.4A1214-603R; Jackson M, 2015, CARCINOGENESIS, V36, P177, DOI 10.1093/carcin/bgu243; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Li HZ, 2004, BIOINFORMATICS, V20, P208, DOI 10.1093/bioinformatics/bth900; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; Li QW, 2003, J PHYSIOL-LONDON, V550, P431, DOI 10.1113/jphysiol.2003.039073; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu Q, 2015, INT J CLIN EXP MED, V8, P22073; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Man JH, 2014, CELL REP, V9, P1812, DOI 10.1016/j.celrep.2014.10.055; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sausville E A, 1996, Cancer J Sci Am, V2, P52; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Sondergaard KL, 2002, NEUROPATH APPL NEURO, V28, P210, DOI 10.1046/j.1365-2990.2002.00391.x; Spence AM, 2008, CLIN CANCER RES, V14, P2623, DOI 10.1158/1078-0432.CCR-07-4995; Stanley AC, 2014, IMMUNOL CELL BIOL, V92, P275, DOI 10.1038/icb.2013.90; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vordermark D, 2003, STRAHLENTHER ONKOL, V179, P801, DOI 10.1007/s00066-003-1150-9; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Weiss WA, 2003, CANCER RES, V63, P1589; Williams JA, 2009, AM J PHYSIOL-ENDOC M, V296, pE405, DOI 10.1152/ajpendo.90874.2008; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yun Z, 2014, ADV EXP MED BIOL, V772, P41, DOI 10.1007/978-1-4614-5915-6_2; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	92	49	49	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1107	1118		10.1038/onc.2017.404	http://dx.doi.org/10.1038/onc.2017.404			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29155422	Green Published, hybrid			2022-12-28	WOS:000425905700013
J	Ando, T; Charindra, D; Shrestha, M; Umehara, H; Ogawa, I; Miyauchi, M; Takata, T				Ando, T.; Charindra, D.; Shrestha, M.; Umehara, H.; Ogawa, I.; Miyauchi, M.; Takata, T.			Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer	ONCOGENE			English	Article							HIPPO PATHWAY; ONCOGENIC ACTIVITY; REGULATES YAP; SIZE-CONTROL; 1 TIMP-1; GROWTH; TEAD; PROGNOSIS; TAZ; TUMORIGENESIS	Tissue inhibitor of metalloproteinase-1 (TIMP-1), a member of the TIMP family (TIMP-1 to 4), is highly expressed in various types of cancer and forms a complex with its receptor CD63 and Integrin beta 1. However, the precise oncogenic mechanism of TIMP-1 remains unclear. Yes-associated protein (YAP) and transcriptional co-activator with PDZ binding motif (TAZ) are transcription co-activators enhancing the transcription of specific genes related to cell proliferation. But the mechanism of aberrant YAP/TAZ activation in cancer is not fully understood. Here, we showed that TIMP-1 activates YAP/TAZ as novel downstream targets to promote cell proliferation. The TIMP-1-CD63-Integrin beta 1 axis activates Src and promotes RhoA-mediated F-actin assembly, leading to LATS1/2 inactivation. This results in under-phosphorylation, protein stabilization and nuclear translocation of YAP/TAZ (YAP/TAZ activation); CTGF production; and cell proliferation. Furthermore, the TIMP-1-YAP/TAZ axis is aberrantly activated in various types of cancer cells or tissues. TIMP-1 knockdown inhibits cell proliferation through YAP/TAZ inactivation in cancer cells. This study found that TIMP-1 accelerates cell proliferation through YAP/TAZ activation in cancer, and suggests the TIMP-1-YAP/TAZ axis may be a novel potential drug target for cancer patients.	[Ando, T.; Charindra, D.; Shrestha, M.; Umehara, H.; Miyauchi, M.; Takata, T.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Hiroshima, Japan; [Ogawa, I.] Hiroshima Univ Hosp, Ctr Oral Clin Examinat, Hiroshima, Japan	Hiroshima University; Hiroshima University	Takata, T (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Pathobiol, Basic Life Sci,Mimami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	ttakata@hiroshima-u.ac.jp	Ando, Toshinori/AAG-4033-2021; Shrestha, Madhu/HHC-3819-2022; Ando, Toshinori/AAA-6401-2021; Miyauchi, Mutsumi/G-5268-2019	Ando, Toshinori/0000-0002-3141-8173; Ando, Toshinori/0000-0002-3141-8173; 	JSPS KAKENHI [JP25293373, JP16H05503, 17K17084]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Professor Koichiro Ozawa (Department of Pharmacotherapy, Hiroshima University) for valuable discussion and Professor Makiko Fujii (Department of Global Dental Medicine and Molecular Oncology, Hiroshima University) for providing us HA-tagged YAP-WT vector and anti-HA antibody. This work was funded, in part, by JSPS KAKENHI Grant Number JP25293373 and JP16H05503 to (TT) and 17K17084 to (TA). Hanako Umehara currently belongs to department of advanced prosthodontics, Hiroshima University.	Aaberg-Jessen C, 2009, J NEURO-ONCOL, V95, P117, DOI 10.1007/s11060-009-9910-8; Ando T, 2017, SCI REP-UK, V7, DOI 10.1038/srep40187; Brodowska K, 2014, EXP EYE RES, V124, P67, DOI 10.1016/j.exer.2014.04.011; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Crocker M, 2011, NEURO-ONCOLOGY, V13, P99, DOI 10.1093/neuonc/noq170; Dechaphunkul A, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/290854; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Egea V, 2012, P NATL ACAD SCI USA, V109, pE309, DOI 10.1073/pnas.1115083109; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Eyckmans J, 2011, DEV CELL, V21, P35, DOI 10.1016/j.devcel.2011.06.015; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Grunnet M, 2013, SCAND J GASTROENTERO, V48, P899, DOI 10.3109/00365521.2013.812235; Honkavuori M, 2008, ANTICANCER RES, V28, P2715; Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Kozlowski M, 2013, ADV MED SCI-POLAND, V58, P227, DOI 10.2478/ams-2013-0017; Liu G, 2015, ONCOGENE, V34, P3536, DOI 10.1038/onc.2014.281; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Liu XW, 2005, CANCER RES, V65, P898; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma J, 2014, INT J CLIN EXP PATHO, V7, P246; Martin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12502; Mi W, 2015, ONCOGENE, V34, P3095, DOI 10.1038/onc.2014.251; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Oh WK, 2011, CANCER-AM CANCER SOC, V117, P517, DOI 10.1002/cncr.25394; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Shanzer M, 2017, P NATL ACAD SCI USA, V114, P1678, DOI 10.1073/pnas.1610223114; Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Tang Y, 2013, DEV CELL, V25, P402, DOI 10.1016/j.devcel.2013.04.011; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Terpos E, 2010, LEUKEMIA RES, V34, P399, DOI 10.1016/j.leukres.2009.08.035; Toricelli M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-22; Wang L, 2016, NATURE, V540, P579, DOI 10.1038/nature20602; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yoo YJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14018; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CURR OPIN PHARMACOL, V29, P26, DOI 10.1016/j.coph.2016.05.002; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	57	28	28	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					263	270		10.1038/onc.2017.321	http://dx.doi.org/10.1038/onc.2017.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925394				2022-12-28	WOS:000422631700012
J	Comiskey, DF; Jacob, AG; Sanford, BL; Montes, M; Goodwin, AK; Steiner, H; Matsa, E; Tapia-Santos, AS; Bebee, TW; Grieves, J; La Perle, K; Boyaka, P; Chandler, DS				Comiskey, D. F., Jr.; Jacob, A. G.; Sanford, B. L.; Montes, M.; Goodwin, A. K.; Steiner, H.; Matsa, E.; Tapia-Santos, A. S.; Bebee, T. W.; Grieves, J.; La Perle, K.; Boyaka, P.; Chandler, D. S.			A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo	ONCOGENE			English	Article							SPLICED MDM2 TRANSCRIPTS; DNA-DAMAGE RESPONSE; MESSENGER-RNA STABILIZATION; P53 MUTANT MICE; GENOMIC INSTABILITY; PEDIATRIC RHABDOMYOSARCOMA; SIGNALING PATHWAY; ONCOPROTEIN MDM2; TUMOR SPECTRUM; CELL-LINES	Alternative splicing of the oncogene murine double minute 2 (MDM2) is induced in response to genotoxic stress. MDM2-ALT1, the major splice variant generated, is known to activate the p53 pathway and impede full-length MDM2's negative regulation of p53. Despite this perceptible tumor-suppressive role, MDM2-ALT1 is also associated with several cancers. Furthermore, expression of MDM2-ALT1 has been observed in aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS), irrespective of histological subtype. Therefore, we generated a transgenic MDM2-ALT1 mouse model that would allow us to investigate the effects of this splice variant on the progression of tumorigenesis. Here we show that when MDM2-ALT1 is ubiquitously expressed in p53 null mice it leads to increased incidence of spindle cell sarcomas, including RMS. Our data provide evidence that constitutive MDM2-ALT1 expression is itself an oncogenic lesion that aggravates the tumorigenesis induced by p53 loss. On the contrary, when MDM2-ALT1 is expressed solely in B-cells in the presence of homozygous wild-type p53 it leads to significantly increased lymphomagenesis (56%) when compared with control mice (27%). However, this phenotype is observable only at later stages in life (>= 18 months). Moreover, flow cytometric analyses for B-cell markers revealed an MDM2-ALT1-associated decrease in the B-cell population of the spleens of these animals. Our data suggest that the B-cell loss is p53 dependent and is a response mounted to persistent MDM2-ALT1 expression in a wild-type p53 background. Overall, our findings highlight the importance of an MDM2 splice variant as a critical modifier of both p53-dependent and -independent tumorigenesis, underscoring the complexity of MDM2 posttranscriptional regulation in cancer. Furthermore, MDM2-ALT1-expressing p53 null mice represent a novel mouse model of fusion-negative RMS.	[Comiskey, D. F., Jr.; Jacob, A. G.; Montes, M.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; [Comiskey, D. F., Jr.; Jacob, A. G.; Montes, M.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Ohio State Univ, Ctr RNA Biol, Columbus, OH 43210 USA; [Comiskey, D. F., Jr.; Jacob, A. G.; Sanford, B. L.; Montes, M.; Goodwin, A. K.; Matsa, E.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, 700 Childrens Dr, Columbus, OH 43205 USA; [Steiner, H.; Grieves, J.; La Perle, K.; Boyaka, P.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Grieves, J.] Takeda Calif Inc, Drug Safety Res & Evaluat 10410 Sci Ctr Dr, San Diego, CA 92121 USA; [Chandler, D. S.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Takeda Pharmaceutical Company Ltd; Takeda Pharmaceuticals USA Inc. (TPUSA); Takeda California Inc; University System of Ohio; Ohio State University	Chandler, DS (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, 700 Childrens Dr, Columbus, OH 43205 USA.	chandler.135@osu.edu	La Perle, Krista Marie DuBray/B-3099-2015	Boyaka, Prosper/0000-0001-6857-9088	NCI Cancer Center Support Grant [P30 CA016058]; Alex's Lemonade Stand; NIH [CA133571]; Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA133571] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Alex's Lemonade Stand; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Matthew Rouhier for optimizing conditions for cell cycle analysis of B-cells; Juliann Rectenwald and The Ohio State University Comparative Pathology & Mouse Phenotyping Shared Resource, supported in part through NCI Cancer Center Support Grant P30 CA016058; and funding sources Alex's Lemonade Stand, Sarcoma Foundation of America, NIH (CA133571) awarded to DSC and Pelotonia (awarded to DFC and AGJ). We also thank Dr Andras Nagy for kindly providing the plasmid used in generating the mouse models.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; ALTMANNSBERGER M, 1985, AM J PATHOL, V118, P85; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartel F, 2001, ONCOL RES, V12, P451, DOI 10.3727/096504001108747459; Bartel F, 2001, INT J CANCER, V95, P168, DOI 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Brien DO, 2012, HISTOL HISTOPATHOL, V27, P13, DOI 10.14670/HH-27.13; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Carr MI, 2016, CELL REP, V16, P2618, DOI 10.1016/j.celrep.2016.08.014; Carrillo AM, 2015, ONCOGENE, V34, P846, DOI 10.1038/onc.2014.27; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Cheng Q, 2011, MOL CELL BIOL, V31, P4951, DOI 10.1128/MCB.05553-11; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Dang JJ, 2002, CANCER RES, V62, P1222; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; de Vree PJP, 2014, NAT BIOTECHNOL, V32, P1019, DOI 10.1038/nbt.2959; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dias CS, 2006, CANCER RES, V66, P9467, DOI 10.1158/0008-5472.CAN-05-3013; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Ellsworth RE, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-297; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Evdokiou A, 2001, INT J ONCOL, V19, P625; FAKHARZADEH SS, 1993, GENOMICS, V15, P283, DOI 10.1006/geno.1993.1058; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fernandez K, 2010, AM J PATHOL, V176, P416, DOI 10.2353/ajpath.2010.090405; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Fridman JS, 2003, CANCER RES, V63, P5703; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Gannon HS, 2012, CANCER CELL, V21, P668, DOI 10.1016/j.ccr.2012.04.011; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Hachitanda Y, 1998, MODERN PATHOL, V11, P1222; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hong SK, 2006, CELL CYCLE, V5, P801, DOI 10.4161/cc.5.8.2638; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Hosur V, 2012, CANCER GENET-NY, V205, P232, DOI 10.1016/j.cancergen.2012.03.005; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacob AG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104444; Jacob AG, 2013, NEOPLASIA, V15, P1049, DOI 10.1593/neo.13286; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jung CH, 2013, CANCER LETT, V335, P270, DOI 10.1016/j.canlet.2013.02.035; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Lukas J, 2001, CANCER RES, V61, P3212; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Lynch CJ, 2006, ONCOGENE, V25, P3463, DOI 10.1038/sj.onc.1209387; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Matsumoto R, 1998, CANCER RES, V58, P609; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; Miron K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8094; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nanni P, 2003, CANCER RES, V63, P2728; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Ognjanovic Simona, 2012, Sarcoma, V2012, P492086, DOI 10.1155/2012/492086; Okoro DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077643; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; RANGDAENG S, 1991, AM J CLIN PATHOL, V96, P32, DOI 10.1093/ajcp/96.1.32; Sanchez-Aguilera A, 2006, ONCOGENE, V25, P2565, DOI 10.1038/sj.onc.1209282; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Singh S, 2013, CELL DEATH DIFFER, V20, P558, DOI 10.1038/cdd.2012.153; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Suzuki C, 2007, MOL CANCER THER, V6, P542, DOI 10.1158/1535-7163.MCT-06-0659; Takano Ai, 2011, Kobe J Med Sci, V56, pE220; Takano A, 2010, DEV DYNAM, V239, P1789, DOI 10.1002/dvdy.22287; Tamborini E, 2001, INT J CANCER, V92, P790, DOI 10.1002/ijc.1271; Tang YA, 2012, CLIN CANCER RES, V18, P4325, DOI 10.1158/1078-0432.CCR-11-2617; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Volk EL, 2009, MOL CANCER RES, V7, P863, DOI 10.1158/1541-7786.MCR-08-0418; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Zanola A, 2012, J CELL MOL MED, V16, P1377, DOI 10.1111/j.1582-4934.2011.01518.x; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11	101	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					95	106		10.1038/onc.2017.282	http://dx.doi.org/10.1038/onc.2017.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892044	Green Accepted			2022-12-28	WOS:000422625000010
J	Provenzano, L; Ryan, Y; Hilton, DA; Lyons-Rimmer, J; Dave, F; Maze, EA; Adams, CL; Rigby-Jones, R; Ammoun, S; Hanemann, CO				Provenzano, L.; Ryan, Y.; Hilton, D. A.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Rigby-Jones, R.; Ammoun, S.; Hanemann, C. O.			Cellular prion protein (PrPC) in the development of Merlin-deficient tumours	ONCOGENE			English	Article							UBIQUITIN LIGASE CRL4(DCAF1); LAMININ RECEPTOR; HUMAN SCHWANNOMA; C-JUN; GENE-EXPRESSION; AMYLOID-BETA; CANCER-CELLS; ACTIVATION; PROLIFERATION; MENINGIOMAS	Loss of function mutations in the neurofibromatosis Type 2 (NF2) gene, coding for a tumour suppressor, Merlin, cause multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas. These tumours may occur sporadically or as part of the hereditary condition neurofibromatosis Type 2 (NF2). Current treatment is confined to (radio) surgery and no targeted drug therapies exist. NF2 mutations and/or Merlin inactivation are also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melanoma and glioblastoma. To study the relationship between Merlin deficiency and tumourigenesis, we have developed an in vitro model comprising human primary schwannoma cells, the most common Merlin-deficient tumour and the hallmark for NF2. Using this model, we show increased expression of cellular prion protein (PrPC) in schwannoma cells and tissues. In addition, a strong overexpression of PrPC is observed in human Merlin-deficient mesothelioma cell line TRA and in human Merlin-deficient meningiomas. PrPC contributes to increased proliferation, cell-matrix adhesion and survival in schwannoma cells acting via 37/67 kDa non-integrin laminin receptor (LR/37/67 kDa) and downstream ERK1/2, PI3K/AKT and FAK signalling pathways. PrPC protein is also strongly released from schwannoma cells via exosomes and as a free peptide suggesting that it may act in an autocrine and/or paracrine manner. We suggest that PrPC and its interactor, LR/37/67 kDa, could be potential therapeutic targets for schwannomas and other Merlin-deficient tumours.	[Provenzano, L.; Ryan, Y.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Ammoun, S.; Hanemann, C. O.] Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Provenzano, L.; Ryan, Y.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Ammoun, S.; Hanemann, C. O.] Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Hilton, D. A.; Rigby-Jones, R.] Derriford Hosp, Dept Cellular & Anat Pathol, Plymouth, Devon, England	University of Plymouth; University of Plymouth; Derriford Hospital	Ammoun, S (corresponding author), Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.; Ammoun, S (corresponding author), Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	sylwia.ammoun@plymouth.ac.uk	Atangana Maze, Emmanuel/HHC-2713-2022; Hanemann, C Oliver/AAV-6257-2020	Atangana Maze, Emmanuel/0000-0003-4632-6324; Hanemann, C Oliver/0000-0002-1951-1025; Adams, Claire/0000-0003-3871-9267; Ryan, Yan/0000-0002-4708-5350; Provenzano, Lucy/0000-0002-2922-0109	Laura Crane Youth Cancer Trust; Brain Tumour Research	Laura Crane Youth Cancer Trust; Brain Tumour Research	We thank Mario Salmona for mock PrP peptide and Joseph Testa for Merlin adenovirus. This work was supported by The Laura Crane Youth Cancer Trust and Brain Tumour Research.	Alais S, 2008, BIOL CELL, V100, P603, DOI 10.1042/BC20080025; Altmeppen HC, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-36; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Ammoun S, 2012, ONCOGENE, V31, P1710, DOI 10.1038/onc.2011.357; Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Arsenault RJ, 2012, PRION, V6, DOI 10.4161/pri.21914; Bacot SM, 2003, J LEUKOCYTE BIOL, V74, P118, DOI 10.1189/jlb.1102521; Blakeley Jaishri O, 2012, Am J Med Genet A, V158A, P24, DOI 10.1002/ajmg.a.34359; Bourteele S, 2007, CELL MICROBIOL, V9, P2202, DOI 10.1111/j.1462-5822.2007.00950.x; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Carimalo J, 2005, EUR J NEUROSCI, V21, P2311, DOI 10.1111/j.1460-9568.2005.04080.x; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Flaiz C, 2009, BRAIN PATHOL, V19, P27, DOI 10.1111/j.1750-3639.2008.00165.x; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Godsave SF, 2015, VIRUS RES, V207, P136, DOI 10.1016/j.virusres.2015.02.004; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Guillot-Sestier MV, 2009, J BIOL CHEM, V284, P35973, DOI 10.1074/jbc.M109.051086; Guo BB, 2016, J BIOL CHEM, V291, P5128, DOI 10.1074/jbc.M115.684258; Hanemann CO, 2008, BRAIN, V131, P606, DOI 10.1093/brain/awm249; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2016, NEUROPATHOLOGY, V36, P250, DOI 10.1111/neup.12266; Kimata A, 2007, J MED CHEM, V50, P5053, DOI 10.1021/jm070688r; Klyubin I, 2014, J NEUROSCI, V34, P6140, DOI 10.1523/JNEUROSCI.3526-13.2014; Li W, 2010, CELL CYCLE, V9, P4433, DOI 10.4161/cc.9.22.13838; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Liang J, 2007, FASEB J, V21, P2247, DOI 10.1096/fj.06-7799com; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes JP, 2009, CELL CYCLE, V8, P97, DOI 10.4161/cc.8.1.7506; Loubet D, 2012, FASEB J, V26, P678, DOI 10.1096/fj.11-185579; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Nunes F, 2005, CANCER GENET CYTOGEN, V162, P135, DOI 10.1016/j.cancergencyto.2005.04.003; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Parkinson DB, 2008, J CELL BIOL, V181, P625, DOI 10.1083/jcb.200803013; Parkinson DB, 2004, J CELL BIOL, V164, P385, DOI 10.1083/jcb.200307132; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Pflanzner T, 2012, J CEREBR BLOOD F MET, V32, P628, DOI 10.1038/jcbfm.2012.7; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; Robertson C, 2006, BLOOD, V107, P3907, DOI 10.1182/blood-2005-02-0802; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Santos TG, 2015, PRION, V9, P165, DOI 10.1080/19336896.2015.1027855; Sarnataro D, 2016, SCI REP-UK, V6, DOI 10.1038/srep24457; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; Shivane A, 2013, HISTOPATHOLOGY, V62, P651, DOI 10.1111/his.12062; Singh N, 2010, ANTIOXID REDOX SIGN, V12, P1271, DOI 10.1089/ars.2009.2628; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Stella R, 2010, MOL CELL BIOL, V30, P4864, DOI 10.1128/MCB.01040-09; Utermark T, 2003, BRAIN PATHOL, V13, P352; van den Munckhof P, 2012, NEUROGENETICS, V13, P1, DOI 10.1007/s10048-011-0300-y; Watts JC, 2007, BBA-MOL BASIS DIS, V1772, P654, DOI 10.1016/j.bbadis.2007.05.001; Weise J, 2008, RESTOR NEUROL NEUROS, V26, P57; Westergard L, 2007, BBA-MOL BASIS DIS, V1772, P629, DOI 10.1016/j.bbadis.2007.02.011; Wozniak K, 2008, CANCER GENET CYTOGEN, V183, P14, DOI 10.1016/j.cancergencyto.2008.01.020; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yap YHY, 2011, CANCER LETT, V306, P111, DOI 10.1016/j.canlet.2011.02.040; Yuzawa S, 2016, BRAIN TUMOR PATHOL, V33, P237, DOI 10.1007/s10014-016-0271-7; Zeng L, 2015, INT J CLIN EXP MED, V8, P8042; Zhou L, 2012, FEBS LETT, V586, P1403, DOI 10.1016/j.febslet.2012.03.016; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060; Zhou XM, 2008, MICROB PATHOGENESIS, V44, P129, DOI 10.1016/j.micpath.2007.08.014; Zuber C, 2008, MOL IMMUNOL, V45, P144, DOI 10.1016/j.molimm.2007.04.030	69	20	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6132	6142		10.1038/onc.2017.200	http://dx.doi.org/10.1038/onc.2017.200			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692055	Green Submitted			2022-12-28	WOS:000414249800007
J	Song, W; Hwang, Y; Youngblood, VM; Cook, RS; Balko, JM; Chen, J; Brantley-Sieders, DM				Song, W.; Hwang, Y.; Youngblood, V. M.; Cook, R. S.; Balko, J. M.; Chen, J.; Brantley-Sieders, D. M.			Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; METASTATIC PROGRESSION; MAMMARY ADENOCARCINOMA; TUMOR ANGIOGENESIS; SIGNALING AXIS; T-ANTIGEN; MYC; DISEASE; MICE; GENE	Basal-like/triple-negative breast cancers (TNBCs) are among the most aggressive forms of breast cancer, and disproportionally affects young premenopausal women and women of African descent. Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targeted therapies, which represents a critical barrier for effective treatment. Here, we identify EphA2 receptor tyrosine kinase as a clinically relevant target for TNBC. EphA2 expression is enriched in the basal-like molecular subtype in human breast cancers. Loss of EphA2 function in both human and genetically engineered mouse models of TNBC reduced tumor growth in culture and in vivo. Mechanistically, targeting EphA2 impaired cell cycle progression through S-phase via downregulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1. A small molecule kinase inhibitor of EphA2 effectively suppressed tumor cell growth in vivo, including TNBC patient-derived xenografts. Thus, our data identify EphA2 as a novel molecular target for TNBC.	[Song, W.; Hwang, Y.; Chen, J.; Brantley-Sieders, D. M.] Vanderbilt Univ, Sch Med, Dept Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA; [Youngblood, V. M.; Cook, R. S.; Balko, J. M.; Chen, J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Cook, R. S.; Balko, J. M.; Chen, J.; Brantley-Sieders, D. M.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Cellular & Dev Biol, Nashville, TN 37212 USA; [Chen, J.] Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chen, J; Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA.; Chen, J (corresponding author), Vanderbilt Univ, Sch Med, T-3107A MCN,1161 21st Ave South, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu; dana.brantley@vanderbilt.edu		Hwang, Yoonha/0000-0001-7420-4477; Chen, Jin/0000-0002-5557-2079	NIH/NCI [R01 CA148934, R01 CA177681, R01 CA95004]; CTSA (via Vanderbilt Institute of Clinical and Translational Research (VICTR)) from the National Center for Advancing Translational Sciences [UL1TR000445, VR10608]; US Department of Veterans Affairs VA Merit Award [5I01BX000134]; NCI Cancer Center Support Grant [P30 CA068485]; NATIONAL CANCER INSTITUTE [R01CA095004, R01CA177681, P30CA068485, R01CA148934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000134] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA (via Vanderbilt Institute of Clinical and Translational Research (VICTR)) from the National Center for Advancing Translational Sciences; US Department of Veterans Affairs VA Merit Award; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Bojana Jovanovic (Dana-Farber Cancer Institute) and Dr Tammy Sobolik (Vanderbilt University) for helpful discussions on the research. This work was supported by NIH/NCI Grants R01 CA148934 (DMB-S); R01 CA177681, and R01 CA95004 (JC). Acquisition of PDX models from the Huntsman Cancer Institute was supported by CTSA award UL1TR000445 (via Vanderbilt Institute of Clinical and Translational Research (VICTR) Grant VR10608 (DMB-S)) from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. JC is also supported by US Department of Veterans Affairs VA Merit Award (5I01BX000134). This work was also supported in part by the NCI Cancer Center Support Grant # P30 CA068485 utilizing the Translational Pathology Shared Resources.	Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Brantley-Sieders DM, 2011, CANCER RES, V71, P976, DOI 10.1158/0008-5472.CAN-10-3396; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Caldon CE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-2; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Choi Y, 2009, BIOORG MED CHEM LETT, V19, P4467, DOI 10.1016/j.bmcl.2009.05.029; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dillon JL, 2016, BREAST, V29, P202, DOI 10.1016/j.breast.2016.06.018; Fosu-Mensah N, 2015, FUTURE MED CHEM, V7, P2019, DOI 10.4155/fmc.15.129; Foulkes WD, 2010, NAT REV CLIN ONCOL, V7, P348, DOI 10.1038/nrclinonc.2010.39; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Guo ZM, 2015, INT J PHARMACEUT, V493, P380, DOI 10.1016/j.ijpharm.2015.05.051; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haibe-Kains B., GENEFU R PACKAGE REL; Hartl M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00132; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hutcheson J, 2015, CELL CYCLE, V14, P3812, DOI 10.1080/15384101.2015.1010922; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lehmann BD, 2015, BREAST, V24, pS36, DOI 10.1016/j.breast.2015.07.009; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Moccia M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128364; Murria R, 2015, AM J CANCER RES, V5, P2330; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Tsouko E, 2015, CARCINOGENESIS, V36, P1051, DOI 10.1093/carcin/bgv087; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Weisman PS, 2016, MODERN PATHOL, V29, P476, DOI 10.1038/modpathol.2016.39; Young CD, 2015, MOL CELL PROTEOMICS, V14, P1959, DOI 10.1074/mcp.M115.049783; Youngblood VM, 2016, CANCER RES, V76, P1825, DOI 10.1158/0008-5472.CAN-15-0847; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73	47	54	55	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5620	5630		10.1038/onc.2017.170	http://dx.doi.org/10.1038/onc.2017.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581527	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000412293600006
J	Szczepny, A; Rogers, S; Jayasekara, WSN; Park, K; McCloy, RA; Cochrane, CR; Ganju, V; Cooper, WA; Sage, J; Peacock, CD; Cain, JE; Burgess, A; Watkins, DN				Szczepny, A.; Rogers, S.; Jayasekara, W. S. N.; Park, K.; McCloy, R. A.; Cochrane, C. R.; Ganju, V.; Cooper, W. A.; Sage, J.; Peacock, C. D.; Cain, J. E.; Burgess, A.; Watkins, D. N.			The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer	ONCOGENE			English	Article							CHROMOSOMAL INSTABILITY; CYCLE PROGRESSION; SONIC HEDGEHOG; TUMORIGENESIS; CARCINOMAS; ANEUPLOIDY; RECEPTOR; PATHWAY	Hedgehog (Hh) signaling regulates cell fate and self-renewal in development and cancer. Canonical Hh signaling is mediated by Hh ligand binding to the receptor Patched (Ptch), which in turn activates Gli-mediated transcription through Smoothened (Smo), the molecular target of the Hh pathway inhibitors used as cancer therapeutics. Small cell lung cancer (SCLC) is a common, aggressive malignancy with universally poor prognosis. Although preclinical studies have shown that Hh inhibitors block the self-renewal capacity of SCLC cells, the lack of activating pathway mutations have cast doubt over the significance of these observations. In particular, the existence of autocrine, ligand-dependent Hh signaling in SCLC has been disputed. In a conditional Tp53;Rb1 mutant mouse model of SCLC, we now demonstrate a requirement for the Hh ligand Sonic Hedgehog (Shh) for the progression of SCLC. Conversely, we show that conditional Shh overexpression activates canonical Hh signaling in SCLC cells, and markedly accelerates tumor progression. When compared to mouse SCLC tumors expressing an activating, ligand-independent Smo mutant, tumors overexpressing Shh exhibited marked chromosomal instability and Smoothened-independent upregulation of Cyclin B1, a putative non-canonical arm of the Hh pathway. In turn, we show that overexpression of Cyclin B1 induces chromosomal instability in mouse embryonic fibroblasts lacking both Tp53 and Rb1. These results provide strong support for an autocrine, ligand-dependent model of Hh signaling in SCLC pathogenesis, and reveal a novel role for non-canonical Hh signaling through the induction of chromosomal instability.	[Szczepny, A.; Jayasekara, W. S. N.; Cochrane, C. R.; Ganju, V.; Cain, J. E.] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Rogers, S.; McCloy, R. A.; Burgess, A.; Watkins, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Rogers, S.; Burgess, A.; Watkins, D. N.] UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Park, K.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Cochrane, C. R.; Ganju, V.] Monash Univ, Sch Clin Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Ganju, V.] Monash Hlth, Dept Med Oncol, Clayton, Vic, Australia; [Cooper, W. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Sage, J.] Stanford Univ, Dept Pediat, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA; [Sage, J.] Stanford Univ, Dept Genet, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA; [Peacock, C. D.] Cleveland Clin, Dept Translat Hematol Oncol Res, Cleveland, OH 44106 USA; [Watkins, D. N.] St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia	Hudson Institute of Medical Research; Garvan Institute of Medical Research; University of New South Wales Sydney; University of Virginia; Monash University; University of Sydney; Stanford Cancer Institute; Stanford University; Stanford Cancer Institute; Stanford University; Cleveland Clinic Foundation; St Vincents Hospital Sydney	Burgess, A; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	a.burgess@garvan.org.au; n.watkins@garvan.org.au	Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Rogers, Samuel/0000-0002-5345-5741; Cochrane, Catherine/0000-0001-9683-8905; Park, Kwon-Sik/0000-0003-3346-9086; McCloy, Rachael/0000-0001-7791-4044	National Health and Medical Research Council of Australia [GNT1048669]; Victorian Cancer Agency [TS10-01]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; National Institutes of Health (NCI) [CA201513]; Cancer Institute of NSW Fellowship [10/FRL/3-02]; Patricia Helen Guest Fellowship; NATIONAL CANCER INSTITUTE [R01CA201513] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Institute of NSW Fellowship; Patricia Helen Guest Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Health and Medical Research Council of Australia (GNT1048669), The Victorian Cancer Agency (TS10-01), The Petre Foundation, the Victorian Government's Operational Infrastructure Support Program, and the National Institutes of Health (NCI CA201513). Also, Cancer Institute of NSW Fellowship (10/FRL/3-02) and the Patricia Helen Guest Fellowship was awarded to JS and AB, respectively.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Badea TC, 2003, J NEUROSCI, V23, P2314; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Cui M, 2014, MOL CANCER RES, V12, P654, DOI 10.1158/1541-7786.MCR-13-0554; de Carcer G, 2014, NAT CELL BIOL, V16, P504, DOI 10.1038/ncb2978; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fombonne J, 2012, P NATL ACAD SCI USA, V109, P10510, DOI 10.1073/pnas.1200094109; Gazdar AF, 2016, J THORAC ONCOL, V11, P287, DOI 10.1016/j.jtho.2015.10.009; Gazdar AF, 2015, J THORAC ONCOL, V10, P553, DOI 10.1097/JTO.0000000000000459; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Marini KD, 2011, GROWTH FACTORS, V29, P221, DOI 10.3109/08977194.2011.610756; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Nagy Andras, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4706; Nam HJ, 2014, NAT CELL BIOL, V16, P535, DOI 10.1038/ncb2952; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Robles-Oteiza C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9783; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; ROOS G, 1993, LAB INVEST, V68, P204; Shaukat Z, 2015, ONCOGENE, V34, P4044, DOI 10.1038/onc.2014.344; Sheltzer JM, 2013, CANCER RES, V73, P6401, DOI 10.1158/0008-5472.CAN-13-0749; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stevens JB, 2013, CANCER METAST REV, V32, P391, DOI 10.1007/s10555-013-9428-6; Wang DH, 2010, GASTROENTEROLOGY, V138, P1810, DOI 10.1053/j.gastro.2010.01.048; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Wu N, 2016, ONCOTARGET, V7, P57514, DOI 10.18632/oncotarget.11583; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031	40	38	38	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5544	5550		10.1038/onc.2017.173	http://dx.doi.org/10.1038/onc.2017.173			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581526	hybrid, Green Accepted			2022-12-28	WOS:000411960500010
J	Han, AL; Veeneman, BA; El-Sawy, L; Day, KC; Day, ML; Tomlins, SA; Keller, ET				Han, A. L.; Veeneman, B. A.; El-Sawy, L.; Day, K. C.; Day, M. L.; Tomlins, S. A.; Keller, E. T.			Fibulin-3 promotes muscle-invasive bladder cancer	ONCOGENE			English	Article							INHIBITS CELL-MIGRATION; BREAST-CANCER; IN-VIVO; POOR-PROGNOSIS; GROWTH; GENE; METHYLATION; EXPRESSION; EFEMP1; IGFBP-5	Urothelial carcinoma is the most common type of bladder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (>= T2). The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurrence rate for these tumors is high and a subset can progress to T2. In this study, we aimed to identify genes differentially expressed between T1 vs T2 bladder cancer to identify key regulators of bladder cancer progression and/or invasion. We performed RNA-Seq on T1 and T2 bladder cancer tissues and used publicly available bladder cancer profiling studies to prioritize differentially expressed genes for validation and functional assessment. This integrative approach nominated an extracellular matrix glycoprotein, fibulin-3 (FBLN3, also known as EFEMP1), as being highly expressed in T2 vs T1 bladder cancer and aggressive vs indolent disease. We confirmed the overexpression of fibulin-3 in >= T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitative reverse transcriptase-PCR. Consistent with these findings, fibulin-3 expression level correlated with the invasive ability of several bladder cancer cell lines and modulation of fibulin-3 expression directly affected invasion. Fibulin-3 knockdown in bladder cancer cells decreased the incidence of MIBCs in a murine orthotopic bladder cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5). Restoring IGFBP5 in these cells rescued their invasive and migratory potential. These results indicate that fibulin-3 serves as a pro-invasive factor in bladder cancer, which may be mediated through modulation of IGFBP5 expression. This also suggests fibulin-3 and IGFBP5 may have potential as biomarkers of aggressive bladder cancer or therapeutic targets.	[Han, A. L.; Tomlins, S. A.; Keller, E. T.] Univ Michigan, Sch Med, Dept Pathol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Veeneman, B. A.] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [El-Sawy, L.; Day, K. C.; Day, M. L.; Tomlins, S. A.; Keller, E. T.] Univ Michigan, Sch Med, Dept Urol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Tomlins, S. A.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Keller, E. T.] Univ Michigan, Biointerfaces Inst, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [El-Sawy, L.] European Egyptian Pharmaceut Ind, Alexandria, Egypt	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Sch Med, Dept Urol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	etkeller@med.umich.edu	Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	University of Michigan Comprehensive Cancer Center Research Grant; Robert M and Elizabeth C Teeter Bladder Cancer Research Fund; A Alfred Taubman Medical Institute; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER	University of Michigan Comprehensive Cancer Center Research Grant; Robert M and Elizabeth C Teeter Bladder Cancer Research Fund; A Alfred Taubman Medical Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the University of Michigan DNA Sequencing Core for the RNA-Seq. University of Michigan Comprehensive Cancer Center Research Grant (to ETK), the Robert M and Elizabeth C Teeter Bladder Cancer Research Fund (to SAT) and the MacLeod Family (to SAT). SAT is supported by the A Alfred Taubman Emerging Scholar Award from the A Alfred Taubman Medical Institute.	Almeida M, 2014, J CELL MOL MED, V18, P2287, DOI 10.1111/jcmm.12394; Arechederra M, 2015, J BIOL CHEM, V290, P4383, DOI 10.1074/jbc.M114.582239; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Botteman MF, 2003, PHARMACOECONOMICS, V21, P1315, DOI 10.1007/BF03262330; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang SS, 2016, J UROLOGY, V196, P1021, DOI 10.1016/j.juro.2016.06.049; Chen JJ, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/768756; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; COOPER MJ, 1994, ONCOL RES, V6, P569; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Kim IG, 2014, ONCOGENE, V33, P3908, DOI 10.1038/onc.2013.373; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; Kricker JA, 2003, ENDOCRINOLOGY, V144, P2807, DOI 10.1210/en.2002-221086; Liang PI, 2013, J CLIN PATHOL, V66, P573, DOI 10.1136/jclinpath-2012-201278; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Raitanen MP, 2001, ANN CHIR GYNAECOL, V90, P261; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sabichi A, 2006, J UROLOGY, V175, P1133, DOI 10.1016/S0022-5347(05)00323-X; Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108; Seeliger H, 2009, MOL CANCER RES, V7, P189, DOI 10.1158/1541-7786.MCR-08-0132; Sercu S, 2009, MATRIX BIOL, V28, P160, DOI 10.1016/j.matbio.2009.02.003; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; SOLOWAY MS, 1985, UROLOGY, V26, P18; Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004; Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016; Sureshbabu A, 2012, J CELL SCI, V125, P1693, DOI 10.1242/jcs.092882; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Tian H, 2015, ONCOGENE, V34, P5635, DOI 10.1038/onc.2015.13; Tong JD, 2011, NEOPLASMA, V58, P441, DOI 10.4149/neo_2011_05_441; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Z, 2012, PATHOL ONCOL RES, V18, P263, DOI 10.1007/s12253-011-9437-0; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Xu S, 2014, ONCOL REP, V31, P79, DOI 10.3892/or.2013.2799; Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018	49	25	25	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5243	5251		10.1038/onc.2017.149	http://dx.doi.org/10.1038/onc.2017.149			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504717				2022-12-28	WOS:000410671700003
J	Kesanakurti, D; Maddirela, D; Banasavadi-Siddegowda, YK; Lai, TH; Qamri, Z; Jacob, NK; Sampath, D; Mohanam, S; Kaur, B; Puduvalli, VK				Kesanakurti, D.; Maddirela, D.; Banasavadi-Siddegowda, Y. K.; Lai, T-H; Qamri, Z.; Jacob, N. K.; Sampath, D.; Mohanam, S.; Kaur, B.; Puduvalli, V. K.			A novel interaction of PAK4 with PPAR gamma to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma	ONCOGENE			English	Article							ACTIVATED-RECEPTOR-GAMMA; OXYGEN SPECIES GENERATION; BREAST-CANCER CELLS; EXTRACELLULAR-MATRIX; DEPENDENT ACTIVATION; MALIGNANT GLIOMA; BETA-CATENIN; STEM-CELLS; KAPPA-B; INVASION	Tumor recurrence in glioblastoma (GBM) is, in part, attributed to increased epithelial-to-mesenchymal transition (EMT) and enhanced tumor cell dissemination in adjacent brain parenchyma after ionizing radiation (IR). EMT is associated with aggressive behavior, increased stem-like characteristics and treatment resistance in malignancies; however, the underlying signaling mechanisms that regulate EMT are poorly understood. We identified grade-dependent p21-activated kinases 4 (PAK4) upregulation in gliomas and further determined its role in mesenchymal transition and radioresistance. IR treatment significantly elevated expression and nuclear localization of PAK4 in correlation with induction of reactive oxygen species (ROS) and mesenchymal transition in GBM cells. Stable PAK4 overexpression promoted mesenchymal transition by elevating EMT marker expression in these cells. Of note, transcription factor-DNA-binding arrays and chromatin immunoprecipitation experiments identified the formation of a novel nuclear PAK4/PPAR gamma complex which was recruited to the promoter of Nox1, a peroxisome proliferator-activated receptor gamma (PPAR gamma) target gene. In addition, IR further elevated PAK4/PPAR gamma complex co-recruitment to Nox1 promoter, and increased Nox1 expression and ROS levels associated with mesenchymal transition in these cells. Conversely, specific PAK4 downregulation decreased PPAR gamma-mediated Nox1 expression and suppressed EMT in IR-treated cells. In vivo orthotopic tumor experiments showed inhibition of growth and suppression of IR-induced PPAR gamma and Nox1 expression by PAK4 downregulation in tumors. Our results provide the first evidence of a novel role for PAK4 in IR-induced EMT and suggest potential therapeutic efficacy of targeting PAK4 to overcome radioresistance in gliomas.	[Kesanakurti, D.; Puduvalli, V. K.] Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Div Neurooncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Kesanakurti, D.; Banasavadi-Siddegowda, Y. K.; Kaur, B.; Puduvalli, V. K.] Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Dept Neurosurg, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Maddirela, D.; Lai, T-H; Sampath, D.; Mohanam, S.] Ohio State Univ, Ctr Comprehens Canc, Div Hematol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA; [Maddirela, D.; Mohanam, S.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL USA; [Qamri, Z.; Jacob, N. K.] Ohio State Univ, Ctr Comprehens Canc, Dept Radiat Oncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Illinois System; University of Illinois Peoria; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Kesanakurti, D (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dardinger Ctr Neurooncol & Neurosci, Div Neurooncol, 320W 10th Ave Starling Loving Hall Suite M410, Columbus, OH 43210 USA.	Divya.Kesanakurti@osumc.edu; Vinay.Puduvalli@osumc.edu	Sampath, Deepa/T-5069-2019	/0000-0002-4730-6918; Sampath, Deepa/0000-0002-4366-8436	Ohio State University Pelotonia Fellowship; NCI [5K24CA160777]; Sanford/Rife Family Glioblastoma Research Fund; Snyder Nation Foundation; Ellen and John Hines Neuro-oncology Research Fund; NATIONAL CANCER INSTITUTE [K24CA160777, P30CA016058] Funding Source: NIH RePORTER	Ohio State University Pelotonia Fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sanford/Rife Family Glioblastoma Research Fund; Snyder Nation Foundation; Ellen and John Hines Neuro-oncology Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jihong Xu, Krishna K Veeravalli and Bharath Chelluboina for technical help. We greatly appreciate Dr. Annie NY Cheung (University of Hong Kong, Hong Kong, China)) and Dr Audrey Minden (Rutgers University, NJ, USA) for kindly providing the PAK4-NLS-Mut and PAK4-K350M plasmids respectively, for our studies. We thank Drs Deepa Sampath and Rosa Lapalombella for manuscript review and helpful comments. This project was supported by the Ohio State University Pelotonia Fellowship (DK), NCI grant 5K24CA160777 (VKP), the Sanford/Rife Family Glioblastoma Research Fund, the Snyder Nation Foundation and the Ellen and John Hines Neuro-oncology Research Fund.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chen L, 2006, J BIOL CHEM, V281, P24575, DOI 10.1074/jbc.M604147200; Dart AE, 2015, J CELL BIOL, V211, P863, DOI 10.1083/jcb.201501072; Davison CA, 2013, CANCER RES, V73, P3704, DOI 10.1158/0008-5472.CAN-12-2482; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Han EJ, 2013, INT J RADIAT ONCOL, V85, pE239, DOI 10.1016/j.ijrobp.2012.11.040; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Jin RS, 2014, J CELL SCI, V127, P3116, DOI 10.1242/jcs.147835; Kahlert UD, 2013, CANCER LETT, V331, P131, DOI 10.1016/j.canlet.2012.12.010; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kesanakurti D, 2013, ONCOGENE, V32, P5144, DOI 10.1038/onc.2012.546; Kesanakurti D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.182; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Komatsu D, 2008, ONCOGENE, V27, P4724, DOI 10.1038/onc.2008.102; Kubelt C, 2015, INT J ONCOL, V46, P2515, DOI 10.3892/ijo.2015.2944; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu F, 2012, J INVEST DERMATOL, V132, P2033, DOI 10.1038/jid.2012.119; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Masuda T, 2005, CLIN CANCER RES, V11, P4012, DOI 10.1158/1078-0432.CCR-05-0087; Meng J, 2014, ONCOTARGET, V5, P4683, DOI 10.18632/oncotarget.2088; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Pestereva E, 2012, BRIT J CANCER, V106, P1702, DOI 10.1038/bjc.2012.161; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Sawayama H, 2014, CANCER RES, V74, P575, DOI 10.1158/0008-5472.CAN-13-1836; Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008-5472.CAN-04-3037; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schwartzbaum JA, 2006, NAT CLIN PRACT NEURO, V2, P494, DOI 10.1038/ncpneuro0289; Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tyagi N, 2016, CANCER LETT, V370, P260, DOI 10.1016/j.canlet.2015.10.028; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang X, 2013, ONCOGENE, V32, P5512, DOI 10.1038/onc.2013.217; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Wu CH, 2012, J BIOL CHEM, V287, P25292, DOI 10.1074/jbc.M111.291195; Zarkoob H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064169; Zaytseva YY, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-90; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022	68	28	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5309	5320		10.1038/onc.2016.261	http://dx.doi.org/10.1038/onc.2016.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28534509	Green Accepted			2022-12-28	WOS:000410671700009
J	Liu, YS; Lin, HY; Lai, SW; Huang, CY; Huang, BR; Chen, PY; Wei, KC; Lu, DY				Liu, Y-S; Lin, H-Y; Lai, S-W; Huang, C-Y; Huang, B-R; Chen, P-Y; Wei, K-C; Lu, D-Y			MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; CANCER-RELATED INFLAMMATION; PROTEIN PHOSPHATASE 2A; TUMOR IMMUNE EVASION; FACTOR RECEPTOR; GLIOMA-CELLS; STIMULATING FACTOR; BREAST-CANCER; STEM-CELLS; MACROPHAGE	Tumor-associated macrophages (TAMs) originate as circulating monocytes, and are recruited to gliomas, where they facilitate tumor growth and migration. Understanding the interaction between TAM and cancer cells may identify therapeutic targets for glioblastoma multiforme (GBM). Vascular cell adhesion molecule-1 (VCAM-1) is a cytokine-induced adhesion molecule expressed on the surface of cancer cells, which is involved in interactions with immune cells. Analysis of the glioma patient database and tissue immunohistochemistry showed that VCAM-1 expression correlated with the clinico-pathological grade of gliomas. Here, we found that VCAM-1 expression correlated positively with monocyte adhesion to GBM, and knockdown of VCAM-1 abolished the enhancement of monocyte adhesion. Importantly, upregulation of VCAM-1 is dependent on epidermal-growth-factor-receptor (EGFR) expression, and inhibition of EGFR effectively reduced VCAM-1 expression and monocyte adhesion activity. Moreover, GBM possessing higher EGFR levels (U251 cells) had higher VCAM-1 levels compared to GBMs with lower levels of EGFR (GL261 cells). Using two-and three-dimensional cultures, we found that monocyte adhesion to GBM occurs via integrin alpha 4 beta 1, which promotes tumor growth and invasion activity. Increased proliferation and tumor necrosis factor-alpha and IFN-gamma levels were also observed in the adherent monocytes. Using a genetic modification approach, we demonstrated that VCAM-1 expression and monocyte adhesion were regulated by the miR-181 family, and lower levels of miR-181b correlated with high-grade glioma patients. Our results also demonstrated that miR-181b/protein phosphatase 2A-modulated SP-1 de-phosphorylation, which mediated the EGFR-dependent VCAM-1 expression and monocyte adhesion to GBM. We also found that the EGFR-dependent VCAM-1 expression is mediated by the p38/STAT3 signaling pathway. Our study suggested that VCAM-1 is a critical modulator of EGFR-dependent interaction of monocytes with GBM, which raises the possibility of developing effective and improved therapies for GBM.	[Liu, Y-S; Lai, S-W] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Lin, H-Y; Lu, D-Y] China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan; [Huang, C-Y; Wei, K-C] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan 33302, Taiwan; [Huang, C-Y; Wei, K-C] Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan; [Huang, B-R] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Neurosurg, Taichung, Taiwan; [Chen, P-Y] Chang Gung Mem Hosp, Dept Neurosurg, Keelung, Taiwan; [Chen, P-Y] Chang Gung Univ, Sch Med, Taoyuan, Taiwan; [Lu, D-Y] Asia Univ, Dept Photon & Commun Engn, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Chang Gung Memorial Hospital; Chang Gung University; Asia University Taiwan	Lu, DY (corresponding author), China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Wei, KC (corresponding author), Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan 33302, Taiwan.; Wei, KC (corresponding author), Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan.	kuochenwei@adm.cgmh.org.tw; dahyuu@mail.cmu.edu.tw		Wei, Kuochen/0000-0003-3505-2196	Ministry of Science Technology [102-2320-B-039-051-MY3, 105-2628-B-039-007-MY3]; China Medical University [CMU104-S-12, CMU105-AWARD-01]; Chang Gung Memorial Hospital [CIRPG3E0032, CMRPG3D1113]; National Health Research Institutes [NHRI-EX106-10502NI]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW106-TDU-B-212-113004]	Ministry of Science Technology; China Medical University(China Medical University); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); National Health Research Institutes(National Health Research Institutes, JapanNational Health Research Institutes - Taiwan); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This work was partly supported by grants from the Ministry of Science & Technology (102-2320-B-039-051-MY3 and 105-2628-B-039-007-MY3) and China Medical University (CMU104-S-12 and CMU105-AWARD-01), Chang Gung Memorial Hospital Research Grant (CIRPG3E0032 and CMRPG3D1113), National Health Research Institutes (NHRI-EX106-10502NI) and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004).	Abou-Ghazal M, 2008, CLIN CANCER RES, V14, P8228, DOI 10.1158/1078-0432.CCR-08-1329; Alvarez James V, 2007, Transl Oncogenomics, V2, P99; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bhat FA, 2014, J NUTR BIOCHEM, V25, P1132, DOI 10.1016/j.jnutbio.2014.06.008; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Chen JH, 2016, MOL NEUROBIOL, V53, P6218, DOI 10.1007/s12035-015-9529-z; Chen Q, 2012, CLIN CANCER RES, V18, P5520, DOI 10.1158/1078-0432.CCR-11-2904; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Clarke J, 2010, ARCH NEUROL-CHICAGO, V67, P279, DOI 10.1001/archneurol.2010.5; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; de Groot J, 2012, ONCOTARGET, V3, P1036; Ding YB, 2003, WORLD J GASTROENTERO, V9, P1409, DOI 10.3748/wjg.v9.i7.1409; Feng X, 2015, ONCOTARGET, V6, P15077, DOI 10.18632/oncotarget.3730; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gopisetty G, 2013, ONCOGENE, V32, P3119, DOI 10.1038/onc.2012.331; Gordon IK, 2015, MOL CANCER THER, V14, P1540, DOI 10.1158/1535-7163.MCT-14-0614; Greenwood J, 2011, NEUROPATH APPL NEURO, V37, P24, DOI 10.1111/j.1365-2990.2010.01140.x; Guan HY, 2012, INT J CANCER, V130, P593, DOI 10.1002/ijc.26049; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hara-Chikuma M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8454; Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Chimal-Ramirez GK, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6031486; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Kumar D, 2009, J IMMUNOL, V182, P1011, DOI 10.4049/jimmunol.182.2.1011; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X; Lin KY, 2007, CANCER RES, V67, P1832, DOI 10.1158/0008-5472.CAN-06-3014; Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo JY, 2015, MOL BIOL CELL, V26, P430, DOI 10.1091/mbc.E14-10-1443; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2007, NATURE, V448, P547, DOI 10.1038/448547a; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Maruno M, 1997, J CLIN PATHOL, V50, P559, DOI 10.1136/jcp.50.7.559; MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099; MUNN DH, 1990, J EXP MED, V172, P231, DOI 10.1084/jem.172.1.231; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Parney IF, 2009, J NEUROSURG, V110, P572, DOI 10.3171/2008.7.JNS08475; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruano Y, 2009, AM J CLIN PATHOL, V131, P257, DOI 10.1309/AJCP64YBDVCTIRWV; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seznec J, 2011, J NEURO-ONCOL, V101, P365, DOI 10.1007/s11060-010-0266-x; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Shinojima N, 2003, CANCER RES, V63, P6962; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Sun XH, 2012, J CLIN INVEST, V122, P1973, DOI 10.1172/JCI61495; Sun YC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-611; Talasila KM, 2013, ACTA NEUROPATHOL, V125, P683, DOI 10.1007/s00401-013-1101-1; Tran CT, 1998, NEUROPATH APPL NEURO, V24, P293, DOI 10.1046/j.1365-2990.1998.00120.x; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vicart A, 2006, J MOL BIOL, V364, P897, DOI 10.1016/j.jmb.2006.09.036; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Wu TC, 2007, CANCER RES, V67, P6003, DOI 10.1158/0008-5472.CAN-07-1543; Yeh WL, 2012, J CELL PHYSIOL, V227, P558, DOI 10.1002/jcp.22746; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zahonero C, 2014, CELL MOL LIFE SCI, V71, P3465, DOI 10.1007/s00018-014-1608-1; Zhan Q, 2011, BRAZ J MED BIOL RES, V44, P489, DOI 10.1590/S0100-879X2011007500052; Zhang LY, 2007, J NEUROIMMUNOL, V184, P188, DOI 10.1016/j.jneuroim.2006.12.006; Zheng QF, 2014, NEURO-ONCOLOGY, V16, P1229, DOI 10.1093/neuonc/nou046; Zheng YH, 2013, J BIOL CHEM, V288, P31488, DOI 10.1074/jbc.M113.499020; Zhi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109124; Zhi F, 2010, EUR J CANCER, V46, P1640, DOI 10.1016/j.ejca.2010.02.003; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	77	47	51	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5006	5022		10.1038/onc.2017.129	http://dx.doi.org/10.1038/onc.2017.129			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459461				2022-12-28	WOS:000408768800006
J	Hernandez-Perez, S; Cabrera, E; Salido, E; Lim, M; Reid, L; Lakhani, SR; Khanna, KK; Saunus, JM; Freire, R				Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Lim, M.; Reid, L.; Lakhani, S. R.; Khanna, K. K.; Saunus, J. M.; Freire, R.			DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer	ONCOGENE			English	Article							DNA-REPLICATION; DEUBIQUITINATING ENZYMES; SUMO DEUBIQUITINASE; STEM-CELLS; CDT1; P53; STABILIZATION; EXPRESSION; STABILITY; TRANSFORMATION	Correct control of DNA replication is crucial to maintain genomic stability in dividing cells. Inappropriate re-licensing of replicated origins is associated with chromosomal instability (CIN), a hallmark of cancer progression that at the same time provides potential opportunities for therapeutic intervention. Geminin is a critical inhibitor of the DNA replication licensing factor Cdt1. To properly achieve its functions, Geminin levels are tightly regulated through the cell cycle by ubiquitin-dependent proteasomal degradation, but the de-ubiquitinating enzymes ( DUBs) involved had not been identified. Here we report that DUB3 and USP7 control human Geminin. Overexpression of either DUB3 or USP7 increases Geminin levels through reduced ubiquitination. Conversely, depletion of DUB3 or USP7 reduces Geminin levels, and DUB3 knockdown increases re-replication events, analogous to the effect of Geminin depletion. In exploring potential clinical implications, we found that USP7 and Geminin are strongly correlated in a cohort of invasive breast cancers (P < 1.01E - 08). As expected, Geminin expression is highly prognostic. Interestingly, we found a non-monotonic relationship between USP7 and breast cancer-specific survival, with both very low or high levels of USP7 associated with poor outcome, independent of estrogen receptor status. Altogether, our data identify DUB3 and USP7 as factors that regulate DNA replication by controlling Geminin protein stability, and suggest that USP7 may be involved in Geminin dysregulation during breast cancer progression.	[Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna 38320, Tenerife, Spain; [Lim, M.; Reid, L.; Lakhani, S. R.; Saunus, J. M.] Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia; [Lim, M.; Reid, L.; Saunus, J. M.] QIMR Berghofer Med Res Inst, Herston, Qld, Australia; [Lakhani, S. R.] Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia; [Lakhani, S. R.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Khanna, K. K.] QIMR Berghofer Inst Med Res, Signal Transduct Lab, Brisbane, Qld, Australia	Universidad de la Laguna; University of Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; QIMR Berghofer Medical Research Institute	Freire, R (corresponding author), Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna 38320, Tenerife, Spain.; Saunus, JM (corresponding author), Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia.	j.saunus@uq.edu.au; rfreire@ull.edu.es	Cabrera, Elisa/GPX-3455-2022; Freire, Raimundo/Q-7660-2019; Saunus, Jodi M/C-6657-2011; Lakhani, Sunil R/I-1970-2018; Saunus, Jodi/AAE-5291-2020; Salido, Eduardo/I-2232-2015	Freire, Raimundo/0000-0003-4473-8894; Saunus, Jodi M/0000-0002-4604-4709; Lakhani, Sunil R/0000-0003-4067-2760; Saunus, Jodi/0000-0002-4604-4709; Salido, Eduardo/0000-0001-9599-9854; Khanna, Kum Kum/0000-0001-8650-5381; Lim, Malcolm/0000-0003-3691-4368	Instituto de Salud Carlos III [BA15/00092]; Spanish Ministry of Economy and Competitiveness [SAF2013-49149-R, BFU2014-51672-REDC]; Fundacion CajaCanarias [AP2015/008]; Australian National Health and Medical Research (NHMRC program grant) [APP1017028]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Fundacion CajaCanarias; Australian National Health and Medical Research (NHMRC program grant)(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to V Smits for critical reading of the manuscript, J Moreira, E Lam, M van Vugt for sending cell lines and A Bravo for logistic help. This work was supported by grants from Instituto de Salud Carlos III (BA15/00092), the Spanish Ministry of Economy and Competitiveness (SAF2013-49149-R, BFU2014-51672-REDC), Fundacion CajaCanarias (AP2015/008) to RF and the Australian National Health and Medical Research (NHMRC program grant to SRL and KKK (APP1017028)).	Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.41; Alonso-de Vega I, 2014, CELL CYCLE, V13, P3921, DOI 10.4161/15384101.2014.973324; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; Cabrera E, 2017, ONCOGENE, V36, P678, DOI 10.1038/onc.2016.239; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Duncker BP, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-214; Epping MT, 2011, NAT CELL BIOL, V13, P102, DOI 10.1038/ncb2142; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Field S, 2016, INT J CANCER, V138, P1959, DOI 10.1002/ijc.29946; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Gonzalez MA, 2004, J PATHOL, V204, P121, DOI 10.1002/path.1625; Hernandez-Perez S, 2016, MOL ONCOL, V10, P1196, DOI 10.1016/j.molonc.2016.05.008; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Jagannathan M, 2014, MOL CELL BIOL, V34, P132, DOI 10.1128/MCB.00639-13; Perez-Castro AJ, 2012, J CELL SCI, V125, P1152, DOI 10.1242/jcs.091124; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Junankar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7548; Kessler BM, 2014, EXPERT OPIN THER PAT, V24, P597, DOI 10.1517/13543776.2014.882320; Lecona E, 2016, NAT STRUCT MOL BIOL, V23, P270, DOI 10.1038/nsmb.3185; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Maire V, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063712, 10.1371/journal.pone.0077372]; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nicholson B, 2011, CELL BIOCHEM BIOPHYS, V60, P61, DOI 10.1007/s12013-011-9185-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Petropoulou C, 2008, FRONT BIOSCI, V13, P4485, DOI 10.2741/3018; Qian J, 2015, ONCOGENE, V34, P4791, DOI 10.1038/onc.2014.394; Rajan SS, 2014, BREAST CANCER RES TR, V143, P91, DOI 10.1007/s10549-013-2786-5; Refolio E, 2011, J CELL SCI, V124, P2488, DOI 10.1242/jcs.081711; Rialland M, 2002, J CELL SCI, V115, P1435; Rivlin N, 2014, P NATL ACAD SCI USA, V111, P7006, DOI 10.1073/pnas.1320428111; Delgado-Diaz MR, 2014, MOL ONCOL, V8, P884, DOI 10.1016/j.molonc.2014.03.003; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Smits VAJ, 2016, BIOESSAYS, V38, P863, DOI 10.1002/bies.201600096; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Srihari S, 2015, BIOL DIRECT, V10, DOI 10.1186/s13062-015-0086-1; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Yagi T, 2016, BREAST CANCER-TOKYO, V23, P224, DOI 10.1007/s12282-014-0556-9; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004; Zlatanou A, 2016, ONCOGENE, V35, P965, DOI 10.1038/onc.2015.149	51	11	11	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4802	4809		10.1038/onc.2017.21	http://dx.doi.org/10.1038/onc.2017.21			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28288134				2022-12-28	WOS:000407702400012
J	Bado, I; Gugala, Z; Fuqua, SAW; Zhang, XHF				Bado, I.; Gugala, Z.; Fuqua, S. A. W.; Zhang, X. H-F			Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis	ONCOGENE			English	Review							CALCIUM-SENSING RECEPTOR; CANCER RISK; POSTMENOPAUSAL WOMEN; ESR1 MUTATIONS; MAMMARY-GLAND; VITAMIN-D; ER-ALPHA; OSTEOCLAST DIFFERENTIATION; OSTEOPONTIN EXPRESSION; MESENCHYMAL TRANSITION	Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer-bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.	[Bado, I.; Fuqua, S. A. W.; Zhang, X. H-F] Baylor Coll Med, Lester & Sue Smith Breast Ctr, BCM600,One Baylor Plaza, Houston, TX 77030 USA; [Bado, I.; Fuqua, S. A. W.; Zhang, X. H-F] Dan L Duncan Canc Ctr, Houston, TX USA; [Bado, I.; Zhang, X. H-F] Dept Mol & Cellular Biol, Houston, TX USA; [Gugala, Z.] Univ Texas Med Branch, Dept Orthopaed Surg & Rehabil, Galveston, TX 77555 USA; [Zhang, X. H-F] Baylor Coll Med, McNair Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Zhang, XHF (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, BCM600,One Baylor Plaza, Houston, TX 77030 USA.	xiangz@bcm.edu	Bado, Igor/AAY-1214-2021; Gugala, Zbigniew/Q-4075-2019	Bado, Igor/0000-0001-8855-4750; Gugala, Zbigniew/0000-0003-2331-7660	NCI NIH HHS [R01 CA183878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA183878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464; Akinyemiju TF, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1282-2; Aktipis C. Athena, 2015, Evolution Medicine and Public Health, P52, DOI 10.1093/emph/eou028; Alluri PG, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0494-7; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Amend K, 2006, CANCER RES, V66, P8327, DOI 10.1158/0008-5472.CAN-06-1927; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Bado I, 2016, ONCOTARGET, V7, P13599, DOI 10.18632/oncotarget.7300; Barone I, 2010, CLIN CANCER RES, V16, P2702, DOI 10.1158/1078-0432.CCR-09-1753; Batra GS, 2003, J PATHOL, V200, P65, DOI 10.1002/path.1332; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756-3282(02)00953-5; Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309; Bouris P, 2015, MATRIX BIOL, V43, P42, DOI 10.1016/j.matbio.2015.02.008; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214; Buga S, 2012, CANCER CONTROL, V19, P154, DOI 10.1177/107327481201900210; Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585-007-9127-1; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Carneiro RM, 2010, J CLIN ENDOCR METAB, V95, P1767, DOI 10.1210/jc.2009-1518; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chan KM, 2012, DEV CELL, V22, P1176, DOI 10.1016/j.devcel.2012.04.014; Chen WY, 2004, CANCER, V101, P1490, DOI 10.1002/cncr.20499; Chlebowski RT, 2007, JNCI-J NATL CANCER I, V99, P1695, DOI 10.1093/jnci/djm224; Chu D, 2016, CLIN CANCER RES, V22, P993, DOI 10.1158/1078-0432.CCR-15-0943; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44; Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388; Deroo BJ, 2014, NATURE, V116, P561, DOI DOI 10.1172/JCI27987.SELECTIVE; Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078-0432.CCR-10-2507; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Faupel-Badger JM, 2013, JNCI-J NATL CANCER I, V105, P166, DOI 10.1093/jnci/djs505; Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Fontanella C, 2015, CLIN EXP METASTAS, V32, P819, DOI 10.1007/s10585-015-9743-0; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Friebel TM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju091; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; FUNK JL, 1995, CLIN ENDOCRINOL, V43, P373, DOI 10.1111/j.1365-2265.1995.tb02046.x; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4; Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017; Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gu GW, 2016, CLIN CANCER RES, V22, P1034, DOI 10.1158/1078-0432.CCR-15-2549; Guttilla IK, 2012, TRENDS ENDOCRIN MET, V23, P73, DOI 10.1016/j.tem.2011.12.001; Holen I, 2016, CLIN EXP METASTAS, V33, P211, DOI 10.1007/s10585-015-9770-x; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Hwang ES, 2005, ARCH SURG-CHICAGO, V140, P58, DOI 10.1001/archsurg.140.1.58; Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124; Imai Y, 2013, PHYSIOL REV, V93, P481, DOI 10.1152/physrev.00008.2012; Imamura T, 2006, ANIM SCI J, V77, P223, DOI 10.1111/j.1740-0929.2006.00341.x; Islami F, 2015, ANN ONCOL, V26, P2398, DOI 10.1093/annonc/mdv379; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Johnson RW, 2016, NAT CELL BIOL, V18, P1260, DOI 10.1038/ncb3433; Joseph JD, 2016, ELIFE, V5, DOI 10.7554/eLife.15828; Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012; Kagiya T, 2015, J CLIN MED, V4, P1741, DOI 10.3390/jcm4091741; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karsenty G, 2000, NAT MED, V6, P970, DOI 10.1038/79655; Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308; Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215; Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kobayashi S, 2012, BREAST CANCER-TOKYO, V19, P302, DOI 10.1007/s12282-012-0384-8; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832; LAVECCHIA C, 1993, INT J CANCER, V53, P215, DOI 10.1002/ijc.2910530207; Lee SJ, 2011, CANCER RES TREAT, V43, P89, DOI 10.4143/crt.2011.43.2.89; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002; Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254; Lopes N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3178; Lorenz-Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Maimoun L, 2011, METABOLISM, V60, P373, DOI 10.1016/j.metabol.2010.03.001; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; MCNEILLY AS, 1994, ANN NY ACAD SCI, V709, P145, DOI 10.1111/j.1749-6632.1994.tb30394.x; Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082; Mock K, 2015, ONCOTARGET, V6, P14399, DOI 10.18632/oncotarget.3882; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025; Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452; Nampei A, 2004, J BONE MINER METAB, V22, P176, DOI 10.1007/s00774-003-0468-9; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121; Oesterreich S, 2015, BREAST CANCER RES TR, V154, P263, DOI 10.1007/s10549-015-3608-8; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10; Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078-0432.CCR-13-1246; Pan H, 2014, CANCER EPIDEMIOL, V38, P1, DOI 10.1016/j.canep.2013.11.004; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Press DJ, 2010, EPIDEMIOLOGY, V21, P566, DOI 10.1097/EDE.0b013e3181e08eb3; Price TT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4059; Prideaux M, 2015, GENE EXPR PATTERNS, V18, P29, DOI 10.1016/j.gep.2015.04.004; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Reed Mary L, 2013, Front Endocrinol (Lausanne), V4, P64, DOI 10.3389/fendo.2013.00064; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; RUBIN CT, 1984, CALCIFIED TISSUE INT, V36, pS11, DOI 10.1007/BF02406128; Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357; Saxon LK, 2012, ENDOCRINOLOGY, V153, P2254, DOI 10.1210/en.2011-1977; Sethi S, 2011, AM J TRANSL RES, V3, P90; Setiawan VW, 2009, AM J EPIDEMIOL, V169, P1251, DOI 10.1093/aje/kwp036; Shenoy PA, 2016, FRONT PHARMACOL, V7, P1; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756-3282(01)00643-3; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; Stark A, 2010, CANCER-AM CANCER SOC, V116, P4926, DOI 10.1002/cncr.25276; Stead LA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2242; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suzuki R, 2006, INT J CANCER, V119, P1683, DOI 10.1002/ijc.22034; Svejme O, 2014, SCAND J MED SCI SPOR, V24, P159, DOI 10.1111/j.1600-0838.2012.01504.x; Svoronos N, 2016, CANCER DISCOV, V7, P1; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita T, 2016, ONCOTARGET, V7, P32504, DOI 10.18632/oncotarget.8839; Tan VPS, 2014, J BONE MINER RES, V29, P2161, DOI 10.1002/jbmr.2254; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P467, DOI 10.1016/j.tem.2015.06.007; Tverberg LA, 2000, ENDOCRINOLOGY, V141, P3696, DOI 10.1210/en.141.10.3696; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Ursini-Siegel J, 2016, CANCER LETT, V380, P281, DOI 10.1016/j.canlet.2015.11.009; Vanhouten JN, 2003, ENDOCRINOLOGY, V144, P5521, DOI 10.1210/en.2003-0892; VanHouten JN, 2013, BEST PRACT RES CL EN, V27, P403, DOI 10.1016/j.beem.2013.02.011; Vidal O, 1999, BIOCHEM BIOPH RES CO, V265, P569, DOI 10.1006/bbrc.1999.1711; Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Walker VR, 2004, ILAR J, V45, P455, DOI 10.1093/ilar.45.4.455; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Wang XJ, 2004, BREAST CANCER RES TR, V83, P109, DOI 10.1023/B:BREA.0000010703.59483.c0; Wardell SE, 2013, CLIN CANCER RES, V19, P2420, DOI 10.1158/1078-0432.CCR-12-3771; Weidle UH, 2016, CANCER GENOM PROTEOM, V13, P1; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Welboren WJ, 2007, MOL ONCOL, V1, P138, DOI 10.1016/j.molonc.2007.04.001; Welsh J, 2007, J BONE MINER RES, V22, pV86, DOI 10.1359/JBMR.07S204; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730; Windahl SH, 2001, J BONE MINER RES, V16, P1388, DOI 10.1359/jbmr.2001.16.8.1388; Wittrant Y, 2004, BBA-REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002; Wu SG, 2016, ONCOTARGET, V7, P47975, DOI 10.18632/oncotarget.10099; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Wysolmerski JJ, 2010, ANN NY ACAD SCI, V1192, P161, DOI 10.1111/j.1749-6632.2009.05249.x; Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yeung C, 2016, CANCER METAST REV, V35, P427, DOI 10.1007/s10555-016-9631-3; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou H, 2013, BONE RES, V1, DOI 10.4248/BR201302001; Zinser GM, 2004, MOL ENDOCRINOL, V18, P2208, DOI 10.1210/me.2003-0469; 2002, LANCET LONDON ENGLAN, V360, P187	184	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4527	4537		10.1038/onc.2017.94	http://dx.doi.org/10.1038/onc.2017.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368409	Bronze, Green Accepted			2022-12-28	WOS:000407246200001
J	Ohm, AM; Tan, AC; Heasley, LE; Reyland, ME				Ohm, A. M.; Tan, A-C; Heasley, L. E.; Reyland, M. E.			Co-dependency of PKC delta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; TUMOR-SUPPRESSOR; NUCLEAR IMPORT; SALIVARY-GLAND; BREAST-CANCER; DNA-DAMAGE; CELLS; APOPTOSIS; MUTATIONS; MIGRATION	Recent studies suggest that the presence of a KRAS mutation may be insufficient for defining a clinically homogenous molecular group, as many KRAS mutant tumors lose reliance on K-Ras for survival. Identifying pathways that support K-Ras dependency may define clinically relevant KRAS subgroups and lead to the identification of new drug targets. We have analyzed a panel of 17 KRAS mutant lung cancer cell lines classified as K-Ras-dependent or -independent for co-dependency on protein kinase C delta (PKC delta). We show that functional dependency on K-Ras and PKC delta co-segregate, and that dependency correlates with a more epithelial-like phenotype. Furthermore, we show that the pro-apoptotic and pro-tumorigenic functions of PKC delta also segregate based on K-Ras dependency, as K-Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKC delta in this subgroup suppresses apoptosis through increased activation of extracellular signal-regulated kinase (ERK). In contrast, K-Ras-dependent lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKC delta can increase apoptosis and decrease activation of ERK in this subgroup. We have previously shown that nuclear translocation of PKC delta is necessary and sufficient for proapoptotic signaling. Our current studies show that K-Ras-dependent cells are refractive to PKC delta-driven apoptosis. Analysis of this subgroup showed increased PKC delta expression and an increase in the nuclear: cytoplasmic ratio of PKC delta. In addition, targeting PKCd to the nucleus induces apoptosis in K-Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells. Our studies provide tools for identification of the subset of patients with KRAS mutant tumors most amenable to targeting of the K-Ras pathway, and identify PKC delta as a potential target in this tumor population. These subgroups are likely to be of clinical relevance, as high PKC delta expression correlates with increased overall survival and a more epithelial tumor phenotype in patients with KRAS mutant lung adenocarcinomas.	[Ohm, A. M.; Heasley, L. E.; Reyland, M. E.] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,MS 8120,POB 6511, Aurora, CO 80045 USA; [Tan, A-C] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,MS 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@UCDenver.edu	Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369	United Against Lung Cancer research award; NIH Lung SPORE [P50 CA58187, R01DE015648]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	United Against Lung Cancer research award; NIH Lung SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We gratefully acknowledge the intellectual contributions of Dr Ross Camidge. This work was supported by a United Against Lung Cancer research award, a pilot grant from NIH Lung SPORE Grant P50 CA58187 and R01DE015648 to MER.	Adwan TS, 2011, J BIOL CHEM, V286, P35716, DOI 10.1074/jbc.M111.255950; Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59; Allen-Petersen BL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.20; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bailey TA, 2014, J BIOL CHEM, V289, P30443, DOI 10.1074/jbc.M114.608992; Beau-Faller M, 2009, BRIT J CANCER, V100, P985, DOI 10.1038/sj.bjc.6604925; Cai QS, 2009, J BIOL CHEM, V284, P2150, DOI 10.1074/jbc.M803235200; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; D'Costa AM, 2006, ONCOGENE, V25, P378, DOI 10.1038/sj.onc.1209065; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Hu CT, 2013, CELL SIGNAL, V25, P1457, DOI 10.1016/j.cellsig.2013.03.011; Humphries MJ, 2008, ONCOGENE, V27, P3045, DOI 10.1038/sj.onc.1210967; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Koo KH, 2015, ONCOTARGET, V6, P21328, DOI 10.18632/oncotarget.4049; Lagory EL, 2010, J BIOL CHEM, V285, P1879, DOI 10.1074/jbc.M109.055392; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Mogi A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/583929; Nguyen HM, 2012, J NEUROSCI, V32, P3474, DOI 10.1523/JNEUROSCI.4167-11.2012; Osaki S, 2000, CANCER GENE THER, V7, P300, DOI 10.1038/sj.cgt.7700096; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Park M, 2013, CLIN CANCER RES, V19, P4961, DOI 10.1158/1078-0432.CCR-13-0131; Paugh BS, 2008, FASEB J, V22, P455, DOI 10.1096/fj.07-8276com; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Reno EM, 2008, HUM PATHOL, V39, P21, DOI 10.1016/j.humpath.2007.05.023; Reyland ME, 2016, PHARMACOL THERAPEUT, V165, P1, DOI 10.1016/j.pharmthera.2016.05.001; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Symonds JM, 2016, ONCOTARGET, V7, P17905, DOI 10.18632/oncotarget.7560; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wie SM, 2014, J BIOL CHEM, V289, P10900, DOI 10.1074/jbc.M114.551366; Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Xia SH, 2009, CELL SIGNAL, V21, P502, DOI 10.1016/j.cellsig.2008.12.002; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Zhu T, 2010, ONCOGENE, V29, P1050, DOI 10.1038/onc.2009.344	49	10	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4370	4378		10.1038/onc.2017.27	http://dx.doi.org/10.1038/onc.2017.27			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368426	Green Accepted			2022-12-28	WOS:000406360600013
J	Zhang, HR; Wang, XD; Yang, X; Chen, D; Hao, J; Cao, R; Wu, XZ				Zhang, H-R; Wang, X-D; Yang, X.; Chen, D.; Hao, J.; Cao, R.; Wu, X-Z			An FGFR inhibitor converts the tumor promoting effect of TGF-beta by the induction of fibroblast-associated genes of hepatoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; CANCER; PROGRESSION; EXPRESSION; ACTIVATION; AZD4547	Tumors consistently mimic wound-generating chronic inflammation; however, why they do not heal like wounds with fibrotic scars remains unknown. The components of the tumor microenvironment, such as transforming growth factor beta (TGF-beta) and fibroblast growth factors (FGFs), may account for this phenomenon. Tumor formation involves continuous activation of the FGF pathway, whereas the repair of tissue injury is a self-limiting process accompanied with controlled activation of the FGF pathway. In the tumor microenvironment TGF-beta increases the secretion of FGFs, further promoting the malignant biological properties of tumors. However, during wound healing, sufficient TGF-beta together with moderate FGFs lead to matrix deposition and the formation of fibrotic scars. In the present study, TGF-beta 1 combined with AZD4547, an FGF receptor (FGFR) inhibitor, transformed hepatoma cells into less malignant fibroblast-like cells with respect to morphology, physiological properties, and gene expression profiles. In vivo experiments showed that TGF-beta 1 combined with AZD4547 not only inhibited tumor growth but also promoted tumor parenchyma fibrosis. Our results indicate that FGFR inhibitor treatment converts the effect of TGF-beta on the hepatocellular carcinoma cells from tumor promotion into tumor inhibition by enhancing the induction effect of TGF-beta on some fibroblast-associated genes. Converting human liver cancer cells into less malignant fibroblast-like cells and inducing tumor parenchyma cell fibrosis provides an alternative strategy for limiting tumor progression.	[Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Wang, X-D] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [Chen, D.] Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Wu, XZ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Zhong Shan Men Inpatient Dept, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.	wuxiongzhi@163.com	Wu, Xiong-Zhi/P-4045-2019		National Natural Science Foundation of China [81473441]; Program for New Century Excellent Talents in University [NCET-11-1068]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by the National Natural Science Foundation of China (81473441) and the Program for New Century Excellent Talents in University (NO. NCET-11-1068).	Abolhassani A, 2014, J CANCER, V5, P537, DOI 10.7150/jca.7797; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Dooley S, 2012, CELL TISSUE RES, V347, P245, DOI 10.1007/s00441-011-1246-y; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Gaarenstroom T, 2014, SEMIN CELL DEV BIOL, V32, P107, DOI 10.1016/j.semcdb.2014.01.009; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Gupta EK, 2014, CANCER GROWTH METAST, V7, P1, DOI 10.4137/CGM.S14205; Islam SS, 2014, J CELL COMMUN SIGNAL, V8, P39, DOI 10.1007/s12079-013-0216-4; Jia LZ, 2012, CANCER LETT, V326, P176, DOI 10.1016/j.canlet.2012.08.004; Jiang WN, 2010, INT J MOL MED, V26, P571, DOI 10.3892/ijmm_00000501; Kajdaniuk D, 2013, ENDOKRYNOL POL, V64, P384, DOI 10.5603/EP.2013.0022; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Krisanaprakornkit S, 2013, ARCH ORAL BIOL, V58, P82, DOI 10.1016/j.archoralbio.2012.06.011; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sandhu DS, 2014, HEPATOLOGY, V59, P1166, DOI 10.1002/hep.26679; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Schulte J, 2012, HISTOCHEM CELL BIOL, V138, P847, DOI 10.1007/s00418-012-0998-0; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Seol Ho Jun, 2012, Genes Cancer, V3, P535, DOI 10.1177/1947601912473603; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Spyrou GE, 2002, BRIT J PLAST SURG, V55, P275, DOI 10.1054/bjps.2002.3831; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Vasdev Nandini, 2003, Indian J Pathol Microbiol, V46, P625	30	6	6	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3831	3841		10.1038/onc.2016.512	http://dx.doi.org/10.1038/onc.2016.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263980				2022-12-28	WOS:000404848200004
J	Qi, M; Jiao, M; Li, X; Hu, J; Wang, L; Zou, Y; Zhao, M; Zhang, R; Liu, H; Mi, J; Zhang, L; Liu, L; Gong, Y; Han, B				Qi, M.; Jiao, M.; Li, X.; Hu, J.; Wang, L.; Zou, Y.; Zhao, M.; Zhang, R.; Liu, H.; Mi, J.; Zhang, L.; Liu, L.; Gong, Y.; Han, B.			CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PROSTATE-CANCER; TUMORIGENESIS; PROGRESSION; CARCINOMA; MICRORNAS; PATHWAY	Cullin 4B (CUL4B) is a scaffold protein overexpressed in several solid malignancies. It is known to silence tumor suppressor through post-transcriptional manner. However, its clinical significance and underlying molecular mechanisms in gastric cancer (GC) remain largely unknown. In this study, we found that CUL4B was significantly overexpressed in GC tissues and its overexpression was correlated with lymph node metastasis and poor prognosis. Through gain-and loss-of-function experiments, we showed that CUL4B promotes GC cell invasion and epithelial-mesenchymal transition (EMT) in vitro, as well as tumor growth and metastasis in vivo. Mechanistically, we identified HER2 as a downstream target gene of CUL4B in GC. CUL4B unregulated HER2 expression via transcriptionally repressing miR-125a. Intriguingly, HER2 inhibitors significantly reversed CUL4B-induced EMT in vitro and partially blocked GC metastasis in tumor xenografts with CUL4B overexpression. Finally, we suggested the involvement of the PI3K/AKT pathway in CUL4B-induced HER2 upregulation in GC. In all, we proposed a model for a CUL4B-miR-125a-HER2 oncoprotein axis, which provided novel insight into how HER2 was activated and contributed to GC progression and metastasis.	[Qi, M.; Jiao, M.; Li, X.; Hu, J.; Zou, Y.; Zhao, M.; Zhang, R.; Liu, H.; Mi, J.; Zhang, L.; Gong, Y.; Han, B.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China; [Qi, M.; Jiao, M.; Li, X.; Hu, J.; Zhao, M.; Zhang, R.; Liu, H.; Zhang, L.; Han, B.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Qi, M.; Liu, L.; Han, B.] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan, Shandong, Peoples R China; [Li, X.] Binzhou Peoples Hosp, Dept Pathol, Binzhou, Peoples R China; [Wang, L.] Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan, Shandong, Peoples R China; [Zou, Y.; Mi, J.; Gong, Y.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China; [Zou, Y.; Mi, J.; Gong, Y.] Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan 250012, Shandong, Peoples R China; [Zhao, M.] Binzhou Med Coll, Affiliated Hosp, Dept Pathol, Binzhou, Peoples R China; [Zhang, R.] Xintai Tradit Chinese Med Hosp, Dept Pathol, Tai An, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Shandong University; Binzhou Medical University	Han, B (corresponding author), Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, QiLu Med Coll, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China.	boh@sdu.edu.cn			National Natural Science Foundation of China [81672554, 81472417, 31371369, 31671427]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Baichun Jiang for technical assistance. This work was supported by National Natural Science Foundation of China (Grants No. 81672554 and 81472417 to BH, 31371369 and 31671427 to YZ).	Bang YJ, 2010, LANCET, V376, P1302; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0534-7; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Lee J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00021; Lin CH, 2016, ONCOTARGET, V7, P39680, DOI 10.18632/oncotarget.9444; Liu HT, 2016, TUMOR BIOL, V37, P15383, DOI 10.1007/s13277-016-5436-9; Liu HT, 2015, ONCOTARGET, V6, P37467, DOI 10.18632/oncotarget.6059; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Mirzaei H, 2016, CURR MED CHEM, V23, P4135, DOI 10.2174/0929867323666160818093854; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084959; Shan YQ, 2015, CANCER GENE THER, V22, P101, DOI 10.1038/cgt.2014.61; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Sukawa Y, 2014, DIGESTION, V89, P12, DOI 10.1159/000356201; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang CN, 2014, PROSTATE, V74, P689, DOI 10.1002/pros.22787; Wang L, 2015, ONCOTARGET, V6, P35978, DOI 10.18632/oncotarget.5427; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhang C.J., 2016, BIOENERG OPEN ACCESS, V5, P1; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	33	31	34	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1075	1085		10.1038/onc.2017.380	http://dx.doi.org/10.1038/onc.2017.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106389				2022-12-28	WOS:000425905700010
J	D'Abundo, L; Callegari, E; Bresin, A; Chillemi, A; Elamin, BK; Guerriero, P; Huang, X; Saccenti, E; Hussein, EMAA; Casciano, F; Secchiero, P; Zauli, G; Calin, GA; Russo, G; Lee, LJ; Croce, CM; Marcucci, G; Sabbioni, S; Malavasi, F; Negrini, M				D'Abundo, L.; Callegari, E.; Bresin, A.; Chillemi, A.; Elamin, B. K.; Guerriero, P.; Huang, X.; Saccenti, E.; Hussein, E. M. A. A.; Casciano, F.; Secchiero, P.; Zauli, G.; Calin, G. A.; Russo, G.; Lee, L. J.; Croce, C. M.; Marcucci, G.; Sabbioni, S.; Malavasi, F.; Negrini, M.			Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model	ONCOGENE			English	Article							INHIBITS CELL-PROLIFERATION; IN-VIVO; MONOCLONAL-ANTIBODIES; CD38 EXPRESSION; CANCER; DELIVERY; PATHOGENESIS; MIR-130A; SURVIVAL; DISEASE	Dysregulation of microRNAs (miRNAs) plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). The E mu-TCL1 transgenic mouse develops a form of leukemia that is similar to the aggressive type of human B-CLL, and this valuable model has been widely used for testing novel therapeutic approaches. Here, we adopted this model to investigate the potential effects of miR-26a, miR-130an and antimiR-155 in CLL therapy. Improved delivery of miRNA molecules into CLL cells was obtained by developing a novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclonal antibody. This methodology has proven to be highly effective in delivering miRNA molecules into leukemic cells. Short-and long-term experiments showed that miR-26a, miR-130a and anti-miR-155 increased apoptosis after in vitro and in vivo treatment. Of this miRNA panel, miR-26a was the most effective in reducing leukemic cell expansion. Following long-term treatment, apoptosis was readily detectable by analyzing cleavage of PARP and caspase-7. These effects could be directly attributed to miR-26a, as confirmed by significant downregulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1. The results of this study are relevant to two distinct areas. The first is related to the design of a technical strategy and to the selection of CD38 as a molecular target on CLL cells, both consenting efficient and specific intracellular transfer of miRNA. The original scientific finding inferred from the above approach is that miR-26a can elicit in vivo anti-leukemic activities mediated by increased apoptosis.	[D'Abundo, L.; Callegari, E.; Bresin, A.; Guerriero, P.; Hussein, E. M. A. A.; Negrini, M.] Univ Ferrara, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy; [Bresin, A.; Russo, G.] IRCCS, IDI, Lab Oncol Mol, Rome, Italy; [Chillemi, A.; Malavasi, F.] Univ Turin, Dept Med Sci, Lab Immunogenet, Turin, Italy; [Chillemi, A.; Malavasi, F.] Lab Immunol Trapianti Citta Salute & Sci, Turin, Italy; [Elamin, B. K.] Univ Khartoum, Fac Med Lab Sci, Microbiol Dept, Khartoum, Sudan; [Elamin, B. K.] Univ Bisha, Coll Med, Microbiol Dept, Bisha, Saudi Arabia; [Huang, X.; Lee, L. J.] Ohio State Univ, Nanoscale Sci & Engn Ctr Affordable Nanoengn Poly, Columbus, OH 43210 USA; [Huang, X.; Lee, L. J.] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA; [Huang, X.; Croce, C. M.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Saccenti, E.] Univ Ferrara, Univ Hosp Arcispedale S Anna, Dept Med Sci, Hematol Sect, Ferrara, Italy; [Hussein, E. M. A. A.] Univ Khartoum, Fac Med Lab Sci, Hematol & Immunohematol Dept, Khartoum, Sudan; [Casciano, F.; Secchiero, P.; Zauli, G.] Univ Ferrara, Surg Expt Med & LTTA Ctr, Dept Morphol, Ferrara, Italy; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med, Houston, TX 77030 USA; [Marcucci, G.] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res Hematol Malignancies, Duarte, CA USA; [Sabbioni, S.] Univ Ferrara, Dept Life Sci & Biotechnol, Ferrara, Italy	University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Khartoum; University of Bisha; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Ferrara; Arcispedale Sant'Anna; University of Khartoum; University of Ferrara; University of Texas System; UTMD Anderson Cancer Center; City of Hope; University of Ferrara	D'Abundo, L; Negrini, M (corresponding author), Univ Ferrara, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	dbnlll@unife.it; ngm@unife.it	Zauli, Giorgio/ABE-8001-2020; Casciano, Fabio FC/H-3219-2015; bresin, antonella/AAG-7189-2020; D'ABUNDO, LUCILLA/AAB-9816-2019; Callegari, Elisa/Q-6135-2019; Calin, George/E-9390-2011; Negrini, Matteo/C-8906-2014; Young, Richard A/F-6495-2012; Russo, Giandomenico/K-9566-2016; NEGRINI, Massimo/J-2377-2016	Casciano, Fabio FC/0000-0002-6431-3335; Callegari, Elisa/0000-0002-4969-5400; Negrini, Matteo/0000-0003-0101-6963; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; D'Abundo, Lucilla/0000-0003-4196-0203; Elamin, Bahaeldin K./0000-0002-1136-4980; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615; BRESIN, antonella/0000-0003-3954-5481; NEGRINI, Massimo/0000-0002-0007-1920; GUERRIERO, Paola/0000-0003-3724-7472	Italian Association for Cancer Research (AIRC) [9980]; University of Ferrara; US National Cancer Institute [CA19-7706]; FIRB Programme of the Ministry of University and Research (Rome, Italy); Fondazione Cassa di Risparmio di Torino; Fondazione Ricerca Molinette Torino	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); University of Ferrara; US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIRB Programme of the Ministry of University and Research (Rome, Italy); Fondazione Cassa di Risparmio di Torino(Fondazione CRT); Fondazione Ricerca Molinette Torino	This work was supported by funds from the Italian Association for Cancer Research (AIRC Special program 5xmille n.9980) and the University of Ferrara to MN, from the US National Cancer Institute grant CA19-7706 to CMC, from FIRB Programme of the Ministry of University and Research (Rome, Italy), Fondazione Cassa di Risparmio di Torino and Fondazione Ricerca Molinette Torino to FM.	Acunzo M, 2012, ONCOGENE, V31, P634, DOI 10.1038/onc.2011.260; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Bende RJ, 2003, AM J PATHOL, V162, P105, DOI 10.1016/S0002-9440(10)63802-3; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Bresin A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.419; Bresin A, 2015, ONCOTARGET, V6, P19807, DOI 10.18632/oncotarget.4415; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2007, BEST PRACT RES CL HA, V20, P425, DOI 10.1016/j.beha.2007.02.003; Callegari E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073964; Chen JS, 2016, ONCOL REP, V35, P3285, DOI 10.3892/or.2016.4719; Chen YC, 2015, ADV DRUG DELIVER REV, V81, P128, DOI 10.1016/j.addr.2014.05.009; Chillemi A, 2013, MOL MED, V19, P99, DOI 10.2119/molmed.2013.00009; Chiorazzi N, 2005, ANN NY ACAD SCI, V1062, P1, DOI 10.1196/annals.1358.002; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Colomo L, 2004, AM J SURG PATHOL, V28, P736, DOI 10.1097/01.pas.0000126781.87158.e3; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Cui B, 2014, BLOOD, V124, P546, DOI 10.1182/blood-2014-03-559690; Cuneo A, 2014, CANCER MED-US, V3, P555, DOI 10.1002/cam4.226; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Di Martino MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090005; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dorrance AM, 2015, LEUKEMIA, V29, P2143, DOI 10.1038/leu.2015.139; Efanov A, 2010, LEUKEMIA, V24, P970, DOI 10.1038/leu.2010.46; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fabbri M, 2011, JAMA-J AM MED ASSOC, V305, P59, DOI 10.1001/jama.2010.1919; Fujita Y, 2015, PROSTATE, V75, P1568, DOI 10.1002/pros.23031; Gao J, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/719179; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ghosh R, 2013, BIOMATERIALS, V34, P807, DOI 10.1016/j.biomaterials.2012.10.023; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Horenstein Alberto L., 2005, V308, P191; Huang XM, 2013, CLIN CANCER RES, V19, P2355, DOI 10.1158/1078-0432.CCR-12-3191; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Jia XQ, 2012, CELL BIOCHEM BIOPHYS, V62, P237, DOI 10.1007/s12013-011-9263-8; Jiang H, 2015, ONCOL REP, V34, P1153, DOI 10.3892/or.2015.4099; Johnson AJ, 2006, BLOOD, V108, P1334, DOI 10.1182/blood-2005-12-011213; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Lee SH, 2015, ONCOTARGET, V6, P33269, DOI 10.18632/oncotarget.5037; Li BK, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0230-2; Li YH, 2015, ONCOTARGET, V6, P1101, DOI 10.18632/oncotarget.2728; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055532; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Malavasi F, 2011, BLOOD, V118, P3470, DOI 10.1182/blood-2011-06-275610; Masotti A, 2016, NANOMED-NANOTECHNOL, V12, P1511, DOI 10.1016/j.nano.2016.02.017; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; Miotto E, 2014, CANCER EPIDEM BIOMAR, V23, P2638, DOI 10.1158/1055-9965.EPI-14-0503; Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450; Negrini M, 2014, CLIN CANCER RES, V20, P4141, DOI 10.1158/1078-0432.CCR-13-2497; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; Pan YQ, 2015, INT J CLIN EXP PATHO, V8, P384; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rossi S, 2010, BLOOD, V116, P945, DOI 10.1182/blood-2010-01-263889; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Scognamiglio I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/217365; Shen SY, 2015, CELL RES, V25, P997, DOI 10.1038/cr.2015.98; Simonetti G, 2014, BLOOD, V124, P1010, DOI 10.1182/blood-2014-05-577122; Taccioli C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv220; Tagawa H, 2013, CANCER SCI, V104, P801, DOI 10.1111/cas.12160; Vaisitti T, 2015, LEUKEMIA, V29, P356, DOI 10.1038/leu.2014.207; van de Donk NWCJ, 2016, BLOOD, V127, P681, DOI 10.1182/blood-2015-10-646810; Vargova K, 2011, BLOOD, V117, P3816, DOI 10.1182/blood-2010-05-285064; Visone R, 2011, BLOOD, V118, P3072, DOI 10.1182/blood-2011-01-333484; Visone R, 2009, BLOOD, V114, P3872, DOI 10.1182/blood-2009-06-229211; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yang X, 2013, HEPATOLOGY, V58, P158, DOI 10.1002/hep.26305; Zanesi Nicola, 2010, J Nucleic Acids Investig, V1, P36; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647; Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015; Zhu X, 2015, CANCER GENE THER, V22, P573, DOI 10.1038/cgt.2015.50; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278	88	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6617	6626		10.1038/onc.2017.269	http://dx.doi.org/10.1038/onc.2017.269			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783166	Green Submitted			2022-12-28	WOS:000416049200010
J	Lee, JH; Han, YS; Yoon, YM; Yun, CW; Yun, SP; Kim, SM; Kwon, HY; Jeong, D; Baek, MJ; Lee, HJ; Lee, SJ; Han, HJ; Lee, SH				Lee, J. H.; Han, Y-S; Yoon, Y. M.; Yun, C. W.; Yun, S. P.; Kim, S. M.; Kwon, H. Y.; Jeong, D.; Baek, M. J.; Lee, H. J.; Lee, S-J; Han, H. J.; Lee, S. H.			Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1 alpha/GP78 axis	ONCOGENE			English	Article							PROMOTES SARCOMA METASTASIS; COLORECTAL-CANCER CELLS; HEAT-SHOCK PROTEINS; STEM-CELLS; NEUROBLASTOMA-CELLS; DEGRADATION; HYPOXIA; ACTIVATION; EXPRESSION; UBIQUITIN	The cellular prion protein (PrPC) is associated with metastasis, tumor progression and recurrence; however, the precise mechanisms underlying its action is not well understood. Our study found that PrPC degradation decreased tumor progression in colorectal cancer (CRC). In a CRC cell line and human CRC tissue exposed to hypoxia, induced heat-shock 70-kDa protein-1-like (HSPA1L) expression stabilized hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein and promoted PrPC accumulation and tumorigenicity in vivo. PrPC was degraded via the proteasome pathway mediated by the ubiquitin-protein E3 ligase glycoprotein 78 (GP78), which interacts directly with PrPC. However, hypoxia-induced HSPA1L interacted with GP78 and inhibited its functions. HSPA1L knockdown facilitated the interaction of GP78 and PrPC, thereby increasing PrPC ubiquitination. Thus, GP78 was identified as the ubiquitinase for PrPC, thereby revealing an essential mechanism that controls PrPC levels in CRC. Our results suggest that the HSPA1L/HIF-1 alpha/GP78 axis has a crucial role in PrPC accumulation during tumor progression.	[Lee, J. H.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham Sch Med, Birmingham, AL USA; [Han, Y-S; Yoon, Y. M.; Yun, C. W.; Lee, S. H.] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea; [Han, Y-S; Yoon, Y. M.; Yun, C. W.; Lee, S. H.] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan, South Korea; [Yun, S. P.; Kim, S. M.] Johns Hopkins Univ, Sch Med, Neuroregenerat & Stem Cell Programs, Inst Cell Engn,Dept Neurol, Baltimore, MD USA; [Kwon, H. Y.] Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea; [Jeong, D.] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan, South Korea; [Baek, M. J.] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, Coll Vet Med, Dept Vet Physiol, Seoul 151741, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, Res Inst Vet Sci, Seoul 151741, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, PLUS Creat Vet Res Ctr BK21, Seoul, South Korea	University of Alabama System; University of Alabama Birmingham; Soonchunhyang University; Soonchunhyang University; Johns Hopkins University; Soonchunhyang University; Soonchunhyang University; Soonchunhyang University; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Han, HJ (corresponding author), Seoul Natl Univ, Coll Vet Med, Dept Vet Physiol, Seoul 151741, South Korea.; Han, HJ (corresponding author), Seoul Natl Univ, Res Inst Vet Sci, Seoul 151741, South Korea.; Lee, SH (corresponding author), Soonchunhyang Univ, Seoul Hosp, Soonchunhyang Med Sci Res Inst, Dept Biochem, 59 Daesagwan Ro,657 Hannam Dong, Seoul 140887, South Korea.	hjhan@snu.ac.kr; ykckss1114@nate.com	lee, sang hun/Q-4650-2019; Baek, Moo-Jun/W-1736-2019; Lee, Sei-Jung/V-8772-2019; Han, Ho Jae/M-1476-2016	lee, sang hun/0000-0002-9005-5966; Baek, Moo-Jun/0000-0003-3567-6687; Han, Ho Jae/0000-0002-0657-1766	Soonchunhyang University Research Fund; National Research Foundation - Korean government [NRF-2011-0009610]; NRF - Ministry of Education [2016R1D1A3B01007727, 2017M3A9B4032528]; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI14C2253]; Next-Generation Bio-Green 21 Program, Rural Development Administration, Republic of Korea [PJ011141]	Soonchunhyang University Research Fund; National Research Foundation - Korean government(Korean Government); NRF - Ministry of Education; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Next-Generation Bio-Green 21 Program, Rural Development Administration, Republic of Korea	This work was supported by the Soonchunhyang University Research Fund; a National Research Foundation grant funded by the Korean government (NRF-2011-0009610); NRF funded by the Ministry of Education (2016R1D1A3B01007727, 2017M3A9B4032528); a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI14C2253); and a grant from the Next-Generation Bio-Green 21 Program (No. PJ011141), Rural Development Administration, Republic of Korea. The funders had no role in the study design, data collection or analysis, decision to publish or preparation of the manuscript.	Amelio I, 2015, P NATL ACAD SCI USA, V112, P226, DOI 10.1073/pnas.1410609111; Atarod S, 2015, TRANSPL IMMUNOL, V32, P188, DOI 10.1016/j.trim.2015.02.002; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Bartolini A, 2016, CLIN CANCER RES, V22, P4923, DOI 10.1158/1078-0432.CCR-15-2664; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Chang E, 2015, CLIN CANCER RES, V21, P335, DOI 10.1158/1078-0432.CCR-14-0217; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Chiche L, 2016, NEW ENGL J MED, V374, P2183, DOI 10.1056/NEJMc1602584; Chieng CKL, 2015, TUMOR BIOL, V36, P8107, DOI 10.1007/s13277-015-3530-z; Corsaro A, 2016, ONCOTARGET, V7, P38638, DOI 10.18632/oncotarget.9575; de Wit M, 2012, GUT, V61, P855, DOI 10.1136/gutjnl-2011-300511; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Grillari J, 2010, ADV EXP MED BIOL, V694, P172; Hu Y, 2015, CELL BIOCHEM BIOPHYS, V72, P131, DOI 10.1007/s12013-014-0420-8; Jain AK, 2010, CANCER BIOL THER, V10, P665, DOI 10.4161/cbt.10.7.13445; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Ledford H, 2011, NATURE, V472, P273, DOI 10.1038/472273a; Lee SH, 2012, J CELL PHYSIOL, V227, P1731, DOI 10.1002/jcp.22897; Li N, 2015, GENE DEV, V29, P157, DOI 10.1101/gad.251785.114; Li NN, 2015, ONCOTARGET, V6, P9240, DOI 10.18632/oncotarget.3284; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026; Liu X, 2016, INT J MOL MED, V37, P825, DOI 10.3892/ijmm.2016.2482; Lopes MH, 2015, ONCOGENE, V34, P3305, DOI 10.1038/onc.2014.261; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mirzaei MR, 2016, CELL J, V17, P608; Mo JH, 2012, CANCER SCI, V103, P464, DOI 10.1111/j.1349-7006.2011.02181.x; Mohammadi A, 2016, INFLAMMATION, V39, P1116, DOI 10.1007/s10753-016-0343-1; Nagaraju GP, 2015, MOL CARCINOGEN, V54, P1147, DOI 10.1002/mc.22185; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Park JY, 2015, ONCOTARGET, V6, P5342, DOI 10.18632/oncotarget.3028; Peer CJ, 2011, CANCER BIOL THER, V11, P549, DOI 10.4161/cbt.11.6.14834; Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808; Pratt WB, 2010, EXP BIOL MED, V235, P278, DOI 10.1258/ebm.2009.009250; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Shao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092290; Sherman MY, 2015, ONCOGENE, V34, P4153, DOI 10.1038/onc.2014.349; Srivastava S, 2016, GENE, V585, P154, DOI 10.1016/j.gene.2016.03.031; Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686; Vilches S, 2016, MOL NEUROBIOL, V53, P4438, DOI 10.1007/s12035-015-9360-6; Wang QW, 2012, ONCOL REP, V28, P2029, DOI 10.3892/or.2012.2025; Ward HA, 2016, BRIT J NUTR, V116, P316, DOI 10.1017/S0007114516001859; Watanabe T, 2012, NEUROSCI LETT, V531, P114, DOI 10.1016/j.neulet.2012.10.032; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Welch HG, 2016, NEW ENGL J MED, V374, P1605, DOI 10.1056/NEJMp1600448; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Young GP, 2005, MOL NUTR FOOD RES, V49, P571, DOI 10.1002/mnfr.200500026; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang TP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118448; Zomosa-Signoret V, 2008, VET RES, V39, DOI 10.1051/vetres:2007048	59	29	29	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6555	6567		10.1038/onc.2017.263	http://dx.doi.org/10.1038/onc.2017.263			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759037				2022-12-28	WOS:000416049200005
J	Teo, Z; Sng, MK; Chan, JSK; Lim, MMK; Li, Y; Li, L; Phua, T; Lee, JYH; Tan, ZW; Zhu, P; Tan, NS				Teo, Z.; Sng, M. K.; Chan, J. S. K.; Lim, M. M. K.; Li, Y.; Li, L.; Phua, T.; Lee, J. Y. H.; Tan, Z. W.; Zhu, P.; Tan, N. S.			Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3 gamma expression	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; CANCER; HYPOXIA; METASTASIS; METABOLISM; CADHERIN; ANGPTL4; PROTEIN; GLYCOLYSIS; INTERACTS	Metastatic cancer cells acquire energy-intensive processes including increased invasiveness and chemoresistance. However, how the energy demand is met and the molecular drivers that coordinate an increase in cellular metabolic activity to drive epithelial-mesenchymal transition (EMT), the first step of metastasis, remain unclear. Using different in vitro and in vivo EMT models with clinical patient's samples, we showed that EMT is an energy-demanding process fueled by glucose metabolism-derived adenosine triphosphate (ATP). We identified angiopoietin-like 4 (ANGPTL4) as a key player that coordinates an increase in cellular energy flux crucial for EMT via an ANGPTL4/14-3-3. signaling axis. This augmented cellular metabolic activity enhanced metastasis. ANGPTL4 knockdown suppresses an adenylate energy charge elevation, delaying EMT. Using an in vivo dualinducible EMT model, we found that ANGPTL4 deficiency reduces cancer metastasis to the lung and liver. Unbiased kinase inhibitor screens and Ingenuity Pathway Analysis revealed that ANGPTL4 regulates the expression of 14-3-3. adaptor protein via the phosphatidylinositol-3-kinase/AKT and mitogen-activated protein kinase signaling pathways that culminate to activation of transcription factors, CREB, cFOS and STAT3. Using a different mode of action, as compared with protein kinases, the ANGPTL4/14-3-3. signaling axis consolidated cellular bioenergetics and stabilized critical EMT proteins to coordinate energy demand and enhanced EMT competency and metastasis, through interaction with specific phosphorylation signals on target proteins.	[Teo, Z.; Sng, M. K.; Chan, J. S. K.; Lim, M. M. K.; Li, Y.; Li, L.; Phua, T.; Lee, J. Y. H.; Tan, Z. W.; Zhu, P.; Tan, N. S.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Phua, T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Tan, N. S.] Nanyang Technol, Lee Kong Chian Sch Med, Singapore, Singapore; [Tan, N. S.] Inst Mol & Cell Biol, Singapore, Singapore; [Tan, N. S.] KK Womens & Childrens Hosp, KK Res Ctr, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Karolinska Institutet; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Teo, Z; Zhu, P; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	zqteo@ntu.edu.sg; PCZhu@ntu.edu.sg; nstan@ntu.edu.sg	Tan, Nguan Soon/A-2220-2011; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Sng, Ming Keat/0000-0002-5529-4371	Ministry of Education, Singapore [MOE2014-T2-1-012, 2012-T1-001-036]	Ministry of Education, Singapore(Ministry of Education, Singapore)	This work was supported by grants from Ministry of Education, Singapore (MOE2014-T2-1-012 and 2012-T1-001-036).	Allalou A, 2009, COMPUT METH PROG BIO, V94, P58, DOI 10.1016/j.cmpb.2008.08.006; ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; Bridges Dave, 2004, Sci STKE, V2004, pre10, DOI 10.1126/stke.2422004re10; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Chu K, 2013, ONCOTARGET, V4, P446, DOI 10.18632/oncotarget.872; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Khong TL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-518; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; LIVE TR, 1975, J BIOL CHEM, V250, P1786; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Mak BC, 2004, CANCER INVEST, V22, P588, DOI 10.1081/CNV-200027144; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; RIDGE JW, 1972, BIOCHEM J, V127, P351, DOI 10.1042/bj1270351; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schito L, 2017, BBA-REV CANCER, V1868, P239, DOI 10.1016/j.bbcan.2017.05.004; Shiraishi T, 2015, ONCOTARGET, V6, P130, DOI 10.18632/oncotarget.2766; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sousa B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-734; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tinti M, 2014, DATABASE-OXFORD, DOI 10.1093/database/bat085; Tsai YP, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-102; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698; Yeung YG, 2009, ANAL BIOCHEM, V389, P89, DOI 10.1016/j.ab.2009.03.017; Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zhu XM, 2016, LUNG, V194, P637, DOI 10.1007/s00408-016-9895-y	48	23	24	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6408	6419		10.1038/onc.2017.244	http://dx.doi.org/10.1038/onc.2017.244			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745316	Green Published, hybrid			2022-12-28	WOS:000415622900005
J	Wang, J; Jia, Y; Zhao, S; Zhang, X; Wang, X; Han, X; Wang, Y; Ma, M; Shi, J; Liu, L				Wang, J.; Jia, Y.; Zhao, S.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Ma, M.; Shi, J.; Liu, L.			BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR BIN1; INTEGRATOR 1 BIN1; PD-L1 EXPRESSION; INFILTRATING LYMPHOCYTES; UP-REGULATION; APOPTOSIS; EGFR; ACTIVATION; DOWNSTREAM; MECHANISMS	Non-small cell lung cancer (NSCLC) is one of the most common and malignant carcinoma worldwide, and the incidence and mortality are increasing rapidly. Immunotherapy targeting programmed death 1/programmed death ligand 1 (PD-L1) signaling has shown prominent clinical effects in treating NSCLC; however, a poor understanding of the associated regulating molecular mechanisms of PD-L1 has become one of the biggest obstacles for further improving efficacy. Bridging integrator-1 (BIN1) can regulate numerous cancer-related molecules to exert multiple tumor-suppressing effects by either interacting or not interacting with c-MYC. In the present study, we observed that there exists a negative correlation between the expression of PD-L1 and BIN1 in NSCLC tissues. The expression levels of BIN1 and PD-L1 were significantly related to the tumor, lymph node and metastasis grade (TNM) stage, invasion range and lymph node metastasis. Simultaneously, for NSCLC patients, the expression statuses of BIN1 and PD-L1 might be independent prognostic factors. Furthermore, the expression of tumor-infiltrating lymphocytes was positively associated with BIN1 expression and negatively related to PD-L1 expression in NSCLC tissues. Importantly, we showed that PD-L1 was under the control of BIN1. In addition, the overexpression of BIN1 could inhibit the c-MYC and epithelial growth factor receptor (EGFR)-dependent PD-L1 expression and reverse the suppressive immuno-microenvironment in vivo. Taken together, our findings indicated that BIN1 restoration in NSCLC could reverse PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/mitogen-activated protein kinase pathways.	[Wang, J.; Jia, Y.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Liu, L.] Hebei Med Univ, Hosp 4, Dept Tumor Immunotherapy, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China; [Wang, J.; Jia, Y.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Ma, M.; Liu, L.] Hebei Canc Inst, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China; [Zhao, S.] Hebei Med Univ, Dept Pathol, Shijiazhuang, Hebei, Peoples R China; [Ma, M.] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang, Hebei, Peoples R China; [Shi, J.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Mol Biol, Beijing, Peoples R China; [Shi, J.] Peking Union Med Coll, Beijing, Peoples R China	Hebei Medical University; Hebei Medical University; Hebei Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Liu, L (corresponding author), Hebei Med Univ, Hosp 4, Dept Tumor Immunotherapy, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China.; Liu, L (corresponding author), Hebei Canc Inst, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China.	cdlihualiu@aliyun.com			National Natural Science Foundation of China [81201607]; Postdoctoral Fund of China [2013M540883]; Outstanding Youth Foundation of Hebei Province [H2014206320]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Fund of China(China Postdoctoral Science Foundation); Outstanding Youth Foundation of Hebei Province	This work was supported by the National Natural Science Foundation of China (81201607), Postdoctoral Fund of China (2013M540883), and Outstanding Youth Foundation of Hebei Province (H2014206320).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; [Anonymous], 2015, CANCER DISCOV, V5, P1232, DOI 10.1158/2159-8290.CD-ND2015-004; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cassimere EK, 2009, CELL DEATH DIFFER, V16, P1641, DOI 10.1038/cdd.2009.98; Chang MY, 2007, CANCER RES, V67, P7605, DOI 10.1158/0008-5472.CAN-07-1100; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; DuHadaway JB, 2001, CANCER RES, V61, P3151; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Ettinger DS, 2013, J NATL COMPR CANC NE, V11, P645, DOI 10.6004/jnccn.2013.0084; Fusi A, 2015, LANCET ONCOL, V16, P1285, DOI 10.1016/S1470-2045(15)00307-1; Ge K, 2000, INT J CANCER, V85, P376; Hirano F, 2005, CANCER RES, V65, P1089; Horne ZD, 2011, J SURG RES, V171, P1, DOI 10.1016/j.jss.2011.03.068; Jia YL, 2015, INT J CANCER, V137, P1095, DOI 10.1002/ijc.29481; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Liu LH, 2009, CELL IMMUNOL, V258, P181, DOI 10.1016/j.cellimm.2009.05.002; Ma M, 2016, SCI REP-UK, V6, DOI 10.1038/srep31315; Martin-Orozco N, 2006, J IMMUNOL, V177, P8291, DOI 10.4049/jimmunol.177.12.8291; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Nurieva RI, 2009, IMMUNOL REV, V229, P88, DOI 10.1111/j.1600-065X.2009.00769.x; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Pan K, 2012, MOL MED, V18, P507, DOI 10.2119/molmed.2011.00319; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prokic I, 2014, J MOL MED, V92, P453, DOI 10.1007/s00109-014-1138-1; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Schumacher K, 2001, CANCER RES, V61, P3932; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Tan MS, 2013, TRENDS MOL MED, V19, P594, DOI 10.1016/j.molmed.2013.06.004; Telfer JF, 2005, CELL SIGNAL, V17, P701, DOI 10.1016/j.cellsig.2004.10.009; Wahlin BE, 2007, CLIN CANCER RES, V13, P388, DOI 10.1158/1078-0432.CCR-06-1734; Wang XX, 2017, ONCOTARGET, V8, P19661, DOI 10.18632/oncotarget.14914; Zhang Y, 2010, CELL MOL IMMUNOL, V7, P389, DOI 10.1038/cmi.2010.28; Zhao LM, 2015, MOL MED REP, V11, P871, DOI 10.3892/mmr.2014.2874	45	57	64	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6235	6243		10.1038/onc.2017.217	http://dx.doi.org/10.1038/onc.2017.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714960				2022-12-28	WOS:000414774800003
J	Feng, J; Yang, H; Zhang, Y; Wei, H; Zhu, Z; Zhu, B; Yang, M; Cao, W; Wang, L; Wu, Z				Feng, J.; Yang, H.; Zhang, Y.; Wei, H.; Zhu, Z.; Zhu, B.; Yang, M.; Cao, W.; Wang, L.; Wu, Z.			Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells	ONCOGENE			English	Article							IMMUNE CHECKPOINT BLOCKADE; AEROBIC GLYCOLYSIS; RECEPTOR; PROTEIN; MECHANISM; SURVIVAL; PATHWAY	The clinical success of immunotherapy that inhibits the negative immune regulatory pathway programmed cell death protein 1/PD-1 ligand (PD-1/PD-L1) has initiated a new era in the treatment of metastatic cancer. PD-L1 expression is upregulated in many solid tumors including lung cancer and functions predominantly in lactate-enriched tumor microenvironments. Here, we provided evidence for PD-L1 induction in response to lactate stimulation in lung cancer cells. Lactate-induced PD-L1 induction was mediated by its receptor GPR81. The silencing of GPR81 signaling in lung cancer cells resulted in a decrease in PD-L1 protein levels and functional inactivation of PD-L1 promoter activity. In addition, GPR81-mediated upregulation of PD-L1 in glucose-stimulated lung cancer cells that recapitulates the enhanced glycolysis in vivo was dependent on lactate dehydrogenase A (LDHA). We also demonstrated that activation of GPR81 decreases intracellular cAMP levels and inhibits protein kinase A (PKA) activity, leading to activation of the transcriptional coactivator TAZ. Interaction of TAZ with the transcription factor TEAD was essential for TAZ activation of PD-L1 and induction of its expression. Furthermore, we found that lactate-induced activation of PD-L1 in tumor cells led to reduced production of interferon-gamma and induction of apoptosis of cocultured Jurkat T-cell leukemia cells. Our findings reveal an unexpected role of lactate in contributing to tumor cell protection from cytotoxic T-cell targeting and establishes a direct connection between tumor cell metabolic reprograming and tumor evasion from the immune response.	[Feng, J.; Wang, L.] Wannan Med Coll, Affiliated Hosp 1, Med Oncol, Wuhu, Peoples R China; [Yang, H.] Tianjin Med Univ Gen Hosp, Tianjin Lung Canc Ctr & Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China; [Zhang, Y.; Wu, Z.] Wannan Med Coll, Anhui Prov Key Lab Act Biol Macromol Res, Wuhu, Peoples R China; [Wei, H.] Wannan Med Coll, Dept Cent Lab, Wuhu, Peoples R China; [Zhu, Z.] Wannan Med Coll, Sch Pharm, Wuhu, Peoples R China; [Zhu, Z.] Wannan Med Coll, Sch Forens Med, Wuhu, Peoples R China; [Yang, M.; Cao, W.] Wannan Med Coll, Sch Anesthesiol, Wuhu, Peoples R China; [Wang, L.; Wu, Z.] Wannan Med Coll, Sch Preclin Med, 22 Wenchang West Rd, Wuhu 241001, Peoples R China	Wannan Medical College; Tianjin Medical University; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College	Wang, L; Wu, Z (corresponding author), Wannan Med Coll, Sch Preclin Med, 22 Wenchang West Rd, Wuhu 241001, Peoples R China.	lucyyjs@163.com; zwu2ster@163.com		Yang, Hui/0000-0002-3938-9530	National Natural Science Foundation of China [81272359]; Wannan Medical College	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wannan Medical College	We thank Dr Hen Wu (Tianjin Lung Cancer Center and Institute, Tianjin Medical University General Hospital) for helping with the correlation analysis in a data set obtained from GEO, and Sean Hackett (Johns Hopkins University) for critical reading and revising of this manuscript. This work was supported by the National Natural Science Foundation of China (81272359 to ZW) and introduction of high-level scientific research start-up fund by Wannan Medical College (to ZW).	Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Kuei C, 2011, MOL PHARMACOL, V80, P848, DOI 10.1124/mol.111.074500; Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148; Lipson EJ, 2015, SEMIN ONCOL, V42, P587, DOI 10.1053/j.seminoncol.2015.05.013; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Shimomura T, 2014, BIOCHEM BIOPH RES CO, V443, P917, DOI 10.1016/j.bbrc.2013.12.100; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	26	154	160	10	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5829	5839		10.1038/onc.2017.188	http://dx.doi.org/10.1038/onc.2017.188			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604752				2022-12-28	WOS:000413292900005
J	Peng, WX; Koirala, P; Mo, YY				Peng, W-X; Koirala, P.; Mo, Y-Y			LncRNA-mediated regulation of cell signaling in cancer	ONCOGENE			English	Review							LONG NONCODING RNA; PROSTATE-SPECIFIC GENE; KAPPA-B; INTERLEUKIN-8 EXPRESSION; INFLAMMATORY RESPONSE; NEGATIVE REGULATION; MALAT1 PROMOTES; ACIDIC PH; C-MYC; GENOME	To date, a large number of long non-coding RNAs (IncRNAs) have been recently discovered through functional genomics studies. Importantly, IncRNAs have been shown, in many cases, to function as master regulators for gene expression and thus, they can play a critical role in various biological functions and disease processes including cancer. Although the IncRNA-mediated gene expression involves various mechanisms, such as regulation of transcription, translation, protein modification, and the formation of RNA-protein or protein-protein complexes, in this review, we discuss the latest developments primarily in important cell signaling pathways regulated by IncRNAs in cancer.	[Peng, W-X] Jiangsu Univ, Sch Med, Dept Cell Biol, Zhenjiang, Peoples R China; [Peng, W-X; Koirala, P.; Mo, Y-Y] Univ Mississippi, Med Ctr, Canc Inst, 2500 N State St, Jackson, MS 39216 USA; [Koirala, P.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; [Mo, Y-Y] Univ Mississippi, Med Ctr, Dept Pharmacol Toxicol, Jackson, MS 39216 USA	Jiangsu University; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Canc Inst, 2500 N State St, Jackson, MS 39216 USA.	ymo@umc.edu	Peng, Wan-Xin/T-1254-2019; Peng, Wan-Xin/AAU-1368-2020; Mo, Yin-Yuan/R-8255-2019; 彭, 琬昕/HDN-9075-2022	彭, 琬昕/0000-0002-2551-8899	NIH [R01 CA154989]; NATIONAL CANCER INSTITUTE [R01CA154989] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant R01 CA154989 (Y-YM).	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009; Baldassarre A, 2012, INT J MOL SCI, V13, P16708, DOI 10.3390/ijms131216708; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Blythe AJ, 2016, BBA-GENE REGUL MECH, V1859, P46, DOI 10.1016/j.bbagrm.2015.08.009; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carotenuto P, 2017, GUT, V66, P1268, DOI 10.1136/gutjnl-2016-312278; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Diaz-Lagares A, 2016, P NATL ACAD SCI USA, V113, pE7535, DOI 10.1073/pnas.1608585113; Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Halaby MJ, 2007, GENE, V395, P1, DOI 10.1016/j.gene.2007.01.029; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Hirata H, 2015, CANCER RES, V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931; Hu GK, 2016, J IMMUNOL, V196, P2799, DOI 10.4049/jimmunol.1502146; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Huang JJ, 2015, INT J DISTRIB SENS N, DOI 10.1155/2015/785143; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Jain AK, 2016, MOL CELL, V64, P967, DOI 10.1016/j.molcel.2016.10.039; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Kawasaki Y, 2016, CELL REP, V16, P2554, DOI 10.1016/j.celrep.2016.08.015; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Koirala P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14422; Krawczyk M, 2014, ELIFE, V3, DOI 10.7554/eLife.01776; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu JH, 2017, FRONT BIOSCI-LANDMRK, V22, P66, DOI 10.2741/4472; Liu Q, 2013, NUCLEIC ACIDS RES, V41, P4976, DOI 10.1093/nar/gkt182; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Marques AC, 2014, CURR OPIN GENET DEV, V27, P48, DOI 10.1016/j.gde.2014.03.009; Mattick JS, 2015, NAT STRUCT MOL BIOL, V22, P5, DOI 10.1038/nsmb.2942; Meller VH, 2015, ANNU REV GENET, V49, P673, DOI 10.1146/annurev-genet-112414-055205; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Nelson BR, 2016, SCIENCE, V351, P271, DOI 10.1126/science.aad4076; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Pan H, 2016, ONCOTARGET, V7, P49948, DOI 10.18632/oncotarget.10521; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Pearson MJ, 2016, ARTHRITIS RHEUMATOL, V68, P845, DOI 10.1002/art.39520; Peppicelli S, 2013, CLIN EXP METASTAS, V30, P957, DOI 10.1007/s10585-013-9595-4; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Qiao Q, 2016, BIOCHEM BIOPH RES CO, V478, P507, DOI 10.1016/j.bbrc.2016.06.160; Rapicavoli NA, 2013, ELIFE, V2, DOI 10.7554/eLife.00762; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673; Shi Q, 2000, J INTERF CYTOK RES, V20, P1023, DOI 10.1089/10799900050198471; Singh R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.168; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.292; Wang YP, 2015, SCI REP-UK, V5, DOI 10.1038/srep13749; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Wilusz JE, 2016, BBA-GENE REGUL MECH, V1859, P128, DOI 10.1016/j.bbagrm.2015.06.003; Wu HW, 2016, BIOCHEM BIOPH RES CO, V471, P240, DOI 10.1016/j.bbrc.2016.01.117; Xu L, 2000, CANCER RES, V60, P4610; Xu SP, 2015, INT J CLIN EXP PATHO, V8, P4881; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Zarnack K, 2013, CELL, V152, P453, DOI 10.1016/j.cell.2012.12.023; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013; Zhang A, 2013, CELL RES, V23, P340, DOI 10.1038/cr.2012.164; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110; Zhang ZQ, 2016, ONCOTARGET, V7, P15481, DOI 10.18632/oncotarget.7139; Zhao G, 2016, FEBS LETT, V590, P2884, DOI 10.1002/1873-3468.12315	88	950	994	7	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5661	5667		10.1038/onc.2017.184	http://dx.doi.org/10.1038/onc.2017.184			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604750	Green Accepted			2022-12-28	WOS:000412843900001
J	Kramer, N; Schmollerl, J; Unger, C; Nivarthi, H; Rudisch, A; Unterleuthner, D; Scherzer, M; Riedl, A; Artaker, M; Crncec, I; Lenhardt, D; Schwarz, T; Prieler, B; Han, X; Hengstschalger, M; Schuler, J; Eferl, R; Moriggl, R; Sommergruber, W; Dolznig, H				Kramer, N.; Schmoellerl, J.; Unger, C.; Nivarthi, H.; Rudisch, A.; Unterleuthner, D.; Scherzer, M.; Riedl, A.; Artaker, M.; Crncec, I.; Lenhardt, D.; Schwarz, T.; Prieler, B.; Han, X.; Hengstschaelger, M.; Schueler, J.; Eferl, R.; Moriggl, R.; Sommergruber, W.; Dolznig, H.			Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression	ONCOGENE			English	Article							GENE-EXPRESSION; UP-REGULATION; BETA-CATENIN; ACTIVATION PROTEIN; TUMOR PROGRESSION; COLON-CANCER; STEM-CELLS; IN-VITRO; CARCINOMA; ESOPHAGEAL	The canonical WNT signaling pathway is crucial for intestinal stem cell renewal and aberrant WNT signaling is an early event in colorectal cancer (CRC) development. Here, we show for the first time that WNT2 is one of the most significantly induced genes in CRC stroma as compared to normal stroma. The impact of stromal WNT2 on carcinoma formation or progression was not addressed so far. Canonical WNT/beta-catenin signaling was assessed using a 7TGP-reporter construct. Furthermore, effects of WNT2 on fibroblast migration and invasion were determined using siRNA-mediated gene silencing. Tumor cell invasion was studied using organotypic raft cultures and in vivo significance was assessed via a xenograft mouse model. We identified cancer-associated fibroblasts (CAFs) as the main source of WNT2. CAF-derived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon cancer cells in a paracrine fashion, whereas no hyperactivation was detectable in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway. Furthermore, WNT2 activated autocrine canonical WNT signaling in primary fibroblasts, which was associated with a pro-migratory and pro-invasive phenotype. We identified FZD8 as the putative WNT2 receptor in CAFs. Three-dimensional organotypic co-culture assays revealed that WNT2-mediated fibroblast motility and extracellular matrix remodeling enhanced cancer cell invasion of cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway. Thus, suggesting a tumor-promoting influence on a broad range of CRC. In line, WNT2 also promotes tumor growth, invasion and metastasis in vivo. Moreover, high WNT2 expression is associated with poor prognosis in human CRC. The identification of the pro-malignant function of stromal derived WNT2 in CRC classifies WNT2 and its receptor as promising stromal targets to confine cancer progression in combination with conventional or targeted therapies.	[Kramer, N.; Schmoellerl, J.; Unger, C.; Unterleuthner, D.; Scherzer, M.; Riedl, A.; Schwarz, T.; Prieler, B.; Hengstschaelger, M.; Dolznig, H.] Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria; [Schmoellerl, J.; Nivarthi, H.; Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Rudisch, A.; Sommergruber, W.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Artaker, M.] Med Univ Vienna, Max F Perutz Labs, Vienna, Austria; [Crncec, I.; Eferl, R.] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Lenhardt, D.; Schueler, J.] Oncotest GmbH, Freiburg, Germany; [Han, X.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [Moriggl, R.] Univ Vet Med Vienna, Inst Anim Breeding & Genet, Vienna, Austria; [Nivarthi, H.] Austrian Acad Sci, Res Ctr Mol Med, CeMM, Lazarettgasse 14, A-1090 Vienna, Austria; [Scherzer, M.] Karolinska Inst, Solnavagen 1, S-17177 Solna, Sweden	Medical University of Vienna; Ludwig Boltzmann Institute; Boehringer Ingelheim; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Oncotest GmbH; Cincinnati Children's Hospital Medical Center; University of Veterinary Medicine Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Karolinska Institutet	Dolznig, H (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	helmut.dolznig@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015; Moriggl, Richard/H-8118-2019	Dolznig, Helmut/0000-0002-6063-3585; Moriggl, Richard/0000-0003-0918-9463; Schwarz, Thomas/0000-0002-1951-9676; Han, Xiaonan/0000-0001-5368-6489; Eferl, Robert/0000-0002-6074-7144; Schmoellerl, Johannes/0000-0002-8461-8881; Kramer, Nina/0000-0002-9058-8076	Herzfelder Family Foundation; Niederosterreichische Forschungs-und Bildungsges.m.b.H; DOC Fellowship of the Austrian Academy of Sciences [24032]; Austrian Science Fund (FWF) [SFB F28, SFB F47, P25925-B20, 0P26908-B20]; Comprehensive Cancer Center (CCC) Vienna Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI103388] Funding Source: NIH RePORTER	Herzfelder Family Foundation; Niederosterreichische Forschungs-und Bildungsges.m.b.H; DOC Fellowship of the Austrian Academy of Sciences; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Comprehensive Cancer Center (CCC) Vienna Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	HD was supported by the Herzfelder Family Foundation and the Niederosterreichische Forschungs-und Bildungsges.m.b.H. AW was a recipient of a DOC Fellowship (24032) of the Austrian Academy of Sciences. RM was supported by the Austrian Science Fund (FWF, SFB F28 & F47). RE was supported by FWF (P25925-B20, 0P26908-B20, DK Inflammation and Immunity) and the Comprehensive Cancer Center (CCC) Vienna Research Grant.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bayle J, 2008, J INVEST DERMATOL, V128, P871, DOI 10.1038/sj.jid.5701101; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Bravo DT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-316; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dale TC, 1996, CANCER RES, V56, P4320; de Castro J, 2000, VIRCHOWS ARCH, V437, P599, DOI 10.1007/s004280000266; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HUGUET EL, 1994, CANCER RES, V54, P2615; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jiang H, 2014, AM J CANCER RES, V4, P537; Katoh M, 2001, INT J ONCOL, V19, P1003; Katoh M, 2003, INT J MOL MED, V12, P811; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Miller MF, 2012, P NATL ACAD SCI USA, V109, P15348, DOI 10.1073/pnas.1201583109; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Neumann S, 2009, TRAFFIC, V10, P334, DOI 10.1111/j.1600-0854.2008.00872.x; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park JK, 2009, NEOPLASMA, V56, P119, DOI 10.4149/neo_2009_02_119; Pu P, 2009, CANCER GENE THER, V16, P351, DOI 10.1038/cgt.2008.78; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Ru MX, 2008, TROP BIOMED, V25, P46; Rupp C, 2006, DIAGN MOL PATHOL, V15, P35, DOI 10.1097/00019606-200603000-00006; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Stanganello E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6846; Suraweera N, 2006, INT J CANCER, V119, P1837, DOI 10.1002/ijc.22046; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vider BZ, 1996, ONCOGENE, V12, P153; Wikberg ML, 2013, TUMOR BIOL, V34, P1013, DOI 10.1007/s13277-012-0638-2; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu HM, 2012, DEVELOPMENT, V139, P4383, DOI 10.1242/dev.083352	52	66	68	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5460	5472		10.1038/onc.2017.144	http://dx.doi.org/10.1038/onc.2017.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28553956				2022-12-28	WOS:000411960500003
J	Antignani, A; Segal, D; Simon, N; Kreitman, RJ; Huang, D; FitzGerald, DJ				Antignani, A.; Segal, D.; Simon, N.; Kreitman, R. J.; Huang, D.; FitzGerald, D. J.			Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins	ONCOGENE			English	Article							HAIRY-CELL LEUKEMIA; PSEUDOMONAS EXOTOXIN; CANCER CELLS; PROTEINS; CYTOSOL; TOXIN; DEATH; GUIDE; BAX	Protein synthesis is crucial for regulating cell homeostasis and, when unrestricted, it can lead to tumorigenesis. Immunotoxins derived from Pseudomonas exotoxin are antibody-toxin fusion proteins that inhibit protein synthesis of mammalian cells via ADP-ribosylation of the eukaryotic elongation factor-2. Here we investigate the role of the Bcl-2 family proteins in the response of cancer cells to immunotoxin challenge. Besides the well-known reduction of the prosurvival Bcl-2 family member, Mcl-1, following inhibition of protein synthesis, we show for the first time that immunotoxins also reduce the levels of selected proapoptotic BH-3-only proteins. Among these, only Bim protein levels correlated with the ability of immunotoxins to induce an apoptotic response. To support our findings, we verified that a Bim knockout completely abolished immunotoxin-mediated apoptosis. Further, mice bearing either wild-type or Bid knockout tumors responded to immunotoxin treatment with a decrease in growth kinetics, whereas mice engrafted with Bim knockout tumors showed no reduction in tumor size or prolongation of survival following immunotoxin treatment. From these results, we conclude that Bim expression is a major susceptibility factor for tumor cell death and, as such, constitutes a potential biomarker that could be evaluated before immunotoxin treatment. In support of this hypothesis, clinically, we analyzed patient cells before immunotoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein responded with a greater decrease in leukemic cell count compared with those samples expressing a low level of Bim.	[Antignani, A.; Simon, N.; Kreitman, R. J.; FitzGerald, D. J.] NCI, Lab Mol Biol, CCR, NIH, Bldg 37,Room 5124,37 Convent Dr, Bethesda, MD 20892 USA; [Segal, D.; Huang, D.] Walter & Eliza Hall Inst Med Res, Canc & Haematol Div, Melbourne, Vic, Australia; [Segal, D.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Melbourne	Antignani, A; FitzGerald, DJ (corresponding author), NCI, Lab Mol Biol, CCR, NIH, Bldg 37,Room 5124,37 Convent Dr, Bethesda, MD 20892 USA.	antignaa@mail.nih.gov; fitzgerd@helix.nih.gov	Huang, David C. S./C-7586-2013	Huang, David C. S./0000-0002-3101-4873	National Cancer Institute, NIH; Australian National Health and Medical Research Council [1057742, 1016701, 9000220]; Cancer Council Victoria; Leukemia and Lymphoma Society (Specialized Centers of Research) [7001-13]; Australian Cancer Research Foundation; Victorian State Government; NATIONAL CANCER INSTITUTE [ZIABC010301, ZIABC008757] Funding Source: NIH RePORTER	National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukemia and Lymphoma Society (Specialized Centers of Research)(Leukemia and Lymphoma Society); Australian Cancer Research Foundation; Victorian State Government; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank R Anderson and W Welch for the gift of reagents and Jianan Gong and Stephen Wilcox for assistance with sequence validation of CRISPR/Cas9 knockout cell lines. We thank E Arons for advice on the RT-PCR. This work was funded by the intramural programs of the National Cancer Institute, NIH and is supported by fellowships, and grants from the Australian National Health and Medical Research Council (research fellowships to DCSH; project grant 1057742 (DCSH); program grant 1016701; and Independent Research Institutes Infrastructure Support Scheme (grant 9000220)), the Cancer Council Victoria (grant-in-aid to DCSH), the Leukemia and Lymphoma Society (Specialized Centers of Research grants 7001-13), the Australian Cancer Research Foundation, a Victorian State Government Operational Infrastructure Support grant.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alewine C, 2015, ONCOLOGIST, V20, P176, DOI 10.1634/theoncologist.2014-0358; Andersson Y, 2004, INT J CANCER, V112, P475, DOI 10.1002/ijc.20371; Antignani A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161415; Antignani A, 2014, MOL CANCER THER, V13, P1655, DOI 10.1158/1535-7163.MCT-13-0998; Antignani A, 2013, TOXINS, V5, P1486, DOI 10.3390/toxins5081486; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; FitzGerald DJ, 2011, CANCER RES, V71, P6300, DOI 10.1158/0008-5472.CAN-11-1374; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Hollevoet K, 2014, J IMMUNOTHER, V37, P8, DOI 10.1097/CJI.0000000000000010; Kreitman RJ, 2015, BEST PRACT RES CL HA, V28, P236, DOI 10.1016/j.beha.2015.09.003; Kreitman RJ, 2012, J CLIN ONCOL, V30, P1822, DOI 10.1200/JCO.2011.38.1756; Lindqvist LM, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.149; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Salvatore G, 2002, BIOCHEM BIOPH RES CO, V294, P813, DOI 10.1016/S0006-291X(02)00560-0; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Traini R, 2010, MOL CANCER THER, V9, P2007, DOI 10.1158/1535-7163.MCT-10-0257; Wayne AS, 2014, BLOOD, V123, P2470, DOI 10.1182/blood-2014-01-492256; Weldon JE, 2011, FEBS J, V278, P4683, DOI 10.1111/j.1742-4658.2011.08182.x; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289	24	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4953	4962		10.1038/onc.2017.111	http://dx.doi.org/10.1038/onc.2017.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28436946				2022-12-28	WOS:000408768800001
J	Ruan, D; He, J; Li, CF; Lee, HJ; Liu, J; Lin, HK; Chan, CH				Ruan, D.; He, J.; Li, C-F; Lee, H-J; Liu, J.; Lin, H-K; Chan, C-H			Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist	ONCOGENE			English	Article							TRANSCRIPTION FACTOR TWIST; MESENCHYMAL TRANSITION; DOCETAXEL RESISTANCE; IMPROVES SURVIVAL; EXPRESSION; P27; UBIQUITINATION; INHIBITOR; CARCINOMA; TUMORIGENESIS	Castration-resistant prostate cancer (CRPC) remains a major clinical challenge because of the lack of effective targeted therapy for its treatment. The mechanism underlying how CRPC gains resistance toward hormone depletion and other forms of chemotherapy is poorly understood. Research on understanding the factors that drive these processes is desperately needed to generate new therapies to cure the disease. Here, we discovered a fundamental role of S-phase protein kinase 2 (Skp2) in the formation and progression of CRPC. In transgenic adenocarcinoma mouse prostate model, Skp2 depletion leads to a profound repression of prostate tumor growth and distal metastasis and substantially prolonged overall survival. We revealed that Skp2 regulates CRPC through Twist-mediated oncogenic functions including epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) acquisitions. Mechanistically, Skp2 interacted with Twist and promoted the non-degradative ubiquitination of Twist. Consequently, Skp2 stabilized Twist protein expression by preventing proteasomal degradation of Twist by beta-TrCP. We found that Twist overexpression augments CSC self-renewal and population and that Skp2 inhibition reverts Twist's effects on CSC regulation. Furthermore, genetically depleting or pharmacologically inactivating Skp2 synergistically re-sensitized CRPC cells toward chemotherapies such as paclitaxel or doxorubicin. Together, this study uncovering Skp2-mediated Twist stabilization and oncogenic functions in CRPC offers new knowledge on how CRPC progresses and acquires chemoresistance during tumor progression. It provides proof of principle that Skp2 targeting is a promising approach to combat metastatic CRPC by targeting Twist and CSCs.	[Ruan, D.; He, J.; Lee, H-J; Lin, H-K; Chan, C-H] SUNY Stony Brook, Dept Pharmacol Sci, 101 Nicolls Rd,BST8-121, Stony Brook, NY 11794 USA; [Ruan, D.; Lee, H-J; Chan, C-H] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY USA; [Li, C-F] Chi Mei Foundat Med Ctr, Dept Pathol, Tainan, Taiwan; [Li, C-F] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan; [Li, C-F] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Liu, J.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY USA; [Lin, H-K; Chan, C-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Lin, H-K] Wake Forest Univ, Dept Canc Biol, Sch Med, Winston Salem, NC USA; [Lin, H-K] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Health Research Institutes - Taiwan; Southern Taiwan University of Science & Technology; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; UTMD Anderson Cancer Center; Wake Forest University; China Medical University Taiwan	Lin, HK; Chan, CH (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, 101 Nicolls Rd,BST8-121, Stony Brook, NY 11794 USA.	hulin@wakehealth.edu; chia-hsin.chan@stonybrook.edu	Chan, Chia-Hsin/AAT-7782-2020	Li, Chien-Feng/0000-0002-9527-7576; Chan, Chia-Hsin/0000-0001-8506-7500	Stony Brook School of Medicine and Cancer Center Fund; NYS grant [DOH01-C31845GG-3450000]; Feldstein Medical Foundation Award; NIH [5 K22 CA181412, R01 CA182424, R01CA193813]; MOHW [MOHW103-TDU-M-221-123017]; NHRI [CA-106-PP-36]; NATIONAL CANCER INSTITUTE [R01CA182424, K22CA181412, R01CA193813] Funding Source: NIH RePORTER	Stony Brook School of Medicine and Cancer Center Fund; NYS grant; Feldstein Medical Foundation Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MOHW(Ministry of Health & Welfare (MOHW), Republic of Korea); NHRI(National Health Research Institutes - Taiwan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We sincerely appreciate Dr Keiichi I Nakayama for providing Skp2<SUP>+/-</SUP> mice. This work was supported by the Stony Brook School of Medicine and Cancer Center Fund, the Feldstein Medical Foundation Award, a NYS grant (DOH01-C31845GG-3450000) and a NIH grant (5 K22 CA181412) to C-HC, and a MOHW grant (MOHW103-TDU-M-221-123017) and a NHRI grant (CA-106-PP-36) to C-FL, as well as NIH grants (R01 CA182424 and R01CA193813) to H-KL.	Ardiani A, 2013, CLIN CANCER RES, V19, P6205, DOI 10.1158/1078-0432.CCR-13-1026; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan CH, 2014, CELL CYCLE, V13, P679, DOI 10.4161/cc.27853; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan CH, 2011, J MOL MED, V89, P857, DOI 10.1007/s00109-011-0766-y; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Cookson MS, 2013, J UROLOGY, V190, P429, DOI 10.1016/j.juro.2013.05.005; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gingrich JR, 1997, CANCER RES, V57, P4687; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585-015-9773-7; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Johnson Sara, 2013, Bio Protoc, V3; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Kwilas AR, 2015, ONCOTARGET, V6, P28194, DOI 10.18632/oncotarget.4442; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lu W, 2017, ONCOGENE, V36, P1364, DOI 10.1038/onc.2016.300; Marchiani S, 2010, INT J ANDROL, V33, P784, DOI 10.1111/j.1365-2605.2009.01030.x; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Nguyen PL, 2011, UROL ONCOL-SEMIN ORI, V29, P302, DOI 10.1016/j.urolonc.2009.03.022; Oh M, 2016, ANGEW CHEM INT EDIT, V55, P602, DOI 10.1002/anie.201508716; Plymate SR, 2015, CANCER CELL, V27, P158, DOI 10.1016/j.ccell.2015.01.008; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Rescigno P, 2012, CURR DRUG TARGETS, V13, P1676, DOI 10.2174/138945012803529956; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shim EH, 2003, CANCER RES, V63, P1583; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang HB, 2008, J CELL SCI, V121, P2578, DOI 10.1242/jcs.030742; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Wei SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047298; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang YG, 2016, ONCOL REP, V36, P559, DOI 10.3892/or.2016.4809; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Yun EJ, 2016, CLIN CANCER RES, V22, P670, DOI 10.1158/1078-0432.CCR-15-0190; Zhang D, 2016, NAT COMMUN, V7, P1; Zhao H, 2016, ONCOGENE, P1; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhong JT, 2013, DISCOV MED, V15, P7	56	40	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4299	4310		10.1038/onc.2017.64	http://dx.doi.org/10.1038/onc.2017.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346424	Green Accepted			2022-12-28	WOS:000406360600007
J	Taylor, E; Alqadri, N; Dodgson, L; Mason, D; Lyulcheva, E; Messina, G; Bennett, D				Taylor, E.; Alqadri, N.; Dodgson, L.; Mason, D.; Lyulcheva, E.; Messina, G.; Bennett, D.			MRL proteins cooperate with activated Ras in glia to drive distinct oncogenic outcomes	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; ACTIN-FILAMENT TURNOVER; CENTRAL-NERVOUS-SYSTEM; CELL-MIGRATION; DROSOPHILA; JNK; EXPRESSION; DYNAMICS; CANCER; GENE	The Mig10/RIAM/Lpd (MRL) adapter protein Lpd regulates actin dynamics through interactions with Scar/WAVE and Ena/VASP proteins to promote the formation of cellular protrusions and to stimulate invasive migration. However, the ability of MRL proteins to interact with multiple actin regulators and to promote serum response factor (SRF) signalling has raised the question of whether MRL proteins employ alternative downstream mechanisms to drive oncogenic processes in a context-dependent manner. Here, using a Drosophila model, we show that overexpression of either human Lpd or its Drosophila orthologue Pico can promote growth and invasion of Ras(V12)-induced cell tumours in the brain. Notably, effects were restricted to two populations of Repo-positive glial cells: an invasive population, characterized by JNK-dependent elevation of Mmp1 expression, and a hyperproliferative population lacking elevated JNK signalling. JNK activation was not triggered by reactive immune cell signalling, implicating the involvement of an intrinsic stress response. The ability to promote dissemination of Ras(V12)-induced tumours was shared by a subset of actin regulators, including, most prominently, Chicadee/Profilin, which directly interacts with Pico, and, Mal, a cofactor for serum response factor that responds to changes in G:F actin dynamics. Suppression of Mal activity partially abrogated the ability of pico to promote invasion of Ras(V12) tumours. Furthermore, we found that larval glia are enriched for serum response factor expression, explaining the apparent sensitivity of glial cells to Pico/Ras(V12) overexpression. Taken together, our findings indicate that MRL proteins cooperate with oncogenic Ras to promote formation of glial tumours, and that, in this context, Mal/serum response factor activation is rate-limiting for tumour dissemination.	[Taylor, E.; Alqadri, N.; Dodgson, L.; Lyulcheva, E.; Messina, G.; Bennett, D.] Univ Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, England; [Dodgson, L.; Mason, D.; Bennett, D.] Univ Liverpool, Ctr Cell Imaging, Biosci Bldg, Liverpool, Merseyside, England; [Taylor, E.] Liverpool Womens NHS Fdn Trust, Crown St, Liverpool L8 7SS, Merseyside, England; [Dodgson, L.; Lyulcheva, E.] Salford Royal NHS Fdn Trust, Salford M6 8HD, Lancs, England	University of Liverpool; University of Liverpool; Salford Royal NHS Foundation Trust	Bennett, D (corresponding author), Univ Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, England.	daimark.bennett@liverpool.ac.uk	Messina, Giovanni/AAE-8668-2022; Bennett, Daimark/E-2701-2014	Messina, Giovanni/0000-0002-0011-867X; Alqadri, Nada/0000-0003-3607-2359; Messina, Giovanni/0000-0002-7597-4972; Bennett, Daimark/0000-0002-0014-2290; Mason, David/0000-0002-8773-5274	BBSRC [BB/L014947/1, BB/M012441/1]; MRC [MR/K015931/1]; CRUK [C20691/A11834]; Biotechnology and Biological Sciences Research Council [BB/L014947/1] Funding Source: researchfish; Medical Research Council [MR/K015931/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the Bloomington Stock Centre, Zhe Han, Julian Ng, Pernille Rorth, Eyal Schejter, Marcos Vidal, Sanjai Patel and the Manchester Fly Facility for Drosophila strains, B Altenhein, I Ando, the Developmental Studies Hybridoma Bank, S Baumgartner and Manzoor Bhat for antibodies, Marco Marcello in the Liverpool Centre for Cell Imaging for assistance with image acquisition, Chris Lofthouse for artwork, and Mirel Lucaci for technical assistance. This work was supported by grants from BBSRC (BB/L014947/1, BB/M012441/1), MRC (MR/K015931/1) and CRUK (C20691/A11834).	Allan C, 2012, NAT METHODS, V9, P245, DOI [10.1038/NMETH.1896, 10.1038/nmeth.1896]; Andersen DS, 2015, NATURE, V522, P482, DOI 10.1038/nature14298; Balcer HI, 2003, CURR BIOL, V13, P2159, DOI 10.1016/S0960-9822(03)00907-2; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bennett D, 2015, OCUL ONCOL PATHOL, V1, P190, DOI 10.1159/000370155; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Carmona G, 2016, ONCOGENE, V35, P5155, DOI 10.1038/onc.2016.47; Choi C, 2014, ONCOGENE, V33, P3668, DOI 10.1038/onc.2013.341; Chotard C, 2005, NEURON, V48, P237, DOI 10.1016/j.neuron.2005.09.019; Chuang HN, 2013, GLIA, V61, P1331, DOI 10.1002/glia.22518; Ciurciu A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003885; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Donlea JM, 2009, SCIENCE, V324, P105, DOI 10.1126/science.1166657; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Friese MA, 2004, ONKOLOGIE, V27, P487, DOI 10.1159/000080371; Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Han Z, 2004, P NATL ACAD SCI USA, V101, P12567, DOI 10.1073/pnas.0405085101; Hansen SD, 2015, ELIFE, V4, DOI 10.7554/eLife.06585; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Kurucz E, 2007, CURR BIOL, V17, P649, DOI 10.1016/j.cub.2007.02.041; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Law AL, 2013, J CELL BIOL, V203, P673, DOI 10.1083/jcb.201304051; Logan MA, 2007, NEURON GLIA BIOL, V3, P63, DOI [10.1017/S1740925X0700049X, 10.1017/S1740925X07000646]; Lyulcheva E, 2008, DEV CELL, V15, P680, DOI 10.1016/j.devcel.2008.09.020; MacDonald JM, 2013, CELL DEATH DIFFER, V20, P1140, DOI 10.1038/cdd.2013.30; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Nawaz S, 2015, DEV CELL, V34, P139, DOI 10.1016/j.devcel.2015.05.013; Ohayon D, 2009, EMBO J, V28, P3228, DOI 10.1038/emboj.2009.247; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Petryszak R, 2016, NUCLEIC ACIDS RES, V44, pD746, DOI 10.1093/nar/gkv1045; Pinheiro EM, 2011, NAT CELL BIOL, V13, P989, DOI 10.1038/ncb2292; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Salvany L, 2014, GENE DEV, V28, P1048, DOI 10.1101/gad.237743.114; Shekhar S, 2016, J CELL SCI, V129, P1085, DOI 10.1242/jcs.179994; Shklover J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.27; Skau CT, 2015, ANNU REV BIOPHYS, V44, P285, DOI 10.1146/annurev-biophys-060414-034308; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Stevenson RP, 2012, J CELL SCI, V125, P1073, DOI 10.1242/jcs.093799; Thran J, 2013, CURR BIOL, V23, P1756, DOI 10.1016/j.cub.2013.07.034; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wu Y, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-53; Ziv-Av A, 2011, CELL SIGNAL, V23, P1936, DOI 10.1016/j.cellsig.2011.07.001	56	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4311	4322		10.1038/onc.2017.68	http://dx.doi.org/10.1038/onc.2017.68			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346426	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000406360600008
J	Guo, X; Koff, JL; Moffitt, AB; Cinar, M; Ramachandiran, S; Chen, Z; Switchenko, JM; Mosunjac, M; Neill, SG; Mann, KP; Bagirov, M; Du, Y; Natkunam, Y; Khoury, HJ; Rossi, MR; Harris, W; Flowers, CR; Lossos, IS; Boise, LH; Dave, SS; Kowalski, J; Bernal-Mizrachi, L				Guo, X.; Koff, J. L.; Moffitt, A. B.; Cinar, M.; Ramachandiran, S.; Chen, Z.; Switchenko, J. M.; Mosunjac, M.; Neill, S. G.; Mann, K. P.; Bagirov, M.; Du, Y.; Natkunam, Y.; Khoury, H. J.; Rossi, M. R.; Harris, W.; Flowers, C. R.; Lossos, I. S.; Boise, L. H.; Dave, S. S.; Kowalski, J.; Bernal-Mizrachi, L.			Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype	ONCOGENE			English	Article							NF-KAPPA-B; ANTI-CD20 MONOCLONAL-ANTIBODY; GENE-EXPRESSION; DNA-DAMAGE; SOMATIC MUTATIONS; MARGINAL ZONE; LYMPHOMA; ACTIVATION; COMPLEX; PROTEIN	Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like (GCB) and activated B-cell like (ABC). Although ABC-DLBCL has been associated with NF-kappa B activation, the relationships between activation of specific NF-.B signals and DLBCL phenotype remain unclear. Application of novel gene expression classifiers identified two new DLBCL categories characterized by selective p100 (NF-kappa B2) and p105 (NF-kappa B1) signaling. Interestingly, our molecular studies showed that p105 signaling is predominantly associated with GCB subtype and histone mutations. Conversely, most tumors with p100 signaling displayed ABC phenotype and harbored ABC-associated mutations in genes such as MYD88 and PIM1. In vitro, MYD88 L265P mutation promoted p100 signaling through TAK1/IKKa and GSK3/Fbxw7a pathways, suggesting a novel role for this protein as an upstream regulator of p100. p100 signaling was engaged during activation of normal B cells, suggesting p100' s role in ABC phenotype development. Additionally, silencing p100 in ABC-DLBCL cells resulted in a GCB-like phenotype, with suppression of Blimp, IRF4 and XBP1 and upregulation of BCL6, whereas introduction of p52 or p100 into GC cells resulted in differentiation toward an ABC-like phenotype. Together, these findings identify specific roles for p100 and p105 signaling in defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activation.	[Guo, X.; Koff, J. L.; Cinar, M.; Ramachandiran, S.; Khoury, H. J.; Harris, W.; Flowers, C. R.; Boise, L. H.; Kowalski, J.; Bernal-Mizrachi, L.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd,Bldg C,3rd Floor, Atlanta, GA 30322 USA; [Moffitt, A. B.; Dave, S. S.] Duke Univ, Duke Inst Genome Sci & Policy, Dept Med, Durham, NC USA; [Chen, Z.; Switchenko, J. M.; Kowalski, J.] Emory Univ, Winship Canc Inst, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Mosunjac, M.; Neill, S. G.; Mann, K. P.; Bagirov, M.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Du, Y.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; [Natkunam, Y.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Rossi, M. R.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Lossos, I. S.] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol Oncol & Mol & Cellular Pharmacol, Miami, FL USA	Emory University; Duke University; Emory University; Emory University; Emory University; Stanford University; Emory University; University of Miami	Bernal-Mizrachi, L (corresponding author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd,Bldg C,3rd Floor, Atlanta, GA 30322 USA.	lbernal@emory.edu	Flowers, Christopher R/F-1953-2010; Boise, Lawrence/AAD-2314-2019; Natkunam, Yasodha/L-5454-2015	Flowers, Christopher R/0000-0002-9524-3990; Natkunam, Yasodha/0000-0002-9816-1018; Moffitt, Andrea/0000-0001-5964-7851; Boise, Lawrence/0000-0001-9436-8815; Kowalski, Jeanne/0000-0003-3458-3024	NIH [R21 CA158686, K24 CA208132, CA109335, CA122105, CA127910, CA129968]; GCCDSW; Dwoskin and Rizzo Family and Fidelity; Byron Davis Research Fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GCCDSW; Dwoskin and Rizzo Family and Fidelity; Byron Davis Research Fund	We thank Dr Sagar Lonial and Dr Jing Chen for their critical review and helpful comments. We thank Dr Anne J Novak for providing the L265P MYD88 lentivirus. CRF was supported by NIH (R21 CA158686 and K24 CA208132) and GCCDSW. ISL by the NIH (CA109335 and CA122105) and the Dwoskin and Rizzo Family and Fidelity. JK was supported by GCCDSW. LHB received funding support from the NIH (CA127910 and CA129968) and a GCCDSW. LB-M received funding from the Byron Davis Research Fund.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Angus SP, 2012, ONCOGENE, V31, P4709, DOI 10.1038/onc.2011.622; Ansell SM, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.4; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Bernal-Mizrachi L, 2006, P NATL ACAD SCI USA, V103, P9220, DOI 10.1073/pnas.0507809103; Bowles JA, 2006, BLOOD, V108, P2648, DOI 10.1182/blood-2006-04-020057; Braggio E, 2012, MODERN PATHOL, V25, P651, DOI 10.1038/modpathol.2011.213; Chan YW, 2009, J CELL BIOL, V185, P859, DOI 10.1083/jcb.200812167; Chang H, 2007, MOL CANCER THER, V6, P24, DOI 10.1158/1535-7163.MCT-06-0443; Chattopadhyay S, 2007, MOL BIOL CELL, V18, P4085, DOI 10.1091/mbc.E06-12-1148; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Gasparini C, 2014, CELL MOL LIFE SCI, V71, P2083, DOI 10.1007/s00018-013-1545-4; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182; Hale JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010127; Harvey D, 2011, RHEUMATOLOGY, V50, P1720, DOI 10.1093/rheumatology/ker199; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Jazirehi AR, 2005, CANCER RES, V65, P264; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; Kaser A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Klon AE, 2002, J MOL BIOL, V320, P677, DOI 10.1016/S0022-2836(02)00469-2; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lenz G, 2010, NEW ENGL J MED, V362, P1417, DOI 10.1056/NEJMra0807082; Lepin EJM, 2000, EUR J IMMUNOL, V30, P3552, DOI 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Loiodice I, 2004, MOL BIOL CELL, V15, P3333, DOI 10.1091/mbc.E03-12-0878; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Navarro F, 1999, EUR J IMMUNOL, V29, P277, DOI 10.1002/(SICI)1521-4141(199901)29:01<277::AID-IMMU277>3.0.CO;2-4; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Ramachandiran S, 2015, INT J CANCER, V136, P2341, DOI 10.1002/ijc.29301; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Roodink I, 2008, AM J PATHOL, V173, P1873, DOI 10.2353/ajpath.2008.080136; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; Thompson MP, 2003, LEUKEMIA, V17, P2196, DOI 10.1038/sj.leu.2403130; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu RP, 2010, P NATL ACAD SCI USA, V107, P7479, DOI 10.1073/pnas.1002890107; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; Zhang BC, 2015, CELL REP, V11, P715, DOI 10.1016/j.celrep.2015.03.059; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037; Zhu DX, 2013, AM J HEMATOL, V88, P730, DOI 10.1002/ajh.23490; Zhu H, 2008, J CELL BIOL, V183, P835, DOI 10.1083/jcb.200807046	71	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4224	4232		10.1038/onc.2017.90	http://dx.doi.org/10.1038/onc.2017.90			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28368397				2022-12-28	WOS:000405835800013
J	Marshall, AD; Bailey, CG; Champ, K; Vellozzi, M; O'Young, P; Metierre, C; Feng, Y; Thoeng, A; Richards, AM; Schmitz, U; Biro, M; Jayasinghe, R; Ding, L; Anderson, L; Mardis, ER; Rasko, JEJ				Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Richards, A. M.; Schmitz, U.; Biro, M.; Jayasinghe, R.; Ding, L.; Anderson, L.; Mardis, E. R.; Rasko, J. E. J.			CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; CELL-LINE; SOMATIC MUTATIONS; EPITHELIAL-CELLS; INTRON RETENTION; DNA METHYLATION; E-CADHERIN; BINDING; CANCER	CTCF is a haploinsufficient tumour suppressor gene with diverse normal functions in genome structure and gene regulation. However the mechanism by which CTCF haploinsufficiency contributes to cancer development is not well understood. CTCF is frequently mutated in endometrial cancer. Here we show that most CTCF mutations effectively result in CTCF haploinsufficiency through nonsense-mediated decay of mutant transcripts, or loss-of-function missense mutation. Conversely, we identified a recurrent CTCF mutation K365T, which alters a DNA binding residue, and acts as a gain-of-function mutation enhancing cell survival. CTCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is associated with poor overall survival. In addition, we have shown that CTCF haploinsufficiency also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endometrial cancer relapse and metastasis. Using shRNA targeting CTCF to recapitulate CTCF haploinsufficiency, we have identified a novel role for CTCF in the regulation of cellular polarity of endometrial glandular epithelium. Overall, we have identified two novel pro-tumorigenic roles (promoting cell survival and altering cell polarity) for genetic alterations of CTCF in endometrial cancer.	[Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Schmitz, U.; Rasko, J. E. J.] Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Schmitz, U.; Anderson, L.; Rasko, J. E. J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Richards, A. M.] Royal Prince Alfred Hosp, Gynaecol Oncol, Camperdown, NSW, Australia; [Biro, M.] Univ New South Wales, Sch Med Sci, Cell Motil & Mech, Sydney, NSW, Australia; [Jayasinghe, R.; Ding, L.; Mardis, E. R.] Washington Univ, McDonnell Genome Inst, Canc Genom, St Louis, MO USA; [Jayasinghe, R.; Ding, L.; Mardis, E. R.] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA; [Anderson, L.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Rasko, J. E. J.] Royal Prince Alfred Hosp, Cell & Mol Therapies, Sydney, NSW, Australia	University of Sydney; Centenary Institute; University of Sydney; University of Sydney; University of New South Wales Sydney; Washington University (WUSTL); Washington University (WUSTL); University of Sydney; University of Sydney	Rasko, JEJ (corresponding author), RPA Hosp, Centenary Inst, Gene & Stem Cell Therapy, Bldg 93, Sydney, NSW 2050, Australia.	j.rasko@centenary.org.au	Schmitz, Ulf/B-5400-2010; Anderson, Lyndal/AAE-5780-2019; Mardis, Elaine/W-2202-2019; Biro, Mate/H-6292-2014	Schmitz, Ulf/0000-0001-5806-4662; Anderson, Lyndal/0000-0002-9405-8195; Biro, Mate/0000-0001-5852-3726; Marshall, Amy/0000-0001-5803-3815; Bailey, Charles/0000-0002-4725-7829; rasko, John/0000-0003-2975-807X	Tour de Cure (Scott Canner Research Fellowship); Cancer Council NSW [RG14-09, RG14-05]; Cure The Future Foundation; National Institute of General Medical Sciences Cell and Molecular Biology [GM 007067]; NATIONAL CANCER INSTITUTE [R01CA180006, U24CA211006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	Tour de Cure (Scott Canner Research Fellowship); Cancer Council NSW(Cancer Council New South Wales); Cure The Future Foundation; National Institute of General Medical Sciences Cell and Molecular Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Financial support was provided by Tour de Cure (Scott Canner Research Fellowship) to CGB and for research grants to ADM, CGB and JEJR; Cancer Council NSW project grants (RG14-09) to JEJR and CGB; (RG14-05) to JEJR; support grants from Cure The Future Foundation and an anonymous foundation; National Institute of General Medical Sciences Cell and Molecular Biology training grant (GM 007067) to RJ. We thank the Centenary Institute Advanced Cytometry Facility for FACS and imaging. The authors acknowledge the University of Sydney HPC service at The University of Sydney for providing HPC, visualisation, database, and/or grid resources that have contributed to the research results reported within this paper. URL: http://sydney.edu.au/research_support/.	Allison KH, 2008, AM J SURG PATHOL, V32, P691, DOI 10.1097/PAS.0b013e318159a2a0; Aulmann S, 2003, BREAST CANCER RES TR, V80, P347, DOI 10.1023/A:1024930404629; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brar AK, 1996, MOL HUM REPROD, V2, P185, DOI 10.1093/molehr/2.3.185; Carico E, 2010, ANTICANCER RES, V30, P4993; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Eritja N, 2010, AM J PATHOL, V176, P2722, DOI 10.2353/ajpath.2010.090974; Filippova GN, 2002, CANCER RES, V62, P48; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Rodilla I, 2013, ANTICANCER RES, V33, P5091; Haidopoulos D, 2010, ACTA OBSTET GYN SCAN, V89, P1326, DOI 10.3109/00016349.2010.515666; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hirosue A, 2012, AGING CELL, V11, P553, DOI 10.1111/j.1474-9726.2012.00809.x; Jimenez-Ayala M., 2008, MONOGRAPHS CLIN CYTO, P32, DOI [10.1159/000117494, DOI 10.1159/000117494]; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kemp CJ, 2014, CELL REP, V7, P1020, DOI 10.1016/j.celrep.2014.04.004; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; KURAMOTO H, 1972, AM J OBSTET GYNECOL, V114, P1012, DOI 10.1016/0002-9378(72)90861-7; Kurman RJ, 2014, WHO CLASSIFICATION T, P128; Lacey JV, 2009, MATURITAS, V63, P39, DOI 10.1016/j.maturitas.2009.02.005; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li R, 2005, CANCER LETT, V219, P33, DOI 10.1016/j.canlet.2004.06.044; Li T, 2007, EXP CELL RES, V313, P3057, DOI 10.1016/j.yexcr.2007.05.018; Llaurado M, 2012, MOL CELL ENDOCRINOL, V358, P244, DOI 10.1016/j.mce.2011.10.003; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Marshall AD, 2016, INT J CANCER, V139, P2529, DOI 10.1002/ijc.30371; Marshall AD, 2014, CURR OPIN GENET DEV, V24, P8, DOI 10.1016/j.gde.2013.10.011; Moore JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034915; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Nakahashi H, 2013, CELL REP, V3, P1678, DOI 10.1016/j.celrep.2013.04.024; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Rakha EA, 2005, INT J CANCER, V114, P720, DOI 10.1002/ijc.20738; Rasko JEJ, 2001, CANCER RES, V61, P6002; Reardon SN, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.112.098871; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; RICHARDSON GS, 1984, GYNECOL ONCOL, V17, P213, DOI 10.1016/0090-8258(84)90080-5; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Tiffen JC, 2013, INT J CANCER, V133, P1603, DOI 10.1002/ijc.28184; Ukraintseva SV, 2008, ADV EXP MED BIOL, V630, P57; Walker C, 2015, JNCI-J NATL CANCER I, V107; Watanabe N, 2007, GENE CHROMOSOME CANC, V46, P929, DOI 10.1002/gcc.20481; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052; Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759; Zighelboim I, 2014, HUM MUTAT, V35, P63, DOI 10.1002/humu.22463	54	29	30	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4100	4110		10.1038/onc.2017.25	http://dx.doi.org/10.1038/onc.2017.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319062	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000405835800002
J	Li, B; Xu, WW; Han, L; Chan, KT; Tsao, SW; Lee, NPY; Law, S; Xu, LY; Li, EM; Chan, KW; Qin, YR; Guan, XY; He, QY; Cheung, ALM				Li, B.; Xu, W. W.; Han, L.; Chan, K. T.; Tsao, S. W.; Lee, N. P. Y.; Law, S.; Xu, L. Y.; Li, E. M.; Chan, K. W.; Qin, Y. R.; Guan, X. Y.; He, Q. Y.; Cheung, A. L. M.			MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; FACTOR EXPRESSION; PROGNOSTIC VALUE; ANGIOGENESIS; ACTIVATION; CHEMORESISTANCE; METASTASIS; ADENOVIRUS; CARCINOMA	Esophageal cancer is one of the most lethal cancers worldwide with poor survival and limited therapeutic options. The discovery of microRNAs created a new milestone in cancer research. miR-377 is located in chromosome region 14q32, which is frequently deleted in esophageal squamous cell carcinoma (ESCC), but the biological functions, clinical significance and therapeutic implication of miR-377 in ESCC are largely unknown. In this study, we found that miR-377 expression was significantly downregulated in tumor tissue and serum of patients with ESCC. Both tumor tissue and serum miR-377 expression levels were positively correlated with patient survival. Higher serum miR-377 expression was inversely associated with pathologic tumor stage, distant metastasis, residual tumor status and chemoradiotherapy resistance. The roles of miR-377 in suppressing tumor initiation and progression, and the underlying molecular mechanisms were investigated. Results of in vitro and in vivo experiments showed that miR-377 overexpression inhibited the initiation, growth and angiogenesis of ESCC tumors as well as metastatic colonization of ESCC cells, whereas silencing of miR-377 had opposite effects. Mechanistically, miR-377 regulated CD133 and VEGF by directly binding to their 3' untranslated region. Moreover, systemic delivery of formulated miR-377 mimic not only suppressed tumor growth in nude mice but also blocked tumor angiogenesis and metastasis of ESCC cells to the lungs without overt toxicity to mice. Collectively, our study established that miR-377 plays a functional and significant role in suppressing tumor initiation and progression, and may represent a promising non-invasive diagnostic and prognostic biomarker and therapeutic strategy for patients with ESCC.	[Li, B.; Xu, W. W.; Han, L.; Tsao, S. W.; Cheung, A. L. M.] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China; [Li, B.; Xu, W. W.; Han, L.; Cheung, A. L. M.] Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China; [Li, B.; Tsao, S. W.; Lee, N. P. Y.; Law, S.; Chan, K. W.; Guan, X. Y.; Cheung, A. L. M.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Peoples R China; [Chan, K. T.; Lee, N. P. Y.; Law, S.] Univ Hong Kong, Dept Surg, Pokfulam, Peoples R China; [Xu, L. Y.; Li, E. M.] Shantou Univ Med Coll, Key Lab Mol Biol High Canc Incidence Coastal Chao, Shantou, Peoples R China; [Chan, K. W.] Univ Hong Kong, Dept Pathol, Pokfulam, Peoples R China; [Qin, Y. R.] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Oncol, Zhengzhou, Peoples R China; [Guan, X. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Pokfulam, Peoples R China; [He, Q. Y.] Jinan Univ, Coll Life Sci & Technol, 601 West Huangpu Blvd, Guangzhou, Guangdong, Peoples R China; [Li, B.] Jinan Univ, Coll Life Sci & Technol, 601 West Huangpu Blvd, Guangzhou 510632, Guangdong, Peoples R China; [Xu, W. W.] Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, 601 West Huangpu Blvd, Guangzhou 510632, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Zhengzhou University; University of Hong Kong; Jinan University; Jinan University; Jinan University	Cheung, ALM (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hku.hk	He, Qing-Yu/H-7078-2014; Law, Simon/C-4324-2009; /C-4230-2009; /A-3639-2009	He, Qing-Yu/0000-0003-0503-9492; Law, Simon/0000-0002-6518-5806; /0000-0003-3217-1456; /0000-0003-1874-9805	Research Grants Council of the Hong Kong SAR, China [HKU 763111M, HKU 17103814]; CRCG [201111159198, 201211159003]; National Natural Science Foundation of China [81472790]; University of Hong Kong SRT Cancer research program	Research Grants Council of the Hong Kong SAR, China(Hong Kong Research Grants Council); CRCG; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Hong Kong SRT Cancer research program	We thank Professor Yutaka Shimada (University of Toyama, Toyama, Japan) and DSMZ for the KYSE cell lines; Prof G Srivastava, Department of Pathology, University of Hong Kong for the HKESC-1 cell line; Dr Hitoshi Kawamata (Dokkyo University School of Medicine, Tochigi, Japan) for the T.Tn cell line; and Mr. Yiwei Xu (Shantou University Medical College, Shantou, Guangdong, China) for collection of patient serum. We also thank Prof Quan Chen (Institute of Zoology, Chinese Academy of Sciences, Beijing, China) for CD133-knockdown and control plasmids as well as virus packaging plasmids, Prof Gregory M. Vercellotti (University of Minnesota Medical School, Minneapolis, MN) for miR-377-expressing constructs, and Dr Anna CM Tsang (School of Biomedical Sciences, University of Hong Kong) for help in flow cytometry. Flow cytometry and cell sorting were performed and analyzed using equipment maintained by the University of Hong Kong Li Ka Shing Faculty of Medicine Faculty Core Facility. This work recieves Grant Support from Research Grants Council of the Hong Kong SAR, China (GRF Project Nos. HKU 763111M and HKU 17103814); The University of Hong Kong SRT Cancer research program and CRCG (Project Nos. 201111159198, 201211159003); National Natural Science Foundation of China (Project No. 81472790). The study sponsors are not involved in study design, or collection, analysis, interpretation of data.	Anson Donald S, 2004, Genet Vaccines Ther, V2, P9, DOI 10.1186/1479-0556-2-9; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Chen YC, 2015, ADV DRUG DELIVER REV, V81, P128, DOI 10.1016/j.addr.2014.05.009; Cheung A., 2015, GASTROINTEST CANC TA, V5, P79; Dong L, 2010, NEUROSCI LETT, V484, P210, DOI 10.1016/j.neulet.2010.08.057; Ebert G, 2011, GASTROENTEROLOGY, V141, P696, DOI 10.1053/j.gastro.2011.05.001; El-Khattouti A, 2015, CANCER LETT, V357, P83, DOI 10.1016/j.canlet.2014.10.043; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hang D, 2012, DIS ESOPHAGUS, V25, P638, DOI 10.1111/j.1442-2050.2011.01298.x; Hu YC, 2000, CANCER GENET CYTOGEN, V118, P112, DOI 10.1016/S0165-4608(99)00193-4; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Ihara Y, 2002, CANCER GENET CYTOGEN, V135, P177, DOI 10.1016/S0165-4608(01)00654-9; Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037; Kawamata H, 2003, CANCER SCI, V94, P699, DOI 10.1111/j.1349-7006.2003.tb01505.x; Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li B, 2014, CLIN CANCER RES, V20, P2651, DOI 10.1158/1078-0432.CCR-13-2735; Li B, 2009, MOL CANCER THER, V8, P2635, DOI 10.1158/1535-7163.MCT-09-0162; Lu CL, 2015, J THORAC CARDIOV SUR, V150, P386, DOI 10.1016/j.jtcvs.2015.05.030; Lu J, 2017, ONCOGENE, V36, P231, DOI 10.1038/onc.2016.194; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Nakajima TE, 2012, CANCER SCI, V103, P233, DOI 10.1111/j.1349-7006.2011.02142.x; Okamoto K, 2016, ONCOL REP, V36, P3333, DOI 10.3892/or.2016.5133; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Peng J, 2013, J BUON, V18, P398; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]; Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991; Tang KH, 2012, HEPATOLOGY, V55, P807, DOI 10.1002/hep.24739; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; Tong DKH, 2010, ANN SURG ONCOL, V17, P2184, DOI 10.1245/s10434-010-0995-2; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Uchino K, 2013, JPN J CLIN ONCOL, V43, P596, DOI 10.1093/jjco/hyt052; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Won C, 2015, HEPATOLOGY, V62, P1160, DOI 10.1002/hep.27968; Xu WW, 2015, ONCOTARGET, V6, P1790, DOI 10.18632/oncotarget.2781; Zaiss AK, 2002, J VIROL, V76, P4580, DOI 10.1128/JVI.76.9.4580-4590.2002; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419	54	109	115	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3986	4000		10.1038/onc.2017.29	http://dx.doi.org/10.1038/onc.2017.29			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288140	Green Published, hybrid			2022-12-28	WOS:000405379900005
J	Jin, L; Chun, J; Pan, C; Alesi, GN; Li, D; Magliocca, KR; Kang, Y; Chen, ZG; Shin, DM; Khuri, FR; Fan, J; Kang, S				Jin, L.; Chun, J.; Pan, C.; Alesi, G. N.; Li, D.; Magliocca, K. R.; Kang, Y.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Fan, J.; Kang, S.			Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis	ONCOGENE			English	Article							LACTATE-DEHYDROGENASE; TYROSINE PHOSPHORYLATION; REDOX HOMEOSTASIS; DOWN-REGULATION; SRC ACTIVATION; NECK-CANCER; HEAD; PROGRESSION; CARCINOMA; METABOLISM	Metastases remain the major cause of death from cancer. Recent molecular advances have highlighted the importance of metabolic alterations in cancer cells, including the Warburg effect that describes an increased glycolysis in cancer cells. However, how this altered metabolism contributes to tumour metastasis remains elusive. Here, we report that phosphorylation-induced activation of lactate dehydrogenase A (LDHA), an enzyme that catalyses the interconversion of pyruvate and lactate, promotes cancer cell invasion, anoikis resistance and tumour metastasis. We demonstrate that LDHA is phosphorylated at tyrosine 10 by upstream kinases, HER2 and Src. Targeting HER2 or Src attenuated LDH activity as well as invasive potential in head and neck cancer and breast cancer cells. Inhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated cell invasion and elevated reactive oxygen species, whereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox homeostasis. In addition, LDHA knockdown or LDHA Y10F rescue expression in human cancer cells resulted in decreased tumour metastasis in xenograft mice. Furthermore, LDHA phosphorylation at Y10 positively correlated with progression of metastatic breast cancer in clinical patient tumour samples. Our findings demonstrate that LDHA phosphorylation and activation provide pro-invasive, antianoikis and pro-metastatic advantages to cancer cells, suggesting that Y10 phosphorylation of LDHA may represent a promising therapeutic target and a prognostic marker for metastatic human cancers.	[Jin, L.; Chun, J.; Pan, C.; Alesi, G. N.; Li, D.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.] Emory Univ, Winship Canc Inst, Sch Med, Dept Hematol Med Oncol, Atlanta, GA 30322 USA; [Magliocca, K. R.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Fan, J.] Emory Univ, Winship Canc Inst, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Princeton University; Emory University	Kang, S (corresponding author), Emory Univ, Winship Canc Inst, Sch Med, Hematol & Med Oncol, 1365-C Clifton Rd NE, Atlanta, GA 30322 USA.	smkang@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Kang, Yibin/0000-0002-1626-6730	NIH [R01 CA175316, F31 CA183365]; ACS grant [RSG-11-08101]; NATIONAL CANCER INSTITUTE [R01CA175316] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01 CA175316 (Sumin Kang), F31 CA183365 (Gina N. Alesi), and ACS grant RSG-11-08101 (Sumin Kang).	Alesi GN, 2016, ONCOGENE, V35, P5412, DOI 10.1038/onc.2016.79; Baumann F, 2009, NEURO-ONCOLOGY, V11, P368, DOI 10.1215/15228517-2008-106; Beckert S, 2006, WOUND REPAIR REGEN, V14, P321, DOI 10.1111/j.1743-6109.2006.00127.x; Birkeland AC, 2016, JAMA OTOLARYNGOL, V142, P559, DOI 10.1001/jamaoto.2016.0335; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; De Souza JA, 2012, CLIN CANCER RES, V18, P2336, DOI 10.1158/1078-0432.CCR-11-2825; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fury MG, 2011, ANTICANCER RES, V31, P249; Gao S, 2016, BIOMED PHARMACOTHER, V81, P388, DOI 10.1016/j.biopha.2016.04.029; Granchi C, 2011, J MED CHEM, V54, P1599, DOI 10.1021/jm101007q; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Li D, 2013, J BIOL CHEM, V288, P32528, DOI 10.1074/jbc.M113.500561; Li J, 2016, NEUROREPORT, V27, P110, DOI 10.1097/WNR.0000000000000506; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; Miao P, 2013, IUBMB LIFE, V65, P904, DOI 10.1002/iub.1216; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Puls LN, 2011, ONCOLOGIST, V16, P566, DOI 10.1634/theoncologist.2010-0408; Rizwan A, 2013, CLIN CANCER RES, V19, P5158, DOI 10.1158/1078-0432.CCR-12-3300; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sheng SL, 2012, FEBS J, V279, P3898, DOI 10.1111/j.1742-4658.2012.08748.x; Stabile LP, 2013, CLIN CANCER RES, V19, P380, DOI 10.1158/1078-0432.CCR-12-1555; Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Xian ZY, 2015, TUMOR BIOL, V36, P8093, DOI 10.1007/s13277-015-3540-x; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yu Y, 2001, BIOCHEM PHARMACOL, V62, P81, DOI 10.1016/S0006-2952(01)00636-0; Zhang X, 2002, CANCER-AM CANCER SOC, V95, P1663, DOI 10.1002/cncr.10837; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690	51	130	138	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3797	3806		10.1038/onc.2017.6	http://dx.doi.org/10.1038/onc.2017.6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28218905	Green Accepted			2022-12-28	WOS:000404848200001
J	Huang, TT; Zhou, YH; Zhang, JL; Wong, CC; Li, WL; Kwan, JSH; Yang, R; Chan, AKY; Dong, YJ; Wu, F; Zhang, B; Cheung, AHK; Wu, WKK; Chen, ASL; Yu, J; Wong, N; Kang, W; To, KF				Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Chi Chun; Li, Weilin; Kwan, Johnny S. H.; Yang, Rui; Chan, Aden K. Y.; Dong, Yujuan; Wu, Feng; Zhang, Bin; Cheung, Alvin H. K.; Wu, William K. K.; Chen, Alfred S. L.; Yu, Jun; Wong, Nathalie; Kang, Wei; To, Ka Fai			SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis	ONCOGENE			English	Article							RHO-GTPASES; BREAST-CANCER; PATHWAY; CARCINOGENESIS; MIGRATION; PROTEINS; PROMOTES; GROWTH; SLIT; ROBO	Slit-Robo GTPase-activating protein 1 (SRGAP1) functions as a GAP for Rho-family GTPases and downstream of Slit-Robo signaling. We aim to investigate the biological function of SRGAP1 and reveal its regulation by deregulated microRNAs (miRNAs) in gastric cancer (GC). mRNA and protein expression of SRGAP1 were examined by quantitative reverse transcription PCR (qRT-PCR) and western blot. The biological role of SRGAP1 was demonstrated through siRNA-mediated knockdown experiments. The regulation of SRGAP1 by miR-340 and miR-124 was confirmed by western blot, dual luciferase activity assays and rescue experiments. SRGAP1 is overexpressed in 9 out of 12 (75.0%) GC cell lines. In primary GC samples from TCGA cohort, SRGAP1 shows gene amplification in 5/258 (1.9%) of cases and its mRNA expression demonstrates a positive correlation with copy number gain. Knockdown of SRGAP1 in GC cells suppressed cell proliferation, reduced colony formation, and significantly inhibited cell invasion and migration. Luciferase reporter assays revealed that SRGAP1 knockdown significantly inhibited Wnt/beta-catenin pathway. In addition, SRGAP1 was found to be a direct target of two tumor-suppressive miRNAs, miR-340 and miR-124. Concordantly, these two miRNAs were downregulated in primary gastric tumors and these decreasing levels w5ere associated with poor outcomes. Expression of miR-340 and SRGAP1 displayed a reverse relationship in primary samples and re-expressed SRGAP1, rescued the anti-cancer effects of miR-340. Taken together, these data strongly suggest that, apart from gene amplification and mutation, the activation of SRGAP1 in GC is partly due to the downregulation of tumor-suppressive miRNAs, miR-340 and miR-124. Thus SRGAP1 is overexpressed in gastric carcinogenesis and plays an oncogenic role through activating Wnt/beta-catenin pathway.	[Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Kwan, Johnny S. H.; Yang, Rui; Chan, Aden K. Y.; Wu, Feng; Cheung, Alvin H. K.; Wong, Nathalie; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Chi Chun; Li, Weilin; Dong, Yujuan; Wu, William K. K.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Partner State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Zhou, Yuhang; Zhang, Jinglin; Wong, Nathalie; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Huang, Tingting; Chen, Alfred S. L.; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Zhang, Bin] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Chen, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Nanjing University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Partner State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Li, Weilin/ABG-9032-2021; KANG, Wei/C-5451-2016; Dong, Yujuan/AAS-3467-2021; Wu, William K.K./A-3277-2009; Cheng, Alfred SL/C-3327-2014; wu, william/HII-5817-2022; Chan, Aden, Ka-yin/I-2535-2015; Jun, Yu/D-8569-2015	KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Cheng, Alfred SL/0000-0003-2345-6951; Cheung, Alvin Ho-Kwan/0000-0002-3913-8117; Chan, Aden, Ka-yin/0000-0001-9176-963X; Jun, Yu/0000-0001-5008-2153	General Research Fund (RGC) from The Research Grants Council of Hong Kong [CUHK14114414, CUHK14110016]	General Research Fund (RGC) from The Research Grants Council of Hong Kong	We acknowledge the TCGA Research Network (http://cancergcnome.nih.gov/), The UCSC Cancer Genomics Browser (https://genome-cancer.uese.edu/), and NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/) for providing the gastric cancer data set and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14114414 and CUHK14110016) from The Research Grants Council of Hong Kong. We also acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong.	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen KX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5682; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Coutinho-Budd J, 2012, J CELL SCI, V125, P3390, DOI 10.1242/jcs.098962; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; He HL, 2013, J CLIN ENDOCR METAB, V98, pE973, DOI 10.1210/jc.2012-3823; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Huang TT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1984-4; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kang W, 2016, WORLD J GASTROENTERO, V22, P1279, DOI 10.3748/wjg.v22.i3.1279; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0281-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-80; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Kutys ML, 2014, NAT CELL BIOL, V16, P909, DOI 10.1038/ncb3026; Li WT, 2014, TUMOR BIOL, V35, P10897, DOI 10.1007/s13277-014-2402-2; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu S., 2015, COMPUT MATH METHODS, V2015, P1, DOI DOI 10.1155/2015/913726); Mason FM, 2011, J BIOL CHEM, V286, P6577, DOI 10.1074/jbc.M110.190397; Neukomm LJ, 2011, NAT CELL BIOL, V13, P79, DOI 10.1038/ncb2138; Peng XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-186; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Shi L, 2014, ASIAN PAC J CANCER P, V15, P10439, DOI 10.7314/APJCP.2014.15.23.10439; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Strong AMP, 2014, ARCH BIOCHEM BIOPHYS, V563, P118, DOI 10.1016/j.abb.2014.07.012; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Weiner OD, 2006, PLOS BIOL, V4, P186, DOI 10.1371/journal.pbio.0040038; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Yamazaki D, 2013, MOL BIOL CELL, V24, P3393, DOI 10.1091/mbc.E13-04-0178; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Ypsilanti AR, 2010, DEVELOPMENT, V137, P1939, DOI 10.1242/dev.044511; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1; Zhang QQ, 2015, ONCOTARGET, V6, P3123, DOI 10.18632/oncotarget.3060; Zhang T, 2014, ACTA BIOCH BIOPH SIN, V46, P1072, DOI 10.1093/abbs/gmu105; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou WJ, 2011, CELL RES, V21, P609, DOI 10.1038/cr.2011.17; Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2	49	31	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1159	1174		10.1038/s41388-017-0029-7	http://dx.doi.org/10.1038/s41388-017-0029-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29234151	hybrid, Green Published			2022-12-28	WOS:000426505400003
J	Zhao, SJ; Jiang, YQ; Xu, NW; Li, Q; Zhang, Q; Wang, SY; Li, J; Wang, YH; Zhang, YL; Jiang, SH; Wang, YJ; Huang, YJ; Zhang, XX; Tian, GA; Zhang, CC; Lv, YY; Dai, M; Liu, F; Zhang, R; Zhou, D; Zhang, ZG				Zhao, S-J; Jiang, Y-Q; Xu, N-W; Li, Q.; Zhang, Q.; Wang, S-Y; Li, J.; Wang, Y-H; Zhang, Y-L; Jiang, S-H; Wang, Y-J; Huang, Y-J; Zhang, X-X; Tian, G-A; Zhang, C-C; Lv, Y-Y; Dai, M.; Liu, F.; Zhang, R.; Zhou, D.; Zhang, Z-G			SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/beta-catenin signaling through stabilization of the WNT-receptor complex	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; NEGATIVE REGULATOR; SELF-RENEWAL; STEM-CELLS; GROWTH; SURVIVAL; CANCER; MECHANISMS; SARCOMAS; PATHWAY	Metastasis significantly reduces the survival rate of osteosarcoma (OS) patients. Therefore, identification of novel targets remains extremely important to prevent metastasis and treat OS. In this report, we show that SPARCL1 is downregulated in OS by epigenetic methylation of promoter DNA. In vitro and in vivo experiments revealed that SPARCL1 inhibits OS metastasis. We further demonstrated that SPARCL1-activated WNT/beta-catenin signaling by physical interaction with various frizzled receptors and lipoprotein receptor-related protein 5/6, leading to WNT-receptor complex stabilization. Activation of WNT/beta-catenin signaling contributes to the SPARCL1-mediated inhibitory effects on OS metastasis. Furthermore, we uncovered a paracrine effect of SPARCL1 on macrophage recruitment through activated WNT/beta-catenin signaling-mediated secretion of chemokine ligand5 from OS cells. These findings suggest that the targeting of SPARCL1 as a new anti-metastatic strategy for OS patients.	[Zhao, S-J; Jiang, Y-Q; Xu, N-W; Zhang, Q.; Wang, S-Y; Wang, Y-J; Huang, Y-J; Zhou, D.] Nanjing Med Univ, Changzhou Peoples Hosp 2, Affiliated Hosp, Dept Orthoped, Changzhou 213003, Jiangsu, Peoples R China; [Li, Q.; Li, J.; Wang, Y-H; Zhang, Y-L; Jiang, S-H; Zhang, X-X; Tian, G-A; Zhang, Z-G] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Sch Med,Ren Ji Hosp, Shanghai, Peoples R China; [Zhang, C-C; Lv, Y-Y; Zhang, R.] Southern Med Univ, Fengxian Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Dai, M.; Liu, F.] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; Southern Medical University - China; Shanghai Jiao Tong University	Zhou, D; Zhang, ZG (corresponding author), Nanjing Med Univ, Changzhou Peoples Hosp 2, Affiliated Hosp, Dept Orthoped, Changzhou 213003, Jiangsu, Peoples R China.	zhoudong1012@hotmail.com; zzhang@shsci.org	Jiang, Shuheng/M-6584-2019	Jiang, Shuheng/0000-0001-8516-6234; Zhao, Shujie/0000-0002-2820-2232	Major Program of Changzhou Health Bureau [CJ20160047]; Nineteenth Batch of Science Technology Program of Changzhou [2014YLC011]; H-level Medical Talents Training Project [2016CZBJ023]	Major Program of Changzhou Health Bureau; Nineteenth Batch of Science Technology Program of Changzhou; H-level Medical Talents Training Project	We are grateful to Dr Xiao-Li Zhou, Dr Xiao-Mei Yang, Dr Qin Yang, Dr Lei Zhu, Dr Li-Peng Hu and and Dr Xiao-Yan Cao for assistance with our experiments. This study was supported by grants from the Major Program of Changzhou Health Bureau (Grant number CJ20160047), the Nineteenth Batch of Science Technology Program of Changzhou (Grant number 2014YLC011) and the H-level Medical Talents Training Project (Grant number 2016CZBJ023).	Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Berraondo P, 2016, IMMUNOL REV, V274, P290, DOI 10.1111/imr.12464; Bhardwaj D, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00052; Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021; Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078-0432.CCR-10-2047; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Claeskens A, 2000, BRIT J CANCER, V82, P1123, DOI 10.1054/bjoc.1999.1051; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dancsok AR, 2017, ONCOTARGET, V8, P7068, DOI 10.18632/oncotarget.12548; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Du XL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-450; Fu Y, 2014, ONCOTARGET, V5, P6701, DOI 10.18632/oncotarget.2239; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522; Halleskog C, 2011, GLIA, V59, P119, DOI 10.1002/glia.21081; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hingorani P, 2016, CANCER GENET-NY, V209, P182, DOI 10.1016/j.cancergen.2016.03.004; Hu HG, 2012, CLIN CANCER RES, V18, P5438, DOI 10.1158/1078-0432.CCR-12-0124; Hurley PJ, 2015, CANCER RES, V75, P4322, DOI 10.1158/0008-5472.CAN-15-0024; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kim J, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6058147; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095; Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008-5472.CAN-04-2463; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Naschberger E, 2016, J CLIN INVEST, V126, P4187, DOI 10.1172/JCI78260; Nie J, 2009, J BIOL CHEM, V284, P1279, DOI 10.1074/jbc.M808285200; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Ren DN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7906; Ribeiro N, 2014, J CELL BIOCHEM, V115, P17, DOI 10.1002/jcb.24649; Sullivan MM, 2008, WOUND REPAIR REGEN, V16, P310, DOI 10.1111/j.1524-475X.2008.00370.x; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Wan Y, 2014, HUM PATHOL, V45, P1459, DOI 10.1016/j.humpath.2014.02.022; Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang ZG, 2006, CELL MOL LIFE SCI, V63, P82, DOI 10.1007/s00018-005-5416-5; Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429	49	46	47	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1049	1061		10.1038/onc.2017.403	http://dx.doi.org/10.1038/onc.2017.403			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084211	Green Published, hybrid			2022-12-28	WOS:000425905700008
J	Qiao, Y; Zhang, C; Li, A; Wang, D; Luo, Z; Ping, Y; Zhou, B; Liu, S; Li, H; Yue, D; Zhang, Z; Chen, X; Shen, Z; Lian, J; Li, Y; Wang, S; Li, F; Huang, L; Wang, L; Zhang, B; Yu, J; Qin, Z; Zhang, Y				Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Ping, Y.; Zhou, B.; Liu, S.; Li, H.; Yue, D.; Zhang, Z.; Chen, X.; Shen, Z.; Lian, J.; Li, Y.; Wang, S.; Li, F.; Huang, L.; Wang, L.; Zhang, B.; Yu, J.; Qin, Z.; Zhang, Y.			IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma	ONCOGENE			English	Article							BREAST-CANCER; CHEMOKINE RECEPTOR; DRUG-RESISTANCE; MYELOMA CELLS; TUMOR-GROWTH; IN-VIVO; MICROENVIRONMENT; METASTASIS; EXPRESSION; SURVIVAL	Various factors and cellular components in the tumor microenvironment are key drivers associated with drug resistance in many cancers. Here, we analyzed the factors and molecular mechanisms involved in chemoresistance in patients with esophageal squamous cell carcinoma (ESCC). We found that interleukin 6 (IL6) derived mainly from cancer-associated fibroblasts played the most important role in chemoresistance by upregulating C-X-C motif chemokine receptor 7 (CXCR7) expression through signal transducer and activator of transcription 3/nuclear factor-kappa B pathway. CXCR7 knockdown resulted in the inhibition of IL6-induced proliferation and chemoresistance. In addition, CXCR7 silencing significantly decreased gene expression associated with stemness, chemoresistance and epithelial-mesenchymal transition and suppressed the proliferation ability of ESCC cells in three-dimensional culture systems and angiogenesis assay. In clinical samples, ESCC patients with high expression of CXCR7 and IL6 presented a significantly worse overall survival and progression-free survival upon receiving cisplatin after operation. These results suggest that the IL6-CXCR7 axis may provide a promising target for the treatment of ESCC.	[Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Ping, Y.; Zhou, B.; Liu, S.; Li, H.; Yue, D.; Zhang, Z.; Chen, X.; Shen, Z.; Lian, J.; Li, Y.; Wang, S.; Li, F.; Huang, L.; Zhang, Y.] Zhengzhou Univ, Affiliated Hosp 1, Biotherapy Ctr, Zhengzhou 450052, Henan, Peoples R China; [Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Yue, D.; Chen, X.; Shen, Z.; Wang, S.; Wang, L.; Zhang, Y.] Zhengzhou Univ, Affiliated Hosp 1, Canc Ctr, Zhengzhou, Henan, Peoples R China; [Zhou, B.; Liu, S.; Lian, J.; Li, Y.; Zhang, Y.] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Henan, Peoples R China; [Zhang, B.] Northwestern Univ, Sch Med, Dept Hematol Oncol, Chicago, IL USA; [Yu, J.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA; [Qin, Z.] Zhengzhou Univ, Affiliated Hosp 1, Med Res Ctr, Zhengzhou, Henan, Peoples R China; [Zhang, Y.] Key Lab Tumor Immunol & Biotherapy Henan Prov, Zhengzhou, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Northwestern University; University System of Ohio; University of Cincinnati; Zhengzhou University	Zhang, Y (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Biotherapy Ctr, Zhengzhou 450052, Henan, Peoples R China.	yizhang@zzu.edu.cn		Zhang, Yi/0000-0001-9861-4681	National Natural Science Foundation of China [81171986]; Research Grant from the Ministry of Public Health [201501004]; Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province [112300410153, 122300410155]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grant from the Ministry of Public Health; Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province	This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81171986), Research Grant from the Ministry of Public Health (Grant No. 201501004) and the Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province (Grant Nos. 112300410153 and 122300410155).	Alas S, 2001, CLIN CANCER RES, V7, P709; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bid HK, 2013, CLIN CANCER RES, V19, P6716, DOI 10.1158/1078-0432.CCR-13-0842; Calinescu AA, 2017, CLIN CANCER RES, V23, P1250, DOI 10.1158/1078-0432.CCR-15-2888; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Demeester SR, 2005, GUT, V54, P440; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Goto M, 2017, ANN SURG ONCOL, V24, P832, DOI 10.1245/s10434-015-4974-5; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111; Hinton CV, 2010, CLIN EXP METASTAS, V27, P97, DOI 10.1007/s10585-008-9210-2; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Jin Z, 2009, INT J CANCER, V125, P2229, DOI 10.1002/ijc.24612; Kerdivel G, 2013, BIOCHEM BIOPH RES CO, V431, P729, DOI 10.1016/j.bbrc.2013.01.050; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lin L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.392; Lippitz BE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1093722; Liu FY, 2011, ONCOL REP, V25, P383, DOI 10.3892/or.2010.1090; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Park YH, 2009, CLIN CANCER RES, V15, P2107, DOI 10.1158/1078-0432.CCR-08-1588; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Schweigert M, 2013, NAT REV GASTRO HEPAT, V10, P230, DOI 10.1038/nrgastro.2012.236; Shi WJ, 2016, WORLD J GASTRO ONCOL, V8, P673, DOI 10.4251/wjgo.v8.i9.673; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Smith MR, 1998, BRIT J HAEMATOL, V102, P1090, DOI 10.1046/j.1365-2141.1998.00850.x; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; Tarnowski M, 2010, EUR J HAEMATOL, V85, P472, DOI 10.1111/j.1600-0609.2010.01531.x; Tarnowski M, 2010, MOL CANCER RES, V8, P1, DOI 10.1158/1541-7786.MCR-09-0259; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Velaei K, 2016, BREAST, V30, P92, DOI 10.1016/j.breast.2016.09.002; Villanueva M Teresa, 2012, Nat Rev Clin Oncol, V9, P490, DOI 10.1038/nrclinonc.2012.129; Wang LH, 2004, IMMUNITY, V20, P205, DOI 10.1016/S1074-7613(04)00030-5; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; Wu K, 2016, AM J TRANSL RES, V8, P3398; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; ZHANG L, 2013, J TRANSL MED, V11; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001	48	95	96	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					873	883		10.1038/onc.2017.387	http://dx.doi.org/10.1038/onc.2017.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059160				2022-12-28	WOS:000425281800005
J	Weisenberger, DJ; Liang, G; Lenz, HJ				Weisenberger, D. J.; Liang, G.; Lenz, H-J			DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC-FACTOR; PLUS CETUXIMAB TREATMENT; GENE BODY METHYLATION; PROMOTER METHYLATION; FECAL DNA; CPG METHYLATION; DOWN-REGULATION; RAS MUTATIONS; VIRAL MIMICRY; HUMAN COLON	Colorectal cancer (CRC) is a worldwide health concern with respect to both incidence and mortality, and as a result, CRC tumorigenesis, progression and metastasis have been heavily studied, especially with respect to identifying genetic, epigenetic, transcriptomic and proteomic profiles of disease. DNA methylation alterations are hallmarks of CRC, and epigenetic driver genes have been identified that are thought to be involved in early stages of tumorigenesis. Moreover, distinct CRC patient subgroups are organized based on DNA methylation profiles. CRC tumors displaying CpG island methylator phenotypes (CIMPs), defined as DNA hypermethylation at specific CpG islands in subsets of tumors, show high concordance with specific genetic alterations, disease risk factors and patient outcome. This review details the DNA methylation alterations in CRC, the significance of CIMP status, the development of treatments based on specific molecular profiles and the application of epigenetic therapies for CRC patient treatment.	[Weisenberger, D. J.] Univ Southern Calif, Dept Biochem & Mol Med, USC Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511D, Los Angeles, CA 90033 USA; [Liang, G.] Univ Southern Calif, Dept Urol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Lenz, H-J] Univ Southern Calif, Dept Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Weisenberger, DJ; Liang, G; Lenz, HJ (corresponding author), Univ Southern Calif, Dept Biochem & Mol Med, USC Norris Comprehens Canc Ctr, 1450 Biggy St,NRT G511D, Los Angeles, CA 90033 USA.	dan.weisenberger@med.usc.edu; gliang@usc.edu; lenz@med.usc.edu	Weisenberger, Daniel/AAA-8314-2020	Weisenberger, Daniel/0000-0001-8303-2603	Vicky Joseph Cancer Research Lab; NIH [5R21 CA201865]; NIH/NCI [P30 CA014089]; NATIONAL CANCER INSTITUTE [R21CA201865] Funding Source: NIH RePORTER	Vicky Joseph Cancer Research Lab; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Vicky Joseph Cancer Research Lab (to GL), NIH 5R21 CA201865 (to GL and DJW) and NIH/NCI P30 CA014089 (to DJW).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Ahn JB, 2011, CANCER-AM CANCER SOC, V117, P1847, DOI 10.1002/cncr.25737; Altobelli E, 2016, J CANCER, V7, P1984, DOI 10.7150/jca.16244; Azad NS, 2017, ONCOTARGET, V8, P35326, DOI 10.18632/oncotarget.15108; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Blaschke K, 2013, NATURE, V500, P222, DOI 10.1038/nature12362; Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Bosch LJW, 2011, CLIN COLORECTAL CANC, V10, P8, DOI 10.3816/CCC.2011.n.002; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204; Chiappinelli KB, 2016, CELL, V164, P1073, DOI 10.1016/j.cell.2015.10.020; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Cohen SA, 2016, CLIN COLORECTAL CANC, V15, P164, DOI 10.1016/j.clcc.2015.10.005; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Demurtas L, 2017, BRIT J CANCER, V117, P315, DOI 10.1038/bjc.2017.178; deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808; Donada M, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-36; Duymich CE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11453; Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; Fang MG, 2014, MOL CELL, V55, P904, DOI 10.1016/j.molcel.2014.08.010; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Flis S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092305; Gallois C, 2016, CRIT REV ONCOL HEMAT, V99, P74, DOI 10.1016/j.critrevonc.2015.11.001; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garrido-Laguna I, 2013, INVEST NEW DRUG, V31, P1257, DOI 10.1007/s10637-013-9947-6; Geissler AL, 2017, ONCOTARGET, V8, P17164, DOI 10.18632/oncotarget.15211; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Heinemann V, 2014, LANCET ONCOL, V15, pE583, DOI 10.1016/S1470-2045(14)71036-8; Herbst A, 2009, EUR J GASTROEN HEPAT, V21, P565, DOI 10.1097/MEG.0b013e328318ecf2; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Iacopetta B, 2008, INT J CLIN ONCOL, V13, P498, DOI 10.1007/s10147-008-0854-3; Ikehata M, 2014, BIOL PHARM BULL, V37, P67, DOI 10.1248/bpb.b13-00574; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Juo YY, 2014, ANN ONCOL, V25, P2314, DOI 10.1093/annonc/mdu149; Kaneko M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2984-8; Kasinathan S, 2014, CANCER CELL, V26, P449, DOI 10.1016/j.ccell.2014.09.004; Kaur S, 2016, ADV EXP MED BIOL, V937, P109, DOI 10.1007/978-3-319-42059-2_6; Kim SE, 2015, GENES NUTR, V10, DOI [10.1007/s12263-014-0444-0, 10.1007/s12263-015-0475-1]; Kisiel JB, 2012, CANCER-AM CANCER SOC, V118, P2623, DOI 10.1002/cncr.26558; Kita Y, 2014, EXPERT REV MOL DIAGN, V14, P673, DOI 10.1586/14737159.2014.925399; Kou CH, 2016, ONCOL LETT, V12, P4838, DOI 10.3892/ol.2016.5265; Lange CPE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050266; Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526; Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X; Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Limsui D, 2010, JNCI-J NATL CANCER I, V102, P1012, DOI 10.1093/jnci/djq201; Liu MM, 2016, P NATL ACAD SCI USA, V113, P10238, DOI 10.1073/pnas.1612262113; Loupakis F, 2015, J NATL CANC I, V107; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Mansour H, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00182; Mayland CR, 2005, PALLIATIVE MED, V19, P17, DOI 10.1191/0269216305pm970oa; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Min BH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-344; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117; Nilsson TK, 2013, INT J ONCOL, V42, P127, DOI 10.3892/ijo.2012.1682; Oberwalder M, 2008, INT J COLORECTAL DIS, V23, P15, DOI 10.1007/s00384-007-0355-2; Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082; Overman MJ, 2016, ONCOTARGET, V7, P67495, DOI 10.18632/oncotarget.11317; Payne SR, 2010, EPIGENOMICS-UK, V2, P575, DOI [10.2217/epi.10.35, 10.2217/EPI.10.35]; Petko Z, 2005, CLIN CANCER RES, V11, P1203; Pfutze K, 2015, GENOMICS, V106, P348, DOI 10.1016/j.ygeno.2015.10.002; Powell AE, 2014, AM J PHYSIOL-GASTR L, V307, pG16, DOI 10.1152/ajpgi.00358.2013; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Raynal N.J., 2016, DRUG DISCOV CANC EPI, P169; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Scartozzi M, 2011, BRIT J CANCER, V104, P1786, DOI 10.1038/bjc.2011.161; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shiovitz S, 2014, GASTROENTEROLOGY, V147, P637, DOI 10.1053/j.gastro.2014.05.009; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797; Tham C, 2014, CANCER-AM CANCER SOC, V120, P3131, DOI 10.1002/cncr.28802; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Toth K, 2016, EXPERT REV MOL DIAGN, V16, P239, DOI 10.1586/14737159.2016.1132164; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Venook AP, 2014, J CLIN ONCOL S, V32, p5S, DOI DOI 10.1200/JCO.2014.32.18_SUPPL.LBA3; Venook AP, 2016, J CLIN ONCOL S, V34; Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Weisenberger DJ, 2015, CANCER EPIDEM BIOMAR, V24, P512, DOI 10.1158/1055-9965.EPI-14-1161; Wu X, 2017, NAT REV GENET; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Yan HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020628; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251; Zarate R, 2012, INT J MOL SCI, V13, P840, DOI 10.3390/ijms13010840	117	42	45	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					566	577		10.1038/onc.2017.374	http://dx.doi.org/10.1038/onc.2017.374			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991233	Green Accepted			2022-12-28	WOS:000423812200003
J	Kim, ES; Kim, SY; Koh, M; Lee, HM; Kim, K; Jung, J; Kim, HS; Moon, WK; Hwang, S; Moon, A				Kim, E-S; Kim, S. Y.; Koh, M.; Lee, H-M; Kim, K.; Jung, J.; Kim, H. S.; Moon, W. K.; Hwang, S.; Moon, A.			C-reactive protein binds to integrin alpha 2 and Fc gamma receptor I, leading to breast cell adhesion and breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-CELLS; H-RAS; INVASIVE PHENOTYPE; ACUTE APPENDICITIS; TUMOR-GROWTH; EXPRESSION; PAXILLIN; KINASE; METASTASIS; INTERLEUKIN-6	C-reactive protein (CRP) is an acute phase protein synthesized upon the inflammatory responses, associated with breast cancer. The process of tumor cell invasion and metastasis involves the adherence of cells to the extracellular matrix via integrin as a receptor for matrix molecules. The present study investigated the role of CRP in the adhesive phenotype of breast cells and the underlying mechanisms. Here, we first showed that CRP induces adhesion of MCF10A human breast epithelial cells through the activation of integrin alpha 2 signaling. Expression of integrin alpha 2 was induced by CRP in which transcription factors c-fos and SP1 may be involved. Binding of CRP with integrin alpha 2 leads to the activation of focal adhesion kinase (FAK), paxillin and ERKs. CRP also binds to an Fc gamma receptor Fc gamma receptor I (Fc gamma RI), and induces activation of paxillin, FAK and ERKs. Integrin alpha 2 and FAK have crucial roles in the adhesive and invasive phenotypes as well as MMP-9 upregulation induced by CRP in MCF10A cells. Treatment with an inflammatory lipid sphingosine-1-phosphate induced CRP, which may be secreted and exert an autocrine effect by binding to Fc gamma RI and integrin alpha 2. Involvement of CRP in adhesion, invasion, anchorage-independent growth and upregulation of integrin alpha 2, paxillin and FAK was observed in MDA-MB-231 triple-negative human breast cancer (TNBC) cells. Using an in vivo invasion model and an orthotopic mouse tumor model with MDA-MB-231 cells, we showed that CRP has an important role in intravasation and tumor growth in vivo, demonstrating the in vivo relevance of our in vitro results. The present study elucidates a critical molecular basis between CRP, integrin alpha 2 and Fc gamma RI pathways in MCF10A breast cells and MDA-MB-231 TNBC cells, thereby providing useful information on CRP-induced aggressiveness of breast cells in the inflammatory microenvironment.	[Kim, E-S; Kim, S. Y.; Koh, M.; Lee, H-M; Kim, K.; Jung, J.; Moon, A.] Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul 132714, South Korea; [Kim, H. S.; Moon, W. K.] Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea; [Hwang, S.] Hanyang Univ, Coll Med, Seoul, South Korea	Duksung Women's University; Seoul National University (SNU); Seoul National University Hospital; Hanyang University	Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul 132714, South Korea.	armoon@duksung.ac.kr			Priority Research Centers Program [2016R1A6A1A03007648]; Bio & Medical Technology Development Program [2015M3A9B6074045]; Basic Science Program of the NRF - Korean government [2014R1A6A3A01059908]	Priority Research Centers Program; Bio & Medical Technology Development Program; Basic Science Program of the NRF - Korean government	The present study was supported by Priority Research Centers Program (no. 2016R1A6A1A03007648), the Bio & Medical Technology Development Program (no. 2015M3A9B6074045) and Basic Science Program (no. 2014R1A6A3A01059908) of the NRF funded by the Korean government.	Allin KH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2891; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Bendas G, 2012, INT J CELL BIOL, V2012; Cance WG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.120pe22; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chi M, 2002, J IMMUNOL, V168, P1413, DOI 10.4049/jimmunol.168.3.1413; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; DEPRAETERE S, 1991, AGENTS ACTIONS, V34, P369, DOI 10.1007/BF01988730; Fujita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093738; Galon J, 1996, J IMMUNOL, V157, P1184; Golubovskaya VM, 2012, CARCINOGENESIS, V33, P1004, DOI 10.1093/carcin/bgs120; Guo Yan, 2014, Biomed Res Int, V2014, P248090, DOI 10.1155/2014/248090; GURLEYIK E, 1995, DIS COLON RECTUM, V38, P1270, DOI 10.1007/BF02049151; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hojilla CV, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1980; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hwang HS, 2015, BMB REP, V48, P407, DOI 10.5483/BMBRep.2015.48.7.050; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ibaragi S, 2011, ANTICANCER RES, V31, P1307; INDIK ZK, 1994, EXP HEMATOL, V22, P599; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim ES, 2014, ONCOGENE, V33, P3583, DOI 10.1038/onc.2013.319; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim KM, 2017, INT J NANOMED, V12, P1917, DOI 10.2147/IJN.S132043; Kim MS, 2003, CANCER RES, V63, P5454; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Koh M, 2015, INT J CANCER, V136, pE508, DOI 10.1002/ijc.29154; KOUKOULIS GK, 1993, J SUBMICR CYTOL PATH, V25, P285; Lee HM, 2016, BIOMOL THER, V24, P62, DOI 10.4062/biomolther.2015.172; MAEMURA M, 1995, CLIN EXP METASTAS, V13, P223, DOI 10.1007/BF00133478; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Mira E, 2002, CLIN EXP METASTAS, V19, P313, DOI 10.1023/A:1015563031769; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Ortiz-Stern A, 2003, IMMUNOL LETT, V90, P137, DOI 10.1016/j.imlet.2003.08.004; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Platz Elizabeth A., 2004, Journal of Urology, V171, pS36, DOI 10.1097/01.ju.0000108131.43160.77; Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Ravishankaran P, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-18; Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656; Rodriguez-Sanjuan JC, 1999, DIS COLON RECTUM, V42, P1325, DOI 10.1007/BF02234223; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sawhney RS, 2003, J BIOL CHEM, V278, P19861, DOI 10.1074/jbc.M213162200; Schaller MD, 2004, J CELL BIOL, V166, P157, DOI 10.1083/jcb.200406151; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schmidt RE, 2005, IMMUNOL LETT, V100, P56, DOI 10.1016/j.imlet.2005.06.022; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; SOULE HD, 1990, CANCER RES, V50, P6075; Tsaur I, 2012, BRIT J CANCER, V107, P847, DOI 10.1038/bjc.2012.313; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Venugopal SK, 2005, AM J PATHOL, V166, P1265, DOI 10.1016/S0002-9440(10)62345-0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Woollard KJ, 2005, INFLAMM RES, V54, P485, DOI 10.1007/s00011-005-1382-5; Yang CQ, 2003, CANCER RES, V63, P8312; Yang J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809; Zou Cai-Yan, 2008, Zhongguo Dang Dai Er Ke Za Zhi, V10, P386; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	67	20	20	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					28	38		10.1038/onc.2017.298	http://dx.doi.org/10.1038/onc.2017.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28846105				2022-12-28	WOS:000422625000004
J	Li, Y; Sun, H; Zhang, C; Liu, J; Zhang, H; Fan, F; Everley, RA; Ning, X; Sun, Y; Hu, J; Liu, J; Zhang, J; Ye, W; Qiu, X; Dai, S; Liu, B; Xu, H; Fu, S; Gygi, SP; Zhou, C				Li, Y.; Sun, H.; Zhang, C.; Liu, J.; Zhang, H.; Fan, F.; Everley, R. A.; Ning, X.; Sun, Y.; Hu, J.; Liu, J.; Zhang, J.; Ye, W.; Qiu, X.; Dai, S.; Liu, B.; Xu, H.; Fu, S.; Gygi, S. P.; Zhou, C.			Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics	ONCOGENE			English	Article							DAMAGE RESPONSE; ATM ACTIVATION; THERAPEUTIC TARGET; TCTP; MECHANISM; ALPHA; SERTRALINE; INHIBITION; INTERACTS; PATHWAYS	Translationally controlled tumor protein (TCTP) has been implicated in the regulation of apoptosis, DNA repair and drug resistance. However, the underlying molecular mechanisms are poorly defined. To better understand the molecular mechanisms underlying TCTP involved in cellular processes, we performed an affinity purification-based proteomic profiling to identify proteins interacting with TCTP in human cervical cancer HeLa cells. We found that a group of proteins involved in DNA repair are enriched in the potential TCTP interactome. Silencing TCTP by short hairpin RNA in breast carcinoma MCF-7 cells leads to the declined repair efficiency for DNA double-strand breaks on the GFP-Pem1 reporter gene by homologous recombination, the persistent activation and the prolonged retention of gamma H2AX and Rad51 foci following ionizing radiation. Reciprocal immunoprecipitations indicated that TCTP forms complexes with Rad51 in vivo, and the stability maintenance of Rad51 requires TCTP in MCF-7 cells under normal cell culture conditions. Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced apoptosis in MCF-7 cells, and causes sensitization to DNA-damaging drug etoposide and DNA repair inhibitor olaparib. Thus, we have identified an important role of TCTP in promoting DNA double-stand break repair via facilitating DNA homologous recombination processes and highlighted the great potential of TCTP as a drug target to enhance conventional chemotherapy for cancer patients with high levels of TCTP expression.	[Li, Y.; Sun, H.; Liu, J.; Zhang, H.; Fan, F.; Ning, X.; Sun, Y.; Hu, J.; Fu, S.; Zhou, C.] Harbin Med Univ, Lab Med Genet, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Zhang, C.; Liu, J.; Zhang, J.; Ye, W.; Qiu, X.] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Everley, R. A.; Gygi, S. P.] Harvard Med Sch, Dept Cell Biol, Boston, MA USA; [Dai, S.; Liu, B.] Harbin Med Univ, Tumor Hosp, Harbin, Heilongjiang, Peoples R China; [Xu, H.] Dalian Med Univ, Affiliated Hosp 1, Dept Clin Lab, Dalian, Peoples R China	Harbin Medical University; Harbin Medical University; Harvard University; Harvard Medical School; Harbin Medical University; Dalian Medical University	Zhou, C (corresponding author), Harbin Med Univ, Lab Med Genet, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.	Chunshuizhou@163.com			National Natural Science Foundation of China [81272582, 31600662]; National Institutes of Health, USA	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Professor Vera Gorbunova of the University of Rochester for providing the GFP-Pem1 reporter plasmid and CMV-HA-I-Sce I expression plasmid for detection of HR. We also thank Drs Bo Zhai, Willi Haas of SPG lab for their assistance and advice, and Dr Noah Dephoure's critical comments on manuscript writing. YL, HS, JL, HZ and CZ are supported by Grant No. 81272582 from the National Natural Science Foundation of China, HX is supported by Grant No. 31600662 from the National Natural Science Foundation of China. RAE and SPG are supported by National Institutes of Health, USA.	Acunzo J, 2014, CANCER TREAT REV, V40, P760, DOI 10.1016/j.ctrv.2014.02.007; Aglipay JA, 2006, J BIOL CHEM, V281, P9710, DOI 10.1074/jbc.M510332200; Amson R, 2013, TRENDS CELL BIOL, V23, P37, DOI 10.1016/j.tcb.2012.10.002; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Batchelor E, 2009, NAT REV CANCER, V9, P371, DOI 10.1038/nrc2604; Baylot V, 2012, MOL THER, V20, P2244, DOI 10.1038/mt.2012.155; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cucchi U, 2010, ANTICANCER RES, V30, P4973; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gachet Y, 1999, J CELL SCI, V112, P1257; Gnanasekar M, 2009, BIOCHEM BIOPH RES CO, V386, P333, DOI 10.1016/j.bbrc.2009.06.028; Gunaratne J, 2011, J BIOL CHEM, V286, P18093, DOI 10.1074/jbc.M111.221184; Hong ST, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3986; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Li TY, 2016, ONCOTARGET, V7, P11838, DOI 10.18632/oncotarget.7864; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Low LH, 2015, J BIOL CHEM, V290, P7141, DOI 10.1074/jbc.M114.613687; Lu GQ, 2016, P NATL ACAD SCI USA, V113, P1256, DOI 10.1073/pnas.1521597113; Lucibello M, 2015, ONCOTARGET, V6, P5275, DOI 10.18632/oncotarget.2971; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rho SB, 2011, FEBS LETT, V585, P29, DOI 10.1016/j.febslet.2010.11.014; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Seo EJ, 2016, ONCOTARGET, V7, P16818, DOI 10.18632/oncotarget.7605; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019; Tkach JM, 2012, NAT CELL BIOL, V14, P966, DOI 10.1038/ncb2549; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Wang LF, 2016, NEUROPSYCH DIS TREAT, V12, P1127, DOI 10.2147/NDT.S106562; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; Xu H, 2015, J PROTEOME RES, V14, P2480, DOI 10.1021/acs.jproteome.5b00004; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang J, 2012, P NATL ACAD SCI USA, V109, pE926, DOI 10.1073/pnas.1106300109; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	11	12	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6839	6849		10.1038/onc.2017.289	http://dx.doi.org/10.1038/onc.2017.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846114	hybrid, Green Published			2022-12-28	WOS:000418041800001
J	Plissonnier, ML; Lahlali, T; Raab, M; Michelet, M; Romero-Lopez, C; Rivoire, M; Strebhardt, K; Durantel, D; Levrero, M; Mehlen, P; Zoulim, F; Parent, R				Plissonnier, M-L; Lahlali, T.; Raab, M.; Michelet, M.; Romero-Lopez, C.; Rivoire, M.; Strebhardt, K.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.			Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; DAP-KINASE; ENDOPLASMIC-RETICULUM; TUMOR SUPPRESSORS; GENE-EXPRESSION; AUTOPHAGY; REPLICATION; DEPENDENCE; PARTICLES; APOPTOSIS	Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC), mainly through cirrhosis induction, spurring research for a deeper understanding of HCV versus host interactions in cirrhosis. The present study investigated crosstalks between HCV infection and UNC5A, a netrin-1 dependence receptor that is inactivated in cancer. UNC5A and HCV parameters were monitored in patients samples (n = 550) as well as in in vitro. In patients, UNC5A mRNA expression is significantly decreased in clinical HCV(+) specimens irrespective of the viral genotype, but not in (HBV)(+) liver biopsies, as compared to uninfected samples. UNC5A mRNA is downregulated in F2 (3-fold; P = 0.009), in F3 (10-fold, P = 0.0004) and more dramatically so in F4/cirrhosis (44-fold; P < 0.0001) histological stages of HCV(+) hepatic lesions compared to histologically matched HCV(-) tissues. UNC5A transcript was found strongly downregulated in HCC samples (33-fold; P < 0.0001) as compared with non-HCC samples. In vivo, association of UNC5A transcripts with polyribosomes is decreased by 50% in HCV(+) livers. Consistent results were obtained in vitro showing HCV-dependent depletion of UNC5A in HCV-infected hepatocyte-like cells and in primary human hepatocytes. Using luciferase reporter constructs, HCV cumulatively decreased UNC5A transcription from the UNC5 promoter and translation in a UNC5A 5'UTR-dependent manner. Proximity ligation assays, kinase assays, as well as knockdown and forced expression experiments identified UNC5A as capable of impeding autophagy and promoting HCV restriction through specific impact on virion infectivity, in a cell death-independent and DAPK-related manner. In conclusion, while the UNC5A dependence receptor counteracts HCV persistence through regulation of autophagy in a DAPK-dependent manner, it is dramatically decreased in all instances in HCC samples, and specifically by HCV in cirrhosis. Such data argue for the evaluation of the implication of UNC5A in liver carcinogenesis.	[Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Zoulim, F.; Parent, R.] Ctr Rech Cancerol Lyon, Pathogenesis Hepatitis B&C Equipe Labellisee LabE, INSERM U1052, 151 Cours Albert Thomas, F-69424 Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.] Univ Lyon, Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.] Univ Lyon 1, ISPB, Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Zoulim, F.; Parent, R.] Ctr Rech Cancerol Lyon, CNRS UMR5286, Lyon, France; [Raab, M.; Strebhardt, K.] Goethe Univ, D-60590 Frankfurt, Germany; [Raab, M.; Strebhardt, K.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Romero-Lopez, C.] Inst Parasitol & Biomed Lopez Neyra, Ave Conocimiento S-N, Armilla, Spain; [Rivoire, M.; Mehlen, P.] Ctr Leon Berard, Lyon, France; [Levrero, M.] Epigenet & Epigenom Hepatocellular Carcinoma, Lyon, France; [Levrero, M.; Zoulim, F.] Hosp Civils Lyon, Serv Hepatogastroenterol, Lyon, France; [Levrero, M.; Mehlen, P.] Ctr Rech Cancerol Lyon, INSERM U1052, Lyon, France; [Mehlen, P.] LabEx DEVweCAN, Apoptosis Canc & Dev Lab Equipe Labellisee La Lig, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); UNICANCER; Centre Leon Berard; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Parent, R (corresponding author), Ctr Rech Cancerol Lyon, Pathogenesis Hepatitis B&C Equipe Labellisee LabE, INSERM U1052, 151 Cours Albert Thomas, F-69424 Lyon, France.	romain.parent@inserm.fr	Durantel, David/I-4639-2018; Zoulim, Fabien/ABD-5594-2021; Strebhardt, Klaus/E-8765-2011; Romero-López, Cristina/G-8282-2015; Parent, Romain/N-7115-2017; Plissonnier, Marie-Laure/Y-9491-2019; Levrero, Massimo/G-5680-2016	Durantel, David/0000-0002-9226-3419; Zoulim, Fabien/0000-0002-2245-0083; Romero-López, Cristina/0000-0001-9818-0529; Parent, Romain/0000-0002-3645-7008; Plissonnier, Marie-Laure/0000-0003-4879-4586; Levrero, Massimo/0000-0002-4978-0875; Strebhardt, Klaus/0000-0003-2173-9763	European Union [248364]; LYric Grant [INCa-DGOS-4664]; French National Agency for AIDS and Viral Hepatitis Research (ANRS) [2011-379]; French Ligue Contre Le Cancer; DevWeCan French Laboratories of Excellence Network (Labex) [ANR-10-LABX-61]	European Union(European Commission); LYric Grant; French National Agency for AIDS and Viral Hepatitis Research (ANRS)(ANRSFrench National Research Agency (ANR)); French Ligue Contre Le Cancer(Ligue nationale contre le cancer); DevWeCan French Laboratories of Excellence Network (Labex)	This study was supported by the European Union (Marie Curie International Reintegration Grant #248364), The LYric Grant (INCa-DGOS-4664), The French National Agency for AIDS and Viral Hepatitis Research (ANRS, Grant #2011-379), The French Ligue Contre Le Cancer and The DevWeCan French Laboratories of Excellence Network (Labex, Grant #ANR-10-LABX-61). We thank T. Wakita (National Institute of Infectious Diseases, Japan), CM Rice (The Rockefeller University, NY, USA) and F Helle (Inserm, France) for Huh7.5 cells and HCV strains.	ANRS Collaborative Study Grp, 2016, J HEPATOL, V65, P734, DOI 10.1016/j.jhep.2016.05.045; Bartoe JL, 2006, J NEUROSCI, V26, P3192, DOI 10.1523/JNEUROSCI.3469-05.2006; Bialik S, 2010, CURR OPIN CELL BIOL, V22, P199, DOI 10.1016/j.ceb.2009.11.004; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Buehler E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051942; Chang TH, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S2-S4; Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015; Dash S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050150; Delgrange D, 2007, J GEN VIROL, V88, P2495, DOI 10.1099/vir.0.82872-0; Dreux M, 2009, AUTOPHAGY, V5, P1224, DOI 10.4161/auto.5.8.10219; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Helle F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070809; Hibi K, 2012, HEPATO-GASTROENTEROL, V59, P2573, DOI 10.5754/hge10616; Huang H, 2013, AUTOPHAGY, V9, P175, DOI 10.4161/auto.22791; Kohli A, 2014, JAMA-J AM MED ASSOC, V312, P631, DOI 10.1001/jama.2014.7085; Levin-Salomon V, 2014, APOPTOSIS, V19, P346, DOI 10.1007/s10495-013-0918-3; Li MMH, 2015, TRENDS CELL BIOL, V25, P320, DOI 10.1016/j.tcb.2015.02.001; Lindenbach Brett D., 2009, V510, P329, DOI 10.1007/978-1-59745-394-3_24; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Llovet JM, 2016, NAT REV GASTRO HEPAT, V13, P561, DOI 10.1038/nrgastro.2016.140; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mehlen P, 2011, NAT REV CANCER, V11, P188, DOI 10.1038/nrc3005; Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1; Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Mohl BP, 2016, J GEN VIROL, V97, P680, DOI 10.1099/jgv.0.000387; Paradisi A, 2008, GASTROENTEROLOGY, V135, P1248, DOI 10.1053/j.gastro.2008.06.080; Parent R, 2007, CANCER RES, V67, P4337, DOI 10.1158/0008-5472.CAN-06-3640; Parent R, 2009, HEPATOLOGY, V49, P1798, DOI 10.1002/hep.22852; Parent R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r19; Picard M, 2009, CELL SIGNAL, V21, P1961, DOI 10.1016/j.cellsig.2009.09.004; Plissonnier ML, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002421; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Romanowski T, 2008, MED SCI MONITOR, V14, pBR147; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; Sainz B, 2006, J VIROL, V80, P10253, DOI 10.1128/JVI.01059-06; Shrivastava S, 2012, J VIROL, V86, P8705, DOI 10.1128/JVI.00616-12; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Stephens SB, 2007, METHOD ENZYMOL, V431, P47, DOI 10.1016/S0076-6879(07)31004-5; Stevens C, 2009, J BIOL CHEM, V284, P334, DOI 10.1074/jbc.M805165200; Stohr S, 2016, GUT, V65, P2017, DOI 10.1136/gutjnl-2014-308971; Tanida I, 2009, AUTOPHAGY, V5, P937, DOI 10.4161/auto.5.7.9243; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Thomas DL, 2013, NAT MED, V19, P850, DOI 10.1038/nm.3184; Tian Y, 2015, CELL DEATH DIFFER, V22, P1025, DOI 10.1038/cdd.2014.201; Trinchet JC, 2015, HEPATOLOGY, V62, P737, DOI 10.1002/hep.27743; van der Meer AJ, 2017, J HEPATOL, V66, P485, DOI 10.1016/j.jhep.2016.10.017; Weil D, 2000, RNA, V6, P962, DOI 10.1017/S1355838200000479; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	55	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6712	6724		10.1038/onc.2017.271	http://dx.doi.org/10.1038/onc.2017.271			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783179				2022-12-28	WOS:000416780800006
J	Klymenko, Y; Kim, O; Loughran, E; Yang, J; Lombard, R; Alber, M; Stack, MS				Klymenko, Y.; Kim, O.; Loughran, E.; Yang, J.; Lombard, R.; Alber, M.; Stack, M. S.			Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis	ONCOGENE			English	Article							COLLECTIVE CELL-MIGRATION; TYPE-1 MATRIX-METALLOPROTEINASE; N-CADHERIN; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; SURFACE EPITHELIUM; MALIGNANT-MELANOMA; MESSENGER-RNA; TUMOR-GROWTH	During epithelial ovarian cancer (EOC) progression, intraperitoneally disseminating tumor cells and multicellular aggregates (MCAs) present in ascites fluid adhere to the peritoneum and induce retraction of the peritoneal mesothelial monolayer prior to invasion of the collagen-rich submesothelial matrix and proliferation into macro-metastases. Clinical studies have shown heterogeneity among EOC metastatic units with respect to cadherin expression profiles and invasive behavior; however, the impact of distinct cadherin profiles on peritoneal anchoring of metastatic lesions remains poorly understood. In the current study, we demonstrate that metastasis-associated behaviors of ovarian cancer cells and MCAs are influenced by cellular cadherin composition. Our results show that mesenchymal N-cadherin-expressing (Ncad+) cells and MCAs invade much more efficiently than E-cadherin-expressing (Ecad+) cells. Ncad+ MCAs exhibit rapid lateral dispersal prior to penetration of three-dimensional collagen matrices. When seeded as individual cells, lateral migration and cell-cell junction formation precede matrix invasion. Neutralizing the Ncad extracellular domain with the monoclonal antibody GC-4 suppresses lateral dispersal and cell penetration of collagen gels. In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not fully inhibit cell invasion. Using intact tissue explants, Ncad+ MCAs were also shown to efficiently rupture peritoneal mesothelial cells, exposing the submesothelial collagen matrix. Acquisition of Ncad by Ecad+ cells increased mesothelial clearance activity but was not sufficient to induce matrix invasion. Furthermore, co-culture of Ncad+ with Ecad+ cells did not promote a 'leader-follower' mode of collective cell invasion, demonstrating that matrix remodeling and creation of invasive micro-tracks are not sufficient for cell penetration of collagen matrices in the absence of Ncad. Collectively, our data emphasize the role of Ncad in intraperitoneal seeding of EOC and provide the rationale for future studies targeting Ncad in preclinical models of EOC metastasis.	[Klymenko, Y.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN USA; [Klymenko, Y.; Kim, O.; Loughran, E.; Yang, J.; Lombard, R.; Alber, M.; Stack, M. S.] Univ Notre Dame, Harper Canc Res Inst, South Bend, IN USA; [Kim, O.; Alber, M.] Univ Notre Dame, Dept Appl & Computat Math & Stat, 153 Hurley Hall, Notre Dame, IN 46556 USA; [Kim, O.; Alber, M.] Univ Calif Riverside, Dept Math, Riverside, CA USA; [Loughran, E.; Yang, J.; Stack, M. S.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; University of California System; University of California Riverside; University of Notre Dame	Alber, M (corresponding author), Univ Notre Dame, Dept Appl & Computat Math & Stat, 153 Hurley Hall, Notre Dame, IN 46556 USA.; Stack, MS (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Harper Canc Res Inst, A200 Harper Hall,1234 Notre Dame Ave, South Bend, IN 46617 USA.	malber@nd.edu; sstack@nd.edu	Alber, Mark/AAR-1280-2020; Loughran, Elizabeth/D-6511-2015	Loughran, Elizabeth/0000-0002-7940-3157; /0000-0001-7324-8427	National Institutes of Health/National Cancer Institute [RO1CA109545, RO1CA086984]; Leo and Anne Albert Charitable Trust; Research Like a Champion grant; Walther Cancer Foundation Seeding Research in Cancer grant; NSF [DGE1313583]; University of Notre Dame Integrated Imaging Facility;  [U01-HL116330]; NATIONAL CANCER INSTITUTE [R01CA086984, R01CA109545] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL116330] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leo and Anne Albert Charitable Trust; Research Like a Champion grant; Walther Cancer Foundation Seeding Research in Cancer grant; NSF(National Science Foundation (NSF)); University of Notre Dame Integrated Imaging Facility; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by Research Grants RO1CA109545 and RO1CA086984 (both to MSS) from the National Institutes of Health/National Cancer Institute, the Leo and Anne Albert Charitable Trust (to MSS); the Research Like a Champion grant (to YK and RL); the Walther Cancer Foundation Seeding Research in Cancer grant (to OK); NSF DGE1313583 (to EL); U01-HL116330 (to OK and MA) and University of Notre Dame Integrated Imaging Facility. We thank Dr Charles Tessier, Indiana University School of Medicine-South Bend for assistance with second-harmonic-generation imaging microscopy.	ACKERMAN AB, 1984, AM J DERMATOPATH, V6, P63; Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Augustine CK, 2008, CANCER RES, V68, P3777, DOI 10.1158/0008-5472.CAN-07-5949; Barbolina MV, 2007, J BIOL CHEM, V282, P4924, DOI 10.1074/jbc.M608428200; BELL CD, 1986, J SURG ONCOL, V31, P39, DOI 10.1002/jso.2930310109; Blaschuk OW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0039; Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033; Bruney L, 2014, BIOL CHEM, V395, P1221, DOI 10.1515/hsz-2014-0155; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Burleson KM, 2004, GYNECOL ONCOL, V93, P170, DOI 10.1016/j.ygyno.2003.12.034; Carey SP, 2013, CLIN EXP METASTAS, V30, P615, DOI 10.1007/s10585-013-9565-x; Coffman LG, 2016, TRANSL RES, V175, P92, DOI 10.1016/j.trsl.2016.03.016; Cosgrove BD, 2016, NAT MATER, V15, P1297, DOI [10.1038/NMAT4725, 10.1038/nmat4725]; Davidowitz RA, 2012, JOVE-J VIS EXP, DOI 10.3791/3888; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; DAY CL, 1981, ANN SURG, V194, P108, DOI 10.1097/00000658-198107000-00019; Desai RA, 2009, J CELL SCI, V122, P905, DOI 10.1242/jcs.028183; Devemy E, 2008, PEPTIDES, V29, P1853, DOI 10.1016/j.peptides.2008.06.025; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fraley SI, 2015, SCI REP-UK, V5, DOI 10.1038/srep14580; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Howlader N, 2011, SEER CANC STAT REV 1, P19; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Ilina O, 2009, J CELL SCI, V122, P3203, DOI 10.1242/jcs.036525; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Klymenko Y, 2017, NEOPLASIA, V19, P549, DOI 10.1016/j.neo.2017.04.002; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lautscham LA, 2015, BIOPHYS J, V109, P900, DOI 10.1016/j.bpj.2015.07.025; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Liu YY, 2015, CANCER RES, V75, P5046, DOI 10.1158/0008-5472.CAN-15-0706; Marcus CS, 2014, J CANCER, V5, P25, DOI 10.7150/jca.7810; Mariotti A, 2007, EXPERT OPIN INV DRUG, V16, P451, DOI 10.1517/13543784.16.4.451; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Page DL, 1987, DIAGNOSTIC HISTOPATH; Pasapera AM, 2015, CURR BIOL, V25, P175, DOI 10.1016/j.cub.2014.11.043; Poncelet C, 2010, FERTIL STERIL, V94, P2909, DOI 10.1016/j.fertnstert.2010.04.055; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sadler NM, 2013, AM J BLOOD RES, V3, P271; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861; Shintani Y, 2008, INT J CANCER, V122, P71, DOI 10.1002/ijc.23027; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sodek KL, 2007, BRIT J CANCER, V97, P358, DOI 10.1038/sj.bjc.6603863; Stewart DJ, 2006, J CLIN ONCOL, V24, p124S; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wolf K, 2006, BRIT J DERMATOL, V154, P11, DOI 10.1111/j.1365-2133.2006.07231.x	75	43	44	0	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5840	5851		10.1038/onc.2017.171	http://dx.doi.org/10.1038/onc.2017.171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628116	Green Accepted, Green Submitted			2022-12-28	WOS:000413292900006
J	Perez-Alea, M; McGrail, K; Sanchez-Redondo, S; Ferrer, B; Fournet, G; Cortes, J; Munoz, E; Hernandez-Losa, J; Tenbaum, S; Martin, G; Costello, R; Ceylan, I; Garcia-Patos, V; Recio, JA				Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Fournet, G.; Cortes, J.; Munoz, E.; Hernandez-Losa, J.; Tenbaum, S.; Martin, G.; Costello, R.; Ceylan, I.; Garcia-Patos, V.; Recio, J. A.			ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment	ONCOGENE			English	Article							ALDEHYDE DEHYDROGENASE-ACTIVITY; STEM-CELLS; LIPID-PEROXIDATION; HUMAN PROSTATE; HL-60 CELLS; CANCER; INHIBITORS; METASTASIS; MARKER; GROWTH	Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.	[Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Garcia-Patos, V.; Recio, J. A.] Barcelona UAB, VHIR Vall dHebron Hosp, Vall dHebron Res Inst, Biomed Res Melanoma Anim Models, Barcelona, Spain; [Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Garcia-Patos, V.; Recio, J. A.] Barcelona UAB, VHIR Vall dHebron Hosp, Vall dHebron Res Inst, Canc Lab,Oncol Program, Barcelona, Spain; [Ferrer, B.; Hernandez-Losa, J.] Barcelona UAB, Vall dHebron Hosp, Anat Pathol Dept, Barcelona, Spain; [Fournet, G.] Univ Claude Bernard Lyon1, UMR CNRS 5246, Inst Chim & Biochim Mol & Supramol, Villeurbanne, France; [Cortes, J.] Ramon y Cajal Univ Hosp, Madrid, Spain; [Cortes, J.; Munoz, E.] Barcelona UAB, Vall dHebron Hosp, Vall dHebron Inst Oncol VHIO, Clin Oncol Program, Barcelona, Spain; [Tenbaum, S.] Vall dHebron Inst Oncol, Stem Cells & Canc Lab, Barcelona, Spain; [Martin, G.; Ceylan, I.] Adv BioDesign, Parc Technol Lyon,Woodstock Batiment Cedre 1, St Priest, France; [Costello, R.] Ctr Hosp Univ La Conception, Serv Hematol & Therapie Cellulaire, Marseille, France; [Garcia-Patos, V.] Barcelona UAB, Vall dHebron Hosp, Dermatol Dept, Barcelona, Spain; [Sanchez-Redondo, S.] CNIO, Microenvironm & Metastasis Grp, Madrid 28029, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Hospital Universitario Ramon y Cajal; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut d'Oncologia (VHIO); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Hospital Universitari Vall d'Hebron; Centro Nacional de Investigaciones Oncologicas (CNIO)	Recio, JA (corresponding author), Inst Recerca Vall dHebron VHIR, Biomed Res Melanoma Anim Models & Canc Lab, Lab 203 Ed Collserola, Barcelona 08035, Spain.	juan.recio@vhir.org	Miquel, Josep Maria/AAG-3508-2019; Varela, Pedro Fuentes/AAD-4607-2020; Javier, Hernandez Losa/C-1173-2008	Varela, Pedro Fuentes/0000-0001-8471-0197; Javier, Hernandez Losa/0000-0003-1526-3201; Mc Grail Fernandez, Kimberley/0000-0001-7227-7306; PEREZ, Mileidys/0000-0002-8739-8087; Cortes, Javier/0000-0001-7623-1583; Recio, Juan Angel/0000-0002-7320-3832; Garcia-Patos Briones, Vicente/0000-0003-1654-6035	Advanced BioDesign; Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) [PI1400375-Fondos FEDER, AECC-GCB15152978SOEN]; Marie Curie Actions [IEF_METABOSET-627869]	Advanced BioDesign; Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS); Marie Curie Actions(European Commission)	Dr G Quash is gratefully acknowledged for critical reading of the manuscript and his contributions. We also thank Dr HG Palmer for his generous contribution. This work was supported by funds from Advanced BioDesign (MPA), the Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) PI1400375-Fondos FEDER, AECC-GCB15152978SOEN, Marie Curie Actions (IEF_METABOSET-627869) supported MPA.	Alnouti Y, 2008, TOXICOL SCI, V101, P51, DOI 10.1093/toxsci/kfm280; Andreu-Perez P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-265; BARRERA G, 1991, EXP CELL RES, V197, P148, DOI 10.1016/0014-4827(91)90416-R; BLACKWELL LF, 1983, BIOCHEMISTRY-US, V22, P3784, DOI 10.1021/bi00285a011; Boonyaratanakornkit JB, 2010, J INVEST DERMATOL, V130, P2799, DOI 10.1038/jid.2010.237; Burger PE, 2009, STEM CELLS, V27, P2220, DOI 10.1002/stem.135; Charafe-Jauffret E, 2013, CANCER RES, V73, P7290, DOI 10.1158/0008-5472.CAN-12-4704; Chen Y, 2009, OCUL SURF, V7, P176, DOI 10.1016/S1542-0124(12)70185-4; Cheung AMS, 2007, LEUKEMIA, V21, P1423, DOI 10.1038/sj.leu.2404721; Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138; Delyon J, 2013, ANN ONCOL, V24, P1697, DOI 10.1093/annonc/mdt027; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; ESTERBAUER H, 1990, MUTAT RES, V238, P223, DOI 10.1016/0165-1110(90)90014-3; Estey T, 2007, J BIOL CHEM, V282, P4382, DOI 10.1074/jbc.M607546200; Fournet G, 2013, CURR MED CHEM, V20, P527; Grammatico P, 1998, EXP DERMATOL, V7, P205, DOI 10.1111/j.1600-0625.1998.tb00325.x; Hill BG, 2009, CIRC RES, V105, P1044, DOI 10.1161/CIRCRESAHA.109.209791; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Jackson Brian, 2011, Human Genomics, V5, P283; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Lopez-Fauqued M, 2010, INT J CANCER, V126, P1549, DOI 10.1002/ijc.24926; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Marcato P, 2015, MOL ONCOL, V9, P17, DOI 10.1016/j.molonc.2014.07.010; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Monneuse O, 2005, J GASTROINTEST SURG, V9, P769, DOI 10.1016/j.gassur.2005.02.006; Moore N, 2012, STEM CELLS DEV, V21, P1822, DOI 10.1089/scd.2011.0477; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Moreb JS, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-87; Pizzimenti S, 2002, FREE RADICAL BIO MED, V32, P233, DOI 10.1016/S0891-5849(01)00798-5; Pizzimenti S, 1999, FREE RADICAL BIO MED, V26, P1578, DOI 10.1016/S0891-5849(99)00022-2; Prasmickaite L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010731; Quash G, 2002, BIOCHEM PHARMACOL, V64, P1279, DOI 10.1016/S0006-2952(02)01294-7; Quash G, 2008, EUR J MED CHEM, V43, P906, DOI 10.1016/j.ejmech.2007.06.004; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Roch AM, 1996, BIOCHEM J, V313, P973, DOI 10.1042/bj3130973; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sovic A, 2001, ANTICANCER RES, V21, P1997; SUMMERFIELD FW, 1984, CHEM-BIOL INTERACT, V50, P87, DOI 10.1016/0009-2797(84)90134-0; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Townsend AJ, 2001, CHEM-BIOL INTERACT, V130, P261, DOI 10.1016/S0009-2797(00)00270-2; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; Vasiliou Vasilis, 2005, Human Genomics, V2, P138; Venza M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/481782; Wittgen HGM, 2007, MELANOMA RES, V17, P400, DOI 10.1097/CMR.0b013e3282f1d312; Wonisch W, 1998, FREE RADICAL BIO MED, V25, P682, DOI 10.1016/S0891-5849(98)00110-5; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Yue LL, 2015, MELANOMA RES, V25, P138, DOI 10.1097/CMR.0000000000000144	57	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5695	5708		10.1038/onc.2017.160	http://dx.doi.org/10.1038/onc.2017.160			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581514				2022-12-28	WOS:000412843900004
J	Geng, C; Kaochar, S; Li, M; Rajapakshe, K; Fiskus, W; Dong, J; Foley, C; Dong, B; Zhang, L; Kwon, OJ; Shah, SS; Bolaki, M; Xin, L; Ittmann, M; O'Malley, BW; Coarfa, C; Mitsiades, N				Geng, C.; Kaochar, S.; Li, M.; Rajapakshe, K.; Fiskus, W.; Dong, J.; Foley, C.; Dong, B.; Zhang, L.; Kwon, O-J; Shah, S. S.; Bolaki, M.; Xin, L.; Ittmann, M.; O'Malley, B. W.; Coarfa, C.; Mitsiades, N.			SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein	ONCOGENE			English	Article							CANCER-ASSOCIATED MUTANTS; WILD-TYPE SPOP; POZ PROTEIN; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; COLORECTAL-CANCER; SIGNALING PATHWAY; DEGRADATION; EXPRESSION; MUTATIONS	The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function. To examine its physiologic role in the prostate epithelium in vivo, we generated mice with prostate-specific biallelic ablation of Spop. These mice exhibited increased prostate mass, prostate epithelial cell proliferation, and expression of c-MYC protein compared to littermate controls, and eventually developed prostatic intraepithelial neoplasia (PIN). We found that SPOPWT can physically interact with c-MYC protein and, upon exogenous expression in vitro, can promote c-MYC ubiquitination and degradation. This effect was attenuated in PC cells by introducing PC-associated SPOP mutants or upon knockdown of SPOP via short-hairpin-RNA, suggesting that SPOP inactivation directly increases c-MYC protein levels. Gene Set Enrichment Analysis revealed enrichment of Myc-induced genes in transcriptomic signatures associated with SPOPMT. Likewise, we observed strong inverse correlation between c-MYC activity and SPOP mRNA levels in two independent PC patient cohorts. The core SPOPMT; MYCHigh transcriptomic response, defined by the overlap between the SPOPMT and c-MYC transcriptomic programmes, was also associated with inferior clinical outcome in human PCs. Finally, the organoid-forming capacity of Spop-null murine prostate cells was more sensitive to c-MYC inhibition than that of Spop-WT cells, suggesting that c-MYC upregulation functionally contributes to the proliferative phenotype of Spop knockout prostates. Taken together, our data highlight SPOP as an important regulator of luminal epithelial cell proliferation and c-MYC expression in prostate physiology, identify c-MYC as a novel bona fide SPOP substrate, and help explain the frequent inactivation of SPOP in human PC. We propose SPOPMT-induced stabilization of c-MYC protein as a novel mechanism that can increase total c-MYC levels in PC cells, in addition to amplification of c-MYC locus.	[Geng, C.; Kaochar, S.; Li, M.; Fiskus, W.; Foley, C.; Dong, B.; Shah, S. S.; Bolaki, M.; Mitsiades, N.] Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407, Houston, TX 77030 USA; [Geng, C.; Kaochar, S.; Li, M.; Rajapakshe, K.; Fiskus, W.; Dong, J.; Foley, C.; Dong, B.; Zhang, L.; Kwon, O-J; Shah, S. S.; Bolaki, M.; Xin, L.; O'Malley, B. W.; Coarfa, C.; Mitsiades, N.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407, Houston, TX 77030 USA; [Xin, L.; Ittmann, M.; Coarfa, C.; Mitsiades, N.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, M.] Dept Pathol & Immunol, Houston, TX USA; [Ittmann, M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Mitsiades, N.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mitsiades, N (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407, Houston, TX 77030 USA.; Coarfa, C; Mitsiades, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407, Houston, TX 77030 USA.	coarfa@bcm.edu; mitsiade@bcm.edu			American Cancer Society [RSG-14-218-01-TBG]; Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology [SPORE P50CA58183]; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine [P30-DK079638]; CPRIT [RP170295, RP170005, RP150578]; NIH [R01CA190378, 5T32CA174647-03, DK56338, CA125123]; NICHD [8818]; Department of Defense Breast Cancer Research Program Innovator Award; John S Dunn Gulf Coast Consortium for Chemical Genomics (NCI Cancer Center Support Grant) [P30CA125123]; Dan L Duncan Cancer Center (NCI Cancer Center Support) [P30CA125123]; Alkek Foundation for Molecular Discovery Pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA190378, T32CA174647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine; CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Department of Defense Breast Cancer Research Program Innovator Award; John S Dunn Gulf Coast Consortium for Chemical Genomics (NCI Cancer Center Support Grant); Dan L Duncan Cancer Center (NCI Cancer Center Support); Alkek Foundation for Molecular Discovery Pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge the joint participation by Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine. This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to NM), the Prostate Cancer Foundation (to BWO and NM); the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to NM) and a Developmental Project from SPORE P50CA58183 (NM); the Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (NM), an Alkek Foundation for Molecular Discovery Pilot grant (CC), CPRIT awards RP170295 and RP170005 (CC); NIH R01CA190378 (LX); NIH 5T32CA174647-03 (SK); and NICHD 8818 and Department of Defense Breast Cancer Research Program Innovator Award (BWO). NM is a Dan L Duncan Scholar, a Caroline Wiess Law Scholar and member of the Center for Drug Discovery at Baylor College of Medicine. The authors also acknowledge the assistance of the BCM Genetically Engineered Mouse and Human Tissue Acquisition and Pathology Core, Human Tissue Acquisition and Pathology Core, Integrated Microscopy Core funded via the NIH (DK56338, and CA125123), CPRIT (RP150578), and John S Dunn Gulf Coast Consortium for Chemical Genomics and the Dan L Duncan Cancer Center (supported by the NCI Cancer Center Support Grant P30CA125123).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; An J, 2015, MOL CELL, V59, P904, DOI 10.1016/j.molcel.2015.07.025; An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Blattner M, 2014, NEOPLASIA, V16, P14, DOI 10.1593/neo.131704; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335-012-9427-x; Chen H, 2010, PROSTATE CANCER P D, V13, P238, DOI 10.1038/pcan.2010.20; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Claiborn KC, 2010, J CLIN INVEST, V120, P3713, DOI 10.1172/JCI40440; Coarfa C, 2016, ONCOGENE, V35, P2345, DOI 10.1038/onc.2015.295; Ding DC, 2015, INT J ONCOL, V46, P333, DOI 10.3892/ijo.2014.2729; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Farrell A.S., 2014, COLD SPRING HARB PER, V4; FLEMING WH, 1986, CANCER RES, V46, P1535; Fromont G, 2013, HUM PATHOL, V44, P1617, DOI 10.1016/j.humpath.2013.01.012; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Garcia-Flores M, 2014, EUR J CANCER, V50, P2994, DOI 10.1016/j.ejca.2014.08.009; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Hubbard GK, 2016, CANCER RES, V76, P283, DOI 10.1158/0008-5472.CAN-14-3280; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jenkins RB, 1997, CANCER RES, V57, P524; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Ju XM, 2013, CANCER RES, V73, P978, DOI 10.1158/0008-5472.CAN-12-2133; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kemp Z, 2005, CANCER RES, V65, P11361, DOI 10.1158/0008-5472.CAN-05-2565; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koh CM, 2011, AM J PATHOL, V178, P1824, DOI 10.1016/j.ajpath.2010.12.040; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Li C, 2011, ONCOGENE, V30, P4350, DOI 10.1038/onc.2011.151; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Nelson WG, 2012, CANCER DISCOV, V2, P206, DOI 10.1158/2159-8290.CD-12-0027; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Pomerantz MM, 2009, CANCER RES, V69, P5568, DOI 10.1158/0008-5472.CAN-09-0387; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wu F, 2017, CANCER LETT, V385, P207, DOI 10.1016/j.canlet.2016.10.021; Xu JF, 2015, J GASTROINTEST SURG, V19, P1484, DOI 10.1007/s11605-015-2767-6; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zeng CY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0075-8; Zhang C, 2014, ONCOGENE, V33, P5582, DOI 10.1038/onc.2013.505; Zhang PZ, 2014, HUM MUTAT, V35, P1142, DOI 10.1002/humu.22614; Zhang Q, 2009, P NATL ACAD SCI USA, V106, P21191, DOI 10.1073/pnas.0912008106; Zhi XF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.435; Zhu HR, 2015, CELL REP, V13, P1183, DOI 10.1016/j.celrep.2015.09.083; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	61	65	71	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4767	4777		10.1038/onc.2017.80	http://dx.doi.org/10.1038/onc.2017.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414305	Green Accepted			2022-12-28	WOS:000407702400009
J	Shin, CH; Robinson, JP; Sonnen, JA; Welker, AE; Yu, DX; VanBrocklin, MW; Holmen, SL				Shin, C. H.; Robinson, J. P.; Sonnen, J. A.; Welker, A. E.; Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.			HBEGF promotes gliomagenesis in the context of Ink4al Arf and Pten loss	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HB-EGF; GENE-EXPRESSION; INK4A/ARF LOSS; ACTIVATION; AXL; RESISTANCE; SUBTYPES; GLIOMAS; LOOP	Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.	[Shin, C. H.; Welker, A. E.; Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA; [Shin, C. H.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Robinson, J. P.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Sonnen, J. A.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84112 USA; [Sonnen, J. A.] ARUP Labs, Salt Lake City, UT USA; [Yu, D. X.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Surg, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Minnesota System; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah	Holmen, SL (corresponding author), Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA.	sheri.holmen@hci.utah.edu	Sonnen, Joshua/AAT-5788-2021; Sonnen, Joshua/H-3738-2016	Robinson, James/0000-0002-6585-0116; Sonnen, Joshua/0000-0001-9267-8705	HCI from the National Cancer Institute (NCI) [P30CA042014]; National Institute of Neurological Disorders and Stroke [NIH R01NS073870]; NCI [NIH F30CA203096]; NATIONAL CANCER INSTITUTE [F30CA203096, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075155, R01NS073870] Funding Source: NIH RePORTER	HCI from the National Cancer Institute (NCI); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the members of the VanBrocklin, McMahon and Holmen labs, as well as E Holland, R DePinho and M Bosenberg for providing mouse strains, reagents and advice. We thank the Huntsman Cancer Institute (HCI) Vivarium staff for assistance. We thank Tim Parnell for his bioinformatics expertise. We acknowledge the use of the Mutation Generation and Detection Core, the DNA Synthesis Core, the DNA Sequencing Core and the Small Animal Imaging Core supported by P30CA042014 awarded to HCI from the National Cancer Institute (NCI). We also acknowledge use of the HCI Shared Resources for high-throughput genomics and bioinformatics analysis, glass wash and research histology. This work was supported by the National Institute of Neurological Disorders and Stroke (NIH R01NS073870, to SLH) and the NCI (NIH F30CA203096, to CHS).	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063074; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu FH, 2016, CANCER CELL, V29, P669, DOI 10.1016/j.ccell.2016.03.027; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Puschmann TB, 2014, J NEUROCHEM, V128, P878, DOI 10.1111/jnc.12519; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Ray KC, 2013, ONCOGENE, V33, P1; Robinson JP, 2011, ONCOGENE, V30, P1341, DOI 10.1038/onc.2010.513; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Robinson JP, 2011, AM J CANCER RES, V1, P155; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sato S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051964; Shin Clifford H, 2015, Genes Cancer, V6, P9; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VanBrocklin MW, 2012, NEURO-ONCOLOGY, V14, P34, DOI 10.1093/neuonc/nor184; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yotsumoto F, 2010, INT J CANCER, V127, P2707, DOI 10.1002/ijc.25472; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	38	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4610	4618		10.1038/onc.2017.83	http://dx.doi.org/10.1038/onc.2017.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368403	Green Accepted			2022-12-28	WOS:000407246200008
J	Han, B; Bhowmick, N; Qu, Y; Chung, S; Giuliano, AE; Cui, X				Han, B.; Bhowmick, N.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.			FOXC1: an emerging marker and therapeutic target for cancer	ONCOGENE			English	Review							TO-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; GENE-EXPRESSION SIGNATURE; SUPERIOR PROGNOSTIC VALUE; BREAST-CANCER; DNA METHYLATION; ESTROGEN-RECEPTOR; HEPATOCELLULAR-CARCINOMA; CELL NICHE; HELIX GENE	The Forkhead box C1 (FOXC1) transcription factor is involved in normal embryonic development and regulates the development and function of many organs. Most recently, a large body of literature has shown that FOXC1 plays a critical role in tumor development and metastasis. Clinical studies have demonstrated that elevated FOXC1 expression is associated with poor prognosis in many cancer subtypes, such as basal-like breast cancer (BLBC). FOXC1 is highly and specifically expressed in BLBC as opposed to other breast cancer subtypes. Its functions in breast cancer have been extensively explored. This review will summarize current knowledge on the function and regulation of FOXC1 in tumor development and progression with a focus on BLBC, as well as the implications of these new findings in cancer diagnosis and treatment.	[Han, B.; Qu, Y.; Chung, S.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Los Angeles, CA 90048 USA; [Bhowmick, N.] Cedars Sinai Med Ctr, Dept Med, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063), David Salomon Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy to Xiaojiang Cui, and the Fashion Footwear Charitable Foundation of New York, Inc., the Entertainment Industry Foundation, the Margie and Robert E Petersen Foundation and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Aldinger KA, 2009, NAT GENET, V41, P1037, DOI 10.1038/ng.422; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berry FB, 2006, J BIOL CHEM, V281, P10098, DOI 10.1074/jbc.M513629200; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Blonska M, 2015, BLOOD, V125, P981, DOI 10.1182/blood-2014-04-568188; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060; De Val S, 2008, CELL, V135, P1053, DOI 10.1016/j.cell.2008.10.049; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Duan S., 2012, ABSTRACT APPL ANAL, V2012, P1, DOI DOI 10.1109/SPC0M.2012.6290252; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Haldipur P, 2014, ELIFE, V3, DOI 10.7554/eLife.03962; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Jia BX, 2012, J NANOMATER, V2012, DOI 10.1155/2012/796815; Jin YL, 2014, ANN SURG ONCOL, V21, pS758, DOI 10.1245/s10434-014-3980-3; Kaestner KH, 2000, GENE DEV, V14, P142; Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Kume T, 2000, DEVELOPMENT, V127, P1387; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lay K, 2016, P NATL ACAD SCI USA, V113, pE1506, DOI 10.1073/pnas.1601569113; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Li C, 2013, COMPUT BIOL CHEM, V47, P192, DOI 10.1016/j.compbiolchem.2013.08.010; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin ZY, 2014, CANCER SCI, V105, P1288, DOI 10.1111/cas.12499; Lines MA, 2002, HUM MOL GENET, V11, P1177, DOI 10.1093/hmg/11.10.1177; Mattiske D, 2006, DEV BIOL, V290, P447, DOI 10.1016/j.ydbio.2005.12.007; Mayeuf-Louchart A, 2016, DEVELOPMENT, V143, P872, DOI 10.1242/dev.128017; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Mirzayans F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049095; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Omatsu Y, 2014, NATURE, V508, P536, DOI 10.1038/nature13071; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Peraldo-Neia C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-31; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788; Prasitsak T, 2015, DEV DYNAM, V244, P703, DOI 10.1002/dvdy.24269; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Ray PS, 2011, ANN SURG ONCOL, V18, P3839, DOI 10.1245/s10434-011-1657-8; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012-1606(03)00355-5; SASAKI H, 1993, DEVELOPMENT, V118, P47; Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035; Siegenthaler JA, 2013, BIOL OPEN, V2, P647, DOI 10.1242/bio.20135009; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Sizemore GM, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.108001; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Skarie JM, 2009, INVEST OPHTH VIS SCI, V50, P5026, DOI 10.1167/iovs.09-3447; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Stute P, 2012, BREAST CANCER RES TR, V133, P617, DOI 10.1007/s10549-011-1811-9; Sun JJ, 2013, DEVELOPMENT, V140, P1034, DOI 10.1242/dev.085225; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; Tribulo C, 2003, DEVELOPMENT, V130, P6441, DOI 10.1242/dev.00878; Tumer Z, 2009, EUR J HUM GENET, V17, P1527, DOI 10.1038/ejhg.2009.93; van der Heul-Nieuwenhuijsen L, 2009, BJU INT, V103, P1574, DOI 10.1111/j.1464-410X.2009.08351.x; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang JH, 2016, ONCOTARGET, V7, P84375, DOI 10.18632/oncotarget.11224; Wang L, 2016, SCIENCE, V351, P613, DOI 10.1126/science.aad5440; Wang YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2906-9; Wei Li, 2013, Zoological Research, V34, P14, DOI 10.3724/SP.J.1141.2013.01014; Wilm B, 2004, DEV BIOL, V271, P176, DOI 10.1016/j.ydbio.2004.03.034; Wu JM, 2008, CLIN CANCER RES, V14, P1938, DOI 10.1158/1078-0432.CCR-07-4082; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu YY, 2016, TUMOR BIOL, V37, P239, DOI 10.1007/s13277-015-3686-6; Xu Y, 2014, INT J DISTRIB SENS N, DOI 10.1155/2014/594782; Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769; Yao T, 2016, ONCOL LETT, V12, P73, DOI 10.3892/ol.2016.4573; Yoshida M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7653; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu-Rice Y, 2016, ONCOGENE, V35, P5400, DOI 10.1038/onc.2016.78; Zarbalis K, 2007, P NATL ACAD SCI USA, V104, P14002, DOI 10.1073/pnas.0702618104; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou Y, 2002, GENOMICS, V80, P465, DOI 10.1006/geno.2002.6860; Zvelebil M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3403	99	67	77	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3957	3963		10.1038/onc.2017.48	http://dx.doi.org/10.1038/onc.2017.48			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288141	Green Accepted			2022-12-28	WOS:000405379900002
J	Kim, J; Jin, H; Zhao, JC; Yang, YA; Li, Y; Yang, X; Dong, X; Yu, J				Kim, J.; Jin, H.; Zhao, J. C.; Yang, Y. A.; Li, Y.; Yang, X.; Dong, X.; Yu, J.			FOXA1 inhibits prostate cancer neuroendocrine differentiation	ONCOGENE			English	Article							ANDROGEN RECEPTOR; PROTEIN-KINASE; CELL-PROLIFERATION; EXPRESSION; INTERLEUKIN-8; TRANSCRIPTION; IDENTIFICATION; CHEMOTHERAPY; DEPRIVATION; METASTASIS	Neuroendocrine prostate cancer (NEPC) has increasingly become a clinical challenge. The mechanisms by which neuroendocrine (NE) cells arises from prostate adenocarcinoma cells are poorly understood. FOXA1 is a transcription factor of the forkhead family that is required for prostate epithelial differentiation. In this study, we demonstrated that FOXA1 loss drives NE differentiation, demarcated by phenotypical changes and NEPC marker expressions. Mechanistically, this is mediated by FOXA1 binding to the promoter of interleukin 8 (IL-8), a chemokine previously shown elevated in NEPC, to directly inhibit its expression. Further, IL-8 upregulation activates the MAPK/ERK pathway, leading to ERK phosphorylation and enolase 2 (ENO2) expression. IL-8 knockdown or ERK inhibition, on the other hand, abolished FOXA1 loss-induced NE differentiation. Analysis of xenograft mouse models confirmed FOXA1 loss in NEPC tumors relative to its adenocarcinoma counterparts. Importantly, FOXA1 is downregulated in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expression is negatively correlated with that of ENO2. These findings indicate that FOXA1 transcriptionally suppresses IL-8, the expression of which would otherwise stimulate the MAPK/ERK pathway to promote NE differentiation of prostate cancer cells. Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.	[Kim, J.; Jin, H.; Zhao, J. C.; Yang, Y. A.; Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Li, Y.; Dong, X.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Yang, X.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Yang, X.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of British Columbia; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Dong, Xuesen/AGF-9228-2022	Kim, Jung/0000-0001-6274-2841; Jin, Hongjian/0000-0003-3833-7170; Yang, Angela/0000-0002-9868-7431	NIH [R01CA172384]; prostate cancer SPORE [P50CA180995]; National Institute of Diabetes and Digestive and Kidney Diseases [T32 DK007169]; NATIONAL CANCER INSTITUTE [R01CA172384, R50CA211271, T32CA009560, P50CA180995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); prostate cancer SPORE; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by the NIH R01CA172384 (to JY), prostate cancer SPORE P50CA180995 (to JY), the Institutional Ruth L. Kirschstein National Research Service Award from the National Institute of Diabetes and Digestive and Kidney Diseases T32 DK007169 (to JK).	Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chen HB, 2012, ENDOCR-RELAT CANCER, V19, P321, DOI 10.1530/ERC-11-0368; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culine S, 2007, J UROLOGY, V178, P844, DOI 10.1016/j.juro.2007.05.044; DeGraff DJ, 2014, LAB INVEST, V94, P726, DOI 10.1038/labinvest.2014.64; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Kim J, 2002, CANCER RES, V62, P1549; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Murphy C, 2005, CLIN CANCER RES, V11, P4117, DOI 10.1158/1078-0432.CCR-04-1518; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Sagnak L, 2011, CLIN GENITOURIN CANC, V9, P73, DOI 10.1016/j.clgc.2011.07.003; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Santoni M, 2014, BBA-REV CANCER, V1846, P630, DOI 10.1016/j.bbcan.2014.10.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Sun YJ, 2009, PROSTATE, V69, P1119, DOI 10.1002/pros.20961; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wightman SC, 2015, BRIT J CANCER, V113, P327, DOI 10.1038/bjc.2015.193; Wilson C, 2008, J PHARMACOL EXP THER, V327, P746, DOI 10.1124/jpet.108.143826; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu Y, 2013, J CLIN ENDOCR METAB, V98, P2887, DOI 10.1210/jc.2012-4000; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764	58	75	77	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4072	4080		10.1038/onc.2017.50	http://dx.doi.org/10.1038/onc.2017.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319070	Green Accepted			2022-12-28	WOS:000405379900012
J	Sodi, VL; Bacigalupa, ZA; Ferrer, CM; Lee, JV; Gocal, WA; Mukhopadhyay, D; Wellen, KE; Ivan, M; Reginato, MJ				Sodi, V. L.; Bacigalupa, Z. A.; Ferrer, C. M.; Lee, J. V.; Gocal, W. A.; Mukhopadhyay, D.; Wellen, K. E.; Ivan, M.; Reginato, M. J.			Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation	ONCOGENE			English	Article							BETA-N-ACETYLGLUCOSAMINE; C-MYC; PROSTATE-CANCER; BREAST-CANCER; TRANSCRIPTION FACTORS; GLCNACYLATION; CELLS; AMPK; LIPOGENESIS; METASTASIS	Elevated O-GlcNAcylation is associated with disease states such as diabetes and cancer. O-GlcNAc transferase (OGT) is elevated in multiple cancers and inhibition of this enzyme genetically or pharmacologically inhibits oncogenesis. Here we show that O-GlcNAcylation modulates lipid metabolism in cancer cells. OGT regulates expression of the master lipid regulator the transcription factor sterol regulatory element binding protein 1 (SREBP-1) and its transcriptional targets both in cancer and lipogenic tissue. OGT regulates SREBP-1 protein expression via AMP-activated protein kinase (AMPK). SREBP-1 is critical for OGT-mediated regulation of cell survival and of lipid synthesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and tumor growth in vitro and in vivo. These results unravel a previously unidentified link between O-GlcNAcylation, lipid metabolism and the regulation of SREBP-1 in cancer and suggests a crucial role for O-GlcNAc signaling in transducing nutritional state to regulate lipid metabolism.	[Sodi, V. L.; Bacigalupa, Z. A.; Ferrer, C. M.; Gocal, W. A.; Mukhopadhyay, D.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th Street, Philadelphia, PA 19102 USA; [Lee, J. V.] Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Ivan, M.] Indiana Univ, Dept Med, Indianapolis, IN USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Indiana University System; Indiana University-Purdue University Indianapolis	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th Street, Philadelphia, PA 19102 USA.	Mauricio.Reginato@drexelmed.edu		Gocal, Wiktoria/0000-0001-8894-8047	NCI [CA192868, CA183574, CA155413]; NATIONAL CANCER INSTITUTE [F31CA192868, F31CA183574, R01CA155413] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Nicholas Xerri for technical support and Mignon Keaton for help in analyzing LC-MS metabolite data. This work was supported by NCI grants CA192868 (to VLS), CA183574 (to CMF) and CA155413 (to MJR).	Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338; Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardiville S, 2014, CELL METAB, V20, P208, DOI 10.1016/j.cmet.2014.07.014; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Jones SF, 2015, CLIN CANCER RES, V21, P5434, DOI 10.1158/1078-0432.CCR-15-0126; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Li XY, 2016, ONCOTARGET, V7, P12869, DOI 10.18632/oncotarget.7331; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Lopez-Ibanez J, 2016, NUCLEIC ACIDS RES, V44, pW201, DOI 10.1093/nar/gkw253; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Ozcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Shaw Reuben J, 2012, F1000 Biol Rep, V4, P2, DOI 10.3410/B4-2; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Varki A., 1999, ESSENTIALS GLYCOBIOL; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068	41	37	42	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					924	934		10.1038/onc.2017.395	http://dx.doi.org/10.1038/onc.2017.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059153	Green Submitted, Green Accepted			2022-12-28	WOS:000425281800009
J	De Melo, J; Kim, SS; Lourenco, C; Penn, LZ				De Melo, J.; Kim, S. S.; Lourenco, C.; Penn, L. Z.			Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism	ONCOGENE			English	Article							C-MYC; TUMOR-SUPPRESSOR; PROTEIN; DEGRADATION; PHOSPHORYLATION; DOMAIN; FBW7; UBIQUITYLATION; TUMORIGENESIS; TRANSCRIPTION	The oncogenic transcription factor c-MYC (MYC) is deregulated and often overexpressed in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease, suggesting that the development of therapeutic inhibitors targeting MYC would markedly impact patient outcome. MYC is highly regulated, with a protein and mRNA half-life of similar to 30 min. The most extensively studied pathway regulating MYC protein stability involves ubiquitylation and proteasomal degradation mediated by the E3-ligase, SCFFbxw7. Here we provide evidence for an SCFFbxw7-independent regulatory mechanism centred on the highly conserved lysine-52 (K52) within MYC Box I. This residue has been shown to be post-translationally modified by both ubiquitylation and SUMOylation, hinting at the interplay of post-translational modifications at this site and the importance of this residue. We demonstrate that mutation of K52 to arginine (R) renders the MYC protein more labile. Mechanistically, we show that the degradation pathway regulated by K52 is independent of the Cullin-RING ligase family of E3-ligases, which includes not only the canonical SCFFbxw7 but also other known MYC-targeting E3-ligases, such as SCFSkp2, SCF beta TCRP, SCFFbxo28 and DCXTRUSS. Taken together, our data identify a novel regulatory pathway centred on K52 that may be exploited for the development of anti-MYC therapeutics.	[De Melo, J.; Kim, S. S.; Lourenco, C.; Penn, L. Z.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Lourenco, C.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Univ Hlth Network, Princess Margaret Canc Res Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	lpenn@uhnresearch.ca		Penn, Linda/0000-0001-8133-5459; De Melo, Jason/0000-0001-6519-4879	Canadian Institutes of Health Research [MOP275788]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Dr Bert Vogelstein for the HCT116 cells (wt/Fbxw7<SUP>-/-</SUP>) and all members of the Penn lab and especially the technical support of Aaliya Tamachi and Natasha Vitkin. LZP holds the Tier 1 Canada Research Chair in Molecular Oncology. This work was also supported by the Canadian Institutes of Health Research (MOP275788).	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chakraborty AA, 2014, ONCOGENE, V34, P1; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Diefenbacher ME, 2015, CANCER RES, V75, P1181, DOI 10.1158/0008-5472.CAN-14-1726; Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005; Gonzalez-Prieto R, 2015, CELL CYCLE, V14, P1859, DOI 10.1080/15384101.2015.1040965; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hakem A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002360; Helander S, 2015, STRUCTURE, V23, P2267, DOI 10.1016/j.str.2015.10.010; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kalkat M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115337; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Prochownik Edward V, 2010, Genes Cancer, V1, P650; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rabellino A, 2016, CELL REP, V15, P2266, DOI 10.1016/j.celrep.2016.05.015; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324; Topham C, 2015, CANCER CELL, V28, P129, DOI 10.1016/j.ccell.2015.06.001; Tu W.B., 2014, BIOCHIM BIOPHYS ACTA, V1849, P469; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wasylishen AR, 2014, ONCOGENE, V33, P1066, DOI 10.1038/onc.2013.36; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Wasylishen AR, 2013, CANCER RES, V73, P6504, DOI 10.1158/0008-5472.CAN-12-4063; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang Q, 2013, P NATL ACAD SCI USA, V110, P978, DOI 10.1073/pnas.1208334110; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	53	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6815	6822		10.1038/onc.2017.268	http://dx.doi.org/10.1038/onc.2017.268			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806398				2022-12-28	WOS:000417282500007
J	Kwun, HJ; Wendzicki, JA; Shuda, Y; Moore, PS; Chang, Y				Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.			Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting	ONCOGENE			English	Article							CENTROSOME OVERDUPLICATION; CHROMOSOMAL INSTABILITY; PROMOTES TUMORIGENESIS; HUMAN PAPILLOMAVIRUSES; MEDIATED DEGRADATION; BINDING PROTEIN-1; E7 ONCOPROTEINS; CYCLE CONTROL; CANCER; ANEUPLOIDY	The formation of a bipolar mitotic spindle is an essential process for the equal segregation of duplicated DNA into two daughter cells during mitosis. As a result of deregulated cellular signaling pathways, cancer cells often suffer a loss of genome integrity that might etiologically contribute to carcinogenesis. Merkel cell polyomavirus (MCV) small T (sT) oncoprotein induces centrosome overduplication, aneuploidy, chromosome breakage and the formation of micronuclei by targeting cellular ligases through a sT domain that also inhibits MCV large T oncoprotein turnover. These results provide important insight as to how centrosome number and chromosomal stability can be affected by the E3 ligase targeting capacity of viral oncoproteins such as MCV sT, which may contribute to Merkel cell carcinogenesis.	[Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.] Univ Pittsburgh, Canc Virol Program, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Moore, PS; Chang, Y (corresponding author), Univ Pittsburgh, Canc Inst, Canc Virol Program, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	psm9@pitt.edu; yc70@pitt.edu	Kwun, Hyun Jin/F-5511-2011; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011; Kwun, Hyun Jin/AAH-2706-2020; Kwun, Hyun jin/AAJ-3365-2020; Moore, Patrick/GVR-8294-2022	Kwun, Hyun Jin/0000-0002-8926-746X; Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Kwun, Hyun jin/0000-0002-8926-746X; 	comprehensive Masonic Cancer Center [P30CA077598]; National Institutes of Health (NIH) [CA136363, CA120726]; NIH [T32AI049820]; UPCI Animal and Cytometry Facilities [P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA077598, P30CA047904, R33CA120726, R01CA136363, R35CA197463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049820] Funding Source: NIH RePORTER	comprehensive Masonic Cancer Center; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UPCI Animal and Cytometry Facilities; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Gutian Xiao for providing the HA-beta TrCP plasmid, Bert Vogelstein for providing the HCT116 cells, and Megan Lambert and Robin Frederick for assistance in mouse studies, and Meredith Monk for help with the manuscript. The cytogenetic analyses were performed in the Cytogenomics Shared Resource at the University of Minnesota with support from the comprehensive Masonic Cancer Center grant P30CA077598. This study was supported by National Institutes of Health (NIH) grants CA136363 and CA120726 to PSM and YC, who are also supported as American Cancer Society Research Professors. Additional support was provided by the NIH grant T32AI049820 to JAW as a predoctoral trainee. This project used the UPCI Animal and Cytometry Facilities that are supported in part by award P30CA047904.	Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Bonassi S, 2007, CARCINOGENESIS, V28, P625, DOI 10.1093/carcin/bgl177; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Chi YH, 2007, J CELL BIOCHEM, V102, P531, DOI 10.1002/jcb.21484; Cizmecioglu O, 2012, J CELL SCI, V125, P981, DOI 10.1242/jcs.095075; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Desmaze C, 2003, CANCER LETT, V194, P173, DOI 10.1016/S0304-3835(02)00704-8; Duensing A, 2008, VIROLOGY, V372, P157, DOI 10.1016/j.virol.2007.10.030; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Fang X, 2011, SEMIN CELL DEV BIOL, V22, P595, DOI 10.1016/j.semcdb.2011.03.002; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Guderian G, 2010, J CELL SCI, V123, P2163, DOI 10.1242/jcs.068502; Holland AJ, 2010, J CELL BIOL, V188, P191, DOI 10.1083/jcb.200911102; Houben R, 2010, J VIROL, V84, P7064, DOI 10.1128/JVI.02400-09; Iarmarcovai G, 2008, MUTAT RES-REV MUTAT, V658, P215, DOI 10.1016/j.mrrev.2007.10.001; Knight LM, 2015, J VIROL, V89, P35, DOI 10.1128/JVI.02317-14; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Korzeniewski N, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-61; Kwun HJ, 2015, J VIROL, V89, P4191, DOI 10.1128/JVI.00157-15; Kwun HJ, 2013, CELL HOST MICROBE, V14, P125, DOI 10.1016/j.chom.2013.06.008; Kwun HJ, 2009, J VIROL, V83, P12118, DOI 10.1128/JVI.01336-09; Lau AW, 2012, FRONT BIOSCI-LANDMRK, V17, P2197, DOI 10.2741/4045; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542; Miron K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8094; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pan HY, 2004, CANCER RES, V64, P4064, DOI 10.1158/0008-5472.CAN-04-0657; Peel Nina, 2013, Worm, V2, pe22497, DOI 10.4161/worm.22497; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rodig SJ, 2012, J CLIN INVEST, V122, P4645, DOI 10.1172/JCI64116; Sahi H, 2014, APMIS, V122, P1157, DOI 10.1111/apm.12274; Shuda M, 2008, P NATL ACAD SCI USA, V105, P16272, DOI 10.1073/pnas.0806526105; Shuda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142329; Shuda M, 2015, P NATL ACAD SCI USA, V112, P5875, DOI 10.1073/pnas.1505787112; Shuda M, 2011, J CLIN INVEST, V121, P3623, DOI 10.1172/JCI46323; Silverman JS, 2012, TRENDS BIOCHEM SCI, V37, P66, DOI 10.1016/j.tibs.2011.10.004; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Verhaegen ME, 2015, J INVEST DERMATOL, V135, P1415, DOI 10.1038/jid.2014.446; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; White EA, 2012, P NATL ACAD SCI USA, V109, pE260, DOI 10.1073/pnas.1116776109; Witt KL, 2008, MUTAT RES-GEN TOX EN, V649, P101, DOI 10.1016/j.mrgentox.2007.08.004; Yun C, 2004, MOL CANCER RES, V2, P159	50	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6784	6792		10.1038/onc.2017.277	http://dx.doi.org/10.1038/onc.2017.277			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846109	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000417282500004
J	Yadav, A; Kumar, B; Lang, JC; Teknos, TN; Kumar, P				Yadav, A.; Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.			A muscle-specific protein 'myoferlin' modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus	ONCOGENE			English	Article							GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID-BINDING; TUMOR-METASTASIS; EXPRESSION; GENE; INTERLEUKIN-6; HEAD; EHD2; IDENTIFICATION	Myoferlin, a member of ferlin family of proteins, was first discovered as a candidate gene for muscular dystrophy and cardiomyopathy. Recently, myoferlin was shown to be also expressed in endothelial and cancer cells where it was shown to modulate vascular endothelial growth factor (VEGFR)-2 and epidermal growth factor receptor (EGFR) signaling by enhancing their stability and recycling. Based on these reports, we hypothesized that myoferlin might be regulating IL-6 signaling by modulating IL-6R stabilization and recycling. However, in our immunoprecipitation (IP) experiments, we did not observe myoferlin binding with IL-6R. Instead, we made a novel discovery that in resting cells myoferlin was bound to EHD2 protein and when cells were treated with IL-6, myoferlin dissociated from EHD2 and binds to activated STAT3. Interestingly, myoferlin depletion did not affect STAT3 phosphorylation, but completely blocked STAT3 translocation to nucleus. In addition, inhibition of STAT3 phosphorylation by phosphorylation-defective STAT3 mutants or JAK inhibitor blocked STAT3 binding to myoferlin and nuclear translocation. Myoferlin knockdown significantly decreased IL-6-mediated tumor cell migration, tumorsphere formation and ALDH-positive cancer stem cell population, in vitro. Furthermore, myoferlin knockdown significantly decreased IL-6-meditated tumor growth and tumor metastasis. Based on these results, we have proposed a novel model for the role of myoferlin in chaperoning phosphorylated STAT3 to the nucleus.	[Yadav, A.; Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Kumar, B.; Lang, J. C.; Teknos, T. N.; Kumar, P.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 420W 12th Ave,Room 464, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kumar, P (corresponding author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 420W 12th Ave,Room 464, Columbus, OH 43210 USA.	Pawan.Kumar@osumc.edu			NIH/NCI [CA178649]; Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R21CA178649] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from NIH/NCI (CA178649 to PK) and The Ohio State University Comprehensive Cancer Center (PK and TNT). NIH/NCI-CA178649 (P Kumar) and The Ohio State University Comprehensive Cancer Center.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; DeFranco DB, 2000, KIDNEY INT, V57, P1241, DOI 10.1046/j.1523-1755.2000.00957.x; Demonbreun AR, 2010, J CELL SCI, V123, P2413, DOI 10.1242/jcs.065375; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Difilippantonio S, 2003, EUR J CANCER, V39, P1936, DOI 10.1016/S0959-8049(03)00419-2; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Eisenberg MC, 2011, P NATL ACAD SCI USA, V108, P20078, DOI 10.1073/pnas.1116327108; Harrell MI, 2008, J IMMUNOL METHODS, V332, P170, DOI 10.1016/j.jim.2007.11.012; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Jimenez JL, 2007, J NEUROL SCI, V260, P114, DOI 10.1016/j.jns.2007.04.016; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Kumar B, 2016, ONCOTARGET, V7, P18665, DOI 10.18632/oncotarget.7625; Kumar Bhavna, 2015, Genes Cancer, V6, P169; Kumar P, 2005, LAB INVEST, V85, P756, DOI 10.1038/labinvest.3700272; Kumar P, 2008, LAB INVEST, V88, P740, DOI 10.1038/labinvest.2008.46; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0396-4; Li RG, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0037127, 10.1371/journal.pone.0029392, 10.1371/journal.pone.0051897]; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Liu YP, 2008, INT J MOL MED, V21, P153; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lv JJ, 2015, CANCER INVEST, V33, P420, DOI 10.3109/07357907.2015.1055757; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Riedel F, 2005, ANTICANCER RES, V25, P2761; Roux I, 2006, CELL, V127, P277, DOI 10.1016/j.cell.2006.08.040; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shi YH, 2015, J MOL HISTOL, V46, P221, DOI 10.1007/s10735-015-9614-7; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TIAN SS, 1994, BLOOD, V84, P1760; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Villalva C, 2011, INT J CANCER, V128, P826, DOI 10.1002/ijc.25416; Wente SR, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000562; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yang XJ, 2015, TUMOR BIOL, V36, P3717, DOI 10.1007/s13277-014-3011-9; Yu C, 2011, VASC PHARMACOL, V55, P26, DOI 10.1016/j.vph.2011.04.001; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	57	14	14	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6374	6382		10.1038/onc.2017.245	http://dx.doi.org/10.1038/onc.2017.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745314	Green Accepted			2022-12-28	WOS:000415622900002
J	Kitamura, H; Onodera, Y; Murakami, S; Suzuki, T; Motohashi, H				Kitamura, H.; Onodera, Y.; Murakami, S.; Suzuki, T.; Motohashi, H.			IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model	ONCOGENE			English	Article							INTERLEUKIN-11; RESISTANCE; EXPRESSION; CELLS; MICROENVIRONMENT; RECOGNITION; SENSITIVITY; P62/SQSTM1; PROGNOSIS; CARCINOMA	The interaction between cancer cells and their microenvironment is an important determinant of the pathological nature of cancers, particularly their tumorigenic abilities. The KEAP1-NRF2 system, originally identified as a critical defense mechanism against oxidative stress, is often dysregulated in various human cancers forming solid tumors, resulting in the aberrant activation of NRF2. Increased accumulation of NRF2 in cancers is strongly associated with the poor prognoses of cancer patients, including those with lung and breast cancers. Multiple lines of evidence suggest that aberrantly activated NRF2 in cancer cells drives their malignant progression and that the cancer cells consequently develop 'NRF2 addiction.' Although the downstream effectors of NRF2 that are responsible for cancer malignancy have been extensively studied, mechanisms of how NRF2 activation contributes to the aggressive tumorigenesis remains to be elucidated. In this study, we found a significant correlation between NRF2 and IL-11 status in breast cancer patients. Based on a recent report demonstrating that IL-11 is induced downstream of NRF2, we examined the significance of IL-11 in NRF2-driven tumorigenesis with a newly established NRF2 addiction cancer model. Expression of Il11 was elevated during the tumorigenesis of the NRF2 addiction cancer model, but intriguingly, it was hardly detected when the cancer model cells were cultured in vitro. These results imply that a signal originating from the microenvironment cooperates with NRF2 to activate Il11. To the best of our knowledge, this is the first report showing the influence of the microenvironment on the NRF2 pathway in cancer cells and the contribution of NRF2 to the secretory phenotypes of cancers. Disruption of Il11 in the NRF2 addiction cancer model remarkably inhibited the tumorigenesis, suggesting an essential role of IL-11 in NRF2-driven tumorigenesis. Thus, this study suggests that IL-11 is a potential therapeutic target for NRF2-addicted breast cancers.	[Kitamura, H.; Murakami, S.; Motohashi, H.] Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Sendai, Miyagi, Japan; [Onodera, Y.] Tohoku Univ, Grad Sch Med, Dept Anat Pathol, Sendai, Miyagi, Japan; [Suzuki, T.] Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tohoku University	Kitamura, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Sendai, Miyagi, Japan.; Kitamura, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Gene Express Regulat, Aoba Ku, 4-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	hozumim@med.tohoku.ac.jp	Motohashi, Hozumi/AAZ-2628-2020; Murakami, Shohei/GPW-9730-2022	Murakami, Shohei/0000-0002-2555-1568	JSPS KAKENHI [JP26860180, 15H04692, 16K15228]; Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation; Mitsubishi Foundation; Naito Foundation; Princess Takamatsu Cancer Research Fund [15-24728]; Grants-in-Aid for Scientific Research [15H04692] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Mitsubishi Foundation; Naito Foundation(Naito Memorial Foundation); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Keiko Nakayama for providing a mutant HRAS-expression vector, pMX-puro- HRASG12V, Drs. Norio Suzuki and Masayuki Yamamoto for providing SV40 T antigen expressing vectors, HA-KEAP1 cDNA and intensive discussion, and Drs Tomohiro Nakamura and Atsushi Hozawa for checking the quality of quantitative data and the adequacy of their presentation. We also thank Ms Nao Ohta for technical assistance and the Biomedical Research Core of Tohoku University Graduate School of Medicine for technical support. This work was supported by JSPS KAKENHI Grant Numbers JP26860180 (HK), 15H04692 (HM) and 16K15228 (HM), Daiichi Sankyo Foundation of Life Science (HM), the Uehara Memorial Foundation (HM), the Mitsubishi Foundation (HM), the Naito Foundation (HM), and the Princess Takamatsu Cancer Research Fund 15-24728 (HM). The funders had no role in the design of the study, data collection and analysis, decision to publish or preparation of the manuscript.	Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393; Bockhorn J, 2013, BREAST CANCER RES TR, V137, P373, DOI 10.1007/s10549-012-2346-4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Ernst M, 2014, CLIN CANCER RES, V20, P5579, DOI 10.1158/1078-0432.CCR-13-2492; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goto M, 2015, GENES CELLS, V20, P464, DOI 10.1111/gtc.12237; Grivennikov SI, 2013, CANCER CELL, V24, P145, DOI 10.1016/j.ccr.2013.07.018; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanavadi S, 2006, ANN SURG ONCOL, V13, P802, DOI 10.1245/ASO.2006.05.028; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Johnstone CN, 2015, CYTOKINE GROWTH F R, V26, P489, DOI 10.1016/j.cytogfr.2015.07.015; Kanamori M, 2015, NEURO-ONCOLOGY, V17, P555, DOI 10.1093/neuonc/nou282; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Nakayama T, 2007, INT J ONCOL, V30, P825; Nishina T, 2017, J BIOL CHEM, V292, P205, DOI 10.1074/jbc.M116.744755; Nishina T, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002056; Ohkoshi A, 2013, CANCER PREV RES, V6, P149, DOI 10.1158/1940-6207.CAPR-12-0401-T; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Onodera Y, 2014, ENDOCR-RELAT CANCER, V21, P241, DOI 10.1530/ERC-13-0234; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Saito T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12030; Satoh H, 2016, CANCER RES, V76, P3088, DOI 10.1158/0008-5472.CAN-15-1584; Satoh H, 2010, CARCINOGENESIS, V31, P1833, DOI 10.1093/carcin/bgq105; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shin SY, 2012, CARCINOGENESIS, V33, P2467, DOI 10.1093/carcin/bgs297; Shirasaki K, 2014, HEPATOLOGY, V59, P2371, DOI 10.1002/hep.27020; Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Taguchi K, 2010, MOL CELL BIOL, V30, P3016, DOI 10.1128/MCB.01591-09; Tsuchida K, 2017, FREE RADICAL BIO MED, V103, P236, DOI 10.1016/j.freeradbiomed.2016.12.041; Uruno A, 2011, NITRIC OXIDE-BIOL CH, V25, P153, DOI 10.1016/j.niox.2011.02.007; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	52	34	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6315	6324		10.1038/onc.2017.236	http://dx.doi.org/10.1038/onc.2017.236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714957				2022-12-28	WOS:000414774800010
J	Katschnig, AM; Kauer, MO; Schwentner, R; Tomazou, EM; Mutz, CN; Linder, M; Sibilia, M; Alonso, J; Aryee, DNT; Kovar, H				Katschnig, A. M.; Kauer, M. O.; Schwentner, R.; Tomazou, E. M.; Mutz, C. N.; Linder, M.; Sibilia, M.; Alonso, J.; Aryee, D. N. T.; Kovar, H.			EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; PROTEIN-COUPLED RECEPTOR; ACTIN CYTOSKELETON; BREAST-CANCER; TRANSCRIPTIONAL REGULATION; CELL-PROLIFERATION; DNA-BINDING; EXPRESSION; MRTF; METASTASIS	Ewing sarcoma (EWS) is a paediatric bone cancer with high metastatic potential. Cellular plasticity resulting from dynamic cytoskeletal reorganization, typically regulated via the Rho pathway, is a prerequisite for metastasis initiation. Here, we interrogated the role of the Ewing sarcoma driver oncogene EWS-FLI1 in cytoskeletal reprogramming. We report that EWS-FLI1 strongly represses the activity of the Rho-F-actin signal pathway transcriptional effector MRTFB, affecting the expression of a large number of EWS-FLI1-anticorrelated genes including structural and regulatory cytoskeletal genes. Consistent with this finding, chromatin immunoprecipitation sequencing (ChIP-seq) revealed strong overlaps in myocardin-related transcription factor B (MRTFB) and EWS-FLI1 chromatin occupation, especially for EWS-FLI1-anticorrelated genes. Binding of the transcriptional co-activator Yes-associated protein (YAP)-1, enrichment of TEAD-binding motifs in these shared genomic binding regions and overlapping transcriptional footprints of MRTFB and TEAD factors led us to propose synergy between MRTFB and the YAP/TEAD complex in the regulation of EWS-FLI1-anticorrelated genes. We propose that EWS-FLI1 suppresses the Rho-actin pathway by perturbation of a MRTFB/YAP-1/TEAD transcriptional module, which directly affects the actin-autoregulatory feedback loop. As spontaneous fluctuations in EWS-FLI1 levels of Ewing sarcoma cells in vitro and in vivo, associated with a switch between a proliferative, non-migratory EWS-FLI1-high and a non-proliferative highly migratory EWS-FLI1-low state, were recently described, our data provide a mechanistic basis for the underlying EWS-FLI1-dependent reversible cytoskeletal reprogramming of Ewing sarcoma cells.	[Katschnig, A. M.; Kauer, M. O.; Schwentner, R.; Tomazou, E. M.; Mutz, C. N.; Aryee, D. N. T.; Kovar, H.] St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria; [Linder, M.; Sibilia, M.] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Alonso, J.] Inst Invest Enfermedades Raras, Unidad Tumores Solidos Infantiles, Madrid, Spain; [Aryee, D. N. T.; Kovar, H.] Med Univ Vienna, Dept Paediat, Vienna, Austria	Saint Anna Children's Hospital; Medical University of Vienna; Instituto de Salud Carlos III; Instituto de Investigacion de Enfermedades Raras (IIER); Medical University of Vienna	Kovar, H (corresponding author), St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at	Tomazou, Eleni M/J-1475-2014; Alonso, Javier/B-6012-2013	Alonso, Javier/0000-0002-6287-8391; Tomazou, Eleni Marina/0000-0002-7497-4567; Schwentner, Raphaela/0000-0001-6839-0322; Sibilia, Maria/0000-0001-6129-5613	Austrian Science Fund [I1125-B19]; Liddy Shriver Initiative; European Commission [259348]	Austrian Science Fund(Austrian Science Fund (FWF)); Liddy Shriver Initiative; European Commission(European CommissionEuropean Commission Joint Research Centre)	This study was supported by the Austrian Science Fund grant I1125-B19, the Liddy Shriver Initiative and by the European Commission Framework Program 7 grant 259348 ('ASSET').	Amsellem V, 2005, EXP CELL RES, V304, P443, DOI 10.1016/j.yexcr.2004.10.035; Asparuhova MB, 2009, SCAND J MED SCI SPOR, V19, P490, DOI 10.1111/j.1600-0838.2009.00928.x; Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hu QD, 2011, MOL CELL BIOL, V31, P3223, DOI 10.1128/MCB.01365-10; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kim T, 2017, EMBO J, V36, P520, DOI 10.15252/embj.201695137; Kovar H, 2010, GENOME MED, V2, DOI 10.1186/gm129; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Liu CY, 2016, ONCOTARGET, V7, P13706, DOI 10.18632/oncotarget.7333; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodenberg JM, 2010, AM J PHYSIOL-CELL PH, V299, pC1058, DOI 10.1152/ajpcell.00080.2010; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schwentner R, 2015, NUCLEIC ACIDS RES, V43, P2780, DOI 10.1093/nar/gkv123; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Speight P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11642; Spraker HL, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan AL, 2011, MOL CELL BIOL, V31, P861, DOI 10.1128/MCB.00836-10; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Yu OM, 2016, MOL CELL BIOL, V36, P39, DOI 10.1128/MCB.00772-15; Yu OM, 2015, MOL PHARMACOL, V88, P171, DOI 10.1124/mol.115.097857; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5995	6005		10.1038/onc.2017.202	http://dx.doi.org/10.1038/onc.2017.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671673	hybrid, Green Published			2022-12-28	WOS:000413841400008
J	Kato, T; Sato, T; Yokoi, K; Sekido, Y				Kato, T.; Sato, T.; Yokoi, K.; Sekido, Y.			E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells	ONCOGENE			English	Article							NF2 TUMOR-SUPPRESSOR; PLEURAL MESOTHELIOMA; OVARIAN-CANCER; SIGNALING PATHWAYS; GROWTH-FACTOR; LUNG-CANCER; GENE NF2; PROLIFERATION; FAK; PROMOTES	Malignant mesothelioma (MM) is an aggressive tumor commonly caused by asbestos exposure after a long latency. Focal adhesion kinase (FAK) inhibitors inhibit the cell growth of Merlin-deficient MM cells; however, their clinical efficacy has not been clearly determined. The aim of this study was to evaluate the growth inhibitory effect of the FAK inhibitor VS-4718 on MM cell lines and identify biomarkers for its efficacy. Although most Merlin-deficient cell lines were sensitive to VS-4718 compared with control MeT-5A cells, a subset of these cell lines exhibited resistance to this drug. Microarray and qRT-PCR analyses using RNA isolated from Merlin-deficient MM cell lines revealed a significant correlation between E-cadherin mRNA levels and VS-4718 resistance. Merlin-and E-cadherin-negative Y-MESO-22 cells underwent apoptosis upon treatment with a low concentration of VS-4718, whereas Merlin-negative, E-cadherin-positive Y-MESO-9 cells did not undergo VS-4718-induced apoptosis. Furthermore, E-cadherin knockdown in Merlin-negative MM cells significantly sensitized cells to VS-4718 and induced apoptotic cell death upon VS-4718 treatment. Together, our results suggest that E-cadherin serves as a predictive biomarker for molecular target therapy with FAK inhibitors for patients with mesothelioma and that its expression endows MM cells with resistance to FAK inhibitors.	[Kato, T.; Sato, T.; Sekido, Y.] Aichi Canc Ctr, Div Mol Oncol, Res Inst, Nagoya, Aichi, Japan; [Kato, T.; Yokoi, K.] Nagoya Univ, Dept Thorac Surg, Grad Sch Med, Nagoya, Aichi, Japan; [Sekido, Y.] Dept Canc Genet, Program Funct Construct Med, Nagoya, Aichi, Japan	Aichi Cancer Center; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp		Kato, Taketo/0000-0003-2568-6603; Sekido, Yoshitaka/0000-0002-2428-3848	JSPS KAKENHI [JP25290053, JP16H04706]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [14-24617]; Project Mirai Cancer Research Grants; P-DIRECT; Grants-in-Aid for Scientific Research [16H04706] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Project Mirai Cancer Research Grants; P-DIRECT; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant Numbers JP25290053 and JP16H04706), the Takeda Science Foundation, a Research Grant from the Princess Takamatsu Cancer Research Fund (14-24617), Project Mirai Cancer Research Grants, and P-DIRECT. We thank Dr Adi F Gazdar for the cell lines, Dr Hideki Murakami for his technical support during gene expression profiling, and Miwako Nishizawa for her excellent technical assistance. We gratefully thank Dr Hirotaka Osada for the study design and his careful supervision of the data (Dr Osada was a member of our lab and passed away on 23 August 2016).	Addis B, 2009, HISTOPATHOLOGY, V54, P55, DOI 10.1111/j.1365-2559.2008.03178.x; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Dong LL, 2012, ACTA PHARMACOL SIN, V33, P817, DOI 10.1038/aps.2012.30; Frank AL, 2014, ANN GLOB HEALTH, V80, P257, DOI 10.1016/j.aogh.2014.09.016; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Ishiguro F, 2012, J THORAC ONCOL, V7, P890, DOI 10.1097/JTO.0b013e31824af2db; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Japan Ministry of Health, 2015, TRENDS DEATHS DUE MA; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kakiuchi T, 2016, CARCINOGENESIS, V37, P1098, DOI 10.1093/carcin/bgw084; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Lallemand D, 2009, J CELL SCI, V122, P4141, DOI 10.1242/jcs.045914; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Lim STS, 2013, MOL CELLS, V36, P1, DOI 10.1007/s10059-013-0139-1; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marlowe TA, 2016, MOL CANCER THER, V15, P3028, DOI 10.1158/1535-7163.MCT-16-0366; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Muller AM, 2002, VIRCHOWS ARCH, V441, P41, DOI 10.1007/s00428-001-0563-z; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Shah NR, 2014, GYNECOL ONCOL, V134, P104, DOI 10.1016/j.ygyno.2014.04.044; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Tanaka I, 2015, ONCOGENE, V34, P73, DOI 10.1038/onc.2013.528; Tang KJ, 2016, CLIN CANCER RES, V22, P5851, DOI 10.1158/1078-0432.CCR-15-2603; Taniguchi T, 2007, CANCER SCI, V98, P438, DOI 10.1111/j.1349-7006.2006.00386.x; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Usami N, 2006, CANCER SCI, V97, P387, DOI 10.1111/j.1349-7006.2006.00184.x; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	55	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5522	5531		10.1038/onc.2017.147	http://dx.doi.org/10.1038/onc.2017.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28553954				2022-12-28	WOS:000411960500008
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction (vol 34, pg 2505, 2015)	ONCOGENE			English	Correction																		Wu DW, 2015, ONCOGENE, V34, P2505, DOI 10.1038/onc.2014.184	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5439	5439		10.1038/onc.2017.249	http://dx.doi.org/10.1038/onc.2017.249			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28714963	Bronze			2022-12-28	WOS:000411382100010
J	Sumner, ET; Chawla, AT; Cororaton, AD; Koblinski, JE; Kovi, RC; Love, IM; Szomju, BB; Korwar, S; Ellis, KC; Grossman, SR				Sumner, E. T.; Chawla, A. T.; Cororaton, A. D.; Koblinski, J. E.; Kovi, R. C.; Love, I. M.; Szomju, B. B.; Korwar, S.; Ellis, K. C.; Grossman, S. R.			Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia	ONCOGENE			English	Article							P53-INDEPENDENT APOPTOSIS; ADENOMATOUS POLYPOSIS; COLORECTAL TUMORS; GENE-EXPRESSION; CTBP; CANCER; MUTATIONS; COREPRESSOR; INHIBITORS; STABILITY	Overexpression of the transcriptional coregulators C-terminal binding proteins 1 and 2 (CtBP1 and 2) occurs in many human solid tumors and is associated with poor prognosis. CtBP modulates oncogenic gene expression programs and is an emerging drug target, but its oncogenic role is unclear. Consistent with this oncogenic potential, exogenous CtBP2 transformed primary mouse and human cells to anchorage independence similarly to mutant H-Ras. To investigate CtBP's contribution to in vivo tumorigenesis, Apc(min/+) mice, which succumb to massive intestinal polyposis, were bred to Ctbp2(+/-) mice. CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabilized in both APC-mutated human colon cancers and Apc(min/+) intestinal polyps. Ctbp2 heterozygosity increased the median survival of Apc(min/+) mice from 21 to 48 weeks, and reduced polyp formation by 90%, with Ctbp2(+/-) polyps exhibiting reduced levels of beta-catenin and its oncogenic transcriptional target, cyclin D1. CtBP's potential as a therapeutic target was studied by treating Apc(min/+) mice with the CtBP small-molecule inhibitors 4-methylthio-2-oxobutyric acid and 2-hydroxy-imino phenylpyruvic acid, both of which reduced polyposis by more than half compared with vehicle treatment. Phenocopying Ctbp2 deletion, both Ctbp inhibitors caused substantial decreases in the protein level of Ctbp2, as well its oncogenic partner beta-catenin, and the effects of the inhibitors on CtBP and beta-catenin levels could be modeled in an APC-mutated human colon cancer cell line. CtBP2 is thus a druggable transforming oncoprotein critical for the evolution of neoplasia driven by Apc mutation.	[Sumner, E. T.; Grossman, S. R.] Virginia Commonwealth Univ, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; [Chawla, A. T.] Virginia Commonwealth Univ, Wright Ctr Clin & Translat Res, Richmond, VA 23298 USA; [Cororaton, A. D.; Love, I. M.; Szomju, B. B.; Grossman, S. R.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, 1201 East Marshall St,Box 980070, Richmond, VA 23298 USA; [Koblinski, J. E.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA; [Koblinski, J. E.; Ellis, K. C.; Grossman, S. R.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; [Kovi, R. C.] NIEHS, Cellular & Mol Pathol Branch, POB 12233, Res Triangle Pk, NC 27709 USA; [Korwar, S.; Ellis, K. C.] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Virginia Commonwealth University	Grossman, SR (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, 1201 East Marshall St,Box 980070, Richmond, VA 23298 USA.	steven.grossman@vcuhealth.org	Chawla, Ayesha/AAW-8696-2021	Chawla, Ayesha/0000-0003-4401-2188; Koblinski, Jennifer/0000-0002-7156-2030	NCI [P30CA016059]; ACS; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank LL for kindly donating BJ-blast cells and VSV-g/gag-pol retroviral expression vectors. We also thank SJ for his insight and thoughtful suggestions. SRG was funded by P30CA016059 from NCI and a Research Scholar Grant from ACS.	Barroilhet L, 2013, ONCOGENE, V32, P3896, DOI 10.1038/onc.2012.380; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438; GRODEN J, 1993, AM J HUM GENET, V52, P263; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Korwar S, 2016, BIOORGAN MED CHEM, V24, P2707, DOI 10.1016/j.bmc.2016.04.037; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Nadauld LD, 2006, J BIOL CHEM, V281, P37828, DOI 10.1074/jbc.M602119200; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Paliwal S, 2007, CANCER RES, V67, P9322, DOI 10.1158/0008-5472.CAN-07-1743; Paliwal Seema, 2012, Genes Cancer, V3, P481, DOI 10.1177/1947601912463695; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Schneikert J, 2011, HUM MOL GENET, V20, P3554, DOI 10.1093/hmg/ddr273; Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Yekkala K, 2007, MOL CANCER RES, V5, P1296, DOI 10.1158/1541-7786.MCR-07-0232; Zhang CW, 2014, GENE, V546, P73, DOI 10.1016/j.gene.2014.05.032	21	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4810	4816		10.1038/onc.2017.106	http://dx.doi.org/10.1038/onc.2017.106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414304	Green Accepted			2022-12-28	WOS:000407702400013
J	Ko, CJ; Lan, SW; Lu, YC; Cheng, TS; Lai, PF; Tsai, CH; Hsu, TW; Lin, HY; Shyu, HY; Wu, SR; Lin, HH; Hsiao, PW; Chen, CH; Huang, HP; Lee, MS				Ko, C-J; Lan, S-W; Lu, Y-C; Cheng, T-S; Lai, P-F; Tsai, C-H; Hsu, T-W; Lin, H-Y; Shyu, H-Y; Wu, S-R; Lin, H-H; Hsiao, P-W; Chen, C-H; Huang, H-P; Lee, M-S			Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E-2; MATRIX DEGRADATION; COX-2 INHIBITORS; DOWN-REGULATION; TUMOR-GROWTH; EXPRESSION; CELECOXIB; INFLAMMATION	Chronic inflammation plays an important role in cancer development and progression. Cyclooxygenases-2 ( COX-2) is a key enzyme in generating prostaglandins causing inflammation, is often found to be overexpressed in prostate cancer (PCa) and is correlated with PCa cell invasion and metastasis. We aim to investigate the molecular mechanism of how COX-2 promotes PCa cell invasion and metastasis and to evaluate the effect of COX-2 inhibitors in a selected model of PCa progression. Our results showed that the expression of COX-2 and Interleukin 1 beta(IL-1 beta) was upregulated in highly invasive PCa cells and was correlated with the activated levels of membrane-anchored serine protease matriptase. The expression levels of COX-2 were increased and were correlated with matriptase levels in PCa specimens. Moreover, results showed that COX-2 overexpression or a COX-2 product Prostaglandin E2 (PGE2) caused an increase in matriptase activation and PCa cell invasion, whereas COX-2 silencing antagonized matriptase activation and cell invasion. In addition, the inhibition of COX-2-mediated matriptase activation by Celebrex and sulindac sulfide suppressed the androgen-independent and COX2-overexpressing PCa PC-3 cell invasion, tumor growth and lung metastasis in an orthotopic xenograft model. Our results indicate that COX-2/matriptase signaling contributes to the invasion, tumor growth and metastasis of COX-2-overexpressing and androgen-independent PCa cells.	[Ko, C-J; Lan, S-W; Lu, Y-C; Cheng, T-S; Lai, P-F; Hsu, T-W; Lin, H-Y; Wu, S-R; Lin, H-H; Lee, M-S] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, R817,8F,1,Sect 1,Jen Ai Rd, Taipei 100, Taiwan; [Tsai, C-H; Hsiao, P-W] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Shyu, H-Y] Minist Justice, Bureau Invest, Taipei, Taiwan; [Chen, C-H] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan; [Huang, H-P] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, R817,8F,1,Sect 1,Jen Ai Rd, Taipei 100, Taiwan.; Huang, HP (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan.	hh691290@gmail.com; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022	Ko, Chun-Jung/0000-0001-6565-7060; CHEN, CHUNG-HSIN/0000-0002-4921-5315; LEE, MING-SHYUE/0000-0002-8673-5088; HUANG, HSIANG-PO/0000-0002-3382-305X	Taiwan National Science Council [NSC 100-2628-B-002-004-MY4]; Ministry of Science and Technology [MOST 103-2321-B-002-096, MOST 104-2320-B-002-044-MY3]; National Health Research Institutes [NHRI-EX102-9909BC, NHRI-EX106-10401BI]; National Taiwan University [NTU-CESRP-104R7602C4, NTU105R89612]; National Taiwan University Hospital [NTUH106-S3387]	Taiwan National Science Council(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); National Taiwan University(National Taiwan University); National Taiwan University Hospital(National Taiwan University)	This study was supported by Taiwan National Science Council Grant NSC 100-2628-B-002-004-MY4, Ministry of Science and Technology Grants MOST 103-2321-B-002-096 and MOST 104-2320-B-002-044-MY3, National Health Research Institutes Grants NHRI-EX102-9909BC and NHRI-EX106-10401BI, and National Taiwan University Grants NTU-CESRP-104R7602C4 and NTU105R89612 to M.S. Lee, and National Taiwan University Hospital Grant NTUH106-S3387 to C.H. Chen and H.P. Huang. We thank Dr Ming-Fong Lin at the Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center for LNCaP cells, and Dr Chen-Yong Lin at the Georgetown University for his gifts of antibodies.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; [Anonymous], 2016, Clin Adv Hematol Oncol, V14, P11; Ansari KM, 2008, MOL CANCER RES, V6, P1003, DOI 10.1158/1541-7786.MCR-07-2144; Armstrong AJ, 2012, LANCET ONCOL, V13, P443, DOI 10.1016/S1470-2045(12)70111-0; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Bieniek J, 2014, PROSTATE, V74, P999, DOI 10.1002/pros.22815; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cai Y, 2008, INT J CANCER, V123, P195, DOI 10.1002/ijc.23481; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chen CJ, 2011, AM J PHYSIOL-CELL PH, V300, pC406, DOI 10.1152/ajpcell.00403.2010; Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T; Cheung AS, 2012, ASIAN J ANDROL, V14, P518, DOI 10.1038/aja.2012.51; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Di Lorenzo G, 2005, PROSTATE CANCER P D, V8, P54, DOI 10.1038/sj.pcan.4500768; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Jeong Y, 2017, ASIA-PAC J CLIN ONCO, V13, P204, DOI 10.1111/ajco.12583; Kattan J, 2016, INVEST NEW DRUG, V34, P474, DOI 10.1007/s10637-016-0357-4; Kim SH, 2017, ASIAN J ANDROL, V19, P458, DOI 10.4103/1008-682X.180798; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Lam ET, 2012, NAT REV UROL, V9, P358, DOI [10.1038/nrurol.2012.112, 10.1038/nruro1.2012.112]; Lee LM, 2001, ANTICANCER RES, V21, P1291; Lee MS, 2005, AM J PHYSIOL-CELL PH, V288, pC932, DOI 10.1152/ajpcell.00497.2004; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Li S, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-11; Li Z, 2013, ONCOGENE, V32, P1408, DOI 10.1038/onc.2012.161; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Milner JM, 2010, ARTHRITIS RHEUM-US, V62, P1955, DOI 10.1002/art.27476; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886; Ruan D, 2014, LIFE SCI, V116, P43, DOI 10.1016/j.lfs.2014.07.042; Ruder EH, 2011, AM J GASTROENTEROL, V106, P1340, DOI 10.1038/ajg.2011.38; Rundhaug JE, 2011, CANCER METAST REV, V30, P465, DOI 10.1007/s10555-011-9317-9; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; SHI YE, 1993, CANCER RES, V53, P1409; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang WZ, 2005, CLIN CANCER RES, V11, P3250, DOI 10.1158/1078-0432.CCR-04-2405; Wang XY, 2007, MOL CARCINOGEN, V46, P912, DOI 10.1002/mc.20320; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Zoratti GL, 2016, ONCOTARGET, V7, P58162, DOI 10.18632/oncotarget.11262	60	30	31	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4597	4609		10.1038/onc.2017.82	http://dx.doi.org/10.1038/onc.2017.82			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368394				2022-12-28	WOS:000407246200007
J	Mi, L; Zhu, F; Yang, X; Lu, J; Zheng, Y; Zhao, Q; Wen, X; Lu, A; Wang, M; Zheng, M; Ji, J; Sun, J				Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Zheng, Y.; Zhao, Q.; Wen, X.; Lu, A.; Wang, M.; Zheng, M.; Ji, J.; Sun, J.			The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation in human colorectal cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RNA-POLYMERASE-II; PROSTATE-CANCER; PROTEASOMAL DEGRADATION; INDUCED UBIQUITINATION; ELEVATED EXPRESSION; LUNG ADENOCARCINOMA; SIGNALING PATHWAYS; GENE-EXPRESSION; DOWN-REGULATION	N-myc downstream-regulated gene 1 (NDRG1) has been reported to act as a key regulatory molecule in tumor progression-related signaling pathways, especially in tumor metastasis. However, the related mechanism has not been fully discovered yet. Herein we demonstrated that the novel molecule of cell migration and invasion, caveolin-1, has direct interaction with NDRG1 in human colorectal cancer (CRC) cells. Moreover, we discovered that NDRG1 reduces caveolin-1 protein expression through promoting its ubiquitylation and subsequent degradation via the proteasome in CRC cells. In addition, caveolin-1 mediates the suppressive function of NDRG1 in epithelial-mesenchymal transition, migration and invasion in vitro and metastasis in vivo. These results help to fulfill the potential mechanisms of NDRG1 in anti-metastatic treatment for human colorectal cancer.	[Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Lu, A.; Wang, M.; Zheng, M.; Sun, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China; [Mi, L.; Zhu, F.; Yang, X.; Lu, J.; Lu, A.; Wang, M.; Zheng, M.; Sun, J.] Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China; [Mi, L.; Ji, J.] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Beijing, Peoples R China; [Mi, L.; Wen, X.; Ji, J.] Peking Univ, Canc Hosp & Inst, Div Gastrointestinal Canc Translat Res Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Zheng, Y.; Zhao, Q.] Shanghai Jiao Tong Univ, Sch Med, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis,Minist Educ, Shanghai, Peoples R China	Shanghai Jiao Tong University; Peking University; Peking University; Shanghai Jiao Tong University	Wang, M; Zheng, M; Sun, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China.	mingliang-99@hotmail.com; zmhtiger@yeah.net; jingsun1982@sina.cn			National High-tech Research and Development Projects (863) [2012AA021103]; National Natural Science Foundation of China (NSFC) [81402423, 81572818]; Science and Technology Commission of Shanghai Municipality [13JC1404100, 14YF1402800]	National High-tech Research and Development Projects (863); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	The study is financially supported by National High-tech Research and Development Projects (863) (2012AA021103), National Natural Science Foundation of China (NSFC) (81402423, 81572818), Science and Technology Commission of Shanghai Municipality (13JC1404100, 14YF1402800).	[Anonymous], MEMBRANE MICRODOMAIN; Bartz R, 2008, INT J CANCER, V122, P520, DOI 10.1002/ijc.23142; Bender F, 2002, BIOL RES, V35, P151, DOI 10.4067/S0716-97602002000200006; Bender FC, 2000, CANCER RES, V60, P5870; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Burgermeister E, 2008, CANCER LETT, V268, P187, DOI 10.1016/j.canlet.2008.03.055; Chen ZQ, 2012, J BIOL CHEM, V287, P17016, DOI 10.1074/jbc.M112.350470; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Fine SW, 2001, AM J CLIN PATHOL, V115, P719; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayer A, 2010, J CELL BIOL, V191, P615, DOI 10.1083/jcb.201003086; He JM, 2010, BIOCHEM BIOPH RES CO, V397, P513, DOI 10.1016/j.bbrc.2010.05.146; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hosoi F, 2009, CANCER RES, V69, P4983, DOI 10.1158/0008-5472.CAN-08-4882; Jin RS, 2014, J CELL SCI, V127, P3116, DOI 10.1242/jcs.147835; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kok LF, 2010, ARCH GYNECOL OBSTET, V281, P293, DOI 10.1007/s00404-009-1094-0; Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25; Kovacevic Z, 2008, BBA-MOL CELL RES, V1783, P1981, DOI 10.1016/j.bbamcr.2008.05.016; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu W, 2012, EMBO MOL MED, V4, P93, DOI 10.1002/emmm.201100190; Liu W, 2011, J BIOL CHEM, V286, P18949, DOI 10.1074/jbc.M111.232637; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luan TY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0644-5; Mao ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068206; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patlolla JMR, 2004, ONCOL REP, V11, P957; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Quest AFG, 2013, CURR MOL MED, V13, P266; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Razani B, 2001, J BIOL CHEM, V276, P38121; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sun J, 2013, CARCINOGENESIS, V34, P1943, DOI 10.1093/carcin/bgt163; Sun J, 2013, MOL PHARMACOL, V83, P454, DOI 10.1124/mol.112.083097; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Golen KL, 2006, EXPERT OPIN THER TAR, V10, P709, DOI 10.1517/14728222.10.5.709; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2007, HUM PATHOL, V38, P1688, DOI 10.1016/j.humpath.2007.03.024; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zhu MJ, 2010, ANTICANCER RES, V30, P3451	59	53	59	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4323	4335		10.1038/onc.2017.74	http://dx.doi.org/10.1038/onc.2017.74			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346422	Green Published, hybrid			2022-12-28	WOS:000406360600009
J	Dart, AE; Worth, DC; Muir, G; Chandra, A; Morris, JD; McKee, C; Verrill, C; Bryant, RJ; Gordon-Weeks, PR				Dart, A. E.; Worth, D. C.; Muir, G.; Chandra, A.; Morris, J. D.; McKee, C.; Verrill, C.; Bryant, R. J.; Gordon-Weeks, P. R.			The drebrin/EB3 pathway drives invasive activity in prostate cancer	ONCOGENE			English	Article							BINDING PROTEIN DREBRIN; ACTIN-BINDING; F-ACTIN; TRANSENDOTHELIAL MIGRATION; MICROTUBULE DYNAMICS; CXCR4; GROWTH; BASAL; LOCALIZATION; METASTASIS	Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain-or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression.	[Dart, A. E.; Worth, D. C.; Gordon-Weeks, P. R.] Kings Coll London, MRC, Ctr Dev Neurobiol, New Hunts House,Guys Campus, London SE1 1UL, England; [Muir, G.] Kings Coll Hosp London, Urol, London, England; [Chandra, A.] St Thomas Hosp, Cellular Pathol, 2nd Floor North Wing, London, England; [Morris, J. D.] Kings Coll London, Div Canc Studies, New Hunts House,Guys Campus, London, England; [McKee, C.] Univ Oxford, Oxford Inst Radiat Oncol, Churchill Hosp, Oxford, England; [Verrill, C.; Bryant, R. J.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford; University of Oxford	Gordon-Weeks, PR (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, New Hunts House,Guys Campus, London SE1 1UL, England.	phillip.gordon-weeks@kcl.ac.uk	Gordon-Weeks, Phillip R./C-5328-2009; Bryant, Richard John/HGA-6778-2022	Gordon-Weeks, Phillip R./0000-0002-4738-4246; Morris, Jonathan/0000-0002-3211-1798; Verrill, Clare/0000-0002-4905-8233	King's Health Partners' Research and Development Challenge Fund; MRC; Cancer Research UK; NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford	King's Health Partners' Research and Development Challenge Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford	We thank Dr Avery August for the kind gift of the K270M, K271M drebrin-GFP mutant. We are especially grateful to Sara Geraldo, Alex Gordon-Weeks, Robert Kypta and Maddy Parsons for their constructive comments on the manuscript. This work was supported by a grant from the King's Health Partners' Research and Development Challenge Fund and by the MRC. We also thank the King's Health Partners Cancer Biobank and the Oxford Centre for Histopathology Research for granting access to human prostate samples. Funding for prostate tissue microarrays construction and CM's research time was provided by the MRC Confidence in Concept programme. RJB's research time was funded by Cancer Research UK. CV's research time was funded by the NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford.	Bazellieres E, 2012, J CELL SCI, V125, P919, DOI 10.1242/jcs.092676; Broster SA, 2015, FUTURE ONCOL, V11, P3197, DOI 10.2217/fon.15.253; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Conley-LaComb MK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0552-0; Dun XP, 2012, MOL CELL NEUROSCI, V49, P341, DOI 10.1016/j.mcn.2012.01.006; Dun XP, 2010, HISTOL HISTOPATHOL, V25, P533, DOI 10.14670/HH-25.533; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fisher KE, 2009, J CELL SCI, V122, P4558, DOI 10.1242/jcs.050724; Frank SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00273; Geraldo S, 2008, NAT CELL BIOL, V10, P1181, DOI 10.1038/ncb1778; Gireesh KK, 2014, BIOCHEMISTRY-US, V53, P5551, DOI 10.1021/bi5007942; Gordon-Weeks PR, 2014, J NEUROCHEM, V129, P206, DOI 10.1111/jnc.12502; Gravina GL, 2015, PROSTATE, V75, P1227, DOI 10.1002/pros.23007; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Komarova Y, 2009, J CELL BIOL, V184, P691, DOI 10.1083/jcb.200807179; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Liang ZX, 2005, CANCER RES, V65, P967; Lin QF, 2014, PROTEOMICS, V14, P1434, DOI 10.1002/pmic.201300462; Mercer JC, 2010, INT J BIOCHEM CELL B, V42, P337, DOI 10.1016/j.biocel.2009.11.019; Merriam EB, 2013, J NEUROSCI, V33, P16471, DOI 10.1523/JNEUROSCI.0661-13.2013; Mitra R, 2011, CLIN CANCER RES, V17, P2934, DOI 10.1158/1078-0432.CCR-10-1803; Peitsch WK, 2005, J INVEST DERMATOL, V125, P761, DOI 10.1111/j.0022-202X.2005.23793.x; Perez-Martinez M, 2010, J CELL SCI, V123, P1160, DOI 10.1242/jcs.064238; ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112; Roth AL, 2003, J COMP NEUROL, V465, P195, DOI 10.1002/cne.10856; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Sonego M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126478; Straube A, 2007, CURR BIOL, V17, P1318, DOI 10.1016/j.cub.2007.06.058; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Sun YN, 2014, TUMOR BIOL, V35, P7765, DOI 10.1007/s13277-014-1816-1; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Taichman RS, 2002, CANCER RES, V62, P1832; Tanabe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092291; Tang EI, 2015, ENDOCRINOLOGY, V156, P680, DOI 10.1210/en.2014-1720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terakawa Y, 2013, EXP CELL RES, V319, P517, DOI 10.1016/j.yexcr.2012.11.008; Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5758; Worth DC, 2013, J CELL BIOL, V202, P793, DOI 10.1083/jcb.201303005; Xu SQ, 2015, ONCOTARGET, V6, P10825, DOI 10.18632/oncotarget.3424; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221	43	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4111	4123		10.1038/onc.2017.45	http://dx.doi.org/10.1038/onc.2017.45			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319065	hybrid, Green Published			2022-12-28	WOS:000405835800003
J	Fischer, M				Fischer, M.			Census and evaluation of p53 target genes	ONCOGENE			English	Review							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE CHECKPOINT; P53-DEPENDENT TRANSCRIPTIONAL REPRESSION; NUCLEAR ANTIGEN PROMOTER; TOPOISOMERASE-II-ALPHA; BREAST-CANCER CELLS; DNA-DAMAGE; RESPONSE ELEMENT; IONIZING-RADIATION	The tumor suppressor p53 functions primarily as a transcription factor. Mutation of the TP53 gene alters its response pathway, and is central to the development of many cancers. The discovery of a large number of p53 target genes, which confer p53's tumor suppressor function, has led to increasingly complex models of p53 function. Recent meta-analysis approaches, however, are simplifying our understanding of how p53 functions as a transcription factor. In the survey presented here, a total set of 3661 direct p53 target genes is identified that comprise 3509 potential targets from 13 high-throughput studies, and 346 target genes from individual gene analyses. Comparison of the p53 target genes reported in individual studies with those identified in 13 high-throughput studies reveals limited consistency. Here, p53 target genes have been evaluated based on the meta-analysis data, and the results show that high-confidence p53 target genes are involved in multiple cellular responses, including cell cycle arrest, DNA repair, apoptosis, metabolism, autophagy, mRNA translation and feedback mechanisms. However, many p53 target genes are identified only in a small number of studies and have a higher likelihood of being false positives. While numerous mechanisms have been proposed for mediating gene regulation in response to p53, recent advances in our understanding of p53 function show that p53 itself is solely an activator of transcription, and gene downregulationby p53 is indirect and requires p21. Taking into account the function of p53 as an activator of transcription, recent results point to an unsophisticated means of regulation.	[Fischer, M.] Univ Leipzig, Med Sch, Mol Oncol, Leipzig, Germany; [Fischer, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Fischer, M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA	Leipzig University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Fischer, M (corresponding author), Univ Leipzig, Mol Oncol, Semmelweisstr 14, D-04103 Leipzig, Germany.	Martin.Fischer@medizin.uni-leipzig.de	Fischer, Martin/I-4825-2014	Fischer, Martin/0000-0002-3429-1876	Medical School, University of Leipzig; Joachim Herz Stiftung	Medical School, University of Leipzig; Joachim Herz Stiftung	thank Dr Sonal Jhaveri, in the Postdoctoral and Graduate Student Affairs office at the Dana-Farber Cancer Institute, for help with editing a draft of the manuscript. I am especially grateful to Dr Kurt Engeland and Dr James A DeCaprio for their inspiring mentorship. My research is supported through a Junior Researcher Grant by the Medical School, University of Leipzig and an Add-On Fellowship for Interdisciplinary Science in Systems Biology by the Joachim Herz Stiftung.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Asano Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep19174; Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Azzam G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074297; Banerjee T, 2009, NUCLEIC ACIDS RES, V37, P2688, DOI 10.1093/nar/gkp110; Bansal N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026156; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Baranello L, 2016, CHROMOSOME RES, V24, P175, DOI 10.1007/s10577-015-9509-1; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baudot AD, 2016, CELL CYCLE, V15, P2299, DOI 10.1080/15384101.2016.1191714; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Benson EK, 2014, ONCOGENE, V33, P3959, DOI 10.1038/onc.2013.378; Bohlig L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464916; Bohlig L, 2011, NUCLEIC ACIDS RES, V39, P440, DOI 10.1093/nar/gkq796; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Bornstein C, 2011, MOL CELL BIOL, V31, P1679, DOI 10.1128/MCB.01072-10; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brown L, 2007, EMBO J, V26, P3410, DOI 10.1038/sj.emboj.7601779; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Ceribelli M, 2006, CELL CYCLE, V5, P1102, DOI 10.4161/cc.5.10.2777; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chang GS, 2014, CELL REP, V8, P513, DOI 10.1016/j.celrep.2014.06.030; Charni M, 2016, CELL DEATH DIFFER, V23, P509, DOI 10.1038/cdd.2015.119; Chau BN, 2009, CANCER RES, V69, P1368, DOI 10.1158/0008-5472.CAN-08-2742; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chen JG, 2005, P NATL ACAD SCI USA, V102, P4813, DOI 10.1073/pnas.0407069102; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Choi W, 2006, CANCER BIOL THER, V5, P1450, DOI 10.4161/cbt.5.11.3271; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Cui HY, 2010, ONCOL REP, V24, P1193, DOI 10.3892/or_00000972; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Elabd S, 2016, ONCOGENE, V35, P5577, DOI 10.1038/onc.2016.33; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Engeland K, 2015, ONCOTARGET, V6, P3, DOI 10.18632/oncotarget.3032; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Fekry B, 2016, J BIOL CHEM, V291, P16586, DOI 10.1074/jbc.M116.716902; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fischer M, 2016, CELL CYCLE, V15, P2852, DOI 10.1080/15384101.2016.1205393; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356; Fischer M, 2014, CELL CYCLE, V13, P3037, DOI 10.4161/15384101.2014.949083; Fischer M, 2014, NUCLEIC ACIDS RES, V42, P163, DOI 10.1093/nar/gkt849; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063187; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Goldstein I, 2012, J HEPATOL, V56, P656, DOI 10.1016/j.jhep.2011.08.022; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Grossi E, 2016, BBA-GENE REGUL MECH, V1859, P200, DOI 10.1016/j.bbagrm.2015.07.011; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hearnes JM, 2005, MOL CELL BIOL, V25, P10148, DOI 10.1128/MCB.25.22.10148-10158.2005; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Imbriano C, 2012, BBA-REV CANCER, V1825, P131, DOI 10.1016/j.bbcan.2011.11.001; Innocente SA, 2005, BIOCHEM BIOPH RES CO, V329, P713, DOI 10.1016/j.bbrc.2005.02.028; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Jaber S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11091; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jackson RS, 2007, CELL CYCLE, V6, P95, DOI 10.4161/cc.6.1.3665; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jen KY, 2005, CANCER RES, V65, P7666, DOI 10.1158/0008-5472.CAN-05-1039; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Jin YJ, 2006, MOL CANCER RES, V4, P769, DOI 10.1158/1541-7786.MCR-06-0178; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawase T, 2008, ONCOGENE, V27, P3797, DOI 10.1038/onc.2008.32; Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Laezza C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.279; Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114; Li H, 2014, CELL DEATH DIFFER, V21, P1493, DOI 10.1038/cdd.2014.69; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Li YY, 2003, FEBS LETT, V544, P112, DOI 10.1016/S0014-5793(03)00485-X; Lickwar CR, 2012, NATURE, V484, P251, DOI 10.1038/nature10985; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Lipski R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042615; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195; Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McDade SS, 2014, NUCLEIC ACIDS RES, V42, P6270, DOI 10.1093/nar/gku299; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Menendez D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001360; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Min SH, 2009, ONCOGENE, V28, P545, DOI 10.1038/onc.2008.409; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62; Nabilsi NH, 2013, J BIOL CHEM, V288, P35940, DOI 10.1074/jbc.M113.523837; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Panjarian S, 2008, PROSTAG OTH LIPID M, V86, P41, DOI 10.1016/j.prostaglandins.2008.02.004; Paolella BR, 2011, STEM CELLS, V29, P1090, DOI 10.1002/stem.660; Park WR, 2005, CANCER RES, V65, P1197, DOI 10.1158/0008-5472.CAN-04-3339; Pierzchalski P, 1997, EXP CELL RES, V234, P57, DOI 10.1006/excr.1997.3604; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Polato F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poorey K, 2013, SCIENCE, V342, P369, DOI 10.1126/science.1242369; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Rashi-Elkeles S, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005032; Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004; Reczek EE, 2003, MOL CANCER RES, V1, P1048; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rinn JL, 2011, TRENDS CELL BIOL, V21, P344, DOI 10.1016/j.tcb.2011.04.002; Robles AI, 2001, CANCER RES, V61, P6660; Rossi M, 2008, NUCLEIC ACIDS RES, V36, P7168, DOI 10.1093/nar/gkn888; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218; Rueda-Rincon N, 2015, ONCOTARGET, V6, P21240, DOI 10.18632/oncotarget.4067; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Saifudeen Z, 2002, AM J PHYSIOL-RENAL, V283, pF727, DOI 10.1152/ajprenal.00114.2002; Sanchez-Macedo N, 2013, CELL DEATH DIFFER, V20, P659, DOI 10.1038/cdd.2012.168; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; Schilling T, 2009, BIOCHEM BIOPH RES CO, V387, P399, DOI 10.1016/j.bbrc.2009.07.063; Schlereth K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003726; Schlereth K, 2010, MOL CELL, V38, P356, DOI 10.1016/j.molcel.2010.02.037; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Scian MJ, 2008, ONCOGENE, V27, P2583, DOI 10.1038/sj.onc.1210898; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Smeenk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017574; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Tabach Y, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100030; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2009, ONCOGENE, V28, P3081, DOI 10.1038/onc.2009.154; Tanikawa C, 2009, CANCER RES, V69, P8761, DOI 10.1158/0008-5472.CAN-09-2280; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Taura M, 2008, MOL CELL BIOL, V28, P6557, DOI 10.1128/MCB.01202-08; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Tebaldi T, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1643-9; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Verfaillie A, 2016, GENOME RES, V26, P882, DOI 10.1101/gr.204149.116; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vrba L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-486; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang B, 2014, CELL DEATH DIFFER, V21, P521, DOI 10.1038/cdd.2013.132; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wang B, 2009, P NATL ACAD SCI USA, V106, P14373, DOI 10.1073/pnas.0903284106; Wang B, 2009, J HEPATOL, V50, P528, DOI 10.1016/j.jhep.2008.10.025; Wang S, 2013, BIOMED RES INT, V2013, P1; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203; Wilhelm MT, 2002, FEBS LETT, V524, P69, DOI 10.1016/S0014-5793(02)03004-1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104; Younger ST, 2015, NUCLEIC ACIDS RES, V43, P4447, DOI 10.1093/nar/gkv284; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeilstra J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072849; Zeron-Medina J, 2013, CELL, V155, P410, DOI 10.1016/j.cell.2013.09.017; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang C, 2002, BIOCHEM BIOPH RES CO, V297, P1302, DOI 10.1016/S0006-291X(02)02382-3; Zhang C, 2014, ONCOTARGET, V5, P5535, DOI 10.18632/oncotarget.2137; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201; Zhang LL, 2000, CANCER RES, V60, P3655; Zhang XY, 2013, CELL CYCLE, V12, P1279, DOI 10.4161/cc.24364; Zhang YH, 2009, CANCER RES, V69, P6049, DOI 10.1158/0008-5472.CAN-09-0621; Zhou Z, 2013, EXP CELL RES, V319, P3104, DOI 10.1016/j.yexcr.2013.09.012; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	291	436	445	12	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3943	3956		10.1038/onc.2016.502	http://dx.doi.org/10.1038/onc.2016.502			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288132	hybrid, Green Published			2022-12-28	WOS:000405379900001
J	Zhai, Z; Liu, W; Kaur, M; Luo, Y; Domenico, J; Samson, JM; Shellman, YG; Norris, DA; Dinarello, CA; Spritz, RA; Fujita, M				Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Domenico, J.; Samson, J. M.; Shellman, Y. G.; Norris, D. A.; Dinarello, C. A.; Spritz, R. A.; Fujita, M.			NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma	ONCOGENE			English	Article							CASPASE-1 ACTIVATION; EXPRESSION PROFILES; CELL-DEATH; CANCER; PROGRESSION; IMMUNITY; NALP1	Inflammasomes are mediators of inflammation, and constitutively activated NLRP3 inflammasomes have been linked to interleukin-1 beta (IL-1 beta)-mediated tumorigenesis in human melanoma. Whereas NLRP3 regulation of caspase-1 activation requires the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD (caspase recruitment domain)), caspase-1 activation by another danger-signaling sensor NLRP1 does not require ASC because NLRP1 contains a C-terminal CARD domain that facilitates direct caspase-1 activation via CARD-CARD interaction. We hypothesized that NLRP1 has additional biological activities besides IL-1 beta maturation and investigated its role in melanoma tumorigenesis. NLRP1 expression in melanoma was confirmed by analysis of 216 melanoma tumors and 13 human melanoma cell lines. Unlike monocytic THP-1 cells with prominent nuclear localization of NLRP1, melanoma cells expressed NLRP1 mainly in the cytoplasm. Knocking down NLRP1 revealed a tumor-promoting property of NLRP1 both in vitro and in vivo. Mechanistic studies showed that caspase-1 activity, IL-1 beta production, IL-1 beta secretion and nuclear factor-kB activity were reduced by knocking down of NLRP1 in human metastatic melanoma cell lines 1205Lu and HS294T, indicating that NLRP1 inflammasomes are active in metastatic melanoma. However, unlike previous reports showing that NLRP1 enhances pyroptosis in macrophages, NLRP1 in melanoma behaved differently in the context of cell death. Knocking down NLRP1 increased caspase-2, -9 and 3/7 activities and promoted apoptosis in human melanoma cells. Immunoprecipitation revealed interaction of NLRP1 with CARD-containing caspase-2 and -9, whereas NLRP3 lacking a CARD motif did not interact with the caspases. Consistent with these findings, NLRP1 activation but not NLRP3 activation reduced caspase-2, -9 and 3/7 activities and provided protection against apoptosis in human melanoma cells, suggesting a suppressive role of NLRP1 in caspase-3/7 activation and apoptosis via interaction with caspase-2 and -9. In summary, we showed that NLRP1 promotes melanoma growth by enhancing inflammasome activation and suppressing apoptotic pathways. Our study demonstrates a tumor-promoting role of NLRP1 in cancer cells.	[Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Domenico, J.; Samson, J. M.; Shellman, Y. G.; Norris, D. A.; Fujita, M.] Univ Colorado Denver SOM, Dept Dermatol, 12801 E 17th Ave,RC-1 South,Room 4124, Aurora, CO 80045 USA; [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA; [Dinarello, C. A.] Univ Colorado Denver SOM, Dept Med, Aurora, CO 80045 USA; [Spritz, R. A.] Univ Colorado Denver SOM, Human Med Genet & Genom Program, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Fujita, M (corresponding author), Univ Colorado Denver SOM, Dept Dermatol, 12801 E 17th Ave,RC-1 South,Room 4124, Aurora, CO 80045 USA.	mayumi.fujita@ucdenver.edu	Dinarello, Charles/C-8524-2013	Zhai, Zili/0000-0001-5164-3696; Shellman, Yiqun/0000-0003-0598-5753	University of Colorado Cancer Center (UCCC) [P30CA046934]; Skin Diseases Research Cores Grant [P30AR057212]; NIH/NCATS Colorado CTSI [UL1 TR001082]; Veterans Affairs Merit Review [5I01BX001228]; NIH/NCI [R01CA197919]; Cancer League of Colorado; NIH/NIAMS [2R01AR045584];  [5T32AR007411-32]; NATIONAL CANCER INSTITUTE [R01CA197919, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045584, T32AR007411, P30AR057212] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001228] Funding Source: NIH RePORTER	University of Colorado Cancer Center (UCCC); Skin Diseases Research Cores Grant; NIH/NCATS Colorado CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs Merit Review(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer League of Colorado; NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)	We thank the University of Colorado Cancer Center (UCCC) Support Grant (P30CA046934), the Skin Diseases Research Cores Grant (P30AR057212), the Flow Cytometry Core (Christine Childs and Karen Helm) for helping with FACS, and Dr Archana Gopalan (University of Colorado Anschutz Medical Campus) for helping with animal experiments. Imaging experiments were performed in the University of Colorado Anschutz Medical Campus Advance Light Microscopy Core (Radu Moldovan) supported in part by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. ZZ and JMS are recipients of a training grant, 5T32AR007411-32. This work was supported, in whole or in part, by Veterans Affairs Merit Review Award 5I01BX001228 (to MF), NIH/NCI R01CA197919 (to MF), Cancer League of Colorado (to MF) and NIH/NIAMS 2R01AR045584 (to RAS and MF).	Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027; Bani MR, 1996, CANCER RES, V56, P3075; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045; Caporali S, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-252; Cervantes J, 2008, CELL MICROBIOL, V10, P41, DOI 10.1111/j.1462-5822.2007.01012.x; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Datta-Mitra A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121626; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Dunn JH, 2012, CANCER LETT, V314, P24, DOI 10.1016/j.canlet.2011.10.001; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kent A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00185; Kodiha M, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-25; Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Labbe K, 2011, PROG INFLAMM RES SER, P17, DOI 10.1007/978-3-0348-0148-5_2; Levinsohn JL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002638; Liu WM, 2013, J INVEST DERMATOL, V133, P518, DOI 10.1038/jid.2012.317; Lo CF, 2008, BIOCHEM BIOPH RES CO, V366, P664, DOI 10.1016/j.bbrc.2007.11.174; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Meng XF, 2014, MOL NEUROBIOL, V49, P673, DOI 10.1007/s12035-013-8551-2; Modlin IM, 2006, ANN SURG, V244, P52, DOI 10.1097/01.sla.0000217617.06782.d5; Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098; Newman ZL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000906; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Raskin L, 2013, J INVEST DERMATOL, V133, P2585, DOI 10.1038/jid.2013.197; Rayamajhi Manira, 2013, Methods Mol Biol, V1040, P85, DOI 10.1007/978-1-62703-523-1_7; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Solinas G, 2010, CANCER METAST REV, V29, P243, DOI 10.1007/s10555-010-9227-2; Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200; Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Watari K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099568; Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001	45	62	67	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3820	3830		10.1038/onc.2017.26	http://dx.doi.org/10.1038/onc.2017.26			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263976	Green Accepted, Green Submitted			2022-12-28	WOS:000404848200003
J	van Attekum, MHA; Terpstra, S; Slinger, E; von Lindern, M; Moerland, PD; Jongejan, A; Kater, AP; Eldering, E				van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; von Lindern, M.; Moerland, P. D.; Jongejan, A.; Kater, A. P.; Eldering, E.			Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; B-CELLS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; UP-REGULATION; CLL CELLS; T-CELLS; APOPTOSIS; EXPRESSION	Protective interactions with bystander cells in micro-environmental niches, such as lymph nodes (LNs), contribute to survival and therapy resistance of chronic lymphocytic leukemia (CLL) cells. This is caused by a shift in expression of B-cell lymphoma 2 (BCL-2) family members. Pro-survival proteins B-cell lymphoma-extra large (BCL-XL), BCL-2-related protein A1 (BFL-1) and myeloid leukemia cell differentiation protein 1 (MCL-1) are upregulated by LN-residing T cells through CD40L interaction, presumably via nuclear factor (NF)-kappa B signaling. Macrophages (M phi s) also reside in the LN, and are assumed to provide important supportive functions for CLL cells. However, if and how M phi s are able to induce survival is incompletely known. We first established that M phi s induced survival because of an exclusive upregulation of MCL-1. Next, we investigated the mechanism underlying MCL-1 induction by M phi s in comparison with CD40L. Genome-wide expression profiling of in vitro M phi-and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. Inhibition of PI3K-AKT-mTOR signaling abrogated MCL-1 upregulation and survival by M phi s, as well as CD40 stimulation. MCL-1 can be regulated at multiple levels, and we established that AKT leads to increased MCL-1 translation, but does not affect MCL-1 transcription or protein stabilization. Furthermore, among M phi-secreted factors that could activate AKT, we found that induction of MCL-1 and survival critically depended on C-C motif chemokine receptor-1 (CCR1). In conclusion, this study indicates that two distinct micro-environmental factors, CD40L and M phi s, signal via CCR1 to induce AKT activation resulting in translational stabilization of MCL-1, and hence can contribute to CLL cell survival.	[van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands; [van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands; [von Lindern, M.] Sanquin Res, Dept Hematopoiesis, Amsterdam, Netherlands; [Moerland, P. D.; Jongejan, A.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands; [Kater, A. P.; Eldering, E.] Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Eldering, E (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands.	e.eldering@amc.nl	von Lindern, Marieke/AAH-2350-2020; Moerland, Perry/AAG-1425-2020	Moerland, Perry/0000-0002-2357-3659; von Lindern, Marieke/0000-0001-6162-6320	Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship) [UVA 2011-5097]	Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship)	We thank Richard Volckmann for his help with the analysis of the microarray data, Jannie Borst for providing the BFL-1 antibody and Steven Pals for providing us with the CLL LN slides. APK is a Dutch Cancer Foundation fellow. This work was supported by the Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship UVA 2011-5097).	Allen JC, 2011, BLOOD, V117, P2414, DOI 10.1182/blood-2010-08-301176; Awan FT, 2009, BLOOD, V113, P535, DOI 10.1182/blood-2008-08-173450; Balakrishnan K, 2010, BLOOD, V116, P1083, DOI 10.1182/blood-2009-10-246199; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Ballou LM, 2007, J BIOL CHEM, V282, P24463, DOI 10.1074/jbc.M704741200; Baudot AD, 2009, ONCOGENE, V28, P3261, DOI 10.1038/onc.2009.179; Buggins AGS, 2010, CANCER RES, V70, P7523, DOI 10.1158/0008-5472.CAN-10-1634; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Castillo JJ, 2012, EXPERT OPIN INV DRUG, V21, P15, DOI 10.1517/13543784.2012.640318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delgado-Martin C, 2011, J BIOL CHEM, V286, P37222, DOI 10.1074/jbc.M111.294116; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Martinez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123352; Masek T, 2011, METHODS MOL BIOL, V703, P293, DOI 10.1007/978-1-59745-248-9_20; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mojsa B, 2014, CELLS-BASEL, V3, P418, DOI 10.3390/cells3020418; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Olsson A, 2007, BRIT J CANCER, V97, P769, DOI 10.1038/sj.bjc.6603951; Pascutti MF, 2013, BLOOD, V122, P3010, DOI 10.1182/blood-2012-11-467670; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Su CC, 2007, J IMMUNOL, V179, P4589, DOI 10.4049/jimmunol.179.7.4589; Takai S, 2007, MOL CELL ENDOCRINOL, V267, P46, DOI 10.1016/j.mce.2006.12.036; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tromp JM, 2010, ONCOGENE, V29, P5071, DOI 10.1038/onc.2010.248; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; van Attekum MHA, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.20; Vary TC, 2007, J NUTR, V137, P1835, DOI 10.1093/jn/137.8.1835; Vogler M, 2008, CELL DEATH DIFFER, V15, P820, DOI 10.1038/cdd.2008.25; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	46	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3651	3660		10.1038/onc.2016.515	http://dx.doi.org/10.1038/onc.2016.515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192408	Green Published, hybrid			2022-12-28	WOS:000404349700001
J	Martinez-Ordonez, A; Seoane, S; Cabezas, P; Eiro, N; Sendon-Lago, J; Macia, M; Garcia-Caballero, T; Gonzalez, LO; Sanchez, L; Vizoso, F; Perez-Fernandez, R				Martinez-Ordonez, Anxo; Seoane, Samuel; Cabezas, Pablo; Eiro, Noemi; Sendon-Lago, Juan; Macia, Manuel; Garcia-Caballero, Tomas; Gonzalez, Luis O.; Sanchez, Laura; Vizoso, Francisco; Perez-Fernandez, Roman			Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CXCR4; PREDICTS POOR-PROGNOSIS; TRANSCRIPTION FACTOR; TUMOR-GROWTH; CXCR4/CXCL12 AXIS; CELL-MIGRATION; EXPRESSION; PIT-1; CXCL12/CXCR4; MICROENVIRONMENT	Development of human tumors is driven by accumulation of alterations in tumor suppressor genes and oncogenes in cells. The POU1F1 transcription factor (also known Pit-1) is expressed in the mammary gland and its overexpression induces profound phenotypic changes in proteins involved in breast cancer progression. Patients with breast cancer and elevated expression of Pit-1 show a positive correlation with the occurrence of distant metastasis and poor overall survival. However, some mediators of Pit-1 actions are still unknown. Here, we show that CXCR4 chemokine receptor and its ligand CXCL12 play a critical role in the pro-tumoral process induced by Pit-1. We found that Pit-1 increases mRNA and protein in both CXCR4 and CXCL12. Knock-down of CXCR4 reduces tumor growth and spread of Pit-1 overexpressing cells in a zebrafish xenograft model. Furthermore, we described for the first time pro-angiogenic effects of Pit-1 through the CXCL12-CXCR4 axis, and that extravasation of Pit-1 overexpressing breast cancer cells is strongly reduced in CXCL12-deprived target tissues. Finally, in breast cancer patients, expression of Pit-1 in primary tumors was found to be positively correlated with CXCR4 and CXCL12, with specific metastasis in liver and lung, and with clinical outcome. Our results suggest that Pit-1-CXCL12-CXCR4 axis could be involved in chemotaxis guidance during the metastatic process, and may represent prognostic and/or therapeutic targets in breast tumors.	[Martinez-Ordonez, Anxo; Seoane, Samuel; Sendon-Lago, Juan; Perez-Fernandez, Roman] Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Dept Physiol, Santiago De Compostela, Spain; [Cabezas, Pablo; Sanchez, Laura] Univ Santiago de Compostela, Dept Genet, Campus Lugo, Lugo, Spain; [Eiro, Noemi; Gonzalez, Luis O.; Vizoso, Francisco] Hosp Fdn Jove, Res Unit, Gijon, Spain; [Macia, Manuel] Univ Santiago de Compostela, Dept Obstet & Gynecol, Santiago De Compostela, Spain; [Garcia-Caballero, Tomas] Univ Santiago de Compostela, Dept Morphol Sci, Santiago De Compostela, Spain	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela	Perez-Fernandez, R (corresponding author), Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Dept Physiol, Santiago De Compostela, Spain.	roman.perez.fernandez@usc.es	Sainz, Pablo Cabezas/AAB-5798-2019; Perez-Fernandez, Roman/L-6342-2014; Sánchez, Laura/L-2411-2014; Gómez, ACUIGEN/ABD-5337-2020; Lago, Juan José Sendón/L-1227-2014; Eiro, Noemi/C-9510-2018; Seoane Ruzo, Samuel/H-6299-2015	Perez-Fernandez, Roman/0000-0002-5894-0615; Sánchez, Laura/0000-0001-7927-5303; Lago, Juan José Sendón/0000-0001-8360-0033; Eiro, Noemi/0000-0001-5840-4807; Garcia-Caballero, Tomas/0000-0002-7938-1437; Cabezas Sainz, Pablo/0000-0002-7158-4459; Seoane Ruzo, Samuel/0000-0002-9178-0887	Ministerio de Economia y Competividad (MINECO/FEDER) [SAF2015-69221-R]; Conselleria de Cultura, Educacion e Ordenacion Universitaria [GPC2014/001]; Ministerio de Educacion [FPU14/00548]; BioBank Complejo Hospitalario Universitario de Santiago (CHUS) [PT17/0015/0002]	Ministerio de Economia y Competividad (MINECO/FEDER); Conselleria de Cultura, Educacion e Ordenacion Universitaria; Ministerio de Educacion; BioBank Complejo Hospitalario Universitario de Santiago (CHUS)	This study was supported by Ministerio de Economia y Competividad (SAF2015-69221-R, MINECO/FEDER), and Conselleria de Cultura, Educacion e Ordenacion Universitaria (GPC2014/001) to RP-F, and Ministerio de Educacion, FPU14/00548 to AM-O. We want to particularly acknowledge the patients and the BioBank Complejo Hospitalario Universitario de Santiago (CHUS) (PT17/0015/0002), integrated in the Spanish National Biobanks Network for its collaboration, to P. Penas for providing biological samples, and to M. Fraile for help us with histological analyses.	Bachelder RE, 2002, CANCER RES, V62, P7203; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chen HW, 2013, CURR MOL MED, V13, P410; Deshane J, 2007, J EXP MED, V204, P605, DOI 10.1084/jem.20061609; DeVries ME, 2006, J IMMUNOL, V176, P401, DOI 10.4049/jimmunol.176.1.401; Doitsidou M, 2002, CELL, V111, P647, DOI 10.1016/S0092-8674(02)01135-2; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Eiro N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.992222; Gao ZC, 2016, MED SCI MONITOR, V22, P4121, DOI 10.12659/MSM.896107; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Gil-Puig C, 2005, EUR J ENDOCRINOL, V153, P335, DOI 10.1530/eje.1.01962; Gil-Puig C, 2002, J ENDOCRINOL, V173, P161, DOI 10.1677/joe.0.1730161; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665; Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044; Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c; Kryczek I, 2005, CANCER RES, V65, P465; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lefort S, 2017, ONCOGENE, V36, P1211, DOI 10.1038/onc.2016.284; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nica G, 2004, MOL ENDOCRINOL, V18, P1196, DOI 10.1210/me.2003-0377; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palevitch O, 2010, GEN COMP ENDOCR, V165, P262, DOI 10.1016/j.ygcen.2009.07.001; Peixoto P, 2008, NUCLEIC ACIDS RES, V36, P3341, DOI 10.1093/nar/gkn208; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Sendon-Lago J, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0505-8; Seoane S, 2006, MOL ENDOCRINOL, V20, P735, DOI 10.1210/me.2005-0253; Seoane S, 2015, ONCOTARGET, V6, P14456, DOI 10.18632/oncotarget.3894; Tiveron MC, 2008, CURR OPIN NEUROBIOL, V18, P237, DOI 10.1016/j.conb.2008.06.004; Tulotta C, 2016, DIS MODEL MECH, V9, P141, DOI 10.1242/dmm.023275; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Xu C, 2015, DRUG DES DEV THER, V9, P4953, DOI 10.2147/DDDT.S84932; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	43	43	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1430	1444		10.1038/s41388-017-0036-8	http://dx.doi.org/10.1038/s41388-017-0036-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321662				2022-12-28	WOS:000427459500003
J	Singh, SS; Vats, S; Chia, AYQ; Tan, TZ; Deng, S; Ong, MS; Arfuso, F; Yap, CT; Goh, BC; Sethi, G; Huang, RYJ; Shen, HM; Manjithaya, R; Kumar, AP				Singh, Shikha Satendra; Vats, Somya; Chia, Amelia Yi-Qian; Tan, Tuan Zea; Deng, Shuo; Ong, Mei Shan; Arfuso, Frank; Yap, Celestial T.; Goh, Boon Cher; Sethi, Gautam; Huang, Ruby Yun-Ju; Shen, Han Ming; Manjithaya, Ravi; Kumar, Alan Prem			Dual role of autophagy in hallmarks of cancer	ONCOGENE			English	Review							HYPOXIA-INDUCED AUTOPHAGY; CELL-DEATH; EPIGENETIC REGULATION; LC3 CONJUGATION; COMPLEX; INHIBITION; INDUCTION; BECLIN-1; STRESS; TUMORIGENESIS	Evolutionarily conserved across eukaryotic cells, macroautophagy (herein autophagy) is an intracellular catabolic degradative process targeting damaged and superfluous cellular proteins, organelles, and other cytoplasmic components. Mechanistically, it involves formation of double-membrane vesicles called autophagosomes that capture cytosolic cargo and deliver it to lysosomes, wherein the breakdown products are eventually recycled back to the cytoplasm. Dysregulation of autophagy often results in various disease manifestations, including neurodegeneration, microbial infections, and cancer. In the case of cancer, extensive attention has been devoted to understanding the paradoxical roles of autophagy in tumor suppression and tumor promotion. In this review, while we summarize how this self-eating process is implicated at various stages of tumorigenesis, most importantly, we address the link between autophagy and hallmarks of cancer. This would eventually provide a better understanding of tumor dependence on autophagy. We also discuss how therapeutics targeting autophagy can counter various transformations involved in tumorigenesis. Finally, this review will provide a novel insight into the mutational landscapes of autophagy-related genes in several human cancers, using genetic information collected from an array of cancers.	[Singh, Shikha Satendra; Tan, Tuan Zea; Goh, Boon Cher; Huang, Ruby Yun-Ju; Kumar, Alan Prem] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Singh, Shikha Satendra; Chia, Amelia Yi-Qian; Goh, Boon Cher; Sethi, Gautam; Kumar, Alan Prem] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Vats, Somya; Manjithaya, Ravi] Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bengaluru, Karnataka, India; [Deng, Shuo; Ong, Mei Shan; Yap, Celestial T.; Shen, Han Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Arfuso, Frank] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Biomed Sci, Stem Cell & Canc Biol Lab, Perth, WA, Australia; [Goh, Boon Cher] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Haematol Oncol, Singapore, Singapore; [Goh, Boon Cher; Kumar, Alan Prem] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore; [Sethi, Gautam] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Biomed Sci, Perth, WA, Australia; [Huang, Ruby Yun-Ju] Natl Univ Hlth Syst, Dept Obstet & Gynaecol, Singapore, Singapore; [Huang, Ruby Yun-Ju] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Shen, Han Ming] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Kumar, Alan Prem] Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA, Australia; [Kumar, Alan Prem] Natl Univ Singapore, Yong Loo Lin Sch Med, Med Sci Cluster, Singapore, Singapore	National University of Singapore; National University of Singapore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); National University of Singapore; Curtin University; National University of Singapore; National University of Singapore; Curtin University; National University of Singapore; National University of Singapore; National University of Singapore; Curtin University; National University of Singapore	Kumar, AP (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.; Kumar, AP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.; Manjithaya, R (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bengaluru, Karnataka, India.; Kumar, AP (corresponding author), Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore.; Kumar, AP (corresponding author), Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA, Australia.; Kumar, AP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Med Sci Cluster, Singapore, Singapore.	ravim@jncasr.ac.in; csiapk@nus.edu.sg	Huang, Ruby Yun-Ju/AAE-8854-2019; Manjithaya, Ravi/T-4248-2019; Sethi, Gautam/F-2372-2011; SHEN, Han-Ming/B-5942-2011; Kumar, Alan Prem/ABE-7492-2020; Tan, Tuan Zea/I-9227-2019; Arfuso, Frank/H-8761-2014	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Manjithaya, Ravi/0000-0002-0923-5485; Sethi, Gautam/0000-0002-8677-8475; SHEN, Han-Ming/0000-0001-7369-5227; Kumar, Alan Prem/0000-0002-3754-5712; Tan, Tuan Zea/0000-0001-6624-1593; Yap, Celestial T/0000-0003-0323-135X; Arfuso, Frank/0000-0001-7678-9472	National Medical Research Council of Singapore; NCIS Yong Siew Yoon Research Grant; Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore; Wellcome Trust/DBT India Alliance Intermediate Fellowship [509159/Z/09/Z]; JNCASR intramural funds; NUHS Basic seed grant [T1-BSRG 2015-02]; Ministry of Education Tier 1 grant; Cancer Council, Western Australia; National Medical Research Council Singapore (NMRC) [NMRC-CIRG/1346/2012, NMRC/CIRG/1373/2013]	National Medical Research Council of Singapore(National Medical Research Council, Singapore); NCIS Yong Siew Yoon Research Grant; Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore(Ministry of Education, SingaporeNational University of Singapore); Wellcome Trust/DBT India Alliance Intermediate Fellowship(Wellcome Trust DBT India Alliance); JNCASR intramural funds; NUHS Basic seed grant; Ministry of Education Tier 1 grant; Cancer Council, Western Australia(Cancer Council Western Australia); National Medical Research Council Singapore (NMRC)(National Medical Research Council, Singapore)	APK was supported by grants from National Medical Research Council of Singapore, NCIS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust and by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore. This work was also supported by Wellcome Trust/DBT India Alliance Intermediate Fellowship (509159/Z/09/Z) and JNCASR intramural funds to RM. The JNCASR doctoral fellowship to SV is also acknowledged. We also thank Dr. Prathibha Ranganathan (Centre for Human Genetics, Bengaluru), Aparna Hebbar and members of Autophagy lab (JNCASR) for critical reading of the manuscript. This work was supported by NUHS Basic seed grant [T1-BSRG 2015-02] and Ministry of Education Tier 1 grant to GS. The John Nott Cancer Fellowship from Cancer Council, Western Australia also supported GS. This work is supported in part by National Medical Research Council Singapore (NMRC) grants (NMRC-CIRG/1346/2012 and NMRC/CIRG/1373/2013) to HMS.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bauckman KA, 2015, METHODS, V75, P120, DOI 10.1016/j.ymeth.2014.12.005; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; Chandra P, 2016, AUTOPHAGY, V12, P608, DOI 10.1080/15548627.2016.1139263; Chatterjee A, 2015, CANCER LETT, V360, P134, DOI 10.1016/j.canlet.2015.01.043; Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024; Chung YC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/306705; Cianfanelli Valentina, 2015, Nat Cell Biol, V17, P706, DOI 10.1038/ncb3171; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/ERA.11.111, 10.1586/era.11.111]; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752; de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; DOI S, 1989, ARCH MICROBIOL, V151, P20; Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gallagher LE, 2013, ESSAYS BIOCHEM, V55, P1, DOI [10.1042/bse0550001, 10.1042/BSE0550001]; Ganley IG, 2013, ESSAYS BIOCHEM, V55, P65, DOI [10.1042/bse0550065, 10.1042/BSE0550065]; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839; Hsieh YY, 2016, AM J CANCER RES, V6, P1661; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001; Jain K, 2013, AM J CANCER RES, V3, P251; Jiang P, 2014, MOL BIOL CELL, V25, P1327, DOI 10.1091/mbc.E13-08-0447; Josset E, 2013, ANTICANCER RES, V33, P1845; Kanzawa T, 2003, CANCER RES, V63, P2103; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008; Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim KW, 2013, AUTOPHAGY, V9, P1579, DOI 10.4161/auto.25987; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708; Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957; Meadows KL, 2012, COLD SPRING HARB PER, P2; Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakatogawa H, 2013, ESSAYS BIOCHEM, V55, P39, DOI [10.1042/bse0550039, 10.1042/BSE0550039]; Nishikawa T, 2010, ANGIOGENESIS, V13, P227, DOI 10.1007/s10456-010-9180-2; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ramakrishnan S, 2007, AUTOPHAGY, V3, P512; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0; Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80; Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Selvi BR, 2010, J BIOL CHEM, V285, P7143, DOI 10.1074/jbc.M109.063933; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008; Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771	131	305	311	6	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1142	1158		10.1038/s41388-017-0046-6	http://dx.doi.org/10.1038/s41388-017-0046-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29255248				2022-12-28	WOS:000426505400002
J	Liu, Y; Zhou, H; Zhu, R; Ding, F; Li, Y; Cao, X; Liu, Z				Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Cao, X.; Liu, Z.			SPSB3 targets SNAIL for degradation in GSK-3 beta phosphorylation-dependent manner and regulates metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER CELLS; C-MYC; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; UBIQUITIN LIGASE; TUMOR RECURRENCE; PROGRESSION; STABILITY; LINES	Epithelial-mesenchymal transition (EMT) is a process during which normal epithelial cells acquire mesenchymal characteristics. EMT has a critical role in various human diseases especially in cancer. EMT facilitates tumor initiation and progression by mediating cancer cell stemness and motility. Zinc finger transcription factor SNAIL is one of the most important initiators of EMT. Therefore, it is of great significance to understand the regulating mechanism of SNAIL. In this study, we carried out a luciferase-based genome-wide screening using small interfering RNA library against similar to 200 of E3 ligases and ubiquitin-related genes and identified SOCS box protein SPSB3 as a novel E3 ligase component that targets SNAIL into polyubiquitination and degradation in response to GSK-3 beta phosphorylation of SNAIL. Functionally, we observed that SPSB3 overexpression greatly inhibits tumor metastasis by regulating SNAIL degradation both in vitro and in vivo. The expression of SPSB3 and SNAIL are negatively correlated in human esophageal squamous cell carcinoma tissues, and low SPSB3 expression indicates lymph node metastasis. Moreover, high SPSB3 expression indicates good survivals in various kinds of cancer. Collectively, these findings suggest that SPSB3-mediated SNAIL degradation has a vital role in regulating EMT and cancer progression.	[Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Liu, Y.; Zhou, H.; Zhu, R.; Ding, F.; Li, Y.; Liu, Z.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Cao, X.] Nanjing Med Univ, Nanjing Hosp 1, Dept Surg Oncol, Nanjing, Jiangsu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nanjing Medical University	Liu, Z (corresponding author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Liu, Z (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	liuzh@cicams.ac.cn	Liu, Yongshuo/AGZ-8274-2022; Liu, Yongshuo/GRX-6416-2022	Liu, Yongshuo/0000-0001-8190-0139; Liu, Yongshuo/0000-0001-8190-0139	National Key R&D program of China [2016YFC1302100, 2013CB911004]; National Science Foundation of China [81420108025]; CAMS Initiative for Innovative Medicine [2016-I2M-1-001]	National Key R&D program of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine	We thank Professor Binhua P Zhou (University of Kentucky College of Medicine, Lexington, KY, USA) for kindly providing the plasmids of WT-GSK-3 beta and KD-GSK-3 beta. This work was supported by grants from the National Key R&D program of China (2016YFC1302100, 2013CB911004), the National Science Foundation of China (81420108025) and CAMS Initiative for Innovative Medicine (2016-I2M-1-001).	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459; Bruyere F, 2010, UROL ONCOL-SEMIN ORI, V28, P591, DOI 10.1016/j.urolonc.2008.11.005; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Diaz VM, 2014, CELL ADHES MIGR, V8, P418, DOI 10.4161/19336918.2014.969998; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Felipe Lima J, 2016, J CLIN MED, V5; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678; Okumura F, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0016-3; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Vinas-Castells R, 2014, NUCLEIC ACIDS RES, V42, P1079, DOI 10.1093/nar/gkt935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479	40	30	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					768	776		10.1038/onc.2017.370	http://dx.doi.org/10.1038/onc.2017.370			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059170				2022-12-28	WOS:000424628100008
J	Liu, Q; Kulak, MV; Borcherding, N; Maina, PK; Zhang, W; Weigel, RJ; Qi, HH				Liu, Q.; Kulak, M. V.; Borcherding, N.; Maina, P. K.; Zhang, W.; Weigel, R. J.; Qi, H. H.			A novel HER2 gene body enhancer contributes to HER2 expression	ONCOGENE			English	Article							BREAST-CANCER CELLS; NEGATIVE REGULATORY ELEMENTS; HUMAN ERBB-2 GENE; TRANSCRIPTION FACTOR; DNA METHYLATION; ACTIVATOR PROTEIN-2; PROMOTER; OVEREXPRESSION; IDENTIFICATION; RECEPTOR	The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanced HER2 expression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumorigenesis and the resistance to therapy. Epigenetic mechanisms are critical for transcription regulation, however, such mechanisms in the transcription regulation of HER2 are limited to the involvement of trimethylated histone 3 lysine 4 (H3K4me3) and acetylated histone 3 lysine 9 (H3K9ac) at the HER2 promoter region. Here, we report the identification of a novel enhancer in the HER2 3' gene body, which we have termed HER2 gene body enhancer (HGE). The HGE starts from the 3' end of intron 19 and extends into intron 22, possesses enhancer histone modification marks in specific cells and enhances the transcriptional activity of the HER2 promoters. We also found that TFAP2C, a known regulator of HER2, binds to HGE and is required for its enhancer function and that DNA methylation in the HGE region inhibits the histone modifications characterizing enhancer and is inversely correlated with HER2 expression in breast cancer samples. The identification of this novel enhancer sheds a light on the roles of epigenetic mechanisms in HER2 transcription, in both HER2-positive breast cancer samples and individuals with HER2-low or HER2-negative breast cancers undergoing radiotherapy or endocrine therapy.	[Liu, Q.; Maina, P. K.; Qi, H. H.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA; [Kulak, M. V.; Weigel, R. J.] Univ Iowa, Dept Surg, Carver Coll Med, Iowa City, IA 52243 USA; [Borcherding, N.; Zhang, W.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52243 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Carver Coll Med, Iowa City, IA 52243 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Qi, HH (corresponding author), Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA.	hank-qi@uiowa.edu		Kulak, Mikhail/0000-0002-4307-5868; Borcherding, Nicholas/0000-0003-1427-6342; Qi, Hank/0000-0002-3401-4940; Maina, Peterson/0000-0002-5909-190X; Weigel, Ronald/0000-0002-9249-0793	Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award from the Roy J Carver Charitable Trust [01-224]; Breast Cancer Research Award by the Holden Comprehensive Cancer Center at University of Iowa; NIH [P30 CA086862, R01CA183702, CA200673, CA203834]; NIH MD/PhD fellowship [F30 CA206255]; V Scholar award from Holden Comprehensive Cancer Center at the University of Iowa; Breast Cancer Research Award from Holden Comprehensive Cancer Center at the University of Iowa; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa [P30 CA086862]; NATIONAL CANCER INSTITUTE [R00CA158055, P30CA086862, F30CA206255, R01CA200673, R01CA203834, R01CA183702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award from the Roy J Carver Charitable Trust; Breast Cancer Research Award by the Holden Comprehensive Cancer Center at University of Iowa; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH MD/PhD fellowship; V Scholar award from Holden Comprehensive Cancer Center at the University of Iowa; Breast Cancer Research Award from Holden Comprehensive Cancer Center at the University of Iowa; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Brad Amendt and his lab for helpful discussions, and the ENCODE Consortium and the ENCODE production laboratories for generating the relevant data sets. The results of the bioinformatical analysis are based, in whole or part, upon data generated by The Cancer Genome Atlas Research Network (http://cancergenome.nih.gov/). The K562 cell line was a kind gift from Dr Fenghuang Zhan. We also thank Drs Christine Blaumueller and Marie Gaine for editorial consultation. This work was supported by to HHQ start-up funds from the Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award (01-224 to HHQ) from the Roy J Carver Charitable Trust; a Breast Cancer Research Award (to HHQ) by the Holden Comprehensive Cancer Center at University of Iowa; The NIH grant (P30 CA086862) to the Genomics and Flow Cytometry core facilities at the University of Iowa. NIH grants R01CA183702 (PI: RJW) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund (PI: RJW). NB was supported by NIH MD/PhD fellowship (F30 CA206255); WZ was supported by NIH grants CA200673, and CA203834, the V Scholar award, a Breast Cancer Research Award and an Oberley Award (National Cancer Institute Award P30 CA086862) from Holden Comprehensive Cancer Center at the University of Iowa.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Benz CC, 2006, GENE CHROMOSOME CANC, V45, P983, DOI 10.1002/gcc.20364; Bofin AM, 2004, AM J CLIN PATHOL, V122, P110, DOI 10.1309/8A2DJFT07NE6EWHE; Bosher JM, 1996, ONCOGENE, V13, P1701; Cao N, 2009, RADIAT RES, V171, P9, DOI 10.1667/RR1472.1; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Contino F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-81; Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Dillon RL, 2007, MOL CELL BIOL, V27, P8648, DOI 10.1128/MCB.00866-07; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; GROOTECLAES M, 1994, CANCER RES, V54, P4193; Hua GQ, 2009, MOL CANCER RES, V7, P402, DOI 10.1158/1541-7786.MCR-08-0175; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; Moarii M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1994-2; Mungamuri SK, 2013, CELL REP, V5, P302, DOI 10.1016/j.celrep.2013.09.009; Nezu M, 1999, BIOCHEM BIOPH RES CO, V258, P499, DOI 10.1006/bbrc.1999.0634; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; PASLEAU F, 1993, ONCOGENE, V8, P849; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tata PR, 2011, NUCLEIC ACIDS RES, V39, P3574, DOI 10.1093/nar/gkq1344; Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238; Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159; Wang H, 2017, CANCER LETT, V385, P137, DOI 10.1016/j.canlet.2016.10.033; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	53	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					687	694		10.1038/onc.2017.382	http://dx.doi.org/10.1038/onc.2017.382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035388	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000423812200013
J	Lambrecht, C; Libbrecht, L; Sagaert, X; Pauwels, P; Hoorne, Y; Crowther, J; Louis, JV; Sents, W; Sablina, A; Janssens, V				Lambrecht, C.; Libbrecht, L.; Sagaert, X.; Pauwels, P.; Hoorne, Y.; Crowther, J.; Louis, J., V; Sents, W.; Sablina, A.; Janssens, V			Loss of protein phosphatase 2A regulatory subunit B56 delta promotes spontaneous tumorigenesis in vivo	ONCOGENE			English	Article							HUMAN CELL-TRANSFORMATION; LI-FRAUMENI-SYNDROME; C-MYC; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; PP2A COMPLEXES; RNA-SEQ; CANCER; MICE; GENE	Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their function is frequently impaired in cancer. PP2A inhibition is indispensable for full transformation of human cells, but whether loss of PP2A is sufficient for tumorigenesis in vivo has remained elusive. Here, we describe spontaneous tumor development in knockout mice for Ppp2r5d, encoding the PP2A regulatory B56 delta subunit. Several primary tumors were observed, most commonly, hematologic malignancies and hepatocellular carcinomas (HCCs). Targeted immunoblot and immunohistochemistry analysis of the HCCs revealed heterogeneous activation of diverse oncogenic pathways known to be suppressed by PP2A-B56. RNA sequencing analysis unveiled, however, a common role for oncogenic c-Myc activation in the HCCs, independently underscored by c-Myc Ser62 hyperphosphorylation. Upstream of c-Myc, GSK-3 beta Ser9 hyperphosphorylation occurred both in the HCCs and non-cancerous B56 delta-null livers. Thus, uncontrolled c-Myc activity due to B56 delta-driven GSK-3 beta inactivation is the likely tumor predisposing factor. Our data provide the first compelling mouse genetics evidence sustaining the tumor suppressive activity of a single PP2A holoenzyme, constituting the final missing incentive for full clinical development of PP2A as cancer biomarker and therapy target.	[Lambrecht, C.; Hoorne, Y.; Louis, J., V; Sents, W.; Janssens, V] Katholieke Univ Leuven, Lab Prot Phosphorylat & Prote, Dept Cellular & Mol Med, Leuven, Belgium; [Libbrecht, L.] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Sagaert, X.] Katholieke Univ Leuven, Translat Cell & Tissue Res, Dept Imaging & Pathol, Leuven, Belgium; [Pauwels, P.] Univ Hosp Antwerp, Dept Pathol, Antwerp, Belgium; [Crowther, J.; Sablina, A.] Katholieke Univ Leuven, Dept Human Genet, VIB Ctr Biol Dis, Leuven, Belgium; [Sablina, A.; Janssens, V] Leuven Canc Inst, LKI, Leuven, Belgium	KU Leuven; Ghent University; Ghent University Hospital; KU Leuven; University of Antwerp; Flanders Institute for Biotechnology (VIB); KU Leuven	Janssens, V (corresponding author), Univ Leuven, Dept Cellular & Mol Med, Lab Prot Phosphorylat & Prote, KU Leuven, Herestr 49,POB 901,Gasthuisberg O&N1, B-3000 Leuven, Belgium.	veerle.janssens@kuleuven.be	Sablina, Anna/B-2217-2017; Sablina, Anna/P-2818-2019; Janssens, Veerle/I-7059-2016	Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014; Janssens, Veerle/0000-0002-6772-8448	KU Leuven Research Fund [GOA/08/016, OT/13/094]; Research Foundation-Flanders [G.0582.11, G.0B01.16N]; Belgian IAP program [P7/13]; Flemish Agency for Innovation by Science and Technology; Flemish Cancer League (Emmanuel van der Schueren fellowship)	KU Leuven Research Fund(KU Leuven); Research Foundation-Flanders(FWO); Belgian IAP program; Flemish Agency for Innovation by Science and Technology; Flemish Cancer League (Emmanuel van der Schueren fellowship)	We thank Y El-Aalamat (KU Leuven, ESAT) for help with statistical analysis, and P Vermaelen (KU Leuven, MOSAIC) for PET-scan analysis. Funding was provided by KU Leuven Research Fund (GOA/08/016 to VJ; OT/13/094 to VJ and AS), Research Foundation-Flanders (G.0582.11 to VJ; G.0B01.16N to VJ), Belgian IAP program (P7/13 to VJ), Flemish Agency for Innovation by Science and Technology (to CL) and the Flemish Cancer League (Emmanuel van der Schueren fellowship to WS).	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arriazu E, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00078; Bluemn EG, 2013, MOL CANCER RES, V11, P568, DOI 10.1158/1541-7786.MCR-12-0710; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Chen LP, 2011, ONCOGENE, V30, P2943, DOI 10.1038/onc.2011.20; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cheng YS, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005561; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Cristobal I, 2013, HAEMATOLOGICA, V98, pE103, DOI [10.3324/haematol.2043.084731, 10.3324/haematol.2013.084731]; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Haesen D, 2016, CANCER RES, V76, P5719, DOI 10.1158/0008-5472.CAN-15-3342; Hahn K, 2010, CELL METAB, V11, P438, DOI 10.1016/j.cmet.2010.03.015; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; He H, 2012, DIAGN MOL PATHOL, V21, P143, DOI 10.1097/PDM.0b013e318249fd8b; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HU NP, 1994, ONCOGENE, V9, P1021; Hung MH, 2016, ONCOGENE, V35, P4891, DOI 10.1038/onc.2016.21; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Jackson JB, 2012, NEOPLASIA, V14, P585, DOI 10.1593/neo.12768; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Khanna A, 2013, CANCER RES, V73, P6548, DOI 10.1158/0008-5472.CAN-13-1994; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Lai TY, 2016, ONCOTARGET, V7, P4542, DOI 10.18632/oncotarget.6609; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Liu Lingfeng, 2012, Genes Cancer, V3, P23, DOI 10.1177/1947601912448067; Louis JV, 2011, P NATL ACAD SCI USA, V108, P6957, DOI 10.1073/pnas.1018777108; Low ICC, 2014, BLOOD, V124, P2223, DOI 10.1182/blood-2014-03-563296; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Miller JP, 2012, J BIOL CHEM, V287, P19775, DOI 10.1074/jbc.M112.361972; Nobumori Y, 2013, MOL CANCER RES, V11, P995, DOI 10.1158/1541-7786.MCR-12-0633; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Pinyol R, 2014, SEMIN LIVER DIS, V34, P363, DOI 10.1055/s-0034-1394137; Puustinen P, 2009, CANCER RES, V69, P2870, DOI 10.1158/0008-5472.CAN-08-2760; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruediger R, 2011, MOL CELL BIOL, V31, P3832, DOI 10.1128/MCB.05744-11; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sents W, PP2A INACTIVATION TR; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shih IM, 2011, J PATHOL, V224, P1, DOI 10.1002/path.2884; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varadkar P, 2014, DEV DYNAM, V243, P778, DOI 10.1002/dvdy.24111; Wandzioch E, 2014, CANCER RES, V74, P4295, DOI 10.1158/0008-5472.CAN-13-3130; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Ward JM, 2006, EXP TOXICOL PATHOL, V57, P377, DOI 10.1016/j.etp.2006.01.007; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	64	28	29	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					544	552		10.1038/onc.2017.350	http://dx.doi.org/10.1038/onc.2017.350			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967903				2022-12-28	WOS:000423331600012
J	Mizrahi, A; Barzilai, A; Gur-Wahnon, D; Ben-Dov, IZ; Glassberg, S; Meningher, T; Elharar, E; Masalha, M; Jacob-Hirsch, J; Tabibian-Keissar, H; Barshack, I; Roszik, J; Leibowitz-Amit, R; Sidi, Y; Avni, D				Mizrahi, A.; Barzilai, A.; Gur-Wahnon, D.; Ben-Dov, I. Z.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Jacob-Hirsch, J.; Tabibian-Keissar, H.; Barshack, I.; Roszik, J.; Leibowitz-Amit, R.; Sidi, Y.; Avni, D.			Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes	ONCOGENE			English	Article							DOWN-REGULATION; POOR-PROGNOSIS; CYCLIN D1; CANCER; EXPRESSION; METASTASIS; CLUSTER; DIFFERENTIATION; METHYLATION; SYSTEM	Skin carcinogenesis is known to be a multi-step process with several stages along its malignant evolution. We hypothesized that transformation of normal epidermis to cutaneous squamous cell carcinoma (cSCC) is causally linked to alterations in microRNAs (miRNA) expression. For this end we decided to evaluate their alterations in the pathologic states ending in cSCC. Total RNA was extracted from formalin fixed paraffin embedded biopsies of five stages along the malignant evolution of keratinocytes towards cSCC: Normal epidermis, solar elastosis, actinic keratosis KIN1-2, advanced actinic keratosis KIN3 and well-differentiated cSCC. Next-generation small RNA sequencing was performed. We found that 18 miRNAs are overexpressed and 28 miRNAs are underexpressed in cSCC compared to normal epidermis. miR-424, miR-320, miR-222 and miR-15a showed the highest fold change among the overexpressed miRNAs. And miR-100, miR-101 and miR-497 showed the highest fold change among the underexpressed miRNAs. Heat map of hierarchical clustering analysis of significantly changed miRNAs and principle component analysis disclosed that the most prominent change in miRNAs expression occurred in the switch from 'early' stages; normal epidermis, solar elastosis and early actinic keratosis to the 'late' stages of epidermal carcinogenesis; late actinic keratosis and cSCC. We found several miRNAs with 'stage specific' alterations while others display a clear 'gradual', either progressive increase or decrease in expression along the malignant evolution of keratinocytes. The observed alterations focused in miRNAs involved in the regulation of AKT/mTOR or in those involved in epithelial to mesenchymal transition. We chose to concentrate on the evaluation of the molecular role of miR-497. We found that it induces reversion of epithelial to mesenchymal transition. We proved that SERPINE-1 is its biochemical target. The present study allows us to further study the pathways that are regulated by miRNAs along the malignant evolution of keratinocytes towards cSCC.	[Mizrahi, A.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Sidi, Y.; Avni, D.] Sheba Med Ctr, Ctr Canc Res, Lab Mol Cell Biol, Tel Hashomer, Israel; [Mizrahi, A.; Glassberg, S.; Meningher, T.; Elharar, E.; Masalha, M.; Sidi, Y.; Avni, D.] Sheba Med Ctr, Dept Med C, Tel Hashomer, Israel; [Barzilai, A.] Sheba Med Ctr, Dept Dermatol, Tel Hashomer, Israel; [Barzilai, A.] Sheba Med Ctr, Inst Pathol, Tel Hashomer, Israel; [Gur-Wahnon, D.; Ben-Dov, I. Z.] Hadassah Hebrew Univ, Med Ctr, Lab Med Transcript Nephrol & Hypertens Serv, Jerusalem, Israel; [Masalha, M.; Barshack, I.; Leibowitz-Amit, R.; Sidi, Y.] Tel Aviv Univ, Sackler Sch Med, Fac Med, Tel Aviv, Israel; [Jacob-Hirsch, J.] Sheba Med Ctr, Ctr Canc Res, Tel Hashomer, Israel; [Tabibian-Keissar, H.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel; [Tabibian-Keissar, H.; Barshack, I.] Sheba Med Ctr, Dept Pathol, Tel Hashomer, Israel; [Roszik, J.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Roszik, J.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Leibowitz-Amit, R.] Sheba Med Ctr, Inst Oncol, Tel Hashomer, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Bar Ilan University; Chaim Sheba Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center	Sidi, Y; Avni, D (corresponding author), Sheba Med Ctr, Ctr Canc Res, Lab Mol Cell Biol, IL-52621 Ramat Gan, Israel.; Sidi, Y; Avni, D (corresponding author), Sheba Med Ctr, Dept Med C, IL-52621 Ramat Gan, Israel.	yehezkel.sidi@sheba.health.gov.il; droravni@msn.com	Avni, Dror/GRE-8325-2022; Ben-Dov, Iddo/F-3282-2010	Ben-Dov, Iddo/0000-0002-9180-3604; Roszik, Jason/0000-0002-4561-6170; sidi, yechezkel/0000-0001-7781-6153; Avni, Dror/0000-0002-8738-1840	Israel Cancer Association (ICA) [20110076, 20160038]; Ministry of Health, State of Israel (Ministry of Health) [3-10132]	Israel Cancer Association (ICA); Ministry of Health, State of Israel (Ministry of Health)	This work was funded by: Israel Cancer Association (ICA)-grant number 20110076 to Avni D, and Ministry of Health, State of Israel (Ministry of Health)-grant number 3-10132 to Avni D, and Israel Cancer Association (ICA)-grant number 20160038 to Avni D.	Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; Barrette K, 2014, BRIT J DERMATOL, V171, P1014, DOI 10.1111/bjd.12967; Barzilai A, 2007, J AM ACAD DERMATOL, V57, P669, DOI 10.1016/j.jaad.2007.04.025; Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555-010-9257-9; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burnworth B, 2007, EUR J CELL BIOL, V86, P763, DOI 10.1016/j.ejcb.2006.11.002; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen ZJ, 2012, ORAL ONCOL, V48, P686, DOI 10.1016/j.oraloncology.2012.02.020; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Cockerell CJ, 2000, J AM ACAD DERMATOL, V42, pS11, DOI 10.1067/mjd.2000.103344; Cockerell Clay J, 2005, J Drugs Dermatol, V4, P462; Corbalan-Velez R, 2010, ACTAS DERMO-SIFILOGR, V101, P517, DOI 10.1016/j.ad.2010.01.008; Dziunycz P, 2010, J INVEST DERMATOL, V130, P2686, DOI 10.1038/jid.2010.169; Eshkoor SA, 2009, BIOSCI TRENDS, V3, P105; Farazi TA, 2012, METHODS, V58, P171, DOI 10.1016/j.ymeth.2012.07.020; Feng FQ, 2016, HUM PATHOL, V58, P47, DOI 10.1016/j.humpath.2016.04.022; Freytag J, 2010, J INVEST DERMATOL, V130, P2179, DOI 10.1038/jid.2010.106; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gillespie J, 2016, J EUR ACAD DERMATOL, V30, P1043, DOI 10.1111/jdv.13098; Green J, 2006, BRIT J CANCER, V94, P1446, DOI 10.1038/sj.bjc.6603135; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Guo R, 2017, J CELL BIOCHEM, V118, P3401, DOI 10.1002/jcb.25997; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Hafner M, 2012, METHODS, V58, P164, DOI 10.1016/j.ymeth.2012.07.030; He XX, 2015, MOL BIOSYST, V11, P532, DOI 10.1039/c4mb00563e; Hu Yang, 2014, Microrna, V3, P108; Hu YS, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0093310, 10.1371/journal.pone.0093425, 10.1371/journal.pone.0092099]; Huang Hou-Gang, 2015, Asian Pac J Cancer Prev, V16, P4937; Huntley MA, 2013, BIOINFORMATICS, V29, P3220, DOI 10.1093/bioinformatics/btt551; Jin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064434; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Ksiazkiewicz M, 2012, PATHOBIOLOGY, V79, P195, DOI 10.1159/000337106; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo M, 2013, SURGERY, V153, P836, DOI 10.1016/j.surg.2012.12.004; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Mathias RA, 2013, J PROTEOMICS, V78, P545, DOI 10.1016/j.jprot.2012.10.016; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Omori K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148969; Pang L., 2014, SCI WORLD J, V2014, P1; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Ra SH, 2011, MODERN PATHOL, V24, P963, DOI 10.1038/modpathol.2011.39; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Sand M, 2012, J DERMATOL SCI, V68, P119, DOI 10.1016/j.jdermsci.2012.09.004; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6; TILGEN W, 1983, CANCER RES, V43, P5995; Toll A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0537-z; Toll A, 2013, J DERMATOL SCI, V72, P93, DOI 10.1016/j.jdermsci.2013.07.001; van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103206; Wang N, 2014, ASIAN PAC J CANCER P, V15, P10355, DOI 10.7314/APJCP.2014.15.23.10355; Wang SH, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-172; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu ZH, 2016, TUMOR BIOL, V37, P7939, DOI 10.1007/s13277-015-4665-7; Xu N, 2012, J BIOL CHEM, V287, P29899, DOI 10.1074/jbc.M112.391243; Yan H, 2014, MOL CARCINOGEN, V53, P960, DOI 10.1002/mc.22064; Yu X, 2016, J CELL MOL MED, V20, P3, DOI 10.1111/jcmm.12649; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zehavi L, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0338-9; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhang L, 2016, WORLD J PSYCHIATR, V6, P1, DOI 10.5498/wjp.v6.i1.1; Zhang N, 2016, ONCOTARGETS THER, V9, P6597, DOI 10.2147/OTT.S114609; Zhao XL, 2015, INT J CLIN EXP PATHO, V8, P758	81	34	36	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					218	230		10.1038/onc.2017.315	http://dx.doi.org/10.1038/onc.2017.315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925390				2022-12-28	WOS:000422631700008
J	Song, C; Liang, L; Jin, Y; Li, Y; Liu, Y; Guo, L; Wu, C; Yun, CH; Yin, Y				Song, C.; Liang, L.; Jin, Y.; Li, Y.; Liu, Y.; Guo, L.; Wu, C.; Yun, C-H; Yin, Y.			RCC2 is a novel p53 target in suppressing metastasis	ONCOGENE			English	Article							CHROMOSOME CONDENSATION RCC1; EXTRACELLULAR-MATRIX CUES; CELL-MIGRATION; TRANSCRIPTION TARGET; COLORECTAL-CANCER; RHO-GTPASES; GENE; REGULATOR; INSTABILITY; EXPRESSION	RCC2 (also known as TD60) is a highly conserved protein involved in prognosis in colorectal cancer. However, its relationship with tumor development is less understood. Here we demonstrate a signaling pathway defining regulation of RCC2 and its functions in tumor progression. We report that p53 is a transcriptional regulator of RCC2 that acts through its binding to a palindromic motif in the RCC2 promoter. RCC2 physically interacts and deactivates a small GTPase Rac1 that is known to be involved in metastasis. We solved a high-resolution crystal structure of RCC2 and revealed one RCC1-like domain with a unique beta-hairpin that is requisite for RCC2 interaction with Rac1. p53 or RCC2 deficiency leads to activation of Rac1 and deterioration of extracellular matrix sensing (haptotaxis) of surface-bound gradients. Ectopic expression of RCC2 restores directional migration in p53-null cells. Our results demonstrate that p53 and RCC2 signaling is important for regulation of cell migration and suppression of metastasis. We propose that the p53/RCC2/Rac1 axis is a potential target for cancer therapy.	Peking Univ, Hlth Sci Ctr, Inst Syst Biomed,Peking Tsinghua Ctr Life Sci, Dept Pathol,Sch Basic Med Sci,Beijing Key Lab Tum, Beijing, Peoples R China; Peking Univ, Hlth Sci Ctr, Inst Syst Biomed,Peking Tsinghua Ctr Life Sci, Dept Biophys,Sch Basic Med Sci,Beijing Key Lab Tu, Beijing, Peoples R China	Peking University; Peking University	Yun, CH; Yin, Y (corresponding author), Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Dept Pathol, 38 XueYuan Rd, Beijing 100191, Peoples R China.	yunch@hsc.pku.edu.cn; yinyuxin@hsc.pku.edu.cn	云, 彩红/E-1437-2018		National Natural Science Foundation of China [81430056, 31420103905, 81301801, 81621063, 31270769]; National Key Research and Development Program of China [2016YFA0500302]; Beijing Natural Science Foundation [7161007]; Lam Chung Nin Foundation for Systems Biomedicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Lam Chung Nin Foundation for Systems Biomedicine	We thank the staff of the Argonne National Laboratory (ID19) and the Shanghai SSRF Beamline (BL17U1 and BL19U1) for technical assistance. We thank X Chen, L Yuan, D Lu, G Wang, J Feng, C Zhang and S He for technical assistance and critical discussion. This work was supported by the following grants to YY including: National Natural Science Foundation of China (Key Grants 81430056, 31420103905, 81301801 and 81621063), National Key Research and Development Program of China (Grant 2016YFA0500302), Beijing Natural Science Foundation (Key Grant 7161007) and the Lam Chung Nin Foundation for Systems Biomedicine. C-HY was supported by the grant 31270769 from the National Natural Science Foundation of China.	Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bosco EE, 2010, BLOOD, V115, P3320, DOI 10.1182/blood-2009-02-202440; Bruun J, 2015, CLIN CANCER RES, V21, P3759, DOI 10.1158/1078-0432.CCR-14-3294; Chan KT, 2014, J CELL BIOL, V207, P299, DOI 10.1083/jcb.201404067; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Gupton SL, 2006, CELL, V125, P1361, DOI 10.1016/j.cell.2006.05.029; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hompland T, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2983664; Humphries JD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000396; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Liu YX, 2008, MOL CANCER RES, V6, P624, DOI 10.1158/1541-7786.MCR-07-2019; Makde RD, 2010, NATURE, V467, P562, DOI 10.1038/nature09321; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MIYASHITA T, 1995, CELL, V80, P293; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Sun Z, 2014, CELL REP, V6, P844, DOI 10.1016/j.celrep.2014.01.030; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu CY, 2012, CELL, V148, P973, DOI 10.1016/j.cell.2011.12.034; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhao RB, 2000, GENE DEV, V14, P981	41	18	20	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					8	17		10.1038/onc.2017.306	http://dx.doi.org/10.1038/onc.2017.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869598	Green Published, hybrid			2022-12-28	WOS:000422625000002
J	Ding, D; Huang, H; Jiang, W; Yu, W; Zhu, H; Liu, J; Saiyin, H; Wu, J; Huang, H; Jiang, S; Yu, L				Ding, D.; Huang, H.; Jiang, W.; Yu, W.; Zhu, H.; Liu, J.; Saiyin, H.; Wu, J.; Huang, H.; Jiang, S.; Yu, L.			Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway	ONCOGENE			English	Article							CELL LUNG-CANCER; IDENTIFICATION; GENES	Hepatocellular carcinoma (HCC) is a major health threat worldwide. Although the involvement of reticulocalbin-2 (RCN2) in cell differentiation has been reported, its function in oncogenesis is poorly understood. Here, we showed that RCN2 was upregulated in tumors compared with adjacent non-tumorous tissues in HCC patients and RCN2 expression clinically correlated with tumor size, disease recurrence and survival rate. Both knockdown and knockout of RCN2 significantly inhibited HCC cell proliferation by inducing G1/S transition arrest and downregulating cyclin D1 expression, while the proliferative ability was restored in knockout HCC cells with exogenously expressed RCN2. Mechanistically, we demonstrated that RCN2 interacted with the epidermal growth factor receptor (EGFR). Knockout of RCN2 in HCC cells not only inhibited activation of the EGFR-ERK pathway by blocking EGF-mediated EGFR dimerization and internalization but also suppressed cell proliferation and EGFR phosphorylation under long exposure to EGF. We further showed that knockout of RCN2 inhibited EGFR phosphorylation, Ki-67 expression and tumor growth in nude mice. Moreover, we demonstrated that RCN2 knockout sensitized HCC cells to tyrosine kinase inhibitors, including erlotinib, lapatinib and sunitinib. Taken together, our results indicate that RCN2 plays a pivotal role in HCC cell proliferation and tumor growth presumably through regulating activation of the EGFR-ERK pathway. Our work also suggests that RCN2 is a potential therapeutic target of HCC.	[Ding, D.; Huang, H.; Yu, W.; Zhu, H.; Saiyin, H.; Wu, J.; Jiang, S.; Yu, L.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Jiang, W.] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai Med Coll, Shanghai, Peoples R China; [Zhu, H.] Fudan Univ, Sch Life Sci, Key Lab Med Mol Virol, Minist Educ Hlth, Shanghai, Peoples R China; [Liu, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Ctr Reprod Med,Shanghai Key Lab Assisted Reprod &, Shanghai, Peoples R China; [Huang, H.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Mayo Clinic	Jiang, S; Yu, L (corresponding author), Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.	smjiang@fudan.edu.cn; longyu@fudan.edu.cn		Saiyin, Hexige/0000-0003-2993-6817; Ding, Donglin/0000-0003-2339-7349	National Key Science and Technology Project of China [2013ZX10002010]; National Basic Research Program of China (973 Program) [2013CB910504]	National Key Science and Technology Project of China; National Basic Research Program of China (973 Program)(National Basic Research Program of China)	We are thankful to Professor Jiahuai Han at Xiamen University for providing RCN2 cDNA. We thank Dr Suqin Shen, Longjiang Liu and Huazheng Yu at Fudan University for their technical support. This study was supported by National Key Science and Technology Project of China (2013ZX10002010), National Basic Research Program of China (973 Program, 2013CB910504).	Cavallo F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S4-S7; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Foerster S, 2013, PROTEOMICS, V13, P3131, DOI 10.1002/pmic.201300154; Giribaldi G, 2013, J PROTEOMICS, V91, P385, DOI 10.1016/j.jprot.2013.07.018; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirano T, 2005, INT J CANCER, V117, P460, DOI 10.1002/ijc.21172; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jiang W., 2015, CELL CYCLE HEPATOCEL, V34, P4460, DOI DOI 10.1038/onc.2014.373; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kishi T, 2007, P NATL ACAD SCI USA, V104, P17418, DOI 10.1073/pnas.0704951104; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li LJ, 2010, P NATL ACAD SCI USA, V107, P1402, DOI 10.1073/pnas.0905657107; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Ludvigsen M, 2009, PROTEOMICS, V9, P5267, DOI 10.1002/pmic.200900321; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manichaikul A, 2011, AM J PHYSIOL-HEART C, V301, pH1056, DOI 10.1152/ajpheart.00366.2011; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Nimmrich I, 2000, CANCER LETT, V160, P37, DOI 10.1016/S0304-3835(00)00553-X; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Wang RY, 2013, GASTROENTEROLOGY, V145, P1436, DOI 10.1053/j.gastro.2013.08.009; Wang ZC, 2015, HEPATOLOGY, V62, P1201, DOI 10.1002/hep.27911; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U	32	21	24	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6691	6700		10.1038/onc.2017.230	http://dx.doi.org/10.1038/onc.2017.230			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28745317				2022-12-28	WOS:000416780800004
J	Conduit, SE; Ramaswamy, V; Remke, M; Watkins, DN; Wainwright, BJ; Taylor, MD; Mitchell, CA; Dyson, JM				Conduit, S. E.; Ramaswamy, V.; Remke, M.; Watkins, D. N.; Wainwright, B. J.; Taylor, M. D.; Mitchell, C. A.; Dyson, J. M.			A compartmentalized phosphoinositide signaling axis at cilia is regulated by INPP5E to maintain cilia and promote Sonic Hedgehog medulloblastoma	ONCOGENE			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; COUPLED RECEPTOR GPR161; CEREBELLAR DEVELOPMENT; TUMOR-SUPPRESSOR; MOUSE MODEL; PROTEIN TRAFFICKING; TRANSITION ZONE; PATHWAY; GROWTH; CELLS	Sonic Hedgehog (SHH) signaling at primary cilia drives the proliferation and progression of a subset of medulloblastomas, the most common malignant paediatric brain tumor. Severe side effects associated with conventional treatments and resistance to targeted therapies has led to the need for new strategies. SHH signaling is dependent on primary cilia for signal transduction suggesting the potential for cilia destabilizing mechanisms as a therapeutic target. INPP5E is an inositol polyphosphate 5-phosphatase that hydrolyses PtdIns(4,5)P-2 and more potently, the phosphoinositide (PI) 3-kinase product PtdIns(3,4,5)P-3. INPP5E promotes SHH signaling during embryonic development via PtdIns(4,5)P-2 hydrolysis at cilia, that in turn regulates the cilia recruitment of the SHH suppressor GPR161. However, the role INPP5E plays in cancer is unknown and the contribution of PI3-kinase signaling to cilia function is little characterized. Here, we reveal INPP5E promotes SHH signaling in SHH medulloblastoma by negatively regulating a cilia-compartmentalized PI3-kinase signaling axis that maintains primary cilia on tumor cells. Conditional deletion of Inpp5e in a murine model of constitutively active Smoothened-driven medulloblastoma slowed tumor progression, suppressed cell proliferation, reduced SHH signaling and promoted tumor cell cilia loss. PtdIns(3,4,5)P-3, its effector pAKT and the target pGSK3 beta, which when non-phosphorylated promotes cilia assembly/stability, localized to tumor cell cilia. The number of PtdIns(3,4,5)P-3/pAKT/pGSK3 beta-positive cilia was increased in cultured Inpp5e-null tumor cells relative to controls. PI3-kinase inhibition or expression of wild-type, but not catalytically inactive HA-INPP5E partially rescued cilia loss in Inpp5e-null tumor cells in vitro. INPP5E mRNA and copy number were reduced in human SHH medulloblastoma compared to other molecular subtypes and consistent with the murine model, reduced INPP5E was associated with improved overall survival. Therefore our study identifies a compartmentalized PtdIns(3,4,5)P-3/AKT/GSK3 beta signaling axis at cilia in SHH-dependent medulloblastoma that is regulated by INPP5E to maintain tumor cell cilia, promote SHH signaling and thereby medulloblastoma progression.	[Conduit, S. E.; Mitchell, C. A.; Dyson, J. M.] Monash Univ, Dept Biochem & Mol Biol, Canc Program, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia; [Ramaswamy, V.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Remke, M.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada; [Watkins, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Watkins, D. N.] UNSW, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Watkins, D. N.] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW, Australia; [Wainwright, B. J.] Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld, Australia	Monash University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Garvan Institute of Medical Research; University of New South Wales Sydney; St Vincents Hospital Sydney; University of Queensland	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Canc Program, Monash Biomed Discovery Inst, Clayton, Vic 3800, Australia.	christina.mitchell@monash.edu		Ramaswamy, Vijay/0000-0002-6557-895X; Wainwright, Brandon/0000-0003-0406-2092; Taylor, Michael/0000-0001-7009-3466	National Health and Medical Research Council [APP1046174]; Australian Postgraduate Award; Alex's Lemonade Stand; CERN foundation; Pediatric Brain Tumor Foundation; National Institutes of Health [R01CA159859, R01CA148699]; NATIONAL CANCER INSTITUTE [R01CA159859, R01CA148699] Funding Source: NIH RePORTER	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Alex's Lemonade Stand; CERN foundation; Pediatric Brain Tumor Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study utilized the Monash Micro Imaging Facility, Monash University, Victoria, Australia and Monash Histology Platform, Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia. This work was funded by a National Health and Medical Research Council project grant (APP1046174). SEC was supported by an Australian Postgraduate Award. VR is supported by a Young Investigator Award from Alex's Lemonade Stand and a Basic Science Fellowship from the CERN foundation. MDT is supported by grants from the Pediatric Brain Tumor Foundation and the National Institutes of Health (R01CA159859 and R01CA148699).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Avasthi P, 2012, DIFFERENTIATION, V83, pS30, DOI 10.1016/j.diff.2011.11.015; Bangs FK, 2015, NAT CELL BIOL, V17, P113, DOI 10.1038/ncb3091; Barakat MT, 2013, CARCINOGENESIS, V34, P1382, DOI 10.1093/carcin/bgt041; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bielas SL, 2009, NAT GENET, V41, P1032, DOI 10.1038/ng.423; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Castellino RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010849; Chavez M, 2015, DEV CELL, V34, P338, DOI 10.1016/j.devcel.2015.06.016; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Conduit SE, 2012, FEBS LETT, V586, P2846, DOI 10.1016/j.febslet.2012.07.037; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowther AJ, 2016, CANCER RES, V76, P3211, DOI 10.1158/0008-5472.CAN-15-0025; Crowther AJ, 2013, J NEUROSCI, V33, P18098, DOI 10.1523/JNEUROSCI.2602-13.2013; Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114; Dyson JM, 2017, J CELL BIOL, V216, P247, DOI 10.1083/jcb.201511055; Elia D, 2007, BBA-MOL CELL RES, V1773, P1438, DOI 10.1016/j.bbamcr.2007.06.006; Eramo MJ, 2016, BIOCHEM SOC T, V44, P240, DOI 10.1042/BST20150214; Franco I, 2014, DEV CELL, V28, P647, DOI 10.1016/j.devcel.2014.01.022; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frick A, 2012, GLIA, V60, P820, DOI 10.1002/glia.22314; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Garcia-Gonzalo FR, 2015, DEV CELL, V34, P400, DOI 10.1016/j.devcel.2015.08.001; Ge XC, 2015, ELIFE, V4, DOI [10.7554/eLife.07068.001, 10.7554/eLife.07068]; Hakim S, 2016, HUM MOL GENET, V25, P2295, DOI 10.1093/hmg/ddw097; Hammond GRV, 2009, BIOCHEM J, V422, P23, DOI 10.1042/BJ20090428; Hamze-Komaiha O, 2016, CELL REP, V17, P2738, DOI 10.1016/j.celrep.2016.11.033; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; He XL, 2014, NAT MED, V20, P1035, DOI 10.1038/nm.3666; Heine VM, 2010, CANCER RES, V70, P5220, DOI 10.1158/0008-5472.CAN-10-0554; Higginbotham H, 2013, NAT NEUROSCI, V16, P1000, DOI 10.1038/nn.3451; Hoffmeister H, 2011, J CELL BIOL, V192, P631, DOI 10.1083/jcb.201007050; Hou CZ, 2014, DEV BIOL, V395, P167, DOI 10.1016/j.ydbio.2014.07.007; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jacoby M, 2009, NAT GENET, V41, P1027, DOI 10.1038/ng.427; Jensen V, 2015, EMBO J, V34, P2537, DOI 10.15252/embj.201488044; Joo W, 2014, SCIENCE, V346, P626, DOI 10.1126/science.1258996; Julian Elaine, 2010, Neural Dev, V5, P27, DOI 10.1186/1749-8104-5-27; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kim JC, 2009, NEURON, V63, P305, DOI 10.1016/j.neuron.2009.07.010; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; Kong AM, 2006, MOL CELL BIOL, V26, P6065, DOI 10.1128/MCB.00203-06; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Larkins CE, 2011, MOL BIOL CELL, V22, P4694, DOI 10.1091/mbc.E10-12-0994; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Lorenz A, 2011, MOL CELL BIOL, V31, P3326, DOI 10.1128/MCB.05718-11; Luo N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066727; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Matei V, 2005, DEV DYNAM, V234, P633, DOI 10.1002/dvdy.20551; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Metcalfe C, 2013, CANCER RES, V73, P7034, DOI 10.1158/0008-5472.CAN-13-1222; Mukhopadhyay S, 2013, CELL, V152, P210, DOI 10.1016/j.cell.2012.12.026; Nielsen BS, 2015, J CELL SCI, V128, P3543, DOI 10.1242/jcs.173559; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Ooms LM, 2015, CANCER CELL, V28, P155, DOI 10.1016/j.ccell.2015.07.003; Otero JJ, 2014, DEV BIOL, V385, P328, DOI 10.1016/j.ydbio.2013.10.019; Pal K, 2016, J CELL BIOL, V212, P861, DOI 10.1083/jcb.201506132; Park J, 2015, CELL REP, V13, P2808, DOI 10.1016/j.celrep.2015.12.009; Pei YX, 2012, DEVELOPMENT, V139, P1724, DOI 10.1242/dev.050104; Plotnikova OV, 2015, J CELL SCI, V128, P364, DOI 10.1242/jcs.161323; Poschl J, 2011, ONCOGENE, V30, P4721, DOI 10.1038/onc.2011.173; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Remke M, 2011, J CLIN ONCOL, V29, P3852, DOI 10.1200/JCO.2011.36.2798; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saeed H, 2015, BIOGERONTOLOGY, V16, P733, DOI 10.1007/s10522-015-9596-6; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yee LE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005627; Yeh C, 2013, DEV CELL, V26, P358, DOI 10.1016/j.devcel.2013.07.014; Yip SC, 2008, BIOCHEM J, V411, P441, DOI 10.1042/BJ20071179; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang H., 2015, EVIDENCE BASED COMPL, V2015, P1; Zhu D, 2009, J CELL SCI, V122, P2760, DOI 10.1242/jcs.046276	92	30	30	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5969	5984		10.1038/onc.2017.208	http://dx.doi.org/10.1038/onc.2017.208			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650469				2022-12-28	WOS:000413841400006
J	Zhao, J; Wang, Y; Mu, C; Xu, Y; Sang, J				Zhao, J.; Wang, Y.; Mu, C.; Xu, Y.; Sang, J.			MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells	ONCOGENE			English	Article							NOTCH SIGNALING PATHWAY; STEM-CELLS; CANCER/TESTIS ANTIGENS; GENE-EXPRESSION; C-JUN; PROTEIN; FAMILY; RESISTANCE; PHENOTYPE; MIGRATION	Melanoma-associated antigen A1 (MAGEA1) is member of the MAGE gene family that is expressed in male germ line cells and placenta under normal physiological conditions. Although MAGEA1's expression levels have been evaluated as one of the cancer testis (CT) antigens for immunotherapy in melanoma and several other cancers, its functional role and signaling mechanisms are largely unknown. In this study, we examined the functional involvement and signaling mechanisms of MAGEA1 in breast and ovarian cancer cells. Inhibitory effects of MAGEA1 on cell proliferation and migration were observed using both gain-of-(MAGEA1 overexpression) and loss-of-(siRNA interference) function approaches in breast (MCF-7 and MDA-MB-231) and ovarian (SKOV3 and SKOV3ip) cancer cell lines. We revealed a novel interaction between MAGEA1 and the intracellular segment of NOTCH1 receptor (NICD1). MAGEA1 reduced NICD1's stability by promoting the ubiquitin modification of NICD1. MAGEA1 also interacted with FBXW7, a subunit of E3 ubiquitin protein ligase complex SCF, and the latter was functionally involved in NICD1 ubiquitination and degradation. In addition, siRNA interference of FBXW7 reversed the inhibitory effect of MAGEA1 on migration and proliferation of MCF-7 and MDA-MB-231 cells. These newly discovered MAGEA1-NICD1 and MAGEA1-FBXW7 interactions have potential clinical implications in breast and ovarian cancer treatment.	[Zhao, J.; Wang, Y.; Mu, C.; Xu, Y.; Sang, J.] Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat, 19 XinJieKouWai St, Beijing 100875, Peoples R China; [Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Beijing Normal University; Indiana University System; Indiana University Bloomington	Xu, Y; Sang, J (corresponding author), Beijing Normal Univ, Coll Life Sci, Key Lab Cell Proliferat & Regulat, 19 XinJieKouWai St, Beijing 100875, Peoples R China.	xu2@iupui.edu; jlsang@bnu.edu.cn			National Basic Research Program of China [2007CB914401]; National High Technology Research and Development Program of China [2006AA02Z4A6]; Mary Fendrich-Hulman Charitable Trust Fund	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); Mary Fendrich-Hulman Charitable Trust Fund	This work was supported in part by The National Basic Research Program of China (Grant no. 2007CB914401) and the National High Technology Research and Development Program of China (Grant no. 2006AA02Z4A6) to JS; as well as in part by the Mary Fendrich-Hulman Charitable Trust Fund to YX. We would like to thank Kevin McClelland for editing the manuscript.	Abd-Elsalam EA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0285-0; Acar A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2498764; Askew EB, 2009, J BIOL CHEM, V284, P34793, DOI 10.1074/jbc.M109.065979; Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bolos V, 2013, BREAST CANCER RES, V15, P15; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brzozowa-Zasada M, 2016, WSPOLCZESNA ONKOL, V20, P267, DOI 10.5114/wo.2016.61845; Daudi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104099; De Plaen E, 1999, GENOMICS, V55, P176, DOI 10.1006/geno.1998.5638; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Ladelfa MF, 2012, CANCER LETT, V325, P11, DOI 10.1016/j.canlet.2012.05.031; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hao JQ, 2015, ONCOTARGET, V6, P42028, DOI 10.18632/oncotarget.5973; Heasley LE, 2006, MOL CELLS, V21, P167; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978-1-4614-0899-4_14; Kim HL, 2001, CANCER RES, V61, P2833; Kitade S, 2016, CANCER SCI, V107, P1399, DOI 10.1111/cas.13026; Kloudova K, 2016, ONCOTARGET, V7, P46120, DOI 10.18632/oncotarget.10028; Kozakova L, 2015, CELL CYCLE, V14, P920, DOI 10.1080/15384101.2014.1000112; Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Marcar L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127713; Marcar L, 2010, CANCER RES, V70, P10362, DOI 10.1158/0008-5472.CAN-10-1341; Matkovic B, 2011, CROAT MED J, V52, P171, DOI 10.3325/cmj.2011.52.171; Minges JT, 2013, J BIOL CHEM, V288, P1939, DOI 10.1074/jbc.M112.428409; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Otte M, 2001, CANCER RES, V61, P6682; Peche LY, 2012, CELL DEATH DIFFER, V19, P926, DOI 10.1038/cdd.2011.173; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Pui CH, 2009, CANCER CELL, V15, P85, DOI 10.1016/j.ccr.2009.01.007; Saha SK, 2017, ONCOGENE, V36, P332, DOI 10.1038/onc.2016.221; She QB, 2002, CANCER RES, V62, P1343; Shukla G, 2017, CURR STEM CELL RES T, V12, P207, DOI 10.2174/1574888X11666161028143224; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; Tseng HY, 2012, CARCINOGENESIS, V33, P1871, DOI 10.1093/carcin/bgs236; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang D, 2016, BIOCHEM BIOPH RES CO, V473, P959, DOI 10.1016/j.bbrc.2016.03.161; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; Weon JL, 2015, CURR OPIN CELL BIOL, V37, P1, DOI 10.1016/j.ceb.2015.08.002; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zhang SQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-163; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	54	21	22	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5023	5034		10.1038/onc.2017.131	http://dx.doi.org/10.1038/onc.2017.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459460				2022-12-28	WOS:000408768800007
J	Chen, Y; Zeng, C; Zhan, Y; Wang, H; Jiang, X; Li, W				Chen, Y.; Zeng, C.; Zhan, Y.; Wang, H.; Jiang, X.; Li, W.			Aberrant low expression of p85 alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b	ONCOGENE			English	Article							PHOSPHOINOSITIDE 3-KINASES; TUMOR-SUPPRESSOR; PI3K PATHWAY; TGF-BETA; ACQUISITION; GROWTH; TUMORIGENESIS; TRANSITIONS; ACTIVATION; MUTATIONS	P85 alpha, which acts as a tumour suppressor, is frequently found to be downregulated in various human cancers. However, the role of p85 alpha in the tumour microenvironment is unknown. Here, we report that aberrantly low expression of p85 alpha in breast cancer stroma is clinically relevant to breast cancer disease progression. Stromal fibroblasts can acquire the hallmarks of cancer-associated fibroblasts (CAFs) as a result of the loss of p85 alpha expression. Paracrine Wnt10b from p85 alpha-deficient fibroblasts can promote cancer progression via epithelial-to-mesenchymal transition (EMT) induced by the canonical Wnt pathway. Moreover, exosomes have a key role in paracrine Wnt10b transport from fibroblasts to breast cancer epithelial cells. Our results reveal that p85 alpha expression in stromal fibroblasts haves a crucial role in regulating breast cancer tumourigenesis and progression by modifying stromal-epithelial crosstalk and remodelling the tumour microenvironment. Therefore, p85 alpha can function as a tumour suppressor and represent a new candidate for diagnosis, prognosis and targeted therapy.	[Chen, Y.; Zeng, C.; Zhan, Y.; Wang, H.; Li, W.] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China; [Jiang, X.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Sinofrance Lab Drug Screening, Key Lab Mol Biophys,Minist Educ, Wuhan, Hubei, Peoples R China	Wuhan University; Huazhong University of Science & Technology	Li, W (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China.	whli@whu.edu.cn			National Basic Research Program of China [2014CB910603]; National Natural Science Foundation of China [81472684, 81072151]; Program for New Century Excellent Talents in University of Ministry of Education of China [NCET-13-0436]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET))	We thank Professor Lewis C Cantley for the gift of the knockout cell lines. This study was supported by National Basic Research Program of China (2014CB910603), the National Natural Science Foundation of China (81472684, 81072151) and Program for New Century Excellent Talents in University of Ministry of Education of China (NCET-13-0436).	Albrengues J, 2014, CELL REP, V7, P1664, DOI 10.1016/j.celrep.2014.04.036; Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bogatkevich GS, 2001, J BIOL CHEM, V276, P45184, DOI 10.1074/jbc.M106441200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Chiu YH, 2014, MOL CELL, V54, P193, DOI 10.1016/j.molcel.2014.02.016; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franch-Marro X, 2008, NAT CELL BIOL, V10, P170, DOI 10.1038/ncb1678; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Gong K, 2012, J BIOL CHEM, V287, P35576, DOI 10.1074/jbc.M112.370585; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu BA, 2013, CURR OPIN RHEUMATOL, V25, P71, DOI 10.1097/BOR.0b013e32835b1352; Hu HM, 2013, FASEB J, V27, P163, DOI 10.1096/fj.12-216622; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klarenbeek S, 2013, MOL ONCOL, V7, P146, DOI 10.1016/j.molonc.2013.02.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Melchor L, 2013, HUM GENET, V132, P845, DOI 10.1007/s00439-013-1299-y; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rajaram M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003789; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shannon KM, 2012, CANCER J, V18, P310, DOI 10.1097/PPO.0b013e318260946f; Shimoda M, 2014, NAT CELL BIOL, V16, P889, DOI 10.1038/ncb3021; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI [10.1586/epr.09.17, 10.1586/EPR.09.17]; Spaeth EL, 2013, CANCER RES, V73, P5347, DOI 10.1158/0008-5472.CAN-13-0087; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Weinberg RA, 2008, NAT GENET, V40, P494, DOI 10.1038/ng0508-494; Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864; Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004; Ye K, 2016, NAT MED, V22, P97, DOI 10.1038/nm.4002; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	56	70	75	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4692	4705		10.1038/onc.2017.100	http://dx.doi.org/10.1038/onc.2017.100			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394344	Green Published, hybrid			2022-12-28	WOS:000407702400003
J	Kenny, TC; Hart, P; Ragazzi, M; Sersinghe, M; Chipuk, J; Sagar, MAK; Eliceiri, KW; LaFramboise, T; Grandhi, S; Santos, J; Riar, AK; Papa, L; D'Aurello, M; Manfredi, G; Bonini, MG; Germain, D				Kenny, T. C.; Hart, P.; Ragazzi, M.; Sersinghe, M.; Chipuk, J.; Sagar, M. A. K.; Eliceiri, K. W.; LaFramboise, T.; Grandhi, S.; Santos, J.; Riar, A. K.; Papa, L.; D'Aurello, M.; Manfredi, G.; Bonini, M. G.; Germain, D.			Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; BREAST-CANCER; OXIDATIVE-PHOSPHORYLATION; EXPRESSION; MUTATIONS; AMPK; TUMORIGENICITY; DEACETYLATION; ACCUMULATION; METABOLISM	By causing mitochondrial DNA (mtDNA) mutations and oxidation of mitochondrial proteins, reactive oxygen species (ROS) leads to perturbations in mitochondrial proteostasis. Several studies have linked mtDNA mutations to metastasis of cancer cells but the nature of the mtDNA species involved remains unclear. Our data suggests that no common mtDNA mutation identifies metastatic cells; rather the metastatic potential of several ROS-generating mutations is largely determined by their mtDNA genomic landscapes, which can act either as an enhancer or repressor of metastasis. However, mtDNA landscapes of all metastatic cells are characterized by activation of the SIRT/FOXO/SOD2 axis of the mitochondrial unfolded protein response (UPRmt). The UPRmt promotes a complex transcription program ultimately increasing mitochondrial integrity and fitness in response to oxidative proteotoxic stress. Using SOD2 as a surrogate marker of the UPRmt, we found that in primary breast cancers, SOD2 is significantly increased in metastatic lesions. We propose that the ability of selected mtDNA species to activate the UPRmt is a process that is exploited by cancer cells to maintain mitochondrial fitness and facilitate metastasis.	[Kenny, T. C.; Riar, A. K.; Papa, L.; Germain, D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl Box 1079, New York, NY 10029 USA; [Hart, P.; Bonini, M. G.] Univ Illinois, Dept Med, Chicago, IL USA; [Ragazzi, M.] Arcispedale Santa Maria Nuova IRCCS, Pathol Unit, Reggio Emilia, Italy; [Sersinghe, M.; Chipuk, J.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Sagar, M. A. K.; Eliceiri, K. W.] Univ Wisconsin, Dept Biomed Engn, Lab Opt & Computat Instrumentat, Madison, WI USA; [LaFramboise, T.; Grandhi, S.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Santos, J.] Natl Inst Environm Hlth Sci, Durham, NC USA; [D'Aurello, M.; Manfredi, G.] Brain & Mind Res Inst, Weill Cornell Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; IRCCS Arcispedale S. Maria Nuova; Icahn School of Medicine at Mount Sinai; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Cornell University	Germain, D (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl Box 1079, New York, NY 10029 USA.	doris.germain@mssm.edu	Eliceiri, Kevin/ABD-4516-2020; Ragazzi, Moira/J-5737-2018; Sagar, Abdul Kader/ABG-8019-2020	Eliceiri, Kevin/0000-0001-8678-670X; Ragazzi, Moira/0000-0002-8761-9265; Sagar, Abdul Kader/0000-0002-1564-0727; Hart, Peter/0000-0003-1843-9102; Riar, Amanjot Kaur/0000-0003-1357-3548; Kenny, Timothy Cole/0000-0001-8258-5716	NIH RO1 [CA1722046]; NATIONAL CANCER INSTITUTE [T32CA078207, R01CA206005, R01CA172046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NIH RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the electron microscopy facility at Mount Sinai and the sequencing core facility at Case Western. We thank Maria Gomez for her help in generating the Supplementary Tables, Elizabeth Slocum for her contribution to the analysis by electron microscopy and Yukie Takabatake for her contribution to the graphical illustration of the model in Figure 7. This work was funded by an NIH RO1 number CA1722046 to DG.	Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Conklin MW, 2009, CELL BIOCHEM BIOPHYS, V53, P145, DOI 10.1007/s12013-009-9046-7; Covarrubias D, 2008, J HUM GENET, V53, P924, DOI 10.1007/s10038-008-0331-x; Cruz-Bermudez A, 2015, ONCOTARGET, V6, P13628, DOI 10.18632/oncotarget.3698; D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326; Desmetz C, 2008, J PROTEOME RES, V7, P3830, DOI 10.1021/pr800130d; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Feeley KP, 2015, CANCER RES, V75, P4429, DOI 10.1158/0008-5472.CAN-15-0074; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Fiorese CJ, 2016, CURR BIOL, V26, P2037, DOI 10.1016/j.cub.2016.06.002; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Hashizume O, 2012, P NATL ACAD SCI USA, V109, P10528, DOI 10.1073/pnas.1202367109; Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Ishikawa K, 2012, J BIOENERG BIOMEMBR, V44, P639, DOI 10.1007/s10863-012-9468-6; Jandova J, 2012, EXP CELL RES, V318, P2215, DOI 10.1016/j.yexcr.2012.06.006; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; McMahon S, 2014, CARCINOGENESIS, V35, P1046, DOI 10.1093/carcin/bgu012; Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361; Mouchiroud L, 2013, CELL, V154, P430, DOI 10.1016/j.cell.2013.06.016; Munch C, 2016, NATURE, V534, P710, DOI 10.1038/nature18302; Nargund AM, 2015, MOL CELL, V58, P123, DOI 10.1016/j.molcel.2015.02.008; Nargund AM, 2012, SCIENCE, V337, P587, DOI 10.1126/science.1223560; Nunes JB, 2015, HUM MOL GENET, V24, P1977, DOI 10.1093/hmg/ddu612; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271; Ragazzi M, 2011, HUM PATHOL, V42, P166, DOI 10.1016/j.humpath.2010.07.014; Rappa F, 2016, CELL STRESS CHAPERON, V21, P927, DOI 10.1007/s12192-016-0721-5; Riggins RB, 2005, MOL CANCER THER, V4, P33; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Seo JH, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002507; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shi T, 2010, J DIGEST DIS, V11, P55, DOI 10.1111/j.1751-2980.2009.00416.x; Takibuchi G, 2013, MITOCHONDRION, V13, P881, DOI 10.1016/j.mito.2013.07.117; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tian Y, 2016, TRENDS CELL BIOL, V26, P563, DOI 10.1016/j.tcb.2016.06.006; van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Yang W, 2016, CELL, V167, P985, DOI 10.1016/j.cell.2016.10.016; Yuan Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1349-z; Yuzefovych LV, 2016, CANCER RES, V76, P30, DOI 10.1158/0008-5472.CAN-15-0692; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	54	59	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4393	4404		10.1038/onc.2017.52	http://dx.doi.org/10.1038/onc.2017.52			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368421	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000406806000002
J	Schaefer, SM; Segalada, C; Cheng, PF; Bonalli, M; Parfejevs, V; Levesque, MP; Dummer, R; Nicolis, SK; Sommer, L				Schaefer, S. M.; Segalada, C.; Cheng, P. F.; Bonalli, M.; Parfejevs, V.; Levesque, M. P.; Dummer, R.; Nicolis, S. K.; Sommer, L.			Sox2 is dispensable for primary melanoma and metastasis formation	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; CANCER STEM-CELLS; INITIATING CELLS; TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; MOUSE MODEL; EXPRESSION; TUMORIGENICITY; NEUROGENESIS; MAINTENANCE	Tumor initiation and metastasis formation in many cancers have been associated with emergence of a gene expression program normally active in embryonic or organ-specific stem cells. In particular, the stem cell transcription factor Sox2 is not only expressed in a variety of tumors, but is also required for their formation. Melanoma, the most aggressive skin tumor, derives from melanocytes that during development originate from neural crest stem cells. While neural crest stem cells do not express Sox2, expression of this transcription factor has been reported in melanoma. However, the role of Sox2 in melanoma is controversial. To study the requirement of Sox2 for melanoma formation, we therefore performed CRISPR-Cas9-mediated gene inactivation in human melanoma cells. In addition, we conditionally inactivated Sox2 in a genetically engineered mouse model, in which melanoma spontaneously develops in the context of an intact stroma and immune system. Surprisingly, in both models, loss of Sox2 did neither affect melanoma initiation, nor growth, nor metastasis formation. The lack of a tumorigenic role of Sox2 in melanoma might reflect a distinct stem cell program active in neural crest stem cells and during melanoma formation.	[Schaefer, S. M.; Segalada, C.; Bonalli, M.; Parfejevs, V.; Sommer, L.] Univ Zurich, Inst Anat, Winterthurerstr 190, CH-8057 Zurich, Switzerland; [Cheng, P. F.; Levesque, M. P.; Dummer, R.] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland; [Nicolis, S. K.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy	University of Zurich; University of Zurich; University Zurich Hospital; University of Milano-Bicocca	Sommer, L (corresponding author), Univ Zurich, Inst Anat, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lukas.sommer@anatom.uzh.ch	Cheng, Phil/AAN-8567-2021	Cheng, Phil/0000-0003-2940-006X; Segalada, Corina/0000-0003-4187-4145; Parfejevs, Vadims/0000-0002-1836-3999; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808	Swiss National Science Foundation (SNF); University Research Priority Program (URPP) 'Translational Cancer Research' Biobank; Swiss Cancer League; AIRC; Telethon	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); University Research Priority Program (URPP) 'Translational Cancer Research' Biobank; Swiss Cancer League; AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon)	We thank Annika Klug for help with hematoxylin and eosin stainings and Jessica Hausel for assistance in histology. We would like to thank Daniel Zingg for his help with statistical analysis. Further, we acknowledge the advice by the Cancer Biology PhD program of the University of Zurich. This work was supported by the Swiss National Science Foundation (SNF), the University Research Priority Program (URPP) 'Translational Cancer Research' Biobank, and the Swiss Cancer League. Work in the Nicolis laboratory was supported by AIRC and Telethon.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; BUTTNER P, 1995, CANCER-AM CANCER SOC, V75, P2499, DOI 10.1002/1097-0142(19950515)75:10<2499::AID-CNCR2820751016>3.0.CO;2-8; Buzaid AC, 1997, J CLIN ONCOL, V15, P1039, DOI 10.1200/JCO.1997.15.3.1039; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Carrasco-Garcia E, 2016, AM J CANCER RES, V6, P701; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cesarini V, ONCOGENE; Chen PL, 2013, MODERN PATHOL, V26, P44, DOI 10.1038/modpathol.2012.132; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Driskell RR, 2009, DEVELOPMENT, V136, P2815, DOI 10.1242/dev.038620; Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kareta MS, 2015, CELL STEM CELL, V16, P39, DOI 10.1016/j.stem.2014.10.019; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Miyagi S, 2008, FEBS LETT, V582, P2811, DOI 10.1016/j.febslet.2008.07.011; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Shakhova O, 2013, CANCER LETT, V338, P74, DOI 10.1016/j.canlet.2012.10.009; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Wakamatsu Y, 2004, DEV DYNAM, V229, P74, DOI 10.1002/dvdy.10498; Weina K, 2016, PIGM CELL MELANOMA R, V29, P453, DOI 10.1111/pcmr.12483; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051; Zipser MC, 2011, PIGM CELL MELANOMA R, V24, P326, DOI 10.1111/j.1755-148X.2010.00823.x	45	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4516	4524		10.1038/onc.2017.55	http://dx.doi.org/10.1038/onc.2017.55			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368416	Green Accepted			2022-12-28	WOS:000406806000013
J	Comisso, E; Scarola, M; Rosso, M; Piazza, S; Marzinotto, S; Ciani, Y; Orsaria, M; Mariuzzi, L; Schneider, C; Schoeftner, S; Benetti, R				Comisso, E.; Scarola, M.; Rosso, M.; Piazza, S.; Marzinotto, S.; Ciani, Y.; Orsaria, M.; Mariuzzi, L.; Schneider, C.; Schoeftner, S.; Benetti, R.			OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness	ONCOGENE			English	Article							CHROMOSOMAL PASSENGER COMPLEX; AURORA-B KINASE; RETINOBLASTOMA PROTEIN; INITIATING CELLS; SELF-RENEWAL; LUNG-CANCER; STEM; EXPRESSION; INHIBITION; GROWTH	OCT4 (Octamer-binding transcription factor 4) is essential for embryonic stem cell self-renewal. Here we show that OCT4 increases the aggressiveness of high-grade serous ovarian cancer (HG-SOC) by inactivating the Retinoblastoma tumor suppressor pathway and enhancing mitotic stability in cancer cells. OCT4 drives the expression of Nuclear Inhibitor of Protein Phosphatase type 1 (NIPP1) and Cyclin F (CCNF) that together inhibit Protein Phosphatase 1 (PP1). This results in pRB hyper-phosphorylation, accelerated cell proliferation and increased in vitro tumorigenicity of ovarian cancer cells. In parallel, OCT4 and NIPP1/CCNF drive the expression of the central Chromosomal Passenger Complex (CPC) components, Borealin, Survivin and the mitotic kinase Aurora B, promoting the clustering of supernumerary centrosomes to increase mitotic stability. Loss of OCT4 or NIPP1/CCNF results in severe mitotic defects, multipolar spindles and supernumerary centrosomes, finally leading to the induction of apoptosis. These phenotypes were recapitulated in different cancer models indicating general relevance for human cancer. Importantly, activation of these parallel pathways leads to dramatically reduced overall survival of HG-SOC patients. Altogether, our data highlights an unprecedented role for OCT4 as central regulator of mitotic fidelity and RB tumor suppressor pathway activity. Disrupting this pathway represents a promising strategy to target an aggressive subpopulation of HG-SOC cells.	[Comisso, E.; Scarola, M.; Rosso, M.; Piazza, S.; Ciani, Y.; Schneider, C.; Schoeftner, S.; Benetti, R.] LNCIB, Canc Epigenet Grp, Area Sci Pk,Palazzina F3,Padriciano 99, Trieste, Italy; [Comisso, E.; Schneider, C.; Benetti, R.] Univ Udine, Dept Med & Biol Sci, Udine, Italy; [Rosso, M.; Schoeftner, S.] Univ Trieste, Dept Life Sci, Trieste, Italy; [Piazza, S.] Univ Trento CIBIO, Ctr Integrat Biol, Trento, Italy; [Marzinotto, S.; Orsaria, M.; Mariuzzi, L.] Univ Hosp Udine, Inst Anat Pathol, Dept Med & Biol Sci, Udine, Italy; [Scarola, M.; Rosso, M.] LNCIB, Genom Instabil Grp, Area Sci Pk,Padriciano 99, I-34149 Trieste, Italy	University of Udine; University of Trieste; University of Trento; University of Udine; University Hospital of Udine	Benetti, R (corresponding author), LNCIB, Canc Epigenet Grp, Area Sci Pk,Palazzina F3,Padriciano 99, Trieste, Italy.; Schoeftner, S (corresponding author), LNCIB, Genom Instabil Grp, Area Sci Pk,Padriciano 99, I-34149 Trieste, Italy.	stefan.schoeftner@lncib.it; roberta.benetti@lncib.it	Orsaria, Maria/AAH-6310-2021	Rosso, Massimo/0000-0002-4473-196X; Piazza, Silvano/0000-0002-7156-5434; Ciani, Yari/0000-0002-9635-2830	AIRC grant [Rif 17756, Rif 10299]; Rotary Club Bari Sud; Italian Ministry of Education, Universities and Research (MIUR) [CTN01_00177_817708]	AIRC grant(Fondazione AIRC per la ricerca sul cancro); Rotary Club Bari Sud; Italian Ministry of Education, Universities and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank Angelica Feresin and Simone Pisano (University of Udine, Italy) for helping with processing of patient samples and with spindle defects experiments. EC and MS are AIRC post-doctoral fellows. MR is enrolled in the PhD program for Molecular Medicine at the University of Trieste. This work was supported by an AIRC grant (Rif 17756 to RB and Rif 10299 to SS), a financial support by the Rotary Club Bari Sud to RB and a grant from the Italian Ministry of Education, Universities and Research (MIUR) CTN01_00177_817708 to CS.	Amato A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-79; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chen ZG, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-10; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086; Darini CY, 2012, ONCOGENE, V31, P2438, DOI 10.1038/onc.2011.421; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Desjardins M, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-70; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Huang P, 2012, MED ONCOL, V29, P829, DOI 10.1007/s12032-011-9962-4; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Kim HJ, 2011, FEBS LETT, V585, P3569, DOI 10.1016/j.febslet.2011.10.022; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Koo BS, 2015, ONCOGENE, V34, P2317, DOI 10.1038/onc.2014.174; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Leber B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000915; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Liedtke S, 2008, BIOL CHEM, V389, P845, DOI 10.1515/BC.2008.098; Lieman JH, 2005, J BIOL CHEM, V280, P10484, DOI 10.1074/jbc.M409371200; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Ngan VK, 2001, MOL PHARMACOL, V60, P225, DOI 10.1124/mol.60.1.225; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Schoeftner S, 2013, STEM CELLS, V31, P717, DOI 10.1002/stem.1315; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927; van der Horst A, 2014, CHROMOSOMA, V123, P25, DOI 10.1007/s00412-013-0437-6; Vathipadiekal V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029079; Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Yu JJ, 2015, ONCOL LETT, V10, P1642, DOI 10.3892/ol.2015.3467; Zhang J, 2010, J CLIN PATHOL, V63, P879, DOI 10.1136/jcp.2009.073593; Zhao Pengpeng, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P643	48	28	28	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4253	4266		10.1038/onc.2017.20	http://dx.doi.org/10.1038/onc.2017.20			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28319064	Green Submitted			2022-12-28	WOS:000406360600003
J	Ferreira, HJ; Heyn, H; Vizoso, M; Moutinho, C; Vidal, E; Gomez, A; Martinez-Cardus, A; Simo-Riudalbas, L; Moran, S; Jost, E; Esteller, M				Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Jost, E.; Esteller, M.			DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia (vol 35, pg 3079, 2016)	ONCOGENE			English	Correction													Esteller, Manel/L-5956-2014; Martinez, Anna/AAA-4939-2020	Esteller, Manel/0000-0003-4490-6093; Vizoso, Miguel/0000-0002-9992-2851				Ferreira HJ, 2016, ONCOGENE, V35, P3079, DOI 10.1038/onc.2015.359	1	4	4	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4233	4233		10.1038/onc.2017.57	http://dx.doi.org/10.1038/onc.2017.57			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28288143	hybrid, Green Published			2022-12-28	WOS:000405835800014
J	Morath, I; Jung, C; Leveque, R; Chen, LF; Toillon, RA; Warth, A; Orian-Rousseau, V				Morath, Iris; Jung, Christian; Leveque, Romain; Chen Linfeng; Toillon, Robert-Alain; Warth, Arne; Orian-Rousseau, Veronique			Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR; SIGNALING PLATFORM; EGF RECEPTOR; C-MET; EXPRESSION; CYTOSKELETON; EZRIN; METASTASIS; ACTIVATION; PROTEINS	Members of the CD44 family of transmembrane glycoproteins control cell signaling pathways from numerous cell surface receptors, including receptor tyrosine kinases (RTKs). The decisive factor (ligand, RTKs or both) that controls the recruitment of specific CD44 isoforms is still unknown. We investigated this question by using the EGFR signaling pathway, in which one receptor can be activated by a broad range of ligands. By means of siRNA-mediated downregulation of CD44 expression and blocking experiments, we identified CD44v6 as a co-receptor for EGF- and ER-induced ErbB1 activation and for NRG1-induced ErbB3 and ErbB4 activation. In contrast, TGFa is independent of all CD44 isoforms, even though it addresses the same receptor pairs as EGF. Moreover, the heparin-sulfated CD44v3 isoform is required for HB-EGF-induced EGFR signaling. These data suggest that specific CD44 isoforms are recruited in a ligand-dependent manner as co-receptors in the EGFR signaling pathways and that the specificity is determined by the ligand and not by the receptors themselves. The in vivo relevance of this interplay between CD44 isoforms and EGFR ligands is underlined by the decreased metastatic spreading of mammary carcinomas in mice treated with a CD44v6-specific peptide. Most importantly, we found a clear correlation between the presence of CD44v6/ErbB1 complexes in breast cancer patients and lymph node metastases.	[Morath, Iris; Jung, Christian; Orian-Rousseau, Veronique] Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany; [Leveque, Romain; Toillon, Robert-Alain] Univ Lille, INSERM, U908, CPAC, Lille, France; [Chen Linfeng] Dana Farber Canc Inst, Boston, MA 02115 USA; [Warth, Arne] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Harvard University; Dana-Farber Cancer Institute; Ruprecht Karls University Heidelberg	Orian-Rousseau, V (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany.	veronique.orian-rousseau@kit.edu	Jung, Christian/AAN-4537-2021; Toillon, Robert-Alain/Q-2286-2018; Orian-Rousseau, Veronique/H-5735-2013	Jung, Christian/0000-0001-8325-250X; Toillon, Robert-Alain/0000-0001-5483-2118; Orian-Rousseau, Veronique/0000-0003-2939-9257	Mildred Scheel Foundation	Mildred Scheel Foundation(Deutsche Krebshilfe)	The authors are very thankful to Selma Huber and the animal facility of the Institute of Toxicology and Genetics for their excellent work and help with the animal experiments. This work was supported by a grant from Mildred Scheel Foundation.	ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bennett R, 2001, J HISTOCHEM CYTOCHEM, V49, P67, DOI 10.1177/002215540104900107; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; Diaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184; Ellis IR, 2007, EXP CELL RES, V313, P732, DOI 10.1016/j.yexcr.2006.11.016; Foekens JA, 1999, INT J CANCER, V84, P209, DOI 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; Kivisaari AK, 2010, BRIT J DERMATOL, V163, P726, DOI 10.1111/j.1365-2133.2010.09924.x; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konstantinovsky S, 2012, CLIN EXP METASTAS, V29, P527, DOI 10.1007/s10585-012-9468-2; Lynch CC, 2007, CANCER RES, V67, P6760, DOI 10.1158/0008-5472.CAN-07-0026; Matsuo I, 2013, CURR OPIN GENET DEV, V23, P399, DOI 10.1016/j.gde.2013.02.004; Matzke A, 2005, CANCER RES, V65, P6105, DOI 10.1158/0008-5472.CAN-05-0207; Matzke-Ogi A, 2016, GASTROENTEROLOGY, V150, P513, DOI 10.1053/j.gastro.2015.10.020; Minuti G, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.06.22; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Olaku V, 2011, MOL BIOL CELL, V22, P2777, DOI 10.1091/mbc.E11-02-0134; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Orian-Rousseau V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00154; Orian-Rousseau V, 2014, ADV CANCER RES, V123, P231, DOI 10.1016/B978-0-12-800092-2.00009-5; Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024; Orian-Rousseau V, 2008, ADV CANCER RES, V101, P63, DOI 10.1016/S0065-230X(08)00404-1; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rodig SJ, 2010, CURR OPIN INVEST DR, V11, P1477; Rowinsky E, 2000, DRUGS, V60, P41; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tremmel M, 2009, BLOOD, V114, P5236, DOI 10.1182/blood-2009-04-219204; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Volz Y, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150093; Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206; Wu WKK, 2009, ANTICANCER RES, V29, P229; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	48	27	27	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1472	1484		10.1038/s41388-017-0030-1	http://dx.doi.org/10.1038/s41388-017-0030-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321661				2022-12-28	WOS:000427459500006
J	Chen, SH; Gong, X; Zhang, Y; Van Horn, RD; Yin, T; Huber, L; Burke, TF; Manro, J; Iversen, PW; Wu, W; Bhagwat, SV; Beckmann, RP; Tiu, RV; Buchanan, SG; Peng, SB				Chen, S-H; Gong, X.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Huber, L.; Burke, T. F.; Manro, J.; Iversen, P. W.; Wu, W.; Bhagwat, S. V.; Beckmann, R. P.; Tiu, R. V.; Buchanan, S. G.; Peng, S-B			RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1	ONCOGENE			English	Article							CELL-CYCLE; ANTITUMOR ACTIVITIES; METASTATIC MELANOMA; ONCOGENIC MUTATIONS; MAPK PATHWAY; B-RAF; VEMURAFENIB; RESISTANCE; REACTIVATION; BRAF(V600E)	KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer. There is currently no effective therapy for the treatment of RAS mutant cancers. LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo. Abemaciclib, a CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS mutant lung cancer. In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination. Further in vitro screen in 328 tumor cell lines revealed that tumor cells with KRAS, NRAS or BRAF mutation, or cyclin D activation are more sensitive, whereas tumor cells with PTEN, PIK3CA, PIK3R1 or retinoblastoma (Rb) mutation are more resistant to this combination treatment. Molecular analysis revealed that abemaciclib alone inhibited Rb phosphorylation partially and caused an increase of cyclin D1. The combinatory treatment cooperatively demonstrated more complete inhibition of Rb phosphorylation, and LY3009120 suppressed the cyclin D1 upregulation mediated by abemaciclib. These results were further verified by CDK4/6 siRNA knockdown. Importantly, the more complete phospho-Rb inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combination led to more significant cell cycle G(0)/G(1) arrest of tumor cells. These preclinical findings suggest that combined inhibition of RAF and D-cyclin-dependent kinases might provide an effective approach to treat patients with tumors harboring mutations in RAS or RAF genes.	[Chen, S-H; Gong, X.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Huber, L.; Burke, T. F.; Wu, W.; Bhagwat, S. V.; Beckmann, R. P.; Buchanan, S. G.; Peng, S-B] Eli Lilly & Co, Oncol Res, Indianapolis, IN 46285 USA; [Manro, J.; Iversen, P. W.] Eli Lilly & Co, Stat, Indianapolis, IN 46285 USA; [Tiu, R. V.] Eli Lilly & Co, Early Phase Oncol & Oncol Business Unit, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Peng, SB (corresponding author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.	peng_sheng-bin@lilly.com			Eli Lilly and Company	Eli Lilly and Company(Eli Lilly)	All authors are employees of Eli Lilly and Company at the time that the work was done. All research described herein was funded by Eli Lilly and Company.	Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dong JL, 2003, CANCER RES, V63, P3883; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Henry JR, 2015, J MED CHEM, V58, P4165, DOI 10.1021/acs.jmedchem.5b00067; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Johnpulle RAN, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-015-0485-6; King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rader J, 2013, CLIN CANCER RES, V19, P6173, DOI 10.1158/1078-0432.CCR-13-1675; Sanchez-Laorden B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004815; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yadav V, 2015, PHARMACOL THERAPEUT, V149, P139, DOI 10.1016/j.pharmthera.2014.12.003; Yadav V, 2014, MOL CANCER THER, V13, P2253, DOI 10.1158/1535-7163.MCT-14-0257; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646	48	40	43	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					821	832		10.1038/onc.2017.384	http://dx.doi.org/10.1038/onc.2017.384			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059158				2022-12-28	WOS:000424628100013
J	Guo, P; Ma, X; Zhao, W; Huai, W; Li, T; Qiu, Y; Zhang, Y; Han, L				Guo, P.; Ma, X.; Zhao, W.; Huai, W.; Li, T.; Qiu, Y.; Zhang, Y.; Han, L.			TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; NLRP3 INFLAMMASOME; DOWN-REGULATION; LIVER-CANCER; PROTEIN; LIGASE; CELLS; TSC1; DEGRADATION; CONTRIBUTES	Tripartite motif (TRIM) 31 is a member of the tripartite motif-containing protein family, and TRIM family proteins are involved in a broad range of biological and pathological processes. However, the role of TRIM31 in hepatocellular carcinoma (HCC) progression is not known. Here we demonstrated that TRIM31 expression was significantly upregulated in liver cancer tissues compared with paired distal non-cancerous liver tissues from HCC patients, and its overexpression was significantly correlated with advanced disease status. Both gain and loss of function assay verified that TRIM31 promoted the malignant behaviors of HCC cells through overactivation of mammalian target of rapamycin complex1 (mTORC1) pathway. We further demonstrated that TRIM31 exerted its oncogenic effect by directly interacting with the tuberous sclerosis complex (TSC) 1 and TSC2 complex, the upstream suppressor of mTORC1 pathway, and promoting the E3 ligase-mediated K48-linked ubiquitination and degradation of this complex. In conclusion, this study demonstrated TRIM31 could promote HCC progression by targeting TSC1-TSC2 complex for degradation and further overactivating mTORC1 pathway. Thus, it revealed a novel molecular mechanism of HCC progression and indicated a potential therapeutic strategy against HCC by targeting TRIM31.	[Guo, P.; Ma, X.; Zhao, W.; Huai, W.; Qiu, Y.; Zhang, Y.; Han, L.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, T.] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250021, Shandong, Peoples R China	Shandong University; Shandong University	Han, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	hanlihui@sdu.edu.cn		Zhao, Wei/0000-0001-8440-2274; Han, Lihui/0000-0003-1030-2232	National Natural Science Foundation of China [81472269, 81672391]; Science and Technology Development Project of Shandong Province [2015GSF118047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Project of Shandong Province	We thank Dr Brendan D Manning (Harvard University) and Dr Cheryl Lyn Walker (Texas A&M University) for providing the TSC1 and TSC2 plasmids. This study was supported by the National Natural Science Foundation of China (No. 81472269 and No. 81672391) and the Science and Technology Development Project of Shandong Province (No. 2015GSF118047).	Argyriou P, 2011, ANN HEMATOL, V90, P315, DOI 10.1007/s00277-010-1070-6; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Chano T, 2006, INT J MOL MED, V18, P425; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Ding QS, 2015, TUMOR BIOL, V36, P8761, DOI 10.1007/s13277-015-3572-2; Dodd KM, 2015, ONCOGENE, V34, P2239, DOI 10.1038/onc.2014.164; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Feng M, 2013, PROTEIN CELL, V4, P142, DOI 10.1007/s13238-012-2088-4; Han S, 2008, CELL SIGNAL, V20, P1084, DOI 10.1016/j.cellsig.2008.01.020; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hu J, 2008, GENE DEV, V22, P866, DOI 10.1101/gad.1624008; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huynh H, 2015, MOL CANCER THER, V14, P1224, DOI 10.1158/1535-7163.MCT-14-0768; Iwai K, 2010, SUBCELL BIOCHEM, V54, P100, DOI 10.1007/978-1-4419-6676-6_8; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kim YH, 2016, BRIT J NEUROSURG, V2016, P1, DOI DOI 10.1155/2016/1489692; Kozakova L, 2015, CELL CYCLE, V14, P920, DOI 10.1080/15384101.2014.1000112; Li H, 2014, TUMOR BIOL, V35, P5747, DOI 10.1007/s13277-014-1763-x; Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388; Ra EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11726; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Shen WC, 2015, AUTOPHAGY, V11, P685, DOI 10.4161/auto.36098; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Sugiura T, 2011, CELL BIOL INT, V35, P657, DOI 10.1042/CBI20100772; Sugiura T, 2008, J CELL BIOCHEM, V105, P1081, DOI 10.1002/jcb.21908; Sun XF, 2013, HEPATOLOGY, V57, P205, DOI 10.1002/hep.25989; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wang Y, 2015, BIOCHEM BIOPH RES CO, V463, P458, DOI 10.1016/j.bbrc.2015.05.117; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Wei Q, 2015, LAB INVEST, V95, P804, DOI 10.1038/labinvest.2015.63; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Wei Q, 2013, PURINERG SIGNAL, V9, P585, DOI 10.1007/s11302-013-9369-0; Yamada D, 2014, J BIOCHEM, V155, P227, DOI 10.1093/jb/mvt112; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Zhang L, 2014, INT J CLIN EXP PATHO, V7, P3887; Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248; Zhao X, 2014, CANCER RES, V74, P2455, DOI 10.1158/0008-5472.CAN-13-3009	40	58	62	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					478	488		10.1038/onc.2017.349	http://dx.doi.org/10.1038/onc.2017.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967907				2022-12-28	WOS:000423331600006
J	Giono, LE; Resnick-Silverman, L; Carvajal, LA; St Clair, S; Manfredi, JJ				Giono, L. E.; Resnick-Silverman, L.; Carvajal, L. A.; St Clair, S.; Manfredi, J. J.			Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase	ONCOGENE			English	Article							INDEPENDENT PROTEASOMAL DEGRADATION; DUAL-SPECIFICITY PHOSPHATASE; UBIQUITIN-DEPENDENT DEGRADATION; INDUCED DOWN-REGULATION; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; ONCOPROTEIN MDM2; S-PHASE; TRANSCRIPTIONAL REPRESSION; EMBRYONIC LETHALITY	Upon different types of stress, the gene encoding the mitosis-promoting phosphatase Cdc25C is transcriptionally repressed by p53, contributing to p53's enforcement of a G2 cell cycle arrest. In addition, Cdc25C protein stability is also decreased following DNA damage. Mdm2, another p53 target gene, encodes a ubiquitin ligase that negatively regulates p53 levels by ubiquitination. Ablation of Mdm2 by siRNA led to an increase in p53 protein and repression of Cdc25C gene expression. However, Cdc25C protein levels were actually increased following Mdm2 depletion. Mdm2 is shown to negatively regulate Cdc25C protein levels by reducing its half-life independently of the presence of p53. Further, Mdm2 physically interacts with Cdc25C and promotes its degradation through the proteasome in a ubiquitin-independent manner. Either Mdm2 overexpression or Cdc25C downregulation delays cell cycle progression through the G2/M phase. Thus, the repression of the Cdc25C promoter by p53, together with p53-dependent induction of Mdm2 and subsequent degradation of Cdc25C, could provide a dual mechanism by which p53 can enforce and maintain a G2/M cell cycle arrest.	Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10021 USA; Icahn Sch Med Mt Sinai, Grad Sch Biol Sci, New York, NY 10021 USA; [Giono, L. E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, Buenos Aires, DF, Argentina; [Giono, L. E.] Univ Buenos Aires, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, Buenos Aires, DF, Argentina; [Carvajal, L. A.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Yeshiva University; Albert Einstein College of Medicine	Manfredi, JJ (corresponding author), Icahn Sch Med Mt Sinai, Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA.	james.manfredi@mssm.edu			National Cancer Institute [F31CA150539, R03CA216466];  [P30CA196521]; NATIONAL CANCER INSTITUTE [R03CA216466, P30CA196521, F31CA150539] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Matthew O'Connell and Zhen-Qiang Pan for their technical advice, helpful discussions and sharing reagents. Present and past members of the Manfredi laboratory: Dana Lukin, Anthony Mastropietro, Wendy Liu, Sejal Patel, Shohreh Varmeh-Ziaie, Pierre-Jacques Hamard and Kester Haye are thanked for their help and support. Quantitative PCR was performed at the Mount Sinai shared research facility. These studies were supported by grants from the National Cancer Institute F31CA150539 to LAC, R03CA216466 to JJM, and developmental support from P30CA196521. Grant support: National Cancer Institute F31CA150539 to LAC, R03CA216466 to JJM, and developmental support from P30CA196521.	Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciznadija D, 2011, CELL CYCLE, V10, P2714, DOI 10.4161/cc.10.16.16725; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Dang JJ, 2002, CANCER RES, V62, P1222; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Eymin B, 2006, CELL CYCLE, V5, P759, DOI 10.4161/cc.5.7.2625; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Folberg-Blum A, 2002, ONCOGENE, V21, P2413, DOI 10.1038/sj.onc.1205305; Garcia P, 1996, ONCOGENE, V13, P695; Giono LE, 2007, MOL CELL BIOL, V27, P4166, DOI 10.1128/MCB.01967-06; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Liu TT, 2012, J BIOL INORG CHEM, V17, P311, DOI 10.1007/s00775-011-0852-1; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Obeyesekere MN, 2004, CELL CYCLE, V3, P655; Ohkubo S, 2006, J BIOL CHEM, V281, P16943, DOI 10.1074/jbc.M601388200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; St Clair S, 2004, MOL CELL, V16, P725; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Thanasoula M, 2012, EMBO J, V31, P3398, DOI 10.1038/emboj.2012.191; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Varmeh-Ziaie S, 2007, J BIOL CHEM, V282, P24633, DOI 10.1074/jbc.M703105200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vecchione A, 2007, CANCER CELL, V11, P275, DOI 10.1016/j.ccr.2007.01.014; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang B, 2010, MOL CELL BIOL, V30, P1508, DOI 10.1128/MCB.01335-09; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Xiao D, 2004, MOL CANCER THER, V3, P567; Xu HX, 2010, J BIOL CHEM, V285, P18407, DOI 10.1074/jbc.M109.059568; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou RZ, 2005, CANCER RES, V65, P1839, DOI 10.1158/0008-5472.CAN-03-3755	82	33	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6762	6773		10.1038/onc.2017.254	http://dx.doi.org/10.1038/onc.2017.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806397	Green Accepted, Green Published			2022-12-28	WOS:000417282500002
J	Li, J; Hu, SB; Wang, LY; Zhang, X; Zhou, X; Yang, B; Li, JH; Xiong, J; Liu, N; Li, Y; Wu, YZ; Zheng, QC				Li, J.; Hu, S. B.; Wang, L. Y.; Zhang, X.; Zhou, X.; Yang, B.; Li, J. H.; Xiong, J.; Liu, N.; Li, Y.; Wu, Y. Z.; Zheng, Q. C.			Autophagy-dependent generation of Axin2+cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA CELLS; SIGNALING PATHWAY; LUNG-CANCER; AXIN2; IDENTIFICATION; PHENOTYPE; TRAITS; EPCAM	Autophagy is a pathophysiological phenomenon in liver cirrhosis that can further progress into hepatocarcinoma. Liver cancer stem cells (CSCs) are believed to initiate hepatocarcinogenesis. To investigate the precise mechanism related to the origin of CSCs in liver cirrhosis and hepatocarcinogenesis, we labeled Axin2+ hepatic cells with EGFP in Axin2Cre;Rosa26EGFP transgenic rats, and then stratified clinical and rat liver cirrhosis samples by autophagy flux. Clinical follow-up and lineage tracing in transgenic rat liver cirrhosis revealed that while Axin2/EGFP+ hepatic cells were present in normal livers and cirrhotic livers without aberrant autophagy, hepatic Axin2/EGFP+CD90+ cells were generated exclusively in cirrhotic livers with aberrant autophagy and promoted hepatocarcinogenesis. Aberrant autophagy in liver cirrhosis resulted in hepatocyte growth factor (HGF) expression, leading to activation of Met/JNK and Met/STAT3 signaling in sorted hepatic Axin2/EGFP+ cells and their transition into Axin2/EGFP+ CD90+ cells that possess CSC properties. In a transgenic rat liver cirrhosis model, induction or inhibition of autophagy in cirrhotic livers by systemic administration of rapamycin or chloroquine or transfection with Atg3- and Atg7-shRNAs significantly induced or suppressed HGF expression, which in turn increased or reduced generation of EGFP+CD90+ hepatic cells by activating or inactivating Met/JNK and Met/STAT3 signaling, thereby promoting or preventing hepatocarcinogenesis. Systemic treatment with HGF-shRNA, SP600125 or stattic also reduced generation of EGFP(Axin2)+ hepatic cell-originated CD90+ CSCs in aberrant autophagic cirrhotic livers by inactivating HGF/Met/JNK or HGF/Met/STAT3 signaling, further preventing hepatocarcinogenesis. These data suggest that activation of Met/JNK and Met/STAT3 signaling in Axin2+ hepatic cells via autophagy-dependent HGF expression and the resultant generation of Axin2+CD90+ CSCs is a major mechanism of hepatocarcinogenesis in cirrhotic livers.	[Li, J.; Liu, N.; Li, Y.] Chongqing Canc Inst & Hosp & Canc Ctr, Dept Urol Oncol Surg, HanYu Rd 181, Chongqing 400030, Peoples R China; [Hu, S. B.; Wang, L. Y.; Zhou, X.; Xiong, J.; Zheng, Q. C.] Huazhong Univ Sci & Technol, Union Hosp, Dept Hepatobiliary Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Zhang, X.] Third Mil Med Univ, Inst Hepatobiliary Surg, Southwest Hosp, Chongqing, Peoples R China; [Yang, B.] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg 2, Coinnovat Ctr Organ Failure Res,State Key Lab Org, Guangzhou, Guangdong, Peoples R China; [Li, J. H.] Huazhong Univ Sci & Technol, Union Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Wu, Y. Z.] Chongqing Canc Inst & Hosp & Canc Ctr, Dept Radiotherapy, Chongqing, Peoples R China	Huazhong University of Science & Technology; Army Medical University; Southern Medical University - China; Huazhong University of Science & Technology	Li, J (corresponding author), Chongqing Canc Inst & Hosp & Canc Ctr, Dept Urol Oncol Surg, HanYu Rd 181, Chongqing 400030, Peoples R China.	herrleej@foxmail.com			National Natural Science Foundation of China [81400674]; China Scholarship Council [201508500057]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council)	This work was supported by the National Natural Science Foundation of China under Grant (No. 81400674) and China Scholarship Council under Grant (No. 201508500057) to JL.	Bourdeau V, 2016, AUTOPHAGY, V12, P1965, DOI 10.1080/15548627.2016.1214779; Bowman AN, 2013, P NATL ACAD SCI USA, V110, P7324, DOI 10.1073/pnas.1305411110; Cao L, 2015, ONCOTARGET, V6, P6627, DOI 10.18632/oncotarget.3113; Capone F, 2014, WORLD J GASTROENTERO, V20, P9261, DOI 10.3748/wjg.v20.i28.9261; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Chai S, 2016, HEPATOLOGY, V64, P2062, DOI 10.1002/hep.28821; Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640; Gong LY, 2016, J PATHOL, V240, P184, DOI 10.1002/path.4767; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kitanaka Chifumi, 2013, Genes Cancer, V4, P388, DOI 10.1177/1947601912474892; Kowalik MA, 2016, ONCOTARGET, V7, P5788, DOI 10.18632/oncotarget.6810; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lim XH, 2016, P NATL ACAD SCI USA, V113, pE1498, DOI 10.1073/pnas.1601599113; Liu D, 2016, ONCOTARGET, V7, P40704, DOI 10.18632/oncotarget.9930; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Martins-Neves SR, 2016, J CELL PHYSIOL, V231, P876, DOI 10.1002/jcp.25179; Oikawa T, 2016, HEPATOLOGY, V64, P645, DOI 10.1002/hep.28485; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Sakai K, 2015, ONCOL LETT, V9, P405, DOI 10.3892/ol.2014.2702; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021; Terris B, 2010, J HEPATOL, V52, P280, DOI 10.1016/j.jhep.2009.10.026; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wiegand J, 2013, DTSCH ARZTEBL INT, V110, P85, DOI 10.3238/arztebl.2013.0085; Wu GY, 2015, ONCOTARGET, V6, P28882, DOI 10.18632/oncotarget.4921; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang ZF, 2008, HEPATOLOGY, V47, P919, DOI 10.1002/hep.22082; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Zhang XZ, 2016, PROCEEDINGS 2016 IEEE INTERNATIONAL CONFERENCE ON INDUSTRIAL TECHNOLOGY (ICIT), P2016, DOI 10.1109/ICIT.2016.7475077; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	36	21	21	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6725	6737		10.1038/onc.2017.272	http://dx.doi.org/10.1038/onc.2017.272			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783177	Green Published, hybrid			2022-12-28	WOS:000416780800007
J	Senturk, JC; Bohlman, S; Manfredi, JJ				Senturk, J. C.; Bohlman, S.; Manfredi, J. J.			Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; GENE AMPLIFICATION; CATALYTIC-ACTIVITY; P-GLYCOPROTEIN; CELL-LINES; CANCER; OVEREXPRESSION; ALPHA; MANAGEMENT; LEUKEMIA	Mdm2 is often overexpressed in tumors that retain wild-type TP53 but may affect therapeutic response independently of p53. Herein is shown that tumor cells with MDM2 amplification are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agents. Tumor cells that overexpress Mdm2 have reduced DNA double-strand breaks in response to doxorubicin or etoposide. This latter result is not due to altered drug uptake. The selective attenuation of DNA damage in response to these agents is dependent on both Mdm2 levels and an intact ubiquitin ligase function. These findings reveal a novel, p53-independent activity of Mdm2 and have important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexpressing tumors.	[Manfredi, J. J.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA; Icahn Sch Med Mt Sinai, Grad Sch Biol Sci, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA.	james.manfredi@mssm.edu			National Cancer Institute [T32CA078207, R03CA216466, P30CA196521]; NATIONAL CANCER INSTITUTE [R03CA216466, T32CA078207, P30CA196521] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank the members of the Manfredi laboratory-Lois Resnick-Silverman, Luis Carvajal, Pierre-Jacques Hamard, Crystal Tonnessen and Nicolas Bartelery-as well as Matthew O'Connell, Miguel Gama-Sosa, Stuart Aaronson and Robert Maki for helpful discussions. We also wish to thank Jonathan Fletcher (Brigham and Women's Hospital) for the LS141 liposarcoma cell line, Ze'ev Ronai (Sanford-Burnham Medical Research Institute) for the expression vector for Flag-tagged Mdm2WT and Shohreh Varmeh for the recombinant Adeno-Mdm2-GFP adenovirus. We wish to thank Carol Prives (Columbia University) for Trp53<SUP>-/-</SUP> MDM2<SUP>+/+</SUP> and Trp53<SUP>-/-</SUP>Mdm2<SUP>-/-</SUP> MEFs. Joseph Tripodi and Vesna Najfeld are gratefully thanked for performing the FISH analysis. These studies were supported by National Cancer Institute grants T32CA078207 to JCS and R03CA216466 to JJM and developmental support from P30CA196521.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Binaschi M, 1998, CANCER RES, V58, P1886; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; Chen W, 2012, DRUG DISCOV THER, V6, P230, DOI 10.5582/ddt.2012.v6.5.230; Cheng QA, 2011, CELL CYCLE, V10, P1162, DOI 10.4161/cc.10.7.15249; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; Chikamori K, 2010, CURR CANCER DRUG TAR, V10, P758, DOI 10.2174/156800910793605785; Conradt L, 2013, INT J CANCER, V132, P2248, DOI 10.1002/ijc.27916; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Dimitriadi M, 2008, BRIT J CANCER, V99, P1144, DOI 10.1038/sj.bjc.6604643; Duhamel LAE, 2012, HISTOPATHOLOGY, V60, P357, DOI 10.1111/j.1365-2559.2011.04023.x; DURAND RE, 1981, CANCER RES, V41, P3489; FRICHE E, 1991, CANCER RES, V51, P4213; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gomez-Herreros F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003226; Grozav AG, 2009, NUCLEIC ACIDS RES, V37, P382, DOI 10.1093/nar/gkn934; Hamard PJ, 2012, J BIOL CHEM, V287, P22397, DOI 10.1074/jbc.M111.331298; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; ISHIDA R, 1995, CANCER RES, V55, P2299; ISSELL BF, 1979, CANCER TREAT REV, V6, P239, DOI 10.1016/S0305-7372(79)80040-7; Ivashkevich A, 2012, CANCER LETT, V327, P123, DOI 10.1016/j.canlet.2011.12.025; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Kondo S, 1996, BRIT J CANCER, V74, P1263, DOI 10.1038/bjc.1996.527; LADANYI M, 1993, CANCER RES, V53, P16; Lamoureux F, 2007, EXPERT REV ANTICANC, V7, P169, DOI 10.1586/14737140.7.2.169; Ledesma FC, 2009, NATURE, V461, P674, DOI 10.1038/nature08444; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUK CK, 1989, JNCI-J NATL CANCER I, V81, P55, DOI 10.1093/jnci/81.1.55; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Movva S, 2011, DRUGS, V71, P2115, DOI 10.2165/11594500-000000000-00000; Nayak MS, 2007, CANCER RES, V67, P5831, DOI 10.1158/0008-5472.CAN-06-4533; Neal JW, 2011, CLIN CHEST MED, V32, P853, DOI 10.1016/j.ccm.2011.07.002; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Ohnstad HO, 2013, CANCER-AM CANCER SOC, V119, P1013, DOI 10.1002/cncr.27837; Onel K, 2004, MOL CANCER RES, V2, P1; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Plo I, 2002, J BIOL CHEM, V277, P31407, DOI 10.1074/jbc.M204654200; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Reis C, 2005, MOL CANCER THER, V4, P1457, DOI 10.1158/1535-7163.MCT-05-0156; RITKE MK, 1995, MOL PHARMACOL, V48, P798; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Vos SM, 2011, NAT REV MOL CELL BIO, V12, P827, DOI 10.1038/nrm3228; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; WATANABE T, 1994, BLOOD, V84, P3158; Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346; Yamazaki K, 1997, CANCER CHEMOTH PHARM, V39, P192; Yeo CQX, 2016, CELL REP, V15, P132, DOI 10.1016/j.celrep.2016.03.011; Zeng ZH, 2011, J BIOL CHEM, V286, P403, DOI 10.1074/jbc.M110.181016	60	8	8	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6085	6096		10.1038/onc.2017.229	http://dx.doi.org/10.1038/onc.2017.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692049	Green Accepted			2022-12-28	WOS:000414249800003
J	Qi, Q; Kang, SS; Zhang, S; Pham, C; Fu, H; Brat, DJ; Ye, K				Qi, Q.; Kang, S. S.; Zhang, S.; Pham, C.; Fu, H.; Brat, D. J.; Ye, K.			Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression	ONCOGENE			English	Article							PIKE-A; GENE; GTPASE; MDM2; CDK4; AMPLIFICATION; INHIBITION; PATHWAYS; GRADE; P53	Glioblastoma (GBM) is the most common primary brain tumor and has a dismal prognosis. Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently observed in numerous human cancers including GBM. Phosphoinositide 3-kinase enhancer (PIKE) is a group of GTP-binding proteins that belong to the subgroup of centaurin GTPase family, encoded by CENTG1 located in CDK4 amplicon. However, the pathological significance of CDK4 amplicon in GBM formation remains incompletely understood. In the current study, we show that co-expression of PIKE-A and CDK4 in TP53/ PTEN double knockout GBM mouse model additively shortens the latency of glioma onset and survival compared to overexpression of these genes alone. Consequently, p-mTOR, p-Akt and p-ERK pathways are highly upregulated in the brain tumors, in alignment with their oncogenic activities by CDK4 and PIKE-A stably transfected in GBM cell lines. Hence, our findings support that PIKE amplification or overexpression coordinately acts with CDK4 to drive GBM tumorigenesis.	[Qi, Q.; Kang, S. S.; Zhang, S.; Brat, D. J.; Ye, K.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA; [Qi, Q.; Pham, C.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Qi, Q.; Pham, C.; Fu, H.] Emory Univ, Sch Med, Emory Chem Biol Discovery Ctr, Atlanta, GA 30322 USA; [Zhang, S.] Jinan Univ, Coll Pharm, Inst Tumor Pharmacol, Guangzhou, Guangdong, Peoples R China; [Fu, H.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Ye, K.] Tongji Univ, Sch Med, Dept Regenerat Med, Translat Ctr Stem Cell Res,Tongji Hosp, Shanghai, Peoples R China	Emory University; Emory University; Emory University; Jinan University; Emory University; Tongji University	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium [HHSN261200800001E]; NIH grant [RO1 CA186918, U01 CA168449]; SBTF Foundation; National Natural Science Foundation of China [81672781]; Winship Cancer Institute of Emory University Cancer Center [P30-CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292, U01CA168449, R01CA186918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [RF1AG051538] Funding Source: NIH RePORTER	Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SBTF Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Winship Cancer Institute of Emory University Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work has been funded in part with Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium Contract HHSN261200800001E (HF; KY), NIH grant RO1 CA186918 (KY), U01 CA168449 (HF), SBTF Foundation (KY), National Natural Science Foundation of China (No. 81672781). We are thankful to Dr Suzanne J. Baker for the PTEN/P53 loxP/loxP mice and to the Winship Cancer Institute of Emory University Cancer Center Support Grant P30-CA138292.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Feng CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090388; Grzmil M, 2010, BBA-PROTEINS PROTEOM, V1804, P476, DOI 10.1016/j.bbapap.2009.10.018; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; Ivanov AA, 2013, TRENDS PHARMACOL SCI, V34, P393, DOI 10.1016/j.tips.2013.04.007; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; LANG FF, 1994, ONCOGENE, V9, P949; Liu R, 2008, P NATL ACAD SCI USA, V105, P7570, DOI 10.1073/pnas.0712306105; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Ma ZN, 2016, ONCOTARGET, V7, P66558, DOI 10.18632/oncotarget.11684; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Muranen T, 2016, CANCER RES, V76, P7168, DOI 10.1158/0008-5472.CAN-16-0155; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Network The Cancer Genome Atlas Research, 2013, Nature, V494, P506, DOI 10.1038/nature11903; Pathak P, 2016, BRAIN PATHOL; Proescholdt MA, 2012, NEURO-ONCOLOGY, V14, P1357, DOI 10.1093/neuonc/nos216; Qi Q, 2013, ONCOGENE, V32, P1030, DOI 10.1038/onc.2012.109; Reifenberger G, 1996, CANCER RES, V56, P5141; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Uras N, 2012, J OBSTET GYNAECOL, V32, P533, DOI 10.3109/01443615.2012.677875; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wikman H, 2005, GENE CHROMOSOME CANC, V42, P193, DOI 10.1002/gcc.20122; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2004, J CELL SCI, V117, P155, DOI 10.1242/jcs.00924; Zhang S, 2016, CELL DEATH DIFFER, V23, P52, DOI 10.1038/cdd.2015.66; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	32	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4562	4572		10.1038/onc.2017.67	http://dx.doi.org/10.1038/onc.2017.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368413	Green Accepted			2022-12-28	WOS:000407246200004
J	Ueno, N; Nishimura, N; Ueno, S; Endo, S; Tatetsu, H; Hirata, S; Hata, H; Matsuoka, M; Mitsuya, H; Okuno, Y				Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.			PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4	ONCOGENE			English	Article							REGULATORY FACTOR FAMILY; MULTIPLE-MYELOMA; DISTAL ELEMENTS; GENE; PROTEINS; EXPRESSION; SURVIVAL; IDENTIFICATION; THALIDOMIDE; MECHANISM	We previously reported that PU.1 is downregulated in the majority of myeloma cell lines and primary myeloma cells of certain myeloma patients, and conditional expression of PU.1 in such myeloma cell lines induced cell cycle arrest and apoptosis. We found downregulation of IRF4 protein in the U266 myeloma cell line following induction of PU.1. Previous studies reported that knockdown of IRF4 in myeloma cell lines induces apoptosis, prompting us to further investigate the role of IRF4 downregulation in PU.1-induced cell cycle arrest and apoptosis in myeloma cells. PU. 1 induced downregulation of IRF4 at the protein level, cell cycle arrest and apoptosis in six myeloma cell lines. Chromatin immunoprecipitation (ChIP) revealed that PU.1 directly binds to the IRF4 promoter, whereas a reporter assay showed that PU.1 may suppress IRF4 promoter activity. Stable expression of IRF4 in myeloma cells expressing PU.1 partially rescued the cells from apoptosis induced by PU.1. As it was reported that IRF4 directly binds to the IRF7 promoter and downregulates its expression in activated B cell-like subtype of diffuse large B cell lymphoma cells, we performed ChIP assays and found that IRF4 directly binds the IRF7 promoter in myeloma cells. It is known that IRF7 positively upregulates interferon-beta (IFN beta) and induces apoptosis in many cell types. Binding of IRF4 to the IRF7 promoter decreased following PU.1 induction, accompanied by downregulation of IRF4 protein expression. Knockdown of IRF7 protected PU.1-expressing myeloma cells from apoptosis. Furthermore, IFN beta, which is a downstream target of IRF7, was upregulated in myeloma cells along with IRF7 after PU.1 induction. Finally, we evaluated the mRNA expression levels of PU.1, IRF4 and IRF7 in primary myeloma cells from patients and found that PU.1 and IRF7 were strongly downregulated in contrast to the high expression levels of IRF4. These data strongly suggest that PU.1-induced apoptosis in myeloma cells is associated with IRF4 downregulation and subsequent IRF7 upregulation.	[Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Hematol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Rheumatol & Infect Dis, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Okuno, Y (corresponding author), Kumamoto Univ, Grad Sch Med, Dept Hematol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.; Okuno, Y (corresponding author), Kumamoto Univ, Grad Sch Med, Dept Rheumatol & Infect Dis, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	yokuno@gpo.kumamoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI) [26461427]	Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI grant number 26461427).	Brugnoli F, 2010, EXP CELL RES, V316, P38, DOI 10.1016/j.yexcr.2009.09.004; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Desai S, 2009, J IMMUNOL, V183, P5778, DOI 10.4049/jimmunol.0901120; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Endo S, 2016, BIOCHEM BIOPH RES CO, V469, P236, DOI 10.1016/j.bbrc.2015.11.116; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Kaufman RM, 1999, BLOOD, V94, P3178, DOI 10.1182/blood.V94.9.3178.421k23_3178_3184; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lehtonen A, 2005, J IMMUNOL, V175, P6570, DOI 10.4049/jimmunol.175.10.6570; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Lopez-Girona A, 2011, BRIT J HAEMATOL, V154, P325, DOI 10.1111/j.1365-2141.2011.08689.x; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Ochiai K, 2013, IMMUNITY, V38, P918, DOI 10.1016/j.immuni.2013.04.009; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; Ozato K, 2007, J BIOL CHEM, V282, P20065, DOI 10.1074/jbc.R700003200; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood-2007-10-117457; Palumbo A, 2014, J CLIN ONCOL, V32, P587, DOI 10.1200/JCO.2013.48.7934; Piya S, 2011, MOL CANCER RES, V9, P1356, DOI 10.1158/1541-7786.MCR-11-0185; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Savickiene J, 2011, DIFFERENTIATION, V81, P57, DOI 10.1016/j.diff.2010.08.003; Schonheit J, 2013, CELL REP, V3, P1617, DOI 10.1016/j.celrep.2013.04.007; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Takaoka A, 2008, CANCER SCI, V99, P467, DOI 10.1111/j.1349-7006.2007.00720.x; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Ueno S, 2009, ONCOGENE, V28, P4116, DOI 10.1038/onc.2009.263; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Yuki H, 2013, BLOOD, V121, P962, DOI 10.1182/blood-2012-05-431429; Zhu YX, 2014, BLOOD, V124, P536, DOI 10.1182/blood-2014-02-557819	47	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4481	4497		10.1038/onc.2017.79	http://dx.doi.org/10.1038/onc.2017.79			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368411				2022-12-28	WOS:000406806000010
J	Principe, DR; Diaz, AM; Torres, C; Mangan, RJ; DeCant, B; McKinney, R; Tsao, MS; Lowy, A; Munshi, HG; Jung, B; Grippo, PJ				Principe, D. R.; Diaz, A. M.; Torres, C.; Mangan, R. J.; DeCant, B.; McKinney, R.; Tsao, M-S; Lowy, A.; Munshi, H. G.; Jung, B.; Grippo, P. J.			TGF beta engages MEK/ERK to differentially regulate benign and malignant pancreas cell function	ONCOGENE			English	Article							ERK MAP KINASE; SIGNALING PATHWAYS; CANCER CELLS; RAS; INHIBITION; EXPRESSION; P21; PROMOTES; ARREST; TRANSCRIPTION	While TGF beta signals are anti-proliferative in benign and well-differentiated pancreatic cells, TGF beta appears to promote the progression of advanced cancers. To better understand dysregulation of the TGF beta pathway, we first generated mouse models of neoplastic disease with TGF beta receptor deficiencies. These models displayed reduced levels of pERK irrespective of KRAS mutation. Furthermore, exogenous TGF beta led to rapid and sustained TGFBR1-dependent ERK phosphorylation in benign pancreatic duct cells. Similar to results that our group has published in colon cancer cells, inhibition of ERK phosphorylation in duct cells mitigated TGF beta-induced upregulation of growth suppressive pSMAD2 and p21, prevented downregulation of the pro-growth signal CDK2 and ablated TGF beta-induced EMT. These observations suggest that ERK is a key factor in growth suppressive TGF beta signals, yet may also contribute to detrimental TGF beta signaling such as EMT. In neoplastic PanIN cells, pERK was not necessary for either TGF beta-induced pSMAD2 phosphorylation or CDK2 repression, but was required for upregulation of p21 and EMT indicating a partial divergence between TGF beta and MEK/ERK in early carcinogenesis. In cancer cells, pERK had no effect on TGF beta-induced upregulation of pSMAD2 and p21, suggesting the two pathways have completely diverged with respect to the cell cycle. Furthermore, inhibition of pERK both reduced levels of CDK2 and prevented EMT independent of exogenous TGF beta, consistent with most observations identifying pERK as a tumor promoter. Combined, these data suggest that during carcinogenesis pERK initially facilitates and later antagonizes TGF beta-mediated cell cycle arrest, yet remains critical for the pathological, EMT-inducing arm of TGF beta signaling.	[Principe, D. R.] Univ Illinois, Coll Med, Chicago, IL USA; [Diaz, A. M.; Torres, C.; Mangan, R. J.; DeCant, B.; McKinney, R.; Jung, B.; Grippo, P. J.] Univ Illinois, Dept Med, Chicago, IL USA; [Tsao, M-S] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON, Canada; [Lowy, A.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Munshi, H. G.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of California System; University of California San Diego; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Principe, DR (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 South Wood St,738A CSB, Chicago, IL 60612 USA.; Grippo, PJ (corresponding author), Univ Illinois, Dept Med, Div Gastroenterol & Hepatol, 840 South Wood St,738A CSB, Chicago, IL 60612 USA.	principe@illinois.edu; pgrippo@uic.edu	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Torres, Carolina/M-1169-2014	Tsao, Ming Sound/0000-0002-9160-5405; Torres, Carolina/0000-0002-7908-6884	Barnum Foundation at Northwestern University; University of Illinois College of Medicine Hazel I. Craig fellowship; Zell Family Foundation at Northwestern University	Barnum Foundation at Northwestern University; University of Illinois College of Medicine Hazel I. Craig fellowship; Zell Family Foundation at Northwestern University	This work is dedicated to the memory of our friend Daniel Wang, who recently lost his long and courageous fight with cancer. We appreciate the contributions of Dr Nancy Krett for her critical evaluation of our work. The authors would also like to thank undergraduate students Carol Cavarson, Saminder Singh, Jacob Hoekstra, Danielle Calloway and Matthew J. Michalik for their hard work, as well as Dr Steven Waters (University of Illinois at Chicago) for his assistance with genotyping. This work was supported by the Barnum and Zell Family Foundations at Northwestern University to PG and the University of Illinois College of Medicine Hazel I. Craig fellowship to DP.	Bachmann J, 2013, NUTR CANCER, V65, P827, DOI 10.1080/01635581.2013.804580; Bauer J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0456-4; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buonato JM, 2014, CANCER RES, V74, P309, DOI 10.1158/0008-5472.CAN-12-4721; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Chow JYC, 2007, CARCINOGENESIS, V28, P2321, DOI 10.1093/carcin/bgm159; Ciccarelli C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-41; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grabliauskaite K, 2015, J PATHOL, V235, P502, DOI 10.1002/path.4440; Hashimoto K, 2001, PANCREAS, V22, P341, DOI 10.1097/00006676-200105000-00002; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Neuzillet C, 2013, CANCER METAST REV, V32, P147, DOI 10.1007/s10555-012-9396-2; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Principe D. R., 2016, ONCOTARGET; Principe DR, 2016, CANCER RES, V76, P2525, DOI 10.1158/0008-5472.CAN-15-1293; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Shen RZ, 2013, CANCER LETT, V339, P135, DOI 10.1016/j.canlet.2013.07.010; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Voss M, 1999, INT J ONCOL, V14, P93; Warmflash A, 2012, P NATL ACAD SCI USA, V109, pE1947, DOI 10.1073/pnas.1207607109; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Yasutome M, 2005, CLIN EXP METASTAS, V22, P461, DOI 10.1007/s10585-005-2891-x; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhou QD, 2012, J MOL MED, V90, P563, DOI 10.1007/s00109-011-0833-4	39	42	42	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4336	4348		10.1038/onc.2016.500	http://dx.doi.org/10.1038/onc.2016.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368414	Green Published, hybrid			2022-12-28	WOS:000406360600010
J	Natsume, A; Kato, T; Kinjo, S; Enomoto, A; Toda, H; Shimato, S; Ohka, F; Motomura, K; Kondo, Y; Miyata, T; Takahashi, M; Wakabayashi, T				Natsume, A.; Kato, T.; Kinjo, S.; Enomoto, A.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Kondo, Y.; Miyata, T.; Takahashi, M.; Wakabayashi, T.			Girdin maintains the stemness of glioblastoma stem cells (vol 31, pg 2715, 2012)	ONCOGENE			English	Correction													Motomura, Kazuya/AAF-8776-2021; Ohka, Fumiharu/A-3420-2016; Enomoto, Atsushi/I-7272-2014; Natsume, Atsushi/I-7364-2014	Motomura, Kazuya/0000-0002-4376-1104; Enomoto, Atsushi/0000-0002-9206-6116; Natsume, Atsushi/0000-0002-9113-0470; Ohka, Fumiharu/0000-0002-5569-5626				Natsume A, 2012, ONCOGENE, V31, P2715, DOI 10.1038/onc.2011.466	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3796	3796		10.1038/onc.2017.17	http://dx.doi.org/10.1038/onc.2017.17			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218901	Bronze			2022-12-28	WOS:000404349700015
J	Zhou, Y; Wang, L; Ban, X; Zeng, T; Zhu, Y; Li, M; Guan, XY; Li, Y				Zhou, Y.; Wang, L.; Ban, X.; Zeng, T.; Zhu, Y.; Li, M.; Guan, X-Y; Li, Y.			DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma	ONCOGENE			English	Article							CANCER CELL; DOWN-REGULATION; BREAST-CANCER; GENE; EXPRESSION; FAMILY; HEP27; ACTIVATION; PROTEINS; INVASION	Esophageal squamous cell carcinoma (ESCC) is highly prevailing in Asia and it is ranked in the most aggressive squamous cell carcinomas. High-frequency loss of heterozygosity occurred in chromosome 14q11.2 in many tumors including ESCC, suggesting that one or more tumor-suppressor genes might exist within this region. In this study, we identified the tumor-suppressing role of DHRS2 (short-chain dehydrogenase/reductase family, member 2) at 14q11.2 in ESCCs. Downregulation of DHRS2 occurred in 30.8% of primary ESCC tumor tissues vs paired non-tumorous tissues. DHRS2 downregulation was associated significantly with ESCC invasion, lymph nodes metastasis and clinical staging (P<0.001). Survival analysis revealed that DHRS2 downregulation was significantly associated with worse outcome of patients with ESCC. In vitro and in vivo studies indicated that both DHRS2 variants could suppress cell proliferation and cell motility. Moreover, we demonstrated that DHRS2 could reduce reactive oxygen species and decrease nicotinamide adenine dinucleotide phosphate (oxidized/reduced), increase p53 stability and decrease Rb phosphorylation; it also decreased p38 mitogen-activated protein kinase phosphorylation and matrix metalloproteinase 2. In summary, these findings demonstrated that DHRS2 had an important part in ESCC development and progression.	[Zhou, Y.; Wang, L.; Ban, X.; Zeng, T.; Zhu, Y.; Li, M.; Guan, X-Y; Li, Y.] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, Y.] Guangdong Esophageal Canc Inst, Guangzhou, Guangdong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Hong Kong	Guan, XY; Li, Y (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	xyguan@hku.hk; liy6@mail.sysu.edu.cn	/A-3639-2009	/0000-0003-1874-9805	National Natural Science Foundation of China [81472255, 81472250]; Guangdong Esophageal Cancer Institute [M201511]; Guangdong Science and Technology Foundation [2016A020214008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Esophageal Cancer Institute; Guangdong Science and Technology Foundation	This research was supported by the National Natural Science Foundation of China (81472255 and 81472250); Guangdong Esophageal Cancer Institute Funding (M201511); Guangdong Science and Technology Foundation (2016A020214008).	Alberghina L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.513; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Binker MG, 2009, BIOCHEM BIOPH RES CO, V379, P445, DOI 10.1016/j.bbrc.2008.12.080; Bjorkqvist AM, 1999, BRIT J CANCER, V81, P1111, DOI 10.1038/sj.bjc.6690816; Bray JE, 2009, CHEM-BIOL INTERACT, V178, P99, DOI 10.1016/j.cbi.2008.10.058; Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015; Crean D, 2012, MOL CELL BIOCHEM, V366, P231, DOI 10.1007/s11010-012-1300-4; Deblec-Rychter M, 2001, GENE CHROMOSOME CANC, V32, P26; Deisenroth C, 2010, MOL CELL BIOL, V30, P3981, DOI 10.1128/MCB.01284-09; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C; Fang L, 2016, CANCER BIOL THER, V17, P664, DOI 10.1080/15384047.2016.1190485; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; GABRIELLI F, 1995, EUR J BIOCHEM, V232, P473, DOI 10.1111/j.1432-1033.1995.tb20833.x; Gabrielli F, 2012, GENE, V511, P461, DOI 10.1016/j.gene.2012.09.013; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Guan XY, 2001, CANCER RES, V61, P3806; Hu L, 2016, TUMOR BIOL, V37, P837, DOI 10.1007/s13277-015-3880-6; Hurd TR, 2012, TRENDS CELL BIOL, V22, P107, DOI 10.1016/j.tcb.2011.11.002; Li J, 2014, INT J BIOL SCI, V10, P142, DOI 10.7150/ijbs.7727; Li Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060027; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Nishikawa M, 2008, CANCER LETT, V266, P53, DOI 10.1016/j.canlet.2008.02.031; Oppermann U, 2007, ANNU REV PHARMACOL, V47, P293, DOI 10.1146/annurev.pharmtox.47.120505.105316; Pelicano H, 2009, CANCER RES, V69, P2375, DOI 10.1158/0008-5472.CAN-08-3359; Pellegrini S, 2002, BBA-GENE STRUCT EXPR, V1574, P215, DOI 10.1016/S0167-4781(01)00323-2; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Shafqat N, 2006, CELL MOL LIFE SCI, V63, P1205, DOI 10.1007/s00018-006-6013-y; Shao JY, 2001, ANTICANCER RES, V21, P3021; Shi ZZ, 2014, CLIN TRANSL ONCOL, V16, P606, DOI 10.1007/s12094-013-1124-z; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tochhawng L, 2013, MITOCHONDRION, V13, P246, DOI 10.1016/j.mito.2012.08.002; Wang J, 2017, INT J CANCER, V140, P2484, DOI 10.1002/ijc.30680; Wang P, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0012-z; Wong ML, 2006, INT J ONCOL, V28, P767; Wu XQ, 2007, MOL CELL ENDOCRINOL, V265, P71, DOI 10.1016/j.mce.2006.12.006	38	27	29	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1086	1094		10.1038/onc.2017.383	http://dx.doi.org/10.1038/onc.2017.383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106393	Green Published, hybrid			2022-12-28	WOS:000425905700011
J	Zhou, H; Qin, Y; Ji, S; Ling, J; Fu, J; Zhuang, Z; Fan, X; Song, L; Yu, X; Chiao, PJ				Zhou, H.; Qin, Y.; Ji, S.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Song, L.; Yu, X.; Chiao, P. J.			SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; UP-REGULATION; DNA-DAMAGE; INHIBITION; ACTIVATION; CARCINOMA	SRY (sex determining region Y)-box 9 (SOX9) is required for oncogenic Kras-mediated acinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasias (PanINs) and ultimately pancreatic ductal adenocarcinoma (PDAC). However, how oncogenic Kras affects SOX9 activity is not yet understood, and SOX9-associated genes in PDAC are also unknown at all. Here, we investigated the mechanistic link between SOX9 and oncogenic Kras, studied biological function of SOX9, and identified SOX9-related genes and their clinical significance in patients with PDAC. Our studies reveal that oncogenic Kras induces SOX9 mRNA and protein expression as well as phosphorylated SOX9 expression in human pancreatic ductal progenitor cells (HPNE) and pancreatic ductal cells (HPDE). Moreover, oncogenic Kras promoted nuclear translocation and transcriptional activity of SOX9 in these cells. TAK1/I kappa Ba/NF-kappa B pathway contributed to induction of SOX9 by oncogenic Kras, and SOX9 in turn enhanced NF-kappa B activation. SOX9 promoted the proliferation of HPNE and PDAC cells, and correlated with minichromosome maintenance complex components (MCMs) and mediator of DNA damage checkpoint 1 (MDC1) expression. The overexpressive MDC1 was associated with less perineural and lymph node invasion of tumors and early TNM-stage of patients. Our results indicate that oncogenic Kras induces constitutive activation of SOX9 in HPNE and HPDE cells, and Kras/TAK1/I kappa Ba/NF-kappa B pathway and a positive feedback between SOX9 and NF-kappa B are involved in this inducing process. SOX9 accelerates proliferation of cells and affects MCMs and MDC1 expression. MDC1 is associated negatively with invasion and metastasis of PDAC.	[Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Chiao, P. J.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107,1515 Holcombe Blvd, Houston, TX 77030 USA; [Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Chiao, P. J.] Fudan Univ, Liver Canc Inst, Shanghai, Peoples R China; [Zhou, H.; Ling, J.; Fu, J.; Zhuang, Z.; Fan, X.; Chiao, P. J.] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Qin, Y.; Ji, S.; Yu, X.] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200032, Peoples R China; [Qin, Y.; Ji, S.; Yu, X.] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Zhuang, Z.] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Dept Gen Surg, Beijing, Peoples R China; [Song, L.] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China; [Chiao, P. J.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Fudan University; Fudan University; Fudan University; Fudan University; Tsinghua University; Zhengzhou University; University of Texas System; University of Texas Health Science Center Houston	Chiao, PJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107,1515 Holcombe Blvd, Houston, TX 77030 USA.; Yu, X (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200032, Peoples R China.	yuxianjun@fudan.edu.cn; pjchiao@mdanderson.org			Skip Viragh foundation; National Cancer Institute [CA109405, CA142674]; Cancer Center Core Supporting grant [CA16672]; China National Natural Science Foundation [81272733]; NATIONAL CANCER INSTITUTE [R01CA207031, P30CA016672] Funding Source: NIH RePORTER	Skip Viragh foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Core Supporting grant; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jun Yao in the Department of Biostatistics, MD Anderson Cancer Center, for statistical analysis of data from RNA-seq. This work was supported in part by grants from Skip Viragh foundation (to PJC), the National Cancer Institute (CA109405 and CA142674 to PJC), a Cancer Center Core Supporting grant (CA16672) and China National Natural Science Foundation (81272733).	Belo J, 2013, STEM CELLS DEV, V22, P2935, DOI 10.1089/scd.2013.0106; Chang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101452; Chang Z, 2013, CLIN CANCER RES, V19, P549, DOI 10.1158/1078-0432.CCR-12-0032; Chen LM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1234570; Coster G, 2010, NUCLEUS-PHILA, V1, P166, DOI 10.4161/nucl.1.2.11176; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Espersen MLM, 2016, HUM PATHOL, V52, P38, DOI 10.1016/j.humpath.2015.12.026; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo D, 2012, MOL CELL BIOCHEM, V363, P179, DOI 10.1007/s11010-011-1170-1; Hong YC, 2015, ONCOTARGET, V6, P31241, DOI 10.18632/oncotarget.5160; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kim JE, 2006, MOL CARCINOGEN, V45, P403, DOI 10.1002/mc.20221; Kist R., MUS MUSCULUS SRY BOX; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Lei M, 2001, J CELL SCI, V114, P1447; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Melisi D, 2007, EXPERT OPIN THER TAR, V11, P133, DOI 10.1517/14728222.11.2.133; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Melisi D, 2009, MOL CANCER RES, V7, P624, DOI 10.1158/1541-7786.MCR-08-0201; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Piper K, 2002, MECH DEVELOP, V116, P223, DOI 10.1016/S0925-4773(02)00145-4; Saegusa M, 2012, AM J PATHOL, V181, P684, DOI 10.1016/j.ajpath.2012.05.008; Simon NE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/549719; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Wang CY, 2015, NUCLEIC ACIDS RES, V43, P4893, DOI 10.1093/nar/gkv394; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Xia SH, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0358-0; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhou HJ, 2010, GUT, V59, P1699, DOI 10.1136/gut.2010.218404; Zou RL, 2015, INT J BIOL SCI, V11, P992, DOI 10.7150/ijbs.10918	40	33	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					912	923		10.1038/onc.2017.393	http://dx.doi.org/10.1038/onc.2017.393			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059173	Green Accepted			2022-12-28	WOS:000425281800008
J	Holmes, B; Benavides-Serrato, A; Freeman, RS; Landon, KA; Bashir, T; Nishimura, RN; Gera, J				Holmes, B.; Benavides-Serrato, A.; Freeman, R. S.; Landon, K. A.; Bashir, T.; Nishimura, R. N.; Gera, J.			mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma	ONCOGENE			English	Article							MTOR COMPLEX 2; HEAT-SHOCK; RICH ELEMENTS; CYCLIN D1; PTEN LOSS; AKT; CANCER; HSF1; TRANSLATION; PATHWAY	Overexpression of Rictor has been demonstrated to result in increased mechanistic target of rapamycin C2 (mTORC2) nucleation and activity leading to tumor growth and increased invasive characteristics in glioblastoma multiforme (GBM). However, the mechanisms regulating Rictor expression in these tumors is not clearly understood. In this report, we demonstrate that Rictor is regulated at the level of mRNA translation via heat-shock transcription factor 1 (HSF1)-induced HuR activity. HuR is shown to directly bind the 3' untranslated region of the Rictor transcript and enhance translational efficiency. Moreover, we demonstrate that mTORC2/AKT signaling activates HSF1 resulting in a feed-forward cascade in which continued mTORC2 activity is able to drive Rictor expression. RNAi-mediated blockade of AKT, HSF1 or HuR is sufficient to downregulate Rictor and inhibit GBM growth and invasive characteristics in vitro and suppress xenograft growth in mice. Modulation of AKT or HSF1 activity via the ectopic expression of mutant alleles support the ability of AKT to activate HSF1 and demonstrate continued HSF1/HuR/Rictor signaling in the context of AKT knockdown. We further show that constitutive overexpression of HuR is able to maintain Rictor expression under conditions of AKT or HSF1 loss. The expression of these components is also examined in patient GBM samples and correlative associations between the relative expression of these factors support the presence of these signaling relationships in GBM. These data support a role for a feed-forward loop mechanism by which mTORC2 activity stimulates Rictor translational efficiency via an AKT/HSF1/HuR signaling cascade resulting in enhanced mTORC2 activity in these tumors.	[Holmes, B.; Benavides-Serrato, A.; Gera, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Holmes, B.; Benavides-Serrato, A.; Freeman, R. S.; Landon, K. A.; Bashir, T.; Nishimura, R. N.; Gera, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA; [Nishimura, R. N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Gera, J.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Gera, J.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gera, J (corresponding author), Greater Los Angeles VA Healthcare Syst, Dept Hematol Oncol, 16111 Plummer St 151,Bldg 1,Room C111A, Los Angeles, CA 91343 USA.	gera@ucla.edu		Holmes, Brent/0000-0002-2768-2991; Gera, Joseph/0000-0002-2908-6894	VA MERIT grant [I01BX002665]; NIH grant [R01CA109312]; NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002665] Funding Source: NIH RePORTER	VA MERIT grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Eugene Kandel, Dr Jacob Fleischmann, Dr Norimoto Yanagawa, Dr Sanjai Sharma and Dr Paul Mischel for cell lines and reagents. We also thank Dr Alan Lichtenstein for comments on the manuscript and Jheralyn Martin and Janine Masri for technical assistance. This work was supported, in whole or in part, by VA MERIT I01BX002665 and NIH R01CA109312 grants.	Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bashir T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047741; Bhattacharya K, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.34; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Cheng HY, 2015, CANCER DISCOV, V5, P1262, DOI 10.1158/2159-8290.CD-14-0971; Chou SD, 2015, ONCOGENE, V34, P2178, DOI 10.1038/onc.2014.177; Cloninger C, 2011, MOL CANCER THER, V10, P2244, DOI 10.1158/1535-7163.MCT-11-0478; Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005; Dai CK, 2012, J CLIN INVEST, V122, P3742, DOI 10.1172/JCI62727; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Driscoll DR, 2016, CANCER RES, V76, P6911, DOI 10.1158/0008-5472.CAN-16-0810; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Gibault L, 2012, MODERN PATHOL, V25, P197, DOI 10.1038/modpathol.2011.163; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Holmes B, 2016, J BIOL CHEM, V291, P14146, DOI 10.1074/jbc.M116.726927; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Koo J, 2015, J BIOL CHEM, V290, P14120, DOI 10.1074/jbc.M114.633057; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Leach MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11704; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Masui K, 2016, BIOESSAYS, V38, P839, DOI 10.1002/bies.201600026; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Nabors LB, 2001, CANCER RES, V61, P2154; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Read RD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003253; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Vartanian R, 2011, MOL CANCER RES, V9, P115, DOI 10.1158/1541-7786.MCR-10-0105; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wu Si-Han, 2014, Cancer Biology Medicine, V11, P255, DOI 10.7497/j.issn.2095-3941.2014.04.004; Yasuda K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142943; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	42	32	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					732	743		10.1038/onc.2017.360	http://dx.doi.org/10.1038/onc.2017.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059166	Green Accepted, Green Submitted			2022-12-28	WOS:000424628100005
J	Ortiz, GJ; Li, Y; Post, SM; Pant, V; Xiong, S; Larsson, CA; El-Naggar, AK; Johnson, DG; Lozano, G				Ortiz, G. J.; Li, Y.; Post, S. M.; Pant, V.; Xiong, S.; Larsson, C. A.; El-Naggar, A. K.; Johnson, D. G.; Lozano, G.			Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; CODON 72 POLYMORPHISM; CANCER-RISK; P53 PATHWAY; PROMOTER POLYMORPHISM; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; IONIZING-RADIATION; COLORECTAL-CANCER	MDM2, an E3 ubiquitin ligase, is a potent inhibitor of the p53 tumor suppressor and is elevated in many human cancers that retain wild-type p53. MDM2 SNP309G is a functional polymorphism that results in elevated levels of MDM2 (due to enhanced SP1 binding to the MDM2 promoter) thus decreasing p53 activity. Mdm2SNP309G/G mice are more prone to spontaneous tumor formation than Mdm2SNP309T/T mice, providing direct evidence for the impact of this SNP in tumor development. We asked whether environmental factors impact SNP309G function and show that SNP309G cooperates with ionizing radiation to exacerbate tumor development. Surprisingly, ultraviolet B light or Benzo(a) pyrene exposure of skin shows that SNP309G allele actually protects against squamous cell carcinoma susceptibility. These contrasting differences led us to interrogate the mechanism by which Mdm2 SNP309 regulates tumor susceptibility in a tissue-specific manner. Although basal Mdm2 levels were significantly higher in most tissues in Mdm2SNP309G/G mice compared with Mdm2SNP309T/T mice, they were significantly lower in Mdm2SNP309G/G keratinocytes, the cell-type susceptible to squamous cell carcinoma. The assessment of potential transcriptional regulators in ENCODE ChIP-seq database identified transcriptional repressor E2F6 as a possible negative regulator of MDM2 expression. Our data show that E2F6 suppresses Mdm2 expression in cells harboring the SNP309G allele but not the SNP309T allele. Thus, Mdm2 SNP309G exhibits tissue-specific regulation and differentially impacts cancer risk.	[Ortiz, G. J.; Pant, V.; Xiong, S.; Larsson, C. A.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Ortiz, G. J.; Larsson, C. A.; Johnson, D. G.; Lozano, G.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Li, Y.; Johnson, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Virginia Harris Cockrell Canc Res Ctr, Smithville, TX USA; [Post, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc, Dept Pathol, Div Pathol Lab Med Unit 085, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Johnson, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1808 Pk Rd 1C,POB 389,Unit 116, Smithville, TX 78957 USA.	djohnson@mdanderson.org; gglozano@mdanderson.org	Xiong, Shunbin/AAR-5823-2021; Ortiz, Guadalupe/P-9425-2017	Ortiz, Guadalupe/0000-0002-8728-5090; Pant, Vinod/0000-0002-3286-1804; Larsson, Connie/0000-0002-7829-0023	NIH [R01ES015587, CA47296]; Cancer Prevention Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [R01CA047296, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015587] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Laura Pageon (MD Anderson Cancer Center) for her pathology advice, Jen Orona for assistance with mouse studies and the members of the Lozano lab for their support and technical advice. NIH Grants R01ES015587 (DGJ), CA47296 (GL) and the Cancer Prevention Institute of Texas (CPRIT) supported this study.	Alvarez S, 2006, INT J RADIAT BIOL, V82, P761, DOI 10.1080/09553000600949624; Asomaning K, 2008, CLIN CANCER RES, V14, P4010, DOI 10.1158/1078-0432.CCR-07-4187; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Azzam GA, 2011, CELL CYCLE, V10, P1352, DOI 10.4161/cc.10.9.15344; Bassi DE, 2007, CURR PROTOC PHARM; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cotignola J, 2012, J INVEST DERMATOL, V132, P1471, DOI 10.1038/jid.2012.15; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eischen CM, 2014, HUM MUTAT, V35, P728, DOI 10.1002/humu.22524; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Glick A, 2007, MOL CARCINOGEN, V46, P605, DOI 10.1002/mc.20345; Hakkinen Lari, 2001, Methods in Cell Science, V23, P189, DOI 10.1023/A:1016385109922; Hu ZB, 2007, CANCER EPIDEM BIOMAR, V16, P2717, DOI 10.1158/1055-9965.EPI-07-0634; Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lazarus P, 1998, CARCINOGENESIS, V19, P509, DOI 10.1093/carcin/19.3.509; Li Guojun, 2006, Curr Oncol Rep, V8, P130, DOI 10.1007/s11912-006-0048-y; Liu GY, 2012, INT J UROL, V19, P914, DOI 10.1111/j.1442-2042.2012.03067.x; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu MX, 2012, MOL CARCINOGEN, V51, pE132, DOI 10.1002/mc.21882; LUNA RMD, 1995, NATURE, V378, P203; MAUTHE RJ, 1995, CARCINOGENESIS, V16, P133, DOI 10.1093/carcin/16.1.133; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MIYASHITA T, 1995, CELL, V80, P293; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003; Pittman AM, 2009, GENOME RES, V19, P987, DOI 10.1101/gr.092668.109; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Qin JX, 2015, J DERMATOL SCI, V79, P171, DOI 10.1016/j.jdermsci.2015.04.008; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Ramzi NH, 2014, INDIAN J MED RES, V139, P873; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Russell JL, 2006, ONCOGENE, V25, P867, DOI 10.1038/sj.onc.1209120; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Stracquadanio G, 2016, NAT REV CANCER, V16, P251, DOI 10.1038/nrc.2016.15; Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wasylishen AR, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026211; Wo XM, 2011, J GENET GENOMICS, V38, P341, DOI 10.1016/j.jgg.2011.07.005; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Yang X, 2016, MOL CLIN ONCOL, V5, P175, DOI 10.3892/mco.2016.868; Yu HP, 2011, MOL CARCINOGEN, V50, P697, DOI 10.1002/mc.20806	53	10	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					332	340		10.1038/onc.2017.344	http://dx.doi.org/10.1038/onc.2017.344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925402	Green Accepted, Green Submitted			2022-12-28	WOS:000422753900006
J	Stelloo, S; Nevedomskaya, E; Kim, Y; Hoekman, L; Bleijerveld, OB; Mirza, T; Wessels, LFA; van Weerden, WM; Altelaar, AFM; Bergman, AM; Zwart, W				Stelloo, S.; Nevedomskaya, E.; Kim, Y.; Hoekman, L.; Bleijerveld, O. B.; Mirza, T.; Wessels, L. F. A.; van Weerden, W. M.; Altelaar, A. F. M.; Bergman, A. M.; Zwart, W.			Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis	ONCOGENE			English	Article							DNA-REPAIR; XENOGRAFT MODELS; RNA-BINDING; CANCER; TRANSCRIPTION; CHROMATIN; IDENTIFICATION; HOXB13; COACTIVATOR; ENHANCERS	Androgen receptor (AR) is a key player in prostate cancer development and progression. Here we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to identify components of the AR transcriptional complex. In total, 66 known and novel AR interactors were identified in the presence of synthetic androgen, most of which were critical for AR-driven prostate cancer cell proliferation. A subset of AR interactors required for LNCaP proliferation were profiled using chromatin immunoprecipitation assays followed by sequencing, identifying distinct genomic subcomplexes of AR interaction partners. Interestingly, three major subgroups of genomic subcomplexes were identified, where selective gain of function for AR genomic action in tumorigenesis was found, dictated by FOXA1 and HOXB13. In summary, by combining proteomic and genomic approaches we reveal subclasses of AR transcriptional complexes, differentiating normal AR behavior from the oncogenic state. In this process, the expression of AR interactors has key roles by reprogramming the AR cistrome and interactome in a genomic location-specific manner.	[Stelloo, S.; Nevedomskaya, E.; Kim, Y.; Mirza, T.; Bergman, A. M.; Zwart, W.] Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Nevedomskaya, E.; Kim, Y.; Wessels, L. F. A.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Hoekman, L.; Bleijerveld, O. B.; Altelaar, A. F. M.] Netherlands Canc Inst, Mass Spectrometry & Prote Facil, Amsterdam, Netherlands; [Wessels, L. F. A.] Delft Univ Technol, Fac EEMCS, Delft, Netherlands; [van Weerden, W. M.] Erasmus Univ, Erasmus MC Canc Inst, Dept Urol, Med Ctr, Rotterdam, Netherlands; [Altelaar, A. F. M.] Univ Utrecht, Biomol Mass Spectrometry & Prote Grp, Bijvoet Ctr Biomol Res, Utrecht, Netherlands; [Altelaar, A. F. M.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Netherlands Prote Ctr, Utrecht, Netherlands; [Bergman, A. M.] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Delft University of Technology; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Utrecht University; Utrecht University; Netherlands Cancer Institute	Stelloo, S; Zwart, W (corresponding author), Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	s.stelloo@nki.nl; w.zwart@nki.nl		Zwart, Wilbert/0000-0002-9823-7289; Kim, Yongsoo/0000-0002-2995-2131	Movember [NKI01]; KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award [NKI 2014-6711]; Netherlands Organisation for Scientific Research (NWO) [016.156.401]; NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands [184.032.201]; VIDI grant [723.012.102]	Movember; KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award; Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands; VIDI grant	We thank the NKI Genomics Core Facility for Illumina sequencing and bioinformatic support. SS is supported by Movember (NKI01). We thank Corrina MA de Ridder for dedicated maintenance and biobanking of the PDX models. WZ is supported by a KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award (NKI 2014-6711) and a VIDI grant (016.156.401) from The Netherlands Organisation for Scientific Research (NWO). This work is further supported by NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands, Proteins@Work (184.032.201) to OBB and AFMA and a VIDI grant (723.012.102) to AFMA.	Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Ameziane N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9829; Andreu-Vieyra C, 2011, MOL CELL BIOL, V31, P4648, DOI 10.1128/MCB.05934-11; Asangani IA, 2016, MOL CANCER RES, V14, P324, DOI 10.1158/1541-7786.MCR-15-0472; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Beltran M, 2016, GENOME RES, V26, P896, DOI 10.1101/gr.197632.115; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bose DA, 2017, CELL, V168, P135, DOI 10.1016/j.cell.2016.12.020; Chen Z, 2015, EMBO J, V34, P502, DOI 10.15252/embj.201490306; Comuzzi Barbara, 2006, Cellscience, V3, P61; Cross DS, 2008, MED ONCOL, V25, P287, DOI 10.1007/s12032-007-9033-z; Etani T, 2015, ONCOTARGET, V6, P2865, DOI 10.18632/oncotarget.3067; Fan SL, 2006, BIOCHEM BIOPH RES CO, V341, P192, DOI 10.1016/j.bbrc.2005.12.167; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Fei T, 2017, P NATL ACAD SCI USA, V114, pE5207, DOI 10.1073/pnas.1617467114; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Goto K, 2003, J STEROID BIOCHEM, V85, P201, DOI 10.1016/S0960-0760(03)00196-1; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hendrickson DG, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0878-3; Hsiao JJ, 2016, J BIOL CHEM, V291, P18818, DOI 10.1074/jbc.M116.732313; Hsiao JJ, 2015, MOL ENDOCRINOL, V29, P1195, DOI 10.1210/me.2015-1021; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Imberg-Kazdan K, 2013, GENOME RES, V23, P581, DOI 10.1101/gr.144774.112; Jangal M, 2014, NUCLEIC ACIDS RES, V42, P11339, DOI 10.1093/nar/gku791; Jasavala R, 2007, MOL CELL PROTEOMICS, V6, P252, DOI 10.1074/mcp.M600169-MCP200; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Jin H, 2014, BIOMED RES INT, V2014, P1; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kim SD, 2010, ANAT CELL BIOL, V43, P284, DOI 10.5115/acb.2010.43.4.284; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mooslehner KA, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/381824; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Paltoglou S, 2017, CANCER RES, V77, P3417, DOI 10.1158/0008-5472.CAN-16-1616; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schiewer MJ, 2016, TRENDS ENDOCRIN MET, V27, P216, DOI 10.1016/j.tem.2016.02.004; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Stelloo S, 2015, EMBO MOL MED, V7, P1450, DOI 10.15252/emmm.201505424; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; Van Tilborgh N, 2013, J ENDOCRINOL INVEST, V36, P699, DOI 10.3275/8927; van Weerden WM, 2009, BRIT J CANCER, V100, P13, DOI 10.1038/sj.bjc.6604822; Vander Griend DJ, 2014, INT J BIOL SCI, V10, P627, DOI 10.7150/ijbs.8756; VANSTEENBRUGGE GJ, 1984, PROSTATE, V5, P639, DOI 10.1002/pros.2990050610; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Yang YA, 2015, GENES DIS, V2, P144, DOI 10.1016/j.gendis.2015.01.003; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou XE, 2010, J BIOL CHEM, V285, P9161, DOI 10.1074/jbc.M109.085779	57	55	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					313	322		10.1038/onc.2017.330	http://dx.doi.org/10.1038/onc.2017.330			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925401				2022-12-28	WOS:000422753900004
J	Padilla, L; Dakhel, S; Adan, J; Masa, M; Martinez, JM; Roque, L; Coll, T; Hervas, R; Calvis, C; Llinas, L; Buenestado, S; Castellsague, J; Messeguer, R; Mitjans, F; Hernandez, JL				Padilla, L.; Dakhel, S.; Adan, J.; Masa, M.; Martinez, J. M.; Roque, L.; Coll, T.; Hervas, R.; Calvis, C.; Llinas, L.; Buenestado, S.; Castellsague, J.; Messeguer, R.; Mitjans, F.; Hernandez, J. L.			S100A7: from mechanism to cancer therapy	ONCOGENE			English	Article							GLYCATION END-PRODUCTS; INVASIVE BREAST-CANCER; TUMOR MICROENVIRONMENT; ENDOTHELIAL-CELLS; BINDING ASSAY; PSORIASIN; RECEPTOR; METASTASIS; EXPRESSION; RAGE	Within the tumor, malignant and stromal cells support each other by secreting a wide variety of growth factors and cytokines, allowing tumor growth and disease progression. The identification and regulation of those key factors in this crosstalk has opened the opportunity to develop new therapeutic strategies that not only act on the tumor cells but also on the stroma. Among these factors, S100A7 protein has gained interest in the last years. With key roles in cell motility its expression correlates with increased tumor growth, angiogenesis and metastatic potential. This work aims to deepen in the role played by extracellular S100A7 in the tumor microenvironment, offering a new integrative insight of its mechanism of action on each cellular compartment (tumor, endothelial, immune and fibroblast). As a result, we demonstrate its implication in cell migration and invasion, and its important contribution to the formation of a proinflammatory and proangiogenic environment that favors tumor progression and metastasis. Furthermore, we define its possible role in the pre-metastatic niche formation. Considering the relevance of S100A7 in cancer progression, we have developed neutralizing monoclonal antibodies, reporting for the first time the proof of principle of this promising therapeutic strategy for cancer treatment.	[Padilla, L.; Dakhel, S.; Adan, J.; Masa, M.; Martinez, J. M.; Roque, L.; Coll, T.; Hervas, R.; Calvis, C.; Llinas, L.; Buenestado, S.; Castellsague, J.; Messeguer, R.; Mitjans, F.; Hernandez, J. L.] LEITAT Technol Ctr, Biomed Div, C Baldiri Reixach 15-21,Barcelona Sci Pk, Barcelona 08028, Spain		Hernandez, JL (corresponding author), LEITAT Technol Ctr, Biomed Div, C Baldiri Reixach 15-21,Barcelona Sci Pk, Barcelona 08028, Spain.	jlhernandez@leitat.org	Masa, Marc/AAO-6133-2021; Mitjans, Francesc/AAZ-8922-2020; Buenestado, Silvia/AAB-3361-2019; Padilla, Leo/GYU-4775-2022	Buenestado, Silvia/0000-0002-2715-9383; Mitjans, Francesc/0000-0001-8331-9954; hernandez, jose luis/0000-0002-9172-6004	Spanish MINECO [RTC-2015-3318-1]	Spanish MINECO(Spanish Government)	The work was partially supported by Grants from the Spanish MINECO (RTC-2015-3318-1).	Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Bettum IJ, 2014, CANCER LETT, V344, P28, DOI 10.1016/j.canlet.2013.10.036; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen HY, 2014, AM J CANCER RES, V4, P89; Chen L, 2015, J HEPATOL, V62, P156, DOI 10.1016/j.jhep.2014.07.035; Choi SH, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-016-0374-6; Dakhel S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.7; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Huber J, 2006, J LIPID RES, V47, P1054, DOI 10.1194/jlr.M500555-JLR200; Jin QE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019375; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kataoka K, 2012, ONCOL LETT, V3, P1149, DOI 10.3892/ol.2012.612; Klingelhofer J, 2012, NEOPLASIA, V14, P1260, DOI 10.1593/neo.121554; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Laenkholm AV, 2012, MOL ONCOL, V6, P428, DOI 10.1016/j.molonc.2012.04.003; Leclerc E, 2015, BBA-MOL BASIS DIS, V1852, P2706, DOI 10.1016/j.bbadis.2015.09.022; Limaverde-Sousa G, 2014, CANCER TREAT REV, V40, P548, DOI 10.1016/j.ctrv.2013.11.009; McCullough KC, 1999, IMMUNOLOGY, V98, P203, DOI 10.1046/j.1365-2567.1999.00867.x; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Moserle L, 2014, CANCER DISCOV, V4, P31, DOI 10.1158/2159-8290.CD-13-0199; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Padilla L, 2014, BIOCHEM BIOPH RES CO, V446, P404, DOI 10.1016/j.bbrc.2014.02.143; Peng QX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075328; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rich L, 2005, BRAZ J MORPHOL SCI, V22, P7; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; Schweizer MT, 2013, CANCER J, V19, P99, DOI 10.1097/PPO.0b013e31827e0b86; Shubbar E, 2012, BREAST CANCER RES TR, V134, P71, DOI 10.1007/s10549-011-1920-5; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Torres I, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068434, 10.1371/journal.pone.0072480]; Tripathi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011939; Vegfors J, 2016, BRIT J DERMATOL, V175, P1263, DOI 10.1111/bjd.14718; West NR, 2010, ONCOGENE, V29, P2083, DOI 10.1038/onc.2009.488; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Wolf S, 2011, AMINO ACIDS, V41, P809, DOI 10.1007/s00726-010-0822-x; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Zhang H, 2008, THORAX, V63, P352, DOI 10.1136/thx.2007.087015; Zhang H, 2007, LUNG CANCER, V57, P37, DOI 10.1016/j.lungcan.2007.02.020	46	21	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6749	6761		10.1038/onc.2017.283	http://dx.doi.org/10.1038/onc.2017.283			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28825725				2022-12-28	WOS:000417282500001
J	Ahmad, R; Kumar, B; Chen, Z; Chen, X; Muller, D; Lele, SM; Washington, MK; Batra, SK; Dhawan, P; Singh, AB				Ahmad, R.; Kumar, B.; Chen, Z.; Chen, X.; Mueller, D.; Lele, S. M.; Washington, M. K.; Batra, S. K.; Dhawan, P.; Singh, A. B.			Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to promote colon cancer malignancy by hyperactivating Wnt/beta-catenin signaling	ONCOGENE			English	Article							BETA-CATENIN; EPITHELIAL-CELLS; TIGHT JUNCTION; GROWTH; TRANSDUCER; PATHWAY; CLDN3; GENE; ACTIVATION; RESISTANCE	The hyperactivated Wnt/beta-catenin signaling acts as a switch to induce epithelial to mesenchymal transition and promote colorectal cancer. However, due to its essential role in gut homeostasis, therapeutic targeting of this pathway has proven challenging. Additionally, IL-6/Stat-3 signaling, activated by microbial translocation through the dysregulated mucosal barrier in colon adenomas, facilitates the adenoma to adenocarcinomas transition. However, inter-dependence between these signaling pathways and key mucosal barrier components in regulating colon tumorigenesis and cancer progression remains unclear. In current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation. Loss of claudin-3 also predicted poor patient survival. These findings however contrasted an upregulated claudin-3 expression in other cancer types and implicated role of the epigenetic regulation. Claudin-3 -/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer. Wnt-signaling hyperactivation, albeit in GSK-3 beta independent manner, differentiated colon cancer in claudin-3 -/- mice versus WT-mice. Claudin-3 loss also upregulated the gp130/IL6/Stat3 signaling in colonic epithelium potentially assisted by infiltrating immune components. Genetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer. Overall, these novel findings identify claudin-3 as a therapeutic target for inhibiting overactivation of Wnt-signaling to prevent CRC malignancy.	[Ahmad, R.; Kumar, B.; Batra, S. K.; Dhawan, P.; Singh, A. B.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Chen, Z.] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou, Henan, Peoples R China; [Chen, X.] Univ Miami, Miller Sch Med, Div Biostat, Miami, FL 33136 USA; [Mueller, D.] Charite, Dept Pediat Nephrol, Berlin, Germany; [Mueller, D.] Berlin Inst Hlth, Berlin, Germany; [Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Dhawan, P.; Singh, A. B.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; Zhengzhou University; University of Miami; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Singh, AB (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	amar.singh@unmc.edu	kumar, Balawant/ABB-2847-2021; Kumar, Balawant/AAW-9616-2021	kumar, Balawant/0000-0002-8187-3078; 	 [BX002086];  [DK088902];  [BX002761]; NATIONAL CANCER INSTITUTE [P50CA095103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088902] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002761, I01BX002086] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by BX002086 (PD), DK088902 and BX002761 (ABS).	Ahmad R, 2014, MUCOSAL IMMUNOL, V7, P1340, DOI 10.1038/mi.2014.21; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bartholow TL, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-12; Bhat AA, 2015, ONCOGENE, V34, P4570, DOI 10.1038/onc.2014.385; Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001; Clark JA, 2006, AM J PHYSIOL-GASTR L, V291, pG938, DOI 10.1152/ajpgi.00090.2006; de Araujo WM, 2010, J CANCER RES CLIN, V136, P1773, DOI 10.1007/s00432-010-0836-5; de Souza WF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074994; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Dube PE, 2012, J CLIN INVEST, V122, P2780, DOI 10.1172/JCI62888; Dzierzewicz Z, 2002, ACTA BIOCHIM POL, V49, P211; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gibson DL, 2008, CELL MICROBIOL, V10, P388, DOI 10.1111/j.1462-5822.2007.01052.x; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Hbibi AT, 2009, FEBS J, V276, P2505, DOI 10.1111/j.1742-4658.2009.06975.x; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; HENTTINEN T, 1995, J IMMUNOL, V155, P4582; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Holmes JL, 2006, GENE EXPR PATTERNS, V6, P581, DOI 10.1016/j.modgep.2005.12.001; Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832; Jiang L, 2014, ONCOTARGET, V5, P7663, DOI 10.18632/oncotarget.2288; KEDINGER M, 1990, DIFFERENTIATION, V43, P87, DOI 10.1111/j.1432-0436.1990.tb00434.x; Kooij G, 2014, ACTA NEUROPATHOL, V128, P267, DOI 10.1007/s00401-013-1227-1; Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lee J, 2012, J BIOL CHEM, V287, P18182, DOI 10.1074/jbc.M111.328831; Long HY, 2001, CANCER RES, V61, P7878; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mullin J M, 2004, Sci STKE, V2004, ppe2, DOI 10.1126/stke.2162004pe2; MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306; MULLIN JM, 1988, CANCER RES, V48, P4886; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Patel RM, 2012, AM J PATHOL, V180, P626, DOI 10.1016/j.ajpath.2011.10.025; Pramanik KC, 2015, ONCOTARGET, V6, P11561, DOI 10.18632/oncotarget.3427; Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021; Ramalingam A, 2010, AM J PHYSIOL-CELL PH, V299, pC1028, DOI 10.1152/ajpcell.00482.2009; Ray S, 2013, J INVEST DERMATOL, V133, P1212, DOI 10.1038/jid.2012.499; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thaker AI, 2012, JOVE-J VIS EXP, DOI 10.3791/4100; Turgeon N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073785; Vucic EA, 2008, PHARMACOGENOMICS, V9, P215, DOI 10.2217/14622416.9.2.215; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Yaqinuddin A, 2009, J UROLOGY, V182, P756, DOI 10.1016/j.juro.2009.03.082; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	54	69	75	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6592	6604		10.1038/onc.2017.259	http://dx.doi.org/10.1038/onc.2017.259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783170	Green Accepted			2022-12-28	WOS:000416049200008
J	Chen, YR; Chou, HC; Yang, CH; Chen, HY; Liu, YW; Lin, TY; Yeh, CL; Chao, WT; Tsou, HH; Chuang, HC; Tan, TH				Chen, Y-R; Chou, H-C; Yang, C-H; Chen, H-Y; Liu, Y-W; Lin, T-Y; Yeh, C-L; Chao, W-T; Tsou, H-H; Chuang, H-C; Tan, T-H			Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; SRC FAMILY KINASES; DOWN-REGULATION; CANCER CELLS; VHR; ACTIVATION; EXPRESSION; JNK; MAP	Vaccinia H1-related phosphatase (VHR/DUSP3) is a member of the dual-specificity phosphatase family. Deregulation of VHR is observed in various malignant diseases. We identified focal adhesion kinase (FAK) as a VHR-interacting molecule. Over-expression of VHR decreased tyrosine phosphorylation of FAK and decreasing VHR promoted FAK tyrosine phosphorylation. In vitro assays proved that recombinant VHR directly dephosphorylated FAK and paxillin. VHR-knockout mice did not have obvious abnormality; however, VHR-knockout cells showed decreased expression of integrins and FAK but stronger FAK and paxillin phosphorylation upon attachment to fibronectin. Additionally, VHR-knockout fibroblast and lung epithelial cells had elevated ligand-induced epidermal growth factor receptor (EGFR) phosphorylation. Inducible expression of VHR suppressed directional cell migration, and VHR deficiency resulted in a higher cell migratory ability. VHR-knockout cells have stronger FAK phosphorylation in cell adhesions, long-lasting trailing ends and slower turnover of focal adhesions. These collective data indicate that VHR is a FAK phosphatase and participates in regulating the formation and disassembly of focal adhesions.	[Chen, Y-R; Chou, H-C; Yang, C-H; Chen, H-Y; Liu, Y-W; Lin, T-Y; Yeh, C-L] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Taiwan; [Chen, H-Y; Chao, W-T] Tunghai Univ, Dept Life Sci, Taichung, Taiwan; [Tsou, H-H] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan; [Chao, W-T] China Med Univ, Coll Publ Hlth, Grad Inst Biostat, Taichung, Taiwan; [Chuang, H-C; Tan, T-H] Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Taiwan; [Tan, T-H] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX USA	National Health Research Institutes - Taiwan; Tunghai University; National Health Research Institutes - Taiwan; China Medical University Taiwan; National Health Research Institutes - Taiwan; Baylor College of Medicine	Chen, YR (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan 35053, Taiwan.; Tan, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Zhunan 35053, Taiwan.	yrchen@nhri.org.tw; ttan@nhri.org.tw	Chuang, Huai-Chia/E-9486-2016; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAF-2186-2022; Tan, Tse-Hua/ABD-7080-2021	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	National Health Research Institutes, Taiwan [MG-102-PP-03, MG-103-PP-03, 105-IMPP01, 105-IMSP01]; Ministry of Science and Technology, Taiwan [102-2628-B-400-003, 105-2314-B-400-027]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	We thank National Health Research Institutes Transgenic Animal Core for assistance in the mouse blastocyst injection and Optical Biology Core for the assistance in confocal microscopy and time-lapsed photography analyses. This work was supported by grants from National Health Research Institutes, Taiwan (MG-102-PP-03 and MG-103-PP-03 to Y-R Chen; 105-IMPP01 and 105-IMSP01 to T-H Tan), and grants from Ministry of Science and Technology, Taiwan (102-2628-B-400-003 to Y-R Chen and 105-2314-B-400-027 to T-H Tan).	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Amand M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-108; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arnoldussen YJ, 2008, CANCER RES, V68, P9255, DOI 10.1158/0008-5472.CAN-08-1224; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gallegos LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27114; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Henkens R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-147; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; Hoyt R, 2007, J IMMUNOL, V179, P3402, DOI 10.4049/jimmunol.179.6.3402; Huang CY, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-24; ILLC D, 1995, NATURE, V377, P539; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lee J, 2015, SCI REP-UK, V5, DOI 10.1038/srep12296; Li JP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4618; Li JP, 2010, J BIOL CHEM, V285, P5472, DOI 10.1074/jbc.M109.060186; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Musumeci L, 2015, CIRCULATION, V131, P656, DOI 10.1161/CIRCULATIONAHA.114.010186; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Pavic K, 2015, FEBS J, V282, P1871, DOI 10.1111/febs.13263; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schumacher MA, 2002, BIOCHEMISTRY-US, V41, P3009, DOI 10.1021/bi015799l; Sieg DJ, 1999, J CELL SCI, V112, P2677; Singh P, 2015, J IMMUNOL, V194, P4951, DOI 10.4049/jimmunol.1402431; Todd JL, 2002, ONCOGENE, V21, P2573, DOI 10.1038/sj.onc.1205344; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Wang JY, 2006, J NEUROCHEM, V98, P89, DOI 10.1111/j.1471-4159.2006.03852.x; Wang JY, 2011, J BIOL CHEM, V286, P10177, DOI 10.1074/jbc.M110.163295; Wang XH, 2012, J BIOL CHEM, V287, P11037, DOI 10.1074/jbc.M111.310946; Xiao Q, 2013, J AM CHEM SOC, V135, P9760, DOI 10.1021/ja401692t; Yang CH, 2015, BBA-MOL BASIS DIS, V1852, P1540, DOI 10.1016/j.bbadis.2015.04.020; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	40	15	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6509	6517		10.1038/onc.2017.255	http://dx.doi.org/10.1038/onc.2017.255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759036				2022-12-28	WOS:000416049200001
J	Nakatsuka, T; Tateishi, K; Kudo, Y; Yamamoto, K; Nakagawa, H; Fujiwara, H; Takahashi, R; Miyabayashi, K; Asaoka, Y; Tanaka, Y; Ijichi, H; Hirata, Y; Otsuka, M; Kato, M; Sakai, J; Tachibana, M; Aburatani, H; Shinkai, Y; Koike, K				Nakatsuka, T.; Tateishi, K.; Kudo, Y.; Yamamoto, K.; Nakagawa, H.; Fujiwara, H.; Takahashi, R.; Miyabayashi, K.; Asaoka, Y.; Tanaka, Y.; Ijichi, H.; Hirata, Y.; Otsuka, M.; Kato, M.; Sakai, J.; Tachibana, M.; Aburatani, H.; Shinkai, Y.; Koike, K.			Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation	ONCOGENE			English	Article							ADVANCED HEPATOCELLULAR-CARCINOMA; MUTATIONAL LANDSCAPE; GENE-EXPRESSION; STEM-CELLS; IN-VIVO; CANCER; LIVER; IDENTIFICATION; JMJD1A; JHDM2A	Epigenetic gene regulation linked to oncogenic pathways is an important focus of cancer research. KDM3A, a histone H3 lysine 9 (H3K9) demethylase, is known to have a pro-tumorigenic function. Here, we showed that KDM3A contributes to liver tumor formation through the phosphatidylinositol 3-kinase (PI3K) pathway, which is often activated in hepatocellular carcinoma. Loss of Kdm3a attenuated tumor formation in Pik3ca transgenic (Tg) mouse livers. Transcriptome analysis of pre-cancerous liver tissues revealed that the expression of activator protein 1 (AP-1) target genes was induced by PI3K activation, but blunted upon Kdm3a ablation. Particularly, the expression of Cd44, a liver cancer stem marker, was regulated by AP-1 in a Kdm3a-dependent manner. We identified Cd44-positive hepatocytes with epithelial-mesenchymal transition-related expression profiles in the Pik3ca Tg liver and confirmed their in vivo tumorigenic capacity. Notably, the number and tumor-initiating capacity of Cd44-positive hepatocytes were governed by Kdm3a. As a mechanism in Kdm3a-dependent AP-1 transcription, Kdm3a recruited c-Jun to the AP-1 binding sites of Cd44, Mmp7 and Pdgfrb without affecting c-Jun expression. Moreover, Brg1, a component of the SWI/SNF chromatin remodeling complex, interacted with c-Jun in a Kdm3a-dependent manner and was bound to the AP-1 binding site of these genes. Finally, KDM3A and c-JUN were co-expressed in 33% of human premalignant lesions with PI3K activation. Our data suggest a critical role for KDM3A in the PI3K/AP-1 oncogenic axis and propose a novel strategy for inhibition of KDM3A against liver tumor development under PI3K pathway activation.	[Nakatsuka, T.; Tateishi, K.; Kudo, Y.; Yamamoto, K.; Nakagawa, H.; Fujiwara, H.; Takahashi, R.; Miyabayashi, K.; Asaoka, Y.; Tanaka, Y.; Ijichi, H.; Hirata, Y.; Otsuka, M.; Koike, K.] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan; [Kato, M.] RIKEN, Adv Sci Inst, Cellular Memory Lab, Wako, Saitama, Japan; [Sakai, J.] Univ Tokyo, RCAST, Div Metab Med, Meguro Ku, Tokyo, Japan; [Tachibana, M.] Tokushima Univ, Inst Enzyme Res, Dept Enzyme Chem, Tokushima, Tokushima, Japan; [Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Meguro Ku, Tokyo, Japan	University of Tokyo; RIKEN; University of Tokyo; Tokushima University; University of Tokyo	Tateishi, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ktate-tky@umin.ac.jp	IJICHI, Hideaki/AGZ-2874-2022; Nakagawa, Hayato/I-2837-2012; Yamamoto, Keisuke/AAT-2794-2021; Masaki, Kato/AAW-2603-2020; Ijichi, Hideaki/AAE-6692-2022; Otsuka, Motoyuki/H-9067-2019; Nakatsuka, Takuma/T-6886-2017; Ijichi, Hideaki/V-2720-2019; Asaoka, Yoshinari/ABC-5412-2021	IJICHI, Hideaki/0000-0002-2379-7986; Nakagawa, Hayato/0000-0002-6973-5094; Yamamoto, Keisuke/0000-0002-6323-9540; Ijichi, Hideaki/0000-0002-2379-7986; Otsuka, Motoyuki/0000-0003-2869-2881; Nakatsuka, Takuma/0000-0002-5727-5385; Asaoka, Yoshinari/0000-0002-2805-8226; Sakai, Juro/0000-0003-4043-1035; Tanaka, Yasuo/0000-0002-2917-3365	Japan Society for the Promotion of Science [23590962]; New Energy and Industrial Technology Development Organization (NEDO); Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED); Grants-in-Aid for Scientific Research [16H01409, 16H01218, 17H06424] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This project is supported by Grants-in-Aid for Scientific Research (23590962) from Japan Society for the Promotion of Science, the grant from New Energy and Industrial Technology Development Organization (NEDO), and the Research Program on Hepatitis from Japan Agency for Medical Research and Development (AMED). We thank Dr E.P. Sandgren for MUP-uPA mice, Mitsuko Tsubouchi for providing assistance with various cell cultures, and all the lab members for their helpful comments.	Abe Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8052; Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173; Bitzer M, 2016, J HEPATOL, V65, P280, DOI 10.1016/j.jhep.2016.02.043; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fan L, 2015, 11 INT C WIR COMM NE, V2015, P1; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Friedman JR, 2004, P NATL ACAD SCI USA, V101, P12986, DOI 10.1073/pnas.0402875101; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Fujimoto A, 2016, NAT GENET, V48, P500, DOI 10.1038/ng.3547; Hasenfuss SC, 2014, CELL METAB, V19, P84, DOI 10.1016/j.cmet.2013.11.018; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Inagaki T, 2009, GENES CELLS, V14, P991, DOI 10.1111/j.1365-2443.2009.01326.x; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kudo Y, 2011, J HEPATOL, V55, P1400, DOI 10.1016/j.jhep.2011.03.025; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Maass T, 2011, INT J CANCER, V128, P1259, DOI 10.1002/ijc.25469; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann DA, 2014, HEPATOLOGY, V60, P1418, DOI 10.1002/hep.27131; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Minguez B, 2009, CURR OPIN GASTROEN, V25, P186, DOI 10.1097/MOG.0b013e32832962a1; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nakagawa H, 2014, P NATL ACAD SCI USA, V111, P1090, DOI 10.1073/pnas.1322731111; Okabe H, 2014, Br J Cancer, V110, P958, DOI 10.1038/bjc.2013.759; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Osawa T, 2013, CANCER RES, V73, P3019, DOI 10.1158/0008-5472.CAN-12-3231; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Shakya A, 2011, J BIOL CHEM, V286, P450, DOI 10.1074/jbc.M110.174045; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Uemura M, 2010, CLIN CANCER RES, V16, P4636, DOI 10.1158/1078-0432.CCR-10-0407; Weglarz TC, 2000, AM J PATHOL, V157, P1963, DOI 10.1016/S0002-9440(10)64835-3; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Xin HW, 2013, GUT, V62, P1777, DOI 10.1136/gutjnl-2012-303261; Yamada D, 2012, ANN SURG ONCOL, V19, pS355, DOI 10.1245/s10434-011-1797-x; Yamamoto K, 2014, CARCINOGENESIS, V35, P2404, DOI 10.1093/carcin/bgu136; Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Zeybel M, 2013, J HEPATOL, V59, P1349, DOI 10.1016/j.jhep.2013.05.039; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	53	33	35	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6262	6271		10.1038/onc.2017.222	http://dx.doi.org/10.1038/onc.2017.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692045				2022-12-28	WOS:000414774800005
J	Kao, SH; Wang, WL; Chen, CY; Chang, YL; Wu, YY; Wang, YT; Wang, SP; Nesvizhskii, AI; Chen, YJ; Hong, TM; Yang, PC				Kao, S-H; Wang, W-L; Chen, C-Y; Chang, Y-L; Wu, Y-Y; Wang, Y-T; Wang, S-P; Nesvizhskii, A. I.; Chen, Y-J; Hong, T-M; Yang, P-C			GSK3 beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug (vol 33, pg 3172, 2013)	ONCOGENE			English	Correction																		Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5916	5916		10.1038/onc.2017.302	http://dx.doi.org/10.1038/onc.2017.302			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28869596	Bronze			2022-12-28	WOS:000413292900015
J	Suleymanova, N; Crudden, C; Shibano, T; Worrall, C; Oprea, I; Tica, A; Calin, GA; Girnita, A; Girnita, L				Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Tica, A.; Calin, G. A.; Girnita, A.; Girnita, L.			Functional antagonism of beta-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes	ONCOGENE			English	Article							FACTOR-I RECEPTOR; PROTEIN-COUPLED RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; GROWTH-FACTOR RECEPTOR; BIASED AGONISM; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; 7-TRANSMEMBRANE RECEPTORS; G(BETA-GAMMA) SUBUNITS; PICROPODOPHYLLIN PPP; ADRENERGIC-RECEPTOR	With very similar 3D structures, the widely expressed beta-arrestin isoforms 1 and 2 play at times identical, distinct or even opposing roles in regulating various aspects of G protein-coupled receptors (GPCR) expression and signalling. Recent evidence recognizes the beta-arrestin system as a key regulator of not only GPCRs, but also receptor tyrosine kinases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R). Binding of beta-arrestin1 to IGF-1R leads to ligand-dependent degradation of the receptor and generates additional MAPK/ERK signalling, protecting cancer cells against anti-IGF-1R therapy. Because the interplay between beta-arrestin isoforms governs the biological effects for most GPCRs, as yet unexplored for the IGF-1R, we sought to investigate specifically the regulatory roles of the beta-arrestin2 isoform on expression and function of the IGF-1R. Results from controlled expression of either beta-arrestin isoform demonstrate that beta-arrestin2 acts in an opposite manner to beta-arrestin1 by promoting degradation of an unstimulated IGF-1R, but protecting the receptor against agonist-induced degradation. Although both isoforms co-immunoprecipitate with IGF-1R, the ligand-occupied receptor has greater affinity for beta-arrestin1; this association lasts longer, sustains MAPK/ERK signalling and mitigates p53 activation. Conversely, beta-arrestin2 has greater affinity for the ligand-unoccupied receptor; this interaction is transient, triggers receptor ubiquitination and degradation without signalling activation, and leads to a lack of responsiveness to IGF-1, cell cycle arrest and decreased viability of cancer cells. This study reveals contrasting abilities of IGF-1R to interact with each beta-arrestin isoform, depending on the presence of the ligand and demonstrates the antagonism between the two beta-arrestin isoforms in controlling IGF-1R expression and function, which could be developed into a practical anti-IGF-1R strategy for cancer therapy.	[Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Girnita, A.; Girnita, L.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol, S-17176 Stockholm, Sweden; [Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Girnita, A.; Girnita, L.] Karolinska Univ Hosp, S-17176 Stockholm, Sweden; [Tica, A.] Univ Med & Pharm Craiova, Dept Pharmacol, Craiova, Romania; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Girnita, A.] Karolinska Univ Hosp, Dermatol Dept, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Medicine & Pharmacy of Craiova; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Karolinska Institutet; Karolinska University Hospital	Girnita, L (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol, S-17176 Stockholm, Sweden.; Girnita, L (corresponding author), Karolinska Univ Hosp, S-17176 Stockholm, Sweden.	Leonard.Girnita@ki.se	Calin, George/E-9390-2011; 柴野, 卓志/AHB-7015-2022; TICA, ANDREI/AAK-8573-2020; Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008; Crudden, Caitrin/Q-5172-2018	Girnita, Leonard/0000-0003-0280-9500; Crudden, Caitrin/0000-0002-7786-112X; TICA, ANDREI ADRIAN/0000-0002-3821-4018; Calin, George/0000-0001-6704-5615; Calin, George/0000-0002-7427-0578	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society, Stockholm County; Karolinska Institute; NATIONAL CANCER INSTITUTE [R01CA182905] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society, Stockholm County; Karolinska Institute(Karolinska Institutet); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert J Lefkowitz and Dr Renato Baserga for generously providing reagents and cell lines. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Stockholm Cancer Society, Stockholm County and Karolinska Institute.	Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Boularan C, 2007, P NATL ACAD SCI USA, V104, P18061, DOI 10.1073/pnas.0705550104; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Conner DA, 1997, CIRC RES, V81, P1021; Crudden C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00064; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Girnita A, 2012, ONCOGENE, V31, P352, DOI 10.1038/onc.2011.239; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Gurevich VV, 2013, PROG MOL BIOL TRANSL, V118, P57, DOI 10.1016/B978-0-12-394440-5.00003-6; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hara MR, 2013, CELL CYCLE, V12, P219, DOI 10.4161/cc.23368; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hongo A, 1996, ONCOGENE, V12, P1231; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Hupfeld CJ, 2007, ANNU REV PHYSIOL, V69, P561, DOI 10.1146/annurev.physiol.69.022405.154626; Ibrahim IAAEH, 2012, J PHARMACOL SCI, V118, P408, DOI 10.1254/jphs.11R10CP; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee MH, 2008, J BIOL CHEM, V283, P2088, DOI 10.1074/jbc.M706892200; Lefkowitz RJ, 2013, PROG MOL BIOL TRANSL, V118, P3, DOI 10.1016/B978-0-12-394440-5.00001-2; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Park JY, 2016, ARCH PHARM RES, V39, P293, DOI 10.1007/s12272-016-0712-1; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Sanni SJ, 2010, BRIT J PHARMACOL, V161, P150, DOI 10.1111/j.1476-5381.2010.00875.x; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Shenoy SK, 2011, TRENDS PHARMACOL SCI, V32, P521, DOI 10.1016/j.tips.2011.05.002; Shukla AK, 2014, NATURE, V512, P218, DOI 10.1038/nature13430; Shukla AK, 2013, NATURE, V497, P137, DOI 10.1038/nature12120; Srivastava A, 2015, TRENDS ENDOCRIN MET, V26, P628, DOI 10.1016/j.tem.2015.09.001; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004; Wisler JW, 2014, CURR OPIN CELL BIOL, V27, P18, DOI 10.1016/j.ceb.2013.10.008; Worrall C, 2017, ONCOGENE, V36, P3274, DOI 10.1038/onc.2016.472; Zhang MF, 2010, DEV BIOL, V339, P407, DOI 10.1016/j.ydbio.2009.12.042; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P20620, DOI 10.1073/pnas.1216348110; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P7055, DOI 10.1073/pnas.1118359109; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	70	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5734	5744		10.1038/onc.2017.179	http://dx.doi.org/10.1038/onc.2017.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581517	hybrid, Green Published			2022-12-28	WOS:000412843900007
J	Semenova, G; Stepanova, DS; Dubyk, C; Handorf, E; Deyev, SM; Lazar, AJ; Chernoff, J				Semenova, G.; Stepanova, D. S.; Dubyk, C.; Handorf, E.; Deyev, S. M.; Lazar, A. J.; Chernoff, J.			Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis	ONCOGENE			English	Article							SCHWANN-CELL TRANSFORMATION; NEUROFIBROMATOSIS TYPE-1; SIGNALING PATHWAY; PAK1 INHIBITOR; MEK INHIBITOR; BETA-CATENIN; ACTIVATION; CANCER; MAPK; TUMORIGENESIS	Malignant peripheral nerve sheath tumors (MPNSTs) are devastating sarcomas for which no effective medical therapies are available. Over 50% of MPSNTs are associated with mutations in NF1 tumor suppressor gene, resulting in activation of Ras and its effectors, including the Raf/Mek/Erk and PI3K/Akt/mTORC1 signaling cascades, and also the WNT/beta-catenin pathway. As Group I p21-activated kinases (Group I Paks, PAK1/2/3) have been shown to modulate Ras-driven oncogenesis, we asked if these enzymes might regulate signaling in MPNSTs. In this study we found a strong positive correlation between the activity of PAK1/2/3 and the stage of human MPNSTs. We determined that reducing Group I Pak activity diminished MPNST cell proliferation and motility, and that these effects were not accompanied by significant blockade of the Raf/Mek/Erk pathway, but rather by reductions in Akt and beta-catenin activity. Using the small molecule PAK1/2/3 inhibitor Frax1036 and the MEK1/2 inhibitor PD0325901, we showed that the combination of these two agents synergistically inhibited MPNST cell growth in vitro and dramatically decreased local and metastatic MPNST growth in animal models. Taken together, these data provide new insights into MPNST signaling deregulation and suggest that co-targeting of PAK1/2/3 and MEK1/2 may be effective in the treatment of patients with MPNSTs.	[Semenova, G.; Deyev, S. M.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Semenova, G.; Stepanova, D. S.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Stepanova, D. S.] Russian Natl Res Med Univ, Moscow, Russia; [Dubyk, C.] Fox Chase Canc Ctr, Biosample Repository, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Handorf, E.] Fox Chase Canc Ctr, Biostat & Bioinformat, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Deyev, S. M.] Natl Res Tomsk Polytech Univ, Tomsk, Russia; [Lazar, A. J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Fox Chase Cancer Center; Pirogov Russian National Research Medical University; Fox Chase Cancer Center; Fox Chase Cancer Center; Tomsk Polytechnic University; University of Texas System; UTMD Anderson Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014; Stepanova, Dina/T-3999-2019; Lazar, Alexander J/A-3416-2008; Deyev, Sergey/F-8191-2014	Chernoff, Jonathan/0000-0002-4803-7836; Lazar, Alexander J/0000-0002-6395-4499; Stepanova, Dina/0000-0001-6138-8502; Deyev, Sergey/0000-0002-3952-0631	NIH [RO1 CA142928]; Children's Tumor Foundation [2011-15-012]; NIH CORE Grant [P30 CA006927]; RSF grant [14-24-00106]; state of Pennsylvania; Russian Science Foundation [17-24-00006] Funding Source: Russian Science Foundation; NATIONAL CANCER INSTITUTE [R01CA142928, P30CA006927] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NIH CORE Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RSF grant(Russian Science Foundation (RSF)); state of Pennsylvania; Russian Science Foundation(Russian Science Foundation (RSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Timothy Cripe and Nancy Ratner for providing MPNST cell lines, Ahmet Hoke for providing immortalized HSC, Maureen Murphy for providing construct pWZL-Luc, Genentech for providing Frax1036, and Erica Golemis for commentary. This work was supported by grants from the NIH (RO1 CA142928), and the Children's Tumor Foundation (2011-15-012) to Jonathan Chernoff, NIH CORE Grant P30 CA006927 and an appropriation fromthe state of Pennsylvania to the Fox Chase Cancer Center. In vitro studies were supported by RSF grant 14-24-00106.	Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barker Nick, 2008, V468, P5, DOI 10.1007/978-1-59745-249-6_1; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chow HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013791; Chow HY, 2015, ONCOTARGET, V6, P1981, DOI 10.18632/oncotarget.2810; Connolly DC, 2009, CURRENT PROTOC PHARM, V45, P14, DOI DOI 10.1002/0471141755.ph1412s45; Crawford AT, 2008, GLIA, V56, P1637, DOI 10.1002/glia.20716; Dasgupta B, 2005, CANCER RES, V65, P236; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Eswaran J, 2008, TRENDS BIOCHEM SCI, V33, P394, DOI 10.1016/j.tibs.2008.06.002; Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920; He H, 2012, CANCER LETT, V317, P65, DOI 10.1016/j.canlet.2011.11.014; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Karpov AS, 2015, ACS MED CHEM LETT, V6, P776, DOI 10.1021/acsmedchemlett.5b00102; Katz D, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001227; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; Mo W, 2013, CELL, V152, P1077, DOI 10.1016/j.cell.2013.01.053; Ndubaku CO, 2015, ACS MED CHEM LETT, V6, P1241, DOI 10.1021/acsmedchemlett.5b00398; Packer RJ, 2002, J CHILD NEUROL, V17, P638, DOI 10.1177/088307380201700816; Prudnikova TY, 2016, ONCOGENE, V35, P2178, DOI 10.1038/onc.2015.278; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tonsgard James H, 2006, Semin Pediatr Neurol, V13, P2, DOI 10.1016/j.spen.2006.01.005; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Yang JL, 2014, EUR J CANCER, V50, P593, DOI 10.1016/j.ejca.2013.11.006; Ye Diana Zi, 2012, Cell Logist, V2, P105	45	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5421	5431		10.1038/onc.2017.143	http://dx.doi.org/10.1038/onc.2017.143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534510	Green Accepted			2022-12-28	WOS:000411382100008
J	Choi, EJ; Jung, BJ; Lee, SH; Yoo, HS; Shin, EA; Ko, HJ; Chang, S; Kim, SY; Jeon, SM				Choi, E-J; Jung, B-J; Lee, S-H; Yoo, H-S; Shin, E-A; Ko, H-J; Chang, S.; Kim, S-Y; Jeon, S-M			A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; CARDIAC-GLYCOSIDES; OXIDATIVE STRESS; GENE-EXPRESSION; RETINOIC ACID; CELLS; LKB1; PATHWAY; ACTIVATION; ASSAY	The Kelch-like ECH-associated protein 1 (KEAP1)-nuclear factor E2-related factor 2 (NRF2) pathway has a central role in cellular antioxidant defense. NRF2 activation due to KEAP1 or NRF2 mutations occurs frequently in many cancers, suggesting that NRF2 inhibition could be a promising therapeutic strategy. However, no potent NRF2 inhibitors are clinically available to date. To develop potent NRF2 inhibitors for therapeutic purpose, we screened similar to 4000 clinical compounds and determined clobetasol propionate (CP) as the most potent NRF2 inhibitor. Mechanistically, CP prevented nuclear accumulation and promoted beta-TrCP-dependent degradation of NRF2 in a glucocorticoid receptor-and a glycogen synthase kinase 3 (GSK3)-dependent manner. As a result, CP induced oxidative stress and strongly suppressed the anchorage-independent growth of tumors with KEAP1 mutation, but not with the wild-type KEAP1. Further, CP alone or in combination with rapamycin strongly inhibited the in vitro and in vivo growth of tumors harboring mutations in KEAP1 or both KEAP1 and LKB1 that are frequently observed in lung cancer. Thus, CP could be a repurposed therapeutic agent for cancers with high NRF2 activity. We also proposed that the use CP and rapamycin in combination could be a potential therapeutic strategy for tumors harboring both KEAP1 and LKB1 mutations.	[Choi, E-J; Jung, B-J; Yoo, H-S; Shin, E-A; Jeon, S-M] Ajou Univ, Coll Pharm, 206 World Cup Ro,Room 207, Suwon 16499, Gyeonggi Do, South Korea; [Lee, S-H; Kim, S-Y] Natl Canc Ctr, Res Inst, Canc Cell & Mol Biol Branch, Goyang, South Korea; [Ko, H-J] Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea; [Ko, H-J] Adv Inst Convergence Technol, Convergence Res Ctr Funct Plant Prod, Suwon, South Korea; [Chang, S.] Univ Ulsan, Dept Biomed Sci, Asan Med Ctr, Sch Med, Seoul, South Korea; [Jeon, S-M] Ajou Univ, Inst Pharmaceut Sci & Technol, Suwon, South Korea	Ajou University; National Cancer Center - Korea (NCC); Kangwon National University; University of Ulsan; Asan Medical Center; Ajou University	Jeon, SM (corresponding author), Ajou Univ, Coll Pharm, 206 World Cup Ro,Room 207, Suwon 16499, Gyeonggi Do, South Korea.	smjeon@ajou.ac.kr	Jeon, Sang-Min/I-7917-2018	Jeon, Sang-Min/0000-0002-0132-925X; Chang, Suhwan/0000-0002-0282-0120; Ko, Hyun-Jeong/0000-0002-3844-928X	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [S2014-A0251-00001]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [S2014-A0403-00067]; National Cancer Center of Korea [NCC1410670]	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning(National Research Foundation of Korea); National Cancer Center of Korea	We thank Y-GL and S-HP for the technical assistance provided. The clinical compound library (with 1887 compounds) was provided by the Korea Chemical Bank (KCB) from the Korea Research Institute of Chemical Technology (KRICT). This work was supported by grants from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (S2014-A0251-00001) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (S2014-A0403-00067) to S-MJ and the National Cancer Center of Korea (NCC1410670) to S-YK.	Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Calderon-Montano JM, 2014, ONCOGENE, V33, P2947, DOI 10.1038/onc.2013.229; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cuadrado A, 2015, FREE RADICAL BIO MED, V88, P147, DOI 10.1016/j.freeradbiomed.2015.04.029; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Ference JD, 2009, AM FAM PHYSICIAN, V79, P135; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gluschnaider U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009060; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jacob SE, 2006, J AM ACAD DERMATOL, V54, P723, DOI 10.1016/j.jaad.2005.12.028; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Ki SH, 2005, MOL CELL BIOL, V25, P4150, DOI 10.1128/MCB.25.10.4150-4165.2005; KIM N, 2016, SCI REP UK, V6; Kratschmar DV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036774; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Lin KT, 2016, STEROIDS, V111, P84, DOI 10.1016/j.steroids.2016.02.019; Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396; Calderon-Montano JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/794930; Meijsing SH, 2009, SCIENCE, V324, P407, DOI 10.1126/science.1164265; Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002; Moghadam-Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365-4632.2009.04322.x; Olayanju A, 2015, FREE RADICAL BIO MED, V78, P202, DOI 10.1016/j.freeradbiomed.2014.11.003; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Scagliotti GV, 2006, EXPERT OPIN THER PAT, V16, P189, DOI 10.1517/13543776.16.2.189; Sharma S, 2006, CARCINOGENESIS, V27, P1721, DOI 10.1093/carcin/bgl052; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Slingerland M, 2013, INVEST NEW DRUG, V31, P1087, DOI 10.1007/s10637-013-9984-1; Spokoini R, 2010, MOL ENDOCRINOL, V24, P1136, DOI 10.1210/me.2009-0466; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Sundahl N, 2015, PHARMACOL THERAPEUT, V152, P28, DOI 10.1016/j.pharmthera.2015.05.001; Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006; Tan KP, 2008, FREE RADICAL BIO MED, V45, P1663, DOI 10.1016/j.freeradbiomed.2008.09.010; Tang XW, 2011, FREE RADICAL BIO MED, V50, P1599, DOI 10.1016/j.freeradbiomed.2011.03.008; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang G, 2008, FREE RADICAL RES, V42, P435, DOI 10.1080/10715760802074462; Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhong D, LUNG CANC, V53, P285	57	64	66	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5285	5295		10.1038/onc.2017.153	http://dx.doi.org/10.1038/onc.2017.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504720				2022-12-28	WOS:000410671700007
J	Lourenco, AR; Coffer, PJ				Lourenco, A. R.; Coffer, P. J.			A tumor suppressor role for C/EBP alpha in solid tumors: more than fat and blood	ONCOGENE			English	Review							BINDING-PROTEIN-ALPHA; HUMAN HEPATOCELLULAR-CARCINOMA; BREAST-CANCER CELLS; GROWTH-INHIBITORY ACTIVITY; ACUTE MYELOID LEUKEMIAS; DOWN-REGULATION; LUNG-CANCER; GENE-EXPRESSION; FACTOR-RECEPTOR; C-MYC	The transcription factor CCAAT/enhancer-binding protein alpha (C/EBP alpha) plays a critical role during embryogenesis and is thereafter required for homeostatic glucose metabolism, adipogenesis and myeloid development. Its ability to regulate the expression of lineage-specific genes and induce growth arrest contributes to the terminal differentiation of several cell types, including hepatocytes, adipocytes and granulocytes. CEBPA loss of-function mutations contribute to the development of similar to 10% of acute myeloid leukemia (AML), stablishing a tumor suppressor role for C/EBP alpha. Deregulation of C/EBP alpha expression has also been reported in a variety of additional human neoplasias, including liver, breast and lung cancer. However, functional CEBPA mutations have not been found in solid tumors, suggesting that abrogation of C/EBP alpha function in non-hematopoietic tissues is regulated by alternative mechanisms. Here we review the function of C/EBP alpha in solid tumors and focus on the molecular mechanisms underlying its tumor suppressive role.	[Lourenco, A. R.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol Med, Utrecht, Netherlands; [Coffer, P. J.] Univ Med Ctr Utrecht, Regenerat Med Ctr, Uppsalalaan 6, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Regenerat Med Ctr, Uppsalalaan 6, NL-3584 CT Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020					Adams BD, 2009, ENDOCRINOLOGY, V150, P14, DOI 10.1210/en.2008-0984; Anand S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112073; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Bennett KL, 2009, INT J CANCER, V124, P1285, DOI 10.1002/ijc.24087; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Cassel TN, 2000, ANN NY ACAD SCI, V923, P300; Chattopadhyay S, 2006, MOL ENDOCRINOL, V20, P984, DOI 10.1210/me.2005-0240; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Cheng JW, 2007, J BIOL CHEM, V282, P30535, DOI 10.1074/jbc.M704829200; Costa DB, 2007, LUNG CANCER, V56, P97, DOI 10.1016/j.lungcan.2006.11.023; Costa DB, 2006, LUNG CANCER, V53, P253, DOI 10.1016/j.lungcan.2006.04.011; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Datta J, 2007, CANCER RES, V67, P2736, DOI 10.1158/0008-5472.CAN-06-4433; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dhawan P, 2009, J BIOL CHEM, V284, P3086, DOI 10.1074/jbc.M803602200; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2000, CANCER RES, V60, P2368; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Foka P, 2009, INT J BIOCHEM CELL B, V41, P1189, DOI 10.1016/j.biocel.2008.10.024; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gaykalova DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093102; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Girard L, 2000, CANCER RES, V60, P4894; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Grandinetti KB, 2011, ONCOGENE, V30, P3328, DOI 10.1038/onc.2011.57; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Hall JR, 2014, CELL CYCLE, V13, P3602, DOI 10.4161/15384101.2014.962957; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halmos B, 2002, CANCER RES, V62, P528; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; House JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009837; Huan HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153117; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kato N, 2011, BLOOD, V117, P221, DOI 10.1182/blood-2010-02-270181; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim YH, 2013, EXP MOL PATHOL, V94, P360, DOI 10.1016/j.yexmp.2012.12.002; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kumagai T, 2009, INT J CANCER, V124, P827, DOI 10.1002/ijc.23994; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Li JN, 2011, ANTICANCER RES, V31, P2683; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lin TC, 2011, LEUKEMIA, V25, P32, DOI 10.1038/leu.2010.222; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Lopez RG, 2009, NAT CELL BIOL, V11, P1181, DOI 10.1038/ncb1960; Lu GD, 2010, GASTROENTEROLOGY, V139, P632, DOI 10.1053/j.gastro.2010.03.051; Lynes MA, 2014, CELL STRESS CHAPERON, V19, P605, DOI 10.1007/s12192-014-0501-z; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Ming J, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150167; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Oeztuerk-Winder F, 2012, EMBO J, V31, P3431, DOI 10.1038/emboj.2012.192; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pan ZM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-417; Patrick BA, 2012, ONCOGENE, V31, P4362, DOI 10.1038/onc.2011.600; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Roe JS, 2014, J EXP MED, V211, P1, DOI 10.1084/jem.20132530; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Rosen ED, 2000, GENE DEV, V14, P1293; Ruttkay-Nedecky B, 2013, INT J MOL SCI, V14, P6044, DOI 10.3390/ijms14036044; Saramaki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Seifeddine R, 2008, CANCER RES, V68, P2158, DOI 10.1158/0008-5472.CAN-07-1190; Shi DB, 2015, CANCER LETT, V369, P376, DOI 10.1016/j.canlet.2015.08.029; Shi YC, 2013, DIGEST LIVER DIS, V45, P844, DOI 10.1016/j.dld.2013.03.013; Shim M, 2005, CANCER RES, V65, P861; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Soriano HE, 1998, HEPATOLOGY, V27, P392, DOI 10.1002/hep.510270212; Sugahara K, 2001, CELL TISSUE RES, V306, P57, DOI 10.1007/s004410100420; Sun CC, 2016, ONCOTARGET, V7, P35960, DOI 10.18632/oncotarget.8482; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tan EH, 2005, CANCER RES, V65, P10330, DOI 10.1158/0008-5472.CAN-04-4486; Tang SH, 2010, CANCER BIOL THER, V9, P88, DOI 10.4161/cbt.9.2.10283; Taylor BS, 2011, CANCER DISCOV, V1, P587, DOI 10.1158/2159-8290.CD-11-0181; Thompson EA, 2011, J INVEST DERMATOL, V131, P1339, DOI 10.1038/jid.2011.31; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tomizawa M, 2003, ANTICANCER RES, V23, P351; Tomizawa M, 2002, INT J MOL MED, V9, P597; Tomizawa M, 2007, ONCOL REP, V17, P341; Tseng HH, 2009, J CANCER RES CLIN, V135, P241, DOI 10.1007/s00432-008-0448-5; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wang CG, 2014, CHINESE J CANCER RES, V26, P17, DOI 10.3978/j.issn.1000-9604.2014.01.01; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang GL, 2008, EXP CELL RES, V314, P1626, DOI 10.1016/j.yexcr.2008.01.028; Wang GL, 2010, J CLIN INVEST, V120, P2549, DOI 10.1172/JCI41933; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QA, 2015, NAT CELL BIOL, V17, P1099, DOI 10.1038/ncb3217; Watkins PJ, 1996, CANCER RES, V56, P1063; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wu YV, 2012, GENE CHROMOSOME CANC, V51, P313, DOI 10.1002/gcc.21917; Yin H, 2005, PROSTATE, V62, P209, DOI 10.1002/pros.20136; Yin H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-158; Yin H, 2009, PROSTATE, V69, P1001, DOI 10.1002/pros.20947; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Yoon S, 2016, MOL THER, V24, P1106, DOI 10.1038/mt.2016.60; Zaragoza K, 2010, MOL CELL BIOL, V30, P2293, DOI 10.1128/MCB.01619-09; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang J, 2010, ONCOGENE, V29, P723, DOI 10.1038/onc.2009.373; Zhang JX, 2015, INT J CLIN EXP PATHO, V8, P14472; Zhang J, 2008, PROSTATE, V68, P1206, DOI 10.1002/pros.20779; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zhang SJ, 2012, J MOL MED, V90, P1069, DOI 10.1007/s00109-012-0879-y; Zhao Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-23	146	52	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5221	5230		10.1038/onc.2017.151	http://dx.doi.org/10.1038/onc.2017.151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504718				2022-12-28	WOS:000410671700001
J	Nandhu, MS; Kwiatkowska, A; Bhaskaran, V; Hayes, J; Hu, B; Viapiano, MS				Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Hayes, J.; Hu, B.; Viapiano, M. S.			Tumor-derived fibulin-3 activates pro-invasive NF-kappa B signaling in glioblastoma cells and their microenvironment	ONCOGENE			English	Article							THERAPEUTIC TARGETS; TISSUE LOCALIZATION; MALIGNANT GLIOMA; GROWTH-FACTOR; STEM-CELLS; ADAM17; RESISTANCE; EXPRESSION; INHIBITOR; EFEMP1	Molecular profiling of glioblastomas has revealed the presence of key signaling hubs that contribute to tumor progression and acquisition of resistance. One of these main signaling mechanisms is the nuclear factor-kappa B (NF-kappa B) pathway, which integrates multiple extracellular signals into transcriptional programs for tumor growth, invasion and maintenance of the tumor-initiating population. We show here that an extracellular protein released by glioblastoma cells, fibulin-3, drives oncogenic NF-kappa B in the tumor and increases NF-kappa B activation in peritumoral astrocytes. Fibulin-3 expression correlates with a NF-kappa B-regulated 'invasive signature' linked to poorer survival, being a possible tissue marker for regions of active tumor progression. Accordingly, fibulin-3 promotes glioblastoma invasion in a manner that requires NF-kappa B activation both in the tumor cells and their microenvironment. Mechanistically, we found that fibulin-3 activates the metalloprotease ADAM17 by competing with its endogenous inhibitor, TIMP3. This results in sustained release of soluble tumor necrosis factor alpha (TNF alpha) by ADAM17, which in turn activates TNF receptors and canonical NF-kappa B signaling. Taken together, our results underscore fibulin-3 as a novel extracellular signal with strong activating effect on NF-kappa B in malignant gliomas. Because fibulin-3 is produced de novo in these tumors and is absent from the normal brain, we propose that targeting the fibulin-3/NF-kappa B axis may provide a novel avenue to disrupt oncogenic NF-kappa B signaling in combination therapies for malignant brain tumors.	[Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Viapiano, M. S.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Nandhu, M. S.; Kwiatkowska, A.; Bhaskaran, V.; Viapiano, M. S.] Harvard Med Sch, Boston, MA USA; [Nandhu, M. S.; Viapiano, M. S.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, 505 Irving Ave,Room 4604, Syracuse, NY 13210 USA; [Hayes, J.] Univ Calif San Francisco, Dept Neurol Surg, Helen Diller Family Canc Ctr, San Francisco, CA USA; [Hu, B.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Hu, B.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University System of Ohio; Ohio State University; Virginia Commonwealth University	Viapiano, MS (corresponding author), SUNY Upstate Med Univ, Dept Neurosci & Physiol, 505 Irving Ave,Room 4604, Syracuse, NY 13210 USA.	viapianm@upstate.edu		Bhaskaran, Vivek/0000-0002-5100-4787	National Institutes of Health [R01CA152065]; National Brain Tumor Society; American Brain Tumor Association; NATIONAL CANCER INSTITUTE [R01CA152065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS091436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Society; American Brain Tumor Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the National Institutes of Health (R01CA152065) and the National Brain Tumor Society to MSV, and the Joel Gingras Jr. Research Fellowship from the American Brain Tumor Association to BH.	Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Baltimore D, 2011, NAT IMMUNOL, V12, P683, DOI 10.1038/ni.2072; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Celiku O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101239; Chen JJ, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/768756; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen XR, 2013, BRAIN RES, V1538, P151, DOI 10.1016/j.brainres.2013.02.025; Chen XR, 2013, NEUROSCI LETT, V537, P44, DOI 10.1016/j.neulet.2013.01.021; Conti Alfredo, 2010, Cancers (Basel), V2, P693, DOI 10.3390/cancers2020693; Creaney J, 2014, THORAX, V69, P895, DOI 10.1136/thoraxjnl-2014-205205; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015; Gray GK, 2014, EXPERT REV NEUROTHER, V14, P1293, DOI 10.1586/14737175.2014.964211; Hiddingh L, 2014, ONCOTARGET, V5, P363, DOI 10.18632/oncotarget.1620; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hu Yuanjie, 2014, Oncoscience, V1, P205; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kim JK, 2014, CANCER LETT, V353, P194, DOI 10.1016/j.canlet.2014.07.034; Kim YJ, 2006, BIOCHEM BIOPH RES CO, V347, P731, DOI 10.1016/j.bbrc.2006.06.149; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Korkolopoulou P, 2008, HUM PATHOL, V39, P1143, DOI 10.1016/j.humpath.2008.01.020; Kusne Y, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005196; Mathis BJ, 2015, CURR DRUG TARGETS, V16, P284, DOI 10.2174/1389450115666141024152421; Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newton RC, 2001, ANN RHEUM DIS, V60, pIII25; Nogueira L, 2011, ONCOTARGET, V2, P646, DOI 10.18632/oncotarget.322; Obaya AJ, 2012, CANCER LETT, V325, P132, DOI 10.1016/j.canlet.2012.06.019; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ohnishi T, 1998, CANCER RES, V58, P2935; Ostrom QT, 2014, NEUROONCOL S4, V16, piv1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pass HI, 2012, NEW ENGL J MED, V367, P1417, DOI 10.1056/NEJMoa1115050; Puliyappadamba VT, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963478; Robe PA, 2004, CLIN CANCER RES, V10, P5595, DOI 10.1158/1078-0432.CCR-03-0392; Rose-John S, 2013, PHARMACOL RES, V71, P19, DOI 10.1016/j.phrs.2013.01.012; Seeliger H, 2009, MOL CANCER RES, V7, P189, DOI 10.1158/1541-7786.MCR-08-0132; Shelest Ekaterina, 2003, In Silico Biology, V3, P71; Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004; Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Watkins S, 2012, TRENDS NEUROSCI, V35, P546, DOI 10.1016/j.tins.2012.05.001; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westhoff MA, 2013, MOL CANCER RES, V11, P1611, DOI 10.1158/1541-7786.MCR-13-0435-T; Wolpert F, 2014, NEURO-ONCOLOGY, V16, P382, DOI 10.1093/neuonc/not232; Zheng XG, 2012, MOL CARCINOGEN, V51, P150, DOI 10.1002/mc.20772; Zong H, 2012, EXPERT REV MOL DIAGN, V12, P383, DOI [10.1586/ERM.12.30, 10.1586/erm.12.30]	66	28	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4875	4886		10.1038/onc.2017.109	http://dx.doi.org/10.1038/onc.2017.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414309	Green Submitted, Green Accepted			2022-12-28	WOS:000408234400005
J	Hu, PS; Xia, QS; Wu, F; Li, DK; Qi, YJ; Hu, Y; Wei, ZZ; Li, SS; Tian, NY; Wei, QF; Shen, LJ; Yin, B; Jiang, T; Yuan, JG; Qiang, BQ; Han, W; Peng, XZ				Hu, P-S; Xia, Q-S; Wu, F.; Li, D-K; Qi, Y-J; Hu, Y.; Wei, Z-Z; Li, S-S; Tian, N-Y; Wei, Q-F; Shen, L-J; Yin, B.; Jiang, T.; Yuan, J-G; Qiang, B-Q; Han, W.; Peng, X-Z			NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 in malignant glioma	ONCOGENE			English	Article							SIDE POPULATION; POLYCOMB GENE; COMPLEX 1; BMI1; GROWTH; IDENTIFICATION; MAINTENANCE; ASTROCYTES; EXPRESSION; REGULATOR	Polycomb group (PcG) proteins play an important role in development and stem cell maintenance, and their dysregulation have been closely linked to oncogenesis and cancer stem cell phenotypes. Here, we found that nervous system polycomb 1 (NSPc1) was highly expressed in stem cell-like glioma cells (SLCs). Knockdown of NSPc1 in SLCs resulted in impaired neurosphere formation and self-renewal abilities, down-regulated expression of stemness markers such as NESTIN, CD133 and SOX2, and decreased capacity to propagate subcutaneous xenografts. In contrast, glioma cells overexpressing NSPc1 exhibited a stem cell-like phenotype, upregulated expression of stemness markers NESTIN, CD133 and SOX2, and an enhanced capacity to propagate subcutaneous xenografts. Furthermore, we identified that NSPc1 epigenetically repressed the expression of retinol dehydrogenase 16 (RDH16) by directly binding to a region upstream (-1073 to -823) of the RDH16 promoter. Next, we confirmed that RDH16 is a stemness suppressor that partially rescues SLCs from the NSPc1-induced increase in neurosphere formation. Finally, we showed that ATRA partly reversed the NSPc1-induced stemness enhancement in SLCs, through mechanisms correlated with an ATRA-dependent decrease in the expression of NSPc1. Thus, our results demonstrate that NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of ATRA via targeting RDH16 and may provide novel targets for glioma treatment in the future.	[Hu, P-S; Xia, Q-S; Wu, F.; Li, D-K; Qi, Y-J; Hu, Y.; Wei, Z-Z; Li, S-S; Tian, N-Y; Wei, Q-F; Shen, L-J; Yin, B.; Yuan, J-G; Qiang, B-Q; Han, W.; Peng, X-Z] Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem,Sch Basic Med,Peking Unio, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China; [Jiang, T.] Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Capital Medical University	Han, W; Peng, XZ (corresponding author), Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing 100005, Peoples R China.; Han, W; Peng, XZ (corresponding author), Peking Union Med Coll, Beijing 100005, Peoples R China.	hanweijx2002@163.com; pengxiaozhong@pumc.edu.cn		wei, zhizhong/0000-0002-9840-1878	National Key Research and Development Plan [2016YFC0902502, 2016YFA0100702]; 973 project [2013CB531304]; National Sciences Foundation of China [31671316, 31301152, 31370789, 31670789]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004]	National Key Research and Development Plan; 973 project(National Basic Research Program of China); National Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work was supported by grants from The National Key Research and Development Plan (2016YFC0902502, 2016YFA0100702), 973 project No. 2013CB531304, National Sciences Foundation of China (31671316, 31301152, 31370789, 31670789), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, CIFMS, 2016-I2M-2-001, 2016-I2M-1-004). We thank Dr Zeper Abliz and Ruiping Zhang from the State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, for assistance with retinoid quantification.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Aguilar-Gallardo C, 2013, SEMIN REPROD MED, V31, P5, DOI 10.1055/s-0032-1331792; Ahmed AU, 2013, EXPERT REV NEUROTHER, V13, P545, DOI [10.1586/ern.13.42, 10.1586/ERN.13.42]; Chen H, 2011, HEAD NECK-J SCI SPEC, V33, P1115, DOI 10.1002/hed.21576; Chockalingam S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083877; Choschzick I, 2014, NEUROSCIENCE, V279, P44, DOI 10.1016/j.neuroscience.2014.07.078; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834; Gong YH, 2005, FEBS LETT, V579, P115, DOI 10.1016/j.febslet.2004.11.056; Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; ISHIDA A, 1993, GENE, V129, P249, DOI 10.1016/0378-1119(93)90275-8; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jiang T, 2016, CANCER LETT, V375, P263, DOI 10.1016/j.canlet.2016.01.024; Jordan CT, 2004, CURR OPIN CELL BIOL, V16, P708, DOI 10.1016/j.ceb.2004.09.002; Jurcic Joseph G, 2007, Curr Oncol Rep, V9, P337, DOI 10.1007/s11912-007-0045-9; Kimura M, 2011, CANCER SCI, V102, P983, DOI 10.1111/j.1349-7006.2011.01891.x; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Li H, 2013, BIOCHEM BIOPH RES CO, V440, P527, DOI 10.1016/j.bbrc.2013.09.095; Liang Y, 2015, FRONT MED-PRC, V9, P57, DOI 10.1007/s11684-015-0389-8; Lorie EP, 2009, ARCH DERMATOL RES, V301, P475, DOI 10.1007/s00403-009-0937-7; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Moon JH, 2008, BIOCHEM BIOPH RES CO, V371, P267, DOI 10.1016/j.bbrc.2008.04.068; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Nunes M, 2001, MECH DEVELOP, V102, P219, DOI 10.1016/S0925-4773(01)00288-X; Oliviero G, 2015, SCI REP-UK, V5, DOI 10.1038/srep18388; Ostrom QT, 2015, CANCER TREAT RES, V163, P1, DOI 10.1007/978-3-319-12048-5_1; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Ross K, 2012, BLOOD, V119, P4152, DOI 10.1182/blood-2011-09-382390; Sakoe Y, 2010, BLOOD, V115, P3787, DOI 10.1182/blood-2009-05-222976; Schwartz YB, 2008, CURR OPIN CELL BIOL, V20, P266, DOI 10.1016/j.ceb.2008.03.002; Sher F, 2011, CELL REPROGRAM, V13, P1, DOI 10.1089/cell.2010.0052; Siddikuzzaman, 2011, IMMUNOPHARM IMMUNOT, V33, P241, DOI 10.3109/08923973.2010.521507; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Udali S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0077-1; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wan F, 2010, BRAIN PATHOL, V20, P877, DOI 10.1111/j.1750-3639.2010.00379.x; Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wang X, 2012, ONCOGENE, V31, P187, DOI 10.1038/onc.2011.232; Wu XD, 2008, NUCLEIC ACIDS RES, V36, P3590, DOI 10.1093/nar/gkn243; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Yadirgi G, 2011, STEM CELLS, V29, P700, DOI 10.1002/stem.614; Yin CL, 2014, FRONT BIOSCI-LANDMRK, V19, P818, DOI 10.2741/4249; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Zhang P, 2009, CANCER LETT, V277, P227, DOI 10.1016/j.canlet.2008.12.015	54	25	26	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4706	4718		10.1038/onc.2017.34	http://dx.doi.org/10.1038/onc.2017.34			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394339				2022-12-28	WOS:000407702400004
J	Howley, BV; Link, LA; Grelet, S; El-Sabban, M; Howe, PH				Howley, Breege V.; Link, Laura A.; Grelet, Simon; El-Sabban, Maya; Howe, Philip H.			A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer	ONCOGENE			English	Article							RETICULUM STRESS-RESPONSE; TRANSCRIPTION FACTOR; MEMBRANE-PROTEIN; LUMINAL DOMAIN; CELL-DEATH; TGF-BETA; CHOLESTEROL; GENES; PROGNOSIS; APPARATUS	In order to better understand the process of breast cancer metastasis, we have generated a mammary epithelial progression series of increasingly aggressive cell lines that metastasize to lung. Here we demonstrate that upregulation of an endoplasmic reticulum (ER) to Golgi trafficking gene signature in metastatic cells enhances transport kinetics, which promotes malignant progression. We observe increased ER-Golgi trafficking, an altered secretome and sensitivity to the retrograde transport inhibitor brefeldin A (BFA) in cells that metastasize to lung. CREB3 was identified as a transcriptional regulator of upregulated ER-Golgi trafficking genes ARF4, COPB1, and USO1, and silencing of these genes attenuated the metastatic phenotype in vitro and lung colonization in vivo. Furthermore, high trafficking gene expression significantly correlated with increased risk of distant metastasis and reduced relapse-free and overall survival in breast cancer patients, suggesting that modulation of ER-Golgi trafficking plays an important role in metastatic progression.	[Howley, Breege V.; Link, Laura A.; Grelet, Simon; El-Sabban, Maya; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Howley, Breege V.; Link, Laura A.; Grelet, Simon; Howe, Philip H.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Link, Laura A.] Kent State Univ, Dept Biomed Sci, Kent, OH 44242 USA	Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Howe, PH (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.	howep@musc.edu		Howe, Philip/0000-0002-1358-1313	National Cancer Institute [CA055536, CA154663]; Abney Foundation; NIH/NIGMS [GM103342, GM103499]; Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC;  [P30 CA138313];  [P30 GM103331]; NATIONAL CANCER INSTITUTE [R01CA154663] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Abney Foundation; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA055536 and CA154663 from the National Cancer Institute to PHH. BVH was supported by funding from the Abney Foundation. This study used the services of the MUSC Proteogenomics Facility supported by NIH/NIGMS (GM103342 and GM103499), the Cell & Molecular Imaging Shared Resource of MUSC supported by P30 CA138313, the MUSC Center for Oral Health Research (COHR), which is partially supported by P30 GM103331, the MUSC Flow Cytometry Facility supported by NIH/NIGMS GM103342, the Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC, and the Gene Targeting and Knockout Shared Resource at MUSC. We thank Annamarie Dalton for assisting us with xenograft experiments and also thank members of the Howe laboratory for providing helpful feedback during the preparation of this manuscript.	Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Bard F, 2016, TRENDS CELL BIOL, V26, P379, DOI 10.1016/j.tcb.2015.12.004; Ben-Tekaya H, 2010, MOL BIOL CELL, V21, P4130, DOI 10.1091/mbc.E10-01-0022; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chan CP, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-6; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; CLERMONT Y, 1993, ANAT REC, V237, P308, DOI 10.1002/ar.1092370303; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Danilov AV, 2008, CANCER METAST REV, V27, P707, DOI 10.1007/s10555-008-9159-2; Dodonova SO, 2015, SCIENCE, V349, P195, DOI 10.1126/science.aab1121; Donizy P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101619; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Fox RM, 2010, J CELL BIOL, V191, P479, DOI 10.1083/jcb.201004062; Guizzunti G, 2016, P NATL ACAD SCI USA, V113, pE6590, DOI 10.1073/pnas.1610844113; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Halberg N, 2016, CANCER CELL, V29, P339, DOI 10.1016/j.ccell.2016.02.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5; Kondo S, 2007, MOL CELL BIOL, V27, P1716, DOI 10.1128/MCB.01552-06; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Li H, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-168; Li T, 2016, MOL NEUROBIOL, V53, P1377, DOI 10.1007/s12035-014-9083-0; Liang GQ, 2006, MOL CELL BIOL, V26, P7999, DOI 10.1128/MCB.01046-06; Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963; Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06; Oku M, 2011, CELL STRUCT FUNCT, V36, P1, DOI 10.1247/csf.10014; Oliveros J.C., 2007, INTERACTIVE TOOL COM; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Popoff V, 2011, J BIOL CHEM, V286, P35634, DOI 10.1074/jbc.M111.261800; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Reiling JH, 2013, NAT CELL BIOL, V15, P1473, DOI 10.1038/ncb2865; Reverter M, 2014, CELL REP, V7, P883, DOI 10.1016/j.celrep.2014.03.043; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962; Serebrenik Y, 2015, FASEB J, V29; Spang A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013391; Taniguchi M, 2016, CELL STRUCT FUNCT, V41, P93, DOI 10.1247/csf.16005; Taniguchi M, 2015, CELL STRUCT FUNCT, V40, P13, DOI 10.1247/csf.14015; Vellanki RN, 2010, ENDOCRINOLOGY, V151, P4146, DOI 10.1210/en.2010-0137; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Yadav S, 2009, MOL BIOL CELL, V20, P1728, DOI 10.1091/mbc.E08-10-1077; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhou JX, 2012, J NEURO-ONCOL, V110, P195, DOI 10.1007/s11060-012-0970-9; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	63	35	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1308	1325		10.1038/s41388-017-0023-0	http://dx.doi.org/10.1038/s41388-017-0023-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249802	Green Accepted			2022-12-28	WOS:000427279300004
J	Chang, C; Liu, J; He, W; Qu, M; Huang, X; Deng, Y; Shen, L; Zhao, X; Guo, H; Jiang, J; Fu, XY; Huang, R; Zhang, D; Yan, J				Chang, C.; Liu, J.; He, W.; Qu, M.; Huang, X.; Deng, Y.; Shen, L.; Zhao, X.; Guo, H.; Jiang, J.; Fu, X. Y.; Huang, R.; Zhang, D.; Yan, J.			A regulatory circuit HP1 gamma/miR-451a/c-Myc promotes prostate cancer progression	ONCOGENE			English	Article							C-MYC ONCOGENE; CELL; HETEROCHROMATIN; HP1-GAMMA; OVEREXPRESSION; CARCINOMA; MICRORNAS; MIR-451A; COMPLEX; PROTEIN	Heterochromatin protein 1 gamma (HP1 gamma) has been implicated in carcinogenesis of various cancer types. However, the role of HP1 gamma in prostate cancer (PCa) progression and the underlying molecular mechanisms remain largely unknown. We found that HP1 gamma is upregulated in PCa and elevated levels of HP1 gamma in PCa predict poor outcome. In addition, depletion of HP1 gamma in PCa cells not only repressed proliferation and induced apoptosis but also impaired tumorigenicity. We also found that c-Myc was capable of upregulating HP1 gamma by directly binding to the E-box element in the first intron of HP1 gamma gene, and the upregulated HP1 gamma, in turn, repressed the expression of miR-451a by enhancing H3K9 methylation at the promoter region of miR-451a. Furthermore, reduction of miR-451a significantly reversed HP1 gamma loss-induced PCa cell apoptosis, whereas miR-451a overexpression repressed cell survival by targeting and downregulating c-Myc. The association among c-Myc, HP1 gamma and miR-451a was further confirmed in human clinical samples. Therefore, we propose that an HP1 gamma/miR-451a/c-Myc regulatory circuitry exists in PCa cells and this circuit has a crucial role in PCa progression.	[Chang, C.; Liu, J.; He, W.; Huang, X.; Shen, L.; Fu, X. Y.; Yan, J.] Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Chang, C.; Liu, J.; He, W.; Huang, X.; Shen, L.; Fu, X. Y.; Yan, J.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Chang, C.; Liu, J.; Huang, X.; Shen, L.; Yan, J.] Collaborat Innovat Ctr Genet & Dev, Shanghai, Peoples R China; [Qu, M.] Nanjing Univ, Jinling Coll, Sch Chem & Life Sci, Dept Biosci & Bioengn, Nanjing, Jiangsu, Peoples R China; [Deng, Y.; Zhao, X.; Guo, H.] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Urol, Med Sch,Inst Urol, Nanjing, Jiangsu, Peoples R China; [Jiang, J.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Urol, Chongqing, Peoples R China; [Huang, R.] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Zhang, D.] Philadelphia Coll Osteopath Med, Dept Biomed Sci, Philadelphia, PA USA; [Yan, J.] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; Army Medical University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Yan, J (corresponding author), Nanjing Univ, Model Anim Res Ctr, 12 Xuefu Rd, Nanjing 210061, Jiangsu, Peoples R China.	yanjun@nju.edu.cn	Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952	National Key Research and Development Plan of China [2016YFC0902202]; National Natural Science Foundation of China [81172009, 81672873, 81372168, 81172442]; Doctoral Fund of Ministry of Education of China [20110091120028]; Natural Science Foundation for Universities in Jiangsu Province, China [BK20151396]; Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine; 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12020108]; One Hundred Talent Program of Chinese Academy of Sciences; Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province [KYZZ_ 0037]; Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University [KF-GN-201602]; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences [SIMM1705KF-02]	National Key Research and Development Plan of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Natural Science Foundation for Universities in Jiangsu Province, China; Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine; 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences; One Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province; Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences(Chinese Academy of Sciences)	This study was financially supported by the National Key Research and Development Plan of China (2016YFC0902202 to JY), the National Natural Science Foundation of China (81172009, 81672873 and 81372168 to JY, and 81172442 to JJ), Doctoral Fund of Ministry of Education of China (20110091120028 to JY), Natural Science Foundation for Universities in Jiangsu Province, China (BK20151396 to JY), the Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine (to DZ), the 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences, Grant No. XDA12020108 (to RH), One Hundred Talent Program of Chinese Academy of Sciences (to RH), Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province (KYZZ_ 0037 to CC), the Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University (KF-GN-201602) and the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM1705KF-02). We also thank Jun Qin and Min Jiang for their help in data retrieval from TCGA database.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Babapoor S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107502; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Bertoli G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030421; Bian HB, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-20; Black JC, 2010, MOL CELL, V40, P736, DOI 10.1016/j.molcel.2010.11.008; Borsos BN, 2017, SCI REP-UK, V7, DOI 10.1038/srep40960; Canzio D, 2014, TRENDS CELL BIOL, V24, P377, DOI 10.1016/j.tcb.2014.01.002; Chen DQ, 2014, EUR J CANCER, V50, P3050, DOI 10.1016/j.ejca.2014.09.008; Choi JD, 2012, NUCLEIC ACIDS RES, V40, P11321, DOI 10.1093/nar/gks947; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Fukumoto I, 2014, BRIT J CANCER, V111, P386, DOI 10.1038/bjc.2014.293; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Guan XW, 2016, BIOORG MED CHEM LETT, V26, P1561, DOI 10.1016/j.bmcl.2016.02.013; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Itsumi M, 2013, J MOL ENDOCRINOL, V50, P401, DOI 10.1530/JME-13-0024; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Jenkins RB, 1997, CANCER RES, V57, P524; Kang H, 2016, METHODS MOL BIOL, V1344, P313, DOI 10.1007/978-1-4939-2966-5_20; Khanmi K, 2015, CLIN CHIM ACTA, V451, P154, DOI 10.1016/j.cca.2015.09.022; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Laitinen VH, 2015, INT J CANCER, V136, P2316, DOI 10.1002/ijc.29276; Lee Young-Ho, 2015, J Nat Sci, V1, pe127; Lemaitre C, 2014, DNA REPAIR, V19, P163, DOI 10.1016/j.dnarep.2014.03.015; Li XY, 2011, J EXP MED, V208, P663, DOI 10.1084/jem.20102384; Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735; Liu ZR, 2016, LIFE SCI, V149, P104, DOI 10.1016/j.lfs.2016.02.059; Liu ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/207684; Lu SZ, 2015, J BIOL CHEM, V290, P24178, DOI 10.1074/jbc.M115.648212; Luoto KR, 2010, CANCER RES, V70, P8748, DOI 10.1158/0008-5472.CAN-10-0944; Minna E, 2016, ONCOTARGET, V7, P12731, DOI 10.18632/oncotarget.7262; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pazin MJ, 2010, PLOS ONE, V5; Pierorazio PM, 2012, BJU INT, V109, P988, DOI 10.1111/j.1464-410X.2011.10514.x; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Riquelme I, 2016, CELL ONCOL, V39, P23, DOI 10.1007/s13402-015-0247-3; Rizzardi AE, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-42; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shapiro E, 2008, J UROLOGY, V179, P2435, DOI 10.1016/j.juro.2008.01.091; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shiota M, 2010, ENDOCR-RELAT CANCER, V17, P455, DOI 10.1677/ERC-09-0321; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slezak J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-148; Supino R, 2007, ANN NY ACAD SCI, V1095, P175, DOI 10.1196/annals.1397.021; Takanashi M, 2009, AM J PATHOL, V174, P309, DOI 10.2353/ajpath.2009.080148; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Vad-Nielsen J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2059-x; Vicent GP, 2013, GENE DEV, V27, P1179, DOI 10.1101/gad.215293.113; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Yamamoto S, 2010, GENE CHROMOSOME CANC, V49, P487, DOI 10.1002/gcc.20759; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zhou J, 2014, TUMOR BIOL, V35, P9777, DOI 10.1007/s13277-014-2182-8	61	29	30	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					415	426		10.1038/onc.2017.332	http://dx.doi.org/10.1038/onc.2017.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967902				2022-12-28	WOS:000423331600001
J	Piscitello, D; Varshney, D; Lilla, S; Vizioli, MG; Reid, C; Gorbunova, V; Seluanov, A; Gillespie, DA; Adams, PD				Piscitello, D.; Varshney, D.; Lilla, S.; Vizioli, M. G.; Reid, C.; Gorbunova, V; Seluanov, A.; Gillespie, D. A.; Adams, P. D.			AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; CELL-CYCLE CHECKPOINT; HEMATOPOIETIC-CELLS; TUMOR-SUPPRESSOR; DAMAGE RESPONSE; ACTIVATION; CANCER; PTEN; PATHWAY; TUMORIGENESIS	Deregulated AKT kinase activity due to PTEN deficiency in cancer cells contributes to oncogenesis by incompletely understood mechanisms. Here, we show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and CHK2 activation in response to irradiation, impaired G2 checkpoint proficiency and radiosensitization. These defects are associated with reduced expression of MRE11, RAD50 and NBS1, components of the apical MRE11/RAD50/NBS1 (MRN) DNA damage response complex. Consistent with reduced MRN complex function, PTEN-deficient cells fail to resect DNA double-strand breaks efficiently after irradiation and show greatly diminished proficiency for DNA repair via the error-free homologous recombination (HR) repair pathway. MRE11 is highly unstable in PTEN-deficient cells but stability can be significantly restored by inhibiting mTORC1 or p70S6 kinase (p70S6K), downstream kinases whose activities are stimulated by AKT, or by mutating a residue in MRE11 that we show is phosphorylated by p70S6K in vitro. In primary human fibroblasts, activated AKT suppresses MRN complex expression to escalate RAS-induced DNA damage and thereby reinforce oncogene-induced senescence. Taken together, our data demonstrate that deregulation of the PI3K-AKT/mTORC1/p70S6K pathways, an event frequently observed in cancer, exert profound effects on genome stability via MRE11 with potential implications for tumour initiation and therapy.	[Piscitello, D.; Lilla, S.] Beatson Inst Canc Res, Garscube Estate, Glasgow, Lanark, Scotland; [Varshney, D.] Univ Dundee, Sch Life Sci, Ctr Gene Regulat & Express, Dundee, Scotland; [Vizioli, M. G.; Reid, C.; Adams, P. D.] Univ Glasgow, Epigenet Canc & Ageing, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland; [Gorbunova, V; Seluanov, A.] Univ Rochester, Dept Biol, Rochester, NY 14627 USA; [Gillespie, D. A.] Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, Tenerife 38071, Spain	Beatson Institute; University of Dundee; University of Glasgow; University of Rochester; Universidad de la Laguna	Adams, PD (corresponding author), Univ Glasgow, Epigenet Canc & Ageing, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.; Gillespie, DA (corresponding author), Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, Tenerife 38071, Spain.; Adams, PD (corresponding author), Sanford Burnham Prebys Med Discovery Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dgillesp@ull.es; p.adams@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Adams, Peter/0000-0002-0684-1770; Seluanov, Andrei/0000-0003-3400-538X; Varshney, Dhaval/0000-0001-9197-9821; Gorbunova, Vera/0000-0001-8979-0333; Piscitello, Desiree/0000-0002-2510-4717	CRUK programme grant [C10652/A16566]; IMBRAIN Project [FP7-REGPOT-2012-CT2012-31637-IMBRAIN]; NIA [P01AG047200]; Cancer Research UK [16566] Funding Source: researchfish; NATIONAL INSTITUTE ON AGING [R01AG027237, P01AG047200, R03AG052365] Funding Source: NIH RePORTER	CRUK programme grant; IMBRAIN Project; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Cancer Research UK(Cancer Research UK); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank members of the Gillespie and Adams labs for critical discussions. Work in the Adams lab was supported by the CRUK programme grant C10652/A16566. DA Gillespie acknowledges the IMBRAIN Project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN: EU FP7 and Gobierno de Canarias) for financial support. V Gorbunova acknowledges the NIA P01AG047200.	Ali SM, 1999, BIODRUGS, V12, P138, DOI 10.2165/00063030-199912020-00006; Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buis J, 2008, CELL, V135, P85, DOI 10.1016/j.cell.2008.08.015; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Guo F, 2013, LEUKEMIA, V27, P2040, DOI 10.1038/leu.2013.93; Harlow E, 1988, ANTIBODIES LAB MANUA; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jastrzebski K, 2007, GROWTH FACTORS, V25, P209, DOI 10.1080/08977190701779101; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; King FW, 2004, CELL CYCLE, V3, P634; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu PD, 2015, MOL CELL, V57, P648, DOI 10.1016/j.molcel.2015.01.005; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; McGarry DJ, 2016, ACS CHEM BIOL, V11, P3300, DOI 10.1021/acschembio.6b00742; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Seluanov Andrei, 2010, J Vis Exp, DOI 10.3791/2002; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wen Q, 2008, MOL BIOL CELL, V19, P1693, DOI 10.1091/mbc.E07-09-0975; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	49	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					427	438		10.1038/onc.2017.340	http://dx.doi.org/10.1038/onc.2017.340			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967905	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000423331600002
J	Zhang, F; Virshup, DM; Cheong, JK				Zhang, F.; Virshup, D. M.; Cheong, J. K.			Oncogenic RAS-induced CK1 alpha drives nuclear FOXO proteolysis	ONCOGENE			English	Article							FORKHEAD TRANSCRIPTION FACTORS; SYNTHETIC LETHAL INTERACTIONS; CANCER-CELLS; SELECTIVE INHIBITORS; MULTIPLE-MYELOMA; HUMAN COLON; FACTOR AFX; E3 LIGASE; PHASE-I; KINASE	Evasion of forkhead box O (FOXO) family of longevity-related transcription factors-mediated growth suppression is necessary to promote cancer development. Since somatic alterations or mutations and transcriptional dysregulation of the FOXO genes are infrequent in human cancers, it remains unclear how these tumour suppressors are eliminated from cancer cells. The protein stability of FOXO3A is regulated by Casein Kinase 1 alpha (CK1 alpha) in an oncogenic RAS-specific manner, but whether this mode of regulation extends to related FOXO family members is unknown. Here we report that CK1 alpha similarly destabilizes FOXO4 in RASmutant cells by phosphorylation at serines 265/268. The CK1 alpha-dependent phosphoregulation of FOXO4 is primed, in part, by the PI3K/AKT effector axis of oncogenic RAS signalling. In addition, mutant RAS coordinately elevates proteasome subunit expression and proteolytic activity to eradicate nuclear FOXO4 proteins from RAS-mutant cancer cells. Importantly, dual inhibition of CK1 alpha and the proteasome synergistically inhibited the growth of multiple RAS-mutant human cancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of caspase-dependent apoptosis. Our findings challenge the current paradigm that nuclear export regulates the proteolysis of FOXO3A/4 tumour suppressors in the context of cancer and illustrates how oncogenic RAS-mediated degradation of FOXOs, via post-translational mechanisms, blocks these important tumour suppressors.	[Zhang, F.; Virshup, D. M.; Cheong, J. K.] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore; [Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA	National University of Singapore; National University of Singapore; Duke University	Virshup, DM; Cheong, JK (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg; jitkong.cheong@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant [NMRC/BNIG/1078/2012]; Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund [Duke-NUSSBF/2015/0004]; Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant [MOE2016-T2-2-052]; Singapore Agency for Science, Technology and Research (A*STAR); Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program; National Research Foundation under its Singapore Translational Research (STaR) Investigator Award; Singapore Ministry of Health's National Medical Research Council [NMRC/STaR/0017/2013]	Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund; Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant(Ministry of Education, Singapore); Singapore Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program(Ministry of Education, SingaporeMinistry of Health-SingaporeNational University of Singapore); National Research Foundation under its Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore)	We thank Chun Wei Chan, Edison and Yun Ka Wong (Duke-NUS) for their excellent technical support. We are greatly indebted to Christopher Counter (Duke), William Kaelin (Harvard), Koji Itahana (Duke-NUS), Sujoy Ghosh (Duke-NUS) and John Chua (NUS) for reagents and helpful discussions. This research is supported by the Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant (NMRC/BNIG/1078/2012), a Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund (Duke-NUSSBF/2015/0004) and the Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant (MOE2016-T2-2-052) awarded to JKC. DMV is supported by the Singapore Agency for Science, Technology and Research (A*STAR) and the Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program Grant, as well as the National Research Foundation under its Singapore Translational Research (STaR) Investigator Award and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC/STaR/0017/2013).	Alexander TB, 2016, J CLIN ONCOL, V34, P4094, DOI 10.1200/JCO.2016.67.5066; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Azmi AS, 2013, HAEMATOLOGICA, V98, P1098, DOI 10.3324/haematol.2012.074781; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cheong JK, 2011, ONCOGENE, V30, P2558, DOI 10.1038/onc.2010.627; Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dobson M, 2011, BBA-MOL CELL RES, V1813, P1453, DOI 10.1016/j.bbamcr.2011.05.001; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gounder MM, 2016, J CLIN ONCOL, V34, P3166, DOI 10.1200/JCO.2016.67.6346; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2016, NATURE, V537, P328, DOI 10.1038/nature19947; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Honaker Y, 2010, ONCOGENE, V29, P3324, DOI 10.1038/onc.2010.96; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Jaras M, 2014, J EXP MED, V211, P605, DOI 10.1084/jem.20131033; Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200; Kattapuram T, 2005, J BIOL CHEM, V280, P15340, DOI 10.1074/jbc.M500214200; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lantermann AB, 2015, CANCER RES, V75, P1; Lapalombella R, 2012, BLOOD, V120, P4621, DOI 10.1182/blood-2012-05-429506; Li J, 2016, ONCOTARGET, V7, P25585, DOI 10.18632/oncotarget.8339; Lin LH, 2014, INT J ONCOL, V44, P557, DOI 10.3892/ijo.2013.2205; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood-2007-08-104950; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029; Razak ARA, 2016, J CLIN ONCOL, V34, P4142, DOI 10.1200/JCO.2015.65.3949; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Steckel M, 2012, CELL RES, V22, P1227, DOI 10.1038/cr.2012.82; Su LN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-378; Sun QX, 2013, P NATL ACAD SCI USA, V110, P1303, DOI 10.1073/pnas.1217203110; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Wang GJ, 2015, BIOCHEM BIOPH RES CO, V459, P629, DOI 10.1016/j.bbrc.2015.02.160; Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yu WJ, 2017, LEUKEMIA LYMPHOMA, V58, P428, DOI 10.1080/10428194.2016.1190968; Zhang W, 2016, CELL REP, V15, P349, DOI 10.1016/j.celrep.2016.03.021; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492; Zhou W, 2009, GASTROENTEROLOGY, V137, P1403, DOI 10.1053/j.gastro.2009.06.049; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	81	16	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					363	376		10.1038/onc.2017.334	http://dx.doi.org/10.1038/onc.2017.334			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945225	Green Published, hybrid			2022-12-28	WOS:000422753900009
J	van Voss, MRH; Vesuna, F; Bol, GM; Afzal, J; Tantravedi, S; Bergman, Y; Kammers, K; Lehar, M; Malek, R; Ballew, M; ter Hoeve, N; Abou, D; Thorek, D; Berlinicke, C; Yazdankhah, M; Sinha, D; Le, A; Abrahams, R; Tran, PT; van Diest, PJ; Raman, V				van Voss, M. R. Heerma; Vesuna, F.; Bol, G. M.; Afzal, J.; Tantravedi, S.; Bergman, Y.; Kammers, K.; Lehar, M.; Malek, R.; Ballew, M.; ter Hoeve, N.; Abou, D.; Thorek, D.; Berlinicke, C.; Yazdankhah, M.; Sinha, D.; Le, A.; Abrahams, R.; Tran, P. T.; van Diest, P. J.; Raman, V.			Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment	ONCOGENE			English	Article							RNA HELICASE DDX3; BREAST-CANCER; COMPLEX-I; THERAPEUTIC TARGET; TUMOR-SUPPRESSOR; RESISTANCE; PROTEIN; CELLS; METABOLISM; APOPTOSIS	DDX3 is a DEAD box RNA helicase with oncogenic properties. RK-33 is developed as a small-molecule inhibitor of DDX3 and showed potent radiosensitizing activity in preclinical tumor models. This study aimed to assess DDX3 as a target in breast cancer and to elucidate how RK-33 exerts its anti-neoplastic effects. High DDX3 expression was present in 35% of breast cancer patient samples and correlated with markers of aggressiveness and shorter survival. With a quantitative proteomics approach, we identified proteins involved in the mitochondrial translation and respiratory electron transport pathways to be significantly downregulated after RK-33 or DDX3 knockdown. DDX3 localized to the mitochondria and DDX3 inhibition with RK-33 reduced mitochondrial translation. As a consequence, oxygen consumption rates and intracellular ATP concentrations decreased and reactive oxygen species (ROS) increased. RK-33 antagonized the increase in oxygen consumption and ATP production observed after exposure to ionizing radiation and reduced DNA repair. Overall, we conclude that DDX3 inhibition with RK-33 causes radiosensitization in breast cancer through inhibition of mitochondrial translation, which results in reduced oxidative phosphorylation capacity and increased ROS levels, culminating in a bioenergetic catastrophe.	[van Voss, M. R. Heerma; Vesuna, F.; Bol, G. M.; Tantravedi, S.; Bergman, Y.; Abou, D.; Thorek, D.; Raman, V.] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA; [van Voss, M. R. Heerma; Bol, G. M.; ter Hoeve, N.; van Diest, P. J.; Raman, V.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Afzal, J.; Abrahams, R.] Johns Hopkins Univ, Dept Cardiol, Sch Med, Baltimore, MD USA; [Kammers, K.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Lehar, M.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA; [Malek, R.; Ballew, M.; Tran, P. T.] Johns Hopkins Univ, Dept Radiat Oncol, Sch Med, Baltimore, MD USA; [Berlinicke, C.; Yazdankhah, M.; Sinha, D.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA; [Le, A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Le, A.; Tran, P. T.; van Diest, P. J.; Raman, V.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Tran, P. T.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	Johns Hopkins University; Utrecht University; Utrecht University Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Raman, V (corresponding author), Johns Hopkins Univ, Dept Radiol, Sch Med, 720 Rutland Ave,Traylor 340, Baltimore, MD 21205 USA.	vraman2@jhmi.edu	Vesuna, Farhad/G-3179-2010; Tran, Phuoc/W-2084-2019; Afzal, Junaid/L-3643-2019; Heerma van Voss, Marise/N-5637-2016	Vesuna, Farhad/0000-0002-0356-5096; Tran, Phuoc/0000-0002-0147-0376; Le, Anne/0000-0002-2958-8149; Afzal, Junaid/0000-0002-2877-234X; Heerma van Voss, Marise/0000-0001-8368-9859	Utrecht University Alexandre Suerman Stipend (MRHvV); Dutch Cancer Foundation [UU2013-5851]; NIH [R01CA166348, R01CA193895, R01CA140226, R01CA131250]; FAMRI; Safeway; NATIONAL CANCER INSTITUTE [R01CA166348, R01CA131250, R01CA193895, R01CA140226] Funding Source: NIH RePORTER	Utrecht University Alexandre Suerman Stipend (MRHvV); Dutch Cancer Foundation(KWF Kankerbestrijding); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI; Safeway; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bob Cole, Tatiana Boronina and Bob O' Meally of the Johns Hopkins Mass Spectrometry and Proteomics core facility for their help with the proteomics experiments; Tri Nguyen for his help with interpretation of the electron microscopy images; the Dawson Laboratory at the Johns Hopkins School of Medicine for their help with the mitochondrial translation assay; and Beth Rodgers, who kindly provided us with S<SUP>35</SUP>-methionine. This work was financially supported by Utrecht University Alexandre Suerman Stipend (MRHvV), the Dutch Cancer Foundation (UU2013-5851; MRHvV), NIH (R01CA166348 to PTT, R01CA193895 to AL, and R01CA140226 and R01CA131250 to VR), FAMRI (VR) and Safeway (VR).	Abaeva IS, 2011, EMBO J, V30, P115, DOI 10.1038/emboj.2010.302; Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Angus AGN, 2010, J GEN VIROL, V91, P122, DOI 10.1099/vir.0.015909-0; [Anonymous], 1998, MED RES INV HUM SUBJ; Antonicka H, 2015, CELL REP, V10, P920, DOI 10.1016/j.celrep.2015.01.030; Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chen CY, 2016, HUM MOL GENET, V25, P2905, DOI 10.1093/hmg/ddw143; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen HH, 2015, ONCOGENE, V34, P2790, DOI 10.1038/onc.2014.190; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Eiermann W, 2012, ANN ONCOL, V23, P30, DOI 10.1093/annonc/mds192; Farnie G, 2015, ONCOTARGET, V6, P30472, DOI 10.18632/oncotarget.5401; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Geissler R, 2012, NUCLEIC ACIDS RES, V40, P4998, DOI 10.1093/nar/gks070; Hagerstrand D, 2013, CANCER DISCOV, V3, P1044, DOI 10.1158/2159-8290.CD-12-0592; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kammers Kai, 2015, EuPA Open Proteom, V7, P11; Kondaskar A, 2011, ACS MED CHEM LETT, V2, P252, DOI 10.1021/ml100281b; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Leary SC, 2009, METHODS MOL BIOL, V554, P143, DOI 10.1007/978-1-59745-521-3_10; LeBleu VS, 2014, NAT CELL BIOL, P1001, DOI DOI 10.1038/NCB3039; Lee CS, 2008, NUCLEIC ACIDS RES, V36, P4708, DOI 10.1093/nar/gkn454; Li Y, 2006, CANCER RES, V66, P8520, DOI 10.1158/0008-5472.CAN-05-4364; Li YF, 2007, J BIOL CHEM, V282, P17557, DOI 10.1074/jbc.M701056200; Lu CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121046; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Moelans CB, 2009, CELL ONCOL, V31, P1, DOI 10.3233/CLO-2009-0461; Oshiumi H, 2010, EUR J IMMUNOL, V40, P940, DOI 10.1002/eji.200940203; Padmanabhan PK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.315; Pelicano H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0434-6; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Qin LL, 2015, CELL REP, V13, P2056, DOI 10.1016/j.celrep.2015.11.015; Rasband W. S, 2015, IMAGEJ; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Shih JW, 2012, BIOCHEM J, V441, P119, DOI 10.1042/BJ20110739; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tarn WY, 2009, RNA BIOL, V6, P17, DOI 10.4161/rna.6.1.7440; Tu YT, 2015, CELL REP, V10, P854, DOI 10.1016/j.celrep.2015.01.033; van Voss MRH, 2015, ONCOTARGET, V6, P28312, DOI 10.18632/oncotarget.4873; Vellinga TT, 2015, CLIN CANCER RES, V21, P2870, DOI 10.1158/1078-0432.CCR-14-2290; Vermeulen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037864; Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008-5472.CAN-15-0491; WARDMAN P, 1982, INT J RADIAT ONCOL, V8, P399, DOI 10.1016/0360-3016(82)90647-2; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wilky BA, 2016, ONCOGENE, V35, P2574, DOI 10.1038/onc.2015.336; Xie Min, 2016, Cancer Res, V76, P6340; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295; Zhang X, 2012, J RADIAT RES, V53, P257, DOI 10.1269/jrr.11124	63	39	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					63	74		10.1038/onc.2017.308	http://dx.doi.org/10.1038/onc.2017.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869602	Green Accepted			2022-12-28	WOS:000422625000007
J	Jiang, X; Bao, Y; Liu, H; Kou, X; Zhang, Z; Sun, F; Qian, Z; Lin, Z; Li, X; Liu, X; Jiang, L; Yang, Y				Jiang, X.; Bao, Y.; Liu, H.; Kou, X.; Zhang, Z.; Sun, F.; Qian, Z.; Lin, Z.; Li, X.; Liu, X.; Jiang, L.; Yang, Y.			VPS34 stimulation of p62 phosphorylation for cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; INTERACTING PROTEIN P62; KAPPA-B ACTIVATION; BECLIN 1; SELECTIVE AUTOPHAGY; BREAST-CANCER; MEDIATED CLEAVAGE; P62/SQSTM1; APOPTOSIS; TUMORIGENESIS	Vps34, a class III PtdIns3 lipid kinase involved in the control of both autophagic and endocytic systems, has been studied extensively in numerous fundamental cellular processes. Accumulating evidence indicates that Vps34 may also contribute to the development and progression of human cancers. However, the mechanism of Vps34 in tumorigenesis remains elusive. Here, we report an unanticipated role of Vps34 in the activation of p62 for cancer development. We identified that Vps34 is a transcriptional activator of p62 through competition of Nrf2 (nuclear factor erythroid 2-related factor 2) for Keap1 binding. Vps34 augments the association of PKC-delta with p62 for its phosphorylation at Serine 349, which leads to positive feedback on the Nrf2-dependent transcription of oncogenes. Additionally, we found that the expression of Vps34 is correlated with the tumorigenic activity of human breast cancer cells. Normally inactive in breast cancer, caspase 8 can cleave Vps34 at residue D285, which directly abolished its lipid kinase activity and dramatically altered cell invasion potential, colony formation, as well as tumorigenesis in orthotopic engraftments in mice. The cleavage at D285 blocks expression of LC3-II, Nrf2 and subsequently, p62, in addition to blocking tumor growth, indicating that the intact structure of Vps34 is essential for its activity. Moreover, either knockout of PKC-delta or knockdown of p62 by small interfering RNA in MCF-7 cells abrogates Vps34-dependent tumor growth. Data presented here suggested that Vps34 stimulates tumor development mainly through PKC-delta-activation of p62.	[Jiang, X.; Bao, Y.; Liu, H.; Kou, X.; Zhang, Z.; Sun, F.; Qian, Z.; Yang, Y.] Fudan Univ, Sch Pharm, Dept Pharmacol & Biochem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China; [Lin, Z.] Roche Innovat Ctr Shanghai, Chem Biol Roche Pharmaceut Res & Early Dev, Shanghai, Peoples R China; [Li, X.] Shanghai Eight People Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Liu, X.] Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; [Jiang, L.] Oakland Univ, Dept Biol Sci, Rochester, MI USA	Fudan University; Georgetown University; Oakland University	Yang, Y (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol & Biochem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.	yonghuayang@hotmail.com	Qian, Zhong Ming/E-8884-2016	Qian, Zhong Ming/0000-0002-6399-938X	National Natural Science Foundation of China [81572721, 81272391]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (No. 81572721 and 81272391 to YY).	Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620; Cai-McRae X, 2015, ONCOGENE, V34, P2968, DOI 10.1038/onc.2014.244; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Germain M, 2011, EMBO J, V30, P395, DOI 10.1038/emboj.2010.327; Hirsch DS, 2010, CANCER RES, V70, P5974, DOI 10.1158/0008-5472.CAN-09-2682; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin MY, 2013, CELL, V152, P368, DOI 10.1016/j.cell.2013.01.004; Kang R, 2012, AUTOPHAGY, V8, P989, DOI 10.4161/auto.20258; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lee E, 2016, ONCOTARGET, V7, P67919, DOI 10.18632/oncotarget.12084; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mbengue A, 2015, NATURE, V520, P683, DOI 10.1038/nature14412; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shapiro G, 2015, CLIN CANCER RES, V21; Shi J, 2014, CELL DEATH DIFFER, V21, P1432, DOI 10.1038/cdd.2014.58; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105; Tang FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021208; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Watanabe Y, 2011, J CELL SCI, V124, P2692, DOI 10.1242/jcs.081232; Wee LJK, 2007, BIOINFORMATICS, V23, P3241, DOI 10.1093/bioinformatics/btm334; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	58	38	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6850	6862		10.1038/onc.2017.295	http://dx.doi.org/10.1038/onc.2017.295			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846113	Green Published, hybrid			2022-12-28	WOS:000418041800002
J	Rupp, M; Hagenbuchner, J; Rass, B; Fiegl, H; Kiechl-Kohlendorfer, U; Obexer, P; Ausserlechner, MJ				Rupp, M.; Hagenbuchner, J.; Rass, B.; Fiegl, H.; Kiechl-Kohlendorfer, U.; Obexer, P.; Ausserlechner, M. J.			FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3	ONCOGENE			English	Article							FOXO TRANSCRIPTION FACTORS; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; CELLS; AKT; ACTIVATION; MUTATIONS; APOPTOSIS; CANCER; BIM	Forkhead box O class transcription factors are homeostasis regulators that control cell death, longevity and therapy-resistance. In neuroblastoma (NB), nuclear FOXO3 correlates with stage M disease and poor prognosis. To analyze whether FOXO3 contributes to drug-resistance in this childhood cancer, we investigated how different high-stage-derived NB cells respond to the activation of an ectopic FOXO3 allele. We found endogenous FOXO3 mostly localized to the nucleus-upon activation of an ectopic, 4OHTactivated FOXO3(A3) ER fusion protein two of the cell lines underwent apoptosis, whereas in the others FOXO3-activation even increased survival during drug-treatment. In the latter cell type, FOXO3 did not induce the BH3-only protein BCL2L11/BIM due to impaired binding of FOXO3 to the BIM-promoter, but still activated other FOXO3 targets. It was shown before that FOXO3 and TP53 physically interact with each other at two different regions-the TP53-N-terminus binds to the FOXO3-DNA binding domain (DBD) and the FOXO3-C-terminus interacts with the TP53-DBD. Interestingly, cell lines that undergo FOXO3-induced cell death carry homozygous point mutations in the TP53-DBD near the structural hotspot-mutation-site R175H, which abrogated FOXO3-TP53 interaction. In contrast, in FOXO3-death-resistant cells no point mutations in the TP53-DBD were found-in these cells FOXO3-TP53 complexes are formed and FOXO3-binding to the BIM-promoter, but not the induction of the detoxifying protein SESN3, were prevented, which in turn increased chemo-protection in this type of high-stage-derived NB cells. Our combined data suggest that FOXO3 steps in as a death inducer in case of TP53-mutation, whereas functional TP53 alters FOXO3-target-promoter-recognition, which prevents death induction by FOXO3 and instead increases chemo-protection and survival of NB cells. This novel mechanism may explain the low incidence of TP53 mutation in high-stage NB at diagnosis and suggests FOXO3 as a therapeutic target for this childhood malignancy.	[Rupp, M.; Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria; [Rupp, M.; Rass, B.; Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria; [Rupp, M.; Obexer, P.] Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; [Fiegl, H.] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Hagenbuchner, J; Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria.; Ausserlechner, MJ (corresponding author), Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria.; Obexer, P (corresponding author), Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria.	judith.hagenbuchner@i-med.ac.at; petra.obexer@i-med.ac.at; michael.j.ausserlechner@i-med.ac.at	Zeimet, Alain/AFK-2441-2022; Zeimet, Alain/AAF-9688-2022; Fiegl, Heidi/K-4445-2017	Hagenbuchner, Judith/0000-0003-1396-3407; Ausserlechner, Michael/0000-0002-1015-2302; Fiegl, Heidi/0000-0002-1236-6806	intramural funding program of the Medical University Innsbruck for young scientists MUI-START [P2012032014]; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; Austrian Wirtschaftsservice [PRIZE P1308459]; Provita Kinderleukamiestiftung; MFF-Tirol [246]; Krebshilfe Tirol [16004]; Austrian Science Fund (FWF) [I 3089 - B28]; Tirol-Kliniken GmbH	intramural funding program of the Medical University Innsbruck for young scientists MUI-START; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; Austrian Wirtschaftsservice; Provita Kinderleukamiestiftung; MFF-Tirol; Krebshilfe Tirol; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Tirol-Kliniken GmbH	We thank Drs Peter Ambros, Todd Waldmann and Andreas Villunger for providing NB cell lines and plasmids. This work was supported by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014), by grants from the 'Kinderkrebshilfe fur Tirol und Vorarlberg', 'Sudtiroler Krebshilfe', 'Kinderkrebshilfe Sudtirol-Regenbogen', the Austrian Wirtschaftsservice (PRIZE P1308459), the 'Provita Kinderleukamiestiftung', the MFF-Tirol (Project Nr. 246), the 'Krebshilfe Tirol (Nr 16004)' the Austrian Science Fund (FWF) (I 3089 - B28) and the 'Tirol-Kliniken GmbH'.	Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Ausserlechner MJ, 2012, NEUROBLASTOMA PRESEN, P325; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; de Keizer PLJ, 2011, ANTIOXID REDOX SIGN, V14, P1093, DOI 10.1089/ars.2010.3403; Gaviraghi M, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-56; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Grignani F, 1998, CANCER RES, V58, P14; Hagenbuchner J, 2016, ONCOGENE, V35, P2052, DOI 10.1038/onc.2015.264; Hagenbuchner J, 2013, ONCOGENE, V32, P4748, DOI 10.1038/onc.2012.500; Hagenbuchner J, 2017, ONCOTARGET, V8, P32009, DOI 10.18632/oncotarget.16434; Hagenbuchner Judith, 2016, Oncotarget, V7, P77591, DOI 10.18632/oncotarget.12728; Hagenbuchner J, 2013, ONCOTARGET, V4, P1241, DOI 10.18632/oncotarget.1147; Hagenbuchner J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00147; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Keshelava N, 2001, CANCER RES, V61, P6185; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Krytska K, 2016, CLIN CANCER RES, V22, P948, DOI 10.1158/1078-0432.CCR-15-0379; Lin Hung-Yu, 2008, Int J Biomed Sci, V4, P248; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Obsilova V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Salcher S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0661-4; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thiele CJ, 1999, HUMAN CELL CULTURE, V1, P21; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Tweddle DA, 2001, CANCER RES, V61, P8; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Wilson MSC, 2011, CURR DRUG TARGETS, V12, P1256; Xie X, 2016, ONCOGENE, V35, P4798, DOI 10.1038/onc.2016.12; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	56	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6190	6203		10.1038/onc.2017.288	http://dx.doi.org/10.1038/onc.2017.288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28869600	hybrid, Green Published			2022-12-28	WOS:000414249800012
J	Sengupta, S; Nagalingam, A; Bonner, NMM; Bonner, MY; Mistriotis, P; Afthinos, A; Kuppusamy, P; Lanoue, D; Cho, S; Korangath, P; Shriver, M; Begum, A; Merino, VF; Huang, CY; Arbiser, JL; Matsui, W; Gyorffy, B; Konstantopoulos, K; Sukumar, S; Marignani, PA; Saxena, NK; Sharma, D				Sengupta, S.; Nagalingam, A.; Muniraj, N.; Bonner, M. Y.; Mistriotis, P.; Afthinos, A.; Kuppusamy, P.; Lanoue, D.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Huang, C-Y; Arbiser, J. L.; Matsui, W.; Gyorffy, B.; Konstantopoulos, K.; Sukumar, S.; Marignani, P. A.; Saxena, N. K.; Sharma, D.			Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR TARGETS; IN-VITRO; CELLS; LEPTIN; EXPRESSION; MIGRATION; INVASION; PATHWAY; INDUCTION	Tumor suppressor and upstream master kinase Liver kinase B1 (LKB1) plays a significant role in suppressing cancer growth and metastatic progression. We show that low-LKB1 expression significantly correlates with poor survival outcome in breast cancer. In line with this observation, loss-of-LKB1 rendered breast cancer cells highly migratory and invasive, attaining cancer stem cell-like phenotype. Accordingly, LKB1-null breast cancer cells exhibited an increased ability to form mammospheres and elevated expression of pluripotency-factors (Oct4, Nanog and Sox2), properties also observed in spontaneous tumors in Lkb1(-/-) mice. Conversely, LKB1-overexpression in LKB1-null cells abrogated invasion, migration and mammosphere-formation. Honokiol (HNK), a bioactive molecule from Magnolia grandiflora increased LKB1 expression, inhibited individual cell-motility and abrogated the stem-like phenotype of breast cancer cells by reducing the formation of mammosphere, expression of pluripotency-factors and aldehyde dehydrogenase activity. LKB1, and its substrate, AMP-dependent protein kinase (AMPK) are important for HNK-mediated inhibition of pluripotency factors since LKB1-silencing and AMPK-inhibition abrogated, while LKB1-overexpression and AMPK-activation potentiated HNK's effects. Mechanistic studies showed that HNK inhibited Stat3-phosphorylation/activation in an LKB1-dependent manner, preventing its recruitment to canonical binding-sites in the promoters of Nanog, Oct4 and Sox2. Thus, inhibition of the coactivation-function of Stat3 resulted in suppression of expression of pluripotency factors. Further, we showed that HNK inhibited breast tumorigenesis in mice in an LKB1-dependent manner. Molecular analyses of HNK-treated xenografts corroborated our in vitro mechanistic findings. Collectively, these results present the first in vitro and in vivo evidence to support crosstalk between LKB1, Stat3 and pluripotency factors in breast cancer and effective anticancer modulation of this axis with HNK treatment.	[Sengupta, S.; Nagalingam, A.; Muniraj, N.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Matsui, W.; Sukumar, S.; Sharma, D.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD USA; [Sengupta, S.; Nagalingam, A.; Muniraj, N.; Cho, S.; Korangath, P.; Shriver, M.; Begum, A.; Merino, V. F.; Matsui, W.; Sukumar, S.; Sharma, D.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Bonner, M. Y.] Emory Univ, Sch Med, Winship Canc Inst, Dept Dermatol, Atlanta, GA USA; [Mistriotis, P.; Afthinos, A.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Kuppusamy, P.; Saxena, N. K.] Univ Maryland, Sch Med, Dept Med, 660W Redwood St,Howard Hall,Rm 301, Baltimore, MD 21201 USA; [Lanoue, D.; Marignani, P. A.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Huang, C-Y] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Div Biostat & Bioinformat, Baltimore, MD USA; [Arbiser, J. L.] Atlanta Vet Adm Med Ctr, Atlanta, GA USA; [Gyorffy, B.] MTA TTK Momentum Canc Biomarker Res Grp, Budapest, Hungary; [Gyorffy, B.] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Saxena, N. K.] Natl Canc Inst, 9609 Med Ctr Dr, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Emory University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Dalhousie University; Johns Hopkins University; Johns Hopkins Medicine; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Saxena, NK (corresponding author), Univ Maryland, Sch Med, Dept Med, 660W Redwood St,Howard Hall,Rm 301, Baltimore, MD 21201 USA.; Sharma, D (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,CRB 1,Rm 145, Baltimore, MD 21231 USA.	nsaxena@medicine.umaryland.edu; dsharma7@jhmi.edu	Bonner, Michael Yi/ABD-6756-2021; MUNIRAJ, NETHAJI/I-6017-2019; Mistriotis, Panagiotis/AAJ-5248-2020; Kuppusamy, Panjamurthy/AAT-1518-2021; sengupta, sonali/F-8830-2016; Gyorffy, Balazs/AAA-9135-2021	Bonner, Michael Yi/0000-0002-8184-0954; MUNIRAJ, NETHAJI/0000-0002-3820-2148; Mistriotis, Panagiotis/0000-0002-8069-3278; Kuppusamy, Panjamurthy/0000-0003-3293-7220; sengupta, sonali/0000-0002-9710-9576; Gyorffy, Balazs/0000-0002-5772-3766; Shriver, Marey/0000-0002-1644-6408; Marignani, Paola/0000-0001-8070-905X; Afthinos, Alexandros/0000-0001-6906-0771; Korangath, Preethi/0000-0002-6623-493X	NCI NIH [R21CA185943, R01AR47901, R01CA131294, R21CA155686]; OTKA [K108655]; Nova Scotia Health Research Foundation; Canadian Breast Cancer Foundation; Nova; Dalhousie Medical Research Foundation; Avon Foundation; Breast Cancer Research Foundation (BCRF) [90047965]; Fetting Fund; NATIONAL CANCER INSTITUTE [K24CA198315, R01CA131294, R21CA155686, R01CA193887, R21CA185943, P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER	NCI NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Nova Scotia Health Research Foundation; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Nova; Dalhousie Medical Research Foundation; Avon Foundation; Breast Cancer Research Foundation (BCRF); Fetting Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NCI NIH, R21CA185943 (to NKS); OTKA K108655 (to BG); NCI NIH R01AR47901 (to JLA); The Nova Scotia Health Research Foundation (DL); The Canadian Breast Cancer Foundation and The Nova and the Dalhousie Medical Research Foundation (PAM); NCI NIH R01CA131294, NCI NIH R21CA155686, Avon Foundation, Breast Cancer Research Foundation (BCRF) 90047965 and The Fetting Fund (to DS).	Andrade-Vieira R, 2014, ONCOTARGET, V5, P12738, DOI 10.18632/oncotarget.2818; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Autanski DB, 2014, MOL ONCOL, V8, P565, DOI 10.1016/j.molonc.2014.01.004; Averett Courey, 2014, Enzymes, V36, P175, DOI 10.1016/B978-0-12-802215-3.00009-4; Avtanski DB, 2015, ONCOTARGET, V6, P16396, DOI 10.18632/oncotarget.3844; Azare J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027851; Bai XH, 2003, J BIOL CHEM, V278, P35501, DOI 10.1074/jbc.M302967200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burdelya L, 2002, MOL CANCER THER, V1, P893; Choi DY, 2012, BRAIN RES BULL, V87, P144, DOI 10.1016/j.brainresbull.2011.11.014; Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113; Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hung WC, 2016, CELL REP, V15, P1430, DOI 10.1016/j.celrep.2016.04.035; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Leeman-Neill RJ, 2010, CLIN CANCER RES, V16, P2571, DOI 10.1158/1078-0432.CCR-10-0333; Li J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0070-0; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Nath-Sain S, 2009, MOL BIOL CELL, V20, P2785, DOI 10.1091/mbc.E08-11-1138; Oh JH, 2009, CHEM-BIOL INTERACT, V180, P506, DOI 10.1016/j.cbi.2009.03.014; Prasad R, 2016, ONCOTARGET, V7, P7899, DOI 10.18632/oncotarget.6860; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008-5472.CAN-08-1952; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Taliaferro-Smith L, 2009, ONCOGENE, V28, P2621, DOI 10.1038/onc.2009.129; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Wang P, 2015, ONCOGENE, V34, P4558, DOI 10.1038/onc.2014.397; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xu Q, 2008, PROG NEURO-PSYCHOPH, V32, P715, DOI 10.1016/j.pnpbp.2007.11.020; Yan D, 2012, J BIOL CHEM, V287, P8598, DOI 10.1074/jbc.M111.322800; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 ; Zhou JJ, 2014, FEBS LETT, V588, P566, DOI 10.1016/j.febslet.2013.11.041	49	67	69	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5709	5721		10.1038/onc.2017.164	http://dx.doi.org/10.1038/onc.2017.164			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581518	Green Accepted, Green Submitted			2022-12-28	WOS:000412843900005
J	Forsberg, J; Zhivotovsky, B; Olsson, M				Forsberg, J.; Zhivotovsky, B.; Olsson, M.			Caspase-2: an orphan enzyme out of the shadows	ONCOGENE			English	Review							CELL-DEATH; MITOTIC CATASTROPHE; METABOLIC-REGULATION; TUMOR SUPPRESSION; DNA-DAMAGE; APOPTOSIS; PIDDOSOME; INSTABILITY; ACTIVATION; PROTEIN	Caspase-2 has been embodied as an initiator or executioner protease in diverse apoptotic scenarios. However, accumulating evidence is challenging this view, pertaining to its true role. The enzyme's catalytic activity is currently implicated in various functions required for correct cell proliferation, such as counteracting genomic instability, as well as suppressing tumorigenesis. Here, apart from summarizing the latest observations in caspase-2-related research, we make an attempt to reconcile these findings and discuss their implications for future directions.	[Forsberg, J.; Zhivotovsky, B.; Olsson, M.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Zhivotovsky, B.] Lomonosov Moscow State Univ, Fac Fundamental Med, Moscow, Russia	Karolinska Institutet; Lomonosov Moscow State University	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423	Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; Swedish Research Council; Russian Science Foundation [14-25-00056-II]; Russian President Fund [NSH-7082.2016]; Russian Science Foundation [17-25-00012] Funding Source: Russian Science Foundation	Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Russian Science Foundation(Russian Science Foundation (RSF)); Russian President Fund; Russian Science Foundation(Russian Science Foundation (RSF))	The work in the authors' laboratories is supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, the Swedish Research Council. BZ was supported by the Russian Science Foundation (14-25-00056-II) and the Russian President Fund (grant number NSH-7082.2016).	Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Bataller M, 2008, MOL CANCER THER, V7, P2988, DOI 10.1158/1535-7163.MCT-08-0420; Biffi G, 2017, NATURE, V542, P34, DOI 10.1038/nature21117; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bouchier-Hayes L, 2012, CELL DEATH DIFFER, V19, P51, DOI 10.1038/cdd.2011.157; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Dawar S, 2017, ONCOGENE, V36, P2704, DOI 10.1038/onc.2016.423; Dawar S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.406; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dorstyn L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.342; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Fava LL, 2012, J CELL SCI, V125, P5911, DOI 10.1242/jcs.115105; Gitenay D, 2014, ONCOTARGET, V5, P5845, DOI 10.18632/oncotarget.2286; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guha M, 2010, ONCOGENE, V29, P1280, DOI 10.1038/onc.2009.428; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Imreh G, 2011, J CELL SCI, V124, P2951, DOI 10.1242/jcs.081612; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Lee JK, 2016, ANNU REV PATHOL-MECH, V11, P283, DOI 10.1146/annurev-pathol-012615-044446; Liu J, 2017, MITOCHONDRIAL DNA B, V2, P1, DOI 10.1080/23802359.2016.1186511; Lopez-Garcia C, 2017, CANCER CELL, V31, P79, DOI 10.1016/j.ccell.2016.11.001; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Mccoy F, 2013, MOL CELL, V52, P325, DOI 10.1016/j.molcel.2013.08.043; McCoy F, 2013, J BIOL CHEM, V288, P8838, DOI 10.1074/jbc.M112.437186; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Ohashi A, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1088503; Ohashi A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8668; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Olsson M, 2015, ONCOGENE, V34, P1877, DOI 10.1038/onc.2014.139; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Peintner L, 2015, CELL DEATH DIFFER, V22, P1803, DOI 10.1038/cdd.2015.31; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Ribe EM, 2012, BIOCHEM J, V444, P591, DOI 10.1042/BJ20111588; Shalini S, 2015, ONCOGENE, V34, P4995, DOI 10.1038/onc.2014.413; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tiwari M, 2014, AUTOPHAGY, V10, P1054, DOI 10.4161/auto.28528; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Vitale I GM, 2017, MOL CELL ON IN PRESS; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yao Y, 2014, J CARCINOG MUTAGEN, V5; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	52	11	11	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5441	5444		10.1038/onc.2017.169	http://dx.doi.org/10.1038/onc.2017.169			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581521				2022-12-28	WOS:000411960500001
J	Unger, C; Kramer, N; Unterleuthner, D; Scherzer, M; Burian, A; Rudisch, A; Stadler, M; Schlederer, M; Lenhardt, D; Riedl, A; Walter, S; Wernitznig, A; Kenner, L; Hengstschlger, M; Schler, J; Sommergruber, W; Dolznig, H				Unger, C.; Kramer, N.; Unterleuthner, D.; Scherzer, M.; Burian, A.; Rudisch, A.; Stadler, M.; Schlederer, M.; Lenhardt, D.; Riedl, A.; Walter, S.; Wernitznig, A.; Kenner, L.; Hengstschlger, M.; Schler, J.; Sommergruber, W.; Dolznig, H.			Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SMOOTH MUSCLE ACTIN; FACTOR-I RECEPTOR; COLORECTAL-CANCER; TUMOR MICROENVIRONMENT; CARCINOMA-CELLS; INSULIN; EXPRESSION; MYOFIBROBLASTS; FIBROBLASTS	The insulin-like growth factor (IGF) 2/IGF1 receptor (IGF1R) signaling axis has an important role in intestinal carcinogenesis and overexpression of IGF2 is an accepted risk factor for colorectal cancer (CRC) development. Genetic amplifications and loss of imprinting contribute to the upregulation of IGF2, but insufficiently explain the extent of IGF2 expression in a subset of patients. Here, we show that IGF2 was specifically induced in the tumor stroma of CRC and identified cancer-associated fibroblasts (CAFs) as the major source. Further, we provide functional evidence that stromal IGF2, via the paracrine IGF1R/insulin receptor axis, activated pro-survival AKT signaling in CRC cell lines. In addition to its effects on malignant cells, autocrine IGF2/IGF1R signaling in CAFs induced myofibroblast differentiation in terms of alpha-smooth muscle actin expression and contractility in floating collagen gels. This was further augmented in concert with transforming growth factor-beta (TGF beta) signaling suggesting a cooperative mechanism. However, we demonstrated that IGF2 neither induced TGF beta/smooth muscle actin/mothers against decapentaplegic (SMAD) signaling nor synergized with TGF beta to hyperactivate this pathway in two dimensional and three dimensional cultures. IGF2-mediated physical matrix remodeling by CAFs, but not changes in extracellular matrix-modifying proteases or other secreted factors acting in a paracrine manner on/in cancer cells, facilitated subsequent tumor cell invasion in organotypic co-cultures. Consistently, colon cancer cells co-inoculated with CAFs expressing endogenous IGF2 in mouse xenograft models exhibited elevated invasiveness and dissemination capacity, as well as increased local tumor regrowth after primary tumor resection compared with conditions with IGF2-deficient CAFs. In line, expression of IGF2 correlated with elevated relapse rates and poor survival in CRC patients. In agreement with our results, high-level coexpression of IGF2 and TGF beta was predicting adverse outcome with higher accuracy than increased expression of the individual genes alone. Taken together, we demonstrate that stromainduced IGF2 promotes colon cancer progression in a paracrine and autocrine manner and propose IGF2 as potential target for tumor stroma cotargeting strategies.	[Unger, C.; Kramer, N.; Unterleuthner, D.; Scherzer, M.; Burian, A.; Stadler, M.; Riedl, A.; Walter, S.; Hengstschlger, M.; Dolznig, H.] Med Univ Vienna, Inst Med Genet, Waehringer Str 10, A-1090 Vienna, Austria; [Rudisch, A.; Riedl, A.; Wernitznig, A.; Sommergruber, W.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Schlederer, M.; Kenner, L.] Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; [Lenhardt, D.; Schler, J.] Oncotest GmbH, Flughafen 12, Freiburg, Germany; [Kenner, L.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Kenner, L.] Univ Vet Med Vienna, Inst Lab Anim Pathol, Vienna, Austria; [Scherzer, M.] Karolinska Inst, Solnavagen 1, S-17177 Solna, Sweden; [Stadler, M.] Deutsch Krebsforschungszentrum DKFZ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany	Medical University of Vienna; Boehringer Ingelheim; Medical University of Vienna; Oncotest GmbH; Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Unger, C; Dolznig, H (corresponding author), Med Univ Vienna, Inst Med Genet, Waehringer Str 10, A-1090 Vienna, Austria.	christine.unger@meduniwien.ac.at; helmut.dolznig@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585; Kenner, Lukas/0000-0003-2184-1338; Kramer, Nina/0000-0002-9058-8076				Albrengues J, 2014, CELL REP, V7, P1664, DOI 10.1016/j.celrep.2014.04.036; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brouwer-Visser J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100165; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Charbonney E, 2011, MOL BIOL CELL, V22, P4472, DOI 10.1091/mbc.E11-04-0335; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Church DN, 2012, ONCOGENE, V31, P3635, DOI 10.1038/onc.2011.526; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; DARBY I, 1990, LAB INVEST, V63, P21; De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393; De Groot JWB, 2007, ENDOCR-RELAT CANCER, V14, P979, DOI 10.1677/ERC-07-0161; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Fukuda I, 2006, GROWTH HORM IGF RES, V16, P211, DOI 10.1016/j.ghir.2006.05.003; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao J, 2011, CANCER RES, V71, P1029, DOI 10.1158/0008-5472.CAN-10-2274; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Greenall SA, 2013, J BIOL CHEM, V288, P59, DOI 10.1074/jbc.M112.432013; Harper J, 2006, CANCER RES, V66, P1940, DOI 10.1158/0008-5472.CAN-05-2036; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hu YP, 2008, CANCER RES, V68, P8004, DOI 10.1158/0008-5472.CAN-08-0280; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kobayashi T, 2006, BIOCHEM BIOPH RES CO, V339, P290, DOI 10.1016/j.bbrc.2005.10.209; Lee JH, 2014, J NANOMATER, V2014, DOI 10.1155/2014/567827; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liles JS, 2011, BRIT J CANCER, V105, P523, DOI 10.1038/bjc.2011.263; Livingstone C, 2013, ENDOCR-RELAT CANCER, V20, pR321, DOI 10.1530/ERC-13-0231; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Park JH, 2014, ANN ONCOL, V25, P644, DOI 10.1093/annonc/mdt593; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Raykha C, 2013, BBA-MOL BASIS DIS, V1832, P1511, DOI 10.1016/j.bbadis.2013.04.018; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosner M, 2010, NAT PROTOC, V5, P1081, DOI 10.1038/nprot.2010.74; Rudisch A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124283; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SINGER C, 1995, CANCER RES, V55, P2448; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; Singh SK, 2008, GROWTH FACTORS, V26, P92, DOI 10.1080/08977190802057258; Small EM, 2012, J CARDIOVASC TRANSL, V5, P794, DOI 10.1007/s12265-012-9397-0; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang HB, 2015, EXP CELL RES, V338, P214, DOI 10.1016/j.yexcr.2015.09.016; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	87	48	49	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5341	5355		10.1038/onc.2017.116	http://dx.doi.org/10.1038/onc.2017.116			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534511				2022-12-28	WOS:000411382100002
J	Moyo, TK; Wilson, CS; Moore, DJ; Eischen, CM				Moyo, T. K.; Wilson, C. S.; Moore, D. J.; Eischen, C. M.			Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; C-MYC; FOLLICULAR LYMPHOMA; TARGETING BTK; SYK; IBRUTINIB; ACTIVATION; PCI-32765; SURVIVAL	Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL). MYC overexpression in B-NHL is associated with more aggressive phenotypes and poor prognosis. Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated. We utilized intracellular phospho-flow cytometry to investigate the relationship between Myc and BCR signaling in pre-malignant B cells. Utilizing the E mu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from E mu-myc mice compared with wild-type littermates. B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plc gamma 2 and Erk1/2. Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor. Furthermore, PI3K/Akt pathway signaling was also increased in E mu-myc B cells, and this increase was partially suppressed with ibrutinib. In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling. Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation. Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.	[Moyo, T. K.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA; [Wilson, C. S.; Moore, D. J.; Eischen, C. M.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Moore, D. J.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Eischen, C. M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, 233 South 10th St,Bluemle Life Sci Bldg,Room 650, Philadelphia, PA 19107 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Jefferson University	Eischen, CM (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, 233 South 10th St,Bluemle Life Sci Bldg,Room 650, Philadelphia, PA 19107 USA.	christine.eischen@jefferson.edu	Moore, Daniel/V-6145-2019; Moore, Daniel J/A-4924-2008	Moore, Daniel/0000-0002-6889-9345; Moore, Daniel J/0000-0002-6889-9345	NIH/NCI [R21CA184352]; Hematology Helping Hands Research Award; NCI Cancer Center [P30CA68485, P30CA056036]; NATIONAL CANCER INSTITUTE [R21CA184352, P30CA068485, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM062459] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hematology Helping Hands Research Award; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Peggy Kendall for providing Btk<SUP>-/-</SUP> mice and members of the Eischen laboratory and Dr Jonathan Irish for their advice. This work was supported by NIH/NCI R21CA184352 (CME), the Hematology Helping Hands Research Award (TKM) and the NCI Cancer Center support grant P30CA68485 that supports the Vanderbilt Flow Cytometry Shared Resource and the NCI Cancer Center support grant P30CA056036.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bye AP, 2015, ARTERIOSCL THROM VAS, V35, P2326, DOI 10.1161/ATVBAHA.115.306130; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Christie L, 2008, LEUKEMIA LYMPHOMA, V49, P470, DOI 10.1080/10428190701836845; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Ding JY, 2000, J BIOL CHEM, V275, P30873, DOI 10.1074/jbc.M004813200; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Geahlen RL, 2009, BBA-MOL CELL RES, V1793, P1115, DOI 10.1016/j.bbamcr.2009.03.004; Gramling MW, 2012, CELL DEATH DIFFER, V19, P1220, DOI 10.1038/cdd.2012.1; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Huh YO, 2008, BRIT J HAEMATOL, V142, P36, DOI 10.1111/j.1365-2141.2008.07152.x; Irish JM, 2006, J IMMUNOL, V177, P1581, DOI 10.4049/jimmunol.177.3.1581; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Manne BK, 2015, J BIOL CHEM, V290, P11557, DOI 10.1074/jbc.M114.629527; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Pede V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060275; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Psathas JN, 2013, BLOOD, V122, P4220, DOI 10.1182/blood-2012-12-473090; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Richter J, 2012, NAT GENET, V44, P1316, DOI 10.1038/ng.2469; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Satterthwaite AB, 1997, P NATL ACAD SCI USA, V94, P13152, DOI 10.1073/pnas.94.24.13152; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Speich HE, 2008, AM J PHYSIOL-CELL PH, V295, pC1045, DOI 10.1152/ajpcell.90644.2007; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xu XX, 2013, INT J CLIN EXP PATHO, V6, P788; Yeomans A, 2016, BLOOD, V127, P449, DOI 10.1182/blood-2015-07-660969; Young KH, 2008, AM J CLIN PATHOL, V129, P157, DOI 10.1309/NKK3FEX2BE5L7EKB	42	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4653	4661		10.1038/onc.2017.95	http://dx.doi.org/10.1038/onc.2017.95			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368423	Green Accepted			2022-12-28	WOS:000407246200012
J	Cesarini, V; Guida, E; Todaro, F; Di Agostino, S; Tassinari, V; Nicolis, S; Favaro, R; Caporali, S; Lacal, PM; Botti, E; Costanzo, A; Rossi, P; Jannini, EA; Dolci, S				Cesarini, V.; Guida, E.; Todaro, F.; Di Agostino, S.; Tassinari, V.; Nicolis, S.; Favaro, R.; Caporali, S.; Lacal, P. M.; Botti, E.; Costanzo, A.; Rossi, P.; Jannini, E. A.; Dolci, S.			Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo	ONCOGENE			English	Article							CELL LUNG-CANCER; MALIGNANT-MELANOMA; SELF-RENEWAL; MOUSE MODEL; STEM; EXPRESSION; MAINTENANCE; ONCOGENE; GENE; PROGRESSION	Melanoma is a dangerous form of skin cancer derived from the malignant transformation of melanocytes. The transcription factor SOX2 is not expressed in melanocytes, however, it has been shown to be differentially expressed between benign nevi and malignant melanomas and to be essential for melanoma stem cell maintenance and expansion in vitro and in xenograft models. By using a mouse model in which BRaf(V600E) mutation cooperates with Pten loss to induce the development of metastatic melanoma, we investigated if Sox2 is required during the process of melanomagenesis, melanoma growth and metastasis and in the acquisition of resistance to BRAF inhibitors (BRAFi) treatments. We found that deletion of Sox2 specifically in Pten null and BRafV600E-expressing melanocytes did not prevent tumor formation and did not modify the temporal kinetics of melanoma occurrence compared to Sox2 wt mice. In addition, tumor growth was similar between Sox2 wt and Sox2 deleted (del) melanomas. By querying publicly available databases, we did not find statistically significant differences in SOX2 expression levels between benign nevi and melanomas, and analysis on two melanoma patient cohorts confirmed that Sox2 levels did not significantly change between primary and metastatic melanomas. Melanoma cell lines derived from both Sox2 genotypes showed a similar sensitivity to vemurafenib treatment and the same ability to develop vemurafenib resistance in long-term cultures. Development of vemurafenib resistance was not dependent on SOX2 expression also in human melanoma cell lines in vitro. Our findings exclude an oncogenic function for Sox2 during melanoma development and do not support a role for this transcription factor in the acquisition of resistance to BRAFi treatments.	[Cesarini, V.; Guida, E.; Todaro, F.; Tassinari, V.; Rossi, P.; Dolci, S.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy; [Di Agostino, S.] Regina Elena Natl Canc Inst IFO, Oncogenom & Epigenet Unit, Rome, Italy; [Nicolis, S.; Favaro, R.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy; [Caporali, S.; Lacal, P. M.] Inst Dermopat Dell Immacolata IRCCS, Mol Oncol Lab, Rome, Italy; [Botti, E.; Jannini, E. A.] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Costanzo, A.] Humanitas Univ, Dept Biomed, Milan, Italy	University of Rome Tor Vergata; IRCCS Istituti Fisioterapici Ospitalieri (IFO); University of Milano-Bicocca; University of Rome Tor Vergata; Humanitas University	Dolci, S (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.	dolci@uniroma2.it	Di Agostino, Silvia/H-1121-2018; Di Agostino, Silvia/S-8566-2019; Tassinari, Valentina/AAW-1649-2021; Costanzo, Antonio/GZG-2433-2022; Cesarini, Valeriana VC/K-5816-2016; Lacal, Pedro M/A-1481-2013; Rossi, Pellegrino/AAA-7072-2019; Favaro, Rebecca/HHZ-8978-2022	Di Agostino, Silvia/0000-0003-3730-1125; Tassinari, Valentina/0000-0003-2167-9414; Costanzo, Antonio/0000-0001-9697-2557; Cesarini, Valeriana VC/0000-0001-9323-1796; Lacal, Pedro M/0000-0003-1166-4593; Favaro, Rebecca/0000-0002-6195-5711; ROSSI, PELLEGRINO/0000-0003-4796-327X; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808; todaro, federica/0000-0001-6544-193X; Guida, Eugenia/0000-0002-1690-3277	Telethon; AIRC; AIRC [17585]; MIUR [2015XSNA83_006, 2015XCR88M]	Telethon(Fondazione Telethon); AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank G Graziani for helpful criticisms and for sharing results with us and G Rossi for histology assistance. We wish to thank Genentek (San Francisco, CA, USA) for the supply of vemurafenib and GlaxoSmithKline (Brentford, UK) for the supply of dabrafenib. SN is supported by Telethon and AIRC grants. SC is recipient of a fellowship from AIRC (Investigator Grant Project 17585). This work has been supported by MIUR Grants 2015XSNA83_006 and 2015XCR88M.	Akasaka K, 2009, J INVEST DERMATOL, V129, P1516, DOI 10.1038/jid.2008.406; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Camilo V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-753; Campolo F, 2013, STEM CELLS, V31, P1408, DOI 10.1002/stem.1392; Chen YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071140; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Graziani G, 2015, BIOCHEM PHARMACOL, V95, P16, DOI 10.1016/j.bcp.2015.03.004; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Irie N, 2015, CELL, V160, P253, DOI 10.1016/j.cell.2014.12.013; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Lacal PM, 2005, INT J ONCOL, V27, P1625; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lundberg IV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101957; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Sanchez-Laorden B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004815; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schaefer SM, ONCOGENE; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Toschi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095303; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Wood HB, 1999, MECH DEVELOP, V86, P197, DOI 10.1016/S0925-4773(99)00116-1	42	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4508	4515		10.1038/onc.2017.53	http://dx.doi.org/10.1038/onc.2017.53			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368402	Green Published			2022-12-28	WOS:000406806000012
J	Harris, NLE; Vennin, C; Conway, JRW; Vine, KL; Pinese, M; Cowley, MJ; Shearer, RF; Lucas, MC; Herrmann, D; Allam, AH; Pajic, M; Morton, JP; Biankin, AV; Ranson, M; Timpson, P; Saunders, DN				Harris, N. L. E.; Vennin, C.; Conway, J. R. W.; Vine, K. L.; Pinese, M.; Cowley, M. J.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Allam, A. H.; Pajic, M.; Morton, J. P.; Biankin, A. V.; Ranson, M.; Timpson, P.; Saunders, D. N.		Australian Pancreatic Canc Genome	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-2; MATRIX METALLOPROTEINASES; EXPRESSION; CARCINOMA; RECEPTOR; PAI-2; ADENOCARCINOMA; SURVIVAL; THERAPY; BIOLOGY	Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of similar to 8%, restricted treatment options and characteristic molecular heterogeneity. SerpinB2 expression, particularly in the stromal compartment, is associated with reduced metastasis and prolonged survival in pancreatic ductal adenocarcinoma (PDAC) and our genomic analysis revealed that SERPINB2 is frequently deleted in PDAC. We show that SerpinB2 is required by stromal cells for normal collagen remodelling in vitro, regulating fibroblast interaction and engagement with collagen in the contracting matrix. In a pancreatic cancer allograft model, co-injection of PDAC cancer cells and SerpinB2(-/-) mouse embryonic fibroblasts (MEFs) resulted in increased tumour growth, aberrant remodelling of the extracellular matrix (ECM) and increased local invasion from the primary tumour. These tumours also displayed elevated proteolytic activity of the primary biochemical target of SerpinB2-urokinase plasminogen activator (uPA). In a large cohort of patients with resected PDAC, we show that increasing uPA mRNA expression was significantly associated with poorer survival following pancreatectomy. This study establishes a novel role for SerpinB2 in the stromal compartment in PDAC invasion through regulation of stromal remodelling and highlights the SerpinB2/uPA axis for further investigation as a potential therapeutic target in pancreatic cancer.	[Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Ctr Med & Mol Biosci, Wollongong, NSW, Australia; [Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia; [Conway, J. R. W.; Pinese, M.; Cowley, M. J.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Allam, A. H.; Pajic, M.; Timpson, P.; Saunders, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, Victoria St, Darlinghurst, NSW 2010, Australia; [Vennin, C.; Conway, J. R. W.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Pajic, M.] Univ New South Wales, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Morton, J. P.] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Biankin, A. V.] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland; [Saunders, D. N.] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia	University of Wollongong; University of Wollongong; University of Wollongong; Garvan Institute of Medical Research; University of New South Wales Sydney; Beatson Institute; University of Glasgow; University of New South Wales Sydney	Timpson, P; Saunders, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Victoria St, Darlinghurst, NSW 2010, Australia.; Saunders, DN (corresponding author), Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia.; Ranson, M; Timpson, P; Saunders, DN (corresponding author), Illawarra Hlth & Med Res Inst, Bldg 32,Northfields Ave, Wollongong, NSW 2522, Australia.	mranson@uow.edu.au; p.timpson@garvan.org.au; d.saunders@unsw.edu.au	Lucas, Morghan C/Y-6452-2019; Ranson, Marie/AAC-4468-2019; Cowley, Mark/K-8731-2019; Ranson, Marie/GRO-5792-2022; Morton, Jennifer/AAJ-5113-2021; Ranson, Marie/A-6324-2008; Timpson, Paul/A-9429-2016; Morton, Jennifer P/E-1633-2011; Lucas, Morghan/S-4982-2018	Lucas, Morghan C/0000-0001-7654-9137; Ranson, Marie/0000-0002-5570-9645; Cowley, Mark/0000-0002-9519-5714; Ranson, Marie/0000-0002-5570-9645; Morton, Jennifer/0000-0001-5766-9141; Ranson, Marie/0000-0002-5570-9645; Morton, Jennifer P/0000-0001-5766-9141; Lucas, Morghan/0000-0001-7654-9137; Pinese, Mark/0000-0001-5078-6687; Conway, James/0000-0003-3787-277X; Pajic, Marina/0000-0002-3871-3829; Vennin, Claire/0000-0001-9088-4177; Herrmann, David/0000-0002-9514-7501; Vine, Kara/0000-0001-6871-1149; Timpson, Paul/0000-0002-5514-7080; Allam, Amr/0000-0002-8743-3639	National Health and Medical Research Council; Cancer Institute NSW; Cancer Council NSW; Tour De Cure; Cure Cancer Australia Foundation; Australian Research Council; University of Wollongong; Illawarra Health and Medical Research Institute; Mostyn Family Foundation; Garvan Research Foundation; Sydney Catalyst; Lens Ainsworth Pancreatic Cancer Fellowship; University of Wollongong Vice Chancellor's Fellowship; Australian Postgraduate Award PhD scholarship; Guest Family Fellowship; Cancer Research UK [22311] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); Tour De Cure; Cure Cancer Australia Foundation; Australian Research Council(Australian Research Council); University of Wollongong; Illawarra Health and Medical Research Institute; Mostyn Family Foundation; Garvan Research Foundation; Sydney Catalyst; Lens Ainsworth Pancreatic Cancer Fellowship; University of Wollongong Vice Chancellor's Fellowship; Australian Postgraduate Award PhD scholarship; Guest Family Fellowship; Cancer Research UK(Cancer Research UK)	This work was supported by funding from the National Health and Medical Research Council (DS, PT, MP); Cancer Institute NSW (DS, PT, MR); Cancer Council NSW (PT, MP); Tour De Cure (PT); Cure Cancer Australia Foundation (KLV); Australian Research Council (PT); University of Wollongong (MR) and Illawarra Health and Medical Research Institute (MR); Mostyn Family Foundation and Guest Family Fellowship (DS) and Garvan Research Foundation (DS, PT), Sydney Catalyst (CV). PT is a recipient of the Lens Ainsworth Pancreatic Cancer Fellowship, KLV was a recipient of a University of Wollongong Vice Chancellor's Fellowship. NLH is supported by an Australian Postgraduate Award PhD scholarship. The authors acknowledge use of the facilities and the assistance of Dr Tony Romeo and Dr Mitchell Nancarrow at the UOW Electron Microscopy Centre, the assistance of Alice Boulghourjian and Anaiis Zaratzian at The Kinghorn Cancer Centre Histopathology facility, and other technical assistance of Elahe Minaei at Illawarra Health and Medical Research Institute.	Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; Babur O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0612-6; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Boyd ZS, 2009, J MOL DIAGN, V11, P290, DOI 10.2353/jmoldx.2009.080124; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cicchi R, 2010, J BIOPHOTONICS, V3, P34, DOI 10.1002/jbio.200910062; Cochran BJ, 2011, J BIOL CHEM, V286, P24467, DOI 10.1074/jbc.M111.225706; Cochran BJ, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-43; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Croucher D, 2006, J BIOL CHEM, V281, P10206, DOI 10.1074/jbc.M513645200; Croucher DR, 2008, NAT REV CANCER, V8, P535, DOI 10.1038/nrc2400; Croucher DR, 2007, BIOCHEM J, V408, P203, DOI 10.1042/BJ20070767; Duffy MJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0428-4; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Goldstein D, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju413; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hinz B, 2016, EXP EYE RES, V142, P56, DOI 10.1016/j.exer.2015.07.009; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; LeBeau AM, 2015, CANCER RES, V75, P1225, DOI 10.1158/0008-5472.CAN-14-2185; Lee J, 2015, CLIN CANCER RES, V21, P4482, DOI 10.1158/1078-0432.CCR-15-0226; Lee JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130136; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Li J, 2010, AAPS J, V12, P223, DOI 10.1208/s12248-010-9181-5; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Ozdemir B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107407; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rowe RG, 2000, CANCER EPIDEM BIOMAR, V9, P1647; Schroder WA, 2010, PARASITE IMMUNOL, V32, P764, DOI 10.1111/j.1365-3024.2010.01241.x; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Shearer RF, 2015, GENES CELLS, V20, P1, DOI 10.1111/gtc.12183; Shekouh AR, 2003, PROTEOMICS, V3, P1988, DOI 10.1002/pmic.200300466; Shiomi H, 2000, AM J PATHOL, V156, P567, DOI 10.1016/S0002-9440(10)64761-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Smith R, 2007, WORLD J SURG, V31, P493, DOI 10.1007/s00268-006-0289-9; Stutchbury TK, 2007, MOL CANCER THER, V6, P203, DOI 10.1158/1535-7163.MCT-06-0264; TAKEUCHI Y, 1993, AM J GASTROENTEROL, V88, P1928; Telgenhoff D, 2005, CELL DEATH DIFFER, V12, P695, DOI 10.1038/sj.cdd.4401632; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0	61	57	60	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4288	4298		10.1038/onc.2017.63	http://dx.doi.org/10.1038/onc.2017.63			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346421	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000406360600006
J	Tonks, ID; Mukhopadhyay, P; Schroder, WA; Sorolla, A; Mould, AW; Handoko, HY; Ferguson, B; Muller, HK; Keith, P; Hayward, NK; Walker, GJ; Kay, GF				Tonks, I. D.; Mukhopadhyay, P.; Schroder, W. A.; Sorolla, A.; Mould, A. W.; Handoko, H. Y.; Ferguson, B.; Muller, H. K.; Keith, P.; Hayward, N. K.; Walker, G. J.; Kay, G. F.			Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; TARGETED DISRUPTION; CDK INHIBITORS; IN-VIVO; P107; RB; PHOSPHORYLATION; P130; PRB; P53	Deregulation of p16INK4A is a critical event in melanoma susceptibility and progression. It is generally assumed that the major effect of loss of p16 function is mediated through the CDK-cyclin pathway via its influence on the pocket protein (PP) pRb. However, there are also two other PPs, p107 and p130, which, when phosphorylated by CDK-cyclin complexes, play a role in permitting cell progression. Cohorts of mice carrying melanocyte-specific knockouts (KOs) of various combinations of the three PPs were generated. Mice null for pRb, p107, p130 or any combination of double mutants did not develop melanoma. Surprisingly, melanocyte-specific loss of all three PPs facilitated melanoma development (median age of onset 308 days, penetrance 40% at 1 year). Tumorigenesis was exacerbated by Trp53 co-deletion (median age of onset 275 days, penetrance 82% at 1 year), with cell culture studies indicating that this difference may result from the apoptotic role of Trp53. Melanomas in PP; Trp53-deficient mice lacked either Ras or Braf mutations, and hence developed in the absence of constitutive MAPK pathway activation. The lag period between induction of total PP or PP/Trp53 KO and melanoma development indicates that additional genetic or epigenetic alterations may account for neoplastic progression. However, exome sequencing of PP; Trp53 KO melanomas failed to reveal any additional recurrent driver mutations. Analysis of the putative mutation signature of the PP; Trp53 KO melanomas suggests that melanocytes are primed for transformation via a mutagenic mechanism involving an excess of T>G substitutions, but not involving a preponderance of C>T substitutions at CpG sites, which is the case for most spontaneous cancers not driven by a specific carcinogen. In sum, deregulation of all three PPs appears central to neoplastic progression for melanoma, and the customary reference to the p16(INKA)/CDK4/pRB pathway may no longer be accurate; all PPs are potentially critical targets of CDK-cyclins in melanoma.	[Tonks, I. D.; Mukhopadhyay, P.; Schroder, W. A.; Mould, A. W.; Handoko, H. Y.; Ferguson, B.; Keith, P.; Hayward, N. K.; Walker, G. J.; Kay, G. F.] QIMR Berghofer Med Res Inst, Cell & Mol Biol Dept, Herston, Qld, Australia; [Sorolla, A.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia; [Mould, A. W.] Univ Oxford, Sir William Dunn Sch Pathol, South Parks Rd, Oxford, England; [Muller, H. K.] Univ Tasmania, Sch Med, Dept Pathol, Hobart, Tas, Australia; [Keith, P.] Univ Queensland, Diamantina Inst Canc Immunol & Metab Med, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Western Australia; University of Oxford; University of Tasmania; University of Queensland	Walker, GJ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimrberghofer.edu.au	Sorolla, Anabel/E-2546-2012; hayward, nick/AAV-8802-2020; hayward, nicholas/C-1367-2015; , Herlina/F-4193-2015	Sorolla, Anabel/0000-0001-8238-8763; Ferguson, Blake/0000-0002-5643-6976; hayward, nicholas/0000-0003-4760-1033; Mould, Arne/0000-0002-2004-4348; , Herlina/0000-0003-3153-2248	Cancer Council of Queensland; National Health and Medical Research Council Fellowship	Cancer Council of Queensland(Cancer Council Queensland); National Health and Medical Research Council Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by research grants and fellowships to GFK and GW from the Cancer Council of Queensland. NKH is supported by a National Health and Medical Research Council Fellowship. We are grateful to Linda Chin and Marcus Bosenberg for the gift of the Tyr::CreERT2 mice.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Epe B, 2012, PHOTOCH PHOTOBIO SCI, V11, P98, DOI 10.1039/c1pp05190c; Ferguson Blake, 2015, Methods Mol Biol, V1267, P251, DOI 10.1007/978-1-4939-2297-0_11; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Huang PH, 2015, MOL CELL ONCOL, V3; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; Mukhopadhyay P, 2016, ONCOGENE, V35, P3342, DOI 10.1038/onc.2015.386; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Tonks ID, 2006, PIGM CELL RES, V19, P260, DOI 10.1111/j.1600-0749.2006.00321.x; Tonks ID, 2010, PIGM CELL MELANOMA R, V23, P564, DOI 10.1111/j.1755-148X.2010.00722.x; Tonks ID, 2005, PIGM CELL RES, V18, P252, DOI 10.1111/j.1600-0749.2005.00245.x; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Yang GA, 2005, J INVEST DERMATOL, V125, P1242, DOI 10.1111/j.0022-202X.2005.23931.x; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3789	3795		10.1038/onc.2016.511	http://dx.doi.org/10.1038/onc.2016.511			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192409				2022-12-28	WOS:000404349700014
J	An, ZY; Aksoy, O; Zheng, TN; Fan, QW; Weiss, WA				An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.			Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies	ONCOGENE			English	Review							PHASE-II; INTRATUMORAL HETEROGENEITY; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; TUMOR-SUPPRESSOR; GLIOMA GROWTH; CELL-SURVIVAL; IN-VITRO; ACTIVATION; AKT	Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.	[An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA; [Weiss, William A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA.	waweiss@gmail.com		Weiss, William/0000-0003-2230-9132	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH [CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, CA82103]; Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE [P01CA217959, P30CA082103, R01CA159859, U01CA217864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS091620, R01NS089868, R01NS088355] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	ZA is supported by the Alex's Lemonade Stand Foundation and by Program for Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. The Weiss lab is supported by NIH grants CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, and CA82103; the Alex's Lemonade Stand, Children's Tumor, Katie Dougherty, Pediatric Brain Tumor, Ross K. MacNeill, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair.	Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Appelboom G, 2016, NEURO-ONCOLOGY, V18, P1601, DOI 10.1093/neuonc/now137; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Boyd PS, 2016, NANOSCALE, V8, P20037, DOI 10.1039/c6nr05880a; Brand TM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag1064; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chakravarti A, 2002, CANCER RES, V62, P200; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi BD, 2013, P NATL ACAD SCI USA, V110, P270, DOI 10.1073/pnas.1219817110; Chong DQ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1191-3; Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008; Chow KKH, 2011, IMMUNOTHERAPY-UK, V3, P423, DOI 10.2217/IMT.10.110; Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432; Cleary JM, 2015, INVEST NEW DRUG, V33, P671, DOI 10.1007/s10637-015-0234-6; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Congdon KL, 2014, NEURO-ONCOLOGY, V16, pviii20, DOI 10.1093/neuonc/nou236; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Ding H, 2003, CANCER RES, V63, P1106; Dreier A, 2012, TUMOR BIOL, V33, P85, DOI 10.1007/s13277-011-0248-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Er EE, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004015; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Feng H, 2014, ONCOGENE, V33, P2504, DOI 10.1038/onc.2013.198; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109; Fousek K, 2015, CLIN CANCER RES, V21, P3384, DOI 10.1158/1078-0432.CCR-14-2675; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Furnari FB, 2015, NAT REV CANCER, V15, P302, DOI 10.1038/nrc3918; Gan HK, 2012, CANCER RES, V72, P2924, DOI 10.1158/0008-5472.CAN-11-3898; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Gong AH, 2015, CANCER RES, V75, P2337, DOI 10.1158/0008-5472.CAN-14-2800; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Greenall SA, 2015, ONCOGENE, V34, P5277, DOI 10.1038/onc.2014.448; Guo G, 2015, CANCER RES, V75, P3436, DOI 10.1158/0008-5472.CAN-15-0989; Halatsch ME, 2000, J NEUROSURG, V92, P297, DOI 10.3171/jns.2000.92.2.0297; Halatsch ME, 2004, J NEUROSURG, V100, P523, DOI 10.3171/jns.2004.100.3.0523; Han JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11483; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iwanami A, 2013, P NATL ACAD SCI USA, V110, P4339, DOI 10.1073/pnas.1217602110; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963; Jun HJ, 2014, STEM CELLS, V32, P338, DOI 10.1002/stem.1554; Kadamur G, 2013, ANNU REV PHYSIOL, V75, P127, DOI 10.1146/annurev-physiol-030212-183750; Kancha RK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-39; Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Lal A, 2002, CANCER RES, V62, P3335; Latha K, 2013, INT J CANCER, V132, P509, DOI 10.1002/ijc.27690; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Li LN, 2010, J NEUROSURG, V113, P192, DOI 10.3171/2010.2.JNS091211; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Malkki H, 2016, NAT REV NEUROL, V12, DOI [10.1038/nrneurol.2016.79, 10.1038/nrneurol.2016.22, 10.1038/nrneurol.2016.78, 10.1038/nrneurol.2016.30, 10.1038/nrneurol.2016.117, 10.1038/nrneurol.2016.52, 10.1038/nrneurol.2016.58, 10.1038/nrneurol.2016.151, 10.1038/nrneurol.2016.139, 10.1038/nrneurol.2016.175]; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Mawrin C, 2003, INT J ONCOL, V23, P641; Mayer BJ, 2015, NAT REV MOL CELL BIO, V16, P691, DOI 10.1038/nrm4068; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Neyns B, 2009, ANN ONCOL, V20, P1596, DOI 10.1093/annonc/mdp032; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Novellasdemunt L, 2013, J BIOL CHEM, V288, P10640, DOI 10.1074/jbc.M113.455998; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Ozes ON, 1999, NATURE, V401, P82; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Reardon DA, 2015, NEURO-ONCOLOGY, V17, P430, DOI 10.1093/neuonc/nou160; Reardon DA, 2013, CLIN CANCER RES, V19, P900, DOI 10.1158/1078-0432.CCR-12-1707; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Roth P, 2014, NEURO-ONCOLOGY, V16, pviii14, DOI 10.1093/neuonc/nou222; Sampson JH, 2009, MOL CANCER THER, V8, P2773, DOI 10.1158/1535-7163.MCT-09-0124; Schijns VEJC, 2015, VACCINE, V33, P2690, DOI 10.1016/j.vaccine.2015.03.095; Schuster J, 2015, NEURO-ONCOLOGY, V17, P854, DOI 10.1093/neuonc/nou348; See AP, 2012, J NEURO-ONCOL, V110, P359, DOI 10.1007/s11060-012-0981-6; Shinojima N, 2003, CANCER RES, V63, P6962; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Swartz AM, 2014, IMMUNOTHERAPY-UK, V6, P679, DOI [10.2217/IMT.14.21, 10.2217/imt.14.21]; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tan CS, 2015, LANCET ONCOL, V16, pE447, DOI 10.1016/S1470-2045(15)00246-6; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Uht RM, 2007, ONCOGENE, V26, P2885, DOI 10.1038/sj.onc.1210090; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Weiss WA, 2003, CANCER RES, V63, P1589; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zahonero C, 2015, MOL CANCER THER, V14, P1548, DOI 10.1158/1535-7163.MCT-14-0736; ZUSSMAN BM, 2015, NEUROSURGERY, V76	149	226	235	5	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1561	1575		10.1038/s41388-017-0045-7	http://dx.doi.org/10.1038/s41388-017-0045-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29321659	Green Accepted, Green Submitted			2022-12-28	WOS:000428626700002
J	Han, W; Gao, S; Barrett, D; Ahmed, M; Han, D; Macoska, JA; He, HH; Cai, C				Han, W.; Gao, S.; Barrett, D.; Ahmed, M.; Han, D.; Macoska, J. A.; He, H. H.; Cai, C.			Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer	ONCOGENE			English	Article							SPLICE VARIANTS; INCREASED SURVIVAL; GENE-EXPRESSION; TUMORIGENESIS; ENZALUTAMIDE; ABIRATERONE; CELLS; DEPRIVATION; METABOLISM; ACTIVATION	Androgen receptor (AR) is a transcriptional activator that, in prostate cells, stimulates gene expression required for various cellular functions, including metabolisms and proliferation. AR signaling is also essential for the development of hormone-dependent prostate cancer (PCa) and its activity can be blocked by androgen-deprivation therapies (ADTs). Although PCa patients initially respond well to ADTs, the cancer inevitably relapses and progresses to lethal castration-resistant prostate cancer (CRPC). Although AR activity is generally restored in CRPC despite the castrate level of androgens, it is unclear whether AR signaling is significantly reprogrammed. In this study, we examined the AR cistrome in a PCa cell line-derived CRPC model using integrated bioinformatical analyses. Significantly, we found that the AR cistrome is largely retained in the CRPC stage. In particular, AR-mediated lipid biosynthesis is highly conserved and reactivated during the progression to CRPC, and increased level of lipid synthesis is associated with poor prognosis. The restoration of lipid biosynthetic pathways is partially due to the increased expression of AR splice variants. Blocking lipid/cholesterol synthesis in AR variants-expressing CRPC cell line and xenograft models markedly reduces tumor growth through inhibition of mTOR pathway. Silencing the expression of a fatty acid elongase, ELOVL7, also leads to the regression of CRPC xenograft tumors. These results demonstrate the importance of reactivation of AR-regulated lipid biosynthetic pathways in driving CRPC progression, and suggest that ADTs may be therapeutically enhanced by blocking lipid biosynthetic pathways.	[Han, W.; Gao, S.; Barrett, D.; Han, D.; Macoska, J. A.; Cai, C.] Univ Massachusetts, Ctr Personalized Canc Therapy, 100 Morrissey Blvd,ISC 4-4720, Boston, MA 02125 USA; [Ahmed, M.; He, H. H.] Univ Hlth Network, Princess Margaret Canc Ctr, 101 Coll St, Toronto, ON M5G 1L7, Canada; [He, H. H.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Massachusetts System; University of Massachusetts Boston; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Cai, C (corresponding author), Univ Massachusetts, Ctr Personalized Canc Therapy, 100 Morrissey Blvd,ISC 4-4720, Boston, MA 02125 USA.; He, HH (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, 101 Coll St, Toronto, ON M5G 1L7, Canada.	hansenhe@uhnresearch.ca; changmeng.cai@umb.edu	Han, Wanting/AEX-5349-2022; Cai, Changmeng/AAE-6835-2020; He, Hansen/ABD-8439-2020; Han, Wanting/GQA-5728-2022	Han, Wanting/0000-0002-2173-3647; He, Hansen/0000-0003-2898-3363; Cai, Changmeng/0000-0002-8701-2586; Gao, Shuai/0000-0002-7304-8801	NIH [R00 CA166507]; NIH (SPORE in Prostate Cancer) [P50 CA090381-13]; DOD [W81XWH-15-1-0554, W81XWH-15-1-0519, W81XWH-16-1-0445]; CIHR [142246]; Prostate Cancer Canada [RS2016-1022]; NSERC [498706]; CCSRI [703800]; Princess Margaret Cancer Foundation; NATIONAL CANCER INSTITUTE [P50CA090381, R00CA166507] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (SPORE in Prostate Cancer)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); CIHR(Canadian Institutes of Health Research (CIHR)); Prostate Cancer Canada; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); CCSRI; Princess Margaret Cancer Foundation(University of Toronto); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH (R00 CA166507 to CC, and SPORE in Prostate Cancer P50 CA090381-13), DOD (W81XWH-15-1-0554 to SG, and W81XWH-15-1-0519 and W81XWH-16-1-0445 to CC), CIHR (142246 to HHH), Prostate Cancer Canada (RS2016-1022 to HHH), NSERC (498706 to HHH), CCSRI (703800 to HHH) and Princess Margaret Cancer Foundation (to HHH). We thank Dr Steven P Balk (Beth Israel Deaconess Medical Center) for the advice of experiment design and Drs Myles Brown and X Shirley Liu (Dana-Farber Cancer Institute) for the support of bioinformatical analyses.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Evans AJ, 2003, J CLIN PATHOL, V56, P892, DOI 10.1136/jcp.56.12.892; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Green SM, 2012, MOL CELL ENDOCRINOL, V360, P3, DOI 10.1016/j.mce.2011.09.046; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harshman LC, 2015, JAMA ONCOL, V1, P495, DOI 10.1001/jamaoncol.2015.0829; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Kichenadasse G, 2013, NEW ENGL J MED, V368, P1457, DOI 10.1056/NEJMc1301594; Kochuparambil ST, 2011, J PHARMACOL EXP THER, V336, P496, DOI 10.1124/jpet.110.174870; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Pon D, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0474-5; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Sivaprasad U, 2006, MOL CANCER THER, V5, P2310, DOI 10.1158/1535-7163.MCT-06-0175; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tamura K, 2009, CANCER RES, V69, P8133, DOI 10.1158/0008-5472.CAN-09-0775; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhuang LY, 2005, J CLIN INVEST, V115, P959	47	48	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					710	721		10.1038/onc.2017.385	http://dx.doi.org/10.1038/onc.2017.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059155	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000424628100003
J	Wang, F; Wang, AY; Chesnelong, C; Yang, Y; Nabbi, A; Thalappilly, S; Alekseev, V; Riabowol, K				Wang, F.; Wang, A. Y.; Chesnelong, C.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Alekseev, V.; Riabowol, K.			ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P33(ING1); HISTONE ACETYLTRANSFERASE; NEURAL PROGENITORS; GROWTH-FACTOR; CANCER CELLS; BRAIN; DIFFERENTIATION; GLIOMA; PROLIFERATION; MUTATIONS	Stem cell-like brain tumor initiating cells (BTICs) cause recurrence of glioblastomas, with BTIC 'stemness' affected by epigenetic mechanisms. The ING family of epigenetic regulators (ING1-5) function by targeting histone acetyltransferase (HAT) or histone deacetylase complexes to the H3K4me3 mark to alter histone acetylation and subsequently, gene expression. Here we find that ectopic expression of ING5, the targeting subunit of HBO1, MOZ and MORF HAT complexes increases expression of the Oct4, Olig2 and Nestin stem cell markers, promotes self-renewal, prevents lineage differentiation and increases stem cell pools in BTIC populations. This activity requires the plant homeodomain region of ING5 that interacts specifically with the H3K4me3 mark. ING5 also enhances PI3K/AKT and MEK/ERK activity to sustain self-renewal of BTICs over serial passage of stem cell-like spheres. ING5 exerts these effects by activating transcription of calcium channel and follicle stimulating hormone pathway genes. In silico analyses of The Cancer Genome Atlas data suggest that ING5 is a positive regulator of BTIC stemness, whose expression negatively correlates with patient prognosis, especially in the Proneural and Classical subtypes, and in tumors with low SOX2 expression. These data suggest that altering histone acetylation status and signaling pathways induced by ING5 may provide useful clinical strategies to target tumor resistance and recurrence in glioblastoma.	[Wang, F.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Alekseev, V.; Riabowol, K.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Wang, F.; Wang, A. Y.; Chesnelong, C.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Riabowol, K.] Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, 311 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Wang, A. Y.; Chesnelong, C.] Univ Calgary, Hotchkiss Brain Inst, Dept Cell Biol & Anat, Calgary, AB, Canada; [Yang, Y.] Harbin Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China	University of Calgary; University of Calgary; University of Calgary; Harbin Medical University	Riabowol, K (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.; Riabowol, K (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, 311 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	karl@ucalgary.ca	Alekseev, Vladislav/G-6157-2019	Alekseev, Vladislav/0000-0001-6751-6210; Thalappilly, Subhash/0000-0003-1766-3057; Nabbi, Arash/0000-0002-3195-7361	Alberta Cancer Foundation [26512]; Canadian Institutes of Health Research [MOP-133646]	Alberta Cancer Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We are grateful to Dr. Samuel Weiss's group, particularly Dr. Artee Luchman and Rozina Hassam, from the University of Calgary for providing the patient-derived BTIC lines and technical support. We thank Dr. Jennifer Cobb and Dr. Derrick Rancourt from the University of Calgary for valuable experimental insights. This work was funded by the Alberta Cancer Foundation (Project 26512) and Canadian Institutes of Health Research (MOP-133646). This work was funded by grants from the Alberta Cancer Foundation (Project 26512) and Canadian Institutes of Health Research (MOP-133646) to KR.	Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bhartiya D, 2015, REPRODUCTION, V149, pR35, DOI 10.1530/REP-14-0220; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brennan DF, 2011, NATURE, V472, P366, DOI 10.1038/nature09860; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Chai SJ, 2015, ONCOTARGET, V6, P16069, DOI 10.18632/oncotarget.3866; Chang KC, 2012, BIOESSAYS, V34, P301, DOI 10.1002/bies.201100090; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Clayton-Smith J, 2011, AM J HUM GENET, V89, P675, DOI 10.1016/j.ajhg.2011.10.008; Cusulin C, 2015, STEM CELL REP, V5, P1, DOI 10.1016/j.stemcr.2015.05.010; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Ding XQ, 2017, ONCOTARGET; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eapen SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040684; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gao XF, 2013, CANCER RES, V73, P1481, DOI 10.1158/0008-5472.CAN-12-3429; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gou WF, 2015, ONCOTARGET, V6, P19552, DOI 10.18632/oncotarget.3735; Guo G, 2010, DEVELOPMENT, V137, P3185, DOI 10.1242/dev.052753; Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hussein SMI, 2014, NATURE, V516, P198, DOI 10.1038/nature14046; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Kang SS, 2010, CANCER RES, V70, P1173, DOI 10.1158/0008-5472.CAN-09-2886; Kataoka H, 2003, CANCER RES, V63, P5785; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; Kim MS, 2015, FEBS LETT, V589, P941, DOI 10.1016/j.febslet.2015.02.029; Konno D, 2008, NAT CELL BIOL, V10, P93, DOI 10.1038/ncb1673; Kosodo Y, 2004, EMBO J, V23, P2314, DOI 10.1038/sj.emboj.7600223; Kraft M, 2011, J CLIN INVEST, V121, P3479, DOI 10.1172/JCI43428; Lawn S, 2015, J BIOL CHEM, V290, P3814, DOI 10.1074/jbc.M114.599373; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Linzen U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123736; Liu L, 2015, BIOCHEM BIOPH RES CO, V461, P525, DOI 10.1016/j.bbrc.2015.04.061; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Liu NS, 2013, CANCER RES, V73, P3749, DOI 10.1158/0008-5472.CAN-12-3684; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Luberg K, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0215-x; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Mulder KW, 2012, NAT CELL BIOL, V14, P753, DOI 10.1038/ncb2520; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Rajarajacholan UK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001502; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Safa AR, 2015, GENES DIS, V2, P152, DOI 10.1016/j.gendis.2015.02.001; Saito M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015541; Sarkar P, 2016, J PROTEOME RES, V15, P2433, DOI 10.1021/acs.jproteome.5b01118; Schafer A, 2013, GENE DEV, V27, P261, DOI 10.1101/gad.186916.112; Scott M, 2001, J CELL SCI, V114, P3455; Sheikh BN, 2012, J CELL SCI, V125, P295, DOI 10.1242/jcs.077271; Shiseki M, 2003, CANCER RES, V63, P2373; Siegel ET, 2013, REPROD SCI, V20, P211, DOI 10.1177/1933719112461184; Signaroldi E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10753; Simpson MA, 2012, AM J HUM GENET, V90, P290, DOI 10.1016/j.ajhg.2011.11.024; Singh SK, 2003, CANCER RES, V63, P5821; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Suzuki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074749; Swartling FJ, 2015, CELL TISSUE RES, V359, P225, DOI 10.1007/s00441-014-2046-y; Tallen G, 2014, FEBS LETT, V588, P2728, DOI 10.1016/j.febslet.2014.03.011; Thomas T, 2000, DEVELOPMENT, V127, P2537; Ullah M, 2008, MOL CELL BIOL, V28, P6828, DOI 10.1128/MCB.01297-08; Velasco I, 2011, CURR TOP MED CHEM, V11, P1684, DOI 10.2174/156802611796117586; Vieyra D, 2003, CLIN CANCER RES, V9, P5952; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vlismas A, 2016, STEM CELLS DEV, V25, P160, DOI 10.1089/scd.2015.0284; Wang Y, 2012, CELL, V150, P816, DOI 10.1016/j.cell.2012.06.034; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Yang HM, 2007, J CELL BIOCHEM, V101, P1198, DOI 10.1002/jcb.21244; You LY, 2015, J BIOL CHEM, V290, P7114, DOI 10.1074/jbc.M114.635250; You LY, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005034; Zhang F, 2015, ONCOTARGET, V6, P16239, DOI 10.18632/oncotarget.3842; Zhang FR, 2011, ADV DIFFER EQU-NY, DOI 10.1155/2011/213485; Zhang ZB, 2013, INT J ONCOL, V43, P1194, DOI 10.3892/ijo.2013.2054; Zhao NJ, 2010, ONCOL REP, V23, P1443, DOI 10.3892/or_00000782; Zhao S, 2017, ONCOTARGET, V8, P56558, DOI 10.18632/oncotarget.17802; Zhao S, 2016, ONCOTARGET, V7, P54596, DOI 10.18632/oncotarget.10519	94	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					286	301		10.1038/onc.2017.324	http://dx.doi.org/10.1038/onc.2017.324			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925404	hybrid, Green Published			2022-12-28	WOS:000422753900002
J	Ambrosio, S; Sacca, CD; Amente, S; Paladino, S; Lania, L; Majello, B				Ambrosio, S.; Sacca, C. D.; Amente, S.; Paladino, S.; Lania, L.; Majello, B.			Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway	ONCOGENE			English	Article							EPIGENETIC REGULATION; MTOR; CANCER; TARGET; P53; INHIBITOR; SESTRIN2; EXPRESSION; STRESS; GENES	Autophagy is a physiological process, important for recycling of macromolecules and maintenance of cellular homeostasis. Defective autophagy is associated with tumorigenesis and has a causative role in chemotherapy resistance in leukemia and in solid cancers. Here, we report that autophagy is regulated by the lysine-specific demethylase LSD1/KDM1A, an epigenetic marker whose overexpression is a feature of malignant neoplasia with an instrumental role in cancer development. In the present study, we determine that two different LSD1 inhibitors (TCP and SP2509) as well as selective ablation of LSD1 expression promote autophagy in neuroblastoma cells. At a mechanistic level, we show that LSD1 binds to the promoter region of Sestrin2 (SESN2), a critical regulator of mTORC1 activity. Pharmacological inhibition of LSD1 triggers SESN2 expression that hampers mTORC1 activity, leading to enhanced autophagy. SESN2 overexpression suffices to promote autophagy in neuroblastoma cells, while loss of SESN2 expression reduces autophagy induced by LSD1 inhibition. Our findings elucidate a mechanism whereby LSD1 controls autophagy in neuroblastoma cells through SESN2 transcription regulation, and we suggest that pharmacological targeting of LSD1 may have effective therapeutic relevance in the control of autophagy in neuroblastoma.	[Ambrosio, S.; Sacca, C. D.; Majello, B.] Univ Naples Federico II, Div Genet, Dept Biol, Via Cinthia,Edificio 7, I-80126 Naples, Italy; [Amente, S.; Paladino, S.; Lania, L.] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Paladino, S.] Ceinge Biotecnol Avanzate Scarl, Naples, Italy	University of Naples Federico II; University of Naples Federico II; CEINGE Biotecnologie Avanzate	Majello, B (corresponding author), Univ Naples Federico II, Div Genet, Dept Biol, Via Cinthia,Edificio 7, I-80126 Naples, Italy.	majello@unina.it	Paladino, Simona/ABH-7826-2020; Amente, Stefano/AAU-7605-2020; Paladino, Simona/J-5383-2018	Amente, Stefano/0000-0003-0612-6096; Paladino, Simona/0000-0001-5332-6774; Sacca, Carmen Daniela/0000-0002-9861-9332; Majello, Barbara/0000-0003-2789-3585	AIRC [IG13173]; Epigenomics Flagship Project-EPIGEN; CNR; MOVIE of Rete delle Biotecnologie, Campania	AIRC(Fondazione AIRC per la ricerca sul cancro); Epigenomics Flagship Project-EPIGEN; CNR(Consiglio Nazionale delle Ricerche (CNR)); MOVIE of Rete delle Biotecnologie, Campania	We thank A Feliciello for helpful discussions, constructive criticisms, Dr M Capasso for help with the R2 package and Dr P Chumakov for providing us the SESN2-Flag expression vector. This work was supported by following grants: AIRC (IG13173 to BM), Epigenomics Flagship Project-EPIGEN, CNR and from Grant MOVIE of the Rete delle Biotecnologie, Campania.	Ambrosio S, 2017, ONCOTARGET, V8, P3854, DOI 10.18632/oncotarget.12924; Amente S, 2015, ONCOTARGET, V6, P14572, DOI 10.18632/oncotarget.3990; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Belounis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2906-9; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Cimmino F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11158; de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13; Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Etani T, 2015, ONCOTARGET, V6, P2865, DOI 10.18632/oncotarget.3067; Feng SJ, 2016, MED SCI MONITOR, V22, P4742, DOI 10.12659/MSM.898825; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Han X, 2014, MOL CELL, V55, P482, DOI 10.1016/j.molcel.2014.06.006; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Maiese K, 2016, BRIT J CLIN PHARMACO, V82, P1245, DOI 10.1111/bcp.12804; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Periz G, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002114; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sehgal AR, 2015, LEUKEMIA, V29, P517, DOI 10.1038/leu.2014.349; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wang JX, 2015, NAT NEUROSCI, V18, P1256, DOI 10.1038/nn.4069; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Zapata PAM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2388-9; Zhang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6775; Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981	51	47	49	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6701	6711		10.1038/onc.2017.267	http://dx.doi.org/10.1038/onc.2017.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783174	hybrid, Green Published			2022-12-28	WOS:000416780800005
J	Li, XX; Zhang, HS; Xu, YM; Zhang, RJ; Chen, Y; Fan, L; Qin, YQ; Liu, Y; Li, M; Fang, J				Li, X-X; Zhang, H-S; Xu, Y-M; Zhang, R-J; Chen, Y.; Fan, L.; Qin, Y-Q; Liu, Y.; Li, M.; Fang, J.			Knockdown of IRE1 alpha inhibits colonic tumorigenesis through decreasing beta-catenin and IRE1 alpha targeting suppresses colon cancer cells	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; TO-MESENCHYMAL TRANSITION; ER STRESS; STEM-CELLS; EPITHELIAL-CELLS; BREAST-CANCER; CYCLIN D1; WNT; PHOSPHORYLATION	The endoplasmic reticulum (ER) stress occurs frequently in cancers. The unfolded protein response (UPR) is activated to cope with ER stress. This has generated widespread interest in targeting UPR as therapeutic strategies. Inositol-requiring transmembrane kinase/endonuclease 1 alpha (IRE1 alpha), an ER stress sensor, is a key component of UPR. However, the role of IRE1 alpha in tumorigenesis remains unclear. The purpose of this work is to investigate the role of IRE1 alpha in colon cancer and to determine whether IRE1 alpha could serve as a target for therapy. We found that knockdown of IRE1 alpha suppressed the proliferation of colon cancer cells in vitro and xenograft growth in vivo. Inhibition of expression of IRE1 alpha decreased stemness of colon cancer stem cells (CSCs) and attenuated growth of intestinal organoids. Genetic ablation of IRE1 alpha prevented the colitis-associated colonic tumorigenesis in mice. The mechanistic study indicates that knockdown of IRE1 alpha repressed the expression of beta-catenin, a key factor that drives colonic tumorigenesis, through activating pancreatic ER kinase/eukaryotic translation initiation factor 2 alpha signaling. We found that the IRE1a-specific inhibitor 4 mu 8C could suppress the production of beta-catenin, inhibited the proliferation of colon cancer cells, repressed colon CSCs and prevented xenograft growth. The results suggest that IRE1a has a critical role in colonic tumorigenesis and IRE1 alpha targeting might be a strategy for treatment of colon cancers.	[Li, X-X; Zhang, H-S; Xu, Y-M; Zhang, R-J; Chen, Y.; Fan, L.; Qin, Y-Q; Fang, J.] Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Food Safety Res,Inst Nutrit Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Liu, Y.] Wuhan Univ, Coll Life Sci, Wuhan, Hubei, Peoples R China; [Li, M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Wuhan University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Fang, J (corresponding author), Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Food Safety Res,Inst Nutrit Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jfang@sibs.ac.cn			STCSM [16JC1406100]; NSFC [31270829, 31470769, 31670785]; Chinese Academy of Sciences [XDA08030300, KFJ-EW-STS-099]; CAS/SAFEA	STCSM(Science & Technology Commission of Shanghai Municipality (STCSM)); NSFC(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); CAS/SAFEA(Chinese Academy of Sciences)	This work was funded by STCSM (16JC1406100), NSFC (31270829, 31470769, 31670785), Chinese Academy of Sciences (XDA08030300, KFJ-EW-STS-099) and CAS/SAFEA International Partnership Program for Creative Research Teams. We thank Dr Xie for kindly providing the vectors.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Jiang DD, 2015, SEMIN CANCER BIOL, V33, P48, DOI 10.1016/j.semcancer.2015.04.010; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Llado V, 2015, CELL REP, V10, P740, DOI 10.1016/j.celrep.2015.01.007; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mao T, 2011, P NATL ACAD SCI USA, V108, P15852, DOI 10.1073/pnas.1107394108; Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633; MORI K, 1993, CELL, V74, P743; Nagelkerke A, 2014, BBA-REV CANCER, V1846, P277, DOI 10.1016/j.bbcan.2014.07.006; Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Qiu YF, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000514; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosekrans SL, 2015, GUT, V64, P195, DOI 10.1136/gutjnl-2013-306347; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Tanjore H, 2011, J BIOL CHEM, V286, P30972, DOI 10.1074/jbc.M110.181164; Thomas SE, 2013, J BIOL CHEM, V288, P7606, DOI 10.1074/jbc.M112.424655; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Ulianich L, 2008, J CELL SCI, V121, P477, DOI 10.1242/jcs.017202; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Zhang F, 2006, J BIOL CHEM, V281, P30036, DOI 10.1074/jbc.M604674200; Zhang HS, 2015, J BIOL CHEM, V290, P15327, DOI 10.1074/jbc.M114.633560; Zhang HS, 2012, J BIOL CHEM, V287, P44164, DOI 10.1074/jbc.M112.401521; Zhao WT, 2013, J BIOL CHEM, V288, P16588, DOI 10.1074/jbc.M113.455121	47	31	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6738	6746		10.1038/onc.2017.284	http://dx.doi.org/10.1038/onc.2017.284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28825721				2022-12-28	WOS:000416780800008
J	D'Abronzo, LS; Bose, S; Crapuchettes, ME; Beggs, RE; Vinall, RL; Tepper, CG; Siddiqui, S; Mudryj, M; Melgoza, FU; Durbin-Johnson, BP; White, RWD; Ghosh, PM				D'Abronzo, L. S.; Bose, S.; Crapuchettes, M. E.; Beggs, R. E.; Vinall, R. L.; Tepper, C. G.; Siddiqui, S.; Mudryj, M.; Melgoza, F. U.; Durbin-Johnson, B. P.; White, R. W. deVere; Ghosh, P. M.			The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer	ONCOGENE			English	Article							INITIATION-FACTOR 4E; CELL-PROLIFERATION; MAMMALIAN TARGET; RAPAMYCIN; TRANSLATION; GROWTH; ACTIVATION; PROTEIN; BICALUTAMIDE; MNK1	The antiandrogen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration-resistant PCa (CRPC) is limited. We previously showed that resistance to bicalutamide results from activation of mechanistic target of rapamycin (mTOR). Interestingly, clinical trials testing combinations of the mTOR inhibitor RAD001 with bicalutamide were effective in bicalutamide-naive CRPC patients, but not in bicalutamide-pretreated ones. Here we investigate causes for their difference in response. Evaluation of CRPC cell lines identified resistant vs sensitive in vitro models, and revealed that increased eIF4E(S209) phosphorylation is associated with resistance to the combination. We confirmed using a human-derived tumor xenograft mouse model that bicalutamide pre-treatment is associated with an increase in eIF4E(S209) phosphorylation. Thus, AR suppressed eukaryotic initiation factor 4E (eIF4E) phosphorylation, while the use of antiandrogens relieved this suppression, thereby triggering its increase. Additional investigation in human prostatectomy samples showed that increased eIF4E phosphorylation strongly correlated with the cell proliferation marker Ki67. Small interfering RNA-mediated knockdown (k/d) of eIF4E-sensitized CRPC cells to RAD001+bicalutamide, whereas eIF4E overexpression induced resistance. Inhibition of eIF4E phosphorylation by treatment with CGP57380 (an inhibitor of mitogen-activated protein kinase-interacting serine-threonine kinases MAP kinase-interacting kinase 1 (Mnk1/2), the eIF4E upstream kinase) or inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2), the upstream kinase-regulating Mnk1/2, also sensitized CRPC cells to RAD001+ bicalutamide. Examination of downstream targets of eIF4E-mediated translation, including survivin, demonstrated that eIF4E(S209) phosphorylation increased cap-independent translation, whereas its inhibition restored cap-dependent translation, which could be inhibited by mTOR inhibitors. Thus, our results demonstrate that while combinations of AR and mTOR inhibitors were effective in suppressing tumor growth by inhibiting both AR-induced transcription and mTOR-induced cap-dependent translation, pre-treatment with AR antagonists including bicalutamide increased eIF4E phosphorylation that induced resistance to combinations of AR and mTOR inhibitors by inducing cap-independent translation. We conclude that this resistance can be overcome by inhibiting eIF4E phosphorylation with Mnk1/2 or ERK1/2 inhibitors.	[D'Abronzo, L. S.; Crapuchettes, M. E.; Beggs, R. E.; Siddiqui, S.; Melgoza, F. U.; Ghosh, P. M.] Univ Calif Davis, VA Northern Calif Hlth Care Syst, Sacramento, CA 95817 USA; [D'Abronzo, L. S.; Bose, S.; Vinall, R. L.; White, R. W. deVere; Ghosh, P. M.] Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA; [Vinall, R. L.] Calif Northstate Univ, Coll Pharm, Elk Grove, CA USA; [Tepper, C. G.; Ghosh, P. M.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Mudryj, M.] Univ Calif Davis, Dept Med Microbiol & Immunol, Sacramento, CA 95817 USA; [Durbin-Johnson, B. P.] Univ Calif Davis, Div Biostat, Dept Publ Hlth, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Ghosh, PM (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	paghosh@ucdavis.edu	Tepper, Clifford G/H-6527-2011; Vinall, Ruth/L-7026-2019		Department of Veterans Affairs [I01BX000400]; National Institutes of Health [R01CA133209, R01CA185509]; NATIONAL CANCER INSTITUTE [R01CA133209, P30CA093373, R01CA185509] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003458, I01BX000400] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Novartis Pharmaceuticals for the gift of RAD001. We also thank Stephanie Soares, Department of Urology, University of California Davis, School of Medicine (Sacramento, CA, USA), for the construction of the tissue microarrays used in this study, and Yu Wang, Department of Urology, for assistance with mice experiments. Human PSA-luciferase construct was kindly provided by Dr XuBao Shi, University of California Davis, Department of Urology. CWR-R1 cells were provided by Dr Elizabeth Wilson (University of North Carolina), pRNS1-1 cells were from Dr Johng Rhim, University of the Health Sciences (Bethesda, MD, USA), whereas PC-346C cells were from Dr WM van Weerden, Josephine Nefkens Institute (Erasmus MC, Rotterdam, Netherlands). We also thank Dr Xinbin Chen (UC Davis School of Veterinary Medicine) for the pRL-HCV-FL plasmid, and Maitreyee K Jathal and Thomas M Steele (UC Davis, Department of Urology) for samples of 22Rv1 xenograft tumors. This work was supported by a Biomedical Laboratory Research and Development (BLRD) Merit Award (I01BX000400, to PMG) from the Department of Veterans Affairs, and by Awards R01CA133209 (to PMG) and R01CA185509 (to PMG) from the National Institutes of Health.	Amato RJ, 2008, CLIN GENITOURIN CANC, V6, P97, DOI 10.3816/CGC.2008.n.015; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Canedo CS, 2010, AM J PHYSIOL-ENDOC M, V298, pE761, DOI 10.1152/ajpendo.00421.2009; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chamie K, 2008, AM J TRANSPLANT, V8, P2668, DOI 10.1111/j.1600-6143.2008.02430.x; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chow H, 2016, CANCER-AM CANCER SOC, V122, P1897, DOI 10.1002/cncr.29927; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edlind MP, 2014, ASIAN J ANDROL, V16, P378, DOI 10.4103/1008-682X.122876; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Gingras AC, 2001, GENE DEV, V15, P2852; Goetz C, 2010, MOL THER, V18, P1937, DOI 10.1038/mt.2010.145; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Idris AI, 2012, METHODS MOL BIOL, V816, P545, DOI 10.1007/978-1-61779-415-5_34; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MacVicar GR, 2013, CURR OPIN ONCOL, V25, P252, DOI 10.1097/CCO.0b013e32835ff161; Mbatia HW, 2015, J MED CHEM, V58, P1900, DOI 10.1021/jm501792c; Mikhailova M, 2008, ADV EXP MED BIOL, V617, P397, DOI 10.1007/978-0-387-69080-3_38; Mooso Benjamin, 2010, Genes Cancer, V1, P927, DOI 10.1177/1947601910385450; Mooso BA, 2012, ENDOCR-RELAT CANCER, V19, P759, DOI 10.1530/ERC-12-0171; Nakabayashi M, 2012, BJU INT, V110, P1729, DOI 10.1111/j.1464-410X.2012.11456.x; R Core Team, 2022, R LANG ENV STAT COMP; Ramamurthy VP, 2015, ONCOTARGET, V6, P3195, DOI 10.18632/oncotarget.3084; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Schayowitz A, 2010, BRIT J CANCER, V103, P1001, DOI 10.1038/sj.bjc.6605882; Sekiyama N, 2015, P NATL ACAD SCI USA, V112, pE4036, DOI 10.1073/pnas.1512118112; Shi XB, 2007, PROSTATE, V67, P591, DOI 10.1002/pros.20544; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Sonenberg N, 2008, BIOCHEM CELL BIOL, V86, P178, DOI 10.1139/O08-034; Squillace RM, 2012, INT J ONCOL, V41, P425, DOI 10.3892/ijo.2012.1487; Stead RL, 2013, FEBS LETT, V587, P2623, DOI 10.1016/j.febslet.2013.06.045; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wang Y, 2008, ONCOGENE, V27, P7106, DOI 10.1038/onc.2008.318; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wen QY, 2016, ONCOTARGET, V7, P27787, DOI 10.18632/oncotarget.8497; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu Y, 2010, ANTICANCER RES, V30, P3895; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	48	26	27	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6359	6373		10.1038/onc.2017.233	http://dx.doi.org/10.1038/onc.2017.233			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745319	Green Accepted, Green Submitted			2022-12-28	WOS:000415622900001
J	Li, W; Hu, M; Wang, C; Lu, H; Chen, F; Xu, J; Shang, Y; Wang, F; Qin, J; Yan, Q; Krueger, BJ; Renne, R; Gao, SJ; Lu, C				Li, W.; Hu, M.; Wang, C.; Lu, H.; Chen, F.; Xu, J.; Shang, Y.; Wang, F.; Qin, J.; Yan, Q.; Krueger, B. J.; Renne, R.; Gao, S-J; Lu, C.			A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HEPATOCYTE GROWTH-FACTOR; PRIMARY EFFUSION LYMPHOMA; LYTIC CYCLE REPLICATION; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; ENCODED MICRORNAS; HIV-1 NEF; PROTEIN EXPRESSION; TETRASPANIN CD82	Kaposi's sarcoma (KS) as the most common AIDS-associated malignancy is etiologically caused by KS-associated herpesvirus (KSHV). KS is a highly disseminated and vascularized tumor. KSHV encodes 12 pre-microRNAs that yield 25 mature microRNAs (miRNAs), but their roles in KSHV-induced tumor metastasis and angiogenesis remain largely unclear. KSHV-encoded miR-K12-6 (miR-K6) can generate two mature miRNAs, miR-K6-5p and miR-K6-3p. Recently, we have shown that miR-K6-3p induced cell migration and angiogenesis via directly targeting SH3 domain binding glutamate-rich protein (SH3BGR). Here, by using mass spectrometry, bioinformatics analysis and luciferase reporter assay, we showed that miR-K6-5p directly targeted the coding sequence of CD82 molecule (CD82), a metastasis suppressor. Ectopic expression of miR-K6-5p specifically inhibited the expression of endogenous CD82 and strongly promoted endothelial cells invasion and angiogenesis. Overexpression of CD82 significantly inhibited cell invasion and angiogenesis induced by miR-K6-5p. Mechanistically, CD82 directly interacted with c-Met to inhibit its activation. MiR-K6-5p directly repressed CD82, relieving its inhibition on c-Met activation and inducing cell invasion and angiogenesis. Lack of miR-K6 abrogated KSHV suppression of CD82 resulting in compromised KSHV activation of c-Met pathway, and KSHV induction of cell invasion and angiogenesis. In conclusion, our data show that by reducing CD82, KSHV miR-K6-5p expedites cell invasion and angiogenesis by activating the c-Met pathway. Our findings illustrate that KSHV miRNAs may be critical for the dissemination and angiogenesis of KSHV-induced malignant tumors.	[Li, W.; Lu, C.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Li, W.; Lu, C.] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing, Jiangsu, Peoples R China; [Li, W.; Chen, F.; Xu, J.; Shang, Y.; Wang, F.; Qin, J.; Yan, Q.; Lu, C.] Nanjing Med Univ, Dept Microbiol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China; [Hu, M.] Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Xuzhou, Peoples R China; [Wang, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Lu, H.] Nanjing Med Univ, Affiliated Hosp 1, Dept Obstet, Nanjing, Jiangsu, Peoples R China; [Krueger, B. J.; Renne, R.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Gao, S-J] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Nanjing Medical University; Nanjing Medical University; State University System of Florida; University of Florida; University of Southern California	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China.	clu@njmu.edu.cn	Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	National Natural Science Foundation of China [81761128003, 81371824, 81401662]; NIH [R01CA213275, R01CA177377, R01CA132637]; Natural Science Youth Foundation of Jiangsu Province [BK20140908]; NATIONAL CANCER INSTITUTE [R01CA096512, R01CA132637, R01CA124332, R01CA197153, R01CA177377, R01CA213275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE025465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017333] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Youth Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from National Natural Science Foundation of China (81761128003, 81371824 and 81401662), grants from NIH (R01CA213275, R01CA177377 and R01CA132637), and the Natural Science Youth Foundation of Jiangsu Province (BK20140908).	Abend JR, 2012, J VIROL, V86, P11663, DOI 10.1128/JVI.01147-12; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; Bari R, 2009, AM J PATHOL, V174, P647, DOI 10.2353/ajpath.2009.080685; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellare P, 2009, CELL HOST MICROBE, V6, P570, DOI 10.1016/j.chom.2009.11.008; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blankaert D, 1998, J ACQ IMMUN DEF SYND, V18, P203, DOI 10.1097/00042560-199807010-00002; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brulois KF, 2012, J VIROL, V86, P9708, DOI 10.1128/JVI.01019-12; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Catrina AM, 2014, PATHOL ONCOL RES, V20, P153, DOI 10.1007/s12253-013-9678-1; Cheung TW, 2004, CANCER INVEST, V22, P774, DOI 10.1081/CNV-200032788; Cullen BR, 2011, GENE DEV, V25, P1881, DOI 10.1101/gad.17352611; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Feng J, 2015, CANCER METAST REV, V34, P619, DOI 10.1007/s10555-015-9585-x; Fuse N, 2016, GASTRIC CANCER, V19, P183, DOI 10.1007/s10120-015-0471-6; Gottwein E, 2011, CELL HOST MICROBE, V10, P515, DOI 10.1016/j.chom.2011.09.012; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Guo XZ, 2005, ONCOL REP, V14, P59; Han YL, 2014, ONCOL LETT, V8, P1618, DOI 10.3892/ol.2014.2390; Hanna JA, 2009, ADV CANCER RES, V103, P1, DOI 10.1016/S0065-230X(09)03001-2; Hansen A, 2010, GENE DEV, V24, P195, DOI 10.1101/gad.553410; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Jain V, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8020054; Koo BS, 2014, ANN SURG ONCOL, V21, P2310, DOI 10.1245/s10434-014-3553-5; Lei XF, 2012, J VIROL, V86, P11698, DOI 10.1128/JVI.06855-11; Leo C, 2007, GYNECOL ONCOL, V104, P181, DOI 10.1016/j.ygyno.2006.07.040; Li W, 2016, ONCOTARGET, V7, P32286, DOI 10.18632/oncotarget.8591; Li W, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005605; Li Y, 2013, INT J BIOCHEM CELL B, V45, P2349, DOI 10.1016/j.biocel.2013.08.002; Lin HR, 2011, P NATL ACAD SCI USA, V108, P5148, DOI 10.1073/pnas.1102033108; Lin XZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016224; Liu WM, 2006, CANCER LETT, V240, P183, DOI 10.1016/j.canlet.2005.08.018; Lu CC, 2010, EMBO REP, V11, P784, DOI 10.1038/embor.2010.132; Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09; Marshall V, 2007, J INFECT DIS, V195, P645, DOI 10.1086/511434; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Neuzillet C, 2015, HISTOPATHOLOGY, V67, P664, DOI 10.1111/his.12691; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; O'Hara AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000389; Pantanowitz L, 2006, J CUTAN PATHOL, V33, P793, DOI 10.1111/j.1600-0560.2006.00567.x; Poon M, 1997, CIRCULATION, V96, P2514, DOI 10.1161/01.CIR.96.8.2514; Qin D, 2008, CELL MICROBIOL, V10, P713, DOI 10.1111/j.1462-5822.2007.01079.x; Qin J, 2017, TRENDS MICROBIOL, V25, P648, DOI 10.1016/j.tim.2017.02.002; Qin Zhiqiang, 2012, Int J Cell Biol, V2012, P603961, DOI 10.1155/2012/603961; Qin ZQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000742; Ramalingam D, 2015, J VIROL, V89, P4249, DOI 10.1128/JVI.03687-14; Rosano L, 2003, AM J PATHOL, V163, P753, DOI 10.1016/S0002-9440(10)63702-9; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Ruseva Z, 2009, EXP CELL RES, V315, P1759, DOI 10.1016/j.yexcr.2009.01.007; Sadagopan S, 2009, J VIROL, V83, P3342, DOI 10.1128/JVI.02052-08; Samols MA, 2005, J VIROL, V79, P9301, DOI 10.1128/JVI.79.14.9301-9305.2005; Samols MA, 2007, PLOS PATHOG, V3, P611, DOI 10.1371/journal.ppat.0030065; Sridhar SC, 2006, ONCOGENE, V25, P2367, DOI 10.1038/sj.onc.1209269; Takahashi M, 2007, INT J CANCER, V121, P1919, DOI 10.1002/ijc.22887; Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200; Tohami T, 2007, FASEB J, V21, P691, DOI 10.1096/fj.06-6610com; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Wei Q, 2014, CIRCULATION, V130, P1493, DOI 10.1161/CIRCULATIONAHA.114.011096; Xue M, 2014, NUCLEIC ACIDS RES, V42, P9862, DOI 10.1093/nar/gku583; Yan Q, 2014, J VIROL, V88, P4987, DOI 10.1128/JVI.00025-14; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yang XH, 2001, CANCER RES, V61, P5284; Yao SH, 2015, NUCLEIC ACIDS RES, V43, P9362, DOI 10.1093/nar/gkv988; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu X, 2014, ONCOGENE, V33, P1986, DOI 10.1038/onc.2013.136; Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	74	24	24	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5407	5420		10.1038/onc.2017.139	http://dx.doi.org/10.1038/onc.2017.139			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534512	Green Accepted			2022-12-28	WOS:000411382100007
J	Niu, N; Mercado-Uribe, I; Liu, J				Niu, N.; Mercado-Uribe, I.; Liu, J.			Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells	ONCOGENE			English	Article							CLEAVAGE-STAGE EMBRYOS; IN-VITRO; CELLULAR SENESCENCE; OVARIAN TUMORIGENESIS; TUMOR-CELLS; DIFFERENTIATION; CYTOKINESIS; THERAPY; FAILURE; ESCAPE	Our recent perplexing findings that polyploid giant cancer cells (PGCCs) acquired embryonic-like stemness and were capable of tumor initiation raised two important unanswered questions: how do PGCCs acquire such stemness, and to which stage of normal development do PGCCs correspond. Intriguingly, formation of giant cells due to failed mitosis/cytokinesis is common in the blastomere stage of the preimplantation embryo. However, the relationship between PGCCs and giant blastomeres has never been studied. Here, we tracked the fate of single PGCCs following paclitaxel-induced mitotic failure. Morphologically, early spheroids derived from PGCCs were indistinguishable from human embryos at the blastomere, polyploid blastomere, compaction, morula and blastocyst-like stages by light, scanning electron or three-dimensional confocal scanning microscopy. Formation of PGCCs was associated with activation of senescence, while budding of daughter cells was associated with senescence escape. PGCCs showed time- and space-dependent activation of expression of the embryonic stem cell markers OCT4, NANOG, SOX2 and SSEA1 and lacked expression of Xist. PGCCs acquired mesenchymal phenotype and were capable of differentiation into all three germ layers in vitro. The embryonic-like stemness of PGCCs was associated with nuclear accumulation of YAP, a key mediator of the Hippo pathway. Spheroids derived from single PGCCs grew into a wide spectrum of human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas and benign tissues. Daughter cells derived from PGCCs showed attenuated capacity for invasion and increased resistance to paclitaxel. We also observed formation of PGCCs and dedifferentiation in ovarian cancer specimens from patients treated with chemotherapy. Taken together, our findings demonstrate that PGCCs represent somatic equivalents of blastomeres, the most primitive cancer stem cells reported to date. Thus, our studies reveal an evolutionarily conserved archaic embryonic program in somatic cells that can be de-repressed for oncogenesis. Our work offers a new paradigm for cancer origin and disease relapse.	[Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA; Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA.	jliu@mdanderson.org			Cancer Prevention and Research Institute of Texas; MD Anderson Cancer Center Global Academic Programs; National Cancer Institute Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; MD Anderson Cancer Center Global Academic Programs; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by a multi-investigator grant from the Cancer Prevention and Research Institute of Texas (JL); a Sister Institution Grant from MD Anderson Cancer Center Global Academic Programs; and National Cancer Institute Cancer Center Support Grant CA016672, which supported the High Resolution Electron Microscopy Facility. We thank Kim Vu for image artwork and Stephanie Deming for editorial assistance. We thank many colleagues for helpful discussions. We apologize for many investigators who embraced embryonic origin of tumor or its variants over past two centuries whose work can not be cited and discussed due to space limitation.	Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; BENKHALIFA M, 1993, HUM REPROD, V8, P895, DOI 10.1093/oxfordjournals.humrep.a138162; Blum B, 2008, ADV CANCER RES, V100, P133, DOI 10.1016/S0065-230X(08)00005-5; Braune EB, 2016, STEM CELL REP, V6, P643, DOI 10.1016/j.stemcr.2016.03.004; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chakradeo S, 2016, CURR DRUG TARGETS, V17, P460, DOI 10.2174/1389450116666150825113500; Chavez SL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2249; Chen HH, 2014, STEM CELL REP, V3, P892, DOI 10.1016/j.stemcr.2014.09.003; Cohnheim J, 1867, PATH ANAT PHYSL KLIN, V40, P1, DOI 10.1007/BF02968135; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Erenpreisa J, 2005, CELL BIOL INT, V29, P1005, DOI 10.1016/j.cellbi.2005.10.008; Erenpreisa JA, 2000, CELL BIOL INT, V24, P635, DOI 10.1006/cbir.2000.0558; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Forsdahl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102559; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Gasser R.F., VIRTUAL HUMAN EMBRYO; GURDON JB, 1958, NATURE, V182, P64, DOI 10.1038/182064a0; HARDY K, 1993, J REPROD FERTIL, V98, P549; Iwata K, 2014, J ASSIST REPROD GEN, V31, P421, DOI 10.1007/s10815-014-0195-2; Kamiyama T, 2006, ANN SURG, V244, P451, DOI 10.1097/01.sla.0000234840.74526.2b; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Kligman I, 1996, HUM REPROD, V11, P1492; Kumar V.A., 2010, ROBBINS CONTRAN PATH, P262; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Ledbetter DH, 2009, NAT MED, V15, P490, DOI 10.1038/nm0509-490; Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267; Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Lopez-Sanchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143; Mertzanidou A, 2013, HUM REPROD, V28, P256, DOI 10.1093/humrep/des362; Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Niu N, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.75; Niu N, 2011, CELL MOL LIFE SCI, V68, P2481, DOI 10.1007/s00018-010-0572-7; Ogden A, 2015, CANCER LETT, V367, P89, DOI 10.1016/j.canlet.2015.06.025; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Pierce G B, 1967, Curr Top Dev Biol, V2, P223; PIERCE GB, 1988, CANCER RES, V48, P1996; PIERCE GB, 1971, CANCER RES, V31, P127; PIERCE GB, 1983, AM J PATHOL, V113, P115; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; Sadler T.W., 2012, LANGMANS MEDICAL EMB, V12th; Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schrode N, 2014, DEV CELL, V29, P454, DOI 10.1016/j.devcel.2014.04.011; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STEVENS LC, 1964, P NATL ACAD SCI USA, V52, P654, DOI 10.1073/pnas.52.3.654; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Szajnik Marta, 2013, Gynecol Obstet (Sunnyvale), VSuppl 4, P3; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Van Royen E, 2003, HUM REPROD, V18, P1062, DOI 10.1093/humrep/deg201; Vanneste E, 2009, NAT MED, V15, P577, DOI 10.1038/nm.1924; Walen KH, 2005, CELL BIOL INT, V29, P1057, DOI 10.1016/j.cellbi.2005.10.016; Wang Q, 2013, INT J CANCER, V132, P1505, DOI 10.1002/ijc.27810; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wirka KA, 2014, FERTIL STERIL, V101, P1637, DOI 10.1016/j.fertnstert.2014.02.050; Wutz A, 2007, TRENDS GENET, V23, P457, DOI 10.1016/j.tig.2007.07.004; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang Shiwu, 2016, Genes Cancer, V7, P60, DOI 10.18632/genesandcancer.102; Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319; Zhang SW, 2013, CANCER LETT, V333, P205, DOI 10.1016/j.canlet.2013.01.037; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021; Zielke N, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012948	72	121	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4887	4900		10.1038/onc.2017.72	http://dx.doi.org/10.1038/onc.2017.72			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436947	Green Published, hybrid			2022-12-28	WOS:000408234400006
J	Wang, LT; Chiou, SS; Chai, CY; Hsi, E; Chiang, CM; Huang, SK; Wang, SN; Yokoyama, KK; Hsu, SH				Wang, L-T; Chiou, S-S; Chai, C-Y; Hsi, E.; Chiang, C-M; Huang, S-K; Wang, S-N; Yokoyama, K. K.; Hsu, S-H			Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer	ONCOGENE			English	Article							SAETHRE-CHOTZEN-SYNDROME; HEPATOCELLULAR-CARCINOMA; EXPRESSION; METASTASIS; PROTEIN; CELLS; GENE; TUMORIGENESIS; PROGRESSION; MECHANISMS	The epithelial-mesenchymal transition (EMT) is an important process in the progression of cancer. However, its occurrence and mechanism of regulation are not fully understood. We propose a regulatory pathway in which spermatogenic leucine zipper 1 (SPZ1) promotes EMT through its transactivating ability in increasing TWIST1 expression. We compared the expression of SPZ1 and TWIST1 in specimens of hepatocarcinoma cells (HCCs) and non-HCCs. Expression of SPZ1 exhibited a tumor-specific expression pattern and a high correlation with patients' survival time, tumor size, tumor number and progression stage. Moreover, forced expression and knockdown of SPZ1 in hepatoma cells showed that SPZ1 was able to regulate the cellular proliferation, invasion, and tumorigenic activity in a TWIST1-dependent manner in vitro and in vivo. These data demonstrate that SPZ1, a newly dscribed molecule, transactivates TWIST1 promoters, and that this SPZ1-TWIST axis mediates EMT signaling and exerts significant regulatory effects on tumor oncogenesis.	[Wang, L-T; Yokoyama, K. K.; Hsu, S-H] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan; [Chiou, S-S] Kaohsiung Med Univ Hosp, Dept Pediat, Fac Med, Kaohsiung, Taiwan; [Chiou, S-S] Kaohsiung Med Univ Hosp, Div Hematol Oncol, Dept Pediat, Kaohsiung, Taiwan; [Chai, C-Y] Kaohsiung Med Univ Hosp, Dept Pathol, Coll Med, Fac Med, Kaohsiung, Taiwan; [Hsi, E.] Kaohsiung Med Univ Hosp, Dept Genome Med, Coll Med, Kaohsiung, Taiwan; [Chiang, C-M] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Chiang, C-M] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Huang, S-K] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan; [Wang, S-N] Kaohsiung Med Univ Hosp, Div Hepatobiliary Surg, Dept Surg, Kaohsiung 807, Taiwan; [Wang, S-N] Kaohsiung Med Univ Hosp, Dept Surg, Fac Med, Kaohsiung, Taiwan; [Yokoyama, K. K.] Tokushima Bunri Univ, Dept Pharmaceut Sci, Sanuki, Japan; [Yokoyama, K. K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan; [Yokoyama, K. K.; Hsu, S-H] Kaohsiung Med Univ, Ctr Infect Dis & Canc Res, Kaohsiung, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Coll Med, Ctr Environm Med, Kaohsiung, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Ctr Stem Cell Res, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Tokushima Bunri University; University of Tokyo; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Yokoyama, KK; Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan.; Wang, SN (corresponding author), Kaohsiung Med Univ Hosp, Div Hepatobiliary Surg, Dept Surg, Kaohsiung 807, Taiwan.	snwang@cc.kmu.edu; kazu@kmu.edu.tw; jackhsu@kmu.edu.tw	Hsu, Shih-Hsien/D-5139-2009	Wang, Li-Ting/0000-0002-3335-8055; Hsu, Shih Hsien/0000-0003-2102-0505; Chai, Chee-Yin/0000-0003-0486-9742	Kaohsiung Medical University Hospital [KMUH 104-4R34, KMUH 105-5R28, 105-5T10]; National Science Council, Taiwan [NSC-102-2320-B-037-032-MY3, MOST 105-2314-B-037-070-MY2]; Ministry of Science and Technology [MOST-104-2314-B-037-043, MOST 104-2320-B-037-033-My2, MOST 104-2314-B-033-002, MOST-105-2314-B-037-049]; National Health Research Institutes [NHRI-Ex102-10109B1, NHRI-Ex104-10416S1]; Kaohsiung Medical University grant [KMU-TP103G00, KMU-TP103G01, KMU-TP103G03, KMU-TP103G04, KMU-TP103G05, KMU-TP103A104, KMU-DT103001, KMU-TP104A04, KMU-TPE23, KMU-DT104001, KMU-TP105PR4, KMU-TP105E00]; NIH [CA103867]; CPRIT [RP110471, RP140367]; Welch Foundation [I-1805]; NATIONAL CANCER INSTITUTE [R01CA103867] Funding Source: NIH RePORTER	Kaohsiung Medical University Hospital; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); Kaohsiung Medical University grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge supports from the Liver Disease Prevention and Treatment Research Foundation in Taiwan. This work was supported in part by research grants KMUH 104-4R34 and KMUH 105-5R28, 105-5T10 from Kaohsiung Medical University Hospital, NSC-102-2320-B-037-032-MY3, MOST 105-2314-B-037-070-MY2 from the National Science Council, Taiwan, MOST-104-2314-B-037-043; MOST 104-2320-B-037-033-My2, MOST 104-2314-B-033-002, and MOST-105-2314-B-037-049 from Ministry of Science and Technology, the National Health Research Institutes (NHRI-Ex102-10109B1; NHRI-Ex104-10416S1), Kaohsiung Medical University grant (KMU-TP103G00, G01, G03, G04, G05, KMU-TP103A104, KMU-DT103001, KMU-TP104A04, KMU-TPE23, KMU-DT104001, KMU-TP105PR4, and KMU-TP105E00), NIH (CA103867), CPRIT (RP110471 and RP140367) and Welch Foundation (I-1805).	[Anonymous], 1989, JPN J SURG, V19, P98; Barnes RM, 2009, INT J DEV BIOL, V53, P909, DOI 10.1387/ijdb.082747rb; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Che N, 2011, HUM PATHOL, V42, P840, DOI 10.1016/j.humpath.2010.03.010; El Ghouzzi V, 1999, EUR J HUM GENET, V7, P27, DOI 10.1038/sj.ejhg.5200240; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hou Y, 2012, CELL RES, V22, P259, DOI 10.1038/cr.2011.139; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008-5472.CAN-04-3658; Hsu SH, 2004, EXP CELL RES, V294, P185, DOI 10.1016/j.yexcr.2003.10.029; Hsu SH, 2001, MECH DEVELOP, V100, P177, DOI 10.1016/S0925-4773(00)00513-X; Hsu SH, 2013, CANCER RES, V73, P508, DOI 10.1158/0008-5472.CAN-12-2795; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Lei PF, 2015, ONCOL LETT, V10, P417, DOI 10.3892/ol.2015.3246; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin A, 2010, NAT CELL BIOL, V12, P924, DOI 10.1038/ncb1010-924; Ohba K, 2014, INT J CLIN EXP PATHO, V7, P3158; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Piccinin S, 2012, CANCER CELL, V22, P404, DOI 10.1016/j.ccr.2012.08.003; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu WL, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00012; Zhou Y, 2015, INT J CLIN EXP MED, V8, P9239; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868	32	15	16	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4405	4414		10.1038/onc.2017.69	http://dx.doi.org/10.1038/onc.2017.69			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368406	Green Published, hybrid			2022-12-28	WOS:000406806000003
J	Colleoni, B; Paternot, S; Pita, JM; Bisteau, X; Coulonval, K; Davis, RJ; Raspe, E; Roger, PP				Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Davis, R. J.; Raspe, E.; Roger, P. P.			JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21	ONCOGENE			English	Article							N-TERMINAL KINASE; THYROID EPITHELIAL-CELLS; CYCLIN-DEPENDENT KINASES; JUN NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; ACTIVATING KINASE; MAMMALIAN TARGET; UBIQUITIN LIGASE; PROTEIN-KINASES; CANCER	Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated by mitogenic/oncogenic pathways. They have a central role in the cell multiplication decision and in its deregulation in cancer cells. We identified T172 phosphorylation of CDK4 rather than cyclin D accumulation as the distinctly regulated step determining CDK4 activation. This finding challenges the view that the only identified metazoan CDK-activating kinase, cyclin H-CDK7-Mat1 (CAK), which is constitutively active, is responsible for the activating phosphorylation of all cell cycle CDKs. We previously showed that T172 phosphorylation of CDK4 is conditioned by an adjacent proline (P173), which is not present in CDK6 and CDK1/2. Although CDK7 activity was recently shown to be required for CDK4 activation, we proposed that proline-directed kinases might specifically initiate the activation of CDK4. Here, we report that JNKs, but not ERK1/2 or CAK, can be direct CDK4-activating kinases for cyclin D-CDK4 complexes that are inactivated by p21-mediated stabilization. JNKs and ERK1/2 also phosphorylated p21 at S130 and T57, which might facilitate CDK7-dependent activation of p21-bound CDK4, however, mutation of these sites did not impair the phosphorylation of CDK4 by JNKs. In two selected tumor cells, two different JNK inhibitors inhibited the phosphorylation and activation of cyclin D1-CDK4-p21 but not the activation of cyclin D3-CDK4 that is mainly associated to p27. Specific inhibition by chemical genetics in MEFs confirmed the involvement of JNK2 in cyclin D1-CDK4 activation. Therefore, JNKs could be activating kinases for cyclin D1-CDK4 bound to p21, by independently phosphorylating both CDK4 and p21.	[Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Raspe, E.; Roger, P. P.] Univ Libre Bruxelles, Inst Interdisciplinary Res IRIBHM, WELBIO, Brussels, Belgium; [Colleoni, B.; Paternot, S.; Pita, J. M.; Bisteau, X.; Coulonval, K.; Raspe, E.; Roger, P. P.] Univ Libre Bruxelles, U CRC, Brussels, Belgium; [Davis, R. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Davis, R. J.] Howard Hughes Med Inst, Worcester, MA USA	Universite Libre de Bruxelles; WELBIO; Universite Libre de Bruxelles; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute	Roger, PP (corresponding author), Univ Libre Bruxelles, IRIBHM, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.; Roger, PP (corresponding author), ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore.	proger@ulb.ac.be	Bisteau, Xavier/Q-7239-2018; Bisteau, Xavier/AAH-6744-2021	Bisteau, Xavier/0000-0002-8896-5098; Davis, Roger/0000-0002-0130-1652	WELBIO (Walloon Excellence in Lifesciences and Biotechnology); Belgian Foundation against Cancer [2014-130]; FRS-FNRS [T003813F, J.0002.16]; Docteur JP Naets Fund; Fondation Rose et Jean Hoguet; Fonds David et Alice Van Buuren; Fondation Jaumotte-Demoulin; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK107220] Funding Source: NIH RePORTER	WELBIO (Walloon Excellence in Lifesciences and Biotechnology)(WELBIO); Belgian Foundation against Cancer; FRS-FNRS(Fonds de la Recherche Scientifique - FNRS); Docteur JP Naets Fund; Fondation Rose et Jean Hoguet; Fonds David et Alice Van Buuren; Fondation Jaumotte-Demoulin; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The p21 expression plasmids and MCF-7 cells were provided by Ludger Hengst (Innsbruck University) and Geert Berx (Ghent University), respectively. Amin Bredan edited the English text. We thank Professor Jacques E. Dumont (Universite Libre de Bruxelles) for continued interest and support. This study was supported by WELBIO (Walloon Excellence in Lifesciences and Biotechnology), the Belgian Foundation against Cancer (Grant 2014-130), the FRS-FNRS Grants T003813F and J.0002.16 and the Docteur JP Naets Fund (managed by the King Baudouin Foundation). BC was a fellow of the FRIA and is supported by the Fondation Rose et Jean Hoguet, the Fonds David et Alice Van Buuren and the Fondation Jaumotte-Demoulin, JMP is a fellow of the Televie and PPR is a Senior Research Associate of the FRS-FNRS.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bisteau X, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003546; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blancquaert S, 2010, MOL ENDOCRINOL, V24, P1453, DOI 10.1210/me.2010-0087; Bockstaele L, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-25; Bockstaele L, 2006, MOL CELL BIOL, V26, P5070, DOI 10.1128/MCB.02006-05; Bockstaele L, 2009, MOL CELL BIOL, V29, P4188, DOI 10.1128/MCB.01823-08; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Coulonval K, 2003, EXP CELL RES, V291, P135, DOI 10.1016/S0014-4827(03)00392-6; Coulonval K, 2011, MOL BIOL CELL, V22, P3971, DOI 10.1091/mbc.E11-02-0136; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Cui J, 2009, MOL CANCER THER, V8, P3214, DOI 10.1158/1535-7163.MCT-09-0408; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fallahi-Sichani M, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145877; Finegan KG, 2010, CANCER RES, V70, P5797, DOI 10.1158/0008-5472.CAN-09-3669; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Ganuza M, 2012, EMBO J, V31, P2498, DOI 10.1038/emboj.2012.94; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Hwang CY, 2009, MOL CELL BIOL, V29, P3379, DOI 10.1128/MCB.01758-08; Jakel H, 2012, CELL CYCLE, V11, P1910, DOI 10.4161/cc.19957; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Jarviluoma A, 2006, MOL CELL BIOL, V26, P2430, DOI 10.1128/MCB.26.6.2430-2440.2006; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Larochelle S, 2006, NAT STRUCT MOL BIOL, V13, P55, DOI 10.1038/nsmb1028; Larochelle S, 2007, MOL CELL, V25, P839, DOI 10.1016/j.molcel.2007.02.003; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu Y, 2004, J BIOL CHEM, V279, P4507, DOI 10.1074/jbc.M309995200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2008, J BIOL CHEM, V283, P34935, DOI 10.1074/jbc.M804970200; Parra E, 2010, ONCOL REP, V24, P1339, DOI 10.3892/or_00000991; Patel R, 1998, J CELL SCI, V111, P2247; Paternot S, 2006, CELL CYCLE, V5, P61, DOI 10.4161/cc.5.1.2265; Paternot S, 2003, J BIOL CHEM, V278, P26533, DOI 10.1074/jbc.M302492200; Paternot S, 2006, MOL ENDOCRINOL, V20, P3279, DOI 10.1210/me.2005-0515; Paternot S, 2014, CELL CYCLE, V13, P2879, DOI 10.4161/15384101.2014.946841; Paternot S, 2010, CELL CYCLE, V9, P689, DOI 10.4161/cc.9.4.10611; Paternot S, 2009, CANCER RES, V69, P4577, DOI 10.1158/0008-5472.CAN-08-3260; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Rocha AS, 2008, MOL BIOL CELL, V19, P4814, DOI 10.1091/mbc.E08-06-0617; ROGER PP, 1992, J CELL BIOL, V117, P383, DOI 10.1083/jcb.117.2.383; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Schachter MM, 2013, MOL CELL, V50, P250, DOI 10.1016/j.molcel.2013.04.003; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349; Tsuiki H, 2003, CANCER RES, V63, P250; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Welcker M, 1998, CANCER RES, V58, P5053; Wesierska-Gadek J, 2009, ACTA BIOCHIM POL, V56, P495; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711; Zhan J, 2007, MOL CELL BIOL, V27, P3530, DOI 10.1128/MCB.00086-06; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200	95	14	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4349	4361		10.1038/onc.2017.7	http://dx.doi.org/10.1038/onc.2017.7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368408	Green Published, hybrid			2022-12-28	WOS:000406360600011
J	He, W; Wang, C; Mu, R; Liang, P; Huang, Z; Zhang, J; Dong, L				He, W.; Wang, C.; Mu, R.; Liang, P.; Huang, Z.; Zhang, J.; Dong, L.			MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; VERSUS-HOST-DISEASE; KAPPA-B ACTIVATION; T-CELLS; CANCER-IMMUNOTHERAPY; SMALL MOLECULES; HEPATIC-INJURY; MOUSE MODEL; MICRORNA-21; PROMOTES	Here we show that miR-21, a microRNA known for its oncogenic activity, is also essential for mediating immune responses against tumor. Knockout of miR-21 in mice slowed the proliferation of both CD4(+) and CD8(+) cells, reduced their cytokine production and accelerated the grafted tumor growth. Further investigations indicated that miR-21 could activate CD4(+) and CD8(+) T cells via the PTEN/Akt pathway in response to stimulations. Taken together, these data suggest the key functions of miR-21 in mediating antitumor immune response and thereby uncover a bi-directional role of this traditionally known ` oncomiR' in tumorigenesis. Our study may provide new insights for the design of cancer therapies targeting microRNAs, with an emphasis on the dynamic and possibly unexpected role of these molecules.	[He, W.; Mu, R.; Liang, P.; Huang, Z.; Zhang, J.; Dong, L.] Nanjing Univ, NJU Adv Inst Life Sci NAILS, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 163 Xianlin Ave, Nanjing 210093, Jiangsu, Peoples R China; [Wang, C.] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China; [Zhang, J.] Nanjing Univ, Jiangsu Prov Lab Nanotechnol, Nanjing, Jiangsu, Peoples R China	Nanjing University; University of Macau; Nanjing University	Zhang, J; Dong, L (corresponding author), Nanjing Univ, NJU Adv Inst Life Sci NAILS, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 163 Xianlin Ave, Nanjing 210093, Jiangsu, Peoples R China.	jfzhang@nju.edu.cn; leidong@nju.edu.cn	Wang, Chunming/I-3392-2013; zhang, jiani/GVS-2052-2022	Wang, Chunming/0000-0001-9185-9678; Mu, Ruoyu/0000-0002-6093-0176	National Basic Research Program of China [2012CB517603]; National High Technology Research and Development Program of China [2014AA020707]; National Natural Science Foundation of China [31671031, 81673380, 31200695, 31400671, 51173076, 91129712, 81102489]; Program for New Century Excellent Talents in University [NCET-13-0272]; Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant [02ZZYJ-201307]; University of Macau [MYRG2014-00069-ICMS-QRCM, MYRG2015-00160-ICMS-QRCM]; opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau [005]	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant; University of Macau; opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau	This project was funded by the National Basic Research Program of China (2012CB517603), the National High Technology Research and Development Program of China (2014AA020707), the National Natural Science Foundation of China (31671031, 81673380, 31200695, 31400671, 51173076, 91129712 and 81102489), the Program for New Century Excellent Talents in University (NCET-13-0272), Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant (02ZZYJ-201307). CW acknowledges the funding supports from University of Macau (MYRG2014-00069-ICMS-QRCM, MYRG2015-00160-ICMS-QRCM) and the opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau (No. 005).	Adams JL, 2015, NAT REV DRUG DISCOV, V14, P603, DOI 10.1038/nrd4596; Barnes SE, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-014-0045-x; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Blanco B, 2015, INT IMMUNOPHARMACOL, V28, P675, DOI 10.1016/j.intimp.2015.07.032; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; Chen H, 2014, CANCER IMMUNOL RES, V2, P167, DOI 10.1158/2326-6066.CIR-13-0155; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Echevarria-Vargas IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097094; Gao SQ, 2015, ACTA BIOMATER, V25, P184, DOI 10.1016/j.actbio.2015.07.020; Garchow B, 2016, CLIN IMMUNOL, V162, P100, DOI 10.1016/j.clim.2015.11.010; Garchow BG, 2011, EMBO MOL MED, V3, P605, DOI 10.1002/emmm.201100171; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gupta SK, 2016, CARDIOVASC RES, V110, P215, DOI 10.1093/cvr/cvw030; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho WY, 2003, CANCER CELL, V3, P431, DOI 10.1016/S1535-6108(03)00113-2; Kim EH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00020; Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235; Kosaka A, 2015, BIOCHEM BIOPH RES CO, V458, P549, DOI 10.1016/j.bbrc.2015.02.003; Lee DH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.95; Lee KC, 2015, J HEPATOL, V63, P1405, DOI 10.1016/j.jhep.2015.07.035; Lei FY, 2011, CANCER RES, V71, P4742, DOI 10.1158/0008-5472.CAN-11-0359; Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078-0432.CCR-12-3325; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu Juan, 2013, Cancer Biology Medicine, V10, P131, DOI 10.7497/j.issn.2095-3941.2013.03.002; Locke FL, 2013, J IMMUNOL, V191, P1677, DOI 10.4049/jimmunol.1202018; Ma XD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8151; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Mahasa KJ, 2016, J THEOR BIOL, V404, P312, DOI 10.1016/j.jtbi.2016.06.012; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Meng YB, 2015, J ORTHOP RES, V33, P957, DOI 10.1002/jor.22884; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Murugaiyan G, 2015, J CLIN INVEST, V125, P1069, DOI 10.1172/JCI74347; Ni YX, 2014, NEURAL REGEN RES, V9, P828, DOI 10.4103/1673-5374.131599; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Pfeffer SR, 2015, DRUG DEVELOP RES, V76, P270, DOI 10.1002/ddr.21257; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Simpson-Abelson Michelle R, 2013, Cancer Immun, V13, P14; Song GS, 2010, HEPATOLOGY, V51, P1735, DOI 10.1002/hep.23547; Soond DR, 2012, J IMMUNOL, V188, P5935, DOI 10.4049/jimmunol.1102116; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Teteloshvili Nato, 2015, Microrna, V4, P117; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tveita AA, 2015, CANCER RES, V75, P3268, DOI 10.1158/0008-5472.CAN-14-3640; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; Wang T, 2012, AM J PATHOL, V181, P1911, DOI 10.1016/j.ajpath.2012.08.022; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Wu YR, 2016, TUMOR BIOL, V37, P12061, DOI 10.1007/s13277-016-5074-2; Wu YH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1611-4; Wu YX, 2015, BLOOD, V126, P1314, DOI 10.1182/blood-2015-02-627356; Xu WD, 2013, EXPERT OPIN THER TAR, V17, P659, DOI 10.1517/14728222.2013.773311; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Yung BC, 2016, MOL PHARMACEUT, V13, P653, DOI 10.1021/acs.molpharmaceut.5b00878; Zhan MM, 2016, DRUG DISCOV TODAY, V21, P1027, DOI 10.1016/j.drudis.2016.04.011; Zhang C, 2008, BIOMATERIALS, V29, P1233, DOI 10.1016/j.biomaterials.2007.11.029; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953; Zhao T, 2014, INT J BIOL MACROMOL, V63, P114, DOI 10.1016/j.ijbiomac.2013.10.037	62	26	27	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4212	4223		10.1038/onc.2017.62	http://dx.doi.org/10.1038/onc.2017.62			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346427				2022-12-28	WOS:000405835800012
J	Hanse, EA; Ruan, C; Kachman, M; Wang, D; Lowman, XH; Kelekar, A				Hanse, E. A.; Ruan, C.; Kachman, M.; Wang, D.; Lowman, X. H.; Kelekar, A.			Cytosolic malate dehydrogenase activity helps support glycolysis in actively proliferating cells and cancer	ONCOGENE			English	Article							LACTIC-DEHYDROGENASE; ALPHA-KETOGLUTARATE; METABOLISM; GROWTH; LACTATE; PATHWAY; GLUCOSE; SENSITIVITY; ACTIVATION; GENOMICS	Increased glucose consumption is a hallmark of cancer cells. The increased consumption and subsequent metabolism of glucose during proliferation creates the need for a constant supply of NAD, a co-factor in glycolysis. Regeneration of the NAD required to support enhanced glycolysis has been attributed to the terminal glycolytic enzyme, lactate dehydrogenase (LDH). However, loss of glucose carbons to biosynthetic pathways early in glycolysis reduces the carbon supply to LDH. Thus, alternative routes for NAD regeneration must exist to support the increased glycolytic rate while allowing for the diversion of glucose to generate biomass and support proliferation. Here we demonstrate, using a variety of cancer cell lines as well as activated primary T cells, that cytosolic malate dehydrogenase 1 (MDH1) is an alternative to LDH as a supplier of NAD. Moreover, our results indicate that MDH1 generates malate with carbons derived from glutamine, thus enabling utilization of glucose carbons for glycolysis and for biomass. Amplification of MDH1 occurs at an impressive frequency in human tumors and correlates with poor prognosis. Together, our findings suggest that proliferating cells rely on both MDH1 and LDH to replenish cytosolic NAD, and that therapies designed at targeting glycolysis must consider both dehydrogenases.	[Hanse, E. A.; Lowman, X. H.; Kelekar, A.] Univ Minnesota, Dept Lab Med & Pathol, 420 SE Washington Ave,MCB 5-126, Minneapolis, MN 55455 USA; [Hanse, E. A.; Lowman, X. H.; Kelekar, A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Ruan, C.; Kachman, M.; Wang, D.] Univ Michigan, Michigan Reg Comprehens Metab Res Core, Ann Arbor, MI 48109 USA; [Lowman, X. H.] City Hope Canc Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope	Kelekar, A (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, 420 SE Washington Ave,MCB 5-126, Minneapolis, MN 55455 USA.	ameeta@umn.edu		Hanse, Eric/0000-0002-1234-0198	University of Minnesota Academic Health Center; National Institutes of Health (NIH) [R01 CA157971, 3002751553]; T32 training fellowship [CA009138]; F31 award [CA177119]; NIH Common Funds Project [U24 DK097153]; NATIONAL CANCER INSTITUTE [T32CA009138, F31CA177119, T32CA186895, P30CA077598, R01CA157971] Funding Source: NIH RePORTER	University of Minnesota Academic Health Center; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 training fellowship; F31 award; NIH Common Funds Project(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs David Sabatini and Kivanc Birsoy for the MDH1 KO Jurkat cells, and Hong-Duk Youn for the MDH1 construct. We would also like to thank Todd Rappe and University of Minnesota Nuclear Magnetic Resonance Core for help with nuclear magnetic resonance analysis. We are grateful to Dr David Bernlohr, Michael Downey, Yan Yan and Dr Jenna Benson for stimulating discussions. We also thank Drs Lucas Sullivan and Sandra Armstrong for valuable suggestions. This study was supported by a Seed Grant and an Infrastructure grant from the University of Minnesota Academic Health Center (to AK), National Institutes of Health (NIH) grant R01 CA157971, P/F grant, 3002751553, through the NIH-funded RCMC in Michigan (to AK), and by T32 training fellowship, CA009138, and F31 award, CA177119 (to EAH). The study utilized Metabolomics Core Services supported by grant U24 DK097153 of NIH Common Funds Project to the University of Michigan.	Augoff K, 2015, CANCER LETT, V358, P1, DOI 10.1016/j.canlet.2014.12.035; Billiard J, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-19; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Calvo MN, 2006, FEBS LETT, V580, P3308, DOI 10.1016/j.febslet.2006.04.093; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GOLDBERG EB, 1965, J BIOL CHEM, V240, P2786; GOLDMAN RD, 1964, CANCER RES, V24, P389; Gui DY, 2016, CELL METAB, V24, P716, DOI 10.1016/j.cmet.2016.09.006; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Lee SM, 2009, CELL DEATH DIFFER, V16, P738, DOI 10.1038/cdd.2009.5; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu L, 2016, NAT CHEM BIOL, V12, P345, DOI [10.1038/NCHEMBIO.2047, 10.1038/nchembio.2047]; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lorenz MA, 2011, ANAL CHEM, V83, P3406, DOI 10.1021/ac103313x; Lowman XH, 2010, MOL CELL, V40, P823, DOI 10.1016/j.molcel.2010.11.035; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Menzies KJ, 2016, NAT REV ENDOCRINOL, V12, P43, DOI 10.1038/nrendo.2015.181; Rani R, 2016, J MED CHEM, V59, P487, DOI 10.1021/acs.jmedchem.5b00168; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Wang YJ, 2016, J MENINGITIS, V1, P1, DOI DOI 10.1016/J.BMC1.2015.12.021; Winer LSP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109916; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yang ZR, 2003, J BIOL CHEM, V278, P8804, DOI 10.1074/jbc.M211892200	33	53	55	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3915	3924		10.1038/onc.2017.36	http://dx.doi.org/10.1038/onc.2017.36			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263970	Green Accepted			2022-12-28	WOS:000404848200011
J	He, DM; Ren, BG; Liu, S; Tan, LZ; Cieply, K; Tseng, G; Yu, YP; Luo, JH				He, D-M; Ren, B-G; Liu, S.; Tan, L-Z; Cieply, K.; Tseng, G.; Yu, Y. P.; Luo, J-H			Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies	ONCOGENE			English	Article							GENE-EXPRESSION ALTERATIONS; PROSTATE-CANCER; DNA-REPLICATION; PROTEIN MCM7; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; CDK4; INHIBITOR; CHROMATIN; KINASES	Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation. MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies. The gain of MCM8 is associated with aggressive clinical features of several human cancers. Increased expression of MCM8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells. As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.	[He, D-M; Ren, B-G; Tan, L-Z; Cieply, K.; Yu, Y. P.; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife S-728, Pittsburgh, PA 15261 USA; [Liu, S.; Tseng, G.] Univ Pittsburgh, Dept Biostat, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife S-728, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu			National Cancer Institute [RO1 CA098249]; University of Pittsburgh Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA098249] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Pittsburgh Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute (RO1 CA098249) to JHL and a grant from University of Pittsburgh Cancer Institute.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; AlAsiri S, 2015, J CLIN INVEST, V125, P258, DOI 10.1172/JCI78473; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Feber A, 2011, GENOME RES, V21, P515, DOI 10.1101/gr.109678.110; Feng CJ, 2008, ANTICANCER RES, V28, P3763; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Fristrup N, 2013, AM J PATHOL, V182, P339, DOI 10.1016/j.ajpath.2012.10.017; Fujioka S, 2009, LUNG CANCER, V65, P223, DOI 10.1016/j.lungcan.2008.11.007; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Han YC, 2010, CANCER RES, V70, P4375, DOI 10.1158/0008-5472.CAN-09-4403; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Iizuka N, 2006, J CANCER RES CLIN, V132, P473, DOI 10.1007/s00432-006-0094-8; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kang W, 2014, ONCOL REP, V31, P2071, DOI 10.3892/or.2014.3094; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145; Lee KY, NAT COMMUN, V6, P7744; Lu ZH, 1999, MOL BIOL CELL, V10, P4091, DOI 10.1091/mbc.10.12.4091; Luo JH, 2002, DRUG TODAY, V38, P713, DOI 10.1358/dot.2002.38.10.704653; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Luo JH, 2013, AM J PATHOL, V182, P2028, DOI 10.1016/j.ajpath.2013.02.040; Luo JH, 2011, WORLD J CLIN ONCOL, V2, P120, DOI 10.5306/wjco.v2.i2.120; Lutzmann M, 2012, MOL CELL, V47, P523, DOI 10.1016/j.molcel.2012.05.048; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ota T, 2011, MODERN PATHOL, V24, P277, DOI 10.1038/modpathol.2010.202; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Park J, 2013, MOL CELL BIOL, V33, P1632, DOI 10.1128/MCB.01503-12; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Ren BG, 2007, J NATL CANCER I, V99, P868, DOI 10.1093/jnci/djk199; Shi YK, 2008, AM J PATHOL, V173, P1758, DOI 10.2353/ajpath.2008.080363; Shohet JM, 2002, CANCER RES, V62, P1123; Siegel RL, 2017, CA CANC J CLIN 2017; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vallot C, 2011, JNCI-J NATL CANCER I, V103, P47, DOI 10.1093/jnci/djq470; van Dekken H, 2009, CANCER GENET CYTOGEN, V189, P37, DOI 10.1016/j.cancergencyto.2008.08.018; Volkening M, 2005, MOL CELL BIOL, V25, P1560, DOI 10.1128/MCB.25.4.1560-1568.2005; Wang H, 2012, J BIOL CHEM, V287, P16890, DOI 10.1074/jbc.M111.322636; Wang LQ, 2013, J NANOMATER, V2013, DOI 10.1155/2013/321459; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu YP, 2013, AM J PATHOL, V183, P1960, DOI 10.1016/j.ajpath.2013.08.018; Yu YP, 2012, AM J PATHOL, V180, P2240, DOI 10.1016/j.ajpath.2012.03.008; Yu YP, 2006, UROLOGY, V68, P578, DOI 10.1016/j.urology.2006.03.027; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227; Yu YP, 2005, CARCINOGENESIS, V26, P471, DOI 10.1093/carcin/bgh310; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhou YM, 2012, LIVER INT, V32, P1505, DOI 10.1111/j.1478-3231.2012.02846.x	64	17	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3629	3639		10.1038/onc.2017.123	http://dx.doi.org/10.1038/onc.2017.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28481876	Green Accepted			2022-12-28	WOS:000403878600012
J	Im, JY; Kim, BK; Lee, JY; Park, SH; Ban, HS; Jung, KE; Won, M				Im, Joo-Young; Kim, Bo-Kyung; Lee, Ji-Young; Park, Seung-Ho; Ban, Hyun Seung; Jung, Kyeong Eun; Won, Misun			DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells	ONCOGENE			English	Article							DEATH RECEPTOR; DNA-DAMAGE; IN-VIVO; C-JUN; SIGNALING COMPLEX; LUNG-CARCINOMA; PROTEIN-KINASE; KEY REGULATOR; DOCKING SITE; EXPRESSION	DNA damage-induced apoptosis suppressor (DDIAS) has an anti-apoptotic function during DNA damage in lung cancer. However, the anti-apoptotic mechanism of DDIAS in cancer cells under other conditions has not been reported. We report here that DDIAS protects cancer cells from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by two distinct mechanisms in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) cells. DDIAS depletion sensitized NSCLC and HCC cells to TRAIL-mediated apoptosis, an effect that was abrogated by pharmacological or genetic inhibition of caspase-8 and was independent of caspase-9, p53, or mitogen-activated protein kinase signaling. Interestingly, we found that the N terminus of DDIAS interacted with the death effector domain of Fas-associated protein death domain (FADD) and prevented its recruitment to the death-inducing signaling complex (DISC), thereby blocking caspase-8 activation. DDIAS knockdown also suppressed epidermal growth factor-induced phosphorylation of p90 ribosomal S6 kinase (RSK) 2 and stabilized caspase-8 by preventing its ubiquitination and proteasomal degradation. This effect was abolished by RSK2 overexpression. Taken together, DDIAS has dual functions in inhibiting DISC formation as well as in destabilizing caspase-8, thereby suppressing TRAIL-mediated apoptosis of cancer cells. Thus, we suggest that DDIAS can serve as an effective therapeutic target in the treatment of NSCLC and HCC.	[Im, Joo-Young; Kim, Bo-Kyung; Lee, Ji-Young; Park, Seung-Ho; Won, Misun] KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea; [Ban, Hyun Seung] KRIBB, Metab Regulat Res Ctr, Daejeon, South Korea; [Jung, Kyeong Eun] ST Pharm Co Ltd, Sihwa Ind Complex 1, Kyunggido, South Korea; [Won, Misun] Korea Univ Sci & Technol UST, KRIBB Sch Biotechnol, Dept Funct Genom, 217 Gajeong Ro, Daejeon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST)	Won, M (corresponding author), KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea.; Won, M (corresponding author), Korea Univ Sci & Technol UST, KRIBB Sch Biotechnol, Dept Funct Genom, 217 Gajeong Ro, Daejeon, South Korea.	misun@kribb.re.kr	Ban, Hyun Seung/F-9526-2014	Ban, Hyun Seung/0000-0002-2698-6037	KRIBB Initiative Program [KGM4751713]; National Research Foundation (NRF) [2017R1A2B2011936, 2017M3A9F9030565]; Health Technology RD [HI13C2162]	KRIBB Initiative Program; National Research Foundation (NRF); Health Technology RD	This work was supported by the KRIBB Initiative Program (KGM4751713), National Research Foundation (NRF; 2017R1A2B2011936 and 2017M3A9F9030565), and Health Technology R&D (HI13C2162).	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng HR, 2012, CELL CYCLE, V11, P3312, DOI 10.4161/cc.21670; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2012, CARCINOGENESIS, V33, P2529, DOI 10.1093/carcin/bgs271; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fu K, 2012, ONCOGENE, V31, P1311, DOI 10.1038/onc.2011.315; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Im JY, 2016, BBA-GENE REGUL MECH, V1859, P1449, DOI 10.1016/j.bbagrm.2016.07.003; Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim BK, 2014, BBA-GENE REGUL MECH, V1839, P364, DOI 10.1016/j.bbagrm.2014.03.004; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagane M, 2000, CANCER RES, V60, P847; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peng C, 2011, J BIOL CHEM, V286, P6946, DOI 10.1074/jbc.M110.172338; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Soung YH, 2005, CANCER RES, V65, P815; Soung YH, 2005, ONCOGENE, V24, P141, DOI 10.1038/sj.onc.1208244; Sun BK, 2011, ONCOL REP, V25, P537, DOI 10.3892/or.2010.1079; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Won KJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.488; Won KJ, 2014, INT J CANCER, V134, P2595, DOI 10.1002/ijc.28600; Zhang ZZ, 2015, INT J CANCER, V137, P765, DOI 10.1002/ijc.29451	40	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1251	1262		10.1038/s41388-017-0025-y	http://dx.doi.org/10.1038/s41388-017-0025-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242605				2022-12-28	WOS:000426505400009
J	Schroyer, AL; Stimes, NW; Saab, WFA; Chadee, DN				Schroyer, A. L.; Stimes, N. W.; Saab, W. F. Abi; Chadee, D. N.			MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells	ONCOGENE			English	Article							LINEAGE KINASE 3; ACTIVATION LOOP; IN-VIVO; B-RAF; IDENTIFICATION; PROMOTES; MIGRATION; COMPLEX; BINDING; SPRK	Mixed lineage kinase 3 (MLK3) functions in migration and/or invasion of several human cancers; however, the role of MLK3 in colorectal cancer (CRC) invasion is unknown. MLK3 is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) which activates MAPK pathways through either kinase-dependent or -independent mechanisms. Human colorectal tumors display increased levels of reactive oxygen species (ROS) or oxidative stress. ROS, such as H2O2, are important for carcinogenesis and activate MAPK signaling pathways. In human colorectal carcinoma (HCT116) cells treated with H2O2, extracellular signal-regulated kinases 1 and 2 (ERK1/2) were activated and MLK3 exhibited reduced electrophoretic mobility (shift) in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which was eliminated by phosphatase treatment. Pretreatment with the ROS scavenger N-acetyl-L-cysteine, the ERK1/2 inhibitor UO126, or ERK1/2 siRNA knockdown blocked the H2O2-induced shift of MLK3, while MLK3 inhibition with Cep1347 did not. In co-immunoprecipitation experiments performed on H2O2-treated HCT116 cells, endogenous MLK3 associated with endogenous ERK1/2 and B-Raf. Active ERK1 phosphorylated kinase dead FLAG-MLK3 in vitro, whereas ERK1 phosphorylation of kinase dead FLAG-MLK3-S705A-S758A was reduced. Both MLK3 siRNA knockdown and FLAGMLK3-S705A-S758A expression decreased ERK1/2 activation in H2O2-treated cells. Prolonged H2O2 treatment activated ERK1/2 and promoted invasion of colon cancer cells, which was attenuated by MLK3 siRNA knockdown. Furthermore, S705A-S758A-FLAG-MLK3 demonstrated decreased oxidative-stress induced colon cancer cell invasion, but increased interaction with GST-B-Raf as compared with wild-type-FLAG-MLK3 in H2O2-treated cells. These results suggest oxidative stress stimulates an ERK1/2-dependent phosphorylation of MLK3 on Ser(705) and Ser(758), which promotes MLK3-dependent B-Raf and ERK1/2 activation; this positive feedback loop enhances the invasion of colon cancer cells.	[Schroyer, A. L.; Stimes, N. W.; Saab, W. F. Abi; Chadee, D. N.] Univ Toledo, Dept Biol Sci, 2801 West Bancroft St, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Chadee, DN (corresponding author), Univ Toledo, Dept Biol Sci, 2801 West Bancroft St, Toledo, OH 43606 USA.	deborah.chadee@utoledo.edu			National Institutes of Health [R15 CA199164, R15 GM102831]; NATIONAL CANCER INSTITUTE [R15CA199164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM102831] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants R15 CA199164 and R15 GM102831 (to DNC).	Blessing NA, 2014, MOL CELL BIOL, V34, P3132, DOI 10.1128/MCB.00296-14; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chen J, 2010, ONCOGENE, V29, P4399, DOI 10.1038/onc.2010.198; Chen J, 2012, CANCER RES, V72, P4130, DOI 10.1158/0008-5472.CAN-12-0655; Chien ST, 2011, MOL CELL BIOCHEM, V350, P135, DOI 10.1007/s11010-010-0692-2; Cronan MR, 2012, ONCOGENE, V31, P3889, DOI 10.1038/onc.2011.544; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; ING YL, 1994, ONCOGENE, V9, P1745; Lan T, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0486-9; Lee HS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005260; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Marusiak AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4901; Misek SA, 2017, MOL CANC RES; Mishra P, 2010, MOL ENDOCRINOL, V24, P598, DOI 10.1210/me.2009-0387; Partridge J, 2009, JOVE-J VIS EXP, P1475; Perse M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/725710; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Schachter KA, 2006, J BIOL CHEM, V281, P19134, DOI 10.1074/jbc.M603324200; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Swenson-Fields KI, 2008, MOL CELL, V32, P43, DOI 10.1016/j.molcel.2008.09.007; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Velho S, 2010, HUM MOL GENET, V19, P697, DOI 10.1093/hmg/ddp536; Wang CY, 2010, PROTEIN CELL, V1, P871, DOI 10.1007/s13238-010-0111-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wlochowitz D, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00042; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Zhan Y, 2012, EXP CELL RES, V318, P1641, DOI 10.1016/j.yexcr.2012.05.002; Zhang J, 2014, CLIN EXP DERMATOL, V39, P376, DOI 10.1111/ced.12286	42	35	35	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1031	1040		10.1038/onc.2017.396	http://dx.doi.org/10.1038/onc.2017.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084209	Green Accepted			2022-12-28	WOS:000425905700006
J	Luo, W; Xu, C; Ayello, J; Dela Cruz, F; Rosenblum, JM; Lessnick, SL; Cairo, MS				Luo, W.; Xu, C.; Ayello, J.; Dela Cruz, F.; Rosenblum, J. M.; Lessnick, S. L.; Cairo, M. S.			Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis	ONCOGENE			English	Article							THERAPEUTIC TARGET; CELL-MIGRATION; GENE; EXPRESSION; CANCER; TUMOR; PHOSPHORYLATION; INHIBITOR-1; DEGRADATION; MECHANISMS	Protein phosphatase inhibitors are often considered as tumor promoters. Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) is a potent protein phosphatase 1 (PP1) inhibitor; however, its role in tumor development is largely undefined. Here we characterize, for the first time, the functions of PPP1R1A in Ewing sarcoma (ES) pathogenesis. We found that PPP1R1A is one of the top ranked target genes of EWS/FLI, the master regulator of ES, and is upregulated by EWS/FLI via a GGAA microsatellite enhancer element. Depletion of PPP1R1A resulted in a significant decrease in oncogenic transformation and cell migration in vitro as well as xenograft tumor growth and metastasis in an orthotopic mouse model. RNA-sequencing and functional annotation analyses revealed that PPP1R1A regulates genes associated with various cellular functions including cell junction, adhesion and neurogenesis. Interestingly, we found a significant overlap of PPP1R1A-regulated gene set with that of ZEB2 and EWS, which regulates metastasis and neuronal differentiation in ES, respectively. Further studies for characterization of the molecular mechanisms revealed that activation of PPP1R1A by PKA phosphorylation at Thr35, and subsequent PP1 binding and inhibition, was required for PPP1R1A-mediated tumorigenesis and metastasis, likely by increasing the phosphorylation levels of various PP1 substrates. Furthermore, we found that a PKA inhibitor impaired ES cell proliferation, tumor growth and metastasis, which was rescued by the constitutively active PPP1R1A. Together, these results offered new insights into the role and mechanism of PPP1R1A in tumor development and identified an important kinase and phosphatase pathway, PKA/PPP1R1A/PP1, in ES pathogenesis. Our findings strongly suggest a potential therapeutic value of inhibition of the PKA/PPP1R1A/PP1 pathway in the treatment of primary and metastatic ES.	[Luo, W.; Ayello, J.; Rosenblum, J. M.; Cairo, M. S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; [Luo, W.; Cairo, M. S.] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; [Xu, C.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA; [Dela Cruz, F.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Lessnick, S. L.] Nationwide Childrens Hosp, Columbus, OH USA; [Cairo, M. S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA; [Cairo, M. S.] New York Med Coll, Dept Immunol & Microbiol, Valhalla, NY 10595 USA; [Cairo, M. S.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	New York Medical College; New York Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Memorial Sloan Kettering Cancer Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; New York Medical College; New York Medical College; New York Medical College	Luo, W (corresponding author), New York Med Coll Grasslands Reservat, Dept Pediat, Vosburgh Room 101, Valhalla, NY 10595 USA.; Luo, W (corresponding author), New York Med Coll Grasslands Reservat, Dept Pathol, Vosburgh Room 101, Valhalla, NY 10595 USA.; Cairo, MS (corresponding author), New York Med Coll, Skyline Off 1N D12, Pediat Med Pathol Microbiol & Immunol & Cell Biol, 40 Sunshine Cottage Rd, Valhalla, NY 10595 USA.	Wen_Luo@nymc.edu; mitchell_cairo@nymc.edu			Pediatric Cancer Research Foundation; Association for Research of Childhood Cancer	Pediatric Cancer Research Foundation; Association for Research of Childhood Cancer	We thank Drs David Virshup, Shirish Shenolikar, Angus Nairn and James Bibb for helpful discussion. We would also like to thank the members of the Cairo and Lessnick laboratories for technical assistance and helpful discussion, and Erin Morris RN for her administrative assistance in the preparation of this manuscript. This work is supported by funds from Pediatric Cancer Research Foundation (MSC) and Association for Research of Childhood Cancer (WL).	Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Chi LM, 2016, ACTA NEUROL BELG, V116, P543, DOI 10.1007/s13760-016-0613-6; Chu YY, 2015, CANCER IMMUNOL RES, V3, P333, DOI 10.1158/2326-6066.CIR-14-0114; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Croft DR, 2006, METHOD ENZYMOL, V406, P541, DOI 10.1016/S0076-6879(06)06042-3; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dela Cruz F, 2012, DIFFERENTIATION, V83, P220, DOI 10.1016/j.diff.2012.01.001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; El-Rifai W, 2002, CANCER RES, V62, P4061; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Finger EC, 2015, P NATL ACAD SCI USA, V112, P4441, DOI 10.1073/pnas.1418164112; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; Huang X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133152; HURTA RAR, 1992, BIOCHEM CELL BIOL, V70, P1081, DOI 10.1139/o92-153; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Li FR, 2012, J NEUROSCI RES, V90, P2237, DOI 10.1002/jnr.23121; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; McKenzie AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026552; Mouravlev A, 2007, BRAIN RES, V1130, P31, DOI 10.1016/j.brainres.2006.10.076; Naviglio S, 2009, EXPERT OPIN THER TAR, V13, P83, DOI [10.1517/14728220802602349, 10.1517/14728220802602349 ]; Nicolaou P, 2009, J MOL CELL CARDIOL, V47, P365, DOI 10.1016/j.yjmcc.2009.05.010; Niedan S, 2014, ONCOGENE, V33, P3927, DOI 10.1038/onc.2013.361; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Potratz J, 2016, MOL ONCOL, V10, P677, DOI 10.1016/j.molonc.2015.12.009; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sainz-Jaspeado M, 2010, MOL CANCER RES, V8, P1489, DOI 10.1158/1541-7786.MCR-10-0060; Sand LGL, 2015, EUR J CANCER, V51, P2624, DOI 10.1016/j.ejca.2015.08.020; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sankar Savita, 2013, Genes Cancer, V4, P213, DOI 10.1177/1947601913489569; Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020; Scotlandi K, 1996, CANCER RES, V56, P4570; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; von Heyking K, 2017, MOL ONCOL, V11, P1288, DOI 10.1002/1878-0261.12057; Waisberg J, 2014, ANTICANCER RES, V34, P5599; Westerlund N, 2011, NAT NEUROSCI, V14, P305, DOI 10.1038/nn.2755; Wiles Elizabeth T, 2013, Genes Cancer, V4, P486, DOI 10.1177/1947601913506115	53	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					798	809		10.1038/onc.2017.378	http://dx.doi.org/10.1038/onc.2017.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059150				2022-12-28	WOS:000424628100011
J	Benthani, FA; Herrmann, D; Tran, PN; Pangon, L; Lucas, MC; Allam, AH; Currey, N; Al-Sohaily, S; Giry-Laterriere, M; Warusavitarne, J; Timpson, P; Kohonen-Corish, MRJ				Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Lucas, M. C.; Allam, A. H.; Currey, N.; Al-Sohaily, S.; Giry-Laterriere, M.; Warusavitarne, J.; Timpson, P.; Kohonen-Corish, M. R. J.			'MCC' protein interacts with E-cadherin and beta-catenin strengthening cell-cell adhesion of HCT116 colon cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; PROMOTER METHYLATION; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; CYTOPLASMIC DOMAIN; SIGNALING PATHWAY; RECTAL-CANCER; K+ CHANNELS; CARCINOMA	E-cadherin and beta-catenin are key proteins that are essential in the formation of the epithelial cell layer in the colon but their regulatory pathways that are disrupted in cancer metastasis are not completely understood. Mutated in colorectal cancer (MCC) is a tumour suppressor gene that is silenced by promoter methylation in colorectal cancer and particularly in patients with increased lymph node metastasis. Here, we show that MCC methylation is found in 45% of colon and 24% of rectal cancers and is associated with proximal colon, poorly differentiated, circumferential and mucinous tumours as well as increasing T stage and larger tumour size. Knockdown of MCC in HCT116 colon cancer cells caused a reduction in E-cadherin protein level, which is a hallmark of epithelial-mesenchymal transition in cancer, and consequently diminished the E-cadherin/beta-catenin complex. MCC knockdown disrupted cell-cell adhesive strength and integrity in the dispase and transepithelial electrical resistance assays, enhanced hepatocyte growth factor-induced cell scatter and increased tumour cell invasiveness in an organotypic assay. The Src/Abl inhibitor dasatinib, a candidate anti-invasive drug, abrogated the invasive properties induced by MCC deficiency. Mechanistically, we establish that MCC interacts with the E-cadherin/beta-catenin complex. These data provide a significant advance in the current understanding of cell-cell adhesion in colon cancer cells.	[Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Lucas, M. C.; Allam, A. H.; Currey, N.; Al-Sohaily, S.; Giry-Laterriere, M.; Warusavitarne, J.; Timpson, P.; Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Benthani, F. A.; Herrmann, D.; Tran, P. N.; Pangon, L.; Timpson, P.; Kohonen-Corish, M. R. J.] UNSW Sydney, St Vincents Clin Sch, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.] Univ Western Sydney, Sch Med, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Western Sydney University	Timpson, P; Kohonen-Corish, MRJ (corresponding author), Garvan Inst Med Res, 370 Victoria St, Darlinghurst, NSW 2010, Australia.	p.timpson@garvan.org.au; m.corish@garvan.org.au	Lucas, Morghan/S-4982-2018; Lucas, Morghan C/Y-6452-2019; Kohonen-Corish, Maija/Q-9763-2019; Timpson, Paul/A-9429-2016	Lucas, Morghan/0000-0001-7654-9137; Lucas, Morghan C/0000-0001-7654-9137; Kohonen-Corish, Maija/0000-0002-4073-1479; Benthani, Fahad/0000-0002-3283-307X; Dyson, Nicola/0000-0002-4173-1913; Timpson, Paul/0000-0002-5514-7080; Herrmann, David/0000-0002-9514-7501	Cancer Council NSW [RG14-08, RG17-05]; NHMRC [1020406, 1043501, 1089497, 1105640, 1129401]; Cancer Institute NSW [10CDF232, 12CDF234]; Australian Research Council Future Fellowship [FT120100880]; Len Ainsworth Pancreatic Cancer Fellowship; Cancer Australia [1049846]; Cure Cancer Australia [1049846]; Gastroenterological Society of Australia; Sydney Catalyst; Tour de Cure	Cancer Council NSW(Cancer Council New South Wales); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Australian Research Council Future Fellowship(Australian Research Council); Len Ainsworth Pancreatic Cancer Fellowship; Cancer Australia; Cure Cancer Australia; Gastroenterological Society of Australia; Sydney Catalyst; Tour de Cure	We thank Irvin Ng, Melissa Abas, Sabine Meessen, Monica Killen and Sean Warren for advice and technical assistance. The work was supported by Cancer Council NSW (RG14-08, RG17-05), NHMRC (1020406, 1043501, 1089497, 1105640, 1129401), Cancer Institute NSW (10CDF232, 12CDF234), the Australian Research Council Future Fellowship (FT120100880), the Len Ainsworth Pancreatic Cancer Fellowship, Cancer Australia and Cure Cancer Australia (1049846), Gastroenterological Society of Australia, Sydney Catalyst and Tour de Cure. The contents of the published material are solely the responsibility of the administering institution, a participating institution or individual authors and do not reflect the views of the NHMRC. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Arnaud C, 2009, FEBS LETT, V583, P2326, DOI 10.1016/j.febslet.2009.06.034; Bard-Chapeau EA, 2014, NAT GENET, V46, P24, DOI 10.1038/ng.2847; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Canel M, 2010, CANCER RES, V70, P9413, DOI 10.1158/0008-5472.CAN-10-1454; Chen CL, 2009, J CELL SCI, V122, P513, DOI 10.1242/jcs.035469; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; David JM, 2012, CANCER RES, V72, P2917, DOI 10.1158/0008-5472.CAN-11-3498; Erami Z, 2016, CELL REP, V14, P152, DOI 10.1016/j.celrep.2015.12.020; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Fu XS, 2012, J CLIN PATHOL, V65, P675, DOI 10.1136/jclinpath-2011-200602; Fukuyama R, 2008, ONCOGENE, V27, P6044, DOI 10.1038/onc.2008.204; Gamazon ER, 2013, BLOOD, V121, P4366, DOI 10.1182/blood-2012-10-464149; Gargalionis AN, 2014, INT J CANCER, V134, P2019, DOI 10.1002/ijc.28299; Giry-Laterriere M, 2011, HUM GENE THER, V22, P1255, DOI 10.1089/hum.2010.179; GRIFFIN MJ, 1976, IN VITRO CELL DEV B, V12, P393, DOI 10.1007/BF02796317; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Huang RYJ, 2012, J CELL SCI, V125, P4417, DOI 10.1242/jcs.099697; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210; Kohonen-Corish MRJ, 2014, INT J CANCER, V134, P2820, DOI 10.1002/ijc.28619; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lim L, 2014, HEPATOLOGY, V59, P202, DOI 10.1002/hep.26662; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Mizuno S, 2013, INT J MOL SCI, V14, P888, DOI 10.3390/ijms14010888; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pangon L, 2016, ONCOGENE, V35, P2834, DOI 10.1038/onc.2015.347; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Pangon L, 2012, BBA-MOL CELL RES, V1823, P1058, DOI 10.1016/j.bbamcr.2012.03.011; Pangon Laurent, 2010, Genes Cancer, V1, P917, DOI 10.1177/1947601910388937; Poursoltan P, 2012, LUNG CANCER, V77, P272, DOI 10.1016/j.lungcan.2012.04.001; Serrels A, 2009, CANCER RES, V69, P2714, DOI 10.1158/0008-5472.CAN-08-4308; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Sigglekow ND, 2012, ANTICANCER RES, V32, P73; Spina A, 2015, BIOMEDICINES, V3, P71, DOI 10.3390/biomedicines3010071; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x	53	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					663	672		10.1038/onc.2017.362	http://dx.doi.org/10.1038/onc.2017.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035389				2022-12-28	WOS:000423812200011
J	Yamaguchi, H; Du, Y; Nakai, K; Ding, M; Chang, SS; Hsu, JL; Yao, J; Wei, Y; Nie, L; Jiao, S; Chang, WC; Chen, CH; Yu, Y; Hortobagyi, GN; Hung, MC				Yamaguchi, H.; Du, Y.; Nakai, K.; Ding, M.; Chang, S-S; Hsu, J. L.; Yao, J.; Wei, Y.; Nie, L.; Jiao, S.; Chang, W-C; Chen, C-H; Yu, Y.; Hortobagyi, G. N.; Hung, M-C			EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer	ONCOGENE			English	Article							EPITHELIAL OVARIAN-CANCER; B-CELL LYMPHOMAS; SUPPRESSES METHYLATION; PROSTATE-CANCER; MAMMARY-TUMORS; DNA-DAMAGE; STEM-CELLS; BRCA1; PHOSPHORYLATION; RESISTANCE	Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents currently used to treat BRCA-mutant ovarian cancer and are in clinical trials for other cancer types, including BRCA-mutant breast cancer. To enhance the clinical response to PARP inhibitors (PARPis), understanding the mechanisms underlying PARPi sensitivity is urgently needed. Here, we show enhancer of zeste homolog 2 (EZH2), an enzyme that catalyzes H3 lysine trimethylation and associates with oncogenic function, contributes to PARPi sensitivity in breast cancer cells. Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2. PARylation of EZH2 by PARP1 then induces PRC2 complex dissociation and EZH2 downregulation, which in turn reduces EZH2-mediated H3 trimethylation. In contrast, inhibition of PARP by PARPi attenuates alkylating DNA damage-induced EZH2 downregulation, thereby promoting EZH2-mediated gene silencing and cancer stem cell property compared with PARPi-untreated cells. Moreover, the addition of an EZH2 inhibitor sensitizes the BRCA-mutant breast cells to PARPi. Thus, these results may provide a rationale for combining PARP and EZH2 inhibition as a therapeutic strategy for BRCA-mutated breast and ovarian cancers.	[Yamaguchi, H.; Du, Y.; Nakai, K.; Chang, S-S; Hsu, J. L.; Yao, J.; Wei, Y.; Nie, L.; Jiao, S.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Ding, M.; Yu, Y.] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX USA; [Chang, W-C; Chen, C-H] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chang, W-C; Hung, M-C] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Chang, W-C; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Academia Sinica - Taiwan; China Medical University Taiwan; China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Du, Yi/0000-0002-3969-2652; NAKAI, KATSUYA/0000-0003-4142-8508; Ding, Ming/0000-0002-9135-9275	National Institutes of Health [CA211615, CCSG CA016672, GM114160]; Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; University of Texas MD Anderson Cancer Center-China Medical University; University of Texas MD Anderson Cancer Center-Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE) [MOST 105-2911-I-002-302]; Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW106-TDU-B-212-144003]; Center for Biological Pathways; UT Southwestern Endowed Scholar Program; Welch Foundation [I-1800]; NATIONAL CANCER INSTITUTE [R01CA109311, P01CA099031, R01CA211615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114160] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; University of Texas MD Anderson Cancer Center-China Medical University(China Medical University); University of Texas MD Anderson Cancer Center-Hospital Sister Institution Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); International Research-intensive Centers of Excellence in Taiwan (I-RiCE); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence; Center for Biological Pathways; UT Southwestern Endowed Scholar Program; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported in part by the following: the National Institutes of Health (CA211615 and CCSG CA016672); Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; The University of Texas MD Anderson Cancer Center-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW106-TDU-B-212-144003); Center for Biological Pathways; The UT Southwestern Endowed Scholar Program, the Welch Foundation (I-1800) and National Institutes of Health (GM114160) to YY. Dr YY is a Virginia Murchison Linthicum Scholar in Medical Research and a CPRIT Scholar in Cancer Research.	Alekseyenko AA, 2014, P NATL ACAD SCI USA, V111, P2488, DOI 10.1073/pnas.1400648111; Barber LJ, 2013, J PATHOL, V229, P422, DOI 10.1002/path.4140; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; DelloRusso C, 2007, MOL CANCER RES, V5, P35, DOI 10.1158/1541-7786.MCR-06-0234; Donizy P, 2014, ONCOL REP, V31, P1777, DOI 10.3892/or.2014.3024; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Edelheit O, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-61; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Ledermann JA, 2015, BRIT J CANCER, V113, pS10, DOI 10.1038/bjc.2015.395; Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Li JL, 2013, NAT NEUROSCI, V16, P1745, DOI 10.1038/nn.3564; Li T, 2014, CANCER BIOL THER, V15, P271, DOI 10.4161/cbt.27306; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Liu C, 2013, NUCLEIC ACIDS RES, V41, P1698, DOI 10.1093/nar/gks1278; Martin KA, 2015, MOL CELL BIOL, V35, P3934, DOI 10.1128/MCB.00635-15; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Roy A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.119; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Sala A, 2008, PLOS BIOL, V6, P2329, DOI 10.1371/journal.pbio.0060252; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vilar E, 2011, CANCER RES, V71, P2632, DOI 10.1158/0008-5472.CAN-10-1120; Wang L, 2017, CLIN RES HEPATOL GAS, V2017, P1, DOI DOI 10.1371/J0URNAL.P0NE.01; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang L, 2013, INT J BIOL SCI, V9, P472, DOI 10.7150/ijbs.5855; Wang YT, 2011, J MOL BIOL, V414, P1, DOI 10.1016/j.jmb.2011.09.027; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Xu JH, 2010, BREAST CANCER RES TR, V120, P593, DOI 10.1007/s10549-009-0422-1; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yang CC, 2015, AM J TRANSL RES, V7, P1009; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603	66	56	57	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					208	217		10.1038/onc.2017.311	http://dx.doi.org/10.1038/onc.2017.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925391	Green Accepted			2022-12-28	WOS:000422631700007
J	Lustig, LC; Dingar, D; Tu, WB; Lourenco, C; Kalkat, M; Inamoto, I; Ponzielli, R; Chan, WCW; Shin, JA; Penn, LZ				Lustig, L. C.; Dingar, D.; Tu, W. B.; Lourenco, C.; Kalkat, M.; Inamoto, I.; Ponzielli, R.; Chan, W. C. W.; Shin, J. A.; Penn, L. Z.			Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth	ONCOGENE			English	Article							C-MYC; TRANSCRIPTIONAL REGULATION; PROTEIN-INTERACTION; INDUCED APOPTOSIS; BET BROMODOMAINS; IN-VIVO; CANCER; MAX; RESISTANCE; OMOMYC	Developing therapeutics to effectively inhibit the MYC oncoprotein would mark a key advance towards cancer patient care as MYC is deregulated in over 50% of human cancers. MYC deregulation is correlated with aggressive disease and poor patient outcome. Despite strong evidence in mouse models that inhibiting MYC would significantly impact tumour cell growth and patient survival, traditional approaches have not yet yielded the urgently needed therapeutic agents that directly target MYC. MYC functions through its interaction with MAX to regulate gene transcription by binding to E-box DNA response elements of MYC target genes. Here we used a structure-based strategy to design ME47, a small minimalist hybrid protein (MHP) able to disrupt the MAX: E-box interaction/binding and block transcriptional MYC activity. We show that inducing ME47 expression in established tumour xenografts inhibits tumour growth and decreases cellular proliferation. Mechanistically, we show by chromatin immunoprecipitation that ME47 binds to E-box binding sites of MYC target genes. Moreover, ME47 occupancy decreases MYC: DNA interaction at its cognate E-box binding sites. Taken together, ME47 is a prototypic MHP inhibitor that antagonizes tumour cell growth in vitro and in vivo and inhibits the interaction of MYC with DNA E-box elements. These results support ME47's role as a MYC inhibitor and suggest that MHPs provide an alternative therapeutic targeting system that can be used to target transcription factors important in human diseases, including cancer.	[Lustig, L. C.; Dingar, D.; Tu, W. B.; Lourenco, C.; Kalkat, M.; Ponzielli, R.; Penn, L. Z.] Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower 13-706, Toronto, ON M5G 1L7, Canada; [Tu, W. B.; Lourenco, C.; Kalkat, M.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Inamoto, I.; Shin, J. A.] Univ Toronto, Dept Chem, Toronto, ON, Canada; [Chan, W. C. W.] Univ Toronto, Inst Biomat & Biomed Engn, Donnelly Ctr Cellular & Biomol Res, Dept Mat Sci & Engn,Dept Chem Engn, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Penn, LZ (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower 13-706, Toronto, ON M5G 1L7, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459; Tu, William/0000-0002-2365-1995; Kalkat, Manpreet/0000-0002-4843-9755	Collaborative Health Research Program; Canadian Research Chairs Program; Natural Sciences and Engineering Research Council; Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship	Collaborative Health Research Program; Canadian Research Chairs Program(Canada Research Chairs); Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship	We would like to thank the Penn, Shin, and Chen labs for their helpful reviews and contributions to this manuscript. Special thanks to Dr Peter Mullen, Dr Sam Sathiamoorthy and Peter Tang. Funding was provided by way of Operating grant support from the Collaborative Health Research Program (JS, WC, LZP). Salary and stipend support from the Canadian Research Chairs Program (LZP), Natural Sciences and Engineering Research Council (LCL), Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship (WBT and MK).	Ahmadpour F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032136; Beaulieu ME, 2012, J MOL RECOGNIT, V25, P414, DOI 10.1002/jmr.2203; Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Bhagwat AS, 2015, TRENDS CANCER, V1, P53, DOI 10.1016/j.trecan.2015.07.001; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Felsher Dean W, 2010, Genes Cancer, V1, P597, DOI 10.1177/1947601910377798; Follis AV, 2009, BIOORG MED CHEM LETT, V19, P807, DOI 10.1016/j.bmcl.2008.12.025; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Fu LL, 2015, ONCOTARGET, V6, P5501, DOI 10.18632/oncotarget.3551; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jung KY, 2015, J MED CHEM, V58, P3002, DOI 10.1021/jm501440q; Kalkat M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115337; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Montagne M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032172; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Ponzielli R, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn735; Posternak V., 2016, F1000RESEARCH, V5, DOI [DOI 10.12688/F1000RESEARCH.7879.1, 10.12688/f1000research.7879.1]; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Shi XR, 2016, P NATL ACAD SCI USA, V113, pE4558, DOI 10.1073/pnas.1608319113; Soodgupta D, 2015, MOL CANCER THER, V14, P1286, DOI 10.1158/1535-7163.MCT-14-0774-T; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wasylishen AR, 2014, ONCOGENE, V33, P1066, DOI 10.1038/onc.2013.36; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Wasylishen AR, 2013, CANCER RES, V73, P6504, DOI 10.1158/0008-5472.CAN-12-4063; Wilson CH, 2014, ONCOGENE, V33, P4877, DOI 10.1038/onc.2014.78; Xu J, 2009, J AM CHEM SOC, V131, P7839, DOI 10.1021/ja901306q; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	43	16	16	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6830	6837		10.1038/onc.2017.275	http://dx.doi.org/10.1038/onc.2017.275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806396				2022-12-28	WOS:000417282500009
J	Sun, Y; Wei, G; Luo, H; Wu, W; Skogerbo, G; Luo, J; Chen, R				Sun, Y.; Wei, G.; Luo, H.; Wu, W.; Skogerbo, G.; Luo, J.; Chen, R.			The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes	ONCOGENE			English	Article							FAR UPSTREAM ELEMENT; C-MYC; CANCER; EXPRESSION; TFIIH	Increasing evidence indicates that long noncoding RNAs (lncRNAs) have important roles in various physiological processes and dysfunction of lncRNAs could be a prevalent cause in human diseases. Here we functionally characterized the nuclear-enriched lncRNA SNHG1, which is highly expressed in multiple types of cancer. We also provide evidence that SNHG1 promotes cancer cell growth by regulating gene expression both in cis and in trans. SNHG1 was involved in the AKT signaling pathway as it promotes the neighboring transcription of the protein-coding gene SLC3A2 in cis by binding the Mediator complex to facilitate the establishment of enhancer-promoter interaction. In trans, SNHG1 directly interacted with central domain of FUBP1 and antagonize the binding of FBP-interacting repressor to FUBP1, thereby coordinating the expression of the oncogene MYC. Collectively, our findings demonstrate that lncRNA SNHG1 can function both in cis and in trans with distinct mechanisms to regulate transcription, promoting tumorigenesis and cancer progression.	[Sun, Y.; Wei, G.; Luo, H.; Wu, W.; Skogerbo, G.; Luo, J.; Chen, R.] Chinese Acad Sci, Inst Biophys, Key Lab RNA Biol, 15 Datun Rd, Beijing 100101, Peoples R China; [Wei, G.] Univ Oxford, Dept Biochem, Oxford, England; [Wu, W.] Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Oxford; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Chen, R (corresponding author), Chinese Acad Sci, Inst Biophys, Key Lab RNA Biol, 15 Datun Rd, Beijing 100101, Peoples R China.	rschen@ibp.ac.cn	Luo, Jianjun/L-1264-2015; Chen, Runsheng/S-9834-2017	Luo, Jianjun/0000-0002-5550-9889; Chen, Runsheng/0000-0001-6049-8347; Wei, Guifeng/0000-0002-5698-426X	National Natural Science Foundation of China [31520103905, 31401098]; National High Technology Research and Development Program ('863' Program of China) [2015AA020108]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program ('863' Program of China)(National High Technology Research and Development Program of China)	We thank Professor Zushen Fan, Dr Greta Pintacuda and Dr Tianyi Zhang for helpful suggestions and critical reading of this manuscript and Professors Yajun Guo and Mingzhou Guo of Chinese PLA General Hospital and Youyong Lu of Peking University Cancer Hospital and Institute for kindly providing clinical samples. We also thank Dr Junbing Wu, Dongpeng Wang, Shuheng Wu and Bao Zhang for helping with animal experiments. This work was supported by grants from the National Natural Science Foundation of China (31520103905, 31401098) and the National High Technology Research and Development Program ('863' Program of China) 2015AA020108. The raw sequencing data reported in this work have been deposited in GEO (GSE85842).	Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Chu C, 2012, JOVE-J VIS EXP, DOI 10.3791/3912; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Herriges MJ, 2014, GENE DEV, V28, P1363, DOI 10.1101/gad.238782.114; Kim T, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju505; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Luo HX, 2015, BIOCHEMISTRY-US, V54, P2895, DOI 10.1021/acs.biochem.5b00259; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miele Adriana, 2008, V464, P105; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Roberts TC, 2015, NAT PROTOC, V10, P1198, DOI 10.1038/nprot.2015.076; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Xiao TF, 2015, STEM CELL REP, V5, P856, DOI 10.1016/j.stemcr.2015.09.007; Yuan J, 2016, ONCOTARGET, V7, P8131, DOI 10.18632/oncotarget.6993; Zhang J, 2013, ONCOGENE, V32, P2907, DOI 10.1038/onc.2012.350; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	40	70	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6774	6783		10.1038/onc.2017.286	http://dx.doi.org/10.1038/onc.2017.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28825722				2022-12-28	WOS:000417282500003
J	Chakraborty, D; Benham, V; Bullard, B; Kearney, T; Hsia, HC; Gibbon, D; Demireva, EY; Lunt, SY; Bernard, JJ				Chakraborty, D.; Benham, V.; Bullard, B.; Kearney, T.; Hsia, H. C.; Gibbon, D.; Demireva, E. Y.; Lunt, S. Y.; Bernard, J. J.			Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer	ONCOGENE			English	Article							BODY-MASS INDEX; SQUAMOUS-CELL CARCINOMA; DIET-INDUCED OBESITY; BREAST-CANCER; WAIST CIRCUMFERENCE; NEOPLASTIC TRANSFORMATION; GENE-EXPRESSION; TUMOR-GROWTH; FACTOR FGF-2; SKIN-CANCER	Epidemiological evidence implicates excess adipose tissue in increasing cancer risk. Despite a steeply rising global prevalence of obesity, how adiposity contributes to transformation (stage a non-tumorigenic cell undergoes to become malignant) is unknown. To determine the factors in adipose tissue that stimulate transformation, we used a novel ex vivo system of visceral adipose tissue (VAT)-condition medium-stimulated epithelial cell growth in soft agar. To extend this system in vivo, we used a murine lipectomy model of ultraviolet light B-induced, VAT-promoted skin tumor formation. We found that VAT from mice and obese human donors stimulated growth in soft agar of non-tumorigenic epithelial cells. The difference in VAT activity was associated with fibroblast growth factor-2 (FGF2) levels. Moreover, human and mouse VAT failed to stimulate growth in soft of agar in cells deficient in FGFR-1 (FGF2 receptor). We also demonstrated that circulating levels of FGF2 were associated with non-melanoma tumor formation in vivo. These data implicate FGF2 as a major factor VAT releases to transform epithelial cells-a novel, potential pathway of VAT-enhanced tumorigenesis. Strategies designed to deplete VAT stores of FGF2 or inhibit FGFR-1 in abdominally obese individuals may be important cancer prevention strategies as well as adjuvant therapies for improving outcomes.	[Chakraborty, D.; Benham, V.; Bullard, B.; Bernard, J. J.] Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Life Sci B420, E Lansing, MI 48824 USA; [Kearney, T.] Rutgers Robert Wood Johnson Med Sch, Div Surg Oncol, New Brunswick, NJ USA; [Hsia, H. C.] Yale Sch Med, Sect Plast Surg, Dept Surg, New Haven, CT USA; [Gibbon, D.] Summit Medical4 Grp, Livingston, NJ USA; [Demireva, E. Y.] Michigan State Univ, Off Vice President Res & Grad Studies, E Lansing, MI 48824 USA; [Lunt, S. Y.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University; Michigan State University; Michigan State University	Bernard, JJ (corresponding author), Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Life Sci B420, E Lansing, MI 48824 USA.	jbernard@msu.edu	Hsia, Henry/W-6140-2019	Hsia, Henry/0000-0001-8674-9140; Lunt, Sophia/0000-0003-4522-6065; Bernard, Jamie/0000-0002-3800-2576	National Institutes of Health [R00 CA177868]; Michigan State University; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-15-1-0453]; AACR-Incyte Corporation NextGen Grant [16-20-46-LUNT]; NATIONAL CANCER INSTITUTE [R00CA177868, K99CA177868] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michigan State University; Office of the Assistant Secretary of Defense for Health Affairs; AACR-Incyte Corporation NextGen Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We acknowledge the MSU Investigative HistoPathology Laboratory, Amy S Porter, HT (ASCP) QIHC and Kathleen A Joseph, HT (ASCP) QIHC. We also thank Dr Karen Liby (MSU) for her consultation and providing antibodies, Dr Richard Neubig (MSU) and Dr Matthew Bernard (MSU) for their consultation and assistance with experimental design and Dr Dalen Agnew (MSU) for his consultation on tumor pathology. JJB is funded by National Institutes of Health Grant R00 CA177868, Michigan State University start-up funds. SYL is funded by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program, under Award No. W81XWH-15-1-0453 and the 2016 AACR-Incyte Corporation NextGen Grant for Transformative Cancer Research, Grant Number 16-20-46-LUNT.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Ahmad I, 2012, BBA-MOL CELL RES, V1823, P850, DOI 10.1016/j.bbamcr.2012.01.004; Amstad PA, 1997, MOL CARCINOGEN, V20, P231, DOI 10.1002/(SICI)1098-2744(199710)20:2<231::AID-MC10>3.0.CO;2-B; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; Ayala-Lopez N, 2015, AM J PHYSIOL-HEART C, V309, pH1904, DOI 10.1152/ajpheart.00308.2015; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; Berg KK, 2009, SCAND J IMMUNOL, V69, P36, DOI 10.1111/j.1365-3083.2008.02187.x; Bernard Jamie J, 2014, J Carcinog Mutagen, V5, P2157; Binai NA, 2010, INT J CANCER, V127, P55, DOI 10.1002/ijc.25010; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Chockalingam R, 2015, J CLIN MED, V4, P1229, DOI 10.3390/jcm4061229; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; Connolly BS, 2002, NUTR CANCER, V44, P127, DOI 10.1207/S15327914NC4402_02; Courneya KS, 2008, CANCER-AM CANCER SOC, V112, P2475, DOI 10.1002/cncr.23455; Cronauer MV, 1997, PROSTATE, V31, P223; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dutta Deep, 2012, Indian J Endocrinol Metab, V16, pS596, DOI 10.4103/2230-8210.105577; Elsheikh SE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1665; Font-Burgada J, 2016, CELL METAB, V23, P48, DOI 10.1016/j.cmet.2015.12.015; Freier K, 2007, ORAL ONCOL, V43, P60, DOI 10.1016/j.oraloncology.2006.01.005; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gabrielsson BG, 2002, OBES RES, V10, P608, DOI 10.1038/oby.2002.83; Garratt M, 2016, AGING CELL, V15, P737, DOI 10.1111/acel.12489; Gaudet MM, 2014, CANCER CAUSE CONTROL, V25, P737, DOI 10.1007/s10552-014-0376-4; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Grazul-Bilska AT, 2002, EXP CLIN ENDOCR DIAB, V110, P176, DOI 10.1055/s-2002-32149; Hajian-Tilaki KO, 2011, MED ONCOL, V28, P1296, DOI 10.1007/s12032-010-9629-6; Hao RH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19868; He ZQ, 2003, J BIOL CHEM, V278, P26435, DOI 10.1074/jbc.M303859200; Hill AL, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000968; Hu MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147374; Huang Z, 1999, AM J EPIDEMIOL, V150, P1316, DOI 10.1093/oxfordjournals.aje.a009963; Huffman DM, 2013, CANCER PREV RES, V6, P177, DOI 10.1158/1940-6207.CAPR-12-0414; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ibiebele TI, 2007, AM J CLIN NUTR, V85, P1401, DOI 10.1093/ajcn/85.5.1401; Ibiebele TI, 2009, INT J CANCER, V125, P1678, DOI 10.1002/ijc.24481; Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x; Itoh N, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00247; Iyengar NM, 2016, CLIN CANCER RES, V22, P2283, DOI 10.1158/1078-0432.CCR-15-2239; JAIN AK, 1989, INDIAN J CHEM A, V28, P992; Jang MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3239; Kakudo N, 2007, BIOCHEM BIOPH RES CO, V359, P239, DOI 10.1016/j.bbrc.2007.05.070; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120073; Kornmann M, 1998, PANCREAS, V17, P169, DOI 10.1097/00006676-199808000-00010; Kuhn MC, 2012, MOL CELL ENDOCRINOL, V349, P180, DOI 10.1016/j.mce.2011.10.018; Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705; Lau MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059083; Lepique AP, 2004, J MOL ENDOCRINOL, V33, P623, DOI 10.1677/jme.1.01485; Li HJ, 2013, ONCOL REP, V30, P2153, DOI 10.3892/or.2013.2678; Ligibel JA, 2014, J CLIN ONCOL, V32, P3568, DOI 10.1200/JCO.2014.58.4680; Liu YH, 2001, CARCINOGENESIS, V22, P607, DOI 10.1093/carcin/22.4.607; Logie A, 2005, HUM MOL GENET, V14, P1153, DOI 10.1093/hmg/ddi127; Lu FJ, 2006, CHEM-BIOL INTERACT, V162, P249, DOI 10.1016/j.cbi.2006.07.007; Lu YP, 2012, P NATL ACAD SCI USA, V109, P9065, DOI 10.1073/pnas.1205810109; Malley CO, 2016, BBA CLIN, V5, P29, DOI 10.1016/j.bbacli.2015.11.003; Marshall Fray F, 2002, J Urol, V168, P877; Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s; Matsui R, 1999, CELL SIGNAL, V11, P221, DOI 10.1016/S0898-6568(98)00070-9; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Moore LL, 2004, INT J OBESITY, V28, P559, DOI 10.1038/sj.ijo.0802606; Murphy RA, 2014, APPL PHYSIOL NUTR ME, V39, P687, DOI 10.1139/apnm-2013-0360; Mydlo JH, 1998, J UROLOGY, V159, P2159, DOI 10.1016/S0022-5347(01)63298-1; NAKAMOTO T, 1992, CANCER RES, V52, P571; NAKAMURA KD, 1989, MECH AGEING DEV, V48, P199, DOI 10.1016/0047-6374(89)90051-1; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; Nan H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-172; Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020; Nunez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Pan RL, 2015, HEPATOLOGY, V61, P1708, DOI 10.1002/hep.27649; Pothiawala S, 2012, CANCER CAUSE CONTROL, V23, P717, DOI 10.1007/s10552-012-9941-x; QUARTO N, 1989, ONCOGENE RES, V5, P101; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Regad T, 2015, CANCERS, V7, P1758, DOI 10.3390/cancers7030860; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; SAHL WJ, 1995, INT J DERMATOL, V34, P398, DOI 10.1111/j.1365-4362.1995.tb04440.x; Samaras K, 2010, OBESITY, V18, P884, DOI 10.1038/oby.2009.443; Sarveswaran S, 2015, J BIOL CHEM, V290, P4994, DOI 10.1074/jbc.M114.599035; Sato T, 2009, ONCOL REP, V21, P211, DOI 10.3892/or_00000210; SCHAPIRA DV, 1994, CANCER, V74, P632, DOI 10.1002/1097-0142(19940715)74:2<632::AID-CNCR2820740215>3.0.CO;2-T; SMITH BM, 1986, CANCER RES, V46, P701; SMITH JS, 1992, CARCINOGENESIS, V13, P189, DOI 10.1093/carcin/13.2.189; SRINIVAS L, 1984, CARCINOGENESIS, V5, P515, DOI 10.1093/carcin/5.4.515; Steringer JP, 2015, J MOL BIOL, V427, P1202, DOI 10.1016/j.jmb.2014.07.012; Tsimafeyeu I, 2011, SCAND J UROL NEPHROL, V45, P190, DOI 10.3109/00365599.2011.552436; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; Vucenik I, 2012, ANN NY ACAD SCI, V1271, P37, DOI 10.1111/j.1749-6632.2012.06750.x; Weber TJ, 2010, J INVEST DERMATOL, V130, P1444, DOI 10.1038/jid.2009.383; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Xiao LP, 2010, BONE, V47, P360, DOI 10.1016/j.bone.2010.05.021; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yakar S, 2006, ENDOCRINOLOGY, V147, P5826, DOI 10.1210/en.2006-0311; Zhang DY, 2009, TOXICOL APPL PHARM, V235, P18, DOI 10.1016/j.taap.2008.11.002; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108	103	24	25	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6668	6679		10.1038/onc.2017.278	http://dx.doi.org/10.1038/onc.2017.278			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783178	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000416780800002
J	Wada, M; Canals, D; Adada, M; Coant, N; Salama, MF; Helke, KL; Arthur, JS; Shroyer, KR; Kitatani, K; Obeid, LM; Hannun, YA				Wada, M.; Canals, D.; Adada, M.; Coant, N.; Salama, M. F.; Helke, K. L.; Arthur, J. S.; Shroyer, K. R.; Kitatani, K.; Obeid, L. M.; Hannun, Y. A.			P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-SPECIFIC DISRUPTION; TRANSGENIC MOUSE MODEL; GROWTH; P38-DELTA; INVASION; EXPRESSION; P38-GAMMA; TUMORIGENESIS; LOCALIZATION	The protein p38 mitogen-activated protein kinase (MAPK) delta isoform (p38 delta) is a poorly studied member of the MAPK family. Data analysis from The Cancer Genome Atlas database revealed that p38 delta is highly expressed in all types of human breast cancers. Using a human breast cancer tissue array, we confirmed elevation in cancer tissue. The breast cancer mouse model, MMTV-PyMT (PyMT), developed breast tumors with lung metastasis; however, mice deleted in p38 delta (PyMT/p38 delta(-/-)) exhibited delayed primary tumor formation and highly reduced lung metastatic burden. At the cellular level, we demonstrate that targeting of p38 delta in breast cancer cells, MCF-7 and MDA-MB-231 resulted in a reduced rate of cell proliferation. In addition, cells lacking p38 delta also displayed an increased cell-matrix adhesion and reduced cell detachment. This effect on cell adhesion was molecularly supported by the regulation of the focal adhesion kinase by p38 delta in the human breast cell lines. These studies define a previously unappreciated role for p38 delta in breast cancer development and evolution by regulating tumor growth and altering metastatic properties. This study proposes MAPK p38 delta protein as a key factor in breast cancer. Lack of p38 delta resulted in reduced primary tumor size and blocked the metastatic potential to the lungs.	[Wada, M.; Canals, D.; Adada, M.; Coant, N.; Salama, M. F.; Obeid, L. M.; Hannun, Y. A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Canals, D.; Adada, M.; Obeid, L. M.; Hannun, Y. A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Salama, M. F.] Mansoura Univ, Dept Biochem, Fac Vet Med, Mansoura, Egypt; [Helke, K. L.] Med Univ South Carolina, Dept Comparat Med, Charleston, SC USA; [Arthur, J. S.] Univ Dundee, Sch Life Sci, MRC Prot Phosphorylat Unit, Dundee, Scotland; [Shroyer, K. R.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Kitatani, K.] Tohoku Univ, Grad Sch Med, Tohoku Med Megabank Org, Sendai, Miyagi, Japan; [Kitatani, K.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Obeid, L. M.] Northport VA Med Ctr, Northport, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Egyptian Knowledge Bank (EKB); Mansoura University; Medical University of South Carolina; University of Dundee; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tohoku University; Tohoku University	Hannun, YA (corresponding author), SUNY Stony Brook, Stony Brook Canc Ctr, Hlth Sci Ctr, L-4,182, Stony Brook, NY 11794 USA.	yusuf.hannun@sbumed.org	Canals, Daniel/AAW-1998-2021; Salama, Mohamed F/C-9010-2017; Canals, Daniel/AAJ-8176-2021; Kitatani, Kazuyuki/H-7100-2019; Salama, Mohamed/S-3493-2019	Canals, Daniel/0000-0002-9293-5123; Salama, Mohamed F/0000-0002-0002-9108; Kitatani, Kazuyuki/0000-0002-8516-6135; Salama, Mohamed/0000-0002-0002-9108; Adada, Mohamad/0000-0002-2988-2081; Helke, Kris/0000-0001-9746-0764; COANT, Nicolas/0000-0001-9237-2132; Arthur, Simon/0000-0002-8135-1958	National Cancer Institute [R01-CA87584]; NIH [CA087584]; NATIONAL CANCER INSTITUTE [R01CA087584, P01CA097132] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eiji Suzuki (Fukushima Medical University), Dr Tatiana Efimova (Washington University), Dr Patricia Watson, Dr Dennis K. Watson and George Washington (Medical University of South Carolina), Dr Hideki Furuya, Dr Toshihiko Kawamori (University of Hawaii), Dr Vincent Yang and members of his laboratory, Mallory Korman, Dr Luisa Escobar-Hoyos, Dr Kai Wang, Dr Chiara Luberto, Dr Achraf Shamsedine, Dr Monica Garcia-Barros, Dr Jean-Philip Truman, Maria Hernandez, Dr Ashley Snider and Dr Magali Trayssac (Stony Brook University) for helpful technical advice and/or assistance. This work is supported by the National Cancer Institute (R01-CA87584). These studies were supported by NIH Grant CA087584.	Adada MM, 2015, FASEB J, V29, P4654, DOI 10.1096/fj.15-274340; Arold ST, 2011, CURR OPIN STRUC BIOL, V21, P808, DOI 10.1016/j.sbi.2011.09.008; Aust S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-67; Chen L, 2009, CANCER RES, V69, P8853, DOI 10.1158/0008-5472.CAN-09-1636; Choi YK, 2013, CANCER GENOM PROTEOM, V10, P265; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gandy KAO, 2013, FASEB J, V27, P3155, DOI 10.1096/fj.13-228460; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ittner A, 2012, J EXP MED, V209, P2229, DOI 10.1084/jem.20120677; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kesson EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2718; Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200; Kohler BA, 2015, JNCI-J NATL CANCER I, V107, P1975, DOI DOI 10.1093/JNCI/DJV048; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Liu Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03098; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; O'Callaghan Carol, 2014, Int J Cell Biol, V2014, P272689, DOI 10.1155/2014/272689; O'Callaghan C, 2013, INT J ONCOL, V43, P405, DOI 10.3892/ijo.2013.1968; OWENS LV, 1995, CANCER RES, V55, P2752; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Risco A, 2012, P NATL ACAD SCI USA, V109, P11200, DOI 10.1073/pnas.1207290109; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tan FLS, 2010, INT J CANCER, V126, P2353, DOI 10.1002/ijc.24944; Zhong J, 2011, LUNG CANCER, V73, P166, DOI 10.1016/j.lungcan.2010.12.003	36	48	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6649	6657		10.1038/onc.2017.274	http://dx.doi.org/10.1038/onc.2017.274			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783172	Green Accepted			2022-12-28	WOS:000416049200013
J	Ramadoss, S; Sen, S; Ramachandran, I; Roy, S; Chaudhuri, G; Farias-Eisner, R				Ramadoss, S.; Sen, S.; Ramachandran, I.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.			Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance	ONCOGENE			English	Correction															Carl and Roberta Deutsch Foundation; NIH/NCI [U54CA143930]	Carl and Roberta Deutsch Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge The Carl and Roberta Deutsch Foundation (PI: Farias-Eisner), Kelly Day, and NIH/NCI U54CA143930 Grant (PI: Farias-Eisner) for their financial support. We thank Professor Oliver Dorigo, Stanford University Medical Center, for the generous gift of cisplatin-resistant ovarian cancer cell lines. We thank Dr Xiangming Ding, UCLA Clinical Microarray Core, for the statistical assistance.	Ramadoss S, 2017, ONCOGENE, V36, P1537, DOI 10.1038/onc.2016.320	1	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6508	6508		10.1038/onc.2017.331	http://dx.doi.org/10.1038/onc.2017.331			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28925393	Green Published, hybrid			2022-12-28	WOS:000415622900014
J	Torrente, L; Sanchez, C; Moreno, R; Chowdhry, S; Cabello, P; Isono, K; Koseki, H; Honda, T; Hayes, JD; Dinkova-Kostova, AT; de la Vega, L				Torrente, L.; Sanchez, C.; Moreno, R.; Chowdhry, S.; Cabello, P.; Isono, K.; Koseki, H.; Honda, T.; Hayes, J. D.; Dinkova-Kostova, A. T.; de la Vega, L.			Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses	ONCOGENE			English	Article							INTERACTING PROTEIN KINASE-2; TUMOR-SUPPRESSOR FUNCTION; TRANSCRIPTION FACTOR NRF2; DNA-DAMAGE RESPONSE; LUNG-CANCER; CELL-PROLIFERATION; MOLECULAR-MECHANISM; GENE-EXPRESSION; GROWTH ARREST; FEEDBACK LOOP	Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.	[Torrente, L.; Sanchez, C.; Moreno, R.; Chowdhry, S.; Cabello, P.; Hayes, J. D.; Dinkova-Kostova, A. T.; de la Vega, L.] Univ Dundee, Div Canc Res, Jacqui Wood Canc Ctr, Sch Med,Ninewells Hosp & Med Sch, James Arrott Dr, Dundee DD1 9SY, Scotland; [Koseki, H.] RIKEN Ctr Integrat Med Sci IMS, Dev Genet, Yokohama, Kanagawa, Japan; [Honda, T.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; [Honda, T.] SUNY Stony Brook, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA	University of Dundee; RIKEN; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	de la Vega, L (corresponding author), Univ Dundee, Div Canc Res, Jacqui Wood Canc Ctr, Sch Med,Ninewells Hosp & Med Sch, James Arrott Dr, Dundee DD1 9SY, Scotland.	l.delavega@dundee.ac.uk	de la Vega, Laureano/AAE-5456-2020	de la Vega, Laureano/0000-0003-2707-7414; Torrente, Laura/0000-0003-0343-0287; Hayes, John/0000-0002-2927-5548; Dinkova-Kostova, Albena/0000-0003-0316-9859; Isono, Kyoichi/0000-0002-4609-8985	Cancer Research UK [C52419/A22869]; Tenovus Scotland [T14/62]; Reata Pharmaceuticals; Stony Brook Foundation; Ninewells Cancer Campaign; Medical Research Institute of the University of Dundee; Grants-in-Aid for Scientific Research [16H02622] Funding Source: KAKEN; Cancer Research UK [13786, 22869] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Tenovus Scotland; Reata Pharmaceuticals; Stony Brook Foundation; Ninewells Cancer Campaign; Medical Research Institute of the University of Dundee; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Cancer Research UK(Cancer Research UK)	We thank Prof Donna D Zhang (University of Arizona) for providing plasmids; Prof Issay Kitabayashi (National Cancer Center Research Institute Tokyo) and Prof Masayuki Yamamoto (Tohoku University) for cell lines; Prof Shyam Biswal (Johns Hopkins University) for sharing their ChIP-seq data; Prof Stephen M Keyse (University of Dundee) for critical reading and insightful comments on the manuscript. We are extremely grateful to the Medical Research Institute of the University of Dundee, Cancer Research UK (C52419/A22869), the Ninewells Cancer Campaign, Tenovus Scotland (grant number T14/62), Reata Pharmaceuticals and Stony Brook Foundation for financial support.	Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Akaike Y, 2015, ONCOGENE, V34, P3463, DOI 10.1038/onc.2014.278; Al-Beiti MAM, 2008, AUST NZ J OBSTET GYN, V48, P329, DOI 10.1111/j.1479-828X.2008.00874.x; Ann EJ, 2016, CANCER RES, V76, P4728, DOI 10.1158/0008-5472.CAN-15-3310; Berber S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19582; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Canet MJ, 2015, DRUG METAB DISPOS, V43, P93, DOI 10.1124/dmd.114.060103; Choi DW, 2013, MOL CELL, V51, P374, DOI 10.1016/j.molcel.2013.06.010; Chorley BN, 2012, NUCLEIC ACIDS RES, V40, P7416, DOI 10.1093/nar/gks409; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; de la Vega L, 2013, NUCLEIC ACIDS RES, V41, P5731, DOI 10.1093/nar/gkt262; de la Vega L, 2012, MOL CELL, V46, P472, DOI 10.1016/j.molcel.2012.03.003; de la Vega L, 2011, BBA-MOL CELL RES, V1813, P283, DOI 10.1016/j.bbamcr.2010.11.022; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Du W, 2013, CANCER LETT, V337, P58, DOI 10.1016/j.canlet.2013.05.016; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Garufi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.163; Giachino C, 2015, CANCER CELL, V28, P730, DOI 10.1016/j.ccell.2015.10.008; Giraud S, 2004, J VIROL, V78, P2984, DOI 10.1128/JVI.78.6.2984-2993.2004; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hailemariam K, 2010, J CELL SCI, V123, P3863, DOI 10.1242/jcs.073627; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Hofmann TG, 2005, J BIOL CHEM, V280, P29224, DOI 10.1074/jbc.M503921200; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Honda T, 2011, J MED CHEM, V54, P1762, DOI 10.1021/jm101445p; Iacovelli S, 2009, CELL PROLIFERAT, V42, P373, DOI 10.1111/j.1365-2184.2009.00601.x; Imberg-Kazdan K, 2013, GENOME RES, V23, P581, DOI 10.1101/gr.144774.112; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin YM, 2012, NAT MED, V18, P580, DOI 10.1038/nm.2685; Kalra S, 2012, CANCER PREV RES, V5, P973, DOI 10.1158/1940-6207.CAPR-12-0041; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Kelleher MO, 2009, CARCINOGENESIS, V30, P1754, DOI 10.1093/carcin/bgp182; Kelly VP, 2000, CANCER RES, V60, P957; Kemmerer ZA, 2015, TOXICOL LETT, V238, P83, DOI 10.1016/j.toxlet.2015.07.004; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Lapin V, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.45; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee OH, 2007, J BIOL CHEM, V282, P36412, DOI 10.1074/jbc.M706517200; Li QK, 2011, J HUM GENET, V56, P230, DOI 10.1038/jhg.2010.172; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Munoz IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109752; Naidu SD, 2016, MOL CELL BIOL, V36, P2403, DOI 10.1128/MCB.00292-16; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Pi JB, 2007, FREE RADICAL BIO MED, V42, P1797, DOI 10.1016/j.freeradbiomed.2007.03.001; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Puca R, 2010, FREE RADICAL BIO MED, V48, P1338, DOI 10.1016/j.freeradbiomed.2010.02.015; Rada P, 2012, MOL CELL BIOL, V32, P3486, DOI 10.1128/MCB.00180-12; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P2498, DOI 10.1089/ars.2014.5843; Sasaki H, 2013, INT J MOL MED, V31, P1135, DOI 10.3892/ijmm.2013.1324; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Schulten HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153681; Shang YL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001527; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Sjolund J, 2014, P NATL ACAD SCI USA, V111, P7373, DOI 10.1073/pnas.1322275111; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743	74	49	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6204	6212		10.1038/onc.2017.221	http://dx.doi.org/10.1038/onc.2017.221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692050	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000414249800013
J	Zimmermannova, O; Doktorova, E; Stuchly, J; Kanderova, V; Kuzilkova, D; Strnad, H; Starkova, J; Alberich-Jorda, M; Falkenburg, JHF; Trka, J; Petrak, J; Zuna, J; Zaliova, M				Zimmermannova, O.; Doktorova, E.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Strnad, H.; Starkova, J.; Alberich-Jorda, M.; Falkenburg, J. H. F.; Trka, J.; Petrak, J.; Zuna, J.; Zaliova, M.			An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; TEL-ABL; CYTOGENETIC CHARACTERIZATION; IMATINIB-MESYLATE; FUSION PROTEINS; BLAST CRISIS; REARRANGEMENT; PATIENT	Leukemias harboring the ETV6-ABL1 fusion represent a rare subset of hematological malignancies with unfavorable outcomes. The constitutively active chimeric Etv6-Abl1 tyrosine kinase can be specifically inhibited by tyrosine kinase inhibitors (TKIs). Although TKIs represent an important therapeutic tool, so far, the mechanism underlying the potential TKI resistance in ETV6-ABL1-positive malignancies has not been studied in detail. To address this issue, we established a TKI-resistant ETV6-ABL1-positive leukemic cell line through long-term exposure to imatinib. ETV6-ABL1-dependent mechanisms (including fusion gene/protein mutation, amplification, enhanced expression or phosphorylation) and increased TKI efflux were excluded as potential causes of resistance. We showed that TKI effectively inhibited the Etv6-Abl1 kinase activity in resistant cells, and using short hairpin RNA (shRNA)-mediated silencing, we confirmed that the resistant cells became independent from the ETV6-ABL1 oncogene. Through analysis of the genomic and proteomic profiles of resistant cells, we identified an acquired mutation in the GNB1 gene, K89M, as the most likely cause of the resistance. We showed that cells harboring mutated GNB1 were capable of restoring signaling through the phosphoinositide-3-kinase (PI3K)/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, whose activation is inhibited by TKI. This alternative GNB1(K89M)-mediated pro-survival signaling rendered ETV6-ABL1-positive leukemic cells resistant to TKI therapy. The mechanism of TKI resistance is independent of the targeted chimeric kinase and thus is potentially relevant not only to ETV6-ABL1-positive leukemias but also to a wider spectrum of malignancies treated by kinase inhibitors.	[Zimmermannova, O.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Starkova, J.; Alberich-Jorda, M.; Trka, J.; Zuna, J.; Zaliova, M.] CLIP Childhood Leukaemia Invest, Prague, Czech Republic; [Zimmermannova, O.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Starkova, J.; Trka, J.; Zuna, J.; Zaliova, M.] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Doktorova, E.; Petrak, J.] Charles Univ Prague, BIOCEV, Fac Med 1, Vestec, Czech Republic; [Strnad, H.] Czech Acad Sci, Dept Genom & Bioinformat, Inst Mol Genet, Prague, Czech Republic; [Alberich-Jorda, M.] Czech Acad Sci, Lab Mol Hematooncol, Inst Mol Genet, Prague, Czech Republic; [Falkenburg, J. H. F.] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands; [Trka, J.; Zuna, J.; Zaliova, M.] Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic	Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Motol University Hospital	Zaliova, M (corresponding author), Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.; Zaliova, M (corresponding author), Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CLIP, V Uvalu 84, Prague 15006, Czech Republic.	marketa.zaliova@lfmotol.cuni.cz	Jorda, Meritxell Alberich/G-3137-2014; Trka, Jan/Y-4820-2019; Stuchly, jan/B-7608-2019; Petrak, Jiri/I-8950-2017; Zuna, Jan/ABA-4620-2021	Jorda, Meritxell Alberich/0000-0002-8093-641X; Stuchly, jan/0000-0003-1896-9533; Petrak, Jiri/0000-0002-8695-4803; Kanderova, Veronika/0000-0001-8513-1066; Kuzilkova, Daniela/0000-0001-8086-9790; Starkova, Julia/0000-0002-2269-5849; Zuna, Jan/0000-0002-0887-3709	Czech Ministry of Health [IGA MZ NT/13170-4]; Grant Agency of Charles University [GAUK 596912]; Czech Science Foundation [P302/12/G101, P304/12/2214]; NPU I [LO1604]; NPU II [LQ1604]; University Hospital Motol [00064203]; ERDF [CZ.1.05/1.1.00/02.0109 BIOCEV]; Ministry of Education, Youth and Sports of the Czech Republic [PRVOUK P24/LF1/3, SVV 260 374/2017]; Charles University [Primus/MED/28]	Czech Ministry of Health(Ministry of Health, Czech Republic); Grant Agency of Charles University; Czech Science Foundation(Grant Agency of the Czech Republic); NPU I; NPU II; University Hospital Motol; ERDF(European Commission); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Charles University	This study was supported by grants from the Czech Ministry of Health (IGA MZ NT/13170-4), the Grant Agency of Charles University (GAUK 596912), the Czech Science Foundation (no. P302/12/G101 and P304/12/2214), by NPU I (no. LO1604) and NPU II (no. LQ1604) and by the project for the conceptual development of research organization (00064203, University Hospital Motol). The authors also acknowledge the support from ERDF (CZ.1.05/1.1.00/02.0109 BIOCEV), from the Ministry of Education, Youth and Sports of the Czech Republic (PRVOUK P24/LF1/3 and SVV 260 374/2017) and from Charles University (Primus/MED/28).	Asari K, 2016, ANN M ABSTR BLOOD, V128, P3957; Baeumler J, 2008, CANCER GENET CYTOGEN, V185, P37, DOI 10.1016/j.cancergencyto.2008.05.001; Barbouti A, 2003, BRIT J HAEMATOL, V122, P85, DOI 10.1046/j.1365-2141.2003.04391.x; Bernt KM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00054; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Eide CA, 2015, CURR HEMATOL MALIG R, V10, P158, DOI 10.1007/s11899-015-0248-3; Gambacorti-Passerini C, 2016, AM J HEMATOL, V91, P67, DOI 10.1002/ajh.24247; Gancheva K, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-39; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; Jones D, 2008, CANCER-AM CANCER SOC, V113, P985, DOI 10.1002/cncr.23666; Kawamata N, 2008, GENE CHROMOSOME CANC, V47, P919, DOI 10.1002/gcc.20593; Kelly JC, 2009, CANCER GENET CYTOGEN, V192, P36, DOI 10.1016/j.cancergencyto.2009.02.012; Kotrova M, 2016, BLOOD, V128, P2263, DOI 10.1182/blood-2016-07-725861; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390; Malone A, 2010, BRIT J HAEMATOL, V151, P101, DOI 10.1111/j.1365-2141.2010.08323.x; Mozziconacci MJ, 2007, AM J HEMATOL, V82, P688, DOI 10.1002/ajh.20873; Nand R, 2009, LEUKEMIA RES, V33, P1144, DOI 10.1016/j.leukres.2009.03.011; O'Brien SG, 2002, BLOOD, V99, P3465, DOI 10.1182/blood.V99.9.3465; Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Okuda K, 1996, ONCOGENE, V13, P1147; Perna F, 2011, HAEMATOL-HEMATOL J, V96, P342, DOI 10.3324/haematol.2010.036673; Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012; Pospisilova J, 2013, INT J MOL MED, V31, P1273, DOI 10.3892/ijmm.2013.1302; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Tirado CA, 2005, CANCER GENET CYTOGEN, V157, P74, DOI 10.1016/j.cancergencyto.2004.06.001; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Yamamoto K, 2014, ANN HEMATOL, V93, P1435, DOI 10.1007/s00277-013-1975-y; Yeung DT, 2015, LEUKEMIA, V29, P230, DOI 10.1038/leu.2014.256; Yoda A, 2015, NAT MED, V21, P71, DOI 10.1038/nm.3751; Zaliova M, 2016, HAEMATOLOGICA, V101, P1082, DOI 10.3324/haematol.2016.144345; Zuna J, 2010, GENE CHROMOSOME CANC, V49, P873, DOI 10.1002/gcc.20796	35	12	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5985	5994		10.1038/onc.2017.210	http://dx.doi.org/10.1038/onc.2017.210			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650474	Green Published, hybrid			2022-12-28	WOS:000413841400007
J	Tian, R; Wang, J; Yan, H; Wu, J; Xu, Q; Zhan, X; Gui, Z; Ding, M; He, J				Tian, R.; Wang, J.; Yan, H.; Wu, J.; Xu, Q.; Zhan, X.; Gui, Z.; Ding, M.; He, J.			Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis	ONCOGENE			English	Article							MICRORNA-21 EXPRESSION; MIR-125B INHIBITOR; BRAIN-TUMORS; GLIOMA; INVASION; TEMOZOLOMIDE; METAANALYSIS; BIOMARKERS; APOPTOSIS; MIR-16-1	The function of miR16 in multiforme glioblastoma multiforme (GBM) and its stem cells (GSCs) remains elusive. To this end, we investigated the patterns of miR16 expression in these cells and their correlation with malignant behaviors and clinical outcomes. The levels of miR16 and its targeted genes in tumor tissue of GBM and GBM SGH44, U87, U251 cells as well as their stem cell counterparts were measured by qRT-PCR or western blot or immunohistochemistry. Luciferase reporter assay was used to confirm the binding of miR16 to 3'-UTR of its target genes. The effects of miR16 on malignant behaviors were investigated, including tumor cell viability, soft-agar colony formation, GSCs Matrigel colony forming and migration and invasion as well as nude mice xenograft model. Differentially expression patterns of miR16 in glioblastoma cells and GSCs cells were found in this study. Changes of miR16 targeted genes, Bcl2 (B cell lymphoma 2), CDK6 (Cyclin-dependent kinase 6), CCND1 (cyclin D1), CCNE1 (cyclin E1) and SOX5 were confirmed in glioblastoma cell lines and tissue specimens. In vitro and in vivo studies showed that tumor cell proliferation was inhibited by miR16 mimic, but enhanced by miR16 inhibitor. The expression level of miR16 positively correlates with GSCs differentiation, but negatively with the abilities of migration, motility, invasion and colony formation in glioblastoma cells. The inhibitory effects of miR16 on its target genes were also found in nude mice xenograft model. Our findings revealed that the miR16 functions as a tumor suppressor in GSCs and its association with prognosis in GBM.	Anhui Med Univ, Anhui Prov Hosp Affiliated, Dept Pathol, Hefei, Anhui, Peoples R China; [He, J.] Anhui Prov Canc Hosp, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China	Anhui Medical University	He, J (corresponding author), Anhui Prov Canc Hosp, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China.; He, J (corresponding author), Anhui Med Univ, Anhui Prov Hosp Affiliated, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China.	hejie2005g@sina.com			National Natural Science of China [81272800, 81072057, 8152323]	National Natural Science of China(National Natural Science Foundation of China (NSFC))	This study was sponsored by National Natural Science of China (Grant Nos. 81272800, 81072057 and 8152323).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Areeb Z, 2015, J NEURO-ONCOL, V125, P237, DOI 10.1007/s11060-015-1912-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blakaj A, 2008, J BIOL CHEM, V283, P9505, DOI 10.1074/jbc.R800002200; Boije M, 2012, CANCER RES S8, V72, P3343; Brower JV, 2014, NEUROCHEM INT, V77, P68, DOI 10.1016/j.neuint.2014.06.002; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chen J, 2014, TUMOR BIOL, V35, P6293, DOI 10.1007/s13277-014-1821-4; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; He XY, 2016, MOL NEUROBIOL, V53, P1856, DOI 10.1007/s12035-015-9140-3; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Li C, 2016, J NEURO-ONCOL, V130, P11, DOI 10.1007/s11060-016-2233-7; Li XD, 2013, ANAT REC, V296, P427, DOI 10.1002/ar.22626; Li XX, 2016, MOL NEUROBIOL, V53, P577, DOI 10.1007/s12035-014-9017-x; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Najbauer J, 2014, PATHOL ONCOL RES, V20, P789, DOI 10.1007/s12253-014-9837-z; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Ouyang Q, 2016, INT J NEUROSCI, V126, P1, DOI 10.3109/00207454.2015.1017881; Pavon LF, 2016, ONCOTARGET, V7, P40546, DOI 10.18632/oncotarget.9658; Rinkenbaugh AL, 2016, ONCOTARGET, V7, P69173, DOI 10.18632/oncotarget.12507; Santhi WS, 2013, ORAL ONCOL, V49, P567, DOI 10.1016/j.oraloncology.2013.01.001; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shan ZN, 2016, ONCOTARGET, V7, P78813, DOI 10.18632/oncotarget.12385; Shi L, 2014, BIODRUGS, V28, P41, DOI 10.1007/s40259-013-0053-2; Shi L, 2012, NEUROMOL MED, V14, P303, DOI 10.1007/s12017-012-8188-8; Shi L, 2012, INT J ONCOL, V40, P119, DOI 10.3892/ijo.2011.1179; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Tchougounova E, 2009, ONCOGENE, V28, P1537, DOI 10.1038/onc.2009.9; Wang Q, 2014, MOL MED REP, V10, P3310, DOI 10.3892/mmr.2014.2583; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Yang TQ, 2014, CANCER SCI, V105, P265, DOI 10.1111/cas.12351; Yue JM, 2010, MAMM GENOME, V21, P88, DOI 10.1007/s00335-009-9240-3; Zhi F, 2010, EUR J CANCER, V46, P1640, DOI 10.1016/j.ejca.2010.02.003	39	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5861	5873		10.1038/onc.2017.182	http://dx.doi.org/10.1038/onc.2017.182			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628119	hybrid, Green Published			2022-12-28	WOS:000413292900008
J	Mu, P; Akashi, T; Lu, F; Kishida, S; Kadomatsu, K				Mu, P.; Akashi, T.; Lu, F.; Kishida, S.; Kadomatsu, K.			A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-kappa B degradation and cell growth suppression in neuroblastoma	ONCOGENE			English	Article							II-DEPENDENT TRANSCRIPTION; PANCREATIC-CANCER CELLS; WASH COMPLEX; PROMOTES NEUROBLASTOMA; DOWN-REGULATION; LAEVIS OOCYTES; GENE; EXPRESSION; UBIQUITINATION; IDENTIFICATION	Downregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin. However, the roles of nuclear DRR1 remain largely unexplored. Here, we identified an interaction between filamentous actin (F-actin) and DRR1 in the nucleus, and demonstrated that copper metabolism MURR1 domain-containing 1 (COMMD1) is another binding partner of DRR1. Accordingly, DRR1, F-actin and COMMD1 were shown to form a complex in the nucleus, and the stability of COMMD1 was enhanced in this complex. Increased nuclear COMMD1 in turn promoted the degradation of NF-kappa B. In addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells. The binding between DRR1 and F-actin in the nucleus was required for these events. Consistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model. This study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-kappa B degradation and cell cycle suppression in neuroblastoma cells.	[Mu, P.; Lu, F.; Kishida, S.; Kadomatsu, K.] Nagoya Univ, Grad Sch Med, Dept Biochem, Nagoya, Aichi, Japan; [Akashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Omics Anal, Nagoya, Aichi, Japan; [Lu, F.] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin, Peoples R China; [Lu, F.] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China	Nagoya University; Nagoya University; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Kadomatsu, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	kkadoma@med.nagoya-u.ac.jp	Kadomatsu, Kenji/G-8083-2012		Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST) [16010731701]; Japan Agency for Medical Research and Development (AMED) [16ck0106011h0503]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22890080]	Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Bernd Knoll for the Flag-NLS-WT-actin, Flag-NLS-S14C-actin and Flag-NLS-R62D-actin constructs. This work was supported in part by a Grants-in-Aid (16010731701) from Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST) to K. Kadomatsu, a Grants-in-Aid (16ck0106011h0503) from Japan Agency for Medical Research and Development (AMED) (Tailor-made Medical Treatment Program) to K. Kadomatsu, and a Grant-in-Aid (22890080) from Ministry of Education, Culture, Sports, Science and Technology (MEXT) to P. Mu.	Almuzzaini B, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0147-z; Asano Y, 2010, BIOCHEM BIOPH RES CO, V394, P829, DOI 10.1016/j.bbrc.2010.03.085; Baarlink C, 2013, SCIENCE, V340, P864, DOI 10.1126/science.1235038; Belin BJ, 2013, MOL BIOL CELL, V24, P982, DOI 10.1091/mbc.E12-09-0685; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLARK TG, 1979, CELL, V18, P1101, DOI 10.1016/0092-8674(79)90223-X; Deng ZH, 2015, J CELL SCI, V128, P373, DOI 10.1242/jcs.161513; Dudley A, 2014, ONCOGENE, V33, P4952, DOI 10.1038/onc.2013.436; Fedoseienko A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165385; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Gomez TS, 2009, DEV CELL, V17, P699, DOI 10.1016/j.devcel.2009.09.009; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Harbour ME, 2012, BIOCHEM J, V442, P209, DOI 10.1042/BJ20111761; Huang J, 2012, HISTOCHEM CELL BIOL, V138, P41, DOI 10.1007/s00418-012-0932-5; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Huang Y, 2008, J BIOL CHEM, V283, P11453, DOI 10.1074/jbc.M708544200; Kishida S, 2013, CANCER RES, V73, P1318, DOI 10.1158/0008-5472.CAN-12-3070; Kokai E, 2014, HISTOCHEM CELL BIOL, V141, P123, DOI 10.1007/s00418-013-1151-4; Le PU, 2010, ONCOGENE, V29, P4636, DOI 10.1038/onc.2010.216; LE PU, 2010, ELIFE, V29, P4636, DOI DOI 10.1038/ONC.2010.216; Li HY, 2014, GASTROENTEROLOGY, V147, P184, DOI 10.1053/j.gastro.2014.04.007; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu Q, 2009, ONCOL REP, V22, P1069, DOI 10.3892/or_00000538; Lu FJ, 2016, ONCOL RES, V24, P171, DOI 10.3727/096504016X14634208142987; Lu FJ, 2015, CANCER SCI, V106, P390, DOI 10.1111/cas.12628; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Masana M, 2014, PSYCHONEUROENDOCRINO, V48, P98, DOI 10.1016/j.psyneuen.2014.06.009; Miyamoto K, 2013, SCIENCE, V341, P1002, DOI 10.1126/science.1240376; Miyamoto K, 2011, GENE DEV, V25, P946, DOI 10.1101/gad.615211; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mu P, 2009, INT J CANCER, V125, P2978, DOI 10.1002/ijc.24382; Muller PAJ, 2009, TRAFFIC, V10, P514, DOI 10.1111/j.1600-0854.2009.00892.x; O'Hara A, 2014, J CELL SCI, V127, P3659, DOI 10.1242/jcs.149328; Obrdlik A, 2011, NUCLEUS-PHILA, V2, P72, DOI 10.4161/nucl.2.1.14508; Pastuszak-Lewandoska D, 2015, ADV EXP MED BIOL, V852, P39, DOI 10.1007/5584_2014_109; Phillips-Krawczak CA, 2015, MOL BIOL CELL, V26, P91, DOI 10.1091/mbc.E14-06-1073; Plessner M, 2015, J BIOL CHEM, V290, P11209, DOI 10.1074/jbc.M114.627166; Pollen AA, 2015, CELL, V163, P55, DOI 10.1016/j.cell.2015.09.004; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sato M, 2013, ONCOL RES, V21, P333, DOI 10.3727/096504014X14024160459249; Schmidt MV, 2011, P NATL ACAD SCI USA, V108, P17213, DOI 10.1073/pnas.1103318108; Takahashi Y, 2013, SCIENCE, V341, P860, DOI 10.1126/science.1230717; Udali S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0077-1; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; van de Sluis B, 2007, MOL CELL BIOL, V27, P4142, DOI 10.1128/MCB.01932-06; van de Sluis B, 2010, J CLIN INVEST, V120, P2119, DOI 10.1172/JCI40583; van den Boom J, 2006, INT J CANCER, V119, P2330, DOI 10.1002/ijc.22108; Vonk WIM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029183; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wu XY, 2006, NAT CELL BIOL, V8, P756, DOI 10.1038/ncb1433; Xia PY, 2014, J EXP MED, V211, P2119, DOI 10.1084/jem.20140169; Yamazaki S, 2016, HISTOCHEM CELL BIOL, V145, P389, DOI 10.1007/s00418-016-1416-9; Yeh DW, 2016, CELL DEATH DIFFER, V23, P841, DOI 10.1038/cdd.2015.147; Yoo YD, 2007, J BIOL CHEM, V282, P7616, DOI 10.1074/jbc.M607596200; Zhao XY, 2007, BIOCHEM BIOPH RES CO, V361, P74, DOI 10.1016/j.bbrc.2007.06.158	57	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5745	5756		10.1038/onc.2017.181	http://dx.doi.org/10.1038/onc.2017.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604741				2022-12-28	WOS:000412843900008
J	Xiang, Z; Zhou, ZJ; Xia, GK; Zhang, XH; Wei, ZW; Zhu, JT; Yu, J; Chen, W; He, Y; Schwarz, RE; Brekken, RA; Awasthi, N; Zhang, CH				Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; He, Y.; Schwarz, R. E.; Brekken, R. A.; Awasthi, N.; Zhang, C-H			A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR 4 AXIS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CELL-MIGRATION; TUMOR HETEROGENEITY; COLORECTAL-CANCER; UP-REGULATION; EXPRESSION; INVASION	The molecular mechanism underlying gastric cancer (GC) invasion and metastasis is still poorly understood. In this study, we tried to investigate the roles of CXCR4 and CXCR2 signalings in gastric cancer metastasis. A highly invasive gastric cancer cell model was established. Chemokines receptors were profiled to search for the accountable ones. Then the underlying molecular mechanism was investigated using both in vitro and in vivo techniques, and the clinical relevance of CXCR4 and CXCR2 expression was studied in gastric cancer samples. CXCR4 and CXCR2 were highly expressed in a high invasive gastric cancer cell model and in gastric cancer tissues. Overexpression of CXCR4 and CXCR2 was associated with more advanced tumor stage and poorer survival for GC patients. CXCR4 and CXCR2 expression strongly correlated with each other in the way that CXCR2 expression changed accordingly with the activity of CXCR4 signaling and CXCR4 expression also changed in agreement with CXCR2 activity. Further studies demonstrated CXCR4 and CXCR2 can both activated NF-kappa B and STAT3 signaling, while NF-kappa Bp65 can then transcriptionally activate CXCR4 and STAT3 can activate CXCR2 expression. This crosstalk between CXCR4 and CXCR2 contributed to EMT, migration and invasion of gastric cancer. Finally, Co-inhibition of CXCR4 and CXCR2 is more effective in reducing gastric cancer metastasis. Our results demonstrated that CXCR4 and CXCR2 cross-activate each other to promote the metastasis of gastric cancer.	[Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; He, Y.; Zhang, C-H] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Xiang, Z.; Zhou, Z-J; Xia, G-K; Zhang, X-H; Wei, Z-W; Zhu, J-T; Yu, J.; Chen, W.; Zhang, C-H] Sun Yat Sen Univ, Gastr Canc Ctr, Guangzhou, Guangdong, Peoples R China; [He, Y.] Sun Yat Sen Univ, Affiliated Hosp 1, Gastrointestinal Ctr, Guangzhou, Guangdong, Peoples R China; [Schwarz, R. E.; Awasthi, N.] Indiana Univ Sch Med, South Bend, IN USA; [Schwarz, R. E.; Awasthi, N.] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA; [Brekken, R. A.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA; [Brekken, R. A.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Indiana University System; Indiana University South Bend; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, CH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.; Zhang, CH (corresponding author), Sun Yat Sen Univ, Gastr Canc Ctr, Guangzhou, Guangdong, Peoples R China.	zhchangh@mail.sysu.edu.cn	Zhou, Zhijun/AAU-9428-2021	Zhou, Zhijun/0000-0003-2226-2223	National Natural Science Foundation of China [81272643, 81272637]; '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University	We acknowledge the use of NCBI GEO database, such as GSE29272, GSE15459 and GSE62254. This study was supported by the National Natural Science Foundation of China (No. 81272643 and No. 81272637) and '3 & 3' project of The First Affiliated Hospital of Sun Yat-sen University.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; An HM, 2015, EUR J CANCER, V51, P1953, DOI 10.1016/j.ejca.2015.06.125; Becker P.S., 2014, BLOOD, V124, P386, DOI [10.1182, DOI 10.1182/blood.V124.21.386.386]; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Bertran E, 2009, CELL SIGNAL, V21, P1595, DOI 10.1016/j.cellsig.2009.06.006; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Borthakur G, 2014, BLOOD, V124, P950, DOI DOI 10.1182/blood.V124.21.950.950; Cambien B, 2009, BRIT J CANCER, V100, P1755, DOI 10.1038/sj.bjc.6605078; Chen G, 2012, J BIOL CHEM, V287, P12132, DOI 10.1074/jbc.M111.302299; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Feng YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136175; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FIDLER IJ, 1978, CANCER RES, V38, P2651; Fontanella R, 2016, CANCER LETT, V370, P100, DOI 10.1016/j.canlet.2015.10.018; Fujita T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130808; Galsky MD, 2014, CLIN CANCER RES, V20, P3581, DOI 10.1158/1078-0432.CCR-13-2686; Garcia-Irigoyen O, 2015, HEPATOLOGY, V62, P166, DOI 10.1002/hep.27798; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Heinrich EL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-68; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hu JJ, 2011, P NATL ACAD SCI USA, V108, P15984, DOI 10.1073/pnas.1113416108; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Kawada K, 2007, ONCOGENE, V26, P4679, DOI 10.1038/sj.onc.1210267; Ko YS, 2015, BRIT J CANCER, V113, P1186, DOI 10.1038/bjc.2015.273; Li Z, 2014, CYTOKINE, V69, P6, DOI 10.1016/j.cyto.2014.05.004; Liu H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9494; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Manu KA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-107; Maxwell PJ, 2007, ONCOGENE, V26, P7333, DOI 10.1038/sj.onc.1210536; Maxwell PJ, 2014, ONCOTARGET, V5, P4895, DOI 10.18632/oncotarget.2052; Mukherjee S, 2016, ONCOGENE, V35, P4937, DOI 10.1038/onc.2016.26; Murakami T, 2013, INT J CANCER, V132, P276, DOI 10.1002/ijc.27670; Naschberger E, 2008, INT J CANCER, V123, P2120, DOI 10.1002/ijc.23764; Nguyen-Jackson H, 2010, BLOOD, V115, P3354, DOI 10.1182/blood-2009-08-240317; Pozzobon T, 2016, IMMUNOL LETT, V177, P6, DOI 10.1016/j.imlet.2016.06.006; Pradelli E, 2009, INT J CANCER, V125, P2586, DOI 10.1002/ijc.24665; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Saintigny P, 2013, CANCER RES, V73, P571, DOI 10.1158/0008-5472.CAN-12-0263; Sarvaiya PJ, 2013, ONCOTARGET, V4, P2171, DOI 10.18632/oncotarget.1426; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002; Singh AK, 2013, CYTOKINE GROWTH F R, V24, P41, DOI 10.1016/j.cytogfr.2012.08.007; Sobolik T, 2014, MOL BIOL CELL, V25, P566, DOI 10.1091/mbc.E13-07-0360; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tsai TYC, 2008, SCIENCE, V321, P126, DOI 10.1126/science.1156951; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wang HY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0169-y; Wang SM, 2016, GUT, V65, P1427, DOI 10.1136/gutjnl-2014-308932; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei ZW, 2015, CANCER LETT, V359, P335, DOI 10.1016/j.canlet.2015.01.033; Xiang JY, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-1114; Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483; Yang JM, 2004, MOL THER, V9, P846, DOI 10.1016/j.ymthe.2004.01.010; YANG K, 2015, MEDICINE, V94; Yao CJ, 2016, MOL NEUROBIOL, V53, P3948, DOI 10.1007/s12035-015-9340-x; Yasumoto K, 2006, CANCER RES, V66, P2181, DOI 10.1158/0008-5472.CAN-05-3393; Zhou SL, 2015, CANCER LETT, V358, P124, DOI 10.1016/j.canlet.2014.11.044	66	59	61	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5122	5133		10.1038/onc.2017.108	http://dx.doi.org/10.1038/onc.2017.108			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481874				2022-12-28	WOS:000409371100004
J	Chen, XW; Yu, TJ; Zhang, J; Li, Y; Chen, HL; Yang, GF; Yu, W; Liu, YZ; Liu, XX; Duan, CF; Tang, HL; Qiu, M; Wang, CL; Zheng, H; Yue, J; Guo, AM; Yang, J				Chen, X. W.; Yu, T. J.; Zhang, J.; Li, Y.; Chen, H. L.; Yang, G. F.; Yu, W.; Liu, Y. Z.; Liu, X. X.; Duan, C. F.; Tang, H. L.; Qiu, M.; Wang, C. L.; Zheng, H.; Yue, J.; Guo, A. M.; Yang, J.			CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis	ONCOGENE			English	Article							MARROW-DERIVED CELLS; PREMETASTATIC NICHE; CANCER METASTASIS; LUNG METASTASIS; POLARIZATION; RECRUITMENT; GROWTH; ACTIVATION; ENZYMES; MATRIX-METALLOPROTEINASE-9	Tumor-associated macrophages (TAMs) play an essential role in metastasis. However, what enables TAMs to have a superior capacity to establish pre-metastatic microenvironment in distant organs is unclear. Here we have begun to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche formation and metastasis. CYP4A(+) TAM infiltration was positively associated with metastasis, pre-metastatic niche formation and poor prognosis in breast cancer patients. The pharmacological inhibition of CYP4A reduced lung pre-metastatic niche formation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)) myeloid cell recruitment and pro-metastatic protein expression) and metastatic burden, accompanied with TAM polarization away from the M2 phenotype in spontaneous metastasis models of 4T1 breast cancer and B16F10 melanoma. Co-implantation of 4T1 cells with CYP4A10(high) macrophages promoted lung pre-metastatic niche formation and metastasis. Depletion of TAMs disrupted lung pre-metastatic niches and thereby prevented metastasis. Treatment with the CM from CYP4A10(high) M2 macrophages (M2) increased pre-metastatic niche formation and metastatic burden in the lungs, whereas CYP4A inhibition attenuated these effects. In vitro TAM polarization away from the M2 phenotype induced by CYP4A inhibition decreased VEGFR1(+) myeloid cell migration and fibronectin expression, accompanied with downregulation of STAT3 signaling. Conversely, overexpression of CYP4A or exogenous addition of 2'-hydroxyeicosatetraenoic acid promoted M2 polarization and cytokine production of macrophages and thereby enhanced migration of VEGFR1(+) myeloid cells, which were reversed by siRNA or pharmacological inhibition of STAT3. Importantly, a combined blocking M2 macrophage-derived factors TGF-beta, VEGF and SDF-1 abolished VEGFR1(+) myeloid cell migration and fibroblast activation induced by CYP4A. In summary, CYP4A in TAMs is crucial for lung pre-metastatic niche formation and metastasis, and may serve as a potential therapeutic target in human cancer.	[Chen, X. W.; Yu, T. J.; Li, Y.; Liu, Y. Z.; Liu, X. X.; Duan, C. F.; Tang, H. L.; Qiu, M.; Wang, C. L.; Zheng, H.; Yue, J.; Yang, J.] Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Zhang, J.] Wuhan Univ, Anim Expt Ctr, Wuhan, Hubei, Peoples R China; [Chen, H. L.] Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Wuhan, Hubei, Peoples R China; [Yang, G. F.] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China; [Yu, W.] China Three Gorges Univ, Dept Oncol, Coll Clin Med 1, Yichang, Peoples R China; [Guo, A. M.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Wuhan University; Wuhan University; Wuhan University; Wuhan University; China Three Gorges University; New York Medical College	Yang, J (corresponding author), Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	yangjingliu2013@163.com		yang, jing/0000-0003-2733-8629	National Natural Science Foundation of China [30973552, 81272464, 81173089, 81402958, 81201261]; Fundamental Research Funds for the Central Universities [2014301020201]; Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment [PJS140011508]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment	This work was supported by the National Natural Science Foundation of China (grant nos 30973552, 81272464, 81173089 (to JY), 81402958 (to WY) and 81201261 (to JZ)), the Fundamental Research Funds for the Central Universities (grant no. 2014301020201) (to XC) and Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment (PJS140011508) (to CW).	Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Alexanian A, 2013, ONCOTARGETS THER, V6, P243, DOI 10.2147/OTT.S31586; Alexanian A, 2012, CANCER GENOM PROTEOM, V9, P163; Borin TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116247; Chen PW, 2013, INT REV CEL MOL BIO, V301, P1, DOI 10.1016/B978-0-12-407704-1.00001-4; Chen YK, 2015, ONCOTARGET, V6, P32575, DOI 10.18632/oncotarget.5331; Cirri P, 2011, AM J CANCER RES, V1, P482; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dayer C, 2015, J BIOL CHEM, V290, P13763, DOI 10.1074/jbc.M114.622274; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Ding L, 2015, ONCOTARGET, V6, P36441, DOI 10.18632/oncotarget.5541; Edson KZ, 2013, CURR TOP MED CHEM, V13, P1429; Fang WY, 2014, CARCINOGENESIS, V35, P1780, DOI 10.1093/carcin/bgu060; Gil-Bernabe AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426; Giles AJ, 2016, CANCER RES, V76, P1335, DOI 10.1158/0008-5472.CAN-15-0204; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jia XM, 2014, BREAST CANCER RES TR, V148, P291, DOI 10.1007/s10549-014-3164-7; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kroetz DL, 2005, ANNU REV PHARMACOL, V45, P413, DOI 10.1146/annurev.pharmtox.45.120403.100045; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Pal SK, 2015, MOL CANCER THER, V14, P2896, DOI 10.1158/1535-7163.MCT-15-0367; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Sun QZ, 2016, CELL SIGNAL, V28, P307, DOI 10.1016/j.cellsig.2016.01.004; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wei J, 2015, J SURG RES, V197, P126, DOI 10.1016/j.jss.2015.03.023; Wu CF, 2015, INT J CANCER, V137, P837, DOI 10.1002/ijc.29444; Yu W, 2011, CANCER CHEMOTH PHARM, V68, P619, DOI 10.1007/s00280-010-1521-8; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904; Zhao HX, 2014, TOXICOL APPL PHARM, V279, P311, DOI 10.1016/j.taap.2014.07.001; Zheng H, 2014, TOXICOL APPL PHARM, V280, P10, DOI 10.1016/j.taap.2014.07.018	39	77	80	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5045	5057		10.1038/onc.2017.118	http://dx.doi.org/10.1038/onc.2017.118			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28481877	hybrid, Green Published			2022-12-28	WOS:000408768800009
J	Hendrick, E; Peixoto, P; Blomme, A; Polese, C; Matheus, N; Cimino, J; Frere, A; Mouithys-Mickalad, A; Serteyn, D; Bettendorff, L; Elmoualij, B; De Tullio, P; Eppe, G; Dequiedt, F; Castronovo, V; Mottet, D				Hendrick, E.; Peixoto, P.; Blomme, A.; Polese, C.; Matheus, N.; Cimino, J.; Frere, A.; Mouithys-Mickalad, A.; Serteyn, D.; Bettendorff, L.; Elmoualij, B.; De Tullio, P.; Eppe, G.; Dequiedt, F.; Castronovo, V.; Mottet, D.			Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; HUMAN CANCER-CELLS; ALZHEIMERS-DISEASE; IRON; PROLIFERATION; CHEMOTHERAPY; EXPRESSION; CISPLATIN; AUTOPHAGY; ANGIOGENESIS	The US FDA approval of broad-spectrum histone deacetylase (HDAC) inhibitors has firmly laid the cancer community to explore HDAC inhibition as a therapeutic approach for cancer treatment. Hitting one HDAC member could yield clinical benefit but this required a complete understanding of the functions of the different HDAC members. Here we explored the consequences of specific HDAC5 inhibition in cancer cells. We demonstrated that HDAC5 inhibition induces an iron-dependent reactive oxygen species (ROS) production, ultimately leading to apoptotic cell death as well as mechanisms of mitochondria quality control (mitophagy and mitobiogenesis). Interestingly, adaptation of HDAC5-depleted cells to oxidative stress passes through reprogramming of metabolic pathways towards glucose and glutamine. Therefore, interference with both glucose and glutamine supply in HDAC5-inhibited cancer cells significantly increases apoptotic cell death and reduces tumour growth in vivo; providing insight into a valuable clinical strategy combining the selective inhibition of HDAC5 with various inhibitors of metabolism as a new therapy to kill cancer cells.	[Hendrick, E.; Polese, C.; Matheus, N.; Frere, A.; Dequiedt, F.; Mottet, D.] Univ Liege, GIGA Mol Biol Dis, Prot Signalisat & Interact PSI Lab, Liege, Belgium; [Peixoto, P.; Blomme, A.; Castronovo, V.] Univ Liege, GIGA Canc, MRL, Liege, Belgium; [Cimino, J.] Univ Liege, Lab Tumor & Dev Biol LBTD, GIGA Canc, Liege, Belgium; [Frere, A.] Univ Liege, Lab Pharmaceut Technol & Biopharm LTPB, CIRM, Liege, Belgium; [Mouithys-Mickalad, A.; Serteyn, D.] Univ Liege, CORD, Inst Chem, Liege, Belgium; [Bettendorff, L.] Univ Liege, Lab Pathol Aging & Epilepsy, GIGA Signal Neurosci, Liege, Belgium; [Elmoualij, B.] Univ Liege, Dept Human Histol CRPP, Liege, Belgium; [De Tullio, P.] Univ Liege, Med Chem Dept, Drug Res Ctr, CIRM, Liege, Belgium; [Eppe, G.] Univ Liege, Chem Dept, CART LSM, Inorgan Analyt Chem, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Mottet, D (corresponding author), Univ Liege, Prot Signalisat & Interact Lab, GIGA, GIGA Bldg,B34,2, B-4000 Liege, Belgium.	dmottet@ulg.ac.be	Blomme, Arnaud/AGO-7915-2022; De Tullio, Pascal/ABE-5585-2021; Blomme, Arnaud/AAM-1440-2020	Blomme, Arnaud/0000-0003-4183-8726; Eppe, Gauthier/0000-0002-4821-3115; Dequiedt, Franck/0000-0003-1234-7477; Peixoto, Paul/0000-0001-6302-7823	National Fund for Scientific Research (FNRS) (Belgium); TELEVIE; Centre Anti-Cancereux; Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege	National Fund for Scientific Research (FNRS) (Belgium)(Fonds de la Recherche Scientifique - FNRS); TELEVIE; Centre Anti-Cancereux; Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege	The authors thank the GIGA 'Cell Imaging and Flow Cytometry', the GIGA 'Transciptomic ' as well as the GIGA 'Animal' core facility for technical assistance. This work was supported by grants from the National Fund for Scientific Research (FNRS) (Belgium), TELEVIE, the Centre Anti-Cancereux, Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege. PP and JC are FNRS-TELEVIE Post Doc. DM is a Research Associate. P DT is Senior Research Associate and LB is Research Director at the National Fund for Scientific Research (FNRS). CP, EH and AB are FNRS-TELEVIE fellows. NM is FRIA fellow.	Agis-Balboa RC, 2013, J ALZHEIMERS DIS, V33, P35, DOI 10.3233/JAD-2012-121009; Ahrens TD, 2016, LAB INVEST, V96, P307, DOI 10.1038/labinvest.2015.148; Allen EL, 2016, CELL REP, V17, P876, DOI 10.1016/j.celrep.2016.09.052; Altamura S, 2009, J ALZHEIMERS DIS, V16, P879, DOI 10.3233/JAD-2009-1010; Arriaga JM, 2014, MOL CANCER THER, V13, P1369, DOI 10.1158/1535-7163.MCT-13-0944; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Buranrat B, 2015, ONCOL REP, V34, P2790, DOI 10.3892/or.2015.4250; Ceusters JD, 2013, MITOCHONDRION, V13, P410, DOI 10.1016/j.mito.2012.12.004; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chekhun VF, 2013, INT J ONCOL, V43, P1481, DOI 10.3892/ijo.2013.2063; Cheng T, 2015, DRUG TODAY, V51, P491, DOI 10.1358/dot.2015.51.8.2362311; Deby-Dupont G, 2005, BIOCHEM BIOPH RES CO, V333, P21, DOI 10.1016/j.bbrc.2005.05.073; Di Domenico F, 2015, EXPERT REV NEUROTHER, V15, P19, DOI 10.1586/14737175.2015.955853; Fan J, 2014, TUMOR BIOL, V35, P11523, DOI 10.1007/s13277-014-2358-2; Gammoh N, 2012, AUTOPHAGY, V8, P1521, DOI 10.4161/auto.21151; Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616; Gaude E, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-10; Grunblatt E, 2011, J NEURAL TRANSM, V118, P371, DOI 10.1007/s00702-010-0426-3; Harris IS, 2015, NATURE, V527, P170, DOI 10.1038/nature15644; He P, 2015, INT J CLIN EXP MED, V8, P6510; Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025; Liu JQ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0753-0; Liu Q, 2014, MOL MED REP, V10, P2045, DOI 10.3892/mmr.2014.2395; Ma PA, 2017, NANO LETT, V17, P928, DOI 10.1021/acs.nanolett.6b04269; Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022; Margalit O, 2012, INT J CANCER, V131, pE562, DOI 10.1002/ijc.26441; McCord MC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00077; McDermott J, 2014, DRUG TODAY, V50, P337, DOI 10.1358/dot.2014.50.5.2138703; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Mottet D, 2008, CLIN EXP METASTAS, V25, P183, DOI 10.1007/s10585-007-9131-5; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004; Patel D, 2016, J BIOL CHEM, V291, P9322, DOI 10.1074/jbc.M115.710145; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Qiu TZ, 2013, FUTURE ONCOL, V9, P255, DOI [10.2217/fon.12.173, 10.2217/FON.12.173]; Rangwala S, 2012, FUTURE MED CHEM, V4, P471, DOI [10.4155/FMC.12.6, 10.4155/fmc.12.6]; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Sag CM, 2014, J MOL CELL CARDIOL, V73, P103, DOI 10.1016/j.yjmcc.2014.02.002; Sawas A, 2015, THER ADV HEMATOL, V6, P202, DOI 10.1177/2040620715592567; Shpyleva SI, 2011, BREAST CANCER RES TR, V126, P63, DOI 10.1007/s10549-010-0849-4; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI 10.2217/FON.11.2; Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Zhang L, 2015, FREE RADICAL BIO MED, V89, P452, DOI 10.1016/j.freeradbiomed.2015.08.030; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zhu X, 2007, CELL MOL LIFE SCI, V64, P2202, DOI 10.1007/s00018-007-7218-4	52	13	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4859	4874		10.1038/onc.2017.103	http://dx.doi.org/10.1038/onc.2017.103			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414307	Green Published			2022-12-28	WOS:000408234400004
J	Yang, J; Liu, K; Yang, J; Jin, B; Chen, H; Zhan, X; Li, Z; Wang, L; Shen, X; Li, M; Yu, W; Mao, Z				Yang, J.; Liu, K.; Yang, J.; Jin, B.; Chen, H.; Zhan, X.; Li, Z.; Wang, L.; Shen, X.; Li, M.; Yu, W.; Mao, Z.			PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; HEMI-METHYLATED DNA; HUMAN-DIPLOID FIBROBLASTS; HISTONE H3 TAIL; STRUCTURAL BASIS; SRA DOMAIN; METHYLTRANSFERASE DNMT1; EPIGENETIC INHERITANCE; TRANSGENIC MICE; PROTEIN UHRF1	PIM1 is a proto-oncogene, encoding a serine/threonine protein kinase that regulates cell proliferation, survival, differentiation and apoptosis. Previous reports suggest that overexpression of PIM1 can induce cellular senescence. However, the molecular mechanism underlying this process is not fully understood. Here we report that UHRF1 is a novel substrate of PIM1 kinase, which could be phosphorylated at Ser311 and therefore promoted to degradation. Our data demonstrates that PIM1 destabilizes UHRF1, leading to DNA hypomethylation, which consequently results in genomic instability, increased p16 expression and subsequent induction of cellular senescence. Taken together, our results suggest that down-regulation of UHRF1 is an important mechanism of PIM1-mediated cellular senescence.	[Yang, J.; Liu, K.; Chen, H.; Zhan, X.; Li, Z.; Wang, L.; Shen, X.; Li, M.; Yu, W.; Mao, Z.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Sch Basic Med Sci, 38 Xueyuan Rd, Beijing 100083, Peoples R China; [Yang, J.] Qingdao Univ, Affiliated Hosp, Dept Cadre Hlth Care, Qingdao, Peoples R China; [Jin, B.] Peking Univ, Dept Clin Lab, Hosp 1, Beijing, Peoples R China	Peking University; Qingdao University; Peking University	Yu, W; Mao, Z (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Sch Basic Med Sci, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	yuwenhua@hsc.pku.edu.cn; zbmao@bjmu.edu.cn		, Jiong/0000-0001-9698-0338	National Basic Research Programs of China [2013CB530801]; Natural Science Foundation of China [81471406, 81541066]; National Natural Science Foundation of China [81471406, 81541066, 81641183]	National Basic Research Programs of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Basic Research Programs of China (Grant number 2013CB530801) and the Natural Science Foundation of China (Grant number 81471406 and Grant number 81541066). This work was supported by the National Basic Research Programs of China (Grant Number 2013CB530801) and the National Natural Science Foundation of China (Grant Number 81471406, 81641183 and 81541066).	Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855; Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Arita K, 2012, P NATL ACAD SCI USA, V109, P12950, DOI 10.1073/pnas.1203701109; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bashtrykov P, 2014, J BIOL CHEM, V289, P4106, DOI 10.1074/jbc.M113.528893; Berkyurek AC, 2014, J BIOL CHEM, V289, P379, DOI 10.1074/jbc.M113.523209; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; BREUER M, 1991, CANCER RES, V51, P958; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JD, 2013, J BIOL CHEM, V288, P1329, DOI 10.1074/jbc.M112.415398; Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; CUYPERS HT, 1984, CELL, V37, P141; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Fang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11197; Fang ZY, 2009, CELL IMMUNOL, V257, P80, DOI 10.1016/j.cellimm.2009.03.001; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Gelato KA, 2014, MOL CELL, V54, P905, DOI 10.1016/j.molcel.2014.04.004; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Harrison JS, 2016, ELIFE, V5, DOI 10.7554/eLife.17101; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109; Hogan C, 2008, J BIOL CHEM, V283, P18012, DOI 10.1074/jbc.M709695200; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hu LL, 2011, CELL RES, V21, P1374, DOI 10.1038/cr.2011.124; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jia YH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.7; Jin B, 2014, AGING CELL, V13, P879, DOI 10.1111/acel.12249; Johansson A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067378; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Liu XL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2562; McClay JL, 2014, HUM MOL GENET, V23, P1175, DOI 10.1093/hmg/ddt511; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Nady N, 2011, J BIOL CHEM, V286, P24300, DOI 10.1074/jbc.M111.234104; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Narlik-Grassow M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060277; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488; O'Sullivan J, 2006, CANCER EPIDEM BIOMAR, V15, P573, DOI 10.1158/1055-9965.EPI-05-0542; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Qin WH, 2011, J CELL BIOCHEM, V112, P439, DOI 10.1002/jcb.22998; Ramesh V, 2016, GENE DEV, V30, P2199, DOI 10.1101/gad.284992.116; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rothbart SB, 2013, GENE DEV, V27, P1288, DOI 10.1101/gad.220467.113; Sadler KC, 2007, P NATL ACAD SCI USA, V104, P1570, DOI 10.1073/pnas.0610774104; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shay KP, 2005, MOL CANCER RES, V3, P170; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Tauber M, 2015, NUCLEUS-PHILA, V6, P123, DOI 10.1080/19491034.2015.1026022; Tittle RK, 2011, DEV BIOL, V350, P50, DOI 10.1016/j.ydbio.2010.11.009; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Tu ZG, 2011, DEV CELL, V21, P1077, DOI 10.1016/j.devcel.2011.10.010; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; von Meyenn F, 2016, MOL CELL, V62, P848, DOI 10.1016/j.molcel.2016.04.025; Wang CK, 2011, CELL RES, V21, P1379, DOI 10.1038/cr.2011.123; Wang Z, 2001, J Vet Sci, V2, P167; Wei S, 1999, CANCER RES, V59, P1539; WELLER EM, 1993, CELL PROLIFERAT, V26, P45, DOI 10.1111/j.1365-2184.1993.tb00005.x; Zemskova M, 2010, MOL CANCER RES, V8, P1126, DOI 10.1158/1541-7786.MCR-10-0174; Zhao JL, 2016, J SENSORS, V2016, DOI 10.1155/2016/3270916; Zhuo DX, 2010, J BIOL CHEM, V285, P31491, DOI 10.1074/jbc.M109.068387	98	26	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4828	4842		10.1038/onc.2017.96	http://dx.doi.org/10.1038/onc.2017.96			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28394343				2022-12-28	WOS:000408234400002
J	Ding, L; Zhang, YQ; Han, LL; Fu, L; Mei, X; Wang, JJ; Itkow, J; Elabid, AEI; Pang, L; Yu, DN				Ding, Lan; Zhang, Yanqing; Han, Lingling; Fu, Lei; Mei, Xia; Wang, Jijun; Itkow, Jacobi; Elabid, Afaf Elabid Ibrahim; Pang, Lei; Yu, Duonan			Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; CELL LYMPHOMAS; MIR-451; CANCER; 14-3-3-ZETA; REPRESSION; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS	Hyper activity of protooncogene c-Myc is one of the hallmarks of highly aggressive lymphomas. However, the mechanism of how c-Myc is subjected to activation and amplification is still not well defined. In this study, we use gene knockout strategy to show that targeted depletion of a well-conserved microRNA gene locus miR-144/451 initiates tumorigenesis including B-lymphoma development in aged mice. This is due, at least in part, to the direct activation of the c-Myc gene by loss of miR-144/451 expression in hematopoietic cells. Moreover, oncoprotein c-Myc inversely regulates miR-144/451 expression by directly binding to the miR-144/451 promoter region, forming a miRNA-Myc positive feedback loop to safeguard the high level of c-Myc in B-lymphocytes. We also demonstrate that this miRNA-Myc crosstalk is disrupted in human diffuse large B-cell lymphomas with aberrant c-Myc expression. Therefore, our findings provide strong evidence, for the first time, that deficiency of miR-144/451 expression may play a bona fide role in derepression of silenced c-Myc, which contributes to tumor development including B-lymphomagenesis.	[Ding, Lan; Fu, Lei; Mei, Xia] Yangzhou Univ, Jiangdu Peoples Hosp, Dept Pathol, Yangzhou, Jiangsu, Peoples R China; [Zhang, Yanqing; Han, Lingling; Wang, Jijun; Itkow, Jacobi; Elabid, Afaf Elabid Ibrahim; Pang, Lei; Yu, Duonan] Yangzhou Univ, Sch Med, Jiangsu Key Lab Expt & Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Yangzhou Univ, Inst Translat Med, Sch Med, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Yangzhou Univ, Inst Comparat Med, Yangzhou, Jiangsu, Peoples R China; [Yu, Duonan] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University; Yangzhou University; Yangzhou University	Yu, DN (corresponding author), Yangzhou Univ, Sch Med, Jiangsu Key Lab Expt & Translat Noncoding RNA Res, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Yangzhou Univ, Inst Translat Med, Sch Med, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Yangzhou Univ, Inst Comparat Med, Yangzhou, Jiangsu, Peoples R China.; Yu, DN (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Jiangsu, Peoples R China.	dnyu@yzu.edu.cn			National Natural Science Foundation of China [81670186, 81470277, 81302041]; Priority Academic Program Development of Jiangsu Higher Education Institution; Natural Science Foundation of Jiangsu Province of China [15KJA320007, BK20130454]; Ministry of Finance of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institution; Natural Science Foundation of Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Ministry of Finance of China	The authors would like to thank Dr. Mitch Weiss (St. Jude Children's Research Hospital), Dr. Andrei Thomas-Tikhonenko (University of Pennsylvania/Children's Hospital of Philadelphia), and their laboratories for the technical supports. We are grateful to Dr. Robert Auerbach (University of Wisconsin-Madison) for YS-PB11 cells and Dr. Kenneth Dorshkind (University of California) for S17 stromal cells. We are also grateful to Yuanjun Yu for language editing. This work is supported by the National Natural Science Foundation of China (Grant No. 81670186 and 81470277, D.Y.; 81302041, Y.Z.), the Priority Academic Program Development of Jiangsu Higher Education Institution (Veterinary Medicine, D.Y.), the Natural Science Foundation of Jiangsu Province of China (15KJA320007, D.Y.; BK20130454, Y.Z.) and grant from the Ministry of Finance of China for "Biology & Medical Science Innovation Team" program (D.Y.).	ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cheng Y, 2009, GENOME RES, V19, P2172, DOI 10.1101/gr.098921.109; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Diez-Roux G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000582; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; Du J, 2015, ONCOTARGET, V6, P14993, DOI 10.18632/oncotarget.3802; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Korac P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040115; Li XY, 2011, J EXP MED, V208, P663, DOI 10.1084/jem.20102384; Li YY, 2015, AM J TRANSL RES, V7, P2775; Lu LS, 1998, J IMMUNOL, V161, P1284; Ott G., 2017, BR J HAEMATOL; Ott G, 2013, BLOOD, V122, P3884, DOI 10.1182/blood-2013-05-498329; Patrick DM, 2010, GENE DEV, V24, P1614, DOI 10.1101/gad.1942810; Perez-Chacon G, 2014, PHARMACOL RES, V89, P46, DOI 10.1016/j.phrs.2014.08.005; Rasmussen KD, 2010, J EXP MED, V207, P1351, DOI 10.1084/jem.20100458; Soltani I, 2017, HEMATOLOGY, V22, P201, DOI 10.1080/10245332.2016.1252020; Su R, 2016, ONCOTARGET, V7, P77430, DOI 10.18632/oncotarget.12679; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; Wang HY, 2016, CANCER IMMUNOL RES, V4, P337, DOI 10.1158/2326-6066.CIR-15-0161; Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642; Wang R, 2014, ONCOTARGET, V5, P6113, DOI 10.18632/oncotarget.2176; Yu D, 2003, BLOOD, V101, P1950, DOI 10.1182/blood-2002-06-1797; Yu DN, 2005, CANCER RES, V65, P5454, DOI 10.1158/0008-5472.CAN-04-4197; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110; Yu LL, 2016, EXP CELL RES, V344, P210, DOI 10.1016/j.yexcr.2016.03.006; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zhang LB, 2011, GENE DEV, V25, P119, DOI 10.1101/gad.1998711; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	40	18	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1293	1307		10.1038/s41388-017-0055-5	http://dx.doi.org/10.1038/s41388-017-0055-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29284789	Green Published, hybrid			2022-12-28	WOS:000427279300003
J	Chhabra, Y; Wong, HY; Nikolajsen, LF; Steinocher, H; Papadopulos, A; Tunny, KA; Meunier, FA; Smith, AG; Kragelund, BB; Brooks, AJ; Waters, MJ				Chhabra, Y.; Wong, H. Y.; Nikolajsen, L. F.; Steinocher, H.; Papadopulos, A.; Tunny, K. A.; Meunier, F. A.; Smith, A. G.; Kragelund, B. B.; Brooks, A. J.; Waters, M. J.			A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation	ONCOGENE			English	Article							SIGNALING PATHWAY; FACTOR-I; EXPRESSION; PROTEIN; PHOSPHORYLATION; MAMMARY; SOCS; IDENTIFICATION; SUPPRESSOR; STAT5	Both humans and mice lacking functional growth hormone (GH) receptors are known to be resistant to cancer. Further, autocrine GH has been reported to act as a cancer promoter. Here we present the first example of a variant of the GH receptor (GHR) associated with cancer promotion, in this case lung cancer. We show that the GHRP495T variant located in the receptor intracellular domain is able to prolong the GH signal in vitro using stably expressing mouse pro-B-cell and human lung cell lines. This is relevant because GH secretion is pulsatile, and extending the signal duration makes it resemble autocrine GH action. Signal duration for the activated GHR is primarily controlled by suppressor of cytokine signalling 2 (SOCS2), the substrate recognition component of the E3 protein ligase responsible for ubiquitinylation and degradation of the GHR. SOCS2 is induced by a GH pulse and we show that SOCS2 binding to the GHR is impaired by a threonine substitution at Pro 495. This results in decreased internalisation and degradation of the receptor evident in TIRF microscopy and by measurement of mature (surface) receptor expression. Mutational analysis showed that the residue at position 495 impairs SOCS2 binding only when a threonine is present, consistent with interference with the adjacent Thr494. The latter is key for SOCS2 binding, together with nearby Tyr487, which must be phosphorylated for SOCS2 binding. We also undertook nuclear magnetic resonance spectroscopy approach for structural comparison of the SOCS2 binding scaffold Ile455-Ser588, and concluded that this single substitution has altered the structure of the SOCS2 binding site. Importantly, we find that lung BEAS-2B cells expressing GHRP495T display increased expression of transcripts associated with tumour proliferation, epithelial-mesenchymal transition and metastases (TWIST1, SNAI2, EGFR, MYC and CCND1) at 2 h after a GH pulse. This is consistent with prolonged GH signalling acting to promote cancer progression in lung cancer.	[Chhabra, Y.; Tunny, K. A.; Brooks, A. J.; Waters, M. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Chhabra, Y.; Tunny, K. A.; Brooks, A. J.] Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld 4102, Australia; [Wong, H. Y.] Univ Queensland, Ctr Clin Res, Herston, Qld, Australia; [Nikolajsen, L. F.; Steinocher, H.; Kragelund, B. B.] Univ Copenhagen, Dept Biol, Struct Biol & NMR Lab SBiNLab, Copenhagen, Denmark; [Papadopulos, A.; Meunier, F. A.] Univ Queensland, Queensland Brain Inst, Clem Jones Ctr Ageing Dementia Res, Brisbane, Qld, Australia; [Smith, A. G.] Queensland Univ Technol, Translat Res Inst, Sch Biomed Sci, Inst Hlth & Biomed Innovat, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland; University of Queensland; University of Copenhagen; University of Queensland; Queensland University of Technology (QUT)	Brooks, AJ (corresponding author), Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld 4102, Australia.	abrooks@uq.edu.au	Chhabra, Yash/C-8801-2018; Brooks, Andrew/A-9969-2011; Meunier, Frederic A/C-8161-2009	Chhabra, Yash/0000-0003-2883-4675; Brooks, Andrew/0000-0002-2691-1668; Meunier, Frederic A/0000-0001-6400-1107; Wong, Ho Yi/0000-0002-1245-4056; Smith, Aaron/0000-0003-2937-1713; Nikolajsen, Louise Fletcher/0000-0002-7573-213X	National Health and Medical Research Council (NHMRC) of Australia [APP1084797, APP1002893, APP1025082]; Lundbeck Foundation; Novo Nordisk Foundation; Australian Research Council [LE0882864, DP170100125]; University of Queensland IPRS scholarship; Novo Nordisk Fonden [NNF15OC0016670, NNF15OC0016076, NNF14OC0010211] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Australian Research Council(Australian Research Council); University of Queensland IPRS scholarship; Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Professor John J Kopchick (Ohio) for ghr-/- mice. We thank Queensland Brain Institute's (QBI) Advanced Microimaging and Analysis Facility for help with TIRF and the Translational Research Institute Microscopy Core Facility for help with imaging. This work was supported by project grants APP1084797, APP1002893 and APP1025082 from the National Health and Medical Research Council (NHMRC) of Australia grants to MJW and AJB, and by the Lundbeck Foundation and the Novo Nordisk Foundation to BBK. FAM is a NHMRC Senior Research Fellow (569596) and supported by Australian Research Council LIEF grant (LE0882864) and Discovery Project Grant (DP170100125). YC is supported by University of Queensland IPRS scholarship. This work is dedicated to Andrew Mitchell.	Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Brooks AJ, 2014, SCIENCE, V344, P710, DOI 10.1126/science.1249783; Bryksin AV, 2010, BIOTECHNIQUES, V48, P463, DOI 10.2144/000113418; Bullock AN, 2007, STRUCTURE, V15, P1493, DOI 10.1016/j.str.2007.09.016; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cao GC, 2008, JPN J CLIN ONCOL, V38, P308, DOI 10.1093/jjco/hyn007; Chhabra Y, 2011, EXPERT REV ENDOCRINO, V6, P71, DOI [10.1586/eem.10.73, 10.1586/EEM.10.73]; Conway-Campbell BL, 2007, P NATL ACAD SCI USA, V104, P13331, DOI 10.1073/pnas.0600181104; Dinkel H, 2016, NUCLEIC ACIDS RES, V44, pD294, DOI 10.1093/nar/gkv1291; Divisova J, 2006, BREAST CANCER RES TR, V98, P315, DOI 10.1007/s10549-006-9168-1; Du L, 2003, ENDOCRINOLOGY, V144, P868, DOI 10.1210/en.2002-220830; Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170; Fujimoto M, 2003, TRENDS IMMUNOL, V24, P659, DOI 10.1016/j.it.2003.10.008; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; Gunnell D, 2001, EPIDEMIOL REV, V23, P313, DOI 10.1093/oxfordjournals.epirev.a000809; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Haxholm GW, 2015, BIOCHEM J, V468, P495, DOI 10.1042/BJ20141243; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huang HL, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0463-x; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; Jaffe CA, 1998, J CLIN INVEST, V102, P153, DOI 10.1172/JCI2908; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Li Y, 2006, ONCOGENE, V25, P1896, DOI 10.1038/sj.onc.1209214; Lin XX, 2014, TOXICOL MECH METHOD, V24, P575, DOI 10.3109/15376516.2014.956909; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; Malaney P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02035; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; Ocaranza P, 2012, J PEDIATR ENDOCR MET, V25, P273, DOI 10.1515/jpem-2011-0491; Papadopulos A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7297; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Plotnikov A, 2008, CANCER RES, V68, P1354, DOI 10.1158/0008-5472.CAN-07-6094; Rudd MF, 2006, GENOME RES, V16, P693, DOI 10.1101/gr.5120106; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; Stajduhar E, 2014, TUMOR BIOL, V35, P6425, DOI 10.1007/s13277-014-1827-y; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Trengove MC, 2013, AM J CLIN EXP IMMUNO, V2, P1; Uyttendaele I, 2007, MOL ENDOCRINOL, V21, P2821, DOI 10.1210/me.2006-0541; Van Dyke AL, 2009, J CANCER EPIDEMIOL, V2009, DOI 10.1155/2009/242151; van Kerkhof P, 2007, J BIOL CHEM, V282, P20475, DOI 10.1074/jbc.M702610200; VANCE ML, 1985, J CLIN INVEST, V75, P1584, DOI 10.1172/JCI111864; Veldhuis JD, 1998, GROWTH HORM IGF RES, V8, P49, DOI 10.1016/S1096-6374(98)80024-5; Vesterlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025358; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Wan Y, 2004, J BIOL CHEM, V279, P44775, DOI 10.1074/jbc.M406092200; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu ZS, 2011, J CLIN ENDOCR METAB, V96, pE1619, DOI 10.1210/jc.2011-1245; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang XXO, 2013, NAT IMMUNOL, V14, P732, DOI 10.1038/ni.2633; Yip PY, 2015, TRANSL LUNG CANCER R, V4, P165, DOI 10.3978/j.issn.2218-6751.2015.01.04; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Yu Y, 2015, CANCER CHEMOTH PHARM, V75, P917, DOI 10.1007/s00280-015-2710-2; Zhang HY, 2003, J BIOMOL NMR, V25, P173, DOI 10.1023/A:1022836027055	67	32	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					489	501		10.1038/onc.2017.352	http://dx.doi.org/10.1038/onc.2017.352			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967904	hybrid, Green Published			2022-12-28	WOS:000423331600007
J	Fu, LN; Wang, YQ; Tan, J; Xu, J; Gao, QY; Chen, YX; Fang, JY				Fu, L-N; Wang, Y-Q; Tan, J.; Xu, J.; Gao, Q-Y; Chen, Y-X; Fang, J-Y			Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms	ONCOGENE			English	Article							HISTONE DEMETHYLATION; RAS-ERK; PROTEIN; DEPRIVATION; GENE; PHOSPHORYLATION; EXPRESSION; STABILITY; PATHWAY; STRESS	Metabolic stress is a common phenomenon in solid tumors. Compensatory mechanisms to overcome metabolic stress (glucose deprivation) are vital to tumor cell survival. The histone demethylase Jumonji domain-containing protein 2B (JMJD2B) is vital for the growth and progression of various cancers. However, the role of JMJD2B during glucose deprivation remains unclear. Our aim was to examine the function of JMJD2B in glucose-deprived colon cancer cells and the involvement of extracellular signal-regulated kinase (ERK) and glucose transporter 1 (GLUT1). Our study demonstrated that JMJD2B expression was upregulated via ERK phosphorylation during glucose deprivation. Further, the cell viability assay showed that the effect of p-ERK on the viability of colon cancer cells was at least partly dependent on JMJD2B expression. Glucose deprivation increased interaction between JMJD2B and p-ERK, as demonstrated by the co-immunoprecipitation and fluorescence assays. Glucose deprivation also resulted in phosphorylation of JMJD2B by p-ERK, as shown by the immunoprecipitation assay and western blotting analysis. In addition, the phosphorylation of JMJD2B via p-ERK at Thr305, Ser352, Ser566 and Thr1065 contribute to JMJD2B stability. p-ERK stabilizes the JMJD2B protein level by protecting JMJD2B from ubiquitination and proteasome degradation. We found that knockdown of JMJD2B significantly impaired colon cancer cell viability, which is accompanied by a significant reduction in glucose uptake and lactate production. Furthermore, knockdown of JMJD2B after glucose deprivation caused decreased level of GLUT1 through increasing H3K9 tri-methylation levels on its promoter, demonstrated by chromatin immunoprecipitation assay. Moreover, targeting JMJD2B in xenograft tumors also decreased the GLUT1 level. Finally, a positive correlation was observed between p-ERK, JMJD2B and GLUT1 expression in 85 human colon cancer tissue specimens. These results indicated that p-ERK-mediated phosphorylation and stabilization of JMJD2B during glucose deprivation contributes to its role in glucose uptake and cell viability, which may be modulated through epigenetically upregulation of GLUT1.	Minist Hlth, State Key Lab Oncogenes & Related Genes, Div Gastroenterol & Hepatol, Key Lab Gastroenterol & Hepatol, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, YX (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes,Minist Hl, Key Lab Gastroenterol & Hepatol,Sch Med,Shanghai, Div Gastroenterol & Hepatol,Renji Hosp,Renji Hosp, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	yingxuanchen71@sjtu.edu.cn			National Key Technology RD Program [2014BAI09B05]; National Natural Science Foundation of China [81572303, 81302085, 81530072]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine [20152210]; Program of Shanghai Academic/Technology Research Leader [15XD1502600]	National Key Technology RD Program(National Key Technology R&D Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine; Program of Shanghai Academic/Technology Research Leader	This project was supported by the National Key Technology R&D Program (No. 2014BAI09B05), the National Natural Science Foundation of China (No. 81572303 to CYX, No. 81302085 to GQY and No. 81530072 to FJY), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20152210) & Program of Shanghai Academic/Technology Research Leader (No. 15XD1502600).	Badeaux AI, 2013, NAT REV MOL CELL BIO, V14, P211, DOI 10.1038/nrm3545; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Calvo MB, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/205357; Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen L, 2014, BRIT J CANCER, V110, P1014, DOI 10.1038/bjc.2013.808; Chen XQ, 2005, J NEUROSCI RES, V79, P798, DOI 10.1002/jnr.20396; Cheng MB, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002026; Ciccarelli R, 2007, MOL PHARMACOL, V71, P1369, DOI 10.1124/mol.106.031617; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Eckert A, 2008, ONCOGENE, V27, P1155, DOI 10.1038/sj.onc.1210732; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Huang C, 2015, ONCOL REP, V33, P875, DOI 10.3892/or.2014.3655; Ipenberg I, 2013, J BIOL CHEM, V288, P14681, DOI 10.1074/jbc.C113.462770; Katoh M, 2004, INT J ONCOL, V24, P1623; Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Kim SH, 2014, STEM CELL RES, V13, P1, DOI 10.1016/j.scr.2014.04.001; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liang CY, 2011, NUCLEIC ACIDS RES, V39, P4151, DOI 10.1093/nar/gkr040; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mayya V, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000007; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290; Traves PG, 2012, J IMMUNOL, V188, P1402, DOI 10.4049/jimmunol.1101781; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Whitmarsh AJ, 2007, BBA-MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	52	19	20	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					389	402		10.1038/onc.2017.345	http://dx.doi.org/10.1038/onc.2017.345			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945223				2022-12-28	WOS:000422753900011
J	Nagaraj, AB; Wang, QQ; Joseph, P; Zheng, C; Chen, Y; Kovalenko, O; Singh, S; Armstrong, A; Resnick, K; Zanotti, K; Waggoner, S; Xu, R; DiFeo, A				Nagaraj, A. B.; Wang, Q. Q.; Joseph, P.; Zheng, C.; Chen, Y.; Kovalenko, O.; Singh, S.; Armstrong, A.; Resnick, K.; Zanotti, K.; Waggoner, S.; Xu, R.; DiFeo, A.			Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment	ONCOGENE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DISEASE GENETICS PREDICTION; STEM-CELLS; RISK; PREVENTION; HEALTH	Computation-based drug-repurposing/repositioning approaches can greatly speed up the traditional drug discovery process. To date, systematic and comprehensive computation-based approaches to identify and validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken. Here, we present a novel drug discovery strategy that combines a computational drug-repositioning system (DrugPredict) with biological testing in cell lines in order to rapidly identify novel drug candidates for EOC. DrugPredict exploited unique repositioning opportunities rendered by a vast amount of disease genomics, phenomics, drug treatment, and genetic pathway and uniquely revealed that non-steroidal anti-inflammatories (NSAIDs) rank just as high as currently used ovarian cancer drugs. As epidemiological studies have reported decreased incidence of ovarian cancer associated with regular intake of NSAIDs, we assessed whether NSAIDs could have chemoadjuvant applications in EOC and found that (i) NSAID Indomethacin induces robust cell death in primary patient-derived platinum-sensitive and platinum-resistant ovarian cancer cells and ovarian cancer stem cells and (ii) downregulation of beta-catenin is partially driving effects of Indomethacin in cisplatin-resistant cells. In summary, we demonstrate that DrugPredict represents an innovative computational drug-discovery strategy to uncover drugs that are routinely used for other indications that could be effective in treating various cancers, thus introducing a potentially rapid and cost-effective translational opportunity. As NSAIDs are already in routine use in gynecological treatment regimens and have acceptable safety profile, our results will provide with a rationale for testing NSAIDs as potential chemoadjuvants in EOC patient trials.	[Nagaraj, A. B.; Joseph, P.; Kovalenko, O.; DiFeo, A.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Wang, Q. Q.] ThinTek LLC, Palo Alto, CA USA; [Zheng, C.; Chen, Y.; Xu, R.] Case Western Reserve Univ, Inst Computat Biol, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Singh, S.] Metrohlth Med Ctr, Dept Gynecol, Div Gynecol Oncol, Cleveland, OH USA; [Armstrong, A.; Zanotti, K.; Waggoner, S.] Univ Hosp Cleveland, Div Gynecol Oncol, Dept Gynecol, Med Ctr, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Xu, R (corresponding author), Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Inst Computat Biol, 2103 Cornell Rd, Cleveland, OH 44106 USA.; DiFeo, A (corresponding author), Case Comprehens Canc Ctr, Gen Med Sci Oncol, 2103 Cornell Rd, Cleveland, OH 44106 USA.	rxx@case.edu; avd11@case.edu	Nagaraj, Anil Belur/V-7779-2019; /S-1190-2019	/0000-0001-7488-250X; DiFeo, Analisa/0000-0001-8319-6763; Xu, Rong/0000-0003-3127-4795; Zheng, Chunlei/0000-0002-9737-461X	Mary Kay Foundation; Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award [DP2HD084068, R011CA197780-01A1]; Athymic Animal and Xenograft Core Facility of the Case Comprehensive Cancer Center [P30CA043703]; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center [P30CA043703]; Young Scientist Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [DP2HD084068] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA197780] Funding Source: NIH RePORTER	Mary Kay Foundation; Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award; Athymic Animal and Xenograft Core Facility of the Case Comprehensive Cancer Center; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center; Young Scientist Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Norma C and Albert I Geller for their constant support of the Gynecological Cancer Translation Research Program at the Case Comprehensive Cancer Center. This work was supported by grants from The Mary Kay Foundation (AD & RX), the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award number DP2HD084068 (RX, The National Cancer Institute Award number R011CA197780-01A1 (AD)) and The Young Scientist Foundation (AD). This research was supported by the Athymic Animal and Xenograft Core Facility and the Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center (P30CA043703).	Abu Saadeh F, 2013, EUR J OBSTET GYN R B, V170, P214, DOI 10.1016/j.ejogrb.2013.06.004; Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Baandrup L, 2013, ACTA OBSTET GYN SCAN, V92, P245, DOI 10.1111/aogs.12069; Brasky TM, 2014, INT J CANCER, V135, P1869, DOI 10.1002/ijc.28823; Bult CJ, 2008, NUCLEIC ACIDS RES, V36, pD724, DOI 10.1093/nar/gkm961; Cai Xiaoshu, 2016, AMIA Jt Summits Transl Sci Proc, V2016, P22; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen Y, 2017, BIOINFORMATICS, V33, P1031, DOI 10.1093/bioinformatics/btw737; Chen Y, 2016, J BIOMED INFORM, V64, P131, DOI 10.1016/j.jbi.2016.09.019; Chen Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2820-1; Chen Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2908-7; Chen Yang, 2015, AMIA Annu Symp Proc, V2015, P1851; Chen Y, 2015, BIOINFORMATICS, V31, P276, DOI 10.1093/bioinformatics/btv245; Chen Y, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S7-S9; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Cooke SL, 2011, LANCET ONCOL, V12, P1169, DOI 10.1016/S1470-2045(11)70123-1; Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813; Dudley JT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002648; Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hoehndorf R, 2014, BIOINFORMATICS, V30, P719, DOI 10.1093/bioinformatics/btt613; Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1; Kino Y, 2005, PROSTAG LEUKOTR ESS, V73, P103, DOI 10.1016/j.plefa.2005.04.014; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020; Liu RH, 2015, ARCH GYNECOL OBSTET, V291, P1361, DOI 10.1007/s00404-014-3555-3; McGettigan P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001826; Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669; Murphy MA, 2012, CANCER CAUSE CONTROL, V23, P1839, DOI 10.1007/s10552-012-0063-2; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Nakanishi M, 2013, SEMIN IMMUNOPATHOL, V35, P123, DOI 10.1007/s00281-012-0342-8; Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Schmidt M, 2011, J THROMB HAEMOST, V9, P1326, DOI 10.1111/j.1538-7836.2011.04354.x; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480; Trabert B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt431; Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801; Ungprasert P, 2015, RHEUMATOLOGY, V54, P736, DOI 10.1093/rheumatology/keu408; Valle BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061836; Wang CJ, 2004, J BONE JOINT SURG AM, V86A, P136, DOI 10.2106/00004623-200401000-00020; Wang QuanQiu, 2015, AMIA Annu Symp Proc, V2015, P1279; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Xu R, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2910-0; Xu R, 2015, J BIOMED INFORM, V56, P348, DOI 10.1016/j.jbi.2015.06.027; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992	50	45	46	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					403	414		10.1038/onc.2017.328	http://dx.doi.org/10.1038/onc.2017.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28967908	Green Published, hybrid			2022-12-28	WOS:000422753900012
J	Anjanappa, M; Hao, Y; Simpson, ER; Bhat-Nakshatri, P; Nelson, JB; Tersey, SA; Mirmira, RG; Cohen-Gadol, AA; Saadatzadeh, MR; Li, L; Fang, F; Nephew, KP; Miller, KD; Liu, Y; Nakshatri, H				Anjanappa, M.; Hao, Y.; Simpson, E. R.; Bhat-Nakshatri, P.; Nelson, J. B.; Tersey, S. A.; Mirmira, R. G.; Cohen-Gadol, A. A.; Saadatzadeh, M. R.; Li, L.; Fang, F.; Nephew, K. P.; Miller, K. D.; Liu, Y.; Nakshatri, H.			A system for detecting high impact-low frequency mutations in primary tumors and metastases	ONCOGENE			English	Article							BREAST-CANCER CELLS; H3K4 MONOMETHYLATION; THERAPEUTIC TARGETS; EARLY DISSEMINATION; BRANCHED EVOLUTION; BRAIN METASTASES; STEM-CELLS; IDENTIFICATION; METABOLISM; REVEALS	Tumor complexity and intratumor heterogeneity contribute to subclonal diversity. Despite advances in next-generation sequencing (NGS) and bioinformatics, detecting rare mutations in primary tumors and metastases contributing to subclonal diversity is a challenge for precision genomics. Here, in order to identify rare mutations, we adapted a recently described epithelial reprograming assay for short-term propagation of epithelial cells from primary and metastatic tumors. Using this approach, we expanded minor clones and obtained epithelial cell-specific DNA/RNA for quantitative NGS analysis. Comparative Ampliseq Comprehensive Cancer Panel sequence analyses were performed on DNA from unprocessed breast tumor and tumor cells propagated from the same tumor. We identified previously uncharacterized mutations present only in the cultured tumor cells, a subset of which has been reported in brain metastatic but not primary breast tumors. In addition, whole-genome sequencing identified mutations enriched in liver metastases of various cancers, including Notch pathway mutations/chromosomal inversions in 5/5 liver metastases, irrespective of cancer types. Mutations/rearrangements in FHIT, involved in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including mutations of different HLA-DR family members affecting OX40 signaling pathway, which could impact the immune response to metastatic cells. Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor and transforming growth factor signaling in metastatic cells. Epigenetic regulators including KMT2C/MLL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver metastases. Thus, irrespective of cancer types, organ-specific metastases may share common genomic aberrations. Since recent studies show independent evolution of primary tumors and metastases and in most cases mutation burden is higher in metastases than primary tumors, the method described here may allow early detection of subclonal somatic alterations associated with metastatic progression and potentially identify therapeutically actionable, metastasis-specific genomic aberrations.	[Anjanappa, M.; Bhat-Nakshatri, P.; Nakshatri, H.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Hao, Y.; Simpson, E. R.; Li, L.; Liu, Y.] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA; [Nelson, J. B.; Tersey, S. A.; Mirmira, R. G.; Saadatzadeh, M. R.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Cohen-Gadol, A. A.] Indiana Univ Sch Med, Dept Neurosurg, Indianapolis, IN 46202 USA; [Li, L.; Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Fang, F.; Nephew, K. P.] Indiana Univ, Med Sci Program, Bloomington, IN USA; [Miller, K. D.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; [Nakshatri, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nakshatri, H.] Roudebush VA Med Ctr, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Liu, Y; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Surg Biochem Mol Biol, C218C,980 West Walnut St, Indianapolis, IN 46202 USA.	Yunliu@iu.edu; hnakshat@iupui.edu	Simpson, Edward/G-1912-2015; Mirmira, Raghavendra G/AAD-7592-2020	Simpson, Edward/0000-0001-9015-9864; Mirmira, Raghavendra G/0000-0002-5013-6075; Tersey, Sarah/0000-0003-0667-2361; Cohen-Gadol, Aaron/0000-0002-4946-1524; Nakshatri, Harikrishna/0000-0001-8876-0052	IUPUI Signature Center for the Cure of Glioblastoma; Susan G Komen for the Cure [SAC110025]; Indiana CTSI Project development pilot grant; IU Simon Cancer Center Breast Cancer Program Pilot grant; National Institutes of Health [P30 DK097512]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK097512] Funding Source: NIH RePORTER	IUPUI Signature Center for the Cure of Glioblastoma; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Indiana CTSI Project development pilot grant; IU Simon Cancer Center Breast Cancer Program Pilot grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank tissue collection team at the IU Simon Cancer Center, Clinical Research Office and Neurooncology Center at IU School of Medicine for collection of fresh tissues for the study. We also thank the flow cytometry core at the IU Simon Cancer Center. Excellent support from New York Genome Center, particularly Mr Benjamin Hubert, is highly appreciated. IUPUI Signature Center for the Cure of Glioblastoma supported brain metastases tissue collection. Susan G Komen for the Cure (SAC110025 to HN), Indiana CTSI Project development pilot grant (to HN, LL and KNP) and IU Simon Cancer Center Breast Cancer Program Pilot grant (to YL and HN) supported this study. This study utilized core services by National Institutes of Health Grant P30 DK097512 to the Indiana University School of Medicine.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burnett RM, 2015, ONCOTARGET, V6, P12682, DOI 10.18632/oncotarget.3707; Buxton ILO, 2010, CANCER LETT, V291, P131, DOI 10.1016/j.canlet.2009.09.021; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DW, 2015, ONCOTARGET, V6, P40815, DOI 10.18632/oncotarget.5886; Chen LX, 2017, SCIENCE, V355, P752, DOI 10.1126/science.aai8690; Cheng J, 2014, MOL CELL, V53, P979, DOI 10.1016/j.molcel.2014.02.032; Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Collins DC, 2017, TRENDS PHARMACOL SCI, V38, P25, DOI 10.1016/j.tips.2016.10.012; Cormier S, 2004, GENE EXPR PATTERNS, V4, P713, DOI 10.1016/j.modgep.2004.04.003; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Fisher MM, 2015, DIABETES, V64, P3867, DOI 10.2337/db15-0430; Flowers M, 2017, CANCER RES, V77, P3386, DOI 10.1158/0008-5472.CAN-17-0232; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giampieri R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072843; Gruber TA, 2015, BLOOD, V126, P943, DOI 10.1182/blood-2015-05-567859; Hao YY, 2017, J COMPUT BIOL, V24, P637, DOI 10.1089/cmb.2017.0057; Hao YY, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2905-x; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Hu X, 2015, INT J MOL MED, V35, P1219, DOI 10.3892/ijmm.2015.2132; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Kloosterman WP, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r103; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kostadinov R, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004413; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; Linch SN, 2016, P NATL ACAD SCI USA, V113, pE319, DOI 10.1073/pnas.1510518113; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Miller CA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12498; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Nakshatri H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13526; Odore E, 2016, CLIN PHARMACOKINET, V55, P397, DOI 10.1007/s40262-015-0327-6; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Pepe C, 2007, BREAST CANCER RES TR, V103, P29, DOI 10.1007/s10549-006-9349-y; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Petit FM, 2013, HUM REPROD, V28, P852, DOI 10.1093/humrep/des452; Prasad V, 2016, LANCET ONCOL, V17, pE81, DOI 10.1016/S1470-2045(15)00620-8; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Sinha R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060142; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; van Bon BWM, 2013, HUM MOL GENET, V22, P3138, DOI 10.1093/hmg/ddt170; Vaque JP, 2013, MOL CELL, V49, P94, DOI 10.1016/j.molcel.2012.10.018; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Yan W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19303; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang Z, 2016, CELL REP, V16, P3146, DOI 10.1016/j.celrep.2016.08.048	65	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					185	196		10.1038/onc.2017.322	http://dx.doi.org/10.1038/onc.2017.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892047	Green Accepted, Green Submitted			2022-12-28	WOS:000422631700005
J	Ruan, H; Zhan, YY; Hou, J; Xu, B; Chen, B; Tian, Y; Wu, D; Zhao, Y; Zhang, Y; Chen, X; Mi, P; Zhang, L; Zhang, S; Wang, X; Cao, H; Zhang, W; Wang, H; Li, H; Su, Y; Zhang, XK; Hu, T				Ruan, H.; Zhan, Y. Y.; Hou, J.; Xu, B.; Chen, B.; Tian, Y.; Wu, D.; Zhao, Y.; Zhang, Y.; Chen, X.; Mi, P.; Zhang, L.; Zhang, S.; Wang, X.; Cao, H.; Zhang, W.; Wang, H.; Li, H.; Su, Y.; Zhang, X. K.; Hu, T.			Berberine binds RXR alpha to suppress beta-catenin signaling in colon cancer cells	ONCOGENE			English	Article							RETINOID-X-RECEPTOR; ADENOMATOUS-POLYPOSIS-COLI; COLORECTAL-CANCER; NUCLEAR RECEPTORS; DOWN-REGULATION; C-CBL; WNT; IDENTIFICATION; GROWTH; INHIBITION	Berberine, an isoquinoline alkaloid, is a traditional oriental medicine used to treat diarrhea and gastroenteritis. Recently, we reported that it could inhibit the growth of intestinal polyp in animals and in patients with the familial adenomatous polyposis by downregulating beta-catenin signaling. However, the intracellular target mediating the effects of berberine remains elusive. Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXR alpha), where berberine concomitantly binding to and synergistically activating RXR alpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXR alpha. Berberine binding promotes RXR alpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells. Furthermore, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXR alpha-dependent manner. Together, our study not only identifies RXRa as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXR alpha, which provide new strategies for the design of new RXR alpha-based antitumor agents and drug combinations.	[Ruan, H.; Zhan, Y. Y.; Hou, J.; Xu, B.; Chen, B.; Tian, Y.; Wu, D.; Zhao, Y.; Zhang, Y.; Chen, X.; Mi, P.; Cao, H.; Zhang, W.; Hu, T.] Xiamen Univ, Canc Res Ctr, Med Coll, 315 Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China; [Zhang, L.] Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China; [Zhang, S.; Wang, X.; Wang, H.; Li, H.] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China; [Su, Y.; Zhang, X. K.] Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China; [Zhang, X. K.] Sanford Burnham Med Res Inst, Canc Ctr, La Jolla, CA USA	Xiamen University; Xiamen University; Tsinghua University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute	Zhan, YY; Hu, T (corresponding author), Xiamen Univ, Canc Res Ctr, Med Coll, 315 Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China.; Zhang, XK (corresponding author), Sanford Burnham Med Res Inst, Canc Ctr, La Jolla, CA USA.	yyzhan@xmu.edu.cn; xkzhang@xmu.edu.cn; thu@xmu.edu.cn	Li, Haitao/B-2668-2012	Li, Haitao/0000-0001-6741-293X; Yujie, Zhao/0000-0002-7028-2408	National Natural Science Foundation of China [U1405228, 81472568, 81572589]; Natural Science Foundation of Fujian [2014J07010, 2017J06020, 2015R1036-1, 2017R1036-4, 2016R1034-1, 2016R1034-4]; Fundamental Research Funds for the Central Universities [20720150058]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian(Natural Science Foundation of Fujian Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the grants from the National Natural Science Foundation of China (U1405228, 81472568 and 81572589), the Natural Science Foundation of Fujian grant (2014J07010, 2017J06020, 2015R1036-1, 2017R1036-4, 2016R1034-1 and 2016R1034-4) and the Fundamental Research Funds for the Central Universities (20720150058).	Albring KF, 2013, BIOFACTORS, V39, P652, DOI 10.1002/biof.1133; Beildeck ME, 2010, EXP CELL RES, V316, P1763, DOI 10.1016/j.yexcr.2010.02.001; Casimiro MC, 2014, EXPERT OPIN INV DRUG, V23, P295, DOI 10.1517/13543784.2014.867017; Cesario RM, 2006, CANCER LETT, V240, P225, DOI 10.1016/j.canlet.2005.09.010; Chai YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090850; Chen LQ, 2014, CHEM BIOL, V21, P596, DOI 10.1016/j.chembiol.2014.02.017; Chitalia V, 2013, J BIOL CHEM, V288, P23505, DOI 10.1074/jbc.M113.473801; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; Dawson MI, 2002, CURR MED CHEM, V9, P623, DOI 10.2174/0929867023370789; de Lera AR, 2007, NAT REV DRUG DISCOV, V6, P811, DOI 10.1038/nrd2398; Delfosse V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9089; Dillard AC, 2008, NUTR CANCER, V60, P97, DOI 10.1080/01635580701586754; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Egan JB, 2010, CANCER RES, V70, P1496, DOI 10.1158/0008-5472.CAN-09-3264; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Guldenschuh L, 2001, DIS COLON RECTUM, V44, P1090, DOI 10.1007/BF02234627; Gwyn K, 2002, AM J GASTROENTEROL, V97, P13, DOI 10.1111/j.1572-0241.2002.05435.x; Han AJ, 2008, CANCER BIOL THER, V7, P454, DOI 10.4161/cbt.7.3.5455; Imanshahidi M, 2008, PHYTOTHER RES, V22, P999, DOI 10.1002/ptr.2399; Jacobs ET, 2010, CARCINOGENESIS, V31, P1412, DOI 10.1093/carcin/bgq127; Janakiram NB, 2013, CANCER PREV RES, V6, P1251, DOI 10.1158/1940-6207.CAPR-13-0249; Kersten S, 1998, J MOL BIOL, V284, P21, DOI 10.1006/jmbi.1998.2168; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Park JJ, 2012, BIOCHEM BIOPH RES CO, V426, P461, DOI 10.1016/j.bbrc.2012.08.091; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Perez E, 2012, BBA-MOL CELL BIOL L, V1821, P57, DOI 10.1016/j.bbalip.2011.04.003; Rayasam GV, 2010, PHYTOTHER RES, V24, P1260, DOI 10.1002/ptr.3165; Saha SK, 2014, EUR J PHARMACOL, V744, P132, DOI 10.1016/j.ejphar.2014.09.048; Sekiya T, 2002, CANCER RES, V62, P3322; Seo HS, 2015, MOL MED REP, V12, P800, DOI 10.3892/mmr.2015.3480; Shivanna S, 2015, J BIOL CHEM, V290, P12537, DOI 10.1074/jbc.M114.616623; Tang H, 2014, CANCER BIOMARK, V14, P313, DOI 10.3233/CBM-140409; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Volate SR, 2009, MOL CARCINOGEN, V48, P920, DOI 10.1002/mc.20542; Wang LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056666; Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418; Wang W, 2011, CELL RES, V21, P730, DOI 10.1038/cr.2011.30; Wu K, 2012, INT J ONCOL, V41, P292, DOI 10.3892/ijo.2012.1423; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yamazaki K, 2007, GUT, V56, P1557, DOI 10.1136/gut.2007.129858; Yu ML, 2014, MOL MED REP, V9, P249, DOI 10.3892/mmr.2013.1762; Zhang HT, 2011, J MOL BIOL, V407, P13, DOI 10.1016/j.jmb.2011.01.032; Zhang H, 2010, METABOLISM, V59, P285, DOI 10.1016/j.metabol.2009.07.029; Zhang JF, 2013, J CELL MOL MED, V17, P1484, DOI 10.1111/jcmm.12119; Zhang XK, 2015, ACTA PHARMACOL SIN, V36, P102, DOI 10.1038/aps.2014.109; Zhang ZG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6493; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023; Zuo F, 2006, DRUG METAB DISPOS, V34, P2064, DOI 10.1124/dmd.106.011361	55	84	91	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6906	6918		10.1038/onc.2017.296	http://dx.doi.org/10.1038/onc.2017.296			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846104	Green Published, hybrid			2022-12-28	WOS:000418041800007
J	Beesetti, S; Mavuluri, J; Surabhi, RP; Oberyszyn, TM; Tober, K; Pitani, RS; Joseph, LD; Venkatraman, G; Rayala, SK				Beesetti, S.; Mavuluri, J.; Surabhi, R. P.; Oberyszyn, T. M.; Tober, K.; Pitani, R. S.; Joseph, L. D.; Venkatraman, G.; Rayala, S. K.			Transcriptional regulation of ataxia-telangiectasia and Rad3-related protein by activated p21-activated kinase-1 protects keratinocytes in UV-B-induced premalignant skin lesions	ONCOGENE			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE; CELLS; PAK1; IRRADIATION; CANCER; PATHWAYS; FOS; PHOSPHORYLATION	Sun-induced skin lesions, in particular actinic keratosis, are generally considered as premalignant skin lesions that can progress into squamous cell carcinoma (SCC) and invasive SCC if left untreated. Therefore, understanding the molecular mechanisms by which the ultraviolet-B (UV-B)-exposed cells are being protected and the signaling pathways that promote the progression of certain premalignant skin lesions to malignant lesions will permit us to prevent or cure skin cancers. In the current study, we found that phospho-p21-activated kinase-1 (Pak1) and Pak1 expression was high in clinical samples of sunlight-induced premalignant skin lesions assessed by immunohistochemistry. Further, we observed that phospho-Pak1 and Pak1 levels are high in UV-B-exposed hairless SKH mouse model skin samples as compared with unexposed skin tissue. Our results from cell line and animal models showed that Pak1 is activated in response to UV-B radiation, and this activated Pak1 translocates from the cytoplasm to the nucleus. Inside the nucleus, Pak1 via C-Fos binds to a specific promoter region of DNA repair kinase ATR (ataxia-telangiectasia and Rad3-related protein) and acts as a transcriptional regulator of ATR. Results from our analysis showed that Pak1 overexpression, knockdown and Pak1 knockout cell line models showed that Pak1 confers protection to keratinocytes from UV-B-induced apoptosis and DNA damage via ATR. To our knowledge, this is the first study that evaluates the functional and clinical significance of a signaling molecule, Pak1, in sun-induced premalignant skin lesions and indicates that increased Pak1 activation and expression could serve as an early warning sign of progression toward non-melanoma skin cancer, if ignored.	[Beesetti, S.; Mavuluri, J.; Surabhi, R. P.; Rayala, S. K.] IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India; [Oberyszyn, T. M.; Tober, K.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Pitani, R. S.] Sri Ramachandra Univ, Dept Community Med, Madras, Tamil Nadu, India; [Joseph, L. D.] Sri Ramachandra Univ, Dept Pathol, Madras, Tamil Nadu, India; [Venkatraman, G.] Sri Ramachandra Univ, Dept Human Genet, Madras 600116, Tamil Nadu, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; University System of Ohio; Ohio State University; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research	Rayala, SK (corresponding author), IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Univ, Dept Human Genet, Madras 600116, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	Venkatraman, Ganesh/AAB-1467-2020; beesetti, swarna/ABD-2044-2020; Joseph, Leena Dennis/AAS-9420-2020; Mavuluri, Jayadev/AAW-6724-2021	Venkatraman, Ganesh/0000-0003-0179-9785; Rayala, Suresh/0000-0003-4394-4450; Oberyszyn, Tatiana/0000-0002-5308-0855; Latha, B Swarna/0000-0001-7598-5607	DRDO-LSRB, Government of India [DLS/81/48222/XXIII/LSRB/2009]; NCI [R01CA133629]; NATIONAL CANCER INSTITUTE [R01CA133629] Funding Source: NIH RePORTER	DRDO-LSRB, Government of India; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Barathidasan, Veterinary Pathologist from Mahatma Gandhi Medical College and Research Institute (MGMCRI), Pondicherry for scoring the mice slides. We also thank Rahul and Venu for help with IHC and animal studies. We thank DRDO-LSRB, Government of India, for the financial support to SKR (Grant No: DLS/81/48222/XXIII/LSRB/2009), and NCI R01CA133629 (to TMO) and Indian Institute of Technology Madras (IITM) for all other facilities.	Anna Brozyna, 2007, Expert Rev Dermatol, V2, P451, DOI 10.1586/17469872.2.4.451; Auclair Y, 2009, CELL CYCLE, V8, P1865, DOI 10.4161/cc.8.12.8800; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bhat M Ramesh, 2012, Indian J Dermatol, V57, P158, DOI 10.4103/0019-5154.94298; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brzoska K, 2009, MUTAGENESIS, V24, P1, DOI 10.1093/mutage/gen056; Carr TD, 2012, CANCER PREV RES, V5, P1394, DOI 10.1158/1940-6207.CAPR-12-0272-T; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cooper SJ, 2007, CURR CANCER DRUG TAR, V7, P325, DOI 10.2174/156800907780809714; Corona R, 1996, Ann Ist Super Sanita, V32, P37; Criscione VD, 2009, CANCER-AM CANCER SOC, V115, P2523, DOI 10.1002/cncr.24284; Dore J F, 2001, IARC Sci Publ, V154, P81; El-Abaseri TB, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/97939; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gan JF, 2015, INT J MOL SCI, V16, P12035, DOI 10.3390/ijms160612035; Ghosal G, 2013, TRANSL CANCER RES, V2, P107, DOI 10.3978/j.issn.2218-676X.2013.04.01; Gill Pavandeep, 2015, CMAJ Open, V3, pE258, DOI 10.9778/cmajo.20140037; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jagadeeshan S, 2015, ONCOGENE, V34, P455, DOI 10.1038/onc.2013.576; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Li DQ, 2012, CELL REP, V2, P1657, DOI 10.1016/j.celrep.2012.11.018; MARKS VJ, 1993, OTOLARYNG CLIN N AM, V26, P23; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Ong CC, 2013, JNCI-J NATL CANCER I, V105, P606, DOI 10.1093/jnci/djt054; Panda Saumya, 2010, Indian J Dermatol, V55, P373, DOI 10.4103/0019-5154.74551; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Sato K, 2013, INT J MOL SCI, V14, P10761, DOI 10.3390/ijms140610761; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Tai MH, 2012, INT J MOL SCI, V13, P4351, DOI 10.3390/ijms13044351; Tse E Y, 2014, J MOL SIGNALING, V9, P7, DOI [10.1186/1750-2187-9-7, DOI 10.1186/1750-2187-9-725093037]; Vodenicharov MD, 2005, COMP SER PHOTOCHEM, V5, P247; Wang N, 2015, ADV APPL BIOTECHNOLO, V65, P627; Wang Y, 2015, MED SCI MONIT BASIC, V21, P21, DOI 10.12659/MSMBR.893143; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Xu YR, 2006, J BIOL CHEM, V281, P27389, DOI 10.1074/jbc.M602355200; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Yang ZB, 2004, CLIN CANCER RES, V10, P658, DOI 10.1158/1078-0432.CCR-0382-03; Zhou MJ, 2012, BIOMED ENVIRON SCI, V25, P583, DOI 10.3967/0895-3988.2012.05.013	44	4	4	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6154	6163		10.1038/onc.2017.218	http://dx.doi.org/10.1038/onc.2017.218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692051				2022-12-28	WOS:000414249800009
J	Tsoi, H; Lam, KC; Dong, Y; Zhang, X; Lee, CK; Zhang, J; Ng, SC; Ng, SSM; Zheng, S; Chen, Y; Fang, J; Yu, J				Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Ng, S. S. M.; Zheng, S.; Chen, Y.; Fang, J.; Yu, J.			Pre-45s rRNA promotes colon cancer and is associated with poor survival of CRC patients	ONCOGENE			English	Article							RNA-POLYMERASE-I; UPSTREAM BINDING-FACTOR; SIGNALING PATHWAY; TRANSCRIPTION; PHOSPHORYLATION; INHIBITION; ACTIVATION; CALCIUM; STRESS; MDM2	One characteristic of cancer cells is the abnormally high rate of cell metabolism to sustain their enhanced proliferation. However, the behind mechanism of this phenomenon is still elusive. Here we find that enhanced precursor 45s ribosomal RNA (pre-45s rRNA) is one of the core mechanisms in promoting the pathogenesis of colorectal cancer (CRC). Pre-45s rRNA expression is significantly higher in primary CRC tumor tissues samples and cancer cell lines compared with the non-tumorous colon tissues, and is associated with tumor sizes. Knockdown of pre-45s rRNA inhibits G1/S cell-cycle transition by stabilizing p53 through inducing murine double minute 2 (MDM2) and ribosomal protein L11 (RpL11) interaction. In addition, we revealed that high rate of cancer cell metabolism triggers the passive release of calcium ion from endoplasmic reticulum to the cytoplasm. The elevated calcium ion in the cytoplasm activates the signaling cascade of calcium/calmodulin-dependent protein kinase II, ribosomal S6 kinase (S6K) and ribosomal S6K (CaMKII-S6K-UBF). The activated UBF promotes the transcription of rDNA, which therefore increases pre-45s rRNA. Disruption of CaMKII-S6K-UBF axis by either RNAi or pharmaceutical approaches leads to reduction of pre-45s rRNA expression, which subsequently suppresses cell proliferation in colon cancer cells by causing cell-cycle arrest. Knockdown of APC activates CaMKII-S6-KUBF cascade and thus enhances pre-45s rRNA expression. Moreover, the high expression level of pre-45s rRNA is associated with poor survival of CRC patients in two independent cohorts. Our study identifies a novel mechanism in CRC pathogenesis mediated by pre-45s rRNA and a prognostic factor of pre-45s rRNA in CRC patients.	[Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China; [Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Shatin, Hong Kong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Zheng, S.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China; [Zheng, S.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou, Zhejiang, Peoples R China; [Chen, Y.; Fang, J.; Yu, J.] Shanghai Jiao Tong Univ, Dept Gastroenterol, Renji Hosp, Sch Med, Shanghai, Peoples R China; [Chen, Y.; Fang, J.; Yu, J.] Shanghai Inst Digest Dis, Shanghai, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Zhejiang University; Zhejiang University; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Ng, Simon S. M./M-1219-2018; ZHANG, Xiang/N-7918-2015; ZHANG, Jingwan/AIC-2560-2022; Ng, Siew Chien/N-4733-2015; Jun, Yu/D-8569-2015	Ng, Simon S. M./0000-0002-5389-9297; ZHANG, Xiang/0000-0002-3222-5824; Ng, Siew Chien/0000-0002-6850-4454; Jun, Yu/0000-0001-5008-2153; tsoi, ho/0000-0003-2037-9575	RGC-GRF Hong Kong [766613, 14106145, 14111216]; HMRF Hong Kong [1196728]; National Key Technology RD Program [2014BAI09B05]; 135 program [2016YFC1303200]; Shenzhen Virtual University	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; National Key Technology RD Program(National Key Technology R&D Program); 135 program; Shenzhen Virtual University	This project was supported by RGC-GRF Hong Kong (766613, 14106145, 14111216) HMRF Hong Kong (1196728), The National Key Technology R&D Program (2014BAI09B05), 135 program project (2016YFC1303200), and Shenzhen Virtual University Park Support Scheme to CUHK-Shenzhen Research Institute.	Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita T, 2010, LANCET, V376, P331, DOI 10.1016/S0140-6736(10)61183-X; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jimenez-Vidal M, 2010, J BIOL CHEM, V285, P36260, DOI 10.1074/jbc.M110.165555; Kestler HA, 2011, J CELL BIOL, V193, P431, DOI 10.1083/jcb.201103167; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; Kim TH, 2014, ONCOTARGET, V5, P860, DOI 10.18632/oncotarget.1784; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Mullineux ST, 2012, BIOCHIMIE, V94, P1521, DOI 10.1016/j.biochi.2012.02.001; Panner A, 2006, CELL CALCIUM, V40, P253, DOI 10.1016/j.ceca.2006.04.029; Panov KI, 2006, EMBO J, V25, P3310, DOI 10.1038/sj.emboj.7601221; Prevarskaya N, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0097; Rodnina MV, 2009, CURR OPIN CELL BIOL, V21, P435, DOI 10.1016/j.ceb.2009.01.023; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Shifman JM, 2006, P NATL ACAD SCI USA, V103, P13968, DOI 10.1073/pnas.0606433103; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	28	24	26	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6109	6118		10.1038/onc.2017.86	http://dx.doi.org/10.1038/onc.2017.86			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692053	Green Published, hybrid			2022-12-28	WOS:000414249800005
J	Zhu, C; Chrifi, I; Mustafa, D; van der Weiden, M; Leenen, PJM; Duncker, DJ; Kros, JM; Cheng, C				Zhu, C.; Chrifi, I.; Mustafa, D.; van der Weiden, M.; Leenen, P. J. M.; Duncker, D. J.; Kros, J. M.; Cheng, C.			CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; ANTIANGIOGENIC THERAPY; VESSEL FORMATION; STROMAL CELLS; ANGIOGENESIS; GLIOBLASTOMA; PERICYTES; PERIOSTIN; MICROGLIA; GROWTH	Glioblastomas (glioblastoma multiforme, GBM) are most malignant brain tumors characterized by profound vascularization. The activation of macrophages strongly contributes to tumor angiogenesis during GBM development. Previously, we showed that extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) is highly expressed by M2-like macrophages in GBM where it defines macrophage M2 polarization and contributes to tumor expansion. In this study, the effect of CECR1 in macrophages on tumor angiogenesis was investigated. Immunohistochemical evaluation of GBM tissue samples showed that the expression of CECR1 correlates with microvascular density in the tumors, confirming data from the TCGA set. In a threedimensional co-culture system consisting of human pericytes, human umbilical vein endothelial cells and THP1-derived macrophages, CECR1 knockdown by siRNA and CECR1 stimulation of macrophages inhibited and promoted new vessel formation, respectively. Loss and gain of function studies demonstrated that PDGFB mRNA and protein levels in macrophages are modulated by CECR1. The proangiogenic properties of CECR1 in macrophages were partially mediated via paracrine activation of pericytes by PDGFB-PDGFR beta signaling. CECR1-PDGFB-PDGFR beta cross-activation between macrophages and pericytes promoted pericyte migration, shown by transwell migration assay, and enhanced expression and deposition of periostin, a matrix component with proangiogenic properties. CECR1 function in (M2-like) macrophages mediates cross talk between macrophages and pericytes in GBM via paracrine PDGFB-PDGFR beta signaling, promoting pericyte recruitment and migration, and tumor angiogenesis. Therefore, CECR1 offers a new portent target for anti-angiogenic therapy in GBM via immune modulation.	[Zhu, C.; Mustafa, D.; van der Weiden, M.; Kros, J. M.] Erasmus MC, Dept Pathol, Room Be 230c,Wytemaweg 80,POB 2040,3015 CN, NL-3000 CA Rotterdam, Netherlands; [Zhu, C.] Shanghai Jiao Tong Univ, Shanghai Xinhua Hosp, Sch Med, Dept Pediat Neurosurg, Shanghai, Peoples R China; [Chrifi, I.; Duncker, D. J.; Cheng, C.] Erasmus MC, Thoraxctr, Div Expt Cardiol, Dept Cardiol, Rotterdam, Netherlands; [Leenen, P. J. M.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Cheng, C.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, DIGD, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Shanghai Jiao Tong University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center	Kros, JM (corresponding author), Erasmus MC, Dept Pathol, Room Be 230c,Wytemaweg 80,POB 2040,3015 CN, NL-3000 CA Rotterdam, Netherlands.	j.m.kros@erasmusmc.nl	Leenen, Pieter JM/I-5839-2013; Mustafa, Dana/AAQ-6530-2021	Leenen, Pieter JM/0000-0001-9860-2920; Mustafa, Dana/0000-0003-0644-078X	Chinese Scholar Council [201206230102]; Netherlands Foundation for Cardiovascular Excellence; Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation [CVON2014-11 RECONNECT]; VIDI grant [91714302]; Erasmus MC fellowship; RM fellowship grant of the UMC Utrecht	Chinese Scholar Council; Netherlands Foundation for Cardiovascular Excellence; Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation(Netherlands Heart Foundation); VIDI grant; Erasmus MC fellowship; RM fellowship grant of the UMC Utrecht	CZ was supported by the Chinese Scholar Council (201206230102). CC was supported by the Netherlands Foundation for Cardiovascular Excellence and by The Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, (CVON2014-11 RECONNECT), VIDI grant 91714302, the Erasmus MC fellowship grant and the RM fellowship grant of the UMC Utrecht. We thank CardioGenx B.V. for providing the recombinant CECR1.	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brandenburg S, 2016, ACTA NEUROPATHOL, V131, P365, DOI 10.1007/s00401-015-1529-6; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Das S, 2013, NEW ENGL J MED, V369, P1561, DOI 10.1056/NEJMcibr1309402; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Garcia-Quintans N, 2016, ANGIOGENESIS, V19, P217, DOI 10.1007/s10456-016-9502-0; Gilbert MR, 2016, J CLIN ONCOL, V34, P1567, DOI 10.1200/JCO.2016.66.5364; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6; Koh W, 2008, METHOD ENZYMOL, V443, P83, DOI 10.1016/S0076-6879(08)02005-3; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Lin L, 2015, ONCOTARGET, V6, P34758, DOI 10.18632/oncotarget.5325; Liu AY, 2014, MATRIX BIOL, V37, P150, DOI 10.1016/j.matbio.2014.04.007; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847; Nijaguna MB, 2015, J BIOL CHEM, V290, P23401, DOI 10.1074/jbc.M115.664037; Ochs K, 2013, J NEUROIMMUNOL, V265, P106, DOI 10.1016/j.jneuroim.2013.09.011; Park SY, 2016, MOL CANCER THER, V15, P2187, DOI 10.1158/1535-7163.MCT-15-0427; Pong WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077571; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075; Roma-Lavisse C, 2015, DIABETES VASC DIS RE, V12, P279, DOI 10.1177/1479164115582351; Squadrito ML, 2015, NAT CELL BIOL, V17, P107, DOI 10.1038/ncb3095; Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477; Sun HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114246; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Takano S, 2012, BRAIN TUMOR PATHOL, V29, P73, DOI 10.1007/s10014-011-0077-6; VIGNAUD JM, 1994, CANCER RES, V54, P5455; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang YL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11385; Zheng PP, 2014, J CELL PHYSIOL, V229, P967, DOI 10.1002/jcp.24538; Zhong XL, 2016, ONCOTARGET, V7, P44365, DOI 10.18632/oncotarget.9744; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; ZHU CB, 2015, CANCER RES S15, V75; Zhu CB, 2017, NEURO-ONCOLOGY, V19, P648, DOI 10.1093/neuonc/now251; Zhu CB, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0405-5	48	38	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5356	5368		10.1038/onc.2017.145	http://dx.doi.org/10.1038/onc.2017.145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534507	Green Published, hybrid			2022-12-28	WOS:000411382100003
J	Wald, JH; Hatakeyama, J; Printsev, I; Cuevas, A; Fry, WHD; Saldana, MJ; VanderVorst, K; Rowson-Hodel, A; Angelastro, JM; Sweeney, C; Carraway, KL				Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Angelastro, J. M.; Sweeney, C.; Carraway, K. L., III			Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; DISHEVELLED DEP DOMAIN; NEURAL-TUBE DEFECTS; CANCER CELLS; NRDP1; PROTEIN; MECHANISMS; INVASION; RECEPTOR; CATENIN	The lethality of the aggressive brain tumor glioblastoma multiforme (GBM) results in part from its strong propensity to invade surrounding normal brain tissue. Although oncogenic drivers such as epidermal growth factor receptor activation and Phosphatase and Tensin homolog inactivation are thought to promote the motility and invasiveness of GBM cells via phosphatidylinostitol 3-kinase activation, other unexplored mechanisms may also contribute to malignancy. Here we demonstrate that several components of the planar cell polarity (PCP) arm of non-canonical Wnt signaling including VANGL1, VANGL2 and FZD7 are transcriptionally upregulated in glioma and correlate with poorer patient outcome. Knockdown of the core PCP pathway component VANGL1 suppresses the motility of GBM cell lines, pointing to an important mechanistic role for this pathway in glioblastoma malignancy. We further observe that restoration of Nrdp1, a RING finger type E3 ubiquitin ligase whose suppression in GBM also correlates with poor prognosis, reduces GBM cell migration and invasiveness by suppressing PCP signaling. Our observations indicate that Nrdp1 physically interacts with the Vangl1 and Vangl2 proteins to mediate the K63-linked polyubiquitination of the Dishevelled, Egl-10 and Pleckstrin (DEP) domain of the Wnt pathway protein Dishevelled (Dvl). Ubiquitination hinders Dvl binding to phosphatidic acid, an interaction necessary for efficient Dvl recruitment to the plasma membrane upon Wnt stimulation of Fzd receptor and for the propagation of downstream signals. We conclude that the PCP pathway contributes significantly to the motility and hence the invasiveness of GBM cells, and that Nrdp1 acts as a negative regulator of PCP signaling by inhibiting Dvl through a novel polyubiquitination mechanism. We propose that the upregulation of core PCP components, together with the loss of the key negative regulator Nrdp1, act coordinately to promote GBM invasiveness and malignancy.	[Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA; [Angelastro, J. M.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.	klcarraway@ucdavis.edu	Rowson-Hodel, Ashley/AAE-2619-2022	Rowson-Hodel, Ashley/0000-0003-0531-9929; Hatakeyama, Jason/0000-0001-8690-5107; Cuevas-Navarro, Antonio/0000-0001-6208-6944	NIH [CA123541, CA166412, CA118384, CA165758, CA165546]; DoD BCRP fellowship [W81XWH-10-1-0069]; NCI [P30CA093373]; NATIONAL CANCER INSTITUTE [F31CA165546, R01CA166412, R01CA118384, P30CA093373, R01CA123541, F31CA165758] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD BCRP fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by NIH grants CA123541 (KLC), CA166412 (KLC) and CA118384 (CS), NIH fellowships CA165758 (JH) and CA165546 (IP), DoD BCRP fellowship W81XWH-10-1-0069 (JHW), and NCI P30CA093373 (Cancer Center Support Grant-FACS core). We thank Drs Paul Knoepfler, Madelon Maurice and Hiroaki Miki for kindly providing reagents and cell lines.	Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Andersson U, 2004, ACTA NEUROPATHOL, V108, P135, DOI 10.1007/s00401-004-0875-6; Cao ZW, 2007, MOL CELL BIOL, V27, P2180, DOI 10.1128/MCB.01245-06; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Courbard JR, 2009, DEV BIOL, V333, P67, DOI 10.1016/j.ydbio.2009.06.024; de Groot REA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004985; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Eke I, 2012, INT J RADIAT ONCOL, V84, pE515, DOI 10.1016/j.ijrobp.2012.06.012; Fry WHD, 2011, MOL CELL BIOL, V31, P3009, DOI 10.1128/MCB.05105-11; Funato Y, 2010, CURR BIOL, V20, P1945, DOI 10.1016/j.cub.2010.09.065; Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hatakeyama J, 2014, ENDOCR-RELAT CANCER, V21, pR345, DOI 10.1530/ERC-14-0141; Huang Z, 2010, PROTEIN CELL, V1, P638, DOI 10.1007/s13238-010-0078-y; Huse JT, 2013, ANNU REV MED, V64, P59, DOI 10.1146/annurev-med-100711-143028; Ingalla EQ, 2010, J BIOL CHEM, V285, P28691, DOI 10.1074/jbc.M110.127977; Jiang YS, 2015, TUMOR BIOL, V36, P1129, DOI 10.1007/s13277-014-2726-y; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Lee KH, 2015, ONCOTARGET, V6, P3240, DOI 10.18632/oncotarget.3087; Lewandowski KT, 2014, J CELL SCI, V127, P315, DOI 10.1242/jcs.129148; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luk SK, 2012, EUR J CANCER, V48, P149, DOI 10.1016/j.ejca.2011.09.006; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Paw I, 2015, CANCER LETT, V362, P1, DOI 10.1016/j.canlet.2015.03.015; Pellegrin S, 2008, CURR PROTOC CELL BIO, V38, DOI DOI 10.1002/0471143030.CB1408S38; Peng Y, 2012, CURR TOP DEV BIOL, V101, P33, DOI 10.1016/B978-0-12-394592-1.00002-8; Printsev I, 2014, J BIOL CHEM, V289, P8570, DOI 10.1074/jbc.M113.527036; Qiu XB, 2004, EMBO J, V23, P800, DOI 10.1038/sj.emboj.7600075; Sewduth RN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5832; Shi HL, 2015, J NEURO-ONCOL, V124, P357, DOI 10.1007/s11060-015-1851-9; Shi HL, 2014, IUBMB LIFE, V66, P704, DOI 10.1002/iub.1320; Simons M, 2009, NAT CELL BIOL, V11, P286, DOI 10.1038/ncb1836; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tauriello DVF, 2012, P NATL ACAD SCI USA, V109, pE812, DOI 10.1073/pnas.1114802109; Tauriello DVF, 2010, CELL CYCLE, V9, P3700, DOI 10.4161/cc.9.18.13204; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Torban E, 2008, P NATL ACAD SCI USA, V105, P3449, DOI 10.1073/pnas.0712126105; Torban E, 2012, CURR TOP DEV BIOL, V101, P237, DOI 10.1016/B978-0-12-394592-1.00005-3; Trinh J., 2009, THESIS; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319	49	26	26	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5158	5167		10.1038/onc.2017.126	http://dx.doi.org/10.1038/onc.2017.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481871	Green Submitted, Green Accepted			2022-12-28	WOS:000409371100007
J	Yang, N; Leung, EH; Liu, C; Li, L; Eguether, T; Yao, XJJ; Jones, EC; Norris, DA; Liu, A; Clark, RA; Roop, DR; Pazour, GJ; Shroyer, KR; Chen, J				Yang, N.; Leung, EL-H; Liu, C.; Li, L.; Eguether, T.; Yao, X-J Jun; Jones, E. C.; Norris, D. A.; Liu, A.; Clark, R. A.; Roop, D. R.; Pazour, G. J.; Shroyer, K. R.; Chen, J.			INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma	ONCOGENE			English	Article							HEDGEHOG PATHWAY; HAIR FOLLICLE; VERTEBRATE DEVELOPMENT; EMBRYONIC-DEVELOPMENT; HUMAN HOMOLOG; STEM-CELLS; POLARITY; MOUSE; DIFFERENTIATION; CILIOGENESIS	Inturned (INTU), a cilia and planar polarity effector, performs prominent ciliogenic functions during morphogenesis, such as in the skin. INTU is expressed in adult tissues but its role in tissue maintenance is unknown. Here, we report that the expression of the INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased primary cilia formation and activated hedgehog (Hh) signaling. Disrupting Intu in an oncogenic mutant Smo (SmoM2)-driven BCC mouse model prevented the formation of BCC through suppressing primary cilia formation and Hh signaling, suggesting that Intu performs a permissive role during BCC formation. INTU is essential for intraflagellar transport A complex assembly during ciliogenesis. To further determine whether Intu is directly involved in the activation of Hh signaling downstream of ciliogenesis, we examined the Hh signaling pathway in mouse embryonic fibroblasts, which readily responds to the Hh pathway activation. Depleting Intu blocked Smo agonist-induced Hh pathway activation, whereas the expression of Gli2 Delta N, a constitutively active Gli2, restored Hh pathway activation in Intu-deficient cells, suggesting that INTU functions upstream of Gli2 activation. In contrast, overexpressing Intu did not promote ciliogenesis or Hh signaling. Taken together, data obtained from this study suggest that INTU is indispensable during BCC tumorigenesis and that its aberrant upregulation is likely a prerequisite for primary cilia formation during Hh-dependent tumorigenesis.	[Yang, N.; Liu, C.; Shroyer, K. R.; Chen, J.] SUNY Stony Brook, Dept Pathol, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA; [Leung, EL-H; Yao, X-J Jun; Chen, J.] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Li, L.] Beijing Union Med Coll Hosp, Dept Dermatol, Beijing, Peoples R China; [Eguether, T.; Pazour, G. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Jones, E. C.; Clark, R. A.; Chen, J.] SUNY Stony Brook, Dept Dermatol, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA; [Norris, D. A.; Roop, D. R.] Univ Colorado Denver, Charles C Gates Ctr Regenerat Med, Aurora, CO USA; [Liu, A.] Penn State Univ, Dept Biol, Eberly Coll Sci, University Pk, PA 16802 USA; [Roop, D. R.] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Macau University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Chen, J (corresponding author), SUNY Stony Brook, Dept Pathol, Sch Med, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA.	jiang.chen@stonybrook.edu	Eguether, Thibaut/AAZ-5403-2020	Eguether, Thibaut/0000-0003-1891-9253; Liu, Aimin/0000-0003-0099-0879	Research Histology Core Laboratory of the Department of Pathology; Cancer Center of Stony Brook University; NIH [AR061485, AR060388, CA052607]; PKD foundation [02YI08A]; SDRC of University of Colorado Denver (NIH) [AR057212]; REACH program of Stony Brook University (NIH) [U01HL127522]; REACH program of Stony Brook University (NYS Department of Economic Development) [C140151]; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL127522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061485, R01AR060388, P30AR057212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060992] Funding Source: NIH RePORTER	Research Histology Core Laboratory of the Department of Pathology; Cancer Center of Stony Brook University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PKD foundation; SDRC of University of Colorado Denver (NIH); REACH program of Stony Brook University (NIH); REACH program of Stony Brook University (NYS Department of Economic Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Stephanie Burke and Mallory Korman for histology assistance. This study is supported by the Research Histology Core Laboratory of the Department of Pathology, the Cancer Center of Stony Brook University, and research grants from NIH (AR061485 to JC; AR060388 and CA052607 to DRR), a Young Investigator Career Development Award from the PKD foundation (02YI08A to AL), a Pilot and Feasibility Award from the SDRC of University of Colorado Denver (NIH, AR057212), and the REACH program of Stony Brook University (NIH, U01HL127522 and the NYS Department of Economic Development, C140151).	Aszterbaum M, 1999, J INVEST DERM SYMP P, V4, P41, DOI 10.1038/sj.jidsp.5640179; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; Basset-Seguin N, 2015, MOL CANCER THER, V14, P633, DOI 10.1158/1535-7163.MCT-14-0703; Chang R, 2015, DEV DYNAM, V244, P736, DOI 10.1002/dvdy.24272; Cui C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001720; Dai D, 2013, CELL DEATH DIFFER, V20, P130, DOI 10.1038/cdd.2012.104; Dai D, 2011, J INVEST DERMATOL, V131, P302, DOI 10.1038/jid.2010.306; DeRouen MC, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-112; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Gray RS, 2009, NAT CELL BIOL, V11, P1225, DOI 10.1038/ncb1966; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Heydeck W, 2011, DEV DYNAM, V240, P1938, DOI 10.1002/dvdy.22696; Heydeck W, 2009, DEV DYNAM, V238, P3035, DOI 10.1002/dvdy.22130; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Metcalfe C, 2011, CANCER RES, V71, P5057, DOI 10.1158/0008-5472.CAN-11-0923; Oh EC, 2012, DEVELOPMENT, V139, P443, DOI 10.1242/dev.050054; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753; Park WJ, 1996, DEVELOPMENT, V122, P961; Peterson SC, 2015, CELL STEM CELL, V16, P400, DOI 10.1016/j.stem.2015.02.006; Pricl S, 2015, MOL ONCOL, V9, P389, DOI 10.1016/j.molonc.2014.09.003; Sanchez-Danes A, 2016, NATURE, V536, P298, DOI 10.1038/nature19069; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Toriyama M, 2016, NAT GENET, V48, P648, DOI 10.1038/ng.3558; Villumsen BH, 2013, EMBO J, V32, P3029, DOI 10.1038/emboj.2013.223; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wong SY, 2014, J INVEST DERMATOL, V134, pE18, DOI 10.1038/skinbio.2014.4; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yasuda Masahito, 2013, Methods Mol Biol, V989, P143, DOI 10.1007/978-1-62703-330-5_12; Youssef KK, 2012, NAT CELL BIOL, V14, P1282, DOI 10.1038/ncb2628; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zeng HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015900; Zeng HQ, 2010, DEV BIOL, V339, P418, DOI 10.1016/j.ydbio.2010.01.003; Zhang ZC, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024608, 10.1371/journal.pone.0028817]; Zilber Y, 2013, MOL BIOL CELL, V24, P555, DOI 10.1091/mbc.E12-06-0437	45	14	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4997	5005		10.1038/onc.2017.117	http://dx.doi.org/10.1038/onc.2017.117			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459465	Green Accepted			2022-12-28	WOS:000408768800005
J	Jalaguier, S; Teyssier, C; Achour, TN; Lucas, A; Bonnet, S; Rodriguez, C; Elarouci, N; Lapierre, M; Cavailles, V				Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Elarouci, N.; Lapierre, M.; Cavailles, V.			Complex regulation of LCoR signaling in breast cancer cells	ONCOGENE			English	Article							RECEPTOR-INTERACTING PROTEIN-140; DEPENDENT COREPRESSOR ACTS; TRANSCRIPTIONAL REPRESSION; ESTROGEN; RIP140; GENE; EXPRESSION; ALPHA; CONTRIBUTES; ACTIVATION	Ligand-dependent corepressor (LCoR) is a transcriptional repressor of ligand-activated estrogen receptors (ERs) and other transcription factors that acts both by recruiting histone deacetylases and C-terminal binding proteins. Here, we first studied LCOR gene expression in breast cancer cell lines and tissues. We detected two mRNAs variants, LCoR and LCoR2 (which encodes a truncated LCoR protein). Their expression was highly correlated and localized in discrete nuclear foci. LCoR and LCoR2 strongly repressed transcription, inhibited estrogen-induced target gene expression and decreased breast cancer cell proliferation. By mutagenesis analysis, we showed that the helix-turn-helix domain of LCoR is required for these effects. Using in vitro interaction, coimmunoprecipitation, proximity ligation assay and confocal microscopy experiments, we found that receptor-interacting protein of 140 kDa (RIP140) is a LCoR and LCoR2 partner and that this interaction requires the HTH domain of LCoR and RIP140 N- and C-terminal regions. By increasing or silencing LCoR and RIP140 expression in human breast cancer cells, we then showed that RIP140 is necessary for LCoR inhibition of gene expression and cell proliferation. Moreover, LCoR and RIP140 mRNA levels were strongly correlated in breast cancer cell lines and biopsies. In addition, RIP140 positively regulated LCoR expression in human breast cancer cells and in transgenic mouse models. Finally, their expression correlated with overall survival of patients with breast cancer. Taken together, our results provide new insights into the mechanism of action of LCoR and RIP140 and highlight their strong interplay for the control of gene expression and cell proliferation in breast cancer cells.	[Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Inst Rech Cancerol Montpellier, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] INSERM, U1194, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Univ Montpellier, Montpellier, France; [Jalaguier, S.; Teyssier, C.; Achour, T. Nait; Lucas, A.; Bonnet, S.; Rodriguez, C.; Lapierre, M.; Cavailles, V.] Inst Reg Canc Montpellier, Montpellier, France; [Elarouci, N.] Ligue Natl Contre Le Canc, Programme Cartes Identite Tumeurs CIT, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Jalaguier, S; Cavailles, V (corresponding author), INSERM, Inst Rech Cancerol Montpellier, U1194, 208 Rue Apothicaires, F-34298 Montpellier 5, France.	stephan.jalaguier@inserm.fr; vincent.cavailles@inserm.fr	Teyssier, Catherine/AAC-2395-2020; Cavailles, Vincent/Y-5379-2019; cavailles, vincent/C-6277-2017; Jalaguier, Stéphan/AAC-1847-2020; Lapierre, Marion/AAB-2845-2020	Teyssier, Catherine/0000-0003-4937-6503; Cavailles, Vincent/0000-0002-7160-3074; Lapierre, Marion/0000-0002-4708-805X; Jalaguier, Stephan/0000-0002-0149-3738	Ligue Nationale contre le Cancer; Association pour la Recherche contre le Cancer; INSERM, Universite de Montpellier; Prix Ruban Rose	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); INSERM, Universite de Montpellier; Prix Ruban Rose	We thank Dr Arnaud Besson (CRCT, Toulouse, France) for providing MEF cells expressing or not p21, Dylane Detilleux for her help in characterizing stably transfected T47D cell lines. TNA received grants from Ligue Nationale contre le Cancer and Association pour la Recherche contre le Cancer. This work was funded by INSERM, Universite de Montpellier and the Prix Ruban Rose.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Achour TN, 2014, MOL ENDOCRINOL, V28, P183, DOI 10.1210/me.2013-1376; Aravind L, 2005, FEMS MICROBIOL REV, V29, P231, DOI 10.1016/j.fmrre.2004.12.008; Asim M, 2011, J BIOL CHEM, V286, P37108, DOI 10.1074/jbc.M111.292771; Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376; Augereau Patrick, 2006, Nucl Recept Signal, V4, pe024; Augereau P, 2006, J STEROID BIOCHEM, V102, P51, DOI 10.1016/j.jsbmb.2006.09.005; Aziz MH, 2015, ONCOTARGET, V6, P39714, DOI 10.18632/oncotarget.5356; Calderon MR, 2014, NUCLEIC ACIDS RES, V42, P7012, DOI 10.1093/nar/gku413; Calderon MR, 2012, J BIOL CHEM, V287, P8662, DOI 10.1074/jbc.M111.311605; Carascossa S, 2006, MOL ENDOCRINOL, V20, P1506, DOI 10.1210/me.2005-0286; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Ho PC, 2012, NAT IMMUNOL, V13, P379, DOI 10.1038/ni.2238; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Lapierre M, 2014, J CLIN INVEST, V124, P1899, DOI 10.1172/JCI65178; Lei JJ, 2015, ONCOTARGET, V6, P25701, DOI 10.18632/oncotarget.4573; Madak-Erdogan Z, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.28; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Muranen TA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3015; Nautiyal J, 2013, DEVELOPMENT, V140, P1079, DOI 10.1242/dev.085720; Orlando S, 2015, NUCLEIC ACIDS RES, V43, P6860, DOI 10.1093/nar/gkv593; Palijan A, 2009, J BIOL CHEM, V284, P30275, DOI 10.1074/jbc.M109.051201; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Poulard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126181; Rosell M, 2011, BBA-MOL BASIS DIS, V1812, P919, DOI 10.1016/j.bbadis.2010.12.016; Savatier J, 2010, BIOCHEMISTRY-US, V49, P772, DOI 10.1021/bi9013006; Song YY, 2012, J HEPATOL, V56, P248, DOI 10.1016/j.jhep.2011.07.014; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002	37	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4790	4801		10.1038/onc.2017.97	http://dx.doi.org/10.1038/onc.2017.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414308	Green Published, hybrid			2022-12-28	WOS:000407702400011
J	Lu, W; Cheng, F; Yan, W; Li, X; Yao, X; Song, W; Liu, M; Shen, X; Jiang, H; Chen, J; Li, J; Huang, J				Lu, W.; Cheng, F.; Yan, W.; Li, X.; Yao, X.; Song, W.; Liu, M.; Shen, X.; Jiang, H.; Chen, J.; Li, J.; Huang, J.			Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA	ONCOGENE			English	Article							CYCLOPHILIN-A; ACQUIRED-RESISTANCE; ISOMERASE ACTIVITY; COMPLEX PROMOTES; CYCLOSPORINE-A; MUTANT P53; CISPLATIN; BINDING; SUPPRESSION; ACTIVATION	TP53 plays essential roles in tumor initiation and progression, and is frequently mutated in cancer. However, pharmacological stabilization and reactivation of p53 have not been actively explored for targeted cancer therapies. Herein, we identify a novel Cyclophilin A (CypA) small molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and apoptosis via restoring p53 expression. We find that HL001 stabilizes p53 through inhibiting the MDM2-mediated p53 ubiquitination. Further mechanistic studies reveal that the downregulation of G3BP1 and the induction of reactive oxygen species and DNA damage by HL001 contribute to p53 stabilization. Surprisingly, HL001 selectively suppresses tumor growth in p53 wildtype NSCLC harboring Arg72 homozygous alleles (p53-72R) through disrupting interaction between MDM2 and p53-72R in a CypA-dependent manner. Moreover, combining HL001 with cisplatin synergistically enhance tumor regression in orthotopic NSCLC mouse model. Collectively, this study demonstrates that pharmacologic inhibition of CypA offers a potential therapeutic strategy via specific activation of p53-72R in NSCLC.	[Lu, W.; Yan, W.; Li, X.; Yao, X.; Shen, X.; Jiang, H.; Li, J.; Huang, J.] East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Sch Life Sci, Shanghai, Peoples R China; [Cheng, F.] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Cheng, F.] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China; [Song, W.; Chen, J.] Vanderbilt Univ, Sch Med, Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Shen, X.; Jiang, H.] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai, Peoples R China; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Cheng, F.] Harvard Med Sch, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA USA; [Cheng, F.] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA	East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; Sichuan University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northeastern University	Li, J; Huang, J (corresponding author), East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China.	jianli@ecust.edu.cn; huangjin@ecust.edu.cn		huang, jin/0000-0002-0698-1693; XUE, YAO/0000-0002-1806-7372; Cheng, Feixiong/0000-0002-1736-2847; Chen, Jin/0000-0002-5557-2079	National Natural Science Foundation of China [21222211, 31371485, 81402482, 91313303, 81573020]; CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology [14ZR1411100, 15431902000]; China Postdoctoral Science Foundation [2014M551361, 2015T80415]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We are grateful to Mr Lianbiao Cheng, Miss Jiaqian Pu and Miss Ningning Dong (all from Jin Huang lab) for material and intellectual help with the design and execution of some of these experiments. The authors thank Professor Jose M Cuezva (Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid, Madrid, Spain) for providing G3BP1 plasmid; Professor Xiangshi Tan (Department of Chemistry, Fudan University, Shanghai, China) for providing the pMAL-c2x-derived MBPHT-Cherry2 vector; Professor Yi Yang (Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China) for providing H23, H838, H1703 and H2126 lung cancer cell lines. The work is supported by the National Natural Science Foundation of China (21222211, 31371485, 81402482, 91313303 and 81573020), CAS Key Laboratory of Receptor Research, the Shanghai Committee of Science and Technology (14ZR1411100 and 15431902000), China Postdoctoral Science Foundation Grant (2014M551361 and 2015T80415).	Abraham S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8286; Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123; Bai JPF, 2013, ANNU REV PHARMACOL, V53, P451, DOI 10.1146/annurev-pharmtox-011112-140248; Baum N, 2009, ONCOGENE, V28, P3915, DOI 10.1038/onc.2009.248; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Bonfils C, 2010, BIOCHEM BIOPH RES CO, V393, P325, DOI 10.1016/j.bbrc.2010.01.135; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cheng FX, 2017, TRENDS IMMUNOL, V38, P77, DOI 10.1016/j.it.2016.11.007; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Choudhury R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4078; Cohen P, 2013, ACS CHEM BIOL, V8, P96, DOI 10.1021/cb300610s; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Hamilton G, 2014, CURR CANCER DRUG TAR, V14, P46, DOI 10.2174/15680096113136660109; Hong F, 2002, FASEB J, V16, P1633, DOI 10.1096/fj.02-0060fje; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Klein DK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6800; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; MUTCH DG, 1992, GYNECOL ONCOL, V47, P28, DOI 10.1016/0090-8258(92)90070-Y; Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Puente XS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-15; Rajagopalan S, 2009, J BIOL CHEM, V284, P21728, DOI 10.1074/jbc.M109.006429; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang HR, 2007, BIOCHEM BIOPH RES CO, V361, P763, DOI 10.1016/j.bbrc.2007.07.085; Zhu D, 2015, NAT MED, V21, P572, DOI 10.1038/nm.3867; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	44	13	13	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4719	4731		10.1038/onc.2017.41	http://dx.doi.org/10.1038/onc.2017.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394340	Green Published, hybrid			2022-12-28	WOS:000407702400005
J	Jain, A; Tripathi, R; Turpin, CP; Wang, C; Plattner, R				Jain, A.; Tripathi, R.; Turpin, C. P.; Wang, C.; Plattner, R.			Ab1 kinase regulation by BRAF/ERK and cooperation with Akt in melanoma	ONCOGENE			English	Article							C-ABL; METASTATIC MELANOMA; MALIGNANT-MELANOMA; MUTANT MELANOMA; FAMILY KINASES; MEK INHIBITION; RAF INHIBITORS; CANCER; RESISTANCE; INVASION	The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring BRAFV600E and PTEN mutations often are resistant to current therapies, including BRAF inhibitors (BRAFi) and immune checkpoint inhibitors. Abl kinases (Abl/Arg) are activated in melanomas and drive progression; however, their mechanism of activation has not been established. Here we elucidate a novel link between BRAF(V600E)/ERK signaling and Abl kinases. We demonstrate that BRAF(V600E)/ERK play a critical role in binding, phosphorylating and regulating Abl localization and Abl/Arg activation by Src family kinases. Importantly, Abl/Arg activation downstream of BRAFV600E has functional and biological significance, driving proliferation, invasion, as well as switch in epithelial-mesenchymal-transition transcription factor expression, which is known to be critical for melanoma cells to shift between differentiated and invasive states. Finally, we describe findings of high translational significance by demonstrating that Abl/Arg cooperate with PI3K/Akt/PTEN, a parallel pathway that is associated with intrinsic resistance to BRAFi and immunotherapy, as Abl/Arg and Akt inhibitors cooperate to prevent viability, cell cycle progression and in vivo growth of melanomas harboring mutant BRAF/PTEN. Thus, these data not only provide mechanistic insight into Abl/Arg regulation during melanoma development, but also pave the way for the development of new strategies for treating patients with melanomas harboring mutant BRAF/PTEN, which often are refractory to current therapies.	[Jain, A.; Tripathi, R.; Turpin, C. P.; Plattner, R.] Univ Kentucky, Sch Med, Dept Pharmacol & Nutr Sci, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Plattner, R.] Univ Kentucky, Sch Med, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Pharmacol & Nutr Sci, 800 Rose St,Combs Res Bldg,Rm 209, Lexington, KY 40536 USA.	rplat2@uky.edu	Tripathi, Rakshamani/J-8450-2019	Tripathi, Rakshamani/0000-0001-9394-1173; Turpin, Courtney/0000-0001-6299-8062	Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources; Research Communication Office [P30CA177558]; NIH Grant [R01CA166499]; NATIONAL CANCER INSTITUTE [P30CA177558, R01CA166499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007778] Funding Source: NIH RePORTER	Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources; Research Communication Office; NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources and the Research Communication Office (P30CA177558). We thank Drs D'Orazio and Kyprianou for critically reading the manuscript. This work was supported by NIH Grant R01CA166499 to RP.	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Tran A, 2012, EXPERT OPIN INV DRUG, V21, P861, DOI 10.1517/13543784.2012.679341; Anderson WF, 2009, CANCER, V115, P4176, DOI 10.1002/cncr.24481; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Choi Y, 2009, J BIOL CHEM, V284, P29005, DOI 10.1074/jbc.M109.026633; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Fiore LS, 2014, ONCOGENE, V33, P4508, DOI 10.1038/onc.2013.399; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Ganguly Sourik S, 2012, Genes Cancer, V3, P414, DOI 10.1177/1947601912458586; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Girotti MR, 2014, MOL ONCOL, V8, P1140, DOI 10.1016/j.molonc.2014.07.027; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Karimkhani C, 2014, AM J CLIN DERMATOL, V15, P323, DOI 10.1007/s40257-014-0083-7; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Li R, 2011, CURR BIOL, V21, P1534, DOI 10.1016/j.cub.2011.08.023; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Murray JC, 2014, CANCER IMMUNOL RES, V2, P1186, DOI 10.1158/2326-6066.CIR-14-0083; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3; Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171; Queirolo P, 2015, CANCER TREAT REV, V41, P519, DOI 10.1016/j.ctrv.2015.04.010; Redondo P, 2004, J INVEST DERMATOL, V123, P1208, DOI 10.1111/j.0022-202X.2004.23496.x; Richard G, 2016, EMBO MOL MED, V8, P1143, DOI 10.15252/emmm.201505971; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sims JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055509; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vandamme N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00352; Vultur A, 2014, ONCOGENE, V33, P1850, DOI 10.1038/onc.2013.131; Wang J, 2015, TRENDS CANCER, V1, P110, DOI 10.1016/j.trecan.2015.07.004; Weiss MB, 2014, MOL CANCER RES, V12, P1314, DOI 10.1158/1541-7786.MCR-14-0170; Wheler J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1029-z; Wilden SM, 2016, J DTSCH DERMATOL GES, V14, P685, DOI [10.1111/ddg.13012_g, 10.1111/ddg.13012]; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zhang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066108; Zhao FS, 2015, BIOSCI TRENDS, V9, P325, DOI 10.5582/bst.2015.01106	54	12	12	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4585	4596		10.1038/onc.2017.76	http://dx.doi.org/10.1038/onc.2017.76			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368422	Green Accepted			2022-12-28	WOS:000407246200006
J	Gupta, R; Yang, Q; Dogra, SK; Wajapeyee, N				Gupta, R.; Yang, Q.; Dogra, S. K.; Wajapeyee, N.			Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression	ONCOGENE			English	Article							APOPTOSIS INDUCTION; WT1 EXPRESSION; METABOLISM; PATHWAY; SHMT1; SUPPRESSORS; CARCINOMA; CELLS; PROLIFERATION; POLYMORPHISMS	High-grade serous (HGS) ovarian cancer accounts for 90% of all ovarian cancer-related deaths. However, factors that drive HGS ovarian cancer tumor growth have not been fully elucidated. In particular, comprehensive analysis of the metabolic requirements of ovarian cancer tumor growth has not been performed. By analyzing The Cancer Genome Atlas mRNA expression data for HGS ovarian cancer patient samples, we observed that six enzymes of the folic acid metabolic pathway were overexpressed in HGS ovarian cancer samples compared with normal ovary samples. Systematic knockdown of all six genes using short hairpin RNAs (shRNAs) and follow-up functional studies demonstrated that serine hydroxymethyl transferase 1 (SHMT1) was necessary for ovarian cancer tumor growth and cell migration in culture and tumor formation in mice. SHMT1 promoter analysis identified transcription factor Wilms tumor 1 (WT1) binding sites, and WT1 knockdown resulted in reduced SHMT1 transcription in ovarian cancer cells. Unbiased large-scale metabolomic analysis and transcriptome-wide mRNA expression profiling identified reduced levels of several metabolites of the amino sugar and nucleotide sugar metabolic pathways, including sialic acid N-acetylneuraminic acid (Neu5Ac), and downregulation of pro-oncogenic cytokines interleukin-6 and 8 (IL-6 and IL-8) as unexpected outcomes of SHMT1 loss. Overexpression of either IL-6 or IL-8 partially rescued SHMT1 loss-induced tumor growth inhibition and migration. Supplementation of culture medium with Neu5Ac stimulated expression of IL-6 and IL-8 and rescued the tumor growth and migratory phenotypes of ovarian cancer cells expressing SHMT1 shRNAs. In agreement with the ovarian tumor-promoting role of Neu5Ac, treatment with Neu5Ac-targeting glycomimetic P-3Fax-Neu5Ac blocked ovarian cancer growth and migration. Collectively, these results demonstrate that SHMT1 controls the expression of pro-oncogenic inflammatory cytokines by regulating sialic acid Neu5Ac to promote ovarian cancer tumor growth and migration. Thus, targeting of SHMT1 and Neu5Ac represents a precision therapy opportunity for effective HGS ovarian cancer treatment.	[Gupta, R.; Yang, Q.; Wajapeyee, N.] Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA; [Dogra, S. K.] ASTAR, Singapore Inst Clin Sci, Brenner Ctr Mol Med, Singapore, Singapore	Yale University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS)	Wajapeyee, N (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA.	Narendra.Wajapeyee@yale.edu	Dogra, Shaillay Kumar/K-7073-2015		National Institutes of Health [R21CA197758-01, R21CA191364-01, R01CA196566-01A1, R01CA200919-01, R41 (1R41CA195908-01A1)]; American Cancer Society [128347-RSG-15-212-01-TBG]; NATIONAL CANCER INSTITUTE [R21CA195077, R21CA197758, R21CA191364, R01CA200919, R01CA196566, R41CA195908] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the following grants from the National Institutes of Health: R21CA197758-01 (to NW), R21CA191364-01 (to NW), R01CA196566-01A1 (to NW), R01CA200919-01 (to NW) and R41 (1R41CA195908-01A1) (to NW). NW is also supported by a research scholar grant from the American Cancer Society (128347-RSG-15-212-01-TBG).	Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Bahari G, 2016, CELL MOL BIOL, V62, P45; Bull C, 2015, ACS NANO, V9, P733, DOI 10.1021/nn5061964; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30404; Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087; Gao B, 2016, J GENE MED, V49, P1325; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haneklaus M, 2015, IMMUNOL REV, V265, P53, DOI 10.1111/imr.12285; Huang WH, 2016, INT J ONCOL, V48, P1125, DOI 10.3892/ijo.2016.3318; Kohnz RA, 2016, ACS CHEM BIOL, V11, P2131, DOI 10.1021/acschembio.6b00433; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Lin L, 2014, CANCER DISCOV, V4, P1168, DOI 10.1158/2159-8290.CD-13-0747; Liu ZY, 2014, ANTICANCER RES, V34, P2331; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Masoodi M, 2015, BBA-MOL CELL BIOL L, V1851, P503, DOI 10.1016/j.bbalip.2014.09.023; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Pabalan N, 2013, INT J COLORECTAL DIS, V28, P925, DOI 10.1007/s00384-013-1639-3; Paone A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.482; Pearce OMT, 2016, GLYCOBIOLOGY, V26, P111, DOI 10.1093/glycob/cwv097; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Succi M, 2014, MOL BIOL REP, V41, P581, DOI 10.1007/s11033-013-2895-6; Tania M, 2010, CURR ONCOL, V17, P6; Vachharajani VT, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8167273; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang YW, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0065-z; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Williams SJ, 2009, GYNECOL ONCOL, V112, P637, DOI 10.1016/j.ygyno.2008.11.015; Wu SJ, 2016, TUMOR BIOL, V37, P5193, DOI 10.1007/s13277-015-4369-z; Yamamoto S, 2007, VIRCHOWS ARCH, V451, P27, DOI 10.1007/s00428-007-0433-4; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Zhang SY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2218-0	42	21	21	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4014	4024		10.1038/onc.2017.37	http://dx.doi.org/10.1038/onc.2017.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288142	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000405379900007
J	Huang, L; Wang, Z; Liu, C; Xu, C; Mbofung, RM; McKenzie, JA; Khong, H; Hwu, P; Peng, W				Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.			CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner	ONCOGENE			English	Article							PLASMACYTOID DENDRITIC CELLS; COMBINING TARGETED THERAPY; METASTATIC MELANOMA; IMMUNE-RESPONSES; VACCINE ADJUVANT; CANCER VACCINES; T-CELLS; TUMOR; ANTIGEN; DNA	Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumors with BRAF mutation rather than showing a synergistic antitumor effect. Our further studies demonstrated that CpG alone was sufficient to dampen BRAF inhibitor-induced antitumor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mice receiving CpG-based peptide vaccine is mainly dependent upon the use of CpG. Mechanistically, CpG increased the number of circulating B cells, which produced elevated amounts of tumor necrosis factor-alpha (TNF alpha) that contributed to the increased tumor resistance to BRAF inhibitors. More importantly, B-cell depletion or TNF alpha neutralization can restore the antitumor effect of BRAF inhibition in mice receiving CpG treatment, indicating that TNF alpha-secreting B cells play an indispensable role in BRAF inhibitor resistance induced by CpG. Taken together, our results strongly suggest that precautions must be implemented when designing combinatorial approaches for cancer treatment, because distinct regimens, despite their respective therapeutic benefit as monotherapy, may together provide antagonistic clinical outcomes.	[Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Peng, W (corresponding author), Univ Texas MD Anderson Canc Ctr, 7455 Fannin St Unit 904, Houston, TX 77054 USA.; Hwu, P (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	phwu@mdanderson.org; wpeng@mdanderson.org	Huang, Lu/I-4148-2018	Mbofung, Rina/0000-0003-3872-3143; Khong, Hiep/0000-0003-4888-7862	National Cancer Institute [R01CA116206, P01CA128913, R01CA187076, P50CA093459, P30CA016672]; NATIONAL CANCER INSTITUTE [R01CA116206, R01CA187076, P30CA016672, P50CA093459, P01CA128913] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hussein Tawbi for constructive comments on the manuscript. The research was supported in part by the following National Cancer Institute grants: R01CA116206 (to PH), P01CA128913 (to PH), R01CA187076 (to PH and MD), P50CA093459 and P30CA016672 (MDACC Melanoma SPORE and MDACC CCSG for JAM and Flow facility, respectively). By the Cancer Prevention and Research Institute of Texas (CPRIT RP140106 to JAM) and by philanthropic contributions to MDACC Melanoma Moon Shot Program; Melanoma Research Alliance Team Science Award; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Aim at Melanoma Foundation, Miriam and Jim Mulva research funds; Jurgen Sager & Transocean Melanoma Research Fund; El Paso Foundation for Melanoma Research; GillsonLogenbaugh Foundation. We thank Cherie Butts from Biogen for providing antimouse CD20 antibody.	Avalos AM, 2009, J IMMUNOL, V183, P6262, DOI 10.4049/jimmunol.0901941; Bauer S, 2002, CURR TOP MICROBIOL, V270, P145; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davila E, 2003, CANCER RES, V63, P3281; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105; Hanten JA, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-39; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Hu-Lieskovan S, 2014, J CLIN ONCOL, V32, P2248, DOI 10.1200/JCO.2013.52.1377; Jerome V, 2006, J IMMUNOTHER, V29, P294; Kim S, 2008, J IMMUNOTHER, V31, P446, DOI 10.1097/CJI.0b013e31816d1d6a; Kim Teresa, 2014, Cancer Biology Medicine, V11, P237, DOI 10.7497/j.issn.2095-3941.2014.04.002; Koya RC, 2012, CANCER RES, V72, P3928, DOI 10.1158/0008-5472.CAN-11-2837; Liu CW, 2008, J CLIN INVEST, V118, P1165, DOI 10.1172/JCI33583; Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626; Lou YY, 2011, J IMMUNOTHER, V34, P279, DOI 10.1097/CJI.0b013e31820d2a05; Mehta NK, 2015, CANCER IMMUNOL RES, V3, P836, DOI 10.1158/2326-6066.CIR-15-0112; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; Menon Dinoop R, 2013, Pigment Cell Melanoma Res, V26, P912, DOI 10.1111/pcmr.12139; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Peng WY, 2010, CLIN CANCER RES, V16, P5458, DOI 10.1158/1078-0432.CCR-10-0712; Perricone MA, 2004, J IMMUNOTHER, V27, P273, DOI 10.1097/00002371-200407000-00003; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Shirota H, 2015, VACCINES-BASEL, V3, P390, DOI 10.3390/vaccines3020390; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Smith MP, 2014, CANCER DISCOV, V4, P1214, DOI 10.1158/2159-8290.CD-13-1007; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tadmor T, 2011, CANCER IMMUNOL IMMUN, V60, P609, DOI 10.1007/s00262-011-0972-z; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833	35	7	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4081	4086		10.1038/onc.2017.35	http://dx.doi.org/10.1038/onc.2017.35			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28263973	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000405379900013
J	Tao, T; Sondalle, SB; Shi, H; Zhu, S; Perez-Atayde, AR; Peng, J; Baserga, SJ; Look, AT				Tao, T.; Sondalle, S. B.; Shi, H.; Zhu, S.; Perez-Atayde, A. R.; Peng, J.; Baserga, S. J.; Look, A. T.			The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma	ONCOGENE			English	Article							POLYMERASE I TRANSCRIPTION; SMALL-SUBUNIT PROCESSOME; NUCLEOLAR RNA; C-MYC; GRANULOCYTE DIFFERENTIATION; SACCHAROMYCES-CEREVISIAE; PROMINENT NUCLEOLI; RDNA TRANSCRIPTION; TUMOR INITIATION; CANCER	The nucleolar factor, digestive organ expansion factor (DEF), has a key role in ribosome biogenesis, functioning in pre-ribosomal RNA (pre-rRNA) processing as a component of the small ribosomal subunit (SSU) processome. Here we show that the peripheral sympathetic nervous system (PSNS) is very underdeveloped in def-deficient zebrafish, and that def haploinsufficiency significantly decreases disease penetrance and tumor growth rate in a MYCN-driven transgenic zebrafish model of neuroblastoma that arises in the PSNS. Consistent with these findings, DEF is highly expressed in human neuroblastoma, and its depletion in human neuroblastoma cell lines induces apoptosis. Interestingly, overexpression of MYCN in zebrafish and in human neuroblastoma cells results in the appearance of intermediate pre-rRNAs species that reflect the processing of pre-rRNAs through Pathway 2, a pathway that processes pre-rRNAs in a different temporal order than the more often used Pathway 1. Our results indicate that DEF and possibly other components of the SSU processome provide a novel site of vulnerability in neuroblastoma cells that could be exploited for targeted therapy.	[Tao, T.; Shi, H.; Look, A. T.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA; [Sondalle, S. B.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Shi, H.; Peng, J.] Zhejiang Univ, Coll Anim Sci, Hangzhou, Zhejiang, Peoples R China; [Zhu, S.] Mayo Clin, Canc Ctr, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA; [Zhu, S.] Mayo Clin, Ctr Individualized Med, Rochester, MN USA; [Zhu, S.] Mayo Clin, Ctr Canc, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA; [Perez-Atayde, A. R.] Harvard Med Sch, Childrens Hosp Boston, Dept Pathol, Boston, MA 02115 USA; [Baserga, S. J.] Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; Zhejiang University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard Medical School; Yale University; Yale University; Yale University; Yale University	Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	susan.baserga@yale.edu; thomas_look@dfci.harvard.edu	Sondalle, Samuel/C-1283-2014	Sondalle, Samuel/0000-0002-4144-9897; Tao, Ting/0000-0003-1260-2351	Innovation Award from Alex's Lemonade Stand Foundation; NIH [CA180692, GM115710, GM07205, HD007149, F30DK109582]; National Natural Science Foundation of China [31330050]; Young Investigator Award from Alex's Lemonade Stand Foundation; David Abraham Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK109582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205, R01GM115710] Funding Source: NIH RePORTER	Innovation Award from Alex's Lemonade Stand Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Investigator Award from Alex's Lemonade Stand Foundation; David Abraham Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John R Gilbert for editorial review of the manuscript and critical comments, and Hillary Layden and Shawna Chamberlin for their excellent care of the zebrafish. This work was supported by an Innovation Award from Alex's Lemonade Stand Foundation (ATL), NIH grant CA180692 (ATL), NIH grant GM115710 (SJB), a National Natural Science Foundation of China (No. 31330050; JP), a Young Investigator Award from Alex's Lemonade Stand Foundation (TT), NIH grants GM07205, HD007149 and F30DK109582 (SBS), and David Abraham Fellowship (HS).	An M, 2002, J COMP NEUROL, V446, P267, DOI 10.1002/cne.10214; Azuma M, 2006, J BIOL CHEM, V281, P13309, DOI 10.1074/jbc.M601892200; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bernstein KA, 2004, EUKARYOT CELL, V3, P1619, DOI 10.1128/EC.3.6.1619-1626.2004; Boglev Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003279; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borovjagin AV, 1999, J MOL BIOL, V286, P1347, DOI 10.1006/jmbi.1999.2527; Bywater MJ, 2013, NAT REV CANCER, V13, P299, DOI 10.1038/nrc3496; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Charette JM, 2010, RNA, V16, P2156, DOI 10.1261/rna.2359810; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dave B, 2014, P NATL ACAD SCI USA, V111, P8838, DOI 10.1073/pnas.1320769111; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Dutton KA, 2001, DEVELOPMENT, V128, P4113; Essers PB, 2014, DEV BIOL, V385, P304, DOI 10.1016/j.ydbio.2013.10.029; Etchin J, 2011, METHOD CELL BIOL, V105, P309, DOI 10.1016/B978-0-12-381320-6.00013-8; Fleurie A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004275; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Goldfeder MB, 2010, FEBS J, V277, P2838, DOI 10.1111/j.1742-4658.2010.07701.x; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Griffin JN, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005018; Hannan KM, 2013, BBA-GENE REGUL MECH, V1829, P342, DOI 10.1016/j.bbagrm.2012.10.014; Harscoet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012829; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Henras AK, 2015, WIRES RNA, V6, P225, DOI 10.1002/wrna.1269; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kang J, 2016, ONCOTARGET, V7, P48887, DOI 10.18632/oncotarget.10346; Kim CH, 1996, NEUROSCI LETT, V216, P109, DOI 10.1016/0304-3940(96)13021-4; Kobayashi C, 2005, CANCER-AM CANCER SOC, V103, P174, DOI 10.1002/cncr.20717; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mitchell NC, 2015, CELL SIGNAL, V27, P2045, DOI 10.1016/j.cellsig.2015.07.018; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Montanaro L, 2013, ONCOTARGETS THER, V6, P909, DOI 10.2147/OTT.S36627; Murphy DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008154; Nakaguro M, 2015, CANCER SCI, V106, P237, DOI 10.1111/cas.12598; Nakamura Y, 2007, BIOCHEM BIOPH RES CO, V354, P892, DOI 10.1016/j.bbrc.2007.01.057; Pei DS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003533; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Pestov Dimitri G, 2008, Curr Protoc Cell Biol, VChapter 22, DOI 10.1002/0471143030.cb2211s39; Pezzolo A, 2009, NEURO-ONCOLOGY, V11, P192, DOI 10.1215/15228517-2008-086; Phipps KR, 2011, WIRES RNA, V2, P1, DOI 10.1002/wrna.57; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Preti M, 2013, NUCLEIC ACIDS RES, V41, P4709, DOI 10.1093/nar/gkt160; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Sloan KE, 2013, J CELL BIOL, V200, P577, DOI 10.1083/jcb.201207131; Stanke M, 1999, DEVELOPMENT, V126, P4087; Stewart RA, 2006, DEV BIOL, V292, P174, DOI 10.1016/j.ydbio.2005.12.035; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Tao T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058858; Tao T, 2013, CELL RES, V23, P620, DOI 10.1038/cr.2013.16; Tornoczky T, 2007, PATHOL ONCOL RES, V13, P269, DOI 10.1007/BF02940304; Wang HZ, 2009, CELL RES, V19, P1150, DOI 10.1038/cr.2009.99; Wang LL, 2013, CANCER-AM CANCER SOC, V119, P3718, DOI 10.1002/cncr.28251; Wang MS, 2014, NUCLEIC ACIDS RES, V42, P11180, DOI 10.1093/nar/gku787; Wang Y, 2012, INT J ANTENN PROPAG, V2012, DOI 10.1155/2012/636349; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WEINBERG RA, 1970, J MOL BIOL, V47, P169, DOI 10.1016/0022-2836(70)90337-2; WEINBERG RA, 1967, P NATL ACAD SCI USA, V58, P1088, DOI 10.1073/pnas.58.3.1088; Wilkins BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077670; Woolford JL, 2013, GENETICS, V195, P643, DOI 10.1534/genetics.113.153197; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010; Zhu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096576	78	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3852	3867		10.1038/onc.2016.527	http://dx.doi.org/10.1038/onc.2016.527			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263972	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000404848200006
J	Sankpal, NV; Fleming, TP; Sharma, PK; Wiedner, HJ; Gillanders, WE				Sankpal, N. V.; Fleming, T. P.; Sharma, P. K.; Wiedner, H. J.; Gillanders, W. E.			A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer	ONCOGENE			English	Article							BREAST-CANCER; STEM-CELLS; E-CADHERIN; CLAUDIN-LOW; THERAPEUTIC TARGET; EXPRESSION; METASTASIS; RESISTANCE; PROGNOSIS; ADHESION	Epithelial-mesenchymal transition (EMT) is an important biological process that has been implicated in cancer metastasis. Epithelial cell adhesion molecule (EpCAM) is expressed at the basolateral membrane of most normal epithelial cells but is overexpressed in many epithelial cancers. In our studies on the role of EpCAM in cancer biology, we observed that EpCAM expression is decreased in mesenchymal-like primary cancer specimens in vivo and following induction of EMT in cancer cell lines in vitro. Extracellular signal-related kinase (ERK) is a key regulator of EMT. We observed that EpCAM expression is decreased with activation of the ERK pathway in primary cancer specimens in vivo and in cancer cell lines in vitro. In experimental models, growth factor stimulation and/or oncogene-induced ERK2 activation suppressed EpCAM expression, whereas genetic or pharmacological inhibition of the ERK pathway restored EpCAM expression. In detailed studies of the EpCAM promoter region, we observed that ERK2 suppresses EpCAM transcription directly by binding to a consensus ERK2-binding site in the EpCAM promoter and indirectly through activation of EMT-associated transcription factors SNAI1, SNAI2, TWIST1 and ZEB1, which bind to E-box sites in the EpCAM promoter. Surprisingly, EpCAM appears to modulate ERK activity. Using multiple cell lines, we demonstrated that specific ablation of EpCAM resulted in increased ERK pathway activity and SNAI2 expression, migration and invasion, whereas forced expression of EpCAM resulted in decreased ERK pathway activity and SNAI2 expression, migration and invasion. These observations provide important insights into the regulation of EpCAM expression during EMT, demonstrate an unexpected role for EpCAM in the regulation of ERK and define a novel double-negative feedback loop between EpCAM and ERK that contributes to the regulation of EMT. These studies have important translational implications as both EpCAM and ERK are currently being targeted in human clinical trials.	[Sankpal, N. V.; Fleming, T. P.; Sharma, P. K.; Wiedner, H. J.; Gillanders, W. E.] Washington Univ, Sch Med, Dept Surg, 660 South Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA; [Gillanders, W. E.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Gillanders, WE (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 South Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	gillandersw@wustl.edu		Wiedner, Hannah/0000-0002-5919-5944; Sharma, Piyush/0000-0002-6247-3503	Susan G Komen for the Cure [BCTR0707917]; Siteman Cancer Center fund [P30CA91842]; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kerry Kornfeld, Dr Jason Weber and Dr Gregory Longmore for reviewing the manuscript and providing valuable advice. This work was supported by a grant from Susan G Komen for the Cure (BCTR0707917) and Siteman Cancer Center fund (P30CA91842).	Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carlson SM, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002010; Cheng JC, 2013, ONCOGENE, V32, P1041, DOI 10.1038/onc.2012.127; Courcelles M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.25; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Eberlein C, 2015, ONCOGENE, V34, P704, DOI 10.1038/onc.2013.600; Feldman S, 2011, CANCER-AM CANCER SOC, V117, P2599, DOI 10.1002/cncr.25822; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gao JJ, 2015, J CELL PHYSIOL, V230, P775, DOI 10.1002/jcp.24802; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Hajra KM, 2002, CANCER RES, V62, P1613; Hook KE, 2012, MOL CANCER THER, V11, P710, DOI 10.1158/1535-7163.MCT-11-0184; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kusewitt DF, 2009, J INVEST DERMATOL, V129, P491, DOI 10.1038/jid.2008.222; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lyons JG, 2008, CANCER RES, V68, P4525, DOI 10.1158/1078-0432.CCR-07-6735; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Maghzal N, 2013, DEV CELL, V27, P263, DOI 10.1016/j.devcel.2013.10.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massoner P, 2014, BRIT J CANCER, V111, P955, DOI 10.1038/bjc.2014.366; Munz M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-44; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sankpal NV, 2013, MOL CANCER RES, V11, P418, DOI 10.1158/1541-7786.MCR-12-0518; Sankpal NV, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3070; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Shin J, 2013, CELL SIGNAL, V25, P2540, DOI 10.1016/j.cellsig.2013.08.014; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Soysal SD, 2013, BRIT J CANCER, V108, P1480, DOI 10.1038/bjc.2013.80; Spizzo G, 2004, BREAST CANCER RES TR, V86, P207, DOI 10.1023/B:BREA.0000036787.59816.01; Tarcic G, 2012, FASEB J, V26, P1582, DOI 10.1096/fj.11-194654; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vannier C, 2013, J BIOL CHEM, V288, P18643, DOI 10.1074/jbc.M113.467787; Yang XJ, 2010, CANCER RES, V70, P9463, DOI 10.1158/0008-5472.CAN-10-2388; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	59	41	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3706	3717		10.1038/onc.2016.504	http://dx.doi.org/10.1038/onc.2016.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192403	Green Accepted			2022-12-28	WOS:000404349700006
J	Li, GB; Zhang, HW; Fu, RQ; Hu, XY; Liu, L; Li, YN; Liu, YX; Liu, X; Hu, JJ; Deng, Q; Luo, QS; Zhang, R; Gao, N				Li, Guo-Bing; Zhang, Hong-Wei; Fu, Ruo-Qiu; Hu, Xiao-Ye; Liu, Lei; Li, Yu-Nong; Liu, Yan-Xia; Liu, Xin; Hu, Jin-Jiao; Deng, Qin; Luo, Qing-Song; Zhang, Rong; Gao, Ning			Mitochondrial fission and mitophagy depend on cofilin-mediated actin depolymerization activity at the mitochondrial fission site	ONCOGENE			English	Article							PINK1; APOPTOSIS; DYNAMICS; TRANSLOCATION; CYTOSKELETON; PARKIN; CONTRIBUTES; MECHANISMS; REGULATORS; RELEASE	Mitochondria fission and mitophagy are fundamentally crucial to cellular physiology and play important roles in cancer progression. Developing a comprehensive understanding of the molecular mechanism underlying mitochondrial fission and mitophagy will provide novel strategies for cancer prevention and treatment. Actin has been shown to participate in mitochondrial fission and mitophagy regulation. Cofilin is best known as an actin-depolymerizing factor. However, the molecular mechanism by which cofilin regulates mitochondrial fission and mitophagy remains largely unknown. Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Cofilin-mediated-PINK1 (PTEN-induced putative kinase 1) accumulation mainly depends on its regulation of mitochondrial proteases, including peptidase mitochondrial processing beta (MPP beta), presenilin-associated rhomboid-like protease (PARL), and ATPase family gene 3-like 2 (AFG3L2), via mitochondrial membrane potential activity. We also found that the interaction and colocalization of G-actin/F-actin with cofilin at mitochondrial fission sites undergo constriction after CCCP treatment. Pretreatment with the actin polymerization inhibitor latrunculin B (LatB) increased and actin-depolymerization inhibitor jasplakinolide (Jas) decreased mitochondrial translocation of actin induced by STS, ETO, and CCCP. Both LatB and Jas abrogated CCCP-mediated mitochondrial fission and mitophagy. Our data suggest that G-actin is the actin form that is translocated to mitochondria, and the actin-depolymerization activity regulated by cofilin at the mitochondrial fission site is crucial for inducing mitochondrial fission and mitophagy.	[Li, Guo-Bing; Zhang, Hong-Wei; Fu, Ruo-Qiu; Hu, Xiao-Ye; Liu, Lei; Li, Yu-Nong; Liu, Yan-Xia; Liu, Xin; Hu, Jin-Jiao; Deng, Qin; Luo, Qing-Song; Gao, Ning] Third Mil Med Univ, Coll Pharm, Chongqing, Peoples R China; [Li, Guo-Bing; Zhang, Rong] Third Mil Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China	Army Medical University; Army Medical University	Gao, N (corresponding author), Third Mil Med Univ, Coll Pharm, Chongqing, Peoples R China.; Zhang, R (corresponding author), Third Mil Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China.	xqpharmacylab@126.com; gaoning59@163.com	Hu, Xiaoye/AAY-2495-2020		National Natural Science Foundation of China [31571425, 81402970, 81402013]; Clinical Research Projects of Xinqiao Hospital, Third Military Medical University [2016YLC12]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical Research Projects of Xinqiao Hospital, Third Military Medical University	We thank James Bamburg (University of Wisconsin) for providing Cofilin-WT; Tamotsu Yoshimori (Osaka University) for RFP-LC3, and Nico Dantuma (Karolinska Institutet) for GFP-UB. This study was supported by the grants from National Natural Science Foundation of China (31571425; 81402970; 81402013) and Clinical Research Projects of Xinqiao Hospital, Third Military Medical University (2016YLC12).	Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110; Beck H, 2012, P NATL ACAD SCI USA, V109, pE2523, DOI 10.1073/pnas.1208141109; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Bordi M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00081; Campello S, 2014, BBA-BIOENERGETICS, V1837, P451, DOI 10.1016/j.bbabio.2013.11.010; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; de Vries RLA, 2013, MOL CELL NEUROSCI, V55, P37, DOI 10.1016/j.mcn.2012.07.008; Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Fedorowicz MA, 2014, EMBO REP, V15, P86, DOI 10.1002/embr.201337294; Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Hatch AL, 2014, J CELL SCI, V127, P4549, DOI 10.1242/jcs.153791; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Ji WK, 2015, ELIFE, V4, DOI [10.7554/eLife.11553.001, 10.7554/eLife.11553]; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Karbowski M, 2010, ADV EXP MED BIOL, V687, P131; Kasahara A, 2014, TRENDS CELL BIOL, V24, P761, DOI 10.1016/j.tcb.2014.08.005; Kast DJ, 2015, AUTOPHAGY, V11, P1702, DOI 10.1080/15548627.2015.1073434; Kim JE, 2014, CELL DEATH DIFFER, V21, P1036, DOI 10.1038/cdd.2014.17; Korobova F, 2014, CURR BIOL, V24, P409, DOI 10.1016/j.cub.2013.12.032; Korobova F, 2013, SCIENCE, V339, P464, DOI 10.1126/science.1228360; Kulikov AV, 2017, BIOCHEM BIOPH RES CO, V482, P432, DOI 10.1016/j.bbrc.2016.10.088; Li GB, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-50; Li GB, 2015, ONCOTARGET, V6, P1834, DOI 10.18632/oncotarget.2795; Li SA, 2015, J CELL BIOL, V208, P109, DOI 10.1083/jcb.201404050; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Matsuda S, 2015, FRONT BIOSCI-LANDMRK, V20, P491, DOI 10.2741/4321; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; O'Flanagan CH, 2014, BBA-REV CANCER, V1846, P590, DOI 10.1016/j.bbcan.2014.10.006; Aguilera MO, 2012, AUTOPHAGY, V8, P1590, DOI 10.4161/auto.21459; Pereira C, 2008, BBA-MOL CELL RES, V1783, P1286, DOI 10.1016/j.bbamcr.2008.03.010; Pi HF, 2013, AUTOPHAGY, V9, P1780, DOI 10.4161/auto.25665; Pon LA, 2013, CURR BIOL, V23, pR279, DOI 10.1016/j.cub.2013.02.042; Preau S, 2016, ANTIOXID REDOX SIGN, V24, P529, DOI 10.1089/ars.2015.6421; Sekino Y, 2007, NEUROCHEM INT, V51, P92, DOI 10.1016/j.neuint.2007.04.029; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490; Springer W, 2011, AUTOPHAGY, V7, P266, DOI 10.4161/auto.7.3.14348; van Raam BJ, 2006, INT J HEMATOL, V84, P199, DOI 10.1532/IJH97.06131; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhu JS, 2012, PHARMACOLOGY, V89, P348, DOI 10.1159/000338757	50	33	34	1	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1485	1502		10.1038/s41388-017-0064-4	http://dx.doi.org/10.1038/s41388-017-0064-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321664				2022-12-28	WOS:000427459500007
J	Mett, V; Komarova, EA; Greene, K; Bespalov, I; Brackett, C; Gillard, B; Gleiberman, AS; Toshkov, IA; Aygun-Sunar, S; Johnson, C; Karasik, E; Bapardekar-Nair, M; Kurnasov, OV; Osterman, AL; Stanhope-Baker, PS; Morrison, C; Moser, MT; Foster, BA; Gudkov, AV				Mett, V; Komarova, E. A.; Greene, K.; Bespalov, I; Brackett, C.; Gillard, B.; Gleiberman, A. S.; Toshkov, I. A.; Aygun-Sunar, S.; Johnson, C.; Karasik, E.; Bapardekar-Nair, M.; Kurnasov, O., V; Osterman, A. L.; Stanhope-Baker, P. S.; Morrison, C.; Moser, M. T.; Foster, B. A.; Gudkov, A., V			Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; TRANSGENIC MOUSE MODEL; ANTITUMOR IMMUNITY; HEPATIC METASTASES; CTLA-4 BLOCKADE; GENE-THERAPY; MURINE MODEL; FLAGELLIN; MELANOMA; AGONIST	Toll-like receptor 5 (TLR5) is considered an attractive target for anticancer immunotherapy. TLR5 agonists, bacterial flagellin and engineered flagellin derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple animal models and to be safe in both animals and humans. Anticancer efficacy of TLR5 agonists stems from TLR5-dependent activation of nuclear factor-kappa B (NF-kappa B) that mediates innate and adaptive antitumor immune responses. To extend application of TLR5-targeted anticancer immunotherapy to tumors that do not naturally express TLR5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expression of self-activating TLR5 signaling cassette comprising of human TLR5 and a secreted derivative of Salmonella flagellin structurally analogous to a clinical stage TLR5 agonist, entolimod. Co-expression of TLR5 receptor and agonist in Mobilan-infected cells established an autocrine/paracrine TLR5 signaling loop resulting in constitutive activation of NF-kappa B both in vitro and in vivo. Injection of Mobilan into primary tumors of the prostate cancer-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice resulted in a strong induction of multiple genes involved in inflammatory responses and mobilization of innate immune cells into the tumors including neutrophils and NK cells and suppressed tumor progression. Intratumoral injection of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts improved animal survival after surgical resection of the tumors, by suppression of tumor metastasis. In addition, vaccination of mice with irradiated Mobilan-transduced prostate tumor cells protected mice against subsequent tumor challenge. These results provide proof-of-concept for Mobilan as a tool for antitumor vaccination that directs TLR5-mediated immune response toward cancer cells and does not require identification of tumor antigens.	[Mett, V; Bespalov, I; Gleiberman, A. S.; Toshkov, I. A.; Aygun-Sunar, S.; Bapardekar-Nair, M.; Stanhope-Baker, P. S.; Gudkov, A., V] Cleveland Biolabs Inc, Buffalo, NY USA; [Komarova, E. A.; Greene, K.; Brackett, C.; Johnson, C.; Gudkov, A., V] Roswell Pk Canc Inst, Dept Cell Stress Biol, CGP L3-310,Elm & Carlton St, Buffalo, NY 14263 USA; [Gillard, B.; Karasik, E.; Moser, M. T.; Foster, B. A.] Roswell Pk Canc Inst, Dept Mol Pharmacol & Canc Therapeut, Buffalo, NY 14263 USA; [Kurnasov, O., V; Osterman, A. L.] Sanford Burnham Prebys Med Discovery Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA USA; [Morrison, C.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Roswell Park Cancer Institute	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, CGP L3-310,Elm & Carlton St, Buffalo, NY 14263 USA.	andrei.gudkov@roswellpark.org		gleiberman, anatoli/0000-0001-8491-0826	Panacela Labs, LLC; National Cancer Institute (NCI) Cancer Center Core Grant [P30CA016056]; DOD the Roswell Park Alliance Foundation [BC140507]; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	Panacela Labs, LLC; National Cancer Institute (NCI) Cancer Center Core Grant; DOD the Roswell Park Alliance Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Cellecta, Inc. and O.D.260, Inc. help with for adenoviral vector construction and manufacturing. This work was supported by contract from Panacela Labs (a biotech company that possesses intellectual property rights for Mobilan), LLC, National Cancer Institute (NCI) Cancer Center Core Grant P30CA016056 and by grants from DOD (BC140507 to AVG) the Roswell Park Alliance Foundation to EAK and AVG.	Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Arlen PM, 2007, J UROLOGY, V178, P1515, DOI 10.1016/j.juro.2007.05.117; Brackett CM, 2016, P NATL ACAD SCI USA, V113, pE874, DOI 10.1073/pnas.1521359113; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Burdelya LG, 2013, P NATL ACAD SCI USA, V110, pE1857, DOI 10.1073/pnas.1222805110; Burdelya LG, 2012, INT J RADIAT ONCOL, V83, P228, DOI 10.1016/j.ijrobp.2011.05.055; Cai ZY, 2011, CANCER RES, V71, P2466, DOI 10.1158/0008-5472.CAN-10-1993; Carvalho FA, 2011, MUCOSAL IMMUNOL, V4, P102, DOI 10.1038/mi.2010.57; Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004; de Melo FM, 2015, IMMUNOL CELL BIOL, V93, P86, DOI 10.1038/icb.2014.74; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Faham A, 2010, J IMMUNOL, V185, P1744, DOI 10.4049/jimmunol.1000027; Fernandez-Garcia EM, 2015, CLIN TRANSL ONCOL, V17, P339, DOI 10.1007/s12094-014-1259-6; Forde PM, 2013, ONCOLOGIST, V18, P1203, DOI 10.1634/theoncologist.2013-0171; Foster BA, 1997, CANCER RES, V57, P3325; Fougere-Deschatrette C, 2006, STEM CELLS, V24, P2098, DOI 10.1634/stemcells.2006-0009; Galli R, 2010, J IMMUNOL, V184, P6658, DOI 10.4049/jimmunol.0902401; Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868; Gingrich JR, 1996, TOXICOL PATHOL, V24, P502, DOI 10.1177/019262339602400414; Glavan TM, 2014, CURR PHARM DESIGN, V20, P6555, DOI 10.2174/1381612820666140826153347; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gupta S, 2000, CANCER RES, V60, P5125; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; Hurwitz AA, 2000, CANCER RES, V60, P2444; Kaczanowska S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1076609; Kaczanowska S, 2013, J LEUKOCYTE BIOL, V93, P847, DOI 10.1189/jlb.1012501; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Krivokrysenko VI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135388; Kwon ED, 1999, P NATL ACAD SCI USA, V96, P15074, DOI 10.1073/pnas.96.26.15074; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lee SE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1081328; Leigh ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085587; Lubaroff DM, 2009, CLIN CANCER RES, V15, P7375, DOI 10.1158/1078-0432.CCR-09-1910; Mamalis A, 2014, ARCH DERMATOL RES, V306, P511, DOI 10.1007/s00403-014-1457-7; Marini FC, 2000, CANCER GENE THER, V7, P816, DOI 10.1038/sj.cgt.7700174; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Mentor-Marcel R, 2001, CANCER RES, V61, P6777; Meyer T, 2008, EXPERT OPIN INV DRUG, V17, P1051, DOI [10.1517/13543784.17.7.1051, 10.1517/13543784.17.7.1051 ]; Michael A, 2005, CLIN CANCER RES, V11, P4469, DOI 10.1158/1078-0432.CCR-04-2337; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patil SA, 2014, GLYCOCONJUGATE J, V31, P509, DOI 10.1007/s10719-014-9548-4; Rauen KA, 2002, CANCER RES, V62, P3812; Rhee SH, 2008, GASTROENTEROLOGY, V135, P518, DOI 10.1053/j.gastro.2008.04.022; Rhee SH, 2011, J NEUROGASTROENTEROL, V17, P28, DOI 10.5056/jnm.2011.17.1.28; Rodriguez GM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1151593; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Shi YF, 2006, CELL RES, V16, P126, DOI 10.1038/sj.cr.7310017; Simons JW, 2006, UROL ONCOL-SEMIN ORI, V24, P419, DOI 10.1016/j.urolonc.2005.08.021; Soto LJ, 2003, J PEDIATR SURG, V38, P1075, DOI 10.1016/S0022-3468(03)00196-9; Sullivan RJ, 2013, CLIN CANCER RES, V19, P5283, DOI 10.1158/1078-0432.CCR-13-2151; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tosch C, 2009, CANCER GENE THER, V16, P310, DOI 10.1038/cgt.2008.85; Vijay-Kumar M, 2010, EUR J IMMUNOL, V40, P3528, DOI 10.1002/eji.201040421; Yam C, 2010, J SURG RES, V164, P248, DOI 10.1016/j.jss.2009.02.023; Yang H, 2016, ONCOTARGET, V7, P2936, DOI 10.18632/oncotarget.6500; Yoon SI, 2012, SCIENCE, V335, P859, DOI 10.1126/science.1215584; Yu XF, 2013, CANCER RES, V73, P2093, DOI 10.1158/0008-5472.CAN-12-1740	63	20	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					439	449		10.1038/onc.2017.346	http://dx.doi.org/10.1038/onc.2017.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967901	Green Published, hybrid			2022-12-28	WOS:000423331600003
J	Corkery, DP; Clarke, LE; Gebremeskel, S; Salsman, J; Pinder, J; Le Page, C; Meunier, L; Xu, Z; Mes-Masson, AM; Berman, JN; Johnston, B; Dellaire, G				Corkery, D. P.; Clarke, L. E.; Gebremeskel, S.; Salsman, J.; Pinder, J.; Le Page, C.; Meunier, L.; Xu, Z.; Mes-Masson, A-M; Berman, J. N.; Johnston, B.; Dellaire, G.			Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking	ONCOGENE			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER; MALIGNANT ASCITES; DOWN-REGULATION; CELL-SURVIVAL; EGF RECEPTOR; SR PROTEINS; SPLICING FACTORS; TYROSINE KINASE	Anoikis acts as a critical barrier to metastasis by inducing cell death upon cancer cell detachment from the extracellular matrix (ECM), thereby preventing tumor cell dissemination to secondary sites. The induction of anoikis requires the lysosomal-mediated downregulation of epidermal growth factor receptors (EGFRs) leading to termination of pro-survival signaling. In this study, we demonstrate that depletion of pre-mRNA splicing factor 4 kinase (PRP4K; also known as PRPF4B) causes dysregulation of EGFR trafficking and anoikis resistance. We also report a novel cytoplasmic localization of PRP4K at the late endosome, and demonstrate both nuclear and cytoplasmic localization in breast, lung and ovarian cancer tissue. Mechanistically, depletion of PRP4K leads to reduced EGFR degradation following cell detachment from the ECM and correlates with increased TrkB, vimentin and Zeb1 expression. As a result, PRP4K loss promotes sustained growth factor signaling and increased cellular resistance to anoikis in vitro and in a novel zebrafish xenotransplantation model of anoikis sensitivity, as well as increased metastasis in a mouse model of ovarian cancer. Thus, PRP4K may serve as a potential biomarker of anoikis sensitivity in ovarian and other epithelial cancers.	[Corkery, D. P.; Dellaire, G.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Corkery, D. P.; Clarke, L. E.; Salsman, J.; Pinder, J.; Xu, Z.; Berman, J. N.; Johnston, B.; Dellaire, G.] Dalhousie Univ, Dept Pathol, POB 15000, Halifax, NS B3H 4R2, Canada; [Gebremeskel, S.; Berman, J. N.; Johnston, B.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada; [Le Page, C.; Meunier, L.; Mes-Masson, A-M] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Montreal, PQ, Canada; [Le Page, C.; Meunier, L.; Mes-Masson, A-M] Inst Canc Montreal, Montreal, PQ, Canada; [Mes-Masson, A-M] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Berman, J. N.] IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada; [Berman, J. N.; Johnston, B.; Dellaire, G.] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada; [Johnston, B.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Dalhousie University; Dalhousie University	Dellaire, G (corresponding author), Dalhousie Univ, Dept Pathol, POB 15000, Halifax, NS B3H 4R2, Canada.; Johnston, B (corresponding author), Dalhousie Univ, Dept Microbiol, POB 15000, Halifax, NS B3H 4R2, Canada.; Johnston, B (corresponding author), Dalhousie Univ, Dept Immunol, POB 15000, Halifax, NS B3H 4R2, Canada.	brent.johnston@dal.ca; dellaire@dal.ca	gebremeskel, Simon/AAZ-3334-2020; Le Page, Cecile/B-3215-2010; Johnston, Brent/E-2607-2013; Dellaire, Graham/L-9948-2014	gebremeskel, Simon/0000-0002-8484-8177; Le Page, Cecile/0000-0002-8020-1544; Johnston, Brent/0000-0001-5456-2824; Dellaire, Graham/0000-0002-3466-6316; Corkery, Dale/0000-0001-7930-0134; Mes-Masson, Anne-Marie/0000-0002-6498-266X	Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS); Canadian Breast Cancer Foundation (CBCF); Breast Cancer Society/QEII Foundation; Canadian Institutes of Health Research (CIHR) [MOP-110988, PJT-153285]; BHCRI; CBCF-Atlantic; Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR; Killam Trusts; CIHR	Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS); Canadian Breast Cancer Foundation (CBCF); Breast Cancer Society/QEII Foundation; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); BHCRI; CBCF-Atlantic; Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR; Killam Trusts; CIHR(Canadian Institutes of Health Research (CIHR))	We thank the Gynecology-Oncology and Pathology services of the CHUM-Hopital Notre-Dame for tumor procurement, Gretchen Wagner for fish care, and Monique Bernard for technical assistance. Ovarian and breast tumor banking was supported by the Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS). This work was funded by research grants from the Canadian Breast Cancer Foundation (CBCF) and the Breast Cancer Society/QEII Foundation awarded to GD, and research grants to BJ from the Canadian Institutes of Health Research (CIHR) (MOP-110988, PJT-153285). GD, JB and BJ are Senior Scientists of the Beatrice Hunter Cancer Research Institute (BHCRI), and DPC, LC, JS and JP were supported by trainee awards from the BHCRI with funds provided by CBCF-Atlantic, The Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR. SG is the recipient of doctoral awards from the Killam Trusts, CIHR, and BHCRI.	Adam RA, 2004, J AM COLL SURGEONS, V198, P999, DOI 10.1016/j.jamcollsurg.2004.01.035; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bedard K, 2009, HUM MUTAT, V30, P1123, DOI 10.1002/humu.21029; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bookman MA, 1996, J CLIN ONCOL, V14, P1895, DOI 10.1200/JCO.1996.14.6.1895; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Corkery DP, 2015, CELL CYCLE, V14, P1059, DOI 10.1080/15384101.2015.1007775; Corkery DP, 2011, BRIT J HAEMATOL, V153, P786, DOI 10.1111/j.1365-2141.2011.08661.x; Dellaire G, 2002, MOL CELL BIOL, V22, P5141, DOI 10.1128/MCB.22.14.5141-5156.2002; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; EARP HS, 1986, J BIOL CHEM, V261, P4777; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; FELDMAN GB, 1972, CANCER RES, V32, P1663; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GARRISON RN, 1986, ANN SURG, V203, P644, DOI 10.1097/00000658-198606000-00009; Gebremeskel S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.995562; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giannoni E, 2008, CELL DEATH DIFFER, V15, P867, DOI 10.1038/cdd.2008.3; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Herzog TJ, 2004, CLIN CANCER RES, V10, P7439, DOI 10.1158/1078-0432.CCR-04-0683; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lam AJ, 2012, NAT METHODS, V9, P1005, DOI [10.1038/NMETH.2171, 10.1038/nmeth.2171]; Le Page C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038541; Letourneau IJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-379; MARKMAN M, 1992, J CLIN ONCOL, V10, P1485, DOI 10.1200/JCO.1992.10.9.1485; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Montembault E, 2007, J CELL BIOL, V179, P601, DOI 10.1083/jcb.200703133; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nguyen LN, 2006, CLIN CANCER RES, V12, P6952, DOI 10.1158/1078-0432.CCR-06-0317; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Parsons SL, 1996, EUR J SURG ONCOL, V22, P237, DOI 10.1016/S0748-7983(96)80009-6; Pinder J, 2015, NUCLEIC ACIDS RES, V43, P9379, DOI 10.1093/nar/gkv993; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; ROSENBERG GH, 1991, MOL GEN GENET, V226, P305, DOI 10.1007/BF00273617; Scharaw S, 2016, J CELL BIOL, V215, P543, DOI 10.1083/jcb.201601090; Schneider M, 2010, NAT STRUCT MOL BIOL, V17, P216, DOI 10.1038/nsmb.1718; Smit MA, 2011, ONCOGENE, V30, P3735, DOI 10.1038/onc.2011.96; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Wang PP, 2014, MOL CELL, V54, P378, DOI 10.1016/j.molcel.2014.03.007; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	65	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					174	184		10.1038/onc.2017.318	http://dx.doi.org/10.1038/onc.2017.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892043	Green Published, hybrid			2022-12-28	WOS:000422631700004
J	Liu, L; Luo, C; Luo, Y; Chen, L; Liu, Y; Wang, Y; Han, J; Zhang, Y; Wei, N; Xie, Z; Wu, W; Wu, G; Feng, Y				Liu, L.; Luo, C.; Luo, Y.; Chen, L.; Liu, Y.; Wang, Y.; Han, J.; Zhang, Y.; Wei, N.; Xie, Z.; Wu, W.; Wu, G.; Feng, Y.			MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression	ONCOGENE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-K; MT-CYB; REVEALS; EVENTS; GENES; MECHANISMS; FAILURE; ROLES	MRPL33 gene encodes a large mitoribosomal subunit protein, which may be involved in mitochondrial translation. Although two splice variants of MRPL33 have been described, its splicing regulation remains elusive. Here we observed that inclusion of alternative exon 3 was greatly promoted in a panel of human cancer cells. Depletion of the exon 3-containing long isoform of MRPL33 (MRPL33-L) led to impaired proliferation and increased apoptosis in cancer cell lines and in a xenograft model. MRPL33-L knockdown could also induce mitochondrial dysfunction including increased accumulation of reactive oxygen species, decreased ATP production and 16 S rRNA levels. We further showed that alternative splicing of MRPL33-L pre-mRNA is regulated by hnRNPK and that knocking down hnRNPK could phenocopy MRPL33-L depletion. More importantly, overexpression of MRPL33-L could increase tumorigenic potential of hnRNPK-depleted cancer cells, likely indicating that hnRNPK mediates tumorigenesis through splicing regulation of MRPL33 pre-mRNA. Finally, we found that inclusion of MRPL33 exon 3 was promoted in human colorectal cancer tissues and this was correlated with hnRNPK levels. In summary, our findings underscore the biological significance of MRPL33-L and hnRNPK in the tumor formation and identifies hnRNPK as a critical splicing regulator of MRPL33 pre-mRNA in cancer cells.	[Liu, L.; Luo, C.; Luo, Y.; Chen, L.; Liu, Y.; Wang, Y.; Zhang, Y.; Wei, N.; Xie, Z.; Feng, Y.] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Food Safety Res,Inst Nutr Sci, Shanghai, Peoples R China; [Han, J.; Wu, G.] Fudan Univ, Zhongshan Hosp, Sch Med, Dept Surg, Shanghai, Peoples R China; [Wu, W.] Zhejiang Agr & Forestry Univ, Nurturing Stn, State Key Lab Subtrop Silviculture, Linan, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Zhejiang A&F University	Wu, G (corresponding author), Fudan Univ, Zhongshan Hosp, Sch Med, Dept Surg, Shanghai, Peoples R China.; Feng, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	wu.guohao@zs-hospital.sh.cn; fengying@sibs.ac.cn		Wu, Guohao/0000-0001-9490-4200; Liu, Yuguo/0000-0002-1421-3854	National Natural Science Foundation [31570818, 31370786, 31601170, 31400677, 81372197]; 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010100]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences	This work was supported by grants from the National Natural Science Foundation 31570818 to Y Feng and 31370786 to Y Feng and 31601170 to N Wei and 31400677 to W Wu and 81372197 to G Wu and also from the 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010100).	Barboro P, 2014, CANCER LETT, V352, P152, DOI 10.1016/j.canlet.2014.06.019; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheng YM, 2016, MOL CELL BIOL, V36, P1628, DOI 10.1128/MCB.01071-15; Danan-Gotthold M, 2015, NUCLEIC ACIDS RES, V43, P5130, DOI 10.1093/nar/gkv210; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; El-Hattab AW, 2016, CELL CALCIUM, V60, P199, DOI 10.1016/j.ceca.2016.03.003; Gopisetty G, 2016, GENE, V589, P27, DOI 10.1016/j.gene.2016.05.008; Guha S, 2006, ANIM GENET, V37, P262, DOI 10.1111/j.1365-2052.2006.01421.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Llorian M, 2010, NAT STRUCT MOL BIOL, V17, P1114, DOI 10.1038/nsmb.1881; Menezes MJ, 2015, HUM MOL GENET, V24, P2297, DOI 10.1093/hmg/ddu747; Nazim M, 2017, NUCLEIC ACIDS RES, V45, P1455, DOI 10.1093/nar/gkw823; Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035; Pandit S, 2013, MOL CELL, V50, P223, DOI 10.1016/j.molcel.2013.03.001; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Wallace L, 2016, TUMOR BIOL, V37, P12465, DOI 10.1007/s13277-016-5101-3; Wei N, 2015, CELL REP, V13, P1647, DOI 10.1016/j.celrep.2015.10.038; Xiao R, 2012, MOL CELL, V45, P656, DOI 10.1016/j.molcel.2012.01.009; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhou XX, 2014, NUCLEIC ACIDS RES, V42, P4019, DOI 10.1093/nar/gkt1387	25	29	31	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					86	94		10.1038/onc.2017.314	http://dx.doi.org/10.1038/onc.2017.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869607				2022-12-28	WOS:000422625000009
J	Kwun, HJ; Wendzicki, JA; Shuda, Y; Moore, PS; Chang, Y				Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.			Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting (vol 36, pg 6784, 2017)	ONCOGENE			English	Correction													Kwun, Hyun jin/AAJ-3365-2020; Moore, Patrick/GVR-8294-2022	Kwun, Hyun jin/0000-0002-8926-746X; 	NCI NIH HHS [R01 CA170354] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA170354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Kwun HJ, 2017, ONCOGENE, V36, P6784, DOI 10.1038/onc.2017.277	1	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6838	6838		10.1038/onc.2017.389	http://dx.doi.org/10.1038/onc.2017.389			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28991223	hybrid, Green Published			2022-12-28	WOS:000417282500010
J	Makhtar, WRW; Browne, G; Karountzos, A; Stevens, C; Alghamdi, Y; Bottrill, AR; Mistry, S; Smith, E; Bushel, M; Pringle, JH; Sayan, AE; Tulchinsky, E				Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Bottrill, A. R.; Mistry, S.; Smith, E.; Bushel, M.; Pringle, J. H.; Sayan, A. E.; Tulchinsky, E.			Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; RNA GENES; POL II; PROTEIN; BINDING; SIP1; EMT; PROGRESSION; METASTASIS	Two proteins comprising the ZEB family of zinc finger transcription factors, ZEB1 and ZEB2, execute EMT programs in embryonic development and cancer. By studying regulation of their expression, we describe a novel mechanism that limits ZEB2 protein synthesis. A protein motif located at the border of the SMAD-binding domain of ZEB2 protein induces ribosomal pausing and compromises protein synthesis. The function of this protein motif is dependent on stretches of rare codons, Leu(UUA)-Gly(GGU)-Val (GUA). Incorporation of these triplets in the homologous region of ZEB1 does not affect protein translation. Our data suggest that rare codons have a regulatory role only if they are present within appropriate protein structures. We speculate that pools of transfer RNA available for protein translation impact on the configuration of epithelial mesenchymal transition pathways in tumor cells.	[Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Pringle, J. H.; Tulchinsky, E.] Univ Leicester, Dept Canc Studies, Leicester, Leics, England; [Makhtar, W. R. Wan; Smith, E.; Bushel, M.] MRC Toxicol Unit, Leicester, Leics, England; [Bottrill, A. R.; Mistry, S.] Univ Leicester, Prot & Nucle Acid Chem Lab PNACL, Leicester, Leics, England; [Sayan, A. E.] Univ Southampton, Canc Sci Div, Tremona Rd, Southampton SO16 6YD, Hants, England; [Makhtar, W. R. Wan; Browne, G.; Karountzos, A.; Stevens, C.; Alghamdi, Y.; Pringle, J. H.; Tulchinsky, E.] Univ Sains Malaysia, Sch Med Sci, George Town, Malaysia	University of Leicester; University of Leicester; University of Southampton; Universiti Sains Malaysia	Sayan, AE (corresponding author), Univ Southampton, Canc Sci Div, Tremona Rd, Southampton SO16 6YD, Hants, England.; Tulchinsky, E (corresponding author), Univ Leicester, Dept Canc Studies, RKCSB, LRI, Leicester LE2 7LX, Leics, England.; Tulchinsky, E (corresponding author), Univ Sains Malaysia, Sch Med Sci, George Town, Malaysia.	A.E.Sayan@soton.ac.uk; et32@le.ac.uk	SAYAN, A. EMRE/H-7330-2012; Tulchinsky, Eugene/ABD-7070-2021; Bottrill, Andrew/ABD-1459-2021; Alghamdi, Yousef G/N-2061-2016	SAYAN, A. EMRE/0000-0002-5291-1485; Bottrill, Andrew/0000-0002-5182-3643; Alghamdi, Yousef G/0000-0003-2671-6771; WAN MAKHTAR, WAN RATMAAZILA/0000-0003-1630-2137; Smith, Ewan/0000-0002-3992-3748	Cancer Research UK [C8851/A10844]; Wellcome Trust ISSF Grant [RM60G0406]	Cancer Research UK(Cancer Research UK); Wellcome Trust ISSF Grant(Wellcome Trust)	This research was supported by a Cancer Research UK project grant C8851/A10844 (ET), and Wellcome Trust ISSF Grant RM60G0406 (ET).	Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Canella D, 2012, GENOME RES, V22, P666, DOI 10.1101/gr.130286.111; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; David A, 2011, J BIOL CHEM, V286, P20688, DOI 10.1074/jbc.M110.209452; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Duret L, 2000, TRENDS GENET, V16, P287, DOI 10.1016/S0168-9525(00)02041-2; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Kaminska M, 2009, J BIOL CHEM, V284, P13746, DOI 10.1074/jbc.M900480200; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Komar AA, 2009, TRENDS BIOCHEM SCI, V34, P16, DOI 10.1016/j.tibs.2008.10.002; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kutter C, 2011, NAT GENET, V43, P948, DOI 10.1038/ng.906; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Miyoshi T, 2006, DEV DYNAM, V235, P1941, DOI 10.1002/dvdy.20799; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Ozturk N, 2006, P NATL ACAD SCI USA, V103, P2178, DOI 10.1073/pnas.0510877103; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Pershing NLK, 2015, J CLIN INVEST, V125, P222, DOI 10.1172/JCI77627; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Sayan AE, 2009, P NATL ACAD SCI USA, V106, P14884, DOI 10.1073/pnas.0902042106; Sha Z, 2009, MOL CELL, V36, P141, DOI 10.1016/j.molcel.2009.09.026; Tsimokha AS, 2017, J CELL PHYSIOL, V232, P842, DOI 10.1002/jcp.25492; Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang F, 2015, BIOCHIMIE, V114, P127, DOI 10.1016/j.biochi.2015.02.006; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825	41	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6640	6648		10.1038/onc.2017.273	http://dx.doi.org/10.1038/onc.2017.273			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783176	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000416049200012
J	Chen, WY; Tsai, YC; Siu, MK; Yeh, HL; Chen, CL; Yin, JJ; Huang, J; Liu, YN				Chen, W-Y; Tsai, Y-C; Siu, M. K.; Yeh, H-L; Chen, C-L; Yin, J. J.; Huang, J.; Liu, Y-N			Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CLASSICAL DENDRITIC CELLS; TRANSCRIPTION FACTOR ZDC; DEPRIVATION THERAPY; BONE METASTASIS; EXPRESSION; PROGRESSION; RESISTANCE; ACTIVATION; SUPPRESSOR	Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.	[Chen, W-Y; Chen, C-L] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei, Taiwan; [Chen, W-Y] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; [Tsai, Y-C; Siu, M. K.; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan; [Siu, M. K.] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei, Taiwan; [Yeh, H-L] Natl Tsing Hua Univ, Inst Informat Syst & Applicat, Hsinchu, Taiwan; [Chen, C-L] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Chen, C-L] Taipei Med Univ, Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan; [Yin, J. J.] NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA; [Huang, J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Tsing Hua University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University	Liu, YN (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan.; Huang, J (corresponding author), Duke Univ, Sch Med, Dept Pathol, Room 301M,Duke South,DUMC 3712,40 Duke Med Circle, Durham, NC 27710 USA.	jiaoti.huang@duke.edu; liuy@tmu.edu.tw	Liu, Yen-Nien/AAW-4698-2021		Ministry of Science and Technology of Taiwan [MOST104-2314-B-038-045-MY3, MOST105-2320-B- 038-044, MOST104-2320-B-038-055-MY3]; National Health Research Institutes of Taiwan [NHRI-EX106-10308BC]; Taipei Medical University [TMU104-AE1-B22]; Health and Welfare Surcharge of Tobacco Products [MOHW106-TDU-B-212-144001]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan); Taipei Medical University; Health and Welfare Surcharge of Tobacco Products	This work was jointly supported by grants from the Ministry of Science and Technology of Taiwan (MOST104-2314-B-038-045-MY3) to YNL, (MOST105-2320-B- 038-044) to WYC, (MOST104-2320-B-038-055-MY3) to YCT, by the National Health Research Institutes of Taiwan (NHRI-EX106-10308BC) to YNL, by Taipei Medical University (TMU104-AE1-B22) to WYC, and by the Health and Welfare Surcharge of Tobacco Products (MOHW106-TDU-B-212-144001) to YNL.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Boyd LK, 2012, NAT REV UROL, V9, P652, DOI 10.1038/nrurol.2012.185; Cao JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077922; Crea F, 2015, TRENDS MOL MED, V21, P206, DOI 10.1016/j.molmed.2015.02.005; De Craene B, 2014, CELL DEATH DIFFER, V21, P310, DOI 10.1038/cdd.2013.148; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Gao J, 2001, CANCER RES, V61, P5038; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Han C, 2015, TUMOR BIOL, V36, P6715, DOI 10.1007/s13277-015-3358-6; Hsieh CL, 2015, CANCER RES, V75, P1944, DOI 10.1158/0008-5472.CAN-14-3602; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365-2559.2011.04039.x; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Jennbacken K, 2010, ENDOCR-RELAT CANCER, V17, P469, DOI 10.1677/ERC-10-0015; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Karatas OF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098675; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Linja MJ, 2001, CANCER RES, V61, P3550; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2015, MOL CELL BIOL, V35, P1940, DOI 10.1128/MCB.00008-15; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Meredith MM, 2012, J EXP MED, V209, P1583, DOI 10.1084/jem.20121003; Meredith MM, 2012, J EXP MED, V209, P1153, DOI 10.1084/jem.20112675; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Siu MK, 2017, PROSTATE CANCER P D, V20, P172, DOI 10.1038/pcan.2017.2; Siu MK, 2014, ONCOTARGET, V5, P3770, DOI 10.18632/oncotarget.1994; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233	50	26	26	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6213	6224		10.1038/onc.2017.226	http://dx.doi.org/10.1038/onc.2017.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692046				2022-12-28	WOS:000414774800001
J	Trinidad, AG; Whalley, N; Rowlinson, R; Delpuech, O; Dudley, P; Rooney, C; Critchlow, SE				Trinidad, A. G.; Whalley, N.; Rowlinson, R.; Delpuech, O.; Dudley, P.; Rooney, C.; Critchlow, S. E.			Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells	ONCOGENE			English	Article							CANCER-CELLS; DICHLOROACETATE DCA; METABOLIC SWITCH; BREAST-CANCER; FATTY-ACIDS; IN-VITRO; RAS; EXPRESSION; PROTEIN; PDK4	RAS signalling is involved in the control of several metabolic pathways including glycolysis, mitochondrial respiration and glutamine metabolism. Importantly, we have found here that loss of PDHK4, a key regulator of the pyruvate dehydrogenase complex, caused a profound cell growth inhibition in tumour cells harbouring KRAS mutations. Using isogenic cells and a panel of colorectal and lung cell lines we demonstrated that KRAS mutant cells showed a dependency on PDHK4 whereas KRAS wild-type cells were significantly resistant to PDHK4 knockdown. We have found that PDHK4 plays a role in the post-translational regulation of mutant KRAS activity. Depletion of PDHK4 causes disruption of KRAS cellular localization, a reduction in KRAS activity which, in turn, results in reduced MAPK signalling. Interestingly, PDHK4 and KRAS depletion resulted in a similar metabolic phenotype consisting of a reduction of glucose and fatty acid oxidation. Moreover, stable expression of PDHK4 increased localization of activated KRAS at the plasma membrane and induced tumour cell growth in vitro and in vivo. Taken together these data support a model where PDHK4 regulates KRAS signalling and its tumorigenic properties and suggest that inhibition of PDHK4 could represent a novel therapeutic strategy to target KRAS mutant colorectal and lung cancers.	[Trinidad, A. G.; Rowlinson, R.; Dudley, P.; Rooney, C.] AstraZeneca iMED Oncol, Alderley Pk, Macclesfield, Cheshire, England; [Trinidad, A. G.; Whalley, N.; Delpuech, O.; Critchlow, S. E.] AstraZeneca iMED Oncol, Cambridge CB10 1XL, England		Trinidad, AG (corresponding author), AstraZeneca iMED Oncol, Cambridge CB10 1XL, England.	antonio.garcia-trinidad@astrazeneca.com			AstraZeneca	AstraZeneca(AstraZeneca)	We would like to thank Dr Oliver Maddocks for helpful discussions, Mike Dymond for fluidigm data analysis support and the AZ laboratory animal sciences group for in vivo support. AZD7545 was discovered by AstraZeneca and the study was funded by the AstraZeneca post-doctoral program.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Cadoudal T, 2008, DIABETES, V57, P2272, DOI 10.2337/db08-0477; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Houten SM, 2009, CELL MOL LIFE SCI, V66, P1283, DOI 10.1007/s00018-009-9066-x; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Hwang B, 2009, BIOCHEM J, V423, P243, DOI 10.1042/BJ20090390; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim YI, 2006, DIABETES, V55, P2311, DOI 10.2337/db05-1606; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38; Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265; Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821; Mazar J, 2016, MOL CELL BIOL, V36, P1090, DOI 10.1128/MCB.00762-15; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Morrell JA, 2003, BIOCHEM SOC T, V31, P1168; Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Puthanveetil P, 2010, ENDOCRINOLOGY, V151, P2306, DOI 10.1210/en.2009-1072; Salloum D, 2014, MOL CANCER THER, V13, P733, DOI 10.1158/1535-7163.MCT-13-0762; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sanchez-Arago M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012; Savkur RS, 2005, BIOCHEM BIOPH RES CO, V329, P391, DOI 10.1016/j.bbrc.2005.01.141; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Srivastava N, 2014, CELL METAB, V20, P650, DOI 10.1016/j.cmet.2014.08.003; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wynn RM, 2008, J BIOL CHEM, V283, P25305, DOI 10.1074/jbc.M802249200; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhang Y, 2016, J BIOL CHEM, V291, P17405, DOI 10.1074/jbc.M116.713735; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	50	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6164	6176		10.1038/onc.2017.224	http://dx.doi.org/10.1038/onc.2017.224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692044	hybrid, Green Published			2022-12-28	WOS:000414249800010
J	Ren, T; Zhang, H; Wang, J; Zhu, J; Jin, M; Wu, Y; Guo, X; Ji, L; Huang, Q; Zhang, H; Yang, H; Xing, J				Ren, T.; Zhang, H.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Zhang, H.; Yang, H.; Xing, J.			MCU-dependent mitochondrial Ca2+ inhibits NAD(+)/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells	ONCOGENE			English	Article							OPERATED CALCIUM-ENTRY; HEPATOCELLULAR-CARCINOMA; PYRUVATE-DEHYDROGENASE; TUMOR PROGRESSION; CANCER CELLS; UNIPORTER; MIGRATION; PROTEIN; DEATH; JNK	Mitochondrial Ca2+ signaling, which is strongly dependent on the mitochondrial Ca2+ uniporter (MCU) complex, has a series of key roles in physiopathological processes, including energy metabolism, reactive oxygen species (ROS) production and cell apoptosis. However, a mechanistic understanding of how the mitochondrial Ca2+ signaling is remodeled and its functional roles remains greatly limited in cancers, especially in hepatocellular carcinoma. Here we demonstrated that the MCU complex was dysregulated in hepatocellular carcinoma (HCC) cells and significantly correlated with metastasis and poor prognosis of HCC patients. Upregulation of MCU clearly enhanced the Ca2+ uptake into mitochondria, which significantly promoted ROS production by downregulating nicotinamide adenine dinucleotide(+) (NAD(+))/reduced form of nicotinamide adenine dinucleotid (NADH) ratio and the NAD+-dependent deacetylase activity of sirtuin 3 to inhibit superoxide dismutase 2 (SOD2) activity. Moreover, our data indicated that the MCU-dependent mitochondrial Ca2+ uptake promotes matrix metalloproteinase-2 activity and cell motility by ROS-activated c-Jun N-terminal kinase pathway, and thus contributed to the increased ability of invasion and migration in vitro and intrahepatic and distal lung metastasis in vivo of HCC cells. In addition, treatment with the mitochondrial Ca2+-buffering protein parvalbumin significantly suppressed ROS production and the ability of HCC metastasis. Our study uncovers a mechanism that links the remodeling of mitochondrial Ca2+ homeostasis to ROS production, and provides evidence supporting a metastasis-promoting role for the MCU-dependent mitochondrial Ca2+ uptake in HCC. Our findings suggest that the mitochondrial Ca2+ uptake machinery may potentially be a novel therapeutic target for HCC metastasis.	[Ren, T.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Xing, J.] Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Ren, T.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Xing, J.] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Zhang, H.; Zhang, H.] Fourth Mil Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China; [Yang, H.] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Div Populat Sci, Philadelphia, PA 19107 USA	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Jefferson University	Xing, J (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Xing, J (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81572727, 81320108021]; National Basic Research Program [2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grants 81572727 and 81320108021) and National Basic Research Program (grant 2015CB553703).	Adam-Vizi V, 2010, J ALZHEIMERS DIS, V20, pS413, DOI 10.3233/JAD-2010-100465; Arvizo RR, 2013, J BIOL CHEM, V288, P17610, DOI 10.1074/jbc.M112.435206; Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Campanella M, 2004, BIOL RES, V37, P653; Chaudhari S, 2014, FASEB J, V28; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Chiba T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084807; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962; Hall DD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096866; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hsu CC, 2013, BBA-GEN SUBJECTS, V1830, P4743, DOI 10.1016/j.bbagen.2013.06.004; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Koch-Nolte F, 2011, FEBS LETT, V585, P1651, DOI 10.1016/j.febslet.2011.03.045; Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; Min LH, 2011, SEMIN CANCER BIOL, V21, P10, DOI 10.1016/j.semcancer.2010.10.011; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Perocchi F, 2010, NATURE, V467, P291, DOI 10.1038/nature09358; Plovanich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055785; Qiu J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3034; Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Sancak Y, 2013, SCIENCE, V342, P1379, DOI 10.1126/science.1242993; Son G, 2006, J HEPATOL, V45, P688, DOI 10.1016/j.jhep.2006.04.011; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Sun YY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0210-7; Tang SH, 2015, BIOCHEM BIOPH RES CO, V458, P186, DOI 10.1016/j.bbrc.2015.01.092; Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Xu P, 2010, MECH AGEING DEV, V131, P287, DOI 10.1016/j.mad.2010.03.006; Ying WH, 2008, FRONT BIOSCI-LANDMRK, V13, P1141, DOI 10.2741/2751; Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104; Zeng X, 2011, HEPATOLOGY, V54, P2036, DOI 10.1002/hep.24647; Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.182	51	101	109	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5897	5909		10.1038/onc.2017.167	http://dx.doi.org/10.1038/onc.2017.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28650465	Bronze			2022-12-28	WOS:000413292900011
J	Colicchia, V; Petroni, M; Guarguaglini, G; Sardina, F; Sahun-Roncero, M; Carbonari, M; Ricci, B; Heil, C; Capalbo, C; Belardinilli, F; Coppa, A; Peruzzi, G; Screpanti, I; Lavia, P; Gulino, A; Giannini, G				Colicchia, V.; Petroni, M.; Guarguaglini, G.; Sardina, F.; Sahun-Roncero, M.; Carbonari, M.; Ricci, B.; Heil, C.; Capalbo, C.; Belardinilli, F.; Coppa, A.; Peruzzi, G.; Screpanti, I.; Lavia, P.; Gulino, A.; Giannini, G.			PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; N-MYC; METASTATIC NEUROBLASTOMA; THERAPEUTIC STRATEGY; GENOMIC INSTABILITY; COMBINATION THERAPY; DNA-REPLICATION; FORK REVERSAL; C-MYC; CELLS	High-risk and MYCN-amplified neuroblastomas are among the most aggressive pediatric tumors. Despite intense multimodality therapies, about 50% of these patients succumb to their disease, making the search for effective therapies an absolute priority. Due to the important functions of poly (ADP-ribose) polymerases, PARP inhibitors have entered the clinical settings for cancer treatment and are being exploited in a variety of preclinical studies and clinical trials. PARP inhibitors based combination schemes have also been tested in neuroblastoma preclinical models with encouraging results. However, the expression of PARP enzymes in human neuroblastoma and the biological consequences of their inhibition remained largely unexplored. Here, we show that high PARP1 and PARP2 expression is significantly associated with high-risk neuroblastoma cases and poor survival, highlighting its previously unrecognized prognostic value for human neuroblastoma. In vitro, PARP1 and 2 are abundant in MYCN amplified and MYCN-overexpressing cells. In this context, PARP inhibitors with high 'PARP trapping' potency, such as olaparib or talazoparib, yield DNA damage and cell death preceded by intense signs of replication stress. Notwithstanding the activation of a CHK1-CDC25A replication stress response, PARP-inhibited MYCN amplified and overexpressing cells fail to sustain a prolonged checkpoint and progress through mitosis in the presence of damaged DNA, eventually undergoing mitotic catastrophe. CHK1-targeted inhibition of the replication stress checkpoint exacerbated this phenotype. These data highlight a novel route for cell death induction by PARP inhibitors and support their introduction, together with CHK1 inhibitors, in therapeutic approaches for neuroblastomas with high MYC(N) activity.	[Colicchia, V.; Sardina, F.; Sahun-Roncero, M.; Ricci, B.; Heil, C.; Capalbo, C.; Belardinilli, F.; Screpanti, I.; Gulino, A.; Giannini, G.] Univ Roma La Sapienza, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy; [Petroni, M.; Peruzzi, G.] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy; [Guarguaglini, G.; Lavia, P.] Univ Roma La Sapienza, Inst Mol Biol & Pathol, CNR, Rome, Italy; [Carbonari, M.] Univ Roma La Sapienza, Dept Clin Med, Rome, Italy; [Coppa, A.] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy; [Giannini, G.] Univ Roma La Sapienza, Dept Mol Med, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Giannini, G (corresponding author), Univ Roma La Sapienza, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	petroni, marialaura/AAB-8637-2019; coppa, anna/N-3274-2016; Lavia, Patrizia/J-5793-2019; Lavia, Patrizia/AAL-3982-2021; Sardina, Francesca/AAC-2143-2022; Giannini, Giuseppe/B-5672-2013; Ricci, Biancamaria/AAT-9935-2021	petroni, marialaura/0000-0002-6021-1657; Lavia, Patrizia/0000-0003-3310-6701; Giannini, Giuseppe/0000-0003-0299-4056; Ricci, Biancamaria/0000-0003-1574-6043; Peruzzi, Giovanna/0000-0002-6517-9107; coppa, anna/0000-0001-9758-5444; Belardinilli, Francesca/0000-0003-4966-7044	Associazione Italiana per la Ricerca sul Cancro [IG17734, IG14723, IG14535]; AIRC [MFAG13350, 5XMILLE]; Ministry of University and Research (FIRB and PRIN); Italian Institute of Technology; FIRC	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministry of University and Research (FIRB and PRIN)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Italian Institute of Technology(Istituto Italiano di Tecnologia - IIT); FIRC(Fondazione AIRC per la ricerca sul cancro)	Time-lapse experiments were performed at the Nikon Reference Center for Central-Southern Italy at IBPM-CNR. Financial Support: This work was supported by grants from: Associazione Italiana per la Ricerca sul Cancro IG17734 (G. Giannini), IG14723 (A. Gulino) and IG14535 (P. Lavia); AIRC MFAG13350 (G. Guarguaglini); AIRC 5XMILLE (A. Gulino); Ministry of University and Research (FIRB and PRIN projects) (A. Gulino and G. Giannini); Italian Institute of Technology (A. Gulino). M.P. has been recipient of a FIRC fellowship David Raffaelli.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bagatell R, 2009, J CLIN ONCOL, V27, P365, DOI 10.1200/JCO.2008.17.9184; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; Berti M, 2013, NAT STRUCT MOL BIOL, V20, P347, DOI 10.1038/nsmb.2501; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Canete A, 2009, J CLIN ONCOL, V27, P1014, DOI 10.1200/JCO.2007.14.5839; Carbonari M, 2016, CYTOM PART A, V89A, P498, DOI 10.1002/cyto.a.22823; Chaudhuri AR, 2012, NAT STRUCT MOL BIOL, V19, P417, DOI 10.1038/nsmb.2258; Chayka O, 2015, J BIOL CHEM, V290, P2198, DOI 10.1074/jbc.M114.624056; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Judware R, 1995, ONCOGENE, V11, P2599; Kuzyk A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014373; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Lupo B, 2014, BBA-REV CANCER, V1846, P201, DOI 10.1016/j.bbcan.2014.07.004; Lutz W, 1996, ONCOGENE, V13, P803; Massimi I, 2013, MOL CARCINOGEN, V52, P526, DOI 10.1002/mc.21887; McCluskey AG, 2012, J NUCL MED, V53, P1146, DOI 10.2967/jnumed.111.095943; McNeil EM, 2013, DNA REPAIR, V12, P1000, DOI 10.1016/j.dnarep.2013.08.017; Mueller S, 2013, ANTICANCER RES, V33, P755; Murai J, 2014, J PHARMACOL EXP THER, V349, P408, DOI 10.1124/jpet.113.210146; Murai J, 2014, MOL CANCER THER, V13, P433, DOI 10.1158/1535-7163.MCT-13-0803; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646; Norris RE, 2014, PEDIATR BLOOD CANCER, V61, P145, DOI 10.1002/pbc.24697; Petroni M, 2016, CELL DEATH DIFFER, V23, P197, DOI 10.1038/cdd.2015.81; Petroni M, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00141; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Rohban S, 2015, BBA-GENE REGUL MECH, V1849, P517, DOI 10.1016/j.bbagrm.2014.04.008; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Srinivasan SV, 2013, CELL REP, V3, P1629, DOI 10.1016/j.celrep.2013.04.002; Utani K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010089; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Veschi V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.68; Veschi V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049139; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099	50	52	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4682	4691		10.1038/onc.2017.40	http://dx.doi.org/10.1038/onc.2017.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394338				2022-12-28	WOS:000407702400002
J	Madapura, HS; Nagy, N; Ujvari, D; Kallas, T; Krohnke, MCL; Amu, S; Bjorkholm, M; Stenke, L; Mandal, PK; McMurray, JS; Keszei, M; Westerberg, LS; Cheng, H; Xue, F; Klein, G; Klein, E; Salamon, D				Madapura, H. S.; Nagy, N.; Ujvari, D.; Kallas, T.; Krohnke, M. C. L.; Amu, S.; Bjorkholm, M.; Stenke, L.; Mandal, P. K.; McMurray, J. S.; Keszei, M.; Westerberg, L. S.; Cheng, H.; Xue, F.; Klein, G.; Klein, E.; Salamon, D.			Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells	ONCOGENE			English	Article							IFN-GAMMA; STEM-CELLS; T-CELLS; TARGETED THERAPY; INHIBITORS; REPRESSION; RESPONSES; SURVIVAL; CANCER; MCL-1	B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment. As several lines of evidence suggest that interferon gamma(IFN gamma) production in CML patients might have a central role in the response to tyrosine kinase inhibitor (TKI) therapy, we analyzed if IFN gamma modulates BCL6 expression in CML cells. Although separate IFN gamma or IM treatment only slightly upregulated BCL6 expression, combined treatment induced remarkable BCL6 upregulation in CML lines and primary human CD34+ CML stem cells. We proved that during combined treatment, inhibition of constitutive signal transducer and activator of transcription (STAT) 5 activation by IM allowed the specific enhancement of the STAT1 dependent, direct upregulation of BCL6 by IFN gamma in CML cells. By using colony-forming assay, we found that IFN gamma enhanced the ex vivo colony or cluster-forming capacity of human CML stem cells in the absence or presence of IM, respectively. Furthermore, inhibition of the transcriptional repressor function of BCL6 in the presence of IM and IFN gamma almost completely blocked the cluster formation of human CML stem cells. On the other hand, by using small interfering RNA knockdown of BCL6, we demonstrated that in an IM-treated CML line the antiapoptotic effect of IFN gamma was independent of BCL6 upregulation. We found that IFN gamma also upregulated several antiapoptotic members of the BCL2 and BIRC gene families in CML cells, including the long isoform of MCL1, which proved to be essential for the antiapoptotic effect of IFN gamma in an IM-treated CML line. Our results suggest that combination of TKIs with BCL6 and MCL1 inhibitors may potentially lead to the complete eradication of CML stem cells.	[Madapura, H. S.; Nagy, N.; Kallas, T.; Krohnke, M. C. L.; Amu, S.; Keszei, M.; Westerberg, L. S.; Klein, G.; Klein, E.; Salamon, D.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Ujvari, D.; Salamon, D.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Bjorkholm, M.; Stenke, L.] Karolinska Univ, Hosp Solna, Dept Med, Div Hematol, Stockholm, Sweden; [Bjorkholm, M.; Stenke, L.] Karolinska Inst, Stockholm, Sweden; [Mandal, P. K.; McMurray, J. S.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cheng, H.; Xue, F.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Salamon, D (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Nobels Vag 16, SE-17177 Stockholm, Sweden.	Daniel.Salamon@ki.se	Ujvari, Dorina/AAS-8724-2021; Salamon, Daniel/AAZ-4807-2021; Westerberg, Lisa/AAB-3808-2019; Nagy, Noemi/J-2936-2012; Keszei, Marton/F-3295-2014	Amu, Sylvie/0000-0001-9593-7952; Salamon, Daniel/0000-0001-6630-3993; Kallas, Tomasz/0000-0001-8838-697X; Westerberg, Lisa/0000-0003-2943-2192; Keszei, Marton/0000-0002-1158-2179; Nagy, Noemi/0000-0002-7800-3493	Swedish Cancer Society (Cancerfonden); Adolf H Lundin Charitable Foundation; Karolinska Institutet; Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles)	Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Adolf H Lundin Charitable Foundation; Karolinska Institutet(Karolinska Institutet); Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles)	This work was supported by grants from the the Swedish Cancer Society (Cancerfonden), Adolf H Lundin Charitable Foundation and Karolinska Institutet. HM, NN, TK and DS are or were recipients of Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles).	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Aswald JM, 2002, CYTOKINES CELL MOL T, V7, P143, DOI 10.1080/13684730210002319; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bonmort M, 2007, BIOCHIMIE, V89, P872, DOI 10.1016/j.biochi.2007.04.014; Bunting KL, 2013, CURR OPIN IMMUNOL, V25, P339, DOI 10.1016/j.coi.2013.05.003; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Chomel JC, 2011, ONCOTARGET, V2, P713; Christiansson L, 2015, MOL CANCER THER, V14, P1181, DOI 10.1158/1535-7163.MCT-14-0849; Cunard R, 2004, J IMMUNOL, V172, P7530, DOI 10.4049/jimmunol.172.12.7530; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; DiNoto R, 1997, LEUKEMIA, V11, P1554; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; Gough DJ, 2008, CYTOKINE GROWTH F R, V19, P383, DOI 10.1016/j.cytogfr.2008.08.004; Green MR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4904; Held SAE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1065368; Hideshima T, 2010, BLOOD, V115, P3772, DOI 10.1182/blood-2010-02-270082; Huang BB, 2001, J INVEST DERMATOL, V116, P305, DOI 10.1046/j.1523-1747.2001.01242.x; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jaras M, 2010, P NATL ACAD SCI USA, V107, P16280, DOI 10.1073/pnas.1004408107; Kim DH, 2010, CLIN CANCER RES, V16, P5339, DOI 10.1158/1078-0432.CCR-10-1638; KLEIN E, 1968, CANCER RES, V28, P1300; Krusch M, 2011, CURR MED CHEM, V18, P5174, DOI 10.2174/092986711798184271; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Mandal PK, 2015, J MED CHEM, V58, P8970, DOI 10.1021/acs.jmedchem.5b01321; Nakayamada S, 2014, J IMMUNOL, V192, P2156, DOI 10.4049/jimmunol.1300675; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Prost S, 2015, NATURE, V525, P380, DOI 10.1038/nature15248; Ritz O, 2013, ONCOTARGET, V4, P1093, DOI 10.18632/oncotarget.1149; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schurch C, 2013, J EXP MED, V210, P605, DOI 10.1084/jem.20121229; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Tsuyama N, 2005, BIOCHEM BIOPH RES CO, V337, P201, DOI 10.1016/j.bbrc.2005.09.036; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Warsch W, 2013, BLOOD, V122, P2167, DOI 10.1182/blood-2013-02-485573; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood-2004-02-0664; Zhou G, 2005, EXP MOL PATHOL, V78, P25, DOI 10.1016/j.yexmp.2004.08.008; Zoubir Moustapha, 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P1	51	26	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4619	4628		10.1038/onc.2017.85	http://dx.doi.org/10.1038/onc.2017.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368400				2022-12-28	WOS:000407246200009
J	Mertz, TM; Baranovskiy, AG; Wang, J; Tahirov, TH; Shcherbakova, PV				Mertz, T. M.; Baranovskiy, A. G.; Wang, J.; Tahirov, T. H.; Shcherbakova, P. V.			Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase delta mutation in human cells	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; MISMATCH REPAIR; GERMLINE MUTATIONS; COLORECTAL-CANCER; HPRT LOCUS; REPLICATION; EPSILON; LINES; GENE; POLE	Mutations in the POLD1 and POLE genes encoding DNA polymerases delta (Pol delta) and epsilon (Pol epsilon) cause hereditary colorectal cancer (CRC) and have been found in many sporadic colorectal and endometrial tumors. Much attention has been focused on POLE exonuclease domain mutations, which occur frequently in hypermutated DNA mismatch repair (MMR)-proficient tumors and appear to be responsible for the bulk of genomic instability in these tumors. In contrast, somatic POLD1 mutations are seen less frequently and typically occur in MMR-deficient tumors. Their functional significance is often unclear. Here we demonstrate that expression of the cancer-associated POLD1-R689W allele is strongly mutagenic in human cells. The mutation rate increased synergistically when the POLD1-R689W expression was combined with a MMR defect, indicating that the mutator effect of POLD1-R689W results from a high rate of replication errors. Purified human Pol delta-R689W has normal exonuclease activity, but the nucleotide selectivity of the enzyme is severely impaired, providing a mechanistic explanation for the increased mutation rate in the POLD1-R689W-expressing cells. The vast majority of mutations induced by the POLD1-R689W are GC -> TA transversions and GC -> AT transitions, with transversions showing a strong strand bias and a remarkable preference for polypurine/polypyrimidine sequences. The mutational specificity of the Pol delta variant matches that of the hypermutated CRC cell line, HCT15, in which this variant was first identified. The results provide compelling evidence for the pathogenic role of the POLD1-R689W mutation in the development of the human tumor and emphasize the need to experimentally determine the significance of Pold variants present in sporadic tumors.	[Mertz, T. M.; Baranovskiy, A. G.; Wang, J.; Tahirov, T. H.; Shcherbakova, P. V.] Univ Nebraska, Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA; [Mertz, T. M.] Washington State Univ, Sch Mol Biosci, Coll Vet Med, Pullman, WA 99164 USA	University of Nebraska System; University of Nebraska Medical Center; Washington State University	Shcherbakova, PV (corresponding author), Univ Nebraska, Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.	pshcherb@unmc.edu		Tahirov, Tahir/0000-0002-1238-0069	National Institutes of Health [ES015869, GM101167, CA140988]; Nebraska Department of Health and Human Services [LB506]; University of Nebraska Medical Center Graduate Studies Research Fellowship; Cancer Biology Training Grant from the National Cancer Institute [T32CA009476]; NATIONAL CANCER INSTITUTE [T32CA009476, R01CA140988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM101167, P30GM106397] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services; University of Nebraska Medical Center Graduate Studies Research Fellowship; Cancer Biology Training Grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rob Lewis and Mike Brattain for cell lines, and Elizabeth Moore and Krista Brown for technical assistance. This work was supported by the National Institutes of Health grants ES015869 to PVS, GM101167 to THT and CA140988 to JW and by Nebraska Department of Health and Human Services grants LB506 to PVS and THT. TMM was supported by a University of Nebraska Medical Center Graduate Studies Research Fellowship and by the Cancer Biology Training Grant T32CA009476 from the National Cancer Institute.	Abaan OD, 2013, CANCER RES, V73, P4372, DOI 10.1158/0008-5472.CAN-12-3342; Agbor AA, 2013, DNA REPAIR, V12, P954, DOI 10.1016/j.dnarep.2013.08.012; Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Daee DL, 2010, P NATL ACAD SCI USA, V107, P157, DOI 10.1073/pnas.0907526106; Flohr T, 1999, INT J CANCER, V80, P919, DOI 10.1002/(SICI)1097-0215(19990315)80:6<919::AID-IJC19>3.0.CO;2-U; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Ghodgaonkar MM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5990; Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Herr AJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002282; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Kane DP, 2014, CANCER RES, V74, P1895, DOI 10.1158/0008-5472.CAN-13-2892; Keohavong Phouthone, 2005, Methods Mol Biol, V291, P161, DOI 10.1385/1-59259-840-4:161; KOI M, 1994, CANCER RES, V54, P4308; Li L, 2005, GENETICS, V170, P569, DOI 10.1534/genetics.104.040295; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Masuda Y, 2007, NUCLEIC ACIDS RES, V35, P6904, DOI 10.1093/nar/gkm822; McElhinny SAN, 2007, J BIOL CHEM, V282, P2324, DOI 10.1074/jbc.M609591200; Mertz TM, 2015, P NATL ACAD SCI USA, V112, pE2467, DOI 10.1073/pnas.1422934112; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; Seshagiri S, 2013, NAT GENET, V45, P121, DOI 10.1038/ng.2540; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; SHCHERBAKOVA PV, 1993, MUTAGENESIS, V8, P417, DOI 10.1093/mutage/8.5.417; Shinbrot E, 2014, GENOME RES, V24, P1740, DOI 10.1101/gr.174789.114; Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202; TIBBETTS LM, 1977, CANCER, V40, P2651, DOI 10.1002/1097-0142(197711)40:5+<2651::AID-CNCR2820400939>3.0.CO;2-V; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; Venkatesan RN, 2006, J BIOL CHEM, V281, P4486, DOI 10.1074/jbc.M510245200; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Yoshida R, 2011, EUR J HUM GENET, V19, P320, DOI 10.1038/ejhg.2010.216	37	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4427	4433		10.1038/onc.2017.22	http://dx.doi.org/10.1038/onc.2017.22			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368425	Green Accepted			2022-12-28	WOS:000406806000005
J	Walls, GV; Stevenson, M; Lines, KE; Newey, PJ; Reed, AAC; Bowl, MR; Jeyabalan, J; Harding, B; Bradley, KJ; Manek, S; Chen, J; Wang, P; Williams, BO; Teh, BT; Thakker, RV				Walls, G. V.; Stevenson, M.; Lines, K. E.; Newey, P. J.; Reed, A. A. C.; Bowl, M. R.; Jeyabalan, J.; Harding, B.; Bradley, K. J.; Manek, S.; Chen, J.; Wang, P.; Williams, B. O.; Teh, B. T.; Thakker, R. V.			Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome	ONCOGENE			English	Article							SUPPRESSOR GENE; DOWN-REGULATION; BETA-CATENIN; HUMAN PAF1; HPT-JT; EXPRESSION; PARAFIBROMIN; MUTATIONS; CANCER; HRPT2	The hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal dominant disorder characterized by occurrence of parathyroid tumours, often atypical adenomas and carcinomas, ossifying jaw fibromas, renal tumours and uterine benign and malignant neoplasms. HPT-JT is caused by mutations of the cell division cycle 73 (CDC73) gene, located on chromosome 1q31.2 and encodes a 531 amino acid protein, parafibromin. To facilitate in vivo studies of Cdc73 in tumourigenesis we generated conventional (Cdc73(+/-)) and conditional parathyroid-specific (Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre) mouse models. Mice were aged to 18-21 months and studied for survival, tumour development and proliferation, and serum biochemistry, and compared to age-matched wild-type (Cdc73(+/+) and Cdc73(+/+)/PTH-Cre) littermates. Survival of Cdc73(+/)-mice, when compared to Cdc73(+/+) mice was reduced (Cdc73+/-= 80%; Cdc73(+/+) = 90% at 18 months of age, P<0.05). Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice developed parathyroid tumours, which had nuclear pleomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyroid adenomas, from 9 months of age. Parathyroid tumours in Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice had significantly increased proliferation, with rates 4fourfold higher than that in parathyroid glands of wild-type littermates (P<0.0001). Cdc73(+/-), Cdc73(+/L)/PTH-Cre and Cdc73(L/L)/PTH-Cre mice had higher mean serum calcium concentrations than wild-type littermates, and Cdc73(+/)-mice also had increased mean serum parathyroid hormone (PTH) concentrations. Parathyroid tumour development, and elevations in serum calcium and PTH, were similar in males and females. Cdc7(3+)/-mice did not develop bone or renal tumours but female Cdc73(+/-)mice, at 18 months of age, had uterine neoplasms comprising squamous metaplasia, adenofibroma and adenomyoma. Uterine neoplasms, myometria and jaw bones of Cdc73(+/)-mice had increased proliferation rates that were 2-fold higher than in Cdc73(+/+) mice (P<0.05). Thus, our studies, which have established mouse models for parathyroid tumours and uterine neoplasms that develop in the HPT-JT syndrome, provide in vivo models for future studies of these tumours.	[Walls, G. V.; Stevenson, M.; Lines, K. E.; Newey, P. J.; Reed, A. A. C.; Bowl, M. R.; Jeyabalan, J.; Harding, B.; Bradley, K. J.; Thakker, R. V.] Univ Oxford, Radcliffe Dept Med, OCDEM, Acad Endocrine Unit,Churchill Hosp, Oxford OX3 7LJ, England; [Manek, S.] John Radcliffe Hosp, Dept Pathol, Headley Way, Oxford, England; [Chen, J.; Wang, P.; Teh, B. T.] Van Andel Res Inst, Lab Canc Genet, Grand Rapids, MI USA; [Williams, B. O.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI USA	University of Oxford; University of Oxford; Van Andel Institute; Van Andel Institute	Thakker, RV (corresponding author), Univ Oxford, Radcliffe Dept Med, OCDEM, Acad Endocrine Unit,Churchill Hosp, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk	Stevenson, Mark/GRF-5876-2022; Williams, Bart/A-3539-2013	Stevenson, Mark/0000-0001-8616-0205; Williams, Bart/0000-0002-5261-5301; Teh, Bin Tean/0000-0003-1514-1124; Bowl, Michael/0000-0001-7971-445X; Lines, Kate/0000-0002-0764-8681	Medical Research Council (MRC), UK [G9825289/2004, G1000467/2010]; Van Andel Foundation, Grand Rapids, USA; United Kingdom Medical Research Council (MRC) [G9825289, G1000467]; Medical Research Council [G9825289, G1000467] Funding Source: researchfish; National Institute for Health Research [CL-2010-13-004] Funding Source: researchfish; MRC [G9825289, G1000467] Funding Source: UKRI	Medical Research Council (MRC), UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Van Andel Foundation, Grand Rapids, USA; United Kingdom Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MRC), UK (grant number G9825289/2004 and G1000467/2010), (GV Walls, M Stevenson, KE Lines, MR Bowl, J Jeyabalan, PJ Newey, AAC Reed, B Harding, KJ Bradley and RV Thakker), and the Van Andel Foundation, Grand Rapids, USA (P Wang, J Chen, BO Williams, BT Teh). GV Walls, PJ Newey and KJ Bradley received MRC Clinical Research Training Fellowships. This work was supported by grants from the United Kingdom Medical Research Council (MRC) (G9825289 and G1000467) to GVW, MS, KEL, PJN, AACR, MRB, JJ, BH, KJB, and RVT; and the Van Andel Foundation, Grand Rapids, USA to JC, PW, BOW and BTT.	Amrich CG, 2012, J BIOL CHEM, V287, P10863, DOI 10.1074/jbc.M111.325647; Arnett-Mansfield RL, 2001, CANCER RES, V61, P4576; Bergero N, 2005, HUM PATHOL, V36, P908, DOI 10.1016/j.humpath.2005.06.020; Bokov AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026891; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Bricaire L, 2013, J CLIN ENDOCR METAB, V98, pE403, DOI 10.1210/jc.2012-2789; Bush BM, 2013, CELL BIOCHEM FUNCT, V31, P228, DOI 10.1002/cbf.2876; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cetani F, 2016, J ENDOCRINOL INVEST, V39, P595, DOI 10.1007/s40618-016-0447-3; Chan JKC, 2013, DIAGNOSTIC HISTOPATH, V2, P1273; Commandeur AE, 2015, HUM REPROD UPDATE, V21, P593, DOI 10.1093/humupd/dmv030; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; CRYNS VL, 1994, J CLIN ENDOCR METAB, V78, P1320, DOI 10.1210/jc.78.6.1320; DeLellis RA, 2004, PATHOLOGY GENETICS T, V8; DeLellis RA, 2011, MODERN PATHOL, V24, pS78, DOI 10.1038/modpathol.2010.132; Duan K, 2015, J CLIN PATHOL, V68, P771, DOI 10.1136/jclinpath-2015-203186; Ensembl, ENSMUSG00000026361; Evans P, 2007, AM FAM PHYSICIAN, V75, P1503; Farber LJ, 2010, MOL CARCINOGEN, V49, P215, DOI 10.1002/mc.20591; FUJIMOTO J, 1995, TUMOR BIOL, V16, P254, DOI 10.1159/000217942; Fukuda K, 1998, GYNECOL ONCOL, V69, P220, DOI 10.1006/gyno.1998.5023; Gill AJ, 2006, AM J SURG PATHOL, V30, P1140; Gill AJ, 2014, ENDOCR PATHOL, V25, P30, DOI 10.1007/s12022-013-9294-3; Givi B, 2010, CLIN ONCOL-UK, V22, P498, DOI 10.1016/j.clon.2010.04.007; Grigorieva IV, 2010, J CLIN INVEST, V120, P2144, DOI 10.1172/JCI42021; Harding B, 2009, ENDOCR-RELAT CANCER, V16, P1313, DOI 10.1677/ERC-09-0082; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hayes MP, 2010, GYNECOL ONCOL, V116, P286, DOI 10.1016/j.ygyno.2009.11.012; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Howitt BE, 2015, J PATHOL, V235, P37, DOI 10.1002/path.4442; Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523; Jenkins PJ, 1997, CLIN ENDOCRINOL, V47, P747, DOI 10.1046/j.1365-2265.1997.3421147.x; Juhlin CC, 2011, VIRCHOWS ARCH, V459, P47, DOI 10.1007/s00428-010-1032-3; Juhlin CC, 2009, INT J ONCOL, V34, P481, DOI 10.3892/ijo_00000173; Juodele L, 2011, MEDICINA-LITHUANIA, V47, P635, DOI 10.3390/medicina47110092; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kruijff S, 2014, ANN SURG ONCOL, V21, P426, DOI 10.1245/s10434-013-3288-8; Kumar NS, 1998, CANCER RES, V58, P1860; Kumari N, 2016, ENDOCR PATHOL, V27, P87, DOI 10.1007/s12022-016-9426-7; Libutti SK, 2003, CANCER RES, V63, P8022; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Loffler KA, 2007, ONCOGENE, V26, P4009, DOI 10.1038/sj.onc.1210163; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Mosimann C, 2009, MECH DEVELOP, V126, P394, DOI 10.1016/j.mod.2009.02.002; Myant K, 2011, EXP CELL RES, V317, P2725, DOI 10.1016/j.yexcr.2011.08.001; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; Newey PJ, 2010, HUM MUTAT, V31, P295, DOI 10.1002/humu.21188; Parker WH, 2007, FERTIL STERIL, V87, P725, DOI 10.1016/j.fertnstert.2007.01.093; Piret SE, 2011, J ENDOCRINOL, V211, P211, DOI 10.1530/JOE-11-0193; Rather MI, 2014, J BIOL CHEM, V289, P968, DOI 10.1074/jbc.M113.483255; REUBER MD, 1981, J GERONTOL, V36, P663, DOI 10.1093/geronj/36.6.663; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Saggiorato E, 2006, AM J CLIN PATHOL, V126, P59, DOI 10.1309/9NXP7FRF87MU2PCK; Sato M, 2000, ENDOCRINE, V12, P223, DOI 10.1385/ENDO:12:3:223; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Svedlund J, 2014, ENDOCR-RELAT CANCER, V21, P231, DOI 10.1530/ERC-13-0497; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Tesfaye A, 2007, CANCER RES, V67, P3998, DOI 10.1158/0008-5472.CAN-05-1684; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Varghese BV, 2013, P NATL ACAD SCI USA, V110, P2187, DOI 10.1073/pnas.1215759110; Vasef MA, 1999, MODERN PATHOL, V12, P412; Walls GV, 2012, ENDOCRINOLOGY, V153, P5167, DOI 10.1210/en.2012-1675; Wang PF, 2008, MOL CELL BIOL, V28, P2930, DOI 10.1128/MCB.00654-07; Witteveen JE, 2011, MODERN PATHOL, V24, P688, DOI 10.1038/modpathol.2010.236; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Yu W, 2015, J CLIN ENDOCR METAB, V100, pE360, DOI 10.1210/jc.2014-3238; Zhang C, 2006, BIOCHEM BIOPH RES CO, V350, P17, DOI 10.1016/j.bbrc.2006.08.169	75	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4025	4036		10.1038/onc.2017.43	http://dx.doi.org/10.1038/onc.2017.43			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288139	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000405379900008
J	Li, Y; Zhou, T; Wang, Y; Ning, C; Lv, Z; Han, G; Morris, JC; Taylor, EN; Wang, R; Xiao, H; Hou, C; Ma, Y; Shen, B; Feng, J; Guo, R; Li, Y; Chen, G				Li, Y.; Zhou, T.; Wang, Y.; Ning, C.; Lv, Z.; Han, G.; Morris, J. C.; Taylor, E. N.; Wang, R.; Xiao, H.; Hou, C.; Ma, Y.; Shen, B.; Feng, J.; Guo, R.; Li, Y.; Chen, G.			The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation	ONCOGENE			English	Article							TUMOR-BEARING MICE; SUPPRESSOR-CELLS; MULTIPLE-SCLEROSIS; HEPATOCELLULAR-CARCINOMA; LYMPHOCYTE EGRESS; GM-CSF; FINGOLIMOD; RECEPTOR; CANCER; ACTIVATION	FTY720 (also called fingolimod) is recognized as an immunosuppressant and has been approved by the Food and Drug Administration to treat refractory multiple sclerosis. However, long-term administration of FTY720 potentially increases the risk for cancer in recipients. The underlying mechanisms remain poorly understood. Herein, we provided evidence that FTY720 administration potentiated tumor growth. Mechanistically, FTY720 enhanced extramedullary hematopoiesis and massive accumulation of myeloid-derived suppressor cells (MDSCs), which actively suppressed antitumor immune responses. Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by MDSCs, was identified as a key factor to mediate these effects of FTY720 in tumor microenvironment. Furthermore, we showed that FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellular signal-regulated kinase-dependent pathway. Thus, our findings provide mechanistic explanation for the protumorigenic potentials of FTY720 and suggest that targeting S1pr3 simultaneously may be beneficial for the patients receiving FTY720 treatment.	[Li, Y.; Zhou, T.; Wang, Y.; Ning, C.; Lv, Z.; Han, G.; Wang, R.; Xiao, H.; Hou, C.; Shen, B.; Feng, J.; Li, Y.; Chen, G.] Inst Basic Med Sci, Dept Immunol, Taiping Rd 27, Beijing 100850, Peoples R China; [Li, Y.; Ma, Y.] Henan Univ, Med Sch, Lab Cellular & Mol Immunol, Kaifeng, Peoples R China; [Li, Y.] Peoples Hosp Luanchuan Cty, Dept Internal Med, Luoyang, Peoples R China; [Li, Y.; Zhou, T.; Han, G.; Wang, R.; Xiao, H.; Hou, C.; Shen, B.; Feng, J.; Li, Y.; Chen, G.] State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Wang, Y.] Acad Mil Med Sci, Affiliated Hosp, Dept Hematol & Transplantat, Beijing, Peoples R China; [Ning, C.] 161st Hosp PLA, Dept Oncol, Wuhan, Peoples R China; [Morris, J. C.; Taylor, E. N.] Univ New South Wales, Sch Chem, Sydney, NSW, Australia; [Guo, R.] Univ Michigan, Dept Pathol, Ann Arbor, MI USA	Henan University; Academy of Military Medical Sciences - China; University of New South Wales Sydney; University of Michigan System; University of Michigan	Han, G; Chen, G (corresponding author), Inst Basic Med Sci, Dept Immunol, Taiping Rd 27, Beijing 100850, Peoples R China.	genchenghan@163.com; guogangch@yahoo.com	Wang, Renxi/AAM-1326-2020; Morris, Jonathan C/A-9923-2008	Morris, Jonathan C/0000-0002-5109-9069; Wang, Renxi/0000-0003-4130-3334	National Key Basic Research Program of China [2015CB553704, 2013CB530506]; National Natural Science Foundation of China [81672803, 81472647, 81272320]; Beijing Natural Science Foundation [7132151]; Service Industry Scientific Research of National Health and Family Planning Commission of China [2015SQ00192]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Service Industry Scientific Research of National Health and Family Planning Commission of China	This work was supported by grants from the National Key Basic Research Program of China (2015CB553704, 2013CB530506), the National Natural Science Foundation of China (81672803, 81472647, 81272320), Beijing Natural Science Foundation (7132151), Service Industry Scientific Research of National Health and Family Planning Commission of China (2015SQ00192).	Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Calabresi PA, 2014, LANCET NEUROL, V13, P545, DOI 10.1016/S1474-4422(14)70049-3; Cohen JA, 2011, ANN NEUROL, V69, P759, DOI 10.1002/ana.22426; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Conzett KB, 2011, ARCH DERMATOL, V147, P991, DOI 10.1001/archdermatol.2011.212; Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Griseri T, 2012, IMMUNITY, V37, P1116, DOI 10.1016/j.immuni.2012.08.025; Hait NC, 2014, NAT NEUROSCI, V17, P971, DOI 10.1038/nn.3728; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hung JH, 2008, CANCER RES, V68, P1204, DOI 10.1158/0008-5472.CAN-07-2621; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kim EK, 2014, CANCER RES, V74, P6705, DOI 10.1158/0008-5472.CAN-14-1482; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee TK, 2005, CLIN CANCER RES, V11, P8458, DOI 10.1158/1078-0432.CCR-05-0447; Liu GW, 2014, J IMMUNOL, V192, P3068, DOI 10.4049/jimmunol.1301193; Liu Q, 2010, CLIN CANCER RES, V16, P3182, DOI 10.1158/1078-0432.CCR-09-2484; Lorvik KB, 2012, BLOOD, V119, P2176, DOI 10.1182/blood-2011-10-388892; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Martinez-Moczygemba M, 2003, J ALLERGY CLIN IMMUN, V112, P653, DOI 10.1067/mai.2003.1796; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Mendelson K, 2014, DEVELOPMENT, V141, P5, DOI 10.1242/dev.094805; Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173; Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Pham THM, 2008, IMMUNITY, V28, P122, DOI 10.1016/j.immuni.2007.11.017; Pitman MR, 2012, CURR MOL MED, V12, P1207, DOI 10.2174/156652412803833599; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Quatromoni JG, 2015, J LEUKOCYTE BIOL, V97, P201, DOI 10.1189/jlb.5TA0814-373; Saddoughi SA, 2013, EMBO MOL MED, V5, P105, DOI 10.1002/emmm.201201283; Schwab SR, 2007, NAT IMMUNOL, V8, P1295, DOI 10.1038/ni1545; Sevko A, 2013, J CANCER, V4, P3, DOI 10.7150/jca.5047; Sio A, 2013, CANCER RES, V73, P5892, DOI 10.1158/0008-5472.CAN-13-0842; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Ueha S, 2011, INT IMMUNOPHARMACOL, V11, P783, DOI 10.1016/j.intimp.2011.03.003; Wu WC, 2014, P NATL ACAD SCI USA, V111, P4221, DOI 10.1073/pnas.1320753111; Yasui H, 2005, CANCER RES, V65, P7478, DOI 10.1158/0008-5472.CAN-05-0850; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791	50	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3760	3771		10.1038/onc.2017.2	http://dx.doi.org/10.1038/onc.2017.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218904				2022-12-28	WOS:000404349700011
J	Wang, GY; Wood, CN; Dolorito, JA; Libove, E; Epstein, EH				Wang, G. Y.; Wood, C. N.; Dolorito, J. A.; Libove, E.; Epstein, E. H., Jr.			Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; DEFICIENT MICE; IN-VIVO; EXPRESSION; SKIN; TUMORIGENESIS; MUTATIONS; HEDGEHOG; GROWTH; GENES	Human basal cell carcinomas (BCCs) very frequently carry p53 mutations, and p53 loss markedly accelerates murine BCC carcinogenesis. We report here our studies of the mechanism by which p53 is activated to suppress BCC carcinogenesis. We find that aberrant hedgehog signaling in microscopic BCCs activates p53 in part via Arf (that is, the oncogene-induced stress pathway) but not via the DNA damage response pathway. However, Arf loss and p53 loss produce differing outcomes-loss of p53 promotes both tumor initiation and progression; loss of Arf promotes tumor progression but not initiation. Intriguingly, increased expression of Arf in tumor stromal cells, as in tumor keratinocytes themselves, contributes to suppression of BCC carcinogenesis.	[Wang, G. Y.; Wood, C. N.; Dolorito, J. A.; Libove, E.; Epstein, E. H., Jr.] Childrens Hosp Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Wang, GY; Epstein, EH (corresponding author), Childrens Hosp Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	gwang@chori.org; eepstein@chori.org		Wood, Carla/0000-0002-6813-7981	NIH [R01CA163611]; American Skin Association; Skin Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA163611] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Skin Association; Skin Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peter Lamb at Exelixis for providing XL-139 and Charles Sherr for both providing mice carrying the Arf-GFP allele and for wise, ongoing counsel. This work was supported by NIH grant # R01CA163611 (PI: EHE), the American Skin Association (PI: GYW) and the Skin Cancer Foundation (PI: GYW).	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Busch SE, 2014, ONCOGENE, V33, P2665, DOI 10.1038/onc.2013.208; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood-2011-06-361626; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Herranz S, 2012, ONCOIMMUNOLOGY, V1, P1227, DOI 10.4161/onci.21207; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Ismail F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021271; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kanellou P, 2009, BRIT J DERMATOL, V160, P1215, DOI 10.1111/j.1365-2133.2009.09079.x; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Konig S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093555; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; Lacour JP, 2002, BRIT J DERMATOL, V146, P17, DOI 10.1046/j.1365-2133.146.s61.5.x; LEWIS JG, 1987, CARCINOGENESIS, V8, P889, DOI 10.1093/carcin/8.7.889; Li ZJ, 2014, ONCOGENE, V33, P2674, DOI 10.1038/onc.2013.212; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Nitzki F, 2010, CANCER RES, V70, P2739, DOI 10.1158/0008-5472.CAN-09-3743; Orlando G, 2014, NUCLEIC ACIDS RES, V42, P2320, DOI 10.1093/nar/gkt1185; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Saridaki Z, 2000, J INVEST DERMATOL, V115, P719, DOI 10.1046/j.1523-1747.2000.00098.x; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Wang GY, 2011, J INVEST DERMATOL, V131, P2298, DOI 10.1038/jid.2011.204; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wang Y, 2003, CANCER RES, V63, P4389; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Wetmore C, 2001, CANCER RES, V61, P513; Young NP, 2011, CANCER RES, V71, P4040, DOI 10.1158/0008-5472.CAN-10-4563; Zerrouqi A, 2012, J CLIN INVEST, V122, P1283, DOI 10.1172/JCI38596; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	47	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3772	3780		10.1038/onc.2017.12	http://dx.doi.org/10.1038/onc.2017.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28263978				2022-12-28	WOS:000404349700012
J	Lopez-Delisle, L; Pierre-Eugene, C; Louis-Brennetot, C; Surdez, D; Raynal, V; Baulande, S; Boeva, V; Grossetete-Lalami, S; Combaret, V; Peuchmaur, M; Delattre, O; Janoueix-Lerosey, I				Lopez-Delisle, Lucille; Pierre-Eugene, Cecile; Louis-Brennetot, Caroline; Surdez, Didier; Raynal, Virginie; Baulande, Sylvain; Boeva, Valentina; Grossetete-Lalami, Sandrine; Combaret, Valerie; Peuchmaur, Michel; Delattre, Olivier; Janoueix-Lerosey, Isabelle			Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; ETS TRANSCRIPTION FACTORS; RECEPTOR TYROSINE KINASE; INHIBITOR PF-06463922; THERAPEUTIC TARGET; UP-REGULATION; RET; MUTATIONS; CANCER; EXPRESSION	Activating mutations of the ALK receptor occur in a subset of neuroblastoma tumors. We previously demonstrated that Alk mutations cooperate with MYCN overexpression to induce neuroblastoma in mice and identified Ret as being strongly upregulated in MYCN/Alk(mu)t tumors. By a genetic approach in vivo, we now document an oncogenic cooperation between activated Ret and MYCN overexpression in neuroblastoma formation. We show that MYCN/Ret(M919T) tumors exhibit histological features and expression profiles close to MYCN/Alk(mut) tumors. We show that RET transcript levels decrease precedes RET protein levels decrease upon ALK inhibition in neuroblastoma cell lines. Etv5 was identified as a candidate transcription factor regulating Ret expression from murine MYCN/Alk(mut) tumor transcriptomic data. We demonstrate that ETV5 is regulated both at the protein and mRNA levels upon ALK activation or inhibition in neuroblastoma cell lines and that this regulation precedes RET modulation. We document that ALK activation induces ETV5 protein upregulation through stabilization in a MEK/ERK- dependent manner. We show that RNAi-mediated inhibition of ETV5 decreases RET expression. Reporter assays indicate that ETV5 is able to drive RET gene transcription. ChIP-seq analysis confirmed ETV5 binding on the RET promoter and identified an enhancer upstream of the promoter. Finally, we demonstrate that combining RET and ALK inhibitors reduces tumor growth more efficiently than each single agent in MYCN and Alk(F1178L)-driven murine neuroblastoma. Altogether, these results define the ERK-ETV5-RET pathway as a critical axis driving neuroblastoma oncogenesis downstream of activated ALK.	[Lopez-Delisle, Lucille; Pierre-Eugene, Cecile; Louis-Brennetot, Caroline; Surdez, Didier; Raynal, Virginie; Grossetete-Lalami, Sandrine; Delattre, Olivier; Janoueix-Lerosey, Isabelle] PSL Res Univ, INSERM, U830, Equipe Labellisee Ligue Canc,Inst Curie, Paris, France; [Raynal, Virginie; Baulande, Sylvain] Inst Curie Res Ctr, Inst Curie Genom Excellence ICGex, Paris, France; [Boeva, Valentina] Univ Paris 05, CNRS, UMR 8104, Inst Cochin,INSERM,U1016,UMR S1016, Paris, France; [Boeva, Valentina] PSL Res Univ, INSERM, U900, Inst Curie,Mines ParisTech, Paris, France; [Combaret, Valerie] Ctr Leon Berard, Lab Rech Translat, Lyon, France; [Peuchmaur, Michel] Hop Univ Robert Debre, AP HP, Dept Pathol, Paris, France; [Peuchmaur, Michel] Univ Diderot Paris 7, Paris Sorbonne Cite, Paris, France; [Delattre, Olivier; Janoueix-Lerosey, Isabelle] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Janoueix-Lerosey, I (corresponding author), PSL Res Univ, INSERM, U830, Equipe Labellisee Ligue Canc,Inst Curie, Paris, France.; Janoueix-Lerosey, I (corresponding author), Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France.	janoueix@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Boeva, Valentina/C-2855-2017; Surdez, Didier/ABG-4565-2020	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Boeva, Valentina/0000-0002-4382-7185; LOUIS, Caroline/0000-0002-4952-3828; Lopez-Delisle, Lucille/0000-0002-1964-4960; BAULANDE, Sylvain/0000-0003-3104-1684; delattre, olivier/0000-0002-8730-2276	Institut National du Cancer [PRT-K 14061]; Ligue Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin "Enfance et Cancer"; Les Bagouz a Manon, les amis de Claire; la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent; Fondation pour la Recherche Medicale [FDT20140930966]; Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program; ATIP-Avenir program; "Who am I?" program; Agence Nationale de la Recherche ("Investissements d'Avenir" program) [ANR-10-EQPX-03, ANR-10-INBS-09-08]; Canceropole Ile-de-France; SiRIC-Curie program-SiRIC [INCa-DGOS-4654]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Association Hubert Gouin "Enfance et Cancer"; Les Bagouz a Manon, les amis de Claire; la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program; ATIP-Avenir program; "Who am I?" program; Agence Nationale de la Recherche ("Investissements d'Avenir" program)(French National Research Agency (ANR)); Canceropole Ile-de-France(Region Ile-de-France); SiRIC-Curie program-SiRIC	The U830 Inserm laboratory is supported by grants from the Institut National du Cancer (PRT-K 14061), the Ligue Nationale contre le Cancer (Equipe labellisee), the Association Hubert Gouin "Enfance et Cancer", Les Bagouz a Manon, les amis de Claire, la Federation Enfants et Sante et la Societe Francaise de Lutte contre les Cancers et les Leucemies de l'Enfant et l'Adolescent. LL-D was the recipient of a fellowship of the Fondation pour la Recherche Medicale (FDT20140930966). DS is supported by the Institut Curie-SIRIC (Site de Recherche Integree en Cancerologie) program. VB is supported by the ATIP-Avenir and the "Who am I?" programs. High-throughput sequencing has been performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Genomique Consortium) from the Agence Nationale de la Recherche ("Investissements d'Avenir" program), by the Canceropole Ile-de-France and by the SiRIC-Curie program-SiRIC Grant "INCa-DGOS-4654". We thank Jean-Luc Baert (Institut de Recherche Interdisciplinaire de Lille, Lille, France) for providing us with the pcDNA3-ETV5 plasmid and Matthias Fischer for providing the ALK status of tumors from the GSE49711 dataset. We thank D Gentien and his team from the translational department of Institut Curie for Affymetrix profiling experiments. We are grateful to the animal facilities team of the Institut Curie and especially to I Grandjean and C Jouhanneau. We thank the Experimental Pathology Department of Institut Curie for their valuable help and the SIRIC-Curie for help in image analyses. We acknowledge our colleagues F Tirode and W Richer for assistance in the analysis of Affymetrix data.	Ashoor H, 2013, BIOINFORMATICS, V29, P2979, DOI 10.1093/bioinformatics/btt524; Baert JL, 2007, ONCOGENE, V26, P415, DOI 10.1038/sj.onc.1209801; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Boeva V, 2017, NAT GENET, V49, P1408, DOI 10.1038/ng.3921; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Cazes A, 2014, ONCOTARGET, V5, P2688, DOI 10.18632/oncotarget.1883; Chatterjee S, 2016, CELL, V167, P355, DOI 10.1016/j.cell.2016.09.005; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Fontanet P, 2013, J NEUROSCI, V33, P15940, DOI 10.1523/JNEUROSCI.0928-13.2013; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Guan J, 2016, DIS MODEL MECH, V9, P941, DOI 10.1242/dmm.024448; Hallberg B, 2016, ANN ONCOL, V27, P4, DOI 10.1093/annonc/mdw301; Infarinato NR, 2016, CANCER DISCOV, V6, P96, DOI 10.1158/2159-8290.CD-15-1056; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Lambertz I, 2015, CLIN CANCER RES, V21, P3327, DOI 10.1158/1078-0432.CCR-14-2024; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lin S, 2006, J BIOL CHEM, V281, P16716, DOI 10.1074/jbc.M602221200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Lu BC, 2009, NAT GENET, V41, P1295, DOI 10.1038/ng.476; Mano H, 2012, CANCER DISCOV, V2, P495, DOI 10.1158/2159-8290.CD-12-0009; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Mazot P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033581; Medina-Rivera A, 2015, NUCLEIC ACIDS RES, V43, pW50, DOI 10.1093/nar/gkv362; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Reiff T, 2011, DEVELOPMENT, V138, P4699, DOI 10.1242/dev.072157; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Simon L, 2007, EXP CELL RES, V313, P3090, DOI 10.1016/j.yexcr.2007.05.002; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Tyagi G, 2009, BIOL REPROD, V81, P258, DOI 10.1095/biolreprod.108.075200; Vitari AC, 2011, NATURE, V474, P403, DOI 10.1038/nature10005; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wood AC, 2017, CLIN CANCER RES, V23, P2856, DOI 10.1158/1078-0432.CCR-16-1114; Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0694-1	49	28	31	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1417	1429		10.1038/s41388-017-0039-5	http://dx.doi.org/10.1038/s41388-017-0039-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321660	Green Published, hybrid			2022-12-28	WOS:000427459500002
J	Omoto, T; Kim-Kaneyama, J; Lei, XF; Orimo, A; Ohnishi, K; Yoshihara, K; Miyauchi, A; Li, S; Gao, L; Umemoto, T; Tanaka, J; Nakahara, K; Takeya, M; Ishida, F; Kudo, S; Haraguchi, S; Miyazaki, T; Miyazaki, A				Omoto, Tomokatsu; Kim-Kaneyama, Joo-ri; Lei, Xiao-Feng; Orimo, Akira; Ohnishi, Koji; Yoshihara, Kosuke; Miyauchi, Aya; Li, Shuo; Gao, Lin; Umemoto, Takahiro; Tanaka, Junichi; Nakahara, Kenta; Takeya, Motohiro; Ishida, Fumio; Kudo, Shin-ei; Haraguchi, Shogo; Miyazaki, Takuro; Miyazaki, Akira			The impact of stromal Hic-5 on the tumorigenesis of colorectal cancer through lysyl oxidase induction and stromal remodeling	ONCOGENE			English	Article							PROSTATE-CANCER; FIBROBLASTS; ACTIVATION; ROLES; CELLS	Carcinoma-associated fibroblasts (CAFs) influence tumor initiation, progression, and metastasis within the tumor-associated stroma. This suggests that CAFs would be a potential target for tumor therapy. Here we found that Hydrogen peroxide- inducible clone-5 (Hic-5), also named transforming growth factor beta-1-induced transcript 1 protein (Tgfb1i1), was strongly induced in CAFs found in human colorectal cancer. To investigate the role of Hic-5 in CAFs, we isolated CAFs and the control counterpart normal fibroblasts (NFs) from human colorectal cancer and non-cancerous regions, respectively. Hic-5 was highly expressed in isolated human CAFs and strongly induced in NFs in culture by the supernatant from cultured colorectal cancer cells as well as cytokines such as TGF-beta, IL-1 beta and stromal cell-derived factor 1 (SDF-1/CXCL12). Furthermore, tumor growth was inhibited in a co-culture assay with Hic-5 knockdown fibroblasts compared with control fibroblasts. To clarify the function and significance of Hic-5 in colorectal cancer in vivo, we utilized a mouse model of azoxymethane (AOM)-induced colorectal cancer using Hic-5-dehcient mice. Lack of Hic-5 in CAFs completely prevented AOM-induced colorectal cancer development in the colon tissues of mice. Mechanistic investigation revealed that Hic-5 promoted the expression of lysyl oxidase and collagen I in human control counterpart fibroblasts. Taken together, these results demonstrate that Hic-5 in CAFs is responsible for orchestrating or generating a tumor-promoting stroma.	[Omoto, Tomokatsu; Kim-Kaneyama, Joo-ri; Lei, Xiao-Feng; Miyauchi, Aya; Li, Shuo; Gao, Lin; Haraguchi, Shogo; Miyazaki, Takuro; Miyazaki, Akira] Showa Univ, Sch Med, Dept Biochem, Tokyo, Japan; [Orimo, Akira] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo, Japan; [Ohnishi, Koji; Takeya, Motohiro] Kumamoto Univ, Fac Life Sci, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan; [Yoshihara, Kosuke] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan; [Umemoto, Takahiro; Tanaka, Junichi] Showa Univ, Fujigaoka Hosp, Dept Gastroenterol & Gen Surg, Yokohama, Kanagawa, Japan; [Nakahara, Kenta; Ishida, Fumio; Kudo, Shin-ei] Showa Univ, Northern Yokohama Hosp, Digest Dis Ctr, Tsuzuki Ku, Yokohama, Kanagawa, Japan	Showa University; Juntendo University; Kumamoto University; Niigata University; Showa University; Showa University	Kim-Kaneyama, J (corresponding author), Showa Univ, Sch Med, Dept Biochem, Tokyo, Japan.	shuri@pharm.showa-u.ac.jp	Yoshihara, Kosuke/AAU-9874-2020	Yoshihara, Kosuke/0000-0002-2254-3378; Orimo, Akira/0000-0001-5330-7282; Miyazaki, Takuro/0000-0003-3354-0292; Haraguchi, Shogo/0000-0002-8731-3311	Japan Society for the Promotion of Science [26461149, 16K10553, 17K10713]; Japan-China Medical Association; Takeda Science Foundation; Private University Research Branding Project; MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities; Grants-in-Aid for Scientific Research [15K15611, 15K14385] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan-China Medical Association; Takeda Science Foundation(Takeda Science Foundation (TSF)); Private University Research Branding Project; MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (26461149 to J-rK-K; 16K10553 to TO; 17K10713 to X-FL) from Japan Society for the Promotion of Science, a research grant from Japan-China Medical Association (to J-rK-K), a research grant from Takeda Science Foundation (to J-rK-K and X-FL) and Private University Research Branding Project. This work was also supported in part by the MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities, 2012-2016.	Allaoui R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13050; Arita-Okubo S, 2015, CARDIOVASC RES, V105, P361, DOI 10.1093/cvr/cvv003; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goreczny GJ, 2017, ONCOGENE, V36, P2693, DOI 10.1038/onc.2016.422; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jamba A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122773; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kim-Kaneyama J, 2011, J MOL CELL CARDIOL, V50, P77, DOI 10.1016/j.yjmcc.2010.09.024; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Lei XF, 2016, J HEPATOL, V64, P110, DOI 10.1016/j.jhep.2015.08.026; Lei XF, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000747; Levental I, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194120; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shola DTN, 2012, ONCOGENE, V31, P2480, DOI 10.1038/onc.2011.422; Solomon JD, 2014, MOL CANCER RES, V12, P1166, DOI 10.1158/1541-7786.MCR-13-0395; Takai K, 2016, ONCOTARGET, V7, P82889, DOI 10.18632/oncotarget.12658; Varney SD, 2016, J CELL SCI, V129, P774, DOI 10.1242/jcs.170589; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Voloshenyuk TG, 2011, CYTOKINE, V55, P90, DOI 10.1016/j.cyto.2011.03.024; Wang TH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010062; Wu JR, 2015, ONCOTARGET, V6, P32526, DOI 10.18632/oncotarget.5322; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865	35	24	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1205	1219		10.1038/s41388-017-0033-y	http://dx.doi.org/10.1038/s41388-017-0033-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242607				2022-12-28	WOS:000426505400006
J	Song, SH; Jeon, MS; Nam, JW; Kang, JK; Lee, YJ; Kang, JY; Kim, HP; Han, SW; Kang, GH; Kim, TY				Song, S. H.; Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Han, S. W.; Kang, G. H.; Kim, T. Y.			Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer	ONCOGENE			English	Article							BETA-GLOBIN LOCUS; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; HELICOBACTER-PYLORI; EMBRYONIC-DEVELOPMENT; LINEAGE-SURVIVAL; POLYCOMB; RISK; DIFFERENTIATION; EXPRESSION	Six GATA transcription factors play important roles in eukaryotic development. Among these, GATA2, an essential factor for the hematopoietic cell lineage, exhibits low expression in human gastric tissues, whereas GATA6, which is crucial for gastrointestinal development and differentiation, is frequently amplified and/or overexpressed in human gastric cancer. Interestingly, we found that GATA6 was overexpressed in human gastric cancer cells only when GATA2 expression was completely absent, thereby showing an inverse correlation between GATA2 and GATA6. In gastric cancer cells that express high GATA6 levels, a GATA2 CpG island is hypermethylated, repressing expression in these cells. In contrast, GATA6 expression is undetectable in GATA2-overexpressing gastric cancer cells, which lack GATA2 DNA methylation. Furthermore, PRC2 complex-mediated transcriptional silencing of GATA6 was observed in the GATA2-overexpressing cells. We also show that the GATA2 and PRC2 complexes are enriched within the GATA6 locus, and that the recruitment of the PRC2 complex is impaired by disrupting GATA2 expression, resulting in GATA6 upregulation. In addition, ectopic GATA2 expression significantly downregulates GATA6 expression, suggesting GATA2 directly represses GATA6. Furthermore, GATA6 downregulation showed antitumor activity by inducing growth arrest. Finally, we show that aberrant GATA2 methylation occurs early during the multistep process of gastric carcinogenesis regardless of Helicobacter pylori infection. Taken together, GATA2 dysregulation by epigenetic modification is associated with unfavorable phenotypes in human gastric cancer cells by allowing GATA6 expression.	[Song, S. H.; Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Han, S. W.; Kim, T. Y.] Seoul Natl Univ, Canc Res Inst, Canc Genom Res Lab, Seoul, South Korea; [Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Kim, T. Y.] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Han, S. W.; Kim, T. Y.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; [Kang, G. H.] Seoul Natl Univ, Canc Res Inst, Lab Epigenet, Seoul, South Korea; [Kang, G. H.] Seoul Natl Univ, Dept Pathol, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.	kimty@snu.ac.kr	/Y-5959-2019; Kang, Gyeong Hoon/F-1051-2010	Kang, Gyeong Hoon/0000-0003-2380-6675	Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Ministry of Health & Welfare, Republic of Korea [HI14C1277]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [NRF-2016M3A9B6026918, NRF-2016M3A9B6026921, 2011-0030049]; NRF - Ministry of Education, Republic of Korea [NRF-2016R1D1A1B03930736]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); NRF - Ministry of Education, Republic of Korea(Ministry of Education (MOE), Republic of KoreaNational Research Foundation of Korea)	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1277), by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (NRF-2016M3A9B6026918, NRF-2016M3A9B6026921 and 2011-0030049) and by Basic Science Research Program through the NRF funded by the Ministry of Education, Republic of Korea (NRF-2016R1D1A1B03930736).	Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Beuling E, 2011, GASTROENTEROLOGY, V140, P1219, DOI 10.1053/j.gastro.2011.01.033; Bresnick EH, 2012, NUCLEIC ACIDS RES, V40, P5819, DOI 10.1093/nar/gks281; Bresnick EH, 2010, J BIOL CHEM, V285, P31087, DOI 10.1074/jbc.R110.159079; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Capo-Chichi CD, 2009, MOL CELL BIOL, V29, P4766, DOI 10.1128/MCB.00087-09; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Dyson MT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004158; Endoh M, 2008, DEVELOPMENT, V135, P1513, DOI 10.1242/dev.014340; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Hattori N, 2014, BIOCHEM BIOPH RES CO, V455, P3, DOI 10.1016/j.bbrc.2014.08.140; Haveri H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-9; Johnson KD, 2012, J CLIN INVEST, V122, P3692, DOI 10.1172/JCI61623; Kang JY, 2015, ONCOGENE, V34, P5677, DOI 10.1038/onc.2015.17; Kang JY, 2015, AM J PATHOL, V185, P666, DOI 10.1016/j.ajpath.2014.11.022; Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005; Kang Y, 2017, BBA-GENE REGUL MECH, V1860, P416, DOI 10.1016/j.bbagrm.2017.01.013; Kang Y, 2015, BBA-GENE REGUL MECH, V1849, P282, DOI 10.1016/j.bbagrm.2014.12.010; Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057; Katsumura KR, 2016, CELL REP, V16, P2428, DOI 10.1016/j.celrep.2016.07.058; Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Liu-Chittenden Y, 2017, ONCOGENE, V36, P3541, DOI 10.1038/onc.2016.497; Lu R, 2011, J BIOL CHEM, V286, P8425, DOI 10.1074/jbc.M110.202150; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Matsusaka K, 2014, WORLD J GASTROENTERO, V20, P3916, DOI 10.3748/wjg.v20.i14.3916; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Moriguchi T, 2014, INT J HEMATOL, V100, P417, DOI 10.1007/s12185-014-1568-0; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Pan XQ, 2000, J BIOCHEM, V127, P105, DOI 10.1093/oxfordjournals.jbchem.a022570; Park SY, 2009, J PATHOL, V219, P410, DOI 10.1002/path.2596; Ping N, 2017, LEUKEMIA, V31, P195, DOI 10.1038/leu.2016.162; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shih AH, 2015, CANCER CELL, V27, P502, DOI 10.1016/j.ccell.2015.03.009; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000; Sulahian R, 2014, ONCOGENE, V33, P5637, DOI 10.1038/onc.2013.517; Tahara T, 2015, EPIGENOMICS-UK, V7, P475, DOI 10.2217/epi.15.4; Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Yun J, 2016, NUCLEIC ACIDS RES, V44, P558, DOI 10.1093/nar/gkv933	51	17	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					993	1004		10.1038/onc.2017.397	http://dx.doi.org/10.1038/onc.2017.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106391				2022-12-28	WOS:000425905700003
J	Cho, HJ; Hwang, YS; Yoon, J; Lee, M; Lee, HG; Daar, IO				Cho, H. J.; Hwang, Y-S; Yoon, J.; Lee, M.; Lee, H. G.; Daar, I. O.			EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1	ONCOGENE			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; EPH RECEPTORS; RHO-GTPASES; GASTRIC-CANCER; EXPRESSION; ACTIVATION; COMPLEX; PHOSPHORYLATION; REGULATORS	Eph receptors and their corresponding ephrin ligands have been associated with regulating cell-cell adhesion and motility, and thus have a critical role in various biological processes including tissue morphogenesis and homeostasis, as well as pathogenesis of several diseases. Aberrant regulation of Eph/ephrin signaling pathways is implicated in tumor progression of various human cancers. Here, we show that a Rho family GTPase regulator, Rho guanine nucleotide dissociation inhibitor 1 (RhoGDI1), can interact with ephrinB1, and this interaction is enhanced upon binding the extracellular domain of the cognate EphB2 receptor. Deletion mutagenesis revealed that amino acids 327-334 of the ephrinB1 intracellular domain are critical for the interaction with RhoGDI1. Stimulation with an EphB2 extracellular domain-Fc fusion protein (EphB2-Fc) induces RhoA activation and enhances the motility as well as invasiveness of wild-type ephrinB1-expressing cells. These Eph-Fc-induced effects were markedly diminished in cells expressing the mutant ephrinB1 construct (Delta 327-334) that is ineffective at interacting with RhoGDI1. Furthermore, ephrinB1 depletion by siRNA suppresses EphB2-Fc-induced RhoA activation, and reduces motility and invasiveness of the SW480 and Hs578T human cancer cell lines. Our study connects the interaction between RhoGDI1 and ephrinB1 to the promotion of cancer cell behavior associated with tumor progression. This interaction may represent a therapeutic target in cancers that express ephrinB1.	[Cho, H. J.; Lee, H. G.] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea; [Cho, H. J.; Hwang, Y-S; Yoon, J.; Lee, M.; Daar, I. O.] NCI, Cancer & Dev Biol Lab, NIH, Frederick, MD 21702 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho, HJ (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.; Daar, IO (corresponding author), NCI, Canc & Dev Biol Lab, Bldg 560,Room 22-90D, Frederick, MD 21702 USA.	hjcho@kribb.re.kr; daari@mail.nih.gov	Lee, Moonsup/AAK-2333-2020	Daar, Ira/0000-0003-2657-526X; Yoon, Jaeho/0000-0003-2730-8606	Intramural Research Program of the NIH, National Cancer Institute; National Research Council of Science and Technology (NST) grant by the Korea government (MSIP) [CRC-15-02-KRIBB]; NATIONAL CANCER INSTITUTE [ZIABC010006, ZIABC010958] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Research Council of Science and Technology (NST) grant by the Korea government (MSIP); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank our colleagues Dr Giovanna Tosato for critically reading of this manuscript, Dr Brad St Croix and Dr Deborah Morrison for cell lines. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, and the National Research Council of Science and Technology (NST) grant by the Korea government (MSIP) (CRC-15-02-KRIBB).	Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122; Barquilla A, 2015, ANNU REV PHARMACOL, V55, P465, DOI 10.1146/annurev-pharmtox-011112-140226; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Brunet N, 2002, TRAFFIC, V3, P342, DOI 10.1034/j.1600-0854.2002.30504.x; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cho HJ, 2014, J BIOL CHEM, V289, P18556, DOI 10.1074/jbc.M114.558809; Cho HJ, 2010, EXPERT OPIN THER TAR, V14, P67, DOI 10.1517/14728220903449251; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Colbert PL, 2015, ONCOTARGET, V6, P953, DOI 10.18632/oncotarget.2823; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Daar IO, 2012, SEMIN CELL DEV BIOL, V23, P65, DOI 10.1016/j.semcdb.2011.10.012; Davy A, 2006, PLOS BIOL, V4, P1763, DOI 10.1371/journal.pbio.0040315; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; DerMardirossian C, 2006, MOL BIOL CELL, V17, P4760, DOI 10.1091/mbc.E06-06-0533; Donnelly SK, 2014, CELL ADHES MIGR, V8, P526, DOI 10.4161/cam.29712; Dovas A, 2010, J BIOL CHEM, V285, P23294, DOI 10.1074/jbc.M109.098129; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Gee HY, 2013, J CLIN INVEST, V123, P3243, DOI 10.1172/JCI69134; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Kandouz M, 2012, CANCER METAST REV, V31, P353, DOI 10.1007/s10555-012-9352-1; Kataoka H, 2002, J CANCER RES CLIN, V128, P343, DOI 10.1007/s00432-002-0355-0; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Lee HS, 2006, NAT CELL BIOL, V8, P55, DOI 10.1038/ncb1344; Lee HS, 2008, NAT CELL BIOL, V10, P979, DOI 10.1038/ncb1758; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Lu Y, 2013, J BIOL CHEM, V288, P34276, DOI 10.1074/jbc.M113.519744; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; McKinney N, 2015, J NEURO-ONCOL, V121, P109, DOI 10.1007/s11060-014-1618-8; Merlos-Suarez A, 2008, CURR OPIN CELL BIOL, V20, P194, DOI 10.1016/j.ceb.2008.01.011; Pandya P, 2017, CURR OPIN CELL BIOL, V48, P87, DOI 10.1016/j.ceb.2017.06.006; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Sabbatini ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066029; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sawai Y, 2003, J HEPATOL, V39, P991, DOI 10.1016/S0168-8278(03)00498-7; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Tanaka M, 2010, CANCER SCI, V101, P87, DOI 10.1111/j.1349-7006.2009.01352.x; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; Wu C, 2009, J NEUROSCI, V29, P7404, DOI 10.1523/JNEUROSCI.5841-08.2009; Xi HQ, 2012, J CELL MOL MED, V16, P2894, DOI 10.1111/j.1582-4934.2012.01612.x; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045	53	22	22	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					861	872		10.1038/onc.2017.386	http://dx.doi.org/10.1038/onc.2017.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059157	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000425281800004
J	Ye, J; Wei, X; Shang, Y; Pan, Q; Yang, M; Tian, Y; He, Y; Peng, Z; Chen, L; Chen, W; Wang, R				Ye, J.; Wei, X.; Shang, Y.; Pan, Q.; Yang, M.; Tian, Y.; He, Y.; Peng, Z.; Chen, L.; Chen, W.; Wang, R.			Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity	ONCOGENE			English	Article							MESENCHYMAL-TRANSITION; SPONTANEOUS COLITIS; PANCREATIC-CANCER; TUMOR-GROWTH; GLYCOSYLATION; METASTASIS; SUPPRESSES; SYNTHASE; TRANSCRIPTION; FIBRONECTIN	The attachment of cell-surface carbohydrates to proteins mediated by the amino acids serine or threonine (O-glycan) is involved in tumor metastasis; the roles of O-glycans vary depending on their structure, but the detailed mechanisms by which O-glycans trigger signaling to control tumor metastasis are largely unknown. In this study, we found that the reduced expression of core 3 synthase correlated with metastasis to lymph nodes and distant organs, resulting in poor prognosis for colorectal cancer (CRC) patients. Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells. This further inhibited the translocation of MUC1-C to the nucleus, initiated p53 gene transcription that was dependent on the inhibition of MUC1-C nucleus translocation, activated p53-mediated miR-200c expression and resulted in mesenchymal-epithelial transition (MET). Inhibition of MUC1 via small interfering RNA (siRNA) in re-expressed core 3 synthase colon cancer cells further inhibited MUC1-C nucleus translocation, increased p53 and miR-200c expression, and enhanced MET. However, inhibition of p53 via siRNA or miR-200c via miR-200c inhibitor in re-expressed core 3 synthase colon cancer cells promoted the epithelial-mesenchymal transition (EMT) in a reversible manner. Core 3 synthase mRNA levels and the p53 mRNA levels or miR-200c levels in the colon cancerous samples were positively correlated. Our findings suggest a novel mechanism linking mucin-type core 3 O-glycan to the EMT-MET plasticity of CRC cells via MUC1/p53/miR-200c-dependent signaling cascade and shed light on therapeutic strategies to treat this malignancy.	[Ye, J.; Wei, X.; Shang, Y.; Pan, Q.; Yang, M.; Tian, Y.; He, Y.; Peng, Z.; Chen, L.; Chen, W.; Wang, R.] Third Mil Med Univ, Inst Gastroenterol PLA, Southwest Hosp, Dept Gastroenterol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China	Army Medical University	Wang, R (corresponding author), Third Mil Med Univ, Inst Gastroenterol PLA, Southwest Hosp, Dept Gastroenterol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	rongquanw@hotmail.com		ye, jun/0000-0002-0631-556X; shang, yangyang/0000-0003-0764-0572; Wang, Rongquan/0000-0001-5307-0086	National Natural Science Foundation of China [81500410, 81170340, 81372557]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the following awards: 81500410 (to YT), 81170340 and 81372557 (to RW) from the National Natural Science Foundation of China.	Bergstrom K, 2017, MUCOSAL IMMUNOL, V10, P91, DOI 10.1038/mi.2016.45; Bergstrom K, 2016, GASTROENTEROLOGY, V151, P152, DOI 10.1053/j.gastro.2016.03.039; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Dimitroff CJ, 2015, CANCER RES, V75, P3195, DOI 10.1158/0008-5472.CAN-15-0834; Du J, 2015, J BIOL CHEM, V290, P12000, DOI 10.1074/jbc.M115.636969; Freire-De-Lima L, 2011, P NATL ACAD SCI USA, V108, P17690, DOI 10.1073/pnas.1115191108; Gabriel M, 2005, CLIN ORAL INVEST, V9, P284, DOI 10.1007/s00784-005-0007-2; Gao N, 2016, AM J PHYSIOL-GASTR L, V311, pG74, DOI 10.1152/ajpgi.00060.2016; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Iwai T, 2005, P NATL ACAD SCI USA, V102, P4572, DOI 10.1073/pnas.0407983102; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kufe D, 2010, ONCOGENE, V29, P5663, DOI 10.1038/onc.2010.334; Lee SH, 2009, J BIOL CHEM, V284, P17157, DOI 10.1074/jbc.M109.010934; Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018; Lillehoj EP, 2004, AM J PHYSIOL-LUNG C, V287, pL809, DOI 10.1152/ajplung.00385.2003; Lu JS, 2014, J BIOL CHEM, V289, P34627, DOI 10.1074/jbc.M114.593392; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Moran AP, 2011, GUT, V60, P1412, DOI 10.1136/gut.2010.212704; Pan Q, 2013, J BIOL CHEM, V288, P5407, DOI 10.1074/jbc.M112.408245; Park JH, 2011, NEOPLASIA, V13, P320, DOI 10.1593/neo.101440; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Radhakrishnan P, 2014, P NATL ACAD SCI USA, V111, pE4066, DOI 10.1073/pnas.1406619111; Radhakrishnan P, 2013, INT J CANCER, V133, P2824, DOI 10.1002/ijc.28322; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Springer SA, 2016, J PROTEOMICS, V135, P90, DOI 10.1016/j.jprot.2015.11.022; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian Y, 2014, J BIOL CHEM, V289, P36101, DOI 10.1074/jbc.M114.598383; Tran DT, 2013, J BIOL CHEM, V288, P6921, DOI 10.1074/jbc.R112.418558; Tsuboi S, 2012, TRENDS MOL MED, V18, P224, DOI 10.1016/j.molmed.2012.02.001; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Ye J, 2015, GUT PATHOG, V7, DOI 10.1186/s13099-015-0078-9; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	44	14	17	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6391	6407		10.1038/onc.2017.241	http://dx.doi.org/10.1038/onc.2017.241			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745318				2022-12-28	WOS:000415622900004
J	To, SKY; Mak, ASC; Fung, YME; Che, CM; Li, SS; Deng, W; Ru, B; Zhang, J; Wong, AST				To, S. K. Y.; Mak, A. S. C.; Fung, Y. M. Eva; Che, C-M; Li, S-S; Deng, W.; Ru, B.; Zhang, J.; Wong, A. S. T.			beta-catenin downregulates Dicer to promote ovarian cancer metastasis	ONCOGENE			English	Article							CLINICOPATHOLOGICAL FEATURES; POOR-PROGNOSIS; STEM-CELLS; EXPRESSION; ROLES; CARCINOMAS; CONTRIBUTE; PATTERN; GRADE	Ovarian cancer is a nearly uniform lethal disease and its highly aggressive metastatic phenotype portends a poor prognosis. Lack of a well-controlled, relevant experimental model has been a major obstacle to identifying key molecules causing metastasis. Here we describe the creation of a new isogenic model of spontaneous human ovarian cancer metastasis exhibiting opposite phenotypes-highly metastatic (HM) and non-metastatic (NM)-both in vitro and in vivo. HM was unique in its ability to metastasize consistently to the peritoneum, mimicking the major dissemination route of human ovarian cancer. In contrast, NM failed to form detectable metastases, although it was equally tumorigenic. Using comparative label-free quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS), we identified beta-catenin, which we demonstrated for the first time as having a direct role in the pathogenesis of ovarian cancer metastasis. Our studies also revealed a previously unrecognized role of beta-catenin in the downregulation of multiple microRNAs (miRNAs) through attenuating miRNA biogenesis by targeting Dicer, a key component of the miRNA-processing machinery. One such downregulated miRNAs was miR-29s involved in epithelial-to-mesenchymal transition and subsequent stem cell traits. Silencing beta-catenin or overexpressing Dicer or miR-29 mimics in HM significantly reduced the ability of these cells to migrate. beta-catenin-knockdown cells also failed to metastasize in an orthotopic model of ovarian cancer. Meta-analysis revealed an increase in CTNNB1 and a decrease in DICER1 expression levels in the high-risk group. These results uncover beta-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between beta-catenin and miRNA downregulation underlying this process.	[To, S. K. Y.; Mak, A. S. C.; Li, S-S; Ru, B.; Zhang, J.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China; [Fung, Y. M. Eva; Che, C-M] Univ Hong Kong, Dept Chem, Chem Biol Ctr, State Key Lab Synthet Chem, Hong Kong, Hong Kong, Peoples R China; [Deng, W.] Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Deng, Wen/M-5208-2019; Zhang, Jiangwen/A-7654-2013; Wong, Alice/AFJ-4595-2022; Ru, Beibei/F-3830-2011	Zhang, Jiangwen/0000-0002-2911-8446; Wong, Alice/0000-0002-0676-6475; To, Sally Kit Yan/0000-0002-8683-2101	Research Grant Council [17141216]; University Grants Committee of the Hong Kong Special Administrative Region, China [SEG_HKU02]; Croucher Senior Research Fellowship	Research Grant Council(Hong Kong Research Grants Council); University Grants Committee of the Hong Kong Special Administrative Region, China; Croucher Senior Research Fellowship	We thank the assistance of the Faculty Core Facility of the Li Ka Shing Faculty of Medicine at the University of Hong Kong. The work described in this paper was supported by the Research Grant Council grant (17141216) and partially the Special Equipment Grant from the University Grants Committee of the Hong Kong Special Administrative Region, China (Project Code: SEG_HKU02). ASTW is a recipient of the Croucher Senior Research Fellowship.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Brodsky AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094476; BUICK RN, 1985, CANCER RES, V45, P3668; Burgos-Ojeda D, 2012, CANCER LETT, V322, P1, DOI 10.1016/j.canlet.2012.02.002; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chau WK, 2013, ONCOGENE, V32, P2767, DOI 10.1038/onc.2012.290; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Dai FR, 2014, HUM PATHOL, V45, P1285, DOI 10.1016/j.humpath.2014.02.008; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Faith JJ, 2007, PLOS BIOL, V5, P54, DOI 10.1371/journal.pbio.0050008; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hasan N, 2015, TRANSL CANCER RES, V4, P14, DOI 10.3978/j.issn.2218-676X.2015.01.02; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Jiang HS, 2014, ONCOL REP, V31, P1509, DOI 10.3892/or.2014.3036; Kang KS, 2013, BIOCHEM BIOPH RES CO, V432, P333, DOI 10.1016/j.bbrc.2013.01.102; Kenny HA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7220; Kildal W, 2005, EUR J CANCER, V41, P1127, DOI 10.1016/j.ejca.2005.01.022; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kok KH, 2007, J BIOL CHEM, V282, P17649, DOI 10.1074/jbc.M611768200; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Lee CM, 2003, GYNECOL ONCOL, V88, P363, DOI 10.1016/S0090-8258(02)00015-X; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Pampalakis G, 2010, CLIN BIOCHEM, V43, P324, DOI 10.1016/j.clinbiochem.2009.09.014; Ricci F, 2013, CANCER TREAT REV, V39, P561, DOI 10.1016/j.ctrv.2013.01.005; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stahl S, 2009, MOL CELL PROTEOMICS, V8, P1117, DOI 10.1074/mcp.M800274-MCP200; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Teng Y, 2015, ONCOTARGET, V6, P40799, DOI 10.18632/oncotarget.5695; Toth K, 2004, CANCER RES, V64, P3638, DOI 10.1158/0008-5472.CAN-03-3882; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wang H, 2014, INT J CLIN EXP PATHO, V7, P264; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	51	33	34	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5927	5938		10.1038/onc.2017.185	http://dx.doi.org/10.1038/onc.2017.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650464				2022-12-28	WOS:000413841400002
J	Spolverini, A; Fuchs, G; Bublik, DR; Oren, M				Spolverini, A.; Fuchs, G.; Bublik, D. R.; Oren, M.			let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery	ONCOGENE			English	Article							BREAST-CANCER; TUMOR-SUPPRESSOR; LUNG-CANCER; CHROMATIN MODIFICATIONS; MESENCHYMAL TRANSITION; DOWN-REGULATION; POOR-PROGNOSIS; SELF-RENEWAL; MONOUBIQUITINATION; EXPRESSION	Monoubiquitylation of histone H2B (H2Bub1) is catalyzed mainly by the RNF20/RNF40 complex and erased by multiple deubiquitylating enzymes (DUBs). H2Bub1 influences many aspects of chromatin function, including transcription regulation and DNA repair. Cancer cells often display reduced levels of H2Bub1, and this reduction may contribute to cancer progression. The let-7 family of microRNAs (miRNAs) comprises multiple members with reported tumor-suppressive features, whose expression is frequently downregulated in cancer. We now report that let-7b and let-7c can positively regulate cellular H2Bub1 levels. Overexpression of let-7b and let-7c in a variety of non-transformed and cancer-derived cell lines results in H2Bub1 elevation. The positive effect of let-7b and let-7c on H2Bub1 levels is achieved through targeting of multiple mRNAs, coding for distinct components of the H2B deubiquitylation machinery. Specifically, let-7b and let-7c bind directly and inhibit the mRNAs encoding the DUBs USP42 and USP44, and also the mRNA encoding the adapter protein ATXN7L3, which is part of the DUB module of the SAGA complex. RNF20 knockdown (KD) strongly reduces H2Bub1 levels and increases the migration of non-transformed mammary epithelial cells and breast cancer-derived cells. Remarkably, overexpression of let-7b, which partly counteracts the effect of RNF20 KD on H2Bub1 levels, also reverses the pro-migratory effect of RNF20 KD. Likewise, ATXN7L3 KD also increases H2Bub1 levels and reduces cell migration, and this anti-migratory effect is abolished by simultaneous KD of RNF20. Together, our findings uncover a novel function of let-7 miRNAs as regulators of H2B ubiquitylation, suggesting an additional mechanism whereby these miRNAs can exert their tumor-suppressive effects.	[Spolverini, A.; Fuchs, G.; Bublik, D. R.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, POB 26,234 Herzl St, IL-7610001 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26,234 Herzl St, IL-7610001 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172	Dr Miriam and Sheldon G. Adelson Medical Research Foundation; European Research Council [293438]; Center of Excellence grant from the Israel Science Foundation; Robert Bosch Foundation [11.5.8000.0094]; Moross Integrated Cancer Center	Dr Miriam and Sheldon G. Adelson Medical Research Foundation; European Research Council(European Research Council (ERC)European Commission); Center of Excellence grant from the Israel Science Foundation; Robert Bosch Foundation; Moross Integrated Cancer Center	We thank Ofra Golani from the Bioinformatics Unit of the Weizmann Institute for expert help with image analysis; Yonit Hoffman and Gali Brand for help with data analysis; and Sharath Chandra Arandkar and Ohad Tarcic for valuable discussions. This study was supported in part by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, grant 293438 (RUBICAN) from the European Research Council, a Center of Excellence grant from the Israel Science Foundation, the Robert Bosch Foundation (project 11.5.8000.0094) and the Moross Integrated Cancer Center. MO is incumbent of the Andre Lwoff chair in molecular biology.	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Atanassov BS, 2011, FEBS LETT, V585, P2016, DOI 10.1016/j.febslet.2010.10.042; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Chandrasekharan MB, 2009, P NATL ACAD SCI USA, V106, P16686, DOI 10.1073/pnas.0907862106; Chen DL, 2015, ONCOTARGET, V6, P10868, DOI 10.18632/oncotarget.3451; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Chiu SC, 2014, CELL TRANSPLANT, V23, P459, DOI 10.3727/096368914X678418; Cole AJ, 2015, ENDOCR-RELAT CANCER, V22, pT19, DOI 10.1530/ERC-14-0185; Cui SY, 2013, MOL CANCER RES, V11, P699, DOI 10.1158/1541-7786.MCR-13-0019-T; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI 10.1038/NCHEMBIO.501; Fuchs G, 2014, BBA-GENE REGUL MECH, V1839, P694, DOI 10.1016/j.bbagrm.2014.01.002; Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023; Gambari R, 2016, INT J ONCOL, V49, P5, DOI 10.3892/ijo.2016.3503; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Haakensen VD, 2016, INT J CANCER, V139, P1117, DOI 10.1002/ijc.30142; Han X, 2015, CANCER GENE THER, V22, P122, DOI 10.1038/cgt.2014.75; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hock AK, 2014, J BIOL CHEM, V289, P34862, DOI 10.1074/jbc.M114.589267; Hu J, 2015, LUNG CANCER, V88, P239, DOI 10.1016/j.lungcan.2015.02.019; Hu XW, 2013, MOL CANCER RES, V11, P240, DOI 10.1158/1541-7786.MCR-12-0432; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen MPHM, 2012, BREAST CANCER RES TR, V133, P937, DOI 10.1007/s10549-011-1877-4; Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Jusufovic E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045577; Kari V, 2011, CELL CYCLE, V10, P3495, DOI 10.4161/cc.10.20.17769; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lan XJ, 2016, CELL REP, V17, P2382, DOI 10.1016/j.celrep.2016.10.076; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lang G, 2011, MOL CELL BIOL, V31, P3734, DOI 10.1128/MCB.05231-11; Lee H, 2016, PROTEIN CELL, V7, P100, DOI 10.1007/s13238-015-0212-y; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Ma L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0773-7; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; Melling N, 2016, PATHOL ONCOL RES, V22, P95, DOI 10.1007/s12253-015-9977-9; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Olive V, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005813; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011; Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun X, 2016, CANCER GENE THER, V23, P83, DOI 10.1038/cgt.2016.3; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tang B, 2015, ONCOTARGET, V6, P12654, DOI 10.18632/oncotarget.3705; Tarcic O, 2017, CELL DEATH DIFFER, V24, P694, DOI 10.1038/cdd.2016.126; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Tommasi S, 2016, ONCOTARGET, V7, P80363, DOI 10.18632/oncotarget.10345; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang PY, 2013, FEBS LETT, V587, P2675, DOI 10.1016/j.febslet.2013.07.004; Wang TZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0402-5; Wang XR, 2012, ONCOL LETT, V3, P955, DOI 10.3892/ol.2012.609; Wang ZJ, 2013, WORLD J GASTROENTERO, V19, P8099, DOI 10.3748/wjg.v19.i44.8099; Wang ZJ, 2015, HUM PATHOL, V46, P1006, DOI 10.1016/j.humpath.2015.04.001; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023389; Zhang YX, 2011, J CANCER RES CLIN, V137, P1245, DOI 10.1007/s00432-011-0998-9; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhao BT, 2014, CANCER LETT, V342, P43, DOI 10.1016/j.canlet.2013.08.030; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2; Zhao YM, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a025064; Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	99	21	22	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5819	5828		10.1038/onc.2017.187	http://dx.doi.org/10.1038/onc.2017.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604753	Green Accepted			2022-12-28	WOS:000413292900004
J	Chi, HC; Chen, SL; Lin, SL; Tsai, CY; Chuang, WY; Lin, YH; Huang, YH; Tsai, MM; Yeh, CT; Lin, KH				Chi, H-C; Chen, S-L; Lin, S-L; Tsai, C-Y; Chuang, W-Y; Lin, Y-H; Huang, Y-H; Tsai, M-M; Yeh, C-T; Lin, K-H			Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover	ONCOGENE			English	Article							VIRUS-X-PROTEIN; HEPATITIS-B; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; REDUCTIVE STRESS; LIVER; METASTASIS; ACTIVATION; DEATH; HYPOTHYROIDISM	Infection by hepatitis B virus (HBV) accounts for 50-80% of hepatocellular carcinoma (HCC) development worldwide, in which the HBV-encoded X protein (HBx) has critical role in the induction of carcinogenesis. Several studies have shown that thyroid hormone (TH) suppresses HCC development and protects hepatocytes from HBx-induced damage, thus it is of interest to examine whether TH can protect hepatocytes from HBx-induced carcinogenesis. By treating HBx-transgenic mice with or without TH, we confirmed the protective effects of TH on HBx-induced hepatocarcinogenesis, which was achieved via reduction of reactive oxygen species (ROS) inflicted DNA damage. We further found that TH induced biogenesis of mitochondria (MITO) and autophagy of HBx-targeted MITO simultaneously, consequently leading to suppression of HBx-promoted ROS and carcinogenesis. Using microarray data analysis, this protective effect of TH was found to be mediated via activation of PTEN-induced kinase 1 (PINK1) in hepatocytes. PINK1, in turn, activated and recruited Parkin, an E3 ligase, to ubiquitinate MITO-associated HBx protein and trigger selective mitophagy. The pathological significance of the TH/PINK1 pathway in liver protection was confirmed by the concomitant decrease in expression of both TR and PINK1 in matched HCC tumor tissues and negatively correlated with aggressive progression of cancer and poor prognosis. Our data indicate that TH/PINK1/Parkin pathway has a critical role in protecting hepatocytes from HBx-induced carcinogenesis. Notably, several liver-targeting therapeutic derivatives of TH facilitating prevention or therapy of steatosis have been identified. Furthermore, our proof-of-concept experiments suggest that application of T3 constitutes an effective novel therapeutic or preventive option for HCC. Thus, the utilization of the agonists of TRs could be the meaningful strategy in liver relative diseases, ranging from simple hepatic steatosis to HCC.	[Chi, H-C; Lin, S-L; Lin, Y-H; Lin, K-H] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Chen, S-L] Natl Cent Univ, Dept Life Sci, Jhongli, Taiwan; [Tsai, C-Y] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kidney Res Ctr, Taoyuan, Taiwan; [Tsai, C-Y] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Nephrol,Chang Gung Immunol Consortium, Taoyuan, Taiwan; [Chuang, W-Y] Chang Gung Mem Hosp, Dept Pathol, Taoyuan, Taiwan; [Chuang, W-Y] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Huang, Y-H; Yeh, C-T; Lin, K-H] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Liver Res Ctr, Taoyuan, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan; [Tsai, M-M] Chang Gung Mem Hosp, Dept Gen Surg, Chiayi, Taiwan; [Lin, K-H] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan	Chang Gung University; National Central University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, 259 Wen Hwa 1 Rd, Taoyuan, Taiwan.	khlin@mail.cgu.edu.tw	Chuang, Wen-Yu/I-8013-2019	Chuang, Wen-Yu/0000-0002-3729-073X	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CRRPD1F0011, CRRPD1F0012]; Ministry of Science and Technology of the Republic of China [MOST 103-2320-B-182-018-MY3, 103-2320-B-182-017-MY3, 105-2811-B-182-018, 105-2321-B-182-002-MY3]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CRRPD1F0011, CRRPD1F0012) and from the Ministry of Science and Technology of the Republic of China (MOST 103-2320-B-182-018-MY3, 103-2320-B-182-017-MY3, 105-2811-B-182-018, 105-2321-B-182-002-MY3). Accession number of transcript profiling: GEO accession: GSE14520.	BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Chi HC, 2012, CELL DEATH DIFFER, V19, P1802, DOI 10.1038/cdd.2012.58; Chi HC, 2016, AUTOPHAGY, V12, P2271, DOI 10.1080/15548627.2016.1230583; Clippinger AJ, 2008, J VIROL, V82, P6798, DOI 10.1128/JVI.00154-08; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; FARBER E, 1991, DIGEST DIS SCI, V36, P973, DOI 10.1007/BF01297150; Frau C, 2015, HEPATOLOGY, V61, P249, DOI 10.1002/hep.27399; Gentric G, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/282430; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GROSS NJ, 1971, J CELL BIOL, V48, P29, DOI 10.1083/jcb.48.1.29; Harper ME, 2008, THYROID, V18, P145, DOI 10.1089/thy.2007.0250; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Jiang TY, 2016, P NATL ACAD SCI USA, V113, P2074, DOI 10.1073/pnas.1525616113; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim HJ, 2008, IUBMB LIFE, V60, P473, DOI 10.1002/iub.68; Kim SJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003722; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559; Ledda-Columbano GM, 2000, CANCER RES, V60, P603; Ledda-Columbano GM, 1999, CARCINOGENESIS, V20, P2299, DOI 10.1093/carcin/20.12.2299; Lee S, 2014, TOX RESEARCH, V30, P243, DOI 10.5487/TR.2014.30.4.243; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Lin YH, 2013, ONCOGENE, V32, P3904, DOI 10.1038/onc.2013.5; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Malhi H, 2008, GASTROENTEROLOGY, V134, P1641, DOI 10.1053/j.gastro.2008.03.002; Mansour-Ghanaei F, 2012, ANN HEPATOL, V11, P667, DOI 10.1016/S1665-2681(19)31440-1; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Nguyen VTT, 2009, J VIRAL HEPATITIS, V16, P453, DOI 10.1111/j.1365-2893.2009.01117.x; Perra A, 2008, FASEB J, V22, P2981, DOI 10.1096/fj.08-108464; Perra A, 2009, HEPATOLOGY, V49, P1287, DOI 10.1002/hep.22750; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Sinha RA, 2015, AUTOPHAGY, V11, P1341, DOI 10.1080/15548627.2015.1061849; Sinha RA, 2012, J CLIN INVEST, V122, P2428, DOI 10.1172/JCI60580; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; Tseng YH, 2014, AUTOPHAGY, V10, P20, DOI 10.4161/auto.26126; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Weitzel JM, 2011, MOL CELL ENDOCRINOL, V342, P1, DOI 10.1016/j.mce.2011.05.009; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028	56	34	36	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5274	5284		10.1038/onc.2017.136	http://dx.doi.org/10.1038/onc.2017.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504722				2022-12-28	WOS:000410671700006
J	Goto, H; Kariya, R; Kudo, E; Okuno, Y; Ueda, K; Katano, H; Okada, S				Goto, H.; Kariya, R.; Kudo, E.; Okuno, Y.; Ueda, K.; Katano, H.; Okada, S.			Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ACUTE MYELOID-LEUKEMIA; KAPOSIS-SARCOMA; CELL-LINE; TRANSCRIPTION FACTOR; REGULATED GENES; EXPRESSION; GROWTH; AIDS; ELEMENTS	Primary effusion lymphoma (PEL), which is an aggressive subgroup of B-cell lymphoma associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8, is refractory to the standard treatment, and exhibits a poor survival. Although PU.1 is downregulated in PEL, the potential role of its reduction remains to be elucidated. In this investigation, we analyzed the DNA methylation of PU.1 cis-regulatory elements in PEL and the effect of restoring PU.1 on PEL cells. The mRNA level of PU.1 was downregulated in PEL cells. The methylated promoter and enhancer regions of the PU.1 gene were detected in PEL cells. Suppression of cell growth and apoptosis were caused by the restoration of PU.1 in PEL cells. A microarray analysis revealed that interferon-stimulated genes (ISGs) including pro-apoptotic ISGs were strongly increased in BCBL-1 cells after the induction of PU.1. Reporter assays showed that PU.1 transactivated pro-apoptotic ISG promoters, such as the XAF1, OAS1 and TRAIL promoters. Mutations at the PU.1 binding sequences suppressed its transactivation. We confirmed the binding of PU.1 to the XAF1, OAS1 and TRAIL promoters in a chromatin immunoprecipitation assay. PU.1 suppressed ORF57 activation by inducing IRF7. The reinduction of PU.1 reduced formation of ascites and lymphoma cell infiltration of distant organs in PEL xenograft model mice. Collectively, PU.1 has a role in tumor suppression in PEL and its down-regulation is associated with PEL development. Restoring PU.1 with demethylation agents may be a novel therapeutic approach for PEL.	[Goto, H.; Kariya, R.; Kudo, E.; Okada, S.] Kumamoto Univ, Div Hematopoiesis, Ctr AIDS Res, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Hematol, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Rheumatol, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Infect Dis, Honjo, Kumamoto, Japan; [Ueda, K.] Osaka Univ, Grad Sch Med, Dept Microbiol & Immunol, Div Virol, Suita, Osaka, Japan; [Katano, H.] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Toyama, Tokyo, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Osaka University; National Institute of Infectious Diseases (NIID)	Okada, S (corresponding author), Kumamoto Univ, Ctr AIDS Res, Div Hematopoiesis, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan.	okadas@kumamoto-u.ac.jp		Okada, Seiji/0000-0003-3124-5206	Japan Agency for Medical Research and Development, AMED [17fk0410208h0002]; Ministry of Education, Science, Sports, and Culture of Japan [16K08742]; Grants-in-Aid for Scientific Research [16H07080] Funding Source: KAKEN	Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Research program on HIV/AIDS (No. 17fk0410208h0002) from the Japan Agency for Medical Research and Development, AMED, and Grants-in-Aid for Science Research (No. 16K08742) from the Ministry of Education, Science, Sports, and Culture of Japan.	Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Arguello M, 2003, ONCOGENE, V22, P964, DOI 10.1038/sj.onc.1206270; Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Deng H, 2007, CURR TOP MICROBIOL, V312, P157; Domingo-Gil E, 2006, APOPTOSIS, V11, P725, DOI 10.1007/s10495-006-5541-0; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Goto H, 2015, J CANCER RES CLIN, V141, P465, DOI 10.1007/s00432-014-1842-9; Goto H, 2014, EUR J CANCER, V50, P1836, DOI 10.1016/j.ejca.2014.03.004; Goto H, 2013, INT J HEMATOL, V97, P624, DOI 10.1007/s12185-013-1339-3; Goto H, 2012, CANCER SCI, V103, P775, DOI 10.1111/j.1349-7006.2012.02212.x; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Hussain AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039945; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Katano H, 1999, J MED VIROL, V58, P394, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;394::AID-JMV12&gt;3.0.CO;2-H; Katano H, 1999, AM J PATHOL, V155, P47, DOI 10.1016/S0002-9440(10)65097-3; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Majerciak V, 2009, FRONT BIOSCI-LANDMRK, V14, P1516, DOI 10.2741/3322; Miyagi J, 2002, INT J HEMATOL, V76, P165, DOI 10.1007/BF02982580; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nishiyama C, 2002, J IMMUNOL, V168, P4546, DOI 10.4049/jimmunol.168.9.4546; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okada S, 2014, INTRACTABLE RARE DIS, V3, P65, DOI 10.5582/irdr.2014.01010; Palmeri D, 2007, J VIROL, V81, P13299, DOI 10.1128/JVI.00732-07; Pang SHM, 2016, LEUKEMIA, V30, P1375, DOI 10.1038/leu.2016.27; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Samarajiwa SA, 2009, NUCLEIC ACIDS RES, V37, pD852, DOI 10.1093/nar/gkn732; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Solomon LA, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1303-0; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Uddin S, 2005, ONCOGENE, V24, P7022, DOI 10.1038/sj.onc.1208864; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158/1078-0432.CCR-04-1857; Ueda K, 2002, J VIROL, V76, P12044, DOI 10.1128/JVI.76.23.12044-12054.2002; Ueno S, 2009, ONCOGENE, V28, P4116, DOI 10.1038/onc.2009.263; Wang JZ, 2005, J VIROL, V79, P2420, DOI 10.1128/JVI.79.4.2420-2431.2005; Wang S, 2001, ARCH VIROL, V146, P1415, DOI 10.1007/s007050170102; Will B, 2015, NAT MED, V21, P1172, DOI 10.1038/nm.3936; Yuki H, 2013, BLOOD, V121, P962, DOI 10.1182/blood-2012-05-431429; Zou B, 2012, MOL CARCINOGEN, V51, P422, DOI 10.1002/mc.20807	54	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5252	5262		10.1038/onc.2017.138	http://dx.doi.org/10.1038/onc.2017.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28481873				2022-12-28	WOS:000410671700004
J	Jen, J; Lin, LL; Lo, FY; Chen, HT; Liao, SY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Lo, F-Y; Chen, H-T; Liao, S-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer (vol 35, pg 2357, 2016)	ONCOGENE			English	Correction													; Huang, Hsuan-Cheng/C-7266-2011	Lin, Li-Ling/0000-0001-9891-5900; Huang, Hsuan-Cheng/0000-0002-3386-0934				Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296	1	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5219	5219		10.1038/onc.2017.203	http://dx.doi.org/10.1038/onc.2017.203			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28628114	hybrid, Green Published			2022-12-28	WOS:000409371100013
J	Sakurai, T; Isogaya, K; Sakai, S; Morikawa, M; Morishita, Y; Ehata, S; Miyazono, K; Koinuma, D				Sakurai, T.; Isogaya, K.; Sakai, S.; Morikawa, M.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.			RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma (vol 35, pg 5000, 2016)	ONCOGENE			English	Correction														Ehata, Shogo/0000-0002-6740-9391				Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35	1	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5083	5083		10.1038/onc.2017.191	http://dx.doi.org/10.1038/onc.2017.191			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28604754	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000408768800013
J	Combes, G; Alharbi, I; Braga, LG; Elowe, S				Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.			Playing polo during mitosis: PLK1 takes the lead	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; CHROMOSOMAL PASSENGER COMPLEX; H3 KINASE HASPIN; AURORA B KINASE; CELL-DIVISION; KINETOCHORE ATTACHMENT; MICROTUBULE-BINDING; PROTEIN BUBR1; MITOTIC ENTRY; PHOSPHORYLATION	Polo-like kinase 1 (PLK1), the prototypical member of the polo-like family of serine/threonine kinases, is a pivotal regulator of mitosis and cytokinesis in eukaryotes. Many layers of regulation have evolved to target PLK1 to different subcellular structures and to its various mitotic substrates in line with its numerous functions during mitosis. Collective work is starting to illuminate an important set of substrates for PLK1: the mitotic kinases that together ensure the fidelity of the cell division process. Amongst these, recent developments argue that PLK1 regulates the activity of the histone kinases Aurora B and Haspin to define centromere identity, of MPS1 to initiate spindle checkpoint signaling, and of BUB1 and its pseudokinase paralog BUBR1 to coordinate spindle checkpoint activation and inactivation. Here, we review the recent work describing the regulation of these kinases by PLK1. We highlight common themes throughout and argue that a major mitotic function of PLK1 is as a master regulator of these key kinases.	[Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.] Univ Laval, Fac Med, Program Mol & Cellular Biol, Quebec City, PQ, Canada; [Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.] CHU Quebec, Res Ctr, Axe Reprod Mother & Youth Hlth, Quebec City, PQ, Canada; [Elowe, S.] Univ Laval, Dept Pediat, Fac Med, Quebec City, PQ, Canada	Laval University; Laval University; Laval University	Elowe, S (corresponding author), Univ Laval, Dept Pediat, 2705 Blvd Laurier,T3-67, Quebec City, PQ G1V 4G2, Canada.	Sabine.Elowe@crchuq.ulaval.ca	Combes, Guillaume/ABA-1771-2021	Combes, Guillaume/0000-0002-6202-1304; Elowe, Sabine/0000-0002-1212-7039				Archambault V, 2015, ONCOGENE, V34, P4799, DOI 10.1038/onc.2014.451; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Asghar A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9364; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Burkard ME, 2012, ACS CHEM BIOL, V7, P978, DOI 10.1021/cb200551p; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Carmena M, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00073; Carmena M, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140162; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carmena M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001250; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Chmielewska AE, 2016, CELL CYCLE, V15, P740, DOI 10.1080/15384101.2016.1148842; Chu YJ, 2011, J MOL CELL BIOL, V3, P260, DOI 10.1093/jmcb/mjq037; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Colnaghi R, 2010, J BIOL CHEM, V285, P22592, DOI 10.1074/jbc.M109.065003; Conde C, 2013, EMBO J, V32, P1761, DOI 10.1038/emboj.2013.109; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Di Fiore B, 2015, DEV CELL, V32, P358, DOI 10.1016/j.devcel.2015.01.003; Diaz-Martinez LA, 2015, J BIOL CHEM, V290, P2431, DOI 10.1074/jbc.M114.616490; Dou Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018793; Edgerton H, 2016, J CELL BIOL, V213, P651, DOI 10.1083/jcb.201511080; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Elowe S, 2011, MOL CELL BIOL, V31, P3085, DOI 10.1128/MCB.05326-11; Elowe S, 2010, J CELL SCI, V123, P84, DOI 10.1242/jcs.056507; Ember SWJ, 2014, ACS CHEM BIOL, V9, P1160, DOI 10.1021/cb500072z; Espert A, 2014, J CELL BIOL, V206, P833, DOI 10.1083/jcb.201406109; Espeut J, 2015, CELL REP, V12, P58, DOI 10.1016/j.celrep.2015.05.039; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Etemad B, 2016, CURR OPIN CELL BIOL, V39, P101, DOI 10.1016/j.ceb.2016.02.016; Fisher D, 2012, J CELL SCI, V125, P4703, DOI 10.1242/jcs.106351; Foley EA, 2011, NAT CELL BIOL, V13, P1265, DOI 10.1038/ncb2327; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Garcia-Alvarez B, 2007, P NATL ACAD SCI USA, V104, P3107, DOI 10.1073/pnas.0609131104; Ghenoiu C, 2013, MOL CELL, V52, P734, DOI 10.1016/j.molcel.2013.10.002; Goto H, 2006, NAT CELL BIOL, V8, P180, DOI 10.1038/ncb1350; Grallert A, 2015, NATURE, V517, P94, DOI 10.1038/nature14019; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hegarat N, 2016, BIOESSAYS, V38, P627, DOI 10.1002/bies.201600057; Hennrich ML, 2013, J PROTEOME RES, V12, P2214, DOI 10.1021/pr400074f; Hertz EPT, 2016, MOL CELL, V63, P686, DOI 10.1016/j.molcel.2016.06.024; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Higgins JMG, 2010, CHROMOSOMA, V119, P137, DOI 10.1007/s00412-009-0250-4; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang HM, 2008, J CELL BIOL, V183, P667, DOI 10.1083/jcb.200805163; Isokane M, 2016, J CELL BIOL, V212, P647, DOI 10.1083/jcb.201408089; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Jelluma N, 2010, J CELL BIOL, V191, P281, DOI 10.1083/jcb.201003038; Jelluma N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002415; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Jia LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10818; Kang JS, 2008, MOL CELL, V32, P394, DOI 10.1016/j.molcel.2008.09.017; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; King EMJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000342; Kitagawa M, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00014; Klebig C, 2009, J CELL BIOL, V185, P841, DOI 10.1083/jcb.200902128; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Krenn V, 2014, CURR BIOL, V24, P29, DOI 10.1016/j.cub.2013.11.046; Kruse T, 2013, J CELL SCI, V126, P1086, DOI 10.1242/jcs.122481; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lera RF, 2016, NAT CHEM BIOL, V12, P411, DOI 10.1038/nchembio.2060; Liu D, 2012, J CELL BIOL, V198, P491, DOI 10.1083/jcb.201205090; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Maciejowski J, 2010, J CELL BIOL, V190, P89, DOI 10.1083/jcb.201001050; Malureanu LA, 2009, DEV CELL, V16, P118, DOI 10.1016/j.devcel.2008.11.004; Mardin BR, 2011, CURR BIOL, V21, P1145, DOI 10.1016/j.cub.2011.05.047; Matsumura S, 2007, J BIOL CHEM, V282, P15217, DOI 10.1074/jbc.M611053200; Moutinho-Santos T, 2014, EMBO REP, V15, P203, DOI 10.1002/embr.201438472; Moutinho-Santos T, 2012, J CELL SCI, V125, P576, DOI 10.1242/jcs.092445; Musacchio A., 2015, CURR BIOL, V25, P18; Nijenhuis W, 2014, NAT CELL BIOL, V16, P1257, DOI 10.1038/ncb3065; Nogueira C, 2014, G3-GENES GENOM GENET, V4, P1849, DOI 10.1534/g3.114.012823; Novak B, 2010, CURR OPIN CELL BIOL, V22, P801, DOI 10.1016/j.ceb.2010.07.001; O'Connor A, 2016, BIOL OPEN, V5, P11, DOI 10.1242/bio.014969; Oppermann FS, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.012351; Overlack K, 2015, ELIFE, V4, DOI 10.7554/eLife.05269; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Primorac I, 2013, ELIFE, V2, DOI 10.7554/eLife.01030; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Raab M, 2015, MOL ONCOL, V9, P140, DOI 10.1016/j.molonc.2014.07.020; Rancati G, 2005, CELL CYCLE, V4, P972, DOI 10.4161/cc.4.7.1829; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Santamaria A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004457; Schittenhelm RB, 2009, EMBO J, V28, P2374, DOI 10.1038/emboj.2009.188; Schmucker S, 2014, MOL CELL ONCOL, V1, DOI 10.1080/23723548.2014.954507; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suijkerbuijk SJE, 2012, DEV CELL, V23, P745, DOI 10.1016/j.devcel.2012.09.005; Suijkerbuijk SJE, 2012, DEV CELL, V22, P1321, DOI 10.1016/j.devcel.2012.03.009; Suijkerbuijk SJE, 2010, CANCER RES, V70, P4891, DOI 10.1158/0008-5472.CAN-09-4319; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Thiru P, 2014, MOL BIOL CELL, V25, P1983, DOI 10.1091/mbc.E14-03-0837; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; van der Horst A, 2014, CHROMOSOMA, V123, P25, DOI 10.1007/s00412-013-0437-6; Villa F, 2009, P NATL ACAD SCI USA, V106, P20204, DOI 10.1073/pnas.0908485106; Vleugel M, 2015, MOL CELL, V57, P824, DOI 10.1016/j.molcel.2014.12.036; Vleugel M, 2012, DEV CELL, V23, P239, DOI 10.1016/j.devcel.2012.06.013; von Schubert C, 2015, CELL REP, V12, P66, DOI 10.1016/j.celrep.2015.06.007; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104723; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wong OK, 2007, J CELL BIOL, V179, P611, DOI 10.1083/jcb.200708044; Wong OK, 2005, J CELL BIOL, V170, P709, DOI 10.1083/jcb.200502163; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xu P, 2013, BIOL OPEN, V2, P479, DOI 10.1242/bio.20134051; Xu QB, 2009, MOL BIOL CELL, V20, P10, DOI 10.1091/mbc.E08-03-0324; Yamagishi Y, 2014, FEMS MICROBIOL REV, V38, P185, DOI 10.1111/1574-6976.12049; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Yoshida MM, 2016, J CELL BIOL, V213, P665, DOI 10.1083/jcb.201511079; Zhang G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8162; Zhang G, 2014, J CELL SCI, V127, P871, DOI 10.1242/jcs.139725; Zhou LL, 2014, EMBO REP, V15, P273, DOI 10.1002/embr.201338080; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	132	87	90	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4819	4827		10.1038/onc.2017.113	http://dx.doi.org/10.1038/onc.2017.113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436952				2022-12-28	WOS:000408234400001
J	Basuli, D; Tesfay, L; Deng, Z; Paul, B; Yamamoto, Y; Ning, G; Xian, W; McKeon, F; Lynch, M; Crum, CP; Hegde, P; Brewer, M; Wang, X; Miller, LD; Dyment, N; Torti, FM; Torti, SV				Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Yamamoto, Y.; Ning, G.; Xian, W.; McKeon, F.; Lynch, M.; Crum, C. P.; Hegde, P.; Brewer, M.; Wang, X.; Miller, L. D.; Dyment, N.; Torti, F. M.; Torti, S. V.			Iron addiction: a novel therapeutic target in ovarian cancer	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; STEM-CELLS; ALDEHYDE DEHYDROGENASE; IN-VITRO; INTERLEUKIN-6; PATHOGENESIS; EXPRESSION; PATHWAY; BIOLOGY; DEATH	Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over 30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron metabolism. Ferroportin (FPN), the iron efflux pump, is decreased, and transferrin receptor (TFR1), the iron importer, is increased in tumor tissue from patients with high grade but not low grade serous ovarian cancer. A similar profile of decreased FPN and increased TFR1 is observed in a genetic model of ovarian cancer tumor-initiating cells (TICs). The net result of these changes is an accumulation of excess intracellular iron and an augmented dependence on iron for proliferation. A forced reduction in intracellular iron reduces the proliferation of ovarian cancer TICs in vitro, and inhibits both tumor growth and intraperitoneal dissemination of tumor cells in vivo. Mechanistic studies demonstrate that iron increases metastatic spread by facilitating invasion through expression of matrix metalloproteases and synthesis of interleukin 6 (IL-6). We show that the iron dependence of ovarian cancer TICs renders them exquisitely sensitive in vivo to agents that induce iron-dependent cell death (ferroptosis) as well as iron chelators, and thus creates a metabolic vulnerability that can be exploited therapeutically.	[Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Torti, S. V.] Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, 263 Farmington Ave, Farmington, CT 06030 USA; [Yamamoto, Y.] Natl Canc Ctr, Res Inst, Tokyo, Japan; [Ning, G.] Jackson Lab Genom Med, Farmington, CT USA; [Xian, W.] Univ Texas Houston, Ctr Hlth, Ctr Stem Cells & Regenerat Med, Houston, TX USA; [McKeon, F.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Lynch, M.] Univ Connecticut, Ctr Hlth, Ctr Quantitat Med, Farmington, CT USA; [Crum, C. P.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hegde, P.; Wang, X.] Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT USA; [Brewer, M.] Univ Connecticut, Ctr Hlth, Dept Obstet & Gynecol, Farmington, CT USA; [Miller, L. D.] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Dyment, N.] Univ Connecticut, Ctr Hlth, Sch Dent Med, Reconstruct Sci, Farmington, CT USA; [Torti, F. M.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA; [Lynch, M.] Los Alamos Natl Lab, Stat Sci Grp CCS 6, Los Alamos, NM USA	University of Connecticut; National Cancer Center - Japan; Jackson Laboratory; University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston; University of Connecticut; Harvard University; Brigham & Women's Hospital; University of Connecticut; University of Connecticut; Wake Forest University; University of Connecticut; University of Connecticut; United States Department of Energy (DOE); Los Alamos National Laboratory	Torti, SV (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, 263 Farmington Ave, Farmington, CT 06030 USA.	storti@uchc.edu	Basuli, Debargha/AAD-7351-2021	Basuli, Debargha/0000-0002-4028-9959; Dyment, Nathaniel/0000-0001-8708-112X; Miller, Lance/0000-0003-3799-2528	NIH [R01 CA188025, R01 CA171101]; Department of Defense [W81XWH-10-1-0289]; Cancer Prevention and Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [R01CA188025, P30CA034196, R01CA171101] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD007070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Cancer Prevention and Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported in part by NIH grants R01 CA188025 (SVT), R01 CA171101 (FMT), the Department of Defense (W81XWH-10-1-0289 to CC), and Scholar grants from the Cancer Prevention and Research Institute of Texas (CPRIT; to WX and FM). We thank Tara L Arvedson (Amgen, Thousand Oaks, CA) for a generous gift of anti-ferroportin antibody.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; BAKER VV, 1990, GYNECOL ONCOL, V38, P340, DOI 10.1016/0090-8258(90)90069-W; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Dai JS, 2004, TOXICOLOGY, V203, P199, DOI 10.1016/j.tox.2004.06.009; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Dietl J, 2014, ARCH GYNECOL OBSTET, V289, P241, DOI 10.1007/s00404-013-3041-3; Dijkgraaf EM, 2012, CURR PHARM DESIGN, V18, P3816; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Gershenson David M, 2013, Am Soc Clin Oncol Educ Book, DOI 10.1200/EdBook_AM.2013.33.e195; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kurman RJ, 2013, ANN ONCOL, V24, P16, DOI 10.1093/annonc/mdt463; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Leong HS, 2015, J PATHOL, V236, P272, DOI 10.1002/path.4536; Li HX, 2014, INT J CLIN EXP PATHO, V7, P848; Liu XB, 2005, BLOOD CELL MOL DIS, V35, P33, DOI 10.1016/j.bcmd.2005.04.005; Lui GYL, 2015, MOL PHARMACOL, V87, P543, DOI 10.1124/mol.114.096529; Manz DH, 2016, ANN NY ACAD SCI, V1368, P149, DOI 10.1111/nyas.13008; Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870; Ng A, 2015, NAT REV MOL CELL BIO, V16, P625, DOI 10.1038/nrm4056; Nguyen DH, 2013, CANCERINCYTES, V2, DOI DOI 10.1038/PROTEX.2013.097; Ning G, 2014, J PATHOL, V234, P478, DOI 10.1002/path.4417; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Reed JC, 2012, CELL, V149, P963, DOI 10.1016/j.cell.2012.05.009; Ross SL, 2012, CELL METAB, V15, P905, DOI 10.1016/j.cmet.2012.03.017; Schimanski LM, 2005, BLOOD, V105, P4096, DOI 10.1182/blood-2004-11-4502; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shah MM, 2014, GYNECOL ONCOL, V132, P483, DOI 10.1016/j.ygyno.2013.12.001; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Wang W, 2014, CANCER RES, V74, P497, DOI 10.1158/0008-5472.CAN-13-1224; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zou M, 2015, METHODS, V83, P3, DOI 10.1016/j.ymeth.2015.05.011	47	190	199	5	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4089	4099		10.1038/onc.2017.11	http://dx.doi.org/10.1038/onc.2017.11			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319068	Green Submitted, Green Accepted			2022-12-28	WOS:000405835800001
J	Xu, Y; Miriyala, S; Fang, F; Bakthavatchalu, V; Noel, T; Schnell, DM; Wang, C; St Clair, WH; St Clair, DK				Xu, Y.; Miriyala, S.; Fang, F.; Bakthavatchalu, V.; Noel, T.; Schnell, D. M.; Wang, C.; St Clair, W. H.; St Clair, D. K.			Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect (vol 34, pg 4229, 2015)	ONCOGENE			English	Correction														Miriyala, Sumitra/0000-0001-7158-9295				Xu Y, 2015, ONCOGENE, V34, P4229, DOI 10.1038/onc.2014.355	1	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4087	4087		10.1038/onc.2016.513	http://dx.doi.org/10.1038/onc.2016.513			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288137	Bronze			2022-12-28	WOS:000405379900014
J	Zhang, Q; Wei, T; Shim, K; Wright, K; Xu, K; Palka-Hamblin, HL; Jurkevich, A; Khare, S				Zhang, Q.; Wei, T.; Shim, K.; Wright, K.; Xu, K.; Palka-Hamblin, H. L.; Jurkevich, A.; Khare, S.			Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition (vol 35, pg 3151, 2016)	ONCOGENE			English	Correction																		Zhang Q, 2016, ONCOGENE, V35, P3151, DOI 10.1038/onc.2015.365	1	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4088	4088		10.1038/onc.2017.56	http://dx.doi.org/10.1038/onc.2017.56			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288131	Green Published, hybrid			2022-12-28	WOS:000405379900015
J	Chattaragada, MS; Riganti, C; Sassoe, M; Principe, M; Santamorena, MM; Roux, C; Curcio, C; Evangelista, A; Allavena, P; Salvia, R; Rusev, B; Scarpa, A; Cappello, P; Novelli, F				Chattaragada, M. S.; Riganti, C.; Sassoe, M.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Evangelista, A.; Allavena, P.; Salvia, R.; Rusev, B.; Scarpa, A.; Cappello, P.; Novelli, F.			FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis	ONCOGENE			English	Article							OXYGEN SPECIES PRODUCTION; PANCREATIC-CANCER; MICROENVIRONMENTAL REGULATION; REDOX REGULATION; GENE-EXPRESSION; ALPHA-ENOLASE; IN-VITRO; CELLS; SURVIVAL; FISSION	Mitochondrial dysregulation plays a central role in cancers and drives reactive oxygen species (ROS)-dependent tumor progression. We investigated the pro-tumoral roles of mitochondrial dynamics and altered intracellular ROS levels in pancreatic ductal adenocarcinoma (PDAC). We identified 'family with sequence similarity 49 member B' (FAM49B) as a mitochondria-localized protein that regulates mitochondrial fission and cancer progression. Silencing FAM49B in PDAC cells resulted in increased fission and mitochondrial ROS generation, which enhanced PDAC cell proliferation and invasion. Notably, FAM49B expression levels in PDAC cells were downregulated by the tumor microenvironment. Overall, the results of this study show that FAM49B acts as a suppressor of cancer cell proliferation and invasion in PDAC by regulating tumor mitochondrial redox reactions and metabolism.	[Chattaragada, M. S.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Cappello, P.; Novelli, F.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Chattaragada, M. S.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Cappello, P.; Novelli, F.] Azienda Univ Osped Citta Salute & Sci Torino, Ctr Expt Res & Med Studies, Turin, Italy; [Riganti, C.] Univ Turin, Dept Oncol, Turin, Italy; [Sassoe, M.] Univ Turin, Dept Neurosci Rita Levi Montalcini, Turin, Italy; [Evangelista, A.] Azienda Univ Osped Citta Salute & Sci, Dept Clin Epidemiol, Turin, Italy; [Evangelista, A.] CPO Piemonte, Turin, Italy; [Allavena, P.] Humanitas Clin & Res Ctr, Dept Gastroenterol, Lab Mol Gastroenterol, Milan, Italy; [Salvia, R.] Univ & Hosp Trust Verona, Pancreas Inst, Dept Surg, Verona, Italy; [Rusev, B.] Univ & Hosp Trust Verona, Dept Pathol & Publ Hlth, Verona, Italy; [Scarpa, A.] Univ & Hosp Trust Verona, ARC NET Res Ctr, Verona, Italy; [Cappello, P.; Novelli, F.] Univ Turin, Mol Biotechnol Ctr, Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Turin	Novelli, F (corresponding author), Citta Salute & Sci Torino, Ctr Expt Res & Med Studies, Via Santena 5, I-10125 Turin, Italy.	franco.novelli@unito.it	Salvia, Roberto/J-1773-2018; Curcio, Claudia/AAB-3638-2019; Novelli, Francesco/Z-5990-2019; Allavena, Paola/HHM-5218-2022; Roux, Cecilia/AAB-9661-2019; Cappello, Paola/J-3127-2018; Scarpa, Aldo/K-6832-2016	Allavena, Paola/0000-0002-6697-6028; Roux, Cecilia/0000-0002-2883-167X; Cappello, Paola/0000-0002-5321-7794; Principe, Moitza/0000-0001-5013-7388; NOVELLI, FRANCESCO/0000-0002-6259-5666; Riganti, Chiara/0000-0001-9787-4836; evangelista, andrea/0000-0003-1901-2805; CURCIO, Claudia/0000-0001-5306-4399; Scarpa, Aldo/0000-0003-1678-739X	Associazione Italiana Ricerca sul Cancro (5 x mille) [12182, 15257, 15232]; University of Turin-Progetti Ateneo-Compagnia di San Paolo (PC-METAIMMUN-OTHER); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PANTHER); Italian Ministry of Health-Progetti Ricerca Finalizzata [RF-2013-02354892]; Fondazione Ricerca Molinette Onlus; Fondazione Nadia Valsecchi; European Community FP7 Grant Cam-Pac [602783]; FIMP, Ministero Salute [CUP_J33G13000210001]; Fondazione Ursula e Giorgio Cytron, Torino	Associazione Italiana Ricerca sul Cancro (5 x mille)(Fondazione AIRC per la ricerca sul cancro); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PC-METAIMMUN-OTHER); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PANTHER); Italian Ministry of Health-Progetti Ricerca Finalizzata; Fondazione Ricerca Molinette Onlus; Fondazione Nadia Valsecchi; European Community FP7 Grant Cam-Pac; FIMP, Ministero Salute; Fondazione Ursula e Giorgio Cytron, Torino	We thank Roberta Curto for technical support in the in vivo experiments, Elena Frola for technical support in the electron microscopy and Dr Radhika Srinivasan for critically reading the manuscript. The nature research language editing service edited this work. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (5 x mille no. 12182 to AS and FN, IG no. 15257 to FN, IG no. 15232 to AS); University of Turin-Progetti Ateneo 2014-Compagnia di San Paolo (PC-METAIMMUN-OTHER to FN and PANTHER to PC), Italian Ministry of Health-Progetti Ricerca Finalizzata (RF-2013-02354892 to FN), Fondazione Ricerca Molinette Onlus, Fondazione Nadia Valsecchi to FN, European Community FP7 Grant Cam-Pac (agreement no: 602783) to AS; FIMP, Ministero Salute (CUP_J33G13000210001) to AS. MSC was supported by Fondazione Ursula e Giorgio Cytron, Torino.	Al Saati T, 2013, AM J PATHOL, V182, P1996, DOI 10.1016/j.ajpath.2013.02.034; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Brahimi-Horn MC, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0133-5; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Campia I, 2009, BRIT J PHARMACOL, V158, P1777, DOI 10.1111/j.1476-5381.2009.00465.x; Cappello P, 2013, GASTROENTEROLOGY, V144, P1098, DOI 10.1053/j.gastro.2013.01.020; Cappello P, 2009, INT J CANCER, V125, P639, DOI 10.1002/ijc.24355; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Ferreira-da-Silva A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122308; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hancock JT, 2009, MOL BIOTECHNOL, V43, P162, DOI 10.1007/s12033-009-9189-1; Handy DE, 2012, ANTIOXID REDOX SIGN, V16, P1323, DOI 10.1089/ars.2011.4123; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hurd TR, 2012, TRENDS CELL BIOL, V22, P107, DOI 10.1016/j.tcb.2011.11.002; Kaistha BP, 2014, BRIT J CANCER, V111, P1780, DOI 10.1038/bjc.2014.460; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kodydkova J, 2013, PANCREAS, V42, P614, DOI 10.1097/MPA.0b013e318288360a; Konstantinidis IT, 2013, ANN SURG, V257, P731, DOI 10.1097/SLA.0b013e318263da2f; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Krska Zdenek, 2015, Prague Med Rep, V116, P253, DOI 10.14712/23362936.2015.65; Lorenz H, 2006, NAT METHODS, V3, P205, DOI 10.1038/nmeth857; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pinzon-Daza ML, 2012, BRIT J PHARMACOL, V167, P1431, DOI 10.1111/j.1476-5381.2012.02103.x; Principe M, 2015, ONCOTARGET, V6, P11098, DOI 10.18632/oncotarget.3572; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rambold Angelika S, 2011, Commun Integr Biol, V4, P752; Riganti C, 2008, TOXICOL APPL PHARM, V228, P277, DOI 10.1016/j.taap.2007.12.013; Riganti C, 2012, FREE RADICAL BIO MED, V53, P421, DOI 10.1016/j.freeradbiomed.2012.05.006; Rishi A, 2015, SEMIN ONCOL, V42, P28, DOI 10.1053/j.seminoncol.2014.12.004; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Saborido A, 2005, FREE RADICAL RES, V39, P921, DOI 10.1080/10715760500188887; Sassoe-Pognetto M, 2000, J NEUROSCI, V20, P2192; Schwamb B, 2015, INT J CANCER, V137, P1318, DOI 10.1002/ijc.29498; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Storz P, 2017, NAT REV GASTRO HEPAT, V14, P296, DOI 10.1038/nrgastro.2017.12; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Tomaino B, 2007, J PROTEOME RES, V6, P4025, DOI 10.1021/pr070281a; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Tung JC, 2015, FREE RADICAL BIO MED, V79, P269, DOI 10.1016/j.freeradbiomed.2014.11.020; Uzhachenko R, 2012, J PATHOL, V227, P456, DOI 10.1002/path.4039; Viltono L, 2008, J COMP NEUROL, V508, P579, DOI 10.1002/cne.21713; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Yu TZ, 2011, ANTIOXID REDOX SIGN, V14, P425, DOI 10.1089/ars.2010.3284; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.215; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494; Zhou LX, 2013, MOL CANCER RES, V11, P272, DOI 10.1158/1541-7786.MCR-12-0395	66	36	36	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					697	709		10.1038/onc.2017.358	http://dx.doi.org/10.1038/onc.2017.358			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059164	hybrid, Green Published			2022-12-28	WOS:000424628100002
J	Xia, L; Xiao, X; Liu, WL; Song, Y; Liu, TJJ; Li, YJ; Zacksenhaus, E; Hao, XJ; Ben-David, Y				Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Li, Y. J.; Zacksenhaus, E.; Hao, X. J.; Ben-David, Y.			Coactosin-like protein CLP/Cot11 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGF beta signaling	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAMMARY-TUMOR CELLS; EXPRESSION; MDA-7/IL-24; APOPTOSIS; 5-LIPOXYGENASE; MEDIATOR; COTL1; SMAD4; LINES	Coactosin-like protein (CLP, or Cotl1), is an F-actin-binding protein, whose role in cancer is largely unknown. Here we show that CLP/Cotl1 is highly expressed in a rat epithelial breast cancer cell line (FE1.3) compared with its mesenchymal counterpart (FE1.2). Knockdown of CLP/Cotl1 in FE1.3 cells increased cell proliferation, whereas its overexpression in FE1.2 cells inhibited proliferation in culture and reduced tumor growth in xenograft assays in mice. Mechanistically, we identified two major pathways through which CLP/Cotl1 exerts its suppressive effects. First, CLP/Cotl1 re-expression in FE1.2 and in human MCF7 breast cancer cells induced expression of the growth-suppressor gene interleukin-24 (IL-24), which independently of p53 upregulates the tumor-suppressor genes p53 apoptosis effector related to PMP-22 (PERP) and p21(cip1). Second, overexpression of CLP/Cotl1 potentiated the growthsuppressive effect of transforming growth factor-beta 1 (TGF beta 1), leading to downregulation of TGF beta-responsive genes vascular growth factor A/B (VEGFA/VEGFB), hypoxia inducing factor 1 alpha (HIF-1 alpha) and trombospondin 1 (TSP1), which mediate various hallmarks of cancer progression including angiogenesis, invasion and metastasis. CLP/Cotl1 inhibited TGF beta signaling via a non-canonical signaling involving IL-24-instigated inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) phosphorylation and subsequent post-transcriptional downregulation of SMAD2 and SMAD4. We also showed that CLP/ COTL1 expression sensitizes breast cancer cells to chemotherapeutic drugs, and this was further enhanced by addition of exogenous TGF beta 1. CLP/Cotl1 expression is lost in many human malignancies including prostate, uterine and breast cancers. Thus, our results uncover a novel tumor-suppressor role for CLP/Cotl1 and identify the downstream effectors interleukin 24 (IL-24)/PERP and IL-24/MAPK/ERK/TGF beta as potential targets for precision therapy.	[Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guiyang, Guizhou, Peoples R China; [Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Key Lab Chem Nat Prod Guizhou Prov, Guiyang, Guizhou, Peoples R China; [Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Chinese Acad Sci, Guiyang, Guizhou, Peoples R China; [Xia, L.; Hao, X. J.] Guizhou Univ, Sch Pharmaceut Sci, Guiyang, Guizhou, Peoples R China; [Li, Y. J.] Jilin Univ, Dept Anat, Norman Bethune Coll Med, Changchun, Jilin, Peoples R China; [Zacksenhaus, E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Zacksenhaus, E.] Univ Hlth Network, Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada	Guizhou Medical University; Chinese Academy of Sciences; Guizhou University; Jilin University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ben-David, Y (corresponding author), State Key Lab Funct & Applicat Med Plants, Guiyang 550014, Guizhou, Peoples R China.	yaacovbendavid@hotmail.com	Zacksenhaus, Eldad/AAD-3584-2020		National Natural Science Foundation of China [81472609]; Science and Technology Department of Guizhou Province Innovation and Project Grant [2013-6012]; Thousand Talent Program of China [WQ20135200171]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Guizhou Province Innovation and Project Grant; Thousand Talent Program of China	This work was supported by research grants from the National Natural Science Foundation of China (81472609), the Science and Technology Department of Guizhou Province Innovation and Project Grant (2013-6012) and Thousand Talent Program of China (WQ20135200171) and to YBD.	Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dai HM, 2006, BBA-PROTEINS PROTEOM, V1764, P1688, DOI 10.1016/j.bbapap.2006.06.017; Dai HM, 2004, J BIOMOL NMR, V29, P455, DOI 10.1023/B:JNMR.0000032550.18424.aa; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Gubin MM, 2014, CELL CYCLE, V9, P3357; Guo SQ, 2017, ONCOTARGET, V8, P644, DOI 10.18632/oncotarget.13501; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Kim JA, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085445, 10.1371/journal.pone.0091940]; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Li XM, 2004, ACTA CRYSTALLOGR D, V60, P2387, DOI [10.1107/S0907444904028112, 10.1107/S097444904028112]; Li XM, 2004, PROTEIN SCI, V13, P2845, DOI 10.1110/ps.04937304; Li YJ, 2003, ONCOGENE, V22, P3452, DOI 10.1038/sj.onc.1206411; Li YJ, 2015, ONCOTARGET, V6, P36943, DOI 10.18632/oncotarget.6046; Liu L, 2004, ACTA CRYSTALLOGR D, V60, P1651, DOI 10.1107/S0907444904016701; Luo K, 2017, COLD SPRING HARB PER, V9; Menezes ME, 2015, ONCOTARGET, V6, P36928, DOI 10.18632/oncotarget.6047; Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978-1-4471-6458-6_6; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nakatsura T, 2002, EUR J IMMUNOL, V32, P826, DOI 10.1002/1521-4141(200203)32:3<826::AID-IMMU826>3.0.CO;2-Y; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Provost P, 2001, BIOCHEM J, V359, P255, DOI 10.1042/0264-6021:3590255; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Sainz-Perez A, 2008, J IMMUNOL, V181, P6051, DOI 10.4049/jimmunol.181.9.6051; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Sun WJ, 2012, J INVEST MED, V60, P689, DOI 10.2310/JIM.0b013e31824963b6; Tian MZ, 2011, CELL SIGNAL, V23, P951, DOI 10.1016/j.cellsig.2010.10.015; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Wang CJ, 2010, ONCOL RES, V18, P561, DOI 10.3727/096504010X12767359113929; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Wylie-Sears J, 2014, BIOCHEM BIOPH RES CO, V446, P870, DOI 10.1016/j.bbrc.2014.03.014; Xia L, 2016, MOL CLIN ONCOL, V5, P717, DOI 10.3892/mco.2016.1059; Xuan WL, 2009, MOL CANCER RES, V7, P433, DOI 10.1158/1541-7786.MCR-08-0252; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	38	16	18	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					323	331		10.1038/onc.2017.342	http://dx.doi.org/10.1038/onc.2017.342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925397				2022-12-28	WOS:000422753900005
J	Youn, H; Lee, HK; Sohn, HR; Park, UH; Kim, EJ; Youn, B; Um, SJ				Youn, H.; Lee, H-K; Sohn, H-R; Park, U-H; Kim, E-J; Youn, B.; Um, S-J			RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; EMBRYONAL CARCINOMA-CELLS; BCL-2 RELATED GENE; RETINOIC ACID; DIFFERENTIATION; CANCER; EXPRESSION; RECEPTORS; APOPTOSIS; GROWTH	Retinoic acid (RA) has broad clinical applications for the treatment of various cancers, particularly acute promyelocytic leukemia. However, RA-based therapy is limited by relapse in patients associated with RA resistance, the mechanism of which is poorly understood. Here, we suggest a new molecular mechanism of RA resistance by a repressor, named RA resistance factor (RaRF). RaRF suppressed transcriptional activity of the RA receptor (RAR) by directly interacting with and sequestering RAR to the nucleolus in response to RA. RaRF was highly expressed in RA-resistant leukemia cells and its expression was strongly correlated with RA sensitivity. MCL1 was upregulated by RA treatment upon RaRF depletion, accompanying leukemic myeloblast differentiation, which is negatively regulated by ectopic RaRF expression. Collectively, we propose that RaRF may be a factor in the resistance mechanism and thus a potential target for leukemia therapy using RA.	[Youn, H.; Lee, H-K; Sohn, H-R; Park, U-H; Um, S-J] Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Cheonan Si, Chungnam, South Korea; [Youn, B.] Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea	Sejong University; Dankook University; Pusan National University	Kim, EJ; Um, SJ (corresponding author), Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea.	nbrejk@dankook.ac.kr; umsj@sejong.ac.kr		LEE, HYE KYUNG/0000-0002-7785-5942	Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea [2014R1A2A1A11052685, 2016R1D1A1B03931405]	Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea	We would like to thank Dr Masahiro Kizaki (Division of Hematology and Clinical Laboratories, Keio University School of Medicine, Japan) and Dr Chi-Dug Kang (Pusan National University School of Medicine, Korea) for providing UF-1 and NB4 cells, respectively. This study was supported in part by a grant from the Korea Food Research Institute (to SJU) and a grant of the Basic Science Research Program through NRF grant (2014R1A2A1A11052685 to SJU and 2016R1D1A1B03931405 to HY), Republic of Korea.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Berghofer-Hochheimer Y, 1998, J CELL BIOCHEM, V69, P1, DOI 10.1002/(SICI)1097-4644(19980401)69:1<1::AID-JCB1>3.0.CO;2-X; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bushue N, 2010, ADV DRUG DELIVER REV, V62, P1285, DOI 10.1016/j.addr.2010.07.003; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; DE LUCA LM, 1991, FASEB J, V5, P2924; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; GRIGNANI F, 1994, BLOOD, V83, P10; Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019; Gushima M, 2010, MOL CELL ENDOCRINOL, V319, P14, DOI 10.1016/j.mce.2010.01.006; Han HS, 2004, INT J CANCER, V109, P58, DOI 10.1002/ijc.11643; Hasina R, 2006, ONCOGENE, V25, P588, DOI 10.1038/sj.onc.1209070; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lall R, 2009, CELL BIOL INT, V33, P447, DOI 10.1016/j.cellbi.2009.01.015; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Martindill DMJ, 2008, CELL CYCLE, V7, P17, DOI 10.4161/cc.7.1.5228; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; O'Malley B, 2008, MOL ENDOCRINOL, V22, P2751, DOI 10.1210/me.2008-0297; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Oren T, 2003, LEUKEMIA LYMPHOMA, V44, P1881, DOI 10.1080/1042819031000116661; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Sanz MA, 2011, J CLIN ONCOL, V29, P495, DOI 10.1200/JCO.2010.32.1067; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Schlenk RF, 2005, LEUKEMIA, V19, P978, DOI 10.1038/sj.leu.2403766; Schulz M, 2001, BIOCHEM BIOPH RES CO, V280, P476, DOI 10.1006/bbrc.2000.4141; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Um SJ, 2003, INT J CANCER, V107, P1038, DOI 10.1002/ijc.11489; Um SJ, 2014, BIOCHEM BIOPH RES CO, V444, P605, DOI 10.1016/j.bbrc.2014.01.105; Um SJ, 2012, BIOCHEM BIOPH RES CO, V418, P290, DOI 10.1016/j.bbrc.2012.01.013; Umezawa A, 1996, CELL STRUCT FUNCT, V21, P143, DOI 10.1247/csf.21.143; Wang R, 2016, CLIN CANCER RES, V22, P1211, DOI 10.1158/1078-0432.CCR-15-0663; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Yang J, 2013, APOPTOSIS, V18, P1403, DOI 10.1007/s10495-013-0872-0; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhuang J, 2006, CELL DEATH DIFFER, V13, P1263, DOI 10.1038/sj.cdd.4401952	50	2	3	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					352	362		10.1038/onc.2017.329	http://dx.doi.org/10.1038/onc.2017.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945224				2022-12-28	WOS:000422753900008
J	Yun, MR; Choi, HM; Kang, HN; Lee, Y; Joo, HS; Kim, DH; Kim, HR; Hong, MH; Yoon, SO; Cho, BC				Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Joo, H-S; Kim, D. H.; Kim, H. R.; Hong, M. H.; Yoon, S. O.; Cho, B. C.			ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma	ONCOGENE			English	Article							I PI3K INHIBITOR; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-I; BUPARLISIB BKM120; LUNG-CANCER; EGFR INHIBITORS; DOSE-ESCALATION; METASTATIC HEAD; COMBINATION	Hyperactivation of phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in head and neck squamous cell carcinoma (HNSCC). However, clinical outcomes of targeting the PI3K pathway have been underwhelming. In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC. Treatment of NVP-BKM120, a pan-PI3K inhibitor, led to upregulation of interleukin-6 (IL-6) and subsequent activation of either extracellular signal-regulated kinase (ERK) or signal transducers and activators of transcription 3 (STAT3), causing modest antitumor effects on the growth of HNSCC cells. Blockade of autocrine IL-6 signaling with siRNA or neutralizing antibody for IL-6 receptor (IL-6R) completely abolished NVP-BKM120-induced activation of ERK and STAT3 as well as expression of c-Myc oncogene, which resulted in enhanced sensitivity to NVP-BKM120. Moreover, when compared with a pharmacologic inhibitor or silencing of STAT3, trametinib, a MEK inhibitor, in combination with NVP-BKM120 yielded more potent anti-proliferative effects by inhibiting S phase transition, arresting cells at G0/G1 phase, and downregulating IL-6 and c-Myc expression. Furthermore, as compared with either agent alone, combination of NVP-BKM120 with trametinib or tocilizumab, a humanized anti-IL-6R antibody, significantly suppressed tumor growth in NVP-BKM120-resistant patient-derived tumor xenograft (PDTX) models, which was also confirmed in PDTX-derived cell lines. Collectively, these results suggested that IL-6/ERK signaling is closely involved in adaptive resistance of NVP-BKM120 in HNSCC cells, providing a rationale for a novel combination therapy to overcome resistance to PI3K inhibitors.	[Yun, M. R.; Kang, H. N.; Joo, H-S; Kim, D. H.; Cho, B. C.] JEUK Co Ltd, JEUK Inst Canc Res, Gumi, Kyungbuk, South Korea; [Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Kim, H. R.; Hong, M. H.; Cho, B. C.] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; [Yoon, S. O.] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, BC (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Canc Ctr,Div Med Oncol, 50 Yonsei Ro, Seoul 120752, South Korea.	cbc1971@yuhs.ac		Kim, Hye Ryun/0000-0002-1842-9070; Hong, Min Hee/0000-0003-3490-2195; Cho, Byoung Chul/0000-0002-5562-270X	National Research Foundation of Korea (NRF) - Korea government [NRF-2014R1A1A1006865, 2015R1A2A1A15055817]	National Research Foundation of Korea (NRF) - Korea government(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government (NRF-2014R1A1A1006865 to MR Yun and 2015R1A2A1A15055817 to BC Cho).	Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bhattacharya N, 2009, J ORAL PATHOL MED, V38, P759, DOI 10.1111/j.1600-0714.2009.00781.x; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Brachmann SM, 2012, MOL CANCER THER, V11, P1747, DOI 10.1158/1535-7163.MCT-11-1021; Du L, 2012, J ONCOL, V2012, DOI 10.1155/2012/450179; Eichten A, 2016, CANCER RES, V76, P2327, DOI 10.1158/0008-5472.CAN-15-1443; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Giudice FS, 2013, J CARCINOG MUTAGEN, V2, P5; Grana B, 2011, J CLIN ONCOL, V29; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Heo TH, 2016, ONCOTARGET, V7, P15460, DOI 10.18632/oncotarget.7102; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jimeno A, 2015, ORAL ONCOL, V51, P383, DOI 10.1016/j.oraloncology.2014.12.013; Kim HS, 2015, CLIN CANCER RES, V21, P544, DOI 10.1158/1078-0432.CCR-14-1756; Kim HR, 2015, CO CLIN TRIALS DEMON; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koul D, 2012, CLIN CANCER RES, V18, P184, DOI 10.1158/1078-0432.CCR-11-1558; Leon X, 2005, CLIN ONCOL-UK, V17, P418, DOI 10.1016/j.clon.2005.02.014; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Ma PF, 2016, THERANOSTICS, V6, P1232, DOI 10.7150/thno.14409; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Michmerhuizen Nicole L, 2016, Otorhinolaryngol Head Neck Surg, V1, P44; Miller A, 2015, ONCOGENE, V34, P1510, DOI 10.1038/onc.2014.99; Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377; Munster PN, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3018; Nagasaki T, 2014, RECEPTORS CLIN INVES, V1, pe202; Neel DS, 2013, CLIN CANCER RES, V19, P3, DOI 10.1158/1078-0432.CCR-12-3232; Patel JD, 2014, J CLIN ONCOL, V32, P129, DOI 10.1200/JCO.2013.53.7076; Ren H, 2016, ONCOTARGET, V7, P67277, DOI 10.18632/oncotarget.11645; Ren H, 2012, CANCER LETT, V325, P139, DOI 10.1016/j.canlet.2012.06.018; Rodon J, 2014, INVEST NEW DRUG, V32, P670, DOI 10.1007/s10637-014-0082-9; Roper J, 2014, CANCER LETT, V347, P204, DOI 10.1016/j.canlet.2014.02.018; Rosell R, 2013, TRANSL LUNG CANCER R, V2, P152, DOI 10.3978/j.issn.2218-6751.2012.12.08; Scherzad A, 2015, INT J ONCOL, V47, P391, DOI 10.3892/ijo.2015.3009; Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sos ML, 2014, CELL REP, V8, P1037, DOI 10.1016/j.celrep.2014.07.010; Stanam A, 2015, MOL ONCOL, V9, P1371, DOI 10.1016/j.molonc.2015.03.008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun SY, 2014, CANCER RES, V74, P7546, DOI 10.1158/0008-5472.CAN-14-0826; Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Von Hoff DD, 2010, J CLIN ONCOL, V28, P2541; Vyse S, 2017, J MOL BIOL, V429, P1767, DOI 10.1016/j.jmb.2017.04.018; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang L, 2014, BIOCHEM BIOPH RES CO, V453, P582, DOI 10.1016/j.bbrc.2014.09.129; Zhang H, 2015, ONCOTARGET, V6, P3085, DOI 10.18632/oncotarget.3099	62	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					377	388		10.1038/onc.2017.339	http://dx.doi.org/10.1038/onc.2017.339			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945228				2022-12-28	WOS:000422753900010
J	Chan, JSK; Sng, MK; Teo, ZQ; Chong, HC; Twang, JS; Tan, NS				Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.			Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors	ONCOGENE			English	Article							METASTATIC COLORECTAL-CANCER; RESISTANT PROSTATE-CANCER; PHASE-II TRIAL; RETINOIC ACID; CELL; PROGRESSION; TRANILAST; MICROENVIRONMENT; HYPOXIA; DISEASE	Most anticancer therapies to date focus on druggable features of tumor epithelia. Despite the increasing repertoire of treatment options, patient responses remain varied. Moreover, tumor resistance and relapse remain persistent clinical challenges. These observations imply an incomplete understanding of tumor heterogeneity. The tumor microenvironment is a major determinant of disease progression and therapy outcome. Cancer-associated fibroblasts (CAFs) are the dominant cell type within the reactive stroma of tumors. They orchestrate paracrine pro-tumorigenic signaling with adjacent tumor cells, thus exacerbating the hallmarks of cancer and accelerating tumor malignancy. Although CAF-derived soluble factors have been investigated for tumor stroma-directed therapy, the underlying transcriptional programs that enable the oncogenic functions of CAFs remain poorly understood. Nuclear receptors (NRs), a large family of ligand-responsive transcription factors, are pharmacologically viable targets for the suppression of CAF-facilitated oncogenesis. In this study, we defined the expression profiles of NRs in CAFs from clinical cutaneous squamous cell carcinoma (SCC) biopsies. We further identified a cluster of driver NRs in CAFs as important modifiers of CAF function with profound influence on cancer cell invasiveness, proliferation, drug resistance, energy metabolism and oxidative stress status. Importantly, guided by the NR profile of CAFs, retinoic acid receptor beta and androgen receptor antagonists were identified for concurrent therapy with cisplatin, resulting in the inhibition of chemoresistance in recurred SCC: CAF xenografts. Our work demonstrates that treatments targeting both the tumor epithelia and the surrounding CAFs can extend the efficacy of conventional chemotherapy.	[Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Sng, M. K.; Tan, N. S.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Tan, N. S.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Tan, N. S.] KK Womens & Children Hosp, Singapore, Singapore; [Chong, H. C.] DeNova Sci Pte Ltd, 16 Nanyang Dr, Singapore 637722, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Chan, JSK; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	CHAN0693@e.ntu.edu.sg; nstan@ntu.edu.sg	Tan, Nguan Soon/A-2220-2011; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Sng, Ming Keat/0000-0002-5529-4371	Singapore Ministry of Education [MOE2014-T2-1-012]; Singapore Ministry of Education (AcRF Tier 1) [RG134/15]; Nanyang President Graduate Scholarship	Singapore Ministry of Education(Ministry of Education, Singapore); Singapore Ministry of Education (AcRF Tier 1)(Ministry of Education, Singapore); Nanyang President Graduate Scholarship	The work was supported by grants from the Singapore Ministry of Education (MOE2014-T2-1-012 and AcRF Tier 1 RG134/15) to NST. JSKC is a recipient of the Nanyang President Graduate Scholarship.	Bhagwat AS, 2015, TRENDS CANCER, V1, P53, DOI 10.1016/j.trecan.2015.07.001; Bizzarri M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/934038; Byun JS, 2013, AM J PATHOL, V182, P1055, DOI 10.1016/j.ajpath.2013.01.009; Chen YY, 2007, BIOMED CHROMATOGR, V21, P628, DOI 10.1002/bmc.798; Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Ghandadi M, 2016, CURR PHARM DESIGN, V22, P518, DOI 10.2174/1381612822666151124234417; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Hong K, 2014, IMMUNOL LETT, V162, P34, DOI 10.1016/j.imlet.2014.06.011; Hong LZ, 2013, ONCOL LETT, V6, P1595, DOI 10.3892/ol.2013.1590; Izumi K, 2010, ANTICANCER RES, V30, P3077; Izumi K, 2009, PROSTATE, V69, P1222, DOI 10.1002/pros.20975; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Lam CRI, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.339; Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Ohshio Y, 2014, SCAND J IMMUNOL, V80, P408, DOI 10.1111/sji.12242; Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI [10.2217/FON.14.83, 10.2217/fon.14.83]; Redmond Aisling M, 2009, Genome Biol, V10, P311, DOI 10.1186/gb-2009-10-7-311; Rieger S, 2015, CELL BIOCHEM FUNCT, V33, P1, DOI 10.1002/cbf.3086; Rio D.C., 2010, COLD SPRING HARBOR P, V2010, ppdb.prot5439, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]; Rothaeusler K, 2007, CURR PROTOC CYTOM, V7, P31; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Simkova D, 2016, BIOMED PAP, V160, P467, DOI 10.5507/bp.2016.037; Sladek FM, 2003, EXPERT OPIN THER TAR, V7, P679; Sonnenschein C, 2016, PROG BIOPHYS MOL BIO, V122, P70, DOI 10.1016/j.pbiomolbio.2016.07.004; Spaw M, 2017, MOL CARCINOGEN, V56, P1199, DOI 10.1002/mc.22583; SUZAWA H, 1992, JPN J PHARMACOL, V60, P91, DOI 10.1254/jjp.60.91; Tan NS, 2016, PROG LIPID RES, V64, P98, DOI 10.1016/j.plipres.2016.09.001; Tesei A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062657; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Togo Shinsaku, 2013, Cancers (Basel), V5, P149, DOI 10.3390/cancers5010149; van de Pavert SA, 2009, NAT IMMUNOL, V10, P1193, DOI 10.1038/ni.1789; Vazquez-Villa F, 2015, TUMOR BIOL, V36, P2213, DOI 10.1007/s13277-015-3295-4; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yin K, 2016, CELL MOL LIFE SCI, V73, P3789, DOI 10.1007/s00018-016-2329-4; Zou CH, 2005, J BIOCHEM BIOPH METH, V64, P207, DOI 10.1016/j.jbbm.2005.08.001	50	44	44	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					160	173		10.1038/onc.2017.319	http://dx.doi.org/10.1038/onc.2017.319			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892046	Green Published, hybrid			2022-12-28	WOS:000422631700003
J	Somasagara, RR; Spencer, SM; Tripathi, K; Clark, DW; Mani, C; da Silva, LM; Scalici, J; Kothayer, H; Westwell, AD; Rocconi, RP; Palle, K				Somasagara, R. R.; Spencer, S. M.; Tripathi, K.; Clark, D. W.; Mani, C.; da Silva, L. Madeira; Scalici, J.; Kothayer, H.; Westwell, A. D.; Rocconi, R. P.; Palle, K.			RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance	ONCOGENE			English	Article							UBIQUITIN-CONJUGATING ENZYME; HISTONE H2B MONOUBIQUITINATION; VITRO ANTICANCER EVALUATION; DAMAGE-INDUCED RESPONSE; S-PHASE CHECKPOINT; BETA-CATENIN; POTENTIAL MECHANISM; POLYMERASE SWITCH; COMPLEX-FORMATION; H3K4 METHYLATION	Ovarian cancer (OC) is the most deadly gynecological cancer and unlike most other neoplasms, survival rates for OC have not significantly improved in recent decades. We show that RAD6, an ubiquitin-conjugating enzyme, is significantly overexpressed in ovarian tumors and its expression increases in response to carboplatin chemotherapy. RAD6 expression correlated strongly with acquired chemoresistance and malignant behavior of OC cells, expression of stem cell genes and poor prognosis of OC patients, suggesting an important role for RAD6 in ovarian tumor progression. Upregulated RAD6 enhances DNA damage tolerance and repair efficiency of OC cells and promotes their survival. Increased RAD6 levels cause histone 2B ubiquitination-mediated epigenetic changes that stimulate transcription of stem cell genes, including ALDH1A1 and SOX2, leading to a cancer stem cell phenotype, which is implicated in disease recurrence and metastasis. Downregulation of RAD6 or its inhibition using a small molecule inhibitor attenuated DNA repair signaling and expression of cancer stem cells markers and sensitized chemoresistant OC cells to carboplatin. Together, these results suggest that RAD6 could be a therapeutic target to prevent and treat acquired chemoresistance and disease recurrence in OC and enhance the efficacy of standard chemotherapy.	[Somasagara, R. R.; Spencer, S. M.; Tripathi, K.; Clark, D. W.; Mani, C.; da Silva, L. Madeira; Scalici, J.; Rocconi, R. P.; Palle, K.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Kothayer, H.] Zagazig Univ, Dept Med Chem, Zagazig, Egypt; [Westwell, A. D.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, Wales	University of South Alabama; Egyptian Knowledge Bank (EKB); Zagazig University; Cardiff University	Palle, K (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	kpalle@health.southalabama.edu	Kothayer, Hend/GRJ-5827-2022; Westwell, Andrew David/M-8126-2014	Kothayer, Hend/0000-0002-2954-0751; Westwell, Andrew David/0000-0002-5166-9236	Abraham Mitchell Cancer Research Scholar Endowment grant; National Institutes of Health [R01GM098956]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098956] Funding Source: NIH RePORTER	Abraham Mitchell Cancer Research Scholar Endowment grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Abraham Mitchell Cancer Research Scholar Endowment grant, and by National Institutes of Health grant [R01GM098956] to KP. We would like to thank Joel Andrews, PhD and Steve McClellan for assistance with microscopy and flow cytometry, respectively.	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; de la Rocha AMA, 2014, AM J CANCER RES, V4, P312; Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Braun S, 2012, EMBO REP, V13, P619, DOI 10.1038/embor.2012.78; Cadigan Ken M., 2002, Trends in Genetics, V18, P340, DOI 10.1016/S0168-9525(02)02707-5; Chandrasekharan MB, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12314; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Chirnomas D, 2006, MOL CANCER THER, V5, P952, DOI 10.1158/1535-7163.MCT-05-0493; Clark DW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.82; Clark DW, 2015, ONCOTARGET, V6, P28816, DOI 10.18632/oncotarget.5006; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Davis A, 2014, GYNECOL ONCOL, V133, P624, DOI 10.1016/j.ygyno.2014.02.038; Djordjevic B, 2012, J BUON, V17, P627; Ferrer Miriam, 2005, Clin Lung Cancer, V6, P250, DOI 10.3816/CLC.2005.n.005; Foley OW, 2013, ONCOLOGY-NY, V27, P288; Geng LY, 2010, J CELL BIOL, V191, P249, DOI 10.1083/jcb.201005101; Gerard B, 2012, BBA-MOL CELL RES, V1823, P1686, DOI 10.1016/j.bbamcr.2012.05.032; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haynes B, 2016, NANOMED-NANOTECHNOL, V12, P745, DOI 10.1016/j.nano.2015.10.010; Helchowski CM, 2013, CELL CYCLE, V12, P3749, DOI 10.4161/cc.26640; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Hung SH, 2017, P NATL ACAD SCI USA, V114, pE2205, DOI 10.1073/pnas.1612633114; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Ishiguro T, 2016, CANCER RES, V76, P150, DOI 10.1158/0008-5472.CAN-15-0361; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Khan IN, 2015, DRUG DISCOV TODAY, V20, P1205, DOI 10.1016/j.drudis.2015.06.013; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kobayashi S, 2015, ONCOGENE, V34, P4403, DOI 10.1038/onc.2014.371; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kothayer H, 2016, BIOORG MED CHEM LETT, V26, P2030, DOI 10.1016/j.bmcl.2016.02.085; Kothayer H, 2014, TETRAHEDRON LETT, V55, P7015, DOI 10.1016/j.tetlet.2014.10.122; Kothayer H, 2013, BIOORG MED CHEM LETT, V23, P6886, DOI 10.1016/j.bmcl.2013.09.087; Kuhl SJ, 2013, BBA-GEN SUBJECTS, V1830, P2297, DOI 10.1016/j.bbagen.2012.08.010; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Lyakhovich A, 2004, ONCOGENE, V23, P3097, DOI 10.1038/sj.onc.1207449; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Meng E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107142; Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Ring A, 2014, STEM CELL REV REP, V10, P512, DOI 10.1007/s12015-014-9515-2; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rosner K, 2014, J SKIN CANCER, V2014, DOI 10.1155/2014/439205; Rosner K, 2014, TRANSL ONCOL, V7, P384, DOI 10.1016/j.tranon.2014.04.009; Sanders MA, 2013, MOL CANCER THER, V12, P373, DOI 10.1158/1535-7163.MCT-12-0793; Shekhar MPV, 2008, CANCER RES, V68, P1741, DOI 10.1158/0008-5472.CAN-07-2111; Shekhar MPV, 2006, MOL CANCER RES, V4, P729, DOI 10.1158/1541-7786.MCR-06-0136; Shekhar MPV, 2002, CANCER RES, V62, P2115; Soares LM, 2013, MOL CELL, V49, P1019, DOI 10.1016/j.molcel.2013.03.012; Somasagara RR, 2016, BIOCHEM BIOPH RES CO, V469, P449, DOI 10.1016/j.bbrc.2015.11.134; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tripathi K, 2014, J BIOL CHEM, V289, P31513, DOI 10.1074/jbc.M114.606483; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zhang Z, 2013, GENE DEV, V27, P1581, DOI 10.1101/gad.211037.112	66	38	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6680	6690		10.1038/onc.2017.279	http://dx.doi.org/10.1038/onc.2017.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28806395	Green Accepted			2022-12-28	WOS:000416780800003
J	Govaere, O; Petz, M; Wouters, J; Vandewynckel, YP; Scott, EJ; Topal, B; Nevens, F; Verslype, C; Anstee, QM; Van Vlierberghe, H; Mikulits, W; Roskams, T				Govaere, O.; Petz, M.; Wouters, J.; Vandewynckel, Y-P; Scott, E. J.; Topal, B.; Nevens, F.; Verslype, C.; Anstee, Q. M.; Van Vlierberghe, H.; Mikulits, W.; Roskams, T.			The PDGFR alpha-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma	ONCOGENE			English	Article							IRES-MEDIATED TRANSLATION; POOR-PROGNOSIS; EXPRESSION; CYTOKERATIN-19; ANGIOGENESIS; DIAGNOSIS; MARKER; B1; LA	Human hepatocellular carcinomas (HCCs) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked with a poor prognosis and exhibit an increase in platelet-derived growth factor receptor a (PDGFR alpha) and laminin beta 1 (LAMB1) expression. PDGFR alpha has been reported to induce de novo synthesis of LAMB1 protein in a Sjogren syndrome antigen B (La/SSB)-dependent manner in a murine metastasis model. However, the role of this cascade in human HCC remains unclear. This study focused on the functional role of the PDGFR alpha-La/SSB-LAMB1 pathway and its molecular link to K19 expression in human HCC. In surgical HCC specimens from a cohort of 136 patients, PDGFR alpha expression correlated with K19 expression, microvascular invasion and metastatic spread. In addition, PDGFR alpha expression in pre-operative needle biopsy specimens predicted poor overall survival during a 5-year follow-up period. Consecutive histological staining demonstrated that the signaling components of the PDGFR alpha-La/SSB-LAMB1 pathway were strongly expressed at the invasive front. K19-positive HCC cells displayed high levels of alpha 2 beta 1 integrin (ITG) receptor, both in vitro and in vivo. In vitro activation of PDGFR alpha signaling triggered the translocation of nuclear La/SSB into the cytoplasm, enhanced the protein synthesis of LAMB1 by activating its internal ribosome entry site, which in turn led to increased secretion of laminin-111. This effect was abrogated by the PDGFR alpha-specific inhibitor crenolanib. Importantly LAMB1 stimulated ITG-dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling. It also promoted the ITG-specific downstream target Rho-associated coiled-coil containing protein kinase 2, induced K19 expression in an autocrine manner, invadopodia formation and cell invasion. Finally, we showed that the knockdown of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in significant loss of cells invading the surrounding stromal tissue and reduced HepG2 colonization into lung and liver after tail vein injection. The PDGFR alpha-LAMB1 pathway supports tumor progression at the invasive front of human HCC through K19 expression.	[Govaere, O.; Wouters, J.; Roskams, T.] Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium; [Govaere, O.; Wouters, J.; Topal, B.; Nevens, F.; Verslype, C.; Roskams, T.] Univ Hosp Leuven, Leuven, Belgium; [Govaere, O.; Scott, E. J.; Anstee, Q. M.] Newcastle Univ, Med Sch, Liver Res Grp, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Petz, M.; Mikulits, W.] Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria; [Vandewynckel, Y-P; Van Vlierberghe, H.] Univ Ghent, Dept Hepatol & Gastroenterol, Ghent, Belgium; [Topal, B.] Katholieke Univ Leuven, Dept Abdominal Surg, Leuven, Belgium; [Nevens, F.; Verslype, C.] Katholieke Univ Leuven, Dept Hematol, Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; Newcastle University - UK; Medical University of Vienna; Ghent University; KU Leuven; KU Leuven	Mikulits, W (corresponding author), Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria.; Govaere, O (corresponding author), Med Sch, Inst Cellular Med, Liver Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	olivier.govaere@ncl.ac.uk; wolfgang.mikulits@meduniwien.ac.at	Govaere, Olivier/R-9372-2019; Anstee, Quentin M./L-2981-2013; Topal, Baki/AAH-9019-2021; Mikulits, Wolfgang/AAH-4043-2021; Scott, Emma/AAG-1311-2019; Wouters, Jasper/AAK-8597-2020	Govaere, Olivier/0000-0002-4426-6930; Anstee, Quentin M./0000-0002-9518-0088; Topal, Baki/0000-0002-2687-7535; Scott, Emma/0000-0002-5358-5132; Wouters, Jasper/0000-0002-7129-2990; Van Vlierberghe, Hans/0000-0003-0647-9238; Roskams, Tania/0000-0002-2816-1530; Mikulits, Wolfgang/0000-0003-4612-7106; Verslype, Chris/0000-0003-3857-466X	Belgian Federal Science Policy Office, Interuniversity Attraction Poles program [P7/83-HEPRO]; Austrian Science Fund, FWF [T597-B13, P25356]; Belgian Kom op tegen Kanker; Medical Research Council [1681148] Funding Source: researchfish	Belgian Federal Science Policy Office, Interuniversity Attraction Poles program; Austrian Science Fund, FWF(Austrian Science Fund (FWF)); Belgian Kom op tegen Kanker; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Belgian Federal Science Policy Office, Interuniversity Attraction Poles program-P7/83-HEPRO (to OG), Austrian Science Fund, FWF, T597-B13 (to MP) and P25356 (to WM) and the Belgian Kom op tegen Kanker (to JW). We thank Kathleen Van den Eynde and the Fibrosis Lab, Newcastle University, UK for their indispensible technical support.	Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coulon S, 2011, LIVER INT, V31, P146, DOI 10.1111/j.1478-3231.2010.02369.x; Desmet VJ, 2011, VIRCHOWS ARCH, V458, P251, DOI 10.1007/s00428-011-1048-3; Dhanasekaran R, 2016, J HEPATOL, V64, P736, DOI 10.1016/j.jhep.2015.09.008; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Fernandez M, 2009, J HEPATOL, V50, P604, DOI 10.1016/j.jhep.2008.12.011; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannelli G, 2014, GUT, V63, P1668, DOI 10.1136/gutjnl-2014-307323; Govaere O, 2016, J HEPATOL, V64, P609, DOI 10.1016/j.jhep.2015.11.011; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Guldiken N, 2016, J HEPATOL, V65, P552, DOI 10.1016/j.jhep.2016.04.024; Heinrich MC, 2012, CLIN CANCER RES, V18, P4375, DOI 10.1158/1078-0432.CCR-12-0625; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kikuchi A, 2015, GENE EXPRESSION, V16, P109, DOI 10.3727/105221615X14181438356210; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Martin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12502; Mu X, 2015, J CLIN INVEST, V125, P3891, DOI 10.1172/JCI77995; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; Petz M, 2012, NUCLEIC ACIDS RES, V40, P9738, DOI 10.1093/nar/gks760; Petz M, 2012, NUCLEIC ACIDS RES, V40, P290, DOI 10.1093/nar/gkr717; Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756-0500-3-294; Tsuchiya K, 2011, ONCOLOGY-BASEL, V80, P278, DOI 10.1159/000328448; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; van Zijl F, 2009, ONCOGENE, V28, P4022, DOI 10.1038/onc.2009.253; Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623; Wei T, 2014, ONCOTARGET, V5, P10307, DOI 10.18632/oncotarget.2537; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Zhuang PY, 2008, CANCER-AM CANCER SOC, V112, P2740, DOI 10.1002/cncr.23488	38	37	38	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6605	6616		10.1038/onc.2017.260	http://dx.doi.org/10.1038/onc.2017.260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783171	Green Published, hybrid			2022-12-28	WOS:000416049200009
J	Liu, Y; Cheng, Y; Xu, Y; Wang, Z; Du, X; Li, C; Peng, J; Gao, L; Liang, X; Ma, C				Liu, Y.; Cheng, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Peng, J.; Gao, L.; Liang, X.; Ma, C.			Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; LIGAND 1 EXPRESSION; HEPATOCELLULAR-CARCINOMA; TUMOR MICROENVIRONMENT; IMMUNE-RESPONSES; PD-1 EXPRESSION; GASTRIC-CANCER; T-CELLS; VIRUS; DYSFUNCTION	Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.	[Liu, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Gao, L.; Liang, X.; Ma, C.] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Gao, L.; Liang, X.; Ma, C.] Shandong Univ, Sch Med, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Y.; Cheng, Y.] Shandong Univ, Dept Radiat Oncol, Qilu Hosp, Jinan, Shandong, Peoples R China; [Peng, J.] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Ma, C (corresponding author), Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Ma, C (corresponding author), Shandong Univ, Sch Med, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	machunhong@sdu.edu.cn	ma, chunhong/C-6043-2008	ma, chunhong/0000-0002-8121-4718; Liu, Yuan/0000-0002-4425-2213; Li, Chunyang/0000-0002-5798-2274	National Science Foundation for Distinguished Young Scholars of China [81425012]; NSFC [91529305, 81371831]; Shandong Provincial Natural Science Foundation [ZR2015HZ005]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); NSFC(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province)	We would like to thank Professor Weiming Zhao from the Department of Pathogenic Biology for the gift of anti-asialoGM1. We would like to thank Mingsheng Zhao from the Department of Immunology for help with the in vivo experiments. This work was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (81425012), NSFC (91529305 and 81371831) and the Shandong Provincial Natural Science Foundation (ZR2015HZ005).	Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355; Beldi-Ferchiou A, 2016, ONCOTARGET, V7, P72961, DOI 10.18632/oncotarget.12150; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bucklein V, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1178421; Chen KY, 2016, ONCOTARGET, V7, P30772, DOI 10.18632/oncotarget.8956; Chen Y, 2017, CELL MOL IMMUNOL, V14, P293, DOI 10.1038/cmi.2015.81; Chen YW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001347; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Ferrone C, 2010, J CLIN ONCOL, V28, P4045, DOI 10.1200/JCO.2010.27.9992; Giannelli G, 2014, GUT, V63, P1668, DOI 10.1136/gutjnl-2014-307323; Golden-Mason L, 2008, J IMMUNOL, V180, P3637, DOI 10.4049/jimmunol.180.6.3637; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hassan SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137646; Huang BY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134715; Hydes Theresa, 2015, Lancet, V385 Suppl 1, pS45, DOI 10.1016/S0140-6736(15)60360-9; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Kinter AL, 2008, J IMMUNOL, V181, P6738, DOI 10.4049/jimmunol.181.10.6738; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Li YY, 2016, INT J POLYM SCI, V2016, DOI 10.1155/2016/8769360; Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34; Ma CQ, 2016, AM J SURG PATHOL, V40, P1496, DOI 10.1097/PAS.0000000000000698; Moreno-Cubero E, 2016, WORLD J GASTROENTERO, V22, P6469, DOI 10.3748/wjg.v22.i28.6469; Norris S, 2012, VIRAL IMMUNOL, V25, P329, DOI 10.1089/vim.2011.0096; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004; Riley JL, 2009, IMMUNOL REV, V229, P114, DOI 10.1111/j.1600-065X.2009.00767.x; Saito H, 2013, J SURG ONCOL, V107, P517, DOI 10.1002/jso.23281; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi LR, 2016, CLIN CANCER RES, V22, P1173, DOI 10.1158/1078-0432.CCR-15-1352; Solaymani-Mohammadi S, 2016, J LEUKOCYTE BIOL, V99, P475, DOI 10.1189/jlb.4A0115-003RR; Tarazona R, 2017, CANCER IMMUNOL IMMUN, V66, P233, DOI 10.1007/s00262-016-1882-x; Toh JWT, 2016, CLIN COLORECTAL CANC, V15, P285, DOI 10.1016/j.clcc.2016.07.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wargo JA, 2016, CURR OPIN IMMUNOL, V41, P23, DOI 10.1016/j.coi.2016.05.006; Watanabe M, 2010, DIS ESOPHAGUS, V23, P675, DOI 10.1111/j.1442-2050.2010.01073.x; Wiesmayr S, 2012, EUR J IMMUNOL, V42, P541, DOI 10.1002/eji.201141832; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Yan WJ, 2015, GUT, V64, P1593, DOI 10.1136/gutjnl-2014-307671; Zhang G, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/384726; Zhang L, 2015, CURR STEM CELL RES T, V10, P245, DOI 10.2174/1574888X09666140812112305	48	200	208	5	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6143	6153		10.1038/onc.2017.209	http://dx.doi.org/10.1038/onc.2017.209			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692048	Green Published, hybrid			2022-12-28	WOS:000414249800008
J	Roarty, K; Pfefferle, AD; Creighton, CJ; Perou, CM; Rosen, JM				Roarty, K.; Pfefferle, A. D.; Creighton, C. J.; Perou, C. M.; Rosen, J. M.			Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression	ONCOGENE			English	Article							BREAST-CANCER; GENE-EXPRESSION; TYROSINE KINASE; ERM PROTEINS; PATHWAY; HETEROGENEITY; ROR2; MODEL; ACTIVATION; PREDICTS	Cellular heterogeneity is a common feature in breast cancer, yet an understanding of the coexistence and regulation of various tumor cell subpopulations remains a significant challenge in cancer biology. In the current study, we approached tumor cell heterogeneity from the perspective of Wnt pathway biology to address how different modes of Wnt signaling shape the behaviors of diverse cell populations within a heterogeneous tumor landscape. Using a syngeneic TP53-null mouse model of breast cancer, we identified distinctions in the topology of canonical Wnt beta-catenin-dependent signaling activity and non-canonical beta-catenin-independent Ror2-mediated Wnt signaling across subtypes and within tumor cell subpopulations in vivo. We further discovered an antagonistic role for Ror2 in regulating canonical Wnt/beta-catenin activity in vivo, where lentiviral shRNA depletion of Ror2 expression augmented canonical Wnt/beta-catenin signaling activity across multiple basal-like models. Depletion of Ror2 expression yielded distinct phenotypic outcomes and divergent alterations in gene expression programs among different tumors, despite all sharing basal-like features. Notably, we uncovered cell state plasticity and adhesion dynamics regulated by Ror2, which influenced Ras Homology Family Member A (RhoA) and Rho-Associated Coiled-Coil Kinase 1 (ROCK1) activity downstream of Dishevelled-2 (Dvl2). Collectively, these studies illustrate the integration and collaboration of Wnt pathways in basal-like breast cancer, where Ror2 provides a spatiotemporal function to regulate the balance of Wnt signaling and cellular heterogeneity during tumor progression.	[Roarty, K.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Texas Med Ctr, One Baylor Plaza,M638A, Houston, TX 77030 USA.	jrosen@bcm.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	Dan L. Duncan Cancer Center; John S. Dunn Gulf Coast Consortium for Chemical Genomics; Lester and Sue Smith Breast Center Pathology Core; National Cancer Institute [NCI R01 CA016303-40, NIH R01 CA195754]; Department of Defense [W81XWH-10-0356, NIH CA125123]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007495, P30HD007495] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA195754, R01CA016303, K22CA207463, P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	Dan L. Duncan Cancer Center; John S. Dunn Gulf Coast Consortium for Chemical Genomics; Lester and Sue Smith Breast Center Pathology Core; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was conducted with the help of the Baylor College of Medicine Cytometry and Cell Sorting Core (National Institutes of Health [NIH] P30 AI036211 and S10 RR024574), the Genomics and RNA Profiling Core, the Integrated Microscopy Core (NIH HD007495, DK56338 and CA125123), with funding from the Dan L. Duncan Cancer Center, the John S. Dunn Gulf Coast Consortium for Chemical Genomics and the Lester and Sue Smith Breast Center Pathology Core. We would also like to thank Yiqun Zhang for help and expertise with the microarray analysis. This work was funded by a National Cancer Institute Award NCI R01 CA016303-40 to JMR, NIH R01 CA195754 to CMP and JMR, a Department of Defense Award W81XWH-10-0356 to KPR and NIH CA125123 to CJC.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Aulehla A, 2008, NAT CELL BIOL, V10, P186, DOI 10.1038/ncb1679; Beermann A, 2011, DEVELOPMENT, V138, P2793, DOI 10.1242/dev.063644; Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008-5472.CAN-14-2761; Brechbuhl HM, 2011, AM J PATHOL, V179, P367, DOI 10.1016/j.ajpath.2011.03.016; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108; Creighton CJ, 2008, RNA, V14, P2290, DOI 10.1261/rna.1188208; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Creighton CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034546; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dass RA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006217; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Dembowy J, 2015, ONCOGENE, V34, P3514, DOI 10.1038/onc.2014.279; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Green JL, 2013, P NATL ACAD SCI USA, V110, P6991, DOI 10.1073/pnas.1303671110; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Henry C, 2015, J CANCER RES CLIN, V141, P243, DOI 10.1007/s00432-014-1824-y; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ho HYH, 2012, P NATL ACAD SCI USA, V109, P4044, DOI 10.1073/pnas.1200421109; Huang SX, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r84; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058329; Jonsson M, 2002, CANCER RES, V62, P409; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Lawson CD, 2016, CANCER RES, V76, P3826, DOI 10.1158/0008-5472.CAN-15-2923; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Martelotto LG, 2013, BREAST CANCER RES, V16, P210; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Neisch AL, 2011, CURR OPIN CELL BIOL, V23, P377, DOI 10.1016/j.ceb.2011.04.011; Ng CKY, 2012, EXPERT REV ANTICANC, V12, P1021, DOI [10.1586/ERA.12.85, 10.1586/era.12.85]; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842; Puvirajesinghe TM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10318; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Roarty K, 2015, J CELL BIOL, V208, P351, DOI 10.1083/jcb.201408058; Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Waclaw B, 2015, NATURE, V525, P261, DOI 10.1038/nature14971; Wang JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007963; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]	75	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5958	5968		10.1038/onc.2017.206	http://dx.doi.org/10.1038/onc.2017.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650466	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000413841400005
J	Wang, J; Kho, DH; Zhou, JY; Davis, RJ; Wu, GS				Wang, J.; Kho, D. H.; Zhou, J-Y; Davis, R. J.; Wu, G. S.			MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance	ONCOGENE			English	Article							PROTEIN-KINASE PHOSPHATASE-1; OVARIAN-CANCER CELLS; ADP-RIBOSE POLYMERASE; HUMAN BREAST-CANCER; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; EXCISION-REPAIR; THERAPEUTIC TARGET; DRUG-RESISTANCE; CARCINOMA-CELLS	Understanding the mechanisms of platinum compound resistance, including cisplatin resistance, has important implications for improving cancer treatments. Previous studies identified a potential role for mitogen-activated protein kinase phosphatase-1 (MKP-1) in cisplatin resistance. This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP-1. We found that MKP-1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistance while its downregulation suppresses PARP-1 and PAR protein expression and cisplatin resistance. Silencing MKP-1 promoted PARP-1 ubiquitination, which decreased PARP-1 protein levels. We also found that silencing c-Jun N-terminal kinase 1/2 (JNK1/2) decreased PARP-1 ubiquitination while increasing total PARP-1 protein levels. Furthermore, we showed that acquired cisplatin-resistant ovarian cancer cells expressed high levels of MKP-1 and PARP-1 proteins, and that silencing MKP-1 or PARP-1 increased cisplatin sensitivity in resistant cells. Notably, the pharmacologic inhibition of PARP activity restored cisplatin sensitivity in MKP-1 overexpressing cells. Thus, this work indicates that suppression of JNK1/2 activity by MKP-1 maintains PARP-1 levels and suggests that MKP-1-mediated cisplatin resistance can be bypassed by PARP-1 inhibition.	[Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA; [Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA; [Wang, J.; Kho, D. H.; Zhou, J-Y; Wu, G. S.] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; [Davis, R. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Davis, R. J.] Howard Hughes Med Inst, Worcester, MA USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute	Wu, GS (corresponding author), Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA.; Wu, GS (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.; Wu, GS (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.	wug@karmanos.org		Davis, Roger/0000-0002-0130-1652	NIH [R01CA174949]; NATIONAL CANCER INSTITUTE [P30CA022453, R01CA174949] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was, in part, supported by the NIH (R01CA174949).	Annunziata CM, 2010, CLIN CANCER RES, V16, P4517, DOI 10.1158/1078-0432.CCR-10-0526; Beale PJ, 2000, BRIT J CANCER, V82, P436; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Cheng TC, 2006, CANCER CHEMOTH PHARM, V58, P384, DOI 10.1007/s00280-005-0171-8; Christmann M, 2006, NUCLEIC ACIDS RES, V34, P6530, DOI 10.1093/nar/gkl895; Cullen KJ, 2003, CANCER RES, V63, P8097; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Gagne JP, 2009, J PROTEOME RES, V8, P1014, DOI 10.1021/pr800810n; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; Howell SB, 2010, MOL PHARMACOL, V77, P887, DOI 10.1124/mol.109.063172; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson SW, 1996, EXP CELL RES, V226, P133, DOI 10.1006/excr.1996.0211; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Kuo MT, 2007, CANCER METAST REV, V26, P71, DOI 10.1007/s10555-007-9045-3; Kwong J, 2006, NEOPLASIA, V8, P268, DOI 10.1593/neo.05502; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Perego P, 1996, CANCER RES, V56, P556; Rojo F, 2009, CLIN CANCER RES, V15, P3530, DOI 10.1158/1078-0432.CCR-08-2070; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tomicic MT, 2011, CELL MOL LIFE SCI, V68, P1785, DOI 10.1007/s00018-010-0546-9; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tummala Mohan K, 2005, Clin Adv Hematol Oncol, V3, P723; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wang J, 2016, AUTOPHAGY, V12, P1791, DOI 10.1080/15548627.2016.1203483; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Wang J, 2009, CELL CYCLE, V8, P3191, DOI 10.4161/cc.8.19.9751; Wang ZQ, 2006, CANCER RES, V66, P8870, DOI 10.1158/0008-5472.CAN-06-1280; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wu GS, 2007, CANCER METAST REV, V26, P579, DOI 10.1007/s10555-007-9079-6; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088	52	19	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5939	5947		10.1038/onc.2017.197	http://dx.doi.org/10.1038/onc.2017.197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650468	Green Accepted			2022-12-28	WOS:000413841400003
J	Raja, E; Komuro, A; Tanabe, R; Sakai, S; Ino, Y; Saito, N; Todo, T; Morikawa, M; Aburatani, H; Koinuma, D; Iwata, C; Miyazono, K				Raja, E.; Komuro, A.; Tanabe, R.; Sakai, S.; Ino, Y.; Saito, N.; Todo, T.; Morikawa, M.; Aburatani, H.; Koinuma, D.; Iwata, C.; Miyazono, K.			Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells	ONCOGENE			English	Article							ACTIVATING ACVR1 MUTATIONS; RECEPTOR KINASE INHIBITOR; CANCER STEM-CELLS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; MALIGNANT GLIOMA; VALPROIC ACID; I RECEPTORS; GLIOBLASTOMA; PATHWAY	Bone morphogenetic protein (BMP) signaling exerts antitumor activities in glioblastoma; however, its precise mechanisms remain to be elucidated. Here, we demonstrated that the BMP type I receptor ALK-2 (encoded by the ACVR1 gene) has crucial roles in apoptosis induction of patient-derived glioma-initiating cells (GICs), TGS-01 and TGS-04. We also characterized a BMP target gene, Distal-less homeobox 2 (DLX2), and found that DLX2 promoted apoptosis and neural differentiation of GICs. The tumor-suppressive effects of ALK-2 and DLX2 were further confirmed in a mouse orthotopic transplantation model. Interestingly, valproic acid (VPA), an anti-epileptic compound, induced BMP2, BMP4, ACVR1 and DLX2 mRNA expression with a concomitant increase in phosphorylation of Smad1/5. Consistently, we showed that treatment with VPA induced apoptosis of GICs, whereas silencing of ALK-2 or DLX2 expression partially suppressed it. Our study thus reveals BMP-mediated inhibitory mechanisms for glioblastoma, which explains, at least in part, the therapeutic effects of VPA.	[Raja, E.; Komuro, A.; Tanabe, R.; Sakai, S.; Morikawa, M.; Koinuma, D.; Iwata, C.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; [Ino, Y.; Todo, T.] Univ Tokyo, Inst Med Sci, Div Innovat Canc Therapy, Tokyo, Japan; [Saito, N.] Univ Tokyo, Grad Sch Med, Dept Neurosurg, Tokyo, Japan; [Aburatani, H.] Univ Tokyo, Res Ctr Adv Sci & Technol RCAST, Genome Sci Div, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Morikawa, Masato/D-1932-2011; Koinuma, Daizo/Y-8716-2018	Morikawa, Masato/0000-0002-6191-7176; Koinuma, Daizo/0000-0001-5611-2122; Todo, Tomoki/0000-0003-0523-8010	Ministry of Education, Culture, Sports and Technology of Japan (MEXT) [KAKENHI 22112002]; Japan Society for the Promotion of Science (JSPS) [24390070, 15H05774]; Ministry of Health, Labour and Welfare of Japan [201220012C]; JSPS; Naito Foundation; Grants-in-Aid for Scientific Research [15H05774] Funding Source: KAKEN	Ministry of Education, Culture, Sports and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Naito Foundation(Naito Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Y Kakiuchi for animal care. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI 22112002) from the Ministry of Education, Culture, Sports and Technology of Japan (MEXT) and Scientific Research (B) and (S) (24390070 and 15H05774, respectively, KM) from the Japan Society for the Promotion of Science (JSPS), Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan (201220012C), the JSPS Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signalling', and a grant from the Naito Foundation.	Andrews GL, 2003, MOL CELL NEUROSCI, V23, P107, DOI 10.1016/S1044-7431(03)00016-2; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Bezecny P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0985-5; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Cai J, 2015, STEM CELL REP, V5, P963, DOI 10.1016/j.stemcr.2015.10.020; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choe Y, 2013, J NEUROSCI, V33, P6766, DOI 10.1523/JNEUROSCI.0128-13.2013; Davis H, 2016, CYTOKINE GROWTH F R, V27, P81, DOI 10.1016/j.cytogfr.2015.11.009; Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090; Du Y, 2010, DIFFERENTIATION, V79, P84, DOI 10.1016/j.diff.2009.10.003; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Fontebasso AM, 2014, NAT GENET, V46, P462, DOI 10.1038/ng.2950; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghanem N, 2012, J NEUROSCI, V32, P8219, DOI 10.1523/JNEUROSCI.1344-12.2012; Guichet PO, 2013, GLIA, V61, P225, DOI 10.1002/glia.22429; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Hide T, 2009, CANCER RES, V69, P7953, DOI 10.1158/0008-5472.CAN-09-2006; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hu WX, 2015, CELL STEM CELL, V17, P204, DOI 10.1016/j.stem.2015.07.006; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Jones C, 2012, NAT REV CLIN ONCOL, V9, P400, DOI 10.1038/nrclinonc.2012.87; Katagiri T, 2016, COLD SPRING HARB PER, V8; Kendall SE, 2005, MOL CELL BIOL, V25, P7711, DOI 10.1128/MCB.25.17.7711-7724.2005; Kodama Y, 2015, NUCLEIC ACIDS RES, V43, pD18, DOI 10.1093/nar/gku1120; Krauze AV, 2015, INT J RADIAT ONCOL, V92, P986, DOI 10.1016/j.ijrobp.2015.04.038; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Li H, 2014, J CELL BIOCHEM, V115, P2004, DOI 10.1002/jcb.24872; Liu S, 2016, ONCOTARGET, V7, P17920, DOI 10.18632/oncotarget.7472; Liu S, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-52; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Mehta S, 2011, CANCER CELL, V19, P359, DOI 10.1016/j.ccr.2011.01.035; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Mohedas AH, 2013, ACS CHEM BIOL, V8, P1291, DOI 10.1021/cb300655w; Moon BS, 2009, EXP MOL MED, V41, P116, DOI 10.3858/emm.2009.41.2.014; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Park GT, 2001, FEBS LETT, V496, P60, DOI 10.1016/S0014-5793(01)02398-5; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Podkowa M, 2013, MOL CELL NEUROSCI, V57, P83, DOI 10.1016/j.mcn.2013.10.005; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Santra M, 2006, CANCER RES, V66, P11726, DOI 10.1158/0008-5472.CAN-06-1978; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yu PB, 2008, J BIOL CHEM, V283, P3877, DOI 10.1074/jbc.M706797200; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	59	21	22	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4963	4974		10.1038/onc.2017.112	http://dx.doi.org/10.1038/onc.2017.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459464				2022-12-28	WOS:000408768800002
J	Motzik, A; Amir, E; Erlich, T; Wang, J; Kim, BG; Han, JM; Kim, JH; Nechushtan, H; Guo, M; Razin, E; Tshori, S				Motzik, A.; Amir, E.; Erlich, T.; Wang, J.; Kim, B-G; Han, J. M.; Kim, J. H.; Nechushtan, H.; Guo, M.; Razin, E.; Tshori, S.			Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells	ONCOGENE			English	Article							TRANSFER-RNA SYNTHETASE; MAST-CELLS; TUMOR-SUPPRESSOR; AXONAL NEUROPATHY; GENE-EXPRESSION; GASTRIC-CANCER; PROTEIN; MICROPHTHALMIA; MECHANISM; NEUROMYOTONIA	Microphthalmia transcription factor (MITF) is a basic helix-loop-helix leucine zipper (bHLH-Zip) DNA-binding protein. This transcription factor plays a crucial role in the physiological and pathological functions of distinct cell types. MITF transcriptional activity is inhibited by the histidine triad nucleotide-binding protein 1 (HINT1) through direct binding. We previously reported that this association is disrupted by the binding of the second messenger Ap4A to HINT1. Ap4A is mainly produced in the mammalian cells by S207-phosphorylated Lysyl-tRNA synthetase. In this study, we found first that HINT1 was subjected to K21 acetylation and Y109 phosphorylation in activated mast cells, together with the Ap4A-triggered HINT1 dissociation from MITF. Mutational analysis confirmed that these modifications promote MITF transcriptional and oncogenic activity in melanoma cell lines, derived from human melanoma patients. Thus, we provided here an example that manipulation of the LysRS-Ap4A-HINT1-MITF signalling pathway in melanoma through post-translational modifications of HINT1 can affect the activity of the melanoma oncogene MITF.	[Motzik, A.; Amir, E.; Erlich, T.; Razin, E.] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel; [Wang, J.] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai, Peoples R China; [Kim, B-G] Seoul Natl Univ, Coll Pharm, Med Bioconvergence Res Ctr, Seoul, South Korea; [Han, J. M.] Yonsei Univ, Dept Integrated OMICS Biomed Sci, Seoul, South Korea; [Han, J. M.] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Kim, J. H.] Yonsei Univ, Coll Pharm, Seoul, South Korea; [Nechushtan, H.] Hadassah Hebrew Univ Med Ctr, Oncol Dept, Jerusalem, Israel; [Guo, M.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA; [Tshori, S.] Kaplan Med Ctr, Dept Nucl Med, Rehovot, Israel	Hebrew University of Jerusalem; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; Seoul National University (SNU); Yonsei University; Seoul National University (SNU); Yonsei University; Hebrew University of Jerusalem; Scripps Research Institute; Hebrew University of Jerusalem; Kaplan Medical Center	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	ehudr@ekmd.huji.ac.il	nechushtan, hovav/Z-3564-2019; Amir, Eitan/L-6052-2019	Han, Jung Min/0000-0003-3372-7575; Wang, Jing/0000-0002-7566-1212; Erlich, Tal/0000-0003-0601-2574	National Institute of Health [GM100136]; American Asthma Foundation [AAF15-0080]; National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise); Israel Science Foundation; Israel Cancer Association, Boca Grove Fellowship Fund	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise); Israel Science Foundation(Israel Science Foundation); Israel Cancer Association, Boca Grove Fellowship Fund	We thank Prof Norman Grover from the Hebrew University for conducting the statistical analysis. Patient-derived cutaneous metastatic melanoma cells (line TC-2514) were kindly provided by Dr John Wunderlich (Surgery Branch National Cancer Institute). This work was supported in part by grants from the National Institute of Health GM100136 and American Asthma Foundation AAF15-0080 to MG, and National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise) and Israel Science Foundation to ER and the Israel Cancer Association, Boca Grove Fellowship Fund to ER.	Aminkeng F, 2013, CLIN GENET, V83, P31, DOI 10.1111/cge.12030; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Carmi-Levy I, 2008, MOL CELL BIOL, V28, P5777, DOI 10.1128/MCB.00106-08; Carmi-Levy I, 2011, MOL CELL BIOL, V31, P2111, DOI 10.1128/MCB.01159-10; Chen Q, 2008, SCHIZOPHR RES, V106, P200, DOI 10.1016/j.schres.2008.08.006; Dolot R, 2016, INT J BIOL MACROMOL, V87, P62, DOI 10.1016/j.ijbiomac.2016.02.047; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Genovese G, 2012, CELL CYCLE, V11, P2206, DOI 10.4161/cc.20765; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hori T, 2000, MOL BIOL CELL, V11, P3645, DOI 10.1091/mbc.11.10.3645; Huang HY, 2011, INT J ONCOL, V38, P1557, DOI 10.3892/ijo.2011.994; Jackson KJ, 2011, PHARMACOGENOMICS J, V11, P251, DOI 10.1038/tpj.2010.41; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Lee YN, 2005, MOL CELL BIOL, V25, P8904, DOI 10.1128/MCB.25.20.8904-8912.2005; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Li HY, 2008, J CELL BIOL, V183, P253, DOI 10.1083/jcb.200711150; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nechushtan H, 2002, MOL IMMUNOL, V38, P1177, DOI 10.1016/S0161-5890(02)00059-7; Ofir-Birin Y, 2013, MOL CELL, V49, P30, DOI 10.1016/j.molcel.2012.10.010; RANDERATH K, 1966, BIOCHEM BIOPH RES CO, V24, P98, DOI 10.1016/0006-291X(66)90416-5; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Sonnenblick A, 2005, J IMMUNOL, V175, P1450, DOI 10.4049/jimmunol.175.3.1450; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Swarbrick JD, 2005, J BIOL CHEM, V280, P8471, DOI 10.1074/jbc.M412318200; Tang TY, 2016, ANTICANCER RES, V36, P3229; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325; Yannay-Cohen N, 2009, MOL CELL, V34, P603, DOI 10.1016/j.molcel.2009.05.019; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; Zimon M, 2012, NAT GENET, V44, P1080, DOI 10.1038/ng.2406; Zuk K, 2012, ONCOL LETT, V3, P219, DOI 10.3892/ol.2011.456	37	25	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4732	4738		10.1038/onc.2017.81	http://dx.doi.org/10.1038/onc.2017.81			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394346				2022-12-28	WOS:000407702400006
J	Sechler, M; Parrish, JK; Birks, DK; Jedlicka, P				Sechler, M.; Parrish, J. K.; Birks, D. K.; Jedlicka, P.			The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-GROWTH; TRANSCRIPTIONAL REPRESSION; CANCER METASTASIS; HUMAN-MELANOMA; IN-VITRO; EXPRESSION; CD146; GENE; CARCINOMA	Ewing Sarcoma is the second most common solid pediatric malignant neoplasm of bone and soft tissue. Driven by EWS/Ets, or rarely variant, oncogenic fusions, Ewing Sarcoma is a biologically and clinically aggressive disease with a high propensity for metastasis. However, the mechanisms underpinning Ewing Sarcoma metastasis are currently not well understood. In the present study, we identify and characterize a novel metastasis-promotional pathway in Ewing Sarcoma, involving the histone demethylase KDM3A, previously identified by our laboratory as a new cancer-promoting gene in this disease. Using global gene expression profiling, we show that KDM3A positively regulates genes and pathways implicated in cell migration and metastasis, and demonstrate, using functional assays, that KDM3A promotes migration in vitro and experimental, post-intravasation, metastasis in vivo. We further identify the melanoma cell adhesion molecule (MCAM) as a novel KDM3A target gene in Ewing Sarcoma, and an important effector of KDM3A pro-metastatic action. Specifically, we demonstrate that MCAM depletion, like KDM3A depletion, inhibits cell migration in vitro and experimental metastasis in vivo, and that MCAM partially rescues impaired migration due to KDM3A knock-down. Mechanistically, we show that KDM3A regulates MCAM expression both through a direct mechanism, involving modulation of H3K9 methylation at the MCAM promoter, and an indirect mechanism, via the Ets1 transcription factor. Finally, we identify an association between high MCAM levels in patient tumors and poor survival, in two different Ewing Sarcoma clinical cohorts. Taken together, our studies uncover a new metastasis-promoting pathway in Ewing Sarcoma, with therapeutically targetable components.	[Sechler, M.; Jedlicka, P.] Canc Biol Grad Training Program, Aurora, CO USA; [Sechler, M.; Parrish, J. K.; Birks, D. K.; Jedlicka, P.] Univ Colorado Denver, Anschutz Med Campus, Aurora, CO 80045 USA; [Parrish, J. K.; Jedlicka, P.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA; [Birks, D. K.] Univ Colorado Denver, Dept Neurosurg, Anschutz Med Campus, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Jedlicka, P (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu			Front Range Cancer Challenge; Children's Hospital Colorado Research Institute; University of Colorado School of Medicine Academic Enrichment Funds; Cancer League of Colorado;  [P30-CA046934];  [R01CA183874];  [F31-CA203053]; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA183874, F31CA203053] Funding Source: NIH RePORTER	Front Range Cancer Challenge; Children's Hospital Colorado Research Institute; University of Colorado School of Medicine Academic Enrichment Funds; Cancer League of Colorado; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Elizabeth Wellberg for assistance with gene expression profiling studies; members of the Tobias Neff and Kathrin Bernt laboratories for assistance with ChIP studies; Elizabeth Lawlor at the University of Michigan for the TC32 cell line, and tumor expression profiling and patient outcome data; and Steve Lessnick at Nationwide Children's Hospital for retroviral packaging constructs. We further wish to thank the University of Colorado Cancer Center Flow Cytometry, Functional Genomics, Tissue Culture, DNA Sequencing and Small Animal Imaging Core Facilities, supported by P30-CA046934. Funding support for this work was provided by the Front Range Cancer Challenge, Children's Hospital Colorado Research Institute, University of Colorado School of Medicine Academic Enrichment Funds, and R01CA183874 (PJ); the Cancer League of Colorado (PJ and MS); and F31-CA203053 (MS).	Pavon MA, 2015, ONCOTARGET, V6, P29016, DOI 10.18632/oncotarget.5032; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bardin N, 2009, ARTERIOSCL THROM VAS, V29, P746, DOI 10.1161/ATVBAHA.108.183251; Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007; Chaturvedi Aashi, 2012, Genes Cancer, V3, P102, DOI 10.1177/1947601912457024; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Choy E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-813; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Du C, 2016, FEBS LETT, V590, P408, DOI 10.1002/1873-3468.12069; Esiashvili N, 2008, J PEDIAT HEMATOL ONC, V30, P425, DOI 10.1097/MPH.0b013e31816e22f3; Fadul John, 2015, Genes Cancer, V6, P129; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Gao Y, 2015, ONCOTARGET, V6, P7828, DOI 10.18632/oncotarget.3488; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Grohar PJ, 2013, PHARMACOL THERAPEUT, V137, P216, DOI 10.1016/j.pharmthera.2012.10.004; Habel N, 2015, ONCOGENE, V34, P3207, DOI 10.1038/onc.2014.232; Hansen AG, 2014, CANCER RES, V74, P1404, DOI 10.1158/0008-5472.CAN-13-1296; Heidenreich B, 2014, CURR OPIN GENET DEV, V24, P30, DOI 10.1016/j.gde.2013.11.005; Herr MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067766; Hospital SJCsR, DIS INF; Hou CH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-236; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263; Jouve N, 2015, INT J CANCER, V137, P50, DOI 10.1002/ijc.29370; Jouve N, 2013, J BIOL CHEM, V288, P2571, DOI 10.1074/jbc.M112.418848; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Li L, 2016, MOL MED REP, V14, P521, DOI 10.3892/mmr.2016.5273; Li XC, 2014, CANCER CELL, V25, P575, DOI 10.1016/j.ccr.2014.03.020; Liang XH, 2014, CANCER SCI, V105, P660, DOI 10.1111/cas.12404; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Lin Y, 2007, ANTICANCER RES, V27, P4219; Liu XS, 2015, MOL CANCER RES, V13, P1206, DOI 10.1158/1541-7786.MCR-15-0169; Mahajan K, 2014, J BIOL CHEM, V289, P28179, DOI 10.1074/jbc.M114.584425; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McFarlane S, 2015, ONCOTARGET, V6, P11465, DOI 10.18632/oncotarget.3410; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Miller NLG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037830; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00194, 10.3389/fonc.2012.00003]; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Pa ML, 2016, J MOL HISTOL, V47, P103, DOI 10.1007/s10735-016-9653-8; Park JS, 2016, ONCOTARGET, V7, P42539, DOI 10.18632/oncotarget.9918; Paron I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021684; Parrish JK, 2015, ONCOGENE, V34, P257, DOI 10.1038/onc.2013.541; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Pedersen EA, 2016, CANCER RES, V76, P5040, DOI 10.1158/0008-5472.CAN-15-3422; Peng DH, 2016, ONCOGENE; Penna E, 2013, CANCER RES, V73, P4098, DOI 10.1158/0008-5472.CAN-12-3686; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Ramadoss S., 2016, ONCOGENE; Rappa G, 2015, ONCOTARGET, V6, P7970, DOI 10.18632/oncotarget.3419; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Rodriguez-Galindo C, 2008, ANN ONCOL, V19, P814, DOI 10.1093/annonc/mdm521; Sang Y, 2015, ONCOTARGET, V6, P29240, DOI 10.18632/oncotarget.5074; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schiano C, 2012, MED ONCOL, V29, P2998, DOI 10.1007/s12032-012-0158-3; Shi WD, 2016, ONCOTARGET, V7, P73160, DOI 10.18632/oncotarget.12248; SHIH IM, 1994, CANCER RES, V54, P2514; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763; Steingen C, 2008, J MOL CELL CARDIOL, V44, P1072, DOI 10.1016/j.yjmcc.2008.03.010; Svoboda LK, 2014, EPIGENETICS-US, V9, P1613, DOI 10.4161/15592294.2014.988048; Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785; Tsai HC, 2014, ONCOTARGET, V5, P3800, DOI 10.18632/oncotarget.1998; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Wu GJ, 2008, MOL CANCER RES, V6, P1666, DOI 10.1158/1541-7786.MCR-07-2200; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xie SH, 1997, CANCER RES, V57, P2295; Yang HY, 2015, INT J CLIN EXP PATHO, V8, P11092; Yang J, 2016, ONCOTARGET, V7, P15632, DOI 10.18632/oncotarget.6695; Yu HG, 2011, CANCER RES, V71, P360, DOI 10.1158/0008-5472.CAN-10-2894; Yu XM, 2016, CLIN CANCER RES, V22, P3582, DOI 10.1158/1078-0432.CCR-15-1749; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhan M, 2016, TUMOR BIOL, V37, P11237, DOI 10.1007/s13277-016-4999-9; Zhang X, 2014, CLIN TRANSL ONCOL, V16, P178, DOI 10.1007/s12094-013-1057-6; Zheng LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055719	92	44	45	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4150	4160		10.1038/onc.2017.44	http://dx.doi.org/10.1038/onc.2017.44			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319067	Green Accepted			2022-12-28	WOS:000405835800006
J	Than, BLN; Linnekamp, JF; Starr, TK; Largaespada, DA; Rod, A; Zhang, Y; Bruner, V; Abrahante, J; Schumann, A; Luczak, T; Walter, J; Niemczyk, A; O'Sullivan, MG; Medema, JP; Fijneman, RJA; Meijer, GA; Van den Broek, E; Hodges, CA; Scott, PM; Vermeulen, L; Cormier, RT				Than, B. L. N.; Linnekamp, J. F.; Starr, T. K.; Largaespada, D. A.; Rod, A.; Zhang, Y.; Bruner, V.; Abrahante, J.; Schumann, A.; Luczak, T.; Walter, J.; Niemczyk, A.; O'Sullivan, M. G.; Medema, J. P.; Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.; Hodges, C. A.; Scott, P. M.; Vermeulen, L.; Cormier, R. T.			CFTR is a tumor suppressor gene in murine and human intestinal cancer (vol 35, pg 4179, 2016)	ONCOGENE			English	Correction									[Walter, J.] Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Walter, J (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA.		Starr, Tim/AAX-9342-2021; Fijneman, Remond/X-4199-2019	Fijneman, Remond/0000-0003-2076-5521; Zhang, Ying/0000-0003-3764-7329; Meijer, Gerrit/0000-0003-0330-3130; Medema, Jan Paul/0000-0003-3045-2924				Than BLN, 2016, ONCOGENE, V35, P4191, DOI 10.1038/onc.2015.483	1	13	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3504	3504		10.1038/onc.2017.3	http://dx.doi.org/10.1038/onc.2017.3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28192405	Bronze			2022-12-28	WOS:000403340700013
J	Peng, F; Wang, JH; Fan, WJ; Meng, YT; Li, MM; Li, TT; Cui, B; Wang, HF; Zhao, Y; An, F; Guo, T; Liu, XF; Zhang, L; Lv, L; Lv, DK; Xu, LZ; Xie, JJ; Lin, WX; Lam, EWF; Xu, J; Liu, Q				Peng, F.; Wang, J-H; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; Zhao, Y.; An, F.; Guo, T.; Liu, X-F; Zhang, L.; Lv, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Lin, W-X; Lam, E. W-F; Xu, J.; Liu, Q.			Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia (vol 37, pg 1062, 2017)	ONCOGENE			English	Correction													Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	Biotechnology and Biological Sciences Research Council [1243234, BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; MRC [MR/N012097/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Peng F, 2018, ONCOGENE, V37, P1062, DOI 10.1038/onc.2017.368	1	23	23	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1119	1119		10.1038/onc.2017.407	http://dx.doi.org/10.1038/onc.2017.407			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29251717	hybrid, Green Published			2022-12-28	WOS:000425905700014
J	Kelly, NJ; Varga, JFA; Specker, EJ; Romeo, CM; Coomber, BL; Uniacke, J				Kelly, N. J.; Varga, J. F. A.; Specker, E. J.; Romeo, C. M.; Coomber, B. L.; Uniacke, J.			Hypoxia activates cadherin-22 synthesis via eIF4E2 to drive cancer cell migration, invasion and adhesion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; DOWN-REGULATION; STEM-CELLS; EXPRESSION; GLIOBLASTOMA; METASTASIS; SNAIL; PROTEINS; NECROSIS	Hypoxia is a driver of cell movement in processes such as development and tumor progression. The cellular response to hypoxia involves a transcriptional program mediated by hypoxia-inducible factors, but translational control has emerged as a significant contributor. In this study, we demonstrate that a cell-cell adhesion molecule, cadherin-22, is upregulated in hypoxia via mTORC1-independent translational control by the initiation factor eIF4E2. We identify new functions of cadherin-22 as a hypoxia-specific cell-surface molecule involved in cancer cell migration, invasion and adhesion. Silencing eIF4E2 or cadherin-22 significantly impaired MDA-MB-231 breast carcinoma and U87MG glioblastoma cell migration and invasion only in hypoxia, while reintroduction of the respective exogenous gene restored the normal phenotype. Cadherin-22 was evenly distributed throughout spheroids and required for their formation and support of a hypoxic core. Conversely, E-cadherin translation was repressed by hypoxia and only expressed in the oxygenated cells of U87MG spheroids. Furthermore, immunofluorescence on paraffin-embedded human tissue from 40 glioma and 40 invasive ductal breast carcinoma patient specimens revealed that cadherin-22 expression colocalized with areas of hypoxia and significantly correlated with tumor grade and progression-free survival or stage and tumor size, respectively. This study broadens our understanding of tumor progression and metastasis by highlighting cadherin-22 as a potential new target of cancer therapy to disable hypoxic cancer cell motility and adhesion.	[Kelly, N. J.; Varga, J. F. A.; Specker, E. J.; Romeo, C. M.; Uniacke, J.] Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd East, Guelph, ON N1G 2W1, Canada; [Coomber, B. L.] Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Guelph, ON, Canada	University of Guelph; University of Guelph	Uniacke, J (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd East, Guelph, ON N1G 2W1, Canada.	juniacke@uoguelph.ca	Varga, Joseph/ABD-2277-2021	Varga, Joseph/0000-0001-8516-225X	Canadian Institutes of Health Research [PJT 152925]; Cancer Research Society	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society	We thank Terry Van Raay for the use of his microscope, Scott Ryan and John Vessey for the use of their cryostat, and Marc Coppolino for technical advice and reagents. This work was funded by grants from the Canadian Institutes of Health Research (PJT 152925) and the Cancer Research Society to JU.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beasley GM, 2009, CANCER-AM CANCER SOC, V115, P4766, DOI 10.1002/cncr.24509; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033; Chaudary N, 2009, LAB INVEST, V89, P587, DOI 10.1038/labinvest.2009.16; Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Espina V, 2013, WOMENS HEALTH, V9, P157, DOI [10.2217/whe.13.5, 10.2217/WHE.13.5]; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; FRANKO AJ, 1979, RADIAT RES, V79, P439, DOI 10.2307/3575173; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Ho JJD, 2016, CELL REP, V14, P1293, DOI 10.1016/j.celrep.2016.01.036; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Indovina P, 2008, ANTICANCER RES, V28, P1013; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kuehn BM, 2010, JAMA-J AM MED ASSOC, V303, P925, DOI 10.1001/jama.2010.236; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Martinez-Gonzalez A, 2012, B MATH BIOL, V74, P2875, DOI 10.1007/s11538-012-9786-1; Perotti A, 2009, ANN ONCOL, V20, P741, DOI 10.1093/annonc/mdn695; Piche B, 2011, AM J CANCER RES, V1, P233; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231; Russell J, 2009, INT J RADIAT ONCOL, V73, P1177, DOI 10.1016/j.ijrobp.2008.12.004; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sugimoto K, 1996, J BIOL CHEM, V271, P11548, DOI 10.1074/jbc.271.19.11548; Tee AR, 2004, FEBS LETT, V564, P58, DOI 10.1016/S0014-5793(04)00313-8; Timpano S, 2016, J BIOL CHEM, V291, P10772, DOI 10.1074/jbc.M116.717363; Uniacke J, 2014, CANCER RES, V74, P1379, DOI 10.1158/0008-5472.CAN-13-2278; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wu J, 2003, J ENDOCRINOL, V176, P381, DOI 10.1677/joe.0.1760381; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2009, TUMOR BIOL, V30, P130, DOI 10.1159/000225242; Zhu Y, 2013, ANAT REC, V296, P1850, DOI 10.1002/ar.22821	60	27	27	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					651	662		10.1038/onc.2017.372	http://dx.doi.org/10.1038/onc.2017.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991229	Green Accepted			2022-12-28	WOS:000423812200010
J	Rowson-Hodel, AR; Wald, JH; Hatakeyama, J; O'Neal, WK; Stonebraker, JR; VanderVorst, K; Saldana, MJ; Borowsky, AD; Sweeney, C; Carraway, KL				Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; O'Neal, W. K.; Stonebraker, J. R.; VanderVorst, K.; Saldana, M. J.; Borowsky, A. D.; Sweeney, C.; Carraway, K. L., III			Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer	ONCOGENE			English	Article							SIALOMUCIN COMPLEX; PANCREATIC-CANCER; MUC4/SIALOMUCIN COMPLEX; INTRAMEMBRANE MODULATOR; MESENCHYMAL TRANSITION; TRANSGENIC MICE; EXPRESSION; GROWTH; HER2; OVEREXPRESSION	Mucin-4 (Muc4) is a large cell surface glycoprotein implicated in the protection and lubrication of epithelial structures. Previous studies suggest that aberrantly expressed Muc4 can influence the adhesiveness, proliferation, viability and invasiveness of cultured tumor cells, as well as the growth rate and metastatic efficiency of xenografted tumors. Although it has been suggested that one of the major mechanisms by which Muc4 potentiates tumor progression is via its engagement of the ErbB2/HER2 receptor tyrosine kinase, other mechanisms exist and remain to be delineated. Moreover, the requirement for endogenous Muc4 for tumor growth progression has not been previously explored in the context of gene ablation. To assess the contribution of endogenous Muc4 to mammary tumor growth properties, we first created a genetically engineered mouse line lacking functional Muc4 (Muc4(ko)), and then crossed these animals with the NDL (Neu DeLetion mutant) model of ErbB2-induced mammary tumorigenesis. We observed that Muc4ko animals are fertile and develop normally, and adult mice exhibit no overt tissue abnormalities. In tumor studies, we observed that although some markers of tumor growth such as vascularity and cyclin D1 expression are suppressed, primary mammary tumors from Muc4(ko)/NDL female mice exhibit similar latencies and growth rates as Muc4(wt)/NDL animals. However, the presence of lung metastases is markedly suppressed in Muc4(ko)/NDL mice. Interestingly, histological analysis of lung lesions from Muc4(ko)/NDL mice revealed a reduced association of disseminated cells with platelets and white blood cells. Moreover, isolated cells derived from Muc4(ko)/NDL tumors interact with fewer blood cells when injected directly into the vasculature or diluted into blood from wild type mice. We further observed that blood cells more efficiently promote the viability of non-adherent Muc4(wt)/NDL cells than Muc4(ko)/NDL cells. Together, our observations suggest that Muc4 may facilitate metastasis by promoting the association of circulating tumor cells with blood cells to augment tumor cell survival in circulation.	[Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; VanderVorst, K.; Saldana, M. J.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA; [Rowson-Hodel, A. R.; Wald, J. H.; Hatakeyama, J.; VanderVorst, K.; Saldana, M. J.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA; [O'Neal, W. K.; Stonebraker, J. R.] Univ North Carolina Chapel Hill, Sch Med, UNC Cyst Fibrosis Res Ctr, Marsico Lung Inst, Chapel Hill, NC USA; [Borowsky, A. D.] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California Davis	Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.; Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.	klcarraway@ucdavis.edu	Rowson-Hodel, Ashley/AAE-2619-2022	Rowson-Hodel, Ashley/0000-0003-0531-9929; Hatakeyama, Jason/0000-0001-8690-5107	NIH [R01 CA166412, R01 CA118384, P01 HL110873, T32 CA108459, F31 CA210467, F31 CA165758, P30 CA093373, P30 DK065988]; Department of Defense fellowship [W81XWH-111-0065]; Cystic Fibrosis Foundation [BOUCHE15R0]; NATIONAL CANCER INSTITUTE [R01CA166412, R01CA118384, P30CA093373, T32CA108459] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL110873] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense fellowship(United States Department of Defense); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We wish to thank the histology core facility at UC Davis for embedding services and slide preparation, the UC Davis animal facilities for routine management of mouse colonies, the UC Davis Mouse Biology Program for breeding assistance, and Lakmal Kotelawala, Maxine Umeh-Garcia, and Heather Workman for technical assistance. These studies were supported by NIH grants R01 CA166412 (KLC), R01 CA118384 (CS), and P01 HL110873 (WKO), NIH fellowships and training grants T32 CA108459 (ARRH), F31 CA210467 (KVV), and F31 CA165758 (JH), NIH Center grants P30 CA093373 and P30 DK065988, Department of Defense fellowship W81XWH-111-0065 (JHW), and a grant from the Cystic Fibrosis Foundation BOUCHE15R0 (WKO).	Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Damsgaard CT, 2009, J IMMUNOL METHODS, V340, P95, DOI 10.1016/j.jim.2008.10.005; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; Fujita N, 2012, J BIOCHEM, V152, P407, DOI 10.1093/jb/mvs108; Funes M, 2006, J BIOL CHEM, V281, P19310, DOI 10.1074/jbc.M603225200; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Gil-Bernabe AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hauselmann I, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00028; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hu QY, 2015, ADV MATER, V27, P7043, DOI 10.1002/adma.201503323; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Li JH, 2016, J CONTROL RELEASE, V228, P38, DOI 10.1016/j.jconrel.2016.02.036; Li JH, 2016, BIOMATERIALS, V76, P52, DOI 10.1016/j.biomaterials.2015.10.046; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Lundmark A, 2015, SCI REP-UK, V5, DOI 10.1038/srep18475; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mitjavila-Garcia MT, 2002, DEVELOPMENT, V129, P2003; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mohanty S, 2010, EXPT METASTASIS ASSA, pe1942; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-7; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Rowson-Hodel AR, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1572-7; Rowson-Hodel AR, 2016, CANCER LETT, V375, P62, DOI 10.1016/j.canlet.2016.02.042; Senapati S, 2011, CLIN CANCER RES, V17, P267, DOI 10.1158/1078-0432.CCR-10-1937; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Tan M, 1997, CANCER RES, V57, P1199; Wald JH, 2017, ONCOGENE, V36, P5158, DOI 10.1038/onc.2017.126; Workman HC, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2364; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089; Yokdang N, 2016, ONCOGENE, V35, P2932, DOI 10.1038/onc.2015.345; Zhang J, 2005, J CELL PHYSIOL, V204, P166, DOI 10.1002/jcp.20277; Zhang J, 2006, CURR EYE RES, V31, P1011, DOI 10.1080/02713680601052155; Zhao QC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-154; Zhi XF, 2014, CANCER LETT, V346, P104, DOI 10.1016/j.canlet.2013.12.021	56	27	28	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					197	207		10.1038/onc.2017.327	http://dx.doi.org/10.1038/onc.2017.327			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892049	Green Submitted, Green Accepted			2022-12-28	WOS:000422631700006
J	Gonyo, P; Bergom, C; Brandt, AC; Tsaih, SW; Sun, Y; Bigley, TM; Lorimer, EL; Terhune, SS; Rui, H; Flister, MJ; Long, RM; Williams, CL				Gonyo, P.; Bergom, C.; Brandt, A. C.; Tsaih, S-W; Sun, Y.; Bigley, T. M.; Lorimer, E. L.; Terhune, S. S.; Rui, H.; Flister, M. J.; Long, R. M.; Williams, C. L.			SmgGDS is a transient nucleolar protein that protects cells from nucleolar stress and promotes the cell cycle by regulating DREAM complex gene expression	ONCOGENE			English	Article							RNA-POLYMERASE-I; C-MYC; RIBOSOME BIOGENESIS; EMERGING TARGET; BRAIN CYTOSOL; TRANSCRIPTION; BINDING; UBF; GROWTH; LUNG	The chaperone protein and guanine nucleotide exchange factor SmgGDS (RAP1GDS1) is a key promoter of cancer cell proliferation and tumorigenesis. SmgGDS undergoes nucleocytoplasmic shuttling, suggesting that it has both cytoplasmic and nuclear functions that promote cancer. Previous studies indicate that SmgGDS binds cytoplasmic small GTPases and promotes their trafficking to the plasma membrane. In contrast, little is known about the functions of SmgGDS in the nucleus, or how these nuclear functions might benefit cancer cells. Here we show unique nuclear localization and regulation of gene transcription pathways by SmgGDS. Strikingly, SmgGDS depletion significantly reduces expression of over 600 gene products that are targets of the DREAM complex, which is a transcription factor complex that regulates expression of proteins controlling the cell cycle. The cell cycle regulators E2F1, MYC, MYBL2 (B-Myb) and FOXM1 are among the DREAM targets that are diminished by SmgGDS depletion. E2F1 is well known to promote G1 cell cycle progression, and the loss of E2F1 in SmgGDS-depleted cells provides an explanation for previous reports that SmgGDS depletion characteristically causes a G1 cell cycle arrest. We show that SmgGDS localizes in nucleoli, and that RNAimediated depletion of SmgGDS in cancer cells disrupts nucleolar morphology, signifying nucleolar stress. We show that nucleolar SmgGDS interacts with the RNA polymerase I transcription factor upstream binding factor (UBF). The RNAi-mediated depletion of UBF diminishes nucleolar localization of SmgGDS and promotes proteasome-mediated degradation of SmgGDS, indicating that nucleolar sequestration of SmgGDS by UBF stabilizes SmgGDS protein. The ability of SmgGDS to interact with UBF and localize in the nucleolus is diminished by expressing DiRas1 or DiRas2, which are small GTPases that bind SmgGDS and act as tumor suppressors. Taken together, our results support a novel nuclear role for SmgGDS in protecting malignant cells from nucleolar stress, thus promoting cell cycle progression and tumorigenesis.	[Gonyo, P.; Brandt, A. C.; Lorimer, E. L.; Williams, C. L.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Gonyo, P.; Bergom, C.; Brandt, A. C.; Lorimer, E. L.; Rui, H.; Flister, M. J.; Williams, C. L.] Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA; [Bergom, C.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA; [Tsaih, S-W; Flister, M. J.] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Sun, Y.; Rui, H.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Bigley, T. M.; Terhune, S. S.; Long, R. M.] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI 53226 USA; [Bigley, T. M.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Terhune, S. S.] Med Coll Wisconsin, Biotechnol & Bioengn Ctr, Milwaukee, WI 53226 USA; [Flister, M. J.] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA; [Flister, M. J.; Williams, C. L.] Med Coll Wisconsin, Cardiovasc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Long, R. M.] Med Coll Wisconsin, Cent Wisconsin Campus, Wausau, WI USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Washington University (WUSTL); Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Williams, CL (corresponding author), Med Coll Wisconsin, Cardiovasc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Williams, CL (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, Canc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	williams@mcw.edu		Rui, Hallgeir/0000-0002-8778-261X; Bigley, Tarin/0000-0001-7443-9436; Sun, Yunguang/0000-0003-4004-9514; Bergom, Carmen/0000-0002-0886-5055	NCI [R01 CA188871, R01 CA193343, R01 CA188575]; NIAID [R01 AI083281]; American Cancer Society [86-004-26]; Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award; Mary Kay Foundation [024.16]; Nancy Laning Sobczak, PhD, Breast Cancer Research Award; National Center for Research Resources; National Center for Advancing Translational Sciences; Office of the Director of the National Institutes of Health [8KL2TR000056]; NATIONAL CANCER INSTITUTE [R01CA188871, R01CA193343, R01CA188575] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083281] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Cancer Society(American Cancer Society); Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award; Mary Kay Foundation; Nancy Laning Sobczak, PhD, Breast Cancer Research Award; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Office of the Director of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Aniko Szabo (Medical College of Wisconsin) for assistance with statistical analysis. This work was supported by NCI R01 CA188871 (CLW), NCI R01 CA193343 (MJF), NIAID R01 AI083281 (SST), NCI R01 CA188575 (HR) and Institutional Research Grant 86-004-26 from the American Cancer Society (CB). Additional support was provided by the Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award (CLW), the Mary Kay Foundation Award Grant No. 024.16 (MJF), the Nancy Laning Sobczak, PhD, Breast Cancer Research Award (CB and CLW), and by the National Center for Research Resources, the National Center for Advancing Translational Sciences and the Office of the Director of the National Institutes of Health through Grant 8KL2TR000056 (CB).	Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Berg TJ, 2010, J BIOL CHEM, V285, P35255, DOI 10.1074/jbc.M110.129916; Bergom C, 2016, J BIOL CHEM, V291, P10948, DOI 10.1074/jbc.A115.696831; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chen DY, 2004, P NATL ACAD SCI USA, V101, P15106, DOI 10.1073/pnas.0404767101; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 2004, J CLIN PATHOL, V57, P755, DOI 10.1136/jcp.2003.015917; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Donati G, 2011, J CELL SCI, V124, P3017, DOI 10.1242/jcs.086074; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Grummt I, 2013, CHROMOSOMA, V122, P487, DOI 10.1007/s00412-013-0430-0; Hamdane N, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004505; Hauser AD, 2014, MOL CANCER RES, V12, P130, DOI 10.1158/1541-7786.MCR-13-0362; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Holmberg Olausson Karl, 2012, Cells, V1, P774, DOI 10.3390/cells1040774; James A, 2014, NUCLEUS-PHILA, V5, P402, DOI 10.4161/nucl.32235; Justilien V, 2017, CANCER CELL, V31, P256, DOI 10.1016/j.ccell.2016.12.010; Kontani K, 2002, J BIOL CHEM, V277, P41070, DOI 10.1074/jbc.M202150200; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Nguyen LXT, 2013, P NATL ACAD SCI USA, V110, P20681, DOI 10.1073/pnas.1313097110; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; McStay B, 2016, GENE DEV, V30, P1598, DOI 10.1101/gad.283838.116; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Ogita Y, 2015, J BIOL CHEM, V290, P20245, DOI 10.1074/jbc.M115.637769; Panov KI, 2006, EMBO J, V25, P3310, DOI 10.1038/sj.emboj.7601221; Pich A, 2000, MICRON, V31, P133, DOI 10.1016/S0968-4328(99)00070-0; Portella G, 2011, CURR MED CHEM, V18, P482, DOI 10.2174/092986711794480203; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/NMETH.2251, 10.1038/nmeth.2251]; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanij E, 2009, EPIGENETICS-US, V4, P274, DOI 10.4161/epi.4.6.9449; Sanij E, 2008, J CELL BIOL, V183, P1259, DOI 10.1083/jcb.200805146; Schuld NJ, 2014, CELL CYCLE, V13, P941, DOI 10.4161/cc.27804; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Stefanovsky V, 2006, MOL CELL, V21, P629, DOI 10.1016/j.molcel.2006.01.023; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Tew GW, 2008, J BIOL CHEM, V283, P963, DOI 10.1074/jbc.M707526200; Thoms HC, 2010, CANCER RES, V70, P139, DOI 10.1158/0008-5472.CAN-09-1397; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Woods SJ, 2015, BBA-GENE REGUL MECH, V1849, P821, DOI 10.1016/j.bbagrm.2014.10.007; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Zhang YD, 2011, MOL CELL BIOL, V31, P4676, DOI 10.1128/MCB.05832-11; Zhi H, 2009, J PATHOL, V217, P389, DOI 10.1002/path.2456; Zhu YH, 2013, CANCER RES, V73, P2298, DOI 10.1158/0008-5472.CAN-12-2663	70	9	9	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6873	6883		10.1038/onc.2017.280	http://dx.doi.org/10.1038/onc.2017.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28806394	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000418041800004
J	Hsu, FF; Chiang, MT; Li, FA; Yeh, CT; Lee, WH; Chau, LY				Hsu, F-F; Chiang, M-T; Li, F-A; Yeh, C-T; Lee, W-H; Chau, L-Y			Acetylation is essential for nuclear heme oxygenase-1-enhanced tumor growth and invasiveness	ONCOGENE			English	Article							SIGNAL PEPTIDE PEPTIDASE; CHRONIC MYELOID-LEUKEMIA; PROSTATE-CANCER CELLS; CONFERS RESISTANCE; HDAC INHIBITORS; LUNG-CANCER; PROLIFERATION; INVASION; JUND; TRANSCRIPTION	Overexpression of heme oxygenase-1 (HO-1), an endoplasmic reticulum-anchored enzyme, is observed in many cancers. HO-1 nuclear translocation has been shown to correlate with progression of several cancers. We recently reported that HO-1 is susceptible to intramembrane proteolysis and translocates to the nucleus to promote cancer growth and invasiveness without depending on its enzymatic activity. In the present study, we show that the HO-1 lacking C-terminal transmembrane segment (t-HO-1) was susceptible to acetylation by p300 and CREB-binding protein (CBP) histone acetyltransferase in the nucleus. Mass spectrometry analysis of HO-1 isolated from human embryonic kidney cells 293T (HEK293T) cells overexpressing CBP and t-HO-1 revealed two acetylation sites located at K243 and K256. Mutation of both lysine residues to arginine (R) abolished t-HO-1-enhanced tumor cell growth, migration and invasion. However, mutation of the lysine residues to glutamine (Q), a mimic of acetylated lysine, had no significant effect on t-HO-1-mediated tumorigenicity. Mechanistic studies demonstrated that transcriptional factor JunD interacted with wild-type (WT) t-HO-1 and mutant carrying K243/256Q but not K243/256 R mutation. Moreover, JunD-induced AP-1 transcriptional activity was significantly enhanced by coexpression with WT and acetylation-mimic but not acetylation-defective t-HO-1. Consistent with the in vitro observations, the implication of K243/256 acetylation in t-HO-1-enhanced tumorigenicity was also demonstrated in xenograft models. Immunohistochemistry performed with a specific antibody against acetyl-HO-1 showed the positive acetyl-HO-1 nuclear staining in human lung cancer tissues but not in the corresponding non-tumor tissues, supporting its clinical significance. Collectively, our findings highlight the importance of nuclear HO-1 post-translational modification in the induction of cancer progression.	[Hsu, F-F; Chiang, M-T; Li, F-A; Chau, L-Y] Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan; [Yeh, C-T; Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Canc Ctr, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	Ministry of Science and Technology Taiwan [MOST 103-2320-B-001-013-MY3]; IBMS proteomics core	Ministry of Science and Technology Taiwan(Ministry of Science and Technology, Taiwan); IBMS proteomics core	This work was supported by the Ministry of Science and Technology Taiwan (MOST 103-2320-B-001-013-MY3). We thank IBMS proteomics core for the LC-MS analysis.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Biswas C, 2014, J BIOL CHEM, V289, P26882, DOI 10.1074/jbc.M114.567685; Boname JM, 2014, J CELL BIOL, V205, P847, DOI 10.1083/jcb.201312009; Chau LY, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0128-0; Collinson EJ, 2011, J BIOL CHEM, V286, P2205, DOI 10.1074/jbc.M110.187062; Das C, 2005, IUBMB LIFE, V57, P137, DOI 10.1080/15216540500090629; Degese MS, 2012, LUNG CANCER, V77, P168, DOI 10.1016/j.lungcan.2012.02.016; Di Biase S, 2016, CANCER CELL, V30, P136, DOI 10.1016/j.ccell.2016.06.005; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Hanna Colton, 2016, J Vis Exp, DOI 10.3791/54944; Hernandez JM, 2008, ONCOGENE, V27, P4757, DOI 10.1038/onc.2008.120; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hsu FF, 2015, ONCOGENE, V34, P2360, DOI 10.1038/onc.2014.166; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Kajanne R, 2009, INT J ONCOL, V35, P1175, DOI 10.3892/ijo_00000434; Kaypee S, 2016, PHARMACOL THERAPEUT, V162, P98, DOI 10.1016/j.pharmthera.2016.01.011; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Lin KT, 2012, CLIN CANCER RES, V18, P4691, DOI 10.1158/1078-0432.CCR-12-0633; Lin PH, 2013, ONCOGENE, V32, P2325, DOI 10.1038/onc.2012.244; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Millena AC, 2016, J BIOL CHEM, V291, P17964, DOI 10.1074/jbc.M116.714899; Miyake M, 2011, ONCOL REP, V25, P653, DOI 10.3892/or.2010.1125; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Otterbein LE, 2011, P NATL ACAD SCI USA, V108, P14491, DOI 10.1073/pnas.1102295108; Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200; Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tibullo D, 2016, ONCOTARGET, V7, P28868, DOI 10.18632/oncotarget.7563; Tibullo D, 2013, CURR PHARM DESIGN, V19, P2765, DOI 10.2174/1381612811319150012; Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931; Wang D, 2008, BIOTECH HISTOCHEM, V83, P179, DOI 10.1080/10520290802451085; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551; Wegiel B, 2013, CANCER RES, V73, P7009, DOI 10.1158/0008-5472.CAN-13-1075; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920; Xu L, 2015, ONCOL REP, V33, P1057, DOI 10.3892/or.2014.3680; Zerbini LF, 2011, CELL CYCLE, V10, P2583, DOI 10.4161/cc.10.15.16057; Zhang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2350-x	44	22	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6805	6814		10.1038/onc.2017.294	http://dx.doi.org/10.1038/onc.2017.294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846111				2022-12-28	WOS:000417282500006
J	Heilmann, K; Toth, R; Bossmann, C; Klimo, K; Plass, C; Gerhauser, C				Heilmann, K.; Toth, R.; Bossmann, C.; Klimo, K.; Plass, C.; Gerhauser, C.			Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAMMALIAN EXPRESSION ATLAS; ENGINEERED MOUSE MODELS; TUMOR-SUPPRESSOR GENE; MAMMARY ADENOCARCINOMA; CPG METHYLATION; BONE METASTASIS; SEQUENCING DATA; SEQ EXPERIMENTS; STEM-CELLS	The majority of long noncoding RNAs (lncRNAs) is still poorly characterized with respect to function, interactions with protein-coding genes, and mechanisms that regulate their expression. As for protein-coding RNAs, epigenetic deregulation of lncRNA expression by alterations in DNA methylation might contribute to carcinogenesis. To provide genome-wide information on lncRNAs aberrantly methylated in breast cancer we profiled tumors of the C3(1) SV40TAg mouse model by MCIp-seq (Methylated CpG Immunoprecipitation followed by sequencing). This approach detected 69 lncRNAs differentially methylated between tumor tissue and normal mammary glands, with 26 located in antisense orientation of a protein-coding gene. One of the hypomethylated lncRNAs, 1810019D21Rik (now called Esrp2-antisense (as)) was identified in proximity to the epithelial splicing regulatory protein 2 (Esrp2) that is significantly elevated in C3(1) tumors. ESRPs were shown previously to have a dual role in carcinogenesis. Both gain and loss have been associated with poor prognosis in human cancers, but the mechanisms regulating expression are not known. Indepth analyses indicate that coordinate overexpression of Esrp2 and Esrp2-as inversely correlates with DNA methylation. Luciferase reporter gene assays support co-expression of Esrp2 and the major short Esrp2-as variant from a bidirectional promoter, and transcriptional regulation by methylation of a proximal enhancer. Ultimately, this enhancer-based regulatory mechanism provides a novel explanation for tissue-specific expression differences and upregulation of Esrp2 during carcinogenesis. Knockdown of Esrp2-as reduced Esrp2 protein levels without affecting mRNA expression and resulted in an altered transcriptional profile associated with extracellular matrix (ECM), cell motility and reduced proliferation, whereas overexpression enhanced proliferation. Our findings not only hold true for the murine tumor model, but led to the identification of an unannotated human homolog of Esrp2-as which is significantly upregulated in human breast cancer and associated with poor prognosis.	[Heilmann, K.; Toth, R.; Bossmann, C.; Klimo, K.; Plass, C.; Gerhauser, C.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gerhauser, C (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, BW, Germany.	c.gerhauser@dkfz.de	Toth, Reka/AAB-1695-2020	Toth, Reka/0000-0002-6096-1052; Plass, Christoph/0000-0003-2554-3952; Gerhauser, Clarissa/0000-0002-5792-3901	DKFZ Helmholtz International Graduate School for Cancer Research	DKFZ Helmholtz International Graduate School for Cancer Research	KH was supported by a Ph.D. scholarship provided by the DKFZ Helmholtz International Graduate School for Cancer Research. We are grateful to Megumio Onishi Seebacher for providing barcoded oligonucleotide sequences, the Genome and Proteome core facility of the DKFZ for providing technical support and excellent MCIp-seq and RNA-seq services, and Lorena Salgueiro and Rocio Sotillo Roman for their instant support in isolating murine mammary epithelial cells and fibroblasts. We further want to thank Oliver Mucke and Monika Helf for excellent technical assistance, and Thomas Risch, Maiwen Caudron-Herger, Odilia Popanda and Dieter Weichenhan for helpful discussion. The results reported here are in part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; Asch-Kendrick R, 2016, HUM PATHOL, V48, P37, DOI 10.1016/j.humpath.2015.09.035; Baer C, 2015, INT J CANCER, V137, P1352, DOI 10.1002/ijc.29491; Bai YG, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0079-7; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Batts TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027841; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bennett CN, 2010, TOXICOL PATHOL, V38, P88, DOI 10.1177/0192623309357074; Bennett CN, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2125; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; Deloria AJ, 2016, ONCOTARGET, V7, P73800, DOI 10.18632/oncotarget.12070; Di Palma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.262; Diederichs S, 2014, TRENDS GENET, V30, P121, DOI 10.1016/j.tig.2014.01.004; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105; Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gottgens EL, 2016, INT REV CEL MOL BIO, V327, P163, DOI 10.1016/bs.ircmb.2016.06.003; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Guil S, 2012, NAT STRUCT MOL BIOL, V19, P1068, DOI 10.1038/nsmb.2428; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayakawa A, 2016, ADV EXP MED BIOL, V925, P33; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Hu GZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107016; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huang HY, 2013, CLIN CANCER RES, V19, P2861, DOI 10.1158/1078-0432.CCR-12-2641; Hwang JA, 2013, ONCOTARGET, V4, P2317, DOI 10.18632/oncotarget.1464; Hynes RO, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a004903; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Iwakiri M, 2009, NEUROPATHOLOGY, V29, P263, DOI 10.1111/j.1440-1789.2008.00978.x; Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Lee C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-37; Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LI Y, 2015, SCI REP UK, V5; Lienhard M, 2014, BIOINFORMATICS, V30, P284, DOI 10.1093/bioinformatics/btt650; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003; Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082; Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566; Pappa G, 2007, CARCINOGENESIS, V28, P1471, DOI 10.1093/carcin/bgm044; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Punj V, 2010, CLIN CANCER RES, V16, P1140, DOI 10.1158/1078-0432.CCR-09-2463; Qin D, 2015, CELL MOL BIOL LETT, V20, P323, DOI 10.1515/cmble-2015-0021; Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47; Reaves DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091747; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sahu A, 2015, TRENDS CANCER, V1, P93, DOI 10.1016/j.trecan.2015.08.010; Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Sonnet Miriam, 2013, Methods Mol Biol, V971, P201, DOI 10.1007/978-1-62703-269-8_11; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun H, 2016, J CELL MOL MED, V20, P1234, DOI 10.1111/jcmm.12783; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tseng YY, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.974467; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851; Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xu Z, 2014, ONCOGENE, V33, P2836, DOI 10.1038/onc.2013.243; Yang F, 2017, CELL MOL LIFE SCI, V74, P951, DOI 10.1007/s00018-016-2334-7; Yao Y, 2010, CARCINOGENESIS, V31, P382, DOI 10.1093/carcin/bgp308; Yarmishyn AA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S9-S7; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu HS, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-251; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	119	50	54	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6446	6461		10.1038/onc.2017.246	http://dx.doi.org/10.1038/onc.2017.246			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759043	hybrid, Green Published			2022-12-28	WOS:000415622900008
J	Peters, AA; Jamaludin, SYN; Yapa, KTDS; Chalmers, S; Wiegmans, AP; Lim, HF; Milevskiy, MJG; Azimi, I; Davis, FM; Northwood, KS; Pera, E; Marcial, DL; Dray, E; Waterhouse, NJ; Cabot, PJ; Gonda, TJ; Kenny, PA; Brown, MA; Khanna, KK; Roberts-Thomson, SJ; Monteith, GR				Peters, A. A.; Jamaludin, S. Y. N.; Yapa, K. T. D. S.; Chalmers, S.; Wiegmans, A. P.; Lim, H. F.; Milevskiy, M. J. G.; Azimi, I.; Davis, F. M.; Northwood, K. S.; Pera, E.; Marcial, D. L.; Dray, E.; Waterhouse, N. J.; Cabot, P. J.; Gonda, T. J.; Kenny, P. A.; Brown, M. A.; Khanna, K. K.; Roberts-Thomson, S. J.; Monteith, G. R.			Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells	ONCOGENE			English	Article							NEURONAL DEGENERATION; MOLECULAR-MECHANISMS; PROSTATE-CANCER; CALCIUM; DEATH; EXPRESSION; NECROSIS; TUMORS; CONSEQUENCES; HOMEOSTASIS	The critical role of calcium signalling in processes related to cancer cell proliferation and invasion has seen a focus on pharmacological inhibition of overexpressed ion channels in specific cancer subtypes as a potential therapeutic approach. However, despite the critical role of calcium in cell death pathways, pharmacological activation of overexpressed ion channels has not been extensively evaluated in breast cancer. Here we define the overexpression of transient receptor potential vanilloid 4 (TRPV4) in a subgroup of breast cancers of the basal molecular subtype. We also report that pharmacological activation of TRPV4 with GSK1016790A reduced viability of two basal breast cancer cell lines with pronounced endogenous overexpression of TRPV4, MDA-MB-468 and HCC1569. Pharmacological activation of TRPV4 produced pronounced cell death through two mechanisms: apoptosis and oncosis in MDA-MB-468 cells. Apoptosis was associated with PARP-1 cleavage and oncosis was associated with a rapid decline in intracellular ATP levels, which was a consequence of, rather than the cause of, the intracellular ion increase. TRPV4 activation also resulted in reduced tumour growth in vivo. These studies define a novel therapeutic strategy for breast cancers that overexpress specific calcium permeable plasmalemmal ion channels with available selective pharmacological activators.	[Peters, A. A.; Jamaludin, S. Y. N.; Yapa, K. T. D. S.; Chalmers, S.; Lim, H. F.; Azimi, I.; Davis, F. M.; Pera, E.; Marcial, D. L.; Cabot, P. J.; Gonda, T. J.; Roberts-Thomson, S. J.; Monteith, G. R.] Univ Queensland, Sch Pharm, 20 Cornwall St, Brisbane, Qld 4102, Australia; [Wiegmans, A. P.] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Brisbane, Qld, Australia; [Milevskiy, M. J. G.; Northwood, K. S.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Azimi, I.; Davis, F. M.; Monteith, G. R.] Univ Queensland, Translat Res Inst, Mater Res Inst, Brisbane, Qld, Australia; [Dray, E.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Dray, E.] Queensland Univ Technol, Translat Res Inst, Sch Biomed Sci, Brisbane, Qld, Australia; [Waterhouse, N. J.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Brisbane, Qld, Australia; [Kenny, P. A.] Gunderson Med Fdn, Kabara Canc Res Inst, La Crosse, WI USA; [Jamaludin, S. Y. N.] Univ Sultan Zainal Abidin, Fac Med, Kuala Terengganu, Terengganu, Malaysia	University of Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; Mater Research; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); QIMR Berghofer Medical Research Institute; Universiti Sultan Zainal Abidin	Monteith, GR (corresponding author), Univ Queensland, Sch Pharm, 20 Cornwall St, Brisbane, Qld 4102, Australia.	gregm@uq.edu.au	Dray, Eloise/AAD-5147-2021; Brown, Melissa A/F-1451-2010; Roberts-Thomson, Sarah J/B-4282-2011; Peters, Amelia/AAP-3886-2021; Roberts-Thomson, Sarah/W-5676-2019; Davis, Felicity M/P-1387-2016; Cabot, Peter John/B-2424-2013; Peters, Amelia A/E-4254-2010; Chalmers, Silke/Q-5731-2019; Monteith, Gregory/B-1626-2008; Chalmers, Silke/GQH-6183-2022; Dray, Eloise/E-3938-2012; Azimi, Iman/E-2043-2011	Roberts-Thomson, Sarah J/0000-0001-8202-5786; Peters, Amelia/0000-0002-0700-7817; Roberts-Thomson, Sarah/0000-0001-8202-5786; Davis, Felicity M/0000-0001-9112-118X; Cabot, Peter John/0000-0003-1778-3753; Monteith, Gregory/0000-0002-4345-530X; Dray, Eloise/0000-0001-6793-9838; Chalmers, Silke/0000-0002-5874-7540; Northwood, Korinne/0000-0001-6268-547X; Brown, Melissa/0000-0002-2830-9259; Jamaludin, Siti Yusrina Nadihah/0000-0002-8006-1406; Gonda, Thomas/0000-0002-8792-3021; Azimi, Iman/0000-0001-9477-9999; Khanna, Kum Kum/0000-0001-8650-5381	National Health and Medical Research Council of Australia [1079671]; Cancer Council Queensland [1042819]; Mater Foundation; Australian Government; Ministry of Higher Education Malaysia Scholarship; NBCF fellowship [ECR13-04]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); Mater Foundation; Australian Government(Australian GovernmentCGIAR); Ministry of Higher Education Malaysia Scholarship; NBCF fellowship	This work was supported by the National Health and Medical Research Council of Australia (1079671) and Cancer Council Queensland (1042819). We are grateful to Sunil Lakhani and The Brisbane Breast Bank (The University of Queensland Centre for Clinical Research, Brisbane, Australia) for providing the MDA-MB-468 and BT-20 cell lines and RNA from 184A1, 184B5, MCF10A and Bre-80-hTERT cells for this study. GM is supported by the Mater Foundation. The Translational Research Institute is supported by a grant from the Australian Government. SYNJ was funded by the Ministry of Higher Education Malaysia Scholarship. ED is the recipient of a NBCF fellowship (ECR13-04).	Adapala RK, 2016, ONCOGENE, V35, P314, DOI 10.1038/onc.2015.83; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Aung CS, 2009, CARCINOGENESIS, V30, P1962, DOI 10.1093/carcin/bgp223; Aydar E, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-23; Azimi I, 2016, MOL ONCOL, V10, P166, DOI 10.1016/j.molonc.2015.09.006; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Chen RB, 2014, UROL ONCOL-SEMIN ORI, V32, P524, DOI 10.1016/j.urolonc.2013.05.011; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarke C, 2013, CARCINOGENESIS, V34, P2300, DOI 10.1093/carcin/bgt208; Curry MC, 2012, J BIOL CHEM, V287, P28598, DOI 10.1074/jbc.M112.364737; Czifra G, 2009, J CANCER RES CLIN, V135, P507, DOI 10.1007/s00432-008-0482-3; Del Nagro C, 2014, J BIOL CHEM, V289, P35182, DOI 10.1074/jbc.M114.580159; Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Frandsen SK, 2012, CANCER RES, V72, P1336, DOI 10.1158/0008-5472.CAN-11-3782; Franken J, 2014, BRIT J PHARMACOL, V171, P2537, DOI 10.1111/bph.12502; Garcia-Elias A, 2014, HANDB EXP PHARMACOL, V222, P293, DOI 10.1007/978-3-642-54215-2_12; GOLDSBY RA, 1963, BIOCHEMISTRY-US, V2, P1142, DOI 10.1021/bi00905a041; Gradilone SA, 2010, GASTROENTEROLOGY, V139, P304, DOI 10.1053/j.gastro.2010.04.010; Haas BE, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-61; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Jo AO, 2016, P NATL ACAD SCI USA, V113, P3885, DOI 10.1073/pnas.1515895113; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laing RJ, 2016, NEUROSCIENTIST, V22, P171, DOI 10.1177/1073858414567884; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27903; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mahieu F, 2007, J BIOL CHEM, V282, P3325, DOI 10.1074/jbc.M605213200; MAJNO G, 1995, AM J PATHOL, V146, P3; Middelbeek J, 2012, CANCER RES, V72, P4250, DOI 10.1158/0008-5472.CAN-11-3863; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Peters AA, 2012, MOL CANCER THER, V11, P2158, DOI 10.1158/1535-7163.MCT-11-0965; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Presson AP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-230; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Shi Y, 2009, GUT, V58, P1443, DOI 10.1136/gut.2009.181735; Solvang HK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-197; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; Weerasinghe P, 2012, EXP MOL PATHOL, V93, P302, DOI 10.1016/j.yexmp.2012.09.018; Willette RN, 2008, J PHARMACOL EXP THER, V326, P443, DOI 10.1124/jpet.107.134551; Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91; Wu TTL, 2014, CELL CALCIUM, V56, P59, DOI 10.1016/j.ceca.2014.04.006; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zhang L, 2004, CANCER RES, V64, P8365, DOI 10.1158/0008-5472.CAN-04-2146; Zhuang LY, 2002, LAB INVEST, V82, P1755, DOI 10.1097/01.LAB.0000043910.41414.E7; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506	58	48	51	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6490	6500		10.1038/onc.2017.234	http://dx.doi.org/10.1038/onc.2017.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759041				2022-12-28	WOS:000415622900012
J	Kang, SM; Rosales, JL; Meier-Stephenson, V; Kim, S; Lee, KY; Narendran, A				Kang, S. M.; Rosales, J. L.; Meier-Stephenson, V.; Kim, S.; Lee, K. Y.; Narendran, A.			Genome-wide loss-of-function genetic screening identifies opioid receptor mu 1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia	ONCOGENE			English	Article							DOWN-REGULATION; CELLS; SYNTHETASE; SENSITIVITY; ACTIVATION; EXPRESSION	L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL). It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death. However, patient relapse often occurs due to development of resistance. The molecular mechanism by which ALL cells acquire resistance to L-asparaginase is unknown. Therefore, we sought to identify genes that are involved in L-asparaginase resistance in primary leukemic cells. By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c). We also found that OPRM1 is expressed in all leukemic cells tested. Specific knockdown of OPRM1 confers L-asparaginase resistance, validating our genome-wide retroviral shRNA library screening data. Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway. Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients. Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones. Oprm1 may also be utilized for effective treatment of L-asparaginase-resistant ALL.	[Kang, S. M.; Lee, K. Y.] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada; [Kang, S. M.; Meier-Stephenson, V.; Narendran, A.] Univ Calgary, Div Pediat Oncol, Alberta Childrens Hosp, Calgary, AB, Canada; [Kang, S. M.; Meier-Stephenson, V.; Narendran, A.] Univ Calgary, POETIC Lab Preclin & Drug Discovery Studies, Arnie Charbonneau Canc Inst, Calgary, AB, Canada; [Rosales, J. L.] Univ Calgary, Snyder Inst Chron Dis, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Kim, S.] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca		Rosales, Jesusa/0000-0002-2543-3801	CIHR [MOP-123400]; NSERC [RGPIN/312985-2011]	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/312985-2011) to KYL.	Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen SH, 2015, PEDIATR NEONATOL, V56, P287, DOI 10.1016/j.pedneo.2014.10.006; Friesen C, 2008, CANCER RES, V68, P6059, DOI 10.1158/0008-5472.CAN-08-1227; Friesen C, 2014, CELL CYCLE, V13, P1560, DOI 10.4161/cc.28493; Friesen C, 2013, ONCOTARGET, V4, P677, DOI 10.18632/oncotarget.952; Howlader N, 2016, SEER CANC STAT REV; KILLANDER D, 1976, CANCER, V37, P220, DOI 10.1002/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W; Krejci O, 2004, LEUKEMIA, V18, P434, DOI 10.1038/sj.leu.2403259; Li BS, 2006, LEUKEMIA, V20, P2199, DOI 10.1038/sj.leu.2404423; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; Su N, 2008, PEDIATR BLOOD CANCER, V50, P274, DOI 10.1002/pbc.21213; Supuran CT, 2017, EXPERT OPIN DRUG DIS, V12, P61, DOI 10.1080/17460441.2017.1253677; Xie CL, 2014, INT J BIOCHEM CELL B, V47, P113, DOI 10.1016/j.biocel.2013.11.023	14	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5910	5913		10.1038/onc.2017.211	http://dx.doi.org/10.1038/onc.2017.211			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28650467	hybrid, Green Published			2022-12-28	WOS:000413292900012
J	Pistore, C; Giannoni, E; Colangelo, T; Rizzo, F; Magnani, E; Muccillo, L; Giurato, G; Mancini, M; Rizzo, S; Riccardi, M; Sahnane, N; Del Vescovo, V; Kishore, K; Mandruzzato, M; Macchi, F; Pelizzola, M; Denti, MA; Furlan, D; Weisz, A; Colantuoni, V; Chiarugi, P; Bonapace, IM				Pistore, C.; Giannoni, E.; Colangelo, T.; Rizzo, F.; Magnani, E.; Muccillo, L.; Giurato, G.; Mancini, M.; Rizzo, S.; Riccardi, M.; Sahnane, N.; Del Vescovo, V.; Kishore, K.; Mandruzzato, M.; Macchi, F.; Pelizzola, M.; Denti, M. A.; Furlan, D.; Weisz, A.; Colantuoni, V.; Chiarugi, P.; Bonapace, I. M.			DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells	ONCOGENE			English	Article							STEM-CELLS; EXPRESSION ANALYSIS; MIRNA EXPRESSION; TUMOR-SUPPRESSOR; FEEDBACK LOOP; PROMOTES; ZEB1; METASTASIS; METHYLTRANSFERASES; INHIBITION	Widespread genome hypo-methylation and promoter hyper-methylation of epithelium-specific genes are hallmarks of stable epithelial-to-mesenchymal transition (EMT), which in prostate cancer (PCa) correlates with castration resistance, cancer stem cells generation, chemoresistance and worst prognosis. Exploiting our consolidated 'ex-vivo' system, we show that cancer-associated fibroblasts (CAFs) released factors have pivotal roles in inducing genome methylation changes required for EMT and stemness in EMT-prone PCa cells. By global DNA methylation analysis and RNA-Seq, we provide compelling evidence that conditioned media from CAFs explanted from two unrelated patients with advanced PCa, stimulates concurrent DNA hypo-and hyper-methylation required for EMT and stemness in PC3 and DU145, but not in LN-CaP and its derivative C4-2B, PCa cells. CpG island (CGI) hyper-methylation associates with repression of genes required for epithelial maintenance and invasion antagonism, whereas activation of EMT markers and stemness genes correlate with CGI hypo-methylation. Remarkably, methylation variations and EMT-regulated transcripts almost completely reverse qualitatively and quantitatively during MET. Unsupervised clustering analysis of the PRAD TCGA data set with the differentially expressed (DE) and methylated EMT signature, identified a gene cluster of DE genes defined by a CAF+ and AR-phenotype and worst diagnosis. This gene cluster includes the relevant factors for EMT and stemness, which display DNA methylation variations in regulatory regions inversely correlated to their expression changes, thus strongly sustaining the ex-vivo data. DNMT3A-dependent methylation is essential for silencing epithelial maintenance and EMT counteracting genes, such as CDH1 and GRHL2, that is, the direct repressor of ZEB1, the key transcriptional factor for EMT and stemness. Accordingly, DNMT3A knock-down prevents EMT entry. These results shed light on the mechanisms of establishment and maintenance of coexisting DNA hypo-and hyper-methylation patterns during cancer progression, the generation of EMT and cell stemness in advanced PCa, and may pave the way to new therapeutic implications.	[Pistore, C.; Magnani, E.; Rizzo, S.; Riccardi, M.; Mandruzzato, M.; Macchi, F.; Bonapace, I. M.] Univ Insubria, Dept Biotechnol & Life Sci, Busto Arsizio, VA, Italy; [Giannoni, E.; Chiarugi, P.] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy; [Colangelo, T.; Muccillo, L.; Colantuoni, V.] Univ Sannio, Dept Sci & Technol, Benevento, Italy; [Rizzo, F.; Muccillo, L.; Weisz, A.] Univ Salerno, Dept Med Surg & Dent, Schola Med Salernitana, Lab Mol Med & Gen, Baronissi, SA, Italy; [Sahnane, N.; Furlan, D.] Univ Insubria, Dept Surg & Morphol Sci, Anat Pathol Unit, Varese, Italy; [Kishore, K.; Pelizzola, M.] Italian Inst Technol, Ctr Genom Sci, Milan, Italy; [Del Vescovo, V.; Denti, M. A.] Univ Trento, Ctr Integrat Biol, Trento, Italy; [Colangelo, T.] IRCCS, Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, San Giovanni Rotondo, Italy	University of Insubria; University of Florence; University of Sannio; University of Salerno; University of Insubria; Istituto Italiano di Tecnologia - IIT; University of Trento; IRCCS Casa Sollievo Della Sofferenza	Bonapace, IM (corresponding author), Univ Insubria I, Dept Biotechnol & Life Sci, Via Manara 7, I-21052 Busto Arsizio, Lombardia, Italy.	ian.bonapace@uninsubria.it	Giurato, Giorgio/K-3859-2018; Rizzo, Francesca/K-3057-2016; Sahnane, Nora/L-1983-2019; Weisz, Alessandro/A-1317-2014; Giannoni, Elisa/AAE-2092-2020; FURLAN, DANIELA/AAB-8271-2022; Chiarugi, Paola/CDD-7988-2022; Denti, Michela A./ABI-4085-2020; COLANGELO, TOMMASO/B-6119-2017	Giurato, Giorgio/0000-0002-0538-8978; Rizzo, Francesca/0000-0003-1783-5015; Sahnane, Nora/0000-0002-6227-8628; Weisz, Alessandro/0000-0003-0455-2083; FURLAN, DANIELA/0000-0002-5958-5379; Denti, Michela A./0000-0001-7203-7062; BONAPACE, IAN MARC/0000-0001-6580-8893; Macchi, Filippo/0000-0001-8226-4816; Pelizzola, Mattia/0000-0001-6672-9636; COLANGELO, TOMMASO/0000-0002-6927-403X; Chiarugi, Paola/0000-0001-7655-2969; Mancini, Monica/0000-0003-4128-9018; Kishore, Kamal/0000-0002-4650-8745	Epigenomics Flagship Project (EPIGEN-CNR-IT); Italian Association for Cancer Research (AIRC) [IG-8797, IG-17426]; AIRC [19548]	Epigenomics Flagship Project (EPIGEN-CNR-IT); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Epigenomics Flagship Project (EPIGEN-CNR-IT: to IMB, VC, DF and AW); Italian Association for Cancer Research (AIRC: grants IG-8797 to PC and IG-17426 to AW). TC is now supported by a three year AIRC fellowship (Project code: 19548). The Ethics approval and consent to participate at the study named 'Ruolo del microambiente stromale nella immunomodulazione e nella progression del carcinoma prostatico (Role of the stromal microenvironment for immunomodulation and for cancer progression in prostatic carcinoma)' was released with reference number 'BIO 15.016' from the Ethics committee 'Area Vasta Centro' of the 'Azienda Ospedaliera Universitaria Correggi' in Florence-Italy on the 26th of June 2015.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aue A, 2015, J AM SOC NEPHROL, V26, P2704, DOI 10.1681/ASN.2014080759; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Babbio F, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-19; Bernhart SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37393; Bhatt T, 2013, CELL COMMUN ADHES, V20, P189, DOI 10.3109/15419061.2013.854778; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608; Carmona FJ, 2014, CANCER RES, V74, P5608, DOI 10.1158/0008-5472.CAN-13-3659; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cheung AKL, 2015, ONCOTARGET, V6, P13434; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Cui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123926; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ficz G, 2015, J EXP BIOL, V218, P14, DOI 10.1242/jeb.107961; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; de Herreros AG, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00071; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Giannoni E, 2013, J MOL MED, V91, P103, DOI 10.1007/s00109-012-0941-9; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Grega-Larson NE, 2015, MOL BIOL CELL, V26, P3803, DOI 10.1091/mbc.E15-06-0443; Guo M, 2012, CANCER RES, V72, P2017, DOI 10.1158/0008-5472.CAN-11-3985; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kgatle MM, 2016, PROSTATE CANCER, V2016, DOI 10.1155/2016/5653862; Krisenko MO, 2015, BBA-MOL CELL RES, V1853, P254, DOI 10.1016/j.bbamcr.2014.10.022; Lawlor H, 2015, TUMOR BIOL, V36, P6019, DOI 10.1007/s13277-015-3278-5; Lee B, 2014, DEV CELL, V29, P47, DOI 10.1016/j.devcel.2014.03.005; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liu FT, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-66; Lu ZX, 2015, MOL CANCER RES, V13, P305, DOI 10.1158/1541-7786.MCR-14-0366; Malouf GG, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r144; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Morita S, 2013, INT J MOL SCI, V14, P14647, DOI 10.3390/ijms140714647; Nogales V, 2016, ONCOTARGET, V7, P3084, DOI 10.18632/oncotarget.6413; Ohka F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023332; Parpart S, 2014, HEPATOLOGY, V60, P872, DOI 10.1002/hep.27200; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Sauer E, 2014, FORENSIC SCI INT-GEN, V13, P217, DOI 10.1016/j.fsigen.2014.08.005; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schubert M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065064; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Spans L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090002; Stefanoli M, 2014, NEUROENDOCRINOLOGY, V100, P26, DOI 10.1159/000365449; Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17; Taddei ML, 2014, MOL ONCOL, V8, P1729, DOI 10.1016/j.molonc.2014.07.009; Taddei ML, 2011, MOL CANCER RES, V9, P149, DOI 10.1158/1541-7786.MCR-10-0298; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vastenhouw NL, 2012, CURR OPIN CELL BIOL, V24, P374, DOI 10.1016/j.ceb.2012.03.009; von Meyenn F, 2016, MOL CELL, V62, P848, DOI 10.1016/j.molcel.2016.04.025; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Yang LL, 2012, CARCINOGENESIS, V33, P1863, DOI 10.1093/carcin/bgs226; Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13; Yaqinuddin A, 2009, J UROLOGY, V182, P756, DOI 10.1016/j.juro.2009.03.082; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhang YJ, 2015, DEVELOPMENT, V142, P3383, DOI 10.1242/dev.125393; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	80	55	57	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5551	5566		10.1038/onc.2017.159	http://dx.doi.org/10.1038/onc.2017.159			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581528	Green Submitted			2022-12-28	WOS:000412293600001
J	Kuo, TF; Chen, TY; Jiang, ST; Chen, KW; Chiang, YM; Hsu, YJ; Liu, YJ; Chen, HM; Yokoyama, KK; Tsai, KC; Yeh, HH; Chen, YR; Yang, MT; Yang, CY; Yang, WC				Kuo, T-F; Chen, T-Y; Jiang, S-T; Chen, K-W; Chiang, Y-M; Hsu, Y-J; Liu, Y-J; Chen, H-M; Yokoyama, K. K.; Tsai, K-C; Yeh, H-H; Chen, Y-R; Yang, M-T; Yang, C-Y; Yang, W-C			Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway	ONCOGENE			English	Article							INDUCED CELL-DEATH; INDUCED APOPTOSIS; STRESS; IDENTIFICATION; INHIBITION; EXPRESSION; VIABILITY; CARCINOMA; CASPASE-3; FAMILY	Protein disulfide isomerase a4 (PDIA4) is implicated in the growth and death of tumor cells; however, its molecular mechanism and therapeutic potential in cancer are unclear. Here, we found that PDIA4 expression was upregulated in a variety of tumor cell lines and human lung adenocarcinoma tissues. Knockdown and overexpression of PDIA4 in tumor cells showed that PDIA4 facilitated cell growth via the reduction of caspases 3 and 7 activity. Consistently, Lewis lung carcinoma cells overexpressing PDIA4 grew faster than did parental cells in tumor-bearing mice, as shown by a reduced survival rate, increased tumor size and metastasis, and decreased cell death and caspases 3 and 7 activity. PDIA4 knockdown resulted in opposite outcomes. Moreover, results obtained in mice with spontaneous hepatoma indicated that PDIA4 deficiency significantly reduced hepatic tumorigenesis and cyst formation and increased mouse survival, tumor death, and caspases 3 and 7 activity. Mechanistic studies illustrated that PDIA4 negatively regulated tumor cell death by inhibiting degradation and activation of procaspases 3 and 7 via their mutual interaction in a CGHC-dependent manner. Finally, we found that 1,2-dihydroxytrideca-5,7,9,11-tetrayne, a PDIA4 inhibitor, reduced tumor development via enhancement of caspase-mediated cell death in TSA tumor-bearing mice. These findings characterize PDIA4 as a negative regulator of cancer cell apoptosis and suggest that PDIA4 is a potential therapeutic target for cancer.	[Kuo, T-F; Chen, T-Y; Chen, K-W; Chiang, Y-M; Hsu, Y-J; Liu, Y-J; Chen, H-M; Chen, Y-R; Yang, M-T; Yang, C-Y; Yang, W-C] Acad Sinica, Agr Biotechnol Res Ctr, 128,Sect 2,Acad Rd, Taipei 11529, Taiwan; [Chen, T-Y] Natl Taiwan Univ, Inst Biotechnol, Taipei, Taiwan; [Jiang, S-T] Natl Appl Res Labs, Natl Lab Anim Ctr, Taipei, Taiwan; [Yokoyama, K. K.] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan; [Tsai, K-C] Natl Res Inst Chinese Med, Minist Hlth & Welf, Taipei, Taiwan; [Tsai, K-C] Taipei Med Univ, PhD Program Biotechnol Med, Taipei, Taiwan; [Yeh, H-H] Chia Nan Univ Pharm & Sci, Drug Discovery & Dev Ctr, Tainan, Taiwan; [Yang, M-T] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung, Taiwan; [Yang, M-T] Acad Sinica, Taiwan Int Grad Program, Mol & Biol Agr Sci, Taipei, Taiwan; [Yang, M-T] Natl Chung Hsing Univ, Taichung, Taiwan; [Yang, W-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Yang, W-C] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; [Yang, W-C] Natl Taiwan Ocean Univ, Dept Aquaculture, Keelung, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Applied Research Laboratories - Taiwan; Kaohsiung Medical University; National Research Institute of Chinese Medicine; Taipei Medical University; Chia Nan University of Pharmacy & Science; National Chung Hsing University; Academia Sinica - Taiwan; National Chung Hsing University; National Chung Hsing University; National Yang Ming Chiao Tung University; National Taiwan Ocean University	Yang, WC (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128,Sect 2,Acad Rd, Taipei 11529, Taiwan.	wcyang@gate.sinica.edu.tw	Yang, Wen-Chin/D-3441-2015	Yang, Wen-Chin/0000-0001-6410-2581; YANG, CHUN-YEN/0000-0002-8672-2981	MOST [104-2320-B-037-033-My2, 104-2314-B-033-002];  [NHRI-EX103-10109B1];  [NHRI-EX106-10416S1];  [KMU-TP104G00];  [KMU-TP104G01];  [KMU-TP104A04];  [KMU-TP105E23];  [KMU-TP105E00];  [KMU-DT105005]	MOST(Ministry of Science & Technology (MOST), Republic of Korea); ; ; ; ; ; ; ; 	We thank the animal facility and the metabolomics facility of the Agricultural Biotechnology Research Center, and the mouse clinics of Academia Sinica for their technical assistance. We thank Drs Jim Stauffer (NCI) and Xin Chen (UCSF) for their SB plasmids, and the National RNAi Core Facility (Academia Sinica) for RNAi reagents. We also thank Ms Miranda Loney for editing the manuscript. This work was supported in part by MOST 104-2320-B-037-033-My2, and MOST 104-2314-B-033-002; NHRI-EX103-10109B1, and NHRI-EX106-10416S1, and KMU-TP104G00, KMU-TP104G01, KMU-TP104A04, KMU-TP105E23, KMU-TP105E23, KMU-TP105E00, and KMU-DT105005.	Almeida S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026454; Andreu CI, 2012, FEBS LETT, V586, P2826, DOI 10.1016/j.febslet.2012.07.023; Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Carbone DL, 2005, CHEM RES TOXICOL, V18, P1324, DOI 10.1021/tx050078z; Ciaffi M, 2006, GENE, V366, P209, DOI 10.1016/j.gene.2005.07.032; Ellerman DA, 2006, DEV CELL, V10, P831, DOI 10.1016/j.devcel.2006.03.011; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Galligan JJ, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-6; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Goplen D, 2006, CANCER RES, V66, P9895, DOI 10.1158/0008-5472.CAN-05-4589; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashida T, 2011, J TOXICOL SCI, V36, P1, DOI 10.2131/jts.36.1; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Krepela E, 2006, J CANCER RES CLIN, V132, P57, DOI 10.1007/s00432-005-0048-6; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; Liu XW, 2004, BIOL CHEM, V385, P633, DOI 10.1515/BC.2004.078; Lovat PE, 2008, CANCER RES, V68, P5363, DOI 10.1158/0008-5472.CAN-08-0035; Manukyan D, 2008, THROMB RES, V122, pS19, DOI 10.1016/S0049-3848(08)70013-6; Na KS, 2007, MOL CELLS, V24, P261; Naguleswaran A, 2005, INT J PARASITOL, V35, P1459, DOI 10.1016/j.ijpara.2005.06.006; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Ou W, 2006, VIROLOGY, V350, P406, DOI 10.1016/j.virol.2006.01.041; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Pawar H, 2011, CANCER BIOL THER, V12, P510, DOI 10.4161/cbt.12.6.16833; Rodriguez-Hernandez A, 2006, APOPTOSIS, V11, P131, DOI 10.1007/s10495-005-3276-y; Santana-Codina N, 2013, MOL CELL PROTEOMICS, V12, P2111, DOI 10.1074/mcp.M112.022772; Satoh M, 2005, CELL STRESS CHAPERON, V10, P211, DOI 10.1379/CSC-109R.1; Schultz-Norton JR, 2006, MOL ENDOCRINOL, V20, P1982, DOI 10.1210/me.2006-0006; Severino A, 2007, J AM COLL CARDIOL, V50, P1029, DOI 10.1016/j.jacc.2007.06.006; Stauffer JK, 2011, CANCER RES, V71, P2718, DOI 10.1158/0008-5472.CAN-10-2705; Tao GZ, 2013, J BIOL CHEM, V288, P17214, DOI 10.1074/jbc.M112.445965; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Tufo G, 2014, CELL DEATH DIFFER, V21, P685, DOI 10.1038/cdd.2013.193; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Xiong Y., 2012, INT J CELL BIOL, V2012, P273549, DOI 10.1155/2012/273549; Xu SL, 2012, P NATL ACAD SCI USA, V109, P16348, DOI 10.1073/pnas.1205226109; Yu SJ, 2012, J BIOENERG BIOMEMBR, V44, P101, DOI 10.1007/s10863-012-9416-5; Zahedi P, 2012, J CONTROL RELEASE, V158, P379, DOI 10.1016/j.jconrel.2011.11.025; Zhu Y, 2014, MOL CELL PROTEOMICS, V13, P2593, DOI 10.1074/mcp.M114.038786	43	22	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5484	5496		10.1038/onc.2017.156	http://dx.doi.org/10.1038/onc.2017.156			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534513				2022-12-28	WOS:000411960500005
J	Lee, JY; Park, JH; Choi, HJ; Won, HY; Joo, HS; Shin, DH; Park, MK; Han, B; Kim, KP; Lee, TJ; Croce, CM; Kong, G				Lee, J-Y; Park, J-H; Choi, H-J; Won, H-Y; Joo, H-s; Shin, D-H; Park, M. K.; Han, B.; Kim, K. P.; Lee, T. J.; Croce, C. M.; Kong, G.			LSD1 demethylates HIF1 alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; LYSINE METHYLATION; TRANSCRIPTIONAL REPRESSION; SET9-MEDIATED METHYLATION; ANDROGEN RECEPTOR; PROSTATE-CANCER; BREAST-CANCER; HISTONE; HYPOXIA; HIF-1-ALPHA	Lysine-specific demethylase 1 (LSD1), which has been considered as a potential therapeutic target in human cancer, has been known to regulate many biological functions through its non-histone substrates. Although LSD1-induced hypoxia-inducible factor alpha (HIF1 alpha) demethylation has recently been proposed, the effect of LSD1 on the relationship between HIF1 alpha post-translational modifications (PTMs) and HIF1 alpha-induced tumor angiogenesis remains to be elucidated. Here, we identify a new methylation site of the HIF1 alpha protein antagonized by LSD1 and the interplay between HIF1 alpha protein methylation and other PTMs in regulating tumor angiogenesis. LSD1 demethylates HIF1 alpha at lysine (K) 391, which protects HIF1 alpha against ubiquitin-mediated protein degradation. LSD1 also directly suppresses PHD2-induced HIF1 alpha hydroxylation, which has a mutually dependent interplay with Set9-mediated HIF1 alpha methylation. Moreover, the HIF1 alpha acetylation that occurs in a HIF1 alpha methylation-dependent manner is inhibited by the LSD1/NuRD complex. HIF1 alpha stabilized by LSD1 cooperates with CBP and MTA1 to enhance vascular endothelial growth factor (VEGF)induced tumor angiogenesis. Thus, LSD1 is a key regulator of HIF1 alpha/VEGF-mediated tumor angiogenesis by antagonizing the crosstalk between PTMs involving HIF1 alpha protein degradation.	[Lee, J-Y; Park, J-H; Kong, G.] Hanyang Univ, IBBR, Seoul, South Korea; [Choi, H-J; Won, H-Y; Joo, H-s; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, 222 Wangsimni Ro, Seoul 04763, South Korea; [Park, M. K.] Natl Canc Ctr, Goyang, South Korea; [Han, B.; Kim, K. P.] Kyung Hee Univ, Dept Appl Chem, Coll Appl Sci, Yongin, South Korea; [Lee, T. J.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Hanyang University; Hanyang University; National Cancer Center - Korea (NCC); Kyung Hee University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 222 Wangsimni Ro, Seoul 04763, South Korea.	gkong@hanyang.ac.kr	Young, Richard A/F-6495-2012; Choi, Hyuk Joong/AAF-7713-2019	Young, Richard A/0000-0001-8855-8647; Kim, Kwang Pyo/0000-0003-0095-3787; Choi, Hee-Joo/0000-0001-6432-8193	National Research Foundation of Korea (NRF) grants - Korean government [2015R1A2A1A10052578]; NATIONAL CANCER INSTITUTE [R35CA197706] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF) grants - Korean government; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (No. 2015R1A2A1A10052578).	Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; Hino S, 2016, CANCER SCI, V107, P1187, DOI 10.1111/cas.13004; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Liu X, 2015, NUCLEIC ACIDS RES, V43, P5081, DOI 10.1093/nar/gkv379; Morera L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0223-4; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Page EL, 2008, MOL BIOL CELL, V19, P86, DOI 10.1091/mbc.E07-06-0612; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	42	68	69	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5512	5521		10.1038/onc.2017.158	http://dx.doi.org/10.1038/onc.2017.158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534506				2022-12-28	WOS:000411960500007
J	Han, H; Yang, B; Wang, W				Han, H.; Yang, B.; Wang, W.			Angiomotin-like 2 interacts with and negatively regulates AKT	ONCOGENE			English	Article							ORGAN SIZE CONTROL; HIPPO PATHWAY; CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; HUMAN CANCER; TISSUE HOMEOSTASIS; FAMILY PROTEINS; YAP ONCOPROTEIN; ACTIN-BINDING	Angiomotin-like 2 (AMOTL2) is a member of Angiomotin family proteins, which are potent inhibitors for the Hippo pathway effector YAP. However, additional cellular functions of AMOTL2 besides YAP inhibition are largely unknown. Here, we reported that AMOTL2 associates with and negatively regulates AKT. Mechanistically, AMOTL2 binds to AKT pleckstrin homology domain and interrupts AKT's membrane localization. Liver-specific depletion of AMOTL2 enlarged mouse liver and activated both YAP and AKT. Downregulation of AMOTL2 is found in human liver cancers, correlating with the concomitant activation of YAP and AKT. Together, our results provide novel insights into a dual tumor suppressive function of AMOTL2 by targeting both YAP and AKT in liver size control and cancer prevention.	[Han, H.; Yang, B.; Wang, W.] Univ Calif Irvine, Dept Dev & Cell Biol, 3302A,Nat Sci 1, Irvine, CA 92697 USA	University of California System; University of California Irvine	Wang, W (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 3302A,Nat Sci 1, Irvine, CA 92697 USA.	wenqiw6@uci.edu	han, han/HDL-7807-2022; HAN, HAN/AAC-5464-2022	HAN, HAN/0000-0003-2222-5270; Wang, Wenqi/0000-0003-4053-5088	Breast Cancer Research Foundation [16-20-26-WANG]; American Cancer Society-Institutional Research Grant	Breast Cancer Research Foundation; American Cancer Society-Institutional Research Grant(American Cancer Society)	WW thanks Dr Junjie Chen at MD Anderson Cancer Center for his mentoring and continuous support. We also thank Kathryn E Aziz and My Kim Tran at MD Anderson Cancer Center for the technical help. WW is a recipient of American Association for Cancer Research Career Development Award for Translational Breast Cancer Research supported by the Breast Cancer Research Foundation (16-20-26-WANG). This work was also partially supported by the American Cancer Society-Institutional Research Grant to WW. WW is a member of Chao Family Comprehensive Cancer Center (P30 CA062203) and a member of Center for Complex Biological Systems at UC Irvine.	Aase K, 2007, GENE DEV, V21, P2055, DOI 10.1101/gad.432007; Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2013, J BIOL CHEM, V288, P37296, DOI 10.1074/jbc.M113.527598; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan TO, 2015, BIOCHEM J, V471, P37, DOI 10.1042/BJ20150325; Dai XM, 2015, CELL RES, V25, P1175, DOI 10.1038/cr.2015.101; Dai XM, 2013, J BIOL CHEM, V288, P34041, DOI 10.1074/jbc.M113.518019; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Hirate Y, 2013, CURR BIOL, V23, P1181, DOI 10.1016/j.cub.2013.05.014; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Leung CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3251; Li YJ, 2015, CELL RES, V25, P801, DOI 10.1038/cr.2015.69; Li Y, 2016, HEPATOLOGY, V63, P1928, DOI 10.1002/hep.28507; Liu PD, 2014, CELL CYCLE, V13, P2162, DOI 10.4161/cc.29584; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lv M, 2016, ONCOTARGET, V7, P12393, DOI 10.18632/oncotarget.7161; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mojallal M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5557; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Nishio M, 2016, P NATL ACAD SCI USA, V113, pE71, DOI 10.1073/pnas.1517188113; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Troilo A, 2016, ONCOTARGET, V7, P28765, DOI 10.18632/oncotarget.9117; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang H, 2016, J BIOL CHEM, V291, P15256, DOI 10.1074/jbc.M116.722967; Wang WQ, 2008, J CELL SCI, V121, P1334, DOI 10.1242/jcs.018176; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	45	9	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4662	4669		10.1038/onc.2017.101	http://dx.doi.org/10.1038/onc.2017.101			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368415				2022-12-28	WOS:000407246200013
J	Bouillez, A; Rajabi, H; Jin, C; Samur, M; Tagde, A; Alam, M; Hiraki, M; Maeda, T; Hu, X; Adeegbe, D; Kharbanda, S; Wong, KK; Kufe, D				Bouillez, A.; Rajabi, H.; Jin, C.; Samur, M.; Tagde, A.; Alam, M.; Hiraki, M.; Maeda, T.; Hu, X.; Adeegbe, D.; Kharbanda, S.; Wong, K-K; Kufe, D.			MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer	ONCOGENE			English	Article							TOLL-LIKE RECEPTOR-9; ONCOPROTEIN; EXPRESSION; ACTIVATION; PATHWAY; ADENOCARCINOMA; INTERFERON; PROGNOSIS; BREAST; IFN	Immunotherapeutic approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have improved the treatment of non-small-cell lung cancer (NSCLC), supporting the premise that evasion of immune destruction is of importance for NSCLC progression. However, the signals responsible for upregulation of PD-L1 in NSCLC cells and whether they are integrated with the regulation of other immune-related genes are not known. Mucin 1 (MUC1) is aberrantly overexpressed in NSCLC, activates the nuclear factor-kappa B (NF-kappa B) p65. ZEB1 pathway and confers a poor prognosis. The present studies demonstrate that MUC1-C activates PD-L1 expression in NSCLC cells. We show that MUC1-C increases NF-kappa B p65 occupancy on the CD274/ PD-L1 promoter and thereby drives CD274 transcription. Moreover, we demonstrate that MUC1-C-induced activation of NF-kappa B -> ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, and that this signature is associated with decreases in overall survival. In concert with these results, targeting MUC1-C in NSCLC tumors suppresses PD-L1 and induces these effectors of innate and adaptive immunity. These findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.	[Bouillez, A.; Rajabi, H.; Jin, C.; Samur, M.; Tagde, A.; Alam, M.; Hiraki, M.; Maeda, T.; Hu, X.; Adeegbe, D.; Kharbanda, S.; Wong, K-K; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Dana Farber Canc Inst, Med Oncol, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu		Samur, Mehmet/0000-0002-9978-5682; Adeegbe, Dennis/0000-0001-9233-3328	National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R21CA216553, P50CA100707, R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480, and by the Lung Cancer Research Foundation.	Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Awaya H, 2004, AM J CLIN PATHOL, V121, P644, DOI 10.1039/U4WGE9EBFJN6CM8R; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Carrizosa DR, 2015, TRANSL LUNG CANCER R, V4, P553, DOI 10.3978/j.issn.2218-6751.2015.06.05; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chatterjee S, 2014, CANCER RES, V74, P5008, DOI 10.1158/0008-5472.CAN-13-2698; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Cherfils-Vicini J, 2010, J CLIN INVEST, V120, P1285, DOI 10.1172/JCI36551; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dajon M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.991615; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Gnemmi V, 2014, CANCER LETT, V346, P225, DOI 10.1016/j.canlet.2013.12.029; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Gowrishankar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123410; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hu XY, 2008, IMMUNOL REV, V226, P41, DOI 10.1111/j.1600-065X.2008.00707.x; Huang G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061602; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jarrard JA, 1998, CANCER RES, V58, P5582; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee J, 2009, BIOCHEM J, V421, P301, DOI 10.1042/BJ20090013; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Lou Y, 2016, CLIN CANCER RES, V31, P245; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mayor M, 2016, EUR J CARDIO-THORAC, V49, P1324, DOI 10.1093/ejcts/ezv371; Metcalf D, 2010, NAT REV CANCER, V10, P425, DOI 10.1038/nrc2843; Pivarcsi A, 2007, P NATL ACAD SCI USA, V104, P19055, DOI 10.1073/pnas.0705673104; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Reck M, 2015, SEMIN ONCOL, V42, P402, DOI 10.1053/j.seminoncol.2015.02.013; Ronkainen H, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-84; Samur MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106397; Sandholm J, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00330; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Situ DR, 2011, MED ONCOL, V28, pS596, DOI 10.1007/s12032-010-9752-4; Sunaga N, 2012, INT J CANCER, V130, P1733, DOI 10.1002/ijc.26164; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Takeshita F, 2004, J IMMUNOL, V173, P2552, DOI 10.4049/jimmunol.173.4.2552; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Welsh EA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-153; Xie Y, 2011, CLIN CANCER RES, V17, P5705, DOI 10.1158/1078-0432.CCR-11-0196; Xu F, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002286	66	69	74	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4037	4046		10.1038/onc.2017.47	http://dx.doi.org/10.1038/onc.2017.47			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288138	Green Accepted, Green Submitted			2022-12-28	WOS:000405379900009
J	Patrick, BA; Jaiswal, AK				Patrick, B. A.; Jaiswal, A. K.			RETRACTION: Stress-induced NQO1 controls stability of C/EBP alpha against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer (Retraction of Vol 31, Pg 4361, 2012)	ONCOGENE			English	Retraction																		Patrick BA, 2012, ONCOGENE, V31, P4362, DOI 10.1038/onc.2011.600	1	2	2	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2920	2920		10.1038/onc.2016.476	http://dx.doi.org/10.1038/onc.2016.476			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28263979	Green Accepted, Bronze			2022-12-28	WOS:000401697800015
J	Lombardo, G; Gili, M; Grange, C; Cavallari, C; Dentelli, P; Togliatto, G; Taverna, D; Camussi, G; Brizzi, MF				Lombardo, Giusy; Gili, Maddalena; Grange, Cristina; Cavallari, Claudia; Dentelli, Patrizia; Togliatto, Gabriele; Taverna, Daniela; Camussi, Giovanni; Brizzi, Maria Felice			IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the beta-catenin pathway	ONCOGENE			English	Article							STAT5/PPAR-GAMMA TRANSCRIPTIONAL COMPLEX; F-BOX PROTEIN; WNT/BETA-CATENIN; STEM-CELLS; SIGNALING PATHWAY; PROGENITOR-CELL; PROMOTES ANGIOGENESIS; HELICOBACTER-PYLORI; COLORECTAL-CANCER; POTENTIAL ROLE	The proangiogenic cytokine Interleukin-3 (IL-3) is released by inflammatory cells in breast and ovarian cancer tissue microenvironments and also acts as an autocrine factor for human breast and kidney tumor-derived endothelial cells (TECs). We have previously shown that IL-3-treated endothelial cells (ECs) release extracellular vesicles (EVs), which serve as a paracrine mechanism for neighboring ECs, by transferring active molecules. The impact of an anti-IL-3R-alpha blocking antibody on the proangiogenic effect of EVs released from TECs (anti-IL-3R-EVs) has therefore been investigated in this study. We have found that anti-IL-3R-EV treatment prevented neovessel formation and, more importantly, also induced the regression of in vivo TEC-derived neovessels. Two miRs that target the canonical wingless (Wnt)/beta-catenin pathway, at different levels, were found to be differentially regulated when comparing the miR-cargo of naive TEC-derived EVs (EVs) and anti-IL-3R-EVs. miR-214-3p, which directly targets beta-catenin, was found to be upregulated, whereas miR-24-3p, which targets adenomatous polyposis coli (APC) and glycogen synthase kinase-3 beta (GSK3 beta), was found to be downregulated. In fact, upon their transfer into the cell, low beta-catenin content and high levels of the two members of the "beta-catenin destruction complex" were detected. Moreover, c-myc downregulation was found in TECs treated with anti-IL-3R-EVs, pre-miR-214-3p-EVs and antago-miR-24-3p-EVs, which is consistent with network analyses of miR-214-3p and miR-24-3p gene targeting. Finally, in vivo studies have demonstrated the impaired growth of vessels in pre-miR-214-3p-EV- and antago-miR-24-3p-EV-treated animals. These effects became much more evident when combo treatment was applied. The results of the present study identify the canonical Wnt/beta-catenin pathway as a relevant mechanism of TEC-derived EV proangiogenic action. Furthermore, we herein provide evidence that IL-3R blockade may yield some significant advantages, than miR targeting, in inhibiting the proangiogenic effects of naive TEC-derived EVs by changing TEC-EV-miR cargo.	[Lombardo, Giusy; Gili, Maddalena; Grange, Cristina; Cavallari, Claudia; Dentelli, Patrizia; Togliatto, Gabriele; Camussi, Giovanni; Brizzi, Maria Felice] Univ Turin, Dept Med Sci, Turin, Italy; [Taverna, Daniela; Camussi, Giovanni; Brizzi, Maria Felice] Univ Torino, MBC, Dept Mol Biotechnol & Hlth Sci, Turin, Italy	University of Turin; University of Turin	Camussi, G; Brizzi, MF (corresponding author), Univ Turin, Dept Med Sci, Turin, Italy.; Camussi, G; Brizzi, MF (corresponding author), Univ Torino, MBC, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.	giovanni.camussi@unito.it; mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; Togliatto, Gabriele/K-5668-2016; Camussi, Giovanni/J-7624-2016	Togliatto, Gabriele/0000-0002-3123-7823; Camussi, Giovanni/0000-0003-2795-232X; GRANGE, CRISTINA/0000-0002-6960-5476	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 2015.16973, IG 2015.17630]; Ministero dell'Istruzione, Universita e Ricerca (MIUR)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, Universita e Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work has been supported by grants obtained by GC and MFB from the Associazione Italiana per la Ricerca sul Cancro (AIRC) projects IG 2015.16973 and IG 2015.17630 and by grants obtained by MFB from Ministero dell'Istruzione, Universita e Ricerca (MIUR) ex 60%. We thank Professor Paolo Provero from the University of Turin for his useful advice on using Ingenuity Pathway Analysis (IPA) Software.	Bastakoty D, 2016, FASEB J, V30, P3271, DOI 10.1096/fj.201600502R; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Brizzi MF, 2004, FASEB J, V18, P1249, DOI 10.1096/fj.03-1053fje; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Bruno S, 2017, TISSUE ENG PT A, V23, P1262, DOI [10.1089/ten.tea.2017.0069, 10.1089/ten.TEA.2017.0069]; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Cavallari C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08250-0; Chang HC, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-015-0242-3; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [10.5493/wjem.v5.i2.84, DOI 10.5493/wjem.v5.i2.84, DOI 10.5493/WJEM.V5.I2.84]; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Collino F, 2017, STEM CELL REV REP, V13, P226, DOI 10.1007/s12015-016-9713-1; D'Angelo B, 2016, ANTICANCER RES, V36, P5571, DOI 10.21873/anticanres.11142; Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010; Dentelli P, 2005, ONCOGENE, V24, P6394, DOI 10.1038/sj.onc.1208786; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 2011, ONCOGENE, V30, P4930, DOI 10.1038/onc.2011.204; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2010, ARTERIOSCL THROM VAS, V30, P1562, DOI 10.1161/ATVBAHA.110.206201; Dentelli P, 2009, ARTERIOSCL THROM VAS, V29, P114, DOI 10.1161/ATVBAHA.108.172247; Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Florea V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073146; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gacche RN, 2013, PROG BIOPHYS MOL BIO, V113, P333, DOI 10.1016/j.pbiomolbio.2013.10.001; Gallo S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162417; Gao FB, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-25; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Giusti I, 2016, TUMOR BIOL, V37, P12743, DOI 10.1007/s13277-016-5165-0; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Grange C, 2006, ONCOL REP, V15, P381; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; GREENBERGER JS, 1983, FED PROC, V42, P2762; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He MY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122087; He SZ, 2015, LEUKEMIA LYMPHOMA, V56, P1406, DOI 10.3109/10428194.2014.956316; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006; Kiewisz J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/854056; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Lee E, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.2; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Lin HY, 2017, EBIOMEDICINE, V18, P62, DOI 10.1016/j.ebiom.2017.03.012; Liu NN, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2351-9; Lombardo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25689; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; METCALF D, 1986, BLOOD, V68, P46; Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1; Moldenhauer LM, 2015, STEM CELL RES, V14, P380, DOI 10.1016/j.scr.2015.04.002; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Penfornis P, 2016, INT J CANCER, V138, P14, DOI 10.1002/ijc.29417; Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Schepeler T, 2012, ONCOGENE, V31, P2750, DOI 10.1038/onc.2011.453; Song XW, 2015, ONCOTARGET, V6, P35579, DOI 10.18632/oncotarget.5758; Spano D, 2012, CLIN EXP METASTAS, V29, P381, DOI 10.1007/s10585-012-9457-5; Sun X, 2013, CELL SIGNAL, V25, P2805, DOI 10.1016/j.cellsig.2013.09.006; Takahashi RU, 2017, CLIN CHEM LAB MED, V55, P648, DOI 10.1515/cclm-2016-0708; Tickner JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00127; Togliatto G, 2016, INT J OBESITY, V40, P102, DOI 10.1038/ijo.2015.123; Trombetta A, 2013, DIABETES, V62, P1245, DOI 10.2337/db12-0646; Uberti B, 2010, ONCOGENE, V29, P6581, DOI 10.1038/onc.2010.384; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Wang WF, 2015, LIFE SCI, V136, P28, DOI 10.1016/j.lfs.2015.06.025; Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039; Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215; Zhang B, 2015, STEM CELL TRANSL MED, V4, P513, DOI 10.5966/sctm.2014-0267	73	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1175	1191		10.1038/s41388-017-0034-x	http://dx.doi.org/10.1038/s41388-017-0034-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29238040	Green Published, hybrid			2022-12-28	WOS:000426505400004
J	Langer, EM; Kendsersky, ND; Daniel, CJ; Kuziel, GM; Pelz, C; Murphy, KM; Capecchi, MR; Sears, RC				Langer, E. M.; Kendsersky, N. D.; Daniel, C. J.; Kuziel, G. M.; Pelz, C.; Murphy, K. M.; Capecchi, M. R.; Sears, R. C.			ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; ENDOTHELIAL DIFFERENTIATION; PROTEASE NEXIN-1; STEM-CELLS; PDGFR-BETA; EXPRESSION; SERPINE2; ZEB1; ANGIOGENESIS	During normal tumor growth and in response to some therapies, tumor cells experience acute or chronic deprivation of nutrients and oxygen and induce tumor vascularization. While this occurs predominately through sprouting angiogenesis, tumor cells have also been shown to directly contribute to vessel formation through vascular mimicry (VM) and/or endothelial transdifferentiation. The extrinsic and intrinsic mechanisms underlying tumor cell adoption of endothelial phenotypes, however, are not well understood. Here we show that serum withdrawal induces mesenchymal breast cancer cells to undergo VM and that knockdown of the epithelial-to-mesenchymal transition (EMT) regulator, Zinc finger E-box binding homeobox 1 (ZEB1), or overexpression of the ZEB1-repressed microRNAs (miRNAs), miR-200c, miR-183, miR-96 and miR-182 inhibits this process. We find that secreted proteins Fibronectin 1 (FN1) and serine protease inhibitor (serpin) family E member 2 (SERPINE2) are essential for VM in this system. These secreted factors are upregulated in mesenchymal cells in response to serum withdrawal, and overexpression of VM-inhibiting miRNAs abrogates this upregulation. Intriguingly, the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1) and Integrin beta 1 (ITGB1), are also targets of the VM-inhibiting miRNAs, suggesting that autocrine signaling stimulating VM is regulated by ZEB1-repressed miRNA clusters. Together, these data provide mechanistic insight into the regulation of VM and suggest that miRNAs repressed during EMT, in addition to suppressing migratory and stem-like properties of tumor cells, also inhibit endothelial phenotypes of breast cancer cells adopted in response to a nutrient-deficient microenvironment.	[Langer, E. M.; Kendsersky, N. D.; Daniel, C. J.; Kuziel, G. M.; Sears, R. C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, 2730 SW Moody Ave, Portland, OR 97201 USA; [Pelz, C.] Oregon Hlth & Sci Univ, Div Bioinformat & Computat Biol, Portland, OR 97201 USA; [Murphy, K. M.; Capecchi, M. R.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Murphy, K. M.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Sears, R. C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Oregon Health & Science University	Langer, EM; Sears, RC (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, 2730 SW Moody Ave, Portland, OR 97201 USA.	langere@ohsu.edu; searsr@ohsu.edu			American Cancer Society [118795-PF-10-022-01-CSM]; NCI [CA100855, CA196228]; Knight NCI Cancer Center Support Grant [5P30CA069533]; National Institutes of Health [U54 HG008100]; National Cancer Institute [5P30CA069533]; Susan G Komen Foundation [SAC110]; NATIONAL CANCER INSTITUTE [P30CA069533, R01CA100855, R01CA196228] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG008100] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Knight NCI Cancer Center Support Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by a postdoctoral fellowship from the American Cancer Society 118795-PF-10-022-01-CSM (EML), as well as philanthropic gifts from the Colson Family Foundation and the Prospect Creek Foundation, and R01s from the NCI CA100855 and CA196228 (RCS). Flow Cytometry was performed in the Oregon Health & Science University (OHSU) Flow Cytometry Shared Resource, hematoxylin and eosin and PAS staining as well as CD31 IHC was performed by the OHSU Histopathology Shared Resource, and short read sequencing assays (RNA-seq) were performed by the OHSU Massively Parallel Sequencing Shared Resource. These OHSU Shared Resources are supported by the Knight NCI Cancer Center Support Grant 5P30CA069533. We thank Dr Sen Wu for providing the PB-CAG-GFP-iNeo plasmid. We thank Dr Joe Gray for providing cell lines supported by the National Institutes of Health grant U54 HG008100, National Cancer Institute grant 5P30CA069533 and by the Susan G Komen Foundation SAC110. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor does it reflect the position or the policy of the Government, and no official endorsement should be inferred.	Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Buchholz M, 2003, CANCER RES, V63, P4945; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Candia BJ, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-16; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Choi YC, 2011, MOL CELLS, V32, P77, DOI 10.1007/s10059-011-1042-2; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Cseh B, 2010, J CELL SCI, V123, P3989, DOI 10.1242/jcs.073346; D'Ippolito E, 2016, CANCER RES, V76, P5562, DOI 10.1158/0008-5472.CAN-16-0140; Dyballa Nadine, 2012, Methods Mol Biol, V893, P47, DOI 10.1007/978-1-61779-885-6_4; Fanti Z, 2011, DEV NEUROBIOL, V71, P870, DOI 10.1002/dneu.20866; Fardin P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-185; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Francescone RA, 2011, JOVE-J VIS EXP, DOI 10.3791/3040; Francois D, 2014, LAB INVEST, V94, P1237, DOI 10.1038/labinvest.2014.111; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Gill JG, 2011, STEM CELLS, V29, P764, DOI 10.1002/stem.628; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Harrell JC, 2014, CLIN EXP METASTAS, V31, P33, DOI 10.1007/s10585-013-9607-4; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Jalvy-Delvaille S, 2012, NUCLEIC ACIDS RES, V40, P1356, DOI 10.1093/nar/gkr843; Karroum A, 2012, EUR J PHARMACOL, V685, P1, DOI 10.1016/j.ejphar.2012.04.004; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li GR, 2010, J BIOL CHEM, V285, P5461, DOI 10.1074/jbc.M109.037127; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Ong YS, 2010, J CELL BIOL, V190, P331, DOI 10.1083/jcb.201003005; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Plantamura I, 2014, MOL ONCOL, V8, P968, DOI 10.1016/j.molonc.2014.03.015; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Quesada AR, 2010, CURR PHARM DESIGN, V16, P3932; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang K, 2015, J CANCER RES CLIN, V141, P805, DOI 10.1007/s00432-014-1858-1; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wong CM, 2015, ONCOTARGET, V6, P13658, DOI 10.18632/oncotarget.3700; Xu CL, 2017, P NATL ACAD SCI USA, V114, P722, DOI 10.1073/pnas.1615735114; Xu Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-16; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zhou XM, 2008, GENE DEV, V22, P1231, DOI 10.1101/gad.1643308; Zhu M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15471	63	34	35	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1005	1019		10.1038/onc.2017.356	http://dx.doi.org/10.1038/onc.2017.356			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084210	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000425905700004
J	Ma, D; Chen, X; Zhang, PY; Zhang, H; Wei, LJ; Hu, S; Tang, JZ; Zhou, MT; Xie, C; Ou, R; Xu, Y; Tang, KF				Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Hu, S.; Tang, J-Z; Zhou, M-T; Xie, C.; Ou, R.; Xu, Y.; Tang, K-F			Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth	ONCOGENE			English	Article							CANCER-CELL PROLIFERATION; DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MODEL ORGANISMS; DNA-DAMAGE; ALDOLASE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; INTERACTS	Dietary restriction (DR) delays the incidence and decreases the growth of various types of tumors; however, the mechanisms responsible for DR-mediated antitumor effects have not been unequivocally identified. Here, we report that DR suppresses xenograft tumor growth by upregulating a novel signaling pathway. DR led to upregulated aldolase A (ALDOA) expression in xenograft tumors. ALDOA physically interacted with the catalytic subunit of DNA-dependent protein kinase (DNA-PK) and promoted DNA-PK activation. Activated DNA-PK phosphorylated p53 and increased its activity. Although ALDOA can function as an oncogene in cultured cells, it can also activate the tumor suppressor p53. Thus, ALDOA overexpression in the presence of p53 suppressed xenograft tumor growth; however, when p53 was suppressed, ALDOA overexpression promoted xenograft tumor growth. Moreover, we demonstrated that p53 suppression inhibited the antitumor effects of DR. Our results indicate that upregulation of the ALDOA/DNA-PK/p53 pathway is a mechanism accounting for the antitumor effects of DR.	[Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Tang, K-F] Wenzhou Med Univ, Affiliated Hosp 1, Digest Canc Ctr, Wenzhou 325015, Zhejiang, Peoples R China; [Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Xu, Y.; Tang, K-F] Wenzhou Med Univ, Affiliated Hosp 1, Inst Translat Med, Wenzhou, Peoples R China; [Hu, S.] Wenzhou Med Univ, Inst Genom Med, Wenzhou, Peoples R China; [Tang, J-Z] Third Mil Med Univ, Daping Hosp, Res Inst Surg, Chongqing, Peoples R China; [Zhou, M-T] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou, Peoples R China; [Xie, C.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Wenzhou, Zhejiang, Peoples R China; [Ou, R.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gynecol, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Army Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Tang, KF (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Digest Canc Ctr, Wenzhou 325015, Zhejiang, Peoples R China.	tang_kaifu@wmu.edu.cn		Zhou, Meng-Tao/0000-0002-0613-1656; Zhou, Mengtao/0000-0002-2455-250X; Hu, Shanshan/0000-0003-4904-0583; Tang, Kai-Fu/0000-0002-2657-4163; Chen, Xiao/0000-0001-6155-6035; Tang, Kai-Fu/0000-0002-6892-1207	National Natural Science Foundation of China [81572780]; Zhejiang Provincial Natural Sciences Foundation [LZ16H160004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Sciences Foundation	We thank Bin Tan (Chongqing Medical University, Chongqing, China), as well as Guiling Li, Tongke Chen and Yixiang Han (Wenzhou Medical University, Wenzhou, China), for providing technical assistance. This work was supported by the National Natural Science Foundation of China (Grant No. 81572780) and the Zhejiang Provincial Natural Sciences Foundation (Grant No. LZ16H160004).	Anzo M, 2008, CANCER RES, V68, P3342, DOI 10.1158/0008-5472.CAN-07-3165; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; Caspi M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-164; Concepcion J, 2009, COMB CHEM HIGH T SCR, V12, P791, DOI 10.2174/138620709789104915; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Du S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085804; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; Goodwin JF, 2014, CANCER DISCOV, V4, P1126, DOI 10.1158/2159-8290.CD-14-0358; Hakvoort TBM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216986; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim K, 2012, ONCOGENE, V31, P4290, DOI 10.1038/onc.2011.605; Lee C, 2011, ONCOGENE, V30, P3305, DOI 10.1038/onc.2011.91; Lessa RC, 2013, HEAD NECK-J SCI SPEC, V35, P1475, DOI 10.1002/hed.23169; Lew CR, 2012, J BIOL CHEM, V287, P42554, DOI 10.1074/jbc.M112.405969; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Meynet O, 2014, TRENDS MOL MED, V20, P419, DOI 10.1016/j.molmed.2014.05.001; Moreschi C, 1909, Z IMMUNITATSFORSCH, V2, P651; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; POGSON CI, 1967, NATURE, V216, P156, DOI 10.1038/216156a0; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; SCHAPIRA F, 1966, ENZYMOL BIOL CLIN, V7, P98, DOI 10.1159/000457208; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIBLEY JA, 1955, CANCER RES, V15, P306; Spindler SR, 2001, ANN NY ACAD SCI, V928, P296; Tang KF, 2008, J CELL BIOL, V182, P233, DOI 10.1083/jcb.200801169; TANNENBAUM A, 1953, CANCER RES, V13, P532; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Zhang PY, 2016, NUCLEIC ACIDS RES, V44, P3629, DOI 10.1093/nar/gkv1504	36	27	28	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1041	1048		10.1038/onc.2017.398	http://dx.doi.org/10.1038/onc.2017.398			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084207				2022-12-28	WOS:000425905700007
J	Araiza-Olivera, D; Feng, Y; Semenova, G; Prudnikova, TY; Rhodes, J; Chernoff, J				Araiza-Olivera, D.; Feng, Y.; Semenova, G.; Prudnikova, T. Y.; Rhodes, J.; Chernoff, J.			Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors	ONCOGENE			English	Article							ZEBRAFISH; MUTATIONS; RAC1; GTPASE; RAS; P21-ACTIVATED-KINASE-1; PROGRESSION	Activating mutations in the RAC1 gene have recently been discovered as driver events in malignant melanoma. Expression of this gene is associated with melanocyte proliferation, and melanoma cells bearing this mutation are insensitive to BRAF inhibitors such as vemurafenib and dabrafenib, and also may evade immune surveillance due to enhanced expression of PD-L1. Activating mutations in RAC1 are of special interest, as small-molecule inhibitors for the RAC effector p21-activated kinase (PAK) are in late-stage clinical development and might impede oncogenic signaling from mutant RAC1. In this work, we explore the effects of PAK inhibition on RAC1(P29S) signaling in zebrafish embryonic development, in the proliferation, survival and motility of RAC1(P29S)-mutant human melanoma cells, and on tumor formation and progression from such cells in mice. We report that RAC1(P29S) evokes a Rasopathy-like phenotype on zebrafish development that can be blocked by inhibitors of PAK or MEK. We also found and that RAC1-mutant human melanoma cells are resistant to clinical inhibitors of BRAF but are uniquely sensitive to PAK inhibitors. These data suggest that suppressing the PAK pathway might be of therapeutic benefit in this type of melanoma.	[Araiza-Olivera, D.; Feng, Y.; Semenova, G.; Prudnikova, T. Y.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Semenova, G.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Rhodes, J.] Fox Chase Canc Ctr, Blood Cell Dev Funct Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Araiza-Olivera, D.] Univ Nacl Autonoma Mexico, Inst Quim, Mexico City, DF, Mexico	Fox Chase Cancer Center; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Fox Chase Cancer Center; Universidad Nacional Autonoma de Mexico	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NIH CORE Grant [P30CA006927];  [R01CA227184]; NATIONAL CANCER INSTITUTE [R01CA142928, P30CA006927] Funding Source: NIH RePORTER	NIH CORE Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Ruth Halaban and Meenhard Herlyn for providing melanoma cell lines, and Dr Rebecca Burdine for Tg(cmlc2:EGFP) zebrafish, Genentech for providing Frax-1036 and the Fox Chase Cancer Center Animal Facility for assistance with zebrafish experiments. This work was supported by R01CA227184 (JC), NIH CORE Grant P30CA006927, and an appropriation from the state of Pennsylvania to the Fox Chase Cancer Center.	Anastasaki C, 2012, DIS MODEL MECH, V5, P546, DOI 10.1242/dmm.008672; Anastasaki C, 2009, HUM MOL GENET, V18, P2543, DOI 10.1093/hmg/ddp186; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Grzmil M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000959; Vu HL, 2015, PIGM CELL MELANOMA R, V28, P590, DOI 10.1111/pcmr.12392; Halaban R, 2016, J INVEST DERMATOL, V136, P1755, DOI 10.1016/j.jid.2016.05.095; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jindal GA, 2015, DIS MODEL MECH, V8, P769, DOI 10.1242/dmm.020339; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Li A, 2011, DEV CELL, V21, P722, DOI 10.1016/j.devcel.2011.07.008; Lightcap CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006025; Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Ong CC, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0564-5; Ong CC, 2013, JNCI-J NATL CANCER I, V105, P606, DOI 10.1093/jnci/djt054; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Rhodes J, 2009, MOL CELL BIOL, V29, P5911, DOI 10.1128/MCB.00558-09; Semenova G, 2017, BIOCHEM SOC T, V45, P79, DOI 10.1042/BST20160134; Shin JT, 2005, NUCLEIC ACIDS RES, V33, P5437, DOI 10.1093/nar/gki853; Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008-5472.CAN-14-1232-T	30	37	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					944	952		10.1038/onc.2017.400	http://dx.doi.org/10.1038/onc.2017.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059171	Green Accepted			2022-12-28	WOS:000425281800011
J	Cuyas, E; Fernandez-Arroyo, S; Verdura, S; Garcia, RAF; Stursa, J; Werner, L; Blanco-Gonzalez, E; Montes-Bayon, M; Joven, J; Viollet, B; Neuzil, J; Menendez, JA				Cuyas, E.; Fernandez-Arroyo, S.; Verdura, S.; Garcia, R. A-F; Stursa, J.; Werner, L.; Blanco-Gonzalez, E.; Montes-Bayon, M.; Joven, J.; Viollet, B.; Neuzil, J.; Menendez, J. A.			Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism	ONCOGENE			English	Article							HUMAN CELL-LINE; MESENCHYMAL TRANSITION; CANCER-CELLS; GENOME-WIDE; BREAST-CANCER; BRCA1 LEADS; AMP-KINASE; BIGUANIDES; SERINE; REVEALS	The anti-diabetic biguanide metformin may exert health-promoting effects via metabolic regulation of the epigenome. Here we show that metformin promotes global DNA methylation in non-cancerous, cancer-prone and metastatic cancer cells by decreasing S-adenosylhomocysteine (SAH), a strong feedback inhibitor of S-adenosylmethionine (SAM)-dependent DNA methyltransferases, while promoting the accumulation of SAM, the universal methyl donor for cellular methylation. Using metformin and a mitochondria/complex I (mCI)-targeted analog of metformin (norMitoMet) in experimental pairs of wild-type and AMP-activated protein kinase (AMPK)-, serine hydroxymethyltransferase 2 (SHMT2)- and mCI-null cells, we provide evidence that metformin increases the SAM: SAH ratio-related methylation capacity by targeting the coupling between serine mitochondrial one-carbon flux and CI activity. By increasing the contribution of one-carbon units to the SAM from folate stores while decreasing SAH in response to AMPK-sensed energetic crisis, metformin can operate as a metabolo-epigenetic regulator capable of reprogramming one of the key conduits linking cellular metabolism to the DNA methylation machinery.	[Cuyas, E.; Verdura, S.; Menendez, J. A.] Catalan Inst Oncol, Metab & Canc Grp, ProCURE Program Canc Therapeut Resistance, Girona, Catalonia, Spain; [Cuyas, E.; Verdura, S.; Menendez, J. A.] Girona Biomed Res Inst IDIBGI, Girona, Catalonia, Spain; [Fernandez-Arroyo, S.; Joven, J.] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ St Joan, Unitat Recerca Biomed, Reus, Spain; [Fernandez-Arroyo, S.; Joven, J.] Campus Int Excellence Southern Catalonia, Tarragona, Spain; [Garcia, R. A-F; Blanco-Gonzalez, E.; Montes-Bayon, M.] Univ Oviedo, Fac Chem, Dept Phys & Analyt Chem, Oviedo, Spain; [Stursa, J.; Werner, L.; Neuzil, J.] Inst Chem Technol, Prague, Czech Republic; [Stursa, J.; Werner, L.] Czech Acad Sci, Inst Biotechnol, Prague West, Czech Republic; [Viollet, B.] Inst Cochin, INSERM, U1016, Paris, France; [Viollet, B.] CNRS, UMR 8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Neuzil, J.] Griffith Univ, Sch Med Sci, Southport, Qld, Australia	Catalan Institute of Oncology; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University of Oviedo; University of Chemistry & Technology, Prague; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Griffith University	Menendez, JA (corresponding author), Girona Biomed Res Inst IDIBGI, Edifici M2,Parc Hosp Marti & Julia, E-17190 Salt, Girona, Spain.	jmenendez@iconcologia.net	Viollet, Benoit/O-6927-2017; Stursa, Jan/J-4255-2014; WERNER, LUKÁŠ/AAL-7888-2021; Cuyas, Elisabet/G-8582-2018; verdura, Sara/AAC-3696-2022; MENENDEZ, JAVIER A/C-6148-2016; Viollet, Benoit/N-2397-2019; Fernández-Arroyo, Salvador/M-6955-2015	Viollet, Benoit/0000-0002-0121-0224; verdura, Sara/0000-0001-8980-0423; MENENDEZ, JAVIER A/0000-0001-8733-4561; Viollet, Benoit/0000-0002-0121-0224; Fernández-Arroyo, Salvador/0000-0003-0147-1712; Alvarez-Fernandez Garcia, Roberto/0000-0002-9537-2215; Cuyas, Elisabet/0000-0001-5353-440X; Montes-Bayon, Maria/0000-0001-6114-9405; /0000-0002-2844-6739	Ministerio de Ciencia e Innovacion [SAF2016-80639-P]; Plan Nacional de I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) [2014 SGR229]; Department d'Economia I Coneixement, Catalonia, Spain; Czech Science Foundation [16-12816S]; Czech Health Research Council [16-31704A]; Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain [CD15/00033]; Armangue family (Girona, Catalonia)	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Plan Nacional de I+D+I, Spain(Spanish Government); Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Department d'Economia I Coneixement, Catalonia, Spain; Czech Science Foundation(Grant Agency of the Czech Republic); Czech Health Research Council; Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain(Instituto de Salud Carlos III); Armangue family (Girona, Catalonia)	This work was supported in part by grants from the Ministerio de Ciencia e Innovacion (Grant SAF2016-80639-P), Plan Nacional de I+D+I, Spain and the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014 SGR229), Department d'Economia I Coneixement, Catalonia, Spain, to Javier A Menendez and grants from the Czech Science Foundation (16-12816S) to Jan Stursa and Lukas Werner and the Czech Health Research Council (16-31704A) to Jiri Neuzil. Elisabet Cuyas is supported by a Sara Borrell post-doctoral contract CD15/00033 from the Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain, The Metabolism and Cancer laboratory is supported by an unrestricted grant from the Armangue family (Girona, Catalonia). This work is in memory of Joan Armangue who passed away after his brave fight against cancer in November 2016.	Banerjee P, 2016, J MOL MED, V94, P1397, DOI 10.1007/s00109-016-1455-7; Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011; Boukalova S, 2016, MOL CANCER THER, V15, P2875, DOI 10.1158/1535-7163.MCT-15-1021; Bridges HR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0287-9; Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; Cecco M, 2013, AGING CELL, V12, P247, DOI 10.1111/acel.12047; Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534; Corominas-Faja B, 2012, AGING-US, V4, P480, DOI 10.18632/aging.100472; Cuyas E, 2016, ONCOTARGET, V7, P52974, DOI 10.18632/oncotarget.9732; Cuyas E, 2014, ONCOTARGET, V5, P3970, DOI 10.18632/oncotarget.2147; Duncan CG, 2012, GENOME RES, V22, P2339, DOI 10.1101/gr.132738.111; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Fernandez-Arroyo S., 2016, ONCOSCIENCE, V2, P958, DOI [10.18632/oncoscience.280, DOI 10.18632/ONCOSCIENCE.280]; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Gravel SP, 2014, CANCER RES, V74, P7521, DOI 10.1158/0008-5472.CAN-14-2643-T; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Houde VP, 2014, BIOCHEM J, V458, P41, DOI 10.1042/BJ20131324; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Iglesias T, 2015, ANAL BIOANAL CHEM, V407, P2423, DOI 10.1007/s00216-014-8070-7; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8; Kodiha M, 2011, AM J PHYSIOL-CELL PH, V301, pC1307, DOI 10.1152/ajpcell.00309.2011; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Kotecki M, 1999, EXP CELL RES, V252, P273, DOI 10.1006/excr.1999.4656; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liu XJ, 2016, CELL METAB, V24, P728, DOI 10.1016/j.cmet.2016.09.005; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Maddocks ODK, 2017, NATURE, V544, P372, DOI 10.1038/nature22056; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; Meiser J, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601273; Meiser J, 2016, FEBS J, V283, P3695, DOI 10.1111/febs.13731; Menendez JA, 2016, ONCOTARGET, V7, P11959, DOI 10.18632/oncotarget.7867; Menendez JA, 2016, STEM CELL REP, V6, P273, DOI 10.1016/j.stemcr.2015.12.012; Miller RA, 2013, NATURE, V494, P256, DOI 10.1038/nature11808; Miousse IR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/131547; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; Newman AC, 2017, BRIT J CANCER, V116, P1499, DOI 10.1038/bjc.2017.118; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Ross FA, 2016, BIOCHEM J, V473, P189, DOI 10.1042/BJ20150910; Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505; Sharma U, 2017, CELL METAB, V25, P544, DOI 10.1016/j.cmet.2017.02.003; Talarico G, 2016, SCI REP-UK, V6, DOI 10.1038/srep18673; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Yang M, 2013, J CLIN INVEST, V123, P3652, DOI 10.1172/JCI67228; Yang QY, 2016, CELL METAB, V24, P542, DOI 10.1016/j.cmet.2016.08.010; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221	56	64	67	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					963	970		10.1038/onc.2017.367	http://dx.doi.org/10.1038/onc.2017.367			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059169				2022-12-28	WOS:000425281800013
J	Dietrich, P; Kuphal, S; Spruss, T; Hellerbrand, C; Bosserhoff, AK				Dietrich, P.; Kuphal, S.; Spruss, T.; Hellerbrand, C.; Bosserhoff, A. K.			Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITION; MEK INHIBITION; METASTATIC MELANOMA; PATHWAY; EXPRESSION; RAF; TUMORIGENESIS; VEMURAFENIB; ACTIVATION; EVOLUTION	Malignant melanoma reveals rapidly increasing incidence and mortality rates worldwide. By now, BRAF inhibition is the standard therapy for advanced melanoma in patients carrying BRAF mutations. However, only approximately 50% of melanoma patients harbor therapeutically attackable BRAF mutations, and overall survival after treatment with BRAF inhibitors is modest. KRAS (Kirsten Rat sarcoma) proteins are acting upstream of BRAF and have a major role in human cancer. Recent approaches awaken the hope to use KRAS inhibition (KRASi) as a clinical tool. In this study, we identified wild-type KRAS as a novel therapeutic target in melanoma. KRASi functions synergistically with BRAF inhibition to reduce melanoma proliferation and to induce apoptosis independently of BRAF mutational status. Moreover, acquired resistance to BRAF inhibitors in melanoma is dependent on dynamic regulation of KRAS expression with subsequent AKT and extracellular-signal regulated kinase activation and can be overcome by KRASi. This suggests KRASi as novel approach in melanoma-alone or in combination with other therapeutic regimes.	[Dietrich, P.; Kuphal, S.; Hellerbrand, C.; Bosserhoff, A. K.] Friedrich Alexander Univ Erlangen Nuremberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany; [Spruss, T.] Univ Regensburg, Inst Pharm, Regensburg, Germany; [Hellerbrand, C.; Bosserhoff, A. K.] Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany	University of Erlangen Nuremberg; University of Regensburg; University of Erlangen Nuremberg	Bosserhoff, AK (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany.	anja.bosserhoff@fau.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X	German Research Association (DFG) [RTG 1962/1]; German Cancer Aid (Deutsche Krebshilfe); Bavarian Research Network for Molecular Biosystems (BioSysNet); Interdisciplinary Center for Clinical Research (IZKF) Erlangen [J55, D24]	German Research Association (DFG)(German Research Foundation (DFG)); German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); Bavarian Research Network for Molecular Biosystems (BioSysNet); Interdisciplinary Center for Clinical Research (IZKF) Erlangen	This work was supported by the German Research Association (DFG) (Research Training Group 'RTG 1962/1', University of Erlangen), the German Cancer Aid (Deutsche Krebshilfe), the Bavarian Research Network for Molecular Biosystems (BioSysNet) and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (J55, to PD and D24, to AB). We thank Meenhard Herlyn (The Wistar Institute, Philadelphia, USA) for providing the resistant cell lines. Furthermore, we thank Rudolf Jung, Annette Serwotka and Darleen Schonwalder for technical assistance.	[Anonymous], 2013, Cancer Discov, V3, pOF20, DOI 10.1158/2159-8290.CD-RW2013-116; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Carlino MS, 2015, J CLIN ONCOL, V33, pE52, DOI 10.1200/JCO.2013.51.5783; Chapuis AG, 2016, J EXP MED, V213, P1133, DOI 10.1084/jem.20152021; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Depasquale I, 2005, HISTOPATHOLOGY, V47, P186, DOI 10.1111/j.1365-2559.2005.02193.x; Dummer R, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mds229; Fan XZ, 2014, J EXP MED, V211, P715, DOI 10.1084/jem.20130590; Gimotty PA, 2005, J CLIN ONCOL, V23, P8048, DOI 10.1200/JCO.2005.02.0735; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Gross A, 2015, TARGET ONCOL, V10, P77, DOI 10.1007/s11523-014-0318-9; Harries M, 2016, EUR J CANCER, V60, P179, DOI 10.1016/j.ejca.2016.01.011; Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Johnson DB, 2015, JAMA ONCOL, V1, P380, DOI 10.1001/jamaoncol.2015.0565; Karimkhani C, 2014, AM J CLIN DERMATOL, V15, P323, DOI 10.1007/s40257-014-0083-7; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Ledford H, 2015, NATURE, V520, P278, DOI 10.1038/520278a; Leiter Ulrike, 2014, Adv Exp Med Biol, V810, P120; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Luke JJ, 2014, DRUG HEALTHC PATIENT, V6, P77, DOI 10.2147/DHPS.S39568; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Milroy LG, 2014, ACS CHEM BIOL, V9, P2447, DOI 10.1021/cb500555h; Monsma DJ, 2015, AM J CANCER RES, V5, P1507; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Perna D, 2015, P NATL ACAD SCI USA, V112, pE536, DOI 10.1073/pnas.1418163112; Posch C, 2015, J INVEST DERMATOL, V135, P2475, DOI 10.1038/jid.2015.198; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Queirolo P, 2015, CANCER TREAT REV, V41, P519, DOI 10.1016/j.ctrv.2015.04.010; Richman J, 2015, EXPERT OPIN PHARMACO, V16, P1285, DOI 10.1517/14656566.2015.1044971; Ruiz C, 2015, PHYS BIOL, V12, DOI 10.1088/1478-3975/12/1/016008; Sale MJ, 2013, BRIT J PHARMACOL, V169, P1708, DOI 10.1111/bph.12220; Schmick M, 2014, CELL, V157, P459, DOI 10.1016/j.cell.2014.02.051; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sweetlove M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00135; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang JH, 2015, J INVEST DERMATOL, V135, P532, DOI 10.1038/jid.2014.418; Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wilson MA, 2016, CLIN CANCER RES, V22, P374, DOI 10.1158/1078-0432.CCR-15-1162; Xue W, 2014, P NATL ACAD SCI USA, V111, pE3553, DOI 10.1073/pnas.1412686111; Yang J, 2015, BIOCHEM BIOPH RES CO, V463, P900, DOI 10.1016/j.bbrc.2015.06.032; Yuan TL, 2014, CANCER DISCOV, V4, P1182, DOI 10.1158/2159-8290.CD-13-0900; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	55	29	30	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					897	911		10.1038/onc.2017.391	http://dx.doi.org/10.1038/onc.2017.391			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059159				2022-12-28	WOS:000425281800007
J	Umeda, Y; Hasegawa, Y; Otsuka, M; Ariki, S; Takamiya, R; Saito, A; Uehara, Y; Saijo, H; Kuronuma, K; Chiba, H; Ohnishi, H; Sakuma, Y; Takahashi, H; Kuroki, Y; Takahashi, M				Umeda, Y.; Hasegawa, Y.; Otsuka, M.; Ariki, S.; Takamiya, R.; Saito, A.; Uehara, Y.; Saijo, H.; Kuronuma, K.; Chiba, H.; Ohnishi, H.; Sakuma, Y.; Takahashi, H.; Kuroki, Y.; Takahashi, M.			Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; PULMONARY COLLECTINS; INNATE IMMUNITY; MECHANISM; BINDING; DISEASE; DOMAIN; LIPOPOLYSACCHARIDE	Tyrosine kinase inhibitor (TKI)-sensitive and TKI-resistant mutations of epidermal growth factor receptor (EGFR) are associated with lung adenocarcinoma. EGFR mutants were previously shown to exhibit ligand-independent activation. We have previously demonstrated that pulmonary surfactant protein D (SP-D, SFTPD) suppressed wild-type EGFR signaling by blocking ligand binding to EGFR. We herein demonstrate that SFTPD downregulates ligand-independent signaling in cells harboring EGFR mutations such as TKI-sensitive exon 19 deletion (Ex19del) and L858R mutation as well as TKI-resistant T790M mutation, subsequently suppressing cellular growth and motility. Lectin blotting and ligand blotting in lung cancer cell lines suggested that EGFR mutants express oligomannose-type N-glycans and interact with SFTPD directly. Cross-linking assay indicated that SFTPD inhibits ligand-independent dimerization of EGFR mutants. We also demonstrated that SFTPD reduced dimerization-independent phosphorylation of Ex19del and T790M EGFR mutants using point mutations that disrupted the asymmetric dimer interface. It was confirmed that SFTPD augmented the viability-suppressing effects of EGFR-TKIs. Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival. These findings suggest that SFTPD downregulates both TKI-sensitive and -resistant EGFR mutant signaling, and SFTPD level is correlated with clinical outcome. These findings illustrate the use of serum SFTPD level as a potential marker to estimate the efficacy of EGFR-TKIs.	[Umeda, Y.; Hasegawa, Y.; Otsuka, M.; Saito, A.; Uehara, Y.; Saijo, H.; Kuronuma, K.; Chiba, H.; Takahashi, H.] Sapporo Med Univ, Res Inst Frontier Med, Dept Resp Med & Allergol, Sch Med, Sapporo, Hokkaido, Japan; [Hasegawa, Y.; Ariki, S.; Takamiya, R.; Saito, A.; Uehara, Y.; Kuroki, Y.; Takahashi, M.] Sapporo Med Univ, Res Inst Frontier Med, Dept Biochem, Sch Med, Sapporo, Hokkaido, Japan; [Ohnishi, H.] Sapporo Med Univ, Res Inst Frontier Med, Dept Publ Hlth, Sch Med, Sapporo, Hokkaido, Japan; [Sakuma, Y.] Sapporo Med Univ, Res Inst Frontier Med, Dept Mol Med, Sch Med, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Takahashi, M (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Biochem, Sch Med,Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	takam@sapmed.ac.jp	Saito, Atsushi/M-7382-2018; Ariki, Shigeru/E-3861-2014; Sakuma, Yuji/HGC-0692-2022; Takahashi, Motoko/I-3154-2013	Saito, Atsushi/0000-0003-3430-884X; Ariki, Shigeru/0000-0001-5838-499X; Sakuma, Yuji/0000-0003-2298-1359; UMEDA, YASUAKI/0000-0001-9577-3353; Uehara, Yasuaki/0000-0002-6439-2715; Ohnishi, Hirofumi/0000-0002-5873-6438; Takahashi, Motoko/0000-0002-2112-6142	Japan Society for the Promotion of Science [26860611]; Northern Advancement Center for Science Technology [H26 T-1-35]; Ito Foundation [H26-23]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Northern Advancement Center for Science Technology; Ito Foundation	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (26860611), grants from the Northern Advancement Center for Science & Technology (H26 T-1-35) and grants from the Ito Foundation (H26-23).	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; BETZ C, 1995, CANCER RES, V55, P4283; Bianco R, 2008, CLIN CANCER RES, V14, P5069, DOI 10.1158/1078-0432.CCR-07-4905; Cho J, 2013, CANCER RES, V73, P6770, DOI 10.1158/0008-5472.CAN-13-1145; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Dokala A, 2017, ONCOGENE, V36, P2337, DOI 10.1038/onc.2016.393; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hase T, 2011, CANCER SCI, V102, P1493, DOI 10.1111/j.1349-7006.2011.01973.x; Hasegawa Y, 2015, ONCOGENE, V34, P838, DOI [10.1038/onc.2014.20, 10.1038/onc.2015.266]; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Nagae H, 1997, CLIN CHIM ACTA, V266, P157, DOI 10.1016/S0009-8981(97)00124-1; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Ohya M, 2006, BIOCHEMISTRY-US, V45, P8657, DOI 10.1021/bi060176z; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Pan JB, 2014, CLIN LAB, V60, P1439, DOI 10.7754/Clin.Lab.2013.131002; Red Brewer M, 2013, P NATL ACAD SCI USA, V110, pE3595, DOI 10.1073/pnas.1220050110; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Sawada K, 2010, J BIOL CHEM, V285, P8434, DOI 10.1074/jbc.M109.074765; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaykhiev R, 2013, P NATL ACAD SCI USA, V110, P12102, DOI 10.1073/pnas.1303058110; Takahashi H, 2000, AM J RESP CRIT CARE, V162, P1109, DOI 10.1164/ajrccm.162.3.9910080; Takahashi H, 2000, AM J RESP CRIT CARE, V162, P258, DOI 10.1164/ajrccm.162.1.9903014; Takahashi H, 1996, RESPIRATION, V63, P390; Takahashi M, 2013, J BIOL CHEM, V288, P32910, DOI 10.1074/jbc.M113.491902; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; VANDEGRAAF EA, 1992, J LAB CLIN MED, V120, P252; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Romero-Ventosa EY, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0891-0; Yamaguchi H, 2011, CANCER CHEMOTH PHARM, V67, P331, DOI 10.1007/s00280-010-1325-x; Yamazoe M, 2008, J BIOL CHEM, V283, P35878, DOI 10.1074/jbc.M807268200; Yatabe Y, 2006, J MOL DIAGN, V8, P335, DOI 10.2353/jmoldx.2006.050104; Yu HA, 2014, CLIN CANCER RES, V20, P5898, DOI 10.1158/1078-0432.CCR-13-2437; Zhang F, 2004, CHEST, V125, p109S, DOI 10.1378/chest.125.5_suppl.109S; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998	49	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6432	6445		10.1038/onc.2017.253	http://dx.doi.org/10.1038/onc.2017.253			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745320				2022-12-28	WOS:000415622900007
J	Frisch, SM; Farris, JC; Pifer, PM				Frisch, S. M.; Farris, J. C.; Pifer, P. M.			Roles of Grainyhead-like transcription factors in cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; 2 GRHL2; TUMOR-SUPPRESSOR; RECIPROCAL FEEDBACK; TIGHT JUNCTIONS; CELL POLARITY; BREAST-CANCER; MOUSE MODELS; BETA-CATENIN; WOUND REPAIR	The mammalian homologs of the D. melanogaster Grainyhead gene, Grainyhead-like 1-3 (GRHL1, GRHL2 and GRHL3), are transcription factors implicated in wound healing, tubulogenesis and cancer. Their induced target genes encode diverse epithelial cell adhesion molecules, while mesenchymal genes involved in cell migration and invasion are repressed. Moreover, GRHL2 suppresses the oncogenic epithelial-mesencyhmal transition, thereby acting as a tumor suppressor. Mechanisms, some involving established cancer-related signaling/transcription factor pathways (for example, Wnt, TGF-beta, mir200, ZEB1, OVOL2, p63 and p300) and translational implications of the Grainyhead proteins in cancer are discussed in this review article.	[Frisch, S. M.; Farris, J. C.; Pifer, P. M.] West Virginia Univ, Inst Canc, 1 Med Ctr Dr,Room 2833, Morgantown, WV 26506 USA	West Virginia University	Frisch, SM (corresponding author), West Virginia Univ, Inst Canc, 1 Med Ctr Dr,Room 2833, Morgantown, WV 26506 USA.	sfrisch@hsc.wvu.edu						Adrain C, 2011, EMBO REP, V12, P421, DOI 10.1038/embor.2011.50; Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Castilla MA, 2014, ENDOCR-RELAT CANCER, V21, P587, DOI 10.1530/ERC-13-0485; Auden A, 2006, GENE EXPR PATTERNS, V6, P964, DOI 10.1016/j.modgep.2006.03.011; Aue A, 2015, J AM SOC NEPHROL, V26, P2704, DOI 10.1681/ASN.2014080759; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Bhandari A, 2013, ONCOGENE, V32, P1497, DOI 10.1038/onc.2012.168; Boglev Y, 2011, DEV BIOL, V349, P512, DOI 10.1016/j.ydbio.2010.11.011; Boon M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5418; Boxer LD, 2014, GENE DEV, V28, P2013, DOI 10.1101/gad.246579.114; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; Brouns MR, 2011, HUM MOL GENET, V20, P1536, DOI 10.1093/hmg/ddr031; Broussard JA, 2015, CELL TISSUE RES, V360, P501, DOI 10.1007/s00441-015-2136-5; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Chen W, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.190; Chen W, 2013, J BIOL CHEM, V285, P40852; Chen W, 2016, CARCINOGENESIS, V37, P500, DOI 10.1093/carcin/bgw027; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Chung MI, 2014, ELIFE, V3, DOI 10.7554/eLife.01439; Chung VY, 2016, SCI REP-UK, V6, DOI 10.1038/srep19943; Cieply B, 2016, CELL REP, V15, P247, DOI 10.1016/j.celrep.2016.03.025; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Clausen KA, 2011, BREAST CANCER RES TR, V129, P737, DOI 10.1007/s10549-010-1261-9; Creedon H, 2016, ONCOTARGET, V7, P11539, DOI 10.18632/oncotarget.7317; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Darido C, 2016, ONCOGENE, V35, P5705, DOI 10.1038/onc.2016.84; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642; Dompe N, 2011, P NATL ACAD SCI USA, V108, pE943, DOI 10.1073/pnas.1100132108; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; Fabian J, 2014, CANCER RES, V74, P2604, DOI 10.1158/0008-5472.CAN-13-1904; Farris JC, 2016, MOL CANCER RES, V14, P528, DOI 10.1158/1541-7786.MCR-16-0050; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Gao X, 2015, J CELL BIOL, V211, P669, DOI 10.1083/jcb.201506014; Gao X, 2013, P NATL ACAD SCI USA, V110, P9356, DOI 10.1073/pnas.1307589110; Gopal S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14105; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hazawa M, 2017, ONCOGENE, V36, P2243, DOI 10.1038/onc.2016.377; Hemphala J, 2003, DEVELOPMENT, V130, P249, DOI 10.1242/dev.00218; Hopkin AS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002829; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052; Jazbutyte V, 2010, CURR DRUG TARGETS, V11, P926, DOI 10.2174/138945010791591403; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kang X, 2009, ONCOGENE, V28, P565, DOI 10.1038/onc.2008.404; Kessenbrock K, 2015, MATRIX BIOL, V44-46, P184, DOI 10.1016/j.matbio.2015.01.022; Kokoszynska K, 2008, CELL CYCLE, V7, P2907, DOI 10.4161/cc.7.18.6680; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; List K, 2009, FUTURE ONCOL, V5, P97, DOI 10.2217/14796694.5.1.97; Mace KA, 2005, SCIENCE, V308, P381, DOI 10.1126/science.1107573; Marazuela M, 2004, HISTOL HISTOPATHOL, V19, P925, DOI 10.14670/HH-19.925; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Margadant C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065341; Martin TA, 2014, SEMIN CELL DEV BIOL, V36, P224, DOI 10.1016/j.semcdb.2014.09.008; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; Mehrazarin S, 2015, J BIOL CHEM, V290, P19999, DOI 10.1074/jbc.M115.659144; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Mlacki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089247; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Oliveras-Ferraros C, 2012, CELL CYCLE, V11, P4020, DOI 10.4161/cc.22225; Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002; Pifer PM, 2016, MOL BIOL CELL, V27, P2479, DOI 10.1091/mbc.E16-04-0249; Previs RA, 2015, CLIN CANCER RES, V21, P955, DOI 10.1158/1078-0432.CCR-14-0809; Pyrgaki C, 2011, DEV BIOL, V353, P38, DOI 10.1016/j.ydbio.2011.02.027; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Ramena G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147489; Ray HJ, 2016, DEVELOPMENT, V143, P1192, DOI 10.1242/dev.129825; Riethdorf S, 2016, INT J CANCER, V138, P949, DOI 10.1002/ijc.29841; Rifat Y, 2010, DEV BIOL, V345, P237, DOI 10.1016/j.ydbio.2010.07.017; Ringel AE, 2013, STRUCTURE, V21, P1479, DOI 10.1016/j.str.2013.08.011; Santer FR, 2011, MOL CANCER THER, V10, P1644, DOI 10.1158/1535-7163.MCT-11-0182; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Senga K, 2012, MOL BIOL CELL, V23, P2845, DOI 10.1091/mbc.E12-02-0097; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Singh BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106937; Somarelli JA, 2016, MOL CELL BIOL, V36, P2503, DOI 10.1128/MCB.00373-16; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Tanimizu N, 2013, J CELL SCI, V126, P5239, DOI 10.1242/jcs.133082; Tarbe NG, 2005, INT J CANCER, V117, P913, DOI 10.1002/ijc.21275; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Ting SB, 2003, BIOCHEM J, V370, P953, DOI 10.1042/BJ20021476; Traylor-Knowles N, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-101; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; Varma S, 2014, AM J PHYSIOL-LUNG C, V306, pL405, DOI 10.1152/ajplung.00143.2013; Varma S, 2012, J BIOL CHEM, V287, P37282, DOI 10.1074/jbc.M112.408401; Walentin K, 2015, DEVELOPMENT, V142, P1125, DOI 10.1242/dev.113829; Wang SQ, 2012, CURR TOP DEV BIOL, V98, P35, DOI 10.1016/B978-0-12-386499-4.00002-1; Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006; Werner S, 2013, J BIOL CHEM, V288, P22993, DOI 10.1074/jbc.M113.456293; Werth M, 2010, DEVELOPMENT, V137, P3835, DOI 10.1242/dev.055483; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; Wilanowski T, 2008, EMBO J, V27, P886, DOI 10.1038/emboj.2008.24; Xiang J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.83; Xiang JF, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0714-5; Xiang XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050781; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu Y, 2014, INT J BIOL SCI, V10, P396, DOI 10.7150/ijbs.8193; Yamaguchi Y, 2006, DEVELOPMENT, V133, P4737, DOI 10.1242/dev.02658; Yang CS, 2014, CELL REP, V8, P326, DOI 10.1016/j.celrep.2014.07.002; Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yeung TL, 2017, ONCOTARGET, V8, P16951, DOI 10.18632/oncotarget.15208; Yu ZQ, 2008, DEV BIOL, V319, P56, DOI 10.1016/j.ydbio.2008.04.001; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Yu ZQ, 2009, EMBO J, V28, P1890, DOI 10.1038/emboj.2009.142; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou BY, 2012, J BIOL CHEM, V287, P7026, DOI 10.1074/jbc.M111.276311	126	33	34	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6067	6073		10.1038/onc.2017.178	http://dx.doi.org/10.1038/onc.2017.178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28714958				2022-12-28	WOS:000414249800001
J	Huskova, H; Ardin, M; Weninger, A; Vargova, K; Barrin, S; Villar, S; Olivier, M; Stopka, T; Herceg, Z; Hollstein, M; Zavadil, J; Korenjak, M				Huskova, H.; Ardin, M.; Weninger, A.; Vargova, K.; Barrin, S.; Villar, S.; Olivier, M.; Stopka, T.; Herceg, Z.; Hollstein, M.; Zavadil, J.; Korenjak, M.			Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing	ONCOGENE			English	Article							TUMOR P53 MUTATIONS; SWI/SNF COMPLEXES; SOMATIC MUTATIONS; ARISTOLOCHIC ACID; PATHWAYS; PATTERNS; GENES; CELLS; IMMORTALIZATION; INVESTIGATE	The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.	[Huskova, H.; Ardin, M.; Villar, S.; Olivier, M.; Hollstein, M.; Zavadil, J.; Korenjak, M.] Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France; [Huskova, H.; Stopka, T.] Charles Univ Prague, Fac Med 1, Biocev, Prague, Czech Republic; [Weninger, A.; Hollstein, M.] Deutsch Krebsforschungszentrum, Heidelberg, Germany; [Vargova, K.] Charles Univ Prague, Fac Med 1, Pathol Physiol, Prague, Czech Republic; [Barrin, S.] Inst Cochin, Inserm U1016, Dynam T Cell Interact Team, Paris, France; [Herceg, Z.] Int Agcy Res Canc, Epigenet Grp, Lyon, France; [Hollstein, M.] Univ Leeds, LIGHT Labs, Fac Med & Hlth, Leeds, W Yorkshire, England	World Health Organization; International Agency for Research on Cancer (IARC); Charles University Prague; Helmholtz Association; German Cancer Research Center (DKFZ); Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; World Health Organization; International Agency for Research on Cancer (IARC); University of Leeds	Zavadil, J; Korenjak, M (corresponding author), Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.; Hollstein, M (corresponding author), Univ Leeds, LIGHT Labs, Fac Med & Hlth, Leeds, W Yorkshire, England.	M.Hollstein@leeds.ac.uk; zavadilj@iarc.fr; korenjakm@iarc.fr	Savvulidi Vargova, Karina/ABE-7513-2021; Stopka, Tomáš/D-5864-2017; Zavadil, Jiri/ABG-1780-2020	Savvulidi Vargova, Karina/0000-0002-4969-4133; Stopka, Tomáš/0000-0001-7236-6894; Zavadil, Jiri/0000-0003-0640-5562; Huskova, Hana/0000-0003-3088-4081	INCa-INSERM Plan Cancer [2015 ENV201507]; Ministry of Education, Youth and sports of the Czech Republic [LQ1604]; European Regional Development Fund [CZ.1.05/1.1.00/02.0109]; Czech Science Foundation GACR [GACR 16-27790A]; Ministry of Health/Grant Agency for Health Research of the Czech Republic [AZV 16-27790A]; Charles University in Prague [LH15170, UNCE 204021]; First Faculty of Medicine, Charles University in Prague, Czech Republic; NIH/NCI [P30 CA016087-33]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	INCa-INSERM Plan Cancer; Ministry of Education, Youth and sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); European Regional Development Fund(European Commission); Czech Science Foundation GACR(Grant Agency of the Czech Republic); Ministry of Health/Grant Agency for Health Research of the Czech Republic; Charles University in Prague; First Faculty of Medicine, Charles University in Prague, Czech Republic; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the group of Hiroyuki Marusawa, Kyoto University, Japan, for providing cells from Hupki-activation-induced cytidine deaminase transgenic mice, Adriana Heguy (NYU Genome Technology Center) for next-generation sequencing support, Christine Carreira (IARC) for antibodies, the Centre Leon Berard in Lyon, France, for providing computational capacity, and Leigh Ellis, Roswell Park Cancer Institute for technical advice. This work was supported by INCa-INSERM Plan Cancer 2015 ENV201507 Grant to JZ; Ministry of Education, Youth and sports of the Czech Republic (LQ1604), European Regional Development Fund (CZ.1.05/1.1.00/02.0109), Czech Science Foundation GACR (GACR 16-27790A) and Ministry of Health/Grant Agency for Health Research of the Czech Republic (AZV 16-27790A) to TS; and Charles University in Prague institutional financing ([LH15170, UNCE 204021) and the Mobility fund, First Faculty of Medicine, Charles University in Prague, Czech Republic to KV. NYU Technology Center is funded in part by grant NIH/NCI P30 CA016087-33.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768; Celis JE, 2006, CELL BIOL LAB HDB, P4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Feldmeyer N, 2006, MUTAT RES-GEN TOX EN, V608, P163, DOI 10.1016/j.mrgentox.2006.02.017; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gonzalez-Perez A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r106; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hollstein M, 2017, ONCOGENE, V36, P158, DOI 10.1038/onc.2016.192; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kim JE, 2017, ONCOGENE, V36, P219, DOI 10.1038/onc.2016.193; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Leiserson MDM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003054; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Miller CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-34; Nedelko T, 2009, INT J CANCER, V124, P987, DOI 10.1002/ijc.24006; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Reinbold M, 2008, ONCOGENE, V27, P2788, DOI 10.1038/sj.onc.1210932; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, BIOINFORMATICS, V29, P2238, DOI 10.1093/bioinformatics/btt395; Vandin F, 2012, GENOME RES, V22, P375, DOI 10.1101/gr.120477.111; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Youn A, 2011, BIOINFORMATICS, V27, P175, DOI 10.1093/bioinformatics/btq630; Zhao JF, 2012, BIOINFORMATICS, V28, P2940, DOI 10.1093/bioinformatics/bts564	51	6	6	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6041	6048		10.1038/onc.2017.215	http://dx.doi.org/10.1038/onc.2017.215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28692054	Green Published, hybrid			2022-12-28	WOS:000413841400012
J	Damsky, WE; Bosenberg, M				Damsky, W. E.; Bosenberg, M.			Melanocytic nevi and melanoma: unraveling a complex relationship	ONCOGENE			English	Review							ONCOGENE-INDUCED SENESCENCE; TERT PROMOTER MUTATIONS; CUTANEOUS MALIGNANT-MELANOMA; DNA-DAMAGE-RESPONSE; TUMOR-INFILTRATING LYMPHOCYTES; STRESS-INDUCED AUTOPHAGY; GENOME-WIDE ASSOCIATION; CELLULAR SENESCENCE; BRAF MUTATIONS; SPONTANEOUS REGRESSION	Approximately 33% of melanomas are derived directly from benign, melanocytic nevi. Despite this, the vast majority of melanocytic nevi, which typically form as a result of BRAFV600E-activating mutations, will never progress to melanoma. Herein, we synthesize basic scientific insights and data from mouse models with common observations from clinical practice to comprehensively review melanocytic nevus biology. In particular, we focus on the mechanisms by which growth arrest is established after BRAFV600E mutation. Means by which growth arrest can be overcome and how melanocytic nevi relate to melanoma are also considered. Finally, we present a new conceptual paradigm for understanding the growth arrest of melanocytic nevi in vivo termed stable clonal expansion. This review builds upon the canonical hypothesis of oncogene-induced senescence in growth arrest and tumor suppression in melanocytic nevi and melanoma.	[Damsky, W. E.; Bosenberg, M.] Yale Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06520 USA; [Bosenberg, M.] Yale Sch Med, Dept Pathol, New Haven, CT USA	Yale University; Yale University	Damsky, WE; Bosenberg, M (corresponding author), Yale Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06520 USA.	william.damsky@yale.edu; marcus.bosenberg@yale.edu			Melanoma Research Alliance; Melanoma Research Foundation; Hervey Family Foundation;  [R01 CA196660];  [P50 CA121974];  [P01CA128814]; NATIONAL CANCER INSTITUTE [P50CA121974, P01CA128814, R01CA196660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016] Funding Source: NIH RePORTER	Melanoma Research Alliance; Melanoma Research Foundation; Hervey Family Foundation; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We would like to acknowledge the following funding sources: R01 CA196660, P50 CA121974, P01CA128814, the Melanoma Research Alliance, the Melanoma Research Foundation and the Hervey Family Foundation (to MB).	Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; AHMED AA, 1995, AM J DERMATOPATH, V17, P222, DOI 10.1097/00000372-199506000-00002; AHMED I, 1990, J AM ACAD DERMATOL, V22, P727, DOI 10.1016/0190-9622(90)70098-3; Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alaibac M, 2003, J AM ACAD DERMATOL, V49, P1020, DOI 10.1016/S0190-9622(03)02482-4; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Annessi G, 2001, J AM ACAD DERMATOL, V45, P77, DOI 10.1067/mjd.2001.114580; Aoude LG, 2015, PIGM CELL MELANOMA R, V28, P148, DOI 10.1111/pcmr.12333; Aoude LG, 2015, JNCI-J NATL CANCER I, V107, P1, DOI DOI 10.1093/JNCI/DJU40825505254; Aouthmany M, 2012, J AM ACAD DERMATOL, V67, P582, DOI 10.1016/j.jaad.2011.11.937; Arumi-Uria M, 2003, MODERN PATHOL, V16, P764, DOI 10.1097/01.MP.0000082394.91761.E5; Ascierto ML, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00152; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Baek KH, 2017, METHODS MOL BIOL, V1534, P185, DOI 10.1007/978-1-4939-6670-7_18; BAKER MA, 1973, LANCET, V1, P1117; Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x; Barnhill R.L., 2014, PATHOLOGY MELANOCYTI; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bastian BC, 2003, ARCH DERMATOL, V139, P667, DOI 10.1001/archderm.139.5.667; Bastian BC, 2003, ONCOGENE, V22, P3081, DOI 10.1038/sj.onc.1206463; Bastian BC, 2003, AM J DERMATOPATH, V25, P83, DOI 10.1097/00000372-200302000-00018; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Bataille V, 2007, CANCER EPIDEM BIOMAR, V16, P1499, DOI 10.1158/1055-9965.EPI-07-0152; Bauer J, 2003, PIGM CELL RES, V16, P297, DOI 10.1034/j.1600-0749.2003.00047.x; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bevona C, 2003, ARCH DERMATOL, V139, P1620, DOI 10.1001/archderm.139.12.1620; Bishop JAN, 2000, J INVEST DERMATOL, V114, P28, DOI 10.1046/j.1523-1747.2000.00823.x; BLACK WC, 1988, CANCER, V62, P163, DOI 10.1002/1097-0142(19880701)62:1<163::AID-CNCR2820620126>3.0.CO;2-N; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bogdan I, 2003, MELANOMA RES, V13, P213, DOI 10.1097/00008390-200304000-00018; Botella-Estrada R, 2015, AM J DERMATOPATH, V37, P376, DOI 10.1097/DAD.0000000000000205; Brewer JD, 2015, INT J DERMATOL, V54, pE287, DOI 10.1111/ijd.12564; Brito MB, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00166; Calado RT, 2013, SEMIN HEMATOL, V50, P165, DOI 10.1053/j.seminhematol.2013.03.030; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; CARR J, 1994, BRIT J DERMATOL, V131, P72, DOI 10.1111/j.1365-2133.1994.tb08460.x; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chai E, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12195; Chan MP, 2010, J CUTAN PATHOL, V37, P843, DOI 10.1111/j.1600-0560.2009.01491.x; Chandeck C, 2010, ADV ANAT PATHOL, V17, P42, DOI 10.1097/PAP.0b013e3181c66f4e; Chen B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042598; Chen HS, 2015, MOL CELL, V59, P719, DOI 10.1016/j.molcel.2015.07.011; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Conway K, 2011, PIGM CELL MELANOMA R, V24, P352, DOI 10.1111/j.1755-148X.2011.00828.x; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; CURRAN RC, 1976, J PATHOL, V119, P135, DOI 10.1002/path.1711190303; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dadzie OE, 2009, BRIT J DERMATOL, V160, P368, DOI 10.1111/j.1365-2133.2008.08887.x; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; Damsky W, 2015, CANCER CELL, V27, P41, DOI 10.1016/j.ccell.2014.11.014; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Snoo FA, 2005, CANCER LETT, V230, P153, DOI 10.1016/j.canlet.2004.12.033; Deichmann M, 2002, BRIT J CANCER, V87, P1431, DOI 10.1038/sj.bjc.6600653; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhawan P, 2002, CANCER RES, V62, P7335; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Mitri D, 2014, NATURE, V515, P134, DOI 10.1038/nature13638; Duffy K, 2012, J AM ACAD DERMATOL, V67, P1, DOI DOI 10.1016/J.JAAD.2012.03.013; Eder J, 2014, BRIT J DERMATOL, V171, P1415, DOI 10.1111/bjd.13132; English DR, 2006, CANCER CAUSE CONTROL, V17, P103, DOI 10.1007/s10552-005-0425-0; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Falchi M, 2009, NAT GENET, V41, P915, DOI 10.1038/ng.410; Famenini S, 2015, J AM ACAD DERMATOL, V72, P78, DOI 10.1016/j.jaad.2014.09.030; Ferrara G, 2013, DERMATOL CLIN, V31, P589, DOI 10.1016/j.det.2013.06.012; Ferringer T, 2012, DERMATOL CLIN, V30, P567, DOI 10.1016/j.det.2012.06.007; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Florell SR, 2005, J CUTAN PATHOL, V32, P45, DOI 10.1111/j.0303-6987.2005.00242.x; Florell SR, 2004, J INVEST DERMATOL, V123, P576, DOI 10.1111/j.0022-202X.2004.23312.x; Fox JC, 2011, ARCH PATHOL LAB MED, V135, P842, DOI 10.1043/2010-0429-RAR.1; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Funk JO, 1998, J CUTAN PATHOL, V25, P291, DOI 10.1111/j.1600-0560.1998.tb01748.x; Gandini S, 2005, EUR J CANCER, V41, P28, DOI 10.1016/j.ejca.2004.10.015; Gao L, 2014, J INVEST DERMATOL, V134, P2957, DOI 10.1038/jid.2014.270; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Gerland LM, 2003, EXP GERONTOL, V38, P887, DOI 10.1016/S0531-5565(03)00132-3; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Glatz K, 2010, AM J DERMATOPATH, V32, P643, DOI 10.1097/DAD.0b013e3181d7ce6f; Godwin LS, 2014, CURR PROTOC CELL BIO, V63; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; Gomes CBF, 2016, AM J PATHOL, V186, P1427, DOI 10.1016/j.ajpath.2016.01.020; Goodson AG, 2011, DERMATOL SURG, V37, P1620, DOI 10.1111/j.1524-4725.2011.02097.x; Goodson AG, 2010, DERMATOL SURG, V36, P1087, DOI 10.1111/j.1524-4725.2010.01589.x; GOOVAERTS G, 1988, AM J DERMATOPATH, V10, P20, DOI 10.1097/00000372-198802000-00003; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; GUTTERMAN JU, 1973, LANCET, V1, P1208; Haenssle HA, 2016, JAMA DERMATOL, V152, P291, DOI 10.1001/jamadermatol.2015.3775; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Hafner C, 2009, J INVEST DERMATOL, V129, P2730, DOI 10.1038/jid.2009.146; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Harada M, 1997, J INVEST DERMATOL, V109, P656, DOI 10.1111/1523-1747.ep12337678; Harland M, 2016, FAM CANCER, V15, P139, DOI 10.1007/s10689-015-9841-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTRUP N, 1991, AM J DERMATOPATH, V13, P378, DOI 10.1097/00000372-199108000-00009; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heidenreich B, 2014, CURR OPIN GENET DEV, V24, P30, DOI 10.1016/j.gde.2013.11.005; Held M, 2010, PIGM CELL MELANOMA R, V23, P481, DOI 10.1111/j.1755-148X.2010.00726.x; Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380; HERLYN M, 1987, LAB INVEST, V56, P461; HERLYN M, 1985, CANCER RES, V45, P5670; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hui P, 2001, J CUTAN PATHOL, V28, P140, DOI 10.1034/j.1600-0560.2001.028003140.x; Hussein MR, 2006, J CLIN PATHOL, V59, P316, DOI 10.1136/jcp.2005.028860; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Ivanov A, 2013, J CELL BIOL, V202, P129, DOI 10.1083/jcb.201212110; Jimenez-Gallo D, 2013, JAMA DERMATOL, V149, P624, DOI 10.1001/jamadermatol.2013.263; Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113; Kakavand H, 2014, PATHOLOGY, V46, P193, DOI 10.1097/PAT.0000000000000077; Kalialis LV, 2009, MELANOMA RES, V19, P275, DOI 10.1097/CMR.0b013e32832eabd5; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kampilafkos P, 2015, AM J DERMATOPATH, V37, P138, DOI 10.1097/DAD.0b013e31828a2d54; KANG SW, 1993, J CUTAN PATHOL, V20, P126, DOI 10.1111/j.1600-0560.1993.tb00228.x; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Kantrow SM, 2007, J CUTAN PATHOL, V34, P593, DOI 10.1111/j.1600-0560.2006.00675.x; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Karim RZ, 2009, INT J SURG PATHOL, V17, P361, DOI 10.1177/1066896909336177; Karram S, 2013, AM J DERMATOPATH, V35, P412, DOI 10.1097/DAD.0b013e31826db181; Katlinskaya YV, 2016, CELL REP, V15, P171, DOI 10.1016/j.celrep.2016.03.006; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Khosravi S, 2015, J INVEST DERMATOL, V135, P1358, DOI 10.1038/jid.2014.552; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; King R, 2009, MODERN PATHOL, V22, P611, DOI 10.1038/modpathol.2009.22; Kittler H, 2000, ARCH DERMATOL, V136, P316, DOI 10.1001/archderm.136.3.316; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuzbicki L, 2013, MELANOMA RES, V23, P8, DOI 10.1097/CMR.0b013e32835d5d6f; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laugier F, 2015, ONCOTARGET, V6, P28120, DOI 10.18632/oncotarget.4866; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lee HJ, 2000, J AM ACAD DERMATOL, V42, P936, DOI 10.1016/S0190-9622(00)90277-9; Lee S, 2016, PIGM CELL MELANOMA R, V29, P391, DOI 10.1111/pcmr.12471; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Li MX, 2013, PROTEOMICS, V13, P2585, DOI 10.1002/pmic.201200298; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Libon F, 2013, CLIN EXP DERMATOL, V38, P276, DOI 10.1111/j.1365-2230.2012.04452.x; Liko D, 2015, J MOL MED, V93, P1061, DOI 10.1007/s00109-015-1326-7; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin WM, 2015, J AM ACAD DERMATOL, V72, P54, DOI 10.1016/j.jaad.2014.09.028; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163; Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864; LIU L, 1995, ONCOGENE, V11, P405; Liu SJ, 2012, LAB INVEST, V92, P1084, DOI 10.1038/labinvest.2012.62; Lott JP, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12322; Lucas CR, 2003, J AM ACAD DERMATOL, V48, P663, DOI 10.1067/mjd.2003.283; Luther H, 1996, ARCH DERMATOL, V132, P1473, DOI 10.1001/archderm.132.12.1473; Lyle S, 2000, MODERN PATHOL, V13, P52, DOI 10.1038/modpathol.3880009; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; Maggi LB, 2014, BBA-MOL BASIS DIS, V1842, P831, DOI 10.1016/j.bbadis.2014.01.016; Maida Y, 2015, CANCER SCI, V106, P1486, DOI 10.1111/cas.12806; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mannavola F, 2016, EXPERT REV CLIN IMMU, V12, P79, DOI 10.1586/1744666X.2016.1100965; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Martinez-Cardus A, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.06.20; Masaki T, 2014, PIGM CELL MELANOMA R, V27, P454, DOI 10.1111/pcmr.12226; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; Masui K, 2014, TRENDS ENDOCRIN MET, V25, P364, DOI 10.1016/j.tem.2014.04.002; Matin RN, 2008, AM J TRANSPLANT, V8, P1891, DOI 10.1111/j.1600-6143.2008.02326.x; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; McClenahan P, 2014, JAMA DERMATOL, V150, P1079, DOI 10.1001/jamadermatol.2014.436; Meng XX, 2015, CLIN EXP PHARMACOL P, V42, P811, DOI 10.1111/1440-1681.12436; Menzies SW, 2011, ARCH DERMATOL, V147, P655, DOI 10.1001/archdermatol.2011.133; Micevic G, 2016, CELL REP, V14, P2180, DOI 10.1016/j.celrep.2016.02.010; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Miracco C, 2002, BRIT J DERMATOL, V146, P399, DOI 10.1046/j.1365-2133.2002.04600.x; Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mocellin S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008955.pub2; Montes M, 2016, FEBS J, V283, P2414, DOI 10.1111/febs.13679; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; MORTON DL, 1970, SURGERY, V68, P158; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nasr MR, 2008, AM J DERMATOPATH, V30, P117, DOI 10.1097/DAD.0b013e3181624054; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nildtovic D, 2014, BBA-GEN SUBJECTS, V1840, P2471, DOI 10.1016/j.bbagen.2014.01.031; Nowsheen S., 2012, Experimental Oncology, V34, P243; O'Rourke EA, 2013, AM J DERMATOPATH, V35, P30, DOI 10.1097/DAD.0b013e3182587ef8; Oba J, 2011, J DERMATOL SCI, V62, P116, DOI 10.1016/j.jdermsci.2011.02.011; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Papp T, 2005, MELANOMA RES, V15, P401, DOI 10.1097/00008390-200510000-00008; Pathak S, 2000, INT J ONCOL, V17, P1219; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pedersen M, 2014, PIGM CELL MELANOMA R, V27, P1162, DOI 10.1111/pcmr.12293; Pennoyer JW, 1997, J AM ACAD DERMATOL, V36, P378, DOI 10.1016/S0190-9622(97)80212-5; Perez LJ, 2006, J CUTAN PATHOL, V33, P139, DOI 10.1111/j.0303-6987.2006.00388.x; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Perier-Muzet M, 2014, J INVEST DERMATOL, V134, P1351, DOI 10.1038/jid.2013.462; Pins A, 2015, HUM PATHOL, V46, P239, DOI 10.1016/j.humpath.2014.10.015; Pluquet O, 2015, AM J PHYSIOL-CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Populo H, 2015, EXPERT OPIN THER TAR, V19, P733, DOI 10.1517/14728222.2015.1045416; Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3; Quijano C, 2012, CELL CYCLE, V11, P1383, DOI 10.4161/cc.19800; Radhi J M, 1999, J Cutan Med Surg, V3, P293; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P563, DOI 10.1016/S0190-9622(83)70171-4; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Robbins HA, 2015, J INVEST DERMATOL, V135, P2657, DOI 10.1038/jid.2015.312; Robinson WA, 1998, MELANOMA RES, V8, P499, DOI 10.1097/00008390-199812000-00004; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rodic N, 2015, J CUTAN PATHOL, V42, P807, DOI 10.1111/cup.12564; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Roh MR, 2016, J INVEST DERMATOL, V136, P1002, DOI 10.1016/j.jid.2016.01.024; Roh MR, 2015, PIGM CELL MELANOMA R, V28, P661, DOI 10.1111/pcmr.12412; Romano E, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0059-z; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubegni P, 2007, SKIN RES TECHNOL, V13, P143, DOI 10.1111/j.1600-0846.2007.00180.x; Rudolph P, 1998, HUM PATHOL, V29, P1480, DOI 10.1016/S0046-8177(98)90019-3; Rudolph P, 2000, AM J PATHOL, V156, P1425, DOI 10.1016/S0002-9440(10)65011-0; SAGEBIEL RW, 1993, J INVEST DERMATOL, V100, pS322, DOI 10.1111/1523-1747.ep12470218; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Sanchez-Sosa S, 2013, CLIN EXP IMMUNOL, V173, P179, DOI 10.1111/cei.12096; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Saroufim M, 2014, AM J DERMATOPATH, V36, P68, DOI 10.1097/DAD.0b013e318293f355; Schaffer JV, 2015, CLIN DERMATOL, V33, P368, DOI 10.1016/j.clindermatol.2014.12.015; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Shitara D, 2015, BRIT J DERMATOL, V173, P671, DOI 10.1111/bjd.13829; Shitara D, 2014, AM J CLIN PATHOL, V142, P485, DOI 10.1309/AJCP4L5CJGKTJVDD; Slominski A, 2014, ARCH BIOCHEM BIOPHYS, V563, P79, DOI 10.1016/j.abb.2014.06.030; SOYER HP, 1989, DERMATOLOGICA, V179, P3, DOI 10.1159/000248090; Spain L, 2016, EXPERT OPIN PHARMACO, V17, P1031, DOI 10.1517/14656566.2016.1168805; Sprecher E, 1999, J CUTAN PATHOL, V26, P72, DOI 10.1111/j.1600-0560.1999.tb01805.x; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; STEGMAIER OC, 1959, J INVEST DERMATOL, V32, P413, DOI 10.1038/jid.1959.70; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; STOLZ W, 1991, J INVEST DERMATOL, V97, P903, DOI 10.1111/1523-1747.ep12491659; Strazzula L, 2014, J AM ACAD DERMATOL, V71, P1234, DOI 10.1016/j.jaad.2014.07.026; Sugianto JZ, 2016, SEMIN DIAGN PATHOL, V33, P219, DOI 10.1053/j.semdp.2016.04.006; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Tan JM, 2015, JAMA DERMATOL, V151, P417, DOI 10.1001/jamadermatol.2014.3775; Teulings HE, 2015, J CLIN ONCOL, V33, P773, DOI 10.1200/JCO.2014.57.4756; Theodosakis N, 2015, MOL CANCER THER, V14, P1680, DOI 10.1158/1535-7163.MCT-15-0080; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tran SL, 2012, J INVEST DERMATOL, V132, P2226, DOI 10.1038/jid.2012.126; Tronnier M, 1997, BRIT J DERMATOL, V137, P534, DOI 10.1111/j.1365-2133.1997.tb03782.x; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Tsao H, 2003, ARCH DERMATOL, V139, P282, DOI 10.1001/archderm.139.3.282; Tschandl P, 2016, BRIT J DERMATOL, V174, P364, DOI 10.1111/bjd.14323; Tschandl P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069639; Uhlenhake Elizabeth E, 2013, Dermatol Online J, V19, P18184; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Vagner J, 2015, HISTOPATHOLOGY, V66, P747, DOI 10.1111/his.12501; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; VANDUINEN CM, 1994, HISTOPATHOLOGY, V24, P33; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wajapeyee N, 2010, CELL, V141, P746, DOI 10.1016/j.cell.2010.05.014; Walesch SK, 2015, CANCERS, V7, P1233, DOI 10.3390/cancers7030834; Wang T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052929; Wang XY, 2015, CANCER RES, V75, P5001, DOI 10.1158/0008-5472.CAN-15-0563; Wasco MJ, 2008, HUM PATHOL, V39, P1614, DOI 10.1016/j.humpath.2008.03.007; Wei S, 1999, CANCER RES, V59, P1539; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wurm EMT, 2012, EXP DERMATOL, V21, P676, DOI 10.1111/j.1600-0625.2012.01543.x; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yeh I, 2013, JNCI-J NATL CANCER I, V105, P917, DOI 10.1093/jnci/djt119; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu QJ, 2015, CELL REP, V11, P785, DOI 10.1016/j.celrep.2015.03.069; Zampino MR, 2006, DERMATOL SURG, V32, P1497, DOI 10.1111/j.1524-4725.2006.32362.x; Zeff RA, 1997, J AM ACAD DERMATOL, V37, P620, DOI 10.1016/S0190-9622(97)70181-6; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zhuang L, 2005, J CLIN PATHOL, V58, P1163, DOI 10.1136/jcp.2005.025957; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	326	86	91	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5771	5792		10.1038/onc.2017.189	http://dx.doi.org/10.1038/onc.2017.189			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604751	Green Accepted			2022-12-28	WOS:000413292900001
J	Pedersen, K; Bilal, F; Morales, CB; Salcedo, MT; Macarulla, T; Masso-Valles, D; Mohan, V; Vivancos, A; Carreras, MJ; Serres, X; Abu-Suboh, M; Balsells, J; Allende, E; Sagi, I; Soucek, L; Tabernero, J; Arribas, J				Pedersen, K.; Bilal, F.; Bernado Morales, C.; Salcedo, M. T.; Macarulla, T.; Masso-Valles, D.; Mohan, V.; Vivancos, A.; Carreras, M-J; Serres, X.; Abu-Suboh, M.; Balsells, J.; Allende, E.; Sagi, I.; Soucek, L.; Tabernero, J.; Arribas, J.			Pancreatic cancer heterogeneity and response to Mek inhibition	ONCOGENE			English	Article							PATIENT-DERIVED XENOGRAFTS; DUCTAL ADENOCARCINOMA; SURVIVAL; MICE; GEMCITABINE; ACTIVATION; PATHWAY	Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer (PC) has not yet translated into effective treatments. Many promising drugs have failed in the clinic, highlighting the need for better preclinical models to assess drug efficacy and characterize mechanisms of resistance. Using different experimental models, including patient-derived xenografts (PDXs), we gauged the efficacy of therapies aimed at two hallmark lesions of PCs: activation of signaling pathways by oncogenic KRAS and inactivation of tumor-suppressor genes. Although the drug targeting inactivation of tumor suppressors by DNA methylation had little effect, the inhibition of Mek, a K-Ras effector, in combination with the standard of care (chemotherapy consisting of gemcitabine/Nab-paclitaxel), reduced the growth of three out of five PC-PDXs and impaired metastasis. The two least responding PC-PDXs were composed of genetically diverse cells, which displayed sensitivities to the Mek inhibitor differing by 410-fold. Unexpectedly, our analysis of this genetic diversity unveiled different KRAS mutations. As mutation in KRAS occurs early during progression, this heterogeneity may reflect the simultaneous appearance of different malignant cellular clones or, alternatively, that cells containing two mutations of KRAS are selected during tumor evolution. In vitro and in vivo analyses indicated that the intratumoral heterogeneity, along with the selective pressure imposed by the Mek inhibitor, resulted in rapid selection of resistant cells. Together with the gemcitabine/Nab-paclitaxel backbone, Mek inhibition could be effective in treatment of PC. However, resistance because of intratumoral heterogeneity is likely to develop frequently, pointing to the necessity of identifying the factors and mechanisms of resistance to further develop this therapy.	[Pedersen, K.; Bilal, F.; Bernado Morales, C.; Masso-Valles, D.; Soucek, L.; Tabernero, J.; Arribas, J.] VHIO, Preclin Res Program, Barcelona, Spain; [Bilal, F.; Bernado Morales, C.; Tabernero, J.; Arribas, J.] CIBER ONC, Barcelona, Spain; [Bilal, F.; Masso-Valles, D.; Soucek, L.; Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Campus UAB, Bellaterra, Spain; [Salcedo, M. T.; Macarulla, T.; Carreras, M-J; Serres, X.; Abu-Suboh, M.; Balsells, J.; Allende, E.; Tabernero, J.] Vall Hebron Univ Hosp HUVH, Barcelona, Spain; [Salcedo, M. T.; Macarulla, T.; Tabernero, J.] Univ Autonoma Barcelona, Barcelona, Spain; [Mohan, V.; Sagi, I.] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Vivancos, A.; Tabernero, J.] VHIO, Clin Res Program, Barcelona, Spain; [Soucek, L.; Arribas, J.] ICREA, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Weizmann Institute of Science; Vall d'Hebron Institut d'Oncologia (VHIO); ICREA	Arribas, J (corresponding author), VHIO, C Natzaret 115-117, Barcelona 08035, Spain.	jarribas@vhio.net	Macarulla, Teresa/AAG-9230-2019; Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019; Arribas, Joaquin/M-4482-2014; Tabernero, Josep/AAG-5026-2019; Miquel, Josep Maria/AAG-3508-2019; Vivancos, Ana/AAG-8331-2019	Soucek, Laura/0000-0002-4750-7971; Arribas, Joaquin/0000-0002-0504-0664; Tabernero, Josep/0000-0002-2495-8139; Vivancos, Ana/0000-0003-2888-6512; Balsells Valls, Joaquim/0000-0002-1202-4136; Bernado Morales, Cristina/0000-0003-1376-0407; Abu-Suboh Abadia, Monder/0000-0003-2373-6400; Macarulla, Teresa/0000-0002-5856-4082; Masso-Valles, Daniel/0000-0003-4231-0456; Serres-Creixams, Xavier/0000-0001-8642-467X	Instituto de Salud Carlos III [PI16/00253]; AECC; AGAUR-FIDGR predoctoral fellowship; Instituto de Salud Carlos III (CIBER-ONC)	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); AECC; AGAUR-FIDGR predoctoral fellowship; Instituto de Salud Carlos III (CIBER-ONC)(Instituto de Salud Carlos III)	We thank Faye Su from Novartis and Daniel Pierce from Celgene for providing reagents and valuable insights. This work was supported by funds from the Instituto de Salud Carlos III (PI16/00253 and CIBER-ONC). KP was supported by the postdoctoral program from the AECC. FB was supported by the AGAUR-FIDGR-2014 predoctoral fellowship.	Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kopetz S, 2012, CLIN CANCER RES, V18, P5160, DOI 10.1158/1078-0432.CCR-12-2408; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; VANCUTSEM E, 2015, J CLIN ONCOL S, V33; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Weisenberger DJ, 2014, J CLIN INVEST, V124, P17, DOI 10.1172/JCI69740; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	19	15	15	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5639	5647		10.1038/onc.2017.174	http://dx.doi.org/10.1038/onc.2017.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581516				2022-12-28	WOS:000412293600008
J	Hu, X; Dong, SH; Chen, J; Zhou, XZ; Chen, R; Nair, S; Lu, KP; Chen, LF				Hu, X.; Dong, S-H; Chen, J.; Zhou, X. Z.; Chen, R.; Nair, S.; Lu, K. P.; Chen, L-F			Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4	ONCOGENE			English	Article							RNA-POLYMERASE-II; NF-KAPPA-B; BET BROMODOMAIN PROTEINS; BREAST-CANCER; CELL-PROLIFERATION; PROSTATE-CANCER; GASTRIC-CANCER; P-TEFB; INHIBITION; EXPRESSION	BRD4 has emerged as an important factor in tumorigenesis by promoting the transcription of genes involved in cancer development. However, how BRD4 is regulated in cancer cells remains largely unknown. Here, we report that the stability and functions of BRD4 are positively regulated by prolyl isomerase PIN1 in gastric cancer cells. PIN1 directly binds to phosphorylated threonine (T) 204 of BRD4 as revealed by peptide binding and crystallographic studies and enhances BRD4's stability by inhibiting its ubiquitination. PIN1 also catalyses the isomerization of proline 205 of BRD4 and induces its conformational change, which promotes its interaction with CDK9 and increases BRD4's transcriptional activity. Substitution of BRD4 with PIN1-binding-defective BRD4-T204A mutant in gastric cancer cells reduces BRD4's stability, attenuates BRD4-mediated gene expression by impairing its interaction with CDK9 and suppresses gastric cancer cell proliferation, migration and invasion, and tumor formation. Our results identify BRD4 as a new target of PIN1 and suggest that interfering with their interaction could be a potential therapeutic approach for cancer treatment.	[Hu, X.; Dong, S-H; Chen, J.; Nair, S.; Chen, L-F] Univ Illinois, Dept Biochem, Urbana, IL USA; [Zhou, X. Z.; Lu, K. P.] Harvard Med Sch, BIDMC, Dept Med, Div Translat Therapeut, Boston, MA USA; [Chen, R.] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Lu, K. P.] Fujian Med Univ, Inst Translat Med, Fuzhou, Fujian, Peoples R China; [Chen, L-F] Univ Illinois, Coll Med, Dept Med Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Xiamen University; Fujian Medical University; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Dept Biochem, 506 S Mathews Ave,MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu	Dong, Shihui/T-4864-2017; Nair, Satish/AAY-2510-2021		UIUC; NIH [DK085158, CA179511]; Natural Science Foundation of China [81361120386]; NATIONAL CANCER INSTITUTE [R01CA167677, R01CA179511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI117080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK085158 and CA179511 (to LFC) and Natural Science Foundation of China Grants 81361120386 (to RC).	Ai NP, 2011, NUCLEIC ACIDS RES, V39, P9592, DOI 10.1093/nar/gkr698; Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746; Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Atkinson GP, 2009, ONCOGENE, V28, P3735, DOI 10.1038/onc.2009.232; Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Basheer F, 2015, EXP HEMATOL, V43, P718, DOI 10.1016/j.exphem.2015.06.004; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Chiang CM, 2009, BIOL REP, V1, P98, DOI DOI 10.3410/B1-98; Chung CW, 2012, PROGR MED CHEM, V51, P1, DOI 10.1016/B978-0-12-396493-9.00001-7; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Hsu TI, 2015, ONCOGENE, V34, P826, DOI 10.1038/onc.2014.22; Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jin J, 2013, NEOPLASMA, V60, P92, DOI 10.4149/neo_2013_013; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu ZM, 2014, CELL RES, V24, P1033, DOI 10.1038/cr.2014.109; Ma T, 2014, BIOMED RES INT; Morishita A, 2014, WORLD J GASTROENTERO, V20, P4536, DOI 10.3748/wjg.v20.i16.4536; Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Pastori C, 2014, EPIGENETICS-US, V9, P611, DOI 10.4161/epi.27906; Proserpio V, 2013, GENE DEV, V27, P1299, DOI 10.1101/gad.217240.113; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shi M, 2015, CELL BIOCHEM BIOPHYS, V71, P857, DOI 10.1007/s12013-014-0274-0; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Takahashi K, 2007, ONCOGENE, V26, P3835, DOI 10.1038/sj.onc.1210153; Tsang YHN, 2013, ONCOGENE, V32, P1488, DOI 10.1038/onc.2012.178; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Wu SY, 2016, CELL REP, V16, P1733, DOI 10.1016/j.celrep.2016.07.001; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Wu XW, 2013, J BIOL CHEM, V288, P36094, DOI 10.1074/jbc.M113.485029; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yang S, 2011, J INT MED RES, V39, P2076, DOI 10.1177/147323001103900603; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yogesha SD, 2014, MOLECULES, V19, P1481, DOI 10.3390/molecules19021481; Zhang Y, 2007, ACS CHEM BIOL, V2, P320, DOI 10.1021/cb7000044; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	56	27	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5177	5188		10.1038/onc.2017.137	http://dx.doi.org/10.1038/onc.2017.137			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481868	Green Submitted, Green Accepted			2022-12-28	WOS:000409371100009
J	Vivo, M; Fontana, R; Ranieri, M; Capasso, G; Angrisano, T; Pollice, A; Calabro, V; La Mantia, G				Vivo, M.; Fontana, R.; Ranieri, M.; Capasso, G.; Angrisano, T.; Pollice, A.; Calabro, V.; La Mantia, G.			p14ARF interacts with the focal adhesion kinase and protects cells from anoikis	ONCOGENE			English	Article							ARF TUMOR-SUPPRESSOR; DAP-KINASE; MOTOR COMPLEX; DNA-DAMAGE; IN-VIVO; CANCER; SURVIVAL; PHOSPHORYLATION; PROGRESSION; APOPTOSIS	The ARF protein functions as an important sensor of hyper-proliferative stimuli restricting cell proliferation through both p53-dependent and - independent pathways. Although to date the majority of studies on ARF have focused on its anti-proliferative role, few studies have addressed whether ARF may also have pro-survival functions. Here we show for the first time that during the process of adhesion and spreading ARF re-localizes to sites of active actin polymerization and to focal adhesion points where it interacts with the phosphorylated focal adhesion kinase. In line with its recruitment to focal adhesions, we observe that hampering ARF function in cancer cells leads to gross defects in cytoskeleton organization resulting in apoptosis through a mechanism dependent on the Death-Associated Protein Kinase. Our data uncover a novel function for p14ARF in protecting cells from anoikis that may reflect its role in anchorage independence, a hallmark of malignant tumor cells.	[Vivo, M.; Fontana, R.; Ranieri, M.; Capasso, G.; Angrisano, T.; Pollice, A.; Calabro, V.; La Mantia, G.] Univ Naples Federico II, Dipartimento Biol, Via Cinthia, I-80126 Naples, Italy	University of Naples Federico II	Vivo, M; La Mantia, G (corresponding author), Univ Naples Federico II, Dipartimento Biol, Via Cinthia, I-80126 Naples, Italy.	maria.vivo@unina.it; lamantia@unina.it	Angrisano, Tiziana/AAC-5353-2022; Vivo, Maria/S-3390-2017; Fontana, Rosa/AAD-7852-2019; Calabro, Viola/H-6156-2013	Vivo, Maria/0000-0003-2458-4226; Fontana, Rosa/0000-0003-0445-6016; Ranieri, Michela/0000-0002-3833-3594; Calabro, Viola/0000-0002-6508-8889	L.R.5; PO FESR 'DiMo'; PO FESR 'Movie'	L.R.5; PO FESR 'DiMo'; PO FESR 'Movie'	We thank Dr Carlo Di Cristo and Dr Tiziana Parisi for critical revision of the manuscript. We thank Dr Valeria R Villella for providing HeLa cells, Dr Giovanna Benvenuto (Confocal Microscopy Service at the Stazione Zoologica Anton Dohrn, Naples) and Dr Per Guldberg for kindly providing GFP-tagged ARF mutants. This work was supported by grants awarded to GLM and AP from L.R.5 (2007), to VC and GLM from PO FESR 2007-2013 'DiMo' and 'Movie', respectively.	Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831; Chen RH, 2006, J BIOMED SCI, V13, P193, DOI 10.1007/s11373-005-9063-5; Chen ZB, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000053; Chiba K, 1998, TOXICOL IN VITRO, V12, P251, DOI 10.1016/S0887-2333(97)00107-0; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Churchman ML, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002157; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Fan HP, 2013, J BIOL CHEM, V288, P3322, DOI 10.1074/jbc.M112.420497; Ferru A, 2006, BRIT J CANCER, V95, P1670, DOI 10.1038/sj.bjc.6603479; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gromley A, 2009, P NATL ACAD SCI USA, V106, P6285, DOI 10.1073/pnas.0902310106; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Ivanovska J, 2014, APOPTOSIS, V19, P329, DOI 10.1007/s10495-013-0916-5; Johnson CL, 2002, MOL CANCER THER, V1, P861; Kadare G, 2003, J BIOL CHEM, V278, P47434, DOI 10.1074/jbc.M308562200; Kamijo T, 1999, CANCER RES, V59, P2217; Kobayashi T, 2013, MOL CANCER RES, V11, P828, DOI 10.1158/1541-7786.MCR-13-0207; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kotsinas A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00236; Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794; Li CL, 2013, P NATL ACAD SCI USA, V110, pE1112, DOI 10.1073/pnas.1302184110; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200; Pollice A, 2008, FEBS LETT, V582, P3257, DOI 10.1016/j.febslet.2008.09.026; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tancioni I, 2014, MOL CANCER THER, V13, P2050, DOI 10.1158/1535-7163.MCT-13-1063; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Vivo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117252; Vivo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053631; Vivo M, 2009, CELL CYCLE, V8, P3545, DOI 10.4161/cc.8.21.9954; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Xie YQ, 2014, MOL ONCOL, V8, P1355, DOI 10.1016/j.molonc.2014.05.006; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	55	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4913	4928		10.1038/onc.2017.104	http://dx.doi.org/10.1038/onc.2017.104			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436949	Green Published, hybrid			2022-12-28	WOS:000408234400008
J	Zoni, E; Chen, L; Karkampouna, S; Granchi, Z; Verhoef, EI; La Manna, F; Kelber, J; Pelger, RCM; Henry, MD; Snaar-Jagalska, E; van Leenders, GJLH; Beimers, L; Kloen, P; Gray, PC; van der Pluijm, G; Julio, MKD				Zoni, E.; Chen, L.; Karkampouna, S.; Granchi, Z.; Verhoef, E. I.; La Manna, F.; Kelber, J.; Pelger, R. C. M.; Henry, M. D.; Snaar-Jagalska, E.; van Leenders, G. J. L. H.; Beimers, L.; Kloen, P.; Gray, P. C.; van der Pluijm, G.; Julio, M. Kruithof-de			CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; TGF-BETA; BONE METASTASIS; EMBRYONIC GENE; GROWTH; EXPRESSION; ZEBRAFISH; PROMOTES; DIFFERENTIATION	CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential.	[Zoni, E.; Karkampouna, S.; La Manna, F.; Pelger, R. C. M.; van der Pluijm, G.; Julio, M. Kruithof-de] Leiden Univ, Dept Urol, Med Ctr, Leiden, Netherlands; [Zoni, E.; Karkampouna, S.; La Manna, F.; Snaar-Jagalska, E.; Julio, M. Kruithof-de] Univ Bern, Urol Res Lab, Dept Urol, Murtenstr 35, CH-3008 Bern, Switzerland; [Zoni, E.; Karkampouna, S.; La Manna, F.; Snaar-Jagalska, E.; Julio, M. Kruithof-de] Univ Bern, Dept Clin Res, Murtenstr 35, CH-3008 Bern, Switzerland; [Chen, L.] Leiden Univ, Inst Biol, Dept Mol Cell Biol, Leiden, Netherlands; [Granchi, Z.] Genome Scan, Leiden, Netherlands; [Verhoef, E. I.; van Leenders, G. J. L. H.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Kelber, J.] Calif State Univ Northbridge, Dept Biol, Northbridge, CA USA; [Henry, M. D.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA USA; [Beimers, L.] Slotervaart Med Ctr, Dept Orthoped Surg, Amsterdam, Netherlands; [Kloen, P.] Acad Med Ctr, Dept Orthoped Trauma Surg, Amsterdam, Netherlands; [Gray, P. C.] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Bern; University of Bern; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; University of Iowa; Slotervaart Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Salk Institute	Julio, MKD (corresponding author), Univ Bern, Urol Res Lab, Dept Urol, Murtenstr 35, CH-3008 Bern, Switzerland.; Julio, MKD (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3008 Bern, Switzerland.	marianna.kruithofdejulio@dkf.unibe.ch	Pelger, Rob/ABF-9029-2021; Zoni, Eugenio/AAH-7016-2019	Pelger, Rob/0000-0001-6328-6462; Zoni, Eugenio/0000-0002-3070-7694; van der Pluijm, Gabri/0000-0002-1351-1884; La Manna, Federico/0000-0003-3644-8395; Kelber, Jonathan/0000-0002-4606-1445; Verhoef, Esther/0000-0002-2734-0254; Granchi, Zoraide/0000-0002-0227-9266; Henry, Michael/0000-0002-7871-245X; Kruithof-de Julio, Marianna/0000-0002-6085-7706	FP7 Marie Curie ITN [264817-BONE-NET]; Dutch Cancer Society [UL2015-7599 KWF]; Leiden University Fond; Clayton Foundation for Biomedical Research; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM121182] Funding Source: NIH RePORTER	FP7 Marie Curie ITN; Dutch Cancer Society(KWF Kankerbestrijding); Leiden University Fond; Clayton Foundation for Biomedical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Tim Rodenburg and Janine Melsen (Department of Urology, LUMC) for technical support and Dr Boudewijn PT Kruithof (Department of Molecular Cell Biology, LUMC) for technical support and critical reading of the manuscript, Guido de Roo from the Flow cytometry facility (Department of Hematology, LUMC) and Jan Kroon (Department of Urology, LUMC) for providing experimental metastases. This research received funding from: FP7 Marie Curie ITN, Grant No. 264817-BONE-NET (to GvdP, EZ, ZG); Dutch Cancer Society, Grant No. UL2015-7599 KWF (to MK-dJ, GvdP, PK); Leiden University Fond (to MK-dJ) and Clayton Foundation for Biomedical Research (to PCG).	Bianco C, 2005, CURR TOP DEV BIOL, V67, P85, DOI 10.1016/S0070-2153(05)67003-2; Castro NP, 2015, ONCOTARGET, V6, P11910, DOI 10.18632/oncotarget.4182; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI [10.2217/fon.10.68, 10.2217/FON.10.68]; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ghotra VPS, 2015, CANCER RES, V75, P230, DOI 10.1158/0008-5472.CAN-14-0629; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gray PC, 2006, MOL CELL BIOL, V26, P9268, DOI 10.1128/MCB.01168-06; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Karkampouna S, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.69; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Klauzinska M, 2014, SEMIN CANCER BIOL, V29, P51, DOI 10.1016/j.semcancer.2014.08.003; Kroon J, 2014, ONCOTARGET, V5, P8986, DOI 10.18632/oncotarget.1510; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Morhayim J, 2015, FASEB J, V29, P274, DOI 10.1096/fj.14-261404; Nagaoka T, 2012, GROWTH FACTORS, V30, P13, DOI 10.3109/08977194.2011.641962; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Ozdemir B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107407; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Pilli VS, 2015, FEBS LETT, V589, P1249, DOI 10.1016/j.febslet.2015.04.005; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Spike BT, 2014, STEM CELL REP, V2, P427, DOI 10.1016/j.stemcr.2014.02.010; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terry S, 2015, ONCOTARGET, V6, P11994, DOI 10.18632/oncotarget.2740; THALMANN GN, 1994, CANCER RES, V54, P2577; van den Hoogen C, 2011, AM J PATHOL, V179, P2559, DOI 10.1016/j.ajpath.2011.07.011; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; Zoni E, 2015, CANCER RES, V75, P2326, DOI 10.1158/0008-5472.CAN-14-2155	44	25	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4739	4749		10.1038/onc.2017.87	http://dx.doi.org/10.1038/onc.2017.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394345	Green Published, hybrid			2022-12-28	WOS:000407702400007
J	Itoh, G; Chida, S; Yanagihara, K; Yashiro, M; Aiba, N; Tanaka, M				Itoh, G.; Chida, S.; Yanagihara, K.; Yashiro, M.; Aiba, N.; Tanaka, M.			Cancer-associated fibroblasts induce cancer cell apoptosis that regulates invasion mode of tumours	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; EXTRACELLULAR VESICLES; CARCINOMA; MICROVESICLES; METASTASIS; ACTIVATION; BODIES	In the process of cancer spreading, different modes of invasion exist. One is expansive invasion, in which a group of cancer cells gradually expands along with cancer cell proliferation. Invasion of cancer cells is also modified by their interaction with stromal cells including cancer-associated fibroblasts (CAFs). Cancer cells co-invade with CAFs, and invasion by CAFs frequently precede invasion by cancer cells, which indicates CAF-led cancer cell invasion. Here, we show that CAFs induce apoptosis in gastric cancer cells, which prevented expansive invasion by cancer cells and instead facilitated CAF-led invasion. Death receptor 4 and activation of caspase-8 in cancer cells mediated cancer cell apoptosis induced by CAFs, which was dependent on contact between cancer cells and CAFs. Apoptotic cancer cells in turn released apoptotic vesicles and stimulated invasion of CAFs. Accordingly, cancer cells followed the migrating CAFs. Treatment with a caspase inhibitor, ZVAD, or forced expression of a death domain fragment in cancer cells prevented cancer cell apoptosis induced by CAFs and increased expansive invasion by cancer cells in extracellular gel invasion assays, while the rate of cancer cell invasion led by CAFs was decreased. Death domain-fragment expression also prevented intramural invasion by gastric cancer cells in the stomach. Because CAF-led invasion is characterized by the movement of individual cancer cells away from the tumour, adequate cancer cell apoptosis may promote cancer dissemination.	[Itoh, G.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita, Japan; [Chida, S.] Akita Univ, Grad Sch Med, Biosci Educ & Res Support Ctr, Akita, Japan; [Yanagihara, K.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, Chiba, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka, Japan	Akita University; Akita University; National Cancer Center - Japan; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, Mol Med & Biochem, 1-1-1 Hondo, Akita, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp			JSPS KAKENHI [26640068, 16H04691]; Research Grant of the Princess Takamatsu Cancer Research Fund [14-24620]; Project Mirai Cancer Research grant; Grants-in-Aid for Scientific Research [17K19579] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Research Grant of the Princess Takamatsu Cancer Research Fund; Project Mirai Cancer Research grant; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI grants (nos. 26640068 and 16H04691 to MT), a Research Grant of the Princess Takamatsu Cancer Research Fund (14-24620 to MT), and Project Mirai Cancer Research grants to MT	Alexander S, 2013, CURR OPIN CELL BIOL, V25, P659, DOI 10.1016/j.ceb.2013.07.001; Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Ding SM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0588-8; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Geraldo S, 2012, EUR J CELL BIOL, V91, P930, DOI 10.1016/j.ejcb.2012.07.005; Hsu HS, 2012, LUNG CANCER, V75, P167, DOI 10.1016/j.lungcan.2011.07.001; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jain MV, 2013, J CELL MOL MED, V17, P12, DOI 10.1111/jcmm.12001; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lin JT, 2013, EXP CELL RES, V319, P2216, DOI 10.1016/j.yexcr.2013.06.003; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Lo YC, 2015, APOPTOSIS, V20, P124, DOI 10.1007/s10495-014-1054-4; Muhsin-Sharafaldine MR, 2016, ONCOTARGET, V7, P56279, DOI 10.18632/oncotarget.10783; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sakamaki K, 2004, GENES CELLS, V9, P1249, DOI 10.1111/j.1365-2443.2004.00802.x; Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Sidani M, 2006, J MAMMARY GLAND BIOL, V11, P151, DOI 10.1007/s10911-006-9021-5; Siegelin MD, 2009, NEUROCHEM INT, V55, P423, DOI 10.1016/j.neuint.2009.04.011; Subramaniam KS, 2016, AM J CANCER RES, V6, P200; Tanaka M, 2016, CANCER SCI, V107, P803, DOI 10.1111/cas.12940; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Turiak L, 2011, J PROTEOMICS, V74, P2025, DOI 10.1016/j.jprot.2011.05.023; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Walczak Henning, 2008, V414, P221; Walczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yoon N, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.90	36	41	46	4	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4434	4444		10.1038/onc.2017.49	http://dx.doi.org/10.1038/onc.2017.49			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368418				2022-12-28	WOS:000406806000006
J	Thewes, V; Simon, R; Hlevnjak, M; Schlotter, M; Schroeter, P; Schmidt, K; Wu, Y; Anzeneder, T; Wang, W; Windisch, P; Kirchgassner, M; Melling, N; Kneisel, N; Buttner, R; Deuschle, U; Sinn, HP; Schneeweiss, A; Heck, S; Kaulfuss, S; Hess-Stumpp, H; Okun, JG; Sauter, G; Lykkesfeldt, AE; Zapatka, M; Radlwimmer, B; Lichter, P; Tonjes, M				Thewes, V.; Simon, R.; Hlevnjak, M.; Schlotter, M.; Schroeter, P.; Schmidt, K.; Wu, Y.; Anzeneder, T.; Wang, W.; Windisch, P.; Kirchgaessner, M.; Melling, N.; Kneisel, N.; Buettner, R.; Deuschle, U.; Sinn, H. P.; Schneeweiss, A.; Heck, S.; Kaulfuss, S.; Hess-Stumpp, H.; Okun, J. G.; Sauter, G.; Lykkesfeldt, A. E.; Zapatka, M.; Radlwimmer, B.; Lichter, P.; Toenjes, M.			The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER alpha-negative breast cancer	ONCOGENE			English	Article							TAMOXIFEN RESISTANCE; CELL-LINES; EXPRESSION; ESTROGEN; AMINOTRANSFERASE; PROLIFERATION; GENES; MICROARRAYS; ACTIVATION; SIGNATURES	Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and two fulvestrant resistant) MCF-7 breast cancer cell lines. The branched-chain amino acid transaminase 1 (BCAT1), which catalyzes the first step in the breakdown of branched-chain amino acids, was among the most upregulated transcripts in antiestrogen-resistant cells. Elevated BCAT1 expression was confirmed in relapsed tamoxifen-resistant breast tumor specimens. High intratumoral BCAT1 levels were associated with a reduced relapse-free survival in adjuvant tamoxifen-treated patients and overall survival in unselected patients. On a tissue microarray (n = 1421), BCAT1 expression was detectable in 58% of unselected primary breast carcinomas and linked to a higher Ki-67 proliferation index, as well as histological grade. Interestingly, BCAT1 was predominantly expressed in estrogen receptor-a-negative/human epidermal growth factor receptor-2-positive (ER alpha-negative/HER-2- positive) and triple-negative breast cancers in independent patient cohorts. The inverse relationship between BCAT1 and ER alpha was corroborated in various breast cancer cell lines and pharmacological long-term depletion of ERa induced BCAT1 expression in vitro. Mechanistically, BCAT1 indirectly controlled expression of the cell cycle inhibitor p27(Kip1) thereby affecting pRB. Correspondingly, phenotypic analyses using a lentiviral-mediated BCAT1 short hairpin RNA knockdown revealed that BCAT1 sustains proliferation in addition to migration and invasion and that its overexpression enhanced the capacity of antiestrogen-sensitive cells to grow in the presence of antiestrogens. Importantly, silencing of BCAT1 in an orthotopic triple-negative xenograft model resulted in a massive reduction of tumor volume in vivo, supporting our findings that BCAT1 is necessary for the growth of hormone-independent breast tumors.	[Thewes, V.; Hlevnjak, M.; Schlotter, M.; Schroeter, P.; Wu, Y.; Wang, W.; Windisch, P.; Kirchgaessner, M.; Kneisel, N.; Heck, S.; Zapatka, M.; Radlwimmer, B.; Lichter, P.; Toenjes, M.] German Canc Res Ctr, German Canc Consortium DKTK, Div Mol Genet, D-69120 Heidelberg, Germany; [Simon, R.; Melling, N.; Sauter, G.] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Hamburg, Germany; [Schmidt, K.; Okun, J. G.] Univ Childrens Hosp, Div Inherited Metab Dis, Heidelberg, Germany; [Anzeneder, T.] PATH Fdn Biobank Patients Tumor Bank Hope, Munich, Germany; [Buettner, R.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Deuschle, U.] Phenex Pharmaceut AG, Heidelberg, Germany; [Sinn, H. P.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Schneeweiss, A.] Heidelberg Univ, Natl Ctr Tumor Dis, Gynecol Oncol, Heidelberg, Germany; [Kaulfuss, S.; Hess-Stumpp, H.] Bayer Pharma AG, Berlin, Germany; [Lykkesfeldt, A. E.] Danish Canc Soc, Res Ctr, Breast Canc Grp, Copenhagen, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Bayer AG; Bayer Healthcare Pharmaceuticals; Danish Cancer Society	Lichter, P (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Div Mol Genet, D-69120 Heidelberg, Germany.	peter.lichter@dkfz-heidelberg.de	Radlwimmer, Bernhard F/I-3229-2013; Wu, Yonghe/N-2269-2019; Zapatka, Marc/G-9896-2013; Schneeweiss, Andreas/HHS-4098-2022; Sinn, Hans-Peter/C-5661-2008	Radlwimmer, Bernhard F/0000-0002-4553-7800; Wu, Yonghe/0000-0001-9667-8198; Zapatka, Marc/0000-0001-8287-5967; Sinn, Hans-Peter/0000-0003-2836-6699	Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ); Helmholtz-Graduate School for Cancer Research	Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ); Helmholtz-Graduate School for Cancer Research	We highly appreciate the excellent technical assistance of Karin Pfleger and Achim Stephan. Further, we thank Nicolas Hafner and Yashna Paul for experimental and computational support and appreciate the help and constructive discussions from Martina Seiffert, and Michael Fletcher. Moreover, we thank the patients, pathologists and gynecologists associated with the PATH Biobank (http://pathbiobank.org/index.php/en/) for their support. This work was supported by the Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ). VT was supported by a scholarship from the Helmholtz-Graduate School for Cancer Research.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Al Saleh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020610; Ananieva EA, 2014, J BIOL CHEM, V289, P18793, DOI 10.1074/jbc.M114.554113; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; BRIAND P, 1984, CANCER RES, V44, P1114; Castro F, 2013, INT J CANCER, V132, P308, DOI 10.1002/ijc.27675; Chang IW, 2016, HISTOPATHOLOGY, V68, P520, DOI 10.1111/his.12778; Chaumeil MM, 2014, CANCER RES, V74, P4247, DOI 10.1158/0008-5472.CAN-14-0680; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; DeSantiago S, 2001, ADV EXP MED BIOL, V501, P93; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Harvell DME, 2008, BREAST CANCER RES TR, V112, P475, DOI 10.1007/s10549-008-9897-4; Heck S, 2009, CANCER RES, V69, P5184, DOI 10.1158/0008-5472.CAN-08-3062; Hull J, 2012, J NEUROCHEM, V123, P997, DOI 10.1111/jnc.12044; Hutson S, 2001, PROG NUCLEIC ACID RE, V70, P175, DOI 10.1016/S0079-6603(01)70017-7; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Ju W, 2009, ONCOL RES, V18, P47, DOI 10.3727/096504009789954672; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mishra P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.992217; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Prest SJ, 1999, CLIN EXP METASTAS, V17, P389, DOI 10.1023/A:1006657109866; Rimawi MF, 2015, ANNU REV MED, V66, P111, DOI 10.1146/annurev-med-042513-015127; Robertson JFR, 2001, BRIT J CANCER, V85, P11, DOI 10.1054/bjoc.2001.1982; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581; Shajahan-Haq AN, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-239; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thewes V, 2015, CANCER RES, V75, P720, DOI 10.1158/0008-5472.CAN-14-0652; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Waldmann A, 2014, GEBURTSH FRAUENHEILK, V74, P361, DOI 10.1055/s-0033-1360263; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yoshikawa R, 2006, WORLD J GASTROENTERO, V12, P5884, DOI 10.3748/wjg.v12.i36.5884; Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2; Zhou W, 2007, ONCOL RES, V16, P405, DOI 10.3727/000000007783980873; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011; Zschocke J, 2004, VADEMECUM METABOLICU	51	44	45	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4124	4134		10.1038/onc.2017.32	http://dx.doi.org/10.1038/onc.2017.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319069				2022-12-28	WOS:000405835800004
J	Yang, M; Schiapparelli, P; Nguyen, HN; Igarashi, A; Zhang, Q; Abbadi, S; Amzel, LM; Sesaki, H; Quinones-Hinojosa, A; Iijima, M				Yang, Jr-M; Schiapparelli, P.; Nguyen, H-N; Igarashi, A.; Zhang, Q.; Abbadi, S.; Amzel, L. M.; Sesaki, H.; Quinones-Hinojosa, A.; Iijima, M.			Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; MIGRATION; GENE; PHOSPHORYLATION; ACTIVATION; SURVIVAL; BINDING	PTEN is a PIP3 phosphatase that antagonizes oncogenic PI3-kinase signalling. Due to its critical role in suppressing the potent signalling pathway, it is one of the most mutated tumour suppressors, especially in brain tumours. It is generally thought that PTEN deficiencies predominantly result from either loss of expression or enzymatic activity. By analysing PTEN in malignant glioblastoma primary cells derived from 16 of our patients, we report mutations that block localization of PTEN at the plasma membrane and nucleus without affecting lipid phosphatase activity. Cellular and biochemical analyses as well as structural modelling revealed that two mutations disrupt intramolecular interaction of PTEN and open its conformation, enhancing polyubiquitination of PTEN and decreasing protein stability. Moreover, promoting mono-ubiquitination increases protein stability and nuclear localization of mutant PTEN. Thus, our findings provide a molecular mechanism for cancer-associated PTEN defects and may lead to a brain cancer treatment that targets PTEN mono-ubiquitination.	[Yang, Jr-M; Nguyen, H-N; Igarashi, A.; Zhang, Q.; Sesaki, H.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725N Wolfe St,107 Hunterian, Baltimore, MD 21205 USA; [Schiapparelli, P.; Abbadi, S.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Schiapparelli, P.; Amzel, L. M.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD USA; [Schiapparelli, P.; Quinones-Hinojosa, A.] Mayo Clin, Coll Med, Dept Neurosurg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Mayo Clinic	Iijima, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725N Wolfe St,107 Hunterian, Baltimore, MD 21205 USA.; Quinones-Hinojosa, A (corresponding author), Mayo Clin, Coll Med, Dept Neurosurg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Quinones-Hinojosa.Alfredo@mayo.edu; miijima@jhmi.edu		schiapparelli, paula/0000-0003-4551-6337; Yang, Jr-Ming/0000-0002-6296-8987	NIH [GM084015, GM089853, NS070024]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070024] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grants to Miho Iijima (GM084015), Hiromi Sesaki (GM089853) and Alfredo Quinones-Hinojosa (NS070024).	Abbadi S, 2014, MOL CANCER RES, V12, P1547, DOI 10.1158/1541-7786.MCR-14-0106-T; Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691; Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137; Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081; Chaichana KL, 2009, J NEUROSCI METH, V180, P116, DOI 10.1016/j.jneumeth.2009.02.014; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.521; Garzon-Muvdi T, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001320; Gil A, 2007, CELL DEATH DIFFER, V14, P395, DOI 10.1038/sj.cdd.4402073; Guerrero-Cazares H, 2011, J COMP NEUROL, V519, P1165, DOI 10.1002/cne.22566; Nguyen HN, 2015, SCI REP-UK, V5, DOI 10.1038/srep12600; Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Kim DH, 2009, BIOMATERIALS, V30, P5433, DOI 10.1016/j.biomaterials.2009.06.042; Kim DH, 2009, ADV FUNCT MATER, V19, P1579, DOI 10.1002/adfm.200801174; Kondapalli KC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7289; Lang V, 2015, METHODS, V77-78, P112, DOI 10.1016/j.ymeth.2014.09.001; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Levy AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092165; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Q, 2014, CLIN CANCER RES, V20, P2375, DOI 10.1158/1078-0432.CCR-13-1415; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Nguyen HN, 2014, ONCOGENE, V33, P5688, DOI 10.1038/onc.2013.507; Nguyen HN, 2015, ONCOGENE, V34, P3737, DOI 10.1038/onc.2014.293; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ravin R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039421; Riddick G, 2011, NAT REV NEUROL, V7, P439, DOI 10.1038/nrneurol.2011.100; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Smith CL, 2016, CELL REP, V15, P2616, DOI 10.1016/j.celrep.2016.05.042; Smith CL, 2015, STEM CELL TRANSL MED, V4, P239, DOI 10.5966/sctm.2014-0149; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tzeng SY, 2011, BIOMATERIALS, V32, P5402, DOI 10.1016/j.biomaterials.2011.04.016; Wang XJ, 2008, BIOCHEM J, V414, P221, DOI 10.1042/BJ20080674; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Yang JM, 2015, METHODS, V77-78, P119, DOI 10.1016/j.ymeth.2014.10.018; Zhang P, 2010, P NATL ACAD SCI US; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107; Zhu MX, 2015, STEM CELLS DEV, V24, P160, DOI 10.1089/scd.2014.0076	50	44	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3673	3685		10.1038/onc.2016.493	http://dx.doi.org/10.1038/onc.2016.493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28263967	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000404349700003
J	He, Y; Zhao, Y; Wang, L; Bohrer, LR; Pan, Y; Huang, H				He, Y.; Zhao, Y.; Wang, L.; Bohrer, L. R.; Pan, Y.; Huang, H.			LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; LARGE GENE LISTS; HISTONE DEMETHYLASE; DNA-DAMAGE; CELLULAR SENESCENCE; STRUCTURAL BASIS; PHOSPHORYLATION; TRANSCRIPTION; MECHANISM; COMPLEX	Histone H3 lysine-9 (H3K9) methylation is essential for retinoblastoma protein (RB)-mediated heterochromatin formation, epigenetic silencing of S-phase genes and permanent cell cycle arrest or cellular senescence. Besides as an H3K4 demethylase, lysine-specific demethylase-1 (LSD1) has been shown to promote H3K9 demethylation. However, it is unexplored whether LSD1 has a causal role in regulating cell cycle entry and senescence. Here we demonstrate that genetic depletion or pharmacological inhibition of LSD1 triggers G1 arrest and cellular senescence. Genome-wide chromatin immunoprecipitation-sequencing analysis reveals that LSD1 binding sites overlap significantly with those bound by the S-phase gene transcription factor E2F1. Gene ontology analysis demonstrates that a large portion of E2F1 and LSD1 cotargeted genes are involved in cell cycle and proliferation. Further analyses show that depletion of LSD1 increases the level of H3K9me2 and thereby represses expression of the LSD1-E2F1 cotarget genes, but has no effects on H3K4me2 level in those loci. In contrast, knockdown of the H3K4me2 reader PHF8 decreases the H3K4me2 level at the LSD1-E2F1 cotargeted loci, but this effect is rescued by codepletion of LSD1. Furthermore, the enzymatic activity of LSD1 is essential for H3K9me2 demethylation at cell cycle gene loci. Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibitor-induced senescence and growth inhibition of cancer cells in vitro and in mice. Our data reveal LSD1 as a molecular rheostat selectively regulating H3K9 demethylation at cell cycle gene loci, thereby representing a key player in oncogenesis and a viable target for cancer therapy.	[He, Y.; Zhao, Y.; Wang, L.; Pan, Y.; Huang, H.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW,Gugg 1311B, Rochester, MN 55905 USA; [Bohrer, L. R.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Wang, L.] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Huang, H.] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA; [Huang, H.] Mayo Clin, Coll Med, Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; Mayo Clinic; Mayo Clinic	Huang, H (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW,Gugg 1311B, Rochester, MN 55905 USA.	huang.haojie@mayo.edu	Zhao, Yu/GQR-1394-2022; zhao, yu/AAD-9494-2021	Wang, Liguo/0000-0003-2072-4826	National Institutes of Health [CA134514, CA130908, CA193239]; Department of Defense [W81XWH-09-1-622]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense)	We thank Binhua Zhou for plasmids. This work was supported in part by grants from the National Institutes of Health (CA134514, CA130908 and CA193239 to HH) and the Department of Defense (W81XWH-09-1-622 to HH).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005; Chau CM, 2008, J VIROL, V82, P3428, DOI 10.1128/JVI.01412-07; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200; Forneris F, 2006, J BIOL CHEM, V281, P35289, DOI 10.1074/jbc.M607411200; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Haberle V, 2014, NATURE, V507, P381, DOI 10.1038/nature12974; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hou HF, 2010, CURR OPIN STRUC BIOL, V20, P739, DOI 10.1016/j.sbi.2010.09.006; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; Zhang BJ, 2016, NATURE, V537, P553, DOI 10.1038/nature19361; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	52	30	30	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					534	543		10.1038/onc.2017.353	http://dx.doi.org/10.1038/onc.2017.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28991226				2022-12-28	WOS:000423331600011
J	Visvanathan, A; Patil, V; Arora, A; Hegde, AS; Arivazhagan, A; Santosh, V; Somasundaram, K				Visvanathan, A.; Patil, V; Arora, A.; Hegde, A. S.; Arivazhagan, A.; Santosh, V; Somasundaram, K.			Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance	ONCOGENE			English	Article							MESSENGER-RNA METHYLATION; ACUTE MYELOID-LEUKEMIA; HOMOLOGOUS RECOMBINATION; PROTEIN EXPRESSION; POINT MUTATION; DNA-DAMAGE; GLIOBLASTOMA; N-6-METHYLADENOSINE; TRANSLATION; CANCER	Despite advances in biology and therapeutic modalities, existence of highly tumorigenic glioma stem-like cells (GSCs) makes glioblastomas (GBMs) invincible. N6-methyl adenosine (m(6)A), one of the abundant mRNA modifications catalyzed by methyltransferase-like 3 and 14 (METTL3/14), influences various events in RNA metabolism. Here, we report the crucial role of METTL3-mediated m(6)A modification in GSC (neurosphere) maintenance and dedifferentiation of glioma cells. METTL3 expression is elevated in GSC and attenuated during differentiation. RNA immunoprecipitation studies identified SOX2 as a bonafide m(6)A target of METTL3 and the m(6)A modification of SOX2 mRNA by METTL3 enhanced its stability. The exogenous overexpression of 3' UTR-less SOX2 significantly alleviated the inhibition of neurosphere formation observed in METTL3 silenced GSCs. METTL3 binding and m(6)A modification in vivo required intact three METTL3/m(6)A sites present in the SOX2-3' UTR. Further, we found that the recruitment of Human antigen R (HuR) to m(6)A-modified RNA is essential for SOX2 mRNA stabilization by METTL3. In addition, we found a preferential binding by HuR to the m(6)A-modified transcripts globally. METTL3 silenced GSCs showed enhanced sensitivity to gamma-irradiation and reduced DNA repair as evidenced from the accumulation of gamma-H2AX. Exogenous overexpression of 3' UTR-less SOX2 in METTL3 silenced GSCs showed efficient DNA repair and also resulted in the significant rescue of neurosphere formation from METTL3 silencing induced radiosensitivity. Silencing METTL3 inhibited RasV12 mediated transformation of mouse immortalized astrocytes. GBM tumors have elevated levels of METTL3 transcripts and silencing METTL3 in U87/TIC inhibited tumor growth in an intracranial orthotopic mouse model with prolonged mice survival. METTL3 transcript levels predicted poor survival in GBMs which are enriched for GSC-specific signature. Thus our study reports the importance of m(6)A modification in GSCs and uncovers METTL3 as a potential molecular target in GBM therapy.	[Visvanathan, A.; Patil, V; Arora, A.; Somasundaram, K.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore, Karnataka, India; [Hegde, A. S.] Sri Satya Sai Inst Higher Med Sci, Bangalore, Karnataka, India; [Arivazhagan, A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India; [Santosh, V] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; National Institute of Mental Health & Neurosciences - India; National Institute of Mental Health & Neurosciences - India	Somasundaram, K (corresponding author), Indian Inst Sci, Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in			IISc; DST, Government of India; DBT, Government of India	IISc; DST, Government of India(Department of Science & Technology (India)); DBT, Government of India(Department of Biotechnology (DBT) India)	The results published here are in part based upon data generated by The Cancer Genome Atlas (TCGA) pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions, which constitute the TCGA research network, can be found at http://cancergenome.nih.gov/. The use of data sets from Institute NC, GSE76976 and GSE22866 is acknowledged. We thank Dr Hiroaki Wakimoto and Dr Samuel Rabkin for providing GSCs and Dr Kenneth Kousik for 3 ' UTR-SOX2-Luc construct. KS thanks DST and DBT, Government of India for financial support. KS is a JC Bose Fellow of the Department of Science and Technology. AV acknowledges IISc for the fellowship.	Aguilo F, 2015, CELL STEM CELL, V17, P689, DOI 10.1016/j.stem.2015.09.005; Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Allamand V, 2006, EMBO REP, V7, P450, DOI 10.1038/sj.embor.7400648; Azari H, 2011, JOVE-J VIS EXP, DOI 10.3791/3633; Bansal H, 2014, LEUKEMIA, V28, P1171, DOI 10.1038/leu.2014.16; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Chen T, 2015, CELL STEM CELL, V16, P289, DOI 10.1016/j.stem.2015.01.016; Cho DY, 2013, CELL TRANSPLANT, V22, P731, DOI 10.3727/096368912X655136; Choi J, 2016, NAT STRUCT MOL BIOL, V23, P110, DOI 10.1038/nsmb.3148; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Halvorsen M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001074; Hongay CF, 2011, P NATL ACAD SCI USA, V108, P14855, DOI 10.1073/pnas.1111577108; Jackson M, 2015, CARCINOGENESIS, V36, P177, DOI 10.1093/carcin/bgu243; Kim BW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2015-1; Kwok CT, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0410-6; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lee G, 2016, MOL CANCER THER, V15, P3064, DOI 10.1158/1535-7163.MCT-15-0675; Lee YS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/520578; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lim YC, 2014, MOL ONCOL, V8, P1603, DOI 10.1016/j.molonc.2014.06.012; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Martin ME, 1998, BLOOD, V91, P319, DOI 10.1182/blood.V91.1.319; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pullmann R, 2007, MOL CELL BIOL, V27, P6265, DOI 10.1128/MCB.00500-07; Schildknecht S, 2012, ALTEX-ALTERN ANIM EX, V29, P261, DOI 10.14573/altex.2012.3.261; Shen LF, 2014, J HISTOCHEM CYTOCHEM, V62, P499, DOI 10.1369/0022155414532654; Spitale RC, 2015, NATURE, V519, P486, DOI 10.1038/nature14263; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tuck MT, 1996, CANCER LETT, V103, P107, DOI 10.1016/0304-3835(96)04203-6; Wakimoto H, 2012, NEURO-ONCOLOGY, V14, P132, DOI 10.1093/neuonc/nor195; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Xiang Y, 2017, NATURE, V543, P573, DOI 10.1038/nature21671; Yi CQ, 2011, ACCOUNTS CHEM RES, V44, P1380, DOI 10.1021/ar200057m; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013	49	337	357	10	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					522	533		10.1038/onc.2017.351	http://dx.doi.org/10.1038/onc.2017.351			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28991227	Green Published			2022-12-28	WOS:000423331600010
J	Tran, DDH; Kessler, C; Niehus, SE; Mahnkopf, M; Koch, A; Tamura, T				Tran, D. D. H.; Kessler, C.; Niehus, S. E.; Mahnkopf, M.; Koch, A.; Tamura, T.			Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs	ONCOGENE			English	Article							GENOME; GROWTH; IDENTIFICATION; PROLIFERATION; EXPRESSION; PROGNOSIS; APOPTOSIS; PROTEIN	Hepatocellular carcinoma (HCC) is a frequent form of cancer with a poor prognosis and with limited possibilities for medical intervention. Recent evidence has accumulated that long noncoding RNAs (lncRNAs) are important regulators of disease processes including cancer. Chromatin remodeling in cancer cells may result in an unusual expression of lncRNAs and indeed it has been shown that more than 7000 unannotated lncRNAs are expressed in HCCs. We identified a novel long intergenic noncoding RNA, Linc00176, that plays a role in proliferation and survival of HCC. Linc00176 regulates expression of more than 200 genes by the sponge function for tumor suppressor miRNAs, miR-9 and miR-185. Linc00176 is expressed at a high level only in HCC, and is activated by Myc, Max and AP-4 transcription regulators. Myc also upregulates miR-9 and miR-185. In Linc00176-depleted HCC, these miRNAs were released from Linc00176 and downregulated their target mRNAs. Thus, depletion of Linc00176 disrupted the cell cycle and induced necroptosis in HCC via released tumor suppressor miRNAs. These data indicate that atypically expressed lncRNAs may be useful targets for cancer therapy.	[Tran, D. D. H.; Kessler, C.; Niehus, S. E.; Mahnkopf, M.; Koch, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de	Tran, Doan Duy Hai/AGU-7573-2022	Tran, Doan Duy Hai/0000-0003-2392-0259	Deutsche Krebshilfe [111153]; DFG [Ta-111/13-3]; Niedersachsische Krebsgesellschaft; DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS; Leistungsorientierte Mittelvergabe; Frauenfaktor from MHH	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Niedersachsische Krebsgesellschaft; DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS; Leistungsorientierte Mittelvergabe; Frauenfaktor from MHH	We thank C Bruce Boschek for critically reading the manuscript. This work is a part of thesis of CK. This research was supported by Deutsche Krebshilfe (111153), DFG Ta-111/13-3, Niedersachsische Krebsgesellschaft to AK and DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS and Leistungsorientierte Mittelvergabe with Frauenfaktor from MHH.	Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Cai L, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0228-2; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Dang YW, 2014, ASIAN PAC J CANCER P, V15, P4969, DOI 10.7314/APJCP.2014.15.12.4969; Deng HX, 2011, CANCER BIOL THER, V11, P401, DOI 10.4161/cbt.11.4.14178; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Tran DDH, 2016, CELL SIGNAL, V28, P1872, DOI 10.1016/j.cellsig.2016.09.002; Drakaki A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1562-9; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Ferrin G, 2015, HEPATIC MED-EVID RES, V7, P1, DOI 10.2147/HMER.S50161; Guria A, 2011, RNA, V17, P1048, DOI 10.1261/rna.2607011; Higashi T, 2015, BRIT J CANCER, V113, P252, DOI 10.1038/bjc.2015.170; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949; Kim HS, 2015, ONCOTARGET, V6, P8089, DOI 10.18632/oncotarget.3512; Levens David, 2008, J Natl Cancer Inst Monogr, P41, DOI 10.1093/jncimonographs/lgn004; Liu SJ, 2017, SCIENCE, V355, DOI 10.1126/science.aah7111; Luscher B, 2012, GENE, V494, P145, DOI 10.1016/j.gene.2011.12.027; Martin G, 2012, CELL REP, V1, P753, DOI 10.1016/j.celrep.2012.05.003; Padgett RA, 2012, TRENDS GENET, V28, P147, DOI 10.1016/j.tig.2012.01.001; Qadir XV, 2014, AM J PATHOL, V184, P2355, DOI 10.1016/j.ajpath.2014.05.004; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Saran S, 2016, ONCOGENE, V35, P3872, DOI 10.1038/onc.2015.433; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Steitz JA, 2009, BIOCHEM SOC T, V37, P931, DOI 10.1042/BST0370931; Sun JC, 2015, INT J CLIN EXP MED, V8, P17748; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu WL, 2015, INT J MOL MED, V36, P1713, DOI 10.3892/ijmm.2015.2379; Yang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023525; Yang Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14421; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Zhang JB, 2015, ONCOTARGET, V6, P42040, DOI 10.18632/oncotarget.5969; Zhu SY, 2016, NAT BIOTECHNOL, V34, P1279, DOI 10.1038/nbt.3715; Zhu XC, 2012, INT J MOL MED, V30, P1321, DOI 10.3892/ijmm.2012.1140	38	65	69	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					75	85		10.1038/onc.2017.312	http://dx.doi.org/10.1038/onc.2017.312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869604				2022-12-28	WOS:000422625000008
J	Ju, HQ; Lu, YX; Wu, QN; Liu, J; Zeng, ZL; Mo, HY; Chen, Y; Tian, T; Wang, Y; Kang, TB; Xie, D; Zeng, MS; Huang, P; Xu, RH				Ju, H-Q; Lu, Y-X; Wu, Q-N; Liu, J.; Zeng, Z-L; Mo, H-Y; Chen, Y.; Tian, T.; Wang, Y.; Kang, T-B; Xie, D.; Zeng, M-S; Huang, P.; Xu, R-H			Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer	ONCOGENE			English	Article							INHIBITS GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; CELLS; MECHANISMS; EXPRESSION; ACETYLATION; OXALIPLATIN; STATISTICS; RESISTANCE; APOPTOSIS; STRESS	Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme that generates NADPH to maintain reduced glutathione (GSH), which scavenges reactive oxygen species (ROS) to protect cancer cell from oxidative damage. In this study, we mainly investigate the potential roles of G6PD in colorectal cancer (CRC) development and chemoresistance. We discover that G6PD is overexpressed in CRC cells and patient specimens. High expression of G6PD predicts poor prognosis and correlated with poor outcome of oxaliplatin-based first-line chemotherapy in patients with CRC. Suppressing G6PD decreases NADPH production, lowers GSH levels, impairs the ability to scavenge ROS levels, and enhances oxaliplatin-induced apoptosis in CRC via ROS-mediated damage in vitro. In vivo experiments further shows that silencing G6PD with lentivirus or non-viral gene delivery vector enhances oxaliplatin anti-tumor effects in cell based xenografts and PDX models. In summary, our finding indicated that disrupting G6PD-mediated NADPH homeostasis enhances oxaliplatin-induced apoptosis in CRC through redox modulation. Thus, this study indicates that G6PD is a potential prognostic biomarker and a promising target for CRC therapy.	[Ju, H-Q; Lu, Y-X; Wu, Q-N; Zeng, Z-L; Mo, H-Y; Chen, Y.; Tian, T.; Wang, Y.; Kang, T-B; Xie, D.; Zeng, M-S; Huang, P.; Xu, R-H] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Liu, J.; Chen, Y.] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Huang, P; Xu, RH (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	huangpeng@sysucc.org.cn; xurh@sysucc.org.cn	Xu, Rui-Hua/AAW-4766-2021; xu, rui/GRX-5734-2022	Xu, Rui-Hua/0000-0001-9771-8534; 	National Natural Science Foundation of China [81602137, 81372570, 81572392]; National High Technology Research and the Development Program of China [2015AA020103]; Science and the Technology Program of Guangdong [2015B020232008]; Science and Technology Program of Guangzhou [158100066, 15570006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and the Development Program of China(National High Technology Research and Development Program of China); Science and the Technology Program of Guangdong; Science and Technology Program of Guangzhou	This work was supported by grants from the National Natural Science Foundation of China (81602137, 81372570, 81572392); the National High Technology Research and the Development Program of China (2015AA020103); Science and the Technology Program of Guangdong (2015B020232008); the Science and Technology Program of Guangzhou (158100066, 15570006).	Ai GQ, 2016, MOL MED REP, V14, P1726, DOI 10.3892/mmr.2016.5449; Becouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739; Biagiotti S, 2016, FEBS J, V283, P3962, DOI 10.1111/febs.13901; Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8; Choi YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22172; Fichtner I, 2004, EUR J CANCER, V40, P298, DOI 10.1016/j.ejca.2003.10.011; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Ju HQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14437; Ju HQ, 2016, THERANOSTICS, V6, P1160, DOI 10.7150/thno.14848; Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285; Ju HQ, 2015, MOL CANCER THER, V14, P788, DOI 10.1158/1535-7163.MCT-14-0420; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; Li SD, 2006, GENE THER, V13, P1313, DOI 10.1038/sj.gt.3302838; Liu B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.322; Margis R, 2008, FEBS J, V275, P3959, DOI 10.1111/j.1742-4658.2008.06542.x; Oronsky B, 2016, DISCOV MED, V21, P251; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Picco G, 2016, JNCI-J NATL CANCER I, V109, P1; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Santoro V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv394; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9; Wang X, 2015, EJSO-EUR J SURG ONC, V41, P1293, DOI 10.1016/j.ejso.2015.08.155; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Yang Z, 2014, NANOSCALE, V6, P10193, DOI 10.1039/c4nr02395a; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Zeng ZL, 2014, CLIN CANCER RES, V20, P1042, DOI 10.1158/1078-0432.CCR-13-0171; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhou JB, 2012, NAT MATER, V11, P82, DOI [10.1038/NMAT3187, 10.1038/nmat3187]; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643; Zhou Q, 2015, CHIN J CANCER, V34, P1, DOI 10.1186/s40880-015-0026-6	38	77	82	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6282	6292		10.1038/onc.2017.227	http://dx.doi.org/10.1038/onc.2017.227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692052	Green Published, hybrid			2022-12-28	WOS:000414774800007
J	Li, Y; Wang, L; Liu, J; Zhang, P; An, M; Han, C; Li, Y; Guan, X; Zhang, K				Li, Y.; Wang, L.; Liu, J.; Zhang, P.; An, M.; Han, C.; Li, Y.; Guan, X.; Zhang, K.			O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer	ONCOGENE			English	Article							GLCNAC TRANSFERASE; CHROMATIN-ASSOCIATION; STEM-CELLS; C-MYC; PHOSPHORYLATION; OGT; IDENTIFICATION; TARGET; GROWTH; DOMAIN	The Polycomb group transcriptional repressor Bmi-1 often overexpressed and participated in stem cells self-renewal and tumorigenesis initiating of prostate cancer. In this progression, Bmi-1 protein was regulated by transcription and post-translational modifications (PTMs). Nobly, the underlying PTMs regulation of Bmi-1 is poorly known. Here we use co-immunoprecipitation show that in C4-2 cell line, Bmi-1 directly interacted with OGT which is the only known enzyme catalyzed the O-GlcNAcylation in human. Furthermore, we identified that Ser255 is the site for Bmi-1 O-GlcNAcylation, and O-GlcNAcylation promoted Bmi-1 protein stability and its oncogenic activity. Finally, microarray analysis has characterized potential oncogenes associated pathway subject to repression via the OGT-Bmi-1 axis. Taken together, these results indicate that OGT-mediated O-GlcNAcylation at Ser255 stabilizes Bmi-1 and hence inhibits the TP53, PTEN and CDKN1A/CDKN2A pathway. The study not only uncovers a novel functional PTMs of Bmi-1 but also reveals a unique oncogenic role of O-GlcNAcylation in prostate cancer.	[Li, Y.; Wang, L.; Liu, J.; An, M.; Han, C.; Li, Y.; Guan, X.] Dalian Med Univ, Affiliated Hosp 1, Sino UK Regenerat Med Ctr, 222 Zhongshan Rd, Dalian 116011, Peoples R China; [Zhang, P.] Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, Dalian, Peoples R China; [Zhang, K.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	Dalian Medical University; Dalian Medical University; University of California System; University of California San Diego	Liu, J (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Sino UK Regenerat Med Ctr, 222 Zhongshan Rd, Dalian 116011, Peoples R China.	liujing@dmu.edu.cn	Wang, Liang/O-8394-2019	Wang, Liang/0000-0003-1952-3525; Wang, Liang/0000-0003-2244-7535; Liu, Jing/0000-0002-0493-296X				Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107; Barlow Lamont J, 2013, Cancer Cell, V24, DOI 10.1016/j.ccr.2013.08.033; Bauer C, 2015, J BIOL CHEM, V290, P4801, DOI 10.1074/jbc.M114.605881; Bommi PV, 2010, CELL CYCLE, V9, P2663, DOI 10.4161/cc.9.13.12147; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Gambetta MC, 2015, CHROMOSOMA, V124, P429, DOI 10.1007/s00412-015-0513-1; Gambetta MC, 2009, SCIENCE, V325, P93, DOI 10.1126/science.1169727; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Hu P, 2010, FEBS LETT, V584, P2526, DOI 10.1016/j.febslet.2010.04.044; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Ito R, 2014, GENES CELLS, V19, P52, DOI 10.1111/gtc.12107; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Malik R, 2009, J PROTEOME RES, V8, P4553, DOI 10.1021/pr9003773; Meng S, 2010, J BIOL CHEM, V285, P33219, DOI 10.1074/jbc.M110.133686; Moon JH, 2011, CELL RES, V21, P1305, DOI 10.1038/cr.2011.107; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Schimpl M, 2010, BIOCHEM J, V432, P1, DOI 10.1042/BJ20101338; Silva J, 2006, CLIN CANCER RES, V12, P6929, DOI 10.1158/1078-0432.CCR-06-0788; Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; Voncken JW, 1999, J CELL SCI, V112, P4627; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Wu J, 2011, J CELL BIOCHEM, V112, P1938, DOI 10.1002/jcb.23114; Xie X, 2014, ONCOGENE, V33, P2040, DOI 10.1038/onc.2013.173; Yadav AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-158; Yoo YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12943; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	37	28	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6293	6305		10.1038/onc.2017.223	http://dx.doi.org/10.1038/onc.2017.223			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714959				2022-12-28	WOS:000414774800008
J	Ivanov, AA; Gonzalez-Pecchi, V; Khuri, LF; Niu, Q; Wang, Y; Xu, Y; Bai, Y; Mo, X; Prochownik, EV; Johns, MA; Du, Y; Khuri, FR; Fu, H				Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Prochownik, E. V.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.			OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc	ONCOGENE			English	Article							GENE-EXPRESSION; TUMOR-CELLS; CANCER; MAX; PHOSPHORYLATION; TRANSFORMATION; INTERACTORS; PATHWAYS; NETWORK; COMPLEX	Mitogen-activated protein kinase kinase 3 (MKK3) is a dual threonine/ tyrosine protein kinase that regulates inflammation, proliferation and apoptosis through specific phosphorylation and activation of the p38 mitogen-activated protein kinase. However, the role of MKK3 beyond p38-signaling remains elusive. Recently, we reported a protein-protein interaction (PPI) network of cancer-associated genes, termed OncoPPi, as a resource for the scientific community to generate new biological models. Analysis of the OncoPPi connectivity identified MKK3 as one of the major hub proteins in the network. Here, we show that MKK3 interacts with a large number of proteins critical for cell growth and metabolism, including the major oncogenic driver MYC. Multiple complementary approaches were used to demonstrate the direct interaction of MKK3 with MYC in vitro and in vivo. Computational modeling and experimental studies mapped the interaction interface to the MYC helix-loop-helix domain and a novel 15-residue MYC-binding motif in MKK3 (MBM). The MBM in MKK3 is distinct from the known binding sites for p38 or upstream kinases. Functionally, MKK3 stabilized MYC protein, enhanced its transcriptional activity and increased expression of MYC-regulated genes. The defined MBM peptide mimicked the MKK3 effect in promoting MYC activity. Together, the exploration of OncoPPi led to a new biological model in which MKK3 operates by two distinct mechanisms in cellular regulation through its phosphorylation of p38 and its activation of MYC through PPI.	[Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Dept Pharmacol, Atlanta, GA USA; [Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA USA; [Prochownik, E. V.] UPMC, Childrens Hosp Pittsburgh, Sect Hematol Oncol, Pittsburgh, PA USA; [Prochownik, E. V.] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA; [Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Winship Canc Inst, Atlanta, GA USA	Emory University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University	Ivanov, AA; Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	andrey.ivanov@emory.edu; hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Gonzalez, Valentina/0000-0002-9163-4118; Ivanov, Andrei A/0000-0001-7476-1329	NIH [U01CA168449]; Winship Cancer Institute [NIH 5P30CA138292]; Emory University Research Committee award; NATIONAL CANCER INSTITUTE [R01CA174713, U01CA168449, P30CA138292, U54CA199092] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship Cancer Institute; Emory University Research Committee award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Min Qui for technical assistance. We thank Lauren Rusnak for editing the manuscript. This research was supported in part by NIH U01CA168449 (HF) and Winship Cancer Institute (NIH 5P30CA138292) and by Emory University Research Committee 2015 award (AAI). The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Babur O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0612-6; Baldari S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.591; Banerjee A, 2006, BIOCHEMISTRY-US, V45, P2333, DOI 10.1021/bi0522551; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Bunkoczi G, 2007, STRUCTURE, V15, P1215, DOI 10.1016/j.str.2007.08.011; Chymkowitch P, 2012, P NATL ACAD SCI USA, V109, P10450, DOI 10.1073/pnas.1200067109; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jung KY, 2015, J MED CHEM, V58, P3002, DOI 10.1021/jm501440q; Kodama Y, 2012, BIOTECHNIQUES, V53, P285, DOI [10.2144/0000113943, 10.2144/000113943]; Kragelj J, 2015, P NATL ACAD SCI USA, V112, P3409, DOI 10.1073/pnas.1419528112; Li S, 2015, CELL DEATH DIFFER, V22, P1000, DOI 10.1038/cdd.2014.188; Li ZG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14356; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Parajuli P, 2015, CELL PROLIFERAT, V48, P421, DOI 10.1111/cpr.12196; Ponzielli R, 2013, METHODS MOL BIOL, V1012, P51, DOI 10.1007/978-1-62703-429-6_4; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; Schreiber SL, 2010, NAT BIOTECHNOL, V28, P904, DOI 10.1038/nbt0910-904; Sultana A, 2015, CURR PROTOC PROTEIN, V79, DOI DOI 10.1002/0471140864.ps1925s79; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tu WB, 2015, BBA-GENE REGUL MECH, V1849, P469, DOI 10.1016/j.bbagrm.2014.06.002; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	36	16	16	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5852	5860		10.1038/onc.2017.180	http://dx.doi.org/10.1038/onc.2017.180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628118	Green Accepted			2022-12-28	WOS:000413292900007
J	Li, H; Xiao, N; Wang, Y; Wang, R; Chen, Y; Pan, W; Liu, D; Li, S; Sun, J; Zhang, K; Sun, Y; Ge, X				Li, H.; Xiao, N.; Wang, Y.; Wang, R.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.; Sun, Y.; Ge, X.			Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKI gamma	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL-PHOSPHATE KINASE; I-GAMMA; LIGASE SMURF1; CADHERIN TRAFFICKING; ACQUIRED-RESISTANCE; SPLICE VARIANT; TALIN HEAD; C2 DOMAIN; TARGETS; PHOSPHORYLATION	Type I. phosphatidylinositol phosphate kinase (PIPKI gamma), a phospholipid kinase generating PIP2, is positively expressed in breast cancer tissues, which correlates intimately with the progression of patients. However, little is known about the expression level of PIPKI. in patients with other cancer types as well as their underlying regulation mechanisms. Here, we report that PIPKI. is highly expressed in lung cancer tissues and its expression level is critical for lung cancer cell proliferation, which may serve as a prognostic marker for lung cancer patients. Meanwhile, we show that E3 ubiquitin ligase Smurf1 directly interacts with PIPKI. and targets PIPKI. for ubiquitination and degradation in lung cancer cells. Also, we discover that Smurf1 directly binds to the kinase domain of PIPKI. via its C2 domain while Lysine 255 in PIPKI. acts as the major ubiquitin acceptor site for Smurf1. In addition, we demonstrate that the phosphorylation mimicking mutant of Smurf1, Smurf1 T306D, prevents PIPKI gamma i2 from ubiquitination and subsequent degradation similar to the effect of forskolin-potentiated cAMP formation, suggesting that Thr306 in Smurf1 is critical for its phosphorylation by PKA. Moreover, PKA-Smurf1-PIPKI. signal transduction takes a significant part in lung cancer cell growth and in vivo tumorigenesis. Thus, we propose that the PKA-Smurf1-PIPKI. pathway has an important role in pulmonary tumorigenesis and imposes substantial clinical impact on development of novel diagnostic markers and therapeutic targets for lung cancer treatment.	[Li, H.; Ge, X.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China; [Li, H.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth, Shanghai, Peoples R China; [Li, H.; Xiao, N.; Wang, Y.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China; [Li, H.; Xiao, N.; Wang, Y.; Chen, Y.; Pan, W.; Liu, D.; Li, S.; Sun, J.; Zhang, K.] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China; [Xiao, N.] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai Peoples Hosp 9,Dept Burns & Plast Surg, Shanghai, Peoples R China; [Wang, Y.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Hematol, Shanghai, Peoples R China; [Wang, R.] Fudan Univ, Canc Inst, Canc Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Sun, Y.] Virginia Commonwealth Univ, Sch Dent, Philips Inst Oral Hlth Res, Richmond, VA USA; [Sun, Y.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Tongji University; Shanghai Jiao Tong University; East China Normal University; East China Normal University; Shanghai Jiao Tong University; Tongji University; Fudan University; Virginia Commonwealth University; Virginia Commonwealth University	Ge, X (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China.	gexx0019@163.com			National Basic Research Program of China (973 program) [2012CB910404, 2010CB529704]; National Natural Science Foundation of China [30971521, 81502559, 81500112, 81602515, 81572645, 30800587, 31171338]; Science and Technology Commission of Shanghai Municipality [11DZ2260300]; Science and Technology Commission of Pudong New Area Foundation [PKJ2016-Y37]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Science and Technology Commission of Pudong New Area Foundation	We thank Dr Dianqing Wu, Jian Luo, Hongrui, Wang, and Lingqiang Zhang for kindly providing reagents. We also appreciate the assistance from other members of the lab. This work was supported by grants from National Basic Research Program of China (973 program 2012CB910404 and 2010CB529704), National Natural Science Foundation of China (30971521, 81502559, 81500112, 81602515, 81572645, 30800587 and 31171338), grant from the Science and Technology Commission of Shanghai Municipality (11DZ2260300) and the Science and Technology Commission of Pudong New Area Foundation (PKJ2016-Y37).	Akieda-Asai S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011755; Ayoola A, 2012, CANCER INVEST, V30, P433, DOI 10.3109/07357907.2012.666691; Bairstow SF, 2006, J BIOL CHEM, V281, P20632, DOI 10.1074/jbc.M601465200; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Cao Y, 2013, CELL MOL LIFE SCI, V70, P2305, DOI 10.1007/s00018-012-1170-7; Chen C, 2015, ONCOGENE, V34, P4635, DOI 10.1038/onc.2014.393; Chen Z, 2016, BIOCHEMISTRY-US, V55, P3658, DOI 10.1021/acs.biochem.6b00448; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Giudici ML, 2004, BIOCHEM J, V379, P489, DOI 10.1042/BJ20031394; Goult BT, 2010, EMBO J, V29, P1069, DOI 10.1038/emboj.2010.4; Heck JN, 2007, CRIT REV BIOCHEM MOL, V42, P15, DOI 10.1080/10409230601162752; Hu J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9205; Huang C, 2009, NAT CELL BIOL, V11, P624, DOI 10.1038/ncb1868; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Jafari N, 2016, J BIOL CHEM, V291, P25729, DOI 10.1074/jbc.M116.742742; Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lee SY, 2005, J CELL BIOL, V168, P789, DOI 10.1083/jcb.200409028; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Li BS, 2015, NAT MED, V21, P563, DOI 10.1038/nm.3840; Li X, 2013, J CELL SCI, V126, P2617, DOI 10.1242/jcs.117044; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Ling K, 2006, TRENDS CELL BIOL, V16, P276, DOI 10.1016/j.tcb.2006.03.007; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760; Lu KF, 2011, J BIOL CHEM, V286, P16861, DOI 10.1074/jbc.M110.211979; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Nader GPF, 2016, NAT CELL BIOL, V18, P491, DOI 10.1038/ncb3333; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Le OTT, 2015, BBA-MOL CELL RES, V1853, P2432, DOI 10.1016/j.bbamcr.2015.07.001; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sangadala S, 2007, J BIOMOL STRUCT DYN, V25, P11, DOI 10.1080/07391102.2007.10507151; Sasaki J, 2005, J EXP MED, V201, P859, DOI 10.1084/jem.20041891; Schill NJ, 2014, J CELL SCI, V127, P2189, DOI 10.1242/jcs.132423; Schill NJ, 2009, BIOCHEM J, V422, P473, DOI 10.1042/BJ20090638; Schill NJ, 2009, BIOCHEM J, V418, P247, DOI 10.1042/BJ20081844; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Thapa N, 2017, ONCOGENE, V36, P899, DOI 10.1038/onc.2016.267; Wan LX, 2011, MOL CELL, V44, P721, DOI 10.1016/j.molcel.2011.09.024; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang YF, 2008, P NATL ACAD SCI USA, V105, P14064, DOI 10.1073/pnas.0804139105; Wang YF, 2007, P NATL ACAD SCI USA, V104, P11748, DOI 10.1073/pnas.0700019104; Wang YJ, 2004, J CELL BIOL, V167, P1005, DOI 10.1083/jcb.200408008; Wieffer M, 2012, METHOD CELL BIOL, V108, P209, DOI 10.1016/B978-0-12-386487-1.00011-0; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Williamson A, 2013, MOL CELL, V49, P591, DOI 10.1016/j.molcel.2013.01.028; Xia Y, 2011, BIOCHEM BIOPH RES CO, V411, P416, DOI 10.1016/j.bbrc.2011.06.168; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Xu WW, 2010, IMMUNITY, V33, P340, DOI 10.1016/j.immuni.2010.08.015; Yamaguchi K, 2008, BIOL CHEM, V389, P405, DOI 10.1515/BC.2008.036; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yoon YD, 2012, J BIOL CHEM, V287, P34078, DOI 10.1074/jbc.M112.372789; Yu YL, 2011, J BIOL CHEM, V286, P9657, DOI 10.1074/jbc.M110.185124; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	70	30	30	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5668	5680		10.1038/onc.2017.166	http://dx.doi.org/10.1038/onc.2017.166			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581524				2022-12-28	WOS:000412843900002
J	Shahi, P; Wang, CY; Chou, J; Hagerling, C; Velozo, HG; Ruderisch, A; Yu, Y; Lai, MD; Werb, Z				Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Lai, M-D; Werb, Z.			GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis	ONCOGENE			English	Article							LUNG-CANCER; CHROMOSOME 3P21.3; LIM-KINASE; EXPRESSION; GROWTH; DIFFERENTIATION; REGULATOR; MORPHOGENESIS; NEUROPILIN-1; RECEPTORS	Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in non-neuronal cells. Here, we show that SEMA3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of breast cancer progression and metastasis.	[Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Werb, Z.] Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA; [Shahi, P.; Wang, C-Y; Chou, J.; Hagerling, C.; Velozo, H. Gonzalez; Ruderisch, A.; Yu, Y.; Werb, Z.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA; [Shahi, P.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wang, C-Y; Lai, M-D] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Dept Biochem & Mol Biol, Tainan, Taiwan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; National Cheng Kung University	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA.; Werb, Z (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,BOX 0452, San Francisco, CA 94143 USA.	zena.werb@ucsf.edu	Wang, Chihyang/ADO-2306-2022; Lai, Ming-Derg/M-8028-2014	Wang, Chihyang/0000-0002-4137-5074; 	National Cancer Institute [R01 CA129523, R01 CA190851]; Institutional National Research Service Award [T32 CA108462]; Ministry of Science and Technology, Taiwan [104-2917-I-006-002]; Tegger Foundation; Wenner-Gren Foundations; Sweden-America Foundation; Swedish Society of Medicine; Swedish Society for Medical Research; Becas Chile Scholarship; NATIONAL CANCER INSTITUTE [R01CA190851, R01CA129523, T32CA108462] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Institutional National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Tegger Foundation; Wenner-Gren Foundations; Sweden-America Foundation; Swedish Society of Medicine; Swedish Society for Medical Research; Becas Chile Scholarship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Gera Neufeld for providing the SEMA3B overexpression DNA construct. We thank Dr Luca Tamagnone for his generous gift of lentiviral SEMA3B short hairpin RNA constructs. We thank Elena Atamaniuc for technical assistance. This study was supported by funds from the National Cancer Institute (R01 CA129523 and R01 CA190851 to ZW); PS was supported by an Institutional National Research Service Award (T32 CA108462); C-YW was supported by a grant from the Ministry of Science and Technology, Taiwan (104-2917-I-006-002); CH was supported by funds from the Tegger Foundation, Wenner-Gren Foundations, Sweden-America Foundation, Swedish Society of Medicine and Swedish Society for Medical Research; and HGV was supported by a Becas Chile Scholarship.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Ballard MS, 2015, CELL REP, V13, P290, DOI 10.1016/j.celrep.2015.09.006; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Du F, 2015, MED RES REV, V35, P1300, DOI 10.1002/med.21362; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hall C, 2001, J BIOL CHEM, V276, P43482, DOI 10.1074/jbc.C100455200; Hoch RV, 1999, INT J CANCER, V84, P122; Home P, 2009, J BIOL CHEM, V284, P28729, DOI 10.1074/jbc.M109.016840; Jiang YZ, 2014, CANCER-AM CANCER SOC, V120, P1329, DOI 10.1002/cncr.28566; Jin Z, 1997, J NEUROSCI, V17, P6256; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Kuroki T, 2003, CANCER RES, V63, P3352; Lagoutte E, 2016, SCI REP-UK, V6, DOI 10.1038/srep24925; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Macias H, 2011, DEV CELL, V20, P827, DOI 10.1016/j.devcel.2011.05.012; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Sellheyer K, 2010, J CUTAN PATHOL, V37, P357, DOI 10.1111/j.1600-0560.2009.01416.x; Shea KF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003398; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tse C, 2002, CANCER RES, V62, P542; Turner LJ, 2004, J BIOL CHEM, V279, P33199, DOI 10.1074/jbc.M402943200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Yagi R, 2011, INT IMMUNOL, V23, P415, DOI 10.1093/intimm/dxr029	51	31	35	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5567	5575		10.1038/onc.2017.165	http://dx.doi.org/10.1038/onc.2017.165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581515	Green Accepted, Green Submitted			2022-12-28	WOS:000412293600002
J	Han, B; Kpark, H; Ching, T; Panneerselvam, J; Wang, H; Shen, Y; Zhang, J; Li, L; Che, R; Garmire, L; Fei, P				Han, B.; KPark, H.; Ching, T.; Panneerselvam, J.; Wang, H.; Shen, Y.; Zhang, J.; Li, L.; Che, R.; Garmire, L.; Fei, P.			Human DBR1 modulates the recycling of snRNPs to affect alternative RNA splicing and contributes to the suppression of cancer development	ONCOGENE			English	Article							DISTINCT METABOLIC SIGNATURE; HUMAN BLADDER-CANCER; TUMOR-SUPPRESSOR; BRANCH POINT; DEBRANCHING ENZYME; DNA-DAMAGE; SPLICEOSOME; PATHWAY; FANCD2; COMPLEX	The contribution of RNA processing to tumorigenesis is understudied. Here, we report that the human RNA debranching enzyme (hDBR1), when inappropriately regulated, induces oncogenesis by causing RNA processing defects, for example, splicing defects. We found that wild-type p53 and hypoxia-inducible factor 1 co-regulate hDBR1 expression, and insufficient hDBR1 leads to a higher rate of exon skipping. Transcriptomic sequencing confirmed the effect of hDBR1 on RNA splicing, and metabolite profiling supported the observation that neoplasm is triggered by a decrease in hDBR1 expression both in vitro and in vivo. Most importantly, when modulating the expression of hDBR1, which was found to be generally low in malignant human tissues, higher expression of hDBR1 only affected exon-skipping activity in malignant cells. Together, our findings demonstrate previously unrecognized regulation and functions of hDBR1, with immediate clinical implications regarding the regulation of hDBR1 as an effective strategy for combating human cancer.	[Han, B.; Panneerselvam, J.; Shen, Y.; Li, L.; Che, R.; Fei, P.] Univ Hawaii, Canc Ctr, Div Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA; [KPark, H.; Wang, H.; Zhang, J.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA; [Ching, T.; Garmire, L.; Fei, P.] Univ Hawaii, Canc Ctr, Div Epidemiol, Honolulu, HI 96813 USA; [Li, L.] Xuzhou Med Coll, Canc Inst, Xuzhou, Peoples R China	Cancer Research Center of Hawaii; University of Hawaii System; Mayo Clinic; Cancer Research Center of Hawaii; University of Hawaii System; Xuzhou Medical University	Fei, P (corresponding author), Univ Hawaii, Canc Ctr, Div Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA.	Pfei@cc.hawaii.edu		Ching, Travers/0000-0002-5577-3516; HAN, BING/0000-0002-0818-409X; li, liantao/0000-0002-8788-2880	NIH [R01CA136532, R01CA188251]; Chinese National Science Foundation (CNSF) [81372171]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD084633] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA188251, P30CA071789, R01CA136532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K01ES025434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103457] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM012373] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese National Science Foundation (CNSF)(National Natural Science Foundation of China (NSFC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This study was supported in part by NIH grants (R01CA136532 and R01CA188251) to PF and Chinese National Science Foundation (CNSF#81372171) to PF. We thank Dr Alberto R Kornblihtt (Universidad de Buenos Aires, Argentina) for providing the FN-EDI reporter construct.	Azubel M, 2004, MOL CELL, V15, P833, DOI 10.1016/j.molcel.2004.07.022; Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540; Bischof O, 2015, IUBMB LIFE, V67, P255, DOI 10.1002/iub.1373; Bitton DA, 2014, GENOME RES, V24, P1169, DOI 10.1101/gr.166819.113; Carstens RP, 2014, MOL CELL, V54, P903, DOI 10.1016/j.molcel.2014.06.014; Chan SP, 2003, SCIENCE, V302, P279, DOI 10.1126/science.1086602; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Clark NE, 2016, P NATL ACAD SCI USA, V113, P14727, DOI 10.1073/pnas.1612729114; Clerte C, 2009, BIOCHEMISTRY-US, V48, P2063, DOI 10.1021/bi8016872; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Fourmann JB, 2013, GENE DEV, V27, P413, DOI 10.1101/gad.207779.112; Frye M, 2016, DEVELOPMENT, V143, P3871, DOI 10.1242/dev.136556; Fu DC, 2013, CELL CYCLE, V12, P803, DOI 10.4161/cc.23755; Gao KP, 2008, NUCLEIC ACIDS RES, V36, P2257, DOI 10.1093/nar/gkn073; Han B, 2017, ONCOTARGET, V8, P22490, DOI 10.18632/oncotarget.14989; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hube F, 2017, NUCLEIC ACIDS RES, V45, P4768, DOI 10.1093/nar/gkw1341; Ilagan JO, 2013, RNA, V19, P400, DOI 10.1261/rna.034223.112; Kataoka N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01090; Kataoka N, 2009, MOL CELL BIOL, V29, P3243, DOI 10.1128/MCB.00360-09; Kock KH, 2015, NUCLEIC ACIDS RES, V43, P6568, DOI 10.1093/nar/gkv617; Kol G, 2005, HUM MOL GENET, V14, P1559, DOI 10.1093/hmg/ddi164; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li ZL, 2016, OXID MED CELL LONGEV, V2016, P12, DOI DOI 10.1007/S10529-016-2066-7; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Ohi MD, 2007, P NATL ACAD SCI USA, V104, P3195, DOI 10.1073/pnas.0611591104; Panneerselvam J, 2016, J PROTEOME RES, V15, P1333, DOI 10.1021/acs.jproteome.6b00076; Panneerselvam J, 2014, ONCOTARGET, V5, P1326, DOI 10.18632/oncotarget.1796; Panneerselvam J, 2013, ONCOTARGET, V4, P1416, DOI 10.18632/oncotarget.1217; Panneerselvam J, 2012, CELL CYCLE, V11, P2947, DOI 10.4161/cc.21400; Park HK, 2011, CELL CYCLE, V10, P2574, DOI 10.4161/cc.10.15.15923; Park HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013313; Pastuszak AW, 2011, NUCLEIC ACIDS RES, V39, P2344, DOI 10.1093/nar/gkq1046; Qiu YP, 2014, CLIN CANCER RES, V20, P2136, DOI 10.1158/1078-0432.CCR-13-1939; Qiu YP, 2013, INT J MOL SCI, V14, P8047, DOI 10.3390/ijms14048047; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SHARP PA, 1987, SCIENCE, V238, P729, DOI 10.1126/science.2445035; Sullenger BA, 2016, SCIENCE, V352, P1417, DOI 10.1126/science.aad8709; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Wahl MC, 2015, CELL, V161, P1474, DOI 10.1016/j.cell.2015.05.050; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Yoshimoto R, 2009, NUCLEIC ACIDS RES, V37, P891, DOI 10.1093/nar/gkn1002; Zheng SM, 2015, CELL, V161, P762, DOI 10.1016/j.cell.2015.03.020	52	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5382	5391		10.1038/onc.2017.150	http://dx.doi.org/10.1038/onc.2017.150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28504715	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000411382100005
J	Li, X; Kang, Y; Roife, D; Lee, Y; Pratt, M; Perez, MR; Dai, B; Koay, EJ; Fleming, JB				Li, X.; Kang, Y.; Roife, D.; Lee, Y.; Pratt, M.; Perez, M. R.; Dai, B.; Koay, E. J.; Fleming, J. B.			Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth	ONCOGENE			English	Article							CANCER; CELLS; EXPRESSION; DORMANCY	We previously demonstrated that pancreatic stellate cells within pancreatic ductal adenocarcinoma (PDAC) stroma secrete lumican and its presence is associated with prolonged survival of patients with localized PDAC. Here, we observed that extracellular lumican decreases PDAC tumour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth inhibition of low-passage human PDAC cells in a species-specific manner. PDAC cells grown in variant culture conditions and exposed to extracellular lumican display typical characterizations of cancer cell in a quiescent state, such as growth inhibition, apoptosis, G0/G1 arrest and chemoresistance. Importantly, extracellular lumican is associated with diminished ERK1/2 phosphorylation and increased p38 phosphorylation within PDAC cells. We further demonstrated that extracellular lumican physically binds with EGFR to trigger EGFR internalization and downregulation of EGFR and its downstream signal molecule ERK. Lumican enhances casitas B-lineage lymphoma expression, which stabilized the TGF beta Type II receptor sensitizing PDAC cells to TGF beta-mediated activation of p38 and SMAD signals. These provide a mechanism for the shift in signalling and phenotypic changes we observed after prolonged exposure to lumican. Together, our findings demonstrate that stromal lumican restrains PDAC cell growth through mediating cell entry into a quiescent state.	[Li, X.; Kang, Y.; Pratt, M.; Perez, M. R.; Dai, B.; Fleming, J. B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA; [Roife, D.] Univ Texas MD Anderson Canc Ctr, Dept Gen Surg, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA; [Lee, Y.; Koay, E. J.] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fleming, JB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA.	jbflemin@mdanderson.org		Roife, David/0000-0001-9052-2248	Skip Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH) [T32CA009599]; CABI GE in-kind grant;  [U54 CA210181-01]; NATIONAL CANCER INSTITUTE [U54CA210181, T32CA009599] Funding Source: NIH RePORTER	Skip Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CABI GE in-kind grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Skip Viragh Family Foundation (to JF), the W. Smith Foundation (to JF), National Institutes of Health (NIH) grant T32CA009599 (to DR and MRP), U54 CA210181-01 'Center for Immunotherapeutic Transport Oncophysics (CITO)' grant (to EK), and CABI GE in-kind grant (to EK). This research was conducted at the MD Anderson Cancer Center for Advanced Biomedical Imaging in-part with equipment support from General Electric Healthcare.	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bui AT, 2015, CELL CYCLE, V14, P1218, DOI 10.1080/15384101.2015.1014145; Baba H, 2001, JPN CIRC J, V65, P445, DOI 10.1253/jcj.65.445; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Gruber T, 2013, J MOL CELL BIOL, V5, P358, DOI 10.1093/jmcb/mjt017; Ishiwata T, 2007, ONCOL REP, V18, P537; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kang Y, 2016, CLIN CANCER RES, V22, P4934, DOI 10.1158/1078-0432.CCR-15-2780; Kim MP, 2012, ANN SURG ONCOL, V19, pS395, DOI 10.1245/s10434-011-1839-4; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Li X, 2016, ONCOGENE, V35, P4881, DOI 10.1038/onc.2016.20; Li XQ, 2014, CLIN CANCER RES, V20, P6529, DOI 10.1158/1078-0432.CCR-14-0970; Lu YP, 2002, PATHOL INT, V52, P519, DOI 10.1046/j.1440-1827.2002.01384.x; Maykel J, 2014, DIGEST DIS SCI, V59, P1169, DOI 10.1007/s10620-014-3168-5; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Proia DA, 2005, CELL CYCLE, V4, P1022, DOI 10.4161/cc.4.8.1903; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Salm SN, 2005, J CELL BIOL, V170, P81, DOI 10.1083/jcb.200412015; Suetsugu A, 2012, J CELL BIOCHEM, V113, P2290, DOI 10.1002/jcb.24099; Williams KE, 2011, CANCER MICROENVIRON, V4, P115, DOI 10.1007/s12307-010-0056-1; Yamamoto T, 2012, CANCER LETT, V320, P31, DOI 10.1016/j.canlet.2012.01.023; Yamanaka O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082730; Zuo W, 2013, MOL CELL, V49, P499, DOI 10.1016/j.molcel.2012.12.002	24	25	26	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5432	5438		10.1038/onc.2017.125	http://dx.doi.org/10.1038/onc.2017.125			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534517	Green Accepted			2022-12-28	WOS:000411382100009
J	Read, ML; Fong, JC; Modasia, B; Fletcher, A; Imruetaicharoenchoke, W; Thompson, RJ; Nieto, H; Reynolds, JJ; Bacon, A; Mallick, U; Hackshaw, A; Watkinson, JC; Boelaert, K; Turnell, AS; Smith, VE; McCabe, CJ				Read, M. L.; Fong, J. C.; Modasia, B.; Fletcher, A.; Imruetaicharoenchoke, W.; Thompson, R. J.; Nieto, H.; Reynolds, J. J.; Bacon, A.; Mallick, U.; Hackshaw, A.; Watkinson, J. C.; Boelaert, K.; Turnell, A. S.; Smith, V. E.; McCabe, C. J.			Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer	ONCOGENE			English	Article							TUMOR-TRANSFORMING-GENE; HUMAN BREAST-CANCER; BINDING-FACTOR; MICROSATELLITE INSTABILITY; GENOMIC INSTABILITY; COLORECTAL-CANCER; CELLS; EXPRESSION; TUMORIGENESIS; GROWTH	The proto-oncogene PTTG and its binding partner PBF have been widely studied in multiple cancer types, particularly thyroid and colorectal, but their combined role in tumourigenesis is uncharacterised. Here, we show for the first time that together PTTG and PBF significantly modulate DNA damage response (DDR) genes, including p53 target genes, required to maintain genomic integrity in thyroid cells. Critically, DDR genes were extensively repressed in primary thyrocytes from a bitransgenic murine model (Bi-Tg) of thyroid-specific PBF and PTTG overexpression. Irradiation exposure to amplify p53 levels further induced significant repression of DDR genes in Bi-Tg thyrocytes (P = 2.4 x 10(-4)) compared with either PBF-(P = 1.5 x 10(-3)) or PTTG-expressing thyrocytes (P = NS). Consistent with this, genetic instability was greatest in Bi-Tg thyrocytes with a mean genetic instability (GI) index of 35.8 +/- 2.6%, as well as significant induction of gross chromosomal aberrations in thyroidal TPC-1 cells following overexpression of PBF and PTTG. We extended our findings to human thyroid cancer using TCGA data sets (n = 322) and found striking correlations with PBF and PTTG expression in well-characterised DDR gene panel RNA-seq data. In addition, genetic associations and transient transfection identified PBF as a downstream target of the receptor tyrosine kinase-BRAF signalling pathway, emphasising a role for PBF as a novel component in a pathway well described to drive neoplastic growth. We also showed that overall survival (P = 1.91 x 10(-5)) and disease-free survival (P = 4.9 x 10(-5)) was poorer for TCGA patients with elevated tumoural PBF/PTTG expression and mutationally activated BRAF. Together our findings indicate that PBF and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outcome.	[Read, M. L.; Fong, J. C.; Modasia, B.; Fletcher, A.; Imruetaicharoenchoke, W.; Thompson, R. J.; Nieto, H.; Bacon, A.; Boelaert, K.; Smith, V. E.; McCabe, C. J.] Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; [Reynolds, J. J.; Turnell, A. S.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England; [Mallick, U.] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Hackshaw, A.] UCL, Canc Res UK, London, England; [Hackshaw, A.] UCL, UCL Canc Trials Ctr, London, England; [Watkinson, J. C.] Univ Hosp Birmingham NHS Fdn Trust, Dept Otolaryngol Head & Neck Surg, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Newcastle Freeman Hospital; Newcastle University - UK; Cancer Research UK; University of London; University College London; University of London; University College London; University of Birmingham	McCabe, CJ (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Metab & Syst Res, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	Read, Martin/A-3505-2012; Smith, Vicki E/F-6972-2010	Read, Martin/0000-0001-8918-4333; Smith, Vicki E/0000-0003-0757-7198; Reynolds, John Joseph/0000-0001-8690-5828; Fletcher, Anne/0000-0003-1534-1142	Medical Research Council [MR/J001414/1]; Wellcome Trust; Cancer Research UK; Get Ahead Charitable Trust; AMEND; Medical Research Council [G0601811, 1367609, MR/P000509/1] Funding Source: researchfish; MRC [G0601811, MR/J001414/1, MR/P000509/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Cancer Research UK(Cancer Research UK); Get Ahead Charitable Trust; AMEND; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MR/J001414/1), Wellcome Trust, Cancer Research UK, Get Ahead Charitable Trust and AMEND. Results are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Byrne M, 2014, ANN NY ACAD SCI, V1310, P89, DOI 10.1111/nyas.12370; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chesnokova V, 2009, ENDOCRINOLOGY, V150, P2603, DOI 10.1210/en.2008-0972; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Fong MY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-532; Gao H, 2016, AM J CANCER RES, V6, P425; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grogan RH, 2013, SURGERY, V154, P1436, DOI 10.1016/j.surg.2013.07.008; Gurvits N, 2016, CELL ONCOL, V39, P319, DOI 10.1007/s13402-016-0277-5; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamid T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-18; Haymart MR, 2009, ONCOLOGIST, V14, P216, DOI 10.1634/theoncologist.2008-0194; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Higgs MR, 2015, MOL CELL, V59, P462, DOI 10.1016/j.molcel.2015.06.007; Hsu YH, 2010, J BIOL CHEM, V285, P22630, DOI 10.1074/jbc.M109.096255; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kim D, 2005, ONCOGENE, V24, P4861, DOI 10.1038/sj.onc.1208659; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Lewy GD, 2013, ENDOCRINOLOGY, V154, P4408, DOI 10.1210/en.2012-2156; Liang HQ, 2015, ONCOTARGET; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Melloni GEM, 2014, GENOME MED, V6, DOI 10.1186/gm563; Mitmaker E, 2008, J SURG RES, V150, P40, DOI 10.1016/j.jss.2007.12.760; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, DOI 10.1155/2013/965212; Read ML, 2016, MOL CARCINOGEN, V55, P15, DOI 10.1002/mc.22254; Read ML, 2014, ENDOCRINOLOGY, V155, P1222, DOI 10.1210/en.2013-1646; Read ML, 2011, CANCER RES, V71, P6153, DOI 10.1158/0008-5472.CAN-11-0720; Ruan JW, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3226; Rubinek T, 2007, AM J PHYSIOL-CELL PH, V293, pC1082, DOI 10.1152/ajpcell.00145.2007; Salehi F, 2008, ENDOCR-RELAT CANCER, V15, P721, DOI 10.1677/ERC-08-0012; Santos JC, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-79; Smith VE, 2009, J CELL SCI, V122, P3393, DOI 10.1242/jcs.045427; Stratford AL, 2005, J CLIN ENDOCR METAB, V90, P4341, DOI 10.1210/jc.2005-0523; Vaish M, 2004, EXP MOL MED, V36, P122, DOI 10.1038/emm.2004.18; Wang H, 2016, MOL CELL, V63, P277, DOI 10.1016/j.molcel.2016.05.038; Wang X, 2015, ONCOTARGET, V6, P40959, DOI 10.18632/oncotarget.5726; Watkins RJ, 2010, CANCER RES, V70, P3739, DOI 10.1158/0008-5472.CAN-09-3531; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Zheng Y, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0126-9; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	53	14	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5296	5308		10.1038/onc.2017.154	http://dx.doi.org/10.1038/onc.2017.154			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504713	Green Submitted, Green Accepted			2022-12-28	WOS:000410671700008
J	Castro, BA; Flanigan, P; Jahangiri, A; Hoffman, D; Chen, W; Kuang, R; De Lay, M; Yagnik, G; Wagner, JR; Mascharak, S; Sidorov, M; Shrivastav, S; Kohanbash, G; Okada, H; Aghi, MK				Castro, B. A.; Flanigan, P.; Jahangiri, A.; Hoffman, D.; Chen, W.; Kuang, R.; De Lay, M.; Yagnik, G.; Wagner, J. R.; Mascharak, S.; Sidorov, M.; Shrivastav, S.; Kohanbash, G.; Okada, H.; Aghi, M. K.			Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy	ONCOGENE			English	Article							ANTIANGIOGENIC THERAPY; VEGF THERAPY; MESENCHYMAL TRANSITION; RECURRENT GLIOBLASTOMA; MEDIATES RESISTANCE; RECEPTOR CD74; CELL INVASION; POLARIZATION; SURVIVAL; CANCER	Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients. This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus, bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in turn promotes tumor growth.	[Castro, B. A.; Flanigan, P.; Jahangiri, A.; Hoffman, D.; Chen, W.; Kuang, R.; De Lay, M.; Yagnik, G.; Wagner, J. R.; Mascharak, S.; Sidorov, M.; Shrivastav, S.; Kohanbash, G.; Okada, H.; Aghi, M. K.] Univ Calif San Francisco, Dept Neurol Surg, Diller Canc Res Bldg,1450 Third St Room HD-465, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Aghi, MK (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Diller Canc Res Bldg,1450 Third St Room HD-465, San Francisco, CA 94158 USA.	aghim@neurosurg.ucsf.edu		Flanigan, Patrick/0000-0002-3611-8575; Chen, William/0000-0001-8924-5853; Hoffman, Daniel/0000-0002-2302-6786	American Brain Tumor Association (ABTA); James S. McDonnell Foundation; American Cancer Society (ACS); University of California Cancer Research Coordinating Committee; NIH [5K02NS64167, 1R01NS079697]; Howard Hughes Medical Institute (HHMI) fellowship; American Association of Neurological Surgeons (AANS); ABTA; UCSF School of Medicine (SOM) Pathways Explore Summer Grant; NATIONAL CANCER INSTITUTE [T32CA151022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS064167, R01NS079697] Funding Source: NIH RePORTER	American Brain Tumor Association (ABTA); James S. McDonnell Foundation; American Cancer Society (ACS)(American Cancer Society); University of California Cancer Research Coordinating Committee(University of California System); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute (HHMI) fellowship; American Association of Neurological Surgeons (AANS); ABTA; UCSF School of Medicine (SOM) Pathways Explore Summer Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	MKA was supported by the American Brain Tumor Association (ABTA), the James S. McDonnell Foundation, American Cancer Society (ACS), University of California Cancer Research Coordinating Committee and the NIH (5K02NS64167 and 1R01NS079697). BC was supported by the Howard Hughes Medical Institute (HHMI) fellowship, the American Association of Neurological Surgeons (AANS) and ABTA. DH was supported by the Howard Hughes Medical Institute (HHMI) fellowship. WC was supported by the UCSF School of Medicine (SOM) Pathways Explore Summer Grant.	Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Cho HR, 2016, ONCOTARGET, V7, P69606, DOI 10.18632/oncotarget.11901; Choudhary S, 2013, CARCINOGENESIS, V34, P2891, DOI 10.1093/carcin/bgt239; Clark AJ, 2012, NEUROSURGERY, V70, P361, DOI 10.1227/NEU.0b013e3182314f9d; de Groot JF, 2011, CLIN CANCER RES, V17, P6109, DOI 10.1158/1078-0432.CCR-11-1853; Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Gabrusiewicz K, 2014, ONCOTARGET, V5, P2208, DOI 10.18632/oncotarget.1893; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Girard E, 2012, BRIT J CANCER, V107, P1498, DOI 10.1038/bjc.2012.392; Gupta Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146482; Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053; Hoppstadter J, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00055; Hu YL, 2012, AUTOPHAGY, V8, P979, DOI 10.4161/auto.20232; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Kessler T, 2015, ONCOTARGET, V6, P31050, DOI 10.18632/oncotarget.2910; Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Li Z, 2004, CHINESE MED J-PEKING, V117, P107; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mao XG, 2016, ONCOTARGET, V7, P47808, DOI 10.18632/oncotarget.10029; Martinez F.O., 2014, F1000PRIME REP, V6, DOI DOI 10.12703/P6-13; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401-011-0858-3; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Moughon DL, 2015, CANCER RES, V75, P4742, DOI 10.1158/0008-5472.CAN-14-3373; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Piette C, 2009, J BIOL CHEM, V284, P32483, DOI 10.1074/jbc.M109.014589; Rahbari NN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5219; Redente EF, 2010, J LEUKOCYTE BIOL, V88, P159, DOI 10.1189/jlb.0609378; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505; Stoger JL, 2012, ATHEROSCLEROSIS, V225, P461, DOI 10.1016/j.atherosclerosis.2012.09.013; Sun B, 2005, CLIN CANCER RES, V11, P1050; Thiele M, 2015, J IMMUNOL, V195, P2343, DOI 10.4049/jimmunol.1500572; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Verschuren L, 2009, CIRC RES, V105, P99, DOI 10.1161/CIRCRESAHA.109.199166; Wang X, 2012, CANCER RES, V72, P2867, DOI 10.1158/0008-5472.CAN-11-3247; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Yaddanapudi K, 2013, J IMMUNOL, V190, P2984, DOI 10.4049/jimmunol.1201650; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194	53	66	69	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3749	3759		10.1038/onc.2017.1	http://dx.doi.org/10.1038/onc.2017.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218903	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000404349700010
J	Fabian, ID; Onadim, Z; Karaa, E; Duncan, C; Chowdhury, T; Scheimberg, I; Ohnuma, SI; Reddy, MA; Sagoo, MS				Fabian, Ido D.; Onadim, Zerrin; Karaa, Esin; Duncan, Catriona; Chowdhury, Tanzina; Scheimberg, Irene; Ohnuma, Shin-Ichi; Reddy, M. Ashwin; Sagoo, Mandeep S.			The management of retinoblastoma	ONCOGENE			English	Review							INTRAOCULAR RETINOBLASTOMA; INTERNATIONAL CLASSIFICATION; INTRAVENOUS CHEMOTHERAPY; INTRAVITREAL CHEMOTHERAPY; RISK; GENE; INTRAARTERIAL; MUTATIONS; RADIOTHERAPY; SURVIVAL	Retinoblastoma (Rb) is the most common primary intraocular malignancy of childhood, but an uncommon paediatric cancer, with a constant incidence worldwide of 1: 15,000-1: 20,000 live births. Despite its rarity, Rb has served as a cornerstone in the field of oncology in many of the aspects that comprise cancer management, including classification schemes, treatment modalities, genetic testing and screening. Until just over half a century ago, the major treatment for Rb was eye removal, and prognosis was poor with outcome fatal for most children. The dramatic evolution, in a short period of time across all fields of Rb management, as well as the development of specialized centres, better infrastructure and introduction of awareness campaigns, has resulted in nearly 100% survival in developed countries and allowed eye salvage in many of the cases. External beam radiotherapy was used as the main treatment choice for four decades, but replaced by chemotherapy at the turn of the century. Initially, and still in many centres, chemotherapy is administered intravenously, but recently is targeted directly into the eye by means of intra-ophthalmic artery and intravitreal chemotherapy. To date, a range of treatments is available to the Rb expert, including enucleation, but there is lack of consensus in a number of scenarios as to what to use and when. In such a rare cancer, treatment outcomes are reported usually via retrospective analyses, with few prospective randomized controlled trials. Classification schemes have also evolved following the introduction of new treatment modalities, but discrepancies exist among centres with respect to the preferred schema and its interpretation. Retinoblastoma management is a remarkable success story, but the future will require a collaborative effort in the form of multicentre randomized controlled trials in order to further improve the quality of care for this subset of young children with ocular cancer.	[Fabian, Ido D.; Reddy, M. Ashwin; Sagoo, Mandeep S.] Moorfields Eye Hosp, London, England; [Fabian, Ido D.; Onadim, Zerrin; Karaa, Esin; Duncan, Catriona; Chowdhury, Tanzina; Scheimberg, Irene; Reddy, M. Ashwin; Sagoo, Mandeep S.] Royal London Hosp, Retinoblastoma Serv, London, England; [Fabian, Ido D.] Tel Aviv Univ, Goldschleger Eye Inst, Sheba Med Ctr, Ocular Oncol Serv, Tel Aviv, Israel; [Duncan, Catriona; Chowdhury, Tanzina] Great Ormond St Hosp Sick Children, Paediat Oncol, London, England; [Ohnuma, Shin-Ichi; Sagoo, Mandeep S.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Ohnuma, Shin-Ichi; Sagoo, Mandeep S.] UCL Inst Ophthalmol, London, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Barts Health NHS Trust; Royal London Hospital; Chaim Sheba Medical Center; Tel Aviv University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Sagoo, MS (corresponding author), Moorfields Eye Hosp, London, England.; Sagoo, MS (corresponding author), Royal London Hosp, Retinoblastoma Serv, London, England.; Sagoo, MS (corresponding author), Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.; Sagoo, MS (corresponding author), UCL Inst Ophthalmol, London, England.	mandeep.sagoo@moorfields.nhs.uk	Onadim, Zerrin/AAX-6490-2021	Onadim, Zerrin/0000-0002-8594-9586; Ohnuma, Shin-ichi/0000-0002-3305-5126; Sagoo, Mandeep/0000-0003-1530-3824				Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014; Abramson DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146582; Abramson DH, 2015, JAMA OPHTHALMOL, V133, P1; Al-Nawaiseh I, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5053961; Chan HSL, 1996, CLIN CANCER RES, V2, P1499; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; ERICSON LA, 1961, ACTA OPHTHALMOL, V39, P569; Fabian ID, 2017, BR J OPHTHALMOL; Fabian ID, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012366.pub2; Fabian ID, 2017, OPHTHALMOLOGY, V124, P851, DOI 10.1016/j.ophtha.2017.01.048; Fabian ID, 2017, BRIT J OPHTHALMOL, V101, P82, DOI 10.1136/bjophthalmol-2016-309710; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gallie BL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1321, DOI 10.1001/archopht.1996.01100140521001; Gatta G, 2002, CANCER-AM CANCER SOC, V95, P1767, DOI 10.1002/cncr.10833; Grigorovski N, 2014, INT J OPHTHALMOL-CHI, V7, P726, DOI 10.3980/j.issn.2222-3959.2014.04.26; Kaliki S, 2015, OPHTHALMOLOGY, V122, P1165, DOI 10.1016/j.ophtha.2015.01.018; Kaliki S, 2011, ARCH OPHTHALMOL-CHIC, V129, P1422, DOI 10.1001/archophthalmol.2011.289; Kaneko A, 2003, JPN J CLIN ONCOL, V33, P601, DOI 10.1093/jjco/hyg113; Kingston JE, 1996, ARCH OPHTHALMOL-CHIC, V114, P1339, DOI 10.1001/archopht.1996.01100140539004; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Leber T, 1911, A VONGRAEFES ARCH OP, V78, P381, DOI [10.1007/BF01947065, DOI 10.1007/BF01947065]; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; MacCarthy A, 2009, BRIT J OPHTHALMOL, V93, P38, DOI 10.1136/bjo.2008.139626; Mallipatna AC., 2017, AJCC CANC STAGING MA, V8th, P819; Moore R F, 1931, Br J Ophthalmol, V15, P673, DOI 10.1136/bjo.15.12.673; Munier FL, 2017, BRIT J OPHTHALMOL, V101, P1086, DOI 10.1136/bjophthalmol-2016-309298; Munier FL, 2012, BRIT J OPHTHALMOL, V96, P1078, DOI 10.1136/bjophthalmol-2011-301450; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; NORDLING CO, 1953, BRIT J CANCER, V7, P68, DOI 10.1038/bjc.1953.8; Novetsky DE, 2009, OPHTHALMIC GENET, V30, P40, DOI 10.1080/13816810802452168; ONADIM Z, 1992, BRIT J CANCER, V65, P711, DOI 10.1038/bjc.1992.150; Pawius P., 1657, OBSERVATIONES ANATOM; Price EA, 2014, J MED GENET, V51, P208, DOI 10.1136/jmedgenet-2013-101821; REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; SEREGARD S, 1995, BRIT J OPHTHALMOL, V79, P194, DOI 10.1136/bjo.79.2.194; Shields CL, 2016, ASIA-PAC J OPHTHALMO, V5, P97, DOI 10.1097/APO.0000000000000172; Shields CL, 2006, OPHTHALMOLOGY, V113, P2276, DOI 10.1016/j.ophtha.2006.06.018; Shields CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1330, DOI 10.1001/archopht.1996.01100140530002; Shields CL, 2001, OPHTHALMOLOGY, V108, P2116, DOI 10.1016/S0161-6420(01)00797-7; Shields CL, 2015, RETINA, V36, P1184; Soliman SE, 2016, OPHTHALMOLOGY, V123, P2610, DOI 10.1016/j.ophtha.2016.08.027; STALLARD HB, 1966, OPHTHALMOLOGICA, V151, P214, DOI 10.1159/000304892; STALLARD HB, 1948, BRIT J OPHTHALMOL, V32, P618, DOI 10.1136/bjo.32.9.618; Taich P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151343; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Wintersteiner H, 1897, NEUROEPITHELIOMA RET; Yamane Takashi, 2004, Int J Clin Oncol, V9, P69, DOI 10.1007/s10147-004-0392-6	54	118	124	6	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1551	1560		10.1038/s41388-017-0050-x	http://dx.doi.org/10.1038/s41388-017-0050-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29321667				2022-12-28	WOS:000428626700001
J	Sun, LL; Yu, SY; Xu, H; Zheng, YW; Lin, JT; Wu, MY; Wang, JD; Wang, AD; Lan, Q; Furnari, F; Cavenee, W; Purow, B; Li, M				Sun, Lili; Yu, Shuye; Xu, Hui; Zheng, Yanwen; Lin, Juntang; Wu, Meiyan; Wang, Jide; Wang, Aidong; Lan, Qing; Furnari, Frank; Cavenee, Webster; Purow, Benjamin; Li, Ming			FHL2 interacts with EGFR to promote glioblastoma growth	ONCOGENE			English	Article							ONLY PROTEIN FHL2; FACTOR RECEPTOR; SCAFFOLD PROTEIN; ACTIVATION; EXPRESSION; TRANSCRIPTION; LOCALIZATION; DEGRADATION; CONTRIBUTES; CANCER	Four-and-a-half LIM protein2 (FHL2) is a member of the LIM-only protein family, which plays a critical role in tumorigenesis. We previously reported that FHL2 is upregulated and plays an oncogenic role in glioblastoma (GBM), the most common and aggressive brain tumor. GBM is also marked by amplification of the epidermal growth factor receptor (EGFR) gene and its mutations, of which EGFRvIII is the most common and functionally significant. Here we report that FHL2 physically interacts with the wild-type EGFR and its mutated EGFRvIII form in GBM cells. Expression of FHL2 caused increased EGFR and EGFRvIII protein levels and this was due to an increase in protein stability rather than an increase in EGFR mRNA expression. In contrast, FHL2 knockdown using RNA interference reduced EGFR and EGFRvIII protein expression and the phosphorylation levels of EGFR and AKT. Consistent with these features, EGFR expression was significantly lower in mouse FHL2-null astrocytes, where reintroduction of FHL2 was able to restore EGFR levels. Using established GBM cell lines and patient-derived neurosphere lines, FHL2 silencing markedly induced cell apoptosis in EGFRvIII-positive cells. Targeting FHL2 significantly prevented EGFRvIII-positive GBM tumor growth in vivo. FHL2 expression also positively correlated with EGFR expression in GBM samples from patients. Taken together, our results demonstrate that FHL2 interacts with EGFR and EGFRvIII to increase their levels and this promotes glioma growth, representing a novel mechanism that may be therapeutically targetable.	[Sun, Lili; Yu, Shuye; Xu, Hui; Zheng, Yanwen; Wang, Aidong; Li, Ming] Soochow Univ, Affiliated Hosp 2, Expt Ctr, Suzhou, Peoples R China; [Yu, Shuye] Soochow Univ, Affiliated Hosp 2, Dept Neurol, Suzhou, Peoples R China; [Xu, Hui; Lan, Qing; Li, Ming] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China; [Lin, Juntang] Xinxiang Med Univ, Stem Cells & Biotherapy Engn Res Ctr Henan, Xinxiang, Peoples R China; [Wu, Meiyan; Wang, Jide] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Furnari, Frank; Cavenee, Webster] Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92103 USA; [Purow, Benjamin; Li, Ming] Univ Virginia, Dept Neurol, Charlottesville, VA 22904 USA	Soochow University - China; Soochow University - China; Soochow University - China; Xinxiang Medical University; Southern Medical University - China; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Virginia	Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Expt Ctr, Suzhou, Peoples R China.; Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China.; Li, M (corresponding author), Univ Virginia, Dept Neurol, Charlottesville, VA 22904 USA.	m2liva@hotmail.com	Sun, lili/GQH-2057-2022	Li, Ming/0000-0002-2540-1738	National Natural Science Foundation of China [81572480, 81172401]; Second Affiliated Hospital of Soochow University Youth pre-Research Fund [SDFEYQN1607]; Jiangsu distinguished Medical Professorship award	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Second Affiliated Hospital of Soochow University Youth pre-Research Fund; Jiangsu distinguished Medical Professorship award	This work was supported by grants from the National Natural Science Foundation of China (81572480 and 81172401, to M.L.) and the Second Affiliated Hospital of Soochow University Youth pre-Research Fund (SDFEYQN1607, to L.S.). We thank Drs. Yu Wei and Ju Chen for the generous gifts of FHL2 null MEF cells and FHL2 knockout newborn mice. M.L. was also partially supported by Jiangsu distinguished Medical Professorship award.	Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Dahan J, 2013, MOL CELL BIOL, V33, P3299, DOI 10.1128/MCB.00105-13; Davies GC, 2006, ONCOGENE, V25, P6497, DOI 10.1038/sj.onc.1209662; Del Vecchio CA, 2012, EXPERT REV VACCINES, V11, P133, DOI [10.1586/ERV.11.177, 10.1586/erv.11.177]; Fielitz J, 2007, P NATL ACAD SCI USA, V104, P4377, DOI 10.1073/pnas.0611726104; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gabriel B, 2006, J SOC GYNECOL INVEST, V13, P69, DOI 10.1016/j.jsgi.2005.10.001; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Hiratani I, 2003, DEVELOPMENT, V130, P4161, DOI 10.1242/dev.00621; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Hua G, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.207; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Jin H, 2016, ONCOGENE, V35, P5106, DOI 10.1038/onc.2016.54; Labalette C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003761; Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109; Latha K, 2013, INT J CANCER, V132, P509, DOI 10.1002/ijc.27690; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li M, 2008, GLIA, V56, P1328, DOI 10.1002/glia.20701; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu ZY, 2016, ONCOTARGET, V7, P4680, DOI 10.18632/oncotarget.6730; Nishi H, 2002, CANCER RES, V62, P827; Nouet Y, 2012, J HEPATOL, V57, P1029, DOI 10.1016/j.jhep.2012.06.035; Padfield E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00005; Paul C, 2006, ONCOGENE, V25, P5475, DOI 10.1038/sj.onc.1209567; Purow BW, 2008, CARCINOGENESIS, V29, P918, DOI 10.1093/carcin/bgn079; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; Sangadala S, 2006, J BIOL CHEM, V281, P17212, DOI 10.1074/jbc.M511013200; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thorne AH, 2016, NEURO-ONCOLOGY, V18, P914, DOI 10.1093/neuonc/nov319; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verset L, 2016, HISTOL HISTOPATHOL, V31, P469, DOI 10.14670/HH-11-709; Vouri M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.66; Wang JD, 2007, GASTROENTEROLOGY, V132, P1066, DOI 10.1053/j.gastro.2006.12.004; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028	40	19	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1386	1398		10.1038/s41388-017-0068-0	http://dx.doi.org/10.1038/s41388-017-0068-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29321665	Green Accepted			2022-12-28	WOS:000427279300009
J	Tanaka, N; Zhao, M; Tang, L; Patel, AA; Xi, Q; Van, HT; Takahashi, H; Osman, AA; Zhang, JX; Wang, J; Myers, JN; Zhou, G				Tanaka, Noriaki; Zhao, Mei; Tang, Lin; Patel, Ameeta A.; Xi, Qing; Van, Hieu T.; Takahashi, Hideaki; Osman, Abdullah A.; Zhang, Jiexin; Wang, Jing; Myers, Jeffrey N.; Zhou, Ge			Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1	ONCOGENE			English	Article							EVOLUTIONARY ACTION SCORE; BREAST-CANCER; TUMOR-SUPPRESSOR; TP53 MUTATIONS; EXPRESSION; PATHWAY; PROTEINS; SURVIVAL; TUMORIGENESIS; PROGRESSION	Many mutant p53 proteins exert oncogenic gain-of-function (GOF) properties that promote cancer cell invasive growth and metastasis, yet the mechanisms mediating these functions still largely remain elusive. We show here that overexpression of the GOF mutant p53 G245D and other GOF p53 mutants enhances the invasive cell growth of p53-deficient head and neck squamous cell carcinoma (HNSCC) UM-SCC-1 cells both in in vitro three-dimensional culture and in an in vivo orthotopic nude mouse model of HNSCC through a novel transcription-independent mechanism. We demonstrate that the expression of the oncogenic forkhead transcription factor FOXM1 is upregulated by GOF mutant p53s. Moreover, we show that overexpression of GOF mutant p53 G245D decreases the AMP-activated protein kinase (AMPK)-mediated phosphorylation of FOXO3a, a tumor suppressive forkhead transcription factor, leading to its cytoplasmic accumulation. This downregulation of FOXO3a's activity, in turn, leads to de-repression of FOXM1 expression. Importantly, we show that either overexpression of FOXO3a or downregulation of FOXM1 impairs both GOF mutant p53-mediated cell invasion in vitro and pulmonary metastases of UM-SCC-1 cells in vivo. Finally, not only do oral cancer patients with p53 mutations exhibit higher levels of FOXM1 expression than patients with wild-type p53, but also HNSCC patients with TP53 mutations and high levels of FOXM1 expression have the poorest survival outcomes. Given our prior demonstration that GOF mutant p53s inhibit AMPK, our current study, establishes and demonstrates a novel transcription-independent GOF mutant p53-AMPK-FOXO3a-FOXM1 signaling cascade that plays an important role in mediating mutant p53s' gain-of-function activities in HNSCCs.	[Tanaka, Noriaki; Zhao, Mei; Tang, Lin; Patel, Ameeta A.; Xi, Qing; Van, Hieu T.; Takahashi, Hideaki; Osman, Abdullah A.; Myers, Jeffrey N.; Zhou, Ge] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Zhang, Jiexin; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Myers, JN; Zhou, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.	jmyers@mdanderson.org; gzhou@mdanderson.org	Van, Hieu Thuan/GMX-1075-2022	Takahashi, Hideaki/0000-0003-3783-9961; Van, Hieu Thuan/0000-0002-3328-915X	National Institute of Health [5R01DE014613-13]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014613] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by the National Institute of Health Grant No. 5R01DE014613-13 (J.N.M.).	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Halasi M, 2013, BIOCHEM PHARMACOL, V85, P644, DOI 10.1016/j.bcp.2012.10.013; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Morris BJ, 2015, GERONTOLOGY, V61, P515, DOI 10.1159/000375235; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Myers JN, 2002, CLIN CANCER RES, V8, P293; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Neskey DM, 2015, CANCER RES, V75, P1527, DOI 10.1158/0008-5472.CAN-14-2735; Nho RS, 2014, AM J PHYSIOL-LUNG C, V307, pL632, DOI 10.1152/ajplung.00127.2014; Osman AA, 2015, CANCER RES, V75, P1205, DOI 10.1158/0008-5472.CAN-14-2729; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Pfister NT, 2015, GENE DEV, V29, P1298, DOI 10.1101/gad.263202.115; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Renault VM, 2011, ONCOGENE, V30, P3207, DOI 10.1038/onc.2011.35; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	47	34	34	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1279	1292		10.1038/s41388-017-0032-z	http://dx.doi.org/10.1038/s41388-017-0032-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29269868	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000427279300002
J	Peng, F; Wang, JH; Fan, WJ; Meng, YT; Li, MM; Li, TT; Cui, B; Wang, HF; Zhao, Y; An, F; Guo, T; Liu, XF; Zhang, L; Lv, L; Lv, DK; Xu, LZ; Xie, JJ; Lin, WX; Lam, EWF; Xu, J; Liu, Q				Peng, F.; Wang, J-H; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; Zhao, Y.; An, F.; Guo, T.; Liu, X-F; Zhang, L.; Lv, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Lin, W-X; Lam, E. W-F; Xu, J.; Liu, Q.			Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia	ONCOGENE			English	Article							PYRUVATE-DEHYDROGENASE KINASE; OXIDATIVE-PHOSPHORYLATION; LUNG-CANCER; DICHLOROACETATE; LONG; GLIOBLASTOMA; METABOLISM; ACTIVATION; PROGRESSION; GENERATION	Glycolysis is critical for cancer stem cell reprogramming; however, the underlying regulatory mechanisms remain elusive. Here, we show that pyruvate dehydrogenase kinase 1 (PDK1) is enriched in breast cancer stem cells (BCSCs), whereas depletion of PDK1 remarkably diminishes ALDH(+) subpopulations, decreases stemness-related transcriptional factor expression, and inhibits sphere-formation ability and tumor growth. Conversely, high levels of PDK1 enhance BCSC properties and are correlated with poor overall survival. In mouse xenograft tumor, PDK1 is accumulated in hypoxic regions and activates glycolysis to promote stem-like traits. Moreover, through screening hypoxia-related long non-coding RNAs (lncRNAs) in PDK1-positive tissue, we find that lncRNA H19 is responsible for glycolysis and BCSC maintenance. Furthermore, H19 knockdown decreases PDK1 expression in hypoxia, and ablation of PDK1 counteracts H19-mediated glycolysis and self-renewal ability in vitro and in vivo. Accordingly, H19 and PDK1 expression exhibits strong correlations in primary breast carcinomas. H19 acting as a competitive endogenous RNA sequesters miRNA let-7 to release Hypoxia-inducible factor 1 alpha, leading to an increase in PDK1 expression. Lastly, aspirin markedly attenuates glycolysis and cancer stem-like characteristics by suppressing both H19 and PDK1. Thus, these novel findings demonstrate that the glycolysis gatekeeper PDK1 has a critical role in BCSC reprogramming and provides a potential therapeutic strategy for breast malignancy.	[Peng, F.; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; An, F.; Liu, X-F; Zhang, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Xu, J.; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Peng, F.; Fan, W-J; Meng, Y-T; Li, M-M; Liu, Q.] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Wang, J-H; Zhao, Y.] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China; [Guo, T.] Dalian Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Dalian, Peoples R China; [Lv, L.] Dalian Med Univ, Affiliated Hosp 2, Dept Pathol, Dalian, Peoples R China; [Xu, L-Z] Dalian Med Univ, Affiliated Hosp 2, Internal Med Dept Oncol, Dalian, Peoples R China; [Lin, W-X] Dalian Maternal & Child Care Serv Ctr, Dalian, Liaoning, Peoples R China; [Lin, W-X] Imperial Coll London, Dept Surg & Canc, London, England	Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Imperial College London	Xu, J; Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Western Sect 9, Lvshun South St, Dalian 116044, Liaoning, Peoples R China.	xujie@dmu.edu.cn; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020; Fan, Wenjun/GLV-2107-2022	Lam, Eric W-F/0000-0003-1274-3576; Fan, Wenjun/0000-0002-5432-4524; Peng, Fei/0000-0003-0772-0273	Innovative Research Team in University of Ministry of Education of China [IRT13049]; National Natural Science Foundation of China [81630005, 81573025, 81201686, 81602588, 81502579, 81602585]; Liaoning high-level talent innovation program [NSF2014029102, NSF 2015020264, 201601231]; Dalian high-level talent innovation program [2016RD12]; CRUK [A12011]; Breast Cancer Now [PR070, PhD016]; Cancer Research UK [12011] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; MRC [MR/N012097/1] Funding Source: UKRI	Innovative Research Team in University of Ministry of Education of China(Ministry of Education, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning high-level talent innovation program; Dalian high-level talent innovation program; CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Quentin Liu's lab members for their critical commends and technical support. This work is supported by Innovative Research Team in University of Ministry of Education of China (No. IRT13049), National Natural Science Foundation of China (No. 81630005 and No. 81573025 to QL, No. 81201686 to JX, No. 81602588 to L-ZX, No. 81502579 to Z-JH, No. 81602585 to F-MZ), the Liaoning (NSF2014029102 to QL, NSF 2015020264 to JX, 201601231 to L-ZX), Dalian high-level talent innovation program (2016RD12 to QL). Eric W-F Lam's work is supported by CRUK (A12011) and Breast Cancer Now (2012 May PR070; 2012 Nov PhD016).	Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; Cuesta E, 2005, EUR J PHARMACOL, V517, P158, DOI 10.1016/j.ejphar.2005.05.024; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662; Feuerecker B, 2015, AM J CANCER RES, V5, P812; Fiorillo M, 2016, ONCOTARGET, V7, P34084, DOI 10.18632/oncotarget.9122; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Guo H, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0892-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho N, 2015, EXP CELL RES, V331, P73, DOI 10.1016/j.yexcr.2014.12.006; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188; Jiang ZF, 2017, BIOCHEM BIOPH RES CO, V483, P32, DOI 10.1016/j.bbrc.2017.01.015; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Kornfeld JW, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00057; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Li ZK, 2014, CANCER SCI, V105, P951, DOI 10.1111/cas.12461; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Ma X. Y., 2014, NAT COMMUN, V5; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Paldino E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/859871; Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552; Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Ruggieri V, 2015, ONCOTARGET, V6, P1217, DOI 10.18632/oncotarget.2721; Rupaimoole R, 2015, CELL REP, V13, P2395, DOI 10.1016/j.celrep.2015.11.047; Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Sancho P, 2016, BRIT J CANCER, V114, P1305, DOI 10.1038/bjc.2016.152; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038; Tordonato C, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00072; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang TH, 2016, ONCOTARGET, V7, P43588, DOI 10.18632/oncotarget.9635; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944; Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043; Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828; Zhang Y, 2015, ONCOTARGET, V6, P9999, DOI 10.18632/oncotarget.3171; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935	69	133	141	8	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1062	1074		10.1038/onc.2017.368	http://dx.doi.org/10.1038/onc.2017.368			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106390	Green Published, hybrid			2022-12-28	WOS:000425905700009
J	Shi, F; Shang, L; Yang, LY; Jiang, YY; Wang, XM; Hao, JJ; Zhang, Y; Huang, DK; Cai, Y; Xu, X; Zhan, QM; Jia, XM; Cao, Y; Wang, MR				Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Huang, D-K; Cai, Y.; Xu, X.; Zhan, Q-M; Jia, X-M; Cao, Y.; Wang, M-R			Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation	ONCOGENE			English	Article							NF-KAPPA-B; GROWTH-FACTOR; CLINICOPATHOLOGICAL FEATURES; HEPATOCELLULAR-CARCINOMA; INCREASED EXPRESSION; PANCREATIC-CANCER; SEMAPHORIN 3A; E-CADHERIN; RECEPTOR; ACTIVATION	Neuropilin-1 (NRP1) is a non-kinase receptor recently implicated in tumor progression. Here we revealed that over-expression of NRP1 correlates with poor prognosis in esophageal squamous cell carcinoma (ESCC). NRP1-knockdown suppressed ESCC cell proliferation and xenograft tumor growth. Reduced NRP1 expression downregulated P65 mRNA and protein expression, and ectopic expression of P65-restored cell proliferation in NRP1-silenced cells. NRP1 regulates P65 transcription by activating cAMP responsive element binding protein (CREB). NRP1 interacted with and activated epidermal growth factor receptor (EGFR), and b1/b2 domain of NRP1 is responsible for the activation of EGFR. We also found that EGFR regulated CREB transcriptional activity via AKT. These data suggest that NRP1 is an upstream regulator in the P65-dependent proliferation signaling pathway and a candidate therapeutic target for ESCC.	[Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Cai, Y.; Xu, X.; Zhan, Q-M; Wang, M-R] Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Cai, Y.; Xu, X.; Zhan, Q-M; Wang, M-R] Chinese Acad Med Sci, Beijing 100021, Peoples R China; [Shi, F.; Shang, L.; Cao, Y.] Cent S Univ, Xiangya Hosp, Sch Basic Med Sci,Canc Res Inst, Key Lab Carcinogenesis & Invas,Chinese Minist Ed, Changsha 410078, Hunan, Peoples R China; [Jia, X-M] Anhui Med Univ, Dept Histol & Embryol, Hefei 230032, Anhui, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Central South University; Anhui Medical University	Wang, MR (corresponding author), Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Wang, MR (corresponding author), Chinese Acad Med Sci, Beijing 100021, Peoples R China.; Cao, Y (corresponding author), Cent S Univ, Xiangya Hosp, Sch Basic Med Sci,Canc Res Inst, Key Lab Carcinogenesis & Invas,Chinese Minist Ed, Changsha 410078, Hunan, Peoples R China.; Jia, XM (corresponding author), Anhui Med Univ, Dept Histol & Embryol, Hefei 230032, Anhui, Peoples R China.	jiaxueme@126.com; ycao98@vip.sina.com; wangmr2015@126.com	Zhang, Yu/G-2453-2011	Zhang, Yu/0000-0003-1375-1594	National Natural Science Foundation of China [31471327, 81330052, 81520108023]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This study was supported by National Natural Science Foundation of China (31471327, 81330052, 81520108023) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1-001).	Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Berge M, 2011, J HEPATOL, V55, P866, DOI 10.1016/j.jhep.2011.01.033; Brand TM, 2011, DISCOV MED, V12, P419; Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0; Chu WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101931; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Dong JC, 2015, J CELL MOL MED, V19, P2286, DOI 10.1111/jcmm.12623; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Ghosh S, 2008, HUM PATHOL, V39, P1835, DOI 10.1016/j.humpath.2008.06.004; Glinka Y, 2012, BIOCHEM BIOPH RES CO, V425, P775, DOI 10.1016/j.bbrc.2012.07.151; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Han ZX, 2015, MOL MED REP, V12, P513, DOI 10.3892/mmr.2015.3405; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu CX, 2016, TARGET ONCOL, V11, P501, DOI 10.1007/s11523-016-0422-0; Izzo JG, 2007, CANCER EPIDEM BIOMAR, V16, P1200, DOI 10.1158/1055-9965.EPI-06-1083; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Jiang HY, 2015, MOL MED REP, V12, P2114, DOI 10.3892/mmr.2015.3580; Lee E, 2013, NEOPLASIA, V15, P112, DOI 10.1593/neo.121638; Li LH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0291-5; Li X, 2016, ONCOTARGET, V7, P86225, DOI 10.18632/oncotarget.13368; Li ZW, 2008, CURR OPIN HEMATOL, V15, P391, DOI 10.1097/MOH.0b013e328302c7f4; Lin DC, 2011, CLIN CANCER RES, V17, P4285, DOI 10.1158/1078-0432.CCR-10-3236; Lu J, 2015, MOL MED REP, V12, P2668, DOI 10.3892/mmr.2015.3752; Matkar PN, 2016, ONCOTARGET, V7, P69489, DOI 10.18632/oncotarget.11060; Muhl L, 2017, J CELL SCI, V130, P1365, DOI 10.1242/jcs.200493; Naik A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03280-0; Nakamura F, 2002, ADV EXP MED BIOL, V515, P55; Ohsaka A, 2015, BIOCHEM BIOPH RES CO, V459, P443, DOI 10.1016/j.bbrc.2015.02.124; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Qiao L, 2006, HUM GENE THER, V17, P280, DOI 10.1089/hum.2006.17.280; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Sakamoto KM, 2015, MOL GENET METAB, V114, P397, DOI 10.1016/j.ymgme.2014.11.017; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Scartozzi M, 2007, J CLIN ONCOL, V25, P3930, DOI 10.1200/JCO.2007.11.5022; Shahrabi-Farahani S, 2016, AM J PATHOL, V186, P1055, DOI 10.1016/j.ajpath.2015.11.021; Shang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111045; Shang L, 2013, FRONT MED-PRC, V7, P401, DOI 10.1007/s11684-013-0286-y; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shi F, 2014, CLIN CANCER RES, V20, P6153, DOI 10.1158/1078-0432.CCR-14-0583; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Song X, 2012, MED ORAL PATOL ORAL, V17, pE962, DOI 10.4317/medoral.18168; Wang XM, 2013, MOL CANCER RES, V11, P986, DOI 10.1158/1541-7786.MCR-12-0704; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Weichert W, 2007, BRIT J CANCER, V97, P523, DOI 10.1038/sj.bjc.6603878; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Xin Y, 2012, CLIN CANCER RES, V18, P6040, DOI 10.1158/1078-0432.CCR-12-1652; Xu Y, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-155; Zhang YF, 2016, PATHOL ONCOL RES, V22, P367, DOI 10.1007/s12253-015-0003-z	53	10	10	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					935	943		10.1038/onc.2017.399	http://dx.doi.org/10.1038/onc.2017.399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059172				2022-12-28	WOS:000425281800010
J	Orth, M; Unger, K; Schoetz, U; Belka, C; Lauber, K				Orth, M.; Unger, K.; Schoetz, U.; Belka, C.; Lauber, K.			Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2	ONCOGENE			English	Article							PANCREATIC-CANCER CELLS; X-RAY-SENSITIVITY; KINASE AURORA-A; LUNG-CANCER; INDUCTION CHEMOTHERAPY; RADIATION SENSITIZER; CLONOGENIC SURVIVAL; COLORECTAL-CANCER; TUMOR-GROWTH; HELA-CELLS	Taxane-based radiochemotherapy is a central treatment option for various cancer entities in locally advanced stages. The therapeutic synergism of this combined modality approach due to taxane-mediated radiosensitization of cancer cells is well-known. However, the underlying molecular mechanisms remain largely elusive, and mechanism-derived predictive markers of taxane-based radiochemotherapy are currently not available. Here, we show that clinically relevant doses of Paclitaxel, the prototype taxane, stimulate a tripolar mode of mitosis leading to chromosomal missegregation and aneuploidization rather than interfering with cell cycle progression. This distinct mitotic phenotype was interlinked with Paclitaxel-mediated radiosensitization via overexpression of mitotic Aurora kinase A (AURKA) and its cofactor TPX2 whose knockdown rescued the bipolar mode of cell division and largely attenuated the radiosensitizing effects of Paclitaxel. In the cancer genome atlas (TCGA) lung adenocarcinoma cohort, high expression levels of AURKA and TPX2 were associated with specifically improved overall survival upon taxane-based radiochemotherapy, but not in case of non-taxane-based radiochemotherapy, chemo- or radiotherapy only. Thus, our data provide insights into Paclitaxel-mediated radiosensitization on a mechanistic and molecular level and identify AURKA and TPX2 as the first potential mechanism-based, predictive markers of taxane-based radiochemotherapy.	[Orth, M.; Schoetz, U.; Belka, C.; Lauber, K.] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany; [Orth, M.; Unger, K.; Schoetz, U.; Belka, C.; Lauber, K.] German Res Ctr Environm Hlth GmbH, Helmholtz Ctr Munich, Clin Cooperat Grp Personalized Radiotherapy Head, Neuherberg, Germany; [Orth, M.; Belka, C.; Lauber, K.] German Canc Consortium DKTK, Munich, Germany; [Orth, M.] German Canc Res Ctr, Heidelberg, Germany; [Unger, K.] Helmholtz Ctr Munich, Res Unit Radiat Cytogenet, Neuherberg, Germany; [Belka, C.] German Ctr Lung Res DZL, Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Lauber, K (corresponding author), Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany.	kirsten.lauber@med.uni-muenchen.de	Orth, Michael/AAQ-7299-2021; Unger, Kristian/F-3730-2018	Orth, Michael/0000-0002-4608-7151; Unger, Kristian/0000-0002-0374-2320; Schotz, Ulrike/0000-0001-8118-3977	grants of the Friedrich-Baur-Stiftung; Verein zur Forderung von Wissenschaft und Forschung	grants of the Friedrich-Baur-Stiftung; Verein zur Forderung von Wissenschaft und Forschung	We thank Olaf Stemmann for the stably transfected HeLa cell line and the centrin antibody, and Oliver J. Gruss for TPX2 antisera. This work was supported by grants of the Friedrich-Baur-Stiftung and the Verein zur Forderung von Wissenschaft und Forschung to MO and CB.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bian ML, 2010, SCI CHINA LIFE SCI, V53, P1322, DOI 10.1007/s11427-010-4086-1; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Choy H, 2001, Expert Opin Pharmacother, V2, P963, DOI 10.1517/14656566.2.6.963; Choy H, 2001, CRIT REV ONCOL HEMAT, V37, P237, DOI 10.1016/S1040-8428(00)00112-8; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Dey S, 2003, CLIN CANCER RES, V9, P1557; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Eberhardt WEE, 2015, J CLIN ONCOL, V33, P4194, DOI 10.1200/JCO.2015.62.6812; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Garrido G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00088; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Giubettini M, 2011, J CELL SCI, V124, P113, DOI 10.1242/jcs.075457; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; HORWITZ SB, 1986, ANN NY ACAD SCI, V466, P733, DOI 10.1111/j.1749-6632.1986.tb38455.x; Huber RM, 2006, J CLIN ONCOL, V24, P4397, DOI 10.1200/JCO.2005.05.4163; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Kinzel L, 2016, ONCOTARGET, V7, P43199, DOI 10.18632/oncotarget.9774; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kurdoglu B, 1999, CLIN CANCER RES, V5, P2580; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; LIEBMANN J, 1994, J NATL CANCER I, V86, P441, DOI 10.1093/jnci/86.6.441; Lin Y, 2012, BRIT J CANCER, V107, P1692, DOI 10.1038/bjc.2012.450; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Mignogna C, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0238-7; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Neumayer G, 2014, CELL MOL LIFE SCI, V71, P3027, DOI 10.1007/s00018-014-1582-7; Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Scharer CD, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-79; Sehdev V, 2013, CANCER-AM CANCER SOC, V119, P904, DOI 10.1002/cncr.27801; Sillars-Hardebol AH, 2012, GUT, V61, P1568, DOI 10.1136/gutjnl-2011-301153; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; STEREN A, 1993, GYNECOL ONCOL, V50, P89, DOI 10.1006/gyno.1993.1169; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Unkel S, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0584-z; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Warner SL, 2009, CLIN CANCER RES, V15, P6519, DOI 10.1158/1078-0432.CCR-09-0077; Xu J, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-200; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zullo KM, 2015, CLIN CANCER RES, V21, P4097, DOI 10.1158/1078-0432.CCR-15-0033	54	21	21	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					52	62		10.1038/onc.2017.304	http://dx.doi.org/10.1038/onc.2017.304			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869599				2022-12-28	WOS:000422625000006
J	Gallagher, EJ; Zelenko, Z; Neel, BA; Antoniou, IM; Rajan, L; Kase, N; LeRoith, D				Gallagher, E. J.; Zelenko, Z.; Neel, B. A.; Antoniou, I. M.; Rajan, L.; Kase, N.; LeRoith, D.			Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia	ONCOGENE			English	Article							MESSENGER-RNA; CELL-GROWTH; RECEPTOR; DENSITY; MICE; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; SURVIVAL; GENE; PROGRESSION	Obesity is associated with an increase in cancer-specific mortality in women with breast cancer. Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in obese women. Here, we aimed to determine the importance of elevated circulating LDL, and LDL receptor (LDLR) expression in tumor cells, on the growth of breast cancer using mouse models of hyperlipidemia. We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/-)/LDLR-/- and Rag1(-/-)/ApoE (apolipoprotein E)(-/-) mice) in addition to established immunocompetent LDLR-/- and ApoE(-/-) mice. The mice were used to study the effects of elevated LDL-C in human triple-negative (MDA-MB-231) and mouse Her2/Neu-overexpressing (MCNeuA) breast cancers. Tumors derived from MCNeuA and MDA-MB-231 cells had high LDLR expression and formed larger tumors in mice with high circulating LDL-C concentrations than in mice with lower LDL-C. Silencing the LDLR in the tumor cells led to decreased growth of Her2/Neu-overexpressing tumors in LDLR-/- and ApoE(-/-) mice, with increased Caspase 3 cleavage. Additionally, in vitro, silencing the LDLR led to decreased cell survival in serum-starved conditions, associated with Caspase 3 cleavage. Examining publically available human data sets, we found that high LDLR expression in human breast cancers was associated with decreased recurrence-free survival, particularly in patients treated with systemic therapies. Overall, our results highlight the importance of the LDLR in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL-C, which may be important contributing factors to the increased recurrence and mortality in obese women with breast cancer.	[Gallagher, E. J.; Zelenko, Z.; Neel, B. A.; Antoniou, I. M.; Rajan, L.; Kase, N.; LeRoith, D.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Gallagher, EJ (corresponding author), Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA.	Emily.Gallagher@mssm.edu			NCI/NIH [K08 CA190779, R01 CA200553]; Tisch Cancer Institute at Mount Sinai Junior Scientist Award; NATIONAL CANCER INSTITUTE [K08CA190770, R01CA190779, R01CA200553] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tisch Cancer Institute at Mount Sinai Junior Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research in this study was funded by NCI/NIH K08 CA190779 to EJG, NCI/NIH R01 CA200553 to DLR and Tisch Cancer Institute at Mount Sinai Junior Scientist Award to EJG. We would like to acknowledge the Icahn School of Medicine at Mount Sinai Mouse Genetics and Gene Targeting Core Facility, Translational and Molecular Imaging Core facility and the Biorepository and Pathology Core Facility.	Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x; Alikhani N, 2013, ONCOGENE, V32, P961, DOI 10.1038/onc.2012.113; Antalis CJ, 2011, CLIN EXP METASTAS, V28, P733, DOI 10.1007/s10585-011-9405-9; Badana A, 2016, J BREAST CANCER, V19, P372, DOI 10.4048/jbc.2016.19.4.372; Bahl M, 2005, BREAST CANCER RES TR, V94, P135, DOI 10.1007/s10549-005-6654-9; Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030668; BROWN MS, 1974, SCIENCE, V185, P61, DOI 10.1126/science.185.4145.61; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Chahil TJ, 2006, ENDOCRIN METAB CLIN, V35, P491, DOI 10.1016/j.ecl.2006.06.002; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Choudhury RP, 2004, ARTERIOSCL THROM VAS, V24, P1904, DOI 10.1161/01.ATV.0000142808.34602.25; Dansky HM, 1999, ARTERIOSCL THROM VAS, V19, P1960, DOI 10.1161/01.ATV.19.8.1960; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; Demark-Wahnefried W, 2012, CANCER EPIDEM BIOMAR, V21, P1244, DOI 10.1158/1055-9965.EPI-12-0485; dos Santos CR, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-132; Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hogarth CA, 2003, COMP BIOCHEM PHYS B, V135, P219, DOI 10.1016/S1096-4959(03)00046-0; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lamas B, 2015, MOL CARCINOGEN, V54, P58, DOI 10.1002/mc.22074; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Liu J, 2013, ONCOTARGET, V4, P1804, DOI 10.18632/oncotarget.1364; Liu X, 2015, INT J OBESITY, V39, P1548, DOI 10.1038/ijo.2015.93; Llaverias G, 2011, AM J PATHOL, V178, P402, DOI 10.1016/j.ajpath.2010.11.005; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Mansourian M, 2016, J PHARM PHARM SCI, V19, P72, DOI 10.18433/J3202B; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mulder M, 2007, NEUROSCI RES, V59, P251, DOI 10.1016/j.neures.2007.07.004; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Pelton K, 2014, AM J PATHOL, V184, P2099, DOI 10.1016/j.ajpath.2014.03.006; Pires LA, 2012, BRAZ J MED BIOL RES, V45, P557, DOI 10.1590/S0100-879X2012007500068; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Ribas V, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0106-5; RUDLING MJ, 1986, BRIT MED J, V292, P580, DOI 10.1136/bmj.292.6520.580; Stranzl A, 1997, BREAST CANCER RES TR, V42, P195, DOI 10.1023/A:1005754026205; Suarez Y, 2004, CARDIOVASC RES, V64, P346, DOI 10.1016/j.cardiores.2004.06.024; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Wang SH, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-175; Weitman ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070703; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Yin W, 2012, J LIPID RES, V53, P51, DOI 10.1194/jlr.M019927; Zelenko Z, 2017, ONCOGENE, V36, P1394, DOI 10.1038/onc.2016.305; Zeng XK, 2009, CLIN CANCER RES, V15, P2840, DOI 10.1158/1078-0432.CCR-08-1401; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	49	97	102	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6462	6471		10.1038/onc.2017.247	http://dx.doi.org/10.1038/onc.2017.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759039	Green Accepted			2022-12-28	WOS:000415622900009
J	Simond, AM; Rao, T; Zuo, D; Zhao, JJ; Muller, WJ				Simond, A. M.; Rao, T.; Zuo, D.; Zhao, J. J.; Muller, W. J.			ErbB2-positive mammary tumors can escape PI3K-p110 alpha loss through downregulation of the Pten tumor suppressor	ONCOGENE			English	Article							PHOSPHOINOSITIDE 3-KINASE PATHWAY; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; HIGH-FREQUENCY; PIK3CA GENE; ISOFORM; PI3K; P110-BETA; P110-ALPHA	Breast cancer is the most common cancer among women and 30% of patients will be diagnosed with an ErbB2-positive tumor. Forty percent of ErbB2-positive breast tumors have an activating mutation in p110 alpha, a catalytic subunit of phosphoinositide 3-kinase. Clinical and experimental data show that breast tumors treated with a p110 alpha-specific inhibitor often circumvent inhibition and resume growth. To understand this mechanism of resistance, we crossed a p110 alpha conditional (p110 alpha(flx/flx)) mouse model with mice that overexpress the ErbB2/Neu-IRES-Cre transgene (NIC) specifically in the mammary epithelium. Although mammary-specific deletion of p110 alpha dramatically delays tumor onset, tumors eventually arise and are dependent on p110 beta. Through biochemical analyses we find that a proportion of p110 alpha-deficient tumors (23%) display downregulation of the Pten tumor suppressor. We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110 alpha to p110 beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110 alpha inhibition.	[Simond, A. M.; Rao, T.; Zuo, D.; Muller, W. J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada; [Zhao, J. J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Pathol, Boston, MA USA	McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca			Canadian Institutes of Health Research (CIHR) [MOP-133706, FDN-148373]; Terry Fox team [RI X-242115]; CRC Chair in Molecular Oncology; Roland and Marcel Gosselin Fellowship; National Institutes of Health (NIH) [P50 CA168504, CA187918-02, R35 CA210057, CA172461]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P50CA168504, R01CA187918, R35CA210057, R01CA172461] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Terry Fox team; CRC Chair in Molecular Oncology; Roland and Marcel Gosselin Fellowship; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Cynthia Lavoie for assistance with the GDC-0941 drug trial and Vasilios Papavasiliou for mammary fat pad injections and transplants; Colin Ratcliffe for technical support with the Metamorph software; Chen Ling for editorial assistance and all the students in the Muller laboratory for their constant feedback and support. Our work is supported by the Canadian Institutes of Health Research (CIHR): MOP-133706 (WJM), FDN-148373 (WJM), Terry Fox team program grant: RI X-242115 (WJM). WJM is supported by CRC Chair in Molecular Oncology. National Institutes of Health (NIH): P50 CA168504 (JJZ), CA187918-02 (JJZ), R35 CA210057 (JJZ), CA172461 (JJZ) and Breast Cancer Research Foundation (JJZ), Roland and Marcel Gosselin Fellowship (AMS).	Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Bellacosa A, 2005, WOM ONCOL REV, V5, P223; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cheng H, 2015, ONCOGENE, V74, P15; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dbouk Hashem A, 2015, Postdoc J, V3, P71; Dbouk HA, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003264; Dbouk HA, 2010, ONCOTARGET, V1, P729; Dourdin N, 2008, CANCER RES, V68, P2122, DOI 10.1158/0008-5472.CAN-07-5727; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Geering B, 2007, P NATL ACAD SCI USA, V104, P7809, DOI 10.1073/pnas.0700373104; Hernandez-Aya LF, 2011, ONCOLOGIST, V16, P404, DOI 10.1634/theoncologist.2010-0402; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Martin V, 2010, BLOOD, V115, P2008, DOI 10.1182/blood-2009-04-217224; Meier TI, 2004, PROTEIN EXPRES PURIF, V35, P218, DOI 10.1016/j.pep.2003.12.010; Mellor P, 2012, BIOCHEM J, V441, P23, DOI 10.1042/BJ20111164; Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmit F, 2014, P NATL ACAD SCI USA, V111, P6395, DOI 10.1073/pnas.1323004111; Schoenwaelder SM, 2010, J BIOL CHEM, V285, P2886, DOI 10.1074/jbc.M109.029132; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wang Q, 2016, ONCOGENE, V35, P3607, DOI 10.1038/onc.2015.406; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	43	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6059	6066		10.1038/onc.2017.264	http://dx.doi.org/10.1038/onc.2017.264			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28783168	Green Submitted, Green Accepted			2022-12-28	WOS:000413841400014
J	Zhang, K; Myllymaki, SM; Gao, P; Devarajan, R; Kytola, V; Nykter, M; Wei, GH; Manninen, A				Zhang, K.; Myllymaki, S-M; Gao, P.; Devarajan, R.; Kytola, V.; Nykter, M.; Wei, G-H; Manninen, A.			Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with alpha V-Class integrins to promote EMT	ONCOGENE			English	Article							BREAST-CANCER CELLS; PROSTATE-CANCER; SIGNALING PATHWAYS; EPITHELIAL-CELLS; SRC; GROWTH; ALPHA-V-BETA-6; INHIBITION; POLARITY; PLATFORM	In many cancer types, integrin-mediated signaling regulates proliferation, survival and invasion of tumorigenic cells. However, it is still unclear how integrins crosstalk with oncogenes to regulate tumorigenesis and metastasis. Here we show that oncogenic K-Ras(V12) upregulates alpha 6-integrin expression in Madin-Darby canine kidney (MDCK) cells via activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)/Fos-related antigen 1-signaling cascade. Activated alpha 6-integrins promoted metastatic capacity and anoikis resistance, and led to perturbed growth of MDCK cysts. Transcriptomic analysis of K-Ras(V12)-transformed MDCK cells also revealed robust downregulation of alpha V-class integrins. Re-expression of alpha V-integrin in K-Ras(V12)-transformed MDCK cells synergistically upregulated the expression of Zinc finger E-box-binding homeobox 1 and Twist-related protein 1 and triggered epithelial-mesenchymal transition leading to induced cell motility and invasion. These results delineate the signaling cascades connecting oncogenic K-Ras(V12) with alpha 6- and alpha V-integrin functions to modulate cancer cell survival and tumorigenesis, and reveal new possible strategies to target highly oncogenic K-Ras(V12) mutants.	[Zhang, K.; Myllymaki, S-M; Gao, P.; Devarajan, R.; Wei, G-H; Manninen, A.] Univ Oulu, Fac Biochem & Mol Med, Ctr Excellence Cell Extracellular Matrix Res, Bioctr Oulu, Aapistie 5, SF-90220 Oulu, Finland; [Kytola, V.; Nykter, M.] Univ Tampere, Inst Biomed Technol & BioMediTech, Prostate Canc Res Ctr, Tampere, Finland; [Kytola, V.; Nykter, M.] Tampere Univ Hosp, Tampere, Finland; [Myllymaki, S-M] Univ Helsinki, Inst Biotechnol, Dev Biol Program, Helsinki, Finland	University of Oulu; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki	Manninen, A (corresponding author), Univ Oulu, Fac Biochem & Mol Med, Ctr Excellence Cell Extracellular Matrix Res, Bioctr Oulu, Aapistie 5, SF-90220 Oulu, Finland.	aki.manninen@oulu.fi	Devarajan, Raman/GOH-0098-2022; Zhang, Kai/M-9831-2017; Manninen, Aki/AAC-8067-2019	Zhang, Kai/0000-0003-2962-3976; Manninen, Aki/0000-0002-6263-8101; Nykter, Matti/0000-0001-6956-2843; Wei, Gong-Hong/0000-0001-6546-9334; Devarajan, Raman/0000-0002-8728-0476; gao, ping/0000-0003-1383-3290; Myllymaki, Satu-Marja/0000-0003-0521-5062	Academy of Finland [251314, 135560, 263770, 140974/AM, 284618, 279760/GHW]	Academy of Finland(Academy of Finland)	We thank Dr Ritva Heljasvaara and Dr Heli Ruotsalainen for their help related to mouse work. Riitta Jokela is acknowledged for overall expert technical assistance, Jaana Traskelin for expert technical assistance at Biocenter Oulu Virus Core Laboratory and Veli-Pekka Ronkainen for expert assistance in microscopy at Biocenter Oulu Tissue Imaging Center. This work was funded by Academy of Finland (251314, 135560, 263770, 140974/AM, 284618 and 279760/GHW).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aoudjit F., 2012, CHEMOTHER RES PRACT, V2012, P1; Arai T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027782; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bandyopadhyay A, 2009, CURR DRUG TARGETS, V10, P645, DOI 10.2174/138945009788680374; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Bunda S, 2014, P NATL ACAD SCI USA, V111, pE3785, DOI 10.1073/pnas.1406559111; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen XF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091830, 10.1371/journal.pone.0085716, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0087752]; Cheng PF, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14183; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hahm K, 2007, AM J PATHOL, V170, P110, DOI 10.2353/ajpath.2007.060158; Halaoui R, 2015, ONCOGENE, V34, P939, DOI 10.1038/onc.2014.59; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Huang QL, 2014, NAT GENET, V46, P126, DOI 10.1038/ng.2862; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee JL, 2014, J CELL SCI, V127, P3217, DOI 10.1242/jcs.146142; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Mamuya FA, 2012, J CELL MOL MED, V16, P445, DOI 10.1111/j.1582-4934.2011.01419.x; Manninen A, 2015, EXP CELL RES, V334, P337, DOI 10.1016/j.yexcr.2015.01.003; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Miura P, 2013, GENOME RES, V23, P812, DOI 10.1101/gr.146886.112; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Myllymaki SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019453; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schuck S, 2004, P NATL ACAD SCI USA, V101, P4912, DOI 10.1073/pnas.0401285101; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimizu H, 2003, ONCOGENE, V22, P831, DOI 10.1038/sj.onc.1206203; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Slattum GM, 2014, NAT REV CANCER, V14, P495, DOI 10.1038/nrc3767; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Zhang K, 2016, ONCOTARGET, V7, P84178, DOI 10.18632/oncotarget.12390	69	39	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5681	5694		10.1038/onc.2017.177	http://dx.doi.org/10.1038/onc.2017.177			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604746	Green Published, hybrid			2022-12-28	WOS:000412843900003
J	Kim, KJ; Kwon, SH; Yun, JH; Jeong, HS; Kim, HR; Lee, E; Ye, SK; Cho, CH				Kim, K-J; Kwon, S-H; Yun, J-H; Jeong, H-S; Kim, H-R; Lee, Eh; Ye, S-K; Cho, C-H			STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression	ONCOGENE			English	Article							NF-KAPPA-B; SIGNAL TRANSDUCER; CANCER; ANGIOGENESIS; GROWTH; RECRUITMENT; INHIBITION; MECHANISMS; MIGRATION; CYTOKINES	Metastasis is a life-threatening feature of cancer and is primarily responsible for cancer patient mortality. Cross talk between tumor cells and endothelium is important for tumor progression and metastasis. However, very little is known about the mechanisms by which endothelial cells (ECs) that are close to tumor cells, respond to the tumor cells during tumor progression and metastasis. In this study, we exploited the use of EC-specific signal transducer activator of transcription 3 (STAT3) knockout mice to investigate the role of STAT3 in ECs in tumor progression and metastasis. We found that the loss of STAT3 in ECs did not affect primary Lewis lung carcinoma (LLC) tumor growth, but it reduced in vivo LLC metastasis in experimental and spontaneous metastasis models. Mechanistically, STAT3 activation upregulated cell adhesion molecule expression, including E-selectin and P-selectin, in murine endothelial MS-1 cells treated with tumor cell-conditioned media in vitro and in pre-metastatic lungs of tumor-bearing mice in vivo. We also found that both E-selectin and P-selectin were, at least in part, responsible for STAT3-induced adhesion and invasion of LLC cells through an EC monolayer. However, tumor cell-conditioned media from B16F10 melanoma cells did not activate STAT3 in MS-1 cells. As a result, EC STAT3 knockout did not affect B16F10 melanoma cell metastasis. In addition, various human cancer cells activated STAT3 in human ECs (HUVECs), resulting in increased cell adhesion molecule expression. Collectively, our findings demonstrate that STAT3 activation in ECs promotes tumor metastasis through the induction of cell adhesion molecules, demonstrating a role for ECs in response to tumor cells during tumor metastasis.	[Kim, K-J; Kwon, S-H; Yun, J-H; Jeong, H-S; Ye, S-K; Cho, C-H] Seoul Natl Univ, Dept Pharmacol, Coll Med, 103 Daehakro Dong, Seoul 110799, South Korea; [Kim, H-R] Seoul Natl Univ, Dept Anat & Cell Biol, Coll Med, Seoul, South Korea; [Lee, Eh] Catholic Univ Korea, Dept Physiol, Coll Med, Seoul, South Korea; [Ye, S-K; Cho, C-H] Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea; [Cho, C-H] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Catholic University of Korea; Seoul National University (SNU); Seoul National University (SNU)	Ye, SK; Cho, CH (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, 103 Daehakro Dong, Seoul 110799, South Korea.	sangkyu@snu.ac.kr; iamhyun@snu.ac.kr		Kwon, Sun-Ho/0000-0003-1592-0638; Kim, Hang-Rae/0000-0002-3983-6193; Lee, Eun Hui/0000-0003-4555-1730	National Research Foundation of Korea grant - Korea government [2014R1A2A1A11050981, 2012R1A5A2A44671346]	National Research Foundation of Korea grant - Korea government	We acknowledge Daeho So for technical support of EV isolation and depletion, and Dr Jong-Wan Park for helpful suggestions during the course of this work. This work is supported by the National Research Foundation of Korea grant funded by the Korea government (2014R1A2A1A11050981 and 2012R1A5A2A44671346 to CHC).	Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Gout S, 2008, CLIN EXP METASTAS, V25, P335, DOI 10.1007/s10585-007-9096-4; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P3725, DOI 10.1073/pnas.1100446108; Hwang JA, 2009, MOL CANCER RES, V7, P1920, DOI 10.1158/1541-7786.MCR-09-0041; JAHROUDI N, 1995, J NEURO-ONCOL, V23, P99, DOI 10.1007/BF01053415; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kim HJ, 2013, BBA-MOL BASIS DIS, V1832, P183, DOI 10.1016/j.bbadis.2012.09.002; Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Laubli H, 2010, CANCER MICROENVIRON, V3, P97, DOI 10.1007/s12307-010-0043-6; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee HT, 2015, ONCOTARGET, V6, P10016, DOI 10.18632/oncotarget.3540; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, CELL CYCLE, V3, P1114; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Miller AM, 2010, ALCOHOL CLIN EXP RES, V34, P719, DOI 10.1111/j.1530-0277.2009.01141.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PARHAR RS, 1987, J EXP MED, V165, P14, DOI 10.1084/jem.165.1.14; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Rao RM, 2007, CIRC RES, V101, P234, DOI 10.1161/CIRCRESAHA.107.151860b; Ray Subrata, 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P251; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Teng CB, 2004, REPRODUCTION, V128, P197, DOI 10.1530/rep.1.00053; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Yang XP, 2005, ARTERIOSCL THROM VAS, V25, P1395, DOI 10.1161/01.ATV.0000168428.96177.24; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yun JH, 2017, J CELL PHYSIOL, V232, P1123, DOI 10.1002/jcp.25575; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014525; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183	51	42	43	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5445	5459		10.1038/onc.2017.148	http://dx.doi.org/10.1038/onc.2017.148			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534515				2022-12-28	WOS:000411960500002
J	von Morgen, P; Burdova, K; Flower, TG; O'Reilly, NJ; Boulton, SJ; Smerdon, SJ; Macurek, L; Horejsi, Z				von Morgen, P.; Burdova, K.; Flower, T. G.; O'Reilly, N. J.; Boulton, S. J.; Smerdon, S. J.; Macurek, L.; Horejsi, Z.			MRE11 stability is regulated by CK2-dependent interaction with R2TP complex	ONCOGENE			English	Article							STRAND BREAK REPAIR; CLINICAL PRESENTATION; DNA; PHOSPHORYLATION; HSP90; PROTEIN; COCHAPERONE; CHAPERONE; MEDIATE; GENES	The MRN (MRE11-RAD50-NBS1) complex is essential for repair of DNA double-strand breaks and stalled replication forks. Mutations of the MRN complex subunit MRE11 cause the hereditary cancer-susceptibility disease ataxia-telangiectasia-like disorder (ATLD). Here we show that MRE11 directly interacts with PIH1D1, a subunit of heat-shock protein 90 cochaperone R2TP complex, which is required for the assembly of large protein complexes, such as RNA polymerase II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1. The MRE11-PIH1D1 interaction is dependent on casein kinase 2 (CK2) phosphorylation of two acidic sequences within the MRE11 C terminus containing serines 558/561 and 688/689. Conversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphorylated by CK2. Consistent with these findings, depletion of PIH1D1 resulted in MRE11 destabilization and affected DNA-damage repair processes dependent on MRE11. Additionally, mutations of serines 688/689, which abolish PIH1D1 binding, also resulted in decreased MRE11 stability. As depletion of R2TP frequently leads to instability of its substrates and as truncation mutation of MRE11 lacking serines 688/689 leads to decreased levels of the MRN complex both in ATLD patients and an ATLD mouse model, our results suggest that the MRN complex is a novel R2TP complex substrate and that their interaction is regulated by CK2 phosphorylation.	[von Morgen, P.; Burdova, K.; Macurek, L.; Horejsi, Z.] ASCR, Inst Mol Genet, Dept Canc Cell Biol, Videnska 1083, Prague 14200 4, Czech Republic; [von Morgen, P.] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Flower, T. G.; Smerdon, S. J.] Francis Crick Inst, Struct Biol DNA Damage Signalling Lab, London, England; [O'Reilly, N. J.] Francis Crick Inst, Peptide Chem, London, England; [Boulton, S. J.] Francis Crick Inst, DSB Repair Metab Lab, London, England; [Horejsi, Z.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Ctr, Charterhouse Sq, London, England	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; University of London; Queen Mary University London	Macurek, L (corresponding author), ASCR, Inst Mol Genet, Dept Canc Cell Biol, Videnska 1083, Prague 14200 4, Czech Republic.; Horejsi, Z (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Ctr, Charterhouse Sq, London, England.	libor.macurek@img.cas.cz; z.horejsi@qmul.ac.uk	Macurek, Libor/C-7865-2014; von Morgen, Patrick/P-6869-2019; Von Morgen, Patrick/M-7566-2017	Macurek, Libor/0000-0002-0987-1238; von Morgen, Patrick/0000-0002-0614-6292; Von Morgen, Patrick/0000-0002-0614-6292; O'Reilly, Nicola/0000-0002-4204-6491; Burdova, Kamila/0000-0003-4402-3688; Flower, Thomas/0000-0002-7890-6473; Smerdon, Stephen/0000-0001-5688-8465; Licenikova Horejsi, Zuzana/0000-0002-9943-1649	Czech Science Foundation [14-34264S]; Institutional grant of IMG [RVO 68378050]; Wellcome Trust [200462/Z/16/Z, FC001156, FC001048, WT104558]; Grant Agency of the Charles University [309015]; Francis Crick Institute - Cancer Research UK [FC001156, FC001048]; UK Medical Research Council [FC001156, FC001048]; European Research Council [ERC 268639]; Cancer Research UK [11581] Funding Source: researchfish; Medical Research Council [MC_U117584228, U117531954, 1254166] Funding Source: researchfish; The Francis Crick Institute [10267, 10156, 10048, 10013] Funding Source: researchfish; MRC [MC_U117584228] Funding Source: UKRI	Czech Science Foundation(Grant Agency of the Czech Republic); Institutional grant of IMG; Wellcome Trust(Wellcome TrustEuropean Commission); Grant Agency of the Charles University; Francis Crick Institute - Cancer Research UK; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); The Francis Crick Institute; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	All cell lines were from the Cell Services of the Friancis Crick Institute and were regularly tested for mycoplasma infection. This work was supported by the Czech Science Foundation (14-34264S), Institutional grant of IMG (RVO 68378050) and the Wellcome Trust (200462/Z/16/Z). PM was partially supported by the Grant Agency of the Charles University (309015). SJS, TF and SJB are supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001156 and FC001048), the UK Medical Research Council (FC001156 and FC001048) and the Wellcome Trust (FC001156 and FC001048). SJB was also supported by Wellcome Trust (WT104558) and European Research Council (ERC 268639).	Aparicio T, 2016, J CELL BIOL, V212, P399, DOI 10.1083/jcb.201504005; Bartkova J, 2008, MOL ONCOL, V2, P296, DOI 10.1016/j.molonc.2008.09.007; Benbahouche NE, 2014, J BIOL CHEM, V289, P6236, DOI 10.1074/jbc.M113.499608; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Boulon S, 2010, MOL CELL, V39, P912, DOI 10.1016/j.molcel.2010.08.023; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Cannavo E, 2014, NATURE, V514, P122, DOI 10.1038/nature13771; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Danielsen JMR, 2009, J BIOL CHEM, V284, P4140, DOI 10.1074/jbc.M808174200; Dery U, 2008, MOL CELL BIOL, V28, P3058, DOI 10.1128/MCB.02025-07; Deshpande RA, 2016, MOL CELL, V64, P593, DOI 10.1016/j.molcel.2016.10.010; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Horejsi Z, 2014, CELL REP, V7, P19, DOI 10.1016/j.celrep.2014.03.013; Horejsi Z, 2010, MOL CELL, V39, P839, DOI 10.1016/j.molcel.2010.08.037; Kiianitsa K, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt171; Kijas AW, 2015, NUCLEIC ACIDS RES, V43, P8352, DOI 10.1093/nar/gkv754; Kim SG, 2013, MOL CELLS, V35, P463, DOI 10.1007/s10059-013-0138-2; Kleibl Z, 2016, BREAST, V28, P136, DOI 10.1016/j.breast.2016.05.006; Lamarche BJ, 2010, FEBS LETT, V584, P3682, DOI 10.1016/j.febslet.2010.07.029; Luo H, 2014, NUCLEIC ACIDS RES, V42, pD574, DOI 10.1093/nar/gkt1131; Machado-Pinilla R, 2012, RNA, V18, P1833, DOI 10.1261/rna.034942.112; Hoa NN, 2016, MOL CELL, V64, P1010, DOI 10.1016/j.molcel.2016.11.028; Pal M, 2014, STRUCTURE, V22, P805, DOI 10.1016/j.str.2014.04.001; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Rao F, 2014, MOL CELL, V54, P119, DOI 10.1016/j.molcel.2014.02.020; Regal JA, 2013, HUM MOL GENET, V22, P5146, DOI 10.1093/hmg/ddt368; Rosenbaum J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003906; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Williams GJ, 2010, DNA REPAIR, V9, P1299, DOI 10.1016/j.dnarep.2010.10.001; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zhao RM, 2008, J CELL BIOL, V180, P563, DOI 10.1083/jcb.200709061	37	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4943	4950		10.1038/onc.2017.99	http://dx.doi.org/10.1038/onc.2017.99			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436950	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000408234400010
J	Lin, MC; Lin, JJ; Hsu, CL; Juan, HF; Lou, PJ; Huang, MC				Lin, M-C; Lin, J-J; Hsu, C-L; Juan, H-F; Lou, P-J; Huang, M-C			GATA3 interacts with and stabilizes HIF-1 alpha to enhance cancer cell invasiveness	ONCOGENE			English	Article							INDUCIBLE FACTOR 1-ALPHA; BREAST-CANCER; TRANSCRIPTION FACTORS; HYPOXIA; DIFFERENTIATION; EXPRESSION; DEGRADATION; METASTASIS; PROTEASOME; REPRESSION	GATA binding protein 3 (GATA3) is indispensable in development of human organs. However, the role of GATA3 in cancers remains elusive. Hypoxia inducible factor (HIF)-1 plays an important role in pathogenesis of human cancers. Regulation of HIF-1 alpha degradation is orchestrated through collaboration of its interacting proteins. In this study, we discover that GATA3 is upregulated in head and neck squamous cell carcinoma (HNSCC) and is an independent predictor for poor disease-free survival. GATA3 promotes invasive behaviours of HNSCC and melanoma cells in vitro and in immunodeficient mice. Mechanistically, GATA3 physically associates with HIF-1 alpha under hypoxia to inhibit ubiquitination and proteasomal degradation of HIF-1 alpha, which is independent of HIF-1 alpha prolyl hydroxylation. Chromatin immunoprecipitation assays show that the GATA3/HIF-1 alpha complex binds to and regulates HIF-1 target genes, which is also supported by the microarray analysis. Notably, the GATA3-mediated invasiveness can be significantly reversed by HIF-1 alpha knockdown, suggesting a critical role of HIF-1 alpha in the underlying mechanism of GATA3-mediated effects. Our findings suggest that GATA3 stabilizes HIF-1 alpha to enhance cancer invasiveness under hypoxia and support the GATA3/ HIF-1 alpha axis as a potential therapeutic target for cancer treatment.	[Lin, M-C] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Otolaryngol, Hsinchu, Taiwan; [Lin, M-C; Lou, P-J; Huang, M-C] Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, 1,Sec 1 Jen Ai Rd, Taipei 100, Taiwan; [Lin, J-J] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei, Taiwan; [Hsu, C-L; Juan, H-F] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan; [Lou, P-J] Natl Taiwan Univ, Hosp & Coll Med, Dept Otolaryngol, 7 Chung Shan South Rd, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University	Lou, PJ; Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, 1,Sec 1 Jen Ai Rd, Taipei 100, Taiwan.; Lou, PJ (corresponding author), Natl Taiwan Univ, Hosp & Coll Med, Dept Otolaryngol, 7 Chung Shan South Rd, Taipei 100, Taiwan.	pjlou@ntu.edu.tw; mchuang@ntu.edu.tw	Hsu, Chia-Lang/O-1458-2013	Hsu, Chia-Lang/0000-0002-7447-8045; LIN, JING-JER/0000-0001-8250-7398; HUANG, MIN-CHUAN/0000-0002-0704-3447; LOU, PEI-JEN/0000-0002-3383-8593	Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine; National Taiwan University Hospital [106C101-D1]; National Taiwan University Hospital, Hsinchu Branch [HCH104-045, 105-HCH020]; Ministry of Science and Technology, ROC [104-2320-B-002 -068 -MY3, 103-2314-B-002 -082 -MY2, 105-2314-B-002 -203 -MY2]; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine; National Taiwan University Hospital(National Taiwan University); National Taiwan University Hospital, Hsinchu Branch; Ministry of Science and Technology, ROC; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	We thank Drs Mien-Chie Hung and Muh-Hwa Yang for editorial advice, Drs Jean-San Chia, Ming-Shyue Lee, Hsiu-Ni Kung, Wan-Lun Hsu and Hung-Lee Chen for technical supports, and Dr Shu-Yun Tung for performing global gene expression analysis. This study was supported by the Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine, and National Taiwan University Hospital (106C101-D1), the National Taiwan University Hospital, Hsinchu Branch, HCH104-045, 105-HCH020 (MC Lin) and Ministry of Science and Technology, ROC 104-2320-B-002 -068 -MY3 (MC Huang), 103-2314-B-002 -082 -MY2 (PJ Lou), 105-2314-B-002 -203 -MY2 (MC Lin), and the Academia Sinica, Taiwan Head and Neck Cancer Biosignature (PJ Lou).	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Haraguchi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156524; Higgins JPT, 2007, AM J SURG PATHOL, V31, P673, DOI 10.1097/01.pas.0000213438.01278.5f; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Hosoya T, 2010, IMMUNOL REV, V238, P110, DOI 10.1111/j.1600-065X.2010.00954.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Joshi S, 2014, J BIOL CHEM, V289, P22785, DOI 10.1074/jbc.M114.587493; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2010, RECENT RESULTS CANC, V180, P15, DOI 10.1007/978-3-540-78281-0_3; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; Lawoko-Kerali G, 2002, J COMP NEUROL, V442, P378, DOI 10.1002/cne.10088; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Moriguchi T, 2006, DEVELOPMENT, V133, P3871, DOI 10.1242/dev.02553; Peng HW, 2015, MOL MED REP, V11, P881, DOI 10.3892/mmr.2014.2809; Popp V, 2017, GASTROENTEROLOGY, V152, P176, DOI 10.1053/j.gastro.2016.09.005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Winter SC, 2006, CANCER-AM CANCER SOC, V107, P757, DOI 10.1002/cncr.21983; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	37	35	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4243	4252		10.1038/onc.2017.8	http://dx.doi.org/10.1038/onc.2017.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28263977	Green Published, hybrid			2022-12-28	WOS:000406360600002
J	Yang, YC; Cheng, TY; Huang, SM; Su, CY; Yang, PW; Lee, JM; Chen, CK; Hsiao, M; Hua, KT; Kuo, ML				Yang, Y-C; Cheng, T-Y; Huang, S-M; Su, C-Y; Yang, P-W; Lee, J-M; Chen, C-K; Hsiao, M.; Hua, K-T; Kuo, M-L			Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association (vol 35, pg 3387, 2016)	ONCOGENE			English	Correction														CHENG, TSU-YAO/0000-0002-7370-5605				Yang YC, 2016, ONCOGENE, V35, P3387, DOI 10.1038/onc.2015.397	1	4	4	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4234	4234		10.1038/onc.2017.18	http://dx.doi.org/10.1038/onc.2017.18			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319058	Bronze			2022-12-28	WOS:000405835800015
J	Ma, X; Meng, Z; Jin, L; Xiao, Z; Wang, X; Tsark, WM; Ding, L; Gu, Y; Zhang, J; Kim, B; He, M; Gan, X; Shively, JE; Yu, H; Xu, R; Huang, W				Ma, X.; Meng, Z.; Jin, L.; Xiao, Z.; Wang, X.; Tsark, W. M.; Ding, L.; Gu, Y.; Zhang, J.; Kim, B.; He, M.; Gan, X.; Shively, J. E.; Yu, H.; Xu, R.; Huang, W.			CAMK2 gamma in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation	ONCOGENE			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; CRITICAL REGULATOR; TARGETING STAT3; IMMUNE CELLS; COLON-CANCER; MOUSE MODEL; RISK; EXPRESSION	Inflammation is one of the major risk factors for cancer. Here, we show that calcium/calmodulin-dependent protein kinase II gamma (CAMK2 gamma) in intestinal epithelial cells (IECs) modulates inflammatory signals and promotes colitis-associated cancer (CAC) in mice. We have identified CAMK2 gamma as a downstream target of colitis-induced WNT5A signaling. Furthermore, we have shown that CAMK2 gamma protects against intestine tissue injury by increasing IEC survival and proliferation. Calcium/calmodulin-dependent protein kinase II gamma knockout mice displayed reduced CAC. Furthermore, we used bone marrow transplantation to reveal that CAMK2 gamma in IECs, but not immune cells, was crucial for its effect on CAC. Consistently, transgenic over-expression of CAMK2 gamma in IECs accelerated CAC development. Mechanistically, CAMK2 gamma in IECs enhanced epithelial signal transducer and activator of transcription 3 (STAT3) activation to promote survival and proliferation of colonic epithelial cells during CAC development. These results thus identify a new molecular mechanism mediated by CAMK2 gamma in IECs during CAC development, thereby providing a potential new therapeutic target for CAC.	[Ma, X.; Meng, Z.; Jin, L.; Xiao, Z.; Wang, X.; Ding, L.; Gu, Y.; Zhang, J.; Kim, B.; Gan, X.; Xu, R.; Huang, W.] City Hope Natl Med Ctr, Diabet & Metab Res Inst, Dept Diabet Complicat & Metab, Mol & Cellular Biol Canc Program, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Ma, X.; Kim, B.; Huang, W.] City Hope Natl Med Ctr, Irell & Manella Grad Sch Biol Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Jin, L.] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Xiao, Z.] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Fujian Prov Key Lab Tumor Biotherapy,Dept Clin La, Fuzhou, Fujian, Peoples R China; [Wang, X.] Cleveland Clin, Robert J Tomsich Inst Pathol & Lab Med, Cleveland, OH 44106 USA; [Tsark, W. M.] City Hope Natl Med Ctr, Transgen Mouse Core, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Zhang, J.; Xu, R.] Zhejiang Univ, Sch Med, Affiliated Hosp 2,Dept Hematol, China Natl Minist Educ,Key Lab Canc Prevent & Int, Hangzhou, Zhejiang, Peoples R China; [He, M.] Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China; [Shively, J. E.] City Hope Natl Med Ctr, Dept Immunol, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Yu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA	City of Hope; City of Hope; Xiamen University; Fujian Medical University; Cleveland Clinic Foundation; City of Hope; Zhejiang University; Guangxi Medical University; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Xu, R; Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Diabet & Metab Dis Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.	zrxyk10@zju.edu.cn; whuang@coh.org	Ma, Xiaoxiao/AFB-9086-2022	Ma, Xiaoxiao/0000-0001-8661-5660; YU, Hua/0000-0003-0931-1000	National Natural Science Foundation of China [81270601, 81328016]; State Key Laboratory of Cellular Stress Biology, Xiamen University [SKLCSB2016KF002]; National Cancer Institute of the National Institutes of Health [P30CA33572];  [2NCI R01-CA139158]; NATIONAL CANCER INSTITUTE [R01CA139158, P30CA033572] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Cellular Stress Biology, Xiamen University; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Johannes Backs for providing the Camk2 gamma KO mice. We thank Dr Richard Ermel and the Animal Resource Center for the technical resources. We thank the pathologists from the City of Hope Pathology Core Lab for sample processing and analysis. We thank Dr Fong-Fong Chu and Dr Mei Kong at City of Hope for discussion. We also thank Dr Nancy Linford for providing editing assistance. This work is supported in part by 2NCI R01-CA139158, the National Natural Science Foundation of China (81270601 and 81328016) and the Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University (SKLCSB2016KF002). Research reported in this publication was also supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572.	Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Backs J, 2010, P NATL ACAD SCI USA, V107, P81, DOI 10.1073/pnas.0912658106; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brandl K, 2010, P NATL ACAD SCI USA, V107, P19967, DOI 10.1073/pnas.1014669107; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Bui JD, 2000, CELL, V100, P457, DOI 10.1016/S0092-8674(00)80681-9; Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104; Cui WW, 2007, NUCLEIC ACIDS RES, V35, pD805, DOI 10.1093/nar/gkl767; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Foersch S, 2014, CELL MOL LIFE SCI, V71, P3523, DOI 10.1007/s00018-014-1636-x; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gibson RM, 2005, BBA-BIOMEMBRANES, V1714, P56, DOI 10.1016/j.bbamem.2005.05.014; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang WD, 2011, NATURE, V470, P414, DOI 10.1038/nature09703; Huang W, 2009, MOL CELL, V35, P48, DOI 10.1016/j.molcel.2009.05.023; Hughes KR, 2011, INFLAMM BOWEL DIS, V17, P213, DOI 10.1002/ibd.21353; Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010; Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lakatos PL, 2008, WORLD J GASTROENTERO, V14, P3937, DOI 10.3748/wjg.14.3937; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Levanen B, 2011, RESP MED, V105, P282, DOI 10.1016/j.rmed.2010.11.018; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Liu XG, 2008, BLOOD, V112, P4961, DOI 10.1182/blood-2008-03-144022; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Nguyen A, FEBS LETT; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Planell N, 2013, GUT, V62, P967, DOI 10.1136/gutjnl-2012-303333; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036; Rubin DC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00107; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sato A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10536; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Solomon L., 2010, COMP CLIN PATHOL, V19, DOI [10.1007/s00580-010-0979-4, DOI 10.1007/S00580-010-0979-4]; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thaker AI, 2012, JOVE-J VIS EXP, DOI 10.3791/4100; Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Van Der Kraak L, 2015, WORLD J GASTROENTERO, V21, P11688, DOI 10.3748/wjg.v21.i41.11688; von Roon AC, 2007, DIS COLON RECTUM, V50, P839, DOI 10.1007/s10350-006-0848-z; Wang Y, 2015, BIOMED RES INT, V2015, P6, DOI DOI 10.1128/MBI0.01280-15; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Wotherspoon A C, 2000, Curr Gastroenterol Rep, V2, P494, DOI 10.1007/s11894-000-0014-z; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 ; Zhao C, 2013, CARCINOGENESIS, V34; Zhao L, 2016, CIRC RES, V118, P1918, DOI 10.1161/CIRCRESAHA.116.308688	67	21	22	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4060	4071		10.1038/onc.2017.16	http://dx.doi.org/10.1038/onc.2017.16			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319059	Green Accepted			2022-12-28	WOS:000405379900011
J	Zahavi, T; Maimon, A; Kushnir, T; Lange, R; Berger, E; Kornspan, D; Grossman, R; Anzi, S; Shaulian, E; Karni, R; Nechushtan, H; Paroush, Z				Zahavi, T.; Maimon, A.; Kushnir, T.; Lange, R.; Berger, E.; Kornspan, D.; Grossman, R.; Anzi, S.; Shaulian, E.; Karni, R.; Nechushtan, H.; Paroush, Z.			Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function	ONCOGENE			English	Article							GROUCHO-MEDIATED REPRESSION; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; CO-REPRESSORS; TRANSCRIPTION FACTORS; BREAST-CANCER; IN-VIVO; DROSOPHILA; PATHWAYS	Signaling mediated by the Ras-extracellular signal-regulated kinase (Erk) pathway often leads to the phosphorylation of transcriptional regulators, thereby modulating their activity and causing concerted changes in gene expression. In Drosophila, the induction of multiple Ras-Erk pathway target genes depends on prior phosphorylation of the general co-repressor Groucho, a modification that downregulates its repressive function. Here, we show that TLE1, one of the four human Groucho orthologs, is similarly phosphorylated in response to Ras-Erk pathway activation, and that this modification attenuates its capacity to repress transcription. Specifically, unphosphorylated TLE1 dominantly suppresses the induction of Ras-Erk pathway target genes in cultured human cells, and the expression of an unphosphorylatable TLE1 derivative causes severe phenotypes in a transgenic Drosophila model system, whereas a phosphomimetic variant of TLE1 exerts only negligible effects. We present data indicating that TLE1 is rapidly excluded from the nucleus following epidermal growth factor receptor pathway activation, an effect that likely accounts for its inability to mediate effective repression under such conditions. Significantly, we find that unphosphorylated TLE1 blocks oncogenic phenotypes induced by mutated H-Ras in human mammary cells, both in vitro and following their implantation in mice. Collectively, our data strongly indicate that phosphorylation of TLE family members and the consequent downregulation of their repressor function is a key conserved step in the transcriptional responses to Ras-Erk signaling, and possibly a critical event in the tumorigenic effects caused by excessive Ras-Erk pathway activity.	[Zahavi, T.; Kushnir, T.; Lange, R.; Berger, E.; Kornspan, D.; Grossman, R.; Paroush, Z.] Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Dev Biol & Canc Res, POB 12272, IL-91120 Jerusalem, Israel; [Maimon, A.; Anzi, S.; Shaulian, E.; Karni, R.] Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Biochem & Mol Biol, Jerusalem, Israel; [Kornspan, D.; Nechushtan, H.] Hadassah Hebrew Univ, Med Ctr, Sharett Inst Oncol, Dept Oncol, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Paroush, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Dev Biol & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	zparoush@cc.huji.ac.il	nechushtan, hovav/Z-3564-2019	Shaulian, Eitan/0000-0001-6242-6849; Kornspan, David/0000-0001-6848-2323	Israel Cancer Research Fund; Israel Science Foundation [1772/13, 1552/16]; Jan M and Eugenia Krol Charitable Foundation; Israel Cancer Association; Tsipora and Moshe Levin Foundation; Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research; Lady Davis Postdoctoral Fellowship; Israel Cancer Research Fund Booster Fellowship	Israel Cancer Research Fund; Israel Science Foundation(Israel Science Foundation); Jan M and Eugenia Krol Charitable Foundation; Israel Cancer Association; Tsipora and Moshe Levin Foundation; Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research; Lady Davis Postdoctoral Fellowship; Israel Cancer Research Fund Booster Fellowship	We thank members of our laboratory for continued help and encouragement during this project; David Engelberg, Shulamit Katzav, Oded Meyuhas, Joel Yisraeli and, particularly, Gerardo Jimenez for their insightful comments on the manuscript; Yosef Yarden and Stefano Stifani for providing us with DNA constructs and reagents; Konstantin Kogan, Vered Levin-Salomon and David Engelberg for their assistance with the Erk2 in vitro kinase assays and for contributing recombinant activated Erk2; Ahmad Mreisat for technical help; and Amir Orian for hosting TZ in his laboratory for some of her experiments. Work was supported by grants from the Israel Cancer Research Fund (Project Grant), Israel Science Foundation (Center of Excellence 1772/13 and 1552/16), and the Jan M and Eugenia Krol Charitable Foundation to ZP; and by the Israel Cancer Association to HN. TK received a Doctoral Fellowship from the Tsipora and Moshe Levin Foundation. DK is a recipient of a Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research, a Lady Davis Postdoctoral Fellowship and an Israel Cancer Research Fund Booster Fellowship. ZP is an incumbent of the Lady Davis Professorship in Experimental Medicine and Cancer Research.	Agarwal M, 2015, IUBMB LIFE, V67, P472, DOI 10.1002/iub.1395; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Barker N, 2000, ADV CANCER RES, V77, P1; Beagle B, 2010, DEV DYNAM, V239, P2795, DOI 10.1002/dvdy.22439; Ben-Hur V, 2013, CELL REP, V3, P103, DOI 10.1016/j.celrep.2012.11.020; Bezniakow Natalia, 2014, Dev Period Med, V18, P285; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Buscarlet M, 2007, TRENDS CELL BIOL, V17, P353, DOI 10.1016/j.tcb.2007.07.002; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Cinnamon E, 2008, DEVELOPMENT, V135, P829, DOI 10.1242/dev.015206; Cinnamon E, 2008, CURR OPIN GENET DEV, V18, P435, DOI 10.1016/j.gde.2008.07.010; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; Dayyani F, 2008, BLOOD, V111, P4338, DOI 10.1182/blood-2007-07-103291; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DELIDAKIS C, 1991, GENETICS, V129, P803; Gasperowicz M, 2005, J CELL BIOCHEM, V95, P670, DOI 10.1002/jcb.20476; Goldstein RE, 2005, MOL CELL BIOL, V25, P10711, DOI 10.1128/MCB.25.24.10711-10720.2005; Hasson P, 2006, BRIT J CANCER, V94, P771, DOI 10.1038/sj.bjc.6603019; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Helman A, 2012, DEVELOPMENT, V139, P3032, DOI 10.1242/dev.075812; Helman A, 2011, CURR BIOL, V21, P1102, DOI 10.1016/j.cub.2011.05.043; Jennings BH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-205; Johnston MJ, 2016, DEVELOPMENT, V143, P4631, DOI 10.1242/dev.143263; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim Y, 2010, CURR BIOL, V20, P446, DOI 10.1016/j.cub.2010.01.019; Kwong PN, 2015, J BIOL CHEM, V290, P30119, DOI 10.1074/jbc.M115.681171; Lee S, 2010, MOL CELL BIOL, V30, P2621, DOI 10.1128/MCB.00782-09; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Lien WH, 2014, NAT CELL BIOL, V16, P179, DOI 10.1038/ncb2903; Maimon A, 2014, CELL REP, V7, P501, DOI 10.1016/j.celrep.2014.03.041; McCurrach ME, 2001, METHOD CELL BIOL, V66, P197; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Mrozek K, 2008, CURR OPIN ONCOL, V20, P711, DOI 10.1097/CCO.0b013e32831369df; Paroush Z, 1997, DEVELOPMENT, V124, P3827; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Turki-Judeh W, 2012, CURR TOP DEV BIOL, V98, P65, DOI 10.1016/B978-0-12-386499-4.00003-3; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Whitmarsh AJ, 2007, BBA-MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011; Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033; Yogev O, 2008, CANCER RES, V68, P1398, DOI 10.1158/0008-5472.CAN-07-2865	47	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3729	3739		10.1038/onc.2016.517	http://dx.doi.org/10.1038/onc.2016.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192406				2022-12-28	WOS:000404349700008
J	Yang, JB; Zhao, ZB; Liu, QZ; Hu, TD; Long, J; Yan, K; Lian, ZX				Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong			FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages	ONCOGENE			English	Article							DENDRITIC CELLS; MYELOID CELLS; IN-VIVO; PROGRESSION; CANCER; POLARIZATION; METASTASIS; HYPOXIA; MICE; INVASION	Macrophages are a critical component in host immune responses against tumor. In this work we investigated the role of forkhead box O1 (FoxO1) in the transcriptional regulation in macrophages, which affects the anti-tumor functions of tumor-associated macrophages (TAMs). First, we showed that TAMs expressed reduced levels of FoxO1, which was associated with their protumoral M2 polarization state. The suppression of FoxO1 expression in TAM was induced by the hypoxic condition in the tumor microenviroment. Next, we confirmed that FoxO1 positively regulates MHC-II genes by binding to the promoter region of Ciita gene, the master activator of multiple MHC-II genes. Loss of FoxO1 in TAMs resulted in reduced MHC-II expression. Furthermore, we used FoxO1 conditional knockout mice to show that FoxO1 deficiency in myeloid cells exacerbates tumor growth. These results demonstrate that the protumoral property of TAMs is induced by the hypoxia-triggered FoxO1 deficiency, which could be a potential target of novel anti-tumor therapies.	[Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Liver Immunol Lab, Hefei, Anhui, Peoples R China; [Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] Univ Sci & Technol China, Med Ctr, Hefei, Anhui, Peoples R China; [Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] South China Univ Technol, Inst Life Sci, Chron Dis Lab, Guangzhou, Guangdong, Peoples R China; [Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Lian, Zhe-Xiong] Hefei Natl Lab Phys Sci Microscale, Innovat Ctr Cell Signaling Network, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; South China University of Technology; South China University of Technology	Lian, ZX (corresponding author), Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Liver Immunol Lab, Hefei, Anhui, Peoples R China.; Lian, ZX (corresponding author), Univ Sci & Technol China, Med Ctr, Hefei, Anhui, Peoples R China.; Lian, ZX (corresponding author), South China Univ Technol, Inst Life Sci, Chron Dis Lab, Guangzhou, Guangdong, Peoples R China.; Lian, ZX (corresponding author), South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China.; Lian, ZX (corresponding author), Hefei Natl Lab Phys Sci Microscale, Innovat Ctr Cell Signaling Network, Hefei, Anhui, Peoples R China.	zxlian1@ustc.edu.cn	Liu, Qing-zhi/B-3140-2019; 刘, 清枝/GLR-7060-2022; Zhao, Zhi-Bin/V-3278-2017	Zhao, Zhi-Bin/0000-0003-0691-2556	National Natural Science Foundation of China [81430034, 91542123]; National Basic Research Program of China under Grant 973 Program [2013CB944900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China under Grant 973 Program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China under Grant 81430034 and 91542123; National Basic Research Program of China under Grant 973 Program-2013CB944900.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Chen J, 2014, TUMOR BIOL, V35, P7195, DOI 10.1007/s13277-014-1913-1; Chung S, 2016, ONCOTARGET, V7, P17532, DOI 10.18632/oncotarget.8162; Chung S, 2015, J LEUKOCYTE BIOL, V97, P327, DOI 10.1189/jlb.3A0514-251R; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Coates PJ, 2008, CANCER RES, V68, P450, DOI 10.1158/0008-5472.CAN-07-3050; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268; Fukuda Koji, 2012, Front Biosci (Schol Ed), V4, P787; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161; Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262-002-0280-8; Li QS, 2004, CANCER RES, V64, P1130, DOI 10.1158/0008-5472.CAN-03-1715; Lu HR, 2011, NEOPLASIA, V13, P854, DOI 10.1593/neo.11594; Maiese K, 2009, OXID MED CELL LONGEV, V2, P119, DOI 10.4161/oxim.2.3.8916; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Moritoki Y, 2009, GASTROENTEROLOGY, V136, P1037, DOI 10.1053/j.gastro.2008.11.035; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Orsini G, 2013, INT J MOL SCI, V14, P22022, DOI 10.3390/ijms141122022; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pardee AD, 2014, J IMMUNOL, V193, P5723, DOI 10.4049/jimmunol.1400725; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Schartner JM, 2005, GLIA, V51, P279, DOI 10.1002/glia.20201; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Tikhanovich I, 2013, J GASTROEN HEPATOL, V28, P125, DOI 10.1111/jgh.12021; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Wang BF, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-43; Wang YC, 2016, CLIN REV ALLERG IMMU, V51, P353, DOI 10.1007/s12016-016-8531-1; White JR, 2004, GENOMICS, V83, P1, DOI 10.1016/S0888-7543(03)00215-5; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yang YQ, 2016, ONCOTARGET, V7, P26992, DOI 10.18632/oncotarget.8853; Yao Y, 2014, J AUTOIMMUN, V51, P99, DOI 10.1016/j.jaut.2014.02.009; Ying W, 2013, JOVE-J VIS EXP, DOI 10.3791/50323; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069	49	25	27	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1192	1204		10.1038/s41388-017-0048-4	http://dx.doi.org/10.1038/s41388-017-0048-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29238041				2022-12-28	WOS:000426505400005
J	Garcia-Mariscal, A; Li, H; Pedersen, E; Peyrollier, K; Ryan, KM; Stanley, A; Quondamatteo, F; Brakebusch, C				Garcia-Mariscal, A.; Li, H.; Pedersen, E.; Peyrollier, K.; Ryan, K. M.; Stanley, A.; Quondamatteo, F.; Brakebusch, C.			Loss of RhoA promotes skin tumor formation and invasion by upregulation of RhoB	ONCOGENE			English	Article							T-CELL LYMPHOMA; MEMBRANE PROTRUSIONS; CANCER GENOMICS; DISTINCT ROLES; STEM-CELLS; IN-VIVO; GTPASE; MUTATIONS; MIGRATION; ADHESION	Cellular movement is controlled by small GTPases, such as RhoA. Although migration is crucial for cancer cell invasion, the specific role of RhoA in tumor formation is unclear. Inducing skin tumors in mice with a keratinocyte-restricted loss of RhoA, we observed increased tumor frequency, growth and invasion. In vitro invasion assays revealed that in the absence of RhoA cell invasiveness is increased in a Rho-associated protein kinase (ROCK) activation and cell contraction-dependent manner. Surprisingly, loss of RhoA causes increased Rho signaling via overcompensation by RhoB because of reduced lysosomal degradation of RhoB in Gamma-aminobutyric acid receptor-associated protein (GABARAP)+autophagosomes and endosomes. In the absence of RhoA, RhoB relocalized to the plasma membrane and functionally replaced RhoA with respect to invasion, clonogenic growth and survival. Our data demonstrate for the first time that RhoA is a tumor suppressor in 7,12-dimethylbenz[a] anthracene/12-O-tetradecanoylphorbol 13-acetate skin carcinogenesis and identify Rho signaling dependent on RhoA and RhoB as a potent driver of tumor progression.	[Garcia-Mariscal, A.; Li, H.; Pedersen, E.; Peyrollier, K.; Brakebusch, C.] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, Copenhagen, Denmark; [Ryan, K. M.] Beatson Inst, Glasgow, Lanark, Scotland; [Stanley, A.; Quondamatteo, F.] NUI, Skin & Extracellular Matrix Res Grp, Anat, Galway, Ireland	University of Copenhagen; Beatson Institute; Ollscoil na Gaillimhe-University of Galway	Brakebusch, C (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, Copenhagen, Denmark.	cord.brakebusch@bric.ku.dk		Stanley, Alanna/0000-0002-0901-8798; Brakebusch, Cord/0000-0002-9342-1634	Cancer Research UK [15816, 22903] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		Alfano D, 2012, J CELL SCI, V125, P2369, DOI 10.1242/jcs.091579; Arshad A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115447; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapman S, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt449; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Filler Renata B, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.prot4837; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ho TTG, 2008, J BIOL CHEM, V283, P21588, DOI 10.1074/jbc.M710033200; Howe GA, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-1; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jackson B, 2011, MOL BIOL CELL, V22, P593, DOI 10.1091/mbc.E09-10-0859; Jennings RT, 2014, BLOOD, V123, P3635, DOI 10.1182/blood-2014-02-557843; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee Stacey, 2016, F1000Res, V5, DOI 10.12688/f1000research.8800.1; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Mazieres J, 2005, EXP CELL RES, V304, P354, DOI 10.1016/j.yexcr.2004.10.019; Meyer N, 2014, J INVEST DERMATOL, V134, P203, DOI 10.1038/jid.2013.278; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Pedersen E, 2012, EXP CELL RES, V318, P1779, DOI 10.1016/j.yexcr.2012.05.004; Pedersen E, 2012, METHODS MOL BIOL, V827, P157, DOI 10.1007/978-1-61779-442-1_11; Perez-Sala D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008117; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Ridley A, 2013, NAT CELL BIOL, V15, P337, DOI 10.1038/ncb2716; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Valero RA, 2010, TRAFFIC, V11, P1221, DOI 10.1111/j.1600-0854.2010.01091.x; Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977; Vega Francisco M, 2018, Small GTPases, V9, P384, DOI 10.1080/21541248.2016.1253528; Vega FM, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120076; Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038; Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916	49	24	24	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					847	860		10.1038/onc.2017.333	http://dx.doi.org/10.1038/onc.2017.333			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059167				2022-12-28	WOS:000425281800003
J	Xue, J; Zhu, W; Song, J; Jiao, Y; Luo, J; Yu, C; Zhou, J; Wu, J; Chen, M; Ding, WQ; Cao, J; Zhang, S				Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Luo, J.; Yu, C.; Zhou, J.; Wu, J.; Chen, M.; Ding, W-Q; Cao, J.; Zhang, S.			Activation of PPAR alpha by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/beta-catenin pathway	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DOWN-REGULATION; WNT PATHWAY; EXPRESSION; FENOFIBRATE; CARCINOMA; GROWTH; RADIOSENSITIVITY; ADENOCARCINOMA; PROLIFERATION	Radiotherapy is emerging as an important modality for the local control of pancreatic cancer, but pancreatic cancer cell radioresistance remains a serious concern. Peroxisome proliferator-activated receptor a (PPAR alpha) is a member of the PPAR nuclear hormone receptor superfamily, which can be activated by fibrate ligands. The clinical relevance of PPAR alpha and its biological function in pancreatic cancer radiosensitivity have not been previously described. In this study, we examined PPAR alpha expression in tissue samples of pancreatic cancer patients. We found significantly higher expression of PPAR alpha in pancreatic cancer tissues than in tumor-adjacent tissues and that the PPAR alpha expression level is inversely associated with higher overall patient survival rate. We further observed that PPAR alpha activation by its agonist clofibrate sensitizes pancreatic cancer cells to radiation by modulating cell cycle progression and apoptosis in several pancreatic cancer cell lines. Small interfering RNA-mediated PPAR alpha silencing and PPAR alpha blockade by the antagonist GW6471 abolish the effect of clofibrate on radiosensitization. An in vivo study showed that PANC1 xenografts treated with clofibrate are more sensitive to radiation than untreated xenografts. mRNA profiling by microarray analysis revealed that the expression of PTPRZ1 and Wnt8a, two core components of the beta-catenin pathway, is downregulated by clofibrate. Chromatin immunoprecipitation analysis confirmed that clofibrate abrogates the binding of nuclear factor-kappa B to the PTPRZ1 and Wnt8a promoters, ultimately decreasing Wnt/beta-catenin signaling activity, which is associated with radiosensitivity. Overall, we demonstrate that PPARa is overexpressed in pancreatic cancer tissues and clofibrate-mediated PPARa activation sensitizes pancreatic cancer cells to radiation through the Wnt/beta-catenin pathway.	[Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Med Coll, Sch Radiat Med & Protect, 199 Renai Rd, Suzhou 215123, Peoples R China; [Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Jiangsu Higher Educ Inst, Collaborat Innovat Ctr Radiat Med, Suzhou, Peoples R China; [Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Yu, C.; Cao, J.; Zhang, S.] Soochow Univ, Jiangsu Prov Key Lab Radiat Med & Protect, Suzhou, Peoples R China; [Luo, J.] Nanjing Med Univ, Affiliated Hosp, Dept Oncol, Changzhou Peoples Hosp 2, Changzhou, Peoples R China; [Zhou, J.; Wu, J.] Nanjing Med Univ, Affiliated Suzhou Hosp, Core Lab, Suzhou Canc Ctr, Suzhou, Peoples R China; [Chen, M.; Zhang, S.] Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Ding, W-Q] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA	Soochow University - China; Soochow University - China; Soochow University - China; Nanjing Medical University; Nanjing Medical University; Zhejiang Cancer Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center	Cao, J; Zhang, S (corresponding author), Soochow Univ, Med Coll, Sch Radiat Med & Protect, 199 Renai Rd, Suzhou 215123, Peoples R China.	jpcao@suda.edu.cn; zhang.shuyu@hotmail.com	Chen, Ming/GYE-1379-2022	Chen, Ming/0000-0001-5041-9342	National Natural Science Foundation of China [81522039, 81573080, 81673100, 31670857]; Key Scientific Development Program of China [2016YFC0904700, 2016YFC0904702]; Suzhou Key Medical Center [SZZX201506]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific Development Program of China; Suzhou Key Medical Center; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (81522039, 81573080, 81673100 and 31670857), the Key Scientific Development Program of China (2016YFC0904700 and 2016YFC0904702), the Suzhou Key Medical Center (SZZX201506) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Afifi MM, 2014, BIOCONJUGATE CHEM, V25, P207, DOI 10.1021/bc400271x; [Anonymous], 2010, J MOL BIOL, V404, P172; [Anonymous], 2010, J MOL BIOL, V388, P225; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chandran K, 2016, ONCOTARGET, V7, P15577, DOI 10.18632/oncotarget.6402; Changela K, 2016, CAN J GASTROENTEROL, V2016, DOI 10.1155/2016/4189358; Chen H, 2014, WORLD J GASTROENTERO, V20, P8681, DOI 10.3748/wjg.v20.i26.8681; Chen J, 2014, J NEUROSCI RES, V92, P1252, DOI 10.1002/jnr.23415; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cunningham TJ, 2015, DEV DYNAM, V244, P797, DOI 10.1002/dvdy.24275; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Gao JM, 2015, EUR J PHARMACOL, V765, P560, DOI 10.1016/j.ejphar.2015.09.027; Ge YY, 2014, TUMOR BIOL, V35, P10765, DOI 10.1007/s13277-014-2149-9; Goodman KA, 2016, CANCER J, V22, P290, DOI 10.1097/PPO.0000000000000206; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hajj C, 2015, REP PRACT ONCOL RADI, V20, P377, DOI 10.1016/j.rpor.2015.05.008; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Hoffe S, 2014, SEMIN RADIAT ONCOL, V24, P113, DOI 10.1016/j.semradonc.2013.11.002; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kostapanos MS, 2013, WORLD J HEPATOL, V5, P470, DOI 10.4254/wjh.v5.i9.470; Li XQ, 2015, TUMORI, V101, P123, DOI 10.5301/tj.5000228; Lin H, 2010, AM J PATHOL, V177, P1697, DOI 10.2353/ajpath.2010.090789; Liu YT, 2007, AM J PATHOL, V171, P1978, DOI 10.2353/ajpath.2007.070741; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Luo JD, 2013, CANCER SCI, V104, P1544, DOI 10.1111/cas.12248; Maggiora M, 2010, CELL BIOCHEM FUNCT, V28, P571, DOI 10.1002/cbf.1691; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Misra P, 2014, BIOCHIMIE, V98, P63, DOI 10.1016/j.biochi.2013.11.011; Pisters PWT, 2002, J CLIN ONCOL, V20, P2537, DOI 10.1200/JCO.2002.11.064; Polireddy K, 2016, J CANCER, V7, P1497, DOI 10.7150/jca.14922; Saitoh T, 2002, INT J ONCOL, V20, P999; Segawa Y, 2002, PROSTATE, V51, P108, DOI 10.1002/pros.10058; Shang DH, 2013, WORLD J UROL, V31, P1547, DOI 10.1007/s00345-013-1077-4; Skrypnyk N, 2014, CANCER RES, V74, P621, DOI 10.1158/0008-5472.CAN-13-1928; Tang YT, 2015, SCI REP-UK, V5, DOI 10.1038/srep09476; Urbanska K, 2008, INT J CANCER, V123, P1015, DOI 10.1002/ijc.23588; Wright MB, 2014, MOL ENDOCRINOL, V28, P1756, DOI 10.1210/me.2013-1427; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; Yamazaki K, 2007, GUT, V56, P1557, DOI 10.1136/gut.2007.129858; Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214; Yin WH, 2013, ACTA CARDIOL SIN, V29, P251; Yokoyama Y, 2007, MOL CANCER THER, V6, P1379, DOI 10.1158/1535-7163.MCT-06-0722; Zhang QH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152407; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhao WL, 2007, RADIAT RES, V167, P581, DOI 10.1667/RR0814.1; Zhou JD, 2012, J BIOL CHEM, V287, P35161, DOI 10.1074/jbc.M112.367367	51	32	35	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					953	962		10.1038/onc.2017.401	http://dx.doi.org/10.1038/onc.2017.401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059162				2022-12-28	WOS:000425281800012
J	Perego, M; Maurer, M; Wang, JX; Shaffer, S; Muller, AC; Parapatics, K; Li, L; Hristova, D; Shin, S; Keeney, F; Liu, S; Xu, X; Raj, A; Jensen, JK; Bennett, KL; Wagner, SN; Somasundaram, R; Herlyn, M				Perego, M.; Maurer, M.; Wang, J. X.; Shaffer, S.; Mueller, A. C.; Parapatics, K.; Li, L.; Hristova, D.; Shin, S.; Keeney, F.; Liu, S.; Xu, X.; Raj, A.; Jensen, J. K.; Bennett, K. L.; Wagner, S. N.; Somasundaram, R.; Herlyn, M.			A slow-cycling subpopulation of melanoma cells with highly invasive properties	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROTEASE NEXIN-1; PROGNOSTIC-SIGNIFICANCE; PLASMINOGEN-ACTIVATOR; SAMPLE PREPARATION; INITIATING CELLS; MESSENGER-RNA; LOW NUMBER; CANCER; EXPRESSION	Melanoma is a heterogeneous tumor with different subpopulations showing different proliferation rates. Slow-cycling cells were previously identified in melanoma, but not fully biologically characterized. Using the label-retention method, we identified a subpopulation of slow-cycling cells, defined as label-retaining cells (LRC), with strong invasive properties. We demonstrate through live imaging that LRC are leaving the primary tumor mass at a very early stage and disseminate to peripheral organs. Through global proteome analyses, we identified the secreted protein SerpinE2/protease nexin-1 as causative for the highly invasive potential of LRC in melanomas.	[Perego, M.; Wang, J. X.; Li, L.; Hristova, D.; Shin, S.; Keeney, F.; Somasundaram, R.; Herlyn, M.] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA; [Maurer, M.; Wagner, S. N.] Med Univ Vienna, Div Immunol Allergy & Infect Dis, Vienna, Austria; [Shaffer, S.; Raj, A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Mueller, A. C.; Parapatics, K.; Bennett, K. L.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Liu, S.; Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Jensen, J. K.] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark	The Wistar Institute; Medical University of Vienna; University of Pennsylvania; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Pennsylvania; Aarhus University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	perego, michela/W-4650-2019	perego, michela/0000-0002-5671-928X; Mueller, Andre/0000-0002-0608-8176; Somasundaram, Rajasekharan/0000-0002-8444-8472; Shin, Sally/0000-0002-9306-2264; Liu, Shujing/0000-0002-2958-093X; Shaffer, Sydney/0000-0003-3539-9886	NIH [P01 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674, CA182890]; Melanoma Research Alliance; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Vienna Science and Technology Fund (WWTF) [LS11-045]; Vienna Hans Mayr-Fund; APART fellowship of the Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE [R01CA182890, P01CA025874, P30CA010815, R01CA047159, P01CA114046, P50CA174523, R01CA076674] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD017998] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Vienna Science and Technology Fund (WWTF); Vienna Hans Mayr-Fund; APART fellowship of the Austrian Academy of Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Jeffrey Faust, Scott Weiss and Christopher Corcoran from Wistar's Flow Cytometry Facility; James Hayden from Wistar's Imaging Facility and Dmitri Gourevitch from Wistar's Histopathology Core Facility for technical support; and Rachel E Locke and Jessica L Kohn for editorial assistance. This work was supported by NIH grants P01 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674, CA182890, by the Melanoma Research Alliance and by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Vienna Science and Technology Fund (WWTF through project LS11-045 to SNW), Vienna Hans Mayr-Fund, and by APART fellowship of the Austrian Academy of Sciences (OAW to MM).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Bianchi-Smiraglia A, 2017, ONCOGENE, V5, P36; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bouton MC, 2012, BLOOD, V119, P2452, DOI 10.1182/blood-2011-10-387464; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; Buchholz M, 2003, CANCER RES, V63, P4945; Chapman A, 2014, CELL REP, V8, P688, DOI 10.1016/j.celrep.2014.06.045; Cheli Y, 2001, ONCOGENE, V19, P30; Cheli Y, 2012, ONCOGENE, V10, P31; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Colinge J, 2006, J PROTEOME RES, V5, P619, DOI 10.1021/pr0504236; Croteau W, 2013, J CELL PHYSIOL, V228, P773, DOI 10.1002/jcp.24225; Czekay RP, 2009, J CELL PHYSIOL, V220, P655, DOI 10.1002/jcp.21806; Dembinski Jennifer L, 2010, Cancers (Basel), V2, P2011, DOI 10.3390/cancers2042011; EVANS DL, 1991, J BIOL CHEM, V266, P22307; Falletta P, 2017, GENE DEV, V1, P31; Fane ME, 2017, EBIOMEDICINE, V16, P63, DOI 10.1016/j.ebiom.2017.01.013; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Faries MB, 2013, J AM COLL SURGEONS, V217, P27, DOI 10.1016/j.jamcollsurg.2013.03.007; Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573; Gao S, 2008, ORAL ONCOL, V44, P309, DOI 10.1016/j.oraloncology.2007.02.009; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Goodall J, 2008, CANCER RES, V1, P68; Heit C, 2013, HUM GENOMICS, V7, DOI 10.1186/1479-7364-7-22; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kersey P, 2000, BIOINFORMATICS, V16, P1048, DOI 10.1093/bioinformatics/16.11.1048; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kousted TM, 2014, THROMB HAEMOSTASIS, V111, P29, DOI 10.1160/TH13-04-0340; Kousted TM, 2012, ANDREASEN PAPROTEASE, P251; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Lee JJ, 2015, ONCOTARGET, V6, P37995, DOI 10.18632/oncotarget.6062; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Manza LL, 2005, PROTEOMICS, V5, P1742, DOI 10.1002/pmic.200401063; Maurer M, 2014, J PROTEOME RES, V13, P2830, DOI 10.1021/pr401270y; Maurer M, 2013, J PROTEOME RES, V12, P1040, DOI 10.1021/pr301009u; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Neesse A, 2007, PANCREATOLOGY, V7, P380, DOI 10.1159/000107400; Olsen R, 2005, ANALYST, V130, P941, DOI 10.1039/b419145e; Ostyn P, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0052-z; Pagliara V, 2014, BBA-MOL CELL RES, V1843, P2631, DOI 10.1016/j.bbamcr.2014.07.008; Pierard-Franchimont C, 2014, ONCOL REV, V8, P54, DOI 10.4081/oncol.2014.252; Raj A, 2008, NAT METHODS, V5, P877, DOI 10.1038/NMETH.1253; Rocken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rossignol P, 2004, J BIOL CHEM, V279, P10346, DOI 10.1074/jbc.M310964200; Scott C F, 1985, Trans Assoc Am Physicians, V98, P344; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Selzer-Plon J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-201; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Vaillant C, 2007, DEVELOPMENT, V134, P1745, DOI 10.1242/dev.02840; Vaillant C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124870; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wang K, 2015, J CANCER RES CLIN, V141, P805, DOI 10.1007/s00432-014-1858-1; Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wu QW, 2016, AM J TRANSL RES, V8, P1985; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xu DM, 2010, CANCER RES, V70, P6988, DOI 10.1158/0008-5472.CAN-10-0242; Yang SF, 2009, NUCL MED BIOL, V36, P313, DOI 10.1016/j.nucmedbio.2008.12.007; Zhou MY, 2006, INVEST OPHTH VIS SCI, V47, P2997, DOI 10.1167/iovs.06-0130	75	41	42	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					302	312		10.1038/onc.2017.341	http://dx.doi.org/10.1038/onc.2017.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925403	Green Published, hybrid			2022-12-28	WOS:000422753900003
J	Chandrasinghe, P; Cereser, B; Moorghen, M; Al Bakir, I; Tabassum, N; Hart, A; Stebbing, J; Warusavitarne, J				Chandrasinghe, P.; Cereser, B.; Moorghen, M.; Al Bakir, I.; Tabassum, N.; Hart, A.; Stebbing, J.; Warusavitarne, J.			Role of SMAD proteins in colitis-associated cancer: from known to the unknown	ONCOGENE			English	Review							INFLAMMATORY-BOWEL-DISEASE; GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; COLON-CANCER; ANTISENSE OLIGONUCLEOTIDE; CROHNS-DISEASE; T-CELLS; SELF-RENEWAL	Small mothers against decapentaplegic (SMAD) proteins are a family of signal transduction molecules in transforming growth factor beta (TGF beta) ligand pathways that have been found to have a key role in the pathogenesis of inflammatory bowel disease (IBD). Long standing IBD predisposes individuals to colitis-associated colorectal cancer (CAC), an entity that possess unique characteristics compared to hereditary and sporadic cancer. The ligands of the TGF beta super family along with SMADs have also been implicated in several aspects of colorectal cancer formation. SMAD proteins are shown to be involved in a number of potentially carcinogenic mechanisms such as altering gene transcription, controlling stem cell differentiation to causing epigenetic changes. Modulation of these proteins has emerged as a novel therapeutic intervention for IBD although its effect on carcinogenesis remains elusive. This account reviews available evidence linking SMAD proteins to CAC and explores the potential areas for future research in this area.	[Chandrasinghe, P.; Cereser, B.; Hart, A.; Stebbing, J.; Warusavitarne, J.] Imperial Coll London, Dept Surg & Canc, London, England; [Chandrasinghe, P.; Moorghen, M.; Al Bakir, I.; Hart, A.; Warusavitarne, J.] St Marks Hosp, Harrow, Middx, England; [Chandrasinghe, P.] Univ Kelaniya, Kelaniya, Sri Lanka; [Al Bakir, I.] Queen Mary Univ London, Barts Canc Inst, London, England	Imperial College London; Imperial College London; University Kelaniya; University of London; Queen Mary University London	Warusavitarne, J (corresponding author), St Marks Hosp, Dept Surg, Watford Rd, Harrow HA1 3UJ, Middx, England.	j.warusavitarne@nhs.net	hart, ailsa/AFO-1919-2022; Cereser, Biancastella/U-3709-2019	Chandrasinghe, Pramodh/0000-0002-3485-961X; Al Bakir, Ibrahim/0000-0001-8775-3459; Cereser, Biancastella/0000-0003-1243-1767; Stebbing, Justin/0000-0002-1117-6947	Medical Research Council [MR/P00122X/1] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; MRC [MR/P00122X/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; [Anonymous], 2002, GENE CHROMOSOME CANC, V35, P121; Atfi A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.126pe33; Aust DE, 2002, CANCER, V94, P1421, DOI 10.1002/cncr.10334; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Boirivant M, 2006, GASTROENTEROLOGY, V131, P1786, DOI 10.1053/j.gastro.2006.09.016; Boulay JL, 2003, INT J CANCER, V104, P446, DOI 10.1002/ijc.10908; BRENTNALL TA, 1994, GASTROENTEROLOGY, V107, P369, DOI 10.1016/0016-5085(94)90161-9; Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x; Choi CHR, 2015, AM J GASTROENTEROL, V110, P1022, DOI 10.1038/ajg.2015.65; Claessen MMH, 2010, CELL ONCOL, V32, P303, DOI 10.3233/CLO-2009-0503; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Damavand Behzad, 2015, Asian Pac J Cancer Prev, V16, P41; Davis H, 2016, CYTOKINE GROWTH F R, V27, P81, DOI 10.1016/j.cytogfr.2015.11.009; De Simone V, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.103; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Elston Rebecca, 2012, J Signal Transduct, V2012, P294097, DOI 10.1155/2012/294097; Fantini MC, 2009, GASTROENTEROLOGY, V136, P1308, DOI 10.1053/j.gastro.2008.12.053; Fernandes MG, 2016, STEM CELL REP, V6, P85, DOI 10.1016/j.stemcr.2015.11.012; Galvin KE, 2010, J BIOL CHEM, V285, P19747, DOI 10.1074/jbc.M109.077347; Garrity-Park MM, 2010, AM J GASTROENTEROL, V105, P1610, DOI 10.1038/ajg.2010.22; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Huang YS, 2016, ONCOTARGET, V7, P75561, DOI 10.18632/oncotarget.12285; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Hussain SP, 2000, CANCER RES, V60, P3333; Jess T, 2013, AM J GASTROENTEROL, V108, P1869, DOI 10.1038/ajg.2013.249; Kalo E, 2007, MOL CELL BIOL, V27, P8228, DOI 10.1128/MCB.00374-07; Kodach LL, 2008, CANCER, V112, P300, DOI 10.1002/cncr.23160; Lu JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14739; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marafini I, SMAD7 SUSTAINS INFLA; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Monteleone G, 2005, GASTROENTEROLOGY, V129, P1420, DOI 10.1053/j.gastro.2005.09.005; Monteleone G, 2015, NEW ENGL J MED, V372, P1104, DOI 10.1056/NEJMoa1407250; Monteleone G, 2012, MOL THER, V20, P870, DOI 10.1038/mt.2011.290; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Riggins GJ, 1997, CANCER RES, V57, P2578; Rizzo A, 2011, CANCER RES, V71, P7423, DOI 10.1158/0008-5472.CAN-11-1895; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Slattery ML, 2010, CANCER RES, V70, P1479, DOI 10.1158/0008-5472.CAN-08-1792; Stolfi C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.49; Stolfi C, 2013, INT J MOL SCI, V14, P23774, DOI 10.3390/ijms141223774; Thompson CL, 2009, CARCINOGENESIS, V30, P982, DOI 10.1093/carcin/bgp086; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Virchow R., 1863, CELLULAR PATHOLOGY B, P566; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wang H, 2017, BIOCHEM BIOPH RES CO, V485, P181, DOI 10.1016/j.bbrc.2017.02.049; Willenbucher RF, 1999, AM J PATHOL, V154, P1825, DOI 10.1016/S0002-9440(10)65438-7; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Yaeger R, 2016, GASTROENTEROLOGY, V151, P278, DOI 10.1053/j.gastro.2016.04.001; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523	66	19	20	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					1	7		10.1038/onc.2017.300	http://dx.doi.org/10.1038/onc.2017.300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869601	Green Submitted			2022-12-28	WOS:000422625000001
J	Park, JL; Lee, YS; Song, MJ; Hong, SH; Ahn, JH; Seo, EH; Shin, SP; Lee, SJ; Johnson, BH; Stampfer, MR; Kim, HP; Kim, SY; Lee, YS				Park, J-L; Lee, Y-S; Song, M-J; Hong, S-H; Ahn, J-H; Seo, E-H; Shin, S-P; Lee, S-J; Johnson, B. H.; Stampfer, M. R.; Kim, H-P; Kim, S-Y; Lee, Y. S.			Epigenetic regulation of RNA polymerase III transcription in early breast tumorigenesis	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; NONCODING RNA; C-MYC; GENOMIC BINDING; P53 FUNCTION; POL II; CANCER; ACTIVATION; CHROMATIN	RNA polymerase III (Pol III) transcribes medium-sized non-coding RNAs (collectively termed Pol III genes). Emerging diverse roles of Pol III genes suggest that individual Pol III genes are exquisitely regulated by transcription and epigenetic factors. Here we report global Pol III expression/methylation profiles and molecular mechanisms of Pol III regulation that have not been as extensively studied, using nc886 as a representative Pol III gene. In a human mammary epithelial cell system that recapitulates early breast tumorigenesis, the fraction of actively transcribed Pol III genes increases reaching a plateau during immortalization. Hyper-methylation of Pol III genes inhibits Pol III binding to DNA via inducing repressed chromatin and is a determinant for the Pol III repertoire. When Pol III genes are hypo-methylated, MYC amplifies their transcription, regardless of its recognition DNA motif. Thus, Pol III expression during tumorigenesis is delineated by methylation and magnified by MYC.	[Park, J-L; Seo, E-H; Kim, S-Y] KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea; [Park, J-L; Seo, E-H; Kim, S-Y] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Lee, Y-S; Hong, S-H] Natl Canc Ctr, Res Inst, Rare Canc Branch, Goyang Si, South Korea; [Song, M-J; Kim, H-P] Yonsei Univ, Dept Environm Med Biol, Coll Med, Seoul, South Korea; [Ahn, J-H] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea; [Ahn, J-H] Kyung Hee Univ, Dept Oriental Pharm, Seoul, South Korea; [Shin, S-P; Lee, S-J] Natl Canc Ctr, Res Inst, Immunotherapeut Branch, Goyang Si, South Korea; [Johnson, B. H.; Lee, Y. S.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Stampfer, M. R.] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA USA; [Kim, H-P] Yonsei Univ, Inst Trop Med, Coll Med, Seoul, South Korea; [Kim, H-P] Yonsei Univ, Brain Korea Plus Project Med Sci 21, Coll Med, Seoul, South Korea; [Lee, Y. S.] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); National Cancer Center - Korea (NCC); Yonsei University; Yonsei University Health System; Kyung Hee University; Kyung Hee University; National Cancer Center - Korea (NCC); University of Texas System; University of Texas Medical Branch Galveston; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; National Cancer Center - Korea (NCC)	Kim, HP; Kim, SY; Lee, YS (corresponding author), Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea.	kimhp@yuhs.ac; kimsy@kribb.re.kr; yslee@ncc.re.kr		Shin, Seung-Phil/0000-0003-4290-3067; Kim, Hyoung-Pyo/0000-0003-1441-8822	American Cancer Society [RSG-12-187-01-RMC]; Ministry of Science, ICT and Future Planning [NRF-2012M3A9D1054670, NRF-2014M3C9A3068554]; KRIBB Research Initiative; National Research Foundation of Korea [2016R1A2B4014183, 2017M3C9A5029978]; National Cancer Center (Korea) [1610090]; US Department of Energy [DE-AC02-05CH11231]	American Cancer Society(American Cancer Society); Ministry of Science, ICT and Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); KRIBB Research Initiative; National Research Foundation of Korea(National Research Foundation of Korea); National Cancer Center (Korea); US Department of Energy(United States Department of Energy (DOE))	This work was supported by a Research Scholar Grant, RSG-12-187-01-RMC from the American Cancer Society to YSL; grants NRF-2012M3A9D1054670 and NRF-2014M3C9A3068554 funded by the Ministry of Science, ICT and Future Planning and KRIBB Research Initiative to S-YK; a grant 2016R1A2B4014183 and 2017M3C9A5029978 funded by National Research Foundation of Korea to H-PK; National Cancer Center (Korea) intramural project # 1610090 to Y-SL; and US Department of Energy under Contract No. DE-AC02-05CH11231 to MRS.	Alla RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085648; Banati F, 2008, FEBS LETT, V582, P705, DOI 10.1016/j.febslet.2008.01.042; Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; BESSER D, 1990, FEBS LETT, V269, P358, DOI 10.1016/0014-5793(90)81193-R; Bhargava P, 2013, BBA-GENE REGUL MECH, V1829, P1015, DOI 10.1016/j.bbagrm.2013.05.005; Canella D, 2012, GENOME RES, V22, P666, DOI 10.1101/gr.130286.111; Canella D, 2010, GENOME RES, V20, P710, DOI 10.1101/gr.101337.109; Cao JZ, 2013, CANCER RES, V73, P3326, DOI 10.1158/0008-5472.CAN-12-3055; Carriere L, 2012, NUCLEIC ACIDS RES, V40, P270, DOI 10.1093/nar/gkr737; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Fu Yu, 2015, Genomics & Informatics, V13, P94, DOI 10.5808/GI.2015.13.4.94; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hines WC, 2016, BREAST CANCER RES TR, V155, P37, DOI 10.1007/s10549-015-3649-z; Hu SS, 2012, INT J BIOCHEM CELL B, V44, P1847, DOI 10.1016/j.biocel.2012.07.013; JUTTERMANN R, 1991, J VIROL, V65, P1735; Kadauke S, 2009, BBA-GENE REGUL MECH, V1789, P17, DOI 10.1016/j.bbagrm.2008.07.002; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; LaBarge MA, 2013, JOVE-J VIS EXP, DOI 10.3791/50011; Lee EK, 2016, ONCOTARGET, V7, P75000, DOI 10.18632/oncotarget.11852; Lee HS, 2014, ONCOTARGET, V5, P3472, DOI 10.18632/oncotarget.1927; Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013; Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111; Lee KS, 2014, ONCOTARGET, V5, P3944, DOI 10.18632/oncotarget.2047; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663; Park JL, 2017, EPIGENOMICS-UK, V9, P171, DOI 10.2217/epi-2016-0108; Park K, 2012, J LEUKOCYTE BIOL, V91, P245, DOI 10.1189/jlb.0111020; Romanelli V, 2014, EPIGENETICS-US, V9, P783, DOI 10.4161/epi.28323; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601; Silver MJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0660-y; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Stampfer MR, 2013, CELL MOL BIOL BREAST, P323, DOI [10.1007/978-1-62703-634-4_15, DOI 10.1007/978-1-62703-634-4_15]; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Varshney D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7569; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Xie HH, 2010, P NATL ACAD SCI USA, V107, P6952, DOI 10.1073/pnas.0913836107	60	16	16	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6793	6804		10.1038/onc.2017.285	http://dx.doi.org/10.1038/onc.2017.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846112	Green Published			2022-12-28	WOS:000417282500005
J	Ding, D; Huang, H; Jiang, W; Yu, W; Zhu, H; Liu, J; Saiyin, H; Wu, J; Huang, H; Jiang, S; Yu, L				Ding, D.; Huang, H.; Jiang, W.; Yu, W.; Zhu, H.; Liu, J.; Saiyin, H.; Wu, J.; Huang, H.; Jiang, S.; Yu, L.			Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway (vol 36, pg 6691, 2017)	ONCOGENE			English	Correction																		Ding D, 2017, ONCOGENE, V36, P6691, DOI 10.1038/onc.2017.230	1	2	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6747	6748		10.1038/onc.2017.366	http://dx.doi.org/10.1038/onc.2017.366			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	29188822	Bronze			2022-12-28	WOS:000416780800009
J	Yan, D; Kowal, J; Akkari, L; Schuhmacher, AJ; Huse, JT; West, BL; Joyce, JA				Yan, D.; Kowal, J.; Akkari, L.; Schuhmacher, A. J.; Huse, J. T.; West, B. L.; Joyce, J. A.			Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas	ONCOGENE			English	Article							KINASE INHIBITOR; TUMOR-GROWTH; GLIOBLASTOMA; CONSORTIUM; RESPONSES; BLOCKADE; CHIR-258; CANCER	Glioblastomas represent the most aggressive glioma grade and are associated with a poor patient prognosis. The current standard of care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 months, underscoring the importance of developing effective new therapeutic strategies. Among the challenges in treating glioblastomas are primary resistance and the rapid emergence of recurrent disease, which can result from tumor cell-intrinsic mechanisms in addition to tumor microenvironment (TME)-mediated extrinsic resistance. Using a PDGF-B-driven proneural glioma mouse model, we assessed a panel of tyrosine kinase inhibitors with different selectivity profiles. We found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks glioma progression, markedly suppresses tumor cell proliferation and reduces tumor grade. By contrast, the multi-targeted tyrosine kinase inhibitors dovitinib and vatalanib, which directly target tumor cells, exert minimal anti-tumoral effects in vivo, despite killing glioma cells in vitro, suggesting a TME-mediated resistance mechanism may be involved. Interestingly, PLX3397 interferes with tumor-mediated education of macrophages and consequently restores the sensitivity of glioma cells to tyrosine kinase inhibitors in vivo in preclinical combination trials. Our findings thus demonstrate that microenvironmental alteration by CSF-1R blockade renders tumor cells more susceptible to receptor tyrosine kinase inhibition in a preclinical glioblastoma model, which may have important translational relevance.	[Yan, D.; Akkari, L.; Schuhmacher, A. J.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Cancer Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA; [Kowal, J.; Akkari, L.; Joyce, J. A.] Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; [Kowal, J.; Akkari, L.; Joyce, J. A.] Univ Lausanne, Dept Oncol, CH-1066 Lausanne, Switzerland; [Huse, J. T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Huse, J. T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [West, B. L.] Plexxikon Inc, Berkeley, CA USA	Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Plexxikon	Joyce, JA (corresponding author), Univ Lausanne, Dept Oncol, CH-1066 Lausanne, Switzerland.	johanna@joycelab.org	Schuhmacher, Alberto J./R-6765-2019	Schuhmacher, Alberto J./0000-0002-0136-1049; West, Brian/0000-0002-5320-3691; Akkari, Leila/0000-0001-5479-641X; Kowal, Joanna/0000-0001-7849-6040	US National Cancer Institute (NCI) [R01CA181355]; Swiss Cancer League [KFS 3990-08-2016]; Ludwig Institute for Cancer Research; NCI Support Grant [P30 CA008748]; American Brain Tumor Association; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA181355] Funding Source: NIH RePORTER	US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss Cancer League; Ludwig Institute for Cancer Research; NCI Support Grant; American Brain Tumor Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Florian Klemm and all members of the Joyce laboratory for insightful comments and experimental advice. We are grateful to Kenishana Simpson, Xiaoping Chen and Nisarg Shah for excellent technical support. We thank Dr Eric Holland for scientific discussion, and for generously providing the Nestin-Tv-a Ink4a/Arf<SUP>-/-</SUP> mouse line. This research was supported by the US National Cancer Institute (NCI) (R01CA181355, JAJ), the Swiss Cancer League (KFS 3990-08-2016, JAJ), the Ludwig Institute for Cancer Research (JAJ), NCI Support Grant for the MSKCC core facilities used (P30 CA008748), and the American Brain Tumor Association (LA).	Agarwal S, 2012, MOL CANCER THER, V11, P2183, DOI 10.1158/1535-7163.MCT-12-0552; Beier D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-128; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Geng L, 2006, INT J RADIAT ONCOL, V64, P263, DOI 10.1016/j.ijrobp.2005.08.025; Hallett Penelope J, 2008, Curr Protoc Neurosci, VChapter 1, DOI 10.1002/0471142301.ns0116s42; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Kennedy BC, 2013, J ONCOL, V2013, DOI 10.1155/2013/486912; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Lee SH, 2005, CLIN CANCER RES, V11, P3633, DOI 10.1158/1078-0432.CCR-04-2129; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mellinghoff IK, 2012, CURR TOP MICROBIOL, V355, P135, DOI 10.1007/82_2011_178; Paul Indranil, 2013, Genes Cancer, V4, P427, DOI 10.1177/1947601913503341; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Reardon DA, 2014, NEURO-ONCOLOGY, V16, P1441, DOI 10.1093/neuonc/nou212; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Schafer N, 2016, J CANCER RES CLIN, V142, P1581, DOI 10.1007/s00432-016-2161-0; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tap WD, 2015, NEW ENGL J MED, V373, P428, DOI 10.1056/NEJMoa1411366; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Uhrbom L, 2004, NAT MED, V10, P1257, DOI 10.1038/nm1120; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wen PY, 2006, CLIN CANCER RES, V12, P4899, DOI 10.1158/1078-0432.CCR-06-0773; Wood JM, 2000, CANCER RES, V60, P2178; Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120	38	117	118	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6049	6058		10.1038/onc.2017.261	http://dx.doi.org/10.1038/onc.2017.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28759044	Green Published, hybrid			2022-12-28	WOS:000413841400013
J	Nakayama, M; Sakai, E; Echizen, K; Yamada, Y; Oshima, H; Han, TS; Ohki, R; Fujii, S; Ochiai, A; Robine, S; Voon, DC; Tanaka, T; Taketo, MM; Oshima, M				Nakayama, M.; Sakai, E.; Echizen, K.; Yamada, Y.; Oshima, H.; Han, T-S; Ohki, R.; Fujii, S.; Ochiai, A.; Robine, S.; Voon, D. C.; Tanaka, T.; Taketo, M. M.; Oshima, M.			Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation	ONCOGENE			English	Article							LI-FRAUMENI-SYNDROME; STEM-CELLS; COLORECTAL-CANCER; COLON-CANCER; PANCREATIC-CANCER; MOUSE MODEL; GAIN; EXPRESSION; GROWTH; MICROENVIRONMENT	Tumor suppressor TP53 is frequently mutated in colorectal cancer (CRC), and most mutations are missense type. Although gain-offunctions by mutant p53 have been demonstrated experimentally, the precise mechanism for malignant progression in in vivo tumors remains unsolved. We generated Apc(Delta 716) Trp53(LSL_R270H) villin-CreER compound mice, in which mutant p53(R270H) was expressed in the intestinal epithelia upon tamoxifen treatment, and examined the intestinal tumor phenotypes and tumor-derived organoids. Mutant Trp53(R270H), but not Trp53-null mutation accelerated submucosal invasion with generation of desmoplastic microenvironment. The nuclear accumulation of p53 was evident in Apc(Delta 716) Trp53(R270H/R270H) homozygous tumors like human CRC. Although p53 was distributed to the cytoplasm in Apc(Delta 716) Trp53(+/R270H) heterozygous tumors, it accumulated in the nuclei at the invasion front, suggesting a regulation mechanism for p53 localization by the microenvironment. Importantly, mutant p53 induced drastic morphological changes in the tumor organoids to complex glandular structures, which was associated with the acquisition of invasiveness. Consistently, the branching scores of human CRC that carry TP53 mutations at codon 273 significantly increased in comparison with those of TP53 wild-type tumors. Moreover, allografted Apc(Delta 716) Trp53(R270H/R270H) organoid tumors showed a malignant histology with an increased number of myofibroblasts in the stroma. These results indicate that nuclear-accumulated mutant p53(R270H) induces malignant progression of intestinal tumors through complex tumor gland formation and acquisition of invasiveness. Furthermore, RNA sequencing analyses revealed global gene upregulation by mutant p53(R270H), which was associated with the activation of inflammatory and innate immune pathways. Accordingly, it is possible that mutant p53(R270H) induces CRC progression, not only by a cell intrinsic mechanism, but also by the generation or activation of the microenvironment, which may synergistically contribute to the acceleration of submucosal invasion. Therefore, the present study indicates that nuclearaccumulated mutant p53(R270H) is a potential therapeutic target for the treatment of advanced CRCs.	[Nakayama, M.; Sakai, E.; Echizen, K.; Oshima, H.; Han, T-S; Voon, D. C.; Oshima, M.] Kanazawa Univ, Div Genet, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan; [Echizen, K.; Han, T-S; Tanaka, T.; Oshima, M.] Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo, Japan; [Yamada, Y.] Kanazawa Univ, Inst Sci & Engn, Kanazawa, Ishikawa, Japan; [Ohki, R.] Natl Canc Ctr, Div Rare Canc Res, Tokyo, Japan; [Fujii, S.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, Chiba, Japan; [Ochiai, A.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Chiba, Japan; [Robine, S.] Inst Curie, Equipe Morphogenese & Signalisat Cellulaires, Paris, France; [Voon, D. C.] Kanazawa Univ, Inst Frontier Sci Initiat, Canc Res Core, Kanazawa, Ishikawa, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan; [Taketo, M. M.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto, Japan; [Taketo, M. M.] Kanazawa Univ, Canc Res Inst, Div Expt Therapeut, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Kanazawa University; Chiba University; Kyoto University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Div Genet, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008; Tanaka, Tomoaki/0000-0002-9761-1750; yamada, yoichi/0000-0001-6103-0658; Voon, Dominic Chih-Cheng/0000-0002-2963-9305	AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan [15H02362, 26430110]	AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Yoshie Jomen, Ayako Tsuda and Manami Watanabe for technical assistance. Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics. This work was supported by AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan, Grants-in-Aid for Scientific Research (A) (#15H02362) tand (C) (26430110) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Amoyel M, 2015, EMBO J, V34, P1287, DOI 10.15252/embj.201591541; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fujii S, 2015, ONCOGENE, V34, P4834, DOI 10.1038/onc.2014.402; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Liebig B, 2005, CANCER LETT, V223, P159, DOI 10.1016/j.canlet.2004.10.013; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oshima H, 2015, CANCER RES, V75, P766, DOI 10.1158/0008-5472.CAN-14-2036; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pfister NT, 2015, GENE DEV, V29, P1298, DOI 10.1101/gad.263202.115; Salahudeen AA, 2015, NAT MED, V21, P215, DOI 10.1038/nm.3818; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	42	35	36	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5885	5896		10.1038/onc.2017.194	http://dx.doi.org/10.1038/onc.2017.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628120	hybrid, Green Published			2022-12-28	WOS:000413292900010
J	Vidal, E; Sayols, S; Moran, S; Guillaumet-Adkins, A; Schroeder, MP; Royo, R; Orozco, M; Gut, M; Gut, I; Lopez-Bigas, N; Heyn, H; Esteller, M				Vidal, E.; Sayols, S.; Moran, S.; Guillaumet-Adkins, A.; Schroeder, M. P.; Royo, R.; Orozco, M.; Gut, M.; Gut, I.; Lopez-Bigas, N.; Heyn, H.; Esteller, M.			A DNA methylation map of human cancer at single base-pair resolution	ONCOGENE			English	Article							EPIGENETIC LANDSCAPE; HYPOMETHYLATION; METHYLOME; REVEALS; SITES	Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination.	[Vidal, E.; Sayols, S.; Moran, S.; Heyn, H.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Vidal, E.] BIST, Ctr Genom Regulat CRG, Barcelona, Spain; [Vidal, E.; Guillaumet-Adkins, A.; Gut, M.; Gut, I.; Heyn, H.] UPF, Barcelona, Spain; [Guillaumet-Adkins, A.; Gut, M.; Gut, I.; Heyn, H.] BIST, Ctr Genom Regulat CRG, CNAG CRG, Barcelona, Spain; [Schroeder, M. P.; Lopez-Bigas, N.] IMIM Hosp, Med Res Inst, Res Program Biomed Informat, Biomed Genom Lab, Barcelona, Spain; [Schroeder, M. P.; Lopez-Bigas, N.] Univ Pompeu Fabra, Barcelona, Spain; [Royo, R.; Orozco, M.] Barcelona Inst Sci & Technol, IRB Barcelona, Joint IRB BSC Program Computat Biol, Barcelona, Spain; [Orozco, M.] IRB Barcelona, Barcelona, Spain; [Orozco, M.] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain; [Lopez-Bigas, N.; Esteller, M.] ICREA, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; ICREA; University of Barcelona	Heyn, H; Esteller, M (corresponding author), Hosp Llobregat, Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Av Gran Via Hosp 199-203, Barcelona 08908, Catalonia, Spain.	hheyn@idibell.cat; mesteller@idibell.cat	Gut, Ivo/ABF-3188-2020; Lopez-Bigas, Nuria/F-6193-2011; Esteller, Manel/L-5956-2014; Vidal, Enrique/R-5593-2019; Moran, Sebastian/G-5293-2013	Gut, Ivo/0000-0001-7219-632X; Lopez-Bigas, Nuria/0000-0003-4925-8988; Esteller, Manel/0000-0003-4490-6093; Vidal, Enrique/0000-0002-4217-1807; Moran, Sebastian/0000-0003-4192-8983; Sayols, Sergi/0000-0002-3877-4170; Orozco Lopez, Modesto/0000-0002-8608-3278; Schroeder, Michael P/0000-0002-7563-509X; Heyn, Holger/0000-0002-3276-1889	Institute of Health Carlos III ISCIII Project [PI11/00321]; Spanish Cancer Research Network (RTICC) [RD12/0036/0039]; European Development Regional Fund; 'A way to achieve Europe' ERDF [SAF2014-55000-R]; Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR [2014SGR633]; Health and Science Departments of the Catalan government (Generalitat de Catalunya); European Community's Seventh Framework Program (FP7) [HEALTH-F5-2011-282510 - BLUEPRINT]	Institute of Health Carlos III ISCIII Project; Spanish Cancer Research Network (RTICC); European Development Regional Fund(European Commission); 'A way to achieve Europe' ERDF; Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation(Foundation CELLEX); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Health and Science Departments of the Catalan government (Generalitat de Catalunya); European Community's Seventh Framework Program (FP7)	This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, 'A way to achieve Europe' ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 - BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher. ME and NLB are ICREA Research Professors.	Agirre X, 2015, GENOME RES, V25, P478, DOI 10.1101/gr.180240.114; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Burger L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt599; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Court F, 2014, GENOME RES, V24, P554, DOI 10.1101/gr.164913.113; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265; Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r83, 10.1186/gb-2012-13-10-R83]; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Heyn H, 2013, CANCER CELL, V23, P563, DOI 10.1016/j.ccr.2013.04.028; Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109; Heyn H, 2012, EPIGENETICS-US, V7, P542, DOI 10.4161/epi.20523; Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kretzmer H, 2015, NAT GENET, V47, P1316, DOI 10.1038/ng.3413; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443; Kumar N, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-21; Landau DA, 2014, CANCER CELL, V26, P813, DOI 10.1016/j.ccell.2014.10.012; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li H, 2011, BIOINFORMATICS, V27, P718, DOI 10.1093/bioinformatics/btq671; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Molaro A, 2011, CELL, V146, P1028, DOI 10.1016/j.cell.2011.08.016; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Pujadas E, 2012, CELL, V148, P1123, DOI 10.1016/j.cell.2012.02.045; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schlesinger F, 2013, GENOME RES, V23, P1601, DOI 10.1101/gr.157271.113; Schroeder DI, 2013, P NATL ACAD SCI USA, V110, P6037, DOI 10.1073/pnas.1215145110; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433	49	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5648	5657		10.1038/onc.2017.176	http://dx.doi.org/10.1038/onc.2017.176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581523	hybrid, Green Published			2022-12-28	WOS:000412293600009
J	Ouyang, H; Gore, J; Deitz, S; Korc, M				Ouyang, H.; Gore, J.; Deitz, S.; Korc, M.			microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions (vol 33, pg 4664, 2014)	ONCOGENE			English	Correction																		Ouyang H, 2014, ONCOGENE, V33, P4664, DOI 10.1038/onc.2013.405	1	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4952	4952		10.1038/onc.2017.190	http://dx.doi.org/10.1038/onc.2017.190			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28604742	Green Published, hybrid			2022-12-28	WOS:000408234400012
J	Hernandez-Perez, S; Cabrera, E; Salido, E; Lim, M; Reid, L; Lakhani, SR; Khanna, KK; Saunus, JM; Freire, R				Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Lim, M.; Reid, L.; Lakhani, S. R.; Khanna, K. K.; Saunus, J. M.; Freire, R.			DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer (vol 36, pg 4802, 2017)	ONCOGENE			English	Correction													Cabrera, Elisa/GPX-3455-2022; Freire, Raimundo/Q-7660-2019	Freire, Raimundo/0000-0003-4473-8894				Cabrera E, 2017, ONCOGENE, V36, P678, DOI 10.1038/onc.2016.239	1	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4817	4817		10.1038/onc.2017.220	http://dx.doi.org/10.1038/onc.2017.220			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28650472	Bronze			2022-12-28	WOS:000407702400014
J	Chen, L; Zhang, S; Wu, J; Cui, J; Zhong, L; Zeng, L; Ge, S				Chen, L.; Zhang, S.; Wu, J.; Cui, J.; Zhong, L.; Zeng, L.; Ge, S.			RETRACTED: circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (Retracted article. See vol. 38, pg. 5750, 2019)	ONCOGENE			English	Article; Retracted Publication							LONG NONCODING RNA; SQUAMOUS-CELL CARCINOMA; CIRCULAR RNAS; INDEPENDENT FUNCTION; IN-VIVO; MICRORNA; EXPRESSION; IDENTIFICATION; TUMORIGENESIS; LNCRNA	Circular RNAs (circRNAs) represent a class of non-coding RNAs that are widely expressed in mammals. However, it is largely unknown about the function of human circRNAs and the roles of circRNAs in human oral squamous cell carcinomas (OSCC). Here we performed a comprehensive study of circRNAs in human OSCC using circRNA and mRNA microarrays, and identified many circRNAs that are differentially expressed between OSCC tissue and paired non-cancerous matched tissue. We further found a circRNA termed circRNA_100290 that served as a critical regulator in OSCC development. We discovered that circRNA_100290 was upregulated and co-expressed with CDK6 in OSCC tissue. Knockdown of circRNA_100290 decreased expression of CDK6 and inhibited proliferation of OSCC cell lines in vitro and in vivo. Via luciferase reporter assays, circRNA_100290 was observed to directly bind to miR-29 family members. Further EGFP/ RFP reporter assays showed that CDK6 was the direct target of miR-29b. Taken together, we conclude that circRNA_100290 may function as a competing endogenous RNA to regulate CDK6 expression through sponging up miR-29b family members. Taken together, it indicates that circRNAs may exert regulatory functions in OSCC and may be a potential target for OSCC therapy.	[Chen, L.; Zhang, S.; Zhong, L.; Zeng, L.; Ge, S.] Cent S Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha 410011, Hunan, Peoples R China; [Wu, J.] New Dist Longhua Shenzhen, Peoples Hosp, Dept Stomatol, Shenzhen, Peoples R China; [Cui, J.] Sichuan Univ, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China	Central South University; Sichuan University	Chen, L (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha 410011, Hunan, Peoples R China.	drlc2011@163.com			National Natural Science Foundation of China [81500832]; High Level Talent Program of Central South University [502035026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High Level Talent Program of Central South University	We thank the members in the department of pathology of the Second Xiangya Hospital for their excellent assistance, and we particularly thank the patients involved in this study. This study was supported by National Natural Science Foundation of China (Contract grant number: 81500832) and High Level Talent Program of Central South University (Contract grant number: 502035026). This work was supported by National Natural Science Foundation of China (Contract grant number: 81500832) and High Level Talent Program of Central South University (Contract grant number: 502035026).	ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; Beenken SW, 2003, CURRENT SURG DIAGNOS, P282; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Ding DP, 2011, CARCINOGENESIS, V32, P1025, DOI 10.1093/carcin/bgr078; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fang ZY, 2014, OR SURG OR MED OR PA, V117, P89, DOI 10.1016/j.oooo.2013.09.007; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gomes CC, 2008, ORAL ONCOL, V44, P910, DOI 10.1016/j.oraloncology.2008.01.002; Guo G, 2015, ONCOGENE, V34, P1768, DOI 10.1038/onc.2014.131; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; HSU MT, 1979, NATURE, V280, P339, DOI 10.1038/280339a0; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Jia LF, 2014, INT J CANCER, V135, P2282, DOI 10.1002/ijc.28667; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kollmann K, 2013, CANCER CELL, V24, P167, DOI 10.1016/j.ccr.2013.07.012; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; La Vecchia C, 2004, ORAL ONCOL, V40, P433, DOI 10.1016/j.oraloncology.2003.09.013; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lasda E, 2014, RNA, V20, P1829, DOI 10.1261/rna.047126.114; Lee DY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013599; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Lin SC, 2010, ORAL ONCOL, V46, P204, DOI 10.1016/j.oraloncology.2009.12.005; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma MZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-156; Massano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Reis PP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-238; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Singh SK, 2008, FEBS J, V275, P4929, DOI 10.1111/j.1742-4658.2008.06624.x; Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041; Tang HK, 2013, MOL MED REP, V7, P761, DOI 10.3892/mmr.2012.1254; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	61	320	337	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4551	4561		10.1038/onc.2017.89	http://dx.doi.org/10.1038/onc.2017.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368401	hybrid, Green Published			2022-12-28	WOS:000407246200003
J	Deng, L; Tang, J; Yang, H; Cheng, C; Lu, S; Jiang, R; Sun, B				Deng, L.; Tang, J.; Yang, H.; Cheng, C.; Lu, S.; Jiang, R.; Sun, B.			MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; DOWN-REGULATION; BREAST-CANCER; C-MYC; EXPRESSION; CELLS; BIOMARKERS; EFFECTOR; PROMOTES; GENE	MTA1 is a metastasis-associated protein, which is essential to epithelial-to-mesenchymal transition (EMT). However, information concerning its up-and downstream regulation is rare. We investigated its upstream regulation and downstream effector in human hepatocellular carcinoma ( HCC). In total, 94 paired HCC and adjacent tissue samples were involved in the study, and the results indicated that decreased miR-30e levels were associated with increased MTA1 levels in human HCC. miR-30e exerted its regulation of MTA1 transcription by binding to its 3'-untranslated region, and was negatively associated with EMT. Furthermore, significantly higher expression of MTA1 was associated with overexpression of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ErbB2) in human HCC, and MTA1 can promote transcription of ErbB2 by binding with histone deacetylase 2 (HDAC2) and acting as a promoter. The EMT promotion effect caused by MTA1 largely depended on ErbB2, and reducing the activity of ErbB2 can significantly attenuate EMT promotion by causing overexpression of MTA1 both in vitro and in vivo. In general, downregulation of miR-30e can increase levels of MTA1 in human HCC, and furthermore promote cell invasion and metastasis by promoting ErbB2.	[Deng, L.; Tang, J.; Jiang, R.; Sun, B.] Nanjing Med Univ, Dept Liver Surg, Minist Hlth, Key Lab Living Donor Liver Transplantat,Affiliate, Nanjing, Jiangsu, Peoples R China; [Yang, H.] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Jiangsu, Peoples R China; [Cheng, C.; Lu, S.] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Jiang, R; Sun, B (corresponding author), Nanjing Med Univ, Key Lab Living Donor Liver Transplantat, Minist Hlth, Dept Liver Surg,Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Jiang, R; Sun, B (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	Jiangrq@njmu.edu.cn; sunbc@njmu.edu.cn	Jiang, Runqiu/T-8844-2018	Jiang, Runqiu/0000-0003-2720-1366	National Natural Science Foundation [81201880, 81201528, 81572370, 81430062]; Six talent peaks project in Jiangsu Province [2013-wsw-20]; National Key Research and Development Program of China [2016YFC0905900]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Six talent peaks project in Jiangsu Province; National Key Research and Development Program of China	This work was supported by grants from the National Natural Science Foundation (81201880 to LD, 81201528, 81572370 to RJ and 81430062 to BS), Six talent peaks project in Jiangsu Province (2013-wsw-20 to RJ). National Key Research and Development Program of China (2016YFC0905900 to BS).	Ahmad A, 2012, MOL CANCER THER, V11, P2193, DOI 10.1158/1535-7163.MCT-12-0232-T; Bhattacharya S, 2016, AM J PATHOL, V186, P242, DOI 10.1016/j.ajpath.2015.10.003; Bruning A, 2014, CANCER METAST REV, V33, P943, DOI 10.1007/s10555-014-9520-6; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Deng L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0248-0; Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006; Hamatsu T, 2003, ONCOL REP, V10, P599; Hayes CN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030280; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Levenson AS, 2014, CANCER METAST REV, V33, P929, DOI 10.1007/s10555-014-9519-z; Li D.S., 2012, INT J DISTRIB SENS N, V2012, P1, DOI DOI 10.1007/S11661-012-1269-3; Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010; Nair SS, 2011, HEPATOLOGY, V54, P1388, DOI 10.1002/hep.24518; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Ryu SH, 2008, HEPATOLOGY, V47, P929, DOI 10.1002/hep.22124; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; TOH Y, 1994, J BIOL CHEM, V269, P22958; van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16; Wang L., 2014, DISCRETE DYN NAT SOC, V2014, P1, DOI DOI 10.1002/ASL2.454; Wang YR, 2016, HEPATOL RES, V46, P89, DOI 10.1111/hepr.12571; Xia Y, 2013, CELL PHYSIOL BIOCHEM, V32, P476, DOI 10.1159/000354452; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207	26	29	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3976	3985		10.1038/onc.2016.491	http://dx.doi.org/10.1038/onc.2016.491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288133				2022-12-28	WOS:000405379900004
J	Azoitei, N; Cobbaut, M; Becher, A; Van Lint, J; Seufferlein, T				Azoitei, Ninel; Cobbaut, Mathias; Becher, Alexander; Van Lint, Johan; Seufferlein, Thomas			Protein kinase D2: a versatile player in cancer biology	ONCOGENE			English	Review							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; CHROMOGRANIN-A SECRETION; D-DEPENDENT ACTIVATION; D PKD ACTIVATION; GROWTH-FACTOR-I; OXIDATIVE STRESS; TUMOR-GROWTH; TNF-ALPHA; MATRIX METALLOPROTEINASES	Protein kinase D2 (PKD2) is a serine/threonine kinase that belongs to the PKD family of calcium-calmodulin kinases, which comprises three isoforms: PKD1, PKD2, and PKD3. PKD2 is activated by many stimuli including growth factors, phorbol esters, and G-protein-coupled receptor agonists. PKD2 participation to uncontrolled growth, survival, neovascularization, metastasis, and invasion has been documented in various tumor types including pancreatic, colorectal, gastric, hepatic, lung, prostate, and breast cancer, as well as glioma multiforme and leukemia. This review discusses the versatile functions of PKD2 from the perspective of cancer hallmarks as described by Hanahan and Weinberg. The PKD2 status, signaling pathways affected in different tumor types and the molecular mechanisms that lead to tumorigenesis and tumor progression are presented. The latest developments of small-molecule inhibitors selective for PKD/PKD2, as well as the need for further chemotherapies that prevent, slow down, or eliminate tumors are also discussed in this review.	[Azoitei, Ninel; Becher, Alexander; Seufferlein, Thomas] Univ Ulm, Ctr Internal Med 1, Ulm, Germany; [Cobbaut, Mathias; Van Lint, Johan] Katholieke Univ Leuven, Lab Prot Phosphorylat & Prote, Dept Cellular & Mol Med, Leuven Canc Inst, Leuven, Belgium	Ulm University; KU Leuven	Azoitei, N (corresponding author), Univ Ulm, Ctr Internal Med 1, Ulm, Germany.	ninel.azoitei@uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Van Lint, Johan/P-9073-2019	Becher, Alexander/0000-0003-1552-1581; Cobbaut, Mathias/0000-0003-0279-0336; Van Lint, Johan/0000-0002-0275-571X	German Research Foundation [AZ.96/1-1, AZ.96/1-3, SE.676/10-1]; German Cancer Aid [109373]; LUNGTARGET [259770]; IWT - Agentschap voor Innovatie door Wetenschap en Technologie	German Research Foundation(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); LUNGTARGET; IWT - Agentschap voor Innovatie door Wetenschap en Technologie(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	This work was supported by the German Research Foundation (grants AZ.96/1-1 and AZ.96/1-3 to NA, grant SE.676/10-1 to TS), the German Cancer Aid (grant 109373 to TS), FP7 grant 259770 - LUNGTARGET (to JVL and TS) and IWT - Agentschap voor Innovatie door Wetenschap en Technologie (to MC).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Aicart-Ramos C, 2016, J BIOL CHEM, V291, P23516, DOI 10.1074/jbc.M116.735399; Aikawa, 2003, J CELL BIOL, V16, P647; Alpsoy A, 2015, TUMOR BIOL, V36, P4417, DOI 10.1007/s13277-015-3081-3; Anel AMD, 2005, J CELL BIOL, V169, P83, DOI 10.1083/jcb.200412089; Armacki M, 2014, ONCOGENE, V33, P1167, DOI 10.1038/onc.2013.43; Auer A, 2005, MOL BIOL CELL, V16, P4375, DOI 10.1091/mbc.E05-03-0251; Avkiran M, 2008, CIRC RES, V102, P157, DOI 10.1161/CIRCRESAHA.107.168211; Azoitei N, 2014, CANCER RES, V74, P7125, DOI 10.1158/0008-5472.CAN-14-1017; Azoitei N, 2011, NEURO-ONCOLOGY, V13, P710, DOI 10.1093/neuonc/nor084; Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernhart E, 2014, NEURO-ONCOLOGY, V16, P933, DOI 10.1093/neuonc/not303; Bernhart E, 2013, EXP CELL RES, V319, P2037, DOI 10.1016/j.yexcr.2013.03.029; Biswas MHU, 2010, CANCER RES, V70, P2095, DOI 10.1158/0008-5472.CAN-09-4155; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Borges S, 2015, MOL CANCER THER, V14, P1306, DOI 10.1158/1535-7163.MCT-14-0945; Bossard C, 2007, J CELL BIOL, V179, P1123, DOI 10.1083/jcb.200703166; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Chen J, 2012, IMMUNOBIOLOGY, V217, P385, DOI 10.1016/j.imbio.2011.10.016; Chen J, 2008, CANCER RES, V68, P3844, DOI 10.1158/0008-5472.CAN-07-5156; Chen J, 2011, CARCINOGENESIS, V32, P1198, DOI 10.1093/carcin/bgr113; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Choi JW, 2004, CANCER RES, V64, P35, DOI 10.1158/0008-5472.CAN-03-0145; Chouaib S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00021; Cobbaut M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00800-w; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Culver C, 2010, MOL CELL BIOL, V30, P4901, DOI 10.1128/MCB.00409-10; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Donaldson JG, 2005, BIOCHEM SOC T, V33, P639, DOI 10.1042/BST0330639; Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Durand N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020020; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eiseler T, 2016, J BIOL CHEM, V291, P462, DOI 10.1074/jbc.M115.673582; Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999; Eiseler T, 2010, J BIOL CHEM, V285, P18672, DOI 10.1074/jbc.M109.093880; Eiseler T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2232; Eisenberg-Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212; Evans IM, 2010, BIOCHEM J, V429, P565, DOI 10.1042/BJ20100578; Fanelli MF, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.4_suppl.21; Fielitz J, 2008, P NATL ACAD SCI USA, V105, P3059, DOI 10.1073/pnas.0712265105; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fugmann T, 2007, J CELL BIOL, V178, P15, DOI 10.1083/jcb.200612017; Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964; Gamber GG, 2011, BIOORG MED CHEM LETT, V21, P1447, DOI 10.1016/j.bmcl.2011.01.014; Geng J, 2009, BIOCHEM BIOPH RES CO, V388, P517, DOI 10.1016/j.bbrc.2009.08.025; George Kara M, 2011, Pharmaceutics, V3, P186, DOI 10.3390/pharmaceutics3020186; Goginashvili A, 2015, SCIENCE, V347, P878, DOI 10.1126/science.aaa2628; Gruber T, 2009, MOL IMMUNOL, V46, P2071, DOI 10.1016/j.molimm.2009.02.030; Guha S, 2002, CANCER RES, V62, P1632; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao Q, 2013, ANTICANCER RES, V33, P393; Hao Q, 2009, AM J PHYSIOL-CELL PH, V296, pC821, DOI 10.1152/ajpcell.00504.2008; Hao Q, 2009, J BIOL CHEM, V284, P799, DOI 10.1074/jbc.M807546200; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Hausser A, 2006, J CELL SCI, V119, P3613, DOI 10.1242/jcs.03104; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hollenbach M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068033; Huck B, 2014, J BIOL CHEM, V289, P3138, DOI 10.1074/jbc.M113.502633; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Ijichi S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1899184; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jackson LN, 2006, BIOCHEM BIOPH RES CO, V348, P945, DOI 10.1016/j.bbrc.2006.07.142; Jaggi M, 2005, CANCER RES, V65, P483; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Janssens K, 2009, CELL SIGNAL, V21, P282, DOI 10.1016/j.cellsig.2008.10.012; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim Y, 2008, J CLIN INVEST, V118, P124, DOI 10.1172/JCI33255; Kleger A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014599; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LaValle CR, 2012, MOL CANCER THER, V11, P1389, DOI 10.1158/1535-7163.MCT-11-0887; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Liu ZC, 2014, CELL TISSUE RES, V358, P491, DOI 10.1007/s00441-014-1953-2; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Malhotra V, 2011, COLD SPRING HARB PER, V3; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2010, BIOCHEM J, V432, P153, DOI 10.1042/BJ20101188; McDonald PC, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00027; Meredith EL, 2010, J MED CHEM, V53, P5400, DOI 10.1021/jm100075z; Meredith EL, 2010, J MED CHEM, V53, P5422, DOI 10.1021/jm100076w; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Miwa D, 2013, ANGIOGENESIS, V16, P675, DOI 10.1007/s10456-013-9345-x; Monovich L, 2010, FEBS LETT, V584, P631, DOI 10.1016/j.febslet.2009.12.014; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Muller M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11742; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277; Nhek S, 2010, MOL BIOL CELL, V21, P2327, DOI 10.1091/mbc.E10-02-0090; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ochi N, 2011, J CELL PHYSIOL, V226, P1074, DOI 10.1002/jcp.22421; Patel S, 2014, ADV EXP MED BIOL, V806, P409, DOI 10.1007/978-3-319-06068-2_20; Pearson Mark A, 2004, Expert Rev Anticancer Ther, V4, P1113, DOI 10.1586/14737140.4.6.1113; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pfeifhofer C, 2006, J IMMUNOL, V176, P6004, DOI 10.4049/jimmunol.176.10.6004; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pusapati GV, 2010, MOL BIOL CELL, V21, P1011, DOI 10.1091/mbc.E09-09-0814; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Scheiter M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00066; Scott KL, 2009, NATURE, V459, P1085, DOI 10.1038/nature08109; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shabelnik M. Yu., 2011, Experimental Oncology, V33, P206; Sharlow ER, 2008, J BIOL CHEM, V283, P33516, DOI 10.1074/jbc.M805358200; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753; Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130; Spitaler M, 2006, IMMUNITY, V24, P535, DOI 10.1016/j.immuni.2006.02.013; Steiner TS, 2010, CELL IMMUNOL, V264, P135, DOI 10.1016/j.cellimm.2010.05.012; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Tandon M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119346; Tandon M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075601, 10.1371/journal.pone.0081521]; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; von Blume J, 2007, EMBO J, V26, P4619, DOI 10.1038/sj.emboj.7601891; von Wicher G, 2008, CELL SIGNAL, V20, P925, DOI 10.1016/j.cellsig.2008.01.003; von Wichert G, 2000, CANCER RES, V60, P4573; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Wei N, 2014, MOL CANCER THER, V13, P1130, DOI 10.1158/1535-7163.MCT-13-0880; Wille Christoph, 2014, Bioarchitecture, V4, P111, DOI 10.4161/bioa.29273; Wille C, 2014, MOL BIOL CELL, V25, P324, DOI 10.1091/mbc.E13-06-0334; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoo J, 2011, BIOCHEM BIOPH RES CO, V413, P30, DOI 10.1016/j.bbrc.2011.08.029; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Young TA, 2005, EXP EYE RES, V80, P651, DOI 10.1016/j.exer.2004.11.015; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang W, 2005, J BIOL CHEM, V280, P19036, DOI 10.1074/jbc.M414674200; Zheng H, 2011, J BIOL CHEM, V286, P35733, DOI 10.1074/jbc.M111.263608; Zhou XP, 2014, CANCER LETT, V355, P121, DOI 10.1016/j.canlet.2014.09.008; Zhu Y, 2016, ONCOTARGET, V7, P5327, DOI 10.18632/oncotarget.6633; Zou ZP, 2012, J CELL SCI, V125, P4800, DOI 10.1242/jcs.106542; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	175	10	10	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1263	1278		10.1038/s41388-017-0052-8	http://dx.doi.org/10.1038/s41388-017-0052-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29259300	Green Published			2022-12-28	WOS:000427279300001
J	Li, S; Liang, X; Ma, L; Shen, L; Li, T; Zheng, L; Sun, A; Shang, W; Chen, C; Zhao, W; Jia, J				Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Chen, C.; Zhao, W.; Jia, J.			MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis	ONCOGENE			English	Article							HELICOBACTER-PYLORI; CANCER DEVELOPMENT; SUPPRESSOR-CELLS; INFLAMMASOME; PROGRESSION; ACTIVATION; MELANOMA; RECEPTOR; DIFFERENTIATION; SUSCEPTIBILITY	Chronic inflammation is the primary cause of gastric cancer (GC). NLRP3, as an important inflammasome component, has crucial roles in initiating inflammation. However, the potential roles of NLRP3 in GC is unknown. Here, we show that NLRP3 expression is markedly upregulated in GC, which promotes NLRP3 inflammasome activation and interleukin-1 beta (IL-1 beta) secretion in macrophages. In addition, NLRP3 binds to cyclin-D1 (CCND1) promoter and promotes its transcription in gastric epithelial cells. Consequently, NLRP3 enhances epithelial cells proliferation and GC tumorigenesis. Furthermore, we identify miR-22, which is constitutively expressed in gastric mucosa, as a suppressor of NLRP3. MiR-22 directly targets NLRP3 and attenuates its oncogenic effects in vitro and in vivo. However, Helicobacter pylori (H. pylori) infection suppresses miR-22 expression, while enhances NLRP3 expression, and that triggers uncontrolled proliferation of epithelial cells and the emergence of GC. Thus, our research describes a mechanism by which miR-22 suppresses NLRP3 and maintains homeostasis of gastric microenvironments and suggests miR-22 as a potential target for the intervention of GC.	[Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Jia, J.] Shandong Univ, Sch Basic Med Sci, Dept Microbiol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Zhao, W.; Jia, J.] Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Chen, C.] Shandong Univ, Qilu Hosp, Canc Ctr, Jinan, Shandong, Peoples R China; [Zhao, W.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Jia, J (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Microbiol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhao, W; Jia, J (corresponding author), Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhao, W (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	wzhao@sdu.edu.cn; jiajihui@sdu.edu.cn	Li, Shuyan/AAE-5060-2020	zheng, lixin/0000-0003-0760-4176; Zhao, Wei/0000-0001-8440-2274	National Natural Science Foundation of China [81772151, 81571960, 81371781, 81670146, 81470318, 81372680, 81471991, 81501720]; Science Foundation of Shandong Province [2017GSF18194, 2017GSF18109, 2014GSF118114, ZR2014HQ070]; Independent Innovation Foundation of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Independent Innovation Foundation of Shandong University	This work was supported by the National Natural Science Foundation of China (Nos. 81772151, 81571960, 81371781, 81670146, 81470318, 81372680, 81471991 and 81501720), the Science Foundation of Shandong Province (2017GSF18194, 2017GSF18109, 2014GSF118114 and ZR2014HQ070), and the Independent Innovation Foundation of Shandong University.	Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Allison CC, 2013, J IMMUNOL, V190, P3706, DOI 10.4049/jimmunol.1200591; Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516; Bruchard M, 2015, NAT IMMUNOL, V16, P859, DOI 10.1038/ni.3202; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castano-Rodriguez N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00336; Castano-Rodriguez N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098899; Chochi K, 2008, CLIN CANCER RES, V14, P2909, DOI 10.1158/1078-0432.CCR-07-4467; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo CS, 2016, IMMUNITY, V45, P802, DOI 10.1016/j.immuni.2016.09.008; Haneklaus M, 2012, J IMMUNOL, V189, P3795, DOI 10.4049/jimmunol.1200312; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Huai WW, 2016, P NATL ACAD SCI USA, V113, P11925, DOI 10.1073/pnas.1601556113; Huai WW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5738; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karki R, 2016, NATURE; Lamb A, 2013, J CELL BIOCHEM, V114, P491, DOI 10.1002/jcb.24389; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Nam KT, 2004, CLIN CANCER RES, V10, P8105, DOI 10.1158/1078-0432.CCR-04-0896; Pasqualini L, 2015, MOL ENDOCRINOL, V29, P1037, DOI 10.1210/me.2014-1358; Petrilli V, 2017, CURR OPIN ONCOL, V29, P35, DOI 10.1097/CCO.0000000000000346; Ping PH, 2016, ARCH BIOCHEM BIOPHYS, V604, P20, DOI 10.1016/j.abb.2016.06.001; Qin Y, 2015, PIGM CELL MELANOMA R, V28, P236, DOI 10.1111/pcmr.12348; Semper RP, 2014, J IMMUNOL, V193, P3566, DOI 10.4049/jimmunol.1400362; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Tatsuta T, 2012, J CLIN PATHOL, V65, P839, DOI 10.1136/jclinpath-2011-200590; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Verma D, 2012, PIGM CELL MELANOMA R, V25, P506, DOI 10.1111/j.1755-148X.2012.01008.x; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wan WN, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0178-8; Wang X, 2014, BIOCHEM BIOPH RES CO, V445, P175, DOI 10.1016/j.bbrc.2014.01.160; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yang F, 2015, J BIOL CHEM, V290, P6507, DOI 10.1074/jbc.M114.620369; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297	53	77	85	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					884	896		10.1038/onc.2017.381	http://dx.doi.org/10.1038/onc.2017.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059152				2022-12-28	WOS:000425281800006
J	Shao, C; Chien, SJ; Farah, E; Li, Z; Ahmad, N; Liu, X				Shao, C.; Chien, S-J; Farah, E.; Li, Z.; Ahmad, N.; Liu, X.			Plk1 phosphorylation of Numb leads to impaired DNA damage response	ONCOGENE			English	Article							MAMMALIAN NUMB; SELF-RENEWAL; P53; PROTEIN; DEGRADATION; BINDING; CELLS; MDM2; UBIQUITINATION; IDENTIFICATION	Although Numb is well-recognized as a cell-fate determinant in stem/progenitor cells, accumulating evidence supports that Numb also has a critical role in adult tissues and cancers, in particular, in the context of regulation of tumor suppressor p53. Herein, we identified Numb as a novel substrate of Polo-like kinase 1 (Plk1). Of significance, we showed that Plk1-mediated phosphorylation of Numb leads to its enhanced proteasomal degradation and impaired Numb/p53 pathway, thus providing another mechanism how Plk1 antagonizes p53 during DNA damage response. In addition, the novel phosphorylation event identified by us further supports the notion that post-translational modifications of Numb uncouple Numb from p53 and lead to p53 destabilization. Finally, our data generated from both human cancer cell lines and mouse xenograft model showed that cancer cells carrying the unphosphorylated form of Numb by Plk1 are more sensitive to doxorubicin, a classical chemotherapeutic drug. Therefore, our work may provide future strategies for improving the efficacy of chemotherapy by targeting Numb phosphorylation by Plk1.	[Shao, C.; Farah, E.; Li, Z.; Liu, X.] Purdue Univ, Dept Biochem, 175S Univ St, W Lafayette, IN 47907 USA; [Chien, S-J] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Ahmad, N.] Univ Wisconsin, Dept Dermatol, Madison, WI USA; [Liu, X.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Wisconsin System; University of Wisconsin Madison; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Liu, X (corresponding author), Purdue Univ, Dept Biochem, 175S Univ St, W Lafayette, IN 47907 USA.	liu8@purdue.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NIH [R01 CA157429, R01 CA192894, R01 CA196835, R01 CA196634, R01 AR059130, R01 CA176748]; Purdue University Center for Cancer Research [P30 CA023168]; NATIONAL CANCER INSTITUTE [R01CA157429, R01CA176748, R01CA196835, R01CA196634, R01CA192894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059130] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Purdue University Center for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIH grants R01 CA157429 (X Liu), R01 CA192894 (X Liu), R01 CA196835 (X Liu), R01 CA196634 (X Liu), R01 AR059130 (N Ahmad) and R01 CA176748 (N Ahmad). The work was also partially supported by Purdue University Center for Cancer Research (P30 CA023168).	Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; George RM, 2013, P NATL ACAD SCI USA, V110, P18549, DOI 10.1073/pnas.1311628110; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Liu D, 2016, HEPATOLOGY, V64, P390, DOI 10.1002/hep.28594; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Pece S, 2011, BBA-REV CANCER, V1815, P26, DOI 10.1016/j.bbcan.2010.10.001; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Sakurai Y, 2014, MOL PHARMACEUT, V11, P2713, DOI 10.1021/mp500245z; Schmit TL, 2012, CANCER RES, V72, P3864, DOI 10.1158/0008-5472.CAN-12-0714; Sczaniecka M, 2012, J BIOL CHEM, V287, P14052, DOI 10.1074/jbc.M111.303875; Shao T, 2015, CELL CYCLE, V14, P755, DOI 10.1080/15384101.2014.998050; Siddique HR, 2015, HEPATOLOGY, V62, P1466, DOI 10.1002/hep.27987; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; Yang XM, 2009, J BIOL CHEM, V284, P18588, DOI 10.1074/jbc.C109.001560; Yogosawa S, 2003, BIOCHEM BIOPH RES CO, V302, P869, DOI 10.1016/S0006-291X(03)00282-1; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhu K, 2016, STRUCTURE, V24, P1110, DOI 10.1016/j.str.2016.04.012	31	10	12	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					810	820		10.1038/onc.2017.379	http://dx.doi.org/10.1038/onc.2017.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059161	Green Accepted			2022-12-28	WOS:000424628100012
J	Lee, S; Liu, P; Teinturier, R; Jakob, J; Tschaffon, M; Tasdogan, A; Wittig, R; Hoeller, S; Baumhoer, D; Frappart, L; Vettorazzi, S; Bertolino, P; Zhang, C; Tuckermann, J				Lee, S.; Liu, P.; Teinturier, R.; Jakob, J.; Tschaffon, M.; Tasdogan, A.; Wittig, R.; Hoeller, S.; Baumhoer, D.; Frappart, L.; Vettorazzi, S.; Bertolino, P.; Zhang, C.; Tuckermann, J.			Deletion of Menin in craniofacial osteogenic cells in mice elicits development of mandibular ossifying fibroma	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; BENIGN FIBROOSSEOUS LESIONS; NEOPLASIA TYPE-1 MEN1; BONE; EXPRESSION; JAW; DIFFERENTIATION; SPECIFICATION; MAINTENANCE; PROGENITORS	Ossifying fibroma (OF) is a rare benign tumor of the craniofacial bones that can reach considerable and disfiguring dimensions if left untreated. Although the clinicopathological characteristics of OF are well established, the underlying etiology has remained largely unknown. Our work indicates that Men1-a tumor suppressor gene responsible of Multiple endocrine neoplasia type 1-is critical for OF formation and shows that mice with targeted disruption of Men1 in osteoblasts (Men1(Runx2Cre)) develop multifocal OF in the mandible with a 100% penetrance. Using lineage-tracing analysis, we demonstrate that loss of Men1 arrests stromal osteoprogenitors in OF at the osterix-positive pre-osteoblastic differentiation stage. Analysis of Men1-lacking stromal spindle cells isolated from OF (OF-derived MSCs (OFMSCs)) revealed a downregulation of the cyclin-dependent kinase (CDK) inhibitor Cdkn1a, consistent with an increased proliferation rate. Intriguingly, the re-expression of Men1 in Men1-deficient OFMSCs restored Cdkn1a expression and abrogated cellular proliferation supporting the tumor-suppressive role of Men1 in OF. Although our work presents the first evidence of Men1 in OF development, it further provides the first genetic mouse model of OF that can be used to better understand the molecular pathogenesis of these benign tumors and to potentially develop novel treatment strategies.	[Lee, S.; Liu, P.; Tschaffon, M.; Vettorazzi, S.; Tuckermann, J.] Univ Ulm, Inst Comparat Mol Endocrinol, Helmholtzstr 8-1, D-89081 Ulm, BW, Germany; [Teinturier, R.; Bertolino, P.; Zhang, C.] Univ Lyon 1, INSERM, Ctr Rech Cancerol Lyon, CNRS UMR5286,U1052, Lyon, France; [Jakob, J.; Frappart, L.] Leibniz Inst Aging, Fritz Lipmann Inst, Jena, Germany; [Tasdogan, A.] Univ Hosp Ulm, Inst Immunol, Ulm, Germany; [Wittig, R.] Ulm Univ, Inst Laser Technol Med & Metrol, Ulm, Germany; [Hoeller, S.; Baumhoer, D.] Univ Hosp, Bone Tumour Reference Ctr, Basel, Switzerland; [Hoeller, S.; Baumhoer, D.] Univ Hosp, DOESAK Registry, Inst Pathol, Basel, Switzerland; [Hoeller, S.; Baumhoer, D.] Univ Basel, Basel, Switzerland; [Frappart, L.] Univ Claude Bernard Lyon 1, INSERM, Oncogenese & Progress Tumorale, Lyon, France	Ulm University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Ulm University; Ulm University; University of Basel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tuckermann, J (corresponding author), Univ Ulm, Inst Comparat Mol Endocrinol, Helmholtzstr 8-1, D-89081 Ulm, BW, Germany.	jan.tuckermann@uni-ulm.de	Wittig, Rainer/AAT-5361-2021; Bertolino, philippe/D-4072-2018; Bertolino, philippe/M-8977-2019; Tasdogan, Alpaslan/U-5133-2017; ZHANG, Chang Xian/G-2905-2013	Wittig, Rainer/0000-0002-3735-9370; Bertolino, philippe/0000-0001-8064-8269; Bertolino, philippe/0000-0001-8064-8269; Vettorazzi, Dr. Sabine/0000-0001-8667-9488; Zhang, Chang Xian/0000-0002-5443-8951; Lee, Sooyeon/0000-0001-6244-4975; Holler, Sylvia/0000-0001-9277-7076	Boehringer Ingelheim Foundation; Deutsche Forschungsgemeinschaft (DFG) [1468, Tu 220/6-1, Tu 220/6-2]; Deutsche Forschungsgemeinschaft (Collaborative Research Centre) [1149, C02/INST 40/492-1]; Deutsche Forschungsgemeinschaft (Trilateral Consortium) [Tu 220/12-1]; Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena	Boehringer Ingelheim Foundation(Boehringer Ingelheim); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (Collaborative Research Centre)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (Trilateral Consortium)(German Research Foundation (DFG)); Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena	We are grateful to the staff of the animal facilities of the University of Ulm, led by Dr Petra Kirsch and in particular to Tobias Rappold. We thank Professor Dr Volker Rasche from the Core Facility Animal MRI, Ulm University and Dr Markus Rojewsky from the Institut fur Transfusionsmedizin Universitatsklinikum Ulm. We thank Dr Merle Stein and Dr Giorgio Caratti for critical reading of the manuscript. This study was supported by the Boehringer Ingelheim Foundation (to JT), Deutsche Forschungsgemeinschaft (DFG, Priority Program Immunobone 1468, Tu 220/6-1, 6-2, Collaborative Research Centre 1149, C02/INST 40/492-1, Trilateral Consortium Tu 220/12-1 to JT) and the Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena (to SL).	Bertolino P, 2003, CANCER RES, V63, P4836; Bhasin M, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/497234; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Darling TN, 1997, ARCH DERMATOL, V133, P853, DOI 10.1001/archderm.133.7.853; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Engleka KA, 2007, DEV BIOL, V311, P524, DOI 10.1016/j.ydbio.2007.08.057; Eversole R, 2008, HEAD NECK PATHOL, V2, P177, DOI 10.1007/s12105-008-0057-2; Falchetti A, 2009, GENET MED, V11, P825, DOI 10.1097/GIM.0b013e3181be5c97; Fauquier T, 2014, DEVELOPMENT, V141, P166, DOI 10.1242/dev.103226; Gherardi S, 2017, BBA-GENE REGUL MECH, V1860, P427, DOI 10.1016/j.bbagrm.2017.02.003; Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125; Isakov O, 2013, GENET RES, V95, P114, DOI 10.1017/S0016672313000141; JACKSON CE, 1990, SURGERY, V108, P1006; Franco-Barrera MJ, 2016, ORAL MAXILLOFAC SURG, V20, P1, DOI 10.1007/s10006-015-0535-0; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kanazawa I, 2015, J BIOL CHEM, V290, P3910, DOI 10.1074/jbc.M114.629899; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; KASSEM M, 1994, CLIN ENDOCRINOL, V41, P415, DOI 10.1111/j.1365-2265.1994.tb02570.x; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Kottemann MC, 2009, DNA REPAIR, V8, P944, DOI 10.1016/j.dnarep.2009.06.001; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165; Liu Y, 2010, DENTOMAXILLOFAC RAD, V39, P57, DOI 10.1259/dmfr/96330046; Matkar S, 2013, TRENDS BIOCHEM SCI, V38, P394, DOI [10.1016/j.tibs.2013.0S.005, 10.1016/j.tibs.2013.05.005]; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013; Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067; Papagerakis P., 2013, DEV STRUCTURE TEETH; Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252; Qin HY, 2013, CELL STEM CELL, V13, P577, DOI 10.1016/j.stem.2013.08.010; Ramaesh T, 2003, J ANAT, V203, P213, DOI 10.1046/j.1469-7580.2003.00210.x; Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Shibata S, 2008, J ANAT, V213, P274, DOI 10.1111/j.1469-7580.2008.00934.x; Slootweg PJ, 2017, WHO CLASSIFICATION H, P251; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sung JH, 2008, TRANSPL P, V40, P2649, DOI 10.1016/j.transproceed.2008.08.009; Toyosawa S, 2007, MODERN PATHOL, V20, P389, DOI 10.1038/modpathol.3800753; Trijolet JP, 2011, EUR ANN OTORHINOLARY, V128, P30, DOI 10.1016/j.anorl.2010.06.005; WALDRON CA, 1973, ORAL SURG ORAL MED O, V35, P340, DOI 10.1016/0030-4220(73)90072-8; Woo SB, 2015, J ORAL MAXIL SURG, V73, pS87, DOI 10.1016/j.joms.2015.05.010; Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042; Yadav R., 2009, J ORAL SCI, V51, P151, DOI [10.2334/josnusd.51.151, DOI 10.2334/JOSNUSD.51.151]; Yamaza T, 2011, J DENT RES, V90, P317, DOI 10.1177/0022034510387796; Yang YJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.98; Zhang H, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/265380; Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008	56	4	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					616	626		10.1038/onc.2017.364	http://dx.doi.org/10.1038/onc.2017.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991228				2022-12-28	WOS:000423812200007
J	Gelato, KA; Schockel, L; Klingbeil, O; Ruckert, T; Lesche, R; Toedling, J; Kalfon, E; Heroult, M; Lejeune, P; Monning, U; Fernandez-Montalvan, AE; Baurle, S; Siegel, S; Haendler, B				Gelato, K. A.; Schoeckel, L.; Klingbeil, O.; Rueckert, T.; Lesche, R.; Toedling, J.; Kalfon, E.; Heroult, M.; Lejeune, P.; Moenning, U.; Fernandez-Montalvan, A. E.; Baeurle, S.; Siegel, S.; Haendler, B.			Super-enhancers define a proliferative PGC-1 alpha-expressing melanoma subgroup sensitive to BET inhibition	ONCOGENE			English	Article							INTEGRATIVE GENOMICS VIEWER; TRANSCRIPTION FACTORS; SELECTIVE-INHIBITION; EXPRESSION PROFILES; BROMODOMAIN; SUPPRESSES; PGC1-ALPHA; APOPTOSIS; LYMPHOMA; I-BET151	Metabolic changes are linked to epigenetic reprogramming and play important roles in several tumor types. PGC-1 alpha is a transcriptional coactivator controlling mitochondrial biogenesis and is linked to oxidative phosphorylation. We provide evidence that melanoma models with elevated PGC-1 alpha levels are characteristic of the proliferative phenotype and are sensitive to bromodomain and extra-terminal domain (BET) inhibitor treatment. A super-enhancer region highly occupied by the BET family member BRD4was identified for the PGC-1 alpha gene. BET inhibitor treatment prevented this interaction, leading to a dramatic reduction of PGC-1 alpha expression. Accordingly, BET inhibition diminished respiration and mitochondrial function in cells. In vivo, melanoma models with high PGC-1 alpha expression strongly responded to BET inhibition by reduction of PGC-1 alpha and impaired tumor growth. Altogether, our findings identify epigenetic regulatory elements that define a subset of melanomas with high sensitivity to BET inhibition, which opens up the opportunity to define melanoma patients most likely to respond to this treatment, depending on their tumor characteristics.	[Gelato, K. A.; Schoeckel, L.; Klingbeil, O.; Rueckert, T.; Lesche, R.; Toedling, J.; Kalfon, E.; Lejeune, P.; Moenning, U.; Fernandez-Montalvan, A. E.; Baeurle, S.; Siegel, S.; Haendler, B.] Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany; [Rueckert, T.] Deutsch Rheuma Forschungszentrum, Innate Immun, Berlin, Germany; [Toedling, J.] Charite, Dept Pediat Oncol & Hematol, Berlin, Germany; [Heroult, M.] Bayer AG, Corp Res & Dev, Leverkusen, Germany; [Klingbeil, O.] Cold Spring Harbor Lab, Canc Ctr, Cold Spring Harbor, NY 11724 USA	Bayer AG; Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Bayer AG; Cold Spring Harbor Laboratory	Haendler, B (corresponding author), Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany.	bernard.haendler@bayer.com		Toedling, Joern/0000-0003-1471-1295; Klingbeil, Olaf/0000-0001-7248-7506; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernasconi E, 2017, BRIT J HAEMATOL, V178, P936, DOI 10.1111/bjh.14803; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bhagwat AS, 2016, CELL REP, V15, P519, DOI 10.1016/j.celrep.2016.03.054; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Gallagher SJ, 2014, J INVEST DERMATOL, V134, P2795, DOI 10.1038/jid.2014.243; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gelato KA, 2016, EXPERT OPIN THER TAR, V20, P783, DOI 10.1517/14728222.2016.1134490; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Heinemann A, 2015, ONCOTARGET, V6, P21507, DOI 10.18632/oncotarget.4242; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Jung M, 2015, EPIGENOMICS-UK, V7, P487, DOI 10.2217/epi.14.91; Klingbeil O, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.271; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Leiter Ulrike, 2014, Adv Exp Med Biol, V810, P120; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Luo C, 2016, NATURE, V537, P422, DOI 10.1038/nature19347; Mochizuki K, 2008, J BIOL CHEM, V283, P9040, DOI 10.1074/jbc.M707603200; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Niezgoda A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/851387; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Salmon-Divon M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-415; Schockel L, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0138-0; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Zhang WJ, 2015, CURR OPIN PHARMACOL, V23, P68, DOI 10.1016/j.coph.2015.05.015	45	22	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					512	521		10.1038/onc.2017.325	http://dx.doi.org/10.1038/onc.2017.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28991225	Green Published, hybrid			2022-12-28	WOS:000423331600009
J	Debruyne, DN; Turchi, L; Burel-Vandenbos, F; Fareh, M; Almairac, F; Virolle, V; Figarella-Branger, D; Baeza-Kallee, N; Lagadec, P; Kubiniek, V; Paquis, P; Fontaine, D; Junier, MP; Chneiweiss, H; Virolle, T				Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Figarella-Branger, D.; Baeza-Kallee, N.; Lagadec, P.; Kubiniek, V.; Paquis, P.; Fontaine, D.; Junier, M-P; Chneiweiss, H.; Virolle, T.			DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression	ONCOGENE			English	Article							CANCER STEM-CELL; GLIOMA-INITIATING CELLS; NANOG; TUMORS	Glioblastomas (GBM) are lethal primitive brain tumours characterized by a strong intra-tumour heterogeneity. We observed in GBM tissues the coexistence of functionally divergent micro-territories either enriched in more differentiated and non-mitotic cells or in mitotic undifferentiated OLIG2 positive cells while sharing similar genomic abnormalities. Understanding the formation of such functionally divergent micro-territories in glioblastomas (GBM) is essential to comprehend GBM biogenesis, plasticity and to develop therapies. Here we report an unexpected anti-proliferative role of beta-catenin in non-mitotic differentiated GBM cells. By cell type specific stimulation of miR-302, which directly represses cyclin D1 and stemness features, beta-catenin is capable to change its known proliferative function. Nuclear beta-catenin accumulation in non-mitotic cells is due to a feed forward mechanism between DOCK4 and beta-catenin, allowed by increased GSK3-beta activity. DOCK4 over expression suppresses selfrenewal and tumorigenicity of GBM stem-like cells. Accordingly in the frame of GBM median of survival, increased level of DOCK4 predicts improved patient survival.	[Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] Univ Cote dAzur, Nice, France; [Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] CNRS, UMR7277, Nice, France; [Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] INSERM, U1091, Nice, France; [Turchi, L.; Almairac, F.; Paquis, P.; Fontaine, D.] CHU Nice, Hop Pasteur, Serv Neurchirurg, Nice, France; [Burel-Vandenbos, F.] CHU Nice, Hop Pasteur, Serv Anatomopathol, Nice, France; [Figarella-Branger, D.; Baeza-Kallee, N.] Aix Marseille Univ, Fac Med Timone, Marseille, France; [Figarella-Branger, D.; Baeza-Kallee, N.] INSERM, UMR 911, CRO2, Marseille, France; [Figarella-Branger, D.] CHU Timone, Dept Pathol, Marseille 5, France; [Kubiniek, V.] Univ Hosp Nice, Lab Solid Tumors Genet, Nice, France; [Junier, M-P; Chneiweiss, H.] CNRS, Neurosci Paris Seine IBPS UMR8246, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] Team Glial Plast, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] INSERM, U1130, Neurosci Paris Seine IBPS, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] Univ Paris 06, UMCR18, Neurosci Paris Seine IBPS, 7 Quai St Bernard, Paris, France	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Nice; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Virolle, T (corresponding author), Univ Nice Sophia Antipolis, Inst Biol, iBV, UFR Sci, Batiment Sci Nat,Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	Virolle@unice.fr	LAGADEC, Patricia/P-4538-2016; herve, chneiweiss/Q-6818-2019; Virolle, Thierry/E-5838-2016	LAGADEC, Patricia/0000-0002-5105-782X; herve, chneiweiss/0000-0001-7675-5061; Fontaine, Denys/0000-0001-5012-6769; Turchi, Laurent/0000-0003-2020-5831; Fareh, Mohamed/0000-0001-9551-8213	Association pour la Recherche sur le Cancer [3161]; Association Sauvons Laura; ADerTU; Association Dimitri Bessiere; Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project"); Fondation de France; ARC projet [SFI20111203773]; INCA PLBIO; ITMO CANCER plan cancer; INSERM; UNSA	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Association Sauvons Laura; ADerTU; Association Dimitri Bessiere; Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project")(French National Research Agency (ANR)); Fondation de France(Fondation de France); ARC projet; INCA PLBIO; ITMO CANCER plan cancer; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); UNSA	This work was supported by grants from the Association pour la Recherche sur le Cancer (subvention 3161), Association Sauvons Laura, ADerTU, Association Dimitri Bessiere, Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project"), Fondation de France, ARC projet (SFI20111203773), INCA PLBIO2012, ITMO CANCER plan cancer, INSERM, UNSA. We thank A Borderie, S Bestree, C Hagnere, F Frassinetti, S Rekima, AC Peyron and F Keslair for their technical assistance and C. Colin for the statistical analysis. We thank Doctor Enzo Lalli for providing the PKF115-584 inhibitor and Doctor Andreas Schedl for the mYhBCATf and the TopFlash reporter plasmid. We thank Doctor Ellen Van Obberghen-Schilling for grammatical corrections.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Dahan P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.509; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fareh M, 2012, CELL DEATH DIFFER, V19, P232, DOI 10.1038/cdd.2011.89; Farhana L, 2012, J ONCOL, V2012, DOI 10.1155/2012/796729; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Germano I, 2010, NEUROPHARMACOLOGY, V58, P903, DOI 10.1016/j.neuropharm.2009.12.019; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Hallett RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033976; Johannessen TCA, 2012, EXPERT REV ANTICANC, V12, P635, DOI [10.1586/era.12.37, 10.1586/ERA.12.37]; Kleppe M, 2012, CELL STEM CELL, V10, P351, DOI 10.1016/j.stem.2012.03.006; Korur S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007443; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; LaFramboise T, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001086; Lee M, 2012, INT J GYNECOL CANCER, V22, P1489, DOI 10.1097/IGJ.0b013e3182738307; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mills CN, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00047; Nagata T, 2014, BREAST CANCER-TOKYO, V21, P96, DOI 10.1007/s12282-012-0357-y; Patru C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-66; Piccirillo SGM, 2007, ERNST SCHERING FOUND, V5, P59, DOI 10.1007/2789_2007_044; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh SK, 2003, CANCER RES, V63, P5821; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Sottoriva A, 2013, CANCER RES, V73, P41, DOI 10.1158/0008-5472.CAN-12-2273; Turchi L, 2013, STEM CELLS, V31, P1252, DOI 10.1002/stem.1373; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	32	17	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					241	254		10.1038/onc.2017.323	http://dx.doi.org/10.1038/onc.2017.323			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925399				2022-12-28	WOS:000422631700010
J	Tao, T; Yang, X; Zheng, J; Feng, D; Qin, Q; Shi, X; Wang, Q; Zhao, C; Peng, Z; Liu, H; Jiang, WG; He, J				Tao, T.; Yang, X.; Zheng, J.; Feng, D.; Qin, Q.; Shi, X.; Wang, Q.; Zhao, C.; Peng, Z.; Liu, H.; Jiang, W. G.; He, J.			PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation	ONCOGENE			English	Article							TYROSINE-PHOSPHATASE SHP-1; BREAST-CANCER; CLEAR-CELL; COLORECTAL-CANCER; TARGETED THERAPY; PROTEIN; EXPRESSION; GROWTH; TUMORIGENESIS; SURVIVAL	Renal cell carcinoma (RCC) is one of the most aggressive urologic cancers, however, the mechanism on supporting RCC carcinogenesis is still not clear. By using gene expression profile analysis and functional clustering, PDZ domain-containing 1 (PDZK1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which was also verified in several independent public ccRCC data sets. Using PDZK1 overexpression and knockdown models in ccRCC cell lines, we demonstrated that PDZK1 inhibited cell proliferation, cell cycle G1/S phase transition, cell migration and invasion, indicating a tumor-suppressor role in the development and progression of ccRCC. Our study further demonstrated that PDZK1 inhibited cell proliferation and migration of ccRCC via targeting SHP-1. PDZK1 was further identified to suppress cell proliferation by blocking SHP-1 phosphorylation at Tyr536 via inhibition of the association between SHP-1 and PLC beta 3, and then retarding Akt phosphorylation and promoting STAT5 phosphorylation in ccRCC cells. Moreover, the inhibitive effects of PDZK1 on SHP-1 phosphorylation and the tumor growth were verified in vivo by xenograft tumor studies. Accordingly, PDZK1 expression was negatively correlated with SHP-1 activation and phosphorylation, advanced pathologic stage, tumor weight and size, and prognosis of ccRCC patients. These findings have provided first lines of evidences that PDZK1 expression is negatively correlated with SHP-1 activation and poor clinical outcomes in ccRCC. PDZK1 was identified as a novel tumor suppressor in ccRCC by negating SHP-1 activity.	[Tao, T.; Yang, X.; Zheng, J.; Qin, Q.; Shi, X.; Wang, Q.; Zhao, C.; Peng, Z.; Liu, H.; He, J.] Capital Med Univ, Dept Biochem & Mol Biol, 10 Xitoutiao, Beijing 100069, Peoples R China; [Yang, X.; Zheng, J.; Qin, Q.; Liu, H.; He, J.] Capital Med Univ, Beijing Int Cooperat Base Sci & Technol China UK, Beijing Key Lab Canc Invas & Metastasis Res, Beijing, Peoples R China; [Feng, D.] Shanxi Med Univ, Hosp 1, Dept Intervent Radiol, Taiyuan, Shanxi, Peoples R China; [Jiang, W. G.] Cardiff Univ, Cardiff China Med Res Collaborat, Sch Med, Heath Pk, Cardiff, S Glam, Wales	Capital Medical University; Capital Medical University; Shanxi Medical University; Cardiff University	Liu, H; He, J (corresponding author), Capital Med Univ, Dept Biochem & Mol Biol, 10 Xitoutiao, Beijing 100069, Peoples R China.	hualh08@ccmu.edu.cn; jq_he@ccmu.edu.cn	Jiang, Wen G/B-1293-2010; jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020	Jiang, Wen G/0000-0002-3283-1111; Jiang, Wen G./0000-0002-3283-1111	National Natural Science Foundation of the People's Republic of China [81472409, 81572333]; Beijing Natural Science Foundation Program; Beijing Municipal Commission of Education [KZ201710025015]; Project of High-level Teachers in Beijing Municipal Universities [IDHT20170516]; Beijing BaiQianWan Talents Program	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation Program(Beijing Natural Science Foundation); Beijing Municipal Commission of Education(Beijing Municipal Commission of Education); Project of High-level Teachers in Beijing Municipal Universities; Beijing BaiQianWan Talents Program	This work was supported by the National Natural Science Foundation of the People's Republic of China (No. 81472409, 81572333); Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ201710025015); Support Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan (IDHT20170516); Beijing BaiQianWan Talents Program (2017-2018).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Caceres W, 2011, P R HEALTH SCI J, V30, P73; Calvo E, 2016, CANCER TREAT REV, V50, P109, DOI 10.1016/j.ctrv.2016.09.002; Ciccarese C, 2016, CANCER TREAT REV, V49, P37, DOI 10.1016/j.ctrv.2016.07.003; Cooper SJ, 2010, ONCOGENE, V29, P2905, DOI 10.1038/onc.2010.64; Du Y, 2016, ONCOTARGET, V7, P41885, DOI 10.18632/oncotarget.9628; Eyre NS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001130; Gardiol D, 2012, FEBS J, V279, P3529, DOI 10.1111/j.1742-4658.2012.08685.x; Ghosh MG, 2000, CANCER RES, V60, P6367; Golebiewska U, 2010, CRIT REV BIOCHEM MOL, V45, P97, DOI 10.3109/10409231003598812; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Kim JK, 2012, J BIOL CHEM, V287, P21012, DOI 10.1074/jbc.M111.337865; Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411; Kroeze SGC, 2010, CANCER BIOMARK, V7, P261, DOI 10.3233/CBM-2010-0195; Li HL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0162-x; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Ma Q, 2015, ONCOTARGET, V6, P35851, DOI 10.18632/oncotarget.5323; Moch H, 2015, CURR DRUG TARGETS, V16, P125, DOI 10.2174/1389450116666150126110632; Montano X, 2009, ONCOGENE, V28, P3787, DOI 10.1038/onc.2009.143; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Poole AW, 2005, CELL SIGNAL, V17, P1323, DOI 10.1016/j.cellsig.2005.05.016; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Rodriguez-Ubreva FJ, 2010, ONCOGENE, V29, P345, DOI 10.1038/onc.2009.329; Saponaro C, 2014, CANCER BIOMARK, V14, P177, DOI 10.3233/CBM-130329; Sharma Y, 2016, FUTURE ONCOL, V12, P1287, DOI 10.2217/fon-2015-0057; Sooman L, 2014, TUMOR BIOL, V35, P4479, DOI 10.1007/s13277-013-1590-5; Stebbing J, 2014, ONCOGENE, V33, P939, DOI 10.1038/onc.2013.80; Subbaiah VK, 2011, BIOCHEM J, V439, P195, DOI 10.1042/BJ20110903; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun LC, 2016, FASEB J, V30, P578, DOI 10.1096/fj.15-275586; Walsh DR, 2015, PHARMACOL REV, V67, P656, DOI 10.1124/pr.115.010728; Xiao WB, 2010, BLOOD, V116, P6003, DOI 10.1182/blood-2010-05-283937; Yao S, 2015, J PATHOL, V236, P65, DOI 10.1002/path.4502; Zheng JF, 2017, EBIOMEDICINE, V15, P62, DOI 10.1016/j.ebiom.2016.12.003	36	21	22	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6119	6131		10.1038/onc.2017.199	http://dx.doi.org/10.1038/onc.2017.199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692056	Green Accepted			2022-12-28	WOS:000414249800006
J	Kumar, R; Deivendran, S; Santhoshkumar, TR; Pillai, MR				Kumar, R.; Deivendran, S.; Santhoshkumar, T. R.; Pillai, M. R.			Signaling coupled epigenomic regulation of gene expression	ONCOGENE			English	Review							PHOSPHORYLATES HISTONE H3; DNA-DAMAGE RESPONSE; KINASE AURORA B; TYROSINE KINASE; BREAST-CANCER; MYELOPROLIFERATIVE DISORDERS; TRANSCRIPTIONAL REGULATION; METHYLTRANSFERASE ACTIVITY; PAK1 PHOSPHORYLATION; CELL-TRANSFORMATION	Inheritance of genomic information independent of the DNA sequence, the epigenetics, as well as gene transcription are profoundly shaped by serine/threonine and tyrosine signaling kinases and components of the chromatin remodeling complexes. To precisely respond to a changing external milieu, human cells efficiently translate upstream signals into post-translational modifications (PTMs) on histones and coregulators such as corepressors, coactivators, DNA-binding factors and PTM modifying enzymes. Because a protein with multiple residues for putative PTMs is expected to undergo more than one PTM in cells stimulated with growth factors, the outcome of combinational PTM codes on histones and coregulators is profoundly shaped by regulatory interplays between PTMs. The genomic functions of signaling kinases in cancer cells are manifested by the downstream effectors of cytoplasmic signaling cascades as well as translocation of the cytoplasmic signaling kinases to the nucleus. Signaling-mediated phosphorylation of histones serves as a regulatory switch for other PTMs, and connects chromatin remodeling complexes into gene transcription and gene activity. Here, we will discuss the recent advances in signaling-dependent epigenomic regulation of gene transcription using a few representative cancer-relevant serine/threonine and tyrosine kinases and their interplay with chromatin remodeling factors in cancer cells.	[Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA; [Kumar, R.; Deivendran, S.; Santhoshkumar, T. R.; Pillai, M. R.] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India	George Washington University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Kumar, R (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India.	rakeshkumar@rgcb.res.in	Sankaran, Deivendran/X-8009-2019; Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803	National Institutes of Health [CA090970, CA088023]; Department of Biotechnology, Government of India; Indian Council of Medical Research [3/1/3/JRF-2010/MPD]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Indian Council of Medical Research(Indian Council of Medical Research (ICMR))	We regret for not discussing the deserving work from many of our colleagues due to space limitations. Over the years, signaling and chromatin remodeling studies in Rakesh Kumar laboratory have been supported by the National Institutes of Health grants CA090970 and CA088023. M. Radhakrishna Pillai laboratory is supported by the Department of Biotechnology, Government of India. S. Deivendran is supported by a Senior Research Fellowship from the Indian Council of Medical Research (No. 3/1/3/JRF-2010/MPD).	Aihara H, 2016, MOL CELL, V64, P176, DOI 10.1016/j.molcel.2016.09.012; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Barnes CJ, 2003, CANCER METAST REV, V22, P301, DOI 10.1023/A:1023726827771; Barros P, 2012, NUCLEIC ACIDS RES, V40, P7776, DOI 10.1093/nar/gks571; Basnet H, 2014, NATURE, V516, P267, DOI 10.1038/nature13736; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chatterjee A, 2014, CELL REP, V9, P1333, DOI 10.1016/j.celrep.2014.10.039; Chen E, 2014, HEMATOL-AM SOC HEMAT, P268, DOI 10.1182/asheducation-2014.1.268; Cheng MB, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002026; Cheung WL, 2005, CURR BIOL, V15, P656, DOI 10.1016/j.cub.2005.02.049; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Choi HS, 2005, J BIOL CHEM, V280, P13545, DOI 10.1074/jbc.M410521200; Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008; Christova R, 2007, J CELL SCI, V120, P3262, DOI 10.1242/jcs.012328; Chu CS, 2011, J BIOL CHEM, V286, P35843, DOI 10.1074/jbc.M111.228064; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; Darieva Z, 2015, ELIFE, V4, DOI 10.7554/eLife.09886; Dawson MA, 2012, CELL REP, V2, P470, DOI 10.1016/j.celrep.2012.08.016; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Duan Q, 2008, J BIOL CHEM, V283, P33585, DOI 10.1074/jbc.M803312200; Dyson MH, 2005, J CELL SCI, V118, P2247, DOI 10.1242/jcs.02373; Eswaran J, 2012, CLIN CANCER RES, V18, P3743, DOI 10.1158/1078-0432.CCR-11-1952; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Frangini A, 2013, MOL CELL, V51, P647, DOI 10.1016/j.molcel.2013.08.022; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Gatchalian J, 2016, NUCLEIC ACIDS RES, V44, P6102, DOI 10.1093/nar/gkw193; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Ghanta KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017135; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Griffiths DS, 2011, NAT CELL BIOL, V13, P13, DOI 10.1038/ncb2135; Hammer A, 2015, FASEB J, V29, P943, DOI 10.1096/fj.14-259366; Happel N, 2009, J MOL BIOL, V386, P339, DOI 10.1016/j.jmb.2008.12.047; Harrison BC, 2010, FEBS LETT, V584, P1103, DOI 10.1016/j.febslet.2010.02.057; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hergeth SP, 2011, J CELL SCI, V124, P1623, DOI 10.1242/jcs.084947; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hossain MB, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501290; Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421; Ishibashi K, 2013, J CELL SCI, V126, P625, DOI 10.1242/jcs.116277; Jagadeeshan S, 2015, ONCOGENE, V34, P455, DOI 10.1038/onc.2013.576; Josefowicz SZ, 2016, MOL CELL, V64, P347, DOI 10.1016/j.molcel.2016.09.026; Kang B, 2011, GENE DEV, V25, P1359, DOI 10.1101/gad.2055511; Kang TH, 2007, MOL CELL BIOL, V27, P8533, DOI 10.1128/MCB.00018-07; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kim K, 2012, ONCOGENE, V31, P4290, DOI 10.1038/onc.2011.605; Kohler J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034973; Krishnamoorthy T, 2006, GENE DEV, V20, P2580, DOI 10.1101/gad.1457006; Kumar R, 2016, ONCOGENE, V35, P4423, DOI 10.1038/onc.2015.513; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kumar R, 2016, GENE, V582, P112, DOI 10.1016/j.gene.2016.02.012; Kurat CF, 2011, GENE DEV, V25, P2489, DOI 10.1101/gad.173427.111; Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590; Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108; Lee JH, 2015, NUCLEIC ACIDS RES, V43, P4505, DOI 10.1093/nar/gkv176; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Li DQ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3545; Li DQ, 2012, CELL REP, V2, P1657, DOI 10.1016/j.celrep.2012.11.018; Li DQ, 2011, P NATL ACAD SCI USA, V108, P8791, DOI 10.1073/pnas.1018389108; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li J, 2016, J CELL SCI, V129, P2448, DOI 10.1242/jcs.181248; Liu F, 2011, CANCER CELL, V19, P283, DOI 10.1016/j.ccr.2010.12.020; Liu Y, 2016, FEBS J, V283, P4462, DOI 10.1111/febs.13951; Liu Y, 2013, FEBS LETT, V587, P847, DOI 10.1016/j.febslet.2013.02.023; Liu Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003199; Mahajan K, 2013, TRENDS GENET, V29, P394, DOI 10.1016/j.tig.2013.02.003; Mahajan K, 2012, NAT STRUCT MOL BIOL, V19, P930, DOI 10.1038/nsmb.2356; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; McCuaig RD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00562; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Molli PR, 2010, J CELL BIOL, V190, P101, DOI 10.1083/jcb.200908050; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; North JA, 2011, NUCLEIC ACIDS RES, V39, P6465, DOI 10.1093/nar/gkr304; O'Sullivan AG, 2015, ONCOTARGET, V6, P26437, DOI 10.18632/oncotarget.4664; Ostrovskyi D, 2016, FUTURE MED CHEM, V8, P1537, DOI 10.4155/fmc-2016-0132; Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998; Park CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044307; Pascreau Gaetan, 2003, Prog Cell Cycle Res, V5, P369; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Reddy SDN, 2011, P NATL ACAD SCI USA, V108, P4200, DOI 10.1073/pnas.1101193108; Rider L, 2007, J BIOL CHEM, V282, P30985, DOI 10.1074/jbc.M701794200; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rosenthal A, 2014, EXPERT OPIN PHARMACO, V15, P1265, DOI 10.1517/14656566.2014.913024; Rothbart SB, 2014, BBA-GENE REGUL MECH, V1839, P627, DOI 10.1016/j.bbagrm.2014.03.001; Sabbattini P, 2014, MOL BIOL CELL, V25, P904, DOI 10.1091/mbc.E13-10-0628; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Sanidas I, 2014, MOL CELL, V53, P577, DOI 10.1016/j.molcel.2013.12.018; Sawa C, 2004, MOL CELL BIOL, V24, P4734, DOI 10.1128/MCB.24.11.4734-4742.2004; Sawicka A, 2014, GENOME RES, V24, P1808, DOI 10.1101/gr.176255.114; Selvi BR, 2010, BBA-GENE REGUL MECH, V1799, P810, DOI 10.1016/j.bbagrm.2010.09.005; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Sutcliffe EL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00260; Sutcliffe EL, 2011, MOL CELL, V41, P704, DOI 10.1016/j.molcel.2011.02.030; Swinstead EE, 2016, BIOESSAYS, V38, P1150, DOI 10.1002/bies.201600137; Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890; Thomas JL, 2015, MOL CELL BIOL, V35, P4110, DOI 10.1128/MCB.00354-15; Toker Alex, 2014, Advances in Biological Regulation, V55, P28, DOI 10.1016/j.jbior.2014.04.001; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Varier RA, 2010, EMBO J, V29, P3967, DOI 10.1038/emboj.2010.261; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-13; Wang YH, 2013, MOL CELL, V49, P283, DOI 10.1016/j.molcel.2012.10.028; Wang Z, 2015, P NATL ACAD SCI USA, V112, P8487, DOI 10.1073/pnas.1423325112; Warsito D, 2016, ONCOTARGET, V7, P42288, DOI 10.18632/oncotarget.9785; Wike CL, 2016, ELIFE, V5, DOI 10.7554/eLife.11402; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Xing S, 2008, BLOOD, V111, P5109, DOI 10.1182/blood-2007-05-091579; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yi SA, 2016, MOL CELL, V62, P443, DOI 10.1016/j.molcel.2016.03.011; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhu F, 2011, CANCER RES, V71, P393, DOI 10.1158/0008-5472.CAN-10-2012	139	18	18	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5917	5926		10.1038/onc.2017.201	http://dx.doi.org/10.1038/onc.2017.201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650470				2022-12-28	WOS:000413841400001
J	Song, ZB; Wu, P; Ni, JS; Liu, T; Fan, C; Bao, YL; Wu, Y; Sun, LG; Yu, CL; Huang, YX; Li, YX				Song, Z-B; Wu, P.; Ni, J-S; Liu, T.; Fan, C.; Bao, Y-L; Wu, Y.; Sun, L-G; Yu, C-L; Huang, Y-X; Li, Y-X			Testes-specific protease 50 promotes cell proliferation via inhibiting activin signaling	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN BREAST-CANCER; GROWTH-FACTOR; TGF-BETA; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; CYCLE ARREST; TSP50; ACTIVATION; APOPTOSIS	Testes-specific protease 50 (TSP50), a novelly identified oncogene, has the capacity to induce cell proliferation, cell invasion and tumor growth. Further studies indicated that CAGA-luc (an activin-responsive reporter construct) reporter activity could be significantly suppressed by TSP50 overexpression, implying that the activin signaling may participate in TSP50-mediated cell proliferation. Here, we reported that TSP50 had an inhibitory effect on activin signaling. Mechanistic studies revealed that TSP50 could interact with ActRIIA, inhibit activin type. receptor (ActRIB) phosphorylation, repress Smad2/3 nuclear accumulation and finally promote cell proliferation by reducing the expression of activin signal target gene p27. Additionally, we found that ActRIB activation could reverse TSP50-mediated cell proliferation and tumor growth. Furthermore, analysis of human breast cancer specimens by immunohistochemistry indicated that TSP50 expression was negatively related to p-Smad2/3 and p27 protein levels. Most importantly, breast cancer diagnosis-related indicators such as tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) levels, were correlated well with TSP50/p-Samd2/3 and TSP50/p27 expression status. Thus, our studies revealed a novel regulatory mechanism underlying TSP50-induced cell proliferation and provided a new favorable intervention target for the treatment of breast cancer.	[Song, Z-B; Wu, P.; Fan, C.; Bao, Y-L; Sun, L-G; Yu, C-L] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, 5268 Renmin St, Changchun 130024, Jilin, Peoples R China; [Song, Z-B; Wu, Y.; Sun, L-G; Yu, C-L; Huang, Y-X; Li, Y-X] Northeast Normal Univ, Inst Genet & Cytol, Changchun, Jilin, Peoples R China; [Ni, J-S; Liu, T.] Jilin Univ, Dept Pathol, Hosp 1, Changchun, Jilin, Peoples R China	Northeast Normal University - China; Northeast Normal University - China; Jilin University	Bao, YL; Li, YX (corresponding author), Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, 5268 Renmin St, Changchun 130024, Jilin, Peoples R China.	baoyl800@nenu.edu.cn; liyx486@nenu.edu.cn			National Natural Science Foundation of China [81272242, 81502284]; National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University [130014561, 130028683]; Jilin outstanding young talent Foundation [20170520031JH]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University; Jilin outstanding young talent Foundation	This research was supported by grants from the National Natural Science Foundation of China (Grant no. 81272242 and 81502284), the Open Project of the National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University (No. 130014561 and 130028683) and Jilin outstanding young talent Foundation (Grant no. 20170520031JH).	Alexander JM, 1996, J CLIN ENDOCR METAB, V81, P783, DOI 10.1210/jc.81.2.783; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Burdette JE, 2007, ENDOCR-RELAT CANCER, V14, P679, DOI 10.1677/ERC-07-0054; Chen XS, 2010, TUMORI J, V96, P103, DOI 10.1177/030089161009600117; Chen YG, 2006, EXP BIOL MED, V231, P534; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Jian-Yi, 2003, Ai Zheng, V22, P1093; Danila DC, 2002, J CLIN ENDOCR METAB, V87, P4741, DOI 10.1210/jc.2002-020527; Deli A, 2008, WORLD J GASTROENTERO, V14, P1699, DOI 10.3748/wjg.14.1699; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Galizia G, 2004, DIS COLON RECTUM, V47, P1904, DOI 10.1007/s10350-004-0695-8; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Huang HJ, 2005, J CLIN PATHOL, V58, P611, DOI 10.1136/jcp.2004.022772; Kaneda H, 2011, BRIT J CANCER, V105, P1210, DOI 10.1038/bjc.2011.348; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Li YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035030; Liu F, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/498246; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; Monteleone G, 2004, J BIOL CHEM, V279, P3925, DOI 10.1074/jbc.M303654200; Mylonas I, 2005, ONCOL REP, V13, P81; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Reis FM, 2004, MOL CELL ENDOCRINOL, V225, P77, DOI 10.1016/j.mce.2004.02.016; Shan JD, 2002, CANCER RES, V62, P290; Shav-Tal Y, 2002, STEM CELLS, V20, P493, DOI 10.1634/stemcells.20-6-493; Shi Y, 2011, J BIOMOL SCREEN, V16, P525, DOI 10.1177/1087057111398486; Song ZB, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.61; Song ZB, 2014, CELL SIGNAL, V26, P2266, DOI 10.1016/j.cellsig.2014.07.012; Song ZB, 2011, BIOCHEM J, V436, P457, DOI 10.1042/BJ20101780; Sozzani S, 2011, BLOOD, V117, P5013, DOI 10.1182/blood-2011-03-342691; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Tsuchida Kunihiro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P157, DOI 10.2174/1568008043339901; Wang X, 2011, MED ONCOL, V28, P1225, DOI 10.1007/s12032-010-9552-x; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yuan J, 2015, CELL BIOCHEM BIOPHYS, V71, P891, DOI 10.1007/s12013-014-0279-8; Yuan LM, 1999, CANCER RES, V59, P3215; Zhang Y, 2010, CHEM-BIOL INTERACT, V185, P174, DOI 10.1016/j.cbi.2010.03.035	47	6	6	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5948	5957		10.1038/onc.2017.198	http://dx.doi.org/10.1038/onc.2017.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650473				2022-12-28	WOS:000413841400004
J	Lin, C; Wang, Y; Wang, Y; Zhang, S; Yu, L; Guo, C; Xu, H				Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.			Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells	ONCOGENE			English	Article							LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; PANCREATIC-CANCER; GENE-EXPRESSION; DOWN-REGULATION; POOR-PROGNOSIS; PROLIFERATION; PROGRESSION	The long non-coding RNA, HOTTIP, has an important role in tumorigenesis. It is known that HOTTIP regulates HOX gene family; however, its regulatory mechanism in esophageal squamous cell carcinoma (ESCC) remains elusive. In this study, we investigated the role of HOTTIP in ESCC and observed that HOTTIP/HOXA13 was upregulated in ESCC and promoted cell proliferation and metastasis in vivo and in vitro. Interestingly, harboring a miR-30b-binding site, HOTTIP as a molecular sponge mainly regulated miR-30b level in the nucleus and modulated the repression of HOXA13 mediated by miR-30b in the cytoplasm, resulting in the positive HOTTIP/HOXA13 correlation. In addition, HOTTIP upregulated snail1 by competitively binding miR-30b, subsequently promoting epithelial-mesenchymal transition (EMT) and invasion. HOTTIP directly bound the adaptor protein WDR5 and drove histone H3 lysine 4 trimethylation and HOXA13 gene transcription in ESCC cells. In conclusion, our findings indicated that HOTTIP modulated HOXA13 at both the transcriptional and posttranscriptional levels in ESCC cells and HOTTIP-miR-30b-HOXA13 axis may serve as potential diagnostic markers or drug targets for ESCC therapies.	[Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.] China Pharmaceut Univ, Ctr Peptide Drug Discovery & Dev, Dept Engn Res, Nanjing, Jiangsu, Peoples R China; [Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.] China Pharmaceut Univ, Dept State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China	China Pharmaceutical University; China Pharmaceutical University	Guo, C; Xu, H (corresponding author), China Pharmaceut Univ, Ctr Peptide Drug Discovery & Dev, Dept Engn Res, Nanjing, Jiangsu, Peoples R China.; Guo, C; Xu, H (corresponding author), China Pharmaceut Univ, Dept State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.	guocha@cpu.edu.cn; 13913925346@126.com			State Key Laboratory of Natural Medicines in China [SKLNMBZ201403]; National Science and Technology Major Projects of New Drugs in China [2012ZX09103301-004, 2014ZX09508007]; National Natural Science Foundation of China [30873073]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Central University Basic Scientific Research Business Expenses [2016ZPY009]	State Key Laboratory of Natural Medicines in China; National Science and Technology Major Projects of New Drugs in China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Central University Basic Scientific Research Business Expenses	We are very grateful to Nanjing General Hospital for providing ESCC tissues and Professor Yifeng Zhou who provided ESCC cell lines. This work was supported by Project Program of State Key Laboratory of Natural Medicines in China (no. SKLNMBZ201403); National Science and Technology Major Projects of New Drugs in China (2012ZX09103301-004 and 2014ZX09508007); National Natural Science Foundation of China (30873073); the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); the Central University Basic Scientific Research Business Expenses (2016ZPY009). We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of the manuscript.	Chen FJ, 2013, MOL CARCINOGEN, V52, P908, DOI 10.1002/mc.21944; Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4; Cheng YT, 2015, ONCOTARGET, V6, P10840, DOI 10.18632/oncotarget.3450; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deng HP, 2015, CELL MOL BIOL, V61, P34; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Feng TB, 2016, ONCOTARGET, V7, P16205, DOI 10.18632/oncotarget.7578; Gagnon KT, 2014, CELL REP, V6, P211, DOI 10.1016/j.celrep.2013.12.013; Garcia-Fernandez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Ge YX, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005726; George J, 2015, SEMIN LIVER DIS, V35, P63, DOI 10.1055/s-0034-1397350; Gu ZD, 2009, CANCER RES, V69, P4969, DOI 10.1158/0008-5472.CAN-08-4546; Guo B, 2011, CUAJ-CAN UROL ASSOC, V5, pE129, DOI DOI 10.5489/CUAJ.09118; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Huang JW, 2013, CANCER SCI, V104, P1609, DOI 10.1111/cas.12291; Jin KZ, 2015, DRUG DES DEV THER, V9, P1247, DOI 10.2147/DDDT.S77597; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Kwak SY, 2015, FEBS J, V282, P1512, DOI 10.1111/febs.13238; Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002; Li WY, 2014, CANCER CELL, V25, P557, DOI 10.1016/j.ccr.2014.04.014; Li ZH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0442-z; Liu ZH, 2016, ONCOTARGET, V7, P25350, DOI 10.18632/oncotarget.8129; Lu ZF, 2015, BLOOD, V126, P1730, DOI 10.1182/blood-2015-07-657999; Mohamadkhani A, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.18794; Pan F, 2014, INT J CLIN EXP PATHO, V7, P2838; Quagliata L, 2014, HEPATOLOGY, V59, P911, DOI 10.1002/hep.26740; Sugihara H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081839; Sun XL, 2017, J CELL PHYSIOL, V232, P625, DOI 10.1002/jcp.25466; Tsang FHC, 2015, LIVER INT, V35, P1597, DOI 10.1111/liv.12746; Wang Guang-Yu, 2014, Bull Cancer, V101, pE27, DOI 10.1684/bdc.2014.2023; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wei Y, 2014, J BIOL CHEM, V289, P10270, DOI 10.1074/jbc.C113.541417; Wu YT, 2015, CURR PHARM DESIGN, V21, P5017, DOI 10.2174/1381612821666150724115625; Xie H, 2015, BIOCHEM BIOPH RES CO, V463, P569, DOI 10.1016/j.bbrc.2015.05.096; Xu YP, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-173; Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443; Ye ZX, 2015, INT J GYNECOL CANCER, V25, P1574, DOI 10.1097/IGC.0000000000000546; Yu HS, 2014, ONCOL LETT, V7, P799, DOI 10.3892/ol.2013.1754; Zhang H, 2015, TUMOR BIOL, V36, P8805, DOI 10.1007/s13277-015-3645-2; Zhong K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-703; Zhong ZP, 2014, MOL MED REP, V10, P2575, DOI 10.3892/mmr.2014.2494; Zhou XY, 2015, CELL PHYSIOL BIOCHEM, V36, P1440, DOI 10.1159/000430309	43	103	107	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5392	5406		10.1038/onc.2017.133	http://dx.doi.org/10.1038/onc.2017.133			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534516				2022-12-28	WOS:000411382100006
J	Kawauchi, D; Ogg, RJ; Liu, L; Shih, DJH; Finkelstein, D; Murphy, BL; Rehg, JE; Korshunov, A; Calabrese, C; Zindy, F; Phoenix, T; Kawaguchi, Y; Gronych, J; Gilbertson, RJ; Lichter, P; Gajjar, A; Kool, M; Northcott, PA; Pfister, SM; Roussel, MF				Kawauchi, D.; Ogg, R. J.; Liu, L.; Shih, D. J. H.; Finkelstein, D.; Murphy, B. L.; Rehg, J. E.; Korshunov, A.; Calabrese, C.; Zindy, F.; Phoenix, T.; Kawaguchi, Y.; Gronych, J.; Gilbertson, R. J.; Lichter, P.; Gajjar, A.; Kool, M.; Northcott, P. A.; Pfister, S. M.; Roussel, M. F.			Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells	ONCOGENE			English	Article							GRANULE NEURON PRECURSORS; CENTRAL-NERVOUS-SYSTEM; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; BETA-CATENIN; MOUSE MODEL; STEM-CELLS; TUMORS; P53; PROGENITORS	Group3 medulloblastoma (MBG3) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MBG3 models are currently lacking, making inferences related to their cellular origin thus far limited. Using in utero electroporation, we here report that MBG3 mouse models can be developed in situ from different multipotent embryonic cerebellar progenitor cells via conditional expression of Myc and loss of Trp53 function in several Cre driver mouse lines. The Blbp-Cre driver that targets embryonic neural progenitors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventricle, recapitulating human MBG3. Enforced co-expression of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic neuronal progenitors as well as cerebellar granule cells give rise to MBG3 with their distinct growth kinetics. Cross-species gene expression analysis revealed that these novel MBG3 models shared molecular characteristics with human MBG3, irrespective of their cellular origin. We here developed MBG3 mouse models in their physiological environment and we show that oncogenic insults drive this MB subgroup in different cerebellar lineages rather than in a specific cell of origin.	[Kawauchi, D.; Liu, L.; Murphy, B. L.; Zindy, F.; Roussel, M. F.] St Jude Childrens Res Hosp SJCRH, Dept Tumor Cell Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Kawauchi, D.; Kool, M.; Pfister, S. M.] German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [Ogg, R. J.] St Jude Childrens Res Hosp SJCRH, Dept Radiol Sci, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Shih, D. J. H.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Toronto, ON, Canada; [Finkelstein, D.] St Jude Childrens Res Hosp SJCRH, Dept Computat Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Rehg, J. E.] St Jude Childrens Res Hosp SJCRH, Dept Vet Pathol Core, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Korshunov, A.] Heidelberg Univ, Dept Neuropathol, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Calabrese, C.] St Jude Childrens Res Hosp SJCRH, Dept Small Anim Imaging Core, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Phoenix, T.; Gilbertson, R. J.; Northcott, P. A.] St Jude Childrens Res Hosp SJCRH, Dept Dev Neurobiol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Kawaguchi, Y.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan; [Gronych, J.; Lichter, P.] German Canc Res Ctr, Dept Mol Genet, Heidelberg, Germany; [Gajjar, A.] St Jude Childrens Res Hosp SJCRH, Dept Oncol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Pfister, S. M.] Heidelberg Univ Hosp, Dept Pediat Hematol & Oncol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Kyoto University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Kawauchi, D; Roussel, MF (corresponding author), St Jude Childrens Res Hosp SJCRH, Dept Tumor Cell Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.; Kawauchi, D (corresponding author), German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.kawauchi@dkfz.de; martine.roussel@stjude.org	Northcott, Paul A/N-4022-2018; Rehg, Jerold E/N-8111-2018; Pfister, Stefan M/F-6860-2013; Gilbertson, Richard James/ABE-1346-2021; Gajjar, Amar/N-8059-2018; Shih, David J. H./AAE-8726-2019; Roussel, Martine F/F-1469-2016	Northcott, Paul A/0000-0002-1220-5252; Pfister, Stefan M/0000-0002-5447-5322; Gilbertson, Richard James/0000-0001-7539-9472; Shih, David J. H./0000-0002-9802-4937; Roussel, Martine F/0000-0002-1740-8139; Korshunov, Andrey/0000-0002-5257-3623	National Institute of Health [CA-096832, CA-21765, HD-049888, RR-029005]; Anderson fellowship; Deutsche Forschungsgemeinschaft [KA 4472/1-1]; Helmholtz Alliance 'Preclinical Comprehensive Cancer Center' [HA-305]; American Lebanese Syrian Associated Charities of SJCRH; Cancer Research UK [22492] Funding Source: researchfish; The Brain Tumour Charity [GN-000356] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049888] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR029005] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Anderson fellowship; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Helmholtz Alliance 'Preclinical Comprehensive Cancer Center'; American Lebanese Syrian Associated Charities of SJCRH(American Lebanese Syrian Associated Charities (ALSAC)); Cancer Research UK(Cancer Research UK); The Brain Tumour Charity; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Y Takahashi (Kyoto University) and K Kawakami (National Institute of Genetics, Japan) for generously providing Tol2 transposon related vectors; L Linke and N Mack (DKFZ), J Grenet, D Farmer, S Wilkerson, S Smith and S Robinson for excellent technical assistance, J Morris and M Loyd for Affymetrix microarray analysis; Drs R Ashmun and A-M Hamilton Easton for fluorescence-activated cell sorting analysis; M Payton and C Winter for in vivo imaging of tumor growth; M Johnson and S Brown for orthotopic transplants; Dr MA Scoggins, L Stokes and A Owens for processing and analysis of human images; Drs O Witt, K Reifenberg, N Denk and K Dell for helpful assistance with animal experiments at DKFZ; Dr C Wright (Vanderbilt University), Y Nakano and M Horiguchi (Kyoto University) for mice; Drs H Liu and W Feng (DKFZ) for sharing R26-LSL-tdTomato mice and helpful discussions; Drs Y Ouyang (SJCRH) and F Bestvater (DKFZ) for Light Microscopy. This work was funded in part by the National Institute of Health Grants CA-096832, CA-21765 (to MFR), HD-049888, RR-029005 (to RJO), the Anderson fellowship and the Deutsche Forschungsgemeinschaft, KA 4472/1-1 (to DK), the Helmholtz Alliance 'Preclinical Comprehensive Cancer Center' Grant HA-305 (to PL, JG and SMP) and the American Lebanese Syrian Associated Charities of SJCRH.	Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Birks DK, 2013, PEDIATR BLOOD CANCER, V60, P1095, DOI 10.1002/pbc.24481; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brett M., 2005, MNI BRAIN TALAIRACH; Cheng FY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035541; Cho KH, 2011, SURG RADIOL ANAT, V33, P523, DOI 10.1007/s00276-011-0796-8; Dastjerdi FV, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00010; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Gajjar AJ, 2014, NAT REV CLIN ONCOL, V11, P714, DOI 10.1038/nrclinonc.2014.181; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Hanaford AR, 2016, CLIN CANCER RES, V22, P3903, DOI 10.1158/1078-0432.CCR-15-3011; Hevner RF, 2006, NEUROSCI RES, V55, P223, DOI 10.1016/j.neures.2006.03.004; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hoshino M, 2005, NEURON, V47, P201, DOI 10.1016/j.neuron.2005.06.007; Hunter NL, 2007, DEVELOPMENT, V134, P3449, DOI 10.1242/dev.003095; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kawauchi D, 2008, DEV BIOL, V322, P345, DOI 10.1016/j.ydbio.2008.08.005; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Khandanpour C, 2013, CANCER CELL, V23, P200, DOI 10.1016/j.ccr.2013.01.011; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li P, 2013, NAT NEUROSCI, V16, P1737, DOI 10.1038/nn.3553; Lorenz A, 2011, MOL CELL BIOL, V31, P3326, DOI 10.1128/MCB.05718-11; McCall MN, 2014, NUCLEIC ACIDS RES, V42, pD938, DOI 10.1093/nar/gkt1204; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Northcott PA, 2012, NAT REV NEUROL, V8, P340, DOI 10.1038/nrneurol.2012.78; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Perreault S, 2014, AM J NEURORADIOL, V35, P1263, DOI 10.3174/ajnr.A3990; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Poschl J, 2013, DEV BIOL, V374, P319, DOI 10.1016/j.ydbio.2012.12.001; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Rogers HA, 2013, BRIT J CANCER, V108, P2130, DOI 10.1038/bjc.2013.170; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Roussel MF, 2011, CURR TOP DEV BIOL, V94, P235, DOI 10.1016/B978-0-12-380916-2.00008-5; Sato Y, 2007, DEV BIOL, V305, P616, DOI 10.1016/j.ydbio.2007.01.043; Schmahmann J.D., 2000, MRI ATLAS HUMAN CERE; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Sgaier SK, 2005, NEURON, V45, P27, DOI 10.1016/S0896-6273(04)00802-5; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Talairach J., 1988, COPLANAR STEREOTAXIC; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wefers AK, 2014, ACTA NEUROPATHOL, V127, P931, DOI 10.1007/s00401-014-1271-5; Wu Xiaochong, 2011, Chin J Cancer, V30, P442, DOI 10.5732/cjc.011.10040; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yokota Y, 2011, DEV BIOL, V353, P382, DOI 10.1016/j.ydbio.2011.02.001; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418; Zuckermann M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8391	57	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5231	5242		10.1038/onc.2017.110	http://dx.doi.org/10.1038/onc.2017.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504719	Green Published, hybrid			2022-12-28	WOS:000410671700002
J	West, AC; Tang, K; Tye, H; Yu, L; Deng, N; Najdovska, M; Lin, SJ; Balic, JJ; Okochi-Takada, E; McGuirk, P; Keogh, B; McCormack, W; Bhathal, PS; Reilly, M; Oshima, M; Ushijima, T; Tan, P; Jenkins, BJ				West, A. C.; Tang, K.; Tye, H.; Yu, L.; Deng, N.; Najdovska, M.; Lin, S. J.; Balic, J. J.; Okochi-Takada, E.; McGuirk, P.; Keogh, B.; McCormack, W.; Bhathal, P. S.; Reilly, M.; Oshima, M.; Ushijima, T.; Tan, P.; Jenkins, B. J.			Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer	ONCOGENE			English	Article							TOLL-LIKE RECEPTORS; HELICOBACTER-PYLORI; INNATE IMMUNITY; TUMORIGENESIS; EXPRESSION; PROGRESSION; CARCINOMA; PROTEIN; TLR2; TOLL-LIKE-RECEPTOR-2	Toll-like receptors (TLRs) are key regulators of innate immune responses, and their dysregulation is observed in numerous inflammation-associated malignancies, including gastric cancer (GC). However, the identity of specific TLRs and their molecular targets which promote the pathogenesis of human GC is ill-defined. Here, we sought to determine the clinical utility of TLR2 in human GC. TLR2 mRNA and protein expression levels were elevated in >50% of GC patient tumors across multiple ethnicities. TLR2 was also widely expressed among human GC cell lines, and DNA microarray-based expression profiling demonstrated that the TLR2-induced growth responsiveness of human GC cells corresponded with the up-regulation of six anti-apoptotic (BCL2A1, BCL2, BIRC3, CFLAR, IER3, TNFAIP3) and down-regulation of two tumor suppressor (PDCD4, TP53INP1) genes. The TLR2-mediated regulation of these anti-apoptotic and tumor suppressor genes was also supported by their increased and reduced expression, respectively, in two independent genetic GC mouse models (gp130(F/F) and Gan) characterized by high tumor TLR2 expression. Notably, enrichment of this TLR2-regulated gene signature also positively correlated with augmented TLR2 expression in human GC tumors, and served as an indicator of poor patient survival. Furthermore, treatment of gp130(F/F) and cell line-derived xenograft (MKN1) GC mouse models with a humanized anti-TLR2 antibody suppressed gastric tumor growth, which was coincident with alterations to the TLR2-driven gene signature. Collectively, our study demonstrates that in the majority of GC patients, elevated TLR2 expression is associated with a growth-potentiating gene signature which predicts poor patient outcomes, thus supporting TLR2 as a promising therapeutic target in GC.	[West, A. C.; Tang, K.; Tye, H.; Yu, L.; Najdovska, M.; Balic, J. J.; Jenkins, B. J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia; [West, A. C.; Tang, K.; Yu, L.; Balic, J. J.; Bhathal, P. S.; Jenkins, B. J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol Translat Sci, Clayton, Vic, Australia; [Deng, N.; Lin, S. J.; Tan, P.] Genome Inst Singapore, Singapore, Singapore; [Okochi-Takada, E.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo, Japan; [McGuirk, P.; Keogh, B.; McCormack, W.; Reilly, M.] Opsona Therapeut Ltd, Dublin, Ireland; [Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan; [Tan, P.] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore; [Tan, P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore	Hudson Institute of Medical Research; Monash University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Cancer Center - Japan; Kanazawa University; National University of Singapore; National University of Singapore	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@hudson.org.au	Oshima, Masanobu/F-9958-2014; Ushijima, Toshikazu/AAP-5742-2021	Oshima, Masanobu/0000-0002-3304-0004; Ushijima, Toshikazu/0000-0003-3405-7817; Deng, Niantao/0000-0001-9717-2236; Jenkins, Brendan/0000-0002-7552-4656; Balic, Jesse/0000-0002-9681-6834	National Health and Medical Research Council (NHMRC) of Australia; Cancer Council Victoria; Victorian Government of Australia; NHMRC; Monash Graduate Scholarship; Monash International Postgraduate Research Scholarship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Victorian Government of Australia; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Monash Graduate Scholarship(Monash University); Monash International Postgraduate Research Scholarship(Monash University)	This work was supported by research grants awarded by the National Health and Medical Research Council (NHMRC) of Australia and Cancer Council Victoria, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. AW is supported by an NHMRC Early Career Fellowship, KT is supported by Monash Graduate and Monash International Postgraduate Research Scholarships and BJJ is supported by an NHMRC Senior Medical Research Fellowship.	[Anonymous], 2012, TUMORI, V98, P663; Asprodites N, 2008, FASEB J, V22, P3628, DOI 10.1096/fj.08-108274; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Castano-Rodriguez N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060327; Chen SY, 2015, LEUKEMIA RES, V39, P976, DOI 10.1016/j.leukres.2015.06.004; Choi HJ, 2010, BIOCHEM BIOPH RES CO, V400, P396, DOI 10.1016/j.bbrc.2010.08.084; Conti L, 2013, FASEB J, V27, P4731, DOI 10.1096/fj.13-230201; Correa Pelayo, 2011, US Gastroenterol Hepatol Rev, V7, P59; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; de Oliveira JG, 2012, WORLD J GASTROENTERO, V18, P1235, DOI 10.3748/wjg.v18.i11.1235; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Jiang PH, 2006, WORLD J GASTROENTERO, V12, P691, DOI 10.3748/wjg.v12.i5.691; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Li ZS, 2011, CANCER LETT, V313, P192, DOI 10.1016/j.canlet.2011.09.007; Lordick F, 2014, CANCER TREAT REV, V40, P692, DOI 10.1016/j.ctrv.2014.03.002; Ma G, 2013, TUMOR BIOL, V34, P3879, DOI 10.1007/s13277-013-0975-9; Maeda Y, 2016, CANCER PREV RES, V9, P253, DOI 10.1158/1940-6207.CAPR-15-0315; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Niccolai E, 2015, WORLD J GASTROENTERO, V21, P5778, DOI 10.3748/wjg.v21.i19.5778; Nihon-Yanagi Y, 2012, CANCER IMMUNOL IMMUN, V61, P71, DOI 10.1007/s00262-011-1085-4; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pimentel-Nunes P, 2013, HELICOBACTER, V18, P22, DOI 10.1111/hel.12008; Pimentel-Nunes P, 2011, PATHOL ONCOL RES, V17, P677, DOI 10.1007/s12253-011-9368-9; Piva R, 2006, J CLIN INVEST, V116, P3171, DOI 10.1172/JCI29401; Reilly M, 2013, CLIN PHARMACOL THER, V94, P593, DOI 10.1038/clpt.2013.150; Savva A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00387; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seya T, 2015, CANCER SCI, V106, P1659, DOI 10.1111/cas.12824; Shi WN, 2014, TUMOR BIOL, V35, P9627, DOI 10.1007/s13277-014-2268-3; Tahara T, 2007, CANCER SCI, V98, P1790, DOI 10.1111/j.1349-7006.2007.00590.x; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Uno K, 2007, AM J PHYSIOL-GASTR L, V293, pG1004, DOI 10.1152/ajpgi.00096.2007; Wei Q, 2012, IUBMB LIFE, V64, P697, DOI 10.1002/iub.1051; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Wu YH, 2013, GUT, V62, P1100, DOI 10.1136/gutjnl-2011-301373; Yang HZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006520; Yang H, 2014, ANN CLIN LAB SCI, V44, P158; Zeng HM, 2011, CANCER EPIDEM BIOMAR, V20, P2594, DOI 10.1158/1055-9965.EPI-11-0702; Zhen Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.376; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	50	40	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5134	5144		10.1038/onc.2017.121	http://dx.doi.org/10.1038/onc.2017.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481875				2022-12-28	WOS:000409371100005
J	Olsen, RR; Otero, JH; Garcia-Lopez, J; Wallace, K; Finkelstein, D; Rehg, JE; Yin, Z; Wang, D; Freeman, KW				Olsen, R. R.; Otero, J. H.; Garcia-Lopez, J.; Wallace, K.; Finkelstein, D.; Rehg, J. E.; Yin, Z.; Wang, D.; Freeman, K. W.			MYCN induces neuroblastoma in primary neural crest cells	ONCOGENE			English	Article							STEM-CELLS; NEURONAL DIFFERENTIATION; MOUSE MODEL; IN-VITRO; N-MYC; B-MYB; TUMORS; THERAPY; SENSITIVITY; EXPRESSION	Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS), which causes 15% of pediatric cancer deaths. High-risk NBL is characterized by N-Myc amplification and segmental chromosomal gains and losses. Owing to limited disease models, the etiology of NBL is largely unknown, including both the cell of origin and the majority of oncogenic drivers. We have established a novel system for studying NBL based on the transformation of neural crest cells (NCCs), the progenitor cells of the SNS, isolated from mouse embryonic day 9.5 trunk neural tube explants. Based on pathology and gene expression analysis, we report the first successful transformation of wild-type NCCs into NBL by enforced expression of N-Myc, to generate phenotypically and molecularly accurate tumors that closely model human MYCN-amplified NBL. Using comparative genomic hybridization, we found that NCC-derived NBL tumors acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL including 17q gain, 2p gain and loss of 1p36. When p53-compromised NCCs were transformed with N-Myc, we generated primitive neuroectodermal tumors with divergent differentiation including osteosarcoma. These subcutaneous tumors were metastatic to regional lymph nodes, liver and lung. Our novel experimental approach accurately models human NBL and establishes a new system with potential to study early stages of NBL oncogenesis, to functionally assess NBL oncogenic drivers and to characterize NBL metastasis.	[Olsen, R. R.; Otero, J. H.; Garcia-Lopez, J.; Wallace, K.; Yin, Z.; Freeman, K. W.] St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA; [Finkelstein, D.; Wang, D.] St Jude Childrens Res Hosp, Computat Biol Dept, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA; [Rehg, J. E.] St Jude Childrens Res Hosp, Pathol Dept, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Freeman, KW (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl,MS 354,Room D5048C, Memphis, TN 38105 USA.	kevin.freeman@stjude.org	Rehg, Jerold E/N-8111-2018; Lopez, Jesus Garcia/N-7952-2019	Lopez, Jesus Garcia/0000-0002-1877-3402	Department of Defense [W81XWH-14-1-0090]; ALSAC	Department of Defense(United States Department of Defense); ALSAC(American Lebanese Syrian Associated Charities (ALSAC))	We thank the following for their contributions: Yasmine A Valentin-Vega for assistance with microscopy and secondary antibodies, Jamy Peng for antibodies to MAP2 and GFAP, Martine Roussel for N-Myc overexpression plasmids, Joe Opferman for providing TH-MycN tumor lysate, Manon Fortier and Michelle Mary-Sinclair for technical assistance, and the services provided by St. Jude core facilities including the Veterinary Pathology Core, the Microscopy Core, the Flow Cytometry Shared Resource and the Hartwell Center. This work was supported by research funds from the Department of Defense award number W81XWH-14-1-0090 and ALSAC.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bielle F, 2012, AM J SURG PATHOL, V36, P1141, DOI 10.1097/PAS.0b013e31825a6895; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Fukuta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112291; Gualdrini F, 2010, ONCOTARGET, V1, P278; Hata JL, 2015, ARCH PATHOL LAB MED, V139, P543, DOI 10.5858/arpa.2014-0255-OA; Huber K, 2015, CELL TISSUE RES, V359, P333, DOI 10.1007/s00441-014-1947-0; Ikegaki N, 2013, P NATL ACAD SCI USA, V110, P6097, DOI 10.1073/pnas.1118262110; Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x; Karunasena E, 2015, ONCOTARGET, V6, P22038, DOI 10.18632/oncotarget.4194; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Mahomed F, 2015, J ORAL MAXIL SURG, V73, P1314, DOI 10.1016/j.joms.2015.01.007; Meany HJ, 2014, PEDIATR BLOOD CANCER, V61, P1932, DOI 10.1002/pbc.25134; Montavon G, 2014, ONCOTARGET, V5, P4452, DOI 10.18632/oncotarget.2036; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Olsen RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116998; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; Russell MR, 2013, CANCER RES, V73, P776, DOI 10.1158/0008-5472.CAN-12-2669; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Schwermer M, 2015, ONCOTARGET, V6, P15425, DOI 10.18632/oncotarget.3908; Simoes-Costa M, 2015, DEVELOPMENT, V142, P242, DOI 10.1242/dev.105445; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Tornoczky T, 2004, CANCER-AM CANCER SOC, V100, P390, DOI 10.1002/cncr.20005; Tornoczky T, 2007, PATHOL ONCOL RES, V13, P269, DOI 10.1007/BF02940304; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Wang ZB, 2011, CANCER RES, V71, P4292, DOI 10.1158/0008-5472.CAN-10-4087; Watt F, 2007, CANCER GENE THER, V14, P287, DOI 10.1038/sj.cgt.7701012; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wolter J, 2010, FUTURE ONCOL, V6, P429, DOI 10.2217/FON.09.176; Wylie LA, 2015, DIS MODEL MECH, V8, P429, DOI 10.1242/dmm.018630	36	54	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5075	5082		10.1038/onc.2017.128	http://dx.doi.org/10.1038/onc.2017.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459463	hybrid, Green Published			2022-12-28	WOS:000408768800012
J	Lee, KM; Choi, WI; Koh, DI; Kim, YJ; Jeon, BN; Yoon, JH; Lee, CE; Kim, SH; Oh, J; Hur, MW				Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Lee, C. E.; Kim, S. H.; Oh, J.; Hur, M. W.			The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding (vol 31, pg 1442, 2012)	ONCOGENE			English	Correction															Basic Science Research Grant [314-2008-1-E00030]; MRC from the National Research Foundation of Korea [R13-2002-054-05002-0]; Faculty Research Grant from Yonsei University School of Medicine [6-2007-0105]	Basic Science Research Grant; MRC from the National Research Foundation of Korea(National Research Foundation of Korea); Faculty Research Grant from Yonsei University School of Medicine	This work was mainly funded by a Basic Science Research Grant (314-2008-1-E00030 to MW Hur and CE Lee) and MRC (R13-2002-054-05002-0) from the National Research Foundation of Korea, and also by a Faculty Research Grant (6-2007-0105 to MW Hur) from Yonsei University School of Medicine.	Lee KM, 2012, ONCOGENE, V31, P1442, DOI 10.1038/onc.2011.331	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4951	4951		10.1038/onc.2017.115	http://dx.doi.org/10.1038/onc.2017.115			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28604745	Bronze			2022-12-28	WOS:000408234400011
J	Huhn, SC; Liu, J; Ye, C; Lu, H; Jiang, X; Feng, X; Ganesan, S; White, E; Shen, Z				Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Ganesan, S.; White, E.; Shen, Z.			Regulation of spindle integrity and mitotic fidelity by BCCIP	ONCOGENE			English	Article							XENOPUS EGG EXTRACTS; MICROTUBULE ATTACHMENT; CHROMOSOME INSTABILITY; SELF-ORGANIZATION; MOTHER CENTRIOLE; TUMOR-SUPPRESSOR; DNA-DAMAGE; CENTROSOMES; PROTEIN; CANCER	Centrosomes together with the mitotic spindle ensure the faithful distribution of chromosomes between daughter cells, and spindle orientation is a major determinant of cell fate during tissue regeneration. Spindle defects are not only an impetus of chromosome instability but are also a cause of developmental disorders involving defective asymmetric cell division. In this work, we demonstrate BCCIP, especially BCCIP alpha, as a previously unidentified component of the mitotic spindle pole and the centrosome. We demonstrate that BCCIP localizes proximal to the mother centriole and participates in microtubule organization and then redistributes to the spindle pole to ensure faithful spindle architecture. We find that BCCIP depletion leads to morphological defects, disoriented mitotic spindles, chromosome congression defects and delayed mitotic progression. Our study identifies BCCIP as a novel factor critical for microtubule regulation and explicates a mechanism utilized by BCCIP in tumor suppression.	[Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Ganesan, S.; White, E.; Shen, Z.] Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA; [Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Shen, Z.] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA; [Ganesan, S.] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ USA; [Jiang, X.] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Jilin University	Shen, Z (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ USA.	shenzh@cinj.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Shen, Zhiyuan/0000-0003-2834-0309; Feng, Xing/0000-0002-2253-4180; feng, xing/0000-0001-8226-3389	NIH [R01CA156706, R01CA195612-01]; New Jersey Commission on Cancer Research Pre-Doctoral fellowship [DFHS15PPC042]; Histopathology and Imaging shared resources of The Cancer Institute of New Jersey [P30CA072720]; NATIONAL CANCER INSTITUTE [R01CA156706, R01CA115488, R01CA195612] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission on Cancer Research Pre-Doctoral fellowship; Histopathology and Imaging shared resources of The Cancer Institute of New Jersey; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH R01CA156706 and R01CA195612-01 to ZS, by New Jersey Commission on Cancer Research Pre-Doctoral fellowship (DFHS15PPC042) to SH and by the Histopathology and Imaging shared resources of The Cancer Institute of New Jersey (P30CA072720).	Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Chandhok NS, 2009, CURR OPIN GENET DEV, V19, P74, DOI 10.1016/j.gde.2008.12.004; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; Delgehyr N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/jcs.02302; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Fan JJ, 2009, CELL CYCLE, V8, P3019; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Godin JD, 2010, NEURON, V67, P392, DOI 10.1016/j.neuron.2010.06.027; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Gruber R, 2011, NAT CELL BIOL, V13, P1325, DOI 10.1038/ncb2342; Guo J, 2006, MOL BIOL CELL, V17, P680, DOI 10.1091/mbc.E05-04-0360; Haren Laurence, 2009, BMC Res Notes, V2, P64, DOI 10.1186/1756-0500-2-64; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Hernandez P, 2010, DIS MODEL MECH, V3, P304, DOI 10.1242/dmm.004507; Hori A, 2014, EMBO REP, V15, P175, DOI 10.1002/embr.201337929; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huang YY, 2013, CANCER RES, V73, P7122, DOI 10.1158/0008-5472.CAN-13-1766; Huang YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030638; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kim DJ, 2013, BLOOD, V121, P3521, DOI 10.1182/blood-2012-11-470179; King JM, 2000, J CELL SCI, V113, P3815; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Lu HM, 2007, NUCLEIC ACIDS RES, V35, P7160, DOI 10.1093/nar/gkm732; Lu HM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002291; Mao NH, 2007, DNA REPAIR, V6, P1651, DOI 10.1016/j.dnarep.2007.05.012; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Mogensen MM, 2000, J CELL SCI, V113, P3013; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Pellman D, 2007, NATURE, V446, P38, DOI 10.1038/446038a; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Raaijmakers JA, 2013, J CELL BIOL, V201, P201, DOI 10.1083/jcb.201208098; Ried T, 2012, BBA-GENE REGUL MECH, V1819, P784, DOI 10.1016/j.bbagrm.2012.02.020; Salisbury JL, 2003, CURR BIOL, V13, pR88, DOI 10.1016/S0960-9822(03)00033-2; Sehrawat S, 2011, BLOOD, V117, P708, DOI 10.1182/blood-2010-02-268870; Shida T, 2010, P NATL ACAD SCI USA, V107, P21517, DOI 10.1073/pnas.1013728107; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Song YY, 2015, TRENDS CELL BIOL, V25, P125, DOI 10.1016/j.tcb.2014.10.004; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thornton GK, 2009, TRENDS GENET, V25, P501, DOI 10.1016/j.tig.2009.09.011; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Waters JC, 1996, J CELL SCI, V109, P2823; Wyler E, 2014, FEBS LETT, V588, P3685, DOI 10.1016/j.febslet.2014.08.013; Yang YF, 2014, P NATL ACAD SCI USA, V111, P2158, DOI 10.1073/pnas.1319341111; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zhou ZW, 2013, DNA REPAIR, V12, P645, DOI 10.1016/j.dnarep.2013.04.017	64	16	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4750	4766		10.1038/onc.2017.92	http://dx.doi.org/10.1038/onc.2017.92			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394342	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000407702400008
J	Dovmark, TH; Saccomano, M; Hulikova, A; Alves, F; Swietach, P				Dovmark, T. H.; Saccomano, M.; Hulikova, A.; Alves, F.; Swietach, P.			Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells	ONCOGENE			English	Article							GAP-JUNCTION; TUMOR-CELLS; CANCER; HYPOXIA; ACID; PH; EXPRESSION; GROWTH; MCT4; COMMUNICATION	Glycolytic cancer cells produce large quantities of lactate that must be removed to sustain metabolism in the absence of oxidative phosphorylation. The only venting mechanism described to do this at an adequate rate is H--(+) coupled lactate efflux on monocarboxylate transporters (MCTs). Outward MCT activity is, however, thermodynamically inhibited by extracellular acidity, a hallmark of solid tumours. This inhibition would feedback unfavourably on metabolism and growth, raising the possibility that other venting mechanisms become important in under-perfused tumours. We investigated connexin-assembled gap junctions as an alternative route for discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells. Diffusive coupling (calcein transmission) in vitro was strong between Colo357 cells, weaker yet hypoxia-inducible between BxPC3 cells, and very low between MiaPaCa2 cells. Coupling correlated with levels of connexin-43 (Cx43), a protein previously linked to late-stage disease. Evoked lactate dynamics, imaged in Colo357 spheroids using cytoplasmic pH as a read-out, indicated that lactate anions permeate gap junctions faster than highly-buffered H+ ions. At steady-state, junctional transmission of lactate (a chemical base) from the spheroid core had an alkalinizing effect on the rim, producing therein a milieu conducive for growth. Metabolite assays demonstrated that Cx43 knockdown increased cytoplasmic lactate retention in Colo357 spheroids (diameter similar to 150 mu m). MiaPaCa2 cells, which are Cx43 negative in monolayer culture, showed markedly increased Cx43 immunoreactivity at areas of invasion in orthotopic xenograft mouse models. These tissue areas were associated with chronic extracellular acidosis (as indicated by the marker LAMP2 near/at the plasmalemma), which can explain the advantage of junctional transmission over MCT in vivo. We propose that Cx43 channels are important conduits for dissipating lactate anions from glycolytic PDAC cells. Furthermore, lactate entry into the better-perfused recipient cells has a favourable alkalinizing effect and supplies substrate for oxidative phosphorylation. Cx43 is thus a novel target for influencing metabolite handling in junctionally-coupled tumours.	[Dovmark, T. H.; Hulikova, A.; Swietach, P.] Univ Oxford, Dept Physiol Anat & Genet, Pk Rd, Oxford OX1 3PT, England; [Saccomano, M.; Alves, F.] Max Planck Inst Expt Med, Gottingen, Germany; [Alves, F.] Univ Med Ctr Goettingen, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Alves, F.] Univ Med Ctr Goettingen, Dept Haematol & Med Oncol, Gottingen, Germany	University of Oxford; Max Planck Society; University of Gottingen; University of Gottingen	Swietach, P (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Pk Rd, Oxford OX1 3PT, England.	pawel.swietach@dpag.ox.ac.uk	Swietach, Pawel/AAK-4169-2020	Swietach, Pawel/0000-0002-9945-9473	European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-ITN Grant) [289648]; Worldwide Cancer Research [2012/0027]; Royal Society; Worldwide Cancer Research [12-0027] Funding Source: researchfish	European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-ITN Grant); Worldwide Cancer Research; Royal Society(Royal Society of London); Worldwide Cancer Research	We thank Barbel Heidrich, Sabine Wolfgramm and Bettina Jeep for excellent technical assistance. We thank Vicky Ball for performing measurements on the ABX Pentra 400 system. This study is supported by the European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-2011-ITN Grant 289648), Royal Society and Worldwide Cancer Research (2012/0027).	Damaghi M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9752; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; ELSABBAN ME, 1991, J CELL BIOL, V115, P1375, DOI 10.1083/jcb.115.5.1375; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Faller BA, 2009, BIOL-TARGETS THER, V3, P419; Gadaleta E, 2011, NUCLEIC ACIDS RES, V39, P7900, DOI 10.1093/nar/gkr533; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Grillo-Hill BK, 2015, ELIFE, V4, DOI 10.7554/eLife.03270; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hulikova A, 2016, P NATL ACAD SCI USA, V113, pE5344, DOI 10.1073/pnas.1610954113; Hulikova A, 2014, J BIOL CHEM, V289, P25418, DOI 10.1074/jbc.M114.547844; Hulikova A, 2011, J BIOL CHEM, V286, P13815, DOI 10.1074/jbc.M111.219899; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Moll W, 2008, J APPL PHYSIOL, V105, P365, DOI 10.1152/japplphysiol.zdg-8016-pcpcomm.2008; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Ojugo ASE, 1999, NMR BIOMED, V12, P495, DOI 10.1002/(SICI)1099-1492(199912)12:8<495::AID-NBM594>3.0.CO;2-K; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Putney LK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-46; Richards M, 2016, CARDIOVASC RES, V110, P395, DOI 10.1093/cvr/cvw080; Saccomano M, 2016, INT J CANCER, V139, P2277, DOI 10.1002/ijc.30277; San Martin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057712; Schilling F, 2013, NMR BIOMED, V26, P557, DOI 10.1002/nbm.2892; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Swietach P, 2007, CIRC RES, V100, P1045, DOI 10.1161/01.RES.0000264071.11619.47; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; TANNOCK IF, 1989, CANCER RES, V49, P4373; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Zhang A, 2015, ONCOTARGET, V6, P11640, DOI 10.18632/oncotarget.3449	45	40	42	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4538	4550		10.1038/onc.2017.71	http://dx.doi.org/10.1038/onc.2017.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368405	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-28	WOS:000407246200002
J	Takahashi, H; Inoue, J; Sakaguchi, K; Takagi, M; Mizutani, S; Inazawa, J				Takahashi, H.; Inoue, J.; Sakaguchi, K.; Takagi, M.; Mizutani, S.; Inazawa, J.			Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells	ONCOGENE			English	Article							MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; P53 STATUS; SYNTHETASE; EXPRESSION; APOPTOSIS; GENE; SENSITIVITY; CANCER; DISEASE	L-asparaginase has been used for more than three decades in acute lymphoblastic leukemia (ALL) patients and remains an essential drug in the treatment of ALL. Poor response to L-asparaginase is associated with increased risk of therapeutic failure in ALL. However, both the metabolic perturbation and molecular context of L-asparaginase-treated ALL cells has not been fully elucidated. Here we identify that treatment with L-asparaginase results in metabolic shutdown via the reduction of both glycolysis and oxidative phosphorylation, accompanied by mitochondrial damage and activation of autophagy. The autophagy is involved in reducing reactive oxygen species (ROS) level by eliminating injured mitochondria. Inhibition of autophagy enhances L-asparaginase-induced cytotoxicity and overcomes the acquired resistance to L-asparaginase in ALL cells. The ROS-p53-positive feedback loop is an essential mechanism of this synergistic cytotoxicity. Thus, our findings provide the rationale for the future development of combined treatment of L-asparaginase and anti-autophagy drug in ALL patients.	[Takahashi, H.; Inoue, J.; Inazawa, J.] TMDU, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Takahashi, H.; Sakaguchi, K.] Hamamatsu Univ, Sch Med, Dept Pediat, Shizuoka, Japan; [Takahashi, H.; Inoue, J.; Inazawa, J.] TMDU, Bioresource Res Ctr, Tokyo, Japan; [Takagi, M.; Mizutani, S.] TMDU, Dept Pediat & Dev Biol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Hamamatsu University School of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inoue, J; Inazawa, J (corresponding author), TMDU, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	jun.cgen@mri.tmd.ac.jp; johinaz.cgen@mri.tmd.ac.jp			JSPS [15H05908, C:15K08301]; MEXT; Joint Usage/Research Program of MRI, TMDU; Grants-in-Aid for Scientific Research [16K14630] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Joint Usage/Research Program of MRI, TMDU; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are deeply grateful to N Hattori (Juntendo University, Japan) for use of the extracellular flux analyzer and H Sato, A Hagiwara and Y Noguchi (Ajinomoto Co., Inc., Japan) for the intracellular amino-acid analysis. We thank U Kevin, S Ikeda and T Muramatsu (Tokyo Medical and Dental University, Japan) for editing this article. We also thank R Mori and K Ayako (Tokyo Medical and Dental University, Japan) for technical assistance in lentivirus preparation and gene expression arrays. This study was supported in part by Grant-in-Aid for Scientific Research (C:15K08301) and Grant-in-Aid for Scientific Research on Innovative Areas "Conquering cancer through NEO-dimensional systems understandings" (15H05908) from JSPS and MEXT, and the Joint Usage/Research Program of MRI, TMDU.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Aslanian AM, 2001, BIOCHEM J, V358, P59, DOI 10.1042/0264-6021:3580059; Barrera V, 2015, J INFECT DIS, V211, P1977, DOI 10.1093/infdis/jiu592; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Bush A, 2015, THORAX, V70, P1078, DOI 10.1136/thoraxjnl-2015-207349; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Curran E, 2015, BLOOD, V125, P3702, DOI 10.1182/blood-2014-11-551481; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Fine BM, 2005, CANCER RES, V65, P291; Fujiwara N, 2015, CANCER RES, V75, P3890, DOI 10.1158/0008-5472.CAN-15-0257; Hermanova I, 2016, LEUKEMIA, V30, P209, DOI 10.1038/leu.2015.213; Hermanova I, 2012, EXP HEMATOL, V40, P657, DOI 10.1016/j.exphem.2012.04.005; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hongo T, 1997, BLOOD, V89, P2959, DOI 10.1182/blood.V89.8.2959; Inoue J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007099; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kaspers GJL, 1997, BLOOD, V90, P2723, DOI 10.1182/blood.V90.7.2723.2723_2723_2729; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46; Lee SW, 2015, CANCER LETT, V360, P195, DOI 10.1016/j.canlet.2015.02.012; Locatelli F, 2012, BLOOD, V120, P2807, DOI 10.1182/blood-2012-02-265884; Lorenzi PL, 2014, AUTOPHAGY, V10, P1316, DOI 10.4161/auto.28773; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; OETTGEN HF, 1967, CANCER RES, V27, P2619; Polak A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155893; Ranjan A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122068; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Reddy PNG, 2012, BLOOD, V120, P1691, DOI 10.1182/blood-2010-08-301416; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sherman BT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-426; Shimbo K, 2009, RAPID COMMUN MASS SP, V23, P1483, DOI 10.1002/rcm.4026; Song P, 2015, ONCOTARGET, V6, P3861, DOI 10.18632/oncotarget.2869; Stams WAG, 2005, BLOOD, V105, P4223, DOI 10.1182/blood-2004-10-3892; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; Stengel A, 2014, BLOOD, V124, P251, DOI 10.1182/blood-2014-02-558833; Su N, 2008, PEDIATR BLOOD CANCER, V50, P274, DOI 10.1002/pbc.21213; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ueno T, 1997, LEUKEMIA, V11, P1858, DOI 10.1038/sj.leu.2400834; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu MS, 2012, J CELL MOL MED, V16, P2369, DOI 10.1111/j.1582-4934.2012.01547.x	45	39	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4267	4276		10.1038/onc.2017.59	http://dx.doi.org/10.1038/onc.2017.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346428	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000406360600004
J	Wan, W; Peng, K; Li, M; Qin, L; Tong, Z; Yan, J; Shen, B; Yu, C				Wan, W.; Peng, K.; Li, M.; Qin, L.; Tong, Z.; Yan, J.; Shen, B.; Yu, C.			Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1 alpha	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; GLUCOSE-METABOLISM; GENE-EXPRESSION; JHDM2A; TRANSCRIPTION; COMPLEX	High aerobic glycolysis not only provides energy to cancer cells, but also supports their anabolic growth. JMJD1A, a histone demethylase that specifically demethylates H3K9me1/2, is overexpressed in multiple cancers, including urinary bladder cancer (UBC). It is unclear whether JMJD1A could promote cancer cell growth through enhancing glycolysis. In this study, we found that downregulation of JMJD1A decreased UBC cell proliferation, colony formation and xenograft tumor growth. Knockdown of JMJD1A inhibited glycolysis by decreasing the expression of genes participated in glucose metabolism, including GLUT1, HK2, PGK1, PGM, LDHA and MCT4. Mechanistically, JMJD1A cooperated with hypoxia inducible factor 1 alpha (HIF1 alpha), an important transcription factor for glucose metabolism, to induce the glycolytic gene expression. JMJD1A was recruited to the promoter of glycolytic gene PGK1 to demethylate H3K9me2. However, the JMJD1A (H1120Y) mutant, which loses the demethylase activity, failed to cooperate with HIF1a to induce the glycolytic gene expression, and failed to demethylate H3K9me2 on PGK1 promoter, suggesting that the demethylase activity of JMJD1A is essential for its coactivation function for HIF1a. Inhibition of glycolysis through knocking down HIF1a or PGK1 decelerated JMJD1A-enhanced UBC cell growth. Consistent with these results, a positive correlation between JMJD1A and several key glycolytic genes in human UBC samples was established by analyzing a microarray-based gene expression profile. In conclusion, our study demonstrates that JMJD1A promotes UBC progression by enhancing glycolysis through coactivation of HIF1a, implicating that JMJD1A is a potential molecular target for UBC treatment.	[Wan, W.; Peng, K.; Li, M.; Qin, L.; Tong, Z.; Yu, C.] Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Peoples R China; [Li, M.] Xiamen Univ, Chenggong Hosp, Xiamen City Key Lab Biliary Tract Dis, Xiamen, Peoples R China; [Yan, J.] Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Yan, J.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Shen, B.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Shanghai, Peoples R China	Xiamen University; Xiamen University; Nanjing University; Nanjing University; Shanghai Jiao Tong University	Yu, C (corresponding author), Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Peoples R China.	cdyu@xmu.edu.cn	Tong, Zhangwei/V-2475-2019; Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952	National Basic Research Program of China (973 Program) [2015CB553800]; National Natural Science Foundation of China [81372176, U1405225, 81372168, 81470116]; Shanghai Natural Science Foundation [14ZR1433200]; Wu Jie Ping Medical Foundation [320.6750.16051]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Wu Jie Ping Medical Foundation	This study was supported by grants from National Basic Research Program of China (973 Program, No. 2015CB553800 to CY), the National Natural Science Foundation of China (No. 81372176 to CY, No. U1405225 to CY; No. 81372168 to JY; No. 81470116 to BS), Shanghai Natural Science Foundation (14ZR1433200 to BS) and Wu Jie Ping Medical Foundation (320.6750.16051 to BS).	Bayley JP, 2012, CURR OPIN ONCOL, V24, P62, DOI 10.1097/CCO.0b013e32834deb9e; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kobayashi T, 2015, NAT REV CANCER, V15, P42, DOI 10.1038/nrc3858; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Lee HY, 2013, CARCINOGENESIS, V34, P2706, DOI 10.1093/carcin/bgt256; Liu ZL, 2010, J BIOL CHEM, V285, P2758, DOI 10.1074/jbc.M109.066845; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Ma DK, 2008, STEM CELLS, V26, P2131, DOI 10.1634/stemcells.2008-0388; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Mo P, 2015, ONCOGENE, V34, P3935, DOI 10.1038/onc.2014.324; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091; Perez-Perri JI, 2016, CELL REP, V16, P37, DOI 10.1016/j.celrep.2016.05.082; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suikki HE, 2010, PROSTATE, V70, P889, DOI 10.1002/pros.21123; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thamotharan S, 2013, AM J PHYSIOL-ENDOC M, V304, pE583, DOI 10.1152/ajpendo.00513.2012; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wollenick K, 2012, NUCLEIC ACIDS RES, V40, P1928, DOI 10.1093/nar/gkr978; Xu Y, 2010, EURASIP J WIREL COMM, DOI 10.1155/2010/818964; Yamada D, 2012, ANN SURG ONCOL, V19, pS355, DOI 10.1245/s10434-011-1797-x; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang CS, 2015, CELL RES, V25, P1025, DOI 10.1038/cr.2015.90; Zhao W, 2014, J BIOL CHEM, V289, P11219, DOI 10.1074/jbc.M113.535989	36	60	64	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3868	3877		10.1038/onc.2017.13	http://dx.doi.org/10.1038/onc.2017.13			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263974				2022-12-28	WOS:000404848200007
J	Zhou, C; Huang, C; Wang, J; Huang, H; Li, J; Xie, Q; Liu, Y; Zhu, J; Li, Y; Zhang, D; Zhu, Q; Huang, C				Zhou, C.; Huang, C.; Wang, J.; Huang, H.; Li, J.; Xie, Q.; Liu, Y.; Zhu, J.; Li, Y.; Zhang, D.; Zhu, Q.; Huang, C.			LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1 alpha translation	ONCOGENE			English	Article							NONCODING RNA MEG3; DNA METHYLTRANSFERASES; POOR-PROGNOSIS; PROLIFERATION; EXPRESSION; APOPTOSIS; GENE; HYPERMETHYLATION; CARCINOGENESIS; GROWTH	Long noncoding RNAs (lncRNAs) are emerging as key factors in various fundamental cellular biological processes, and many of them are likely to have functional roles in tumorigenesis. Maternally expressed gene 3 (MEG3) is an imprinted gene located at 14q32 that encodes a lncRNA, and the decreased MEG3 expression has been reported in multiple cancer tissues. However, nothing is known about the alteration and role of MEG3 in environmental carcinogen-induced lung tumorigenesis. Our present study, for the first time to the best of our knowledge, discovered that environmental carcinogen nickel exposure led to MEG3 downregulation, consequently initiating c-Jun-mediated PHLPP1 transcriptional inhibition and hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein translation upregulation, in turn resulting in malignant transformation of human bronchial epithelial cells. Mechanistically, MEG3 downregulation was attributed to nickel-induced promoter hypermethylation via elevating DNMT3b expression, whereas PHLPP1 transcriptional inhibition was due to the decreasing interaction of MEG3 with its inhibitory transcription factor c-Jun. Moreover, HIF-1 alpha protein translation was upregulated via activating the Akt/p70S6K/S6 axis resultant from PHLPP1 inhibition in nickel responses. Collectively, we uncover that nickel exposure results in DNMT3b induction and MEG3 promoter hypermethylation and expression inhibition, further reduces its binding to c-Jun and in turn increasing c-Jun inhibition of PHLPP1 transcription, leading to the Akt/p70S6K/S6 axis activation, and HIF-1 alpha protein translation, as well as malignant transformation of human bronchial epithelial cells. Our studies provide a significant insight into understanding the alteration and role of MEG3 in nickel-induced lung tumorigenesis.	[Zhou, C.; Zhu, Q.] Anhui Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China; [Zhou, C.; Huang, H.; Xie, Q.; Huang, C.] Wenzhou Med Univ, Sch Life Sci, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou, Zhejiang, Peoples R China; [Zhou, C.; Huang, C.; Wang, J.; Li, J.; Zhu, J.; Li, Y.; Zhang, D.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA; [Liu, Y.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Wenzhou, Zhejiang, Peoples R China	Anhui Medical University; Wenzhou Medical University; New York University; Wenzhou Medical University	Zhu, Q (corresponding author), Anhui Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.; Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	zqxing@yeah.net; chuanshu.huang@nyumc.org	Zhu, Qixing/AAM-4214-2020; Zhou, Chengfan/AAM-4097-2020		NIH/NCI [CA112557, CA165980, CA177665]; NIH/NIEHS [ES000260]; National Natural Science Foundation of China [81441090, 81229002, 81372946, 81673141, 81371730]; Specialized Research Fund for the Doctoral Program of Higher Education [20133420110001]; Grant for Scientific Research of BSKY from Anhui Medical University [XJ201418]; NATIONAL CANCER INSTITUTE [R01CA177665, R01CA112557, P01CA165980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Grant for Scientific Research of BSKY from Anhui Medical University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We greatly appreciated Dr Shau-Ping Lin (Institute of Biotechnology, National Taiwan University, Taipei, Taiwan) for his generous gifts about shRNA constructs against MEG3 and control vector. This work was supported partially by grants from NIH/NCI CA112557, CA165980 and CA177665, NIH/NIEHS ES000260, National Natural Science Foundation of China (81441090, 81229002, 81372946, 81673141 and 81371730), the Specialized Research Fund for the Doctoral Program of Higher Education (20133420110001), and the Grant for Scientific Research of BSKY (XJ201418) from Anhui Medical University. We also thank Ms Nedda Tichi for her critical reading of the manuscript.	Anwar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049462; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Benetatos L, 2011, INT J CANCER, V129, P773, DOI 10.1002/ijc.26052; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Field RW, 2012, CLIN CHEST MED, V33, P681, DOI 10.1016/j.ccm.2012.07.001; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Huang HS, 2015, CLIN CANCER RES, V21, P3783, DOI 10.1158/1078-0432.CCR-14-2829; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1; Li J, 2016, INT J ONCOL, V48, P723, DOI 10.3892/ijo.2015.3285; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; Liu LX, 2016, INT J ONCOL, V48, P421, DOI 10.3892/ijo.2015.3248; Lu HT, 2005, MOL CELL BIOCHEM, V279, P45, DOI 10.1007/s11010-005-8215-2; Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461; Luo G, 2015, CELL PHYSIOL BIOCHEM, V37, P2209, DOI 10.1159/000438577; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x; Murphy SK, 2003, HUM MUTAT, V22, P92, DOI 10.1002/humu.10237; Newton AC, 2014, ANNU REV PHARMACOL, V54, P537, DOI 10.1146/annurev-pharmtox-011112-140338; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ouyang WM, 2009, J CELL PHYSIOL, V218, P205, DOI 10.1002/jcp.21590; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 2008, CHEM RES TOXICOL, V21, P28, DOI 10.1021/tx700198a; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Wang PJ, 2012, J CELL BIOCHEM, V113, P1868, DOI 10.1002/jcb.24055; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; WILLEY JC, 1991, CANCER RES, V51, P5370; Xu Z, 2016, NEURO-ONCOLOGY, V18, P830, DOI 10.1093/neuonc/nov298; Yin DD, 2015, TUMOR BIOL, V36, P4851, DOI 10.1007/s13277-015-3139-2; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Yu Y, 2014, ONCOGENE, V33, P996, DOI 10.1038/onc.2013.8; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang J, 2016, CANCER BIOL THER, V17, P104, DOI 10.1080/15384047.2015.1108496; Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848; Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008	50	78	83	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3878	3889		10.1038/onc.2017.14	http://dx.doi.org/10.1038/onc.2017.14			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263966	Green Accepted			2022-12-28	WOS:000404848200008
J	Patrick, BA; Gong, X; Jaiswal, AK				Patrick, B. A.; Gong, X.; Jaiswal, A. K.			RETRACTION: Disruption of NAD(P)H: quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer (Retraction of Vol 30, Pg 1098, 2011)	ONCOGENE			English	Retraction																		Patrick BA, 2011, ONCOGENE, V30, P1098, DOI 10.1038/onc.2010.491	1	2	2	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2919	2919		10.1038/onc.2016.475	http://dx.doi.org/10.1038/onc.2016.475			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28263975	Green Accepted, Bronze			2022-12-28	WOS:000401697800014
J	Guo, PY; Wang, Y; Dai, CX; Tao, CL; Wu, F; Xie, XZ; Yu, HT; Zhu, QD; Li, JJ; Ye, LY; Yu, FX; Shan, YF; Yu, ZP; Dhanasekaran, R; Zheng, RY; Chen, G				Guo, Pengyi; Wang, Yi; Dai, Chunxiu; Tao, Chonglin; Wu, Fang; Xie, Xiaozai; Yu, Haitao; Zhu, Qiandong; Li, Junjian; Ye, Longyun; Yu, Fuxiang; Shan, Yunfeng; Yu, Zhengping; Dhanasekaran, Renumathy; Zheng, Rongyuan; Chen, Gang			Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/beta-catenin-induced FGF18 expression in hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; VIRUS-X PROTEIN; DOWN-REGULATION; CELL-PROLIFERATION; COLORECTAL-CANCER; IN-VITRO; GENES; TRANSFORMATION; MUTATIONS; LEUKEMIA	Ribosomal protein s15a (RPS15A) plays a promotive role in the mRNA/ribosome interactions during early translation. Our previous study has found that inhibiting RPS15A expression can decrease proliferation and induce cell cycle arrest in hepatocellular carcinoma (HCC) cell lines. However, the mechanism underlying the involvement of RPS15A in HCC pathogenesis and the clinical significance of RPS15A expression remain unclear. In this study, an evaluation of RPS15A expression in 110 surgically resected HCCs and matched tumor-adjacent normal tissues revealed an overexpression of RPS15A in HCC, which was correlated with worse survival. In addition, tumor tissue with higher RPS15A expression demonstrated a higher microvascular density (MVD). Subsequently, two HCC cell lines, Huh7 (low-level constitutive RPS15A expression) and HepG2 (high RPS15A expression) were used to further evaluate the role of RPS15A in angiogenesis. The co-culture experiment of HCC cells with endothelial cells revealed that the induced overexpression of RPS15A in Huh7 cells increased the angiogenic potential of HUVEC in a paracrine fashion; conversely, knockdown of RPS15A in HepG2 cells showed an opposite effect. Further analysis indicated that RPS15A modulated FGF signaling by enhancing Wnt/beta-catenin-mediated FGF18 expression in HCC cells. FGF18, in turn, through binding to its FGFR3 receptor on endothelial cells, can activate the AKT and ERK pathway and promotes angiogenesis in a tumor microenvironment. Our in vivo experiment further confirmed that inhibition of RPS15A expression in HCC xenografts dramatically hindered tumor growth and inhibited tumor angiogenesis. Together, our findings suggest that RPS15A promotes angiogenesis in HCCs by enhancing Wnt/beta-catenin induced FGF18 expression. The RPS15A/FGF18 pathway may be a rational target for anti-angiogenic therapy of HCC.	[Guo, Pengyi; Tao, Chonglin; Xie, Xiaozai; Yu, Haitao; Zhu, Qiandong; Li, Junjian; Ye, Longyun; Yu, Fuxiang; Shan, Yunfeng; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou 2, Zhejiang, Peoples R China; [Wang, Yi] Wenzhou Med Univ, Res Ctr Evidence Based Med & Clin Epidemiol, Sch Publ Hlth & Management, Wenzhou, Zhejiang, Peoples R China; [Dai, Chunxiu] Wenzhou Med Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Wenzhou, Zhejiang, Peoples R China; [Wu, Fang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou, Zhejiang, Peoples R China; [Dhanasekaran, Renumathy] Stanford Univ, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA; [Zheng, Rongyuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurol, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Stanford University; Wenzhou Medical University	Chen, G (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou 2, Zhejiang, Peoples R China.; Zheng, RY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurol, Wenzhou, Zhejiang, Peoples R China.	zhengry@aliyun.com; cg_2188@hotmail.com	dhanasekaran, renumathy/B-3300-2014	dhanasekaran, renumathy/0000-0001-8819-7511	Natural Science Foundation of Zhejiang Province [LY17H160047]; National Natural Science Foundation of China [81201953]; Research Found for the Doctoral Fund of Ministry of Education of China [20113321120003]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Found for the Doctoral Fund of Ministry of Education of China(Ministry of Education, China)	This work was supported by the grants from the Natural Science Foundation of Zhejiang Province (LY17H160047), the National Natural Science Foundation of China (81201953), the Research Found for the Doctoral Fund of Ministry of Education of China (20113321120003).	Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Antoine M, 2006, BIOCHEM BIOPH RES CO, V346, P224, DOI 10.1016/j.bbrc.2006.05.105; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Bertram J, 1998, EUR J CANCER, V34, P731, DOI 10.1016/S0959-8049(97)10081-8; Carli A, 2012, EUR CELLS MATER, V24, P107, DOI 10.22203/eCM.v024a08; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chen JW, 2016, INT J ONCOL, V48, P1628, DOI 10.3892/ijo.2016.3366; Cinque L, 2015, NATURE, V528, P272, DOI 10.1038/nature16063; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; de las Heras-Rubio A, 2014, CANCER METAST REV, V33, P115, DOI 10.1007/s10555-013-9460-6; Fancello L, 2017, ONCOTARGET, V8, P14462, DOI 10.18632/oncotarget.14895; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Goudarzi KM, 2016, INT J ONCOL, V48, P1313, DOI 10.3892/ijo.2016.3387; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hofman IJF, 2017, LEUKEMIA, V31, P1706, DOI 10.1038/leu.2016.370; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Jones DT, 2013, DIS MODEL MECH, V6, P115, DOI 10.1242/dmm.009183; Kapoun AM, 2004, CIRC RES, V94, P453, DOI 10.1161/01.RES.0000117070.86556.9F; Kumar P, 2016, GENE DEV, V30, P1573, DOI 10.1101/gad.282418.116; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lian ZR, 2004, MOL CARCINOGEN, V40, P34, DOI 10.1002/mc.20012; Lim KH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022258; Lim S, 2013, P NATL ACAD SCI USA, V110, pE2298, DOI 10.1073/pnas.1301838110; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Ljungstrom V, 2016, BLOOD, V127, P1007, DOI 10.1182/blood-2015-10-674572; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Perdu J, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<74::AID-HUMU14>3.0.CO;2-F; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200; Ronca R, 2015, EXPERT OPIN THER TAR, V19, P1361, DOI 10.1517/14728222.2015.1062475; Ruptier C, 2011, ONCOGENE, V30, P4656, DOI 10.1038/onc.2011.171; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shimokawa T, 2003, CANCER RES, V63, P6116; Shukla SK, 2012, FEBS J, V279, P3859, DOI 10.1111/j.1742-4658.2012.08745.x; SLOVAK ML, 1995, CANCER RES, V55, P4214; Uechi T, 2001, GENOMICS, V72, P223, DOI 10.1006/geno.2000.6470; Wang CM, 2015, HEPATOLOGY, V61, P200, DOI 10.1002/hep.27396; Wang F, 2011, CANCER SCI, V102, P2007, DOI 10.1111/j.1349-7006.2011.02065.x; Xu MY, 2014, GENE, V536, P84, DOI 10.1016/j.gene.2013.11.075; Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730; Zhang C, 2014, CANCER BIOTHER RADIO, V29, P451, DOI 10.1089/cbr.2014.1698; Zhao XM, 2015, TUMOR BIOL, V36, P6733, DOI 10.1007/s13277-015-3371-9	48	31	33	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1220	1236		10.1038/s41388-017-0017-y	http://dx.doi.org/10.1038/s41388-017-0017-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242604				2022-12-28	WOS:000426505400007
J	Otani, Y; Ichikawa, T; Kurozumi, K; Inoue, S; Ishida, J; Oka, T; Shimizu, T; Tomita, Y; Hattori, Y; Uneda, A; Matsumoto, Y; Michiue, H; Date, I				Otani, Y.; Ichikawa, T.; Kurozumi, K.; Inoue, S.; Ishida, J.; Oka, T.; Shimizu, T.; Tomita, Y.; Hattori, Y.; Uneda, A.; Matsumoto, Y.; Michiue, H.; Date, I.			Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion	ONCOGENE			English	Article							INCREASED EXPRESSION; GLIOBLASTOMA; PHENOTYPES; CANCER; TEMOZOLOMIDE; TRANSITION; RESISTANT; THERAPY; TARGETS; MODELS	Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens. To determine the role of the invasion-related genes, invasive activities were evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens, when compared to that of normal human astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models. FGF13 was negatively regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.	[Otani, Y.; Ichikawa, T.; Kurozumi, K.; Ishida, J.; Oka, T.; Shimizu, T.; Tomita, Y.; Hattori, Y.; Uneda, A.; Matsumoto, Y.; Date, I.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan; [Inoue, S.] Okayama City Hosp, Dept Neurosurg, Okayama, Japan; [Michiue, H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Physiol, Okayama, Japan	Okayama University; Okayama University	Ichikawa, T (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Kita Ku, 2-5-1 Shikata, Okayama 7008558, Japan.	tomoichi@cc.okayama-u.ac.jp	Otani, Yoshihiro/AEG-1263-2022; Kurozumi, Kazuhiko/AGT-1723-2022; MICHIUE, Hiroyuki/B-2320-2011; Uneda, Atsuhito/ABB-2477-2021	Otani, Yoshihiro/0000-0002-1615-5125; Kurozumi, Kazuhiko/0000-0002-6942-9919; Matsumoto, Yuji/0000-0001-8798-381X; Uneda, Atsuhito/0000-0001-9709-6034	Japanese Ministry of Education, Culture, Sports, Science, and Technology [22591611, 25462261, 23592125, 26462182]	Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by grants-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology to TI (No. 22591611 and No. 25462261) and KK (No. 23592125 and No. 26462182). We thank Dr H Wakimoto at Massachusetts General Hospital for providing the human glioblastoma-derived cancer stem cell line.<SUP>18,42</SUP> We thank M Arao and U Ukai in the Department of Neurological Surgery and A Ueda in the Department of Physiology for their technical assistance. The following medical students also contributed to our experiments: K Yamamoto and Y Inoue. The accession number for the gene expression data reported in this paper is GSE88740.	Barker CA, 2013, INT J RADIAT ONCOL, V86, P504, DOI 10.1016/j.ijrobp.2013.02.012; BERENS ME, 1993, IN VITRO CELL DEV-AN, V29A, P310, DOI 10.1007/BF02633959; Berezovsky AD, 2014, NEOPLASIA, V16, pe19; Berges R, 2012, MOL THER, V20, P1367, DOI 10.1038/mt.2012.45; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390; Draberova E, 2011, J NEUROPATH EXP NEUR, V70, P811, DOI 10.1097/NEN.0b013e31822c256d; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Fujimura A, 2013, NEOPLASIA, V15, P1272, DOI 10.1593/neo.131440; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Hampl JA, 2003, HUM GENE THER, V14, P611, DOI 10.1089/104303403321618137; Hayashi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep23372; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ichikawa T, 2002, NEOPLASIA, V4, P523, DOI 10.1038/sj.neo.7900266; Ichikawa T, 2016, NEUROL MED-CHIR, V56, P387, DOI 10.2176/nmc.ra.2016-0077; Inoue S, 2012, WORLD NEUROSURG, V78, P670, DOI 10.1016/j.wneu.2011.09.005; Ishida J, 2014, TRANSL ONCOL, V7, P292, DOI 10.1016/j.tranon.2014.02.016; Katsetos CD, 2015, SEMIN PEDIATR NEUROL, V22, P49, DOI 10.1016/j.spen.2015.03.009; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maruo T, 2013, NEUROPATHOLOGY, V33, P264, DOI 10.1111/j.1440-1789.2012.01361.x; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Nishimoto S, 2007, J BIOL CHEM, V282, P24255, DOI 10.1074/jbc.M704277200; Oehler C, 2012, ONCOLOGY-BASEL, V83, P1, DOI 10.1159/000339152; Oka T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33319; Okada T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02899; Onishi M, 2015, BRAIN TUMOR PATHOL, V32, P184, DOI 10.1007/s10014-015-0216-6; Onishi M, 2013, NEUROPATHOLOGY, V33, P162, DOI 10.1111/j.1440-1789.2012.01344.x; Onishi M, 2011, BRAIN TUMOR PATHOL, V28, P13, DOI 10.1007/s10014-010-0007-z; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Saito N, 2014, STEM CELLS, V32, P301, DOI 10.1002/stem.1528; Scherer HJ, 1940, J NEUROL PSYCHIATRY, V3, P147, DOI 10.1136/jnnp.3.2.147; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Song YW, 2014, ACTA BIOCH BIOPH SIN, V46, P1034, DOI 10.1093/abbs/gmu099; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Wakimoto H, 2012, NEURO-ONCOLOGY, V14, P132, DOI 10.1093/neuonc/nor195; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wang F, 2015, ONCOTARGET, V6, P21468, DOI 10.18632/oncotarget.4097; Wittmack EK, 2004, J NEUROSCI, V24, P6765, DOI 10.1523/JNEUROSCI.1628-04.2004; Wu QF, 2012, CELL, V149, P1549, DOI 10.1016/j.cell.2012.04.046; Yu L, 2016, INT J CANCER, V139, P140, DOI 10.1002/ijc.30048	44	22	24	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					777	786		10.1038/onc.2017.373	http://dx.doi.org/10.1038/onc.2017.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059154	Green Submitted			2022-12-28	WOS:000424628100009
J	Jing, Y; Nguyen, MM; Wang, D; Pascal, LE; Guo, W; Xu, Y; Ai, J; Deng, FM; Masoodi, KZ; Yu, X; Zhang, J; Nelson, JB; Xia, S; Wang, Z				Jing, Y.; Nguyen, M. M.; Wang, D.; Pascal, L. E.; Guo, W.; Xu, Y.; Ai, J.; Deng, F-M; Masoodi, K. Z.; Yu, X.; Zhang, J.; Nelson, J. B.; Xia, S.; Wang, Z.			DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNAL; BOX RNA HELICASE; TRANSCRIPTIONAL ACTIVITY; LIGASE SIAH2; TERMINAL SEQUENCES; SPLICING FACTORS; SPLICEOSOME; BINDING; STABILITY; RESPONSES	Androgen receptor (AR) activation is critical for prostate cancer (PCa) development and progression, including castration resistance. The nuclear export signal of AR (NESAR) has an important role in AR intracellular trafficking and proteasome-dependent degradation. Here, we identified the RNA helicase DHX15 as a novel AR co-activator using a yeast mutagenesis screen and revealed that DHX15 regulates AR activity by modulating E3 ligase Siah2-mediated AR ubiquitination independent of its ATPase activity. DHX15 and Siah2 form a complex with AR, through NESAR. DHX15 stabilized Siah2 and enhanced its E3 ubiquitin-ligase activity, resulting in AR activation. Importantly, DHX15 was upregulated in PCa specimens and its expression was correlated with Gleason scores and prostate-specific antigen recurrence. Furthermore, DHX15 immunostaining correlated with Siah2. Finally, DHX15 knockdown inhibited the growth of C4-2 prostate tumor xenografts in mice. Collectively, our data argue that DHX15 enhances AR transcriptional activity and contributes to PCa progression through Siah2.	[Jing, Y.; Xia, S.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Urol, Sch Med, Shanghai, Peoples R China; [Jing, Y.; Nguyen, M. M.; Wang, D.; Pascal, L. E.; Guo, W.; Xu, Y.; Ai, J.; Masoodi, K. Z.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, Inst Canc, Pittsburgh, PA 15232 USA; [Guo, W.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China; [Xu, Y.] Cent S Univ, Xiangya Hosp 2, Dept Urol, Changsha, Hunan, Peoples R China; [Xu, Y.] Cent S Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Deng, F-M] NYU, Sch Med, Dept Pathol, New York, NY USA; [Masoodi, K. Z.] SKUAST K, Div Plant Biotechnol, Transcript Lab, Srinagar, Jammu & Kashmir, India; [Yu, X.] Guangzhou Gen Hosp Guangzhou Mil Command, Dept Geriatr, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Guangdong Prov Key Lab Geriatr Infect & Organ Fun, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Guangzhou Key Lab Geriatr Infect & Organ Funct Su, Guangzhou, Guangdong, Peoples R China; [Yu, X.] Southern Med Univ, Tradit Chinese Med Integrated Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Zhang, J.] Guangxi Med Univ, Ctr Translat Med, Nanning, Guangxi, Peoples R China; [Zhang, J.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15232 USA; [Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA 15232 USA	Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Shanghai Jiao Tong University; Central South University; Central South University; New York University; Sher-e-Kashmir University of Agricultural Sciences & Technology of Kashmir (SKUAST Kashmir); Southern Theater Command General Hospital; Southern Medical University - China; Guangxi Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xia, S; Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA 15232 USA.; Xia, S; Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol,Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA.	xsjurologist@163.com; wangz2@upmc.edu	Masoodi, Khalid Z/F-1787-2015; Pascal, Laura E./AAH-5743-2019; Masoodi, KhalidZ./ABG-5492-2021	Masoodi, Khalid Z/0000-0002-4889-5558; Pascal, Laura E./0000-0003-3840-1662; Masoodi, KhalidZ./0000-0002-4889-5558	NIH [R01 CA186780, R01 CA108675, R50 CA211242-01]; ACS [PF-05-229-01-CSM]; Department of Defense Prostate Cancer Research Program Award [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062 PCBN]; National Nature Science Foundation of China [81402091]; National Natural Science Foundation of China [81130046, 2013GXNSFEA053004]; Urology Care Foundation of the American Urological Association; Mellam Family Fellowship; Tippens Scholarship; UPCI; Tissue and Research Pathology Services (TARPS) [NCI CCSG P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904, R01CA186780, R01CA108675, R50CA211242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); Department of Defense Prostate Cancer Research Program Award(United States Department of Defense); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Urology Care Foundation of the American Urological Association; Mellam Family Fellowship; Tippens Scholarship; UPCI; Tissue and Research Pathology Services (TARPS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aiyuan Zhang for technical support, Richard Gaber (Northwestern University) for advice on yeast screen, the PCBN for TMA with PCa specimens, Megan Lambert, Krystal Roskov and Robin Frederick for animal husbandry, and members of the Wang Lab for discussion. This work was supported in part by NIH R01 CA186780 (ZW), NIH R01 CA108675 (ZW), ACS #PF-05-229-01-CSM (MMN), the Department of Defense Prostate Cancer Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062 PCBN, National Nature Science Foundation of China # 81402091 (YJ), and National Natural Science Foundation of China Key Project 81130046 (JZ) and 2013GXNSFEA053004 (JZ). This work was also supported by a post-doctoral fellowship from the Urology Care Foundation of the American Urological Association (DW), the Mellam Family Fellowship (DW and KZM), the Tippens Scholarship (LEP) and NIH R50 CA211242-01 (LEP). In addition, this research was supported by the UPCI Animal Facility, Vector Core and Tissue and Research Pathology Services (TARPS) funded through NCI CCSG P30CA047904.	Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Chan Siu Chiu, 2014, Adv Pharmacol, V70, P327, DOI 10.1016/B978-0-12-417197-8.00011-0; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; Combs DJ, 2006, MOL CELL BIOL, V26, P523, DOI 10.1128/MCB.26.2.523-534.2006; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fouraux MA, 2002, RNA, V8, P1428, DOI 10.1017/S1355838202021076; Fourmann JB, 2013, GENE DEV, V27, P413, DOI 10.1101/gad.207779.112; Freeman MR, 2013, ASIAN J ANDROL, V15, P447, DOI 10.1038/aja.2013.62; Fukuba H, 2008, NEUROSCI LETT, V433, P209, DOI 10.1016/j.neulet.2007.12.069; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gong YQ, 2012, ENDOCRINOLOGY, V153, P5716, DOI 10.1210/en.2012-1841; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Haider AS, 2010, INTERN MED J, V40, P281, DOI 10.1111/j.1445-5994.2009.02041.x; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Hu G, 1999, MOL CELL BIOL, V19, P724; Kobayashi T, 2013, INT J MOL SCI, V14, P15615, DOI 10.3390/ijms140815615; Koodathingal P, 2010, MOL CELL, V39, P385, DOI 10.1016/j.molcel.2010.07.014; Li B., 2014, RECEPTORS CLIN INVES, V1, DOI 10.14800%14802Frci.14122; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Mosallanejad K, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004841; Nadeau RJ, 2007, J CELL BIOCHEM, V100, P151, DOI 10.1002/jcb.21040; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nakayama K, 2009, MOL CANCER RES, V7, P443, DOI 10.1158/1541-7786.MCR-08-0458; Nguyen MM, 2014, INT J CLIN EXP PATHO, V7, P2768; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Poukka H, 2000, J CELL SCI, V113, P2991; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Scortegagna M, 2011, J BIOL CHEM, V286, P27333, DOI 10.1074/jbc.M111.218214; Shafi AA, 2013, PHARMACOL THERAPEUT, V140, P223, DOI 10.1016/j.pharmthera.2013.07.003; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tanaka N, 2007, GENE DEV, V21, P2312, DOI 10.1101/gad.1580507; Walbott H, 2010, EMBO J, V29, P2194, DOI 10.1038/emboj.2010.102; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	46	33	34	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					638	650		10.1038/onc.2017.371	http://dx.doi.org/10.1038/onc.2017.371			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991234	Green Accepted			2022-12-28	WOS:000423812200009
J	Feng, GX; Li, J; Yang, Z; Zhang, SQ; Liu, YX; Zhang, WY; Ye, LH; Zhang, XD				Feng, G. X.; Li, J.; Yang, Z.; Zhang, S. Q.; Liu, Y. X.; Zhang, W. Y.; Ye, L. H.; Zhang, X. D.			Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; EXTRACELLULAR-MATRIX; CELL-CELL; EXPRESSION; MICRORNAS; PROLIFERATION; BIOMARKERS; METASTASIS; CIRRHOSIS; ENHANCE	Hepatitis B virus (HBV)-induced liver necrosis takes great part in liver cirrhosis progression. However, less is known about whether hepatitis B virus X protein (HBx) has effect on liver fibrosis. Here, we report that HBV leads to liver fibrosis and hepatocarcinogenesis through miR-30e targeting P4HA2. HBV transgenic mouse was treated by CCl4 to generate a model of liver fibrosis. A crucial enzyme catalyzing collagen formation, prolyl 4-hydroxylase subunit alpha 2 (P4HA2) was evaluated by immunohistochemistry, western blotting or quantitative reverse transcription-PCR analysis. The function of HBV-modulated P4HA2 in hepatoma cell growth in vitro and in vivo was analyzed by EdU, MTT, colony-forming assay and animal transplantation assay. HBV transgenic mice exhibited more collagen deposition in liver after intraperitoneal injection of CCl4. P4HA2 was dramatically augmented in liver samples of HBV transgenic mice, clinical liver cirrhosis and liver cancer patients. Mechanistically, HBx was capable of inducing P4HA2 through suppressing miR-30e, in which miR-30e could target P4HA2 mRNA 3' untranslated region in liver cancer cells. HBx inhibited the miR-30e expression through increasing methylation of CpG islands in its promoter mediated by EZH2-formed complexes. Functionally, HBx-elevated P4HA2 enhanced the collagen deposition in the liver in vivo and in vitro, leading to liver fibrosis and liver cancer progression. In conclusion, HBx promotes the development of liver fibrosis and hepatocellular carcinoma through miR-30e targeting P4HA2 mRNA. We provide novel perspective on how HBx induces liver fibrosis.	[Feng, G. X.; Li, J.; Yang, Z.; Zhang, S. Q.; Liu, Y. X.; Zhang, W. Y.; Zhang, X. D.] Nankai Univ, Dept Canc Res, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Ye, L. H.] Nankai Univ, Dept Biochem, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China	Nankai University; Nankai University	Zhang, WY; Zhang, XD (corresponding author), Nankai Univ, Dept Canc Res, Coll Life Sci, Tianjin 300071, Peoples R China.; Ye, LH (corresponding author), Nankai Univ, Dept Biochem, Coll Life Sci, Tianjin 300071, Peoples R China.	zhwybao@nankai.edu.cn; yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Feng, Guoxing/AAD-6163-2019		National Natural Science Foundation of China [81372186, 31470756, 31670769, 31670771]; National Basic Research Program of China (973 Program) [2015CB553905, 2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This work was supported by the grants of National Natural Science Foundation of China (No. 81372186, 31470756, 31670769, 31670771) and National Basic Research Program of China (973 Program, No. 2015CB553905, 2015CB553703).	Bhattacharya S, 2016, AM J PATHOL, V186, P242, DOI 10.1016/j.ajpath.2015.10.003; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chang KP, 2011, J PROTEOME RES, V10, P4935, DOI 10.1021/pr200311p; Chen RJ, 2015, NEUROSCIENCE, V305, P36, DOI 10.1016/j.neuroscience.2015.07.045; Cushing L, 2015, BIOCHEM CELL BIOL, V93, P109, DOI 10.1139/bcb-2014-0095; de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969; Feng GL, 2016, PROCEEDINGS 2016 FIRST INTERNATIONAL CONFERENCE ON MULTIMEDIA AND IMAGE PROCESSING (ICMIP 2016), P1, DOI 10.1109/ICMIP.2016.13; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Haflidadottir BS, 2015, EUR UROL, V67, P42, DOI 10.1016/j.eururo.2014.08.067; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jin ZX, 2011, HEPATOLOGY, V53, P219, DOI 10.1002/hep.23983; Joo SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09660; Karsdal MA, 2016, J HEPATOL, V64, P103, DOI 10.1016/j.jhep.2015.08.014; Kayashima H, 2015, SURGERY, V158, P1670, DOI 10.1016/j.surg.2015.06.001; Kriegel AJ, 2015, HYPERTENSION, V66, P793, DOI 10.1161/HYPERTENSIONAHA.115.05645; Li J, 2013, J HEPATOL, V58, P522, DOI 10.1016/j.jhep.2012.11.011; Lin Cong, 2013, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V29, P704; McMillen P, 2015, CURR OPIN CELL BIOL, V36, P48, DOI 10.1016/j.ceb.2015.07.002; Park ES, 2013, HEPATOLOGY, V58, P762, DOI 10.1002/hep.26379; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; PIHLAJANIEMI T, 1991, J HEPATOL, V13, pS2, DOI 10.1016/0168-8278(91)90002-S; Pungpapong S, 2007, MAYO CLIN PROC, V82, P967, DOI 10.4065/82.8.967; Shan CL, 2011, CARCINOGENESIS, V32, P1190, DOI 10.1093/carcin/bgr106; Shi Xiao-Yan, 2011, Chin J Cancer, V30, P273; Sim JY, 2015, MOL BIOL CELL, V26, P2456, DOI 10.1091/mbc.E14-12-1618; Sinn DH, 2015, HEPATOLOGY, V62, P694, DOI 10.1002/hep.27889; Song K, 2013, HEPATOLOGY, V58, P1681, DOI 10.1002/hep.26514; Su XQ, 2013, CHINESE J CANCER RES, V25, P235, DOI 10.3978/j.issn.1000-9604.2013.03.08; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Tameda M, 2014, INT J ONCOL, V45, P541, DOI 10.3892/ijo.2014.2445; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang YH, 2016, ONCOL LETT, V11, P801, DOI 10.3892/ol.2015.3976; Wells RG, 2008, CLIN LIVER DIS, V12, P759, DOI 10.1016/j.cld.2008.07.008; Wong CM, 2012, HEPATOLOGY, V55, P1453, DOI 10.1002/hep.25512; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Xu C, 2014, CANCER LETT, V345, P216, DOI 10.1016/j.canlet.2013.08.035; Yang SL, 2016, J GASTROENTEROL, V51, P722, DOI 10.1007/s00535-015-1146-0; Yi T, 2017, SCI REP, V7, P1; You X, 2014, ONCOGENE, V33, P449, DOI 10.1038/onc.2012.618; You XN, 2013, CARCINOGENESIS, V34, P1644, DOI 10.1093/carcin/bgt089; Zanotti S, 2015, BBA-MOL BASIS DIS, V1852, P1451, DOI 10.1016/j.bbadis.2015.04.013; Zhang R, 2015, INT J CORROS, V2015, DOI 10.1155/2015/823172; Zhang S, 2013, FEBS LETT, V587, P645, DOI 10.1016/j.febslet.2013.01.019; Zhang T, 2013, NEOPLASIA, V15, P1282, DOI 10.1593/neo.131362; Zhang W, 2014, MOL CANCER, V13, P1; Zhang Xiao-Dong, 2014, Cancer Biology Medicine, V11, P182, DOI 10.7497/j.issn.2095-3941.2014.03.004; Zhang Y, 2012, HEPATOLOGY, V56, p617A; Zhu MY, 2015, ONCOTARGET, V6, P12196, DOI 10.18632/oncotarget.2906	48	35	38	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6895	6905		10.1038/onc.2017.291	http://dx.doi.org/10.1038/onc.2017.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846110				2022-12-28	WOS:000418041800006
J	Guerrero, PA; Tchaicha, JH; Chen, Z; Morales, JE; McCarty, N; Wang, Q; Sulman, EP; Fuller, G; Lang, FF; Rao, G; McCarty, JH				Guerrero, P. A.; Tchaicha, J. H.; Chen, Z.; Morales, J. E.; McCarty, N.; Wang, Q.; Sulman, E. P.; Fuller, G.; Lang, F. F.; Rao, G.; McCarty, J. H.			Glioblastoma stem cells exploit the alpha v beta 8 integrin-TGF beta 1 signaling axis to drive tumor initiation and progression	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ANTI-VEGF THERAPY; TGF-BETA; INTEGRIN ALPHA-V-BETA-8; ANTIANGIOGENIC THERAPY; CEREBRAL-HEMORRHAGE; SELF-RENEWAL; BRAIN; CANCER; EXPRESSION	Glioblastoma (GBM) is a primary brain cancer that contains populations of stem-like cancer cells (GSCs) that home to specialized perivascular niches. GSC interactions with their niche influence self-renewal, differentiation and drug resistance, although the pathways underlying these events remain largely unknown. Here, we report that the integrin alpha v beta 8 and its latent transforming growth factor beta 1 (TGF beta 1) protein ligand have central roles in promoting niche co-option and GBM initiation. alpha v beta 8 integrin is highly expressed in GSCs and is essential for self-renewal and lineage commitment in vitro. Fractionation of beta 8(high) cells from freshly resected human GBM samples also reveals a requirement for this integrin in tumorigenesis in vivo. Whole-transcriptome sequencing reveals that alpha v beta 8 integrin regulates tumor development, in part, by driving TGF beta 1-induced DNA replication and mitotic checkpoint progression. Collectively, these data identify the av beta 8 integrin-TGF beta 1 signaling axis as crucial for exploitation of the perivascular niche and identify potential therapeutic targets for inhibiting tumor growth and progression in patients with GBM.	[Guerrero, P. A.; Tchaicha, J. H.; Chen, Z.; Morales, J. E.; Lang, F. F.; Rao, G.; McCarty, J. H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit 1004, Houston, TX 77030 USA; [McCarty, N.] Univ Texas Hlth Sci Ctr Houston, Brown Inst Mol Med, Houston, TX 77030 USA; [Wang, Q.; Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Wang, Q.; Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Fuller, G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit 1004, Houston, TX 77030 USA.	jhmccarty@mdanderson.org		Sulman, Erik/0000-0003-4933-9120	NIH/NINDS [R01NS0 7635, R01NS078402]; Cancer Prevention and Research Institute of Texas [RP140411]; NIH/NCI SPORE in Brain Cancer [P50CA127001]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA127001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078402, R01NS094615, R01NS087635] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Cancer Prevention and Research Institute of Texas; NIH/NCI SPORE in Brain Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank colleagues in the M.D. Anderson Neurosurgery department for providing freshly resected human samples. This work was supported by grants to JHM from NIH/NINDS (R01NS0 7635 and R01NS078402), the Cancer Prevention and Research Institute of Texas (RP140411), and in part by an NIH/NCI SPORE in Brain Cancer (P50CA127001).	Allinson KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039336; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Arnold TD, 2014, DEVELOPMENT, V141, P4489, DOI 10.1242/dev.107193; Arnold TD, 2012, J NEUROSCI, V32, P1197, DOI 10.1523/JNEUROSCI.5648-11.2012; Arrillaga-Romany I, 2014, EXPERT OPIN INV DRUG, V23, P199, DOI 10.1517/13543784.2014.856880; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Batchelor TT, 2014, CLIN CANCER RES, V20, P5612, DOI 10.1158/1078-0432.CCR-14-0834; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Cheerathodi M, 2016, MOL CANCER RES, V14, P1277, DOI 10.1158/1541-7786.MCR-16-0251; Dardiotis E, 2017, NEUROMOL MED, V19, P69, DOI 10.1007/s12017-016-8429-3; Delamarre E, 2009, AM J PATHOL, V175, P844, DOI 10.2353/ajpath.2009.080920; Ding Y, 2013, CANCER DISCOV, V3, P198, DOI 10.1158/2159-8290.CD-12-0353; Ellis LM, 2009, NATURE, V458, P290, DOI 10.1038/458290a; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Frei K, 2015, ONCOTARGET, V6, P5963, DOI 10.18632/oncotarget.3467; Gilbert MR, 2012, J NEURO-ONCOL, V106, P147, DOI 10.1007/s11060-011-0650-1; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Hamidi H, 2016, BRIT J CANCER, V115, P1017, DOI 10.1038/bjc.2016.312; Hirota S, 2015, DEVELOPMENT, V142, P4363, DOI 10.1242/dev.113746; Hirota S, 2011, DEVELOPMENT, V138, P5157, DOI 10.1242/dev.069153; Huang JJ, 2016, BIOCHEM SOC T, V44, P1441, DOI 10.1042/BST20160065; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee HS, 2015, MOL CELL BIOL, V35, P1401, DOI 10.1128/MCB.00112-15; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Ma L, 2016, TRANSL STROKE RES, V7, P488, DOI 10.1007/s12975-016-0478-2; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarty JH, 2002, MOL CELL BIOL, V22, P7667, DOI 10.1128/MCB.22.21.7667-7677.2002; McCarty JH, 2013, CLIN CANCER RES, V19, P1631, DOI 10.1158/1078-0432.CCR-13-0051; McCarty JH, 2009, CURR OPIN HEMATOL, V16, P209, DOI 10.1097/MOH.0b013e32832a07eb; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Mobley AK, 2011, GLIA, V59, P1579, DOI 10.1002/glia.21199; Mobley AK, 2009, J CELL SCI, V122, P1842, DOI 10.1242/jcs.043257; Nakajima H, 2008, J CELL BIOL, V181, P89, DOI 10.1083/jcb.200708176; Nguyen HL, 2011, LAB INVEST, V91, P1554, DOI 10.1038/labinvest.2011.124; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; Nyati S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005379; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Proctor JM, 2005, J NEUROSCI, V25, P9940, DOI 10.1523/JNEUROSCI.3467-05.2005; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Robertson IB, 2016, COLD SPRING HARB PER, V8, P6; Rojas A, 2009, BBA-MOL CELL RES, V1793, P1165, DOI 10.1016/j.bbamcr.2009.02.001; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sathyan P, 2015, J NEUROSCI, V35, P15097, DOI 10.1523/JNEUROSCI.1265-15.2015; Schittenhelm J, 2013, INT J CLIN EXP PATHO, V6, P2719; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Su H, 2010, AM J PATHOL, V176, P1018, DOI 10.2353/ajpath.2010.090453; Tchaicha JH, 2010, ONCOGENE, V29, P4460, DOI 10.1038/onc.2010.199; Tchaicha JH, 2011, CANCER RES, V71, P6371, DOI 10.1158/0008-5472.CAN-11-0991; Toledo CM, 2015, CELL REP, V13, P2425, DOI 10.1016/j.celrep.2015.11.021; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; Wee B, 2016, SCI REP-UK, V6, DOI 10.1038/srep25956; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; Weis SM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006478; Worthington JJ, 2011, TRENDS BIOCHEM SCI, V36, P47, DOI 10.1016/j.tibs.2010.08.002; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	69	31	31	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6568	6580		10.1038/onc.2017.248	http://dx.doi.org/10.1038/onc.2017.248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783169	Green Accepted			2022-12-28	WOS:000416049200006
J	Rodriguez-Blanco, J; Pednekar, L; Penas, C; Li, B; Martin, V; Long, J; Lee, E; Weiss, WA; Rodriguez, C; Mehrdad, N; Nguyen, DM; Ayad, NG; Rai, P; Capobianco, AJ; Robbins, DJ				Rodriguez-Blanco, J.; Pednekar, L.; Penas, C.; Li, B.; Martin, V.; Long, J.; Lee, E.; Weiss, W. A.; Rodriguez, C.; Mehrdad, N.; Nguyen, D. M.; Ayad, N. G.; Rai, P.; Capobianco, A. J.; Robbins, D. J.			Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma	ONCOGENE			English	Article							BASAL-CELL CARCINOMA; HEDGEHOG PATHWAY INHIBITOR; SMALL-MOLECULE INHIBITORS; TUMOR-INITIATING CELLS; CANCER STEM-CELLS; NEVUS SYNDROME; MOUSE; IDENTIFICATION; VISMODEGIB; RESISTANCE	The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an ontarget manner, leading to increased survival. Our results imply that the tumor-propagating cells driving the growth of bulk SHH-dependent MB are themselves WNT dependent. Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated with vismodegib.	[Rodriguez-Blanco, J.; Pednekar, L.; Li, B.; Long, J.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Mol Oncol Program, 1600 NW 10th Ave, Miami, FL 33136 USA; [Penas, C.; Ayad, N. G.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Therapeut Innovat, Miami, FL 33136 USA; [Martin, V.; Rodriguez, C.] Univ Oviedo, Morphol & Cell Biol Dept, Asturias, Spain; [Lee, E.] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurobiol, San Francisco, CA 94143 USA; [Mehrdad, N.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Nguyen, D. M.] Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Div Cardiothorac Surg, Miami, FL 33136 USA; [Nguyen, D. M.; Ayad, N. G.; Rai, P.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Rai, P.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Oviedo; Vanderbilt University; University of California System; University of California San Francisco; University of Miami; University of Miami; University of Miami; University of Miami	Robbins, DJ (corresponding author), Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Mol Oncol Program, 1600 NW 10th Ave, Miami, FL 33136 USA.	drobbins@miami.edu	MARTIN, VANESA/A-7312-2012; Long, Jun/S-2382-2019; Rodriguez, Jezabel/B-7613-2019; Rodríguez, Carmen/R-9541-2019; penas, clara/K-3480-2017	MARTIN, VANESA/0000-0001-6923-2529; Long, Jun/0000-0002-8229-9653; Rodriguez, Jezabel/0000-0003-1839-6181; Rodríguez, Carmen/0000-0002-3203-4753; penas, clara/0000-0003-0554-3832; Rai, Priyamvada/0000-0001-7822-7553; Weiss, William/0000-0003-2230-9132; Capobianco, Anthony/0000-0002-3706-6797	Alex Lemonade Stand Foundation [M1201547]; University of Miami Women's Cancer Association; B*Cured; Childhood Brain Tumor Foundation; FICYT [POST10-27]; Sylvester Cancer Center; NIH [R01GM081635, R01GM103926];  [1R21NS096502-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM103926, R35GM122516, R01GM081635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS096502] Funding Source: NIH RePORTER	Alex Lemonade Stand Foundation; University of Miami Women's Cancer Association; B*Cured; Childhood Brain Tumor Foundation; FICYT; Sylvester Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Alex Lemonade Stand Foundation M1201547 (DJR), 1R21NS096502-01 (DJR), The University of Miami Women's Cancer Association (DJR), B*Cured 2016 (DJR), Childhood Brain Tumor Foundation (JR-B), FICYT POST10-27 (JR-B), funds from the Sylvester Cancer Center (DJR), NIH R01GM081635 (EL), and R01GM103926 (EL).	Ahlfeld J, 2013, CANCER RES, V73, P3796, DOI 10.1158/0008-5472.CAN-13-0238; Anne SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081769; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Atwood SX, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a013581; Azad N, 2011, CELL J, V13, P39; Boman BM, 2008, J CLIN ONCOL, V26, P2795, DOI 10.1200/JCO.2008.17.7436; Cha YH, 2012, CELL CYCLE, V11, P1273, DOI 10.4161/cc.19618; Corno D, 2012, CANCER DISCOV, V2, P554, DOI 10.1158/2159-8290.CD-11-0199; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eguchi M, 2005, MED CHEM, V1, P467, DOI 10.2174/1573406054864098; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Fan X, 2008, J CLIN ONCOL, V26, P2821, DOI 10.1200/JCO.2007.15.2264; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Gritti A, 1996, J NEUROSCI, V16, P1091; HEPPNER GH, 1984, CANCER RES, V44, P2259; Huang X, 2010, J VIS EXP, P2086; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kennedy MWL, 2011, BIOCHEM J, V435, P247, DOI 10.1042/BJ20101801; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lange C, 2006, NEURODEGENER DIS, V3, P76, DOI 10.1159/000092097; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Lewis SL, 2008, DEVELOPMENT, V135, P1791, DOI 10.1242/dev.018853; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Meani RE, 2014, AUSTRALAS J DERMATOL, V55, P218, DOI 10.1111/ajd.12196; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2012, EXPERT REV NEUROTHER, V12, P871, DOI [10.1586/ERN.12.66, 10.1586/ern.12.66]; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Olson JM, 2014, CANCER CELL, V25, P267, DOI 10.1016/j.ccr.2014.03.003; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Poschl J, 2014, ACTA NEUROPATHOL, V127, P605, DOI 10.1007/s00401-014-1258-2; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Remke M, 2013, CURR OPIN ONCOL, V25, P674, DOI 10.1097/CCO.0000000000000008; Robinson GW, 2015, J CLIN ONCOL, V33, P2646, DOI 10.1200/JCO.2014.60.1591; Rodriguez-Blanco J, 2008, J NEUROCHEM, V107, P127, DOI 10.1111/j.1471-4159.2008.05588.x; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; Tam WL, 2014, CANCER CELL, V26, P3, DOI 10.1016/j.ccr.2014.06.024; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Ward RJ, 2009, CANCER RES, V69, P4682, DOI 10.1158/0008-5472.CAN-09-0342; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Wetmore C, 2001, CANCER RES, V61, P513; Wolfe CM, 2012, DERMATOL SURG, V38, P1863, DOI 10.1111/j.1524-4725.2012.02513.x; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Youssef KK, 2012, NAT CELL BIOL, V14, P1282, DOI 10.1038/ncb2628; Zhao XS, 2015, CANCER RES, V75, P3623, DOI 10.1158/0008-5472.CAN-14-2999-T; Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052; Zinke J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0294-4	67	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6306	6314		10.1038/onc.2017.232	http://dx.doi.org/10.1038/onc.2017.232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714964	Green Accepted			2022-12-28	WOS:000414774800009
J	Wang, Q; Zhu, J; Wang, YW; Dai, Y; Wang, YL; Wang, C; Liu, J; Baker, A; Colburn, NH; Yang, HS				Wang, Q.; Zhu, J.; Wang, Y-W; Dai, Y.; Wang, Y-L; Wang, C.; Liu, J.; Baker, A.; Colburn, N. H.; Yang, H-S			Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma	ONCOGENE			English	Article							MAMMALIAN TARGET; DOWN-REGULATION; DEPENDENT TRANSCRIPTION; EUKARYOTIC TRANSLATION; PROMOTES INVASION; BETA-CATENIN/TCF; EXPRESSION; AKT; COMPLEX; PROTEIN	Programmed cell death 4 (Pdcd4), a tumor invasion suppressor, is frequently downregulated in colorectal cancer and other cancers. In this study, we find that loss of Pdcd4 increases the activity of mammalian target of rapamycin complex 2 (mTORC2) and thereby upregulates Snail expression. Examining the components of mTORC2 showed that Pdcd4 knockdown increased the protein but not mRNA level of stress-activated-protein kinase interacting protein 1 (Sin1), which resulted from enhanced Sin1 translation. To understand how Pdcd4 regulates Sin1 translation, the SIN1 5' untranslated region (5'UTR) was fused with luciferase reporter and named as 5'Sin1-Luc. Pdcd4 knockdown/knockout significantly increased the translation of 5' Sin1-Luc but not the control luciferase without the SIN1 5'UTR, suggesting that Sin1 5'UTR is necessary for Pdcd4 to inhibit Sin1 translation. Ectopic expression of wild-type Pdcd4 and Pdcd4(157-469), a deletion mutant that binds to translation initiation factor 4A (eIF4A), sufficiently inhibited Sin1 translation, and thus suppressed mTORC2 kinase activity and invasion in colon tumor cells. By contrast, Pdcd4(157-469)(D253A, D418A), a mutant that does not bind to eIF4A, failed to inhibit Sin1 translation, and consequently failed to repress mTORC2 activity and invasion. In addition, directly inhibiting eIF4A with silvestrol significantly suppressed Sin1 translation and attenuated invasion. These results indicate that Pdcd4-inhibited Sin1 translation is through suppressing eIF4A, and functionally important for suppression of mTORC2 activity and invasion. Moreover, in colorectal cancer tissues, the Sin1 protein but not mRNA was significantly upregulated while Pdcd4 protein was downregulated, suggesting that loss of Pdcd4 might correlate with Sin1 protein level but not mRNA level in colorectal cancer patients. Taken together, our work reveals a novel mechanism by which Pdcd4 inhibits Sin1 translation to attenuatemTORC2 activity and thereby suppresses invasion.	[Wang, Q.; Yang, H-S] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, 350 HSRB,800 Rose St, Lexington, KY 40536 USA; [Zhu, J.; Wang, Y-W] Shandong Univ, Qilu Hosp, Dept Breast Surg, 107 West Wenhua Rd, Jinan, Shandong, Peoples R China; [Dai, Y.] Shandong Univ, Qilu Hosp, Dept Colorectal & Anal Surg, Jinan, Shandong, Peoples R China; [Wang, C.] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.; Liu, J.; Yang, H-S] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Baker, A.; Colburn, N. H.] NCI, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA	University of Kentucky; Shandong University; Shandong University; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, HS (corresponding author), Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, 350 HSRB,800 Rose St, Lexington, KY 40536 USA.; Zhu, J (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, 107 West Wenhua Rd, Jinan, Shandong, Peoples R China.	drjiangzhu@hotmail.com; hyang3@uky.edu	Yang, Hsin-Sheng/AAF-6793-2020; Zhu, Jiang/AAX-7274-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Zhu, Jiang/0000-0002-7869-9857; Yang, Hsin-Sheng/0000-0002-0566-3036	NIH/NCI grant [R01CA129015, R03CA187839]; NCI/NIH center core support grant [P30CA177558]; National Natural Science Foundation of China [81402192]; NCI Center Core Support Grant [P30CA177558]; NATIONAL CANCER INSTITUTE [R01CA129015, P30CA177558, R03CA187839] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH center core support grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NCI Center Core Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH/NCI grant to H.-S. Yang (R01CA129015 and R03CA187839), NCI/NIH center core support grant to C. Wang (P30CA177558) and National Natural Science Foundation of China grant to J. Zhu (81402192). The Flow Cytometry facility is supported in part by NCI Center Core Support Grant (P30CA177558). We thank Dr Jian-Li Wang (Shandong University) for experimental supports and Ms Donna Gilbreath and Ms Catherine Anthony (Markey Cancer Center) for editing the manuscript.	Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen CH, 2011, J BIOL CHEM, V286, P40386, DOI 10.1074/jbc.M111.282590; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fehler O, 2014, NUCLEIC ACIDS RES, V42, P11107, DOI 10.1093/nar/gku800; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gaubitz C, 2016, TRENDS BIOCHEM SCI, V41, P532, DOI 10.1016/j.tibs.2016.04.001; Glidden EJ, 2012, J BIOL CHEM, V287, P581, DOI 10.1074/jbc.M111.304337; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Guo Xiaoling, 2011, Genes Cancer, V2, P818, DOI 10.1177/1947601911431082; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kogure T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076136; Lankat-Buttgereit B, 2008, BIOL CELL, V100, P703, DOI 10.1042/BC20080052; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Liwak U, 2012, MOL CELL BIOL, V32, P1818, DOI 10.1128/MCB.06317-11; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Moraitis D, 2014, SURGERY, V156, P1542, DOI 10.1016/j.surg.2014.08.095; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Svitkin YV, 2001, RNA, V7, P1743; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang Q, 2010, ONCOGENE, V29, P128, DOI 10.1038/onc.2009.302; Wang Q, 2013, EUR J CANCER, V49, P1761, DOI 10.1016/j.ejca.2012.12.014; Wang Q, 2012, BBA-MOL CELL RES, V1823, P1807, DOI 10.1016/j.bbamcr.2012.07.004; Wei N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030311; Wei ZT, 2009, CANCER SCI, V100, P1408, DOI 10.1111/j.1349-7006.2009.01210.x; Wiegering A, 2015, CANCER DISCOV, V5, P768, DOI 10.1158/2159-8290.CD-14-1040; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu JF, 2013, CANCER-AM CANCER SOC, V119, P2247, DOI 10.1002/cncr.28023; Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2014, TRANSLATION ITS REGU, P135; Zhang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1080/10298436.2015.1019502; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6225	6234		10.1038/onc.2017.228	http://dx.doi.org/10.1038/onc.2017.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692058	Green Accepted			2022-12-28	WOS:000414774800002
J	Liu, L; He, J; Wei, X; Wan, G; Lao, Y; Xu, W; Li, Z; Hu, H; Hu, Z; Luo, X; Wu, J; Xie, W; Zhang, Y; Xu, N				Liu, L.; He, J.; Wei, X.; Wan, G.; Lao, Y.; Xu, W.; Li, Z.; Hu, H.; Hu, Z.; Luo, X.; Wu, J.; Xie, W.; Zhang, Y.; Xu, N.			MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; EXPRESSION PROFILES; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; CANCER; MICRORNAS; GENE; BECLIN-1; CLUSTER; DISEASE	Gene expression analysis of The Cancer Genome Atlas (TCGA) breast cancer data set show that miR-20a is upregulated in human breast cancer, especially in triple-negative subtype. Gene Set Enrichment Analysis suggests that miR-20a expression negatively correlates with the autophagy/ lysosome pathway. We report here that miR-20a inhibits the basal and nutrient starvation-induced autophagic flux and lysosomal proteolytic activity, increases intracellular reactive oxygen species levels and DNA damage response by targeting several key regulators of autophagy, including BECN1, ATG16L1 and SQSTM1. Re-introduction of exogenous BECN1, ATG16L1 or SQSTM1 reverses the inhibitory effect of miR-20a on autophagy and decreases DNA damage. A negative correlation between miR-20a and its target genes is observed in breast cancer tissues. Lower levels of BECN1, ATG16L1 and SQSTM1 are more common in triple-negative cancers than in other subtypes. High levels of miR-20a also associate with higher frequency of copynumber alterations and DNA mutations in breast cancer patients. Further studies in a xenograft mouse model show that miR-20a promotes tumor initiation and tumor growth. Collectively, these findings suggest that miR-20a-mediated autophagy defect might be a new mechanism underlying the oncogenic function of miRNA during breast tumorigenesis.	[Liu, L.; Wan, G.; Xu, W.; Wu, J.] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China; [Liu, L.; He, J.; Wei, X.; Wan, G.; Xu, W.; Luo, X.; Wu, J.; Xie, W.; Zhang, Y.; Xu, N.] Tsinghua Univ, Div Life Sci, Key Lab Hlth Sci & Technol, Grad Sch Shenzhen, Shenzhen, Peoples R China; [Lao, Y.] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Li, Z.] Peking Univ, Grad Sch Shenzhen, Sch Chem Biol & Biotechnol, Shenzhen, Peoples R China; [Hu, H.] Peking Univ, Dept Breast Surg, Shenzhen Hosp, Shenzhen, Peoples R China; [Hu, Z.] Wuhan 1 Hosp, Dept Clin Oncol, Wuhan, Hubei, Peoples R China; [Xie, W.; Zhang, Y.; Xu, N.] Tsinghua Univ, Open FIESTA Ctr, Shenzhen, Peoples R China	Tsinghua University; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Shanghai University of Traditional Chinese Medicine; Peking University; Peking University; Tsinghua University	Zhang, Y; Xu, N (corresponding author), Tsinghua Univ, Grad Sch Shenzhen, Key Lab Hlth Sci & Technol, Bldg L,Tsinghua Campus, Shenzhen 518055, Peoples R China.	zhangyo@sz.tsinghua.edu.cn; xu.naihan@sz.tsinghua.edu.cn	Wu, Jiangbin/GWC-7165-2022; Xu, Naihan/C-2778-2018; , Yuanzhi/D-3936-2015	Wu, Jiangbin/0000-0003-3109-417X; Zhang, Yaou/0000-0002-2501-8093; He, Jie/0000-0002-5880-8112; , Yuanzhi/0000-0002-7803-4484	National Natural Science Foundation of China [31571418, 31371315]; Shenzhen Science and Technology Innovation Committee [JCYJ20160226185623304, JCYJ20140417115840281]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Innovation Committee	We thank the National Natural Science Foundation of China (No. 31571418 and 31371315) and the Shenzhen Science and Technology Innovation Committee (JCYJ20160226185623304, JCYJ20140417115840281) for financial support.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai ZQ, 2015, J BIOL CHEM, V290, P19967, DOI 10.1074/jbc.M115.661504; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Conkrite K, 2011, GENE DEV, V25, P1734, DOI 10.1101/gad.17027411; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124; Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112; Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708; Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Pickering MT, 2009, ONCOGENE, V28, P140, DOI 10.1038/onc.2008.372; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72; Shi J, 2007, CURR BIOINFORM, V2, P133, DOI 10.2174/157489307780618231; Singh R, 2013, CANCER BIOL THER, V14, P201, DOI 10.4161/cbt.23296; Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Xu W, 2015, BIOCHEM BIOPH RES CO, V457, P300, DOI 10.1016/j.bbrc.2014.12.104; Yan HJ, 2010, HUM GENE THER, V21, P1723, DOI 10.1089/hum.2010.061; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	54	43	46	4	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5874	5884		10.1038/onc.2017.193	http://dx.doi.org/10.1038/onc.2017.193			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628113	Green Published, hybrid			2022-12-28	WOS:000413292900009
J	Wang, G; Fu, Y; Yang, X; Luo, X; Wang, J; Gong, J; Hu, J				Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Wang, J.; Gong, J.; Hu, J.			Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis (vol 35, pg 651, 2016)	ONCOGENE			English	Correction									[Wang, G.] Huazhong Univ Sci & Technol, Canc Res Inst, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Wang, G (corresponding author), Huazhong Univ Sci & Technol, Canc Res Inst, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.							Wang G, 2016, ONCOGENE, V35, P651, DOI 10.1038/onc.2015.124	1	3	3	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5915	5915		10.1038/onc.2017.317	http://dx.doi.org/10.1038/onc.2017.317			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28846106	Bronze			2022-12-28	WOS:000413292900014
J	Zhang, Y; Hu, Y; Wang, JL; Yao, H; Wang, H; Liang, L; Li, C; Shi, H; Chen, Y; Fang, JY; Xu, J				Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Shi, H.; Chen, Y.; Fang, J-Y; Xu, J.			Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp	ONCOGENE			English	Article							GAIN-OF-FUNCTION; PROTEIN 29 ERP29; CANCER CELLS; UNFOLDED PROTEIN; EXPRESSION; APOPTOSIS; GENE; DNA; CHEMOTHERAPY; PROGRESSION	Mutation of the TP53 gene represents a prevalent genetic alteration in human cancers, and a subset of p53 mutants may form amyloid-like aggregates that contribute to the gain of oncogenic functions (GOFs) and chemoresistance. Here we identify the pathways that may mediate the aggregation-associated GOF by using combined proteomic analysis and genome-wide recruitment profiling. Mass spectrometry revealed activation of unfolded protein response (UPR) pathway and upregulation of endoplasmic reticulum protein 29 (ERp29) in (R282W)TP53-expressing cells that were exposed to cisplatin stress. Chromatin immunoprecipitation sequencing identified a significant 'CCCASS' binding motif of Arg282Trp, which is present in the promoter region of ERP29 gene. The mutant p53 upregulated ERP29 mRNA and protein expression levels, whereas targeting ERP29 by specific small interfering RNAs suppressed the chemoresistant effect of Arg282Trp. The anti-aggregation peptide ReACp53 significantly decreased ERP29 expression and suppressed the chemoresistant effect. These findings highlight a role of ERP29 in the acquired chemoresistance of cancer cells expressing the aggregating p53 mutant Arg282Trp. Our results also suggest that ERP29-mediated GOF can be targeted by the anti-aggregation peptide ReACp53.	[Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Chen, Y.; Fang, J-Y; Xu, J.] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol,Renji Hosp, State Key Lab Oncogenes & Related Genes,Sch Med, Div Gastroenterol & Hepatol,Minist Hlth, Shanghai, Peoples R China; [Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Chen, Y.; Fang, J-Y; Xu, J.] Shanghai Inst Digest Dis, Shanghai, Peoples R China; [Hu, Y.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Shi, H.] Sichuan Univ, West China Hosp, Div Canc Biotherapy, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Shi, H.] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Sichuan, Peoples R China; [Shi, H.] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Sichuan University; Sichuan University	Xu, J (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Hosp, Sch Med, Shanghai 200001, Peoples R China.	jiexu@sjtu.edu.cn	Xu, Jie/K-3712-2019; li, chu/GPS-7224-2022	Xu, Jie/0000-0001-9163-3898; zhang, yao/0000-0003-1174-7049; Li, Chushu/0000-0001-6658-2208	National Natural Science Foundation of China [81572326, 81322036, 81272383, 81421001, 81320108024, 81530072, 81602518, 81502015, 81572303]; Top-Notch Young Talents Program of China [ZTZ2015-48]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152514]; National Key Research & Development (RD) Plan [2016YFC0906000, 2016YFC0906002]; National Key Technology Support Program [2015BAI13B07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Top-Notch Young Talents Program of China; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; National Key Research & Development (RD) Plan; National Key Technology Support Program(National Key Technology R&D Program)	This project was supported by grants from National Natural Science Foundation of China (81572326, 81322036, 81272383, 81421001, 81320108024, 81530072, 81602518, 81502015 and 81572303); Top-Notch Young Talents Program of China (ZTZ2015-48); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152514); National Key Research & Development (R&D) Plan (2016YFC0906000 and 2016YFC0906002); and National Key Technology Support Program (2015BAI13B07). The sponsors of this study had no role in the collection of the data, the analysis and interpretation of the data, the decision to submit the manuscript for publication or the writing of the manuscript.	Acin S, 2011, J PATHOL, V225, P479, DOI 10.1002/path.2971; Al-Rawashdeh FY, 2010, EUR J GASTROEN HEPAT, V22, P1099, DOI 10.1097/MEG.0b013e3283378405; Ali A, 2014, CANCER LETT, V354, P87, DOI 10.1016/j.canlet.2014.07.045; Bailey TL, 2011, BIOINFORMATICS, V27, P1653, DOI 10.1093/bioinformatics/btr261; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chen SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14723; Chen SH, 2015, FEBS OPEN BIO, V5, P91, DOI 10.1016/j.fob.2015.01.004; Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006; Chiang MF, 2012, BIOMED PHARMACOTHER, V66, P433, DOI 10.1016/j.biopha.2012.03.003; Cino EA, 2016, SCI REP-UK, V6, DOI 10.1038/srep32535; Coffill CR, 2012, EMBO REP, V13, P638, DOI 10.1038/embor.2012.74; Das S, 2009, MOL BIOL CELL, V20, P2593, DOI 10.1091/mbc.E08-07-0790; Datta A, 2016, GENOM DATA, V8, P47, DOI 10.1016/j.gdata.2016.03.003; Di Fiore R, 2014, BONE, V60, P198, DOI 10.1016/j.bone.2013.12.021; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Epple LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; He C, 2017, CHEMOTHERAPY, V62, P43, DOI 10.1159/000446361; Hirsch I, 2014, APOPTOSIS, V19, P801, DOI 10.1007/s10495-013-0961-0; Hume MA, 2015, NUCLEIC ACIDS RES, V43, pD117, DOI 10.1093/nar/gku1045; Humpton TJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026146; Kim E, 2007, ONCOGENE, V26, P2185, DOI 10.1038/sj.onc.1210312; Kim MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120536; Kiprijanovska S., 2014, INT J PROTEOMICS, V2014, DOI DOI 10.1155/2014/594761; Krishnan SR, 2015, BREAST CANCER RES TR, V150, P487, DOI 10.1007/s10549-015-3339-x; Lasagna-Reeves CA, 2013, BIOCHEM BIOPH RES CO, V430, P963, DOI 10.1016/j.bbrc.2012.11.130; Lavra L, 2009, J PATHOL, V218, P66, DOI 10.1002/path.2510; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Levy CB, 2011, INT J BIOCHEM CELL B, V43, P60, DOI 10.1016/j.biocel.2010.10.017; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Lu Jin-Jian, 2015, Chin J Nat Med, V13, P673, DOI 10.1016/S1875-5364(15)30065-0; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Magdeldin S, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-16; Mantovani F, 2017, FEBS J, V284, P837, DOI 10.1111/febs.13948; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; May Caroline, 2012, Methods Mol Biol, V893, P37, DOI 10.1007/978-1-61779-885-6_3; Mori-Iwamoto S, 2007, INT J ONCOL, V31, P1345; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pi LH, 2014, ONCOL LETT, V7, P685, DOI 10.3892/ol.2013.1753; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Qi L, 2012, MED ONCOL, V29, P721, DOI 10.1007/s12032-011-9929-5; Schwartz M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0145-x; Silva JL, 2014, TRENDS BIOCHEM SCI, V39, P260, DOI 10.1016/j.tibs.2014.04.001; Song IK, 2016, SCI REP-UK, V6, DOI 10.1038/srep34432; Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002; Vaughan CA, 2012, BIOCHEM BIOPH RES CO, V428, P6, DOI 10.1016/j.bbrc.2012.09.029; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Walerych D, 2016, CELL CYCLE, V15, P3009, DOI 10.1080/15384101.2016.1215703; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Wang X, 2014, ANN SURG ONCOL, V21, P1337, DOI 10.1245/s10434-013-3380-0; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Xu J, 2014, SCI REP-UK, V4, DOI 10.1038/srep04223; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Zhang DH, 2010, EXP CELL RES, V316, P3522, DOI 10.1016/j.yexcr.2010.08.014; Zhang Y, 2016, ONCOTARGET, V7, P11056, DOI 10.18632/oncotarget.7090; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	66	17	19	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5473	5483		10.1038/onc.2017.152	http://dx.doi.org/10.1038/onc.2017.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534505				2022-12-28	WOS:000411960500004
J	Wang, Q; Ma, J; Lu, Y; Zhang, S; Huang, J; Chen, J; Bei, JX; Yang, K; Wu, G; Huang, K; Chen, J; Xu, S				Wang, Q.; Ma, J.; Lu, Y.; Zhang, S.; Huang, J.; Chen, J.; Bei, J-X; Yang, K.; Wu, G.; Huang, K.; Chen, J.; Xu, S.			CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells	ONCOGENE			English	Article							CYCLE-RELATED KINASE; TRANSCRIPTION FACTOR NRF2; PROTEASOMAL DEGRADATION; PROTEOMIC ANALYSIS; EMERGING ROLE; E3 LIGASE; PROLIFERATION; GENE; CHEMORESISTANCE; CARCINOMA	Radiochemoresistance is considered the main cause of local recurrence and distant metastasis in lung cancer. However, the underlying mechanisms of radiochemoresistance remain to be uncovered. In this study, we determine the functions of cell cyclerelated kinase (CDK20) in radiochemoresistance. CDK20 is a newly identified protein kinase, which plays critical roles in cell growth and proliferation in several types of cancer. Using tandem affinity purification technology, we provide evidences that CDK20 binds to the ubiquitin ligase Kelch-like ECH-associated protein 1 (KEAP1), which targets transcriptional factor nuclear factor erythroid-2-related factor 2 (NRF2) for degradation. We show that this interaction is mediated by an evolutionarily conserved ETGE motif on CDK20. Furthermore, we demonstrate that CDK20 competes with NRF2 for KEAP1 binding, enhances the transcriptional activity of NRF2 and lowers the cellular reactive oxygen species level. Moreover, CDK20-depleted cells display impaired cell proliferation, defective G2/M arrest and increased radiochemosensitivity in lung cancer. These phenotypes induced by CDK20 knockdown are partially dependent on NRF2 inactivation. More importantly, CDK20 is overexpressed in human lung cancer tissues, as determined by immunostaining. Collectively, our results suggest that CDK20 positively modulate the KEAP1-NRF2 cytoprotective pathway to regulate tumor progression and radiochemoresistance, implying that CDK20 is a novel, promising therapeutic target for lung cancer.	[Wang, Q.; Ma, J.; Lu, Y.; Zhang, S.; Huang, J.; Chen, J.; Yang, K.; Wu, G.; Xu, S.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China; [Bei, J-X] Sun Yat Sen Univ, Ctr Canc, South China Collaborat Innovat Ctr Canc Med, State Key Lab Oncol,Dept Expt Res, Guangzhou, Guangdong, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Gene Res, Wuhan, Hubei, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan, Hubei, Peoples R China; [Chen, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center	Yang, K; Xu, S (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Hubei, Peoples R China.	yangkunyu@medmail.com.cn; xsb723@hust.edu.cn	Bei, Jin-Xin/AAO-1259-2020		National Natural Science Foundation of China [81301719, 81372435]; State Key Laboratory of Oncology in South China [HN2014-10]; Wuhan Science and Technology Bureau [2015060101010041]; Department of Defense Era of Hope research scholar award [W81XWH-09-1-0409]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncology in South China; Wuhan Science and Technology Bureau; Department of Defense Era of Hope research scholar award(United States Department of Defense)	This work was supported by the National Natural Science Foundation of China (81301719 to SX), Open Funds of State Key Laboratory of Oncology in South China (HN2014-10 to SX), a grant from the Wuhan Science and Technology Bureau (2015060101010041 to SX), the National Natural Science Foundation of China (81372435 to KY) and Department of Defense Era of Hope research scholar award (W81XWH-09-1-0409 to JC).	Addario BJ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.20; Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056; Feng H, 2015, J HEPATOL, V62, P1100, DOI 10.1016/j.jhep.2014.11.040; Feng H, 2011, J CLIN INVEST, V121, P3159, DOI 10.1172/JCI45967; Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee S, 2012, FREE RADICAL BIO MED, V53, P807, DOI 10.1016/j.freeradbiomed.2012.05.038; Liu Y, 2004, J BIOL CHEM, V279, P4507, DOI 10.1074/jbc.M309995200; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Mikell JL, 2015, J THORAC ONCOL, V10, P462, DOI 10.1097/JTO.0000000000000411; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Ng SSM, 2007, J NATL CANCER I, V99, P936, DOI 10.1093/jnci/djm011; O'Connell MA, 2015, BIOCHEM SOC T, V43, P687, DOI 10.1042/BST20150069; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tian Y, 2012, ONCOL LETT, V4, P601, DOI 10.3892/ol.2012.828; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Xu S, 2011, ONCOGENE, V30, P2219, DOI 10.1038/onc.2010.596; Xu SB, 2014, MOL CELL PROTEOMICS, V13, P2986, DOI 10.1074/mcp.M113.036699; Xu Y, 2013, CANCER RES, V73, P4406, DOI 10.1158/0008-5472.CAN-12-4297; Yang Y, 2013, EMBO REP, V14, P741, DOI 10.1038/embor.2013.80; Yu Z, 2014, GUT, V63, P1793, DOI 10.1136/gutjnl-2013-305584; Zhan LJ, 2012, FREE RADICAL BIO MED, V53, P758, DOI 10.1016/j.freeradbiomed.2012.05.041; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhou SN, 2013, CRIT REV ONCOL HEMAT, V88, P706, DOI 10.1016/j.critrevonc.2013.09.001	43	47	49	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5321	5330		10.1038/onc.2017.161	http://dx.doi.org/10.1038/onc.2017.161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28534518				2022-12-28	WOS:000410671700010
J	Shakya, R; Tarulli, GA; Sheng, L; Lokman, NA; Ricciardelli, C; Pishas, KI; Selinger, CI; Kohonen-Corish, MRJ; Cooper, WA; Turner, AG; Neilsen, PM; Callen, DF				Shakya, R.; Tarulli, G. A.; Sheng, L.; Lokman, N. A.; Ricciardelli, C.; Pishas, K. I.; Selinger, C. I.; Kohonen-Corish, M. R. J.; Cooper, W. A.; Turner, A. G.; Neilsen, P. M.; Callen, D. F.			Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer	ONCOGENE			English	Article							WILD-TYPE; PROGNOSTIC-SIGNIFICANCE; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; MOUSE MODELS; GAIN; MUTATIONS; P63; INHIBITION; COMPLEX	Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the 'secretome') that facilitates the invasion of lung cancer cell lines. Proteomic characterization of the secretome from mutant p53-inducible H1299 human non-small cell lung cancer cell line discovered that the mutant p53 drives its oncogenic pathways through modulating the gene expression of numerous targets that are subsequently secreted from the cells. Of these genes, alpha-1 antitrypsin (A1AT) was identified as a critical effector of mutant p53 that drives invasion in vitro and in vivo, together with induction of epithelial-mesenchymal transition markers expression. Mutant p53 upregulated A1AT transcriptionally through the involvement with its family member p63. Conditioned medium containing secreted A1AT enhanced cell invasion, while an A1AT-blocking antibody attenuated the mutant p53-driven migration and invasion. Importantly, high A1AT expression correlated with increased tumor stage, elevated p53 staining and shorter overall survival in lung adenocarcinoma patients. Collectively, these findings suggest that A1AT is an indispensable target of mutant p53 with prognostic and therapeutic potential in mutant p53-expressing tumors.	[Shakya, R.; Sheng, L.; Pishas, K. I.; Turner, A. G.; Callen, D. F.] Univ Adelaide, Sch Med, Fac Hlth Sci, Ctr Personalised Canc Med,Canc Therapeut Lab, Level 3,Hanson Inst Bldg,Frome Rd, Adelaide, SA 5005, Australia; [Tarulli, G. A.] Univ Adelaide, Fac Hlth Sci, Sch Med, DRMCRL, Adelaide, SA, Australia; [Lokman, N. A.; Ricciardelli, C.] Univ Adelaide, Robinson Res Inst, Fac Hlth Sci, Sch Med,Discipline Obstet & Gynaecol, Adelaide, SA, Australia; [Lokman, N. A.] Univ Adelaide, Sch Mol & Biol Sci, Adelaide Prote Ctr, Adelaide, SA, Australia; [Selinger, C. I.] Royal Prince Alfred Hosp, Camperdown, NSW, Australia; [Kohonen-Corish, M. R. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.] UNSW Australia, St Vincents Clin Sch, Sydney, NSW, Australia; [Kohonen-Corish, M. R. J.; Cooper, W. A.] Univ Western Sydney, Sch Med, Parramatta, NSW, Australia; [Cooper, W. A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Cooper, W. A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Neilsen, P. M.] Swinburne Univ Technol Sarawak Campus, Kuching, Sarawak, Malaysia	Hanson Institute; University of Adelaide; University of Adelaide; Robinson Research Institute; University of Adelaide; University of Adelaide; University of Sydney; Garvan Institute of Medical Research; University of New South Wales Sydney; Western Sydney University; University of Sydney; University of Sydney	Shakya, R (corresponding author), Univ Adelaide, Sch Med, Fac Hlth Sci, Ctr Personalised Canc Med,Canc Therapeut Lab, Level 3,Hanson Inst Bldg,Frome Rd, Adelaide, SA 5005, Australia.	reshma.shakya@adelaide.edu.au	Tarulli, Gerard A/D-8863-2013; Ricciardelli, Carmela/U-1814-2019; Ricciardelli, Carmela/K-2212-2015; Kohonen-Corish, Maija/Q-9763-2019	Ricciardelli, Carmela/0000-0001-7415-1854; Ricciardelli, Carmela/0000-0001-7415-1854; Kohonen-Corish, Maija/0000-0002-4073-1479; Lokman, Noor/0000-0002-2071-5308; Turner, Andrew/0000-0003-0374-1181; Neilsen, Paul/0000-0001-7937-3675; Tarulli, Gerard/0000-0002-1327-4655; Sheng, Lei/0000-0003-1814-809X; Shakya, Reshma/0000-0002-8154-432X	NHMRC Project [44107714, 44112162]; University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship	NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia); University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship	We thank TCGA research network for publicly sharing their data. The results published here are in part based upon data generated by the TCGA project, which was established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov. We also thank Rebecca C Haycox for her technical assistance. This work was supported by the NHMRC Project grants (44107714 and 44112162). K Pishas acknowledges financial contributions from the University of Adelaide Florey Medical Research Foundation Clinical Cancer Research Fellowship.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ahrendt SA, 2003, J NATL CANCER I, V95, P961, DOI 10.1093/jnci/95.13.961; Alamanova D, 2010, BMC BIOINFORMATICS, V11, P1; Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Aryee DNT, 2013, BRIT J CANCER, V109, P2696, DOI 10.1038/bjc.2013.635; Baker L, 2010, BRIT J CANCER, V102, P719, DOI 10.1038/sj.bjc.6605540; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang YH, 2012, MOL CELL PROTEOMICS, V11, P1320, DOI 10.1074/mcp.M112.017384; Chee JLY, 2013, CELL CYCLE, V12, P278, DOI 10.4161/cc.23054; Chen JT, 2000, ANTICANCER RES, V20, P2687; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Coffill CR, 2012, EMBO REP, V13, P638, DOI 10.1038/embor.2012.74; Cordani M, 2016, CANCER LETT, V376, P303, DOI 10.1016/j.canlet.2016.03.046; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; El-Akawi ZJ, 2008, NEUROENDOCRINOL LETT, V29, P482; El-Telbany Ahmed, 2012, Genes Cancer, V3, P467, DOI 10.1177/1947601912465177; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Frenzel E, 2015, J IMMUNOL, V195, P3605, DOI 10.4049/jimmunol.1500740; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grellety T, 2015, BMC CANCER, V15, P1; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719; Kwon CH, 2014, BRIT J CANCER, V111, P1993, DOI 10.1038/bjc.2014.490; Kwon CH, 2015, ONCOTARGET, V6, P20312, DOI 10.18632/oncotarget.3964; LAINE A, 1990, CLIN CHIM ACTA, V190, P163, DOI 10.1016/0009-8981(90)90170-W; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lehmann BD, 2012, J CLIN ONCOL, V30, P3648, DOI 10.1200/JCO.2012.44.0412; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Miyake M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-322; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petrache I, 2006, AM J PATHOL, V169, P1155, DOI 10.2353/ajpath.2006.060058; Pishas KI, 2015, SCI REP-UK, V5, DOI 10.1038/srep11465; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Rivlin N, 2014, P NATL ACAD SCI USA, V111, P7006, DOI 10.1073/pnas.1320428111; Russo D, 2013, BBA-MOL CELL RES, V1833, P1904, DOI 10.1016/j.bbamcr.2013.03.020; Samowitz WS, 2002, INT J CANCER, V99, P597, DOI 10.1002/ijc.10405; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skaug V, 2000, CLIN CANCER RES, V6, P1031; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tseng IC, 2008, AM J PHYSIOL-CELL PH, V295, pC423, DOI 10.1152/ajpcell.00164.2008; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Wang B, 2012, ACTA BIOCH BIOPH SIN, V44, P685, DOI 10.1093/abbs/gms053; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Yousef GM, 2003, BBA-GENE STRUCT EXPR, V1628, P88, DOI 10.1016/S0167-4781(03)00116-7; Zelvyte I, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-7; Zhang G, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0200-1	68	28	29	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4469	4480		10.1038/onc.2017.66	http://dx.doi.org/10.1038/onc.2017.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368395				2022-12-28	WOS:000406806000009
J	Zhang, Y; Ren, YJ; Guo, LC; Ji, C; Hu, J; Zhang, HH; Xu, QH; Zhu, WD; Ming, ZJ; Yuan, YS; Ren, X; Song, J; Yang, JM				Zhang, Y.; Ren, Y-J; Guo, L-C; Ji, C.; Hu, J.; Zhang, H-H; Xu, Q-H; Zhu, W-D; Ming, Z-J; Yuan, Y-S; Ren, X.; Song, J.; Yang, J-M			Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1 alpha axis	ONCOGENE			English	Article							HISTONE DEACETYLASE-4; INDUCIBLE FACTORS; OVARIAN-CANCER; NACL; PLURIPOTENCY; ACETYLATION; BEVACIZUMAB; NETWORK; KINASE; GROWTH	Nucleus accumbens-associated protein-1 (NAC1), a nuclear factor of the BTB/POZ gene family, has emerging roles in cancer. In this study, we identified the NAC1-HDAC4-HIF-1 alpha axis as an important pathway in regulating glycolysis and hypoxic adaptation in tumor cells. We show that nuclear NAC1 binds to histone deacetylase type 4 (HDAC4), hindering phosphorylation of HDAC4 at Ser(246) and preventing its nuclear export that leads to cytoplasmic degradation of the deacetylase. Accumulation of HDAC4 in the nuclei results in an attenuation of HIF-1 alpha acetylation, enhancing the stabilization and transcriptional activity of HIF-1 alpha and strengthening adaptive response of cells to hypoxia. We also show the role of NAC1 in promoting glycolysis in a mouse xenograft model, and demonstrate that knockdown of NAC1 expression can reinforce the antitumor efficacy of bevacizumab, an inhibitor of angiogenesis. Clinical implication of the NAC1-HDAC4-HIF-1 alpha pathway is suggested by the results showing that expression levels of these proteins are significantly correlative in human tumor specimens and associated with the disease progression. This study not only reveals an important function of NAC1 in regulating glycolysis, but also identifies the NAC1-HDAC4-HIF-1 alpha axis as a novel molecular pathway that promotes survival of hypoxic tumor cells.	[Zhang, Y.; Ren, Y-J; Guo, L-C; Ji, C.; Hu, J.; Zhang, H-H; Xu, Q-H; Zhu, W-D; Ming, Z-J] Soochow Univ, Dept Pharmacol, Coll Pharmaceut Sci, Affiliated Hosp 1, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China; [Yuan, Y-S] Shanghai Jiao Tong Univ, Sch Pharm, Engn Res Ctr Cell & Therapeut Antibody, Shanghai, Peoples R China; [Ren, X.; Song, J.; Yang, J-M] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol & Microbiol & Immunol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA	Soochow University - China; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhang, Y (corresponding author), Soochow Univ, Dept Pharmacol, Coll Pharmaceut Sci, Affiliated Hosp 1, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.; Yang, JM (corresponding author), Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol & Microbiol & Immunol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.	zhangyi@suda.edu.cn; juy16@psu.edu			National Natural Sciences Foundation of China [81473240, BK20151209]; China Postdoctoral Science Foundation [2015T80585, 2014M550308]; Natural Science Foundation of Jiangsu Province of China [BK20151209, BK20141197]; Science and Technology Foundation of Suzhou City [SYS201319]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Science and Technology Foundation of Suzhou City	This work was supported by grants from National Natural Sciences Foundation of China (81473240), Special Financial Grant by China Postdoctoral Science Foundation (2015T80585), China Postdoctoral Science Foundation (2014M550308), Natural Science Foundation of Jiangsu Province of China (BK20141197), Science and Technology Foundation of Suzhou City (SYS201319) to Yi Zhang; and Natural Science Foundation of Jiangsu Province of China (BK20151209) to Cheng Ji.	Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Cardenas-Navia LI, 2007, FRONT BIOSCI-LANDMRK, V12, P4061, DOI 10.2741/2372; Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10-07-0616; Cheng Y, 2016, ONCOGENE, V35, P6293, DOI 10.1038/onc.2016.166; Fack F, 2015, ACTA NEUROPATHOL, V129, P115, DOI 10.1007/s00401-014-1352-5; Folkman J, 2007, J PEDIATR SURG, V42, P1, DOI 10.1016/j.jpedsurg.2006.09.048; Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Korutla L, 2005, J NEUROCHEM, V94, P786, DOI 10.1111/j.1471-4159.2005.03206.x; Korutla L, 2014, NEUROSCIENCE, V257, P86, DOI 10.1016/j.neuroscience.2013.11.001; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Malleshaiah M, 2016, CELL REP, V14, P1181, DOI 10.1016/j.celrep.2015.12.101; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mesange P, 2014, ONCOTARGET, V5, P4709, DOI 10.18632/oncotarget.1671; Moeller BJ, 2004, SEMIN RADIAT ONCOL, V14, P215, DOI 10.1016/j.semradonc.2004.04.005; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2010, GYNECOL ONCOL, V119, P469, DOI 10.1016/j.ygyno.2010.08.031; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Rahman MT, 2012, BRIT J CANCER, V107, P300, DOI 10.1038/bjc.2012.246; Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274; Rivera LB, 2014, SCIENCE, V344, P1449, DOI 10.1126/science.1257071; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shao MH, 2012, MOL CANCER THER, V11, P1576, DOI 10.1158/1535-7163.MCT-11-0961; Shih IM, 2011, MODERN PATHOL, V24, P638, DOI 10.1038/modpathol.2010.230; Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699; Stead MA, 2014, BIOSCIENCE REP, V34, P227, DOI 10.1042/BSR20140049; Ueda SM, 2010, J ONCOL, V2010, DOI 10.1155/2010/285191; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yeasmin S, 2012, HUM PATHOL, V43, P506, DOI 10.1016/j.humpath.2011.05.021; Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290; Zhang Y, 2012, CANCER RES, V72, P4262, DOI 10.1158/0008-5472.CAN-12-0139; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	47	25	26	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4171	4181		10.1038/onc.2017.51	http://dx.doi.org/10.1038/onc.2017.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319066	hybrid, Green Published			2022-12-28	WOS:000405835800008
J	Zhou, M; Mok, MTS; Sun, H; Chan, AW; Huang, Y; Cheng, ASL; Xu, G				Zhou, M.; Mok, M. T. S.; Sun, H.; Chan, A. W.; Huang, Y.; Cheng, A. S. L.; Xu, G.			The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; HEPATIC STEATOSIS; SIGNAL TRANSDUCER; MOUSE MODELS; CANCER; LIVER; ASSOCIATION; EXPRESSION	Epidemiological studies have demonstrated a close association of type 2 diabetes and hepatocellular carcinoma (HCC). Exenatide (Ex-4), a potent diabetes drug targeting glucagon-like peptide-1 receptor (GLP-1R), is protective against non-alcoholic fatty liver disease (NAFLD). However, the Ex-4 function and GLP-1R status have yet been explored in HCC. Herein we investigated the effect of Ex-4 in diethylnitrosamine (DEN)-treated mice consuming control or high-fat high-carbohydrate diet. Administration of Ex-4 significantly improved obesity-induced hyperglycemia and hyperlipidemia and reduced HCC multiplicity in obese DEN-treated mice, in which suppressed proliferation and induced apoptosis were confined to tumor cells. The tumor suppression effects of Ex-4 were associated with high expression of GLP-1R and activation of cyclic AMP ( cAMP) and protein kinase A (PKA). Importantly, Ex-4 also downregulated epidermal growth factor receptor ( EGFR) and signal transducer and activator of transcription 3 (STAT3), which lie downstream of cAMP-PKA signaling, resulting in suppression of multiple STAT3-targeted genes including c-Myc, cyclin D1, survivin, Bcl-2 and Bcl-xl. The growth inhibitory effects of Ex-4 were consistent in GLP-1R-abundant hepatoma cell lines and xenograft mouse model, wherein both PKA and EGFR had obligatory roles in mediating Ex-4 functions. In addition, Ex- 4 also effectively suppressed inflammatory and fibrotic phenotypes in mice fed with methionine-choline-deficient (MCD) diet and choline-deficient ethionine-supplemented (CDE) diet, respectively. In summary, Ex-4 elicits protective functions against NAFLD and obesity-associated HCC through cAMP-PKA-EGFR-STAT3 signaling, suggesting its administration as a novel approach to reduce HCC risk in diabetic patients.	[Zhou, M.; Sun, H.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Huang, Y.; Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Mok, M. T. S.; Cheng, A. S. L.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Sun, H.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg, Shanghai, Peoples R China; [Chan, A. W.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Cheng, A. S. L.] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Xu, G.] Sun Yat Sen Univ, Diabet Ctr, Affiliated Hosp 8, Shenzhen, Peoples R China; [Xu, G.] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 8, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University	Cheng, ASL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.; Cheng, ASL (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Xu, G (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China.	alfredcheng@cuhk.edu.hk; gangxu55@yahoo.com	Huang, Yu/K-2866-2017; Chan, Anthony W.H./N-6719-2016; Cheng, Alfred SL/C-3327-2014; Mok, Myth/M-2958-2013; Chan, Anthony Wing Hung/HGB-4311-2022; Chan, Anthony/U-7768-2019	Huang, Yu/0000-0002-1277-6784; Chan, Anthony W.H./0000-0002-1771-163X; Cheng, Alfred SL/0000-0003-2345-6951; Mok, Myth/0000-0003-3156-4944; Chan, Anthony Wing Hung/0000-0002-1771-163X; Chan, Anthony/0000-0002-1771-163X	Collaborative Research Fund [C4017-14G]; Research Grants Council of Hong Kong [14120816]; National Natural Science Foundation of China [81272305, 81170722, 81270438, 81302167, 81501210]; Chinese University of Hong Kong [1907301]	Collaborative Research Fund; Research Grants Council of Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese University of Hong Kong(Chinese University of Hong Kong)	This study is supported by the Collaborative Research Fund (C4017-14G) and the General Research Fund (14120816) of the Research Grants Council of Hong Kong, National Natural Science Foundation of China (81272305, 81170722, 81270438, 81302167 and 81501210) and Focused Investments Scheme B (1907301) of the Chinese University of Hong Kong.	Absood A, 2008, REGUL PEPTIDES, V146, P285, DOI 10.1016/j.regpep.2007.11.002; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; Caretta Antonio, 2011, Cancers (Basel), V3, P913, DOI 10.3390/cancers3010913; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chang CH, 2012, HEPATOLOGY, V55, P1462, DOI 10.1002/hep.25509; Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl-2011-301708; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Ding XK, 2006, HEPATOLOGY, V43, P173, DOI 10.1002/hep.21006; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Egan AG, 2014, NEW ENGL J MED, V370, P794, DOI 10.1056/NEJMp1314078; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Elashoff M, 2011, GASTROENTEROLOGY, V141, P150, DOI 10.1053/j.gastro.2011.02.018; Fan R, 2010, DIABETES OBES METAB, V12, P815, DOI 10.1111/j.1463-1326.2010.01238.x; Farrell GC, 2013, NAT REV GASTRO HEPAT, V10, P307, DOI 10.1038/nrgastro.2013.34; Feng X, 2013, J PHARMACOVIGILANCE, V1, P110; Gupta NA, 2010, HEPATOLOGY, V51, P1584, DOI 10.1002/hep.23569; Hopfner M, 2004, J HEPATOL, V41, P1008, DOI 10.1016/j.jhep.2004.08.024; Hosokawa T, 2013, WORLD J GASTROENTERO, V19, P249, DOI 10.3748/wjg.v19.i2.249; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Ito Y, 2001, BRIT J CANCER, V84, P1377, DOI 10.1054/bjoc.2000.1580; Kang ZF, 2013, DIABETOLOGIA, V56, P423, DOI 10.1007/s00125-012-2776-x; Koehler JA, 2006, DIABETES, V55, P1369, DOI 10.2337/db05-1145; Koehler JA, 2011, ENDOCRINOLOGY, V152, P3362, DOI 10.1210/en.2011-1201; Korner M, 2007, J NUCL MED, V48, P736, DOI 10.2967/jnumed.106.038679; Kohli R, 2010, HEPATOLOGY, V52, P934, DOI 10.1002/hep.23797; Kovach SJ, 2006, J CELL PHYSIOL, V206, P411, DOI 10.1002/jcp.20474; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Ligumsky H, 2012, BREAST CANCER RES TR, V132, P449, DOI 10.1007/s10549-011-1585-0; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Nauck M, 2016, DIABETES OBES METAB, V18, P203, DOI 10.1111/dom.12591; Nauck MA, 2013, DIABETES CARE, V36, pS245, DOI 10.2337/dcS13-2004; Nomiyama T, 2014, DIABETES, V63, P3891, DOI 10.2337/db13-1169; Otsuka M, 2004, HEPATOLOGY, V40, P243, DOI 10.1002/hep.20260; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; Shao H, 2003, CANCER RES, V63, P3923; Svegliati-Baroni G, 2011, LIVER INT, V31, P1285, DOI 10.1111/j.1478-3231.2011.02462.x; Targher G, 2007, DIABETES CARE, V30, P1212, DOI 10.2337/dc06-2247; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Wang P, 2012, DIABETES-METAB RES, V28, P109, DOI 10.1002/dmrr.1291; Watanabe J, 2004, SURGERY, V135, P604, DOI 10.1016/j.surg.2003.11.015; Yang Y, 2011, MED ONCOL, V28, P796, DOI 10.1007/s12032-010-9519-y; Yu Z, 2014, GUT, V63, P1793, DOI 10.1136/gutjnl-2013-305584	46	19	20	7	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4135	4149		10.1038/onc.2017.38	http://dx.doi.org/10.1038/onc.2017.38			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319060				2022-12-28	WOS:000405835800005
J	Hardbower, DM; Coburn, LA; Asim, M; Singh, K; Sierra, JC; Barry, DP; Gobert, AP; Piazuelo, MB; Washington, MK; Wilson, KT				Hardbower, D. M.; Coburn, L. A.; Asim, M.; Singh, K.; Sierra, J. C.; Barry, D. P.; Gobert, A. P.; Piazuelo, M. B.; Washington, M. K.; Wilson, K. T.			EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CANCER CELL-LINES; EPITHELIAL-CELLS; PROLIFERATION; INFLAMMATION; POLARIZATION; EXPRESSION; ANGIOGENESIS; PHENOTYPE; MODEL	Epidermal growth factor receptor (EGFR) signaling is a known mediator of colorectal carcinogenesis. Studies have focused on the role of EGFR signaling in epithelial cells, although the exact nature of the role of EGFR in colorectal carcinogenesis remains a topic of debate. Here, we present evidence that EGFR signaling in myeloid cells, specifically macrophages, is critical for colon tumorigenesis in the azoxymethane-dextran sodium sulfate (AOM-DSS) model of colitis-associated carcinogenesis (CAC). In a human tissue microarray, colonic macrophages demonstrated robust EGFR activation in the pre-cancerous stages of colitis and dysplasia. Utilizing the AOM-DSS model, mice with a myeloid-specific deletion of Egfr had significantly decreased tumor multiplicity and burden, protection from high-grade dysplasia and significantly reduced colitis. Intriguingly, mice with gastrointestinal epithelial cell-specific Egfr deletion demonstrated no differences in tumorigenesis in the AOM-DSS model. The alterations in tumorigenesis in myeloid-specific Egfr knockout mice were accompanied by decreased macrophage, neutrophil and T-cell infiltration. Pro-tumorigenic M2 macrophage activation was diminished in myeloid-specific Egfr-deficient mice, as marked by decreased Arg1 and Il10 mRNA expression and decreased interleukin (IL)-4, IL10 and IL-13 protein levels. Surprisingly, diminished M1 macrophage activation was also detectable, as marked by significantly reduced Nos2 and Il1b mRNA levels and decreased interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and IL-1 beta protein levels. The alterations in M1 and M2 macrophage activation were confirmed in bone marrow-derived macrophages from mice with the myeloid-specific Egfr knockout. The combined effect of restrained M1 and M2 macrophage activation resulted in decreased production of pro-angiogenic factors, CXCL1 and vascular endothelial growth factor (VEGF), and reduced CD31(+) blood vessels, which likely contributed to protection from tumorigenesis. These data reveal that EGFR signaling in macrophages, but not in colonic epithelial cells, has a significant role in CAC. EGFR signaling in macrophages may prove to be an effective biomarker of CAC or target for chemoprevention in patients with inflammatory bowel disease.	[Hardbower, D. M.; Washington, M. K.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Hardbower, D. M.; Coburn, L. A.; Asim, M.; Singh, K.; Sierra, J. C.; Barry, D. P.; Gobert, A. P.; Piazuelo, M. B.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Coburn, L. A.; Gobert, A. P.; Piazuelo, M. B.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Coburn, L. A.; Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Wilson, K. T.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Wilson, K. T.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University	Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Med Gastroenterol Hepatol & Nutr, 1030C Med Res Bldg 4,2215 Garland Ave, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Barry, Daniel P/B-5647-2008	Barry, Daniel P/0000-0002-3972-3914; Coburn, Lori/0000-0003-3249-9806	NIH [P30CA068485, U24DK059637, R01DK053620, R01AT004821, R01CA190612, P01CA116087, P01CA028842, P50CA095103, P30DK058404]; DMH [T32GM008554, F31DK10715]; Veterans Affairs Career Development [1IK2BX002126]; Veterans Affairs Merit Review [I01BX001453]; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Mouse Metabolic Phenotyping Center; Thomas F Frist Sr Endowment; NATIONAL CANCER INSTITUTE [P01CA028842, R01CA190612, P30CA068485, P01CA116087] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, P30DK058404, F31DK107159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453, IK2BX002126] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DMH; Veterans Affairs Career Development(US Department of Veterans Affairs); Veterans Affairs Merit Review(US Department of Veterans Affairs); Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Mouse Metabolic Phenotyping Center; Thomas F Frist Sr Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	CD3, CD45R and CD31 staining was performed by the Vanderbilt University Medical Center Translational Pathology Shared Resource supported by NIH grant P30CA068485 and the Vanderbilt Mouse Metabolic Phenotyping Center, supported by NIH grant U24DK059637. Slide imaging and quantification was performed in the Digital Histology Shared Resource (www.mc.vanderbilt.edu/dhsr). This work was funded by NIH grants R01DK053620, R01AT004821, R01CA190612, P01CA116087 and P01CA028842 (KTW), Veterans Affairs Merit Review grant I01BX001453 (KTW), the Thomas F Frist Sr Endowment (KTW) and the Vanderbilt Center for Mucosal Inflammation and Cancer (KTW). The human TMA was supported by NIH grant P50CA095103 and the DDRC Tissue Morphology Subcore (NIH grant P30DK058404). DMH was supported by T32GM008554 and F31DK10715. LAC was supported by Veterans Affairs Career Development Award 1IK2BX002126.	Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Angelo LS, 2007, CLIN CANCER RES, V13, P2825, DOI 10.1158/1078-0432.CCR-06-2416; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Brower V, 2005, J NATL CANCER I, V97, P251, DOI 10.1093/jnci/97.4.251; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; Dube PE, 2012, J CLIN INVEST, V122, P2780, DOI 10.1172/JCI62888; Engstrom A, 2014, INT J ONCOL, V44, P385, DOI 10.3892/ijo.2013.2203; Erreni M, 2011, CANCER MICROENVIRON, V4, P141, DOI 10.1007/s12307-010-0052-5; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Georgoudaki AM, 2016, CELL REP, V15, P2000, DOI 10.1016/j.celrep.2016.04.084; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardbower DM, 2016, AMINO ACIDS, V48, P2375, DOI 10.1007/s00726-016-2231-2; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hiemisch H, 1997, EMBO J, V16, P3995, DOI 10.1093/emboj/16.13.3995; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Holmfeldt P, 2016, J EXP MED, V213, P433, DOI 10.1084/jem.20150806; Huaux F, 2015, J PATHOL, V235, P698, DOI 10.1002/path.4487; Isidro RA, 2016, AM J PHYSIOL-GASTR L, V311, pG59, DOI 10.1152/ajpgi.00123.2016; Kanneganti M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/342637; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Krasinskas A. M., 2011, PATHOLOG RES INT, V2011, P6, DOI DOI 10.4061/2011/932932; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Markman B, 2010, ADV CLIN CHEM, V51, P71, DOI 10.1016/S0065-2423(10)51004-7; Martinez F.O., 2014, F1000PRIME REP, V6, DOI DOI 10.12703/P6-13; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Mousa Luay, 2015, Biomark Cancer, V7, P13, DOI 10.4137/BIC.S25250; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Norton SE, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.21; Parang B, 2016, GUT, P1; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Payne CM, 1999, ANTIOXID REDOX SIGN, V1, P449, DOI 10.1089/ars.1999.1.4-449; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sasaki T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/546318; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Shibata W, 2010, GASTROENTEROLOGY, V138, P1022, DOI 10.1053/j.gastro.2009.11.054; Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Sweet MJ, 2003, ARCH IMMUNOL THER EX, V51, P169; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Uronis JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006026; Valbuena G, 2003, AM J PATHOL, V163, P1357, DOI 10.1016/S0002-9440(10)63494-3; Van Overmeire E, 2016, CANCER RES, V76, P35, DOI 10.1158/0008-5472.CAN-15-0869; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025; Xie WD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058639; Yang JL, 2004, GUT, V53, P123, DOI 10.1136/gut.53.1.123; Yu HY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6218; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yue Xuetian, 2015, Cancer Cell Microenviron, V2	61	45	48	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3807	3819		10.1038/onc.2017.23	http://dx.doi.org/10.1038/onc.2017.23			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263971	Green Accepted			2022-12-28	WOS:000404848200002
J	Zhang, W; Hong, R; Xue, L; Ou, Y; Liu, X; Zhao, Z; Xiao, W; Dong, D; Dong, L; Fu, M; Ma, L; Lu, N; Chen, H; Song, Y; Zhan, Q				Zhang, W.; Hong, R.; Xue, L.; Ou, Y.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Lu, N.; Chen, H.; Song, Y.; Zhan, Q.			Piccolo mediates EGFR signaling and acts as a prognostic biomarker in esophageal squamous cell carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PRESYNAPTIC ACTIVE ZONES; NEUROTRANSMITTER RELEASE; EPITHELIAL-CELLS; CANCER GENOMICS; PROTEIN; BASSOON; OVEREXPRESSION; MUTATIONS; SYNAPSE	The presynaptic cytomatrix protein Piccolo, encoded by PCLO, is frequently mutated and amplified in esophageal squamous cell carcinoma (ESCC), but its exact roles in ESCC remain unclear. Here we report that Piccolo expression correlates significantly with clinical stage, patient survival and tumor embolus. Functional studies demonstrate that PCLO knockdown remarkably attenuates ESCC malignancy in vitro and in vivo, and ectopic EGFR expression partially compensates for Piccolo loss. PCLO knockdown promotes ubiquitination and degradation of EGFR, which is associated with the negative regulatory effect of Piccolo on E3 ligase Siah1. An anti-Piccolo monoclonal antibody inhibited tumor proliferation in a mouse model of ESCC. These results demonstrate that Piccolo contributes to tumor aggressiveness in ESCC, likely by stabilizing EGFR and promoting EGFR-dependent signaling. Our results further suggest that Piccolo may represent a novel prognostic biomarker and therapeutic target for patients with ESCC.	[Zhang, W.; Ou, Y.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Song, Y.; Zhan, Q.] Chinese Acad Med Sci, Canc Inst & Canc Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Zhang, W.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Song, Y.; Zhan, Q.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, W.; Zhan, Q.] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Sichuan, Peoples R China; [Zhang, W.; Chen, H.] Guangdong Koheala Precis Med Inst, Guangzhou, Guangdong, Peoples R China; [Hong, R.] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Xue, L.; Lu, N.] Peking Union Med Coll, Canc Inst & Canc Hosp, Dept Pathol, Beijing, Peoples R China; [Xue, L.; Lu, N.] Chinese Acad Med Sci, Beijing, Peoples R China; [Ou, Y.] Capital Med Univ, Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China; [Liu, X.] Dalian Med Univ, Canc Ctr, Inst Canc Stem Cell, Dalian, Peoples R China; [Zhan, Q.] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Sichuan University; State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Capital Medical University; Dalian Medical University; Peking University	Zhan, Q (corresponding author), Chinese Acad Med Sci, Canc Inst & Canc Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Zhan, Q (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	zhanqimin@bjmu.edu.cn	Dong, Dezuo/EUE-3308-2022		National 973 Program [2015CB553904]; National Natural Fund of China [81230047, 81321091]	National 973 Program(National Basic Research Program of China); National Natural Fund of China	We appreciated Jie Chen and Tian Lan for revising this manuscript and offering constructive advices. This work is supported by the National 973 Program (2015CB553904) and National Natural Fund of China (81230047 and 81321091).	Abedi-Ardekani B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-602; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Cao HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106007; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cremona O, 2001, J CELL SCI, V114, P1041; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Fujimoto A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7120; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao ZH, 2014, ONCOL LETT, V7, P1118, DOI 10.3892/ol.2014.1881; Garcia J, 2004, NAT STRUCT MOL BIOL, V11, P45, DOI 10.1038/nsmb707; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Kalabis J, 2012, NAT PROTOC, V7, P235, DOI 10.1038/nprot.2011.437; Lehman HL, 2015, AM J PATHOL, V185, P240, DOI 10.1016/j.ajpath.2014.09.008; Limbach C, 2011, P NATL ACAD SCI USA, V108, pE392, DOI 10.1073/pnas.1101707108; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Navarini D, 2012, GASTROENT RES PRACT, V2012; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Shang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111045; Shen ZY, 2002, WORLD J GASTROENTERO, V8, P357; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sunpaweravong P, 2005, J CANCER RES CLIN, V131, P111, DOI 10.1007/s00432-004-0610-7; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; Waites CL, 2013, EMBO J, V32, P954, DOI 10.1038/emboj.2013.27; Wang QF, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-278; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Xue LY, 2012, MODERN PATHOL, V25, P1364, DOI 10.1038/modpathol.2012.89; Yang F, 2013, J BIOL CHEM, V288, P6552, DOI 10.1074/jbc.M112.418335; Yang YL, 2012, CHINESE MED J-PEKING, V125, P450, DOI 10.3760/cma.j.issn.0366-6999.2012.03.009; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhang H, 2006, CANCER GENET CYTOGEN, V165, P25, DOI 10.1016/j.cancergencyto.2005.07.016; Zhang YN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100854	39	20	20	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3890	3902		10.1038/onc.2017.15	http://dx.doi.org/10.1038/onc.2017.15			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263981				2022-12-28	WOS:000404848200009
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			RETRACTION: PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2 (Retraction of Vol 27, Pg 6571, 2008)	ONCOGENE			English	Retraction													Wiman, Klas/AAB-8399-2021; Zhivotovsky, Boris/A-4346-2014	Wiman, Klas/0000-0002-7113-524X; Zhivotovsky, Boris/0000-0002-2238-3482				Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249	1	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3650	3650		10.1038/onc.2017.9	http://dx.doi.org/10.1038/onc.2017.9			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28192401	Bronze			2022-12-28	WOS:000403878600015
J	Abbaci, A; Talbot, H; Saada, S; Gachard, N; Abraham, J; Jaccard, A; Bordessoule, D; Fauchais, AL; Naves, T; Jauberteau, MO				Abbaci, A.; Talbot, H.; Saada, S.; Gachard, N.; Abraham, J.; Jaccard, A.; Bordessoule, D.; Fauchais, A. L.; Naves, T.; Jauberteau, M. O.			Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; CHEMOKINE RECEPTOR; SIGNALING PATHWAY; COUPLED RECEPTORS; IN-VITRO; EXPRESSION; ACTIVATION; SURVIVAL; BCL-2; OVEREXPRESSION	B-cell chronic lymphocytic leukemia (B-CLL) cells are resistant to apoptosis, and consequently accumulate to the detriment of normal B cells and patient immunity. Because current therapies fail to eradicate these apoptosis-resistant cells, it is essential to identify alternative survival pathways as novel targets for anticancer therapies. Overexpression of cell-surface G protein-coupled receptors drives cell transformation, and thus plays a critical role in malignancies. In this study, we identified neurotensin receptor 2 (NTSR2) as an essential driver of apoptosis resistance in B-CLL. NTSR2 was highly expressed in B-CLL cells, whereas expression of its natural ligand, neurotensin (NTS), was minimal in both B-CLL cells and patient plasma. Surprisingly, NTSR2 remained in a constitutively active phosphorylated state, caused not by a mutation-induced gain-of-function but rather by an interaction with the oncogenic tyrosine kinase receptor TrkB. Functional and biochemical characterization revealed that the NTSR2-TrkB interaction acts as a conditional oncogenic driver requiring the TrkB ligand brain-derived neurotrophic factor (BDNF), which unlike NTS is highly expressed in B-CLL cells. Together, NTSR2, TrkB and BDNF induce autocrine and/or paracrine survival pathways that are independent of mutation status and indolent or progressive disease course. The NTSR2-TrkB interaction activates survival signaling pathways, including the Src and AKT kinase pathways, as well as expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL. When NTSR2 was downregulated, TrkB failed to protect B-CLL cells from a drastic decrease in viability via typical apoptotic cell death, reflected by DNA fragmentation and Annexin V presentation. Together, our findings demonstrate that the NTSR2-TrkB interaction plays a crucial role in B-CLL cell survival, suggesting that inhibition of NTSR2 represents a promising targeted strategy for treating B-CLL malignancy.	[Abbaci, A.; Talbot, H.; Saada, S.; Fauchais, A. L.; Naves, T.; Jauberteau, M. O.] Limoges Univ, Equipe Accueil Cellular Homeostasis & Dis 3842, Fac Med, Limoges, France; [Gachard, N.] Dupuytren Hosp Univ Ctr Limoges, Hematol Lab, Limoges, France; [Gachard, N.; Jaccard, A.; Bordessoule, D.] Limoges Univ, CNRS, UMR 7276, Limoges, France; [Abraham, J.; Jaccard, A.; Bordessoule, D.] Dupuytren Hosp Univ Ctr Limoges, Dept Hematol, Limoges, France; [Fauchais, A. L.] Dupuytren Hosp Univ Ctr Limoges, Dept Internal Med, Limoges, France; [Jauberteau, M. O.] Dupuytren Hosp Univ Ctr Limoges, Dept Immunol, Limoges, France	CHU Limoges; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Limoges; CHU Limoges; CHU Limoges	Jauberteau, MO (corresponding author), Fac Med Limoges, Lab Homeostasie Cellulaire & Pathol, EA3842, 2 Rue Docteur Marcland, F-87025 Limoges, France.	m-o.jauberteau-marchan@unilim.fr	Naves, Thomas/AAB-5874-2020	Naves, Thomas/0000-0002-5291-5689; Jauberteau, Marie-Odile/0000-0002-8811-8948; SAADA, Sofiane/0000-0003-2057-3159; Talbot, Hugo/0000-0001-9774-8573	Limousin regional council from Limoges; La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) from Limoges; CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges	Limousin regional council from Limoges; La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) from Limoges; CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges	This work was supported and funded by grants from the Limousin regional council, La Ligue Nationale Contre le Cancer (Comite Departemental de La Haute-Vienne) and CORC (Comite d'Orientation de la Recherche en Cancerologie) from Limoges.	Ai LS, 2013, INT J CANCER, V133, P1074, DOI 10.1002/ijc.28116; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Bellanger C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027213; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Cattaneo F, 2014, INT J MOL SCI, V15, P19700, DOI 10.3390/ijms151119700; Cazorla M, 2011, J CLIN INVEST, V121, P1846, DOI 10.1172/JCI43992; Chiorazzi N., 2005, NEW ENGL J MED, V352, P804, DOI [10.1056/NEJMra041720, DOI 10.1056/NEJMRA041720, 10.1002/9781444300857.ch36]; Choi SY, 1999, BRIT J PHARMACOL, V126, P1050, DOI 10.1038/sj.bjp.0702378; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Dalwadi H, 2003, J IMMUNOL, V170, P1707, DOI 10.4049/jimmunol.170.4.1707; De la Cruz-Morcillo MA, 2016, ONCOTARGET, V7, P34480, DOI 10.18632/oncotarget.8911; Delcourt N, 2007, TRENDS PHARMACOL SCI, V28, P602, DOI 10.1016/j.tips.2007.09.007; Dielschneider RF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.391; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Drost AC, 2012, LEUKEMIA LYMPHOMA, V53, P665, DOI 10.3109/10428194.2011.625578; Dupouy S, 2014, ONCOTARGET, V5, P8235, DOI 10.18632/oncotarget.1632; Dupouy S, 2011, BIOCHIMIE, V93, P1369, DOI 10.1016/j.biochi.2011.04.024; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; Fauchais AL, 2008, J IMMUNOL, V181, P3027, DOI 10.4049/jimmunol.181.5.3027; Frade JM, 1996, NATURE, V383, P166; Ghosh AK, 2013, ADV EXP MED BIOL, V792, P215, DOI 10.1007/978-1-4614-8051-8_10; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kehrl JH, 2016, BIOCHEM PHARMACOL, V114, P40, DOI 10.1016/j.bcp.2016.04.005; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Liu Y, 2016, CANCER LETT, V376, P226, DOI 10.1016/j.canlet.2016.03.031; Longo PG, 2007, LEUKEMIA, V21, P110, DOI 10.1038/sj.leu.2404417; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Magazin M, 2004, J INVEST DERMATOL, V122, P111, DOI 10.1046/j.0022-202X.2003.22131.x; Martin S, 2002, J CELL SCI, V115, P165; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mira E, 2001, EMBO REP, V2, P151, DOI 10.1093/embo-reports/kve027; Mohle R, 1999, LEUKEMIA, V13, P1954, DOI 10.1038/sj.leu.2401602; Moughal NA, 2004, CELL SIGNAL, V16, P127, DOI 10.1016/j.cellsig.2003.08.004; Moughal NA, 2006, J NEUROCHEM, V98, P1920, DOI 10.1111/j.1471-4159.2006.04009.x; Ohman L, 2002, GUT, V51, P392, DOI 10.1136/gut.51.3.392; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Raijmakers R, 2010, ANAL CHEM, V82, P824, DOI 10.1021/ac901764g; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; Rossi D, 2013, BLOOD, V121, P1403, DOI 10.1182/blood-2012-09-458265; Saada S, 2012, J IMMUNOL, V189, P5293, DOI 10.4049/jimmunol.1102937; Saiya-Cork K, 2011, CLIN CANCER RES, V17, P2679, DOI 10.1158/1078-0432.CCR-10-2058; Schrottner P, 2010, ANN HEMATOL, V89, P437, DOI 10.1007/s00277-009-0876-6; Somai S, 2002, BIOCHEM BIOPH RES CO, V295, P482, DOI 10.1016/S0006-291X(02)00703-9; Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111; Sun CY, 2012, INT J CANCER, V130, P827, DOI 10.1002/ijc.26059; Swift SL, 2010, CANCER RES, V70, P347, DOI 10.1158/0008-5472.CAN-09-1252; Thiele CJ, 2009, CLIN CANCER RES, V15, P5962, DOI 10.1158/1078-0432.CCR-08-0651; Ticchioni M, 2007, ONCOGENE, V26, P7081, DOI 10.1038/sj.onc.1210519; Tomasi ML, 2015, ONCOTARGET, V6, P37706, DOI 10.18632/oncotarget.5342; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; Wilson CM, 2014, CNS NEUROL DISORD-DR, V13, P1354, DOI 10.2174/1871527313666141023151642; Wilson CM, 2014, J CELL SCI, V127, P3983, DOI 10.1242/jcs.149336; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Wu ZR, 2017, CANCER LETT, V388, P73, DOI 10.1016/j.canlet.2016.11.032; Yaktapour N, 2013, BLOOD, V122, P1621, DOI 10.1182/blood-2013-02-484386; Younes M, 2014, ONCOTARGET, V5, P8252, DOI 10.18632/oncotarget.1633	62	15	15	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					756	767		10.1038/onc.2017.365	http://dx.doi.org/10.1038/onc.2017.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059151	Green Published, hybrid			2022-12-28	WOS:000424628100007
J	Mitamura, T; Pradeep, S; McGuire, M; Wu, SY; Ma, S; Hatakeyama, H; Lyons, YA; Hisamatsu, T; Noh, K; Villar-Prados, A; Chen, X; Ivan, C; Rodriguez-Aguayo, C; Hu, W; Lopez-Berestein, G; Coleman, RL; Sood, AK				Mitamura, T.; Pradeep, S.; McGuire, M.; Wu, S. Y.; Ma, S.; Hatakeyama, H.; Lyons, Y. A.; Hisamatsu, T.; Noh, K.; Villar-Prados, A.; Chen, X.; Ivan, C.; Rodriguez-Aguayo, C.; Hu, W.; Lopez-Berestein, G.; Coleman, R. L.; Sood, A. K.			Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)	ONCOGENE			English	Article							OVARIAN-CANCER; BEVACIZUMAB; ANGIOGENESIS; CARCINOMA; PROTEIN; PANOBINOSTAT; UPDATE; GENES; TRIAL; CTCF	Anti-vascular endothelial growth factor (VEGF) therapy has demonstrated efficacy in treating human metastatic cancers, but therapeutic resistance is a practical limitation and most tumors eventually become unresponsive. To identify microenvironmental factors underlying the resistance of cancer to antiangiogenesis therapy, we conducted genomic analyses of intraperitoneal ovarian tumors in which adaptive resistance to anti-VEGF therapy (B20 antibody) developed. We found that expression of the microseminoprotein, prostate-associated (MSMP) gene was substantially upregulated in resistant compared with control tumors. MSMP secretion from cancer cells was induced by hypoxia, triggering MAPK signaling in endothelial cells to promote tube formation in vitro. Recruitment of the transcriptional repressor CCCTC-binding factor (CTCF) to the MSMP enhancer region was decreased by histone acetylation under hypoxic conditions in cancer cells. MSMP siRNA, delivered in vivo using the DOPC nanoliposomes, restored tumor sensitivity to anti-VEGF therapy. In ovarian cancer patients treated with bevacizumab, serum MSMP concentration increased significantly only in non-responders. These findings imply that MSMP inhibition combined with the use of antiangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.	[Mitamura, T.; Pradeep, S.; McGuire, M.; Wu, S. Y.; Ma, S.; Hatakeyama, H.; Lyons, Y. A.; Hisamatsu, T.; Noh, K.; Villar-Prados, A.; Chen, X.; Hu, W.; Coleman, R. L.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Mitamura, T.] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Pradeep, S.] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Noh, K.] Korea Res Inst Bioscience & Biotechnol, Gene Therapy Res Unit, Daejeon, South Korea; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University; Medical College of Wisconsin; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1515 Holcombe Blvd, Houston, TX 77030 USA.	asood@mdanderson.org	Sood, Anoop Kumar/A-7344-2013; Hatakeyama, Hiroto/V-9987-2017; Coleman, Robert/E-4346-2019; Chen, Xiuhui/CAE-9641-2022	Sood, Anoop Kumar/0000-0001-5702-4108; Hatakeyama, Hiroto/0000-0003-3899-0508; Chen, Xiuhui/0000-0002-7184-9568; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ivan, Cristina/0000-0002-4848-0168	Foundation for Women's Cancer grant; Ovarian Cancer Research Fund Alliance; Foundation for Women's Cancer; Texas Center for Cancer Nanomedicine; Cancer Prevention and Research Institute of Texas training grants [RP101502, RP101489]; Ovarian Cancer Research Fund Alliance [292015]; KRIBB Research Initiative Program; Uehara Memorial Foundation Research Fellowships for Research Abroad; National Institutes of Health [CA016672, CA109298, P50 CA083639, P50 CA098258, UH3 TR000943]; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); American Cancer Society Research Professor Award; Blanton-Davis Ovarian Cancer Research Program; RGK Foundation; Frank McGraw Memorial Chair in Cancer Research; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA098258, P50CA083639, R01CA109298] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000943] Funding Source: NIH RePORTER	Foundation for Women's Cancer grant; Ovarian Cancer Research Fund Alliance; Foundation for Women's Cancer; Texas Center for Cancer Nanomedicine; Cancer Prevention and Research Institute of Texas training grants; Ovarian Cancer Research Fund Alliance; KRIBB Research Initiative Program; Uehara Memorial Foundation Research Fellowships for Research Abroad; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); American Cancer Society Research Professor Award(American Cancer Society); Blanton-Davis Ovarian Cancer Research Program; RGK Foundation; Frank McGraw Memorial Chair in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	SP is supported by a Foundation for Women's Cancer grant and Ovarian Cancer Research Fund Alliance. SW is supported by Ovarian Cancer Research Fund Alliance, Foundation for Women's Cancer, Texas Center for Cancer Nanomedicine, and Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489, respectively). KN is supported by the Ovarian Cancer Research Fund Alliance (grant 292015) and KRIBB Research Initiative Program. TH is supported by Uehara Memorial Foundation Research Fellowships for Research Abroad. Portions of this work were supported by the National Institutes of Health grants (CA016672, CA109298, P50 CA083639, P50 CA098258 and UH3 TR000943), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), American Cancer Society Research Professor Award, Blanton-Davis Ovarian Cancer Research Program, RGK Foundation and the Frank McGraw Memorial Chair in Cancer Research.	BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BUICK RN, 1985, CANCER RES, V45, P3668; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Drappatz J, 2012, J NEURO-ONCOL, V107, P133, DOI 10.1007/s11060-011-0717-z; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Ghirlando R, 2016, GENE DEV, V30, P881, DOI 10.1101/gad.277863.116; Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; LAU DHM, 1991, CANCER RES, V51, P5181; Lee EQ, 2015, NEURO-ONCOLOGY, V17, P862, DOI 10.1093/neuonc/nou350; Pei XL, 2014, J IMMUNOL, V192, P1878, DOI 10.4049/jimmunol.1300758; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Strickler JH, 2012, CANCER CHEMOTH PHARM, V70, P251, DOI 10.1007/s00280-012-1911-1; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Valtonen-Andre C, 2007, BIOL CHEM, V388, P289, DOI 10.1515/BC.2007.032; Weth O, 2014, NUCLEIC ACIDS RES, V42, P11941, DOI 10.1093/nar/gku937; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	25	24	24	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					722	731		10.1038/onc.2017.348	http://dx.doi.org/10.1038/onc.2017.348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059175	Green Accepted, Green Submitted			2022-12-28	WOS:000424628100004
J	Wang, CH; Wang, PJ; Hsieh, YC; Lo, S; Lee, YC; Chen, YC; Tsai, CH; Chiu, WC; Hu, SCS; Lu, CW; Yang, YF; Chiu, CC; Ou-Yang, F; Wang, YM; Hou, MF; Yuan, SSF				Wang, C-H; Wang, P-J; Hsieh, Y-C; Lo, S.; Lee, Y-C; Chen, Y-C; Tsai, C-H; Chiu, W-C; Hu, S. Chu-Sung; Lu, C-W; Yang, Y-F; Chiu, C-C; Ou-Yang, F.; Wang, Y-M; Hou, M-F; Yuan, S-S F.			Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; 3T3-L1 ADIPOCYTES; EPITHELIAL-CELLS; REGULATED KINASE; GENE-EXPRESSION; INFLAMMATION; TRANSITION; PATHWAYS; BINDING; ALLIANCE	Growing evidence indicates that resistin-an obesity-related cytokine-is upregulated in breast cancer patients, yet its impact on breast cancer behavior remains to be ascertained. Similarly, Toll-like receptor 4 (TLR4) has been implicated in breast cancer progression, however, its clinically relevant endogenous ligand remains elusive. In this study, we observed that high serum resistin levels in breast cancer patients positively correlated with tumor stage, size and lymph node metastasis. These findings were replicated in animal models of breast cancer tumorigenesis and metastasis. Resistin was found to promote epithelial-mesenchymal transition and stemness in breast cancer cells-mechanisms critical to tumorigenesis and metastasis-through a TLR4/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B)/signal transducer and activator of transcription 3 (STAT3) signaling pathway and negated by TLR4-specific antibody and antagonist. These findings provide clear evidence that resistin is a clinically relevant endogenous ligand for TLR4, which promotes tumor progression via TLR4/NF-kappa B/STAT3 signaling, providing insights into a novel therapeutic target in breast cancer.	[Wang, C-H; Wang, P-J; Lo, S.; Lee, Y-C; Chen, Y-C; Tsai, C-H; Lu, C-W; Yang, Y-F; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung 807, Taiwan; [Wang, C-H; Chen, Y-C; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Wang, C-H; Chen, Y-C; Yuan, S-S F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Hsieh, Y-C] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Lo, S.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Lee, Y-C] Kaohsiung Med Univ, Sch Med, Dept Anat, Coll Med, Kaohsiung, Taiwan; [Tsai, C-H; Ou-Yang, F.] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Chiu, W-C] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Thorac Surg, Dept Surg, Kaohsiung, Taiwan; [Hu, S. Chu-Sung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung, Taiwan; [Hu, S. Chu-Sung] Kaohsiung Med Univ, Dept Dermatol, Coll Med, Kaohsiung, Taiwan; [Chiu, C-C] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan; [Ou-Yang, F.] Kaohsiung Med Univ Hosp, Dept Surg, Kaohsiung, Taiwan; [Wang, Y-M] Natl Chiao Tung Univ, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Wang, Y-M] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Municipal Shiao Kang Hosp, Dept Surg, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of Glasgow; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Yuan, SSF (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung 807, Taiwan.; Yuan, SSF (corresponding author), 100,Zihyou 1st Rd, Kaohsiung 80708, Taiwan.	yuanssf@kmu.edu.tw		Wang, Chie-Hong/0000-0003-0774-5323; Hou, Ming-Feng/0000-0001-6030-9702; Hu, Stephen Chu-Sung/0000-0002-1832-4471; yuan, shyng-shiou/0000-0002-4753-788X	Kaohsiung Medical University Hospital [KMUH102-2T07, KMUH103-3R28, KMUH104-4R29]; Kaohsiung Medical University (Aim for the Top Journals Grant) [KMU-DT105008, KMU-TP104D17]; National Health Research Institutes [NHRI-EX104-10212BI]; Ministry of Health and Welfare, Health and welfare surcharge of tobacco products of Taiwan [MOHW105-TDU-B-212-134007]	Kaohsiung Medical University Hospital; Kaohsiung Medical University (Aim for the Top Journals Grant); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health and Welfare, Health and welfare surcharge of tobacco products of Taiwan	We thank Dr Tsung-Hsien Chuang and Dr Wen-Chun Hung from National Health Research Institutes, Taiwan, for providing plasmid. This work was supported by Kaohsiung Medical University Hospital (KMUH102-2T07, KMUH103-3R28, KMUH104-4R29); Kaohsiung Medical University (Aim for the Top Journals Grant, KMU-DT105008, KMU-TP104D17); National Health Research Institutes (NHRI-EX104-10212BI); and Ministry of Health and Welfare, Health and welfare surcharge of tobacco products (MOHW105-TDU-B-212-134007) of Taiwan.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Assiri AMA, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/253519; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; Chen YH, 2006, ENDOCRINOLOGY, V147, P4496, DOI 10.1210/en.2005-1655; Chung SS, 2015, ANTICANCER RES, V35, P39; Codoner-Franch P, 2015, CLIN CHIM ACTA, V438, P46, DOI 10.1016/j.cca.2014.07.043; Conde J, 2011, BIOFACTORS, V37, P413, DOI 10.1002/biof.185; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Ehsan N, 2013, TUMOR BIOL, V34, P1053, DOI 10.1007/s13277-013-0645-y; Franco HL, 2015, MOL CELL, V58, P21, DOI 10.1016/j.molcel.2015.02.001; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gonzalez-Reyes S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-665; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hsieh YY, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-59; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Iqbal J, 2013, J CLIN PATHOL, V66, P485, DOI 10.1136/jclinpath-2012-201304; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jing YY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-98; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Lee JO, 2016, SCI REP-UK, V6, DOI 10.1038/srep18923; Lee MJ, 2008, AM J PHYSIOL-CELL PH, V294, pC1542, DOI 10.1152/ajpcell.00403.2007; Lee YC, 2012, GYNECOL ONCOL, V125, P742, DOI 10.1016/j.ygyno.2012.02.032; Li L, 2013, OCHSNER J, V13, P109; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; Mehmeti M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0640-x; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Oblak A, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/609579; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pradhan M, 2010, J BIOL CHEM, V285, P31100, DOI 10.1074/jbc.M110.155309; Schwartz DR, 2011, TRENDS ENDOCRIN MET, V22, P259, DOI 10.1016/j.tem.2011.03.005; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Song JM, 2007, PLOS PATHOG, V3, P541, DOI 10.1371/journal.ppat.0030060; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Tarkowski A, 2010, J CELL MOL MED, V14, P1419, DOI 10.1111/j.1582-4934.2009.00899.x; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Wang W, 2015, CURR MED CHEM, V22, P264; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109980; Yokota S, 2010, INFECT IMMUN, V78, P468, DOI 10.1128/IAI.00903-09; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang XJ, 2015, INT J ONCOL, V46, P1141, DOI 10.3892/ijo.2014.2809; Zhou CC, 2012, ORAL ONCOL, V48, P1068, DOI 10.1016/j.oraloncology.2012.06.005	50	72	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					589	600		10.1038/onc.2017.357	http://dx.doi.org/10.1038/onc.2017.357			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991224				2022-12-28	WOS:000423812200005
J	Chi, XZ; Lee, JW; Lee, YS; Park, IY; Ito, Y; Bae, SC				Chi, X-Z; Lee, J-W; Lee, Y-S; Park, I. Y.; Ito, Y.; Bae, S-C			Runx3 plays a critical role in restriction-point and defense against cellular transformation	ONCOGENE			English	Article							K-RAS ONCOGENE; GENE-EXPRESSION; LUNG-CANCER; P53; FAMILY; PROLIFERATION; SUPPRESSION; ACTIVATION; INDUCTION; CYCLE	The restriction (R)-point decision is fundamental to normal differentiation and the G(1)-S transition, and the decision-making machinery is perturbed in nearly all cancer cells. The mechanisms underlying the cellular context-dependent R-point decision remain poorly understood. We found that the R-point was dysregulated in Runx3(-/-) mouse embryonic fibroblasts (MEFs), which formed tumors in nude mice. Ectopic expression of Runx3 restored the R-point and abolished the tumorigenicity of Runx3-/-MEFs and K-Ras-activated Runx3(-/-) MEFs (Runx3(-/-); K-Ras(G12D/+)). During the R-point, Runx3 transiently formed a complex with pRb and Brd2 and induced Cdkn1a (p21(Waf1/Cip1/Sdi1); p21), a key regulator of the R-point transition. Cyclin D-CDK4/6 promoted dissociation of the pRb-Runx3-Brd2 complex, thus turning off p21 expression. However, cells harboring oncogenic K-Ras maintained the pRb-Runx3-Brd2 complex and p21 expression even after introduction of Cyclin D1. Thus, Runx3 plays a critical role in R-point regulation and defense against cellular transformation.	[Chi, X-Z; Lee, J-W; Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea; [Chi, X-Z; Lee, J-W; Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea; [Park, I. Y.] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea; [Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Ctr Translat Med, Singapore, Singapore	Chungbuk National University; Chungbuk National University; Chungbuk National University; National University of Singapore	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea.	scbae@chungbuk.ac.kr			National Research Foundation (NRF) of Korea [2014R1A3A2030690]; Basic Science Research Program [2014R1A1A2007204]; NRF - Ministry of Education of Korea [2013R1A1A2057659]; Rural Development Administration, Republic of Korea [PJ01226101]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Basic Science Research Program; NRF - Ministry of Education of Korea; Rural Development Administration, Republic of Korea(Rural Development Administration (RDA), Republic of Korea)	S-C Bae is supported by a Creative Research Grant (2014R1A3A2030690) through the National Research Foundation (NRF) of Korea. J-W Lee is supported by the Basic Science Research Program (2014R1A1A2007204) Y-S Lee is supported by Basic Science Research Program (2013R1A1A2057659) through the NRF funded by the Ministry of Education of Korea. IY Park was supported by "Cooperative Research Program for Agriculture Science and Technology Development (PJ01226101)" Rural Development Administration, Republic of Korea.	Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Berns A, 2010, NATURE, V468, P519, DOI 10.1038/468519a; Blagosklonny MV, 2002, CELL CYCLE, V1, P100, DOI 10.4161/cc.1.2.107; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drosten M, 2016, J MOL MED, V94, P121, DOI 10.1007/s00109-015-1360-5; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HARPER JW, 1993, CELL, V75, P805; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Martinsson HS, 2005, EXP CELL RES, V305, P383, DOI 10.1016/j.yexcr.2005.01.023; MICHIELI P, 1994, CANCER RES, V54, P3391; Muzumdar MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12685; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Weinberg Reditor, 2007, BIOL CANC; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	43	14	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6884	6894		10.1038/onc.2017.290	http://dx.doi.org/10.1038/onc.2017.290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846108	Green Published, hybrid			2022-12-28	WOS:000418041800005
J	Zhang, T; Li, J; Yin, F; Lin, B; Wang, Z; Xu, J; Wang, H; Zuo, D; Wang, G; Hua, Y; Cai, Z				Zhang, T.; Li, J.; Yin, F.; Lin, B.; Wang, Z.; Xu, J.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.			Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; BREAST-CANCER; TUMOR-METASTASIS; MALIGNANT-CELLS; EXPRESSION; ANGIOGENESIS; ACTIVATION; PATHWAY; OVEREXPRESSION; SPECIFICITY	Signal transducer and activator of transcription 3(STAT3) is an emerging target for cancer therapy. In this study, we identify Toosendanin (TSN) is an effective inhibitor of STAT3, leading to the impediment of various oncogenic processes in osteosarcoma. TSN selectively inactivates phospho-STAT3 (Tyr-705); subsequent molecular docking and in vitro SPR analysis uncover TSN directly binds to the SH2 domain of STAT3. Consequently, TSN blocks STAT3 dimerization and impairs the complex formation of STAT3 and epidermal growth factor receptor (EGFR). In an animal tumor model study, TSN is well tolerated, inhibits osteosarcoma growth and metastasis. In another osteosarcoma patient-derived xenografts (PDX) model, we find TSN triggers strong inhibitory effects on patient-derived tumors. Further studies show that TSN also displays activity against other solid tumors. Our preclinical work therefore supports that TSN acts as a novel inhibitor of STAT3 that blocks tumorigenesis in ostoesarcoma.	[Zhang, T.; Yin, F.; Wang, Z.; Hua, Y.; Cai, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China; [Zhang, T.; Yin, F.; Lin, B.; Wang, Z.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.] Shanghai Bone Tumor Inst, Shanghai, Peoples R China; [Li, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Inst Translat Med, Shanghai, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, Y; Cai, Z (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthopaed, 100 Haining Rd, Shanghai 200080, Peoples R China.	zhangtaoabc@2008.sina.com; hua_yingqi@163.com; czd856@vip.163.com			NSFC [81502604]; Shanghai Science and Technology Commission [14140904000]; Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine [BXJ201732]; Research Grant from Shanghai Hospital Development Center [SHDC12013107]	NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine; Research Grant from Shanghai Hospital Development Center	This work was supported by NSFC (81502604); Shanghai Science and Technology Commission (14140904000); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine (No. BXJ201732) and Research Grant from Shanghai Hospital Development Center (SHDC12013107).	Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f; Cao L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111928; Chun J, 2015, CANCER LETT, V357, P393, DOI 10.1016/j.canlet.2014.11.049; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fossey SL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-81; Haan S, 1999, J BIOL CHEM, V274, P1342, DOI 10.1074/jbc.274.3.1342; Hao WS, 2008, BIOORG MED CHEM LETT, V18, P4988, DOI 10.1016/j.bmcl.2008.08.032; Hayakawa F, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.63; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Li JJ, 2015, BRIT J PHARMACOL, V172, P3817, DOI 10.1111/bph.13165; Lu XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34225; Malaney P, 2014, CANCER LETT, V344, P1, DOI 10.1016/j.canlet.2013.10.010; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Nair RR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00030; Nakajima M, 1991, Semin Cancer Biol, V2, P115; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang JQ, 2014, BREAST CANCER RES TR, V148, P279, DOI 10.1007/s10549-014-3165-6; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang HY, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3640; ZHANG T, 2016, CELL DEATH DIS, V7; Zhang T, 2014, NEOPLASIA, V16, P665, DOI 10.1016/j.neo.2014.07.009; Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5; Zhang XL, 2013, CANCER RES, V73, P1922, DOI 10.1158/0008-5472.CAN-12-3175; Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001	43	81	84	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6627	6639		10.1038/onc.2017.270	http://dx.doi.org/10.1038/onc.2017.270			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783167	Green Published, hybrid			2022-12-28	WOS:000416049200011
J	Debebe, A; Medina, V; Chen, CY; Mahajan, IM; Jia, C; Fu, D; He, L; Zeng, N; Stiles, BW; Chen, CL; Wang, M; Aggarwal, KR; Peng, Z; Huang, J; Chen, J; Li, M; Dong, T; Atkins, S; Borok, Z; Yuan, W; Machida, K; Ju, C; Kahn, M; Johnson, D; Stiles, BL				Debebe, A.; Medina, V.; Chen, C-Y; Mahajan, I. M.; Jia, C.; Fu, D.; He, L.; Zeng, N.; Stiles, B. W.; Chen, C-L; Wang, M.; Aggarwal, K-R; Peng, Z.; Huang, J.; Chen, J.; Li, M.; Dong, T.; Atkins, S.; Borok, Z.; Yuan, W.; Machida, K.; Ju, C.; Kahn, M.; Johnson, D.; Stiles, B. L.			Wnt/beta-catenin activation and macrophage induction during liver cancer development following steatosis	ONCOGENE			English	Article							INTESTINAL STEM-CELLS; HEPATOCELLULAR-CARCINOMA; LIPID-METABOLISM; BETA-CATENIN; PERIPORTAL HEPATOCYTES; PROGENITOR CELLS; MICE LACKING; FATTY LIVER; PTEN; EXPRESSION	Obesity confers an independent risk for carcinogenesis. In the liver, steatosis often proceeds cancer formation; however, the mechanisms by which steatosis promotes carcinogenesis is unknown. We hypothesize that steatosis alters the microenvironment to promote proliferation of tumor initiating cells (TICs) and carcinogenesis. We used several liver cancer models to address the mechanisms underlying the role of obesity in cancer and verified these findings in patient populations. Using bioinformatics analysis and verified by biochemical assays, we identified that hepatosteatosis resulting from either Pten deletion or transgenic expression of HCV core/NS5A proteins, promotes the activation of Wnt/beta-catenin. We verified that high fat diet lipid accumulation is also capable of inducing Wnt/beta-catenin. Caloric restriction inhibits hepatosteatosis, reduces Wnt/beta-catenin activation and blocks the expansion of TICs leading to complete inhibition of tumorigenesis without affecting the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) loss regulated protein kinase B (AKT) activation. Pharmacological inhibition or loss of the Wnt/beta-catenin signal represses TIC growth in vitro, and decreases the accumulation of TICs in vivo. In human liver cancers, ontology analysis of gene set enrichment analysis (GSEA)-defined Wnt signature genes indicates that Wnt signaling is significantly induced in tumor samples compared with healthy livers. Indeed, Wnt signature genes predict 90% of tumors in a cohort of 558 patient samples. Selective depletion of macrophages leads to reduction of Wnt and suppresses tumor development, suggesting infiltrating macrophages as a key source for steatosis-induced Wnt expression. These data established Wnt/beta-catenin as a novel signal produced by infiltrating macrophages induced by steatosis that promotes growth of tumor progenitor cells, underlying the increased risk of liver tumor development in obese individuals.	[Debebe, A.; Medina, V.; Chen, C-Y; Mahajan, I. M.; Jia, C.; He, L.; Zeng, N.; Aggarwal, K-R; Peng, Z.; Huang, J.; Chen, J.; Li, M.; Dong, T.; Atkins, S.; Kahn, M.; Stiles, B. L.] Univ Southern Calif, Sch Pharm, Pharmacol & Pharmaceut Sci, PSC 402,1985 Zonal Ave, Los Angeles, CA 90089 USA; [Jia, C.] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai, Peoples R China; [Fu, D.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Cent Lab Med Res, Shanghai, Peoples R China; [Stiles, B. W.] CALTECH, Jet Prop Lab, Pasadena, CA USA; [Chen, C-L; Yuan, W.; Machida, K.] Univ Southern Calif, Keck Sch Med, Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Wang, M.; Ju, C.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Pharmaceut Sci, Aurora, CO USA; [Borok, Z.] Univ Southern Calif, Keck Sch Med, Will Rogers Inst Pulm Res Ctr, Med, Los Angeles, CA 90033 USA; [Borok, Z.] Univ Southern Calif, Keck Sch Med, Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Borok, Z.; Kahn, M.; Stiles, B. L.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Johnson, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Stiles, B. L.] Univ Southern Calif, Keck Sch Med, Pathol, Los Angeles, CA 90033 USA	University of Southern California; Tongji University; Tongji University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Southern California; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Southern California; University of Southern California; University of Southern California; Baylor College of Medicine; University of Southern California	Stiles, BL (corresponding author), Univ Southern Calif, Sch Pharm, Pharmacol & Pharmaceut Sci, PSC 402,1985 Zonal Ave, Los Angeles, CA 90089 USA.	bstiles@usc.edu	Fu, Da/GXF-2656-2022; Jia, Chengyou/AAV-1153-2021; peng, zhechu/AAA-5942-2022; AVILA, MATIAS A/Y-6342-2019	Dong, Tiange/0000-0002-0612-4261; AVILA, MATIAS A/0000-0001-6570-3557; Peng, Zhechu/0000-0002-9301-7164	NIH [R01CA154986-01, R01 HL112638-01, 1R01AA018857, P50AA11999, R01CA108614-06A1]; NIDDK [R01DK084241-01]; USC center for Liver Disease [P30DK48522]; Norris Comprehensive Cancer Center [P30CA014089]; CIRM; USC; Hastings Foundation; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA154986, R01CA108614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084241, P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM086262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999, R01AA018857, R01AA025204] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); USC center for Liver Disease; Norris Comprehensive Cancer Center; CIRM(California Institute for Regenerative Medicine); USC; Hastings Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We acknowledge the technical support from Ms Mungoma, Carrithers, Zhang, Barsky and Mr Li, Dr Bryan W Stiles would like to state that 'this work was done as a private venture and not in the author's capacity as an employee of the Jet Propulsion Laboratory, California Institute of Technology'. This work was supported by NIH grants R01CA154986-01 (BLS). Dr Stiles also acknowledges support from NIDDK (R01DK084241-01). Dr Borok was supported by NIH grant R01 HL112638-01. Dr Machida would like to acknowledge NIH grants 1R01AA018857 and P50AA11999. We acknowledge support from USC center for Liver Disease (P30DK48522) and Norris Comprehensive Cancer Center (P30CA014089). Dr Johnson acknowledges funding from NIH grant R01CA108614-06A1. AD, ZP and VM are partially supported by CIRM pre- and post-doctoral and F32 Developmental Biology training fellowship. NZ acknowledges the support of USC provost postdoctoral fellowship. ZB is Edgington Chair in Medicine and was supported by the Hastings Foundation.	Adinolfi LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060803; ALBANES D, 1987, Nutrition and Cancer, V9, P199; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carpentier R, 2011, GASTROENTEROLOGY, V141, P1432, DOI 10.1053/j.gastro.2011.06.049; Casali A, 2009, CELL STEM CELL, V4, P124, DOI 10.1016/j.stem.2009.01.009; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Domagala-Kulawik J, 2015, TRANSL LUNG CANCER R, V4, P177, DOI 10.3978/j.issn.2218-6751.2015.01.11; Eckert C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00179; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Galicia VA, 2010, GASTROENTEROLOGY, V139, P2170, DOI 10.1053/j.gastro.2010.09.002; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gentzler R, 2016, IMMUNOTHERAPY-UK, V8, P583, DOI 10.2217/imt-2015-0029; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; He LN, 2010, AM J PATHOL, V176, P2302, DOI 10.2353/ajpath.2010.090931; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; Johnson DL, 2016, TRENDS ENDOCRIN MET, V27, P742, DOI 10.1016/j.tem.2016.04.016; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kaler P, 2009, ONCOGENE, V28, P3892, DOI 10.1038/onc.2009.247; Lamb JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020090; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Li Y, 2013, J BIOL CHEM, V288, P25007, DOI 10.1074/jbc.M113.450353; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Moon BC, 2012, ARTERIOSCL THROM VAS, V32, P236, DOI 10.1161/ATVBAHA.111.241356; Palian BM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004789; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Qian Yan, 2005, Hepatobiliary Pancreat Dis Int, V4, P173; Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Spranger S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1086862; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Staal FJT, 2010, J CELL BIOCHEM, V109, P844, DOI 10.1002/jcb.22467; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Taniguchi CM, 2006, CELL METAB, V3, P343, DOI 10.1016/j.cmet.2006.04.005; Ueda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002800; Widelitz Randall B, 2008, Organogenesis, V4, P123; Woo SR, 2015, ANNU REV IMMUNOL, V33, P445, DOI 10.1146/annurev-immunol-032414-112043; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024	47	47	51	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6020	6029		10.1038/onc.2017.207	http://dx.doi.org/10.1038/onc.2017.207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671671	hybrid, Green Published			2022-12-28	WOS:000413841400010
J	Zhang, H; Ma, RR; Wang, XJ; Su, ZX; Chen, X; Shi, DB; Guo, XY; Liu, HT; Gao, P				Zhang, H.; Ma, R-R; Wang, X-J; Su, Z-X; Chen, X.; Shi, D-B; Guo, X-Y; Liu, H-T; Gao, P.			KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer	ONCOGENE			English	Article							KINESIN; EXPRESSION; THERAPY; GENE; THERAPEUTICS; INHIBITION; PROTEINS; ADHESION; BIOLOGY; STAGE	Tumor metastasis is the main reason of cancer-related death for gastric cancer (GC) patients and gene expression microarray data indicate that kinesin family member 26B (KIF26B) is one of the most upregulated genes in metastatic GC samples. Specifically, KIF26B expression was upregulated in a stepwise manner from non-tumorous gastric mucosa, primary GC tissues without metastasis, via primary GC tissues with metastasis, to secondary lymph node metastatic (LNM) foci. Increased expression of KIF26B was correlated with tumor size, positive LNM or distant metastases and poor prognosis. KIF26B, negatively regulated by miR-372, promoted GC cell proliferation and metastasis in vitro and in vivo. Mechanistic investigations confirmed that the main target of KIF26B was the vascular endothelial growth factor (VEGF) signaling pathway, particularly by inhibition or overexpression of VEGFA, PXN, FAK, PIK3CA, BCL2 and CREB1. Thus, KIF26B, a novel oncogene regulated by miR-372, promotes proliferation and metastasis through the VEGF pathway in GC.	[Zhang, H.; Ma, R-R; Wang, X-J; Chen, X.; Shi, D-B; Guo, X-Y; Liu, H-T; Gao, P.] Shandong Univ, Sch Med, Dept Pathol, Jinan Wen Hua Xi Rd 44, Jinan 250012, Shandong, Peoples R China; [Zhang, H.] Shandong Univ, Qilu Hosp, Dept Pathol, Shandong, Peoples R China; [Su, Z-X] Shandong Prov Hosp, Dept Hepatobiliary Surg, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Gao, P (corresponding author), Shandong Univ, Sch Med, Dept Pathol, Jinan Wen Hua Xi Rd 44, Jinan 250012, Shandong, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81372856, 81672842]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of the manuscript. This study was supported by the National Natural Science Foundation of China (grant no. 81372856 and 81672842) and the Taishan Scholars Program of Shandong Province (grant no. ts201511096).	Adomas A, 2008, TREE PHYSIOL, V28, P885, DOI 10.1093/treephys/28.6.885; Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727; Crociani O, 2014, CLIN CANCER RES, V20, P1502, DOI 10.1158/1078-0432.CCR-13-2633; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FIDLER IJ, 1990, CANCER RES, V50, P6130; Gandhi NS, 2014, J CONTROL RELEASE, V194, P238, DOI 10.1016/j.jconrel.2014.09.001; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Grothey A, 2013, LANCET ONCOL, V14, P2, DOI 10.1016/S1470-2045(12)70516-8; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Hippo Y, 2002, CANCER RES, V62, P233; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593; Liu XR, 2013, CANCER SCI, V104, P651, DOI 10.1111/cas.12138; Paul-Samojedny M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768181; Petri A, 2009, CANCER RES, V69, P393, DOI 10.1158/0008-5472.CAN-08-2749; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Terabayashi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039714; Uchiyama Y, 2010, P NATL ACAD SCI USA, V107, P9240, DOI 10.1073/pnas.0913748107; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Waller T, 2015, BIODATA MIN, V8, DOI 10.1186/s13040-015-0052-6; Wang JT, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0129-6; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061640; Wang YW, 2015, ONCOTARGET, V6, P10646, DOI 10.18632/oncotarget.3392; Wu DW, 2016, ONCOGENE, V35, P621, DOI 10.1038/onc.2015.120; Wu G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-107; Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465; Zhou RY, 2009, CELL, V139, P802, DOI 10.1016/j.cell.2009.10.023	36	43	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5609	5619		10.1038/onc.2017.163	http://dx.doi.org/10.1038/onc.2017.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581513				2022-12-28	WOS:000412293600005
J	Chen, X; Bosques, L; Sung, P; Kupfer, GM				Chen, X.; Bosques, L.; Sung, P.; Kupfer, G. M.			A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage (vol 35, pg 22, 2016)	ONCOGENE			English	Correction															 [R01CA168635]		This work was supported by R01CA168635 (PS and GMK).	Chen X, 2016, ONCOGENE, V35, P22, DOI 10.1038/onc.2015.68	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5220	5220		10.1038/onc.2017.238	http://dx.doi.org/10.1038/onc.2017.238			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28671668	Bronze			2022-12-28	WOS:000409371100014
J	Xin, B; Yamamoto, M; Fujii, K; Ooshio, T; Chen, X; Okada, Y; Watanabe, K; Miyokawa, N; Furukawa, H; Nishikawa, Y				Xin, B.; Yamamoto, M.; Fujii, K.; Ooshio, T.; Chen, X.; Okada, Y.; Watanabe, K.; Miyokawa, N.; Furukawa, H.; Nishikawa, Y.			Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways	ONCOGENE			English	Article							C-MYC; HEPATOCELLULAR-CARCINOMA; SLEEPING-BEAUTY; IN-VIVO; SOMATIC INTEGRATION; TRANSPOSON SYSTEM; N-RAS; CANCER; CELLS; MICE	MYC activation at modest levels has been frequently found in hepatocellular carcinoma. However, its significance in hepatocarcinogenesis has remained obscure. Here we examined the role of Myc activation in mouse liver tumours induced by hepatocytic expression of myristoylated AKT (AKT) and/or mutant HRAS(V12) (HRAS) via transposon-mediated gene integration. AKT or HRAS alone required 5 months to induce liver tumours, whereas their combination generated hepatocellular carcinoma within 8 weeks. Co-introduction of AKT and HRAS induced lipid-laden preneoplastic cells that grew into nodules composed of tumour cells with or without intracytoplasmic lipid, with the latter being more proliferative and associated with spontaneous Myc expression. AKT/HRAS-induced tumorigenesis was almost completely abolished when MadMyc, a competitive Myc inhibitor, was expressed simultaneously. The Tet-On induction of MadMyc in preneoplastic cells significantly inhibited the progression of AKT/HRAS-induced tumours; its induction in transformed cells suppressed their proliferative activity with alterations in lipid metabolism and protein translation. Transposon-mediated Myc overexpression facilitated tumorigenesis by AKT or HRAS, and when it was co-introduced with AKT and HRAS, diffusely infiltrating tumours without lipid accumulation developed as early as 2 weeks. Examination of the dose-responses of Myc in the enhancement of AKT/HRAS-induced tumorigenesis revealed that a reduction to one-third retained enhancing effect but three-times greater introduction damped the process with increased apoptosis. Myc overexpression suppressed the mRNA expression of proteins involved in the synthesis of fatty acids, and when combined with HRAS introduction, it also suppressed the mRNA expression of proteins involved in their degradation. Finally, the MYC-positive human hepatocellular carcinoma was characterized by the cytoplasm devoid of lipid accumulation, prominent nucleoli and a higher proliferative activity. Our results demonstrate that in hepatocarcinogenesis induced by both activated AKT and HRAS, activation of endogenous Myc is an enhancing factor and adequate levels of Myc deregulation further facilitate the process with alterations in cellular metabolism.	[Xin, B.; Yamamoto, M.; Fujii, K.; Ooshio, T.; Chen, X.; Okada, Y.; Watanabe, K.; Nishikawa, Y.] Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan; [Watanabe, K.; Furukawa, H.] Asahikawa Med Univ, Dept Surg, Div Gastroenterol & Gen Surg, Asahikawa, Hokkaido, Japan; [Miyokawa, N.] Asahikawa Med Univ, Dept Surg Pathol, Asahikawa, Hokkaido, Japan	Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College	Nishikawa, Y (corresponding author), Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	nishikwa@asahikawa-med.ac.jp		Xin, Bing/0000-0002-8644-2429	Ministry of Education, Culture, Sports, Science, and Technology of Japan [26870025, 18590362, 21590426, 24390092]; Grants-in-Aid for Scientific Research [15K15107] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#26870025 to MY; #18590362, #21590426 and #24390092 to YN). We thank Mr Yoshiyasu Satake for animal care and Ms Ema Yamatomi, Ms Hiroko Chiba, and Ms Aya Kitano for secretarial assistance. We are also grateful to the staff of the Department of Pathology, Asahikawa Medical University Hospital for generous help.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Akita H, 2014, CANCER RES, V74, P5903, DOI 10.1158/0008-5472.CAN-14-0527; Antonov A, 2014, ONCOTARGET, V5, P11004, DOI 10.18632/oncotarget.2668; Bell JB, 2007, NAT PROTOC, V2, P3153, DOI 10.1038/nprot.2007.471; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Carlson CM, 2005, P NATL ACAD SCI USA, V102, P17059, DOI 10.1073/pnas.0502974102; Carroll M, 2013, J INTERF CYTOK RES, V33, P227, DOI 10.1089/jir.2012.0142; Castellano E, 2007, ONCOGENE, V26, P917, DOI 10.1038/sj.onc.1209845; Castellano E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r123; Chen X, 2015, CANCER SCI, V106, P972, DOI 10.1111/cas.12700; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; De Ponti A, 2015, CANCER LETT, V369, P396, DOI 10.1016/j.canlet.2015.09.005; Diersch S, 2016, ONCOGENE, V35, P3880, DOI 10.1038/onc.2015.437; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; FUJIWARA Y, 1993, CANCER RES, V53, P857; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Ho C, 2012, HEPATOLOGY, V55, P833, DOI 10.1002/hep.24736; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Qu AJ, 2014, J HEPATOL, V60, P331, DOI 10.1016/j.jhep.2013.09.024; Ren JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153863; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stein TJ, 2011, LIVER INT, V31, P1298, DOI 10.1111/j.1478-3231.2011.02596.x; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wahlstrom T, 2015, BBA-GENE REGUL MECH, V1849, P563, DOI 10.1016/j.bbagrm.2014.07.004; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang YX, 2014, MOL ENDOCRINOL, V28, P116, DOI 10.1210/me.2013-1268; Zhu JD, 2008, P NATL ACAD SCI USA, V105, P6584, DOI 10.1073/pnas.0802785105; Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	48	22	22	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5087	5097		10.1038/onc.2017.114	http://dx.doi.org/10.1038/onc.2017.114			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481866	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000409371100001
J	Zamborszky, J; Szikriszt, B; Gervai, JZ; Pipek, O; Poti, A; Krzystanek, M; Ribli, D; Szalai-Gindl, JM; Csabai, I; Szallasi, Z; Swanton, C; Richardson, AL; Szuts, D				Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Pipek, O.; Poti, A.; Krzystanek, M.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.; Szallasi, Z.; Swanton, C.; Richardson, A. L.; Szuts, D.			Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions (vol 36, pg 746, 2017)	ONCOGENE			English	Correction													Pipek, Orsolya/J-3124-2018; Csabai, Istvan/F-6045-2011; Szuts, David/N-1149-2016	Pipek, Orsolya/0000-0001-8109-0340; Csabai, Istvan/0000-0001-9232-9898; Szallasi, Zoltan/0000-0001-5395-7509; Szuts, David/0000-0001-7985-0136	Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish; The Danish Cancer Society [R90-A6213] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)		Zamborszky J, 2017, ONCOGENE, V36, P746, DOI 10.1038/onc.2016.243	1	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5085	5086		10.1038/onc.2017.213	http://dx.doi.org/10.1038/onc.2017.213			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28650471	Green Published, hybrid			2022-12-28	WOS:000408768800015
J	Po, A; Silvano, M; Miele, E; Capalbo, C; Eramo, A; Salvati, V; Todaro, M; Besharat, ZM; Catanzaro, G; Cucchi, D; Coni, S; Di Marcotullio, L; Canettieri, G; Vacca, A; Stassi, G; De Smaele, E; Tartaglia, M; Screpanti, I; De Maria, R; Ferretti, E				Po, A.; Silvano, M.; Miele, E.; Capalbo, C.; Eramo, A.; Salvati, V.; Todaro, M.; Besharat, Z. M.; Catanzaro, G.; Cucchi, D.; Coni, S.; Di Marcotullio, L.; Canettieri, G.; Vacca, A.; Stassi, G.; De Smaele, E.; Tartaglia, M.; Screpanti, I.; De Maria, R.; Ferretti, E.			Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma	ONCOGENE			English	Article							HEDGEHOG PATHWAY; ABC TRANSPORTERS; SONIC HEDGEHOG; CELL-SURVIVAL; CANCER-CELLS; EXPRESSION; IDENTIFICATION; NEUROPILIN-2; ACTIVATION; TARGET	Aberrant Hedgehog/GLIsignaling has been implicated in a diverse spectrum of human cancers, but its role in lung adenocarcinoma (LAC) is still under debate. We show that the downstream effector of the Hedgehog pathway, GLI1, is expressed in 76% of LACs, but in roughly half of these tumors, the canonical pathway activator, Smoothened, is expressed at low levels, possibly owing to epigenetic silencing. In LAC cells including the cancer stem cell compartment, we show that GLI1 is activated noncanonically by MAPK/ERK signaling. Different mechanisms can trigger the MAPK/ERK/GLI1 cascade including KRAS mutation and stimulation of NRP2 by VEGF produced by the cancer cells themselves in an autocrine loop or by stromal cells as paracrine cross talk. Suppression of GLI1, by silencing or drug-mediated, inhibits LAC cells proliferation, attenuates their stemness and increases their susceptibility to apoptosis in vitro and in vivo. These findings provide insight into the growth of LACs and point to GLI1 as a downstream effector for oncogenic pathways. Thus, strategies involving direct inhibition of GLI1 may be useful in the treatment of LACs.published online 3 April 2017	[Po, A.; Silvano, M.; Capalbo, C.; Besharat, Z. M.; Cucchi, D.; Coni, S.; Di Marcotullio, L.; Canettieri, G.; Screpanti, I.] Sapienza Univ, Dept Mol Med, Rome, Italy; [Miele, E.; Screpanti, I.] IIT, Ctr Life NanoSci Sapienza, Rome, Italy; [Eramo, A.; Salvati, V.; De Maria, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy; [Todaro, M.; Stassi, G.] Univ Palermo, Surg & Oncol Sci, Palermo, Italy; [Todaro, M.] Univ Palermo, Cent Lab Adv Diag & Biomed Res CLADIBIOR, Palermo, Italy; [Catanzaro, G.; Vacca, A.; De Smaele, E.; Ferretti, E.] Sapienza Univ, Dept Expt Med, Viale Regina Elena,291, I-00161 Rome, Italy; [Tartaglia, M.] Osped Pediat Bambino Gesu, Genet & Rare Dis Res Div, Rome, Italy; [De Maria, R.] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito,1, I-00168 Rome, Italy; [Ferretti, E.] IRCCS Neuromed, Pozzilli, Italy; [Miele, E.] IRCCS, Bambino Gesu Childrens Hosp, Dept Hematol Oncol & Stem Cell Transplantat, I-00165 Rome, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Istituto Superiore di Sanita (ISS); University of Palermo; University of Palermo; Sapienza University Rome; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Neuromed; IRCCS Bambino Gesu	Ferretti, E (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena,291, I-00161 Rome, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito,1, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; elisabetta.ferretti@uniroma1.it	De Smaele, Enrico/C-1124-2013; Miele, Evelina/M-4611-2013; De Maria, Ruggero/S-6385-2019; Po, Agnese/AEQ-0192-2022; todaro, matilde/AAC-1003-2022; Po, Agnese/G-8754-2015; Tartaglia, Marco/K-2955-2018; catanzaro, giuseppina/AGZ-8080-2022; Miele, Evelina/ABB-7545-2021; Eramo, Adriana/K-6694-2016; salvati, Valentina/J-1264-2018; Miele, Evelina/AAK-1963-2021; Stassi, Giorgio/AAC-1175-2022; Besharat, Zein Mersini/G-5413-2013; Ferretti, Elisabetta/G-5413-2013	De Smaele, Enrico/0000-0003-4524-4423; Miele, Evelina/0000-0002-4747-1032; De Maria, Ruggero/0000-0003-2255-0583; Po, Agnese/0000-0002-9346-8782; todaro, matilde/0000-0001-8686-8043; Po, Agnese/0000-0002-9346-8782; Tartaglia, Marco/0000-0001-7736-9672; catanzaro, giuseppina/0000-0001-8427-9691; Miele, Evelina/0000-0002-4747-1032; Eramo, Adriana/0000-0002-0814-6683; salvati, Valentina/0000-0002-0322-3504; Besharat, Zein Mersini/0000-0003-0317-9854; CANETTIERI, Gianluca/0000-0001-6694-2613; Ferretti, Elisabetta/0000-0001-7265-6429; VACCA, Alessandra/0000-0002-0006-5379; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; Cucchi, Danilo/0000-0002-9934-510X	Associazione Italiana Ricerca Cancro (AIRC); Ministry of University and Research (FIRB); Ministry of University and Research (PRIN); Ministry of University and Research (PON); Sapienza University of Rome (Ateneo); Pasteur Institute/Cenci Bolognetti Foundation; Umberto Di Mario ONLUS Foundation; Italian Institute of Technology (IIT) projects; Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy)	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministry of University and Research (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of University and Research (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Ministry of University and Research (PON); Sapienza University of Rome (Ateneo); Pasteur Institute/Cenci Bolognetti Foundation(Istituto Pasteur Italia Fondazione Cenci Bolognetti); Umberto Di Mario ONLUS Foundation; Italian Institute of Technology (IIT) projects; Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy)	We thank Alberto Gulino, friend, mentor and colleague, who passed away while the manuscript was in preparation, for his inspiring vision and continued support. This work was supported by Associazione Italiana Ricerca Cancro (AIRC and AIRC 5XMILLE), Ministry of University and Research (FIRB, PRIN and PON), Sapienza University of Rome (Ateneo), Pasteur Institute/Cenci Bolognetti Foundation, Umberto Di Mario ONLUS Foundation, Italian Institute of Technology (IIT) projects. Medical writing support was provided by ME Kent (EMWA) and funded by the Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy).	Agyeman A, 2014, ONCOTARGET, V5, P4492, DOI 10.18632/oncotarget.2046; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Beauchamp EM, 2011, J CLIN INVEST, V121, P148, DOI 10.1172/JCI42874; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Belani CP, 2016, CANCER-AM CANCER SOC, V122, P2371, DOI 10.1002/cncr.30062; Bermudez O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063226; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chen X, 2008, STEM CELLS, V26, P2759, DOI 10.1634/stemcells.2008-0398; Chen Y, 2014, MOL CARCINOGEN, V53, P625, DOI 10.1002/mc.22015; Chenge J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26628; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; D'Amico D, 2015, DEV CELL, V35, P21, DOI 10.1016/j.devcel.2015.09.008; Davidson MR, 2013, J THORAC DIS, V5, pS463, DOI 10.3978/j.issn.2072-1439.2013.08.43; De Smaele E, 2010, CURR OPIN INVEST DR, V11, P707; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Garvalov BK, 2011, J MOL MED, V89, P95, DOI 10.1007/s00109-010-0685-3; Glinka Y, 2012, BIOCHEM BIOPH RES CO, V425, P775, DOI 10.1016/j.bbrc.2012.07.151; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Gonnissen A, 2015, ONCOTARGET, V6, P13899, DOI 10.18632/oncotarget.4224; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Huang LL, 2014, CLIN CANCER RES, V20, P1566, DOI 10.1158/1078-0432.CCR-13-2195; Huang W-Y, 2014, NUCLEIC ACIDS RES, V43; Hwang J, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-268; Infante P, 2015, EMBO J, V34, P200, DOI 10.15252/embj.201489213; Ingram WJ, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-26; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Johnson DH, 2014, J CLIN ONCOL, V32, P1389, DOI 10.1200/JCO.2014.55.1929; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kober P, 2011, MOL CARCINOGEN, V50, P846, DOI 10.1002/mc.20763; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee RTH, 2016, DEVELOPMENT, V143, P367, DOI 10.1242/dev.120154; Matchett KB, 2014, STEM CELLS, V32, P2563, DOI 10.1002/stem.1798; Mills LD, 2013, J BIOL CHEM, V288, P11786, DOI 10.1074/jbc.M112.438846; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pinato DJ, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1213934; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Raz G, 2012, LUNG CANCER, V76, P191, DOI 10.1016/j.lungcan.2011.10.015; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rodriguez-Blanco J, 2013, ONCOGENE, V32, P2335, DOI 10.1038/onc.2012.243; Ronci M, 2015, MOL BIOSYST, V11, P1603, DOI 10.1039/c5mb00034c; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Seluanov Andrei, 2010, J Vis Exp, DOI 10.3791/2033; Seto M, 2009, MOL CARCINOGEN, V48, P703, DOI 10.1002/mc.20516; Sette G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.217; Silvano M, 2015, J STEM CELL RES THER, V5, P2; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Singh RR, 2011, ONCOGENE, V30, P4874, DOI 10.1038/onc.2011.195; Singh S, 2011, CANCER RES, V71, P4454, DOI 10.1158/0008-5472.CAN-10-2313; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhu YH, 2004, CANCER LETT, V207, P205, DOI 10.1016/j.canlet.2003.10.025; Zinzi L, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00163	83	64	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4641	4652		10.1038/onc.2017.91	http://dx.doi.org/10.1038/onc.2017.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368412	Green Published, hybrid			2022-12-28	WOS:000407246200011
J	Chen, H; Cai, W; Chu, ESH; Tang, J; Wong, CC; Wong, SH; Sun, W; Liang, Q; Fang, J; Sun, Z; Yu, J				Chen, H.; Cai, W.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Fang, J.; Sun, Z.; Yu, J.			Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TUMOR-GROWTH; CANCER-CELLS; PROSTAGLANDIN E-2; INDUCED APOPTOSIS; DNA METHYLATION; MESSENGER-RNA; IN-VIVO; EXPRESSION; 5-HYDROXYMETHYLCYTOSINE	Cyclooxygenase (COX)-2 is upregulated in hepatocellular carcinoma (HCC). However, the direct causative effect of COX-2 in spontaneous HCC formation remains unknown. We thus investigate the role and molecular pathogenesis of COX-2 in HCC by using liver-specific COX-2 transgenic (TG) mice. We found spontaneous HCC formation with elevated inflammatory infiltrates and neovessels in male TG mice (3/21, 14.3%), but not in any of male WT mice (0/19). Reduced representation bisulfite sequencing (RRBS) and gene expression microarrays were performed in the HCC tumor and non-HCC liver tissues to investigate the molecular mechanisms of COX-2-driven HCC. By RRBS, DNA promoter hypermethylation was identified in HCC from TG mice. Induction of promoter hypermethylation was associated with reduced tet methylcytosine dioxygenase 1 (TET1) expression by COX-2. TET1 could catalyze the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) and prevents DNA hypermethylation. In keeping with this, loss of 5hmC was demonstrated in COX-2-induced HCC. Consistently, COX-2 overexpression in human HCC cell lines could reduce both TET1 expression and 5hmc levels. Integrative analyses of DNA methylation and gene expression profiles further identified significantly downregulated genes including LTBP1, ADCY5 and PRKCZ by promoter methylation in COX-2-induced HCC. Reduced expression of LTBP1, ADCY5 and PRKCZ by promoter hypermethylation was further validated in human HCCs. Bio-functional investigation revealed that LTBP1 inhibited cell proliferation in HCC cell lines, suggesting its potential role as a tumor suppressor in HCC. Gene expression microarrays revealed that signaling cascades (AKT (protein kinase B), STK33 (Serine/Threonine kinase 33) and MTOR (mechanistic target of rapamycin) pathways) were enriched in COX-2-induced HCC. In conclusion, this study demonstrated for the first time that enhanced COX-2 expression in hepatocytes is sufficient to induce HCC through inducing promoter hypermethylation by reducing TET1, silencing tumor-suppressive genes and activating key oncogenic pathways. Inhibition of COX-2 represents a mechanism-based target for HCC prevention.	[Chen, H.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China; [Chen, H.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,State Key Lab Digest Di, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China; [Cai, W.; Sun, Z.] Chinese Acad Sci, Beijing Inst Life Sci, Beijing, Peoples R China; [Tang, J.; Fang, J.] Shanghai Jiao Tong Univ, Sch Med,State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Key Lab Gastroenterol & Hepatol, Div Gastroenterol & Hepatol,Minist Hlth, Shanghai, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese Academy of Sciences; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,State Key Lab Digest Di, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Chen, Huarong/ABZ-5810-2022; chen, huarong/ABH-8561-2020; Wong, Sunny H/N-3754-2015; Liang, Qiaoyi Jessie/G-9612-2019; Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	chen, huarong/0000-0003-2192-1864; Wong, Sunny H/0000-0002-3354-9310; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Jun, Yu/0000-0001-5008-2153	RGC-GRF from Hong Kong [766613, 14106145, 14111216]; National Basic Research Program of China (973 Program) [2013CB531401]; Shenzhen Virtual University Park Support Scheme; CUHK [4054100]	RGC-GRF from Hong Kong; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shenzhen Virtual University Park Support Scheme; CUHK(Chinese University of Hong Kong)	This project was supported by research funds from RGC-GRF (766613, 14106145 and 14111216) from Hong Kong; National Basic Research Program of China (973 Program, 2013CB531401); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; Direct grant for Research 2013/2014, CUHK (4054100).	Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Birkenkamp-Demtroder K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073593; Chan G, 1999, CANCER RES, V59, P991; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Drews F, 2008, BBA-MOL CELL RES, V1783, P34, DOI 10.1016/j.bbamcr.2007.08.004; Goc A, 2013, J BIOL CHEM, V288, P3025, DOI 10.1074/jbc.M112.424770; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Hamidi T, 2015, EPIGENOMICS-UK, V7, P247, DOI [10.2217/EPI.14.80, 10.2217/epi.14.80]; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kishimoto Y, 2002, J GASTROENTEROL, V37, P186, DOI 10.1007/s005350200019; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kuehn HS, 2011, J BIOL CHEM, V286, P391, DOI 10.1074/jbc.M110.164772; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lim HY, 2000, CLIN CANCER RES, V6, P519; Liu C., 2013, ABSTR APPL ANAL, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0084849; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Morinaga S, 2002, J GASTROEN HEPATOL, V17, P1110, DOI 10.1046/j.1440-1746.2002.02836.x; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; OBERHAMMER F, 1991, CANCER RES, V51, P2478; Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907; Ryder SD, 2003, GUT, V52, pIII1, DOI 10.1136/gut.52.suppl_3.iii1; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569; Sheng HM, 1998, CANCER RES, V58, P362; Singh B, 2005, INT J ONCOL, V26, P1393; Sobolewski Cyril, 2010, Int J Cell Biol, V2010, P215158, DOI 10.1155/2010/215158; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang TC, 2005, WORLD J GASTROENTERO, V11, P1896; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132866; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yoshida S, 2003, LAB INVEST, V83, P1385, DOI 10.1097/01.LAB.0000090159.53224.B9; Yu J, 2006, HEPATOLOGY, V43, P134, DOI 10.1002/hep.20994; Yu J, 2007, GUT, V56, P991, DOI 10.1136/gut.2006.097923; Zhang Y, 2016, COLD SPRING HARB PER	48	63	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4415	4426		10.1038/onc.2017.73	http://dx.doi.org/10.1038/onc.2017.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28346420	Green Published, hybrid			2022-12-28	WOS:000406806000004
J	Jen, J; Lin, LL; Lo, FY; Chen, HT; Liao, SY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Lo, F-Y; Chen, H-T; Liao, S-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer (vol 35, pg 2357, 2016)	ONCOGENE			English	Correction													Huang, Hsuan-Cheng/C-7266-2011	Huang, Hsuan-Cheng/0000-0002-3386-0934; Jen, Jayu/0000-0002-0926-9984				Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4526	4526		10.1038/onc.2017.77	http://dx.doi.org/10.1038/onc.2017.77			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368404	Green Published, hybrid			2022-12-28	WOS:000406806000015
J	Yang, H; Kircher, DA; Kim, KH; Grossmann, AH; VanBrocklin, MW; Holmen, SL; Robinson, JP				Yang, H.; Kircher, D. A.; Kim, K. H.; Grossmann, A. H.; VanBrocklin, M. W.; Holmen, S. L.; Robinson, J. P.			Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma	ONCOGENE			English	Article							BRAF V600E MUTATION; ACQUIRED-RESISTANCE; METASTATIC MELANOMA; RAF INHIBITION; INK4A/ARF LOSS; OPEN-LABEL; B-RAF; VEMURAFENIB; BRAF(V600E); MULTICENTER	The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventually become resistant. Mitogen-activated protein kinase kinase (MEK) mutations are found in primary melanomas and frequently reported in BRAF melanomas that develop resistance to targeted therapy; however, melanoma is a molecularly heterogeneous cancer, and which mutations are drivers and which are passengers remains to be determined. In this study, we demonstrate that in BRAFV600E melanoma cell lines, activating MEK mutations drive resistance and contribute to suboptimal growth of melanoma cells following the withdrawal of BRAF inhibition. In this manner, the cells are drug-addicted, suggesting that melanoma cells evolve a 'just right' level of mitogen-activated protein kinase signaling and the additive effects of MEK and BRAF mutations are counterproductive. We also used a novel mouse model of melanoma to demonstrate that several of these MEK mutants promote the development, growth and maintenance of melanoma in vivo in the context of Cdkn2a and Pten loss. By utilizing a genetic approach to control mutant MEK expression in vivo, we were able to induce tumor regression and significantly increase survival; however, after a long latency, all tumors subsequently became resistant. These data suggest that resistance to BRAF or MEK inhibitors is probably inevitable, and novel therapeutic approaches are needed to target dormant tumors.	[Yang, H.; Kim, K. H.; Robinson, J. P.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Kircher, D. A.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT USA; [Kircher, D. A.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT USA; [Grossmann, A. H.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; [Grossmann, A. H.] ARUP Labs, Salt Lake City, UT USA; [VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Surg, Salt Lake City, UT USA	University of Minnesota System; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah	Robinson, JP (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	jrobinson@hi.umn.edu		YANG, HANA/0000-0002-7008-6837; Kircher, David/0000-0003-4122-0336; KIM, KWAN HYUN/0000-0003-4975-2839; Robinson, James/0000-0002-6585-0116	Hormel Institute; National Cancer Institute [R01 CA121118]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Hormel Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the members of the Holmen labs as well as W. Pavan, M. McMahon, M. Bosenberg, R. DePinho and L. Chin for providing mouse strains, reagents and advice. This work was largely supported by The Hormel Institute. We thank our lab technicians Selena Hataye and Anne Holtz for their assistance with our experiments and in preparing reagents. We also thank the Huntsman Cancer Institute and Hormel Vivarium staff for assistance. This work was also supported by Award Number R01 CA121118 from the National Cancer Institute (to SLH).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bromberg-White JL, 2004, J VIROL, V78, P4914, DOI 10.1128/JVI.78.9.4914-4916.2004; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Jang S, 2013, LANCET ONCOL, V14, pE60, DOI 10.1016/S1470-2045(12)70539-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914; Kunz M, 2013, EXP DERMATOL, V22, P10, DOI 10.1111/exd.12054; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Livingstone E, 2014, CHIN CLIN ONCOL, V3, DOI 10.3978/j.issn.2304-3865.2014.03.03; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Narita Y, 2014, MOL CANCER THER, V13, P823, DOI 10.1158/1535-7163.MCT-13-0667; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Robinson JP, 2011, ONCOGENE, V30, P1341, DOI 10.1038/onc.2010.513; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Shin Clifford H, 2015, Genes Cancer, V6, P9; Shull AY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043369; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; VanBrocklin MW, 2012, NEURO-ONCOLOGY, V14, P34, DOI 10.1093/neuonc/nor184; VanBrocklin MW, 2010, PIGM CELL MELANOMA R, V23, P531, DOI 10.1111/j.1755-148X.2010.00717.x; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001	46	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3842	3851		10.1038/onc.2016.526	http://dx.doi.org/10.1038/onc.2016.526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263969	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000404848200005
J	Moon, SJ; Jeong, BC; Kim, HJ; Lim, JE; Kwon, GY; Kim, JH				Moon, Sue Jin; Jeong, Byong Chang; Kim, Hwa Jin; Lim, Joung Eun; Kwon, Ghee Young; Kim, Jeong Hoon			DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7	ONCOGENE			English	Article							RECEPTOR SPLICE VARIANTS; LENGTH ANDROGEN RECEPTOR; CELL-LINES; EXPRESSION; SIRT1; TRANSCRIPTION; ACTIVATION; GENES; P53; IDENTIFICATION	Constitutively active AR-V7, one of the major androgen receptor (AR) splice variants lacking the ligand-binding domain, plays a key role in the development of castration-resistant prostate cancer (CRPC) and anti-androgen resistance. However, our understanding of the regulatory mechanisms of AR-V7-driven transcription is limited. Here we report DBC1 as a key regulator of AR-V7 transcriptional activity and stability in CRPC cells. DBC1 functions as a coactivator for AR-V7 and is required for the expression of AR-V7 target genes including CDH2, a mesenchymal marker linked to CRPC progression. DBC1 is required for recruitment of AR-V7 to its target enhancers and for long-range chromatin looping between the CDH2 enhancer and promoter. Mechanistically, DBC1 enhances DNA-binding activity of AR-V7 by direct interaction and inhibits CHIP E3 ligase-mediated ubiquitination and degradation of AR-V7 by competing with CHIP for AR-V7 binding, thereby stabilizing and activating AR-V7. Importantly, DBC1 depletion suppresses the tumorigenic and metastatic properties of CRPC cells. Our results firmly establish DBC1 as a critical AR-V7 coactivator that plays a key role in the regulation of DNA binding and stability of AR-V7 and has an important physiological role in CRPC progression.	[Moon, Sue Jin; Kim, Hwa Jin; Kim, Jeong Hoon] Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea; [Moon, Sue Jin; Kim, Hwa Jin; Kim, Jeong Hoon] Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea; [Jeong, Byong Chang; Lim, Joung Eun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea; [Kwon, Ghee Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, JH (corresponding author), Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul, South Korea.; Kim, JH (corresponding author), Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea.	jeongkim@skku.edu			National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2016R1A2B4008661]; Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI17C0117]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	We thank Dr. Robert Roeder (Rockefeller University) for HA-Ubiquitin expression plasmid. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning [2016R1A2B4008661]; and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [HI17C0117].	An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Antonarakis ES, 2016, PROSTATE CANCER P D, V19, P231, DOI 10.1038/pcan.2016.17; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270; Cottard F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063466; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; DePaolo JS, 2016, ONCOTARGET, V7, P71417, DOI 10.18632/oncotarget.12163; Fu JJ, 2009, J BIOL CHEM, V284, P6832, DOI 10.1074/jbc.M808988200; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Jennbacken K, 2010, ENDOCR-RELAT CANCER, V17, P469, DOI 10.1677/ERC-10-0015; Kim HO, 2015, IEEE GEOSC REM SEN M, V3, P34, DOI 10.1109/MGRS.2014.2382652; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kong DJ, 2015, PROSTATE, V75, P161, DOI 10.1002/pros.22901; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li ZY, 2009, J BIOL CHEM, V284, P10361, DOI 10.1074/jbc.M900956200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu G, 2015, ONCOTARGET, V6, P288, DOI 10.18632/oncotarget.2672; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Makkonen H, 2009, NUCLEIC ACIDS RES, V37, P4135, DOI 10.1093/nar/gkp352; Masuda K, 2005, J MOL BIOL, V353, P763, DOI 10.1016/j.jmb.2005.09.009; McClurg UL, 2017, NUCLEIC ACIDS RES, V45, P1793, DOI 10.1093/nar/gkw1162; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Noh SJ, 2013, PATHOLOGY, V45, P574, DOI 10.1097/PAT.0b013e3283652c7a; Park HS, 2013, TRANSL ONCOL, V6, P370, DOI 10.1593/tlo.13250; Portillo-Lara R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130118; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; Shafi AA, 2013, PHARMACOL THERAPEUT, V140, P223, DOI 10.1016/j.pharmthera.2013.07.003; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van de Wijngaart DJ, 2012, MOL CELL ENDOCRINOL, V352, P57, DOI 10.1016/j.mce.2011.08.007; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; Wagle S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13144; Yu EJ, 2016, ONCOGENE, V35, P3410, DOI 10.1038/onc.2015.401; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347	45	18	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1326	1339		10.1038/s41388-017-0047-5	http://dx.doi.org/10.1038/s41388-017-0047-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249800				2022-12-28	WOS:000427279300005
J	Jinesh, GG; Sambandam, V; Vijayaraghavan, S; Balaji, K; Mukherjee, S				Jinesh, G. G.; Sambandam, V.; Vijayaraghavan, S.; Balaji, K.; Mukherjee, S.			Molecular genetics and cellular events of K-Ras-driven tumorigenesis	ONCOGENE			English	Review							POTENTIAL TUMOR-SUPPRESSOR; ONCOGENIC KRAS; LUNG-CANCER; MUTANT KRAS; COLORECTAL-CANCER; NONCODING RNA; STEM-CELLS; CHROMOSOMAL INSTABILITY; EMERGENCY PROGRAM; EPITHELIAL-CELLS	Cellular transformation and the accumulation of genomic instability are the two key events required for tumorigenesis. K-Ras (Kirsten-rat sarcoma viral oncogene homolog) is a prominent oncogene that has been proven to drive tumorigenesis. K-Ras also modulates numerous genetic regulatory mechanisms and forms a large tumorigenesis network. In this review, we track the genetic aspects of K-Ras signaling networks and assemble the sequence of cellular events that constitute the tumorigenesis process, such as regulation of K-Ras expression (which is influenced by miRNA, small nucleolar RNA and lncRNA), activation of K-Ras (mutations), generation of reactive oxygen species (ROS), induction of DNA damage and apoptosis, induction of DNA damage repair pathways and ROS detoxification systems, cellular transformation after apoptosis by the blebbishield emergency program and the accumulation of genomic/chromosomal instability that leads to tumorigenesis.	[Jinesh, G. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Sambandam, V.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol Dept, Houston, TX 77030 USA; [Vijayaraghavan, S.; Balaji, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Mukherjee, S.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Jinesh, GG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	goodwinjinesh@gmail.com	Jinesh, Goodwin G./M-5956-2013; Vijayaraghavan, Smruthi/O-3576-2018; Sambandam, Vaishnavi/I-4247-2018	Jinesh, Goodwin G./0000-0002-2170-3245; Vijayaraghavan, Smruthi/0000-0002-8131-0988; Sambandam, Vaishnavi/0000-0003-0013-8838				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Alvarez-Moya B, 2010, ONCOGENE, V29, P5911, DOI 10.1038/onc.2010.298; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Balaji K, 2017, MOL CANCER RES, V15, P45, DOI 10.1158/1541-7786.MCR-16-0157; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bartos JD, 2004, MUTAT RES-FUND MOL M, V568, P283, DOI 10.1016/j.mrfmmm.2004.06.052; Baykara O, 2015, J CANCER, V6, P270, DOI 10.7150/jca.10638; Beyer K, 2015, PATHOL RES PRACT, V211, P646, DOI 10.1016/j.prp.2015.05.008; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Castellano L, 2017, NUCLEIC ACIDS RES, V45, P4401, DOI 10.1093/nar/gkx022; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Feijoo P, 2014, CURR PHARM DESIGN, V20, P6375, DOI 10.2174/1381612820666140630085416; Fiala O, 2016, TUMOR BIOL, V37, P6823, DOI 10.1007/s13277-015-4523-7; Hahnel PS, 2014, BLOOD, V123, P2355, DOI 10.1182/blood-2013-01-477620; Han ZY, 2012, CARCINOGENESIS, V33, P131, DOI 10.1093/carcin/bgr226; Hara T, 2014, ONCOTARGET, V5, P7635, DOI 10.18632/oncotarget.2284; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hjortland GO, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-455; Hobbs GA, 2016, CANCER CELL, V29, P251, DOI 10.1016/j.ccell.2016.02.015; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hoogwater FJH, 2010, GASTROENTEROLOGY, V138, P2357, DOI 10.1053/j.gastro.2010.02.046; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jinesh GG, 2016, CELL DEATH DIFFER, V23, P757, DOI 10.1038/cdd.2016.26; Jinesh GG, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.3; Jinesh GG, 2013, CELL DEATH DIFFER, V20, P382, DOI 10.1038/cdd.2012.140; Jinesh G, 2012, J LEUKOCYTE BIOL, V92, P233, DOI 10.1189/jlb.1211623; Jinesh GG, 2016, CELL DEATH DISCOV, V2; Jinesh GG, 2017, CANCER RES, V77, P6144, DOI 10.1158/0008-5472.CAN-17-0522; Jinesh GG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08796-z; Jinesh GG, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.23; Jinesh GG, 2017, BIOFACTORS, V43, P181, DOI 10.1002/biof.1335; Jinesh GG, 2016, APOPTOSIS, V21, P1203, DOI 10.1007/s10495-016-1289-3; Jinesh GG, 2016, SCI REP-UK, V6, DOI 10.1038/srep23965; Jinesh GG, 2016, BIOCHEM J, V473, P99, DOI 10.1042/BJ20150877; Jinesh GG, 2014, CURR STEM CELL RES T, V9, P89; Jinesh GG, 2012, ONCOIMMUNOLOGY, V1, P1161, DOI 10.4161/onci.20928; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Kerr EM, 2016, NATURE, V531, P110, DOI 10.1038/nature16967; Kim WY, 2012, CANCER-AM CANCER SOC, V118, P3993, DOI 10.1002/cncr.26656; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Kotake Y, 2016, CYTOTECHNOLOGY, V68, P1591, DOI 10.1007/s10616-014-9834-9; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23; Lagarda H, 2001, J PATHOL, V193, P193, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9; Liu RL, 2015, INT J BIOL MACROMOL, V81, P491, DOI 10.1016/j.ijbiomac.2015.08.016; Lo AWI, 2002, NEOPLASIA, V4, P531, DOI 10.1038/sj.neo.7900267; Ma CC, 2014, TUMOR BIOL, V35, P9163, DOI 10.1007/s13277-014-2185-5; Meng LY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13964; MILO GE, 1985, FEBS LETT, V179, P332, DOI 10.1016/0014-5793(85)80546-9; Monticone M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-92; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Nadal E, 2015, J THORAC ONCOL, V10, pE9, DOI 10.1097/JTO.0000000000000438; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Niemela JE, 2011, BLOOD, V117, P2883, DOI 10.1182/blood-2010-07-295501; Ortega J, 2015, P NATL ACAD SCI USA, V112, P5667, DOI 10.1073/pnas.1417711112; Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Purdom-Dickinson SE, 2007, MOL PHARMACOL, V72, P1074, DOI 10.1124/mol.107.035360; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rodrigues CFD, 2009, MUTAT RES-FUND MOL M, V670, P42, DOI 10.1016/j.mrfmmm.2009.07.004; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Schimanski CC, 2010, INT J COLORECTAL DIS, V25, P181, DOI 10.1007/s00384-009-0843-7; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tang FH, 2017, INT J CANCER, V140, P1860, DOI 10.1002/ijc.30591; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Taoka R, 2017, APOPTOSIS, V22, P719, DOI 10.1007/s10495-017-1359-1; Tape CJ, 2016, CELL, V165, P910, DOI 10.1016/j.cell.2016.03.029; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran MN, 2010, CURR STEM CELL RES T, V5, P387; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Tsang WP, 2009, CARCINOGENESIS, V30, P953, DOI 10.1093/carcin/bgp094; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang XR, 2013, NEURO-ONCOLOGY, V15, P1491, DOI 10.1093/neuonc/not107; Wang YA, 2005, ONCOGENE, V24, P3042, DOI 10.1038/sj.onc.1208390; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weiss MB, 2010, ONCOGENE, V29, P4715, DOI 10.1038/onc.2010.220; Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905; Xu SD, 2016, ONCOTARGET, V7, P45687, DOI 10.18632/oncotarget.9920; Yilmaz A, 2014, INT J ENV RES PUB HE, V11, P9491, DOI 10.3390/ijerph110909491; Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; You CY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37459; Zhang XH, 2013, CANCER BIOL THER, V14, P597, DOI 10.4161/cbt.24592; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zhou Y, 2016, CANCER RES, V76, P5777, DOI 10.1158/0008-5472.CAN-15-2936	105	55	57	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					839	846		10.1038/onc.2017.377	http://dx.doi.org/10.1038/onc.2017.377			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059163	Green Published, hybrid			2022-12-28	WOS:000425281800002
J	Heydt, Q; Larrue, C; Saland, E; Bertoli, S; Sarry, JE; Besson, A; Manenti, S; Joffre, C; Mas, VMD				Heydt, Q.; Larrue, C.; Saland, E.; Bertoli, S.; Sarry, J-E; Besson, A.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De			Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia	ONCOGENE			English	Article							INTEGRATED STRESS-RESPONSE; CELL-DEATH; AML CELLS; INHIBITOR; DEGRADATION; CANCER; PROLIFERATION; SURVIVAL; THERAPY; PATHWAY	In acute myeloid leukemia (AML), internal tandem duplication mutations in the FLT3 tyrosine kinase receptor (FLT3-ITD) account for up to 25% of cases and are associated with a poor outcome. In order to better target this AML subtype, a comprehensive view of how FLT3-ITD impacts AML cell biology is required. Here, we found that FLT3-ITD expression increased basal autophagy in AML cells, and that both pharmacological and genetic inhibition of the receptor reduced autophagy in primary AML samples and cell lines. Conditional expression of shRNAs against key autophagy proteins demonstrated that autophagy is required for AML cell proliferation in vitro and for leukemic cells survival in a mouse model of xenograft. Importantly, autophagy inhibition also overcame FLT3 inhibitor resistance both in vitro and in vivo. The transcription factor ATF4 was identified as an essential actor of FLT3-ITD-induced autophagy. Cellular levels of ATF4 were highly dependent on FLT3-ITD activity, and downregulation of ATF4 inhibited autophagy-dependent AML cell proliferation and improved overall mouse survival similarly to autophagy inhibition. These results suggest that targeting autophagy or ATF4 in patients expressing FLT3 mutations may represent a novel promising and innovative therapeutic strategy for AML.	[Heydt, Q.; Larrue, C.; Saland, E.; Sarry, J-E; Besson, A.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De] Univ Toulouse, CNRS, INSERM, U1037,ERL5294,CRCT, Toulouse, France; [Heydt, Q.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De] La Ligue Canc, Equipe Labellisee, Toulouse, France; [Bertoli, S.] IUCT O, Serv Hematol, Toulouse, France; [Mas, V. Mansat-De] Inst Univ Canc Toulouse Oncopole, Lab Hematol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Mas, VMD (corresponding author), Inst Univ Canc Toulouse Oncopole, Lab Hematol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.; Joffre, C (corresponding author), CRCT, 2 Ave Hubert Curien, F-31037 Toulouse 1, France.	carine.joffre@inserm.fr; demas.veronique@iuct-oncopole.fr	De Mas, Véronique/P-2414-2014; SALAND, Estelle/W-7996-2019; JOFFRE, Carine/P-1551-2014; Sarry, Jean-Emmanuel/P-1633-2014; manenti, stephane/P-1518-2014; Sarry, Jean-Emmanuel/AAC-3664-2020; Bertoli, Sarah/GMZ-5043-2022; Besson, Arnaud/J-6254-2014	JOFFRE, Carine/0000-0002-7551-356X; Sarry, Jean-Emmanuel/0000-0002-6704-2032; manenti, stephane/0000-0002-4793-3196; Sarry, Jean-Emmanuel/0000-0002-6704-2032; Bertoli, Sarah/0000-0003-1084-2781; Besson, Arnaud/0000-0002-9599-3943; Larrue, Clement/0000-0001-5827-8433	ANR LABEX TOUCAN; Canceropole GSO; la Ligue regionale contre le Cancer; la Ligue nationale contre le Cancer; Ligue Nationale contre le Cancer	ANR LABEX TOUCAN(French National Research Agency (ANR)); Canceropole GSO; la Ligue regionale contre le Cancer; la Ligue nationale contre le Cancer(Ligue nationale contre le cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	We are very grateful to Jerome Tamburini (Institut Cochin, Paris, France), Paulo De Sepulveda (CRCM, Marseille, France) and Pierre Brousset (CRCT, Toulouse, France) for providing us with specific leukemic cell lines (MOLM-14-TKD and MV4-11 shFLT3, TF-1-FLT3-ITD, and OCI-AML3 respectively). We thank Florence Capilla for performing and managing histochemistry experiments, and we acknowledge excellent technical assistance of Mathilde Gotanegre. We are grateful to Manon Farce and Laetitia Ligat for assistance with flow cytometry and microscopy, respectively. We thank HIMIP collection for patients' samples. This work was supported by the ANR LABEX TOUCAN, the Canceropole GSO, la Ligue regionale contre le Cancer and la Ligue nationale contre le Cancer. Quentin Heydt is a recipient of the Ligue Nationale contre le Cancer.	Alvarado Y, 2014, CANCER-AM CANCER SOC, V120, P2142, DOI 10.1002/cncr.28705; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bosnjak M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094374; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Colecchia D, 2015, AUTOPHAGY, V11, P1790, DOI 10.1080/15548627.2015.1084454; Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Gallogly MM, 2016, J BLOOD MED, V7, P73, DOI 10.2147/JBM.S100283; Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040; Ishizawa J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac4380; Jia W, 2015, AUTOPHAGY, V11, P2335, DOI 10.1080/15548627.2015.1110666; Kayser S, 2009, BLOOD, V114, P2386, DOI 10.1182/blood-2009-03-209999; Kiyoi H, 2015, NAGOYA J MED SCI, V77, P7; Larrue C, 2016, BLOOD, V127, P882, DOI 10.1182/blood-2015-05-646497; Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799; Mitou G, 2015, ONCOTARGET, V6, P30149, DOI 10.18632/oncotarget.4999; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352; Piya S, 2016, BLOOD, V128, P1260, DOI 10.1182/blood-2016-01-692244; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681; Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207; Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063; Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629; Visconte V, 2017, LEUKEMIA, V31, P505, DOI 10.1038/leu.2016.295; Watson AS, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.8; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou C, 2017, LEUKEMIA, V31, P1196, DOI 10.1038/leu.2016.329	37	63	66	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					787	797		10.1038/onc.2017.376	http://dx.doi.org/10.1038/onc.2017.376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059168	Green Published, hybrid			2022-12-28	WOS:000424628100010
J	Xie, X; Guo, P; Yu, H; Wang, Y; Chen, G				Xie, X.; Guo, P.; Yu, H.; Wang, Y.; Chen, G.			Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma	ONCOGENE			English	Review							GASTRIC-CANCER CELLS; VIRUS-X PROTEIN; PROGNOSTIC MARKER; COLORECTAL-CANCER; SIGNALING PATHWAY; RACK1 PROMOTES; IN-VITRO; MITOCHONDRIAL RIBOSOME; CELLULAR PROLIFERATION; MULTIDRUG-RESISTANCE	Ribosomes, which are important sites for the synthesis of proteins related to expression and transmission of genetic information in humans, have a complex structure and diverse functions. They consist of a variety of ribosomal proteins (RPs), ribosomal RNAs (rRNAs) and small nucleolar RNAs. Owing to the involvement of ribosomes in many important biological processes of cells, their major components, rRNAs and RPs, have an important role in human diseases, including the initiation and evolvement of malignancies. However, the main mechanisms underlying the involvement of ribosomes in cancer remain unclear. This review describes the crucial role of ribosomes in various common malignant tumors; in particular, it examines the effects of RPs, including S6, the receptor for activated C-kinase and RPS15A, on the development and progression of hepatocellular carcinoma.	[Xie, X.; Guo, P.; Yu, H.; Chen, G.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 453 Dist, Wenzhou 325000, Zhejiang, Peoples R China; [Wang, Y.] Wenzhou Med Univ, Sch Publ Hlth & Management, Res Ctr Evidence Based Med & Clin Epidemiol, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University	Chen, G (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 453 Dist, Wenzhou 325000, Zhejiang, Peoples R China.	cg_2188@hotmail.com			Natural Science Foundation of Zhejiang Province [LY17H160047]; National Natural Science Foundation of China [81201953, 81772628, 81703310]; Research Found for the Doctoral Program of High Education of China from the Ministry of Education [20113321120003]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Found for the Doctoral Program of High Education of China from the Ministry of Education	This work was supported by the grants from the Natural Science Foundation of Zhejiang Province (LY17H160047), the National Natural Science Foundation of China (81201953, 81772628, 81703310) and the Research Found for the Doctoral Program of High Education of China from the Ministry of Education (20113321120003).	Ahuja R, 2015, BBA-MOL CELL RES, V1853, P1783, DOI 10.1016/j.bbamcr.2015.04.012; Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Baba HA, 2009, LIVER INT, V29, P399, DOI 10.1111/j.1478-3231.2008.01798.x; Bee A, 2006, CLIN CANCER RES, V12, P2061, DOI 10.1158/1078-0432.CCR-05-2445; Bee A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022672; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100; Chen JW, 2016, INT J ONCOL, V48, P1628, DOI 10.3892/ijo.2016.3366; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Da Costa L, 2003, BLOOD, V101, P318, DOI 10.1182/blood-2002-04-1131; Danilova N, 2015, DIS MODEL MECH, V8, P1013, DOI 10.1242/dmm.020529; Desai N, 2017, SCIENCE, V355, P528, DOI 10.1126/science.aal2415; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Du JP, 2005, CANCER BIOL THER, V4, P242; Fatima G, 2012, J GEN VIROL, V93, P706, DOI 10.1099/vir.0.035691-0; Fumagalli S, 2011, SEMIN HEMATOL, V48, P97, DOI 10.1053/j.seminhematol.2011.02.004; Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Gruschke S, 2010, BIOESSAYS, V32, P1050, DOI 10.1002/bies.201000081; Guo XY, 2011, J CELL MOL MED, V15, P296, DOI 10.1111/j.1582-4934.2009.00969.x; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; Hagner PR, 2011, ONCOGENE, V30, P1531, DOI 10.1038/onc.2010.533; He H, 2007, ONCOGENE, V26, P2707, DOI 10.1038/sj.onc.1210073; Hegde V, 2004, BIOCHEMISTRY-US, V43, P14211, DOI 10.1021/bi049234b; Hinnebusch AG, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011544; Huang CJ, 2008, J CELL MOL MED, V12, P1936, DOI 10.1111/j.1582-4934.2008.00253.x; Huang CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067043; Iadevaia V, 2014, SEMIN CELL DEV BIOL, V36, P113, DOI 10.1016/j.semcdb.2014.08.004; Jang CY, 2004, FEBS LETT, V560, P81, DOI 10.1016/S0014-5793(04)00074-2; Jimenez L, 2004, PARASITOL RES, V92, P414, DOI 10.1007/s00436-003-1021-4; Kasai H, 2003, J HISTOCHEM CYTOCHEM, V51, P567, DOI 10.1177/002215540305100502; Khatter H, 2015, NATURE, V520, P640, DOI 10.1038/nature14427; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; Kim JH, 2004, HEPATOLOGY, V39, P129, DOI 10.1002/hep.20017; Kim SH, 2013, MODERN PATHOL, V26, P327, DOI 10.1038/modpathol.2012.161; Kobayashi T, 2006, INT J MOL MED, V18, P161; Kowalczyk P, 2002, ACTA BIOCHIM POL, V49, P615; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; Leung THY, 2010, LIVER INT, V30, P1315, DOI 10.1111/j.1478-3231.2010.02307.x; Li CD, 2012, MOL CELL BIOCHEM, V370, P127, DOI 10.1007/s11010-012-1404-x; Li W, 2008, ONCOL REP, V20, P713, DOI 10.3892/or_00000064; Lian ZR, 2004, MOL CARCINOGEN, V40, P34, DOI 10.1002/mc.20012; Lin KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017193; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McDonald JM, 2008, CLIN CANCER RES, V14, P7832, DOI 10.1158/1078-0432.CCR-08-0565; Melnikov S, 2012, NAT STRUCT MOL BIOL, V19, P560, DOI 10.1038/nsmb.2313; Milosevic N, 2013, NEOPLASIA, V15, P1354, DOI 10.1593/neo.131660; Moss T, 2007, CELL MOL LIFE SCI, V64, P29, DOI 10.1007/s00018-006-6278-1; Muro S, 2015, DIGESTION, V91, P164, DOI 10.1159/000371545; Nakhoul H, 2014, CLIN MED INSIGHTS-BL, V7, P7, DOI 10.4137/CMBD.S16952; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Ni JQ, 2006, GENE DEV, V20, P1959, DOI 10.1101/gad.390106; Orelle C, 2015, NATURE, V524, P119, DOI 10.1038/nature14862; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; Ramesh M, 2016, RNA, V22, P1153, DOI 10.1261/rna.056705.116; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Ray S, 2013, GENE, V526, P46, DOI 10.1016/j.gene.2013.04.018; Raychaudhuri S, 2009, CANCER RES, V69, P2057, DOI 10.1158/0008-5472.CAN-08-3468; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Shen FR, 2013, MOL MED REP, V8, P999, DOI 10.3892/mmr.2013.1612; Shenoy N, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-32; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Shukla SK, 2012, FEBS J, V279, P3859, DOI 10.1111/j.1742-4658.2012.08745.x; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; Song MJ, 2011, PATHOL INT, V61, P638, DOI 10.1111/j.1440-1827.2011.02716.x; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Teng T, 2013, CURR OPIN GENET DEV, V23, P63, DOI 10.1016/j.gde.2013.02.001; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsofack SP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-303; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wang CM, 2015, HEPATOLOGY, V61, P200, DOI 10.1002/hep.27396; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; Wang H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-91; Wang M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-6; Wang S, 2010, NEOPLASIA, V12, P284, DOI 10.1593/neo.91610; Wang W, 2015, MED RES REV, V35, P225, DOI 10.1002/med.21327; Wang WD, 2015, ONCOL LETT, V9, P2767, DOI 10.3892/ol.2015.3129; Wei F, 2016, ONCOTARGET, V7, P85259, DOI 10.18632/oncotarget.13269; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu J, 2013, BIOMED PHARMACOTHER, V67, P313, DOI 10.1016/j.biopha.2013.01.011; Wu Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026401; Xu MY, 2014, GENE, V536, P84, DOI 10.1016/j.gene.2013.11.075; Yang MX, 2014, ONCOL REP, V32, P139, DOI 10.3892/or.2014.3187; Yang MX, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0646-0; Yang ZY, 2013, CARCINOGENESIS, V34, P2851, DOI 10.1093/carcin/bgt226; Yu F, 2015, SCI REP-UK, V5, DOI 10.1038/srep18100; Zeng FX, 2017, NATURE, V541, P554, DOI 10.1038/nature21053; Zeng MQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0030-x; Zhan Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010488; Zhang YF, 2010, J GENE MED, V12, P147, DOI 10.1002/jgm.1424; Zhou SL, 2016, ONCOL LETT, V12, P5303, DOI 10.3892/ol.2016.5339; Zhou T, 2015, ONCOL REP, V33, P3006, DOI 10.3892/or.2015.3920; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014	113	19	21	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					277	285		10.1038/onc.2017.343	http://dx.doi.org/10.1038/onc.2017.343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945227				2022-12-28	WOS:000422753900001
J	Hata, AN; Rowley, S; Archibald, HL; Gomez-Caraballo, M; Siddiqui, FM; Ji, F; Jung, J; Light, M; Lee, JS; Debussche, L; Sidhu, S; Sadreyev, RI; Watters, J; Engelman, JA				Hata, A. N.; Rowley, S.; Archibald, H. L.; Gomez-Caraballo, M.; Siddiqui, F. M.; Ji, F.; Jung, J.; Light, M.; Lee, J. S.; Debussche, L.; Sidhu, S.; Sadreyev, R. I.; Watters, J.; Engelman, J. A.			Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers	ONCOGENE			English	Article							CELL LUNG-CANCER; BH3-ONLY PROTEINS PUMA; P53 PATHWAY; EXPRESSION ANALYSIS; ANTAGONIST RG7112; IMPROVED SURVIVAL; FEEDBACK LOOP; TUMOR-GROWTH; MUTATIONS; ACTIVATION	There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for KRAS mutant non-small cell lung cancers (NSCLC) and colorectal carcinomas that harbor wild-type TP53. The combination of pimasertib (MEK inhibitor) and SAR405838 (MDM2 inhibitor) was synergistic and induced the expression of PUMA and BIM, led to apoptosis and growth inhibition in vitro, and tumor regression in vivo. Acquired resistance to the combination commonly resulted from the acquisition of TP53 mutations, conferring complete resistance to MDM2 inhibition. In contrast, resistant clones exhibited marked variability in sensitivity to MEK inhibition, which significantly impacted sensitivity to subsequent treatment with alternative MEK inhibitor-based combination therapies. These results highlight both the potential promise and limitations of combining MEK and MDM2 inhibitors for treatment of KRAS mutant NSCLC and colorectal cancers.	[Hata, A. N.; Archibald, H. L.; Gomez-Caraballo, M.; Siddiqui, F. M.; Engelman, J. A.] Massachusetts Gen Hosp, Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA; [Hata, A. N.; Engelman, J. A.] Harvard Med Sch, Dept Med, Boston, MA USA; [Rowley, S.; Jung, J.; Light, M.; Lee, J. S.; Watters, J.] Sanofi Oncol, Cambridge, MA USA; [Ji, F.; Sadreyev, R. I.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Debussche, L.; Sidhu, S.] Sanofi Oncol, 13 Quai Jules Guesde, Vitry Sur Seine, France; [Sadreyev, R. I.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hata, AN (corresponding author), Massachusetts Gen Hosp, Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	ahata@mgh.harvard.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	NIH [R01CA14059408]; Uniting Against Lung Cancer; Conquer Cancer Foundation of ASCO; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA140594] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Uniting Against Lung Cancer; Conquer Cancer Foundation of ASCO; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Engelman Lab for helpful discussions and feedback. We thank MercK KGaA, Darmstadt, Germany for provision of pimasertib for our research and for scientific review of this manuscript. This study was funded by support from the NIH R01CA14059408 (JAE), Uniting Against Lung Cancer (ANH), Conquer Cancer Foundation of ASCO (ANH).	Aziz MH, 2011, ONCOGENE, V30, P4678, DOI 10.1038/onc.2011.185; Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Hoffman-Luca CG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128807; Ji ZY, 2013, CLIN CANCER RES, V19, P4383, DOI 10.1158/1078-0432.CCR-13-0074; Ji ZY, 2012, J INVEST DERMATOL, V132, P356, DOI 10.1038/jid.2011.313; Jung J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12609; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Mose LE, 2014, BIOINFORMATICS, V30, P2813, DOI 10.1093/bioinformatics/btu376; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saiki AY, 2014, ONCOTARGET, V5, P2030, DOI 10.18632/oncotarget.1918; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Streibig, 2014, SYNERGY, V1, P22, DOI [10.1016/j.synres.2014.07.010, DOI 10.1016/J.SYNRES.2014.07.010]; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Team RC., 2013, R LANG ENV STAT COMP; Tovar C, 2013, CANCER RES, V73, P2587, DOI 10.1158/0008-5472.CAN-12-2807; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang SM, 2014, CANCER RES, V74, P5855, DOI 10.1158/0008-5472.CAN-14-0799; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zhang WG, 2010, CANCER RES, V70, P2424, DOI 10.1158/0008-5472.CAN-09-0878	56	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6581	6591		10.1038/onc.2017.258	http://dx.doi.org/10.1038/onc.2017.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783173	Green Submitted, Green Accepted			2022-12-28	WOS:000416049200007
J	Ando, S; Malivindi, R; Catalano, S; Rizza, P; Barone, I; Panza, S; Rovito, D; Emprou, C; Bornert, JM; Laverny, G; Metzger, D				Ando, S.; Malivindi, R.; Catalano, S.; Rizza, P.; Barone, I.; Panza, S.; Rovito, D.; Emprou, C.; Bornert, J-M; Laverny, G.; Metzger, D.			Conditional expression of Ki-Ras(G12V) in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ER alpha)-positive adenocarcinoma	ONCOGENE			English	Article							SITE-SPECIFIC RECOMBINATION; BREAST-CANCER; MOUSE MODEL; GENE-EXPRESSION; RAS ACTIVATION; TUMOR-GROWTH; K-RAS; MYC; INHIBITION; ONCOGENE	Appropriate 'in vivo' models are crucial for studying breast cancer biology and evaluating the efficacy of therapeutic agents. Thus we engineered a novel transgenic mouse line expressing the human Ki-Ras bearing an activating mutation (Ki-Ras(G12V)) selectively in the mammary epithelium after lactation. These mice develop invasive ductal adenocarcinomas with 100% incidence within 3-9 months after Ki-Ras(G12V) induction. Immunophenotyping revealed that the mammary tumors express luminal markers, are positive for estrogen and progesterone receptors, negative for HER2 and have a low proliferation index. Moreover, cell lines derived from such tumors are estrogen-responsive and, when transplanted into nude mice, form tumors that respond to the antiestrogen ICI 182780. In conclusion, the mammary tumors of these transgenic mice and the derived cell lines exhibit key features of the major form of human breast cancer, that is, luminal A subtype and thus have a high potential for breast cancer research and treatment.	[Ando, S.; Malivindi, R.; Catalano, S.; Rizza, P.; Barone, I.; Panza, S.; Rovito, D.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Edificio Polifunz,Via P Bucci, I-87036 Arcavacata Di Renda, CS, Italy; [Ando, S.] Univ Calabria, Ctr Sanit, Arcavacata Di Renda, CS, Italy; [Rovito, D.; Emprou, C.; Bornert, J-M; Laverny, G.; Metzger, D.] Univ Strasbourg, Dept Funct Genom & Canc, U964, CNRS,INSERM,IGBMC,UMR 7104, F-67404 Illkirch Graffenstaden, France	University of Calabria; University of Calabria; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ando, S (corresponding author), Univ Calabria, Dept Pharm Hlth & Nutr Sci, Edificio Polifunz,Via P Bucci, I-87036 Arcavacata Di Renda, CS, Italy.; Metzger, D (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, U964, CNRS,INSERM,IGBMC,UMR 7104, F-67404 Illkirch Graffenstaden, France.	sebastiano.ando@unical.it; metzger@igbmc.fr	Malivindi, Rocco/ABB-8562-2021; Rovito, Daniela/AEN-0314-2022; Laverny, Gilles/G-5412-2017; Emprou, Camille/F-3854-2019	Rovito, Daniela/0000-0001-5390-5477; Emprou, Camille/0000-0002-0185-3668; MALIVINDI, Rocco/0000-0002-8313-2492; CATALANO, Stefania/0000-0002-6352-9628; Laverny, Gilles/0000-0002-2666-6877; Metzger, Daniel/0000-0002-5555-046X; BARONE, Ines/0000-0002-9769-1615	PRIN [2015B7M39T]; Fondazione Italiana per la Ricerca sul Cancro (AIRC) [11595]; PROGRAMMA 'FUTURO IN RICERCA' [RBFR12FI27]; AIRC Fellowships [19552]; EMBO ASTF [182010]; European Social Fund operational programme of the Calabria region; Faculte de Medecine, Universite de Strasbourg; Centre National pour la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite de Strasbourg; French state funds through the Agence Nationale de la Recherche [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]; MFAG [16899]	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Fondazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); PROGRAMMA 'FUTURO IN RICERCA'; AIRC Fellowships(Fondazione AIRC per la ricerca sul cancro); EMBO ASTF(European Molecular Biology Organization (EMBO)); European Social Fund operational programme of the Calabria region; Faculte de Medecine, Universite de Strasbourg; Centre National pour la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite de Strasbourg; French state funds through the Agence Nationale de la Recherche(French National Research Agency (ANR)); MFAG	We thank Dr Watson and Dr Whitelaw for BLG-Cre mice, Merck Research Laboratories for the MMTV-Ki-Ras<SUP>(G12V)</SUP> plasmid and Catherine Tomasetto and Fabien Alpy for helpful discussions. We also thank Neil E Hubbard and Judith Walls (Center for Comparative Medicine, University of California, Davis, CA, USA), the staff of the mouse and genetic engineering facilities from ICS and IGBMC and Elise Grelet for their excellent assistance. This work was supported by: PRIN2015 #2015B7M39T (to SA), Fondazione Italiana per la Ricerca sul Cancro (AIRC) grants: IG no. 11595 (to SA), MFAG no. 16899 (to IB), PROGRAMMA 'FUTURO IN RICERCA' Anno 2012 no. RBFR12FI27 (to IB), AIRC Fellowships for abroad no. 19552 (to DR), EMBO ASTF no. 182010 (to RM), European Social Fund operational programme of the Calabria region (to SP), Faculte de Medecine, Universite de Strasbourg (to CE) and by the Centre National pour la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), the Universite de Strasbourg and French state funds through the Agence Nationale de la Recherche ANR-10-LABX-0030-INRT under the frame programme Investissements d'Avenir labelled ANR-10-IDEX-0002-02.	Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Barone I, 2012, ENDOCRINOLOGY, V153, P5157, DOI 10.1210/en.2012-1561; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Catalano S, 2016, MINI-REV MED CHEM, V16, P691, DOI 10.2174/1389557516666160321113041; Catalano S, 2013, INT J CANCER, V132, P2237, DOI 10.1002/ijc.27915; Catalano S, 2009, MOL ENDOCRINOL, V23, P1634, DOI 10.1210/me.2009-0039; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen M, 2013, ONCOL LETT, V6, P118, DOI 10.3892/ol.2013.1324; Dabydeen SA, 2014, ENDOCR-RELAT CANCER, V21, pR195, DOI 10.1530/ERC-13-0512; DATI C, 1991, INT J CANCER, V47, P833, DOI 10.1002/ijc.2910470607; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Giordano C, 2016, SCI REP-UK, V6, DOI 10.1038/srep21782; Giordano C, 2016, ONCOTARGET, V7, P1262, DOI 10.18632/oncotarget.6014; Grande F, 2016, FUTURE MED CHEM, V8, P93, DOI 10.4155/fmc.15.176; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Habashy HO, 2012, HISTOPATHOLOGY, V60, P854, DOI 10.1111/j.1365-2559.2011.03912.x; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Howe LR, 2011, CANCER PREV RES, V4, P1149, DOI 10.1158/1940-6207.CAPR-11-0334; Imai T, 2000, GENESIS, V26, P147, DOI 10.1002/(SICI)1526-968X(200002)26:2<147::AID-GENE15>3.0.CO;2-3; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Mauro L, 2007, CANCER RES, V67, P3412, DOI 10.1158/0008-5472.CAN-06-2890; McGlynn LM, 2013, EUR J CANCER, V49, P1176, DOI 10.1016/j.ejca.2012.11.020; Metzger D, 2001, METHODS, V24, P71, DOI 10.1006/meth.2001.1159; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; O'Hagan Ronan C, 2011, Genes Cancer, V2, P335, DOI 10.1177/1947601911408080; Omer CA, 2000, CANCER RES, V60, P2680; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Reddy Haritha K D L, 2010, Genes Cancer, V1, P69, DOI 10.1177/1947601909358105; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shen Q, 2005, MUTAT RES-FUND MOL M, V576, P93, DOI 10.1016/j.mrfmmm.2004.10.013; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6420	6431		10.1038/onc.2017.252	http://dx.doi.org/10.1038/onc.2017.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745321	Green Submitted			2022-12-28	WOS:000415622900006
J	Guo, Y; Cui, J; Ji, Z; Cheng, C; Zhang, K; Zhang, C; Chu, M; Zhao, Q; Yu, Z; Zhang, Y; Fang, YX; Gao, WQ; Zhu, HH				Guo, Y.; Cui, J.; Ji, Z.; Cheng, C.; Zhang, K.; Zhang, C.; Chu, M.; Zhao, Q.; Yu, Z.; Zhang, Y.; Fang, Y-X; Gao, W-Q; Zhu, H. H.			miR-302/367/LATS2/YAP pathway is essential for prostate tumor- propagating cells and promotes the development of castration resistance	ONCOGENE			English	Article							HIPPO PATHWAY; ANDROGEN RECEPTOR; DOWN-REGULATION; CANCER; EXPRESSION; ANTIGEN; HYPERMETHYLATION; SUPPRESSION; REGULATORS; THERAPY	Clinical intervention for patients with advanced prostate cancer (PCa) remains challenging due to the inevitable recurrence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT). Cancer stem cells (CSCs) with serial tumor-propagating capacity are considered to be the driving force for PCa progression and recurrence. In this study, we report that the miR-302/367 cluster, a previously identified potent pluripotency regulator, is upregulated in prostate tumors. Specifically, the forced expression of the miR-302/367 cluster accelerates the in vitro and in vivo growth of PCa cells and their resistance to androgen ablation, whereas the knockdown of the miR-302/367 cluster using anti-sense RNA suppresses the incidence of formation, growth rate and endpoint weight of PCa cell tumors. Mechanistically, we find that LATS2, a key component of the tumor-suppressive Hippo signaling pathway, acts as a direct target of the miR-302/367 cluster in PCa cells. The downregulation of LATS2 by the miR-302/367 cluster reduces the phosphorylation and enhances the nuclear translocation of the YAP oncoprotein. Conversely, the restoration of LATS2 expression abrogates the tumor-promoting effects of forced miR-302/367 cluster expression. Collectively, the potent pluripotency regulator-triggered miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes castration resistance. Thus, targeting this signaling axis may represent a promising therapeutic strategy for CRPC.	[Guo, Y.; Cui, J.; Zhang, C.; Chu, M.; Fang, Y-X; Gao, W-Q; Zhu, H. H.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Ren Ji Med X Clin Stem Cell Res Ctr,State Key Lab, Shanghai, Peoples R China; [Ji, Z.; Cheng, C.; Zhang, K.; Gao, W-Q] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Ji, Z.; Cheng, C.; Zhang, K.; Gao, W-Q] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Zhao, Q.; Yu, Z.; Zhang, Y.] Tongji Univ, Sch Med, Shanghai East Hosp, Res Ctr Translat Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Gao, WQ; Zhu, HH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Stem Cell Res Ctr, 160 Pujian Rd, Shanghai 200127, Peoples R China.	gao.weiqiang@sjtu.edu.cn; zhuhecrane@shsmu.edu.cn	Gao, Wei/GXH-0380-2022	ji, Zhongzhong/0000-0003-0562-2477; Chu, Mingliang/0000-0003-0559-8921	Chinese Ministry of Science and Technology [2017YFA0102900]; National Natural Science Foundation of China [81372189, 81630073]; Science and Technology Commission of Shanghai Municipality [16JC1405700]; KC Wong foundation; Shanghai Eastern Hospital Stem Cell Research Base Fund; State Key Laboratory of Oncogenes and Related Genes [90-16-03]; Shanghai Rising-Star Program [17QA1402100]; Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar) [QD2015002]; School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant) [16XJ11003]; Ren Ji Hospital [RJZZ14-010]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); KC Wong foundation; Shanghai Eastern Hospital Stem Cell Research Base Fund; State Key Laboratory of Oncogenes and Related Genes; Shanghai Rising-Star Program; Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar); School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant); Ren Ji Hospital	The study is supported by grants from the Chinese Ministry of Science and Technology (2017YFA0102900), the National Natural Science Foundation of China (81372189 and 81630073), the Science and Technology Commission of Shanghai Municipality (16JC1405700), the KC Wong foundation, and the Shanghai Eastern Hospital Stem Cell Research Base Fund to Wei-Qiang Gao, and Helen He Zhu received support from the State Key Laboratory of Oncogenes and Related Genes (90-16-03), Shanghai Rising-Star Program (17QA1402100), Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar) QD2015002), School of Medicine at Shanghai Jiao Tong University (Excellent Youth Scholar Initiation Grant 16XJ11003) and Ren Ji Hospital (Seed Project RJZZ14-010).	Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001; Badcock G, 1999, CANCER RES, V59, P4715; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen EJ, 2015, CLIN CANCER RES, V21, P1273, DOI 10.1158/1078-0432.CCR-14-1220; Chen L, 2015, COMP BIOCHEM PHYS D, V16, P83, DOI 10.1016/j.cbd.2015.08.002; Chu ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116197; Dai JL, 1996, STEROIDS, V61, P531; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Fang YX, 2010, MOL BIOTECHNOL, V45, P71, DOI 10.1007/s12033-010-9244-y; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; GERDES J, 1984, J IMMUNOL, V133, P1710; GROGAN TM, 1988, BLOOD, V71, P1157; Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hong AW, 2016, NAT REV GASTRO HEPAT, V13, P324, DOI 10.1038/nrgastro.2016.59; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Li WQ, 2011, CANCER RES, V71, P2162, DOI 10.1158/0008-5472.CAN-10-3268; Lu Y, 2014, CELL STEM CELL, V15, P92, DOI 10.1016/j.stem.2014.04.002; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Sebio A, 2015, CLIN CANCER RES, V21, P5002, DOI 10.1158/1078-0432.CCR-15-0411; Suzuki H, 1998, CANCER RES, V58, P204; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Torre LA, 2016, CA-CANCER J CLIN, V66, P182, DOI 10.3322/caac.21335; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2016, GYNECOL ONCOL, V141, P592, DOI 10.1016/j.ygyno.2015.11.034; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang K, 2016, ONCOGENE, V35, P1271, DOI 10.1038/onc.2015.184; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao LY, 2016, SHOCK VIB, V2016, DOI 10.1155/2016/3891429; Zlotorynski Eytan, 2016, Nat Rev Cancer, V16, P481, DOI 10.1038/nrc.2016.78	48	49	51	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6336	6347		10.1038/onc.2017.240	http://dx.doi.org/10.1038/onc.2017.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28745315				2022-12-28	WOS:000414774800012
J	Chen, D; Fan, Z; Rauh, M; Buchfelder, M; Eyupoglu, IY; Savaskan, N				Chen, D.; Fan, Z.; Rauh, M.; Buchfelder, M.; Eyupoglu, I. Y.; Savaskan, N.			ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-4; ENDOPLASMIC-RETICULUM STRESS; TUMOR ANGIOGENESIS; ER-STRESS; MALIGNANT GLIOMAS; CANCER-THERAPY; GROWTH; BRAIN; PATHWAY; RESISTANCE	Activating transcription factor 4 (ATF4) is a critical mediator of metabolic and oxidative homeostasis and cell survival. ATF4 is elevated in response to diverse microenvironmental stresses, including starvation, ER stress damages and exposure to toxic factors. Here we show that ATF4 expression fosters the malignancy of primary brain tumors (WHO grade III and IV gliomas) and increases proliferation and tumor angiogenesis. Hence, ATF4 expression promotes cell migration and anchorage-independent cell growth, whereas siRNA-mediated knockdown of ATF4 attenuates these features of malignancy in human gliomas. Further experiments revealed that ATF4-dependent tumor promoting effects are mediated by transcriptional targeting the glutamate antiporter xCT/SCL7A11 (also known as system Xc(-)). Thus, xCT is elevated as a consequence of ATF4 activation. We further found evidence that ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition and ferroptosis inducers such as sorafenib, erastin and GPx4 inhibitor RSL3. Further, fostered xCT expression promotes cell survival and growth in ATF4 knockdown cells. Moreover, increased xCT levels ameliorate sorafenib and erastin-induced ferroptosis. Conversely, ATF4 knockdown renders cells susceptible for erastin, sorafenib and RSL3-induced ferroptosis. We further identified that ATF4 promotes tumor-mediated neuronal cell death which can be alleviated by xCT inhibition. Moreover, elevated ATF4 expression in gliomas promotes tumor angiogenesis. Noteworthy, ATF4-induced angiogenesis could be diminished by ferroptosis inducers erastin and by GPx4 inhibitor RSL3. Our data provide proof-of-principle evidence that ATF4 fosters proliferation and induces a toxic microenvironmental niche. Furthermore, ATF4 increases tumor angiogenesis and shapes the vascular architecture in a xCT-dependent manner. Thus, inhibition of ATF4 is a valid target for diminishing tumor growth and vasculature via sensitizing tumor cells for ferroptosis.	[Chen, D.; Fan, Z.; Eyupoglu, I. Y.; Savaskan, N.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Translat Cell Biol & Neurooncol Lab, Schwabachanlage 6, D-91054 Erlangen, Germany; [Chen, D.] Chinese Peoples Liberat Army Gen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Fan, Z.] ETHZ Zurich, ETH Zurich, Lab Exercise & Hlth, Dept Hlth Sci & Technol, Zurich, Switzerland; [Rauh, M.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Dept Pediat & Adolescent Med, Erlangen, Germany; [Buchfelder, M.; Eyupoglu, I. Y.; Savaskan, N.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Dept Neurosurg, Erlangen, Germany; [Savaskan, N.] BiMECON Ent, Berlin, Germany	University of Erlangen Nuremberg; Chinese People's Liberation Army General Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Savaskan, N (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen UKER, Translat Cell Biol & Neurooncol Lab, Schwabachanlage 6, D-91054 Erlangen, Germany.; Savaskan, N (corresponding author), BiMECON, Schwabachanlage 6, D-91054 Erlangen, Germany.	savaskan@gmx.net	Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X	China Scholarship Council (CSC) [201308110471]; Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V.	China Scholarship Council (CSC)(China Scholarship Council); Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V.	We thank all members of the Translational Neurooncology laboratory for valuable comments on this study and helpful suggestions. Christiane Muhle (Department of Psychiatry, Erlangen, Germany) is gratefully acknowledged for providing assistance with the digital qRT-PCR procedure. Christoph J. Wruck (from the RWTH Aachen, Germany) as well as Jana Wrosch and Marc Dahlmanns (from the Department of Psychiatry, Erlangen, Germany, and Molecular Medicine program at the Universitatsklinikum Erlangen) are acknowledged for sharing imaging technics and constructs exchange. DC holds a grant from the China Scholarship Council (CSC: 201308110471). This study was funded by the Verein zur Forderung des Tumorzentrums der Universitat Erlangen-Nurnberg e.V. to NES.	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Broggini T, 2016, AGING-US, V8, P2463, DOI 10.18632/aging.101066; Castranova D, 2016, ARTERIOSCL THROM VAS, V36, P655, DOI 10.1161/ATVBAHA.115.307087; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Eyupoglu IY, 2013, NAT REV NEUROL, V9, P141, DOI 10.1038/nrneurol.2012.279; Fan Z, 2016, ONCOTARGET, V7, P26692, DOI 10.18632/oncotarget.8592; Fan Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093264; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Ghoochani A, 2016, ONCOTARGET, V7, P38306, DOI 10.18632/oncotarget.9439; Ghoochani A, 2016, ONCOTARGET, V7, P1838, DOI 10.18632/oncotarget.6550; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Mao XY, 2016, ONCOTARGET, V7, P33451, DOI 10.18632/oncotarget.7962; McConkey DJ, 2017, BIOCHEM BIOPH RES CO, V482, P450, DOI 10.1016/j.bbrc.2016.11.047; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pereira ER, 2014, J BIOL CHEM, V289, P3352, DOI 10.1074/jbc.M113.507194; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Savaskan NE, 2011, ONCOGENE, V30, P43, DOI 10.1038/onc.2010.391; Savaskan NE, 2010, ANN ANAT, V192, P309, DOI 10.1016/j.aanat.2010.07.003; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Savaskan NE, 2015, CURR NEUROPHARMACOL, V13, P258, DOI 10.2174/1570159X13666150122224158; Sehm T, 2016, ONCOTARGET, V7, P74630, DOI 10.18632/oncotarget.11858; Sehm T, 2016, ONCOTARGET, V7, P36021, DOI 10.18632/oncotarget.8651; Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207; Takeuchi S, 2013, NEUROSURGERY, V72, P33, DOI 10.1227/NEU.0b013e318276b2de; Tanabe M, 2003, CANCER RES, V63, P8592; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang YG, 2013, NEOPLASIA, V15, P989, DOI 10.1593/neo.13262; Xu TF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19799; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zeng H, 2016, ONCOTARGET, V7, P7329, DOI 10.18632/oncotarget.6940; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	42	171	177	8	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5593	5608		10.1038/onc.2017.146	http://dx.doi.org/10.1038/onc.2017.146			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28553953	hybrid, Green Published			2022-12-28	WOS:000412293600004
J	Xie, G; Liu, X; Zhang, Y; Li, W; Liu, S; Chen, Z; Xu, B; Yang, J; He, L; Zhang, Z; Jin, T; Yi, X; Sun, L; Shang, Y; Liang, J				Xie, G.; Liu, X.; Zhang, Y.; Li, W.; Liu, S.; Chen, Z.; Xu, B.; Yang, J.; He, L.; Zhang, Z.; Jin, T.; Yi, X.; Sun, L.; Shang, Y.; Liang, J.			UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; INTEGRATIVE GENOMICS VIEWER; H3K27ME3 DEMETHYLASE UTX; CANCER-CELLS; GENE-REGULATION; TUMOR MICROENVIRONMENT; ER-ALPHA; POLYCOMB; JMJD3; METHYLATION	UTX is implicated in embryonic development and lineage specification. However, how this X-linked histone demethylase contributes to the occurrence and progression of breast cancer remains to be clarified. Here we report that UTX is physically associated with estrogen receptor (ER) and functions in ER-regulated transcription. We showed that UTX coordinates with JHDM1D and CBP to direct H3K27 methylation-acetylation transition and to create a permissive chromatin state on ER targets. Genome-wide analysis of the transcriptional targets of UTX by ChIP-seq identified a set of genes such as chemokine receptor CXCR4 that are intimately involved in breast cancer tumorigenesis and metastasis. We demonstrated that UTX promotes the proliferation and migration of ER+ breast cancer cells. Interestingly, UTX itself is transactivated by ER, forming a feed-forward loop in the regulation of hormone response. Indeed, UTX is upregulated during ER+ breast cancer progression, and the expression level of UTX is positively correlated with that of CXCR4 and negatively correlated with the overall survival of ER+ breast cancer patients. Our study identified a feed-forward loop between UTX and ER in the regulation of hormonally responsive breast carcinogenesis, supporting the pursuit of UTX as an emerging therapeutic target for the intervention of certain ER+ breast cancer with specific epigenetic vulnerability.	[Xie, G.; Zhang, Y.; Li, W.; Liu, S.; Chen, Z.; Xu, B.; Yang, J.; He, L.; Zhang, Z.; Jin, T.; Yi, X.; Sun, L.; Shang, Y.; Liang, J.] Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [Liu, X.; Shang, Y.] Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin, Peoples R China; [Shang, Y.] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Peking University; Tianjin Medical University; Capital Medical University	Liang, J (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	liang_jing@bjmu.edu.cn	Chen, Zhe/AAA-3235-2020	Chen, Zhe/0000-0002-5303-9879; Xie, Guojia/0000-0002-8250-6157	Ministry of Science and Technology of China [2014CB542004]; National Natural Science Foundation of China [31371301, 81572771, 91219201, 81130048]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants (973 Program: 2014CB542004 to JL and YS) from the Ministry of Science and Technology of China, and grants (31371301 and 81572771 to JL and 91219201 and 81130048 to YS) from the National Natural Science Foundation of China.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Benyoucef A, 2016, GENE DEV, V30, P508, DOI 10.1101/gad.276790.115; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665; Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Ezponda T, 2014, CLIN CANCER RES, V20, P5001, DOI 10.1158/1078-0432.CCR-13-2499; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Harburg GC, 2011, J MAMMARY GLAND BIOL, V16, P257, DOI 10.1007/s10911-011-9225-1; Hart CD, 2015, NAT REV CLIN ONCOL, V12, P541, DOI 10.1038/nrclinonc.2015.99; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Lee YH, 2014, TUMOR BIOL, V35, P7699, DOI 10.1007/s13277-014-2027-5; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park UH, 2016, ONCOGENE, V35, P3742, DOI 10.1038/onc.2015.443; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rocha-Viegas L, 2014, MOL CELL BIOL, V34, P3765, DOI 10.1128/MCB.00839-14; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Simons SS, 2013, MOL CELL ENDOCRINOL, V376, P81, DOI 10.1016/j.mce.2013.06.007; Smith E, 2014, NAT STRUCT MOL BIOL, V21, P210, DOI 10.1038/nsmb.2784; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tsukada YI, 2010, GENE DEV, V24, P432, DOI 10.1101/gad.1864410; Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Xu C, 2015, DRUG DES DEV THER, V9, P4953, DOI 10.2147/DDDT.S84932; Yu YC, 2014, DNA CELL BIOL, V33, P543, DOI 10.1089/dna.2013.2289; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838; Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368	62	26	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5497	5511		10.1038/onc.2017.157	http://dx.doi.org/10.1038/onc.2017.157			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534508				2022-12-28	WOS:000411960500006
J	Maurus, K; Hufnagel, A; Geiger, F; Graf, S; Berking, C; Heinemann, A; Paschen, A; Kneitz, S; Stigloher, C; Geissinger, E; Otto, C; Bosserhoff, A; Schartl, M; Meierjohann, S				Maurus, K.; Hufnagel, A.; Geiger, F.; Graf, S.; Berking, C.; Heinemann, A.; Paschen, A.; Kneitz, S.; Stigloher, C.; Geissinger, E.; Otto, C.; Bosserhoff, A.; Schartl, M.; Meierjohann, S.			The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation	ONCOGENE			English	Article							C-JUN; METASTATIC MELANOMA; CANCER METASTASIS; CELLS; ACTIVATION; FRA-1; MITF; GENE; DEDIFFERENTIATION; PHOSPHORYLATION	The MAPK pathway is activated in the majority of melanomas and is the target of therapeutic approaches. Under normal conditions, it initiates the so-called immediate early response, which encompasses the transient transcription of several genes belonging to the AP-1 transcription factor family. Under pathological conditions, such as continuous MAPK pathway overactivation due to oncogenic alterations occurring in melanoma, these genes are constitutively expressed. The consequences of a permanent expression of these genes are largely unknown. Here, we show that FOSL1 is the main immediate early AP-1 member induced by melanoma oncogenes. We first examined its role in established melanoma cells. We found that FOSL1 is involved in melanoma cell migration as well as cell proliferation and anoikis-independent growth, which is mediated by the gene product of its target gene HMGA1, encoding a multipotent chromatin modifier. As FOSL1 expression is increased in patient melanoma samples compared to nevi, we investigated the effect of enhanced FOSL1 expression on melanocytes. Intriguingly, we found that FOSL1 acts oncogenic and transforms melanocytes, enabling subcutaneous tumor growth in vivo. During the process of transformation, FOSL1 reprogrammed the melanocytes and downregulated MITF in a HMGA1-dependent manner. At the same time, AXL was upregulated, leading to a shift in the MITF/AXL balance. Furthermore, FOSL1 re-enforced pro-tumorigenic transcription factors MYC, E2F3 and AP-1. Together, this led to the enhancement of several growth-promoting processes, such as ribosome biogenesis, cellular detachment and pyrimidine metabolism. Overall, we demonstrate that FOSL1 is a novel reprogramming factor for melanocytes with potent tumor transformation potential.	[Maurus, K.; Hufnagel, A.; Geiger, F.; Kneitz, S.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Phys Chem, Wurzburg, Germany; [Maurus, K.; Geissinger, E.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Graf, S.; Berking, C.] Munich Univ Hosp LMU, Dept Dermatol & Allergy, Munich, Germany; [Heinemann, A.] Paul Ehrlich Inst, Div Immunol, Langen, Germany; [Paschen, A.] Univ Duisburg Essen, Univ Hosp Essen, Dept Dermatol, Partner Site Essen, Essen, Germany; [Paschen, A.] German Canc Consortium DKTK, Partner Site Essen Dusseldorf, Essen, Germany; [Stigloher, C.] Univ Wurzburg, Div Elect Microscopy, Dept Cell & Dev Biol, Wurzburg, Germany; [Otto, C.] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Wurzburg, Germany; [Bosserhoff, A.] Friedrich Alexander Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, Nurnberg, Germany; [Bosserhoff, A.] Univ Erlangen Nurnberg, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany; [Schartl, M.; Meierjohann, S.] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Schartl, M.] Texas A&M Univ, Texas A&M Inst Adv Studies, College Stn, TX USA; [Schartl, M.] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	University of Wurzburg; University of Wurzburg; University of Munich; Paul Ehrlich Institute; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg; University of Wurzburg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Wurzburg; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de	Bosserhoff, Anja/GNH-4801-2022	Geiger, Fabienne/0000-0002-7550-9739; Bosserhoff, Anja/0000-0001-8147-394X	Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid); research unit FOR2314, German Research Foundation	Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid)(Deutsche Krebshilfe); research unit FOR2314, German Research Foundation	This work was supported by the Melanoma Research Network of the Deutsche Krebshilfe eV (German Cancer Aid) and by the research unit FOR2314, project 5 (German Research Foundation). We are furthermore grateful to Manfred Gessler (Dept of Developmental Biochemistry, University of Wurzburg) for providing us with the pSB-ET-iE vector and to Stefan Gaubatz (Dept. of Physiological Chemistry, University of Wurzburg) for the E2F3 antibody. We would also like to thank Marie-Christine Dabauvalle (Dept of Zoology and Developmental Biology, University of Wurzburg) for sharing the fibrillarin antibody with us.	Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belton A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030034; Bianchi-Smiraglia A, 2017, ONCOGENE, V36, P84, DOI 10.1038/onc.2016.178; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das KC, 2010, MOL CELL BIOCHEM, V337, P53, DOI 10.1007/s11010-009-0285-0; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Elkon R, 2015, EMBO REP, V16, P1723, DOI 10.15252/embr.201540717; Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71; Lister JA, 2014, J INVEST DERMATOL, V134, P133, DOI 10.1038/jid.2013.293; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Mandal R, 2016, ONCOGENE, V35, P2547, DOI 10.1038/onc.2015.329; Martin RM, 2007, HISTOCHEM CELL BIOL, V127, P243, DOI 10.1007/s00418-006-0256-4; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Renaud SJ, 2014, J BIOL CHEM, V289, P5025, DOI 10.1074/jbc.M113.523746; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shah SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048533; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Spangler B, 2011, PIGM CELL MELANOMA R, V24, P148, DOI 10.1111/j.1755-148X.2010.00787.x; Spangler B, 2012, INT J CANCER, V130, P2801, DOI 10.1002/ijc.26277; Thomas S, 2008, HUM MOL GENET, V17, P3411, DOI 10.1093/hmg/ddn235; Tice DA, 2002, J BIOL CHEM, V277, P6118, DOI 10.1074/jbc.M111255200; Ting CH, 2016, ONCOTARGET, V7, P40329, DOI 10.18632/oncotarget.9612; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Vincek V, 2010, J CUTAN PATHOL, V37, P3, DOI 10.1111/j.1600-0560.2009.01299.x; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216	45	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5110	5121		10.1038/onc.2017.135	http://dx.doi.org/10.1038/onc.2017.135			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481878				2022-12-28	WOS:000409371100003
J	Hanley, MP; Hahn, MA; Li, AX; Wu, X; Lin, J; Wang, J; Choi, AH; Ouyang, Z; Fong, Y; Pfeifer, GP; Devers, TJ; Rosenberg, DW				Hanley, M. P.; Hahn, M. A.; Li, A. X.; Wu, X.; Lin, J.; Wang, J.; Choi, A. H.; Ouyang, Z.; Fong, Y.; Pfeifer, G. P.; Devers, T. J.; Rosenberg, D. W.			Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia	ONCOGENE			English	Article							ABERRANT CRYPT FOCI; CPG ISLAND METHYLATION; TUMOR-SUPPRESSOR GENES; COLORECTAL-CANCER; EXPRESSION; HYPERMETHYLATION; CELLS; HYPOMETHYLATION; TRANSCRIPTION; MUTATION	Colorectal cancer (CRC) is characterized by genome-wide alterations to DNA methylation that influence gene expression and genomic stability. Less is known about the extent to which methylation is disrupted in the earliest stages of CRC development. In this study, we have combined laser-capture microdissection with reduced representation bisulfite sequencing to identify cancer-associated DNA methylation changes in human aberrant crypt foci (ACF), the earliest putative precursor to CRC. Using this approach, methylation profiles have been generated for 10 KRAS-mutant ACF and 10 CRCs harboring a KRAS mutation, as well as matched samples of normal mucosa. Of 811 differentially methylated regions (DMRs) identified in ACF, 537 (66%) were hypermethylated and 274 (34%) were hypomethylated. DMRs located within intergenic regions were heavily enriched for AP-1 transcription factor binding sites and were frequently hypomethylated. Furthermore, gene ontology analysis demonstrated that DMRs associated with promoters were enriched for genes involved in intestinal development, including homeobox genes and targets of the Polycomb repressive complex 2. Consistent with their role in the earliest stages of colonic neoplasia, 75% of the loci harboring methylation changes in ACF were also altered in CRC samples, though the magnitude of change at these sites was lesser in ACF. Although aberrant promoter methylation was associated with altered gene expression in CRC, this was not the case in ACF, suggesting the insufficiency of methylation changes to modulate gene expression in early colonic neoplasia. Altogether, these data demonstrate that DNA methylation changes, including significant hypermethylation, occur more frequently in early colonic neoplasia than previously believed, and identify epigenomic features of ACF that may provide new targets for cancer chemoprevention or lead to the development of new biomarkers for CRC risk.	[Hanley, M. P.; Rosenberg, D. W.] UConn Hlth, Sch Med, Ctr Mol Med, Farmington, CT USA; [Hanley, M. P.; Rosenberg, D. W.] UConn Hlth, Dept Genet & Genome Sci, Farmington, CT USA; [Hahn, M. A.; Choi, A. H.; Fong, Y.] City Hope Natl Med Ctr, Dept Surg, Duarte, CA USA; [Li, A. X.] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA USA; [Wu, X.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA USA; [Lin, J.; Ouyang, Z.] Jackson Lab Genom Med, Farmington, CT USA; [Wang, J.] City Hope Natl Med Ctr, Beckman Res Inst, Integrat Genom Core, Duarte, CA USA; [Ouyang, Z.] Univ Connecticut, Inst Syst Genom, Farmington, CT USA; [Pfeifer, G. P.] Van Andel Res Inst, Ctr Epigenet, Grand Rapids, MI USA; [Devers, T. J.] UConn Hlth, Sch Med, Div Gastroenterol, Farmington, CT USA; [Rosenberg, D. W.] UConn Hlth, Neag Comprehens Canc Ctr, Colon Canc Prevent Program, Farmington, CT USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Jackson Laboratory; City of Hope; Beckman Research Institute of City of Hope; University of Connecticut; Van Andel Institute	Rosenberg, DW (corresponding author), Univ Connecticut, Ctr Hlth, 263 Farmington Ave, Farmington, CT 06030 USA.	rosenberg@uchc.edu	Lin, Jianan/T-7238-2019; Lin, Jianan/AAV-1954-2020	Lin, Jianan/0000-0003-3894-6902	NIH [CA159976, CA084469, CA160965]; NATIONAL CANCER INSTITUTE [R01CA084469, R01CA159976, P30CA034196, R01CA160965] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA159976 to DWR, and NIH grants CA084469 and CA160965 to GPP.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; American Cancer Society, 2016, CANC FACTS FIGURES 2; Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Benoit YD, 2012, J CELL SCI, V125, P3454, DOI 10.1242/jcs.102061; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y; Campbell JD, 2016, CANCER PREV RES, V9, P119, DOI 10.1158/1940-6207.CAPR-16-0024; Chai H, 2009, ANN CLIN LAB SCI, V39, P331; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Drew DA, 2014, MOL CANCER RES, V12, P823, DOI 10.1158/1541-7786.MCR-13-0624; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333; Freschi G, 2005, INT J MOL MED, V16, P581; Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373; Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190; Haberland M, 2009, GENE DEV, V23, P1625, DOI 10.1101/gad.1809209; Hahn MA, 2015, METHODS MOL BIOL, V1238, P273, DOI 10.1007/978-1-4939-1804-1_14; Hahn MA, 2014, CANCER RES, V74, P3617, DOI 10.1158/0008-5472.CAN-13-3147; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hill ME, 1999, MOL ENDOCRINOL, V13, P1474, DOI 10.1210/me.13.9.1474; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Inoue A, 2015, BRIT J CANCER, V112, P403, DOI 10.1038/bjc.2014.545; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawakami K, 2006, BRIT J CANCER, V94, P593, DOI 10.1038/sj.bjc.6602940; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Noordermeer D, 2011, SCIENCE, V334, P222, DOI 10.1126/science.1207194; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; Pabst O, 1999, DEVELOPMENT, V126, P2215; Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rosenberg DW, 2007, CANCER RES, V67, P3551, DOI 10.1158/0008-5472.CAN-07-0343; Sakai E, 2014, WORLD J GASTROENTERO, V20, P978, DOI 10.3748/wjg.v20.i4.978; Sarabi MM, 2015, CELL BIOCHEM FUNCT, V33, P427, DOI 10.1002/cbf.3126; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Silviera ML, 2012, CANCER PREV RES, V5, P374, DOI 10.1158/1940-6207.CAPR-11-0336; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yagi K, 2012, AM J PATHOL, V180, P616, DOI 10.1016/j.ajpath.2011.10.010; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Zimmerman SG, 2010, DEV BIOL, V340, P54, DOI 10.1016/j.ydbio.2010.01.021	57	48	49	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5035	5044		10.1038/onc.2017.130	http://dx.doi.org/10.1038/onc.2017.130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459462	Green Accepted			2022-12-28	WOS:000408768800008
J	Raschell, G; Melino, G; Malewicz, M				Raschell, G.; Melino, G.; Malewicz, M.			New factors in mammalian DNA repair-the chromatin connection	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; PK-MEDIATED PHOSPHORYLATION; DAMAGE RESPONSE; TRANSCRIPTIONAL REGULATION; PROTEIN-KINASE; GENOME INTEGRITY; STRUCTURAL BASIS; ATM; PROMOTES; XLF	In response to DNA damage mammalian cells activate a complex network of stress response pathways collectively termed DNA damage response (DDR). DDR involves a temporary arrest of the cell cycle to allow for the repair of the damage. DDR also attenuates gene expression by silencing global transcription and translation. Main function of DDR is, however, to prevent the fixation of debilitating changes to DNA by activation of various DNA repair pathways. Proper execution of DDR requires careful coordination between these interdependent cellular responses. Deregulation of some aspects of DDR orchestration is potentially pathological and could lead to various undesired outcomes such as DNA translocations, cellular transformation or acute cell death. It is thus critical to understand the regulation of DDR in cells especially in the light of a strong linkage between the DDR impairment and the occurrence of common human diseases such as cancer. In this review we focus on recent advances in understanding of mammalian DNA repair regulation and a on the function of PAXX/c9orf142 and ZNF281 proteins that recently had been discovered to play a role in that process. We focus on regulation of double-strand DNA break (DSB) repair via the non-homologous end joining pathway, as unrepaired DSBs are the primary cause of pathological cellular states after DNA damage. Interestingly these new factors operate at the level of chromatin, which reinforces a notion of a central role of chromatin structure in the regulation of cellular DDR regulation.	[Raschell, G.] ENEA Res Ctr Casaccia, Lab Biosafety & Risk Assessment, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Melino, G.; Malewicz, M.] MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England	Italian National Agency New Technical Energy & Sustainable Economics Development; University of Rome Tor Vergata; University of Leicester	Malewicz, M (corresponding author), MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm531@le.ac.uk			Medical Research Council, UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [AIRC 2014 IG15653, AIRC 5xmille MCO9979, AIRC 2011 IG11955]; Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD); MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_UP_A600_1109, MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD)(Fondazione Roma); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by the Medical Research Council, UK; grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC): AIRC 2014 IG15653 (to GM), AIRC 5xmille MCO9979 (to GM) and AIRC 2011 IG11955 (to GM), Fondazione Roma malattie Non trasmissibili Cronico-Degenerative (NCD) Grant (to GM).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adamowicz M, 2016, CELL REP, V16, P2068, DOI 10.1016/j.celrep.2016.07.038; Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Alam SK, 2016, CELL DEATH DIFFER, V23, P707, DOI 10.1038/cdd.2015.133; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Balmus G, 2016, GENE DEV, V30, P2152, DOI 10.1101/gad.290510.116; Barroso-Gonzalez J, 2016, CELL DEATH DIFFER, V23, P1448, DOI 10.1038/cdd.2016.23; Beck C, 2014, EXP CELL RES, V329, P18, DOI 10.1016/j.yexcr.2014.07.003; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Boehler C, 2011, METHODS MOL BIOL, V780, P313, DOI 10.1007/978-1-61779-270-0_19; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Brouwer I, 2016, NATURE, V535, P566, DOI 10.1038/nature18643; Bruinsma W, 2016, ONCOGENE; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Bunch H, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0040-x; Callen E, 2012, IMMUNITY, V37, P971, DOI 10.1016/j.immuni.2012.10.007; Caron P, 2015, CELL REP, V13, P1, DOI 10.1016/j.celrep.2015.10.024; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; Craxton A, 2015, CELL DEATH DIFFER, V22, P890, DOI 10.1038/cdd.2015.22; Cuella-Martin R, 2016, MOL CELL, V64, P51, DOI 10.1016/j.molcel.2016.08.002; Dantuma NP, 2016, EMBO J, V35, P6, DOI 10.15252/embj.201592595; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; El Ghamrasni S, 2016, ONCOGENE, V35, P4836, DOI 10.1038/onc.2016.16; Fattah KR, 2008, DNA REPAIR, V7, P762, DOI 10.1016/j.dnarep.2008.02.008; Fidalgo M, 2016, CELL STEM CELL, V19, P355, DOI 10.1016/j.stem.2016.05.025; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Gibbs-Seymour I, 2016, MOL CELL, V62, P432, DOI 10.1016/j.molcel.2016.03.008; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Goggolidou P, 2014, DEVELOPMENT, V141, P3966, DOI 10.1242/dev.107755; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Goodarzi AA, 2013, ADV GENET, V82, P1, DOI 10.1016/B978-0-12-407676-1.00001-9; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gunn AR, 2016, J CELL SCI, V129, P3845, DOI 10.1242/jcs.193375; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn S, 2014, J MOL MED, V92, P571, DOI 10.1007/s00109-014-1160-3; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Han BY, 2016, GENE DEV, V30, P1509, DOI 10.1101/gad.279406.116; Hedstrom E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.250; Izhar L, 2015, CELL REP, V11, P1486, DOI 10.1016/j.celrep.2015.04.053; Jang ER, 2010, EXP MOL MED, V42, P195, DOI 10.3858/emm.2010.42.3.020; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kumar V, 2016, P NATL ACAD SCI USA, V113, P10619, DOI 10.1073/pnas.1611882113; Law DJ, 2006, NUCLEIC ACIDS RES, V34, P1342, DOI 10.1093/nar/gkl022; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lescale C, 2016, CELL REP, V16, P2967, DOI 10.1016/j.celrep.2016.08.069; Li G, 2008, MOL CELL, V31, P631, DOI 10.1016/j.molcel.2008.07.017; Li Z, 2016, CELL DEATH DIFFER, V23, P1765, DOI 10.1038/cdd.2016.65; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu H, 2014, GENOME BIOL EVOL, V6, P510, DOI 10.1093/gbe/evu030; Liu XS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9325; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; Luijsterburg MS, 2016, MOL CELL, V61, P547, DOI 10.1016/j.molcel.2016.01.019; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Luscombe NM, 2000, GENOME BIOL, V1; Malewicz M, 2014, EXP CELL RES, V329, P94, DOI 10.1016/j.yexcr.2014.08.032; Malewicz M, 2011, GENE DEV, V25, P2031, DOI 10.1101/gad.16872411; Mallo M, 2010, DEV BIOL, V344, P7, DOI 10.1016/j.ydbio.2010.04.024; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mehrotra PV, 2011, MOL CELL, V41, P46, DOI 10.1016/j.molcel.2010.12.008; Messina DN, 2004, GENOME RES, V14, P2041, DOI 10.1101/gr.2584104; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640; Montenegro MF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.85; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Musselman CA, 2012, P NATL ACAD SCI USA, V109, P787, DOI 10.1073/pnas.1113655109; Nakahashi H, 2013, CELL REP, V3, P1678, DOI 10.1016/j.celrep.2013.04.024; Nicolai S, 2015, AGING-US, V7, P1050, DOI 10.18632/aging.100858; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Paiva C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.161; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pederiva C, 2016, CELL DEATH DIFFER, V23, P1648, DOI 10.1038/cdd.2016.58; Petrus NCM, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0105-z; Pieraccioli M, 2016, ONCOGENE, V35, P2592, DOI 10.1038/onc.2015.320; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Roach JC, 2007, P NATL ACAD SCI USA, V104, P16245, DOI 10.1073/pnas.0707757104; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Shah MY, 2016, ONCOGENE, V35, P5905, DOI 10.1038/onc.2016.116; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Starnes LM, 2016, GENE DEV, V30, P149, DOI 10.1101/gad.268797.115; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Thacker J, 2004, DNA REPAIR, V3, P1081, DOI 10.1016/j.dnarep.2004.04.012; Thorslund T, 2015, NATURE, V527, P389, DOI 10.1038/nature15401; Tong KI, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.298; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.198; Wang Y, 2016, NUCLEIC ACIDS RES, V45, P1177; Waters CA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5286; Waters CA, 2014, DNA REPAIR, V17, P39, DOI 10.1016/j.dnarep.2014.02.008; Wilson MD, 2016, NATURE, V536, P100, DOI 10.1038/nature18951; Wu GK, 2006, CELL CYCLE, V5, P1592, DOI 10.4161/cc.5.15.3127; Xing MT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7233; Xu Y, 2012, MOL CELL, V48, P723, DOI 10.1016/j.molcel.2012.09.026; Yang Q, 2016, CELL DEATH DIFFER, V23, P1406, DOI 10.1038/cdd.2016.29; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang CZY, 2010, BBA-REV CANCER, V1806, P36, DOI 10.1016/j.bbcan.2010.03.002; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zuniga A, 2015, DEVELOPMENT, V142, P3810, DOI 10.1242/dev.125757	123	15	15	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4673	4681		10.1038/onc.2017.60	http://dx.doi.org/10.1038/onc.2017.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394347	hybrid, Green Published			2022-12-28	WOS:000407702400001
J	Yurugi, H; Marini, F; Weber, C; David, K; Zhao, Q; Binder, H; Desaubry, L; Rajalingam, K				Yurugi, H.; Marini, F.; Weber, C.; David, K.; Zhao, Q.; Binder, H.; Desaubry, L.; Rajalingam, K.			Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours	ONCOGENE			English	Article							CELL-PROLIFERATION; SIGNALING PATHWAYS; RAS; ACTIVATION; CRAF; DIMERIZATION; MUTATIONS; BRAF	KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a direct RAS effector protein, is required for KRAS-mediated tumourigenesis. Thus, the molecular mechanisms driving the activation of CRAF are intensively studied. Prohibitin 1 (PHB1) is an evolutionarily conserved adaptor protein and interaction of CRAF with PHB1 at the plasma membrane is essential for CRAF activation. Here, we demonstrate that PHB1 is highly expressed in NSCLC patients and correlates with poor survival. Targeting of PHB1 with two chemical ligands (rocaglamide and fluorizoline) inhibits epidermal growth factor (EGF)/RAS-induced CRAF activation. Consistently, treatment with rocaglamide inhibited proliferation, migration and anchorage-independent growth of KRAS-mutated lung carcinoma cell lines. Surprisingly, rocaglamide treatment inhibited Ras-GTP loading in KRAS-mutated cells as well as in EGF-stimulated cells. Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models. Our results suggest rocaglamide as a RAS inhibitor and that targeting plasma membrane-associated PHB1 with chemical ligands would be a viable therapeutic strategy to combat KRAS-mediated NSCLCs.	[Yurugi, H.; Rajalingam, K.] Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Mainz, Germany; [Marini, F.; Binder, H.] Univ Med Ctr Mainz, Inst Med Biostat Epidemiol & Informat, Mainz, Germany; [Weber, C.; David, K.] Indivumed GmbH, Hamburg, Germany; [Zhao, Q.; Desaubry, L.] Univ Strasbourg, Therapeut Innovat Lab, CNRS, UMR7200, Strasbourg, France; [Desaubry, L.] Tianjin Univ Sci & Technol, Coll Biotechnol, Sinofrench Joint Lab Food Nutr Safety & Med Chem, Tianjin, Peoples R China; [Rajalingam, K.] German Canc Consortium DKTK, DKFZ, Partner Site Frankfurt Mainz, UCT, Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tianjin University Science & Technology; Helmholtz Association; German Cancer Research Center (DKFZ)	Rajalingam, K (corresponding author), JGU Mainz, Univ Med Ctr Mainz, Inst Immunol, Mol Signaling Unit FZI, Langebeck St 1, D-55131 Mainz, Germany.	Krishna@uni-mainz.de; Krishna@uni-mainz.de	Marini, Federico/AAQ-2427-2020; Desaubry, Laurent G/R-5446-2017; Binder, Harald/C-7413-2009	Marini, Federico/0000-0003-3252-7758; Desaubry, Laurent G/0000-0002-1192-2970; Binder, Harald/0000-0002-5666-8662	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing; Association pour la Recherche sur le Cancer; 'Association Nationale de la Recherche et de la Technologie' (ANRT)	BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing(Boehringer Ingelheim); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); 'Association Nationale de la Recherche et de la Technologie' (ANRT)	We thank Alexandra Dimitrijevic for the excellent technical assistance, and Dr Melzer for her help and advice with the animal experiments. We thank Professors Tyler Jacks, Susan Horwitz, Scott Randell, Channing Der and Ulf Rapp for contributing several constructs and cell lines that are employed in this study. We thank Professor Hartmut Juhl and Dr Bernd Gromoll (Indivumed GmbH) for assistance with the analyses of the NSCLC tissue microarrays. This work is supported through a BIS-PLUS3 fellowship of the Boehringer Ingelheim Stiftuing to KR. KR is a Heisenberg Professor of the DFG (RA1739/4-1) and a GFK fellow. A generous financial support for this work was provided by the 'Association pour la Recherche sur le Cancer' to LD. We are also grateful to AAREC Filia Research and the 'Association Nationale de la Recherche et de la Technologie' (ANRT) for fellowships to QZ.	Ande SR, 2010, BIOCHEM CELL BIOL, V88, P553, DOI [10.1139/O09-177, 10.1139/o09-177]; Becker MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.528; Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Chiu CF, 2013, ONCOGENE, V32, P777, DOI 10.1038/onc.2012.86; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Doudican NA, 2017, ONCOGENE, V36, P423, DOI 10.1038/onc.2016.214; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 2011, NAT MED, V17, P286, DOI 10.1038/nm0311-286; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Fischer A, 2009, J BIOL CHEM, V284, P3183, DOI 10.1074/jbc.M804795200; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Luan Z, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-38; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Merkwirth C, 2008, GENE DEV, V22, P476, DOI 10.1101/gad.460708; Merkwirth C, 2009, BBA-MOL CELL RES, V1793, P27, DOI 10.1016/j.bbamcr.2008.05.013; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Perez-Perarnau A, 2014, ANGEW CHEM INT EDIT, V53, P10150, DOI 10.1002/anie.201405758; Polier G, 2012, CHEM BIOL, V19, P1093, DOI 10.1016/j.chembiol.2012.07.012; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Yurugi H, 2013, BIOCHEM BIOPH RES CO, V434, P376, DOI 10.1016/j.bbrc.2013.03.085; Yurugi H, 2012, BIOCHEM BIOPH RES CO, V420, P275, DOI 10.1016/j.bbrc.2012.02.149	37	19	23	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4778	4789		10.1038/onc.2017.93	http://dx.doi.org/10.1038/onc.2017.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414306				2022-12-28	WOS:000407702400010
J	Foo, TK; Tischkowitz, M; Simhadri, S; Boshari, T; Zayed, N; Burke, KA; Berman, SH; Blecua, P; Riaz, N; Huo, Y; Ding, YC; Neuhausen, SL; Weigelt, B; Reis, JS; Foulkes, WD; Xia, B				Foo, T. K.; Tischkowitz, M.; Simhadri, S.; Boshari, T.; Zayed, N.; Burke, K. A.; Berman, S. H.; Blecua, P.; Riaz, N.; Huo, Y.; Ding, Y. C.; Neuhausen, S. L.; Weigelt, B.; Reis-Filho, J. S.; Foulkes, W. D.; Xia, B.			Compromised BRCA1-PALB2 interaction is associated with breast cancer risk	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; SOMATIC MUTATIONS; FANCONI-ANEMIA; FALLOPIAN-TUBE; COPY NUMBER; PALB2; GENES; BRCA2; LANDSCAPE; GERMLINE	The major breast cancer suppressor proteins BRCA1 and BRCA2 play essential roles in homologous recombination (HR)-mediated DNA repair, which is thought to be critical for tumor suppression. The two BRCA proteins are linked by a third tumor suppressor, PALB2, in the HR pathway. While truncating mutations in these genes are generally pathogenic, interpretation of missense variants remains a challenge. To date, patient-derived missense variants that disrupt PALB2 binding have been identified in BRCA1 and BRCA2; however, there has not been sufficient evidence to prove their pathogenicity in humans, and no variants in PALB2 that disrupt either its BRCA1 or BRCA2 binding have been reported. Here we report on the identification of a novel PALB2 variant, c.104T>C (p.L35P), that segregates in a family with a strong history of breast cancer. Functional analyses showed that L35P abrogates the PALB2-BRCA1 interaction and completely disables its abilities to promote HR and confer resistance to platinum salts and PARP inhibitors. Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P. Parallel analyses of other germline variants in the PALB2 N-terminal BRCA1-binding domain identified multiple variants that affect HR function to varying degrees, suggesting their possible contribution to cancer development. Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression.	[Foo, T. K.; Simhadri, S.; Huo, Y.; Xia, B.] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA; [Tischkowitz, M.] Univ Cambridge, Dept Med Genet, Cambridge, England; [Boshari, T.; Zayed, N.; Foulkes, W. D.] McGill Univ, Dept Med Genet, Jewish Gen Hosp, Montreal, PQ, Canada; [Boshari, T.; Zayed, N.; Foulkes, W. D.] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Burke, K. A.; Berman, S. H.; Weigelt, B.; Reis-Filho, J. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Blecua, P.; Riaz, N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA; [Ding, Y. C.; Neuhausen, S. L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Cambridge; McGill University; Lady Davis Institute; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; City of Hope; Beckman Research Institute of City of Hope	Xia, B (corresponding author), Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	xiabi@cinj.rutgers.edu	Foo, Tzeh Keong/AAE-5830-2021; Tischkowitz, Marc/O-4452-2018; Foulkes, William D./AAR-9586-2021; Blecua, Pedro/AAA-4589-2019	Foo, Tzeh Keong/0000-0003-0168-7054; Tischkowitz, Marc/0000-0002-7880-0628; Foulkes, William D./0000-0001-7427-4651; Blecua, Pedro/0000-0002-1012-0300; Boshari, Talia/0000-0002-4838-9276; Riaz, Nadeem/0000-0001-9873-5862; HUO, YANYING/0000-0003-4747-4951	National Cancer Institute [R0A138804, R01CA188096, R01CA184585, P30CA008748]; Susan G Komen; Quebec Breast Cancer Foundation; European Union Seventh Framework Program [2007Y2013]; European Research Council [310018]; Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School; Shared Resource of The Rutgers Cancer Institute of New Jersey [P30CA072720]; NIH Shared Instrumentation Grant [1 S10 RR025468]; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA188096, R01CA138804, R01CA184585] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen(Susan G. Komen Breast Cancer Foundation); Quebec Breast Cancer Foundation; European Union Seventh Framework Program(European Commission); European Research Council(European Research Council (ERC)European Commission); Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School; Shared Resource of The Rutgers Cancer Institute of New Jersey; NIH Shared Instrumentation Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Olga Aleynikova MD, Andrew Shuen MD, Nelly Sabbaghian MSc, Sonya Zaor MSc and Nancy Hamel MSc for their assistance. BX is supported by the National Cancer Institute (R0A138804 and R01CA188096). WDF is funded by Susan G Komen and the Quebec Breast Cancer Foundation. KAB, SHB, BW and JRF are supported in part by a Cancer Center Support Grant of the National Cancer Institute (grant No P30CA008748). MT is funded by the European Union Seventh Framework Program (2007Y2013)/European Research Council (Grant No. 310018). SLN is supported by Morris and Horowitz Endowed Professorship and the National Cancer Institute (R01CA184585). NZ is a Mitch Garber Postdoctoral Fellow. This research was supported by the Flow Cytometry Core Facility of Rutgers Robert Wood Johnson Medical School, a Shared Resource of The Rutgers Cancer Institute of New Jersey (P30CA072720), and a NIH Shared Instrumentation Grant (1 S10 RR025468).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673]; Blanco A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067538; Bogdanova N, 2011, BREAST CANCER RES TR, V126, P545, DOI 10.1007/s10549-010-1290-4; Buisson R, 2012, NUCLEIC ACIDS RES, V40, P10312, DOI 10.1093/nar/gks807; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Ding YC, 2011, BREAST CANCER RES TR, V126, P771, DOI 10.1007/s10549-010-1195-2; Ding YC, 2011, BREAST CANCER RES TR, V126, P227, DOI 10.1007/s10549-010-1271-7; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Hartford SA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006236; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Hu Y, 2014, CANCER INFORM, V13, P13, DOI 10.4137/CIN.S13495; Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Pennington KP, 2014, CLIN CANCER RES, V20, P764, DOI 10.1158/1078-0432.CCR-13-2287; Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840; Piscuoglio S, 2016, J PATHOL, V238, P381, DOI 10.1002/path.4675; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Simhadri S, 2014, J BIOL CHEM, V289, P24617, DOI 10.1074/jbc.M114.566141; Sy SMH, 2009, J BIOL CHEM, V284, P18302, DOI 10.1074/jbc.M109.016717; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Teo ZL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3392; Tischkowitz M, 2008, PROSTATE, V68, P675, DOI 10.1002/pros.20729; Tischkowitz M, 2007, P NATL ACAD SCI USA, V104, P6788, DOI 10.1073/pnas.0701724104; Tischkowitz M, 2012, HUM MUTAT, V33, P674, DOI 10.1002/humu.22022; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Tu ND, 2015, BREAST CANCER RES TR, V149, P547, DOI 10.1007/s10549-014-3260-8; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang L, 2014, INT J BIOL SCI, V10, P563, DOI 10.7150/ijbs.8579; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zheng YL, 2012, CANCER-AM CANCER SOC, V118, P1362, DOI 10.1002/cncr.26388	55	53	57	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4161	4170		10.1038/onc.2017.46	http://dx.doi.org/10.1038/onc.2017.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319063	Green Accepted, Green Submitted			2022-12-28	WOS:000405835800007
J	Hu, X; Zhao, Y; Wei, L; Zhu, B; Song, D; Wang, J; Yu, L; Wu, J				Hu, X.; Zhao, Y.; Wei, L.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.			CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis	ONCOGENE			English	Article							NF-KAPPA-B; ACTIVATION; PROTEIN; GROWTH; CANCER; PATHWAY; GENOME; BIM	Hepatocellular carcinoma (HCC) is one of the most malignant tumors with high rate of recurrence and metastasis. Coiled-coil domain-containing protein 178 (CCDC178) has been reported to be mutated in HCC, whereas its role in physiological and pathologic process, including in human cancer, remains largely unknown. Here, we found that CCDC178 is upregulated in HCC tissues and its overexpression is correlated with pathological stage (P = 0.003). CCDC178 deficiency reduced the anchorageindependent growth and anoikis resistance of HCC cells, and inhibited the HCC metastasis in vivo. Mechanistically, CCDC178 associated with BRCA1-associated protein 2 (BRAP2), a negative regulator of extracellular signal-regulated kinase (ERK) pathway, and promoted its degradation. Moreover, CCDC178 deficiency impaired the ERK activation, which is dependent on BRAP2. In conclusion, we identify CCDC178 as a novel candidate oncogene involved in anoikis resistance and HCC metastasis, and raise the possibility that CCDC178 may be a new therapeutic target for HCC.	[Hu, X.; Zhao, Y.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.] Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, 2005 SongHu Rd, Shanghai 200438, Peoples R China; [Hu, X.; Zhao, Y.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.] Fudan Univ, Sch Life Sci, 2005 SongHu Rd, Shanghai 200438, Peoples R China; [Wei, L.] 401 Hosp PLA, Dept Oncol, Qingdao, Peoples R China	Fudan University; Fudan University	Wu, J (corresponding author), Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, 2005 SongHu Rd, Shanghai 200438, Peoples R China.; Wu, J (corresponding author), Fudan Univ, Sch Life Sci, 2005 SongHu Rd, Shanghai 200438, Peoples R China.	jiaxue@fudan.edu.cn	wang, juanjuan/GYV-5540-2022	Wang, Juanjuan/0000-0001-5477-8860; Hu, xiaoding/0000-0002-3144-1859	National Key Research and Development Plan [2016YFC0902401]; National Key Sci-Tech Special Project of China [2013ZX10002010-08]; National Natural Science Foundation of China [81272250, 81472619]	National Key Research and Development Plan; National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Yongjun Dang at School of Basic Medical Science, Fudan University for fruitful scientific discussions and sharing some reagents. This work was supported by National Key Research and Development Plan (2016YFC0902401 to JW); the National Key Sci-Tech Special Project of China (2013ZX10002010-08 to JW) and the National Natural Science Foundation of China (81272250 and 81472619 to JW).	Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen C, 2008, J BIOL CHEM, V283, P12789, DOI 10.1074/jbc.M709305200; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galante JM, 2009, J SURG RES, V152, P18, DOI 10.1016/j.jss.2008.05.017; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Kairouz-Wahbe R, 2008, P NATL ACAD SCI USA, V105, P1528, DOI 10.1073/pnas.0711357105; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Malin D, 2015, ONCOGENE, V34, P5626, DOI 10.1038/onc.2015.12; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matheny SA, 2006, METHOD ENZYMOL, V407, P237, DOI 10.1016/S0076-6879(05)07020-5; Matheny SA, 2009, J BIOL CHEM, V284, P11007, DOI 10.1074/jbc.R800082200; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Takashima O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058911; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810; Zhang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13750; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x	35	23	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4047	4059		10.1038/onc.2017.10	http://dx.doi.org/10.1038/onc.2017.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319061				2022-12-28	WOS:000405379900010
J	Thaper, D; Vahid, S; Nip, KM; Moskalev, I; Shan, X; Frees, S; Roberts, ME; Ketola, K; Harder, KW; Gregory-Evans, C; Bishop, JL; Zoubeidi, A				Thaper, D.; Vahid, S.; Nip, K. M.; Moskalev, I.; Shan, X.; Frees, S.; Roberts, M. E.; Ketola, K.; Harder, K. W.; Gregory-Evans, C.; Bishop, J. L.; Zoubeidi, A.			Targeting Lyn regulates Snail family shuttling and inhibits metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RESISTANT PROSTATE-CANCER; BREAST-CANCER; GENE-EXPRESSION; TYROSINE KINASE; GSK-3-BETA-MEDIATED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; LEUKEMIA-CELLS; IN-VIVO	The acquisition of an invasive phenotype by epithelial cells occurs through a loss of cellular adhesion and polarity, heralding a multistep process that leads to metastatic dissemination. Since its characterization in 1995, epithelial-mesenchymal transition (EMT) has been closely linked to the metastatic process. As a defining aspect of EMT, loss of cell adhesion through downregulation of E-cadherin is carried out by several transcriptional repressors; key among them the SNAI family of transcription factors. Here we identify for the first time that Lyn kinase functions as a key modulator of SNAI family protein localization and stability through control of the Vav-Rac1-PAK1 (Vav-Rac1-p21-activated kinase) pathway. Accordingly, targeting Lyn in vitro reduces EMT and in vivo reduces metastasis of primary tumors. We also demonstrate the clinical relevance of targeting Lyn as a key player controlling EMT; patient samples across many cancers revealed a strong negative correlation between Lyn and E-cadherin, and high Lyn expression in metastatic tumors as well as metastasis-prone primary tumors. This work reveals a novel pancancer mechanism of Lyndependent control of EMT and further underscores the role of this kinase in tumor progression.	[Thaper, D.; Vahid, S.; Nip, K. M.; Moskalev, I.; Frees, S.; Ketola, K.; Bishop, J. L.; Zoubeidi, A.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Thaper, D.; Vahid, S.; Nip, K. M.; Zoubeidi, A.] Univ British Columbia, Dept Urol Sci, Fac Med, Vancouver, BC, Canada; [Shan, X.; Gregory-Evans, C.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Vancouver, BC, Canada; [Roberts, M. E.; Harder, K. W.] Univ British Columbia, Dept Microbiol & Immunol, Fac Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Zoubeidi, A (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	azoubeidi@prostatecentre.com	Gregory-Evans, Cheryl Y/G-9550-2011; Ketola, Kirsi/O-1071-2016	Ketola, Kirsi/0000-0001-6484-9861; Roberts, Morgan/0000-0002-5850-7985	Terry Fox Research Institute; Prostate Cancer Canada; Canadian Institutes of Health Research; Michael Smith Foundation	Terry Fox Research Institute; Prostate Cancer Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation(Michael Smith Foundation for Health Research)	This work was supported by the Terry Fox Research Institute, Michael Smith Foundation, Prostate Cancer Canada and Canadian Institutes of Health Research. We would like to thank Dr Peter Black for the UC13 and UC13-luciferase cells, and Dr Yuzhou Wang for Oncomine access. We also appreciate the assistance of Eliana Beraldi and Shannon Awery for experimental support.	Bates RC, 2001, CANCER RES, V61, P5275; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Choi YL, 2010, CANCER RES, V70, P2296, DOI 10.1158/0008-5472.CAN-09-3141; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; De Mesquita DD, 2001, FEBS LETT, V502, P84, DOI 10.1016/S0014-5793(01)02669-2; Delaney MK, 2012, ARTERIOSCL THROM VAS, V32, P2761, DOI 10.1161/ATVBAHA.112.254920; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eswaran J, 2012, CLIN CANCER RES, V18, P3743, DOI 10.1158/1078-0432.CCR-11-1952; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gelman IH, 2014, MOL CANCER RES, V12, P1470, DOI 10.1158/1541-7786.MCR-13-0490-T; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan H, 2008, MOL CANCER THER, V7, P1807, DOI 10.1158/1535-7163.MCT-08-0058; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; HIBBS ML, 1995, GENE, V156, P175, DOI 10.1016/0378-1119(95)00022-X; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Jager W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059536; Kantarjian H, 2010, CANCER-AM CANCER SOC, V116, P2665, DOI 10.1002/cncr.25079; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Kasahara K, 2004, J CELL BIOL, V165, P641, DOI 10.1083/jcb.200403011; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Kim J, 2014, EMBO REP, V15, P1062, DOI 10.15252/embr.201438587; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rahaman SO, 2011, J BIOL CHEM, V286, P7010, DOI 10.1074/jbc.M110.192450; Ren XP, 2002, CANCER BIOL THER, V1, P703, DOI 10.4161/cbt.323; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Stettner AR, 2005, CANCER RES, V65, P5535, DOI 10.1158/0008-5472.CAN-04-3688; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu J, 2008, BLOOD, V111, P3821, DOI 10.1182/blood-2007-08-109330; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yokota A, 2007, BLOOD, V109, P306, DOI 10.1182/blood-2006-03-013250; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zardan A, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.30; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	66	25	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3964	3975		10.1038/onc.2017.5	http://dx.doi.org/10.1038/onc.2017.5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288135				2022-12-28	WOS:000405379900003
J	Liu, Z; Yanagisawa, K; Griesing, S; Iwai, M; Kano, K; Hotta, N; Kajino, T; Suzuki, M; Takahashi, T				Liu, Z.; Yanagisawa, K.; Griesing, S.; Iwai, M.; Kano, K.; Hotta, N.; Kajino, T.; Suzuki, M.; Takahashi, T.			TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas	ONCOGENE			English	Article							DNA-DAMAGE; THYROID TRANSCRIPTION; CHK1; ONCOGENE; EXPRESSION; CANCER; GENE; ACTIVATION; SURVIVAL; TARGETS	TTF-1, also known as NKX2-1, is a transcription factor that has indispensable roles in both lung development and physiology. We and others have reported that TTF-1 frequently exhibits high expression with increased copy number in lung adenocarcinomas, and also has a role as a lineage-survival oncogene through transcriptional activation of crucial target genes including ROR1 and LMO3. In the present study, we employed a global proteomic search for proteins that interact with TTF-1 in order to provide a more comprehensive picture of this still enigmatic lineage-survival oncogene. Our results unexpectedly revealed a function independent of its transcriptional activity, as TTF-1 was found to interact with DDB1 and block its binding to CHK1, which in turn attenuated ubiquitylation and subsequent degradation of CHK1. Furthermore, TTF-1 overexpression conferred resistance to cellular conditions under DNA replication stress (RS) and prevented an increase in consequential DNA double-strand breaks, as reflected by attenuated induction of pCHK2 and gamma H2AX. Our findings suggest that the novel non-transcriptional function of TTF-1 identified in this study may contribute to lung adenocarcinoma development by conferring tolerance to DNA RS, which is known to be inherently elicited by activation of various oncogenes.	[Liu, Z.; Yanagisawa, K.; Griesing, S.; Iwai, M.; Kano, K.; Hotta, N.; Kajino, T.; Suzuki, M.; Takahashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi, Japan	Nagoya University	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Liu, Zhuoran/0000-0002-6679-4136	Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; China Scholarship Council; Grants-in-Aid for Scientific Research [16H06277, 25293191, 15H05910, 25640076] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); China Scholarship Council(China Scholarship Council); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by a Grant-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science (JSPS) and by a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. Zhuoran Liu was supported by a fellowship from the China Scholarship Council.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Cardnell RJG, 2015, CLIN CANCER RES, V21, P3480, DOI 10.1158/1078-0432.CCR-14-3286; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo TN, 2015, NAT MED, V21, P407, DOI 10.1038/nm.3807; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Meuth M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-21; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yamaguchi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10060; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	41	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3740	3748		10.1038/onc.2016.524	http://dx.doi.org/10.1038/onc.2016.524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192407				2022-12-28	WOS:000404349700009
J	Rasheed, SAK; Leong, HS; Lakshmanan, M; Raju, A; Dadlani, D; Chong, FT; Shannon, NB; Rajarethinam, R; Skanthakumar, T; Tan, EY; Hwang, JSG; Lim, KH; Tan, DSW; Ceppi, P; Wang, M; Tergaonkar, V; Casey, PJ; Iyer, NG				Rasheed, Suhail Ahmed Kabeer; Leong, Hui Sun; Lakshmanan, Manikandan; Raju, Anandhkumar; Dadlani, Dhivya; Chong, Fui-Teen; Shannon, Nicholas B.; Rajarethinam, Ravisankar; Skanthakumar, Thakshayeni; Tan, Ern Yu; Hwang, Jacqueline Siok Gek; Lim, Kok Hing; Tan, Daniel Shao-Weng; Ceppi, Paolo; Wang, Mei; Tergaonkar, Vinay; Casey, Patrick J.; Iyer, N. Gopalakrishna			GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers	ONCOGENE			English	Article							HETEROTRIMERIC G-PROTEINS; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; STEM-CELLS; MESENCHYMAL TRANSITION; MICROARRAY DATA; BETA-CATENIN; LUNG-CANCER; G12 FAMILY; METASTASIS	Treatment failure in solid tumors occurs due to the survival of specific subpopulations of cells that possess tumor-initiating (TIC) phenotypes. Studies have implicated G protein-coupled-receptors (GPCRs) in cancer progression and the acquisition of TIC phenotypes. Many of the implicated GPCRs signal through the G protein GNA13. In this study, we demonstrate that GNA13 is upregulated in many solid tumors and impacts survival and metastases in patients. GNA13 levels modulate drug resistance and TIC-like phenotypes in patient-derived head and neck squamous cell carcinoma (HNSCC) cells in vitro and in vivo. Blockade of GNA13 expression, or of select downstream pathways, using small-molecule inhibitors abrogates GNA13-induced TIC phenotypes, rendering cells vulnerable to standard-of-care cytotoxic therapies. Taken together, these data indicate that GNA13 expression is a potential prognostic biomarker for tumor progression, and that interfering with GNA13-induced signaling provides a novel strategy to block TICs and drug resistance in HNSCCs.	[Rasheed, Suhail Ahmed Kabeer; Dadlani, Dhivya; Wang, Mei; Casey, Patrick J.; Iyer, N. Gopalakrishna] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore; [Leong, Hui Sun; Chong, Fui-Teen; Tan, Daniel Shao-Weng; Iyer, N. Gopalakrishna] Natl Canc Ctr, Canc Therapeut Res Lab, Singapore, Singapore; [Lakshmanan, Manikandan; Raju, Anandhkumar; Tergaonkar, Vinay] Inst Mol & Cell Biol, Mouse Models Human Canc Unit, Singapore, Singapore; [Shannon, Nicholas B.; Skanthakumar, Thakshayeni; Iyer, N. Gopalakrishna] Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; [Rajarethinam, Ravisankar] Adv Mol Pathol Lab, Singapore, Singapore; [Tan, Ern Yu] Tan Tock Seng Hosp, Dept Gen Surg, Singapore, Singapore; [Hwang, Jacqueline Siok Gek; Lim, Kok Hing] Singapore Gen Hosp, Dept Pathol, Singapore, Singapore; [Ceppi, Paolo] Friedrich Alexander Univ Erlangen Nuernberg, IZKF Jr Res Grp, Erlangen, Germany; [Casey, Patrick J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA	National University of Singapore; National Cancer Centre Singapore (NCCS); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Cancer Centre Singapore (NCCS); Tan Tock Seng Hospital; Singapore General Hospital; University of Erlangen Nuremberg; Duke University	Casey, PJ; Iyer, NG (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore.; Iyer, NG (corresponding author), Natl Canc Ctr, Canc Therapeut Res Lab, Singapore, Singapore.; Iyer, NG (corresponding author), Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore.	patrick.casey@duke-nus.edu.sg; gopaliyer@nccs.com.sg	Ceppi, Paolo/GPS-8668-2022; Rasheed, Suhail Ahmed Kabeer/P-1257-2019	Rasheed, Suhail Ahmed Kabeer/0000-0002-7674-7560; Casey, Patrick/0000-0002-7366-9309; Wang, Mei/0000-0001-6887-6840; Ceppi, Paolo/0000-0002-3632-8476; Shannon, Nicholas Brian/0000-0001-8742-8285	National Medical Research Council, Singapore [NMRC/BNIG/2041/2015, NMRC/CBRG/0044/2013, NMRC/CSA-INV/011/2016, NMRC/CIRG/1434/2015]; Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg	National Medical Research Council, Singapore(National Medical Research Council, Singapore); Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg	This work was supported by grants from National Medical Research Council, Singapore (NMRC/BNIG/2041/2015 to SAKR, NMRC/CBRG/0044/2013 to PJC, NMRC/CSA-INV/011/2016 and NMRC/CIRG/1434/2015 to NGI). PC was supported by the Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chia S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00451-5; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghosh P, 2015, AGING-US, V7, P469, DOI 10.18632/aging.100781; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuo SZ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-556; Lappano R, 2012, ACTA PHARMACOL SIN, V33, P351, DOI 10.1038/aps.2011.183; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leong HS, 2014, STEM CELL TRANSL MED, V3, P1055, DOI 10.5966/sctm.2013-0214; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Montgomery ER, 2014, MOL PHARMACOL, V85, P586, DOI 10.1124/mol.113.088443; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rasheed SAK, 2010, INT J CANCER, V127, P1475, DOI 10.1002/ijc.25315; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Teo CR, 2016, CELL SIGNAL, V28, P1479, DOI 10.1016/j.cellsig.2016.07.001; Turm H, 2010, J BIOL CHEM, V285, P15137, DOI 10.1074/jbc.M109.072843; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; von Rahden BHA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-23; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yi TF, 2014, P NATL ACAD SCI USA, V111, pE2182, DOI 10.1073/pnas.1404943111; Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang HH, 2013, INT J CLIN EXP PATHO, V6, P1734; Zhang JX, 2014, ANN ONCOL, V25, P2196, DOI 10.1093/annonc/mdu439; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625	52	26	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1340	1353		10.1038/s41388-017-0038-6	http://dx.doi.org/10.1038/s41388-017-0038-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29255247	hybrid, Green Published			2022-12-28	WOS:000427279300006
J	Boulianne, B; Feldhahn, N				Boulianne, B.; Feldhahn, N.			Transcribing malignancy: transcription-associated genomic instability in cancer	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; INDUCED CYTIDINE DEAMINASE; DOUBLE-STRAND BREAKS; NUCLEOTIDE EXCISION-REPAIR; TOPOISOMERASE-II-BETA; R-LOOP FORMATION; DAMAGE-INDUCED DIFFERENTIATION; REPLICATION FORK PROGRESSION; LINEAGE-SURVIVAL ONCOGENE	Transcription is an essential process in all living cells. However, transcription also sensitises genomic DNA to damage from a number of endogenous sources. Although various mechanisms protect the integrity of DNA during transcription, transcription-associated genomic instability occurs in normal and malignant cells and, if unrepaired, can result in genomic alterations. Numerous studies have implicated genomic alterations found in cancer genomes to transcription. Hence, transcription-associated genomic instability can be considered as a major driver of cancer development. In this review, we summarise the body of knowledge on transcription-associated genomic instability and highlight recent discoveries in the field on both healthy and malignant cells. We also discuss how transcription-associated DNA damage might promote transforming lesions at cell type-and lineage-specific genes.	[Boulianne, B.; Feldhahn, N.] Imperial Coll London, Dept Med, Ctr Haematol, London, England	Imperial College London	Boulianne, B; Feldhahn, N (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Med, Ctr Haematol, Du Cane Rd, London W12 0NN, England.	bboulianne@gmail.com; n.feldhahn@imperial.ac.uk						Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293; Alzu A, 2012, CELL, V151, P835, DOI 10.1016/j.cell.2012.09.041; Ashour ME, 2015, NAT REV CANCER, V15, P137, DOI 10.1038/nrc3892; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Bermejo R, 2012, MOL CELL, V45, P710, DOI 10.1016/j.molcel.2012.03.001; Bhatia V, 2014, NATURE, V511, P362, DOI 10.1038/nature13374; BOGUSLAWSKI SJ, 1986, J IMMUNOL METHODS, V89, P123, DOI 10.1016/0022-1759(86)90040-2; Bonnet A, 2017, MOL CELL, V67, P608, DOI 10.1016/j.molcel.2017.07.002; Boulianne B, 2017, CELL REP, V18, P1687, DOI 10.1016/j.celrep.2017.01.057; Buchanan Justin, 2016, Journal of the Association of Genetic Technologists, V42, P24; Bunch H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10191; Bunch H, 2014, NAT STRUCT MOL BIOL, V21, P876, DOI 10.1038/nsmb.2878; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Calderwood SK, 2016, TRANSCR-AUSTIN, V7, P75, DOI 10.1080/21541264.2016.1181142; Canela A, 2017, CELL, V170, P507, DOI 10.1016/j.cell.2017.06.034; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Chan LN, 2017, NATURE, V542, P479, DOI 10.1038/nature21076; Chan YJA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004288; Chang EYC, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010033; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chiarle R, 2011, CELL, V147, P107, DOI 10.1016/j.cell.2011.07.049; Coombs CC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.25; Cortez D, 2015, DNA REPAIR, V32, P149, DOI 10.1016/j.dnarep.2015.04.026; Costantino L, 2015, CURR OPIN CELL BIOL, V34, P39, DOI 10.1016/j.ceb.2015.04.008; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; De Keersmaecker K, 2010, NAT MED, V16, P1321, DOI 10.1038/nm.2246; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Dominguez-Sanchez MS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002386; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Drolet M, 2006, MOL MICROBIOL, V59, P723, DOI 10.1111/j.1365-2958.2005.05006.x; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Feldhahn N, 2007, J EXP MED, V204, P1157, DOI 10.1084/jem.20062662; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fleenor CJ, 2015, STEM CELLS, V33, P1345, DOI 10.1002/stem.1936; Gaillard H, 2016, ANNU REV BIOCHEM, V85, P291, DOI 10.1146/annurev-biochem-060815-014908; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Muse T, 2016, NAT REV MOL CELL BIO, V17, P553, DOI 10.1038/nrm.2016.88; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Ginno PA, 2013, GENOME RES, V23, P1590, DOI 10.1101/gr.158436.113; Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017; Gomez-Gonzalez B, 2011, EMBO J, V30, P3106, DOI 10.1038/emboj.2011.206; Gomez-Herreros F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00307-y; Gomez-Herreros F, 2014, NAT GENET, V46, P516, DOI 10.1038/ng.2929; Gontan C, 2008, DEV BIOL, V317, P296, DOI 10.1016/j.ydbio.2008.02.035; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Green P, 2003, NAT GENET, V33, P514, DOI 10.1038/ng1103; Gutierrez A, 2011, BLOOD, V118, P4169, DOI 10.1182/blood-2010-11-318873; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; Ha VL, 2017, LEUKEMIA, V31, P2503, DOI 10.1038/leu.2017.70; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hamperl S, 2017, CELL, V170, P774, DOI 10.1016/j.cell.2017.07.043; Hamperl S, 2014, DNA REPAIR, V19, P84, DOI 10.1016/j.dnarep.2014.03.023; Hartono SR, 2015, NUCLEIC ACIDS RES, V43, P9729, DOI 10.1093/nar/gkv811; Hatchi E, 2015, MOL CELL, V57, P636, DOI 10.1016/j.molcel.2015.01.011; Havelange V, 2011, BLOOD, V118, P2827, DOI 10.1182/blood-2011-04-350579; Healy S, 2013, PHARMACOL THERAPEUT, V137, P64, DOI 10.1016/j.pharmthera.2012.09.001; Heinaniemi M, 2016, ELIFE, V5, DOI 10.7554/eLife.13087; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; HERMAN RK, 1971, J BACTERIOL, V106, P543, DOI 10.1128/JB.106.2.543-550.1971; Hill SJ, 2016, P NATL ACAD SCI USA, V113, pE7701, DOI 10.1073/pnas.1611673113; Hobson DJ, 2012, MOL CELL, V48, P365, DOI 10.1016/j.molcel.2012.08.027; Hoopes JI, 2016, CELL REP, V14, P1273, DOI 10.1016/j.celrep.2016.01.021; Hraiky C, 2000, J BIOL CHEM, V275, P11257, DOI 10.1074/jbc.275.15.11257; Hsieh HJ, 2017, DNA REPAIR, V49, P9, DOI 10.1016/j.dnarep.2016.11.002; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; IKEDA H, 1979, P NATL ACAD SCI USA, V76, P4571, DOI 10.1073/pnas.76.9.4571; Imielinski M, 2017, CELL, V168, P460, DOI 10.1016/j.cell.2016.12.025; Iqbal J, 2007, LEUKEMIA, V21, P2332, DOI 10.1038/sj.leu.2404856; Jenjaroenpun P, 2015, NUCLEIC ACIDS RES, V43, pW527, DOI 10.1093/nar/gkv344; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Ju BG, 2006, CELL CYCLE, V5, P2557, DOI 10.4161/cc.5.22.3497; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Klein IA, 2011, CELL, V147, P95, DOI 10.1016/j.cell.2011.07.048; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Lada AG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005217; Lang KS, 2017, CELL, V170, P787, DOI 10.1016/j.cell.2017.07.044; Lensing SV, 2016, NAT METHODS, V13, P855, DOI 10.1038/nmeth.3960; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; Leung-Hagesteijn C, 2013, CANCER CELL, V24, P289, DOI 10.1016/j.ccr.2013.08.009; Li M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7720; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin YF, 2007, MOL CELL BIOL, V27, P6209, DOI 10.1128/MCB.00739-07; Lippert MJ, 2011, P NATL ACAD SCI USA, V108, P698, DOI 10.1073/pnas.1012363108; Lippert MJ, 2004, MOL CELL BIOL, V24, P4801, DOI 10.1128/MCB.24.11.4801-4809.2004; Liu GJ, 2014, GENE DEV, V28, P1337, DOI 10.1101/gad.240416.114; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Luna R, 2008, CHROMOSOMA, V117, P319, DOI 10.1007/s00412-008-0158-4; Lyu YL, 2006, MOL CELL BIOL, V26, P7929, DOI 10.1128/MCB.00617-06; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Madabhushi R, 2015, CELL, V161, P1592, DOI 10.1016/j.cell.2015.05.032; Mandal PK, 2012, CELL, V148, P847, DOI 10.1016/j.cell.2012.02.011; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Meng FL, 2014, CELL, V159, P1538, DOI 10.1016/j.cell.2014.11.014; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mischo HE, 2011, MOL CELL, V41, P21, DOI 10.1016/j.molcel.2010.12.007; Morales JC, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006107; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Mussil B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073641; Naughton C, 2013, NAT STRUCT MOL BIOL, V20, P387, DOI 10.1038/nsmb.2509; NICKOLOFF JA, 1992, MOL CELL BIOL, V12, P5311, DOI 10.1128/MCB.12.12.5311; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nonaka T, 2016, J CLIN INVEST, V126, P1367, DOI 10.1172/JCI81522; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Orlovetskie N, 2017, BBA-REV CANCER, V1867, P42, DOI 10.1016/j.bbcan.2016.11.004; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Papaemmanuil E, 2014, NAT GENET, V46, P116, DOI 10.1038/ng.2874; Parsa JY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002518; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pavri R, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060154; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Peng HZ, 1999, BLOOD, V93, P2167, DOI 10.1182/blood.V93.7.2167.407a35_2167_2172; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Polak P, 2008, GENOME RES, V18, P1216, DOI 10.1101/gr.076570.108; Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Qian J, 2014, CELL, V159, P1524, DOI 10.1016/j.cell.2014.11.013; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Roy D, 2009, MOL CELL BIOL, V29, P3124, DOI 10.1128/MCB.00139-09; Rui LX, 2011, NAT IMMUNOL, V12, P933, DOI 10.1038/ni.2094; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Santos-Pereira JM, 2015, NAT REV GENET, V16, P583, DOI 10.1038/nrg3961; Sanz LA, 2016, MOL CELL, V63, P167, DOI 10.1016/j.molcel.2016.05.032; Schuetz JM, 2012, LEUKEMIA, V26, P1383, DOI 10.1038/leu.2011.378; Schwieger M, 2004, BLOOD, V103, P2744, DOI 10.1182/blood-2003-07-2280; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shing DC, 2003, CANCER RES, V63, P4568; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Skourti-Stathaki K, 2011, MOL CELL, V42, P794, DOI 10.1016/j.molcel.2011.04.026; Sollier J, 2015, TRENDS CELL BIOL, V25, P514, DOI 10.1016/j.tcb.2015.05.003; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Sridhara SC, 2017, CELL REP, V18, P334, DOI 10.1016/j.celrep.2016.12.050; Stirling PC, 2012, GENE DEV, V26, P163, DOI 10.1101/gad.179721.111; Stork CT, 2016, ELIFE, V5, DOI 10.7554/eLife.17548; Swaminathan S, 2015, NAT IMMUNOL, V16, P766, DOI 10.1038/ni.3160; Takahashi T, 2011, P NATL ACAD SCI USA, V108, P692, DOI 10.1073/pnas.1012582108; Tam W, 2006, BLOOD, V107, P4090, DOI 10.1182/blood-2005-09-3778; Taylor BJM, 2014, ELIFE, V3, DOI 10.7554/eLife.03553; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tous C, 2007, BIOCHEM BIOPH RES CO, V360, P428, DOI 10.1016/j.bbrc.2007.06.098; Trotter KW, 2015, MOL CELL BIOL, V35, P2799, DOI 10.1128/MCB.00230-15; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Urban V, 2016, J CELL BIOL, V214, P401, DOI 10.1083/jcb.201507099; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Vijayraghavan S, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006277; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; Wahba L, 2011, MOL CELL, V44, P978, DOI 10.1016/j.molcel.2011.10.017; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Wang Q, 2014, P NATL ACAD SCI USA, V111, P18667, DOI 10.1073/pnas.1420575111; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Wei PC, 2016, CELL, V164, P644, DOI 10.1016/j.cell.2015.12.039; Wellinger RE, 2006, MOL CELL BIOL, V26, P3327, DOI 10.1128/MCB.26.8.3327-3334.2006; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiedemann EM, 2016, CELL REP, V17, P2927, DOI 10.1016/j.celrep.2016.11.041; Williamson LM, 2011, CARCINOGENESIS, V32, P279, DOI 10.1093/carcin/bgq255; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yamane A, 2011, NAT IMMUNOL, V12, P62, DOI 10.1038/ni.1964; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yang YZ, 2014, MOL CELL, V53, P484, DOI 10.1016/j.molcel.2014.01.011; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412	205	14	14	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					971	981		10.1038/onc.2017.402	http://dx.doi.org/10.1038/onc.2017.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106394	Green Submitted			2022-12-28	WOS:000425905700001
J	Di Ruocco, F; Basso, V; Rivoire, M; Mehlen, P; Ambati, J; De Falco, S; Tarallo, V				Di Ruocco, F.; Basso, V.; Rivoire, M.; Mehlen, P.; Ambati, J.; De Falco, S.; Tarallo, V.			Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; POOR-PROGNOSIS; NONCODING RNAS; 7SL RNA; EXPRESSION; DICER; METASTASIS; INITIATION; ELEMENTS	Alu sequences are the most abundant short interspersed repeated elements in the human genome. Here we show that in a cell culture model of colorectal cancer (CRC) progression, we observe accumulation of Alu RNA that is associated with reduced DICER1 levels. Alu RNA induces epithelial-to-mesenchymal transition (EMT) by acting as a molecular sponge of miR-566. Moreover, Alu RNA accumulates as consequence of DICER1 deficit in colorectal, ovarian, renal and breast cancer cell lines. Interestingly, Alu RNA knockdown prevents DICER1 depletion-induced EMT despite global microRNA (miRNA) downregulation. Alu RNA expression is also induced by transforming growth factor-beta 1, a major driver of EMT. Corroborating this data, we found that non-coding Alu RNA significantly correlates with tumor progression in human CRC patients. Together, these findings reveal an unexpected DICER1-dependent, miRNA-independent role of Alu RNA in cancer progression that could bring mobile element transcripts in the fields of cancer therapeutic and prognosis.	[Di Ruocco, F.; De Falco, S.; Tarallo, V.] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Angiogenesis Lab, 111 Pietro Castellino St, I-80131 Naples, Italy; [Basso, V.; Mehlen, P.] Univ Lyon, CNRS UMR5286, Equipe Labellisee La Ligue,Ctr Leon Berard,INSERM, LabEx DEVweCAN,Ctr Rech Cancerol Lyon,Apoptosis C, Lyon, France; [Rivoire, M.] Ctr Leon Berard, Surg Dept, Lyon, France; [Ambati, J.] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Dept Ophthalmol, Charlottesville, VA 22908 USA; [Ambati, J.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; [Ambati, J.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; University of Virginia; University of Virginia; University of Virginia	Tarallo, V (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Angiogenesis Lab, 111 Pietro Castellino St, I-80131 Naples, Italy.	valeria.tarallo@igb.cnr.it		De Falco, Sandro/0000-0002-6501-1697; Tarallo, Valeria/0000-0002-6920-4402	Marie Curie Action [FP7-PEOPLE-2013-CIG 631311 CanAlu]; Italian Ministry of Scientific Research [PON 01_01434 REACT]; EU Horizon (TRANSCAN-2, project BeFIT); Nuovo-Soldati Cancer Research Foundation	Marie Curie Action(European Commission); Italian Ministry of Scientific Research(Ministry of Education, Universities and Research (MIUR)); EU Horizon (TRANSCAN-2, project BeFIT); Nuovo-Soldati Cancer Research Foundation	We thank the IGB integrated microscopy and FACS facilities and Grazia Mercadante for technical assistance, and Ivana Apicella, Valeria Cicatiello, Nagaraj Kerur and Monica Autiero for discussions. This work was supported by Marie Curie Action (FP7-PEOPLE-2013-CIG 631311 CanAlu) to VT, Italian Ministry of Scientific Research (PON 01_01434 REACT) and EU Horizon2020 (TRANSCAN-2, project BeFIT) to SDF, and Nuovo-Soldati Cancer Research Foundation to VB.	Alsaleh G, 2016, ARTHRITIS RHEUMATOL, V68, P1839, DOI 10.1002/art.39641; Baryakin DN, 2013, ACTA NATURAE, V5, P83, DOI 10.32607/20758251-2013-5-4-83-93; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Cordaux R, 2010, METHODS MOL BIOL, V628, P137, DOI 10.1007/978-1-60327-367-1_8; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236; Drusco A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096670; Faggad A, 2012, HISTOPATHOLOGY, V61, P552, DOI 10.1111/j.1365-2559.2011.04110.x; Gomez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018023; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Hasler J, 2007, CELL MOL LIFE SCI, V64, P1793, DOI 10.1007/s00018-007-7084-0; Hewitt RE, 2000, J PATHOL, V192, P446; Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442; Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Kitagawa N, 2013, CANCER SCI, V104, P543, DOI 10.1111/cas.12126; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110; Liu CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33947; Ma X., 2014, UROL ONCOL, V32, P46; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Pandey R, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-r117; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shaikh TH, 1997, J MOL BIOL, V271, P222, DOI 10.1006/jmbi.1997.1161; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Tang RB, 2005, MOL CARCINOGEN, V42, P93, DOI 10.1002/mc.20057; Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036; Tsushima H, 2001, CLIN CANCER RES, V7, P1258; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Wang W, 2016, MOL CELL ENDOCRINOL, V426, P91, DOI 10.1016/j.mce.2016.02.008; Xiang SY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-44; Zhang KL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-63	41	28	28	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					627	637		10.1038/onc.2017.369	http://dx.doi.org/10.1038/onc.2017.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991230	Green Published, hybrid			2022-12-28	WOS:000423812200008
J	Hsieh, HY; Jou, YC; Tung, CL; Tsai, YS; Wang, YH; Chi, CL; Lin, RI; Hung, SK; Chuang, YM; Wu, SF; Li, C; Shen, CH; Chan, MWY; Hsu, CD				Hsieh, H-Y; Jou, Y-C; Tung, C-L; Tsai, Y-S; Wang, Y-H; Chi, C-L; Lin, R-I; Hung, S-K; Chuang, Y-M; Wu, S-F; Li, C.; Shen, C-H; Chan, M. W. Y.; Hsu, C-D			Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE 4; PROMOTES VENOUS INVASION; LARGE GENE LISTS; BLADDER-CANCER; VASCULAR-PERMEABILITY; KAPOSIS-SARCOMA; ANGIOGENESIS; EXPRESSION; PROTEIN; METASTASIS	Urothelial carcinoma (UC) carcinogenesis has been hypothesized to occur through epigenetic repression of tumor-suppressor genes (TSGs). By quantitative real-time polymerase chain reaction array, we found that one potential TSG, angiopoietin-like 4 (ANGPTL4), was expressed at very low levels in all bladder cancer cell lines we examined. Previous studies had demonstrated that ANGPTL4 is highly expressed in some cancers, but downregulated, by DNA methylation, in others. Consequently, owing to these seemingly conflicting functions in distinct cancers, the precise role of ANGPTL4 in the etiology of UC remains unclear. In this study, using methylation-specific PCR and bisulfite pyrosequencing, we show that ANGPTL4 is transcriptionally repressed by DNA methylation in UC cell lines and primary tumor samples, as compared with adjacent noncancerous bladder epithelium. Functional studies further demonstrated that ectopic expression of ANGPTL4 potently suppressed UC cell proliferation, monolayer colony formation in vitro, and invasion, migration, and xenograft formation in vivo. Surprisingly, circulating ANGPTL4 was significantly higher in plasma samples from UC patients than normal control, suggesting it might be secreted from other cell types. Interestingly, our data also indicated that exogenous cANGPTL4 could promote cell proliferation and cell migration via activation of signaling through the Erk/focal adhesion kinase axis. We further confirmed that mouse xenograft tumor growth could be promoted by administration of exogenous cANGPTL4. Finally, immunohistochemistry demonstrated that ANGPTL4 was downregulated in tumor cells but overexpressed in tumor adjacent stromal tissues of muscle-invasive UC tissue samples. In conclusion, our data support dual roles for ANGPTL4 in UC progression, either as a tumor suppressor or oncogene, in response to microenvironmental context.	[Hsieh, H-Y; Hsu, C-D] Ditmanson Med Fountain Chiayi Christian Hosp, Dept Med Res, Chiayi, Taiwan; [Hsieh, H-Y; Jou, Y-C; Shen, C-H; Hsu, C-D] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Urol, 539 Zhongxiao Rd, Chiayi 600, Taiwan; [Hsieh, H-Y; Chuang, Y-M; Wu, S-F; Li, C.; Chan, M. W. Y.; Hsu, C-D] Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan; [Hsieh, H-Y] Natl Museum Nat Sci, Dept Biol, Taichung, Taiwan; [Tung, C-L] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Pathol, Chiayi, Taiwan; [Tsai, Y-S] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Urol, Coll Med, Tainan, Taiwan; [Wang, Y-H] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Wang, Y-H] Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Urol, New Taipei, Taiwan; [Chi, C-L] Buddhist Dalin Tzu Chi Gen Hosp, Dept Pathol, Chiayi, Taiwan; [Lin, R-I; Hung, S-K] Buddhist Dalin Tzu Chi Gen Hosp, Dept Radiat Oncol, Chiayi, Taiwan; [Hung, S-K] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chuang, Y-M; Wu, S-F; Li, C.; Chan, M. W. Y.] Natl Chung Cheng Univ, Inst Mol Biol, Chiayi, Taiwan	Chia-Yi Christian Hospital; National Chung Cheng University; Chia-Yi Christian Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; National Chung Cheng University	Hsu, CD (corresponding author), Ditmanson Med Fdn Chiayi Christian Hosp, Dept Urol, 539 Zhongxiao Rd, Chiayi 600, Taiwan.; Chan, MWY (corresponding author), Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan.	biowyc@ccu.edu.tw; cdh199712@gmail.com	Chuang, Yu-Ming/AAE-4901-2021; Chan, Michael/F-9615-2018	Chan, Michael/0000-0003-1431-322X; Chan, Michael/0000-0003-0314-2437; Hung, Shih-Kai/0000-0002-4945-528X	Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan [R101-9]; Ministry of Science and Technology, Taiwan [MOST 104-2314-B-194-001-MY3]	Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants from the Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan (grant no. R101-9) and the Ministry of Science and Technology, Taiwan (MOST 104-2314-B-194-001-MY3). The authors would like to thank Dr Curt Balch for English editing.	Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079-009-0072-4; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170; Chong HC, 2012, J ONCOL, V2012, DOI 10.1155/2012/351089; Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396; Costa VL, 2010, EPIGENETICS-US, V5, P343, DOI 10.4161/epi.5.4.11749; Feng S, 2010, ENDOCR-RELAT CANCER, V17, P1021, DOI 10.1677/ERC-10-0073; Foreman JE, 2010, CANCER LETT, V288, P219, DOI 10.1016/j.canlet.2009.07.006; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Girroir EE, 2008, TOXICOLOGY, V243, P236, DOI 10.1016/j.tox.2007.10.023; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hattori N, 2011, CANCER SCI, V102, P1337, DOI 10.1111/j.1349-7006.2011.01955.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsieh HY, 2016, CANCER LETT, V370, P56, DOI 10.1016/j.canlet.2015.09.018; Hu J, 2011, ORAL ONCOL, V47, P371, DOI 10.1016/j.oraloncology.2011.02.018; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Ito Y, 2003, CANCER RES, V63, P6651; Kakizoe T, 2006, CANCER SCI, V97, P821, DOI 10.1111/j.1349-7006.2006.00264.x; Kaneda A, 2002, CANCER RES, V62, P6645; Kastritis E, 2009, INT J CANCER, V124, P103, DOI 10.1002/ijc.23917; Katoh Y, 2006, INT J MOL MED, V17, P1145; Kersten S, 2005, BIOCHEM SOC T, V33, P1059, DOI 10.1042/BST0331059; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kim WJ, 2008, CANCER SCI, V99, P646, DOI 10.1111/j.1349-7006.2008.00735.x; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lin HY, 2015, ONCOTARGET, V6, P915, DOI 10.18632/oncotarget.2821; Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107; Muendlein A, 2014, ATHEROSCLEROSIS, V237, P632, DOI 10.1016/j.atherosclerosis.2014.10.028; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Ng KTP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-196; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pasin Erik, 2008, Rev Urol, V10, P31; Roupret M, 2011, EUR UROL, V59, P584, DOI 10.1016/j.eururo.2010.12.042; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Shibata K, 2010, J CLIN PATHOL, V63, P1054, DOI 10.1136/jcp.2010.078600; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; STUDER UE, 1994, J UROLOGY, V152, P81, DOI 10.1016/S0022-5347(17)32822-7; Swales C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109524; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tjeerdema N, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/bmjdrc-2014-000034; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Verine J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010421; Wang YH, 2009, TOXICOL APPL PHARM, V241, P111, DOI 10.1016/j.taap.2009.08.008; Wang YH, 2009, UROLOGY, V73, P670, DOI 10.1016/j.urology.2008.09.048; Wang ZM, 2010, BIOMARKERS, V15, P39, DOI 10.3109/13547500903261362; Wu YQ, 2016, EUR REV MED PHARMACO, V20, P44; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yeh CM, 2014, INT J ONCOL, V45, P2101, DOI 10.3892/ijo.2014.2627; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhang H, 2013, EXP THER MED, V5, P119, DOI 10.3892/etm.2012.750; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zordan MD, 2011, CYTOM PART A, V79A, P227, DOI 10.1002/cyto.a.21029	68	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					673	686		10.1038/onc.2017.375	http://dx.doi.org/10.1038/onc.2017.375			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035390				2022-12-28	WOS:000423812200012
J	Idoux-Gillet, Y; Nassour, M; Lakis, E; Bonini, F; Theillet, C; Du Manoir, S; Savagner, P				Idoux-Gillet, Y.; Nassour, M.; Lakis, E.; Bonini, F.; Theillet, C.; Du Manoir, S.; Savagner, P.			Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma	ONCOGENE			English	Article							CADHERIN ADHESION MOLECULES; TRANSCRIPTION FACTOR SLUG; PANCREATIC-CANCER CELLS; REPRESSES E-CADHERIN; RHO-FAMILY GTPASES; P-CADHERIN; STEM-CELL; MESENCHYMAL TRANSITIONS; PROMOTES MOTILITY; GENE-EXPRESSION	Mammary gland morphogenesis results from the coordination of proliferation, cohort migration, apoptosis and stem/progenitor cell dynamics. We showed earlier that the transcription repressor Slug is involved in these functions during mammary tubulogenesis. Slug is expressed by a subpopulation of basal epithelial cells, co-expressed with P-cadherin (Pcad). Slug-knockout mammary glands showed excessive branching, similarly to Pcad-knockout. Here, we found that Slug unexpectedly binds and activates Pcad promoter through E-boxes, inducing Pcad expression. We determined that Pcad can mediate several functions of Slug: Pcad promoted clonal mammosphere growth, basal epithelial differentiation, cell-cell dissociation and cell migration, rescuing Slug depletion. Pcad also promoted cell migration in isolated cells, in association with Src activation, focal adhesion reorganization and cell polarization. Pcad, similarly to Slug, was required for in vitro 3D tubulogenesis. Therefore, Pcad appears to be responsible for epithelial-mesenchymal transition-linked plasticity in mammary epithelial cells. In addition, we found that genes from the Slug/Pcad pathway components were co-expressed and specifically correlated in human breast carcinomas subtypes, carrying pathophysiological significance.	[Idoux-Gillet, Y.; Nassour, M.; Lakis, E.; Bonini, F.; Theillet, C.; Du Manoir, S.; Savagner, P.] Univ Montpellier, Inst Reg Canc Montpellier ICM, IRCM, Inserm,U1194, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Savagner, P (corresponding author), Univ Montpellier, Inst Rech Cancerol Montpellier, Inst Reg Canc Montpellier ICM, F-34298 Montpellier 5, France.	Pierre.Savagner@icm.unicancer.fr	du manoir, stan p/O-8677-2017; Theillet, Charles/O-7634-2018; Savagner, Pierre/AAD-9357-2020; Idoux-Gillet, Ysia/ABH-3112-2020	du manoir, stan p/0000-0002-2200-2651; Idoux-Gillet, Ysia/0000-0002-0436-1968; Theillet, Charles/0000-0001-5555-2759; Lakis, Emile/0000-0001-8629-1862; Savagner, Pierre/0000-0002-8287-2229	Fondation de France [E 2009 006685]; Ligue Nationale contre le Cancer; Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche); Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon); Ligue Regionale (Ardeche); Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour	Fondation de France(Fondation de France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche); Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon); Ligue Regionale (Ardeche); Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour	Financial support was provided by the Fondation de France (no. E 2009 006685), the Ligue Nationale contre le Cancer, the Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche) and Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon). In addition, the authors gratefully acknowledge support from the Ligue Regionale (Ardeche) and Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We are grateful to L Larue for plasmid vector Ecad, Professor M Takeichi for Pcad vector, Marisa M Faraldo and Marie-Ange Deugnier for Luciferase gene reporter and constructive discussions.	Albergaria A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055749; Albergaria A, 2011, INT J DEV BIOL, V55, P811, DOI 10.1387/ijdb.113382aa; Albergaria A, 2010, HUM MOL GENET, V19, P2554, DOI 10.1093/hmg/ddq134; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Arnoux V, 2008, MOL BIOL CELL, V19, P4738, DOI 10.1091/mbc.E07-10-1078; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Bernardes N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069023; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Faraldo MM, 2007, FEBS LETT, V581, P831, DOI 10.1016/j.febslet.2007.01.053; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hajra KM, 2002, CANCER RES, V62, P1613; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Ko SY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-170; Kumper S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011801; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; MEDINA D, 1986, J NATL CANCER I, V76, P1143; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nassour M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053498; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; Onodera T, 2010, SCIENCE, V329, P562, DOI 10.1126/science.1191880; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Plutoni C, 2016, J CELL BIOL, V212, P199, DOI 10.1083/jcb.201505105; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Rakshit S, 2012, P NATL ACAD SCI USA, V109, P18815, DOI 10.1073/pnas.1208349109; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rembold M, 2014, GENE DEV, V28, P167, DOI 10.1101/gad.230953.113; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338; Ribeiro AS, 2013, J PATHOL, V229, P705, DOI 10.1002/path.4143; Sarrio D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-74; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2015, CURR TOP DEV BIOL, V112, P273, DOI 10.1016/bs.ctdb.2014.11.021; Shields MA, 2012, J BIOL CHEM, V287, P6218, DOI 10.1074/jbc.M111.308940; Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718; Stefansson IM, 2004, J CLIN ONCOL, V22, P1242, DOI 10.1200/JCO.2004.09.034; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; Tang Y, 2016, NAT CELL BIOL, V18, P917, DOI 10.1038/ncb3394; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Thuault S, 2013, ONCOGENE, V32, P1876, DOI 10.1038/onc.2012.217; Turashvili G, 2011, MODERN PATHOL, V24, P64, DOI 10.1038/modpathol.2010.189; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Uygur B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-139; Vieira AF, 2014, ONCOTARGET, V5, P679, DOI 10.18632/oncotarget.1459; Vieira AF, 2012, STEM CELLS, V30, P854, DOI 10.1002/stem.1075; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897	68	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					578	588		10.1038/onc.2017.355	http://dx.doi.org/10.1038/onc.2017.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991231				2022-12-28	WOS:000423812200004
J	Ferrara, M; Sessa, G; Fiore, M; Bernard, F; Asteriti, IA; Cundari, E; Colotti, G; Ferla, S; Desideri, M; Buglioni, S; Trisciuoglio, D; Del Bufalo, D; Brancale, A; Degrassi, F				Ferrara, M.; Sessa, G.; Fiore, M.; Bernard, F.; Asteriti, I. A.; Cundari, E.; Colotti, G.; Ferla, S.; Desideri, M.; Buglioni, S.; Trisciuoglio, D.; Del Bufalo, D.; Brancale, A.; Degrassi, F.			Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization	ONCOGENE			English	Article							NDC80 COMPLEX; BINDING-SITE; SPINDLE; HEC1; ATTACHMENT; DYNAMICS; INSTABILITY; CATASTROPHE; ANEUPLOIDY; STABILITY	Highly expressed in cancer protein 1 (Hec1) is a subunit of the kinetochore (KT)-associated Ndc80 complex, which ensures proper segregation of sister chromatids at mitosis by mediating the interaction between KTs and microtubules (MTs). HEC1 mRNA and protein are highly expressed in many malignancies as part of a signature of chromosome instability. These properties render Hec1 a promising molecular target for developing therapeutic drugs that exert their anticancer activities by producing massive chromosome aneuploidy. A virtual screening study aimed at identifying small molecules able to bind at the Hec1-MT interaction domain identified one positive hit compound and two analogs of the hit with high cytotoxic, pro-apoptotic and anti-mitotic activities. The most cytotoxic analog (SM15) was shown to produce chromosome segregation defects in cancer cells by inhibiting the correction of erroneous KT-MT interactions. Live cell imaging of treated cells demonstrated that mitotic arrest and segregation abnormalities lead to cell death through mitotic catastrophe and that cell death occurred also from interphase. Importantly, SM15 was shown to be more effective in inducing apoptotic cell death in cancer cells as compared to normal ones and effectively reduced tumor growth in a mouse xenograft model. Mechanistically, cold-induced MT depolymerization experiments demonstrated a hyper-stabilization of both mitotic and interphase MTs. Molecular dynamics simulations corroborate this finding by showing that SM15 can bind the MT surface independently from Hec1 and acts as a stabilizer of both MTs and KT-MT interactions. Overall, our studies represent a clear proof of principle that MT-Hec1-interacting compounds may represent novel powerful anticancer agents.	[Ferrara, M.; Sessa, G.; Fiore, M.; Bernard, F.; Asteriti, I. A.; Cundari, E.; Colotti, G.; Trisciuoglio, D.; Degrassi, F.] CNR, Inst Mol Biol & Pathol, Natl Res Council, Via Apuli 4, I-00185 Rome, Italy; [Ferla, S.; Brancale, A.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Redwood Bldg,King Edward 7 Ave, Cardiff CF10 3XF, S Glam, Wales; [Desideri, M.; Buglioni, S.; Trisciuoglio, D.; Del Bufalo, D.] Regina Elena Inst Canc Res, Adv Diagnost & Technol Innovat Dept, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Cardiff University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Degrassi, F (corresponding author), CNR, Inst Mol Biol & Pathol, Natl Res Council, Via Apuli 4, I-00185 Rome, Italy.; Brancale, A (corresponding author), Cardiff Univ, Sch Pharm & Pharmaceut Sci, Redwood Bldg,King Edward 7 Ave, Cardiff CF10 3XF, S Glam, Wales.	brancalea@cf.ac.uk; francesca.degrassi@uniroma1.it	Colotti, Gianni/AAG-4918-2019; Colotti, Gianni/D-2015-2010; Brancale, Andrea/N-9445-2014; Del Bufalo, Donatella/K-8673-2016; trisciuoglio, daniela/AAL-4002-2021; Del Bufalo, Donatella/AAC-1594-2021; Ferla, Salvatore/F-7976-2016	Colotti, Gianni/0000-0002-9913-0635; Brancale, Andrea/0000-0002-9728-3419; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; buglioni, simonetta/0000-0002-5066-1523; Ferla, Salvatore/0000-0002-5918-9237	Life Science Research Net-work Wales through the Welsh Government's Ser Cymru program [NRNPGSep14008]; Italian Association for Cancer Research [IG 18560]; FIRC fellowship [18313]	Life Science Research Net-work Wales through the Welsh Government's Ser Cymru program; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); FIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	Live cell imaging experiments were performed at the Nikon Reference Centre, IBPM CNR. The authors thank G Guarguaglini and P Lavia for advice and support with live cell analysis, L Lanzetti, W Malorni and C Rinaldo for cell lines and reagents. AB acknowledges the support of the Life Science Research Net-work Wales grant no. NRNPGSep14008, an initiative funded through the Welsh Government's Ser Cymru program. Work in the laboratory of DDB is supported by grants from the Italian Association for Cancer Research (IG 18560). IAA is supported by a FIRC fellowship (18313).	Alushin GM, 2010, NATURE, V467, P805, DOI 10.1038/nature09423; [Anonymous], 2016, SCHROD REL 2016 1 MA; [Anonymous], 2015, MOL OP ENV MOE 2015; Avdoshina V, 2016, J NEUROCHEM, V137, P287, DOI 10.1111/jnc.13557; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2012, CURR OPIN CELL BIOL, V24, P48, DOI 10.1016/j.ceb.2011.11.003; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Galimberti F, 2010, CLIN CANCER RES, V16, P109, DOI 10.1158/1078-0432.CCR-09-2151; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Janssen A, 2013, ONCOGENE, V32, P4459, DOI 10.1038/onc.2012.576; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kaneko N, 2009, BIOCHEM BIOPH RES CO, V390, P1235, DOI 10.1016/j.bbrc.2009.10.127; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Magnani M, 2009, FEBS J, V276, P2701, DOI 10.1111/j.1742-4658.2009.06994.x; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Mattiuzzo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016307; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; Orticello M, 2015, ONCOGENE, V34, P3325, DOI 10.1038/onc.2014.265; Sundin LJR, 2011, MOL BIOL CELL, V22, P759, DOI 10.1091/mbc.E10-08-0671; Tooley JG, 2011, MOL BIOL CELL, V22, P1217, DOI 10.1091/mbc.E10-07-0626; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wei RR, 2007, NAT STRUCT MOL BIOL, V14, P54, DOI 10.1038/nsmb1186; Wilson-Kubalek EM, 2008, J CELL BIOL, V182, P1055, DOI 10.1083/jcb.200804170	33	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					231	240		10.1038/onc.2017.320	http://dx.doi.org/10.1038/onc.2017.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925395	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000422631700009
J	Swayampakula, M; McDonald, PC; Vallejo, M; Coyaud, E; Chafe, SC; Westerback, A; Venkateswaran, G; Shankar, J; Gao, G; Laurent, EMN; Lou, Y; Bennewith, KL; Supuran, CT; Nabi, IR; Raught, B; Dedhar, S				Swayampakula, M.; McDonald, P. C.; Vallejo, M.; Coyaud, E.; Chafe, S. C.; Westerback, A.; Venkateswaran, G.; Shankar, J.; Gao, G.; Laurent, E. M. N.; Lou, Y.; Bennewith, K. L.; Supuran, C. T.; Nabi, I. R.; Raught, B.; Dedhar, S.			The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; BREAST-CANCER; MATRIX-METALLOPROTEINASES; FIBROBLAST COLLAGENASE; PROTEOMIC PIPELINE; THERAPEUTIC TARGET; ACTIVATION-ENERGY; MAMMALIAN-CELLS; METASTASIS	Carbonic anhydrase IX (CAIX) is a hypoxia inducible factor 1-induced, cell surface pH regulating enzyme with an established role in tumor progression and clinical outcome. However, the molecular basis of CAIX-mediated tumor progression remains unclear. Here, we have utilized proximity dependent biotinylation (BioID) to map the CAIX 'interactome' in breast cancer cells in order to identify physiologically relevant CAIX-associating proteins with potential roles in tumor progression. High confidence proteins identified include metabolic transporters, beta 1 integrins, integrin-associated protein CD98hc and matrix metalloprotease 14 (MMP14). Biochemical studies validate the association of CAIX with alpha 2 beta 1 integrin, CD98hc and MMP14, and immunofluorescence microscopy demonstrates colocalization of CAIX with alpha 2 beta 1 integrin and MMP14 in F-actin/cofilin-positive lamellipodia/pseudopodia, and with MMP14 to cortactin/Tks5-positive invadopodia. Modulation of CAIX expression and activity results in significant changes in cell migration, collagen degradation and invasion. Mechanistically, we demonstrate that CAIX associates with MMP14 through potential phosphorylation residues within its intracellular domain, and that CAIX enhances MMP14-mediated collagen degradation by directly contributing hydrogen ions required for MMP14 catalytic activity. These findings establish hypoxia-induced CAIX as a novel metabolic component of cellular migration and invasion structures, and provide new mechanistic insights into its role in tumor cell biology.	[Swayampakula, M.; McDonald, P. C.; Vallejo, M.; Chafe, S. C.; Westerback, A.; Venkateswaran, G.; Lou, Y.; Bennewith, K. L.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada; [Vallejo, M.; Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Coyaud, E.; Laurent, E. M. N.; Raught, B.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Shankar, J.; Gao, G.; Nabi, I. R.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada; [Supuran, C. T.] Univ Firenze, Lab Chim Bioinorgan, Florence, Italy	British Columbia Cancer Agency; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of British Columbia; University of Florence	Dedhar, S (corresponding author), Univ British Columbia, BC Canc Res Ctr, Dept Integrat Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca	Nabi, Ivan/GWZ-5144-2022; Laurent, Estelle/AFV-5442-2022; COYAUD, Etienne/ABD-9726-2020	Nabi, Ivan/0000-0002-0670-0513; COYAUD, Etienne/0000-0002-5893-4557; Dedhar, Shoukat/0000-0003-4355-1657; Chafe, Shawn/0000-0001-8802-651X	Canadian Institutes for Health Research (CIHR); Canadian Cancer Society Research Institute (CCSRI); Canadian Cancer Society; Pancreas Centre, BC	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Pancreas Centre, BC	This work was supported by research grants to B. Raught and S. Dedhar from the Canadian Institutes for Health Research (CIHR), the Canadian Cancer Society Research Institute (CCSRI) through funds raised by the Canadian Cancer Society, and Pancreas Centre, BC. KL Bennewith is a Michael Smith Foundation for Health Research Biomedical Research Scholar. We thank Jordan Gillespie and Nancy LePard for help with the in vivo and clonogenic experiments.	Amith SR, 2015, INT J DEV BIOL, V59, P367, DOI 10.1387/ijdb.140336lf; Amith SR, 2017, CELL SIGNAL, V29, P69, DOI 10.1016/j.cellsig.2016.10.005; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Beaty BT, 2014, J CELL BIOL, V205, P737, DOI 10.1083/jcb.201312046; Busco G, 2010, FASEB J, V24, P3903, DOI 10.1096/fj.09-149518; Chafe SC, 2015, CANCER RES, V75, P996, DOI 10.1158/0008-5472.CAN-14-3000; Chafe SC, 2010, MOL BIOL CELL, V21, P2483, DOI 10.1091/mbc.E10-03-0176; Chan PK, 2014, DATA BRIEF, V1, P76, DOI 10.1016/j.dib.2014.10.001; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Choi-Rhee E, 2004, PROTEIN SCI, V13, P3043, DOI 10.1110/ps.04911804; Counillon L, 2016, BBA-MOL CELL RES, V1863, P2465, DOI 10.1016/j.bbamcr.2016.02.018; Coyaud E, 2015, MOL CELL PROTEOMICS, V14, P1781, DOI 10.1074/mcp.M114.045658; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deutsch EW, 2010, PROTEOMICS, V10, P1150, DOI 10.1002/pmic.200900375; Diaz B, 2013, J CELL BIOL, V201, P279, DOI 10.1083/jcb.201209151; Dingar D, 2015, J PROTEOMICS, V118, P95, DOI 10.1016/j.jprot.2014.09.029; Ditte P, 2011, CANCER RES, V71, P7558, DOI 10.1158/0008-5472.CAN-11-2520; Eng JK, 2013, PROTEOMICS, V13, P22, DOI 10.1002/pmic.201200439; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Gioia M, 2010, J BIOL INORG CHEM, V15, P1219, DOI 10.1007/s00775-010-0680-8; Gould CM, 2014, CELL ADHES MIGR, V8, P226, DOI 10.4161/cam.28346; Gupta GD, 2015, CELL, V163, P1484, DOI 10.1016/j.cell.2015.10.065; Hamilton MJ, 2014, J IMMUNOL, V192, P512, DOI 10.4049/jimmunol.1300096; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Hauff SJ, 2014, OTOLARYNG HEAD NECK, V151, P612, DOI 10.1177/0194599814545083; Innocenti A, 2009, BIOORG MED CHEM LETT, V19, P5825, DOI 10.1016/j.bmcl.2009.08.088; JEFFREY JJ, 1983, J BIOL CHEM, V258, P1123; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kaewprag J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071611; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Liu GM, 2010, NAT BIOTECHNOL, V28, P1015, DOI 10.1038/nbt1010-1015; Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008-5472.CAN-15-2962; Lock FE, 2013, ONCOGENE, V32, P5210, DOI 10.1038/onc.2012.550; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Lohse I, 2014, CANCERS, V6, P459, DOI 10.3390/cancers6010459; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Lucien F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028851; Macpherson IR, 2014, J CELL SCI, V127, P3893, DOI 10.1242/jcs.135947; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McDonald PC, 2012, ONCOTARGET, V3, P84, DOI 10.18632/oncotarget.422; McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877; Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554; Ng SSW, 2000, CANCER RES, V60, P5451; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x; Parks SK, 2015, J CELL PHYSIOL, V230, P1954, DOI 10.1002/jcp.24930; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Pedrioli PGA, 2010, METHODS MOL BIOL, V604, P213, DOI 10.1007/978-1-60761-444-9_15; Peitzsch C, 2014, INT J RADIAT BIOL, V90, P636, DOI 10.3109/09553002.2014.916841; Radvak P, 2013, ONCOL REP, V29, P1147, DOI 10.3892/or.2013.2226; Robey IF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/485196; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Tomari T, 2009, CANCER SCI, V100, P1284, DOI 10.1111/j.1349-7006.2009.01173.x; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Ward C, 2015, ONCOTARGET, V6, P24856, DOI 10.18632/oncotarget.4498; WELGUS HG, 1981, J BIOL CHEM, V256, P9516; WILBUR KM, 1948, J BIOL CHEM, V176, P147; Yamaguchi H., 2006, ADHESIVE INTERACTION, P37; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278	69	71	72	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6244	6261		10.1038/onc.2017.219	http://dx.doi.org/10.1038/onc.2017.219			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692057	Green Published, hybrid			2022-12-28	WOS:000414774800004
J	Garzon, J; Rodriguez, R; Kong, Z; Chabes, A; Rodriguez-Acebes, S; Mendez, J; Moreno, S; Garcia-Higuera, I				Garzon, J.; Rodriguez, R.; Kong, Z.; Chabes, A.; Rodriguez-Acebes, S.; Mendez, J.; Moreno, S.; Garcia-Higuera, I.			Shortage of dNTPs underlies altered replication dynamics and DNA breakage in the absence of the APC/C cofactor Cdh1	ONCOGENE			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE CONTROL; RIBONUCLEOTIDE REDUCTASE; FORK PROGRESSION; GENOMIC INSTABILITY; UBIQUITIN LIGASES; TUMOR SUPPRESSION; MAMMALIAN-CELLS; DORMANT ORIGINS; EXCESS MCM2-7	The APC/C-Cdh1 ubiquitin-ligase complex targets cell cycle regulators for proteosomal degradation and helps prevent tumor development and accumulation of chromosomal aberrations. Replication stress has been proposed to be the main driver of genomic instability in the absence of Cdh1, but the real contribution of APC/C-Cdh1 to efficient replication, especially in normal cells, remains unclear. Here we show that, in primary MEFs, acute depletion or permanent ablation of Cdh1 slowed down replication fork movement and increased origin activity. Partial inhibition of origin firing does not accelerate replication forks, suggesting that fork progression is intrinsically limited in the absence of Cdh1. Moreover, exogenous supply of nucleotide precursors, or ectopic overexpression of RRM2, the regulatory subunit of Ribonucleotide Reductase, restore replication efficiency, indicating that dNTP availability could be impaired upon Cdh1 loss. Indeed, we found reduced dNTP levels in Cdh1-deficient MEFs. Importantly, DNA breakage is also significantly alleviated by increasing intracellular dNTP pools, strongly suggesting that genomic instability is the result of aberrant replication. These observations highlight the relevance of APC/C-Cdh1 activity during G1 to ensure an adequate supply of dNTPs to the replisome, prevent replication stress and the resulting chromosomal breaks and, ultimately, suppress tumorigenesis.	[Garzon, J.; Rodriguez, R.; Moreno, S.; Garcia-Higuera, I.] Univ Salamanca, CSIC, IBFG, C Zacarias Gonzalez 2, Salamanca 37007, Spain; [Kong, Z.; Chabes, A.] Umea Univ, Dept Med Biochem & Biophys, Umea, Sweden; [Rodriguez-Acebes, S.; Mendez, J.] Spanish Natl Canc Res Ctr CNIO, DNA Replicat Grp, Madrid, Spain; [Moreno, S.; Garcia-Higuera, I.] Salamanca Univ, Inst Biomed Res Salamanca IBSAL, Salamanca, Spain; [Garzon, J.] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Umea University; Centro Nacional de Investigaciones Oncologicas (CNIO); University of Salamanca; University of Aberdeen	Moreno, S; Garcia-Higuera, I (corresponding author), Univ Salamanca, CSIC, IBFG, C Zacarias Gonzalez 2, Salamanca 37007, Spain.	smo@usal.es; igh@usal.es	Garcia-Higuera, Irene/L-5004-2014; Moreno, Sergio/K-3671-2014; Rodriguez, Sara/AAA-8972-2019; Mendez, Juan/K-8001-2014	Garcia-Higuera, Irene/0000-0001-6331-075X; Moreno, Sergio/0000-0002-8039-1413; Rodriguez, Sara/0000-0002-9867-7591; Mendez, Juan/0000-0002-3235-2559; Chabes, Andrei/0000-0003-1708-8259	Spanish Ministry of Economy and Competitiveness MINECO [CSD2007-0015, BFU2011-28274, BFU2014-55439]; Junta de Castilla y Leon [CSI151U13, CSI084U16]; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; Swedish Research Council; Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC); CSIC JAE predoctoral fellowship (MINECO); CSIC FPU predoctoral fellowship (MINECO)	Spanish Ministry of Economy and Competitiveness MINECO(Spanish Government); Junta de Castilla y Leon(Junta de Castilla y Leon); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC); CSIC JAE predoctoral fellowship (MINECO); CSIC FPU predoctoral fellowship (MINECO)	This research was funded by grants from the Spanish Ministry of Economy and Competitiveness MINECO (CSD2007-0015, BFU2011-28274 and BFU2014-55439) and Junta de Castilla y Leon (CSI151U13 and CSI084U16), the Swedish Cancer Society, the Knut and Alice Wallenberg Foundation and the Swedish Research Council (AC). IGH is supported by Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC). JG and RR were recipients of CSIC JAE and FPU predoctoral fellowships (MINECO).	Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Ayuda-Duran P, 2014, NUCLEIC ACIDS RES, V42, P7057, DOI 10.1093/nar/gku313; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chang LF, 2014, CURR OPIN STRUC BIOL, V29, P1, DOI 10.1016/j.sbi.2014.08.003; Choudhury R, 2016, CELL REP, V16, P3359, DOI 10.1016/j.celrep.2016.08.058; Craney A, 2013, CURR OPIN CELL BIOL, V25, P704, DOI 10.1016/j.ceb.2013.07.004; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Delgado-Esteban M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3879; Eguren M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3880; Eguren M, 2011, SEMIN CELL DEV BIOL, V22, P572, DOI 10.1016/j.semcdb.2011.03.010; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Greil C, 2016, ONCOGENE, V35, P3062, DOI 10.1038/onc.2015.367; Guarino E, 2014, SEMIN CELL DEV BIOL, V30, P97, DOI 10.1016/j.semcdb.2014.03.030; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Ke PY, 2005, GENE DEV, V19, P1920, DOI 10.1101/gad.1322905; Kitamura K, 1998, MOL BIOL CELL, V9, P1065, DOI 10.1091/mbc.9.5.1065; Labib K, 2011, PHILOS T R SOC B, V366, P3554, DOI 10.1098/rstb.2011.0071; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Montagnoli A, 2008, NAT CHEM BIOL, V4, P357, DOI 10.1038/nchembio.90; Mouron S, 2013, NAT STRUCT MOL BIOL, V20, P1383, DOI 10.1038/nsmb.2719; Munoz S, 2017, CHROMOSOMA, V126, P1, DOI 10.1007/s00412-016-0573-x; Pines J, 2011, NAT REV MOL CELL BIO, V12, P427, DOI 10.1038/nrm3132; Poli J, 2012, EMBO J, V31, P883, DOI 10.1038/emboj.2011.470; Pu X, 2015, CURR PROTOC TOXICOL, V65; Ruiz S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9036; Ruzankina Y, 2008, MECH AGEING DEV, V129, P460, DOI 10.1016/j.mad.2008.03.009; Sigl R, 2009, J CELL SCI, V122, P4208, DOI 10.1242/jcs.054197; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sivakumar S, 2015, NAT REV MOL CELL BIO, V16, P82, DOI 10.1038/nrm3934; Sivaprasad U, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-8; Stillman B, 2013, P NATL ACAD SCI USA, V110, P14120, DOI 10.1073/pnas.1312901110; Teixeira LK, 2015, CURR BIOL, V25, P1327, DOI 10.1016/j.cub.2015.03.022; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wilhelm T, 2014, P NATL ACAD SCI USA, V111, P763, DOI 10.1073/pnas.1311520111; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Yokochi T, 2007, CURR PROTOC CELL BIO, P10; Yuan X, 2014, MOL BIOL CELL, V25, P441, DOI 10.1091/mbc.E13-08-0480; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang JF, 2014, BBA-REV CANCER, V1845, P277, DOI 10.1016/j.bbcan.2014.02.001; Zhong Y, 2013, J CELL BIOL, V201, P373, DOI 10.1083/jcb.201208060	50	15	15	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5808	5818		10.1038/onc.2017.186	http://dx.doi.org/10.1038/onc.2017.186			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604743	Green Submitted			2022-12-28	WOS:000413292900003
J	Kiyohara, MH; Dillard, C; Tsui, J; Kim, SR; Lu, J; Sachdev, D; Goodglick, L; Tong, M; Torous, VF; Aryasomayajula, C; Wang, W; Najafzadeh, P; Gordon, LK; Braun, J; McDermott, S; Wicha, MS; Wadehra, M				Kiyohara, M. H.; Dillard, C.; Tsui, J.; Kim, S. R.; Lu, J.; Sachdev, D.; Goodglick, L.; Tong, M.; Torous, V. F.; Aryasomayajula, C.; Wang, W.; Najafzadeh, P.; Gordon, L. K.; Braun, J.; McDermott, S.; Wicha, M. S.; Wadehra, M.			EMP2 is a novel therapeutic target for endometrial cancer stem cells	ONCOGENE			English	Article							EPITHELIAL MEMBRANE PROTEIN-2; EXPRESSION; RESISTANCE; CHEMOTHERAPY; ASSOCIATION; NICHE; TUMORIGENESIS; METASTASIS; INHIBITION; PREDICTOR	Previous studies have suggested that overexpression of the oncogenic protein epithelial membrane protein-2 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from disease. To understand the role of EMP2 in the etiology of disease, gene analysis was performed to show transcripts that are reciprocally regulated by EMP2 levels. In particular, EMP2 expression correlates with and helps regulate the expression of several cancer stem cell associated markers including aldehyde dehydrogenase 1 (ALDH1). ALDH expression significantly promotes tumor initiation and correlates with the levels of EMP2 expression in both patient samples and tumor cell lines. As therapy against cancer stem cells in endometrial cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor formation using xenograft HEC1A models was determined. Anti-EMP2 IgG1 reduced the expression and activity of ALDH and correspondingly reduced both primary and secondary tumor load. Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells.	[Kiyohara, M. H.; Dillard, C.; Tsui, J.; Goodglick, L.; Tong, M.; Aryasomayajula, C.; Najafzadeh, P.; Braun, J.; Wadehra, M.] UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, 675 Charles Young Dr South,Box 951732, Los Angeles, CA 90095 USA; [Lu, J.; Wadehra, M.] Charles Drew Univ, Ctr Eliminate Canc Hlth Dispar, Los Angeles, CA USA; [Sachdev, D.; Goodglick, L.; Braun, J.; Wadehra, M.] UCLA, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA USA; [Torous, V. F.] Beth Israel Deaconess Med Ctr, Dept Pathol & Lab Med, Boston, MA USA; [Wang, W.; Gordon, L. K.] UCLA, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA USA; [McDermott, S.; Wicha, M. S.] Univ Michigan, Med Oncol, Ann Arbor, MI USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan	Wadehra, M (corresponding author), UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, 675 Charles Young Dr South,Box 951732, Los Angeles, CA 90095 USA.	mwadehra@mednet.ucla.edu	Wicha, Max/AAE-7268-2019	Braun, Jonathan/0000-0003-1646-2974; Dillard, Christen/0000-0002-7218-9960	Early Detection Research Network [NCI CA-86366, CA016042]; Charles Drew University/UCLA NIH [U54-CA-143931]; NIH/National Center for Advancing Translational Sciences (NCATS) [UL1TR000124]; NCI [R01 CA163971]; NATIONAL CANCER INSTITUTE [U24CA086366, P30CA016042, R01CA163971, U54CA143931] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER	Early Detection Research Network; Charles Drew University/UCLA NIH; NIH/National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was generously supported by the Early Detection Research Network NCI CA-86366 (L Goodglick), CA016042 (University of California at Los Angeles Jonsson Comprehensive Cancer Center Flow Cytometry Core), Charles Drew University/UCLA NIH U54-CA-143931 (JL and MW), the NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR000124, and NCI R01 CA163971 (MW).	Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223; Ayhan A, 2001, GYNECOL ONCOL, V80, P355, DOI 10.1006/gyno.2000.6014; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Boman BM, 2008, J CLIN ONCOL, V26, P2795, DOI 10.1200/JCO.2008.17.7436; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y; Daoud SA, 2013, J AM SCI, V9, P900; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dossus L, 2011, INT J CANCER, V129, P2032, DOI 10.1002/ijc.25840; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Fu M, 2014, MOL CANCER THER, V13, P902, DOI 10.1158/1535-7163.MCT-13-0199; Fu MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019945; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Glinsky GV, 2007, STEM CELL REV, V3, P79, DOI 10.1007/s12015-007-0011-9; Gordon LK, 2013, ONCOGENE, V32, P5369, DOI 10.1038/onc.2012.622; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Habeeb O, 2010, CANCER-AM CANCER SOC, V116, P4718, DOI 10.1002/cncr.25259; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hubbard SA, 2009, CANCER RES, V69, P8241, DOI 10.1158/0008-5472.CAN-08-4808; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kim RJ, 2013, CANCER LETT, V333, P18, DOI 10.1016/j.canlet.2012.11.026; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kurebayashi J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-568; Kyo S, 2013, CURR OBSTET GYNECOL, V2, P1, DOI 10.1007/s13669-012-0030-7; Leblanc M, 2001, VIRCHOWS ARCH, V438, P78, DOI 10.1007/s004280000269; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Liang DM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-201; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Mamat Suhana, 2011, Genes Cancer, V2, P979, DOI 10.1177/1947601911436009; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; Mirantes C, 2013, HUM PATHOL, V44, P1973, DOI 10.1016/j.humpath.2013.04.009; Morales SA, 2007, EXP EYE RES, V85, P790, DOI 10.1016/j.exer.2007.08.014; Nandy SB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-644; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Rahadiani N, 2011, CANCER SCI, V102, P903, DOI 10.1111/j.1349-7006.2011.01864.x; Rutella S, 2009, CLIN CANCER RES, V15, P4299, DOI 10.1158/1078-0432.CCR-08-1883; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Soltysova A, 2005, NEOPLASMA, V52, P435; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tirino Virginia, 2012, Methods Mol Biol, V879, P513, DOI 10.1007/978-1-61779-815-3_32; Wadehra M, 2006, DEV BIOL, V292, P430, DOI 10.1016/j.ydbio.2006.01.015; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Whitcomb BP, 2008, SURG CLIN N AM, V88, P301, DOI 10.1016/j.suc.2008.01.004; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Ye J, 2014, TUMOR BIOL, V35, P3945, DOI 10.1007/s13277-013-1561-x	66	25	25	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5793	5807		10.1038/onc.2017.142	http://dx.doi.org/10.1038/onc.2017.142			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604744	Green Accepted			2022-12-28	WOS:000413292900002
J	Liao, SY; Chiang, CW; Hsu, CH; Chen, YT; Jen, J; Juan, HF; Lai, WW; Wang, YC				Liao, S-Y; Chiang, C-W; Hsu, C-H; Chen, Y-T; Jen, J.; Juan, H-F; Lai, W-W; Wang, Y-C			CK1 delta/GSK3 beta/FBXW7 alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FBW7 UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; BETA-CATENIN; PHOSPHORYLATION; RECOGNITION; PROTEOLYSIS; MECHANISMS; GROWTH; MCL1	Overexpression of Cys2His2 zinc-finger 322A (ZNF322A) oncogenic transcription factor is associated with lung tumorigenesis. However, the mechanism of ZNF322A overexpression remains poorly understood. Here, we discover that protein stability of ZNF322A is regulated by coordinated phosphorylation and ubiquitination through the CK1 delta/GSK3 beta/FBXW7 alpha axis. CK1 delta and GSK3 beta kinases sequentially phosphorylate ZNF322A at serine-396 and then serine-391. Moreover, the doubly phosphorylated ZNF322A protein creates a destruction motif for the ubiquitin ligase FBXW7 alpha leading to ZNF322A protein destruction. Overexpression of FBXW7a induces ZNF322A protein degradation, thereby blocks ZNF322A transcription activity and suppresses ZNF322A-induced tumor growth and metastasis in vitro and in vivo. Clinically, overexpression of ZNF322A correlates with low FBXW7a or defective CK1 delta/GSK3 beta-mediated phosphorylation in lung cancer patients. Multivariate Cox regression analysis indicates that patients with ZNF322A high/FBXW7 low expression profile can be used as an independent factor to predict the clinical outcome in lung cancer patients. Our results reveal a new mechanism of ZNF322A oncoprotein destruction regulated by the CK1 delta/GSK3 beta/FBXW7 alpha axis. Deregulation of this signaling axis results in ZNF322A overexpression and promotes cancer progression.	[Liao, S-Y; Chiang, C-W; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan; [Chiang, C-W] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Hsu, C-H] Natl Taiwan Univ, Dept Agr Chem, Taipei, Taiwan; [Chen, Y-T; Jen, J.; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan; [Juan, H-F] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Inst Mol & Cellular Biol, Dept Life Sci, Taipei, Taiwan; [Lai, W-W] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan.; Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	, 賴吾為/T-8615-2019; Wang, Yi-Ching/J-8702-2019; HSU, CHUN-HUA/W-4554-2019	, 賴吾為/0000-0001-9174-8310; Wang, Yi-Ching/0000-0002-7694-2067; HSU, CHUN-HUA/0000-0002-0008-7383	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology [104-2627-B-006-001, 104-2627-B-002-001]; Taiwan Ministry of Education [D105-35A07]	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology; Taiwan Ministry of Education(Ministry of Education, Taiwan)	We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We thank Mr Chien-Hsun Lin for providing technical support. We acknowledge Dr Ruey-Hwa Chen, Institute of Biological Chemistry, Academia Sinica for discussion and comments on the manuscript. This work was supported in part by the Taiwan Ministry of Science and Technology grants (104-2627-B-006-001; 104-2627-B-002-001) and the Aim for the Top University Project grant from the Taiwan Ministry of Education (D105-35A07).	Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Hergovich A, 2006, MOL CELL BIOL, V26, P5784, DOI 10.1128/MCB.00232-06; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296; Jia D, 2013, BLOOD, V121, P707, DOI 10.1182/blood-2012-05-433045; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Thollet A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-291; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Wang R, 2013, CELL RES, V23, P803, DOI 10.1038/cr.2013.42; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Xu Y, 2010, ONCOGENE, V29, P3124, DOI 10.1038/onc.2010.77; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	28	10	11	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5722	5733		10.1038/onc.2017.168	http://dx.doi.org/10.1038/onc.2017.168			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581525				2022-12-28	WOS:000412843900006
J	Zhang, F; Tang, H; Jiang, Y; Mao, Z				Zhang, F.; Tang, H.; Jiang, Y.; Mao, Z.			The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression	ONCOGENE			English	Article							DNA-END RESECTION; DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; CHECKPOINT CONTROL; CANCER; PATHWAY; BRCA1; TUMORIGENESIS; GENES; CELLS	GATA3, a critical transcription factor involved in the development of the mammary gland, also plays important roles in mammary tumorigenesis by regulating transcription in coordination with two essential DNA repair factors, PARP1 and BRCA1. However, whether and how GATA3 participates in the process of DNA repair, which is often associated with tumorigenesis, has not been investigated. Here we demonstrate that GATA3 is required for the repair of DNA double-strand breaks (DSBs) by homologous recominbation (HR). Mechanistic studies indicate that at both the protein and the mRNA level, depleting GATA3 leads to reduced expression of CtIP, an essential HR factor involved in end resection, thereby suppressing the repair of DSBs by HR and sensitizing cells to etoposide induced DNA DSBs. Further studies indicate that upon the occurrence of DNA DSBs GATA3 directly binds to the CtIP promoter at the region of -2119 to -2130 and -2274 to -2285, and promotes the transcription of CtIP. Overexpression of CtIP in GATA3 depleted cells rescues the decline of HR, and cell survival in the presence of etoposide. In addition, through data mining analysis, we observed an extremely strong correlation between the expression levels of GATA3 and CtIP in paratumors, but the correlation turned insignificant in mammary tumors. Using vectors encoding GATA3 with mutations frequently occurring in mammary tumors, we found that several mutations on GATA3 led to a dysregulation of CtIP, and therefore HR repair. In summary, our data delineates the regulatory mechanisms of GATA3 in DNA DSB repair and strongly suggests that it might act as a tumor suppressor by promoting CtIP expression and HR to stabilize genomes.	[Zhang, F.; Tang, H.; Jiang, Y.; Mao, Z.] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Key Lab Signaling & Dis Res, Clin & Translat Res Ctr,Sch Life Sci & Technol, Shanghai, Peoples R China	Tongji University	Jiang, Y; Mao, Z (corresponding author), Tongji Univ, Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.	ying_jiang@tongji.edu.cn; zhiyong_mao@tongji.edu.cn		Mao, Zhiyong/0000-0002-5298-1918	Chinese National Program on Key Basic Research Project [2013CB967600, 2015CB964800]; National Science Foundation of China [81502385, 81622019, 31371396, 31570813, 81402543, 81601212]; 1000 Youth Talents Program; Shanghai Municipal Natural Science Foundation [15ZR1442600]; Fundamental Research Funds for the Central Universities	Chinese National Program on Key Basic Research Project; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1000 Youth Talents Program; Shanghai Municipal Natural Science Foundation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Dr Michael Van Meter for critically reading the manuscript. We thank Yang Yu for helping with the clonogenic assay. We thank Lu Chen for helping create the vector encoding GATA3. We thank TCGA for providing high quality high-throughput data for public analysis. The work was supported by grants from Chinese National Program on Key Basic Research Project (Grant No. 2013CB967600, 2015CB964800), the National Science Foundation of China (Grant No. 81502385, 81622019, 31371396, 31570813, 81402543, 81601212), the 1000 Youth Talents Program, Shanghai Municipal Natural Science Foundation (Grant No. 15ZR1442600), and the Fundamental Research Funds for the Central Universities.	Aqeilan RI, 2007, J CELL PHYSIOL, V212, P307, DOI 10.1002/jcp.21099; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Ciocca V, 2009, HUM PATHOL, V40, P489, DOI 10.1016/j.humpath.2008.09.010; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Haveri H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-9; Hsu HM, 2007, CANCER EPIDEM BIOMAR, V16, P2024, DOI 10.1158/1055-9965.EPI-07-0116; Huhn D, 2015, ONCOGENE, V34, P3977, DOI 10.1038/onc.2014.329; Jimeno S, 2015, NUCLEIC ACIDS RES, V43, P987, DOI 10.1093/nar/gku1384; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li Z, 2016, CELL DEATH DIFFER, V23, P1765, DOI 10.1038/cdd.2016.65; Liu F, 2006, MOL CELL BIOL, V26, P3124, DOI 10.1128/MCB.26.8.3124-3134.2006; Mao ZY, 2007, P NATL ACAD SCI USA, V104, P13068, DOI 10.1073/pnas.0702410104; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Minchenko DO, 2012, AM J MOL BIOL, V2, P21; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NIE ZR, 1995, CANCER RES, V55, P4760; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pikkarainen S, 2004, CARDIOVASC RES, V63, P196, DOI 10.1016/j.cardiores.2004.03.025; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Soria-Bretones I, 2013, CANCER MED-US, V2, P774, DOI 10.1002/cam4.141; Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Wu GK, 2006, CELL CYCLE, V5, P1592, DOI 10.4161/cc.5.15.3127; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006; Zhang L, 2015, CANCER BIOL THER, V16, P1585, DOI 10.1080/15384047.2015.1078021	37	7	7	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5168	5176		10.1038/onc.2017.127	http://dx.doi.org/10.1038/onc.2017.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481869				2022-12-28	WOS:000409371100008
J	Whelan, KA; Chandramouleeswaran, PM; Tanaka, K; Natsuizaka, M; Guha, M; Srinivasan, S; Darling, DS; Kita, Y; Natsugoe, S; Winkler, JD; Klein-Szanto, AJ; Amaravadi, RK; Avadhani, NG; Rustgi, AK; Nakagawa, H				Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Guha, M.; Srinivasan, S.; Darling, D. S.; Kita, Y.; Natsugoe, S.; Winkler, J. D.; Klein-Szanto, A. J.; Amaravadi, R. K.; Avadhani, N. G.; Rustgi, A. K.; Nakagawa, H.			Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL CANCER; PROMOTES; GROWTH; TUMORIGENESIS; CARCINOMA; PROGNOSIS; SUBPOPULATION; SUPPRESSION; INHIBITION	High CD44 expression is associated with enhanced malignant potential in esophageal squamous cell carcinoma (ESCC), among the deadliest of all human carcinomas. Although alterations in autophagy and CD44 expression are associated with poor patient outcomes in various cancer types, the relationship between autophagy and cells with high CD44 expression remains incompletely understood. In transformed oesophageal keratinocytes, CD44(Low)-CD24(High) (CD44L) cells give rise to CD44(High)-CD24(-/Low) (CD44H) cells via epithelial-mesenchymal transition (EMT) in response to transforming growth factor (TGF)-beta. We couple patient samples and xenotransplantation studies with this tractable in vitro system of CD44L to CD44H cell conversion to investigate the functional role of autophagy in generation of cells with high CD44 expression. We report that high expression of the autophagy marker cleaved LC3 expression correlates with poor clinical outcome in ESCC. In ESCC xenograft tumours, pharmacological autophagy inhibition with chloroquine derivatives depletes cells with high CD44 expression while promoting oxidative stress. Autophagic flux impairment during EMT-mediated CD44L to CD44H cell conversion in vitro induces mitochondrial dysfunction, oxidative stress and cell death. During CD44H cell generation, transformed keratinocytes display evidence of mitophagy, including mitochondrial fragmentation, decreased mitochondrial content and mitochondrial translocation of Parkin, essential in mitophagy. RNA interference-mediated Parkin depletion attenuates CD44H cell generation. These data suggest that autophagy facilitates EMT-mediated CD44H generation via modulation of redox homeostasis and Parkin-dependent mitochondrial clearance. This is the first report to implicate mitophagy in regulation of tumour cells with high CD44 expression, representing a potential novel therapeutic avenue in cancers where EMT and CD44H cells have been implicated, including ESCC.	[Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Div Gastroenterol, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Whelan, K. A.; Chandramouleeswaran, P. M.; Tanaka, K.; Natsuizaka, M.; Winkler, J. D.; Amaravadi, R. K.; Rustgi, A. K.; Nakagawa, H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Guha, M.; Srinivasan, S.; Avadhani, N. G.] Univ Penn, Dept Anim Biol, Mari Lowe Ctr Comparat Oncol, Sch Vet Med, Philadelphia, PA 19104 USA; [Darling, D. S.] Univ Louisville, Dept Oral Immunol & Infect Dis, Louisville, KY 40292 USA; [Darling, D. S.] Univ Louisville, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Kita, Y.; Natsugoe, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Surg Breast & Thyroid Surg, Kagoshima, Japan; [Winkler, J. D.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Histopathol Facil, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Amaravadi, R. K.] Univ Penn, Div Hematol Oncol, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Louisville; University of Louisville; Kagoshima University; University of Pennsylvania; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania; Pennsylvania Medicine	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, 421 Curie Blvd,956 Biomed Res Bldg 2-3, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu	Darling, Douglas S/D-4573-2009	Natsuizaka, Mitsuteru/0000-0002-1819-1955; Darling, Douglas/0000-0002-9039-1169	NIH [P01CA098101, K26RR032714]; American Cancer Society [RP-10-033-01-CCE]; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases [P30DK050306]; Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities; Pennsylvania Department of Health, Pennsylvania CURE Program Grant; Ministry of Education, Culture, Sports, Science and Technology of Japan [15K15501, 26293306, 15K10108]; University of Pennsylvania Center of Excellence in Environmental Toxicology [P30ES013508, K01DK103953, F32CA174176, T32DK007066]; Japan Society for the Promotion of Science; NATIONAL CANCER INSTITUTE [P01CA098101, P30CA016520, F32CA174146, P01CA114046, P30CA006927, F31CA174176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR032714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK103953, P30DK050306, T32DK007066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases; Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities; Pennsylvania Department of Health, Pennsylvania CURE Program Grant; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); University of Pennsylvania Center of Excellence in Environmental Toxicology; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We appreciate the support the support of members the Nakagawa and Rustgi laboratories for thoughtful discussions and support. We thank Ben Rhodes, Sanders Chang, Andy Guo, Amanda B. Muir, MD and Ashley Lento, PhD for technical support. We acknowledge the Flow Cytometry and Cell Sorting Resource Laboratory, the Electron Microscopy Resource Laboratory, and the Cell and Developmental Biology Microscopy Core at the University of Pennsylvania. This study was supported by the following NIH Grants: P01CA098101 (KAW, KT, PMC, AJK-S, HN, AKR), K26RR032714 (HN), P30ES013508 University of Pennsylvania Center of Excellence in Environmental Toxicology (HN), K01DK103953 (KAW), F32CA174176 (KAW), T32DK007066 (KAW), the American Cancer Society RP-10-033-01-CCE (AKR), NIH/NIDDK P30DK050306 Center of Molecular Studies in Digestive and Liver Diseases, The Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture and Mouse Core Facilities. Additional support was provided by the Pennsylvania Department of Health, Pennsylvania CURE Program Grant (HN). KT is a recipient of the Japan Society for the Promotion of Science Postdoctoral Fellowship. His study was supported by the Grant-in-Aid for challenging Exploratory Research, Grant in Aid for Scientific Research B and Grant in Aid for Scientific Research C from the Ministry of Education, Culture, Sports, Science and Technology of Japan (15K15501 and 26293306 to SN; and 15K10108 to YK).	Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Biddle A, 2016, EBIOMEDICINE, V4, P138, DOI 10.1016/j.ebiom.2016.01.007; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623; Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976; Darling DS, 2003, GENE EXPR PATTERNS, V3, P709, DOI 10.1016/S1567-133X(03)00147-9; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Garcia-Prat L, 2016, ONCOTARGET, V7, P12286, DOI 10.18632/oncotarget.7766; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Hao CL, 2014, INT J CLIN EXP PATHO, V7, P4213; Hoshino A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3308; Kagawa S, 2015, ONCOGENE, V34, P2347, DOI 10.1038/onc.2014.169; Kalabis J, 2012, NAT PROTOC, V7, P235, DOI 10.1038/nprot.2011.437; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kinugasa H, 2015, ONCOGENE, V34, P5229, DOI 10.1038/onc.2014.449; Kishimoto T., 1998, P 6 INT WORKSH C 10; Kleinberg L, 2007, NAT CLIN PRACT ONCOL, V4, P282, DOI 10.1038/ncponc0796; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kong JP, 2016, MOL CARCINOGEN, V55, P1526, DOI 10.1002/mc.22406; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Long A, 2015, CARCINOGENESIS, V36, P598, DOI 10.1093/carcin/bgv025; Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Martegani MP, 1999, AM J PATHOL, V154, P291, DOI 10.1016/S0002-9440(10)65275-3; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Nozoe T, 2004, J CANCER RES CLIN, V130, P334, DOI 10.1007/s00432-004-0542-2; Ohashi S, 2011, CANCER RES, V71, P6836, DOI 10.1158/0008-5472.CAN-11-0846; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reznik E, 2016, ELIFE, V5, DOI 10.7554/eLife.10769; Rubio N, 2012, AUTOPHAGY, V8, P1312, DOI 10.4161/auto.20763; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Schlossman SF, 1995, P 5 INT WORKSH C 3 7; Shiozaki M, 2011, ONCOL LETT, V2, P429, DOI 10.3892/ol.2011.264; Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826; Tanaka K, 2016, AM J CANCER RES, V6, P781; Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341; Yang H, 2014, J THORAC DIS, V6, P91, DOI 10.3978/j.issn.2072-1439.2013.11.16; Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028; Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020; Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	64	54	56	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4843	4858		10.1038/onc.2017.102	http://dx.doi.org/10.1038/onc.2017.102			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414310	Green Accepted			2022-12-28	WOS:000408234400003
J	Batisse-Lignier, M; Sahut-Barnola, I; Tissier, F; Dumontet, T; Mathieu, M; Drelon, C; Pointud, JC; Damon-Soubeyrand, C; Marceau, G; Kemeny, JL; Bertherat, J; Tauveron, I; Val, P; Martinez, A; Lefrancois-Martinez, AM				Batisse-Lignier, M.; Sahut-Barnola, I.; Tissier, F.; Dumontet, T.; Mathieu, M.; Drelon, C.; Pointud, J-C; Damon-Soubeyrand, C.; Marceau, G.; Kemeny, J-L; Bertherat, J.; Tauveron, I.; Val, P.; Martinez, A.; Lefrancois-Martinez, A-M			P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model	ONCOGENE			English	Article							BETA-CATENIN; GENOMIC CHARACTERIZATION; PROGNOSTIC ROLE; TUMORS; CANCER; TUMORIGENESIS; MUTATIONS; PATHWAYS; REVEALS; GROWTH	Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Pan-genomic analyses identified p53/Rb and WNT/beta-catenin signaling pathways as main contributors to the disease. However, isolated beta-catenin constitutive activation failed to induce malignant progression in mouse adrenocortical tumors. Therefore, there still was a need for a relevant animal model to study ACC pathogenesis and to test new therapeutic approaches. Here, we have developed a transgenic mice model with adrenocortical specific expression of SV40 large T-antigen (AdTAg mice), to test the oncogenic potential of p53/Rb inhibition in the adrenal gland. All AdTAg mice develop large adrenal carcinomas that eventually metastasize to the liver and lungs, resulting in decreased overall survival. Consistent with ACC in patients, adrenal tumors in AdTAg mice autonomously produce large amounts of glucocorticoids and spontaneously activate WNT/beta-catenin signaling pathway during malignant progression. We show that this activation is associated with downregulation of secreted frizzled related proteins (Sfrp) and Znrf3 that act as inhibitors of the WNT signaling. We also show that mTORC1 pathway activation is an early event during neoplasia expansion and further demonstrate that mTORC1 pathway is activated in ACC patients. Preclinical inhibition of mTORC1 activity induces a marked reduction in tumor size, associated with induction of apoptosis and inhibition of proliferation that results in normalization of corticosterone plasma levels in AdTAg mice. Altogether, these data establish AdTAg mice as the first preclinical model for metastatic ACC.	[Batisse-Lignier, M.; Sahut-Barnola, I.; Dumontet, T.; Mathieu, M.; Drelon, C.; Pointud, J-C; Damon-Soubeyrand, C.; Tauveron, I.; Val, P.; Martinez, A.; Lefrancois-Martinez, A-M] Univ Clermont Auvergne, CNRS UMR6293, INSERM U1103, GReD, Campus Univ Cezeaux,10 Ave Blaise Pascal, F-63178 Aubiere, France; [Batisse-Lignier, M.; Tauveron, I.] Ctr Hosp Univ, Endocrinol Diabetol & Metab Dis Dept, Sch Med, Clermont Ferrand, France; [Tissier, F.; Bertherat, J.] Hop Cochin, Assistance Publ Hop Paris, Reference Ctr Rare Adrenal Dis, Dept Pathol, Paris, France; [Tissier, F.] Univ Paris 06, Hop Pitie Salpetriere, Dept Pathol, Paris, France; [Marceau, G.] Ctr Hosp Univ, Dept Biochem & Mol Biol, Clermont Ferrand, France; [Kemeny, J-L] Clermont Ferrand Hosp, Dept Anatomopathol, Clermont Ferrand, France; [Bertherat, J.] Univ Paris 05, CNRS UMR8104, INSERM U1016, Inst Cochin, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; Universite de Franche-Comte; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Martinez, A; Lefrancois-Martinez, AM (corresponding author), Univ Clermont Auvergne, CNRS UMR6293, INSERM U1103, GReD, Campus Univ Cezeaux,10 Ave Blaise Pascal, F-63178 Aubiere, France.	antoine.martinez@uca.fr; a-marie.lefrancois-martinez@uca.fr	Dumontet, Typhanie/AAA-3605-2022	MARCEAU, GEOFFROY/0000-0003-4713-7162; BERTHERAT, Jerome/0000-0003-2551-3008	Universite Blaise Pascal; Universite d'Auvergne; CNRS; INSERM; Agence National de la Recherche [ANR-14-CE12-0007]; Fondation ARC pour la Recherche sur le Cancer [PJA 20141201894]; La Fondation de France	Universite Blaise Pascal; Universite d'Auvergne; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence National de la Recherche(French National Research Agency (ANR)); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); La Fondation de France(Fondation de France)	We thank Lucile Mounier for technical assistance and Sandrine Plantade, Khirredine Ouchen and Philippe Mazuel for animal care. Tissue analyses were performed at Anipath Clermont core facility. This work was supported by Universite Blaise Pascal, Universite d'Auvergne, CNRS, INSERM, Agence National de la Recherche (grant ANR-14-CE12-0007), grants from Fondation ARC pour la Recherche sur le Cancer (PJA 20141201894) and from La Fondation de France. We thank the Cochin tumor bank and COMETE (COrtico MEdullo Tumeurs Endocrines) network for the provision of ACA and ACC tissue samples.	Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Allolio B, 2006, J CLIN ENDOCR METAB, V91, P2027, DOI 10.1210/jc.2005-2639; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Assie G, 2010, TRENDS ENDOCRIN MET, V21, P325, DOI 10.1016/j.tem.2009.12.009; Baudin E, 2015, ENDOCRIN METAB CLIN, V44, P411, DOI 10.1016/j.ecl.2015.03.001; Bernichtein S, 2008, ENDOCRINOLOGY, V149, P651, DOI 10.1210/en.2007-0925; Berruti A, 2014, EUR UROL, V65, P832, DOI 10.1016/j.eururo.2013.11.006; Berthon A, 2010, HUM MOL GENET, V19, P1561, DOI 10.1093/hmg/ddq029; Beuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; De Martino MC, 2012, ENDOCR-RELAT CANCER, V19, P351, DOI 10.1530/ERC-11-0270; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Doghman M, 2012, MOL CELL ENDOCRINOL, V364, P101, DOI 10.1016/j.mce.2012.08.014; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Drelon C, 2016, HUM MOL GENET, V25, P2789, DOI 10.1093/hmg/ddw136; Drelon C, 2013, J CLIN ENDOCR METAB, V98, P505, DOI 10.1210/jc.2012-3310; Drelon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044171; Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029; Faillot S, 2016, EUR J ENDOCRINOL, V174, pR249, DOI 10.1530/EJE-15-1118; Fassnacht M, 2015, LANCET ONCOL, V16, P426, DOI 10.1016/S1470-2045(15)70081-1; Fassnacht M, 2012, NEW ENGL J MED, V366, P2189, DOI 10.1056/NEJMoa1200966; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Fraenkel M, 2013, ENDOCRINE, V44, P187, DOI 10.1007/s12020-013-9878-1; Gangadhar TC, 2011, CLIN CANCER RES, V17, P1956, DOI 10.1158/1078-0432.CCR-10-2061; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Gibb N, 2013, DEVELOPMENT, V140, P1537, DOI 10.1242/dev.088047; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; Heinze B, 2014, EUR J ENDOCRINOL, V170, P707, DOI 10.1530/EJE-13-0788; Hershkovitz L, 2007, ENDOCRINOLOGY, V148, P976, DOI 10.1210/en.2006-1100; Hisada M, 1998, JNCI-J NATL CANCER I, V90, P606, DOI 10.1093/jnci/90.8.606; Juhlin CC, 2015, J CLIN ENDOCR METAB, V100, pE493, DOI 10.1210/jc.2014-3282; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; Lambert-Langlais S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007309; Latronico AC, 2001, J CLIN ENDOCR METAB, V86, P4970, DOI 10.1210/jc.86.10.4970; Libe R, 2005, EUR J ENDOCRINOL, V153, P477, DOI 10.1530/eje.1.02004; Libe R, 2007, CLIN CANCER RES, V13, P844, DOI 10.1158/1078-0432.CCR-06-2085; Martino MCD, 2014, ENDOCR-RELAT CANCER, V21, P601; Naing A, 2011, CLIN CANCER RES, V17, P6052, DOI 10.1158/1078-0432.CCR-10-2979; Paglin S, 2006, AUTOPHAGY, V2, P291, DOI 10.4161/auto.2835; Papotti Mauro, 2011, Hormones & Cancer, V2, P333, DOI 10.1007/s12672-011-0088-0; Ragazzon B, 2006, ENDOCRINOLOGY, V147, P1805, DOI 10.1210/en.2005-1279; Ragazzon B, 2014, EUR J ENDOCRINOL, V170, P385, DOI 10.1530/EJE-13-0778; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; REINCKE M, 1994, J CLIN ENDOCR METAB, V78, P790, DOI 10.1210/jc.78.3.790; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Romero DG, 2007, ENDOCRINOLOGY, V148, P2644, DOI 10.1210/en.2006-1509; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Tissier F, 2012, AM J SURG PATHOL, V36, P1194, DOI 10.1097/PAS.0b013e31825a6308; Yamamura S, 2010, MOL CANCER THER, V9, P1680, DOI 10.1158/1535-7163.MCT-10-0012; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	56	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4445	4456		10.1038/onc.2017.54	http://dx.doi.org/10.1038/onc.2017.54			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368424				2022-12-28	WOS:000406806000007
J	Lin, MC; Lin, JJ; Hsu, CL; Juan, HF; Lou, PJ; Huang, MC				Lin, M-C; Lin, J-J; Hsu, C-L; Juan, H-F; Lou, P-J; Huang, M-C			GATA3 interacts with and stabilizes HIF-1 alpha to enhance cancer cell invasiveness (vol 36, pg 4243, 2017)	ONCOGENE			English	Correction														LOU, PEI-JEN/0000-0002-3383-8593; HUANG, MIN-CHUAN/0000-0002-0704-3447				Lin MC, 2017, ONCOGENE, V36, P4243, DOI 10.1038/onc.2017.8	1	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4380	4380		10.1038/onc.2017.196	http://dx.doi.org/10.1038/onc.2017.196			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28604747	Green Published, hybrid			2022-12-28	WOS:000406360600015
J	Otsubo, K; Goto, H; Nishio, M; Kawamura, K; Yanagi, S; Nishie, W; Sasaki, T; Maehama, T; Nishina, H; Mimori, K; Nakano, T; Shimizu, H; Mak, TW; Nakao, K; Nakanishi, Y; Suzuki, A				Otsubo, K.; Goto, H.; Nishio, M.; Kawamura, K.; Yanagi, S.; Nishie, W.; Sasaki, T.; Maehama, T.; Nishina, H.; Mimori, K.; Nakano, T.; Shimizu, H.; Mak, T. W.; Nakao, K.; Nakanishi, Y.; Suzuki, A.			MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation	ONCOGENE			English	Article							BULLOUS-PEMPHIGOID ANTIGEN; STEM-CELLS; TRANSCRIPTIONAL COACTIVATOR; HIPPO PATHWAY; CO-REPRESSOR; LUNG STEM; TAZ; EXPRESSION; PROTEIN; GENE	Mps One Binder Kinase Activator (MOB) 1A/1B are core components of the Hippo pathway. These proteins, which coactivate LArge Tumour Suppressor homologue kinases, are also tumour suppressors. To investigate MOB1A/B's roles in normal physiology and lung cancer, we generated doxycycline (Dox)-inducible, bronchioalveolar epithelium-specific, null mutations of MOB1A/B in mice (SPC-rtTA/(tetO) 7-Cre/Mob1a flox/flox/Mob1b(-/-); termed luMob1DKO mice). Most mutants (70%) receiving Dox in utero (luMob1DKO (E6.5-18.5) mice) died of hypoxia within 1 h post-birth. Their alveolar epithelial cells showed increased proliferation, impaired YAP1/TAZ-dependent differentiation and decreased surfactant protein production, all features characteristic of human respiratory distress syndrome. Intriguingly, mutant mice that received Dox postnatally (luMob1DKO (P21-41) mice) did not develop spontaneous lung adenocarcinomas, and urethane treatment-induced lung tumour formation was decreased (rather than increased). Lungs of luMob1DKO (P21-41) mice exhibited increased detachment of bronchiolar epithelial cells and decreased numbers of the bronchioalveolar stem cells thought to initiate lung adenocarcinomas. YAP1/TAZ-NKX2.1-dependent expression of collagen XVII, a key hemidesmosome component, was also reduced. Thus, a MOB1-YAP1/TAZ-NKX2.1 axis is essential for normal lung homeostasis and expression of the collagen XVII protein necessary for alveolar stem cell maintenance in the lung niche.	[Otsubo, K.; Goto, H.; Nishio, M.; Suzuki, A.] Med Inst Bioregulat, Div Canc Genet, Fukuoka, Japan; [Otsubo, K.; Nakanishi, Y.] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan; [Nishio, M.; Suzuki, A.] Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Kobe, Hyogo, Japan; [Kawamura, K.] Waseda Univ, Fac Sci & Engn, Tokyo, Japan; [Yanagi, S.] Miyazaki Univ, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Kiyotake, Miyazaki, Japan; [Nishie, W.; Shimizu, H.] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan; [Sasaki, T.] Akita Univ, Grad Sch Med, Dept Med Biol, Akita, Japan; [Maehama, T.] Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo, Japan; [Nishina, H.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Dev & Regenerat Biol, Tokyo, Japan; [Mimori, K.] Kyushu Univ, Beppu Hosp, Dept Surg, Beppu, Oita, Japan; [Nakano, T.] Osaka Univ, Med Sch, Dept Pathol, Suita, Osaka, Japan; [Nakano, T.] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka, Japan; [Mak, T. W.; Nakao, K.] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON, Canada; [Nakao, K.] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Kyoto, Japan	Kyushu University; Kobe University; Waseda University; University of Miyazaki; Hokkaido University; Akita University; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Kyushu University; Osaka University; Osaka University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Kyoto University	Suzuki, A (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Cellular Biol, Chuo Ku, Kusunoki Cho 7-5-1, Kobe, Hyogo 6500017, Japan.	suzuki@med.kobe-u.ac.jp	Maehama, Tomohiko/AAX-8926-2020; Suzuki, Akira/GYD-6697-2022; Maehama, Tomohiko/HGB-4896-2022	Suzuki, Akira/0000-0002-5950-8808; Maehama, Tomohiko/0000-0002-9685-2317	MEXT [26860214, 24240120]; JSPS [26860214, 24240120]; Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT [11088019]; AMED [16770279]; Uehara Memorial Foundation; Grants-in-Aid for Scientific Research [17H03982, 15K19026] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT; AMED(Japan Agency for Medical Research and Development (AMED)); Uehara Memorial Foundation(Uehara Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Jeffrey A Whitsett (Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, USA) for giving us SPC-rtTA/(tetO)<INF>7</INF>-Cre mice, and to A Fujimoto, M Kamihashi and M Suzuki (all of Kyushu Univ.), S Maegawa, J Utsumi, F Ishikawa, M Seiki and T Noda (all of AMED), for expert technical assistance and helpful discussions. This work was supported by MEXT and JSPS (grants 26860214 to MN, 24240120 to AS and HG); the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT (grants 11088019 to AS); AMED (grants 16770279 to AS and HG); and the Uehara Memorial Foundation (to AS).	Chen HY, 2015, J CLIN ONCOL, V33, P2303, DOI 10.1200/JCO.2014.59.3590; Chung C, 2013, P NATL ACAD SCI USA, V110, P7732, DOI 10.1073/pnas.1220603110; Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Debbabi H, 2005, AM J PHYSIOL-LUNG C, V289, pL274, DOI 10.1152/ajplung.00004.2005; Demello DE, 2002, IN VITRO CELL DEV-AN, V38, P154; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Driscoll Barbara, 2012, Methods Mol Biol, V879, P109, DOI 10.1007/978-1-61779-815-3_7; Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Lange AW, 2015, J MOL CELL BIOL, V7, P35, DOI 10.1093/jmcb/mju046; Lin CW, 2015, DEV BIOL, V403, P101, DOI 10.1016/j.ydbio.2015.04.014; Makita R, 2008, AM J PHYSIOL-RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Matsumura H, 2016, SCIENCE, V351, DOI 10.1126/science.aad4395; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Mitani A, 2009, AM J RESP CRIT CARE, V180, P326, DOI 10.1164/rccm.200812-1827OC; Nakayama H, 2001, JPN CIRC J, V65, P783, DOI 10.1253/jcj.65.783; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Nishio M, 2016, P NATL ACAD SCI USA, V113, pE71, DOI 10.1073/pnas.1517188113; Nishio M, 2013, CANCER SCI, V104, P1271, DOI 10.1111/cas.12227; Nishio M, 2012, J CLIN INVEST, V122, P4505, DOI 10.1172/JCI63735; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Powell AM, 2005, CLIN EXP DERMATOL, V30, P682, DOI 10.1111/j.1365-2230.2005.01937.x; Sasaki H, 2007, CLIN LUNG CANCER, V8, P273, DOI 10.3816/CLC.2007.n.006; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029; Valencia-Sama I, 2015, J BIOL CHEM, V290, P16906, DOI 10.1074/jbc.M115.642363; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Whitsett JA, 2004, HUM MOL GENET, V13, pR207, DOI 10.1093/hmg/ddh252; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Yamada M, 2005, J HISTOCHEM CYTOCHEM, V53, P735, DOI 10.1369/jhc.4A6483.2005; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	49	37	41	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4201	4211		10.1038/onc.2017.58	http://dx.doi.org/10.1038/onc.2017.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346423	Green Accepted			2022-12-28	WOS:000405835800011
J	Liang, WC; Ren, JL; Wong, CW; Chan, SO; Waye, MMY; Fu, WM; Zhang, JF				Liang, Wei-Cheng; Ren, Jia-Lin; Wong, Cheuk-Wa; Chan, Sun-On; Waye, Mary Miu-Yee; Fu, Wei-Ming; Zhang, Jin-Fang			LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/beta-catenin signaling	ONCOGENE			English	Article							LONG NONCODING RNAS; BETA-CATENIN; DIFFERENTIATION; EXPRESSION; PROMOTES; GENE; SUPPRESSES; CARCINOMA; ASSOCIATE	Emerging evidence indicates that the long noncoding RNAs extensively participate in cancer progression. Nevertheless, the molecular pathogenesis of how these lncRNAs regulate tumorigenesis has not been fully elucidated especially in hepatocellular carcinoma (HCC). Here, we sought to define the role of a novel lncRNA named lncRNA-NEF in modulating epithelial to mesenchymal transition (EMT) in HCC. It was found that the lncRNA-NEF was transcriptionally activated by EMT suppressor FOXA2 and frequently downregulated in HCC cell lines as well as clinical specimens. Although enhanced expression of lncRNA-NEF did not affect tumor cell growth, ectopic expression of lncRNA-NEF significantly suppressed EMT program and cell migration. Animal studies validated that lncRNA-NEF alleviated in vivo tumor metastasis and protected mice from tumor-induced mortality. Interestingly, we verified that lncRNA-NEF acted as a novel activator of its neighbor gene FOXA2, which formed a positive feedback loop. Subsequent studies revealed that lncRNA-NEF physically interacted with beta-catenin to increase the binding of GSK3 beta with beta-catenin and therefore promoted the inhibitory phosphorylation of beta-catenin, leading to the suppression on Wnt/beta-catenin signaling and activation of FOXA2 expression. Hence, our findings illustrated a novel feedback loop including FOXA2 and its neighboring gene lncRNA-NEF, which might provide mechanistic insights into the metastatic progress of HCC.	[Liang, Wei-Cheng; Ren, Jia-Lin; Wong, Cheuk-Wa; Chan, Sun-On; Waye, Mary Miu-Yee] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Waye, Mary Miu-Yee] Chinese Univ Hong Kong, Nethersole Sch Nursing, Shatin, Hong Kong, Peoples R China; [Fu, Wei-Ming] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Fu, Wei-Ming] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China; [Zhang, Jin-Fang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Clin Med Coll 1, Key Lab Orthopaed & Traumatol, Guangzhou, Guangdong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Southern Medical University - China; Southern Medical University - China; Guangzhou University of Chinese Medicine	Fu, WM (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.; Fu, WM (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Guangdong, Peoples R China.; Zhang, JF (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Clin Med Coll 1, Key Lab Orthopaed & Traumatol, Guangzhou, Guangdong, Peoples R China.	fuweiming76@smu.edu.cn; zhangjf06@cuhk.edu.hk	Chan, Sun-On/R-6547-2018; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008	Chan, Sun-On/0000-0002-3221-3786; 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917	National Natural Science Foundation of China [81773066, 81772404]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81773066 to W.F. and 81772404 to J.Z.).	Akagi T, 2008, BRIT J CANCER, V99, P781, DOI 10.1038/sj.bjc.6604544; Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Fu WM, 2016, ONCOTARGET, V7, P4712, DOI 10.18632/oncotarget.6731; Fu WM, 2015, J HEPATOL, V63, P886, DOI 10.1016/j.jhep.2015.05.016; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang W, 2015, CELL REP, V11, P137, DOI 10.1016/j.celrep.2015.03.008; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HK, 2006, NUCLEIC ACIDS RES, V34, P5705, DOI 10.1093/nar/gkl698; Liang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20121; Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154; Liang WC, 2015, J CELL BIOCHEM, V116, P2658, DOI 10.1002/jcb.25214; Liang WC, 2014, RNA BIOL, V11, P845, DOI 10.4161/rna.29356; Liang WC, 2013, J CELL BIOCHEM, V114, P2699, DOI 10.1002/jcb.24617; Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi W, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/358902; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Rossi L, 2010, WORLD J GASTRO ONCOL, V2, P348, DOI 10.4251/wjgo.v2.i9.348; Simons BW, 2012, DEV BIOL, V371, P246, DOI 10.1016/j.ydbio.2012.08.016; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Vance KW, 2014, EMBO J, V33, P296, DOI 10.1002/embj.201386225; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang D, 2015, HEPATOL INT, V9, P438, DOI 10.1007/s12072-015-9642-0; Wang J, 2014, CARCINOGENESIS, V35, P2576, DOI 10.1093/carcin/bgu180; Xiang C, 2015, FASEB J, V29, P1986, DOI 10.1096/fj.14-264580; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	38	93	99	4	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1445	1456		10.1038/s41388-017-0041-y	http://dx.doi.org/10.1038/s41388-017-0041-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29311643				2022-12-28	WOS:000427459500004
J	Diehl, K; Dinges, LA; Helm, O; Ammar, N; Plundrich, D; Arlt, A; Rocken, C; Sebens, S; Schafer, H				Diehl, K.; Dinges, L-A; Helm, O.; Ammar, N.; Plundrich, D.; Arlt, A.; Roecken, C.; Sebens, S.; Schaefer, H.			Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells	ONCOGENE			English	Article							KEAP1-NRF2 PATHWAY; OXIDATIVE STRESS; PROTEASOME ACTIVITY; KEAP1/NRF2 PATHWAY; PROTEIN EXPRESSION; SIGNALING PATHWAY; BREAST CANCERS; NRF2; FIBROBLASTS; ACTIVATION	Malignant tumors, such as colorectal cancer (CRC), are heterogeneous diseases characterized by distinct metabolic phenotypes. These include Warburg-and reverse Warburg phenotypes depending on differential distribution of the lactate carrier proteins monocarboxylate transporter-4 and -1 (MCT4 and MCT1). Here, we elucidated the role of the antioxidant transcription factor nuclear factor E2-related factor-2 (Nrf2) as the key regulator of cellular adaptation to inflammatory/environmental stress in shaping the metabolism toward a reverse Warburg phenotype in malignant and premalignant colonic epithelial cells. Immunohistochemistry of human CRC tissues revealed reciprocal expression of MCT1 and MCT4 in carcinoma and stroma cells, respectively, accompanied by strong epithelial Nrf2 activation. In colorectal tissue from inflammatory bowel disease patients, MCT1 and Nrf2 were coexpressed as well, relating to CD68+inflammatory infiltrates. Indirect coculture of human NCM460 colonocytes with M1- but not M2 macrophages induces MCT1 as well as G6PD, LDHB and TALDO expression, whereas MCT4 expression was decreased. Nrf2 knockdown or reactive oxygen species (ROS) scavenging blocked these coculture effects in NCM460 cells. Likewise, Nrf2 knockdown inhibited similar effects of tBHQ-mediated Nrf2 activation on NCM460 and HCT15 CRC cells. M1 coculture or Nrf2 activation/overexpression greatly altered the lactate uptake but not glucose uptake and mitochondrial activities in these cells, reflecting the reverse Warburg phenotype. Depending on MCT1-mediated lactate uptake, Nrf2 conferred protection from TRAIL-induced apoptosis in NCM460 and HCT15 cells. Moreover, metabolism-dependent clonal growth of HCT15 cells was induced by Nrf2-dependent activation of MCT1-driven lactate exchange. These findings indicate that Nrf2 has an impact on the metabolism already in premalignant colonic epithelial cells exposed to inflammatory M1 macrophages, an effect accompanied by growth and survival alterations. Favoring the reverse Warburg effect, these Nrf2-dependent alterations add to malignant transformation of the colonic epithelium.	[Diehl, K.; Arlt, A.; Schaefer, H.] Lab Mol Gastroenterol, Dept Internal Med 1, UKSH Campus Kiel, Kiel, Germany; [Dinges, L-A; Helm, O.; Ammar, N.; Plundrich, D.; Sebens, S.; Schaefer, H.] Univ Kiel, Inst Expt Canc Res, UKSH Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Roecken, C.] Univ Kiel, Inst Pathol, UKSH Campus Kiel, Kiel, Germany; [Roecken, C.; Sebens, S.] Comprehens Canc Ctr Kiel, Biomat Bank, UKSH Campus Kiel, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Kiel, Inst Expt Canc Res, UKSH Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Sebens, Susanne/C-1222-2010; Röcken, Christoph/A-9239-2010; Arlt, Alexander/G-7308-2019; Schäfer, Heiner/C-1055-2011	Röcken, Christoph/0000-0002-6989-8002; Arlt, Alexander/0000-0002-6160-1059; Schafer, Heiner/0000-0001-6936-9090	Wilhelm-Sander-Stiftung [2015.011.01]; German-Cancer-Aid [111555]; Cluster of Excellence 'Inflammation at Interfaces'	Wilhelm-Sander-Stiftung; German-Cancer-Aid(Deutsche Krebshilfe); Cluster of Excellence 'Inflammation at Interfaces'	We thank Maike Witt-Ramdohr and Iris Kosmol (both from the Institute of Experimental Cancer Research), and Sandra Kruger and Deniza Hajzeri (both from the Institute of Pathology) for excellent technical assistance. We also thank Dr Jens Dischinger for supporting with radioactivity experiments. Financial support by the Wilhelm-Sander-Stiftung (2015.011.01 to HS), the German-Cancer-Aid (111555 to KD) and the Cluster of Excellence 'Inflammation at Interfaces' (to HS, AA and SS) is greatly acknowledged.	Alvarez Z, 2016, CEREB CORTEX, V26, P1046, DOI 10.1093/cercor/bhu281; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Bolanos JP, 2016, J NEUROCHEM, V139, P115, DOI 10.1111/jnc.13486; Chartoumpekis DV, 2015, BIOCHEM SOC T, V43, P639, DOI 10.1042/BST20150049; Fang ZS, 2016, BBA-MOL CELL RES, V1863, P2245, DOI 10.1016/j.bbamcr.2016.05.016; Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025; Ferro S, 2016, ONCOTARGET, V7, P70639, DOI 10.18632/oncotarget.12156; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Folmes CDL, 2016, SEMIN CELL DEV BIOL, V52, P68, DOI 10.1016/j.semcdb.2016.02.010; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041; Geismann C, 2014, ONCOTARGETS THER, V7, P1497, DOI 10.2147/OTT.S36624; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Hadjiagapiou C, 2005, AM J PHYSIOL-GASTR L, V288, pG1118, DOI 10.1152/ajpgi.00312.2004; Hai T, 1999, GENE EXPRESSION, V7, P321; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hawkins KE, 2016, CELL REP, V14, P1883, DOI 10.1016/j.celrep.2016.02.003; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu TH, 2013, J BIOMED RES, V27, P283, DOI 10.7555/JBR.27.20130069; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Ji LL, 2014, INT J CLIN EXP PATHO, V7, P1124; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260; Kruse ML, 2016, INFLAMM BOWEL DIS, V22, P2593, DOI 10.1097/MIB.0000000000000925; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Lambert DW, 2002, BRIT J CANCER, V86, P1262, DOI 10.1038/sj.bjc.6600264; Lee Minjong, 2015, World J Biol Chem, V6, P148, DOI 10.4331/wjbc.v6.i3.148; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li LN, 2015, PHARMACOL THERAPEUT, V150, P33, DOI 10.1016/j.pharmthera.2015.01.004; Martinez-Outschoorn UE, 2011, INT J BIOCHEM CELL B, V43, P1045, DOI 10.1016/j.biocel.2011.01.023; Martins SF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2566-9; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143, DOI 10.1152/ajpendo.1996.271.1.E143; Menendez JA, 2016, STEM CELL REP, V6, P273, DOI 10.1016/j.stemcr.2015.12.012; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Nakajima EC, 2013, MOL CARCINOGEN, V52, P329, DOI 10.1002/mc.21863; Nakayama Y, 2012, EXP THER MED, V3, P25, DOI 10.3892/etm.2011.361; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5; Pinheiro C, 2012, J BIOENERG BIOMEMBR, V44, P127, DOI 10.1007/s10863-012-9428-1; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Sanita P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-154; Schafer H, 2013, ONCOGENE, V32, P180, DOI 10.1038/onc.2012.44; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373; Shan T, 2017, ONCOL REP, V37, P1971, DOI 10.3892/or.2017.5479; Sivridis E, 2005, J CLIN PATHOL, V58, P1033, DOI 10.1136/jcp.2005.026260; Slocum SL, 2016, ARCH BIOCHEM BIOPHYS, V591, P57, DOI 10.1016/j.abb.2015.11.040; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Upadhyay M, 2013, PHARMACOL THERAPEUT, V137, P318, DOI 10.1016/j.pharmthera.2012.11.003; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; Visconti R, 2009, IDRUGS, V12, P240; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Winiarska K, 2003, METABOLISM, V52, P739, DOI 10.1016/S0026-0495(03)00035-0; Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530; Witkiewicz AK, 2011, CELL CYCLE, V10, P1794, DOI 10.4161/cc.10.11.15675; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xu XD, 2015, ONCOL RES TREAT, V38, P117, DOI 10.1159/000375435; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y	70	32	36	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					39	51		10.1038/onc.2017.299	http://dx.doi.org/10.1038/onc.2017.299			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28846107				2022-12-28	WOS:000422625000005
J	Larmonie, NSD; Arentsen-Peters, TCJM; Obulkasim, A; Valerio, D; Sonneveld, E; Danen-van Oorschot, AA; de Haas, V; Reinhardt, D; Zimmermann, M; Trka, J; Baruchel, A; Pieters, R; van den Heuvel-Eibrink, MM; Zwaan, CM; Fornerod, M				Larmonie, N. S. D.; Arentsen-Peters, T. C. J. M.; Obulkasim, A.; Valerio, D.; Sonneveld, E.; Danen-van Oorschot, A. A.; de Haas, V.; Reinhardt, D.; Zimmermann, M.; Trka, J.; Baruchel, A.; Pieters, R.; van den Heuvel-Eibrink, M. M.; Zwaan, C. M.; Fornerod, M.			MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; EXPRESSION; MUTATIONS; CELLS; MAINTENANCE; RESISTANCE; CHILDREN; PATTERNS; PROGRAMS	In acute myeloid leukemia (AML), specific genomic aberrations induce aberrant methylation, thus directly influencing the transcriptional programing of leukemic cells. Therefore, therapies targeting epigenetic processes are advocated as a promising therapeutic tool for AML treatment. However, to develop new therapies, a comprehensive understanding of the mechanism(s) driving the epigenetic changes as a result of acquired genetic abnormalities is necessary. This understanding is still lacking. In this study, we performed genome-wide CpG-island methylation profiling on pediatric AML samples. Six differentially methylated genomic regions within two genes, discriminating inv(16)(p13;q22) from non-inv(16) pediatric AML samples, were identified. All six regions had a hypomethylated phenotype in inv(16) AML samples, and this was most prominent at the regions encompassing the meningioma (disrupted in balanced translocation) 1 (MN1) oncogene. MN1 expression primarily correlated with the methylation level of the 3' end of the MN1 exon-1 locus. Decitabine treatment of different cell lines showed that induced loss of methylation at the MN1 locus can result in an increase of MN1 expression, indicating that MN1 expression is coregulated by DNA methylation. To investigate this methylation-associated mechanism, we determined the expression of DNA methyltransferases in inv(16) AML. We found that DNMT3B expression was significantly lower in inv(16) samples. Furthermore, DNMT3B expression correlated negatively with MN1 expression in pediatric AML samples. Importantly, depletion of DNMT3B impaired remethylation efficiency of the MN1 exon-1 locus in AML cells after decitabine exposure. These findings identify DNMT3B as an important coregulator of MN1 methylation. Taken together, this study shows that the methylation level of the MN1 exon-1 locus regulates MN1 expression levels in inv(16) pediatric AML. This methylation level is dependent on DNMT3B, thus suggesting a role for DNMT3B in leukemogenesis in inv(16) AML, through MN1 methylation regulation.	[Larmonie, N. S. D.; Arentsen-Peters, T. C. J. M.; Obulkasim, A.; Valerio, D.; Danen-van Oorschot, A. A.; Zwaan, C. M.; Fornerod, M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Sonneveld, E.; de Haas, V.] DCOG, The Hague, Netherlands; [Reinhardt, D.; Zimmermann, M.] Med High Sch, Dept Pediat Oncol Hematol, Hannover, Germany; [Trka, J.] Charles Univ Prague, Med Sch 2, Pediat Hematol Oncol, Prague, Czech Republic; [Baruchel, A.] CHU Paris, Hop Robert Debre, Paris, France; [Pieters, R.; van den Heuvel-Eibrink, M. M.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Dutch Childhood Oncology Group; Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Fornerod, M (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.fornerod@erasmusmc.nl	Reinhardt, Dirk/N-7003-2016; Trka, Jan/Y-4820-2019	Reinhardt, Dirk/0000-0002-7027-4483; Fornerod, Maarten/0000-0002-6166-3030	Children Cancer Free Foundation (KIKA) [64]	Children Cancer Free Foundation (KIKA)	We acknowledge L Verboon, NJ Basheer and JM Boer for technical support and advice. This project was supported by grants from the Children Cancer Free Foundation (KIKA), project no. 64, entitled: Aberrant signal transduction profiling in pediatric AML.	Alvarez S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012197; Alvarez-Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Balgobind BV, 2008, BLOOD, V111, P4322, DOI 10.1182/blood-2007-06-095075; Balgobind BV, 2011, HAEMATOL-HEMATOL J, V96, P221, DOI 10.3324/haematol.2010.029660; Bernt KM, 2011, HEMATOL-AM SOC HEMAT, P354, DOI 10.1182/asheducation-2011.1.354; Bullinger L, 2010, CANCER CELL, V17, P1, DOI 10.1016/j.ccr.2009.12.033; Carella C, 2007, LEUKEMIA, V21, P1679, DOI 10.1038/sj.leu.2404778; Chang HM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1909; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chowdhury B, 2015, SCI REP-UK, V5, DOI 10.1038/srep09281; Coombes KR, 2009, CLASSES METHODS CLAS; Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood-2012-03-362608; Deneberg S, 2011, BLOOD, V118, P5573, DOI 10.1182/blood-2011-01-332353; Duymich CE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11453; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; FOA P, 1982, CELL TISSUE KINET, V15, P399, DOI 10.1111/j.1365-2184.1982.tb01057.x; Gaidzik VI, 2012, J CLIN ONCOL, V30, P1350, DOI 10.1200/JCO.2011.39.2886; Grosveld GC, 2007, BLOOD CELL MOL DIS, V39, P336, DOI 10.1016/j.bcmd.2007.06.009; Heuser M, 2007, BLOOD, V110, P1639, DOI 10.1182/blood-2007-03-080523; Heuser M, 2006, BLOOD, V108, P3898, DOI 10.1182/blood-2006-04-014845; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Hollink IHIM, 2009, BLOOD, V113, P5951, DOI 10.1182/blood-2008-09-177949; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Inaba H, 2008, CANCER, V113, P522, DOI 10.1002/cncr.23581; KASPERS GJL, 1994, BRIT J CANCER, V70, P1047, DOI 10.1038/bjc.1994.446; Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Larmonie NSD, 2014, GENES IMMUN, V15, P72, DOI 10.1038/gene.2013.63; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Mandoli A, 2014, LEUKEMIA, V28, P770, DOI 10.1038/leu.2013.257; Mitschka S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11126; Moore AS, 2013, LEUKEMIA, V27, P1451, DOI 10.1038/leu.2013.106; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Qu XY, 2015, EPIGENETICS-US, V10, P526, DOI 10.1080/15592294.2015.1048060; R Core Team, 2013, LANG ENV STAT COMP; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Saied MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033213; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stumpel DJPM, 2009, BLOOD, V114, P5490, DOI 10.1182/blood-2009-06-227660; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Van Vlierberghe P, 2006, BLOOD, V108, P3520, DOI 10.1182/blood-2006-04-019927; Walton EL, 2011, EPIGENETICS-US, V6, P1373, DOI 10.4161/epi.6.11.17978; Wilop S, 2011, BRIT J HAEMATOL, V155, P65, DOI 10.1111/j.1365-2141.2011.08801.x; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Yan Pearlly S, 2002, Methods Mol Biol, V200, P87; Zwaan CM, 2015, J CLIN ONCOL, V33, P2949, DOI 10.1200/JCO.2015.62.8289	53	13	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					107	115		10.1038/onc.2017.293	http://dx.doi.org/10.1038/onc.2017.293			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892045				2022-12-28	WOS:000422625000011
J	Khan, KA; Naylor, AJ; Khan, A; Noy, PJ; Mambretti, M; Lodhia, P; Athwal, J; Korzystka, A; Buckley, CD; Willcox, BE; Mohammed, F; Bicknell, R				Khan, K. A.; Naylor, A. J.; Khan, A.; Noy, P. J.; Mambretti, M.; Lodhia, P.; Athwal, J.; Korzystka, A.; Buckley, C. D.; Willcox, B. E.; Mohammed, F.; Bicknell, R.			Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MOLECULAR CHARACTERIZATION; SPROUTING ANGIOGENESIS; ELEVATED EXPRESSION; COLORECTAL-CANCER; IN-VITRO; ENDOSIALIN; MARKER; GROWTH; RECEPTOR	The C-type lectin domain containing group 14 family members CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family and is expressed by tumour-associated fibroblasts and pericytes. Multimerin-2 (MMRN2) is a unique endothelial specific extracellular matrix protein that has been implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent on a predicted long-loop region in the C-type lectin domain and is abrogated by mutation within the domain. CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2 spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial cell surface as well as increasing adherence of human umbilical vein endothelial cells to the active peptide. This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These findings identify novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel formation.	[Khan, K. A.; Khan, A.; Noy, P. J.; Mambretti, M.; Lodhia, P.; Athwal, J.; Korzystka, A.; Bicknell, R.] Univ Birmingham, Inst Biomed Res & Cardiovasc Sci, Coll Med & Dent Sci, Mol Angiogenesis Lab, Birmingham B15 2TT, W Midlands, England; [Naylor, A. J.; Buckley, C. D.] Univ Birmingham, Inst Inflammat & Ageing, Rheumatol Res Grp, Birmingham, W Midlands, England; [Willcox, B. E.; Mohammed, F.] Univ Birmingham, Inst Immunol & Immunotherapy, Canc Immunol & Immunotherapy Ctr, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Inst Biomed Res & Cardiovasc Sci, Coll Med & Dent Sci, Mol Angiogenesis Lab, Birmingham B15 2TT, W Midlands, England.	r.bicknell@bham.ac.uk	Buckley, Christopher/AAN-6378-2021; Khan, Kabir/U-8350-2018	Buckley, Christopher/0000-0001-6924-6402; Khan, Kabir/0000-0001-8453-3485; Noy, Peter/0000-0001-6142-8957; Khan, Abdullah/0000-0003-0825-3179; Bicknell, Roy/0000-0002-0941-8919; Mambretti, Marco/0000-0003-2765-3805; Naylor, Amy/0000-0001-8384-8215	UoB; MRC [GBT1465]; Versus Arthritis [19791] Funding Source: researchfish	UoB; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Versus Arthritis(Versus Arthritis)	We thank the University of Birmingham (UoB) Protein expression facility for use of CD248-ECD-Fc; Raj Mehta and Tassos Konstantinou from Cancer Research Technologies for useful discussions. This work was funded by UoB and MRC grant GBT1465.	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Bao LL, 2016, BIOCHEM BIOPH RES CO, V476, P467, DOI 10.1016/j.bbrc.2016.05.146; Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239; Brady J, 2004, J NEUROPATH EXP NEUR, V63, P1274, DOI 10.1093/jnen/63.12.1274; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Colladel R, 2016, ONCOTARGET, V7, P2022, DOI 10.18632/oncotarget.6515; Diaz LA, 2015, CLIN CANCER RES, V21, P1281, DOI 10.1158/1078-0432.CCR-14-1829; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; GUAN E, 1991, J BIOL CHEM, V266, P20345; Huber MA, 2006, J CUTAN PATHOL, V33, P145, DOI 10.1111/j.0303-6987.2006.00446.x; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; Kaur S, 2011, ARTERIOSCL THROM VAS, V31, P657, DOI 10.1161/ATVBAHA.110.216341; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Kontsekova S, 2016, NEOPLASMA, V63, P183, DOI 10.4149/202_15090N474; Langenkamp E, 2015, CANCER RES, V75, P4504, DOI 10.1158/0008-5472.CAN-14-3636; Lee SM, 2013, Publication number, Patent No. [WO2013187724 A1, 2013187724]; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; McGreal EP, 2002, J IMMUNOL, V168, P5222, DOI 10.4049/jimmunol.168.10.5222; Naylor AJ, 2012, ARTHRITIS RHEUM-US, V64, P3334, DOI 10.1002/art.34556; Nepomuceno RR, 1998, J IMMUNOL, V160, P1929; Noy PJ, 2015, ONCOGENE, V34, P5821, DOI 10.1038/onc.2015.34; Noy PJ, 2016, FASEB J, V30, P2311, DOI 10.1096/fj.201500122R; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Olsen RS, 2015, INT J COLORECTAL DIS, V30, P883, DOI 10.1007/s00384-015-2247-1; Opavsky R, 2001, J BIOL CHEM, V276, P38795, DOI 10.1074/jbc.M105241200; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Rmali KA, 2005, WORLD J GASTROENTERO, V11, P1283, DOI 10.3748/wjg.v11.i9.1283; Simonavicius N, 2008, MODERN PATHOL, V21, P308, DOI 10.1038/modpathol.3801006; Simonavicius N, 2012, BLOOD, V120, P1516, DOI 10.1182/blood-2011-01-332338; Simossis VA, 2005, NUCLEIC ACIDS RES, V33, pW289, DOI 10.1093/nar/gki390; Tomkowicz B, 2007, P NATL ACAD SCI USA, V104, P17965, DOI 10.1073/pnas.0705647104; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	38	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6097	6108		10.1038/onc.2017.214	http://dx.doi.org/10.1038/onc.2017.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28671670	Green Published, hybrid			2022-12-28	WOS:000414249800004
J	Manent, J; Banerjee, S; de Matos Simoes, R; Zoranovic, T; Mitsiades, C; Penninger, JM; Simpson, KJ; Humbert, PO; Richardson, HE				Manent, J.; Banerjee, S.; de Matos Simoes, R.; Zoranovic, T.; Mitsiades, C.; Penninger, J. M.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.			Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species	ONCOGENE			English	Article							CELL-DEATH; DROSOPHILA-MELANOGASTER; TUMOR PROGRESSION; GENETIC SCREEN; ONCOGENIC RAS; CANCER; PROMOTES; EXPRESSION; GROWTH; TRANSFORMATION	Activation of Ras signalling occurs in similar to 30% of human cancers; however, activated Ras alone is not sufficient for tumourigenesis. In a screen for tumour suppressors that cooperate with oncogenic Ras (Ras(V12)) in Drosophila, we identified genes involved in the autophagy pathway. Bioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers. In Drosophila, we demonstrate that blocking autophagy at any step of the pathway enhances Ras(V12)-driven epithelial tissue overgrowth via the accumulation of reactive oxygen species and activation of the Jun kinase stress response pathway. Blocking autophagy in Ras(V12) clones also results in non-cell-autonomous effects with autophagy, cell proliferation and caspase activation induced in adjacent wild-type cells. Our study has implications for understanding the interplay between perturbations in Ras signalling and autophagy in tumourigenesis, which might inform the development of novel therapeutics targeting Ras-driven cancers.	[Manent, J.; Richardson, H. E.] La Trobe Univ, Sch Mol Sci, La Trobe Inst Mol Sci, Cell Polar & Signaling Lab,Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Manent, J.; Banerjee, S.; Richardson, H. E.] Peter MacCallum Canc Ctr, Cell Cycle & Dev Lab, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Simpson, K. J.] Peter MacCallum Canc Ctr, Victorian Ctr Funct Gen, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [de Matos Simoes, R.; Mitsiades, C.] Harvard Med Sch, Dept Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; [Zoranovic, T.; Penninger, J. M.] Inst Mol Biotechnol, Vienna, Austria; [Humbert, P. O.; Richardson, H. E.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Humbert, P. O.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Canc Biol Cell Polar & Tissue Architecture Lab, Melbourne, Vic, Australia; [Richardson, H. E.] Univ Melbourne, Dept Anat & Neurobiol, Melbourne, Vic, Australia; [Manent, J.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Zoranovic, T.] Max Planck Inst Infect Biol, Berlin, Germany	La Trobe University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Melbourne; University of Melbourne; La Trobe University; University of Melbourne; Monash University; Max Planck Society	Richardson, HE (corresponding author), La Trobe Univ, Sch Mol Sci, La Trobe Inst Mol Sci, Cell Polar & Signaling Lab,Dept Biochem & Genet, Melbourne, Vic 3086, Australia.	h.richardson@latrobe.edu.au	Pryjda, Tamara/O-5714-2019; Penninger, Josef M/I-6860-2013; Humbert, Patrick O/L-4264-2016; Richardson, Helena E/A-8080-2013	Penninger, Josef M/0000-0002-8194-3777; Humbert, Patrick O/0000-0002-1366-6691; Richardson, Helena E/0000-0003-3852-4953; zoranovic, tamara/0000-0002-5369-6385; de Matos Simoes, Ricardo/0000-0002-1700-5276; Simpson, Kaylene/0000-0001-9136-1781; Manent, Jan/0000-0001-9152-5459	National Health and Medical Research Council (NHMRC) [1020525]; PeterMac Foundation; LIMS; La Trobe University; NHMRC [1020525]; Australian Postgraduate Research Award; Marie Curie Excellence grant; NHMRC	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); PeterMac Foundation; LIMS; La Trobe University; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Research Award; Marie Curie Excellence grant(European Commission); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We thank Donna Denton, Sharad Kumar, Louise Cheng, Tor Erik Rusten, Lee Jun, Gabor Juhasz, Tom Neufeld, Stephen Gregory and Zeeshan Shaukat for reagents, and Tor Erik Rusten, Andreas Bergmann, Donna Denton, Sharad Kumar and Stephen Gregory for discussions. We thank Edwina McGlinn for critical reading of the manuscript. We are grateful to the Peter MacCallum Microscopy core and the LIMS Bioimaging facility for their help with imaging and analysis. We are grateful to OzDros and to Peter Burke for quarantine, shipment and maintenance of Drosophila stocks. The project was supported by grants from the National Health and Medical Research Council (NHMRC, no. 1020525) and from the PeterMac Foundation to HER, JMP, KJS and POH, and funds from LIMS and La Trobe University. JM was supported by an NHMRC grant (no. 1020525) and LIMS and La Trobe University, SB by a Australian Postgraduate Research Award and TZ by a Marie Curie Excellence grant. HER and POH are supported by fellowships of the (NHMRC) and funds from LIMS and La Trobe University.	Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021; [Anonymous], MODELLING CANC DROSO; Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980; Belaid A, 2013, CANCER RES, V73, P4311, DOI 10.1158/0008-5472.CAN-12-4142; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Colombani J, 2012, SCIENCE, V336, P582, DOI 10.1126/science.1216689; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2012, CELL DEATH DIFFER, V19, P1299, DOI 10.1038/cdd.2012.43; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Doggett K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132987; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fogarty CE, 2016, CURR BIOL, V26, P575, DOI 10.1016/j.cub.2015.12.064; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gargini R, 2016, ONCOL REP, V35, P3689, DOI 10.3892/or.2016.4699; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Guruharsha KG, 2011, CELL, V147, P690, DOI 10.1016/j.cell.2011.08.047; Halfar K, 2001, DEVELOPMENT, V128, P1687; Hu YH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-357; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Karim FD, 1998, DEVELOPMENT, V125, P1; Karim FD, 1996, GENETICS, V143, P315; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Khoo P, 2013, DIS MODEL MECH, V6, P661, DOI 10.1242/dmm.010066; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Li ML, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0293-y; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu ZY, 2014, J NEURO-ONCOL, V116, P465, DOI 10.1007/s11060-013-1325-x; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mauvezin C, 2014, METHODS, V68, P134, DOI 10.1016/j.ymeth.2014.03.014; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Morelli E, 2014, AUTOPHAGY, V10, P2251, DOI 10.4161/15548627.2014.981913; Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nagy P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003664; Nakamura M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6264; O'Farrell F, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001612; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Qin WJ, 2015, ONCOTARGET, V6, P39839, DOI 10.18632/oncotarget.5674; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Sacco E, 2012, EXPERT OPIN THER PAT, V22, P1263, DOI 10.1517/13543776.2012.728586; Santabarbara-Ruiz P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005595; Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775; Shaukat Z, 2015, ONCOGENE, V34, P4044, DOI 10.1038/onc.2014.344; Su TT, 2015, AIMS GENET, V2, P54, DOI 10.3934/genet.2015.1.54; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Takats S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160; Tomiyama L, 2015, ONCOGENE, V34, P1141, DOI 10.1038/onc.2014.31; Wang YH, 2012, P NATL ACAD SCI USA, V109, P13325, DOI 10.1073/pnas.1120193109; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Willecke M, 2011, ONCOGENE, V30, P4067, DOI 10.1038/onc.2011.125; Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhou ZH, 2015, EXP CELL RES, V331, P399, DOI 10.1016/j.yexcr.2014.11.015	85	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5576	5592		10.1038/onc.2017.175	http://dx.doi.org/10.1038/onc.2017.175			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581519	Green Published, hybrid			2022-12-28	WOS:000412293600003
J	Schito, L; Rey, S; Konopleva, M				Schito, L.; Rey, S.; Konopleva, M.			Integration of hypoxic HIF-alpha signaling in blood cancers	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW MICROENVIRONMENT; MODELING PO(2) DISTRIBUTIONS; ACUTE MYELOGENOUS LEUKEMIA; SCID-REPOPULATING CELLS; INDUCIBLE FACTOR-1-ALPHA; LYMPHOCYTIC-LEUKEMIA	Hypoxia (low O-2) is a fundamental microenvironmental determinant of bone marrow (BM) pathophysiology. Recent data from molecular and clinical studies indicate that hematopoiesis and leukemogenesis are dependent upon hypoxia-inducible factors (HIFs), a family of essential transcriptional activators mediating the metazoan hypoxic response. In blood cancers, the synergism between HIF overexpression and stabilization within the hypoxic BM microenvironment promotes disease progression, therapy resistance and relapse. In this review, we will summarize current advances in the understanding of HIF signaling in blood cancers and its translational implications for hypoxic-targeted therapy.	[Schito, L.; Rey, S.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Konopleva, M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA; [Konopleva, M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Konopleva, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA.	mkonople@mdanderson.org	Rey, Sergio/I-4918-2017	Rey, Sergio/0000-0001-8954-7712				Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Almarza E, 2004, EXP HEMATOL, V32, P360, DOI 10.1016/j.exphem.2004.01.005; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Asosingh K, 2005, HAEMATOLOGICA, V90, P810; Battisti V, 2008, CLIN BIOCHEM, V41, P511, DOI 10.1016/j.clinbiochem.2008.01.027; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bonnet D., 2015, TARGETED THERAPY ACU, P559; BUICK RN, 1984, CANCER RES, V44, P4909; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; CAMPOS L, 1993, BLOOD, V81, P3091; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen H, 2015, CELL BIOCHEM BIOPHYS, V72, P179, DOI 10.1007/s12013-014-0434-2; Chen HJ, 2000, BLOOD, V96, P3181; Chen HX, 2016, LEUKEMIA RES, V42, P28, DOI 10.1016/j.leukres.2016.01.013; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho BS, 2015, BLOOD, V126, P222, DOI 10.1182/blood-2015-02-628677; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Chow DC, 2001, BIOPHYS J, V81, P675, DOI 10.1016/S0006-3495(01)75732-3; Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006-3495(01)75733-5; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Chua YL, 2010, J BIOL CHEM, V285, P31277, DOI 10.1074/jbc.M110.158485; CIPOLLESCHI MG, 1993, BLOOD, V82, P2031; Colla S, 2010, LEUKEMIA, V24, P1967, DOI 10.1038/leu.2010.193; Coltella N, 2014, EMBO MOL MED, V6, P640, DOI 10.1002/emmm.201303065; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Deeb G, 2011, LEUKEMIA RES, V35, P579, DOI 10.1016/j.leukres.2010.10.020; Desplat V, 2002, STEM CELLS, V20, P347, DOI 10.1634/stemcells.20-4-347; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; DRAENERT K, 1980, Scanning Electron Microscopy, P113; Duan CM, 2016, AM J PHYSIOL-CELL PH, V310, pC260, DOI 10.1152/ajpcell.00315.2015; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Evans RG, 2008, AM J PHYSIOL-RENAL, V295, pF1259, DOI 10.1152/ajprenal.90230.2008; Fiegl M, 2009, BLOOD, V113, P1504, DOI 10.1182/blood-2008-06-161539; Forristal CE, 2015, LEUKEMIA, V29, P2075, DOI 10.1038/leu.2015.102; Forristal CE, 2015, LEUKEMIA, V29, P1366, DOI 10.1038/leu.2015.8; Frolova O, 2012, CANCER BIOL THER, V13, P858, DOI 10.4161/cbt.20838; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Giambra V, 2015, BLOOD, V125, P3917, DOI 10.1182/blood-2014-10-609370; Giatromanolaki A, 2010, ANTICANCER RES, V30, P2831; Giuntoli S, 2007, STEM CELLS, V25, P1119, DOI 10.1634/stemcells.2006-0637; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Griessinger E, 2014, STEM CELL TRANSL MED, V3, P520, DOI 10.5966/sctm.2013-0166; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Han ZB, 2008, CARCINOGENESIS, V29, P1853, DOI 10.1093/carcin/bgn066; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hubbi ME, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003417; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Hussong JW, 2000, BLOOD, V95, P309; IKEDA H, 1991, BLOOD, V78, P2962; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ivanovic Z, 2004, STEM CELLS, V22, P716, DOI 10.1634/stemcells.22-5-716; Ivanovic Z, 2000, BRIT J HAEMATOL, V108, P424; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kirito K, 2005, BLOOD, V105, P4258, DOI 10.1182/blood-2004-07-2712; Kocabas F, 2012, BLOOD, V120, P4963, DOI 10.1182/blood-2012-05-432260; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Konoplev S, 2007, CANCER, V109, P1152, DOI 10.1002/cncr.22510; Konopleva M, 2015, BONE MARROW TRANSPL, V50, P939, DOI 10.1038/bmt.2015.58; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Konopleva M, 2009, DRUG RESIST UPDATE, V12, P103, DOI 10.1016/j.drup.2009.06.001; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Koomagi R, 2001, CLIN CANCER RES, V7, P3381; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763; Lehmann-Che J, 2014, NEW ENGL J MED, V371, P1170, DOI 10.1056/NEJMc1409040; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li L, 2011, CANCER CELL, V20, P591, DOI 10.1016/j.ccr.2011.09.011; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434; Lundberg LG, 2000, AM J PATHOL, V157, P15, DOI 10.1016/S0002-9440(10)64511-7; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mantel CR, 2015, CELL, V161, P1553, DOI 10.1016/j.cell.2015.04.054; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martin SK, 2010, HAEMATOL-HEMATOL J, V95, P776, DOI 10.3324/haematol.2009.015628; Matsunaga T, 2012, LEUKEMIA RES, V36, pE122, DOI 10.1016/j.leukres.2012.02.028; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Molica S, 1999, BRIT J HAEMATOL, V107, P605, DOI 10.1046/j.1365-2141.1999.01752.x; Ng KP, 2014, BLOOD, V123, P3316, DOI 10.1182/blood-2013-07-511907; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Nombela-Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730; Padro T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Pedersen M, 2008, BIOCHEM BIOPH RES CO, V377, P98, DOI 10.1016/j.bbrc.2008.09.102; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; Petit C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2776-1; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Rey S, 2017, ADV DRUG DELIVER REV, V109, P45, DOI 10.1016/j.addr.2016.10.002; Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045; Ria R, 2014, CLIN CANCER RES, V20, P847, DOI 10.1158/1078-0432.CCR-13-1950; Rombouts EJC, 2004, BLOOD, V104, P550, DOI 10.1182/blood-2004-02-0566; Rouault-Pierre K, 2013, CELL STEM CELL, V13, P549, DOI 10.1016/j.stem.2013.08.011; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Tong HY, 2012, LEUKEMIA LYMPHOMA, V53, P2412, DOI 10.3109/10428194.2012.696637; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Valsecchi R, 2016, BLOOD, V127, P1987, DOI 10.1182/blood-2015-07-657056; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Verstovsek S, 2002, BLOOD, V99, P2265, DOI 10.1182/blood.V99.6.2265; Vukovic M, 2016, BLOOD, V127, P2841, DOI 10.1182/blood-2015-10-677138; Vukovic M, 2015, J EXP MED, V212, P2223, DOI 10.1084/jem.20150452; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang Y, 2014, BLOOD, V124, P1127, DOI 10.1182/blood-2013-12-544221; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Wellmann S, 2004, LEUKEMIA, V18, P926, DOI 10.1038/sj.leu.2403332; Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Zhang CC, 2014, ANTIOXID REDOX SIGN, V20, P1891, DOI 10.1089/ars.2012.5019; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381; Zhang J, 2009, CANCER RES, V69, P5082, DOI 10.1158/0008-5472.CAN-08-4603; Zhao F, 2010, ONCOGENE, V29, P2962, DOI 10.1038/onc.2010.67; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou FL, 2010, J BIOL CHEM, V285, P15010, DOI 10.1074/jbc.M110.103713; Zhou FL, 2013, J LEUKOCYTE BIOL, V94, P423, DOI 10.1189/jlb.0113006; Zou J, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-3	156	22	23	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5331	5340		10.1038/onc.2017.119	http://dx.doi.org/10.1038/onc.2017.119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534514				2022-12-28	WOS:000411382100001
J	Di Giacomo, V; Tian, TV; Mas, A; Pecoraro, M; Batlle-Morera, L; Noya, L; Martin-Caballero, J; Ruberte, J; Keyes, WM				Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Noya, L.; Martin-Caballero, J.; Ruberte, J.; Keyes, W. M.			Delta Np63 alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82	ONCOGENE			English	Article							PROGENITOR CELLS; SUPPRESSOR GENE; P53 HOMOLOG; STEM-CELLS; P63; PROLIFERATION; SURVIVAL; PC3; COMMITMENT; EXPRESSION	Delta Np63 alpha is a critical mediator of epithelial development and stem cell function in a variety of tissues including the skin and breast, while overexpression of Delta Np63 alpha acts as an oncogene to drive tumor formation and cancer stem cell properties in squamous cell carcinoma. However, with regards to the prostate, while Delta Np63 alpha is expressed in the basal stem cells of the mature gland, during adenocarcinoma development, its expression is lost and its absence is used to clinically diagnose the malignant state. Surprisingly, here we identify a sub-population of bone metastatic prostate cancer cells in the PC3 cell line that express Delta Np63 alpha. Interestingly, we discovered that Delta Np63 alpha favors adhesion and stem-like growth of these cells in the bone microenvironment. In addition, we show that these properties require expression of the target gene CD82. Together, this work uncovers a population of bone metastatic prostate cancer cells that express Delta Np63 alpha, and provides important information about the mechanisms of bone metastatic colonization. Finally, we identify metastasis-promoting properties for the tetraspanin family member CD82.	[Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Keyes, W. M.] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Gene Regulat Stem Cells & Canc Program, Barcelona, Spain; [Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Keyes, W. M.] UPF, Barcelona, Spain; [Noya, L.] Univ Autonoma Barcelona, Dept Anim Hlth & Anat, Barcelona, Spain; [Noya, L.] Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, Barcelona, Spain; [Martin-Caballero, J.] PRBB, Unidad Anim Lab, Barcelona, Spain; [Keyes, W. M.] Univ Strasbourg, Inserm U964, CNRS UMR7104,Dev & Stem Cells program, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Di Giacomo, V.] ZeClinics, Barcelona, Spain; [Pecoraro, M.] Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Autonomous University of Barcelona; Autonomous University of Barcelona; Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society	Keyes, WM (corresponding author), Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Carrer Dr Aiguader 88, Barcelona 08003, Spain.	bill.keyes@crg.eu	Ruberte, Jesus/AAS-9240-2021; TIAN, TIAN/O-1726-2015	BATLLE MORERA, LAURA/0000-0002-6924-9002; TIAN, TIAN/0000-0002-9906-0980; RUBERTE, JESUS/0000-0003-1540-1432	La Caixa; Spanish Ministry; Ministerio de Economia y Competitividad [SAF2010-18829, SAF2013-49082-P]; Marie Curie International Reintegration Grant [PIRG5-GA-2009-248262]	La Caixa(La Caixa Foundation); Spanish Ministry(Spanish Government); Ministerio de Economia y Competitividad(Spanish Government); Marie Curie International Reintegration Grant(European Commission)	We thank Roger Gomis and Marc Guiu for help with tumor imaging analysis, Jason Doles for help in the short hairpin design and the CRG Bioinformatics facility for assistance with microarray and sequencing data analysis. VDG was supported by a fellowship from 'La Caixa', and MP with an F. P. I. fellowship from the Spanish Ministry. This work was funded by Grants SAF2010-18829 (WMK) and SAF2013-49082-P (WMK) from the Ministerio de Economia y Competitividad and a Marie Curie International Reintegration Grant PIRG5-GA-2009-248262 (WMK).	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Burchert A, 1999, BRIT J HAEMATOL, V107, P494, DOI 10.1046/j.1365-2141.1999.01741.x; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chae YS, 2012, FEBS LETT, V586, P1128, DOI 10.1016/j.febslet.2012.03.021; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Doherty RE, 2011, BIOCHEM BIOPH RES CO, V414, P801, DOI 10.1016/j.bbrc.2011.10.010; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ferone G, 2015, CELL TISSUE RES, V360, P513, DOI 10.1007/s00441-014-2108-1; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Grisanzio C, 2008, J CELL BIOCHEM, V103, P1354, DOI 10.1002/jcb.21555; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Larochelle A, 2012, BLOOD, V119, P1848, DOI 10.1182/blood-2011-08-371583; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Lee HA, 2011, CELL PHYSIOL BIOCHEM, V27, P575, DOI 10.1159/000329979; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Liu QX, 2013, CANCER RES, V73, P3297, DOI 10.1158/0008-5472.CAN-12-3970; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Olsen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062547; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Park SI, 2010, CURR PROTOC PHARM, V51, P14, DOI [DOI 10.1002/0471141755.PH1415S51, 10.1002/0471141755.ph1415s51]; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Termini CM, 2014, MOL BIOL CELL, V25, P1560, DOI 10.1091/mbc.E13-11-0660; Tien JCY, 2013, CANCER RES, V73, P3997, DOI 10.1158/0008-5472.CAN-12-3929; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Valkenburg KC, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/895238; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.239; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang KX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-319	49	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4381	4392		10.1038/onc.2017.42	http://dx.doi.org/10.1038/onc.2017.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368419	Green Published, hybrid			2022-12-28	WOS:000406806000001
J	Shi, Z; He, F; Chen, M; Hua, L; Wang, W; Jiao, S; Zhou, Z				Shi, Z.; He, F.; Chen, M.; Hua, L.; Wang, W.; Jiao, S.; Zhou, Z.			DNA-binding mechanism of the Hippo pathway transcription factor TEAD4	ONCOGENE			English	Article							ORGAN SIZE CONTROL; EMERGING ROLES; YAP; TEF-1; GENE; INSIGHTS; MOTIFS; DOMAIN; TAZ	TEA domain (TEAD) family transcription factors are key regulators in development, tissue homeostasis and cancer progression. TEAD4 acts as a critical downstream effector of the evolutionarily conserved Hippo signaling pathway. The well-studied oncogenic protein YAP forms a complex with TEAD4 to regulate gene transcription; so does the tumor suppressor VGLL4. Although it is known that TEAD proteins can bind promoter regions of target genes through the TEA domain, the specific and detailed mechanism of DNA recognition by the TEA domain remains partially understood. Here, we report the crystal structure of TEAD4 TEA domain in complex with a muscle-CAT DNA element. The structure revealed extensive interactions between the TEA domain and the DNA duplex involving both the major and minor grooves of DNA helix. The DNA recognition helix, a3 helix, determines the specificity of the TEA domain binding to DNA sequence. Structure-guided biochemical analysis identified two major binding sites on the interface of the TEA domain-DNA complex. Mutation of TEAD4 at either site substantially decreases its occupancy on the promoter region of target genes, and largely impaired YAP-induced TEAD4 transactivation and target gene transcription, leading to inhibition of growth and colony formation of gastric cancer cell HGC-27. Collectively, our work provides a structural basis for understanding the regulatory mechanism of TEAD-mediated gene transcription.	[Shi, Z.; He, F.; Chen, M.; Hua, L.; Wang, W.; Jiao, S.; Zhou, Z.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci,State Key Lab Cel, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Zhou, Z.] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; ShanghaiTech University	Zhou, Z (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci,State Key Lab Cel, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zczhou@sibcb.ac.cn	Shi, Zhubing/F-9490-2010	Shi, Zhubing/0000-0002-9624-4960; He, Feng/0000-0002-6286-8134	Ministry of Science and Technology of China [2012CB910204]; National Natural Science Foundation of China [31270808, 31300734, 31470736, 31470868, 31600731, 91442125, 91542125]; Youth Innovation Promotion Association of Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [2014KIP202]; Chinese Academy of Sciences [XDA12020342, XDB19020202]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences(Knowledge Innovation Program of the Chinese Academy of SciencesChinese Academy of Sciences); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank the staff at beamline BL17U of Shanghai Synchrotron Radiation Facility (SSRF) for assistance with data collection. This work was supported by the 973 program of the Ministry of Science and Technology of China (2012CB910204), the National Natural Science Foundation of China (31270808, 31300734, 31470736, 31470868, 31600731, 91442125 and 91542125), the Youth Innovation Promotion Association of Chinese Academy of Sciences, the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2014KIP202), and the 'Strategic Priority Research Program' of the Chinese Academy of Sciences (XDA12020342 and XDB19020202).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Aravind L, 2005, FEMS MICROBIOL REV, V29, P231, DOI 10.1016/j.fmrre.2004.12.008; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Chan P, 2016, NAT CHEM BIOL, V12, P282, DOI [10.1038/nchembio.2036, 10.1038/NCHEMBIO.2036]; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Guo T, 2013, CELL RES, V23, P1201, DOI 10.1038/cr.2013.120; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021; Lee DS, 2016, J MOL BIOL, V428, P2557, DOI 10.1016/j.jmb.2016.03.008; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; Noland CL, 2016, STRUCTURE, V24, P179, DOI 10.1016/j.str.2015.11.005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Shi ZB, 2015, ACTA BIOCH BIOPH SIN, V47, P29, DOI 10.1093/abbs/gmu107; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	37	36	39	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4362	4369		10.1038/onc.2017.24	http://dx.doi.org/10.1038/onc.2017.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368398				2022-12-28	WOS:000406360600012
J	Tang, X; Ding, CK; Wu, J; Sjol, J; Wardell, S; Spasojevic, I; George, D; McDonnell, DP; Hsu, DS; Chang, JT; Chi, JT				Tang, X.; Ding, C-K; Wu, J.; Sjol, J.; Wardell, S.; Spasojevic, I.; George, D.; McDonnell, D. P.; Hsu, D. S.; Chang, J. T.; Chi, J-T			Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling (vol 36, pg 4235, 2017)	ONCOGENE			English	Correction																		Tang X, 2017, ONCOGENE, V36, P4235, DOI 10.1038/onc.2016.394	1	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4379	4379		10.1038/onc.2017.192	http://dx.doi.org/10.1038/onc.2017.192			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28604749	Bronze			2022-12-28	WOS:000406360600014
J	Yu, L; Di, Y; Xin, L; Ren, Y; Liu, X; Sun, X; Zhang, W; Yao, Z; Yang, J				Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.			SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGF beta 1 response and breast cancer metastasis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; NUCLEASE TUDOR-SN; TGF-BETA; TUMOR-SUPPRESSOR; ACETYLTRANSFERASE ACTIVITY; COACTIVATOR; ENHANCE; PROTEIN; REGULATOR; CARCINOMA	As an AEG-1/MTDH/LYRIC-binding protein, Staphylococcal nuclease domain-containing 1 (SND1) is upregulated in numerous human cancers where it has been assigned multiple functional roles. In this study, we discovered that SND1 was upregulated in breast cancer tissues, particularly the tissues from patients with distant metastases. The underlying molecular mechanisms demonstrated a novel role of SND1 in regulating the activity of transforming growth factor beta 1 (TGF beta 1) signaling pathway, which promotes metastasis in breast cancer. We illustrated that SND1 physically associated with and recruited the histone acetylase GCN5 to the promoter regions of Smad2/3/4, and consequently enhanced the gene transcriptional activation of Smad2/3/4, which are essential downstream regulators in the TGF beta 1 pathway. An electrophoretic mobility shift assay experiment further verified that SND1 could recognize the conserved domains (motifs 1 and 2) in the promoter regions of the Smad genes. Glutathione S-transferase (GST) pulldown assays indicated that the tudor domain of SND1 was responsible for the recruitment of GCN5, which increased histone H3K9 acetylation. Consistent with these results, a loss-of-function of SND1 reduced the protein level of Smads and the phosphorylation of R-Smads, thereby attenuating the R-Smad/Co-Smad depended transcription and, as a result, inhibited TGF beta signaling activation.	[Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yang, J.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Sch Basic Med Sci, Dept Immunol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Mol Immunol, Tianjin, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Educ Minist China, Key Lab, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China; [Yu, L.; Di, Y.; Xin, L.; Ren, Y.; Liu, X.; Sun, X.; Zhang, W.; Yao, Z.; Yang, J.] Tianjin Med Univ, Tianjin Key Lab Cellular & Mol Immunol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Yu, L; Yao, Z; Yang, J (corresponding author), Tianjin Med Univ, Educ Minist China, Key Lab, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.; Yu, L; Yao, Z; Yang, J (corresponding author), Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol,Res Ctr Basic Med Sci, Dept Immunol,Lab Mol Immunol,Tianjin Key Lab Cell, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	onoblivion@tmu.edu.cn; yaozhi@tijmu.edu.cn; yangj@tijmu.edu.cn	Yu, Lin/AAH-1131-2019	Yu, Lin/0000-0002-9972-3799	National Science Foundation for Distinguished Young Scholars of China [31125012]; National Natural Science Foundation of China [81202102, 81672592, 31370749, 31670759, 81572882]; Project for Innovative Research Team of Ministry of Education [IRT13085]; Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission [13JCQNJC12100]; Specialized Research Fund for the Doctoral Program of Higher Education [20121202120018]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project for Innovative Research Team of Ministry of Education; Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by grant from the National Science Foundation for Distinguished Young Scholars of China (31125012 to JY), grants from the National Natural Science Foundation of China (81202102 and 81672592 to LY, 31370749 and 31670759 to JY and 81572882 to ZY), grant from Project for Innovative Research Team of Ministry of Education (IRT13085 to JY), grants from Project of Applicative Basic Research and Advanced Technology of Tianjin Municipal Science and Technology Commission (13JCQNJC12100 to LY) and grant from Specialized Research Fund for the Doctoral Program of Higher Education (20121202120018 to LY).	Adams-Cioaba MA, 2009, BIOCHEM CELL BIOL, V87, P93, DOI 10.1139/O08-129; Bai X, 2016, ANGEW CHEM INT EDIT, V55, P7993, DOI 10.1002/anie.201602558; Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008-5472.CAN-14-2761; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Cappellari M, 2014, ONCOGENE, V33, P3794, DOI 10.1038/onc.2013.360; Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039; Do TV, 2008, MOL CANCER RES, V6, P695, DOI 10.1158/1541-7786.MCR-07-0294; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Gao XJ, 2012, J BIOL CHEM, V287, P18130, DOI 10.1074/jbc.M111.311852; He YB, 2014, NAT NEUROSCI, V17, P943, DOI 10.1038/nn.3732; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang L, 2007, J BIOL CHEM, V282, P27923, DOI 10.1074/jbc.M704194200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kannan N, 2014, CELL STEM CELL, V15, P118, DOI 10.1016/j.stem.2014.07.010; Kuruma H, 2009, AM J PATHOL, V174, P2044, DOI 10.2353/ajpath.2009.080776; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; Lee SG, 2013, ADV CANCER RES, V120, P1, DOI 10.1016/B978-0-12-401676-7.00001-2; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li CL, 2008, NUCLEIC ACIDS RES, V36, P3579, DOI 10.1093/nar/gkn236; Liu L, 2015, NUCLEIC ACIDS RES, V43, P3873, DOI 10.1093/nar/gkv255; Liu X, 2011, CELL MOL IMMUNOL, V8, P88, DOI 10.1038/cmi.2010.47; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Nam JS, 2006, CANCER RES, V66, P6327, DOI 10.1158/0008-5472.CAN-06-0068; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Quintana AM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-30; Riss A, 2015, J BIOL CHEM, V290, P28997, DOI 10.1074/jbc.M115.668533; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shaw N, 2007, NAT STRUCT MOL BIOL, V14, P779, DOI 10.1038/nsmb1269; Su C, 2015, J BIOL CHEM, V290, P7208, DOI 10.1074/jbc.M114.625046; Valineva T, 2005, J BIOL CHEM, V280, P14989, DOI 10.1074/jbc.M410465200; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Wang G, 2015, ONCOGENE, V35, P4388; Wang N, 2012, MOL BIOL REP, V39, P10497, DOI 10.1007/s11033-012-1933-0; [王旭 WANG Xu], 2010, [高分子通报, Polymer Bulletin], P1; Xie W, 2002, CANCER RES, V62, P497; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yan XH, 2016, J BIOL CHEM, V291, P382, DOI 10.1074/jbc.M115.694281; Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3; Yin J, 2013, ANAT REC, V296, P1568, DOI 10.1002/ar.22737; Yoo BK, 2011, HEPATOLOGY, V53, P1538, DOI 10.1002/hep.24216; Yu L, 2015, CANCER RES, V75, P1275, DOI 10.1158/0008-5472.CAN-14-2387	41	28	30	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3903	3914		10.1038/onc.2017.30	http://dx.doi.org/10.1038/onc.2017.30			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263968				2022-12-28	WOS:000404848200010
J	Monteverde, T; Tait-Mulder, J; Hedley, A; Knight, JR; Sansom, OJ; Murphy, DJ				Monteverde, T.; Tait-Mulder, J.; Hedley, A.; Knight, J. R.; Sansom, O. J.; Murphy, D. J.			Calcium signalling links MYC to NUAK1	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; TARGETING NUAK1; C-ALPHA; INDUCED APOPTOSIS; POOR-PROGNOSIS; AMPK; CANCER; BETA; EXPRESSION	NUAK1 is a member of the AMPK-related family of kinases. Recent evidence suggests that NUAK1 is an important regulator of cell adhesion and migration, cellular and organismal metabolism, and regulation of TAU stability. As such, NUAK1 may play key roles in multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer. Previous work revealed a crucial role for NUAK1 in supporting viability of tumour cells specifically when MYC is overexpressed. This role is surprising, given that NUAK1 is activated by the tumour suppressor LKB1. Here we show that, in tumour cells lacking LKB1, NUAK1 activity is maintained by an alternative pathway involving calcium-dependent activation of PKC alpha. Calcium/PKC alpha-dependent activation of NUAK1 supports engagement of the AMPK-TORC1 metabolic checkpoint, thereby protecting tumour cells from MYC-driven cell death, and indeed, MYC selects for this pathway in part via transcriptional regulation of PKC alpha and ITPR. Our data point to a novel role for calcium in supporting tumour cell viability and clarify the synthetic lethal interaction between NUAK1 and MYC.	[Monteverde, T.; Tait-Mulder, J.; Sansom, O. J.; Murphy, D. J.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Hedley, A.; Knight, J. R.; Sansom, O. J.; Murphy, D. J.] CRUK Beatson Inst, Garscube Estate, Glasgow, Lanark, Scotland	University of Glasgow; Beatson Institute	Murphy, DJ (corresponding author), Univ Glasgow, Inst Canc Sci, CRUK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	daniel.murphy@glasgow.ac.uk	Murphy, Daniel/V-1079-2019; Knight, John/V-2922-2019	Murphy, Daniel/0000-0002-5538-5468; Knight, John/0000-0002-8771-5484; Sansom, Owen J./0000-0001-9540-3010	British Lung Foundation [APHD13-5]; Wellcome trust [105614/Z/14/Z]; European Commission Marie Curie actions [CIG 618448]; Cancer Research UK [22311] Funding Source: researchfish; Versus Arthritis [21139] Funding Source: researchfish	British Lung Foundation; Wellcome trust(Wellcome Trust); European Commission Marie Curie actions(European Commission); Cancer Research UK(Cancer Research UK); Versus Arthritis(Versus Arthritis)	We acknowledge valuable input from the entire Murphy laboratory and numerous colleagues at the University of Glasgow Institute of Cancer Sciences and CRUK Beatson Institute. Nuak1 inhibitors were generously provided by Nathanael Gray prior to commercial availability. TM was supported by grant APHD13-5 from the British Lung Foundation. Additional support was provided by Wellcome trust grant 105614/Z/14/Z; the European Commission Marie Curie actions CIG 618448 'SERPLUC' to DJM and institutional support provided by the University of Glasgow & CRUK Beatson Institute to DJM.	ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Adey A, 2013, NATURE, V500, P207, DOI 10.1038/nature12064; Banerjee S, 2014, BIOCHEM J, V457, P215, DOI 10.1042/BJ20131152; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Bell RE, 2014, J INVEST DERMATOL, V134, P441, DOI 10.1038/jid.2013.340; Benaich N, 2014, CELL REP, V9, P104, DOI 10.1016/j.celrep.2014.08.062; Carling D, 2008, INT J OBESITY, V32, pS55, DOI 10.1038/ijo.2008.124; Cermelli S, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014209; Chen P, 2013, EXP LUNG RES, V39, P9, DOI 10.3109/01902148.2012.744115; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; Courchet J, 2013, CELL, V153, P1510, DOI 10.1016/j.cell.2013.05.021; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; DREXLER HG, 1989, BLOOD, V73, P1656; Evan GI, 2005, COLD SH Q B, V70, P263, DOI 10.1101/sqb.2005.70.054; Fisher JS, 2005, AM J PHYSIOL-ENDOC M, V289, pE986, DOI 10.1152/ajpendo.00335.2004; Fogarty S, 2010, BIOCHEM J, V426, P109, DOI 10.1042/BJ20091372; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hirano M, 2006, DEV DYNAM, V235, P2229, DOI 10.1002/dvdy.20823; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Huang X, 2014, INT J MOL MED, V34, P1599, DOI 10.3892/ijmm.2014.1940; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Inazuka F, 2012, J BIOL CHEM, V287, P16379, DOI 10.1074/jbc.M111.302687; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Lasagna-Reeves CA, 2016, NEURON, V92, P407, DOI 10.1016/j.neuron.2016.09.022; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Li RJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19360; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Monteverde T, 2015, FEBS J, V282, P4658, DOI 10.1111/febs.13534; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Muthalagu N, 2014, CELL REP, V8, P1347, DOI 10.1016/j.celrep.2014.07.057; Obayashi M, 2016, ONCOTARGET, V7, P8223, DOI 10.18632/oncotarget.6972; Ohmura T, 2012, DEV DYNAM, V241, P1350, DOI 10.1002/dvdy.23816; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Phippen NT, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2015.00213; Popovics P, 2015, EXPERT OPIN THER TAR, V19, P617, DOI 10.1517/14728222.2015.1005603; Raffeiner P, 2017, ONCOTARGET, V8, P3327, DOI 10.18632/oncotarget.13759; Reihill JA, 2007, BIOCHEM BIOPH RES CO, V354, P1084, DOI 10.1016/j.bbrc.2007.01.110; Reyland ME, 2007, APOPTOSIS CELL SIGNA, V2, P1; Riester M, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju048; Ross FA, 2016, FEBS J, V283, P2987, DOI 10.1111/febs.13698; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shi L, 2014, BRIT J CANCER, V111, P2316, DOI 10.1038/bjc.2014.580; Vincent EE, 2015, ONCOGENE, V34, P3627, DOI 10.1038/onc.2014.301; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Whelan RDH, 1999, CELL GROWTH DIFFER, V10, P271; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiong XK, 2015, BIOCHEM BIOPH RES CO, V465, P262, DOI 10.1016/j.bbrc.2015.08.013; Zagorska A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000616; Zhang HY, 2015, ONCOL REP, V34, P1193, DOI 10.3892/or.2015.4113; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010	64	18	19	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					982	992		10.1038/onc.2017.394	http://dx.doi.org/10.1038/onc.2017.394			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106388	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000425905700002
J	Wang, LF; Liu, YS; Yang, B; Li, P; Cheng, XS; Xiao, CX; Liu, JJ; Li, S; Ren, JL; Guleng, B				Wang, L-F; Liu, Y-S; Yang, B.; Li, P.; Cheng, X-S; Xiao, C-X; Liu, J-J; Li, S.; Ren, J-L; Guleng, B.			The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation	ONCOGENE			English	Article							PATTERN-RECOGNITION MOLECULE; TRANSCRIPTION FACTOR EGR-1; THYROID-HORMONE; BREAST-CANCER; CELLS; EXPRESSION; GROWTH; SPONDIN-2; INJURY; IDENTIFICATION	Mindin, a secreted, highly conserved extracellular matrix (ECM) protein, exerts a broad spectrum of effects on the innate immune system. However, its function in colorectal cancer (CRC) progression is not well established, and its upstream regulation mechanisms remain unclear. Contrary to previous reports, this study used two different enzyme-linked immunosorbent assay (ELISA) kits to show that the serum level of mindin was significantly decreased in CRC patients and that this decreased level is more significantly associated with the early stages of the disease. To explore the regulation of mindin, we used a bioinformatics approach to predict potential transcription factors and determined that early growth response factor (Egr)-1 directly regulates mindin expression at the transcriptional level using dual luciferase, chromatin immunoprecipitation (ChIP) DNA and electrophoretic mobility shift assay (EMSA) methods. Egr-1 regulates mindin mRNA and protein expression in CRC cells, and the protein expression of both Egr-1 and mindin was significantly decreased in tumor lesions of patients compared with adjacent control tissues. Mindin is essential for Egr-1-mediated inhibition of endothelial cell tube formation, and mindin inhibits endotheliocyte proliferation, migration and angiogenic sprouts in vitro. Overexpression of mindin suppressed xenograft tumor growth by blocking angiogenesis instead of directly suppressing CRC cell proliferation. Mechanically, mindin inhibits the hypoxia-induced HIF-1a and VEGFA protein expression in CRC cells and the phosphorylation of VEGFR-2 in endothelial cells. The results suggest that the serum level of mindin can be used as a novel biomarker for early detection of CRC and that the Egr-1/mindin axis is a potential therapeutic target for the inhibition of angiogenesis in CRC development.	[Wang, L-F; Liu, Y-S; Yang, B.; Li, P.; Cheng, X-S; Xiao, C-X; Liu, J-J; Ren, J-L; Guleng, B.] Xiamen Univ, Dept Gastroenterol, Zhongshan Hosp, 201 Hubin South Rd, Xiamen 361004, Fujian, Peoples R China; [Li, P.] Zhejiang Univ, Childrens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Li, S.] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing, Peoples R China; [Guleng, B.] Xiamen Univ, Fac Clin Med, Med Coll, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China; [Guleng, B.] Xiamen Univ, State Key Lab Cellular Stress Biol, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Zhejiang University; Tsinghua University; Xiamen University; Xiamen University	Guleng, B (corresponding author), Xiamen Univ, Dept Gastroenterol, Zhongshan Hosp, 201 Hubin South Rd, Xiamen 361004, Fujian, Peoples R China.; Guleng, B (corresponding author), Xiamen Univ, Fac Clin Med, Med Coll, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China.; Guleng, B (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, 168 Univ Rd, Xiamen 361005, Fujian, Peoples R China.	bayasi@xmu.edu.cn	Li, Shao/GPX-5473-2022	Guleng, Bayasi/0000-0003-1106-5304; Li, Shao/0000-0002-8709-9167	National Natural Science Foundation of China [81570496, 81370505, 81370591, 91229201]; 973 programs in China [2015CB553800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 programs in China(National Basic Research Program of China)	The National Natural Science Foundation of China (No. 81570496, 81370505, 81370591 and 91229201) and 973 programs (2015CB553800) in China supported this study.	Adams JC, 2000, DEV DYNAM, V218, P280; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bergers G, 1998, INT J DEV BIOL, V42, P995; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cai H, 2017, ONCOGENE, V36, P318, DOI 10.1038/onc.2016.212; Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024; Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06; Duclot F, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00035; Feinstein Y, 2004, INT J BIOCHEM CELL B, V36, P975, DOI 10.1016/j.biocel.2004.01.002; Ferraro B, 2005, J CLIN ONCOL, V23, P1921, DOI 10.1200/JCO.2005.08.127; Folkman J, 2000, ACAD RADIOL, V7, P783, DOI 10.1016/S1076-6332(00)80625-X; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Fontao L, 1999, EXP CELL RES, V250, P298, DOI 10.1006/excr.1999.4549; Fournier ML, 2010, MOL CELL PROTEOMICS, V9, P271, DOI 10.1074/mcp.M900415-MCP200; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Guleng B, 2010, WORLD J GASTROENTERO, V16, P1070, DOI 10.3748/wjg.v16.i9.1070; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He YW, 2004, NAT IMMUNOL, V5, P88, DOI 10.1038/ni1021; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jia W, 2005, BLOOD, V106, P3854, DOI 10.1182/blood-2005-04-1658; Jia W, 2008, J IMMUNOL, V180, P6255, DOI 10.4049/jimmunol.180.9.6255; Jing FY, 2014, TUMOR BIOL, V35, P9233, DOI 10.1007/s13277-014-2197-1; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Li DP, 2013, ONCOTARGET, V4, P1373, DOI 10.18632/oncotarget.1165; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liu Jingbo, 2007, Cancer Genomics & Proteomics, V4, P377; Liu MJ, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-14; Liu Y, 2007, VISION RES, V47, P2314, DOI 10.1016/j.visres.2007.04.023; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155; Murakoshi M, 2011, NEPHROL DIAL TRANSPL, V26, P2153, DOI 10.1093/ndt/gfq708; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nie L, 2014, SMALL, V10, P1441; Parry R, 2005, CANCER RES, V65, P8397, DOI 10.1158/0008-5472.CAN-05-1203; Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Qin M, 2015, INT J COLORECTAL DIS, V30, P353, DOI 10.1007/s00384-014-2090-9; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Romanuik TL, 2009, AM J PATHOL, V175, P2264, DOI 10.2353/ajpath.2009.080868; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Scharnhorst V, 2000, ONCOGENE, V19, P791, DOI 10.1038/sj.onc.1203390; Schmid F, 2016, ONCOGENE, V35, P5942, DOI 10.1038/onc.2015.451; Shin SY, 2010, MOL CANCER RES, V8, P507, DOI 10.1158/1541-7786.MCR-09-0454; Simon I, 2007, GYNECOL ONCOL, V106, P112, DOI 10.1016/j.ygyno.2007.03.007; Sobolewski C, 2015, BIOMOLECULES, V5, P2035, DOI 10.3390/biom5032035; Tan K, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-22; Villani F, 2008, TUMORI J, V94, P803; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Zhang M, 2014, WORLD J GASTROENTERO, V20, P5082, DOI 10.3748/wjg.v20.i17.5082; Zhang Q, 2015, ONCOTARGET, V6, P15095, DOI 10.18632/oncotarget.3822; Zhu LH, 2015, CLIN SCI, V129, P129, DOI 10.1042/CS20140679; Zhu LH, 2014, J HEPATOL, V60, P1046, DOI 10.1016/j.jhep.2014.01.011; Zwang Y, 2012, CANCER RES, V72, P1051, DOI 10.1158/0008-5472.CAN-11-3382	56	34	35	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					601	615		10.1038/onc.2017.359	http://dx.doi.org/10.1038/onc.2017.359			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991232				2022-12-28	WOS:000423812200006
J	Ashikari, D; Takayama, K; Tanaka, T; Suzuki, Y; Obinata, D; Fujimura, T; Urano, T; Takahashi, S; Inoue, S				Ashikari, D.; Takayama, K.; Tanaka, T.; Suzuki, Y.; Obinata, D.; Fujimura, T.; Urano, T.; Takahashi, S.; Inoue, S.			Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; BINDING-PROTEINS; RECEPTOR; MDM2; PROMOTES; CELLS; EXPRESSION; NETWORK; RNA; TUMORIGENESIS	The androgen receptor (AR) has a central role in prostate cancer progression, particularly treatment-resistance disease including castration-resistant prostate cancer. Loss of the p53 tumor suppressor, a nuclear transcription factor, is also known to contribute to prostate malignancy. Here we report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of AR. G3BP2 induces both cell cycle progression and blocks apoptosis. Translocation of p53 is regulated by androgen-dependent sumoylation mediated by the G3BP2-interacting SUMO-E3 ligase, RanBP2. G3BP2 knockdown results in reduced tumor growth and increased nuclear p53 accumulation in mouse xenograft models of prostate cancer with or without long-term androgen deprivation. Moreover, strong cytoplasmic p53 localization is correlated clinically with elevated G3BP2 expression and predicts poor prognosis and disease progression to the hormone-refractory state. Our findings reveal a new AR-mediated mechanism of p53 inhibition that promotes treatment-resistant prostate cancer.	[Ashikari, D.; Takayama, K.; Obinata, D.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Tokyo, Japan; [Ashikari, D.; Obinata, D.; Takahashi, S.] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Takayama, K.; Obinata, D.; Inoue, S.] Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontol, Tokyo, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chiba, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Div Endocrinol & Metab, Chiba, Japan; [Suzuki, Y.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Funct Genom, Chiba, Japan; [Fujimura, T.] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; [Inoue, S.] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Hidaka, Japan	University of Tokyo; Nihon University; Tokyo Metropolitan Institute of Gerontology; Chiba University; Chiba University; University of Tokyo; University of Tokyo; Saitama Medical University	Inoue, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	sinoue@tmig.or.jp	Urano, Tomohiko/AFS-9574-2022; Takayama, Kenichi/AAK-9238-2020	Tanaka, Tomoaki/0000-0002-9761-1750	Grants of the Cell Innovation Program; P-Direct from the MEXT, Japan; JSPS, Japan; MHLW, Japan; Program for Promotion of Fundamental Studies in Health Sciences; NIBIO, Japan; Takeda Science Foundation; Mochida Memorial Research Foundation, Japan; Yasuda Memorial Foundation; Princess Takamatsu Cancer Research Fund	Grants of the Cell Innovation Program; P-Direct from the MEXT, Japan; JSPS, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW, Japan; Program for Promotion of Fundamental Studies in Health Sciences; NIBIO, Japan(National Institute of Biomedical Innovation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Research Foundation, Japan; Yasuda Memorial Foundation; Princess Takamatsu Cancer Research Fund	We thank Professor Takashi Suzuki (Tohoku University) for comments on our pathological analysis. We thank E Sakamoto and N Sasaki for technical assistance. This work was supported by Grants of the Cell Innovation Program and the P-Direct (both to SI) from the MEXT, Japan; by Grants (to SI and KT) from the JSPS, Japan; by Grants-in-Aid (to SI) from the MHLW, Japan; by the Program for Promotion of Fundamental Studies in Health Sciences (to SI), NIBIO, Japan; by Grants from Takeda Science Foundation (to SI and KT); and by Grants from Mochida Memorial Research Foundation (to KT), Japan, the Yasuda Memorial Foundation (to KT) and Princess Takamatsu Cancer Research Fund (to KT).	Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chappell WH, 2012, CELL CYCLE, V11, P4579, DOI 10.4161/cc.22852; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guttler T, 2011, EMBO J, V30, P3457, DOI 10.1038/emboj.2011.287; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irvine K, 2004, INT J DEV BIOL, V48, P1065, DOI 10.1387/ijdb.041893ki; Jenkins LMM, 2012, CARCINOGENESIS, V33, P1441, DOI 10.1093/carcin/bgs145; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Lu X, 2013, ONCOGENE, V32, P2900, DOI 10.1038/onc.2012.299; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Misawa A, 2016, J BIOL CHEM, V291, P17861, DOI 10.1074/jbc.M116.718536; Moretti RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093713; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Ohtsubo C, 2009, CANCER SCI, V100, P1291, DOI 10.1111/j.1349-7006.2009.01180.x; Parker F, 1996, MOL CELL BIOL, V16, P2561; Quinn DI, 2000, CANCER RES, V60, P1585; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Santiago A, 2013, MOL BIOL CELL, V24, P2739, DOI 10.1091/mbc.E12-10-0771; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Stattin P, 1996, EUR UROL, V30, P65; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; Winslow S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-156	47	40	44	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6272	6281		10.1038/onc.2017.225	http://dx.doi.org/10.1038/onc.2017.225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692047				2022-12-28	WOS:000414774800006
J	Garnett, S; Dutchak, KL; McDonough, RV; Dankort, D				Garnett, S.; Dutchak, K. L.; McDonough, R. V.; Dankort, D.			p53 loss does not permit escape from Braf(V600E)-induced senescence in a mouse model of lung cancer	ONCOGENE			English	Article							CELL-CYCLE ARREST; K-RAS ONCOGENE; SOMATIC MUTATIONS; SIGNALING PATHWAY; CDKN2A LOCUS; OPEN-LABEL; PTEN LOSS; IN-VIVO; BRAF; ACTIVATION	Lung cancer arises through the acquisition of a number of genetic lesions, with a preponderance of activating mutations in the canonical mitogen-activated protein kinase (MAPK) cascade (RTK-RAS-RAF-MEK). Braf(V600E) expression induces benign lung adenomas that fail to progress to adenocarcinoma because of oncogene-induced senescence (OIS). BrafV600E expression, coupled with simultaneous p53 ablation, permits bypass of senescence and progression to lung adenocarcinoma. However, spontaneous human tumors sustain mutations in a temporally separated manner. Here, we use a mouse lung cancer model where oncogene activation (Braf(V600E) expression) and tumor suppressor loss (p53 ablation) are independently controlled through the actions of Flp and Cre recombinase, respectively. We show that p53 loss before OIS is permissive for the transition from lung adenoma to adenocarcinoma. In contrast, p53 loss after senescence is established fails to enable escape from senescence and disease progression. This study demonstrates that Braf(V600E) induced senescence is irreversible in vivo and suggests that therapy-induced senescence would halt further tumor progression.	[Garnett, S.; Dutchak, K. L.; McDonough, R. V.; Dankort, D.] McGill Univ, Dept Biol, 1205 Ave Docteur Penfield,Stewart Bldg,N3-17, Montreal, PQ H3A 1B1, Canada; [Dankort, D.] Goodman Canc Res Ctr, Montreal, PQ, Canada	McGill University	Dankort, D (corresponding author), McGill Univ, Dept Biol, 1205 Ave Docteur Penfield,Stewart Bldg,N3-17, Montreal, PQ H3A 1B1, Canada.	david.dankort@mcgill.ca		Dankort, David/0000-0002-5862-6829	Canadian Institutes of Health Research (CIHR) [MOP-97925]; Canadian Cancer Society Research Initiative [704228]; Cancer Research Society [19087]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Initiative; Cancer Research Society	DD would like to thank Martin McMahon for his generosity and guidance, which enabled this work. We thank members of the Dankort lab for discussions, Eve Bigras for administrative assistance, Drs Siegfried Hekimi, Alain Nepveu and Peter M Siegel for critical comments. We thank the lab of Dr Hoang Trang for providing necessary reagents. These studies were supported by grants from the Canadian Institutes of Health Research (CIHR, MOP-97925), Canadian Cancer Society Research Initiative (no. 704228) and Cancer Research Society (no. 19087).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Ameyar-Zazoua M, 2005, ONCOGENE, V24, P2298, DOI 10.1038/sj.onc.1208424; Baek KH, 2013, J CLIN INVEST, V123, P4375, DOI 10.1172/JCI67465; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; BENNETT WP, 1995, CANCER DETECT PREV, V19, P503; Bieging-Rolett KT, 2016, ONCOGENE, V35, P4414, DOI 10.1038/onc.2015.490; Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091; Chakradeo S, 2016, CURR DRUG TARGETS, V17, P460, DOI 10.2174/1389450116666150825113500; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Eroglu Z, 2016, THER ADV MED ONCOL, V8, P48, DOI 10.1177/1758834015616934; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Huillard E, 2012, P NATL ACAD SCI USA, V109, P8710, DOI 10.1073/pnas.1117255109; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim ES, 2016, ADV EXP MED BIOL, V893, P189, DOI 10.1007/978-3-319-24223-1_10; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Ko A, 2016, BMB REP, V49, P598, DOI 10.5483/BMBRep.2016.49.11.120; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Lemjabbar-Alaoui H, 2015, BBA-REV CANCER, V1856, P189, DOI 10.1016/j.bbcan.2015.08.002; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lipsyc M, 2015, J GASTROINTEST ONCOL, V6, P645, DOI 10.3978/j.issn.2078-6891.2015.045; Mallakin A, 2007, CANCER CELL, V12, P381, DOI 10.1016/j.ccr.2007.08.034; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Muzumdar MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12685; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Noguchi M, 2010, CANCER METAST REV, V29, P15, DOI 10.1007/s10555-010-9210-y; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Puzanov I, 2010, SEMIN CUTAN MED SURG, V29, P196, DOI 10.1016/j.sder.2010.06.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shai A, 2015, CANCER RES, V75, P3167, DOI 10.1158/0008-5472.CAN-14-3701; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tabor V, 2014, CANCER RES, V74, P4222, DOI 10.1158/0008-5472.CAN-13-3234; Trejo CL, 2013, CANCER RES, V73, P6448, DOI 10.1158/0008-5472.CAN-13-0681; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Turski ML, 2016, MOL CANCER THER, V15, P533, DOI 10.1158/1535-7163.MCT-15-0643; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Volanakis EJ, 2009, BLOOD, V114, P4451, DOI 10.1182/blood-2009-07-233346; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang JQ, 2012, CANCER RES, V72, P4765, DOI 10.1158/0008-5472.CAN-12-0820; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	86	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6325	6335		10.1038/onc.2017.235	http://dx.doi.org/10.1038/onc.2017.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28745322				2022-12-28	WOS:000414774800011
J	Jain, P; Fierst, TM; Han, HJ; Smith, TE; Vakil, A; Storm, PB; Resnick, AC; Waanders, AJ				Jain, P.; Fierst, T. M.; Han, H. J.; Smith, T. E.; Vakil, A.; Storm, P. B.; Resnick, A. C.; Waanders, A. J.			CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles	ONCOGENE			English	Article							RNA-BINDING PROTEIN; RAF INHIBITORS; MAPK PATHWAY; PARADOXICAL ACTIVATION; PROSTATE-CANCER; KINASE FUSIONS; NERVOUS-SYSTEM; GASTRIC-CANCER; SOLID TUMORS; BRAF	Pediatric low-grade gliomas (PLGGs) are commonly associated with BRAF gene fusions that aberrantly activate the mitogenactivated protein kinase (MAPK) signaling pathway. This has led to PLGG clinical trials utilizing RAF- and MAPK pathway-targeted therapeutics. Whole-genome profiling of PLGGs has also identified rare gene fusions involving another RAF isoform, CRAF/RAF1, in PLGGs and cancers occuring in adults. Whereas BRAF fusions primarily dysregulate MAPK signaling, the CRAF fusions QKI-RAF1 and SRGAP3-RAF1 aberrantly activate both the MAPK and phosphoinositide-3 kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathways. Although ATP-competitive, first-generation RAF inhibitors (vemurafenib/PLX4720, RAFi) cause paradoxical activation of the MAPK pathway in BRAF-fusion tumors, inhibition can be achieved with 'paradox breaker' RAFi, such as PLX8394. Here we report that, unlike BRAF fusions, CRAF fusions are unresponsive to both generations of RAFi, vemurafenib and PLX8394, highlighting a distinct responsiveness of CRAF fusions to clinically relevant RAFi. Whereas PLX8394 decreased BRAF-fusion dimerization, CRAF-fusion dimerization is unaffected primarily because of robust protein-protein interactions mediated by the N-terminal non-kinase fusion partner, such as QKI. The pan-RAF dimer inhibitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling. In addition, as CRAF fusions activate both the MAPK and PI3K/mTOR signaling pathways, we identify combinatorial inhibition of the MAPK/mTOR pathway as a potential therapeutic strategy for CRAF-fusiondriven tumors. Overall, we define a mechanistic distinction between PLGG-associated BRAF-and CRAF/RAF1 fusions in response to RAFi, highlighting the importance of molecularly classifying PLGG patients for targeted therapy. Furthermore, our study uncovers an important contribution of the non-kinase fusion partner to oncogenesis and potential therapeutic strategies against PLGG-associated CRAF fusions and possibly pan-cancer CRAF fusions.	[Jain, P.; Han, H. J.; Storm, P. B.; Resnick, A. C.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Jain, P.] Univ Penn, Perelman Sch Med, Cell & Mol Grad Grp, Philadelphia, PA 19104 USA; [Jain, P.; Fierst, T. M.; Han, H. J.; Smith, T. E.; Vakil, A.; Storm, P. B.; Resnick, A. C.] Childrens Hosp Philadelphia, Div Neurosurg, CTRB 4052,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Fierst, T. M.] Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA USA; [Storm, P. B.; Resnick, A. C.; Waanders, A. J.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Storm, P. B.; Resnick, A. C.; Waanders, A. J.] Childrens Hosp Philadelphia, Ctr Data Driven Discovery Biomed D3b, Philadelphia, PA 19104 USA; [Resnick, A. C.] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Waanders, A. J.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Waanders, A. J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Resnick, AC (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, CTRB 4052,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.; Waanders, AJ (corresponding author), Dept Pediat, CTRB 4030,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	RESNICK@email.chop.edu; WAANDERSA@email.chop.edu		Jain, Payal/0000-0002-5914-9083	Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation; Voices Against Brain Cancer; Children's Brain Tumor Foundation; Damon-Runyon Sohn Pediatric Fellowship Award; Hyundai Scholar Grant; Bear Necessities Pediatric Cancer Foundation; Rally Foundation for Childhood Cancer Research; Thea's Star of HopeNIH National Center for Advancing Translational Sciences Award [TL1TR000138]; National Institute of Health grant [R01NS085336]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS085336] Funding Source: NIH RePORTER	Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation; Voices Against Brain Cancer; Children's Brain Tumor Foundation; Damon-Runyon Sohn Pediatric Fellowship Award; Hyundai Scholar Grant; Bear Necessities Pediatric Cancer Foundation; Rally Foundation for Childhood Cancer Research; Thea's Star of HopeNIH National Center for Advancing Translational Sciences Award; National Institute of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Plexxikon Inc. for providing PLX4720 and PLX8394/PB-3 compounds and GlaxoSmithKline for providing trametinib. We greatly appreciate Jake Budlow, Tim Delaney, Namrata Choudhari and Katie Boucher for excellent technical assistance, and all members of the Resnick Lab for helpful discussion. We thank Dr Matthew Weitzman and Dr Mateusz P Koptyra for careful reading of the manuscript, and Dr Koptyra for helping with revision. This work was funded by the A Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation (ACR), Voices Against Brain Cancer (ACR), the Children's Brain Tumor Foundation (ACR, AJW), the Damon-Runyon Sohn Pediatric Fellowship Award (AJW), a Hyundai Scholar Grant (AJW), the Bear Necessities Pediatric Cancer Foundation (AJW, ACR), the Rally Foundation for Childhood Cancer Research (AJW), Thea's Star of Hope (ACR, AJW), NIH National Center for Advancing Translational Sciences Award TL1TR000138 (HJH) and the National Institute of Health grant R01NS085336 (ACR).	Ali M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057345; Antony R, 2013, CANCER RES, V73, P4840, DOI 10.1158/0008-5472.CAN-12-4089; Bandopadhayay P, 2016, NAT GENET, V48, P273, DOI 10.1038/ng.3500; Bax DA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005209; Beuck C, 2012, J MOL BIOL, V423, P766, DOI 10.1016/j.jmb.2012.08.027; Bian YQ, 2012, BIOCHEM BIOPH RES CO, V422, P187, DOI 10.1016/j.bbrc.2012.04.138; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Carlson BR, 2011, J NEUROSCI, V31, P2447, DOI 10.1523/JNEUROSCI.4433-10.2011; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Danan-Gotthold M, 2015, NUCLEIC ACIDS RES, V43, P5130, DOI 10.1093/nar/gkv210; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Freeman Alyson K, 2013, Small GTPases, V4, P180, DOI 10.4161/sgtp.26117; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; FRIEDRIC.VL, 1974, BRAIN RES, V82, P168, DOI 10.1016/0006-8993(74)90902-0; Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Henne WM, 2007, STRUCTURE, V15, P839, DOI 10.1016/j.str.2007.05.002; Henry JR, 2015, J MED CHEM, V58, P4165, DOI 10.1021/acs.jmedchem.5b00067; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Karajannis MA, 2014, NEURO-ONCOLOGY, V16, P1408, DOI 10.1093/neuonc/nou059; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lahoz A, 2013, ONCOGENE, V32, P4854, DOI 10.1038/onc.2012.489; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li ZZ, 2002, JPN J CANCER RES, V93, P167, DOI 10.1111/j.1349-7006.2002.tb01255.x; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Olow A, 2016, CLIN CANCER RES, V22, P5312, DOI 10.1158/1078-0432.CCR-15-1101; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Phillips JJ, 2016, ACTA NEUROPATHOL, V132, P757, DOI 10.1007/s00401-016-1616-3; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rothrock CR, 2005, EMBO J, V24, P2792, DOI 10.1038/sj.emboj.7600745; Selt F, 2017, ONCOTARGET, V8, P11460, DOI 10.18632/oncotarget.14004; Shingu T, 2017, NAT GENET, V49, P75, DOI 10.1038/ng.3711; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Sievert AJ, 2009, BRAIN PATHOL, V19, P449, DOI 10.1111/j.1750-3639.2008.00225.x; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Tolcher AW, 2015, ANN ONCOL, V26, P58, DOI 10.1093/annonc/mdu482; Varga A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8482; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Wu X, 2012, MOL CELL BIOL, V32, P3872, DOI 10.1128/MCB.00751-12; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Zhao Y, 2014, CANCER BIOL THER, V15, P108, DOI 10.4161/cbt.26722; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	55	38	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6348	6358		10.1038/onc.2017.276	http://dx.doi.org/10.1038/onc.2017.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28806393	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000414774800013
J	Song, Y; Li, S; Ray, A; Das, DS; Qi, J; Samur, MK; Tai, YT; Munshi, N; Carrasco, RD; Chauhan, D; Anderson, KC				Song, Y.; Li, S.; Ray, A.; Das, D. S.; Qi, J.; Samur, M. K.; Tai, Y-T; Munshi, N.; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.			Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; 26S PROTEASOME; MITOCHONDRIAL MORPHOLOGY; DEUBIQUITINATING ENZYMES; PROTEIN-DEGRADATION; SUBUNIT RPN11; UBIQUITIN; CYCLE; DEXAMETHASONE; COMBINATION	Proteasome inhibition is an effective therapy for multiple myeloma (MM) patients; however, the emergence of drug resistance is common. Novel therapeutic strategies to overcome proteasome inhibitor resistance are needed. In this study, we examined whether targeting deubiquitylating (DUB) enzymes upstream of 20S proteasome overcomes proteasome inhibitor resistance. Gene expression analysis, immunohistochemical studies of MM patient bone marrow, reverse transcription-PCR and protein analysis show that Rpn11/POH1, a DUB enzyme upstream of 20S proteasome, is more highly expressed in patient MM cells than in normal plasma cells. Importantly, Rpn11 expression directly correlates with poor patient survival. Loss-of-function studies show that Rpn11-siRNA knockdown decreases MM cell viability. Pharmacological inhibition of Rpn11 with O-phenanthroline (OPA) blocks cellular proteasome function, induces apoptosis in MM cells and overcomes resistance to proteasome inhibitor bortezomib. Mechanistically, Rpn11 inhibition in MM cells activates caspase cascade and endoplasmic stress response signaling. Human MM xenograft model studies demonstrate that OPA treatment reduces progression of tumor growth and prolongs survival in mice. Finally, blockade of Rpn11 increases the cytotoxic activity of anti-MM agents lenalidomide, pomalidomide or dexamethasone. Overall, our preclinical data provide the rationale for targeting DUB enzyme Rpn11 upstream of 20S proteasome to enhance cytotoxicity and overcome proteasome inhibitor resistance in MM.	[Song, Y.; Ray, A.; Das, D. S.; Samur, M. K.; Tai, Y-T; Munshi, N.; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, LeBow Inst Myeloma Therapeut, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA; [Song, Y.; Ray, A.; Das, D. S.; Samur, M. K.; Tai, Y-T; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA; [Li, S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Qi, J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, LeBow Inst Myeloma Therapeut, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA.; Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA.	Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021	Samur, Mehmet/0000-0002-9978-5682	National Institutes of Health Specialized Programs of Research Excellence (SPORE) [P50100707, R01CA207237, RO1CA050947]; NATIONAL CANCER INSTITUTE [P01CA155258, R01CA207237, R01CA050947, P50CA100707] Funding Source: NIH RePORTER	National Institutes of Health Specialized Programs of Research Excellence (SPORE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This investigation was supported by National Institutes of Health Specialized Programs of Research Excellence (SPORE) Grants P50100707, R01CA207237 and RO1CA050947. KCA is an American Cancer Society Clinical Research Professor.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Avet-Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood-2006-08-040410; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Chauhan D, 2013, CLIN CANCER RES, V19, P3019, DOI 10.1158/1078-0432.CCR-12-3752; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Gallery M, 2007, MOL CANCER THER, V6, P262, DOI 10.1158/1535-7163.MCT-06-0542; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7; Hershko A, 2005, ANGEW CHEM INT EDIT, V44, P5932, DOI 10.1002/anie.200501724; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888; Lander GC, 2012, NATURE, V482, P186, DOI 10.1038/nature10774; Lasker K, 2012, P NATL ACAD SCI USA, V109, P1380, DOI 10.1073/pnas.1120559109; Lee MJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R110.003871; Lim KH, 2013, CURR PHARM DESIGN, V19, P4039, DOI 10.2174/1381612811319220013; Liu CW, 2013, TRENDS BIOCHEM SCI, V38, P103, DOI 10.1016/j.tibs.2012.11.009; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11; Richardson PG, 2014, BLOOD, V123, P1461, DOI 10.1182/blood-2013-07-517276; Richardson PG, 2014, BLOOD, V123, P1826, DOI 10.1182/blood-2013-11-538835; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Richardson PG, 2009, J CLIN ONCOL, V27, P5713, DOI 10.1200/JCO.2009.22.2679; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rinaldi T, 2004, BIOCHEM J, V381, P275, DOI 10.1042/BJ20040008; Rinaldi T, 2002, GENE, V286, P43, DOI 10.1016/S0378-1119(01)00799-5; Song Y, 2016, LEUKEMIA, V30, P1877, DOI 10.1038/leu.2016.97; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Spataro V, 2002, ANTICANCER RES, V22, P3905; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang B., 2015, MATH PROBL ENG, V2015, P1, DOI DOI 10.13140/RG.2.1.1735.6249; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	47	56	57	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5631	5638		10.1038/onc.2017.172	http://dx.doi.org/10.1038/onc.2017.172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581522	Green Accepted			2022-12-28	WOS:000412293600007
J	Pek, M; Yatim, SMJM; Chen, Y; Li, J; Gong, M; Jiang, X; Zhang, F; Zheng, J; Wu, X; Yu, Q				Pek, M.; Yatim, S. M. J. M.; Chen, Y.; Li, J.; Gong, M.; Jiang, X.; Zhang, F.; Zheng, J.; Wu, X.; Yu, Q.			Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer	ONCOGENE			English	Article							SYNTHETIC LETHAL INTERACTION; RECEPTOR TYROSINE KINASES; PANCREATIC-CANCER; MUTATION STATUS; DNA-DAMAGE; CELL-CYCLE; FOXM1; PROLIFERATION; SUPPRESSION; TRANSCRIPTION	Therapeutic strategies against KRAS mutant colorectal cancers are developed using cell line models, which do not accurately represent the transcriptome driven by oncogenic KRAS in tumors. We sought to identify a KRAS-associated gene signature from colorectal tumors to develop a precise treatment strategy. Integrative analysis of quantitative KRAS mutation detection and matched gene expression profiling in 55 CRC bulk tumors was carried out to define a gene signature enriched in CRC tumors with high KRAS mutation. The KRAS-associated gene signature identified exhibits functional enrichment in cell cycle and mitosis processes, and includes mitotic transcription factor, FOXM1. Combination treatment of CDK4/6 inhibitor Palbociclib and MEK inhibitor PD0325901 was tested in KRAS-mutant, BRAF-mutant CRC, normal colon epithelial lines and xenografts models to determine their efficacy and toxicity and to monitor the changes in the gene signature. Inhibiting CDK4/6, an upstream regulator of FOXM1, and MEK synergistically depleted FOXM1 and KRAS-associated gene signature, suggesting that CDK4/6 and MEK regulate the KRAS gene signature. The combined inhibition of CDK4/6 and MEK elicited a robust therapeutic response in KRAS-dependent and BRAF-mutant CRC, both in vitro and in vivo and this correlated with downregulation of the KRAS-associated gene signature. Our preclinical study demonstrated the efficacy of Palbociclib and PD0325901 combinatorial treatment selectively in KRAS-dependent and BRAF-mutant CRC but not in normal colon epithelial cells. The KRAS-associated gene signature could facilitate the identification of responsive metastatic CRC to this therapeutic strategy in clinical settings.	[Pek, M.; Yatim, S. M. J. M.; Chen, Y.; Gong, M.; Jiang, X.; Yu, Q.] ASTAR, Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Singapore, Singapore; [Pek, M.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Chen, Y.; Wu, X.] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China; [Chen, Y.; Wu, X.] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China; [Li, J.] ASTAR, Genome Inst Singapore, Computat Biol, Singapore, Singapore; [Zhang, F.; Zheng, J.] Nanyang Technol Univ, Sch Comp Engn, 50 Nanyang Ave, Singapore, Singapore; [Wu, X.] Guangdong Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Yu, Q.] Jinan Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Yu, Q.] Duke Natl Univ Singapore, Grad Med Sch Singapore, Canc & Stem Cell Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Sun Yat Sen University; Sun Yat Sen University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Jinan University; National University of Singapore	Yu, Q (corresponding author), Genome Inst Singapore, Canc Therapeut & Stratified Oncol, 60 Biopolis St,02-01, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg	Zheng, Jie/C-1356-2011; Zheng, Jie/AAX-1454-2021	Zheng, Jie/0000-0001-6774-9786; Yu, Qiang/0000-0003-2132-8278; Zhang, Fan/0000-0001-8377-0235	A*STAR of Singapore; International S&T Cooperation Program of China (ISTCP) [2013DFG32990]; National High Technology Research and Development Program (863) of China [2012AA02A520]	A*STAR of Singapore(Agency for Science Technology & Research (A*STAR)); International S&T Cooperation Program of China (ISTCP); National High Technology Research and Development Program (863) of China(National High Technology Research and Development Program of China)	This work was supported by the A*STAR of Singapore, International S&T Cooperation Program of China (ISTCP) (No. 2013DFG32990) and National High Technology Research and Development Program (863) of China (No. 2012AA02A520). We thank Puay Leng Lee for technical assistance in western blot analysis.	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kosmidou V, 2014, HUM MUTAT, V35, P329, DOI 10.1002/humu.22496; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Russo A, 2005, ANN ONCOL, V16, P44, DOI 10.1093/annonc/mdi907; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tan Y, 2010, CELL PROLIFERAT, V43, P494, DOI 10.1111/j.1365-2184.2010.00699.x; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Ziemke EK, 2016, CLIN CANCER RES, V22, P405, DOI 10.1158/1078-0432.CCR-15-0829; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	43	49	51	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4975	4986		10.1038/onc.2017.120	http://dx.doi.org/10.1038/onc.2017.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459468				2022-12-28	WOS:000408768800003
J	Cohen, N; Shani, O; Raz, Y; Sharon, Y; Hoffman, D; Abramovitz, L; Erez, N				Cohen, N.; Shani, O.; Raz, Y.; Sharon, Y.; Hoffman, D.; Abramovitz, L.; Erez, N.			Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; INFLAMMATION; CELLS; EXPRESSION; YKL-40; PROGRESSION; METASTASIS; CHI3L1; CHEMOTHERAPY; RESPONSES	Cancer-Associated Fibroblasts (CAFs) are the most prominent stromal cell type in breast tumors. CAFs promote tumor growth and metastasis by multiple mechanisms, including by mediating tumor-promoting inflammation. Immune modulation in the tumor microenvironment plays a central role in determining disease outcome. However, the functional interactions of CAFs with immune cells are largely unknown. Here we report a novel signaling axis between fibroblasts, cancer cells and immune cells in breast tumors that drives an immunosuppressive microenvironment, mediated by CAF-derived Chi3L1. We demonstrate that Chi3L1 is highly upregulated in CAFs isolated from mammary tumors and pulmonary metastases of transgenic mice, and in the stroma of human breast carcinomas. Genetic ablation of Chi3L1 in fibroblasts in vivo attenuated tumor growth, macrophage recruitment and reprogramming to an M2-like phenotype, enhanced tumor infiltration by CD8(+) and CD4(+) T cells and promoted a Th1 phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor growth and shifts the balance of the immune milieu towards type 2 immunity. Taken together, our findings implicate fibroblast-derived Chi3L1 as a novel key player in the complex reciprocal interactions of stromal cells that facilitate tumor progression and metastasis, and suggest that targeting Chi3L1 may be clinically beneficial in breast cancer.	[Cohen, N.; Shani, O.; Raz, Y.; Sharon, Y.; Hoffman, D.; Abramovitz, L.; Erez, N.] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; [Raz, Y.] Tel Aviv Sourasky Med Ctr, Dept Obstet & Gynecol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Erez, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel.	netaerez@post.tau.ac.il	Yana, Yael Raz/S-7100-2019	Abramovitz, Lilach/0000-0001-9961-9986; Erez, Neta/0000-0001-6506-9074	European Research Council under the European Union's Horizon research and innovation programme [637069 MetCAF]; Israel Science Foundation [813/12]; Israel Cancer Association; Israel Cancer Research Fund (Research Career Development Award)	European Research Council under the European Union's Horizon research and innovation programme; Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israel Cancer Research Fund (Research Career Development Award)	This research was supported by grants to NE from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 637069 MetCAF), from the Israel Science Foundation (#813/12), the Israel Cancer Association and The Israel Cancer Research Fund (Research Career Development Award). We would like to thank Dr Yaron Carmi for scientific discussions, Shahar Biechonski and Hila Schwartz for their help with data analysis and helpful discussions, and Elad Yana for graphical assistance. We thank Dr Ariel Munitz for critical reading of the manuscript. This work was performed in partial fulfillment of the requirements for a PhD of Noam Cohen, Sackler School of Medicine, Tel Aviv University.	Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Bigg HF, 2006, J BIOL CHEM, V281, P21082, DOI 10.1074/jbc.M601153200; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Erez N, 2013, BIOCHEM BIOPH RES CO, V437, P397, DOI 10.1016/j.bbrc.2013.06.089; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Eurich K, 2009, WORLD J GASTROENTERO, V15, P5249, DOI 10.3748/wjg.15.5249; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Johansen JS, 2003, BREAST CANCER RES TR, V80, P15, DOI 10.1023/A:1024431000710; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karo-Atar D, 2015, J ASTHMA, V52, P545, DOI 10.3109/02770903.2014.988222; Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498; Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Libreros S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00392; Libreros S, 2013, IMMUNOL RES, V57, P99, DOI 10.1007/s12026-013-8459-y; Libreros S, 2012, INT J CANCER, V131, P377, DOI 10.1002/ijc.26379; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Ma B, 2015, CANCER RES, V75, P487, DOI 10.1158/0008-5472.CAN-13-3339; Mantovani A, 2007, BREAST, V16, pS27, DOI 10.1016/j.breast.2007.07.013; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Martey CA, 2004, AM J PHYSIOL-LUNG C, V287, pL981, DOI 10.1152/ajplung.00239.2003; Mizrachy-Schwartz S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000628; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; Zhou Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007096	53	140	148	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4457	4468		10.1038/onc.2017.65	http://dx.doi.org/10.1038/onc.2017.65			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368410	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000406806000008
J	Loskutov, YV; Griffin, CL; Marinak, KM; Bobko, A; Margaryan, NV; Geldenhuys, WJ; Sarkaria, JN; Pugacheva, EN				Loskutov, Yuriy V.; Griffin, Caryn L.; Marinak, Kristina M.; Bobko, Andrey; Margaryan, Naira V.; Geldenhuys, Werner J.; Sarkaria, Jann N.; Pugacheva, Elena N.			LPA signaling is regulated through the primary cilium: a novel target in glioblastoma	ONCOGENE			English	Article							LYSOPHOSPHATIDIC ACID; BREAST-CANCER; CELL-PROLIFERATION; PROTEIN; RECEPTORS; GROWTH; DIFFERENTIATION; SENSITIVITY; METASTASIS; ACTIVATION	The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through G alpha 12/G alpha q was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, G alpha 12 and G alpha q are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with G alpha 12 and G alpha q. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.	[Loskutov, Yuriy V.; Griffin, Caryn L.; Marinak, Kristina M.; Pugacheva, Elena N.] West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA; [Bobko, Andrey; Margaryan, Naira V.; Pugacheva, Elena N.] West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Geldenhuys, Werner J.] West Virginia Univ, Sch Med, Dept Pharmaceut Sci, Morgantown, WV USA; [Sarkaria, Jann N.] Mayo Clin, Rochester, MN USA; [Pugacheva, Elena N.] West Virginia Univ, Sch Med, Dept Radiat Oncol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; Mayo Clinic; West Virginia University	Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, WVU Canc Inst, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, Sch Med, Dept Radiat Oncol, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu		Loskutov, Juergen/0000-0003-3472-4093; Whately, Kristina/0000-0002-5908-8145	NIH/NCI [R21CA208875, R01CA148671]; NIGMS/NIH [U54GM104942]; WVU Cancer Institute Undergraduate Research Fellowship; "Let the Journey Begin" fund; WVCTSI [U54GM104942]; WVU Cancer Institute; NIH [P20RR016440, P20 RR016477, P30RR032138/P30GM103488]; NATIONAL CANCER INSTITUTE [R21CA208875, R01CA148671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); WVU Cancer Institute Undergraduate Research Fellowship; "Let the Journey Begin" fund; WVCTSI; WVU Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants R21CA208875 (E.N. P), R01CA148671 (E.N. P) from the NIH/NCI, U54GM104942 (W.J. G) from the NIGMS/NIH, WVU Cancer Institute Undergraduate Research Fellowship (C.L.G), and "Let the Journey Begin" fund established by Erin Dunmire, WVU Cancer Institute. Andrey Bobko is supported by startup funding from WVCTSI. Naira V. Margaryan is supported by U54GM104942 from WVCTSI. West Virginia University Microscope Imaging Facility is supported by the WVU Cancer Institute and NIH grants P20RR016440, P20 RR016477 and P30RR032138/P30GM103488.	Barzi M, 2011, J BIOL CHEM, V286, P8067, DOI 10.1074/jbc.M110.178772; Barzi M, 2010, J CELL SCI, V123, P62, DOI 10.1242/jcs.060020; Basten Sander G, 2013, Cilia, V2, P6, DOI 10.1186/2046-2530-2-6; Basten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046-2530-2-2; Butowski N. A., 2016, CNS ONCOL, V6, P61; Cao ZM, 2009, ENDOCR RES, V34, P101, DOI 10.3109/07435800903204082; Carlson BL, 2011, CURR PROTOC PHARM, V14, P14; Carlson BL, 2009, INT J RADIAT ONCOL, V75, P212, DOI 10.1016/j.ijrobp.2009.04.026; Christensen ST, 2012, J PATHOL, V226, P172, DOI 10.1002/path.3004; Ezratty EJ, 2011, CELL, V145, P1129, DOI 10.1016/j.cell.2011.05.030; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gastrointestinal Complications (PDQ(R)), 2002, HLTH PROF VERS; Geldenhuys W, 2015, PHARM DEV TECHNOL, V20, P497, DOI 10.3109/10837450.2014.892130; Goldsmith Zachariah G, 2011, Genes Cancer, V2, P563, DOI 10.1177/1947601911419362; Gonzalez-Gil I, 2015, MEDCHEMCOMM, V6, P13, DOI 10.1039/c4md00333k; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Gschwind A, 2002, CANCER RES, V62, P6329; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hassounah NB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068521; Hoang-Minh LB, 2016, ONCOTARGET, V7, P7029, DOI 10.18632/oncotarget.6854; Hoelzinger DB, 2008, J NEURO-ONCOL, V86, P297, DOI 10.1007/s11060-007-9480-6; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kasaharaa K, 2014, ACTA MED OKAYAMA, V68, P317; Kim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9087; Koutcher JA, 2002, NEOPLASIA, V4, P480, DOI 10.1038/sj.neo.7900269; Kozyreva VK, 2016, MOL CANCER THER, V15, P1809, DOI 10.1158/1535-7163.MCT-15-0688; Li L, 2016, NAT CELL BIOL, V18, P418, DOI 10.1038/ncb3327; Loskutov YV, 2015, ONCOGENE, V34, P3662, DOI 10.1038/onc.2014.297; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Marley A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070857; McDowell KA, 2011, CURR PHARM DESIGN, V17, P2411; Moser JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-448; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Pal K, 2015, METHOD CELL BIOL, V127, P303, DOI 10.1016/bs.mcb.2014.12.003; Patel BR, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.45; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Portnoy S., 2008, P INT SOC MAG RESON, P3206; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Ries LAG., 2007, NIH PUB; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkisian MR, 2014, J NEURO-ONCOL, V117, P15, DOI 10.1007/s11060-013-1340-y; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Schou KB, 2015, EMBO REP, V16, P1099, DOI 10.15252/embr.201540530; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; Shano S, 2008, NEUROCHEM INT, V52, P216, DOI 10.1016/j.neuint.2007.07.004; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Wang G, 2013, J CELL SCI, V126, P1355, DOI 10.1242/jcs.114918; Yang Y, 2013, EMBO REP, V14, P741, DOI 10.1038/embor.2013.80; Yoshimura K, 2011, GLIA, V59, P333, DOI 10.1002/glia.21105; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856; Yung YC, 2014, J LIPID RES, V55, P1192, DOI 10.1194/jlr.R046458; Zhu D, 2009, J CELL SCI, V122, P2760, DOI 10.1242/jcs.046276	56	28	28	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1457	1471		10.1038/s41388-017-0049-3	http://dx.doi.org/10.1038/s41388-017-0049-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321663	Green Accepted, Green Submitted			2022-12-28	WOS:000427459500005
J	Knopfova, L; Biglieri, E; Volodko, N; Masarik, M; Hermanova, M; Garzon, JFG; Ducka, M; Kucirkova, T; Soucek, K; Smarda, J; Benes, P; Borsig, L				Knopfova, L.; Biglieri, E.; Volodko, N.; Masarik, M.; Hermanova, M.; Garzon, J. F. Glaus; Ducka, M.; Kucirkova, T.; Soucek, K.; Smarda, J.; Benes, P.; Borsig, L.			Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding	ONCOGENE			English	Article							INFLAMMATORY CHEMOKINES; GENE; CCL2; ESTROGEN; EXTRAVASATION; SURVIVAL; REVEALS; TARGET; GROWTH; BRAIN	Metastasis accounts for most of cancer-related deaths. Paracrine signaling between tumor cells and the stroma induces changes in the tumor microenvironment required for metastasis. Transcription factor c-Myb was associated with breast cancer (BC) progression but its role in metastasis remains unclear. Here we show that increased c-Myb expression in BC cells inhibits spontaneous lung metastasis through impaired tumor cell extravasation. On contrary, BC cells with increased lung metastatic capacity exhibited low c-Myb levels. We identified a specific inflammatory signature, including Ccl2 chemokine, that was expressed in lung metastatic cells but was suppressed in tumor cells with higher c-Myb levels. Tumor cell-derived Ccl2 expression facilitated lung metastasis and rescued trans-endothelial migration of c-Myb overexpressing cells. Clinical data show that the identified inflammatory signature, together with a MYB expression, predicts lung metastasis relapse in BC patients. These results demonstrate that the c-Myb-regulated transcriptional program in BCs results in a blunted inflammatory response and consequently suppresses lung metastasis.	[Knopfova, L.; Ducka, M.; Kucirkova, T.; Soucek, K.; Smarda, J.; Benes, P.] Masaryk Univ, Dept Expt Biol, Fac Sci, Brno, Czech Republic; [Knopfova, L.; Biglieri, E.; Garzon, J. F. Glaus; Benes, P.; Borsig, L.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Knopfova, L.; Biglieri, E.; Garzon, J. F. Glaus; Benes, P.; Borsig, L.] Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Knopfova, L.; Ducka, M.; Kucirkova, T.; Soucek, K.; Benes, P.] St Annes Univ Hosp, Ctr Biol & Cellular Engn, Int Clin Res Ctr, Brno, Czech Republic; [Volodko, N.] Danylo Galytsky Lviv Natl Med Univ, Dept Oncol & Med Radiol, Lvov, Ukraine; [Masarik, M.] Masaryk Univ, Dept Physiol, Fac Med, Brno, Czech Republic; [Masarik, M.] Masaryk Univ, Dept Pathol Physiol, Fac Med, Brno, Czech Republic; [Hermanova, M.] St Annes Univ Hosp, Dept Pathol Anat 1, Brno, Czech Republic; [Hermanova, M.] Masaryk Univ, Fac Med, Brno, Czech Republic; [Soucek, K.] Czech Acad Sci, Inst Biophys, Brno, Czech Republic	Masaryk University Brno; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); St Anne's University Hospital Brno (FNUSA-ICRC); Danylo Halytsky Lviv National Medical University; Masaryk University Brno; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Masaryk University Brno; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Benes, P; Borsig, L (corresponding author), Univ Zurich, Zurich Ctr Integrat Human Physiol, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	pbenes@sci.muni.cz; lborsig@access.uzh.ch	Soucek, Karel/B-3621-2008; Masarik, Michal/D-9920-2012; Benes, Petr/K-6369-2016	Soucek, Karel/0000-0001-7283-8150; Masarik, Michal/0000-0003-1172-7195; Benes, Petr/0000-0002-8297-9675; Borsig, Lubor/0000-0003-2263-9545; Hermanova, Marketa/0000-0002-3889-0905; Knopfova, Lucia/0000-0003-4897-0404	SCOPES/SNF [IZ73Z0-152361]; Czech Science Foundation [17-08985Y]; National Program of Sustainability II [LQ1605-MEYS CR]; ICRC-ERA-HumanBridge [316345]; Grant Agency of Masaryk University [MUNI/0877/2016]; SNF [310030-152901]	SCOPES/SNF; Czech Science Foundation(Grant Agency of the Czech Republic); National Program of Sustainability II; ICRC-ERA-HumanBridge; Grant Agency of Masaryk University; SNF	This work was funded by SCOPES/SNF grant IZ73Z0-152361 (L Borsig, L Knopfova and N Volodko). Further by Czech Science Foundation grant 17-08985Y (L Knopfova), National Program of Sustainability II LQ1605-MEYS CR; and ICRC-ERA-HumanBridge/no. 316345 and by the MUNI/0877/2016 project of Grant Agency of Masaryk University. This work was also supported by the SNF grant #310030-152901 (L Borsig). We acknowledge the assistance of the Center for Microscopy and Image Analysis and the Functional Genomic Center at University of Zurich.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Bauer K, 2007, INT J CANCER, V121, P1910, DOI 10.1002/ijc.22879; Bengtsen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133280; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drabsch Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2614; Fang WB, 2016, ONCOTARGET, V7, P49349, DOI 10.18632/oncotarget.9885; Gonda TJ, 2008, EXPERT OPIN BIOL TH, V8, P713, DOI [10.1517/14712598.8.6.713, 10.1517/14712598.8.6.713 ]; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gruvberger S, 2001, CANCER RES, V61, P5979; Gundem G, 2012, GENOME MED, V4, DOI 10.1186/gm327; Guo P, 2014, P NATL ACAD SCI USA, V111, P14710, DOI 10.1073/pnas.1408556111; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hatakeyama M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1104-8; Hauselmann I, 2016, CANCER RES, V76, P5302, DOI 10.1158/0008-5472.CAN-16-0784; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hugo HJ, 2015, J MAMMARY GLAND BIOL, V20, P109, DOI 10.1007/s10911-015-9333-4; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Johnstone CN, 2015, DIS MODEL MECH, V8, P237, DOI 10.1242/dmm.017830; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Knopfova L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-15; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li YH, 2016, CANCER RES, V76, P3364, DOI 10.1158/0008-5472.CAN-15-2302; Liu LYD, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/813067; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; Maurice D, 2007, EMBO J, V26, P3629, DOI 10.1038/sj.emboj.7601801; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Pekarcikova L, 2016, CELL SIGNAL, V28, P924, DOI [10.1016/j.cellsig2016.04.007, 10.1016/j.cellsig.2016.04.007]; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Roberts TK, 2012, LAB INVEST, V92, P1213, DOI 10.1038/labinvest.2012.80; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Tichy M, 2016, TUMOR BIOL, V37, P10723, DOI 10.1007/s13277-016-4956-7; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024	52	12	12	5	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1020	1030		10.1038/onc.2017.392	http://dx.doi.org/10.1038/onc.2017.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084208	Green Accepted			2022-12-28	WOS:000425905700005
J	Lucanus, AJ; Yip, GW				Lucanus, A. J.; Yip, G. W.			Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics	ONCOGENE			English	Review							SPINDLE PROTEIN INHIBITOR; FAST AXONAL-TRANSPORT; MOTOR PROTEIN; HEAVY-CHAIN; LAMELLIPODIA FORMATION; CELLS; MICROTUBULES; GENES; OVEREXPRESSION; APOPTOSIS	Breast cancer pathobiology is known to be influenced by the differential expression of a group of proteins called the kinesin superfamily (KIFs), which is instrumental in the intracellular transport of chromosomes along microtubules during mitosis. During cellular division, kinesins are strictly regulated through temporal synthesis so that they are present only when needed. However, their misregulation may contribute to uncontrolled cell growth owing to premature sister chromatid separation, highlighting their importance in cancer. This review covers the functions of kinesins in normal and breast cancer cells, the use of kinesins for breast cancer patient prognosis, and the targeting of these molecules for therapeutics. A better understanding of KIF proteins may be pivotal to improved disease outcomes for breast cancer patients.	[Lucanus, A. J.] Univ Western Australia, Sch Anat Human Biol & Physiol, Crawley, WA, Australia; [Lucanus, A. J.; Yip, G. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,Block MD 10, Singapore 117594, Singapore	University of Western Australia; National University of Singapore	Yip, GW (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,Block MD 10, Singapore 117594, Singapore.	georgeyip@nus.edu.sg		Lucanus, Anton/0000-0003-1801-5166	National Medical Research Council, Singapore [NMRC/CSA/0041/2012, NMRC/CIRG/1436/2015]; Australian Government's Department of Foreign Affairs and Trade	National Medical Research Council, Singapore(National Medical Research Council, Singapore); Australian Government's Department of Foreign Affairs and Trade(Australian Government)	The technical assistance of SL Bay in the preparation of Figure 1 is deeply appreciated. Work in the laboratory of GW Yip is supported by Grants NMRC/CSA/0041/2012 and NMRC/CIRG/1436/2015 from the National Medical Research Council, Singapore. AJ Lucanus thanks the Australian Government's Department of Foreign Affairs and Trade for the New Colombo Plan Scholarship. We apologise for the use of review articles and the failure to cite many relevant primary articles as a result of space constraints.	Ahmed SM, 2012, J CELL BIOL, V199, P951, DOI 10.1083/jcb.201206051; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Banerjee M, 2010, FEBS J, V277, P3437, DOI 10.1111/j.1742-4658.2010.07750.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Cardoso CMP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004424; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; Corson TW, 2006, INT J CANCER, V119, P1088, DOI 10.1002/ijc.21954; Corson TW, 2005, ONCOGENE, V24, P4741, DOI 10.1038/sj.onc.1208641; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Dagenbach EM, 2004, J CELL SCI, V117, P3, DOI 10.1242/jcs.00875; De Iuliis F, 2016, INVEST NEW DRUG, V34, P399, DOI 10.1007/s10637-016-0345-8; De S, 2009, CANCER RES, V69, P8035, DOI 10.1158/0008-5472.CAN-09-1224; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Feng Yu-mei, 2006, Zhonghua Yi Xue Za Zhi, V86, P2749; Feng Yu-Mei, 2006, Ai Zheng, V25, P744; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Froidevaux-Klipfel L, 2011, PROTEOMICS, V11, P3877, DOI 10.1002/pmic.201000789; Ganguly A, 2011, MOL CANCER THER, V10, P929, DOI 10.1158/1535-7163.MCT-10-1109; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Gomez HL, 2012, ANTI-CANCER DRUG, V23, P335, DOI 10.1097/CAD.0b013e32834e74d6; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Guerrero-Preston R, 2014, ONCOL REP, V32, P505, DOI 10.3892/or.2014.3262; Guido BC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1274-1; Hallen MA, 2008, J CELL SCI, V121, P3834, DOI 10.1242/jcs.038497; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holen KD, 2011, CANCER CHEMOTH PHARM, V67, P447, DOI 10.1007/s00280-010-1346-5; Hurd DD, 1996, GENETICS, V144, P1075; Itzel T, 2015, BIOINFORMATICS, V31, P216, DOI 10.1093/bioinformatics/btu586; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kasahara M, 2016, ONCOL LETT, V12, P1909, DOI 10.3892/ol.2016.4823; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Kim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9087; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Li YH, 2015, CANCER BIOL THER, V16, P1316, DOI 10.1080/15384047.2015.1070980; Liu XR, 2012, J CELL MOL MED, V16, P1298, DOI 10.1111/j.1582-4934.2011.01396.x; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Oki E, 2012, J GASTROENTEROL, V47, P351, DOI 10.1007/s00535-012-0565-4; Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304; Pannu V, 2015, ONCOTARGET, V6, P6076, DOI 10.18632/oncotarget.3475; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sanhaji M, 2011, ONCOTARGET, V2, P935; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; Scanlan M J, 2001, Cancer Immun, V1, P4; Shankaraiah N, 2014, BIOORG MED CHEM LETT, V24, P5413, DOI 10.1016/j.bmcl.2014.10.038; Shimo A, 2008, CANCER SCI, V99, P62, DOI 10.1111/j.1349-7006.2007.00635.x; Singel SM, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.008; Singel SM, 2013, CLIN CANCER RES, V19, P2061, DOI 10.1158/1078-0432.CCR-13-0082; Skold HN, 2005, J CELL SCI, V118, P1745, DOI 10.1242/jcs.02304; Suzuki K, 2008, BIOCHEM BIOPH RES CO, V368, P199, DOI 10.1016/j.bbrc.2008.01.069; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Takahashi K, 2008, EXP CELL RES, V314, P2313, DOI 10.1016/j.yexcr.2008.04.009; Tan MH, 2012, BREAST CANCER RES TR, V131, P849, DOI 10.1007/s10549-011-1500-8; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wang CQ, 2015, CANCER LETT, V368, P105, DOI 10.1016/j.canlet.2015.07.037; Wang H, 2014, MOL CELLS, V37, P812, DOI 10.14348/molcells.2014.0210; Wang JL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-461; Wang L, 2002, CURR BIOL, V12, P1496, DOI 10.1016/S0960-9822(02)01078-3; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061640; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; Wordeman L, 2010, SEMIN CELL DEV BIOL, V21, P260, DOI 10.1016/j.semcdb.2010.01.018; Wu JQ, 2013, ACS CHEM BIOL, V8, P2201, DOI 10.1021/cb400186w; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Yoon JR, 2011, BREAST CANCER RES TR, V129, P691, DOI 10.1007/s10549-010-1239-7; Zhang CP, 2010, CARCINOGENESIS, V31, P1676, DOI 10.1093/carcin/bgq134; Zhang W, 2016, BIOCHEM J, V473, P1027, DOI 10.1042/BJ20150992; Zhu L, 2016, ANTI-CANCER DRUG, V27, P863, DOI 10.1097/CAD.0000000000000402; Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459	75	64	68	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					833	838		10.1038/onc.2017.406	http://dx.doi.org/10.1038/onc.2017.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059174				2022-12-28	WOS:000425281800001
J	Serio, J; Ropa, J; Chen, W; Mysliwski, M; Saha, N; Chen, L; Wang, J; Miao, H; Cierpicki, T; Grembecka, J; Muntean, AG				Serio, J.; Ropa, J.; Chen, W.; Mysliwski, M.; Saha, N.; Chen, L.; Wang, J.; Miao, H.; Cierpicki, T.; Grembecka, J.; Muntean, A. G.			The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia	ONCOGENE			English	Article							RNA-POLYMERASE-II; ACUTE MYELOID-LEUKEMIA; JAW TUMOR SYNDROME; ARGININE-METHYLTRANSFERASE; H2B UBIQUITYLATION; MOUSE DEVELOPMENT; GENE-EXPRESSION; CELLS; TRANSCRIPTION; METHYLATION	Acute myeloid leukemia (AML) is a disease associated with epigenetic dysregulation. 11q23 translocations involving the H3K4 methyltransferase MLL1 (KMT2A) generate oncogenic fusion proteins with deregulated transcriptional potential. The polymeraseassociated factor complex (PAFc) is an epigenetic co-activator complex that makes direct contact with MLL fusion proteins and is involved in AML, however, its functions are not well understood. Here, we explored the transcriptional targets regulated by the PAFc that facilitate leukemia by performing RNA-sequencing after conditional loss of the PAFc subunit Cdc73. We found Cdc73 promotes expression of an early hematopoietic progenitor gene program that prevents differentiation. Among the target genes, we confirmed the protein arginine methyltransferase Prmt5 is a direct target that is positively regulated by a transcriptional unit that includes the PAFc, MLL1, HOXA9 and STAT5 in leukemic cells. We observed reduced PRMT5-mediated H4R3me2s following excision of Cdc73 placing this histone modification downstream of the PAFc and revealing a novel mechanism between the PAFc and Prmt5. Knockdown or pharmacologic inhibition of Prmt5 causes a G1 arrest and reduced proliferation resulting in extended leukemic disease latency in vivo. Overall, we demonstrate the PAFc regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for AMLs.	[Serio, J.; Ropa, J.; Chen, W.; Mysliwski, M.; Saha, N.; Chen, L.; Wang, J.; Miao, H.; Cierpicki, T.; Grembecka, J.; Muntean, A. G.] Univ Michigan, Dept Pathol, Med Sch, 7520B Med Sci Res Bldg 1,1301 Catherine Rd, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Muntean, AG (corresponding author), Univ Michigan, Dept Pathol, Med Sch, 7520B Med Sci Res Bldg 1,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	andrewmu@umich.edu	Saha, Nirmalya/AEF-3616-2022	SAHA, NIRMALYA/0000-0002-5624-8879; Chen, Wei/0000-0002-8316-1728; Ropa, James/0000-0001-6120-1859; Muntean, Andrew/0000-0003-3034-0682	NIH [R00 CA158136]; American Society of Hematology Scholar Award; Leukemia Research Foundation award; American Cancer Society Scholar Award [RSG-15-046]; Children's Leukemia Research Association; NATIONAL CANCER INSTITUTE [R00CA158136, R01CA207272, T32CA140044, R01CA160467] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Hematology Scholar Award; Leukemia Research Foundation award; American Cancer Society Scholar Award(American Cancer Society); Children's Leukemia Research Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Dong-Er Zhang (UCSD), Dr Wei Xu (University of Wisconsin), Dr Jean-Francois Rual and Dr Tao Xu (University of Michigan) for providing the Prmt1, Prmt4 and Prmt5 constructs, respectively, Dr Yali Dou (University of Michigan) for the MLLc antibody. This work was supported by NIH grants R00 CA158136 (AGM), an American Society of Hematology Scholar Award (AGM), a Leukemia Research Foundation award (AGM), an American Cancer Society Scholar Award RSG-15-046 (AGM) and Children's Leukemia Research Association (AGM).	Aplan PD, 2006, DNA REPAIR, V5, P1265, DOI 10.1016/j.dnarep.2006.05.034; Bandyopadhyay S, 2012, MOL CELL BIOL, V32, P1202, DOI 10.1128/MCB.05977-11; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chaudhary K, 2007, ONCOGENE, V26, P7499, DOI 10.1038/sj.onc.1210582; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen FX, 2015, CELL, V162, P1003, DOI 10.1016/j.cell.2015.07.042; Chen L, 2015, LEUKEMIA, V29, P1290, DOI 10.1038/leu.2015.18; Chen LL, 2016, ONCOTARGET, V7, P25208, DOI 10.18632/oncotarget.8199; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Cheung N, 2016, CANCER CELL, V29, P32, DOI 10.1016/j.ccell.2015.12.007; Collins CT, 2016, ONCOGENE, V35, P1090, DOI 10.1038/onc.2015.174; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; Dey P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026926; Garcia-Cuellar MP, 2016, CELL REP, V15, P310, DOI 10.1016/j.celrep.2016.03.018; Girardot M, 2014, NUCLEIC ACIDS RES, V42, P235, DOI 10.1093/nar/gkt884; Hanks S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5398; He NH, 2011, P NATL ACAD SCI USA, V108, pE636, DOI 10.1073/pnas.1107107108; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Jaehning JA, 2010, BBA-GENE REGUL MECH, V1799, P379, DOI 10.1016/j.bbagrm.2010.01.001; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Kim J, 2010, CELL, V140, P491, DOI 10.1016/j.cell.2009.12.050; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Li Li, 2003, Cancer Immun, V3, P8; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Liu F, 2015, J CLIN INVEST, V125, P3532, DOI 10.1172/JCI81749; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Miller CA, 2013, NEW ENGL J MED, V369, P1473, DOI 10.1056/NEJMc1308782; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Muntean AG, 2013, BLOOD, V122, P1914, DOI 10.1182/blood-2013-02-486977; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Newey PJ, 2010, HUM MUTAT, V31, P295, DOI 10.1002/humu.21188; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Penheiter KL, 2005, MOL CELL, V20, P213, DOI 10.1016/j.molcel.2005.08.023; Qiu HF, 2006, MOL CELL BIOL, V26, P3135, DOI 10.1128/MCB.26.8.3135-3148.2006; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Tee WW, 2010, GENE DEV, V24, P2772, DOI 10.1101/gad.606110; Tomson BN, 2013, BBA-GENE REGUL MECH, V1829, P116, DOI 10.1016/j.bbagrm.2012.08.011; Van Oss SB, 2016, MOL CELL, V64, P815, DOI 10.1016/j.molcel.2016.10.008; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Wade PA, 1996, PROTEIN EXPRES PURIF, V8, P85, DOI 10.1006/prep.1996.0077; Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yang H, 2016, ONCOTARGET, V7, P72131, DOI 10.18632/oncotarget.12351; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Youn MY, 2007, J BIOL CHEM, V282, P34727, DOI 10.1074/jbc.M705411200; Yu M, 2015, SCIENCE, V350, P1383, DOI 10.1126/science.aad2338; Zeng H, 2015, GENE DEV, V29, P2153, DOI 10.1101/gad.268722.115; Zhang BL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0721-8; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	64	20	20	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					450	460		10.1038/onc.2017.337	http://dx.doi.org/10.1038/onc.2017.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28945229	Green Accepted			2022-12-28	WOS:000423331600004
J	Venkatesan, N; Wong, JF; Tan, KP; Chung, HH; Yau, YH; Cukuroglu, E; Allahverdi, A; Nordenskiold, L; Goke, J; Geifman-Shochat, S; Lin, VCL; Madhusudhan, MS; Su, IH				Venkatesan, N.; Wong, J. F.; Tan, K. P.; Chung, H. H.; Yau, Y. H.; Cukuroglu, E.; Allahverdi, A.; Nordenskiold, L.; Goke, J.; Geifman-Shochat, S.; Lin, V. C. L.; Madhusudhan, M. S.; Su, I-h			EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms	ONCOGENE			English	Article							GROUP PROTEIN EZH2; C-MYC PROMOTER; ACUTE LYMPHOBLASTIC-LEUKEMIA; EMBRYONIC STEM-CELLS; POLYCOMB GROUP GENE; PROSTATE-CANCER; TYROSINE PHOSPHORYLATION; BREAST-CANCER; H3K27 METHYLATION; E-CADHERIN	Recently, we reported that the histone methyltransferase, EZH2, controls leukocyte migration through interaction with the cytoskeleton remodeling effector, VAV, and direct methylation of the cytoskeletal regulatory protein, Talin. However, it is unclear whether this extranuclear, epigenetic-independent function of EZH2 has a profound impact on the initiation of cellular transformation and metastasis. Here, we show that EZH2 increases Talin1 methylation and cleavage, thereby enhancing adhesion turnover and promoting accelerated tumorigenesis. This transforming capacity is abolished by targeted disruption of EZH2 interaction with VAV. Furthermore, our studies demonstrate that EZH2 in the cytoplasm is closely associated with cancer stem cell properties, and that overexpression of EZH2, a mutant EZH2 lacking its nuclear localization signal (EZH2 Delta NLS), or a methylmimicking Talin1 mutant substantially promotes JAK2-dependent STAT3 activation and cellular transformation. Taken together, our results suggest a critical role for the VAV interaction-dependent, extranuclear action of EZH2 in neoplastic transformation.	[Venkatesan, N.; Wong, J. F.; Chung, H. H.; Yau, Y. H.; Allahverdi, A.; Nordenskiold, L.; Geifman-Shochat, S.; Lin, V. C. L.; Su, I-h] Nanyang Technol Univ, Coll Sci, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Tan, K. P.; Madhusudhan, M. S.] Agcy Sci Technol & Res, Biopolis, Bioinformat Inst, Singapore, Singapore; [Tan, K. P.] Nanyang Technol Univ, Sch Comp Engn, Singapore, Singapore; [Cukuroglu, E.; Goke, J.] Agcy Sci Technol & Res, Biopolis, Genome Inst Singapore, Singapore, Singapore; [Goke, J.] Natl Canc Ctr Singapore, Singapore, Singapore; [Madhusudhan, M. S.] Indian Inst Sci Educ & Res, Pune, Maharashtra, India; [Madhusudhan, M. S.] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Cancer Centre Singapore (NCCS); Indian Institute of Science Education & Research (IISER) Pune; National University of Singapore	Su, IH (corresponding author), Nanyang Technol Univ, Coll Sci, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	ihsu@ntu.edu.sg	Allahverdi, Abdollah/AAE-1244-2022; Chun Ling, Valerie Lin/A-2188-2011; NORDENSKIÖLD, LARS/ABD-4725-2020; Su, I-hsin/A-2207-2011; Hoe, YAU Yin/A-2817-2011	NORDENSKIÖLD, LARS/0000-0002-3681-209X; Su, I-hsin/0000-0002-5894-9580; Hoe, YAU Yin/0000-0001-8136-2393; Goke, Jonathan/0000-0002-0825-4991; Wong, Jong Fu/0000-0001-6539-5865	Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant [10/1/22/19/666]; Singapore Ministry of Education [MOE2009-T21-034, MOE2013-T2-2-038]; Ministry of Health, National Medical Research Council [NMRC-CBRG/0057/201]	Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant(Agency for Science Technology & Research (A*STAR)); Singapore Ministry of Education(Ministry of Education, Singapore); Ministry of Health, National Medical Research Council	We thank S Stromblad for critical reading, discussions and comments on the manuscript; Y Zhang (Harvard University) for the EZH2, SUZ12 and EED baculovirus expression vectors; we thank Y Or for providing BALB/c mice and technical support, LY Lu for advice on statistical analysis and A Sullivan from Obrizus Communications for editing the manuscript. This work was supported by the Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant (10/1/22/19/666) to LN, Singapore Ministry of Education (MOE2009-T21-034 and MOE2013-T2-2-038) and Ministry of Health, National Medical Research Council (NMRC-CBRG/0057/201)to I-hS.	Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao Q, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4127; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chang KH, 2012, BLOOD, V120, P800, DOI 10.1182/blood-2011-06-361709; Chen YH, 2012, AM J TRANSL RES, V4, P364; Chen YT, 2016, CANCER CHEMOTH PHARM, V77, P757, DOI 10.1007/s00280-016-2990-1; Chou RH, 2011, AM J TRANSL RES, V3, P243; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, MECH DEVELOP, V55, P171, DOI 10.1016/0925-4773(96)00499-6; Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Huq MDM, 2007, MOL CELL PROTEOMICS, V6, P677, DOI 10.1074/mcp.M600223-MCP200; Jain N, 2013, P NATL ACAD SCI USA, V110, P11349, DOI 10.1073/pnas.1300801110; Jiao LY, 2015, SCIENCE, V350, DOI 10.1126/science.aac4383; Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lock JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090593; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nagano Makoto, 2012, Int J Cell Biol, V2012, P310616, DOI 10.1155/2012/310616; Natsume A, 2013, CANCER RES, V73, P4559, DOI 10.1158/0008-5472.CAN-13-0109; Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; Rodriguez JL, 2006, BIOCHEM J, V398, P431, DOI 10.1042/BJ20060380; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Su I, 2006, CURR OPIN IMMUNOL, V18, P152, DOI 10.1016/j.coi.2006.01.012; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; Thalappilly S, 2010, ONCOGENE, V29, P2528, DOI 10.1038/onc.2010.1; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vergani L, 2004, INT J BIOCHEM CELL B, V36, P1447, DOI 10.1016/j.biocel.2003.11.015; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064; Zhao ED, 2016, NAT IMMUNOL, V17, P95, DOI 10.1038/ni.3313; Zhu PP, 2016, NAT STRUCT MOL BIOL, V23, P631, DOI 10.1038/nsmb.3235	81	10	10	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					461	477		10.1038/onc.2017.309	http://dx.doi.org/10.1038/onc.2017.309			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967906	Green Accepted			2022-12-28	WOS:000423331600005
J	Tu, Q; Hao, J; Zhou, X; Yan, L; Dai, H; Sun, B; Yang, D; An, S; Lv, L; Jiao, B; Chen, C; Lai, R; Shi, P; Zhao, X				Tu, Q.; Hao, J.; Zhou, X.; Yan, L.; Dai, H.; Sun, B.; Yang, D.; An, S.; Lv, L.; Jiao, B.; Chen, C.; Lai, R.; Shi, P.; Zhao, X.			CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A	ONCOGENE			English	Article							ONCOGENIC K-RAS; DUCTAL ADENOCARCINOMA; INDUCED SENESCENCE; ACINAR-CELLS; TGF-BETA; TRANSCRIPTION; P15(INK4B); COOPERATE; MOUSE; PROGRESSION	Pancreatic cancer is among the deadliest malignancies; however, the genetic events that lead to pancreatic carcinogenesis in adults remain unclear. In vivo models in which these genetic alterations occur in adult animals may more accurately reflect the features of human cancer. In this study, we demonstrate that inactivation of Cdkn2b (p15ink4b) is necessary for induction of pancreatic cancer by oncogenic KRAS(G12D) expression and inactivation of Tp53 and Cdkn2a in adult mouse pancreatic ductal cells (P60 or older). KRAS(G12D) overexpression in these cells activated transforming growth factor-beta signaling and expression of CDKN2B, which, along with CDKN2A, led to cellular senescence and protected cells from KRAS-mediated transformation via inhibition of retinoblastoma phosphorylation. These results show a critical role of CDKN2B inactivation in pancreatic carcinogenesis, and provide a useful adult animal model by genetic engineering via lentiviral delivery.	[Tu, Q.; Zhou, X.; Yan, L.; Dai, H.; Sun, B.; Yang, D.; An, S.; Chen, C.; Lai, R.; Zhao, X.] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, 32 East Jiaochang Rd, Kunming 650223, Yunnan, Peoples R China; [Tu, Q.; Zhou, X.; Sun, B.; Yang, D.; An, S.] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China; [Hao, J.; Jiao, B.; Shi, P.] Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China; [Yan, L.; Lv, L.; Zhao, X.] Chinese Acad Sci, Kunming Primate Res Ctr, Kunming, Yunnan, Peoples R China; [Zhao, X.] Soochow Univ, KIZ SU Joint Lab Anim Model & Drug Dev, Coll Pharmaceut Sci, Suzhou, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Soochow University - China	Shi, P; Zhao, X (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming Inst Zool, 32 East Jiaochang Rd, Kunming 650223, Yunnan, Peoples R China.	ship@mail.kiz.ac.cn; zhaoxudong@mail.kiz.ac.cn	Shi, Peng/B-3372-2008	Shi, Peng/0000-0002-4075-4902; zhao, zhao xu dong/0000-0001-9126-7365; Sun, Bin/0000-0002-5663-4294	'Strategic Priority Research Program' of the Chinese Academy of Sciences [XDB13020400, XDA 01040403]; National Natural Science Foundation of China (NSFC) [81472862]; Top Talents Program of Yunnan Province, China [2012HA014]	'Strategic Priority Research Program' of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Top Talents Program of Yunnan Province, China	We thank Dr Ronald Depinho, Dr Gerry Chu and Dr Haoqiang Ying for constructive opinions on this study. We thank Dr Antonio Lavarone for the useful discussion on the regulation of CDKN2B. We thank Dr Jumin Zhou for manuscript revision. We thank Yujie Xia for technical assistance with the histological analysis. This work was supported by by the 'Strategic Priority Research Program' of the Chinese Academy of Sciences (grant no. XDB13020400 to PS and XDA 01040403 to XZ), the National Natural Science Foundation of China (NSFC, 81472862) and the Top Talents Program of Yunnan Province, China (2012HA014) to XZ.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Ben-Chetrit N, 2013, CELL ADHES MIGR, V7, P33, DOI 10.4161/cam.22263; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Brembeck FH, 2001, GASTROENTEROLOGY, V120, P1720, DOI 10.1053/gast.2001.24846; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gallardo T, 2007, GENESIS, V45, P413, DOI 10.1002/dvg.20310; Gopinathan A, 2015, DIS MODEL MECH, V8, P1185, DOI 10.1242/dmm.021055; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Houbracken I, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-74; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kohn D. F., 1997, ANESTHESIA ANALGESIA; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; McNeal AS, 2015, CANCER DISCOV, V5, P1072, DOI 10.1158/2159-8290.CD-15-0196; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Patel RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030619; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schuster K, 2014, MOL CANCER RES, V12, P912, DOI 10.1158/1541-7786.MCR-13-0620-T; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Singh SK, 2013, GUT, V62, P1364, DOI 10.1136/gutjnl-2012-302793; Tanaka H, 2010, CANCER SCI, V101, P341, DOI 10.1111/j.1349-7006.2009.01410.x; Tang Y, 2015, ONCOL LETT, V9, P55, DOI 10.3892/ol.2014.2684; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115	49	27	27	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					128	138		10.1038/onc.2017.316	http://dx.doi.org/10.1038/onc.2017.316			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892048	Green Published, hybrid			2022-12-28	WOS:000422625000013
J	Sizemore, GM; Balakrishnan, S; Hammer, AM; Thies, KA; Trimboli, AJ; Wallace, JA; Sizemore, ST; Kladney, RD; Woelke, SA; Yu, L; Fernandez, SA; Chakravarti, A; Leone, G; Ostrowski, MC				Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Yu, L.; Fernandez, S. A.; Chakravarti, A.; Leone, G.; Ostrowski, M. C.			Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1 (vol 36, pg 2297, 2017)	ONCOGENE			English	Correction													Sizemore, Gina/ABI-7542-2020					Sizemore GM, 2017, ONCOGENE, V36, P2297, DOI 10.1038/onc.2016.383	1	2	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6658	6658		10.1038/onc.2017.347	http://dx.doi.org/10.1038/onc.2017.347			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	29035387	Bronze			2022-12-28	WOS:000416049200014
J	Kim, J; Xu, S; Xiong, L; Yu, L; Fu, X; Xu, Y				Kim, J.; Xu, S.; Xiong, L.; Yu, L.; Fu, X.; Xu, Y.			SALL4 promotes glycolysis and chromatin remodeling via modulating HP1 alpha-Glut1 pathway	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; MURINE HOMOLOG; CELL; CANCER; GENE; ATM; EXPRESSION; PROLIFERATION; PLURIPOTENCY; METABOLISM	SALL4 has recently been identified to promote chemo-resistance in multiple types of cancer, but the underlying mechanism remains to be fully established. Open chromatin structure is important for DNA damage response (DDR) and DNA repair. Here, we demonstrate that SALL4 promotes open chromatin by destabilizing heterochromatin protein 1a (HP1a) by recruiting ubiquitin E3 ligase CUL4B to HP1 alpha. The silencing of SALL4 in cancer cells decreased the expression levels of Glut1 and inhibited glycolysis in cancer cells. The upregulation of HP1 alpha in human cancer cells suppressed open chromatin, glycolysis and Glut1 expression levels. Therefore, SALL4 promotes the expression of Glut1 and open chromatin through a HP1 alpha-dependent mechanism. Impaired DDR in SALL4-deficient human cancer cells can be rescued by the restored expression of Glut1, indicating the importance of HP1 alpha-Glut1 axis in SALL4-mediated DDR. These findings demonstrate that SALL4 could induce drug resistance by enhancing DDR and DNA repair through promoting glycolysis and subsequent chromatin remodeling.	[Kim, J.; Xu, S.; Yu, L.; Xu, Y.] Southern Med Univ, Canc Res Inst, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Kim, J.; Xiong, L.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Yu, L.; Fu, X.] Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China	Southern Medical University - China; University of California System; University of California San Diego; Sun Yat Sen University	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Xiong, Lingyun/0000-0003-4594-4120	National Natural Science Foundation of China [815300045, 81373166, 81430032]; National High-tech R&D Program (863 Program) [2015AA020310]; Guangdong Provincial Key Laboratory of Tumor Immunotherapy, South Wisdom Valley Innovative Research Team Program [365]; Major basic research developmental project of the Natural Science Foundation of Guangdong Province; Shenzhen Municipal Science and Technology Innovation Council [20140405201035]; California Institute for Regenerative Medicine [TR3-05559, RT3-07899]; Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program [365]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-tech R&D Program (863 Program)(National High Technology Research and Development Program of China); Guangdong Provincial Key Laboratory of Tumor Immunotherapy, South Wisdom Valley Innovative Research Team Program; Major basic research developmental project of the Natural Science Foundation of Guangdong Province; Shenzhen Municipal Science and Technology Innovation Council; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program	We thank Michael Qiu for technical support. This study is supported by the National Natural Science Foundation of China (No. 815300045, 81373166, 81430032), a grant from the National High-tech R&D Program (863 Program No. 2015AA020310), Guangdong Provincial Key Laboratory of Tumor Immunotherapy and Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program (2014) No. 365, Major basic research developmental project of the Natural Science Foundation of Guangdong Province, Shenzhen Municipal Science and Technology Innovation Council (20140405201035), and grants from California Institute for Regenerative Medicine (TR3-05559, RT3-07899).	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Chen YY, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0055-y; Cheng J, 2016, ONCOTARGET, V7, P24314, DOI 10.18632/oncotarget.8237; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Faucher D, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001082; Forghanifard MM, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-6; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Han SX, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/262385; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; Kim JA, 2007, J CELL BIOL, V178, P209, DOI 10.1083/jcb.200612031; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Li A, 2015, ONCOGENE, V34, P63, DOI 10.1038/onc.2013.529; Liu L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138515; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mai V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020647; Masuda S, 2013, NEW ENGL J MED, V369, P1171, DOI 10.1056/NEJMc1308785; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; Molina-Serrano D, 2013, NUCLEUS-AUSTIN, V4, P343, DOI 10.4161/nucl.26051; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Xiong JH, 2015, J CELL BIOL, V208, P513, DOI 10.1083/jcb.201408106; Yanagihara N, 2015, INT J ONCOL, V46, P1527, DOI 10.3892/ijo.2015.2866; Yang MY, 2016, ONCOL REP, V35, P1796, DOI 10.3892/or.2016.4545; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	44	20	21	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6472	6479		10.1038/onc.2017.265	http://dx.doi.org/10.1038/onc.2017.265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759035				2022-12-28	WOS:000415622900010
J	Szymiczek, A; Carbone, M; Pastorino, S; Napolitano, A; Tanji, M; Minaai, M; Pagano, I; Mason, JM; Pass, HI; Bray, MR; Mak, TW; Yang, H				Szymiczek, A.; Carbone, M.; Pastorino, S.; Napolitano, A.; Tanji, M.; Minaai, M.; Pagano, I.; Mason, J. M.; Pass, H. I.; Bray, M. R.; Mak, T. W.; Yang, H.			Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma	ONCOGENE			English	Article							PLEURAL MESOTHELIOMA; CHROMOSOMAL INSTABILITY; ASBESTOS EXPOSURE; CANCER; BAP1; PROTEIN; ANEUPLOIDY; MUTATIONS; CFI-402257; MURINE	Malignant mesothelioma (MM) is an aggressive malignancy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically show a high level of aneuploidy and genomic instability. We tested our hypothesis that targeting chromosomal instability in MM would improve response to therapy. Thr/Tyr kinase (TTK)/monopolar spindle 1 kinase (Mps-1) is a kinase of the spindle assembly checkpoint that controls cell division and cell fate. CFI-402257 is a novel, selective inhibitor of Mps-1 with antineoplastic activity. We found that CFI-402257 suppresses MM growth. We found that Mps-1 is overexpressed in MM and that its expression correlates with poor patients' outcome. In vitro, CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more so when used in combination with cisplatin+pemetrexed, the current standard of care. Our preclinical findings indicate that CFI-402257 is a promising novel therapeutic agent to improve the efficacy of the current chemotherapeutic regimens for MM patients.	[Szymiczek, A.; Carbone, M.; Pastorino, S.; Napolitano, A.; Tanji, M.; Minaai, M.; Pagano, I.; Yang, H.] Univ Hawaii Manoa, Univ Hawaii, Ctr Canc, Thorac Oncol Program, Honolulu, HI 96822 USA; [Mason, J. M.; Bray, M. R.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, MaRS Ctr, TMDT East Tower, Toronto, ON, Canada; [Pass, H. I.] NYU, Langone Med Ctr, Dept Cardiothorac Surg, New York, NY USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; New York University; NYU Langone Medical Center	Carbone, M (corresponding author), Univ Hawaii Manoa, Univ Hawaii, Ctr Canc, 701 Ilalo St,Room 437, Honolulu, HI 96813 USA.; Yang, H (corresponding author), Univ Hawaii, Canc Biol Program, Ctr Canc, 701 Ilalo St,Room 439, Honolulu, HI 96813 USA.	mcarbone@cc.hawaii.edu; hyang@cc.hawaii.edu	Napolitano, Andrea/I-3146-2019	Napolitano, Andrea/0000-0002-7509-1555; Bray, Mark/0000-0003-4609-6127; Pass, Harvey/0000-0003-3222-3471	NCI-R01 [CA198138, CA160715]; University of Hawai'i Foundation; NATIONAL CANCER INSTITUTE [R01CA198138, R01CA160715, P30CA071789] Funding Source: NIH RePORTER	NCI-R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Hawai'i Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NCI-R01 CA198138 to MC; by the NCI-R01 CA160715 to HY; and by the University of Hawai'i Foundation, which received an unrestricted gift to support MM research from Honeywell International Inc., to MC; and from United-4-a-Cure, to MC and HY CFI-402257 was synthesized and provided by our collaborators and co-authors at the Campbell Family Institute for Breast Cancer Research, Toronto, Canada.	Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Carbone M, 2016, J THORAC ONCOL, V11, P1246, DOI 10.1016/j.jtho.2016.04.028; Carbone M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005633; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Comertpay S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0301-3; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Fisk HA, 2004, CELL CYCLE, V3, P439; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gazdar Adi F, 2003, Clin Lung Cancer, V5, P177, DOI 10.3816/CLC.2003.n.031; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hao JQ, 2008, CHINESE MED J-PEKING, V121, P602, DOI 10.1097/00029330-200804010-00006; Henley SJ, 2013, INT J OCCUP ENV HEAL, V19, P1, DOI 10.1179/2049396712Y.0000000016; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; ISOBE H, 1994, INT J CANCER, V57, P581, DOI 10.1002/ijc.2910570423; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Jemaa M, 2013, CELL DEATH DIFFER, V20, P1532, DOI 10.1038/cdd.2013.105; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Ling YG, 2014, BIOCHEM BIOPH RES CO, V450, P1690, DOI 10.1016/j.bbrc.2014.07.071; Liu XD, 2012, ANNU REV BIOCHEM, V81, P561, DOI 10.1146/annurev-biochem-061611-090435; Liu Y, 2016, ACS MED CHEM LETT, V7, P671, DOI 10.1021/acsmedchemlett.5b00485; Lo Iacono M, 2015, J THORAC ONCOL, V10, P492, DOI 10.1097/JTO.0000000000000436; Mason JM, 2017, P NATL ACAD SCI USA, V114, P3127, DOI 10.1073/pnas.1700234114; Meyerhoff RR, 2015, J SURG RES, V196, P23, DOI 10.1016/j.jss.2015.01.043; Mezzapelle R, 2016, SCI REP-UK, V6, DOI 10.1038/srep22850; Napolitano A, 2016, ONCOGENE, V35, P1996, DOI 10.1038/onc.2015.243; Napolitano A, 2016, CLIN CANCER RES, V22, P3087, DOI 10.1158/1078-0432.CCR-15-1130; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Nijenhuis W, 2013, J CELL BIOL, V201, P217, DOI 10.1083/jcb.201210033; Ostroff RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046091; Singhi AD, 2016, MODERN PATHOL, V29, P14, DOI 10.1038/modpathol.2015.121; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; TAGUCHI T, 1993, CANCER RES, V53, P4349; Taniguchi T, 2007, CANCER SCI, V98, P438, DOI 10.1111/j.1349-7006.2006.00386.x; Tardif KD, 2011, MOL CANCER THER, V10, P2267, DOI 10.1158/1535-7163.MCT-11-0453; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Ugurluer G, 2016, ANTICANCER RES, V36, P2331; van Jaarsveld RH, 2016, TRENDS CANCER, V2, P561, DOI 10.1016/j.trecan.2016.09.003; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yoshikawa Y, 2016, P NATL ACAD SCI USA, V113, P13432, DOI 10.1073/pnas.1612074113; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	58	13	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6501	6507		10.1038/onc.2017.266	http://dx.doi.org/10.1038/onc.2017.266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759042	Green Accepted			2022-12-28	WOS:000415622900013
J	Manent, J; Banerjee, S; Simoes, RD; Zoranovic, T; Mitsiades, C; Penninger, JM; Simpson, KJ; Humbert, PO; Richardson, HE				Manent, J.; Banerjee, S.; Simoes, R. de Matos; Zoranovic, T.; Mitsiades, C.; Penninger, J. M.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.			Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species (vol 36, pg 5576, 2017)	ONCOGENE			English	Correction													Penninger, Josef M/I-6860-2013; Pryjda, Tamara/O-5714-2019; Richardson, Helena E/A-8080-2013	Penninger, Josef M/0000-0002-8194-3777; Richardson, Helena E/0000-0003-3852-4953; Simpson, Kaylene/0000-0001-9136-1781				Manent J, 2017, ONCOGENE, V36, P5576, DOI 10.1038/onc.2017.175	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5658	5660		10.1038/onc.2017.239	http://dx.doi.org/10.1038/onc.2017.239			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28980625	Green Published, Bronze			2022-12-28	WOS:000412293600010
J	Weng, CC; Hawse, JR; Subramaniam, M; Chang, VHS; Yu, WCY; Hung, WC; Chen, LT; Cheng, KH				Weng, C-C; Hawse, J. R.; Subramaniam, M.; Chang, V. H. S.; Yu, W. C. Y.; Hung, W-C; Chen, L-T; Cheng, K-H			KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model	ONCOGENE			English	Article							INDUCIBLE EARLY GENE; TGF-BETA; MESENCHYMAL TRANSITION; TUMOR SUPPRESSION; CELL-MIGRATION; CANCER; GROWTH; RECEPTOR; EXPRESSION; CXCR4	Kruppel-like transcription factor 10 (KLF10), also named as TIEG1, plays essential roles in mediating transforming growth factor beta (TGF beta) signaling and has been shown to function as a tumor suppressor in multiple cancer types. However, its roles in mediating cancer progression in vivo have yet to be fully characterized. Here, we have employed two well-characterized Pdx-1CreLSL-Kras(G12D) and Pdx-1CreLSL-Kras(G12D)p53(L/L) pancreatic cancer models to ablate KLF10 expression and determine the impact of KLF10 deletion on tumor development and progression. We show that loss of KLF10 cooperates with Kras(G12D) leading to an invasive and widely metastatic phenotype of pancreatic ductal adenocarcinoma (PDAC). Mechanistically, loss of KLF10 in PDAC is shown to increase distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways. Furthermore, we demonstrate that targeting the SDF-1/CXCR4 pathway in the context of KLF10 deletion substantially suppresses PDAC progression suggesting that inhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.	[Weng, C-C; Cheng, K-H] Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan; [Hawse, J. R.; Subramaniam, M.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [Chang, V. H. S.] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Yu, W. C. Y.; Hung, W-C; Chen, L-T; Cheng, K-H] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hung, W-C] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Basic Med Sci, Tainan, Taiwan; [Chen, L-T] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Cheng, K-H] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan	National Sun Yat Sen University; Mayo Clinic; Taipei Medical University; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Medical University	Chen, LT; Cheng, KH (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan.	leochen@nhri.org.tw; khcheng@faculty.nsysu.edu.tw			Ministry of Science and Technology, Taiwan ROC [MOST 104-2320-B-110-003, 105-2320-B-110-004, MOST 101-2628-B-400-003-MY2, MOST 105-2321-B-400-010]; Kaohsiung Medical University, Kaohsiung, Taiwan [KMU-TP104G00, KMU-TP105G00]; National Institutes of Health, USA [R01 DE14036]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	Ministry of Science and Technology, Taiwan ROC(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University, Kaohsiung, Taiwan; National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants MOST 104-2320-B-110-003 and 105-2320-B-110-004 (to KH Cheng), MOST 101-2628-B-400-003-MY2 (to LT Chen) and MOST 105-2321-B-400-010 (to LT Chen and KH Cheng) from the Ministry of Science and Technology, Taiwan ROC, and grants KMU-TP104G00, KMU-TP105G00 (to KH Cheng) from Kaohsiung Medical University, Kaohsiung, Taiwan, and grant R01 DE14036 (to JRH and MS) from the National Institutes of Health, USA.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Cao ZX, 2009, J BIOL CHEM, V284, P24914, DOI 10.1074/jbc.M109.000059; Chang VHS, 2012, AM J PATHOL, V181, P423, DOI 10.1016/j.ajpath.2012.04.025; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Dubrovsky L, 2014, BLOOD, V123, P3296, DOI 10.1182/blood-2014-01-549022; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gu HJ, 2008, CLIN CANCER RES, V14, P3627, DOI 10.1158/1078-0432.CCR-07-4808; Hawse JR, 2008, BONE, V42, P1025, DOI 10.1016/j.bone.2008.02.004; Hawse JR, 2008, MOL ENDOCRINOL, V22, P1579, DOI 10.1210/me.2007-0253; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacopetta BJ, 1998, J PATHOL, V184, P390; Im KS, 2017, VET COMP ONCOL, V15, P315, DOI 10.1111/vco.12165; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jiang L, 2009, CANCER LETT, V274, P101, DOI 10.1016/j.canlet.2008.09.017; Jin W, 2012, MOL CELL BIOL, V32, P50, DOI 10.1128/MCB.06152-11; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Papadakis KA, 2015, AM J PHYSIOL-CELL PH, V308, pC362, DOI 10.1152/ajpcell.00262.2014; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Sioletic S, 2014, J PATHOL, V234, P190, DOI 10.1002/path.4379; Spittau B, 2012, CELL TISSUE RES, V347, P65, DOI 10.1007/s00441-011-1186-6; Spittau G, 2010, J NEUROSCI RES, V88, P2017, DOI 10.1002/jnr.22364; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Subramaniam M, 2010, BIOFACTORS, V36, P8, DOI 10.1002/biof.67; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	55	21	21	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5532	5543		10.1038/onc.2017.155	http://dx.doi.org/10.1038/onc.2017.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581520				2022-12-28	WOS:000411960500009
J	Wu, TS; Tan, CT; Chang, CC; Lin, BR; Lai, WT; Chen, ST; Kuo, MYP; Rau, CL; Jaw, FS; Chang, HH				Wu, T-S; Tan, C-T; Chang, C-C; Lin, B-R; Lai, W-T; Chen, S-T; Kuo, M. Yen-Ping; Rau, C-L; Jaw, F-S; Chang, H-H			B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway (vol 34, pg 1207, 2015)	ONCOGENE			English	Correction									[Wu, T-S; Lai, W-T; Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, Taipei, Taiwan; [Tan, C-T] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Chang, C-C] Natl Taiwan Univ, Grad Inst Oral Biol, Sch Dent, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Taipei, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, YunLin Branch, Dept Pediat, Yunlin, Taiwan; [Rau, C-L; Jaw, F-S] Natl Taiwan Univ, Inst Biomed Engn, Taipei, Taiwan; [Rau, C-L] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, H-H] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University	Wu, TS (corresponding author), Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, Taipei, Taiwan.			LIN, BEEN-REN/0000-0001-8354-1758				Wu TS, 2015, ONCOGENE, V34, P1207, DOI 10.1038/onc.2014.43	1	4	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5440	5440		10.1038/onc.2017.250	http://dx.doi.org/10.1038/onc.2017.250			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28714961	Bronze			2022-12-28	WOS:000411382100011
J	Kitajima, S; Yoshida, A; Kohno, S; Li, F; Suzuki, S; Nagatani, N; Nishimoto, Y; Sasaki, N; Muranaka, H; Wan, Y; Thai, TC; Okahashi, N; Matsuda, F; Shimizu, H; Nishiuchi, T; Suzuki, Y; Tominaga, K; Gotoh, N; Suzuki, M; Ewen, ME; Barbie, DA; Hirose, O; Tanaka, T; Takahashi, C				Kitajima, S.; Yoshida, A.; Kohno, S.; Li, F.; Suzuki, S.; Nagatani, N.; Nishimoto, Y.; Sasaki, N.; Muranaka, H.; Wan, Y.; Thai, T. C.; Okahashi, N.; Matsuda, F.; Shimizu, H.; Nishiuchi, T.; Suzuki, Y.; Tominaga, K.; Gotoh, N.; Suzuki, M.; Ewen, M. E.; Barbie, D. A.; Hirose, O.; Tanaka, T.; Takahashi, C.			The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity	ONCOGENE			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; COMPREHENSIVE MOLECULAR PORTRAITS; FATTY-ACID OXIDATION; CANCER STEM-CELLS; RB; METABOLISM; INHIBITION; DEFICIENT; GLUTAMINE; NETWORKS	Retinoblastoma (RB) protein inactivation during tumor progression is often associated with acquisition of immature phenotypes and resistance to therapy. Determination of an RB inactivation signature in a context of gaining undifferentiated phenotype in a p53-null sarcoma system revealed a critical role for interleukin (IL)-6. Using a Gene Set Enrichment Analysis (GSEA), we discovered that poorly differentiated breast cancers are enriched for this RB inactivation signature. Accelerated IL-6 secretion following RB inactivation in an RB-intact luminal-type breast cancer cell line MCF-7 promoted a positive feed forward loop between IL-6 and STAT3 driving tumor growth and endocrine therapy resistance. In addition, some of RB-intact basal-like type breast cancer cell lines exhibited a similar phenotype following RB depletion. The mechanism whereby RB inactivation increases IL-6 production in MCF-7 cells appeared to involve fatty acid oxidation (FAO)-dependent mitochondrial metabolism and c-Jun NH(2)-terminal kinase (JNK). In addition, IL-6, via STAT3-mediated feedback to mitochondria, autonomously adjusts mitochondrial superoxide to levels suitable to maintain stem cell-like activity. The gene expression profile of luminal-type breast cancer patients with low RB expression revealed high enrichment of genes involved in mitochondrial respiration and downstream targets of IL-6. These findings unveiled an unexpected strategy whereby RB suppresses malignant features of cancer cells through metabolic reprogramming and cell-autonomous inflammation.	[Kitajima, S.; Yoshida, A.; Kohno, S.; Li, F.; Nagatani, N.; Nishimoto, Y.; Sasaki, N.; Muranaka, H.; Wan, Y.; Suzuki, M.; Takahashi, C.] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan; [Kitajima, S.; Thai, T. C.; Barbie, D. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Yoshida, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan; [Suzuki, S.; Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan; [Okahashi, N.; Matsuda, F.; Shimizu, H.] Osaka Univ, Grad Sch Informat Sci & Technol, Dept Bioinformat Engn, Suita, Osaka, Japan; [Nishiuchi, T.] Kanazawa Univ, Adv Sci Res Ctr, Div Funct Genom, Kanazawa, Ishikawa, Japan; [Suzuki, Y.] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Chiba, Japan; [Tominaga, K.] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, Tokyo, Japan; [Gotoh, N.] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa, Japan; [Ewen, M. E.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA; [Barbie, D. A.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Hirose, O.] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Elect Engn & Comp Sci, Kanazawa, Ishikawa, Japan	Kanazawa University; Harvard University; Dana-Farber Cancer Institute; Kanazawa University; Chiba University; Osaka University; Kanazawa University; University of Tokyo; University of Tokyo; Kanazawa University; Tufts Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Kanazawa University	Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan.	chtakaha@staff.kanazawa-u.ac.jp	Sasaki, Nobunari/ABF-6656-2020; Okahashi, Nobuyuki/AAL-6437-2021; Hirose, Osamu/K-7890-2015; Okahashi, Nobuyuki/AAM-5359-2021; Shimizu, Hiroshi/C-3688-2017; GOTOH, Noriko/D-8430-2015	Okahashi, Nobuyuki/0000-0001-9582-355X; Hirose, Osamu/0000-0002-8077-8589; Okahashi, Nobuyuki/0000-0001-9582-355X; Shimizu, Hiroshi/0000-0002-8986-0861; Nishiuchi, Takumi/0000-0001-9429-5396; Gotoh, Noriko/0000-0003-3733-260X; Tominaga, Kana/0000-0001-5136-5091	Funding Program for Next Generation World-Leading Researchers; Hokuriku Bank Research Grant for Young Scientists	Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Hokuriku Bank Research Grant for Young Scientists	We thank Drs T Kitamura, N Mukaida, K Yoshioka and Chugai Pharmaceuticals Co. Ltd. for providing materials, Drs T Baba, K Hinohara, A Hirao, T Hoshii, A Ishimura, K Matsumoto, K Sakai, S Sasaki, T Sato, T Shimamura, T Suzuki and Y Tadokoro for technical instruction, Dr A Ooi for pathological diagnosis, Drs I Ajioka and R Jenkins for critical reading of this manuscript, and Dr C Prives for advice. This work was supported by Funding Program for Next Generation World-Leading Researchers to CT, Grant-in-Aid for Scientific Research to CT, S Kitajima and NS, and Hokuriku Bank Research Grant for Young Scientists to S Kitajima.	Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Choi J, 2010, AM J PATHOL, V177, P2645, DOI 10.2353/ajpath.2010.100306; Ciavarra G, 2010, J CELL BIOL, V191, P291, DOI 10.1083/jcb.201005067; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; Cuperus R, 2010, CELL MOL LIFE SCI, V67, P807, DOI 10.1007/s00018-009-0212-2; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Denechaud PD, 2016, J CLIN INVEST, V126, P137, DOI 10.1172/JCI81542; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Guo DJ, 2012, ONCOL LETT, V4, P311, DOI 10.3892/ol.2012.733; HARVEY M, 1995, CANCER RES, V55, P1146; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kadota K, 2008, ALGORITHM MOL BIOL, V3, DOI 10.1186/1748-7188-3-8; Kareta MS, 2015, CELL STEM CELL, V16, P39, DOI 10.1016/j.stem.2014.10.019; Kitajima S, 2015, STEM CELLS, V33, P1657, DOI 10.1002/stem.1971; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohno S, 2016, WORLD J STEM CELLS, V8, P170, DOI 10.4252/wjsc.v8.i4.170; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Li F, 2010, CELL STEM CELL, V7, P508, DOI 10.1016/j.stem.2010.09.003; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pajcini KV, 2010, CELL STEM CELL, V7, P198, DOI 10.1016/j.stem.2010.05.022; Petrov PD, 2016, J CELL PHYSIOL, V231, P708, DOI 10.1002/jcp.25121; Petrov PD, 2015, AM J PHYSIOL-ENDOC M, V308, pE172, DOI 10.1152/ajpendo.00308.2014; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Sage J, 2012, GENE DEV, V26, P1409, DOI 10.1101/gad.193730.112; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Shamma A, 2013, MOL CELL BIOL, V33, P3113, DOI 10.1128/MCB.01597-12; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Takahashi C, 2012, CANCER SCI, V103, P1182, DOI 10.1111/j.1349-7006.2012.02284.x; Takebayashi S, 2015, AGING CELL, V14, P689, DOI 10.1111/acel.12351; TSUKADA T, 1993, ONCOGENE, V8, P3313; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang LY, 2016, CELL REP, V16, P3016, DOI 10.1016/j.celrep.2016.08.018; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wruck CJ, 2011, J BIOL CHEM, V286, P4493, DOI 10.1074/jbc.M110.162008; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	68	25	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5145	5157		10.1038/onc.2017.124	http://dx.doi.org/10.1038/onc.2017.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481867				2022-12-28	WOS:000409371100006
J	Li, Z; Xiong, Y				Li, Z.; Xiong, Y.			Cytoplasmic E3 ubiquitin ligase CUL9 controls cell proliferation, senescence, apoptosis and genome integrity through p53	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; 3M COMPLEX; IN-VIVO; PATHWAY; RESCUE; CANCER	CUL9 is a member of the cullin family of E3 ubiquitin ligases, and it localizes predominantly in the cytoplasm. Deletion of Cul9 in mice results in increased DNA damage, widespread aneuploidy, spontaneous tumor development, accelerated E mu-Myc-induced lymphomagenesis and susceptibility to carcinogenesis. CUL9 binds to p53 and causes cell apoptosis when ectopically expressed. Whether the function of CUL9 in maintaining genomic integrity and suppressing tumorigenesis is linked to p53 has not been genetically tested. Here we report that deletion of CUL9 in human cells results in attenuated p21 induction and impaired cellular response to DNA damage. We show that disruption of Cul9-p53 binding in mouse embryo fibroblasts (MEFs) by a knock-in mutation in Cul9 (Delta p53) increases S-phase cell population, accumulates DNA damage during DNA replication and decreases apoptosis to both endogenous and exogenous DNA-damaging agents. The extent of these alterations in Cul9(Delta p53) MEFs is indistinguishable to those seen in Cul9(-/-) MEFs and comparable to those seen in p53(-/-) MEFs. Deletion of CUL9 in p53 null cells does not lead to further increase of DNA damages. Both Cul9(-/-) and Cul9(Delta p53) MEFs proliferate faster and undergo spontaneous immortalization while retaining both Arf and p53. These results demonstrate that the functions of CUL9 in regulating cell proliferation and maintaining genomic integrity are mainly mediated by p53, and that CUL9 is a critical p53 activator.	[Li, Z.; Xiong, Y.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA; [Xiong, Y.] Univ North Carolina Chapel Hill, Dept Biochem & Biophys, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xiong, Y (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA.; Xiong, Y (corresponding author), Univ North Carolina Chapel Hill, Dept Biochem & Biophys, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu			National Institutes of Health [R01CA068377]; UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA068377] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Hui Xiao Chao, Jeremy Purvis and Matthew Smith for reading the manuscript, Dale Ramsden for discussion throughout this study, and members of the Xiong Laboratory for helpful discussions and encouragement. This work was supported by National Institutes of Health (grant R01CA068377 to YX) and a Team Innovation Award by the UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund.	Andrews P, 2006, ONCOGENE, V25, P4534, DOI 10.1038/sj.onc.1209490; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Li ZJ, 2014, MOL CELL, V54, P805, DOI 10.1016/j.molcel.2014.03.046; LUNA RMD, 1995, NATURE, V378, P203; Marin I, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-267; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pei XH, 2011, CANCER RES, V71, P2969, DOI 10.1158/0008-5472.CAN-10-4300; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sharpless NE, 2006, CELL BIOL, V1, P223; Stracquadanio G, 2016, NAT REV CANCER, V16, P251, DOI 10.1038/nrc.2016.15; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Yan J, 2014, MOL CELL, V54, P791, DOI 10.1016/j.molcel.2014.03.047	21	12	13	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5212	5218		10.1038/onc.2017.141	http://dx.doi.org/10.1038/onc.2017.141			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481879	Green Accepted, Green Submitted			2022-12-28	WOS:000409371100012
J	Zhai, W; Sun, Y; Jiang, M; Wang, M; Gasiewicz, TA; Zheng, J; Chang, C				Zhai, W.; Sun, Y.; Jiang, M.; Wang, M.; Gasiewicz, T. A.; Zheng, J.; Chang, C.			Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2 alpha/C-MYC axis under hypoxia (vol 35, pg 4866, 2016)	ONCOGENE			English	Correction																		Zhai W, 2016, ONCOGENE, V35, P4866, DOI 10.1038/onc.2016.19	1	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4525	4525		10.1038/onc.2016.514	http://dx.doi.org/10.1038/onc.2016.514			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368407	Bronze			2022-12-28	WOS:000406806000014
J	Shang, Y; He, J; Wang, Y; Feng, Q; Zhang, Y; Guo, J; Li, J; Li, S; Wang, Y; Yan, G; Ren, F; Shi, Y; Xu, J; Zeps, N; Zhai, Y; He, D; Chang, Z				Shang, Y.; He, J.; Wang, Y.; Feng, Q.; Zhang, Y.; Guo, J.; Li, J.; Li, S.; Wang, Y.; Yan, G.; Ren, F.; Shi, Y.; Xu, J.; Zeps, N.; Zhai, Y.; He, D.; Chang, Z.			CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE M2; UBIQUITIN LIGASE; CELL-METABOLISM; CHIP; GLYCOLYSIS; ISOFORM; IDENTIFICATION; TARGET; ROLES	Tumor cells preferentially adopt aerobic glycolysis for their energy supply, a phenomenon known as the Warburg effect. It remains a matter of debate as to how the Warburg effect is regulated during tumor progression. Here, we show that CHIP (carboxyl terminus of Hsc70-interacting protein), a U-box E3 ligase, suppresses tumor progression in ovarian carcinomas by inhibiting aerobic glycolysis. While CHIP is downregulated in ovarian carcinoma, induced expression of CHIP results in significant inhibition of the tumor growth examined by in vitro and in vivo experiments. Reciprocally, depletion of CHIP leads to promotion of tumor growth. By a SiLAD proteomics analysis, we identified pyruvate kinase isoenzyme M2 (PKM2), a critical regulator of glycolysis in tumors, as a target that CHIP mediated for degradation. Accordingly, we show that CHIP regulates PKM2 protein stability and thereafter the energy metabolic processes. Depletion or knockout of CHIP increased the glycolytic products in both tumor and mouse embryonic fibroblast cells. Simultaneously, we observed that CHIP expression inversely correlated with PKM2 levels in human ovarian carcinomas. This study reveals a mechanism that the Warburg effect is regulated by CHIP through its function as an E3 ligase, which mediates the degradation of PKM2 during tumor progression. Our findings shed new light into understanding of ovarian carcinomas and may provide a new therapeutic strategy for ovarian cancer.	[Shang, Y.; He, J.; Yan, G.; Zhai, Y.; He, D.] Beijing Normal Univ, Coll Life Sci, Dept Cell Biol, Minist Educ,Key Lab Cell Proliferat & Regulat Bio, Beijing, Peoples R China; [Shang, Y.; Wang, Y.; Zhang, Y.; Guo, J.; Li, J.; Li, S.; Wang, Y.; Ren, F.; Chang, Z.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, State Key Lab Membrane Biol, Beijing, Peoples R China; [Feng, Q.] Zhengzhou Univ, Affiliated Hosp 3, Dept Gynecol & Obstet, Zhengzhou, Peoples R China; [Shi, Y.] Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA USA; [Xu, J.] Univ Western Australia, Sch Pathol & Lab Med, M504, Crawley, WA, Australia; [Zeps, N.] Univ Western Australia, Sch Surg, M509, Crawley, WA, Australia; [Zeps, N.] St John God HealthCare, Bendat Family Comprehens Canc Ctr, Subiaco, WA, Australia	Beijing Normal University; Tsinghua University; Zhengzhou University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Western Australia; University of Western Australia; St John of God Health Care	Shang, Y; Chang, Z (corresponding author), Tsinghua Univ, Sch Med, New Med Sci Bldg A307, Beijing 100084, Peoples R China.	shangyu@bnu.edu.cn; zhijiec@tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019; Zhang, Yanquan/D-5615-2017; Zeps, Nikolajs/AAF-3186-2021	Zhang, Yanquan/0000-0003-3527-9972; Zeps, Nikolajs/0000-0002-6404-6839; Xu, Jiake/0000-0003-2021-8309	Ministry of Science and Technology, China [2016YFA0500300, 2011CB910502, 2011CB915504]; NSFC [81672715, 81301701, 81572729, 81402293, 81230044]	Ministry of Science and Technology, China(Ministry of Science and Technology, China); NSFC(National Natural Science Foundation of China (NSFC))	We thank Dr Deyin Guo for providing PKM2 constructs (Wuhan University, China), and Dr Beihua Kong for providing HEY and A278O cells (Shandong University, China). We also thank Dr Suneng Fu and Yilie Liao for their technical support on the extracellular acidification rate and oxygen consumption rate experiment. We thank Dr Suozhu Sun (The Second Artillery General Hospital, China) for his help with the pathological analyses on the tumor samples. This work was supported by Grants from Ministry of Science and Technology, China (2016YFA0500300, 2011CB910502 and 2011CB915504) and NSFC (81672715, 81301701, 81572729, 81402293 and 81230044) in China.	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Chaneton B, 2012, TRENDS BIOCHEM SCI, V37, P309, DOI 10.1016/j.tibs.2012.04.003; Chao CCK, 2015, CLIN CHIM ACTA, V438, P139, DOI 10.1016/j.cca.2014.08.015; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dayton TL, 2016, GENE DEV, V30, P1020, DOI 10.1101/gad.278549.116; Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hosios AM, 2015, MOL CELL, V59, P850, DOI 10.1016/j.molcel.2015.07.013; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Huang LQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092949; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Li RF, 2007, J MOL BIOL, V374, P777, DOI 10.1016/j.jmb.2007.09.082; Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044; Li ZW, 2014, BBA-REV CANCER, V1846, P285, DOI 10.1016/j.bbcan.2014.07.008; Liu AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086872; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Paul I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/918183; Poersch A, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-A138; Shang Y, 2014, CELL SIGNAL, V26, P1098, DOI 10.1016/j.cellsig.2014.01.030; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Sun C, 2014, J CANCER RES CLIN, V140, P189, DOI 10.1007/s00432-013-1571-5; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Viana R, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0053-6; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Zhang Z, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002991	37	38	45	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4191	4200		10.1038/onc.2017.31	http://dx.doi.org/10.1038/onc.2017.31			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346425				2022-12-28	WOS:000405835800010
J	Sunshine, JC; Jahchan, NS; Sage, J; Choi, J				Sunshine, J. C.; Jahchan, N. S.; Sage, J.; Choi, J.			Are there multiple cells of origin of Merkel cell carcinoma?	ONCOGENE			English	Review							SMALL T-ANTIGEN; TRANSGENIC MOUSE MODEL; MUTATIONAL LANDSCAPE; PROSTATE-CANCER; LUNG-CANCER; ANTIANDROGEN RESISTANCE; LINEAGE PLASTICITY; TUMOR-DEVELOPMENT; STEM-CELLS; POLYOMAVIRUS	Merkel cell carcinoma (MCC) is a rare but lethal cancer with the highest case-by-case fatality rate among all skin cancers. Eighty percent of cancers are associated with the Merkel cell polyomavirus (MCPyV). Twenty percent of MCCs are virus negative. Recent epidemiological data suggest that there are important, clinically relevant differences between these two subtypes of MCC. Recent studies in cancer genomics, mouse genetics, and virology experiments have transformed our understanding of MCC pathophysiology. Importantly, dramatic differences in the genetics of these two MCC subtypes suggest fundamental differences in their pathophysiology. We review these recent works and find that they provocatively suggest that MCPyV-positive and MCPyV-negative MCCs arise from two different cells of origin: the MCPyV-negative MCC from epidermal keratinocytes and the MCPyV-positive MCC from dermal fibroblasts. If true, this would represent the first cancer that we are aware of that evolves from cells of origin from two distinct germ layers: MCPyV-negative MCCs from ectodermal keratinocytes and MCPyV-positive MCCs from mesodermal fibroblasts. Future epigenetic experiments may prove valuable in confirming these distinct lineages for these MCC subtypes, especially for the clinical importance the cell of origin has on MCC treatment and prevention.	[Sunshine, J. C.; Choi, J.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Jahchan, N. S.; Sage, J.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Jahchan, N. S.; Sage, J.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Choi, J.] Northwestern Univ, Feinberg Sch Med, Dept Biochem Mol Genet, Chicago, IL 60611 USA; [Choi, J.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Stanford University; Stanford University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA.; Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem Mol Genet, Chicago, IL 60611 USA.; Choi, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA.	jaehyuk.choi@northwestern.edu	Choi, Jaehyuk/N-6532-2019	Choi, Jaehyuk/0000-0003-2379-2226; Sunshine, Joel/0000-0001-9987-6712	NCI [K08 CA 191019, R21 CA167104-01]; NATIONAL CANCER INSTITUTE [R01CA201513, R21CA167104] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	S.J.C. is the Ruth K. Freinkel Assistant Professor of Dermatology. S.J.C. is supported by the NCI (K08 CA 191019). S. J.S. is the Harriet and Mary Zelencik Scientist in Children's Cancer and Blood Diseases. The mouse work was supported by the NCI (R21 CA167104-01). The mice were maintained according to practices prescribed by the NIH at Stanford's Research Animal Facility accredited by the AAPLAC (protocol 13565). We thank Dr. David MacPherson for the Pten mutant mice and Dr. Anton Berns for the Trp53 mutant mice. We would like to thank everyone in the Sage laboratory who helped in the generation and characterization of all the mutant mouse cohorts, specifically Margaret Zhu, Kim Tran, Garrett Seitz, and Anuradha Tathireddy, as well as Dr. Jinah Kim for help with the histopathology.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Busam KJ, 2009, AM J SURG PATHOL, V33, P1378, DOI 10.1097/PAS.0b013e3181aa30a5; Chitsazzadeh V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12601; Choi J, 2015, NAT GENET, V47, P1011, DOI 10.1038/ng.3356; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Cui M, 2014, MOL CANCER RES, V12, P654, DOI 10.1158/1541-7786.MCR-13-0554; Gonzalez-Vela MDC, 2017, J INVEST DERMATOL, V137, P197, DOI 10.1016/j.jid.2016.08.015; Elston D, 2013, DERMATOPATHOLOGY; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Furney SJ, 2014, PIGM CELL MELANOMA R, V27, P835, DOI 10.1111/pcmr.12279; Garneski KM, 2009, J INVEST DERMATOL, V129, P246, DOI 10.1038/jid.2008.229; Goh G, 2016, ONCOTARGET, V7, P3393, DOI 10.18632/oncotarget.6494; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Heath M, 2008, J AM ACAD DERMATOL, V58, P375, DOI 10.1016/j.jaad.2007.11.020; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Houben R, 2012, INT J CANCER, V130, P847, DOI 10.1002/ijc.26076; Houben R, 2010, J VIROL, V84, P7064, DOI 10.1128/JVI.02400-09; Jayaraman SS, 2014, J INVEST DERMATOL, V134, P213, DOI 10.1038/jid.2013.276; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lemasson G, 2012, J EUR ACAD DERMATOL, V26, DOI 10.1111/j.1468-3083.2011.04132.x; Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Maricich SM, 2009, SCIENCE, V324, P1580, DOI 10.1126/science.1172890; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; McGirt LY, 2015, BLOOD, V126, P508, DOI 10.1182/blood-2014-11-611194; Milholland B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15183; Moll I, 2005, EUR J CELL BIOL, V84, P259, DOI 10.1016/j.ejcb.2004.12.023; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Puram RV, 2016, CELL, V165, P303, DOI 10.1016/j.cell.2016.03.015; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Sauer CM, 2017, CRIT REV ONCOL HEMAT, V116, P99, DOI 10.1016/j.critrevonc.2017.05.009; Schadendorf D, 2017, EUR J CANCER, V71, P53, DOI 10.1016/j.ejca.2016.10.022; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Semenova EA, 2015, GENE DEV, V29, P1447, DOI 10.1101/gad.263145.115; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shuda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142329; Shuda M, 2014, J INVEST DERMATOL, V134, P1479, DOI 10.1038/jid.2013.483; SIBLEY RK, 1985, AM J SURG PATHOL, V9, P95, DOI 10.1097/00000478-198502000-00004; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; Spurgeon ME, 2015, CANCER RES, V75, P1068, DOI 10.1158/0008-5472.CAN-14-2425; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Tilling T, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/680410; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Van Keymeulen A, 2009, J CELL BIOL, V187, P91, DOI 10.1083/jcb.200907080; Verhaegen ME, 2017, CANCER RES, V77, P3151, DOI 10.1158/0008-5472.CAN-17-0035; Verhaegen ME, 2015, J INVEST DERMATOL, V135, P1415, DOI 10.1038/jid.2014.446; Viatour P, 2008, CELL STEM CELL, V3, P416, DOI 10.1016/j.stem.2008.07.009; Vieites B, 2009, ACTA DERM-VENEREOL, V89, P184, DOI 10.2340/00015555-0563; VISSCHER D, 1989, MODERN PATHOL, V2, P331; Wendzicki JA, 2015, CURR OPIN VIROL, V11, P38, DOI 10.1016/j.coviro.2015.01.009; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Woo SH, 2010, DEVELOPMENT, V137, P3965, DOI 10.1242/dev.055970; zur Hausen A, 2013, CANCER RES, V73, P4982, DOI 10.1158/0008-5472.CAN-13-0616	68	62	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1409	1416		10.1038/s41388-017-0073-3	http://dx.doi.org/10.1038/s41388-017-0073-3			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29321666	Green Accepted			2022-12-28	WOS:000427459500001
J	Zheng, X; Chi, J; Zhi, J; Zhang, H; Yue, D; Zhao, J; Li, D; Li, Y; Gao, M; Guo, J				Zheng, X.; Chi, J.; Zhi, J.; Zhang, H.; Yue, D.; Zhao, J.; Li, D.; Li, Y.; Gao, M.; Guo, J.			Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration	ONCOGENE			English	Article							TUMOR-SUPPRESSOR LKB1; EML4-ALK FUSION GENE; CELL LUNG-CANCER; KINASE INHIBITOR; PROSTATE-CANCER; POOR-PROGNOSIS; AMPK ACTIVITY; SURVIVAL; MLN8237; AURKA	Deletion or loss-of-function mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant caution of NSCLC initiation and progression. However, the upstream signaling pathways governing LKB1 activation are largely unknown. Here, we report that LKB1 undergoes Aurora kinase A (AURKA)-mediated phosphorylation, which largely compromises the LKB1/AMPK signaling axis, in turn leading to the elevation of NSCLC cell proliferation, invasion and migration. Mechanically, AURKA-mediated phosphorylation of LKB1 impairs LKB1 interaction with and phosphorylation of its downstream target AMPKa, which has critical roles in governing cancer cell energy metabolic homeostasis and tumorigenesis. Clinically, AURKA displays high levels in NSCLC patients, and correlates with poor outcome of patients with lung adenocarcinoma. Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.	[Zheng, X.; Chi, J.; Zhi, J.; Zhao, J.; Li, D.; Li, Y.; Gao, M.] Tianjin Med Univ, Dept Thyroid & Neck Tumor, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Zhang, H.] Tianjin Med Univ, Canc Prevent Ctr, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Yue, D.] Tianjin Med Univ, Dept Lung Tumor, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Guo, J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, E CLS 628,3 Blackfan Circle, Boston, MA 02115 USA	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gao, M; Guo, J (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, E CLS 628,3 Blackfan Circle, Boston, MA 02115 USA.	gaoming68@aliyun.com; Jguo3@bidmc.harvard.edu			National Natural Science Foundation of China [81402392, 81472580, 81502322, 81501983]; Tianjin Municipal Science and technology project [15JCQNJC12800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and technology project	This work was partially supported by grants from National Natural Science Foundation of China (Grant No. 81402392, 81472580, 81502322 and 81501983) and Tianjin Municipal Science and technology project (Grant No. 15JCQNJC12800).	Al-Khafaji ASK, 2017, ONCOL LETT, V13, P4463, DOI 10.3892/ol.2017.6012; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Brose MS, 2002, CANCER RES, V62, P6997; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Cheng J, 2016, BBA-REV CANCER, V1866, P232, DOI 10.1016/j.bbcan.2016.09.006; Dees EC, 2012, CLIN CANCER RES, V18, P4775, DOI 10.1158/1078-0432.CCR-12-0589; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goos JACM, 2013, BRIT J CANCER, V109, P2445, DOI 10.1038/bjc.2013.608; Guo J, 2013, ONCOGENE, V32, P151, DOI 10.1038/onc.2012.39; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Katayama H, 2010, BBA-GENE REGUL MECH, V1799, P829, DOI 10.1016/j.bbagrm.2010.09.004; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Liu X, 2016, ONCOTARGET, V7, P33152, DOI 10.18632/oncotarget.8888; Lo Iacono M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-100; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Mahadevan D, 2012, CLIN CANCER RES, V18, P2210, DOI 10.1158/1078-0432.CCR-11-2413; Marcus AI, 2010, J THORAC ONCOL, V5, P1883, DOI 10.1097/JTO.0b013e3181fbc28a; Matulonis UA, 2012, GYNECOL ONCOL, V127, P63, DOI 10.1016/j.ygyno.2012.06.040; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel AV, 2012, CLIN CANCER RES, V18, P5020, DOI 10.1158/1078-0432.CCR-12-1072; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Pollard JR, 2009, J MED CHEM, V52, P2629, DOI 10.1021/jm8012129; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang LL, 2017, CANCER LETT, V390, P11, DOI 10.1016/j.canlet.2017.01.003; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng XQ, 2014, ONCOGENE, V33, P4985, DOI 10.1038/onc.2013.444	47	24	25	1	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					502	511		10.1038/onc.2017.354	http://dx.doi.org/10.1038/onc.2017.354			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967900				2022-12-28	WOS:000423331600008
J	Weijts, BGMW; Westendorp, B; Hien, BT; Martinez-Lopez, LM; Zijp, M; Thurlings, I; Thomas, RE; Schulte-Merker, S; Bakker, WJ; de Bruin, A				Weijts, B. G. M. W.; Westendorp, B.; Hien, B. T.; Martinez-Lopez, L. M.; Zijp, M.; Thurlings, I.; Thomas, R. E.; Schulte-Merker, S.; Bakker, W. J.; de Bruin, A.			Atypical E2Fs inhibit tumor angiogenesis	ONCOGENE			English	Article							CELL-MIGRATION; TRANSCRIPTION; VASCULATURE; ACTIVATION; NETWORK; GROWTH; CANCER; ROLES; DLL4	Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a) anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.	[Weijts, B. G. M. W.; Westendorp, B.; Hien, B. T.; Martinez-Lopez, L. M.; Zijp, M.; Thurlings, I.; Thomas, R. E.; Bakker, W. J.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Utrecht, Netherlands; [Weijts, B. G. M. W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Schulte-Merker, S.] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Schulte-Merker, S.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Bakker, W. J.] Univ Munster, Inst Cardiovasc Organogenesis & Regenerat, Cells In Mot Cluster Excellence, Munster, Germany; [de Bruin, A.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands; [Weijts, B. G. M. W.; Westendorp, B.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands	Utrecht University; University of California System; University of California San Diego; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; University of Munster; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Bakker, WJ; de Bruin, A (corresponding author), Acad Med Ctr UvA, Lab Expt Dermatol, Room L3-119,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	w.j.bakker@amc.uva.nl; a.debruin@uu.nl	Weijts, Bart/O-7107-2019; de Bruin, Alain/AAL-9195-2020	Weijts, Bart/0000-0003-4843-3019; Westendorp, Bart/0000-0003-1043-3638	Dutch Cancer Society [UU2009-4353, UU2013-5777]; Association of International Cancer Research [09-0718]; Netherlands Organization for Scientific Research [NWO-ALW 11-28]	Dutch Cancer Society(KWF Kankerbestrijding); Association of International Cancer Research; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This study was financially supported by grants from the Dutch Cancer Society (UU2009-4353) to WJB, and (UU2013-5777) to BW and AdB. From the Association of International Cancer Research (09-0718) to WJB, and from the Netherlands Organization for Scientific Research (NWO-ALW 11-28) to AdB.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Bakker WJ, 2013, TRANSCR-AUSTIN, V4, P62, DOI 10.4161/trns.23680; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; de Bruin A, 2016, NUCLEIC ACIDS RES, V44, P3549, DOI 10.1093/nar/gkv1471; DeGregori J, 2006, CURR MOL MED, V6, P739; Deng Q, 2010, CANCER RES, V70, P782, DOI 10.1158/0008-5472.CAN-09-3082; Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Hogan BM, 2009, DEVELOPMENT, V136, P4001, DOI 10.1242/dev.039990; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Magliozzi R, 2013, DEV CELL, V27, P574, DOI 10.1016/j.devcel.2013.10.023; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Pandit SK, 2012, NAT CELL BIOL, V14, P1181, DOI 10.1038/ncb2585; Park SA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv151; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Raimondi C, 2013, SEMIN CELL DEV BIOL, V24, P172, DOI 10.1016/j.semcdb.2013.01.001; Thurlings I, 2017, ONCOGENE, V36, P829, DOI 10.1038/onc.2016.251; Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203	31	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					271	276		10.1038/onc.2017.336	http://dx.doi.org/10.1038/onc.2017.336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925392	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000422631700013
J	Shih, CH; Chang, YJ; Huang, WC; Jang, TH; Kung, HJ; Wang, WC; Yang, MH; Lin, MC; Huang, SF; Chou, SW; Chang, E; Chiu, H; Shieh, TY; Chen, YJ; Wang, LH; Chen, L				Shih, C-H; Chang, Y-J; Huang, W-C; Jang, T-H; Kung, H-J; Wang, W-C; Yang, M-H; Lin, M-C; Huang, S-F; Chou, S-W; Chang, E.; Chiu, H.; Shieh, T-Y; Chen, Y-J; Wang, L-H; Chen, L.			EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; AVIAN-SARCOMA VIRUS-UR2; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; FUSION PROTEINS; C-ROS; GENE; EXPRESSION; CAVITY	Current anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory efficacy due to drug resistance or reduced EGFR level. As an alternative candidate target for therapy, here we identified an oncogene, ROS1, as an important driver for oral squamous cell carcinoma (OSCC) metastasis. Among tumors from 188 oral cancer patients, upregulated ROS1 expression strongly correlated with metastasis to lung and lymph nodes. Mechanistic studies uncover that the activated ROS1 results from highly expressed ROS1 gene instead of gene rearrangement, a phenomenon distinct from other cancers. Our data further reveal a novel mechanism that reduced histone methyltransferase EZH2 leads to a lower trimethylation of histone H3 lysine 27 suppressive modification, relaxes chromatin, and promotes the accessibility of the transcription factor STAT1 to the enhancer and the intron regions of ROS1 target genes, CXCL1 and GLI1, for upregulating their expressions. Down-regulation of ROS1 in highly invasive OSCC cells, nevertheless, reduces cell proliferation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models. Our findings highlight ROS1 as a candidate biomarker and therapeutic target for OSCC. Finally, we demonstrate that co-targeting of ROS1 and EGFR could potentially offer an effective oral cancer therapy.	[Shih, C-H; Chang, Y-J; Lin, M-C; Chou, S-W; Chang, E.; Chiu, H.; Chen, L.] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan; [Huang, W-C; Jang, T-H; Kung, H-J; Huang, S-F; Wang, L-H] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan; [Kung, H-J] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; [Wang, W-C] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Dept Biotechnol, Taipei, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Lab Sci Med, Taipei, Taiwan; [Shieh, T-Y] Kaohsiung Med Univ, Dept Oral Hyg, Kaohsiung, Taiwan; [Chen, Y-J] MacKay Mem Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Chen, L.] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan; [Wang, L-H] China Med Univ, Presidents Off, Taichung, Taiwan	National Tsing Hua University; National Health Research Institutes - Taiwan; University of California System; University of California Davis; National Tsing Hua University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Mackay Memorial Hospital; National Tsing Hua University; China Medical University Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.; Chen, L (corresponding author), Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan.; Chen, L (corresponding author), Natl Tsing Hua Univ, Inst Mol Med, Hsinchu, Taiwan.; Wang, LH (corresponding author), China Med Univ, Presidents Off, Taichung, Taiwan.	lu-hai.wang@nhri.org.tw; lchen@life.nthu.edu.tw	Chen, Linyi/AAV-2632-2020; Wang, Wen-Ching/ABI-2253-2020; Yang, Muh-Hwa/AAE-4691-2020	Chen, Linyi/0000-0001-7258-8817; Wang, Wen-Ching/0000-0002-7422-3667; Chang, Yu-Jung/0000-0002-4781-0946	Ministry of Science and Technology, Taiwan [NSC 105-2320-B-007-002-MY3, NSC 106-2811-B-007-001]; National Tsing Hua University, Taiwan [104N2739E1, 105N722CV7, 105N183DE1]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Tsing Hua University, Taiwan	This study was supported by grants from Ministry of Science and Technology, Taiwan (NSC 105-2320-B-007-002-MY3) and National Tsing Hua University, Taiwan (104N2739E1 and 105N722CV7) and postdoctoral fellowships from Ministry of Science and Technology, Taiwan (NSC 106-2811-B-007-001 to YJC) and National Tsing Hua University, Taiwan (105N183DE1 to YJC). We thank Professor Rong-Long Pan for commenting on our manuscript.	BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Davare MA, 2013, P NATL ACAD SCI USA, V110, P19519, DOI 10.1073/pnas.1319583110; Davies KD, 2013, CLIN CANCER RES, V19, P4040, DOI 10.1158/1078-0432.CCR-12-2851; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dionne KR, 2015, INT J CANCER, V136, P503, DOI 10.1002/ijc.28754; Ernani V, 2015, ONCOLOGY-BASEL, V89, P187, DOI 10.1159/000398801; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ettl T, 2012, HUM PATHOL, V43, P921, DOI 10.1016/j.humpath.2011.08.006; Fan HX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0041-5; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328; Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297; Johnson N W, 2011, Adv Dent Res, V23, P237, DOI 10.1177/0022034511402082; Jun HJ, 2012, CANCER RES, V72, P3764, DOI 10.1158/0008-5472.CAN-11-3990; Jun HJ, 2009, CANCER RES, V69, P2180, DOI 10.1158/0008-5472.CAN-08-3351; Kawanishi H, 2008, CLIN CANCER RES, V14, P2579, DOI 10.1158/1078-0432.CCR-07-1922; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kimura I, 2016, ONCOL LETT, V11, P201, DOI 10.3892/ol.2015.3833; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lin SC, 2004, J ORAL PATHOL MED, V33, P79, DOI 10.1111/j.1600-0714.2004.00034.x; Lu YC, 2012, CANCER PREV RES, V5, P665, DOI 10.1158/1940-6207.CAPR-11-0358; Markopoulos AK, 2012, OPEN DENT J, V6, P126, DOI 10.2174/1874210601206010126; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; Mimeault M, 2010, PHARMACOL REV, V62, P497, DOI 10.1124/pr.109.002329; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Okumura K, 1996, J CANCER RES CLIN, V122, P243, DOI 10.1007/BF01209653; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ryott M, 2009, EUR J CANCER, V45, P1700, DOI 10.1016/j.ejca.2009.02.027; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Shaib W, 2012, J ONCOL, V2012, DOI 10.1155/2012/521215; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsien CI, 2013, HEAD NECK-J SCI SPEC, V35, P1323, DOI 10.1002/hed.23128; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; Wang YF, 2012, HEAD NECK-J SCI SPEC, V34, P1556, DOI 10.1002/hed.21958; Warnakulasuriya S, 2010, ORAL ONCOL, V46, P407, DOI 10.1016/j.oraloncology.2010.02.015; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; Yang C C, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P357; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	51	27	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6542	6554		10.1038/onc.2017.262	http://dx.doi.org/10.1038/onc.2017.262			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759046	Green Published			2022-12-28	WOS:000416049200004
J	Fettig, LM; McGinn, O; Finlay-Schultz, J; LaBarbera, DV; Nordeen, SK; Sartorius, CA				Fettig, L. M.; McGinn, O.; Finlay-Schultz, J.; LaBarbera, D. V.; Nordeen, S. K.; Sartorius, C. A.			Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells	ONCOGENE			English	Article							NEGATIVE RESPONSE ELEMENTS; STEM-CELL; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; LINE T-47D; EXPRESSION; POPULATION; ALPHA; RESPONSIVENESS; MODULATORS	Half of estrogen receptor-positive breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy resistant and exhibit increased cancer stem cell (CSC) properties. We and others have demonstrated that progesterone (P4) increases CK5+ breast cancer cells. We previously discovered that retinoids block P4 induction of CK5+ cells. Here we investigated the mechanisms by which progesterone receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity. After P4 treatment, sorted CK5+ compared to CK5 - cells were more tumorigenic in vivo. In vitro, P4-treated breast cancer cells formed larger mammospheres and silencing of CK5 using small hairpin RNA abolished this P4-dependent increase in mammosphere size. Retinoic acid (RA) treatment blocked the P4 increase in CK5+ cells and prevented the P4 increase in mammosphere size. Dual small interfering RNA (siRNA) silencing of RAR alpha and RAR gamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE). We confirmed by chromatin immunoprecipitation that P4 recruits PR to the CK5 promoter near the - 1.1 kb essential PRE, and also to a proximal region near - 130 bp that contains PRE half-sites and a RA response element (RARE). RA induced loss of PR binding only at the proximal site. Interestingly, RARa was recruited to the - 1.1 kb PRE and the - 130 bp PRE/RARE regions with P4, but not RA alone or RA plus P4. Treatment of breast cancer xenografts in vivo with the retinoid fenretinide reduced the accumulation of CK5+ cells during estrogen depletion. This reduction, together with the inhibition of CK5+ cell expansion through RAR/PR cross talk, may explain the efficacy of retinoids in prevention of some breast cancer recurrences.	[Fettig, L. M.; McGinn, O.; Finlay-Schultz, J.; Nordeen, S. K.; Sartorius, C. A.] Univ Colorado, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA; [LaBarbera, D. V.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Sartorius, CA (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA.	Carol.Sartorius@ucdenver.edu	McGinn, Olivia/J-8337-2015	McGinn, Olivia/0000-0003-0769-5581; Finlay-Schultz, Jessica/0000-0002-7855-9870	University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores [P30CA046934]; Colorado Clinical and Translational Sciences Institute NIH [TL1 TR001081]; National Institutes of Health [NIH F31 CA210519, NIH 2R01 CA140985]; Breast Cancer Research Foundation [16-072]; Breast Cancer Research Foundation (CAS); Breast Cancer Research Foundation (co-PI); NATIONAL CANCER INSTITUTE [F31CA210519, R01CA140985, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores; Colorado Clinical and Translational Sciences Institute NIH; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Breast Cancer Research Foundation (CAS); Breast Cancer Research Foundation (co-PI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores supported by P30CA046934 and the University of Colorado Department of Pathology Sequencing Core for their technical assistance and services. We thank Andrea Osypuk and Story Wilson for their assistance with Aperio imaging and analysis. This work was supported by grants from the Colorado Clinical and Translational Sciences Institute NIH TL1 TR001081 (LMF), National Institutes of Health grants NIH F31 CA210519 (LMF), NIH 2R01 CA140985 (CAS) and Breast Cancer Research Foundation (16-072, CAS, co-PI).	Allan Alison L, 2006, Breast Dis, V26, P87; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; Daniel AR, 2015, ONCOGENE, V34, P506, DOI 10.1038/onc.2013.579; Finlay-Schultz J, 2015, ONCOGENE, V34, P3676, DOI 10.1038/onc.2014.298; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garattini E, 2014, CANCER TREAT REV, V40, P739, DOI 10.1016/j.ctrv.2014.01.001; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Goodman CR, 2016, ONCOGENE, V35, P1373, DOI 10.1038/onc.2015.193; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jho SH, 2001, J BIOL CHEM, V276, P45914, DOI 10.1074/jbc.M103144200; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Knox AJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0418-6; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; le Maire A, 2012, CURR TOP MED CHEM, V12, P505, DOI 10.2174/156802612799436687; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 2005, BREAST, V14, P458, DOI 10.1016/j.breast.2005.08.024; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Reid Brian G, 2014, Curr Chem Genom Transl Med, V8, P27, DOI 10.2174/2213988501408010027; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROMAN SD, 1992, CANCER RES, V52, P2236; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Singhal H, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501924; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Widschwendter M, 1997, CANCER RES, V57, P4158; Yoo BH, 2012, J BIOMOL SCREEN, V17, P1211, DOI 10.1177/1087057112452138	58	17	17	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6074	6084		10.1038/onc.2017.204	http://dx.doi.org/10.1038/onc.2017.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692043	Green Accepted			2022-12-28	WOS:000414249800002
J	Valentino, A; Calarco, A; Di Salle, A; Finicelli, M; Crispi, S; Calogero, R; Riccardo, F; Sciarra, A; Gentilucci, A; Galderisi, U; Margarucci, S; Peluso, G				Valentino, A.; Calarco, A.; Di Salle, A.; Finicelli, M.; Crispi, S.; Calogero, Ra; Riccardo, F.; Sciarra, A.; Gentilucci, A.; Galderisi, U.; Margarucci, S.; Peluso, G.			Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences	ONCOGENE			English	Article							FATTY-ACID OXIDATION; CELL-PROLIFERATION; LIPID OXIDATION; BETA-OXIDATION; METABOLISM; EXPRESSION; PROGRESSION; SIGNATURES; MIGRATION; INVASION	Cancer cells reprogram their metabolism to maintain both viability and uncontrolled proliferation. Although an interplay between the genetic, epigenetic and metabolic rewiring in cancer is beginning to emerge, it remains unclear how this metabolic plasticity occurs. Here, we report that in prostate cancer cells (PCCs) microRNAs (miRNAs) greatly contribute to deregulation of mitochondrial fatty acid (FA) oxidation via carnitine system modulation. We provide evidence that the downregulation of hsa-miR-124-3p, hsa-miR-129-5p and hsa-miR-378 induced an increase in both expression and activity of CPT1A, CACT and CrAT in malignant prostate cells. Moreover, the analysis of human prostate cancer and prostate control specimens confirmed the aberrant expression of miR-124-3p, miR-129-5p and miR-378 in primary tumors. Forced expression of the miRNAs mentioned above affected tumorigenic properties, such as proliferation, migration and invasion, in PC3 and LNCaP cells regardless of their hormone sensitivity. CPT1A, CACT and CrAT overexpression allow PCCs to be more prone on FA utilization than normal prostate cells, also in the presence of high pyruvate concentration. Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria. Indeed, the downregulation of only one of these proteins reduces PCCs metabolic flexibility with the accumulation of FA-intermediate metabolites in the mitochondria. Together, our data implicate carnitine cycle as a primary regulator of adaptive metabolic reprogramming in PCCs and suggest new potential druggable pathways for prevention and treatment of prostate cancer.	[Valentino, A.; Calarco, A.; Di Salle, A.; Peluso, G.] CNR, IBAF, Via P Castellino,111, Naples, Italy; [Finicelli, M.; Crispi, S.; Margarucci, S.] CNR, Inst Biosci & BioResources, Naples, Italy; [Calogero, Ra; Riccardo, F.] Univ Turin, Lab Immunol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Sciarra, A.; Gentilucci, A.] Univ Sapienza, Policlin Umberto 1, Dept Urol, Prostate Canc Unit, Rome, Italy; [Galderisi, U.] Univ Campania Luigi Vanvitelli, Dept Expt Med, Biotechnol & Mol Biol Sect, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioscienze e Biorisorse (IBBR-CNR); University of Turin; Sapienza University Rome; University Hospital Sapienza Rome; Universita della Campania Vanvitelli	Peluso, G (corresponding author), CNR, IBAF, Via P Castellino,111, Naples, Italy.	gianfranco.peluso@ibaf.cnr.it	Finicelli, Mauro/ABC-1392-2020; Calarco, Anna/P-2568-2019; Di Salle, A/AAF-5416-2019; SCIARRA, ALESSANDRO/AAC-8088-2021; Riccardo, Federica/AGT-3153-2022; Calogero, Raffaele/K-9428-2019; Antonelli, Alessandro/AAU-2291-2020	Calarco, Anna/0000-0002-1441-7662; Di Salle, A/0000-0001-6763-3636; Riccardo, Federica/0000-0002-9692-0172; Calogero, Raffaele/0000-0002-2848-628X; Sciarra, Alessandro/0000-0002-7899-8056; Crispi, Stefania/0000-0002-7566-1554; Finicelli, Mauro/0000-0003-2289-0916; Valentino, Anna/0000-0001-8041-2221; MARGARUCCI, SABRINA/0000-0001-5361-1241	Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy; Progetto PON - 'Ricerca e Competitivita' [PON01_01802, PON01_02512]	Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy(Ministry of Education, Universities and Research (MIUR)); Progetto PON - 'Ricerca e Competitivita'(Ministry of Education, Universities and Research (MIUR))	This work was supported from Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy, Progetto PON - 'Ricerca e Competitivita 2007-2013'- PON01_01802: 'Sviluppo di molecole capaci di modulare vie metaboliche intracellulari redoxsensibili per la prevenzione e la cura di patologie infettive, tumorali, neurodegenerative e loro delivery mediante piattaforme nano tecnologiche', and PON01_02512: 'Ricerca e sviluppo di bioregolatori attivi sui meccanismi epigenetici dei processi infiammatori nelle malattie croniche e degenerative'. Precis: this study reports the critical role of specific miRNAs (hsa-miR-124-3p, hsa-miR-129-5p and hsa-miR-378) to sustain prostate cancer metabolic flexibility via modulation of CPT1A, CACT and CrAT expression.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Arora Aastha, 2015, Transl Oncogenomics, V7, P11, DOI 10.4137/TOG.S29652; Bastin J, 2014, BIOCHIMIE, V96, P113, DOI 10.1016/j.biochi.2013.05.012; BERTHON P, 1995, INT J ONCOL, V6, P333; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; BRASS EP, 1980, BIOCHEM J, V190, P495, DOI 10.1042/bj1900495; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109; Costello LC, 2000, ONCOLOGY-BASEL, V59, P269, DOI 10.1159/000012183; Costello LC, 2005, MOL CELL BIOCHEM, V280, P1, DOI 10.1007/s11010-005-8841-8; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Dong PX, 2016, ONCOTARGET, V7, P20260, DOI 10.18632/oncotarget.7754; Dossing KBV, 2015, GENES-BASEL, V6, P1, DOI 10.3390/genes6010001; Duan LJ, 2014, FEBS LETT, V588, P1644, DOI 10.1016/j.febslet.2014.03.002; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; Fritz V, 2013, ONCOGENE, V32, P5101, DOI 10.1038/onc.2012.523; Gill BS, 2016, TUMOR BIOL, V37, P5683, DOI 10.1007/s13277-016-4900-x; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Ijlst L, 2001, BIOCHEM BIOPH RES CO, V280, P700, DOI 10.1006/bbrc.2000.4178; Jogl G, 2004, ANN NY ACAD SCI, V1033, P17, DOI 10.1196/annals.1320.002; Johnson IR, 2014, PROSTATE, V74, P547, DOI 10.1002/pros.22777; Khanmi K, 2015, CLIN CHIM ACTA, V451, P154, DOI 10.1016/j.cca.2015.09.022; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Kurisetty VV, 2014, FRONT BIOSCI-LANDMRK, V19, P1, DOI 10.2741/4192; Li XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070987; Liu XL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-96; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Liu YY, 2010, ANTICANCER RES, V30, P369; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Palmieri F, 2010, ESSAYS BIOCHEM, V47, P37, DOI [10.1042/BSE0470037, 10.1042/bse0470037]; Peluso G, 2002, FRONT BIOSCI, V7, pA109, DOI 10.2741/peluso; Pinweha P, 2016, COMPUT STRUCT BIOTEC, V14, P223, DOI 10.1016/j.csbj.2016.05.005; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Price DT, 2002, J UROLOGY, V168, P273, DOI 10.1016/S0022-5347(05)64906-3; Priore P, 2007, BBA-MOL CELL BIOL L, V1771, P1299, DOI 10.1016/j.bbalip.2007.08.005; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Riehle C, 2012, TRENDS CARDIOVAS MED, V22, P98, DOI 10.1016/j.tcm.2012.07.003; Schaefer A, 2010, UROL ONCOL-SEMIN ORI, V28, P4, DOI 10.1016/j.urolonc.2008.10.021; Schlaepfer IR, 2015, MOL IMAGING BIOL, V17, P529, DOI 10.1007/s11307-014-0814-4; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shahabi A, 2016, PROSTATE, V76, P1239, DOI 10.1002/pros.23211; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Shen N, 2016, TUMOR BIOL, V37, P1789, DOI 10.1007/s13277-015-3969-y; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shi XB, 2015, CANCER RES, V75, P5309, DOI 10.1158/0008-5472.CAN-14-0795; Song CJ, 2015, PROSTATE, V75, P500, DOI 10.1002/pros.22936; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Teahan O, 2011, INT J BIOCHEM CELL B, V43, P1002, DOI 10.1016/j.biocel.2010.07.003; Wang XY, 2016, ONCOL REP, V35, P3115, DOI 10.3892/or.2016.4648; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111	62	39	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6030	6040		10.1038/onc.2017.216	http://dx.doi.org/10.1038/onc.2017.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671672				2022-12-28	WOS:000413841400011
J	Yurugi, H; Marini, F; Weber, C; David, K; Zhao, Q; Binder, H; Desaubry, L; Rajalingam, K				Yurugi, H.; Marini, F.; Weber, C.; David, K.; Zhao, Q.; Binder, H.; Desaubry, L.; Rajalingam, K.			Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours (vol 36, pg 4778, 2017)	ONCOGENE			English	Correction													Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970				Yurugi H, 2017, ONCOGENE, V36, P4778, DOI 10.1038/onc.2017.93	1	6	7	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5914	5914		10.1038/onc.2017.307	http://dx.doi.org/10.1038/onc.2017.307			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28846116	Bronze			2022-12-28	WOS:000413292900013
J	Zeng, AL; Yan, W; Liu, YW; Wang, Z; Hu, Q; Nie, E; Zhou, X; Li, R; Wang, XF; Jiang, T; You, YP				Zeng, A-L; Yan, W.; Liu, Y-W; Wang, Z.; Hu, Q.; Nie, E.; Zhou, X.; Li, R.; Wang, X-F; Jiang, T.; You, Y-P			Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma	ONCOGENE			English	Article							CANCER STEM-CELLS; EXTRACELLULAR VESICLES; MESENCHYMAL TRANSITION; EFFECTIVE STRATEGY; SIGNALING PATHWAY; EMERGING ROLE; MICROVESICLES; GROWTH; GENE; RNA	Exosomes are carriers of pro-tumorigenic factors that participate in glioblastoma (GBM) progression, and many fusion genes are strong driver mutations in neoplasia and are involved in tumorigenesis. However, the ability of fusion genes to be transduced by exosomes is unknown. We characterized exosomes from GBM cells harbouring and not harbouring PTPRZ1-MET fusion (ZM fusion). We also determined the effect of the exosomes from ZM fusion cells (ZM exosomes) on pro-oncogenic secretions and showed that ZM exosomes are internalized by the recipient cells. In addition, we studied the effect of ZM exosome-mediated intercellular communication in the GBM microenvironment. MET proto-oncogene expression was higher in ZM exosomes. Moreover, phosphorylated MET was detected only in ZM exosomes and not in exosomes released by non-ZM fusion GBM cells. ZM exosomes transferred to non-ZM fusion GBM cells and normal human astrocytes altered gene expression and induced epithelial-mesenchymal transition. The uptake of ZM exosomes also induced an exosome-dependent phenotype defined by GBM cell migration and invasion, neurosphere growth and angiogenesis. In addition, ZM exosomes conferred temozolomide resistance to the GBM cells, and exosomederived ZM fusion network proteins targeted multiple pro-oncogenic effectors in recipient cells within the GBM microenvironment. Our findings show that exosomes mediate the aggressive character of GBM and demonstrate the role of ZM fusion in the exacerbation of this effect. These findings have possible implications for the foundation of gene fusion-based therapy for managing GBM.	[Zeng, A-L; Yan, W.; Hu, Q.; Nie, E.; Zhou, X.; Li, R.; Wang, X-F; You, Y-P] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Y-W; Wang, Z.; Jiang, T.] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [Jiang, T.] Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China; [Jiang, T.] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Nanjing Medical University; Beijing Neurosurgical Institute; Capital Medical University; Capital Medical University	Yan, W; You, YP (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	neuro_yw@126.com; yypl9@njmu.edu.cn	zeng, ailiang/AAF-4498-2020	Zeng, Ailiang/0000-0003-2869-9899	National Natural Science Foundation of China [81402056, 81472362]; National High Technology Research, Development Program of China (863) [2012AA02A508]; National Key Research and Development Plan [2016YFC0902500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research, Development Program of China (863); National Key Research and Development Plan	This work was supported by a grant from the National Natural Science Foundation of China (No. 81402056 and 81472362), National High Technology Research, Development Program of China (863) (No. 2012AA02A508) and the National Key Research and Development Plan (No. 2016YFC0902500).	Adachi E, 2016, ONCOTARGET, V7, P70779, DOI 10.18632/oncotarget.12221; Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66; Anastasiadou E, 2014, SCIENCE, V346, P1459, DOI 10.1126/science.aaa4024; Annala MJ, 2013, CANCER LETT, V340, P192, DOI 10.1016/j.canlet.2013.01.011; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Belting M, 2008, J CELL BIOL, V183, P1187, DOI 10.1083/jcb.200810038; Boccaccio C, 2013, CANCER RES, V73, P3193, DOI 10.1158/0008-5472.CAN-12-4039; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen HM, 2015, FEBS LETT, V589, P1437, DOI 10.1016/j.febslet.2015.04.032; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; D'Asti E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00294; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Javeed N, 2015, CLIN CANCER RES, V21, P1722, DOI 10.1158/1078-0432.CCR-14-2022; Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Le MTN, 2014, J CLIN INVEST, V124, P5109, DOI 10.1172/JCI75695; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Li CCY, 2013, RNA BIOL, V10, P1333, DOI 10.4161/rna.25281; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Lopez-Bertoni H, 2015, ONCOGENE, V34, P3994, DOI 10.1038/onc.2014.334; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Martinez MC, 2011, CIRC RES, V109, P110, DOI 10.1161/CIRCRESAHA.110.233049; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P772, DOI 10.1016/j.drudis.2015.02.014; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Roma-Rodrigues C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/179486; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang L, 2014, ONCOTARGET, V5, P5416, DOI 10.18632/oncotarget.2116; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wickramasinghe D, 2005, CELL CYCLE, V4, P683, DOI 10.4161/cc.4.5.1688; Zeng AL, 2015, ONCOTARGET, V6, P30232, DOI 10.18632/oncotarget.4920; Zhang YN, 2016, ONCOTARGET, V7, P37370, DOI 10.18632/oncotarget.8276; Zomer A, 2016, CANCER RES, V76, P2071, DOI 10.1158/0008-5472.CAN-15-2804	49	80	84	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5369	5381		10.1038/onc.2017.134	http://dx.doi.org/10.1038/onc.2017.134			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28504721	Green Published, hybrid			2022-12-28	WOS:000411382100004
J	Marzook, H; Deivendran, S; George, B; Reshmi, G; Santhoshkumar, TR; Kumar, R; Pillai, MR				Marzook, H.; Deivendran, S.; George, B.; Reshmi, G.; Santhoshkumar, T. R.; Kumar, R.; Pillai, M. R.			Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells	ONCOGENE			English	Article							GLUCOCORTICOID-INDUCIBLE KINASE; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; STEM-CELLS; METASTASIS; SERUM; ACTIVATION; SURVIVAL; PROTEIN	Chromatin remodeling factor metastatic tumor protein 1 (MTA1), one of the most upregulated oncogene in human cancer, has an important role in gene expression, cell survival and promoting hypoxic response. Successful cancer progression is dependent on the ability of cells to utilize its survival pathways for adapting to hypoxic microenvironment. Although MTA1 is a stress-responsive gene, but whether hypoxia modulates its function and its role in engaging other core stress-responsive survival pathway(s) remains unknown. Here we have discovered that MTA1 is a novel corepressor of serum and glucocorticoid-inducible kinase 1 (SGK1). Surprisingly, this regulatory corepressive function of MTA1 is lost under hypoxia, allowing upregulation of SGK1 expression and engaging the MTA1-SGK1 axis for the benefit of the cell survival. The underlying mechanism of the noticed stimulation of SGK1 expression by hypoxia includes de-repression of SGK1 transcription because of hypoxia-triggered nucleus-to-cytoplasmic translocation of MTA1. In addition, the newly recognized cytoplasmic translocation of MTA1 was dependent on the chaperoning function of heat shock protein 90 (HSP90) and co-accompanied by the formation of MTA1, HSP90 and HIF1 alpha complex under hypoxic condition but not under normoxic condition. Hypoxia-triggered redistribution of MTA1, SGK1 upregulation and cell survival functions were compromised by a pharmacological SGK1 inhibitor. In summary, for the first time, we report MTA1 regulation of SGK1 expression, hypoxia-dependent MTA1 translocation to the cytoplasm and de-repression of SGK1 transcription. These findings illustrate how cancer cells utilize a chromatin remodeling factor to engage a core survival pathway to support its cancerous phenotypes, and reveal new facets of MTA1-SGK1 axis by a physiologic signal in cancer progression.	[Marzook, H.; Deivendran, S.; George, B.; Reshmi, G.; Santhoshkumar, T. R.; Kumar, R.; Pillai, M. R.] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India; [Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); George Washington University	Kumar, R; Pillai, MR (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India.; Kumar, R (corresponding author), Sch Med & Hlth Sci, 530 Ross Hall,2300 Eye St NW, Washington, DC 20037 USA.	bcmrxk@gwu.edu; mrpillai@rgcb.res.in	Kumar, Rakesh/ABD-1065-2020; Sankaran, Deivendran/X-8009-2019	Kumar, Rakesh/0000-0001-7664-0803; 	NIH [CA098823]; Department of Biotechnology, Government of India; Council of Science and Industrial Research [09/716(0142)/2010-EMR-1]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council of Science and Industrial Research	We thank Christie P Thomas, University of Iowa for the promoter construct pGL3bas_hsgkF4R4, Nirmalya Sen from Kumar's laboratory for identifying SGK1 as a MTA1 target from an in-house, microarray data set generated using NIH grant CA098823. Assistance from Vipin Mohan Dan for MTT analyses, Indu Ramachandran (Core facility for FACS), Confocal Microscopy facility, as well as Prakash R and Ishaque P (Central Cell Line Repository) for hypoxia standardization. This work was supported by Department of Biotechnology, Government of India and Hezlin Marzook is supported by a Senior Research Fellowship from the Council of Science and Industrial Research (09/716(0142)/2010-EMR-1).	Amato R, 2013, ONCOGENE, V32, P4572, DOI 10.1038/onc.2012.470; Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; Azeez JM, 2015, DRUG DES DEV THER, V9, P5987, DOI 10.2147/DDDT.S89390; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cong BH, 2014, CAN J CARDIOL, V30, P687, DOI 10.1016/j.cjca.2014.03.024; Dickmanns A, 2015, CELLS-BASEL, V4, P538, DOI 10.3390/cells4030538; Ellen TP, 2008, CARCINOGENESIS, V29, P2, DOI 10.1093/carcin/bgm200; Feng XH, 2014, MOL CELLS, V37, P699, DOI 10.14348/molcells.2014.0029; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Guo XF, 2013, THORAC CANCER, V4, P312, DOI 10.1111/1759-7714.12024; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hall BA, 2012, BREAST CANCER RES TR, V135, P469, DOI 10.1007/s10549-012-2161-y; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Itani OA, 2002, AM J PHYSIOL-ENDOC M, V283, pE971, DOI 10.1152/ajpendo.00021.2002; Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001; Kumar R, 2016, GENE, V582, P112, DOI 10.1016/j.gene.2016.02.012; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Liu J, 2014, CANCER METAST REV, V33, P843, DOI 10.1007/s10555-014-9511-7; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Matschke J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0647-1; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Moon HE, 2006, ONCOL REP, V16, P929; Murakami Y, 2010, BIOCHEM BIOPH RES CO, V396, P376, DOI 10.1016/j.bbrc.2010.04.100; Newman B, 2012, CANCER RES, V72, P4551, DOI 10.1158/0008-5472.CAN-11-3600; Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998; Rusai K, 2009, CELL PHYSIOL BIOCHEM, V24, P577, DOI 10.1159/000257527; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Talarico C, 2015, ONCOTARGET, V6, P37520, DOI 10.18632/oncotarget.5527; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Wang K, 2013, ISRN HEPATOL, V2013, P1; Wang RA, 2014, CANCER METAST REV, V33, P1001, DOI 10.1007/s10555-014-9525-1; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yu L, 2013, FEBS LETT, V587, P2542, DOI 10.1016/j.febslet.2013.06.029; Zhang C, 2015, INT J CANCER, V136, P2001, DOI 10.1002/ijc.28975	50	8	8	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5263	5273		10.1038/onc.2017.19	http://dx.doi.org/10.1038/onc.2017.19			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504714				2022-12-28	WOS:000410671700005
J	Guo, H; Zhu, Q; Yu, X; Merugu, SB; Mangukiya, HB; Smith, N; Li, Z; Zhang, B; Negi, H; Rong, R; Cheng, K; Wu, Z; Li, D				Guo, H.; Zhu, Q.; Yu, X.; Merugu, S. B.; Mangukiya, H. B.; Smith, N.; Li, Z.; Zhang, B.; Negi, H.; Rong, R.; Cheng, K.; Wu, Z.; Li, D.			Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization	ONCOGENE			English	Article							GROWTH-FACTOR; ANTIANGIOGENIC THERAPIES; MONOCLONAL-ANTIBODY; INTERSTITIAL FLUID; AGR2 EXPRESSION; ANGIOGENESIS; MICROENVIRONMENT; PATHWAYS; MECHANISMS; RESISTANCE	The importance of the tumor microenvironment in targeted anticancer therapies has been well recognized. Various protein factors participate in the cross-talk between tumor cells and non-malignant cells. Anterior gradient-2 (AGR2) is overexpressed in diverse human adenocarcinomas and it exists in both intracellular and extracellular spaces. Although intracellular AGR2 has been intensively investigated, the function of secreted AGR2, especially its exact mechanism of action is still poorly understood. Here we report that the secreted AGR2 promotes the angiogenesis and the invasion of vascular endothelial cells and fibroblasts by enhancing the activities of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2). Further study indicated that AGR2 directly binds to these extracellular signaling molecules, and enhances their homodimerization. The extracellular AGR2 activity can be blocked to reduce angiogenesis and inhibit tumor growth in vitro and in vivo by a monoclonal antibody targeting the AGR2 self-dimerization region, and combined treatment with bevacizumab produced maximum inhibition effect. In conclusion, our investigation reveals a mechanism that directly links the secreted AGR2 with extracellular signaling networks, and we propose that the secreted AGR2 is a blockable molecular target, which acts as a chaperon-like enhancer to VEGF and FGF2.	[Guo, H.; Zhu, Q.; Merugu, S. B.; Mangukiya, H. B.; Zhang, B.; Negi, H.; Rong, R.; Wu, Z.; Li, D.] Shanghai Jiao Tong Univ, Sch Pharm, 308-BLDG6,800 Dongchuan Rd, Shanghai 200240, Peoples R China; [Guo, H.; Zhu, Q.; Zhang, B.; Li, D.] Shanghai Jiao Tong Univ, Sch Pharm, Minist Educ, Engn Res Ctr Cell & Therapeut Antibody, Shanghai, Peoples R China; [Yu, X.] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, Shanghai, Peoples R China; [Smith, N.; Li, Z.] Univ Pittsburgh, Sch Med, Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA USA; [Cheng, K.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Resp Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tongji University	Wu, Z; Li, D (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, 308-BLDG6,800 Dongchuan Rd, Shanghai 200240, Peoples R China.	wuzhenghua@sjtu.edu.cn; daweili@sjtu.edu.cn		Mangukiya, Hitesh/0000-0002-8460-4850	National Natural Science Foundation of China [81373319]; Shanghai Science and Technology Commission Foundation [14431903400]; Guangdong Major Science and Technology Projects Foundation [2012A080202014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission Foundation; Guangdong Major Science and Technology Projects Foundation	This research was supported by National Natural Science Foundation of China No. 81373319; Shanghai Science and Technology Commission Foundation No. 14431903400; Guangdong Major Science and Technology Projects Foundation No. 2012A080202014.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Abuharbeid S, 2006, INT J BIOCHEM CELL B, V38, P1463, DOI 10.1016/j.biocel.2005.10.017; Ahn SM, 2007, PROTEOM CLIN APPL, V1, P1004, DOI 10.1002/prca.200700217; Armes JE, 2013, PATHOLOGY, V45, P49, DOI 10.1097/PAT.0b013e32835bd561; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bamias A, 2012, CRIT REV ONCOL HEMAT, V84, P314, DOI 10.1016/j.critrevonc.2012.04.002; Brychtova V, 2015, SEMIN CANCER BIOL, V33, P16, DOI 10.1016/j.semcancer.2015.04.005; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Edgell TA, 2010, CLIN SCI, V118, P717, DOI 10.1042/CS20090537; Fang H, 2013, CANCER RES, V73, P4965, DOI 10.1158/0008-5472.CAN-13-0661; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Gavalas NG, 2013, INT J MOL SCI, V14, P15885, DOI 10.3390/ijms140815885; Gray TA, 2013, PROTEIN SCI, V22, P1266, DOI 10.1002/pro.2299; Hagedorn M, 2000, CRIT REV ONCOL HEMAT, V34, P89, DOI 10.1016/S1040-8428(00)00056-1; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Haslene-Hox H, 2014, BBA CLIN, V2, P18, DOI 10.1016/j.bbacli.2014.08.002; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hong XY, 2013, CELL BIOCHEM BIOPHYS, V67, P1487, DOI 10.1007/s12013-013-9650-4; Hwang H, 2014, INTEGR BIOL-UK, V6, P267, DOI 10.1039/c3ib40183a; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kim JY, 2015, J CONTROL RELEASE, V199, P122, DOI 10.1016/j.jconrel.2014.12.015; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; Li BH, 2013, CANCER RES, V73, P6471, DOI 10.1158/0008-5472.CAN-13-0657; Li DW, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-4320; Li ZQ, 2015, CANCER SCI, V106, P1041, DOI 10.1111/cas.12714; Lieu C, 2011, CLIN CANCER RES, V17, P6130, DOI 10.1158/1078-0432.CCR-11-0659; Moserle L, 2014, CANCER DISCOV, V4, P31, DOI 10.1158/2159-8290.CD-13-0199; Nadkarni NJ, 2013, CANCER LETT, V331, P99, DOI 10.1016/j.canlet.2012.12.016; Petrillo M, 2012, EXPERT OPIN INV DRUG, V21, P451, DOI 10.1517/13543784.2012.661715; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Schmitt J, 2012, CANCER TREAT REV, V38, P272, DOI 10.1016/j.ctrv.2011.06.004; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Teoh DGK, 2011, CANCER CONTROL, V18, P31, DOI 10.1177/107327481101800105; Tsuji T, 2015, CANCER RES, V75, P356, DOI 10.1158/0008-5472.CAN-14-1693; Wiggins HL, 2010, BIOTECHNIQUES, V48, P120, DOI 10.2144/000113353; Wiig H, 2003, AM J PHYSIOL-HEART C, V284, pH416, DOI 10.1152/ajpheart.00327.2002; Wu Zheng-Hua, 2010, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V26, P49; Xia Y, 2014, SCI REP UK, V4, P6031; Zhang X, 2008, ACTA PHARMACOL SIN, V29, P942, DOI 10.1111/j.1745-7254.2008.00830.x; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	49	36	38	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5098	5109		10.1038/onc.2017.132	http://dx.doi.org/10.1038/onc.2017.132			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481872				2022-12-28	WOS:000409371100002
J	Kim, M; Jang, K; Miller, P; Picon-Ruiz, M; Yeasky, TM; El-Ashry, D; Slingerland, JM				Kim, M.; Jang, K.; Miller, P.; Picon-Ruiz, M.; Yeasky, T. M.; El-Ashry, D.; Slingerland, J. M.			VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; MIR-200 FAMILY; DOWN-REGULATION; TUMOR	Cancer stem cells (CSC) appear to have increased metastatic potential, but mechanisms underlying this are poorly defined. Here we show that VEGFA induction of Sox2 promotes EMT and tumor metastasis. In breast lines and primary cancer culture, VEGFA rapidly upregulates SOX2 expression, leading to SNAI2 induction, EMT, increased invasion and metastasis. We show Sox2 downregulates miR-452, which acts as a novel metastasis suppressor to directly target the SNAI2 3'-untranslated region (3'-UTR). VEGFA stimulates Sox2- and Slug-dependent cell invasion. VEGFA increases lung metastasis in vivo, and this is abrogated by miR-452 overexpression. Furthermore, SNAI2 transduction rescues metastasis suppression by miR-452. Thus, in addition to its angiogenic action, VEGFA upregulates Sox2 to drive stem cell expansion, together with miR-452 loss and Slug upregulation, providing a novel mechanism whereby cancer stem cells acquire metastatic potential. Prior work showed EMT transcription factor overexpression upregulates CSC. Present work indicates that stemness and metastasis are a two-way street: Sox2, a major mediator of CSC self-renewal, also governs the metastatic process.	[Kim, M.; Jang, K.; Miller, P.; Picon-Ruiz, M.; Yeasky, T. M.; El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA; [Kim, M.; Jang, K.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [El-Ashry, D.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Slingerland, JM (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Ruiz, Manuel Picón/I-3624-2015	Ruiz, Manuel Picón/0000-0002-9427-0946	Breast Cancer Research Foundation	Breast Cancer Research Foundation	This work was supported by funding from the Breast Cancer Research Foundation to JMS.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Adams J, 2000, CANCER RES, V60, P2898; Arias-Pulido H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-298; Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558; Bachelder RE, 2002, CANCER RES, V62, P7203; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Berns EMJJ, 2003, CLIN CANCER RES, V9, P1253; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; ETHIER SP, 1993, CANCER RES, V53, P627; Fang XF, 2010, OMICS, V14, P369, DOI 10.1089/omi.2010.0053; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Gonzalez-Moreno O, 2010, EXP CELL RES, V316, P554, DOI 10.1016/j.yexcr.2009.11.020; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gyorffy B, 2012, BREAST CANCER RES TR, V132, P1025, DOI 10.1007/s10549-011-1676-y; Hajra KM, 2002, CANCER RES, V62, P1613; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim LS, 2004, CLIN EXP METASTAS, V21, P107, DOI 10.1023/B:CLIN.0000024761.00373.55; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LP, 2013, CLIN CANCER RES, V19, P3429, DOI 10.1158/1078-0432.CCR-12-3794; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Manders P, 2002, BRIT J CANCER, V87, P772, DOI 10.1038/sj.bjc.6600555; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mercurio AM, 2005, J MAMMARY GLAND BIOL, V10, P283, DOI 10.1007/s10911-006-9001-9; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Montero AJ, 2012, CURR ONCOL REP, V14, P1, DOI 10.1007/s11912-011-0202-z; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Picon-Ruiz M, 2016, CANC RES, V76; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Qian PX, 2012, CANCER RES, V72, P6036, DOI 10.1158/0008-5472.CAN-12-1507; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sa-Nguanraksa D, 2015, MOL CLIN ONCOL, V3, P1103, DOI 10.3892/mco.2015.574; Senger DR, 2010, MOL BIOL CELL, V21, P377, DOI 10.1091/mbc.E09-07-0591; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Sullivan LA, 2010, MABS-AUSTIN, V2, P165, DOI 10.4161/mabs.2.2.11360; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	103	51	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5199	5211		10.1038/onc.2017.4	http://dx.doi.org/10.1038/onc.2017.4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28504716	hybrid, Green Published			2022-12-28	WOS:000409371100011
J	Agaesse, G; Barbollat-Boutrand, L; Sulpice, E; Bhajun, R; El Kharbili, M; Berthier-Vergnes, O; Degoul, F; de la Fouchardiere, A; Berger, E; Voeltzel, T; Lamartine, J; Gidrol, X; Masse, I				Agaesse, G.; Barbollat-Boutrand, L.; Sulpice, E.; Bhajun, R.; El Kharbili, M.; Berthier-Vergnes, O.; Degoul, F.; de la Fouchardiere, A.; Berger, E.; Voeltzel, T.; Lamartine, J.; Gidrol, X.; Masse, I.			A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion (vol 36, pg 446, 2017)	ONCOGENE			English	Correction														Sulpice, Eric/0000-0001-7695-0561; Gidrol, Xavier/0000-0002-4233-3749; Lamartine, Jerome/0000-0003-2322-1618				Agaesse G, 2017, ONCOGENE, V36, P446, DOI 10.1038/onc.2016.219	1	6	6	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5084	5084		10.1038/onc.2017.195	http://dx.doi.org/10.1038/onc.2017.195			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28628117	Bronze			2022-12-28	WOS:000408768800014
J	Dai, L; Lin, Z; Qiao, J; Chen, Y; Flemington, EK; Qin, Z				Dai, L.; Lin, Z.; Qiao, J.; Chen, Y.; Flemington, E. K.; Qin, Z.			Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma	ONCOGENE			English	Article							CELL-CYCLE ARREST; KAPOSIS-SARCOMA; DNA-SEQUENCES; HERPESVIRUS; IRON; CANCER; APOPTOSIS; AIDS; INHIBITORS; COMPONENT	Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus. PEL prognosis is poor and patients barely survive >6 months even following active chemotherapy interventions. There is therefore an urgent need to discover more effective targets for PEL management. We recently found that the ribonucleotide reductase (RR) subunit M2 is potentially regulated by the key oncogenic hepatocyte growth factor/c-MET pathway in PEL. In this study, we set to investigate the role of RR in PEL pathogenesis and to evaluate its potential as a therapeutic target. We report that the RR inhibitor 3-AP actively induces PEL cell cycle arrest through inhibiting the activity of the nuclear factor-kappa B pathway. Using a xenograft model, we found that 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) effectively suppresses PEL progression in immunodeficient mice. Transcriptome analysis of 3-AP-treated PEL cell lines reveals altered cellular genes, most of whose roles in PEL have not yet been reported. Taken together, we propose that RR and its signaling pathway may serve as novel actionable targets for PEL management.	[Dai, L.; Qiao, J.; Qin, Z.] Tongji Univ, Sch Med, Dept Pediat, East Hosp, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Tongji Univ, Sch Med, Res Ctr Translat Med, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave,Suite 902, New Orleans, LA 70112 USA; [Lin, Z.; Flemington, E. K.] Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Pathol, New Orleans, LA 70118 USA	Tongji University; Tongji University; Tongji University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tulane University	Qin, Z (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave,Suite 902, New Orleans, LA 70112 USA.	zqin@lsuhsc.edu			DOD [CA140437]; Leukemia Research Foundation; Louisiana Clinical and Translational Science Center from NIH [U54GM104940]; NIH [AI101046, AI106676]; National Natural Science Foundation of China [81472547, 81672924, 81400164]; NATIONAL CANCER INSTITUTE [P01CA214091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676, R01AI101046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Leukemia Research Foundation; Louisiana Clinical and Translational Science Center from NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was partially supported by grants from a DOD Career Development Award (CA140437), the Leukemia Research Foundation, the Louisiana Clinical and Translational Science Center Pilot grants (U54GM104940 from NIH), NIH RO1s (AI101046 and AI106676), as well as awards from the National Natural Science Foundation of China (81472547, 81672924 and 81400164). Funding sources had no role in the study design, data collection/analysis, decision to publish and/or manuscript preparation.	Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; CAZZOLA M, 1990, BLOOD, V75, P1903; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Dai L, 2016, ONCOTARGET, V7, P3806, DOI 10.18632/oncotarget.6584; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dai L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090349; Defee MR, 2011, AM J CANCER RES, V1, P687; Falchook GS, 2015, SEMIN ONCOL, V42, P832, DOI 10.1053/j.seminoncol.2015.09.022; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Flepisi BT, 2014, BIOMED PHARMACOTHER, V68, P665, DOI 10.1016/j.biopha.2014.04.010; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Gottwein E, 2010, J VIROL, V84, P5229, DOI 10.1128/JVI.00202-10; IWAKI T, 1995, BRAIN RES, V673, P47, DOI 10.1016/0006-8993(94)01393-V; LARSSON A, 1986, ANTIMICROB AGENTS CH, V30, P598, DOI 10.1128/AAC.30.4.598; LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395-267; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Qin Z, 2011, LEUKEMIA, V25, P1598, DOI 10.1038/leu.2011.144; Qin ZQ, 2014, MOL CANCER THER, V13, P154, DOI 10.1158/1535-7163.MCT-13-0466; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sasai K, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00247; Shao JM, 2005, BIOCHEM PHARMACOL, V69, P627, DOI 10.1016/j.bcp.2004.11.016; Simonart T, 2000, J INVEST DERMATOL, V115, P893, DOI 10.1046/j.1523-1747.2000.00119.x; Simonart T, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-1; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200/JCO.2003.06.013; Stadler WM, 2008, CANCER CHEMOTH PHARM, V61, P689, DOI 10.1007/s00280-007-0524-6; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Weinberg ED, 1996, EUR J CANCER PREV, V5, P19, DOI 10.1097/00008469-199609001-00004; Yen Y, 2004, CANCER CHEMOTH PHARM, V54, P331, DOI 10.1007/s00280-004-0821-2; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094	33	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5068	5074		10.1038/onc.2017.122	http://dx.doi.org/10.1038/onc.2017.122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459467	Green Accepted			2022-12-28	WOS:000408768800011
J	Li, J; Huang, Q; Long, X; Guo, X; Sun, X; Jin, X; Li, Z; Ren, T; Yuan, P; Huang, X; Zhang, H; Xing, J				Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Jin, X.; Li, Z.; Ren, T.; Yuan, P.; Huang, X.; Zhang, H.; Xing, J.			Mitochondrial elongation-mediated glucose metabolism reprogramming is essential for tumour cell survival during energy stress	ONCOGENE			English	Article							CANCER-CELLS; FISSION; PHOSPHORYLATION; DYNAMICS; SIRTUINS; HYPOXIA; FUSION; DEGRADATION; STARVATION; AUTOPHAGY	To date, mechanisms of tumour cell survival under energy stress are not well understood. Cumulative evidence is beginning to reveal that specific mitochondrial morphologies are often associated with energetic states and survival of cells. However, the functional roles of mitochondria in the metabolic adaptation of tumour cells to energy stress remain to be elucidated. In this study, we first investigated the changes in mitochondrial morphology induced by nutrition deprivation in tumour cells, and the underlying molecular mechanism. We then systematically explored glucose metabolism reprogramming by energy stress-induced alteration of mitochondrial morphology and its effect on tumour cell survival. Our results showed that starvation treatment resulted in a dramatic mitochondrial elongation, which was mainly mediated by DRP1(S637) phosphorylation through protein kinase A activation and subsequent suppression of mitochondrial translocation of DRP1. We further observed that tumour cells under an energy stress condition exhibited a clear shift from glycolysis towards oxidative phosphorylation, which was reversed by the recovery of mitochondrial fission induced by forced expression of mutant DRP1(S637A). Mechanistically, energy stress-induced mitochondrial elongation facilitated cristae formation and assembly of respiratory complexes to enhance oxidative phosphorylation, which in turn exhibited a feedback inhibitory effect on glycolysis through NAD(+)-dependent SIRT1 activation. In addition, our data indicated that DRP1(S637)-mediated mitochondrial elongation under energy stress was essential for tumour cell survival both in vitro and in vivo and predicted poor prognosis of hepatocellular carcinoma patients. Overall, our study demonstrates that remodelling of mitochondrial morphology plays a critical role in tumour cell adaptation to energy stress by reprogramming glucose metabolism.	[Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Li, Z.; Ren, T.; Huang, X.; Xing, J.] Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Li, J.; Huang, Q.; Long, X.; Guo, X.; Sun, X.; Li, Z.; Ren, T.; Huang, X.; Xing, J.] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Jin, X.] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian, Shaanxi, Peoples R China; [Yuan, P.; Zhang, H.] Fourth Mil Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Xing, J (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Xing, J (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81320108021, 81572304]; National Basic Research Program of China [2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grants 81320108021 and 81572304) and National Basic Research Program (grant 2015CB553703) of China.	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Ferretti AC, 2016, ONCOTARGET, V7, P17815, DOI 10.18632/oncotarget.7404; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Guido C, 2012, ONCOTARGET, V3, P798, DOI 10.18632/oncotarget.574; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hong J, 2014, J BIOL CHEM, V289, P20012, DOI 10.1074/jbc.M114.560078; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Huang Q., 2016, AUTOPHAGY, P1; Huang QC, 2014, J HEPATOL, V61, P859, DOI 10.1016/j.jhep.2014.04.035; Ikeda Y, 2015, CIRC RES, V116, P264, DOI 10.1161/CIRCRESAHA.116.303356; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Jakobs S, 2003, J CELL SCI, V116, P2005, DOI 10.1242/jcs.00423; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Liu ZG, 2015, SPR TRACTS MECH ENG, P1, DOI 10.1007/978-3-662-45673-6_1; Loh JK, 2015, BBA-MOL CELL RES, V1853, P1796, DOI 10.1016/j.bbamcr.2015.04.013; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Molina AJA, 2009, DIABETES, V58, P2303, DOI 10.2337/db07-1781; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Rahman S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-11; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Strauss M, 2008, EMBO J, V27, P1154, DOI 10.1038/emboj.2008.35; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Toda C, 2016, CELL, V164, P872, DOI 10.1016/j.cell.2016.02.010; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Verdin E, 2014, NAT MED, V20, P25, DOI 10.1038/nm.3447; Xing JL, 2008, JNCI-J NATL CANCER I, V100, P1104, DOI 10.1093/jnci/djn213; Yoon H, 2014, BIOCHEM BIOPH RES CO, V444, P36, DOI 10.1016/j.bbrc.2014.01.001; Zeng W, 2015, CANCER LETT, V356, P263, DOI 10.1016/j.canlet.2014.01.032	38	68	69	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4901	4912		10.1038/onc.2017.98	http://dx.doi.org/10.1038/onc.2017.98			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436948				2022-12-28	WOS:000408234400007
J	Vinyoles, M; Del Valle-Perez, B; Curto, J; Padilla, M; Villarroel, A; Yang, J; de Herreros, AG; Dunach, M				Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Yang, J.; de Herreros, A. G.; Dunach, M.			Activation of CK1 epsilon by PP2A/PR61 epsilon is required for the initiation of Wnt signaling (vol 36, pg 429, 2017)	ONCOGENE			English	Correction													Dunach, Mireia/E-3604-2015	Dunach, Mireia/0000-0001-9844-5603				Vinyoles M, 2017, ONCOGENE, V36, P429, DOI 10.1038/onc.2016.209	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4670	4670		10.1038/onc.2017.84	http://dx.doi.org/10.1038/onc.2017.84			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368396	Bronze			2022-12-28	WOS:000407246200014
J	Zhang, W; Ding, Y; Zhang, C; Lu, Q; Liu, Z; Coughlan, K; Okon, I; Zou, MH				Zhang, W.; Ding, Y.; Zhang, C.; Lu, Q.; Liu, Z.; Coughlan, K.; Okon, I.; Zou, M-H			Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor	ONCOGENE			English	Article							PEUTZ-JEGHERS-SYNDROME; FACTOR MESSENGER-RNA; MICROVASCULAR PERMEABILITY; SUPPRESSOR KINASE; SPLICE VARIANT; LKB1; VEGF; METABOLISM; EXPRESSION; INVASION	Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells. It was first identified in PeutzJeghers syndrome as a tumor suppressor gene. Whether endothelial LKB1 regulates angiogenesis and tumor growth is unknown. In this study, we generated endothelial cell-specific LKB1- knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelialcadherin-Cre mice with LKB1(flox/flox) mice. Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice. Consistently, LKB1(endo-/-) mouse tissues including the lung, skin, kidney and liver showed increased vascular permeability. Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1- knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wildtype mice. Injection of VEGF-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and tumor growth in vivo. Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration. Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1(endo-/-) cells. Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression. Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.	[Zhang, W.; Zhang, C.; Zou, M-H] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan, Peoples R China; [Zhang, W.; Zhang, C.; Zou, M-H] Shandong Univ, Qilu Hosp, Key Lab Translat Cardiovasc Med, Chinese Minist Hlth,State & Shandong Prov Joint, Jinan, Peoples R China; [Ding, Y.; Lu, Q.; Liu, Z.; Okon, I.; Zou, M-H] Georgia State Univ, Ctr Mol & Translat Med, Atlanta, GA 30303 USA; [Coughlan, K.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Mol Med, Oklahoma City, OK USA	Shandong University; Shandong University; University System of Georgia; Georgia State University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhang, W (corresponding author), Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan, Peoples R China.; Zhang, W (corresponding author), Shandong Univ, Qilu Hosp, Key Lab Translat Cardiovasc Med, Chinese Minist Hlth,State & Shandong Prov Joint, Jinan, Peoples R China.	zhangwencheng@sdu.edu.cn	Zhang, Wencheng/AAO-8445-2020		National Natural Science Foundation of China [81570393]; Natural Science Foundation of Shandong Province [ZR2015HM002]; Taishan Scholar Project of Shandong Province of China [tsqn20161066]; National Institute of Health [CA213022, HL080499, HL089920, HL110488, HL105157]; NATIONAL CANCER INSTITUTE [R01CA213022] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080499, R01HL132500, R01HL128014, R01HL110488, R01HL074399, R01HL105157, R01HL089920, R01HL079584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG047776] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Taishan Scholar Project of Shandong Province of China; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to Dr Lexi Ding who helped with the retinal angiogenesis experiments. This study was supported by grants from the National Natural Science Foundation of China (81570393 to WZ), the Natural Science Foundation of Shandong Province (ZR2015HM002 to WZ), the Taishan Scholar Project of Shandong Province of China (tsqn20161066 to WZ) and the National Institute of Health (CA213022, HL080499, HL089920, HL110488 and HL105157 to M-HZ).	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; Greenberg Y, 2008, FASEB J, V22, P1597, DOI 10.1096/fj.07-9973com; JENSEN JS, 1995, ARTERIOSCL THROM VAS, V15, P1324, DOI 10.1161/01.ATV.15.9.1324; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liang X, 2014, INT J ONCOL, V44, P1989, DOI 10.3892/ijo.2014.2351; Liu ZY, 2015, J BIOL CHEM, V290, P2312, DOI 10.1074/jbc.M114.616441; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ollila S, 2011, J MOL CELL BIOL, V3, P330, DOI 10.1093/jmcb/mjr016; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Pal S, 2001, CANCER RES, V61, P6952; Pasula S, 2012, J CLIN INVEST, V122, P4424, DOI 10.1172/JCI64537; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Uemura AK, 2006, EXP CELL RES, V312, P676, DOI 10.1016/j.yexcr.2005.10.030; Xie ZL, 2009, MOL CELL BIOL, V29, P3582, DOI 10.1128/MCB.01417-08; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhang WC, 2014, CIRCULATION, V129, P1428, DOI 10.1161/CIRCULATIONAHA.113.004146; Zhuang ZG, 2006, MOL CANCER RES, V4, P843, DOI 10.1158/1541-7786.MCR-06-0118	30	12	13	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4277	4287		10.1038/onc.2017.61	http://dx.doi.org/10.1038/onc.2017.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346429	Green Accepted			2022-12-28	WOS:000406360600005
J	Junk, DJ; Bryson, BL; Smigiel, JM; Parameswaran, N; Bartel, CA; Jackson, MW				Junk, D. J.; Bryson, B. L.; Smigiel, J. M.; Parameswaran, N.; Bartel, C. A.; Jackson, M. W.			Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-TUMOR CELLS; TGF-BETA; STEM-CELL; INTERLEUKIN-6 EXPRESSION; MALIGNANT-TRANSFORMATION; STAT3; ACTIVATION; IL-6; CHEMOTHERAPY	Increasing evidence supports the idea that cancer cell plasticity promotes metastasis and tumor recurrence, resulting in patient mortality. While it is clear that the tumor microenvironment (TME) contributes to cancer cell plasticity, the specific TME factors most actively controlling plasticity remain largely unknown. Here, we performed a screen to identify TME cytokines and growth factors that promote epithelial-mesenchymal plasticity, and acquisition of cancer stem cell (CSC) properties. Of 28 TME cytokines and growth factors tested, we identified Oncostatin M (OSM) as the most potent inducer of mesenchymal/CSC properties. OSM-induced plasticity was Signal Transducer and Activator of Transcription 3 (STAT3)-dependent, and also required a novel intersection with transforming growth factor-alpha (TGF-alpha)/SMAD signaling. OSM/STAT3 activation promoted SMAD3 nuclear accumulation, DNA binding and induced SMAD3-dependent transcriptional activity. Suppression of TGF-alpha receptor activity or ablation of SMAD3 or SMAD4, but not SMAD2, strongly suppressed OSM/ STAT3-mediated plasticity. Moreover, removal of OSM or inhibition of STAT3 or SMAD3 resulted in a marked reversion to a non-invasive, epithelial phenotype. We propose that targeted blockade of the STAT3/SMAD3 axis in tumor cells may represent a novel therapeutic approach to prevent the plasticity required for metastatic progression and tumor recurrence.	[Junk, D. J.; Bryson, B. L.; Smigiel, J. M.; Parameswaran, N.; Bartel, C. A.; Jackson, M. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, 2103 Cornell Rd,WRB 3134, Cleveland, OH 44106 USA; [Jackson, M. W.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Jackson, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, 2103 Cornell Rd,WRB 3134, Cleveland, OH 44106 USA.	mark.w.jackson@case.edu	Bryson, Benjamin L/D-1070-2014	Bryson, Benjamin L/0000-0003-4131-0200	NIH [T32 CA059366]; US National Institutes of Health [R01CA138421]; American Cancer Society [RSG CCG-122517]; Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [R21CA178327, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	DJJ was supported by NIH T32 CA059366. MWJ is supported by the US National Institutes of Health (R01CA138421) and the American Cancer Society (Research Scholar Award # RSG CCG-122517). Additional support was provided by the Case Comprehensive Cancer Center (P30 CA43703; Cytometry & Imaging Microscopy).	Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225; Akizu N, 2010, DEVELOPMENT, V137, P2915, DOI 10.1242/dev.049395; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bastid J, 2012, CANCER METAST REV, V31, P277, DOI 10.1007/s10555-011-9344-6; Baulida J, 2015, BBA-REV CANCER, V1856, P55, DOI 10.1016/j.bbcan.2015.05.005; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Boero Ferdinando, 2015, F1000Prime Rep, V7, P49, DOI 10.12703/P7-49; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Buijs JT, 2012, ONCOGENE, V31, P2164, DOI 10.1038/onc.2011.400; Celis JE, 2004, MOL CELL PROTEOMICS, V3, P327, DOI 10.1074/mcp.M400009-MCP200; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Doherty MR, 2016, CANCERS, V8, DOI 10.3390/cancers8010008; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; ELIAS JA, 1991, J IMMUNOL, V146, P3437; Fang YY, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/478641; Farrell J, 2014, J PROTEOME RES, V13, P2874, DOI 10.1021/pr5000285; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Hart JR, 2011, P NATL ACAD SCI USA, V108, P13247, DOI 10.1073/pnas.1110486108; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Heldin P, 2014, ADV CANCER RES, V123, P211, DOI 10.1016/B978-0-12-800092-2.00008-3; Hermanns HM, 2015, CYTOKINE GROWTH F R, V26, P545, DOI 10.1016/j.cytogfr.2015.07.006; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Junk DJ, 2014, CANCERS, V6, P741, DOI 10.3390/cancers6020741; Junk DJ, 2013, NEOPLASIA, V15, P1086, DOI 10.1593/neo.131114; Junk DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053776; Kan CE, 2011, CANCER RES, V71, P6930, DOI 10.1158/0008-5472.CAN-10-3860; Khoo BL, 2015, ONCOTARGET, V6, P15578; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Luo LY, 2014, TUMOR BIOL, V35, P8379, DOI 10.1007/s13277-014-2203-7; Luwor RB, 2013, ONCOGENE, V32, P2433, DOI 10.1038/onc.2012.260; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Moon SU, 2015, ONCOL REP, V33, P185, DOI 10.3892/or.2014.3582; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Reilly S, 2014, J BIOL CHEM, V289, P9952, DOI 10.1074/jbc.M113.545822; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Plater-Zyberk C, 2001, ARTHRITIS RHEUM, V44, P2697, DOI 10.1002/1529-0131(200111)44:11<2697::AID-ART450>3.0.CO;2-#; Poling J, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-013-0396-3; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richards Carl D, 2013, ISRN Inflamm, V2013, P512103, DOI 10.1155/2013/512103; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Saitoh M, 2016, ONCOGENE, V35, P1049, DOI 10.1038/onc.2015.161; Seong GJ, 2009, MOL VIS, V15, P2123; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh RAK, 1998, IMMUNOL LETT, V62, P159, DOI 10.1016/S0165-2478(98)00040-6; Smith DA, 2013, MOL CANCER RES, V11, P1159, DOI 10.1158/1541-7786.MCR-13-0238; Sodhi A, 1997, IMMUNOL CELL BIOL, V75, P492, DOI 10.1038/icb.1997.76; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tang BW, 1999, CANCER RES, V59, P4834; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; TURNER M, 1990, Cytokine, V2, P211, DOI 10.1016/1043-4666(90)90018-O; Underhill-Day N, 2006, CANCER RES, V66, P10891, DOI 10.1158/0008-5472.CAN-06-1766; Unternaehrer JJ, 2014, STEM CELL REP, V3, P691, DOI 10.1016/j.stemcr.2014.09.008; Vlaicu P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-197; Walia B, 2003, FASEB J, V17, P2130, DOI 10.1096/fj.02-1211fje; Wang G, 2016, ONCOGENE, V35, P4388, DOI 10.1038/onc.2015.446; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wang YX, 2013, P NATL ACAD SCI USA, V110, P16975, DOI 10.1073/pnas.1315862110; Weiss RB, 2003, J CLIN ONCOL, V21, P1825, DOI 10.1200/JCO.2003.09.006; Wendt MK, 2013, ONCOGENE, V32, P2005, DOI 10.1038/onc.2012.230; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; West NR, 2014, ONCOGENE, V33, P1485, DOI 10.1038/onc.2013.105; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Xie GZ, 2012, INT J ONCOL, V40, P1171, DOI 10.3892/ijo.2011.1275; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu MY, 2014, BBA-MOL BASIS DIS, V1842, P2237, DOI 10.1016/j.bbadis.2014.07.025; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123; Zhu MJ, 2015, ONCOL REP, V34, P129, DOI 10.3892/or.2015.3951	98	66	66	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4001	4013		10.1038/onc.2017.33	http://dx.doi.org/10.1038/onc.2017.33			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288136	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000405379900006
J	Blomme, A; Van Simaeys, G; Doumont, G; Costanza, B; Bellier, J; Otaka, Y; Sherer, F; Lovinfosse, P; Boutry, S; Palacios, AP; De Pauw, E; Hirano, T; Yokobori, T; Hustinx, R; Bellahcene, A; Delvenne, P; Detry, O; Goldman, S; Nishiyama, M; Castronovo, V; Turtoi, A				Blomme, Arnaud; Van Simaeys, Gaetan; Doumont, Gilles; Costanza, Brunella; Bellier, Justine; Otaka, Yukihiro; Sherer, Felicie; Lovinfosse, Pierre; Boutry, Sebastien; Palacios, Ana Perez; De Pauw, Edwin; Hirano, Touko; Yokobori, Takehiko; Hustinx, Roland; Bellahcene, Akeila; Delvenne, Philippe; Detry, Olivier; Goldman, Serge; Nishiyama, Masahiko; Castronovo, Vincent; Turtoi, Andrei			Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases	ONCOGENE			English	Article							BREAST-CANCER; TUMOR XENOGRAFTS; MOUSE MODELS; F-18-FDG PET; THERAPY; MICE; DISEASE	Cancer research is increasingly dependent of patient-derived xenograft model (PDX). However, a major point of concern regarding the PDX model remains the replacement of the human stroma with murine counterpart. In the present work we aimed at clarifying the significance of the human-to-murine stromal replacement for the fidelity of colorectal cancer (CRC) and liver metastasis (CRC-LM) PDX model. We have conducted a comparative metabolic analysis between 6 patient tumors and corresponding PDX across 4 generations. Metabolic signatures of cancer cells and stroma were measured separately by MALDI-imaging, while metabolite changes in entire tumors were quantified using mass spectrometry approach. Measurement of glucose metabolism was also conducted in vivo using [F-18]-fluorodeoxyglucose (FDG) and positron emission tomography (PET). In CRC/CRC-LM PDX model, human stroma was entirely replaced at the second generation. Despite this change, MALDI-imaging demonstrated that the metabolic profiles of both stromal and cancer cells remained stable for at least four generations in comparison to the original patient material. On the tumor level, profiles of 86 water-soluble metabolites as well as 93 lipid mediators underlined the functional stability of the PDX model. In vivo PET measurement of glucose uptake (reflecting tumor glucose metabolism) supported the ex vivo observations. Our data show for the first time that CRC/CRC-LM PDX model maintains the functional stability at the metabolic level despite the early replacement of the human stroma by murine cells. The findings demonstrate that human cancer cells actively educate murine stromal cells during PDX development to adopt the human-like phenotype.	[Blomme, Arnaud; Costanza, Brunella; Bellier, Justine; Palacios, Ana Perez; Bellahcene, Akeila; Castronovo, Vincent; Turtoi, Andrei] GIGA Canc Univ Liege, Metastasis Res Lab, Liege, Belgium; [Van Simaeys, Gaetan; Sherer, Felicie; Goldman, Serge] Univ Libre Bruxelles, Hop Erasme, Brussels, Belgium; [Van Simaeys, Gaetan; Doumont, Gilles; Sherer, Felicie; Goldman, Serge] Univ Libre Bruxelles, Ctr Microscopy & Mol Imaging, Brussels, Belgium; [Otaka, Yukihiro; Yokobori, Takehiko; Nishiyama, Masahiko] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Lovinfosse, Pierre; Hustinx, Roland] Liege Univ Hosp, Med Phys Dept, Nucl Med & Oncol Imaging Div, Liege, Belgium; [Boutry, Sebastien] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Boutry, Sebastien] Univ Mons UMONS, Ctr Microscopy & Mol Imaging, Charleroi, Gosselies, Belgium; [De Pauw, Edwin] Univ Liege, Mass Spectrometry Lab, Liege, Belgium; [Hirano, Touko] Gunma Univ, Lab Analyt Instruments, Grad Sch Med, Gunma, Japan; [Delvenne, Philippe] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium; [Detry, Olivier] Univ Liege, Univ Hosp, Dept Abdominal Surg, Liege, Belgium; [Turtoi, Andrei] Inst Rech Cancerol Montpellier, Tumor Microenvironm & Resistance Treatment Lab, Montpellier, France; [Turtoi, Andrei] Inst Canc Montpellier, Montpellier, France; [Turtoi, Andrei] INSERM, U1194, Montpellier, France; [Turtoi, Andrei] Univ Montpellier, Montpellier, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Gunma University; University of Liege; University of Mons; University of Liege; Gunma University; University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Turtoi, A (corresponding author), GIGA Canc Univ Liege, Metastasis Res Lab, Liege, Belgium.; Turtoi, A (corresponding author), Inst Rech Cancerol Montpellier, Tumor Microenvironm & Resistance Treatment Lab, Montpellier, France.; Turtoi, A (corresponding author), Inst Canc Montpellier, Montpellier, France.; Turtoi, A (corresponding author), INSERM, U1194, Montpellier, France.; Turtoi, A (corresponding author), Univ Montpellier, Montpellier, France.	andrei.turtoi@inserm.fr	Bonnemaison, Marc/AAD-9243-2021; Turtoi, Andrei/ABD-1271-2021; Blomme, Arnaud/AGO-7915-2022; Costanza, Brunella/AAB-6354-2022; Detry, Olivier/I-9333-2019; Van Simaeys, Gaetan/AAR-8082-2020; Blomme, Arnaud/AAM-1440-2020	Turtoi, Andrei/0000-0003-3813-6635; Blomme, Arnaud/0000-0003-4183-8726; Detry, Olivier/0000-0002-9436-6673; Van Simaeys, Gaetan/0000-0002-2678-542X; Otaka, Yukihiro/0000-0002-9162-7188; Costanza, Brunella/0000-0001-8279-805X	University of Fiege; National Fund for Scientific Research (FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund (ERDF); Walloon Region; Fondation ULB; Fonds Erasme; "Association Vingotte Nuclear" (AVN); ERDF; FabEx Mablmprove Starting Grant	University of Fiege; National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund (ERDF)(European Commission); Walloon Region; Fondation ULB; Fonds Erasme; "Association Vingotte Nuclear" (AVN); ERDF(European Commission); FabEx Mablmprove Starting Grant	The authors acknowledge the experimental support of Dr. Chantal Humblet, Mrs. Alice Marquet (GIGA-histology platform, ULg), Mr. Vincent Hennequiere, Mrs. Naima Maloujahmoum (Metastasis Research Laboratory), Mrs. Yezza Ben Salah (Tumor Microenvironment and Resistance to Treatment Lab, IRCM), Mr. Nicolas Passon (CMMI) and Mrs. Mari-Aline Laute (CMMI). The authors are thankful to Dr. Stephanie Gofflot (Biobank, University Hospital Liege) for providing patient material as well as the Cyclotron Unit of Erasme Hospital (Brussels, Belgium) for providing [18F]-FDG. Prof. Robert N. Muller (CMMI, Director of international partnerships) is thanked for his scientific input and support. Mr. Mathieu Roch (CMMI) is thanked for tumor volume measurements on MR images.This work was supported with grants from the University of Fiege, National Fund for Scientific Research (FNRS) and Gunma University (GIAR Research Program for Omics-Based Medical Science). The CMMI is supported by the European Regional Development Fund (ERDF), the Walloon Region, the Fondation ULB, the Fonds Erasme and the "Association Vingotte Nuclear" (AVN). GD is supported by the ERDF and the Walloon Region. Akeila Bellahcene is a Research Director at the FNRS. AT is a senior research fellow of the French National Institute of Health and Medical Research (INSERM) and is supported by FabEx Mablmprove Starting Grant. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams MC, 2010, AM J ROENTGENOL, V195, P310, DOI 10.2214/AJR.10.4923; Amos-Landgraf JM, 2014, P NATL ACAD SCI USA, V111, P16514, DOI 10.1073/pnas.1323064111; Blomme A, 2017, ONCOGENE, V36, P2116, DOI 10.1038/onc.2016.369; Boellaard R, 2010, EUR J NUCL MED MOL I, V37, P181, DOI 10.1007/s00259-009-1297-4; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Chiavarina B, 2017, CURR MED CHEM, V24, P2846, DOI 10.2174/0929867324666170428104311; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Fueger BJ, 2006, J NUCL MED, V47, P999; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; HOUGHTON JA, 1981, CANCER RES, V41, P144; Hylander BL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-110; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lin D, 2017, ONCOTARGET, V8, P25928, DOI 10.18632/oncotarget.15237; Lou S, 2017, BBA-PROTEINS PROTEOM, V1865, P957, DOI 10.1016/j.bbapap.2016.09.020; McDonnell LA, 2014, J PROTEOME RES, V13, P1138, DOI 10.1021/pr400620y; Sanz L, 2009, LAB INVEST, V89, P91, DOI 10.1038/labinvest.2008.108; Sha W, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-51; Siolas D, 2013, CANCER RES, V73, P5315, DOI 10.1158/0008-5472.CAN-13-1069; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Valtorta S, 2017, J NUCL MED, V58, P42, DOI 10.2967/jnumed.116.176404; van Velden FHP, 2011, EUR J NUCL MED MOL I, V38, P1636, DOI 10.1007/s00259-011-1845-6; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Werner-Klein M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097860; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081	29	33	37	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1237	1250		10.1038/s41388-017-0018-x	http://dx.doi.org/10.1038/s41388-017-0018-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242606				2022-12-28	WOS:000426505400008
J	Han, BC; Zhou, B; Qu, Y; Gao, BW; Xu, YL; Chung, S; Tanaka, H; Yang, W; Giuliano, AE; Cui, XJ				Han, Bingchen; Zhou, Bo; Qu, Ying; Gao, Bowen; Xu, Yali; Chung, Stacey; Tanaka, Hisashi; Yang, Wei; Giuliano, Armando E.; Cui, Xiaojiang			FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer	ONCOGENE			English	Article							NF-KAPPA-B; MESENCHYMAL TRANSITION; CELL MOTILITY; DNA-BINDING; INVASION; PROTEIN; IDENTIFICATION; SUBTYPES; METASTASIS; EXPRESSION	Triple-negative breast cancer (TNBC) has high rates of local recurrence and distant metastasis, partially due to its high invasiveness. The Forkhead box C1 (FOXC1) transcription factor has been shown to be specifically overexpressed in TNBC and associated with poor clinical outcome. How TNBC's high invasiveness is driven by FOXC1 and its downstream targets remains poorly understood. In the present study, pathway-specific PCR array assays revealed that WNT5A and matrix metalloproteinase-7 (MMP7) were upregulated by FOXC1 in TNBC cells. Interestingly, WNT5A mediates the upregulation of MMP7 by FOXC1 and the WNT5A-MMP7 axis is essential for FOXC1-induced invasiveness of TNBC cells in vitro. Xenograft models showed that the lung extravasation and metastasis of FOXC1-overexpressing TNBC cells were attenuated by knocking out WNT5A, but could be restored by MMP7 overexpression. Mechanistically, FOXC1 can bind directly to the WNT5A promoter region to activate its expression. Engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP), coupled with mass spectrometry, identified FOXC1-interacting proteins including a group of heterogeneous nuclear ribonucleoproteins involved in WNT5A transcription induction. Finally, we found that WNT5A activates NF-kappa B signaling to induce MMP7 expression. Collectively, these data demonstrate a FOXC1-elicited noncanonical WNT5A signaling mechanism comprising NF-kappa B and MMP7 that is essential for TNBC cell invasiveness, thereby providing implications toward developing an effective therapy for TNBC.	[Han, Bingchen; Zhou, Bo; Qu, Ying; Gao, Bowen; Chung, Stacey; Tanaka, Hisashi; Yang, Wei; Giuliano, Armando E.; Cui, Xiaojiang] Cedars Sinai Med Ctr, Dept Surg, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Xu, Yali] Beijing Union Med Coll Hosp, Dept Breast Surg, Beijing, Peoples R China	Cedars Sinai Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Cui, XJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org	Yang, Wei/C-3047-2008; Yang, Wei/ABA-5268-2020; Tanaka, Hisashi/ABE-7637-2020	Yang, Wei/0000-0003-2575-3570; Tanaka, Hisashi/0000-0001-9223-4186	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; Entertainment Industry Foundation; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063), and David Salomon Translational Breast Cancer Research Fund to Xiaojiang Cui, and the Fashion Footwear Charitable Foundation of New York, Inc., the Entertainment Industry Foundation, the Margie and Robert E. Petersen Foundation, and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Bunch H, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0040-x; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fujita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103084; Fujita T, 2013, BIOCHEM BIOPH RES CO, V439, P132, DOI 10.1016/j.bbrc.2013.08.013; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guan PP, 2015, ONCOTARGET, V6, P9140, DOI 10.18632/oncotarget.3274; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Han B, 2013, MOL BIOL BREAST CANC, P91; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Han SP, 2010, BIOCHEM J, V430, P379, DOI 10.1042/BJ20100396; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Honda K, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0031-0; Jang M, 2009, ONCOGENE, V28, P1529, DOI 10.1038/onc.2009.11; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim GE, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-959; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Morley S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12136; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nishita M, 2010, TRENDS CELL BIOL, V20, P346, DOI 10.1016/j.tcb.2010.03.001; Phoomak C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27853; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weng MT, 2013, PROTEIN CELL, V4, P807, DOI 10.1007/s13238-013-3056-3; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Zhao Y, 2014, J BIOL CHEM, V289, P21028, DOI 10.1074/jbc.M113.546523	39	51	56	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1399	1408		10.1038/s41388-017-0021-2	http://dx.doi.org/10.1038/s41388-017-0021-2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249801	Green Accepted			2022-12-28	WOS:000427279300010
J	Lv, SD; Ji, LY; Chen, B; Liu, SQ; Lei, CY; Liu, X; Qi, XX; Wang, Y; Leung, ELH; Wang, HY; Zhang, L; Yu, XM; Liu, ZQ; Wei, Q; Lu, LL				Lv, Shidong; Ji, Liyan; Chen, Bin; Liu, Shuqiang; Lei, Chengyong; Liu, Xi; Qi, Xiaoxiao; Wang, Ying; Leung, Elaine Lai-Han; Wang, Hongyi; Zhang, Lin; Yu, Xiaoming; Liu, Zhongqiu; Wei, Qiang; Lu, Linlin			Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; CANCER STATISTICS; GENE; EXPRESSION; MUTATIONS; IDENTIFICATION; PROLIFERATION; PROGRESSION; LEUKEMIA	Abnormalities in epigenetic modifiers are emerging as driving events in prostate cancer (PCa). The histone methyltransferase KMT2D, a frequently aberrant epigenetic modifier in various tumors, has an undefined role in PCa. Moreover, little is known regarding KMT2D's mutation in Chinese patients or its downstream signaling pathways and targets. Here, we profiled the mutational spectrum of 32 significantly PCa-associated genes by using disease-targeted sequencing, and found that KMT2D was highly mutated (63.04%, 29/46) in Chinese patients. Moreover, high KMT2D transcription was also associated with poor prognosis in an independent cohort (n = 51). In KMT2D-knockdown PC-3 and DU145 cells, cell proliferation (P < 0.01), invasion (P < 0.001), and migration (P < 0.01) were consequently suppressed. KMT2D depletion effectively suppressed tumor growth by 92.21% in vivo. Notably, integrative analyses of RNAseq and ChIPseq characterized two crucial genes downregulated by KMT2D, leukemia inhibitory factor receptor (LIFR) and Kruppel-like factor-4 (KLF4), which are regulators in PI3K/Akt and EMT, respectively. Our present study revealed that KMT2D epigenetically activates PI3K/Akt pathway and EMT by targeting LIFR and KLF4 and thus serves as a putative epigenetic-based target for treating PCa.	[Lv, Shidong; Lei, Chengyong; Wang, Hongyi; Zhang, Lin; Yu, Xiaoming; Wei, Qiang] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Lv, Shidong; Ji, Liyan; Liu, Shuqiang; Liu, Xi; Qi, Xiaoxiao; Wang, Ying; Liu, Zhongqiu; Lu, Linlin] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China; [Chen, Bin] Peoples Liberat Army, Guangzhou Mil Command, Gen Hosp, Dept Sci & Training, Guangzhou, Guangdong, Peoples R China; [Leung, Elaine Lai-Han; Liu, Zhongqiu; Lu, Linlin] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China	Southern Medical University - China; Guangzhou University of Chinese Medicine; Southern Theater Command General Hospital; Macau University of Science & Technology	Wei, Q (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Guangdong, Peoples R China.; Liu, ZQ; Lu, LL (corresponding author), Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou, Guangdong, Peoples R China.; Liu, ZQ; Lu, LL (corresponding author), Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	liuzq@gzucm.edu.cn; qwei@smu.edu.cn; lllu@gzucm.edu.cn	Liu, Zhongqiu/ABB-8204-2021; Liu, Zhongqiu/AHC-9661-2022; lu, Linlin/K-6600-2016	Liu, Zhongqiu/0000-0001-6986-9677; lu, Linlin/0000-0002-9943-2422; Lv, Shidong/0000-0002-6875-7697	National Natural Science Foundation of China [81720108033]; Natural Science Foundation of Guangdong Province [2015A030312012, 2016A050502052, 2015B020233015]; Science and Technology Planning Project of Guangdong Province [2016A020215122]; Bureau for Science and Information Technology of Guangzhou Municipality [201509010004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province; Bureau for Science and Information Technology of Guangzhou Municipality	This work was mainly supported by National Natural Science Foundation of China (81720108033), Natural Science Foundation of Guangdong Province (2015A030312012, 2016A050502052, and 2015B020233015), the Science and Technology Planning Project of Guangdong Province (2016A020215122), Bureau for Science and Information Technology of Guangzhou Municipality (201509010004).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Augert A, 2017, J THORAC ONCOL, V12, P704, DOI 10.1016/j.jtho.2016.12.011; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.3.CO;2-H; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Dawkins JBN, 2016, CANCER RES, V76, P4861, DOI 10.1158/0008-5472.CAN-16-0481; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Ford DJ, 2015, CANCER GENET-NY, V208, P178, DOI 10.1016/j.cancergen.2015.01.005; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Fukagai T, 2006, BJU INT, V97, P1190, DOI 10.1111/j.1464-410X.2006.06201.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso C, 2015, J MOL DIAGN, V17, P53, DOI 10.1016/j.jmoldx.2014.09.008; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo CC, 2013, ONCOTARGET, V4, P2144, DOI 10.18632/oncotarget.1555; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Jung SH, 2016, EUR UROL, V69, P823, DOI 10.1016/j.eururo.2015.10.031; Kantidakis T, 2016, GENE DEV, V30, P408, DOI 10.1101/gad.275453.115; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Komai Y, 2014, UROLOGY, V83, P500, DOI 10.1016/j.urology.2013.09.053; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r134; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Mathelier A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0648-7; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Roychowdhury S, 2013, J CLIN ONCOL, V31, P1866, DOI 10.1200/JCO.2012.45.3662; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shao Z, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r16; Shin SH, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.34; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2010, HUM MUTAT, V31, P99, DOI 10.1002/humu.21145; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zhang B, 2016, INSECT BIOCHEM MOLEC, V79, P108, DOI 10.1016/j.ibmb.2016.11.001; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhao MH, 2016, IN VITRO CELL DEV-AN, V52, P699, DOI 10.1007/s11626-016-0017-1	50	68	68	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1354	1368		10.1038/s41388-017-0026-x	http://dx.doi.org/10.1038/s41388-017-0026-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29269867	Green Published, hybrid			2022-12-28	WOS:000427279300007
J	Kristensen, LS; Hansen, TB; Veno, MT; Kjems, J				Kristensen, L. S.; Hansen, T. B.; Veno, M. T.; Kjems, J.			Circular RNAs in cancer: opportunities and challenges in the field	ONCOGENE			English	Review							CELL-GROWTH; NONCODING RNAS; MESSENGER-RNA; EXPRESSION; BIOMARKER; REVEALS; IDENTIFICATION; PROLIFERATION; INVASION; GENE	Circular RNA (circRNA) is a novel member of the noncoding cancer genome with distinct properties and diverse cellular functions, which is being explored at a steadily increasing pace. The list of endogenous circRNAs involved in cancer continues to grow; however, the functional relevance of the vast majority is yet to be discovered. In general, circRNAs are exceptionally stable molecules and some have been shown to function as efficient microRNA sponges with gene-regulatory potential. Many circRNAs are highly conserved and have tissue-specific expression patterns, which often do not correlate well with host gene expression. Here we review the current knowledge on circRNAs in relation to their implications in tumorigenesis as well as their potential as diagnostic and prognostic biomarkers and as possible therapeutic targets in future personalized medicine. Finally, we discuss future directions for circRNA cancer research and current caveats, which must be addressed to facilitate the translation of basic circRNA research into clinical use.	[Kristensen, L. S.; Hansen, T. B.; Veno, M. T.; Kjems, J.] Aarhus Univ, Dept Mol Biol & Genet MBG, Gustav Wieds Vej 14, DK-8000 Aarhus, Denmark; [Kristensen, L. S.; Hansen, T. B.; Veno, M. T.; Kjems, J.] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark	Aarhus University; Aarhus University	Kristensen, LS (corresponding author), Aarhus Univ, Dept Mol Biol & Genet MBG, Gustav Wieds Vej 14, DK-8000 Aarhus, Denmark.	lasse@mbg.au.dk	Kjems, Jorgen/I-3490-2016; Kristensen, Lasse Sommer/G-6042-2016	Kjems, Jorgen/0000-0003-4128-9317; Hansen, Thomas/0000-0002-7573-9657; Kristensen, Lasse Sommer/0000-0002-5980-7939	Novo Nordisk Fonden [NNF16OC0019874] Funding Source: researchfish; Villum Fonden [00013393] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); Villum Fonden(Villum Fonden)		Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Ahmed I, 2016, ONCOTARGET, V7, P36366, DOI 10.18632/oncotarget.8917; Aktas T, 2017, NATURE, V544, P115, DOI 10.1038/nature21715; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Aslan D, 2016, ONCOTARGET, V7, P9951, DOI 10.18632/oncotarget.7127; Bachmayr-Heyda A, 2016, ONCOTARGET, V7, P39640, DOI 10.18632/oncotarget.9243; Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bahn JH, 2015, CLIN CHEM, V61, P221, DOI 10.1373/clinchem.2014.230433; Barbagallo D, 2016, ONCOTARGET, V7, P4746, DOI 10.18632/oncotarget.6621; Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540; Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319; Bonizzato A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.81; Bustin SA, 2013, NAT METHODS, V10, P1063, DOI 10.1038/nmeth.2697; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89; Chen SJ, 2017, CLIN CHIM ACTA, V466, P167, DOI 10.1016/j.cca.2017.01.025; Chen YG, 2017, MOL CELL, V67, P228, DOI 10.1016/j.molcel.2017.05.022; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; de Miguel FJ, 2016, MOL ONCOL, V10, P1437, DOI 10.1016/j.molonc.2016.08.001; Denzler R, 2016, MOL CELL, V64, P565, DOI 10.1016/j.molcel.2016.09.027; Denzler R, 2014, MOL CELL, V54, P766, DOI 10.1016/j.molcel.2014.03.045; Dou YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep37982; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Dudekulay DB, 2016, RNA BIOL, V13, P34, DOI 10.1080/15476286.2015.1128065; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Esteller M, 2017, CANCER DISCOV, V7, P359, DOI 10.1158/2159-8290.CD-16-1292; Fei T, 2017, P NATL ACAD SCI USA, V114, pE5207, DOI 10.1073/pnas.1617467114; Fu LY, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22239; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Gou Q, 2017, ONCOTARGET; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Guo JN, 2016, ONCOTARGETS THER, V9, P7451, DOI 10.2147/OTT.S123220; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Guo WZ, 2017, ONCOTARGET, V8, P48169, DOI 10.18632/oncotarget.18327; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen TB, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1458; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883; HSU MT, 1979, NATURE, V280, P339, DOI 10.1038/280339a0; Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin H, 2017, ONCOTARGET, V8, P25571, DOI 10.18632/oncotarget.16104; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Kim KM, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1413; Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Lee T, 2016, ONCOTARGET, V7, P42716, DOI 10.18632/oncotarget.8446; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469; Li PF, 2017, BRIT J CANCER, V116, P626, DOI 10.1038/bjc.2016.451; Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018; Li W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030597; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114; Liang HF, 2017, AM J CANCER RES, V7, P1566; Lu WY, 2017, CELL CYCLE, V16, P589, DOI 10.1080/15384101.2017.1278935; Memczak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141214; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nair AA, 2016, ONCOTARGET, V7, P80967, DOI 10.18632/oncotarget.13134; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Panda AC, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx297; Panda AC, 2017, NUCLEIC ACIDS RES, V45, P4021, DOI 10.1093/nar/gkw1201; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552; Rigatti R, 2004, NUCLEIC ACIDS RES, V32, P441, DOI 10.1093/nar/gkh197; Rupaimoole R, 2016, CANCER DISCOV, V6, P235, DOI 10.1158/2159-8290.CD-15-0893; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sand M, 2016, TUMOR BIOL, V37, P10595, DOI 10.1007/s13277-016-4927-z; Sand M, 2016, J DERMATOL SCI, V83, P210, DOI 10.1016/j.jdermsci.2016.05.012; Sand M, 2016, EPIGENOMICS-UK, V8, P619, DOI 10.2217/epi-2015-0019; Shang XC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003811; Song XF, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw075; Starke S, 2015, CELL REP, V10, P103, DOI 10.1016/j.celrep.2014.12.002; Su HF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0977-7; Szabo L, 2016, NAT REV GENET, V17, P679, DOI 10.1038/nrg.2016.114; Thomas LF, 2014, BIOINFORMATICS, V30, P2243, DOI 10.1093/bioinformatics/btu257; Veno MT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0801-3; Wan L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1579490; Wang FL, 2016, AM J CANCER RES, V6, P1167; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541; Xia WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35576; Xu LL, 2017, J CANCER RES CLIN, V143, P17, DOI 10.1007/s00432-016-2256-7; Xuan LJ, 2016, AM J TRANSL RES, V8, P932; Yang P, 2016, ONCOTARGET, V7, P63449, DOI 10.18632/oncotarget.11523; Yang W, 2016, ONCOGENE, V35, P3919, DOI 10.1038/onc.2015.460; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yao ZC, 2017, MOL ONCOL, V11, P422, DOI 10.1002/1878-0261.12045; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zhang H, 2017, ONCOTARGET, V8, P61687, DOI 10.18632/oncotarget.18671; Zhang PL, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694546; Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001; Zhang Y, 2017, ONCOTARGET, V8, P22936, DOI 10.18632/oncotarget.15288; Zheng J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0422-2; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919; Zhu MC, 2017, BIOMED PHARMACOTHER, V88, P138, DOI 10.1016/j.biopha.2016.12.097; Zhu XL, 2017, FEBS J, V284, P2170, DOI 10.1111/febs.14132; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	114	905	928	11	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					555	565		10.1038/onc.2017.361	http://dx.doi.org/10.1038/onc.2017.361			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991235	Green Published, hybrid			2022-12-28	WOS:000423812200002
J	Tarade, D; Ohh, M				Tarade, D.; Ohh, M.			The HIF and other quandaries in VHL disease	ONCOGENE			English	Review							TUMOR-SUPPRESSOR PROTEIN; RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU GENE; BIOLOGICALLY-ACTIVE PRODUCT; ENDOTHELIAL GROWTH-FACTOR; HORMONE-RELATED PROTEIN; GERMLINE MUTATIONS; CONGENITAL POLYCYTHEMIA; PROLINE-HYDROXYLATION	Mutations in VHL underlie von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome with several subtypes depending on the risk of developing certain combination of classic features, such as clear cell renal cell carcinoma (ccRCC), hemangioblastoma and pheochromocytoma. Although numerous potential substrates and functions of pVHL have been described over the past decade, the best-defined role of pVHL has remained as the negative regulator of the heterodimeric hypoxia-inducible factor (HIF) transcription factor via the oxygen-dependent ubiquitin-mediated degradation of HIF-alpha subunit. Despite the seminal discoveries that led to the molecular elucidation of the mammalian oxygen-sensing VHL-HIF axis, which have provided several rational therapies, the mechanisms underlying the complex genotype-phenotype correlation in VHL disease are unclear. This review will discuss and highlight the studies that have provided interesting insights as well as uncertainties to the underlying mechanisms governing VHL disease.	[Tarade, D.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, MaRS Ctr West Tower,661 Univ Ave,Suite 1512, Toronto, ON M5G 1M1, Canada; [Ohh, M.] Univ Toronto, Dept Biochem, MaRS Ctr West Tower, Toronto, ON, Canada	University of Toronto; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MaRS Ctr West Tower,661 Univ Ave,Suite 1512, Toronto, ON M5G 1M1, Canada.	michael.ohh@utoronto.ca		Tarade, Daniel/0000-0001-7029-9640	Canadian Institutes of Health Research (CIHR) [MOP 77718, 136978]; CIHR Scholarship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR Scholarship(Canadian Institutes of Health Research (CIHR))	We thank Dr Claire Robinson, Shelley He and Aline Zara for helpful discussions and comments. This work was supported by funds from the Canadian Institutes of Health Research (CIHR, MOP 77718 and 136978). DT is a recipient of the CIHR Scholarship.	Albers J, 2013, EMBO MOL MED, V5, P949, DOI 10.1002/emmm.201202231; An JB, 2005, ONCOGENE, V24, P1563, DOI 10.1038/sj.onc.1208348; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Arias-Gonzalez L, 2013, NEOPLASIA, V15, P649, DOI 10.1593/neo.121896; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bisgrove BW, 2006, DEVELOPMENT, V133, P4131, DOI 10.1242/dev.02595; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Buffet A, 2014, J CLIN ENDOCR METAB, V99, pE369, DOI 10.1210/jc.2013-2600; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Comino-Mendez I, 2013, HUM MOL GENET, V22, P2169, DOI 10.1093/hmg/ddt069; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Danilin S, 2009, CARCINOGENESIS, V30, P387, DOI 10.1093/carcin/bgn275; Darr R, 2016, ENDOCR-RELAT CANCER, V23, P899, DOI 10.1530/ERC-16-0231; Dart A, 2016, NAT REV CANCER, V16, P675, DOI 10.1038/nrc.2016.107; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Favier J, 2015, NAT REV ENDOCRINOL, V11, P101, DOI 10.1038/nrendo.2014.188; Fliedner SMJ, 2016, NEOPLASIA, V18, P567, DOI 10.1016/j.neo.2016.07.008; Fu LP, 2015, MOL CANCER RES, V13, P870, DOI 10.1158/1541-7786.MCR-14-0423; Fu LP, 2013, CANCER RES, V73, P2916, DOI 10.1158/0008-5472.CAN-12-3983; Fu LP, 2011, CANCER RES, V71, P6848, DOI 10.1158/0008-5472.CAN-11-1745; Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A; Garcia-Donas J, 2013, ANN ONCOL, V24, P2409, DOI 10.1093/annonc/mdt219; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Gu YF, 2017, CANCER DISCOV, V7, P900, DOI 10.1158/2159-8290.CD-17-0292; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hildebrandt F, 2005, NAT REV GENET, V6, P928, DOI 10.1038/nrg1727; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Ladroue C, 2008, NEW ENGL J MED, V359, P2685, DOI 10.1056/NEJMoa0806277; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; LINDAU ARVID, 1927, ACTA OPHTHALMOL, V4, P193; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lolkema MP, 2007, FEBS LETT, V581, P4571, DOI 10.1016/j.febslet.2007.08.050; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lorenzo FR, 2013, J MOL MED, V91, P507, DOI 10.1007/s00109-012-0967-z; Los M, 1996, LAB INVEST, V75, P231; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Lutz MS, 2006, CANCER RES, V66, P6903, DOI 10.1158/0008-5472.CAN-06-0501; MAHER ER, 1990, J MED GENET, V27, P311, DOI 10.1136/jmg.27.5.311; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maher ER, 1996, J MED GENET, V33, P328, DOI 10.1136/jmg.33.4.328; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Massfelder T, 2004, CANCER RES, V64, P180, DOI 10.1158/0008-5472.CAN-03-1968; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107; Morris MR, 2009, ANTICANCER RES, V29, P4337; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pacak K, 2013, J CLIN ONCOL, V31, P1690, DOI 10.1200/JCO.2012.47.1912; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pastore Y, 2003, AM J HUM GENET, V73, P412, DOI 10.1086/377108; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Robinson CM, 2014, FEBS LETT, V588, P2704, DOI 10.1016/j.febslet.2014.02.026; Russell RC, 2011, NAT MED, V17, P845, DOI 10.1038/nm.2370; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Schonenberger D, 2016, CANCER RES, V76, P2025, DOI 10.1158/0008-5472.CAN-15-1859; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sergeyeva A, 1997, BLOOD, V89, P2148, DOI 10.1182/blood.V89.6.2148; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Sun XF, 2007, HISTOL HISTOPATHOL, V22, P1387, DOI 10.14670/HH-22.1387; Taieb D, 2013, J CLIN ENDOCR METAB, V98, pE908, DOI 10.1210/jc.2013-1217; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Toledo RA, 2013, ENDOCR-RELAT CANCER, V20, P349, DOI 10.1530/ERC-13-0101; Toyoda H, 2014, PEDIATRICS, V133, pE1787, DOI 10.1542/peds.2013-2419; Von-Hippel E, 1904, ARCH OPHTHALMOL-CHIC, V59, P23, DOI [10.1007/BF01994821, DOI 10.1007/BF01994821]; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Welander J, 2014, ENDOCR-RELAT CANCER, V21, P495, DOI 10.1530/ERC-13-0384; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Yang CZ, 2013, BLOOD, V121, P2563, DOI 10.1182/blood-2012-10-460972; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119; Zimmer M, 2004, MOL CANCER RES, V2, P89	125	45	46	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					139	147		10.1038/onc.2017.338	http://dx.doi.org/10.1038/onc.2017.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925400				2022-12-28	WOS:000422631700001
J	Chiang, WF; Cheng, TM; Chang, CC; Pan, SH; Changou, CA; Chang, TH; Lee, KH; Wu, SY; Chen, YF; Chuang, KH; Shieh, DB; Chen, YL; Tu, CC; Tsui, WL; Wu, MH				Chiang, W-F; Cheng, T-M; Chang, C-C; Pan, S-H; Changou, C. A.; Chang, T-H; Lee, K-H; Wu, S-Y; Chen, Y-F; Chuang, K-H; Shieh, D-B; Chen, Y-L; Tu, C-C; Tsui, W-L; Wu, M-H			Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation	ONCOGENE			English	Article							SINGLE-DOMAIN ANTIBODY; CANCER PROGRESSION; PROTEIN; ADENOCARCINOMA; INVASIVENESS; DIMERIZATION; ACTIVATION; FRAGMENTS; INVASION; THERAPY	Aberrant protein glycosylation could be a distinct surface-marker of cancer cells that influences cancer progression and metastasis because glycosylation can regulate membrane protein folding which alters receptor activation and changes epitope exposure for antibody (Ab) recognition. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a glycophosphoinositol-anchored protein, is a heavily glycosylated tumor antigen. However, the clinical significance and biological effect of CEACAM6 glycosylation has not been addressed in cancers. We recently developed an anti-CEACAM6 Ab (TMU) from an immune llama library which can be engineered to a single-domain (sd)Ab or a heavy-chain (HC)Ab. The TMU HCAb specifically recognized glycosylated CEACAM6 compared to the conventional antibodies. Using the TMU HCAb, we found that glycosylated CEACAM6 was a tumor marker associated with recurrence in early-stage OSCC (oral squamous cell carcinoma) patients. CEACAM6 promoted OSCC cell invasion, migration, cytoskeletal rearrangement, and metastasis via interaction with epidermal growth factor (EGF) receptor (EGFR) and enhancing EGFR activation, clustering and intracellular signaling cascades. These functions were modulated by N-acetylglucosaminyltransferase 5 (MGAT5) which mediated N-glycosylation at Asn(256) (N256) of CEACAM6. Finally, the TMU sdAb and HCAb treatment inhibited the migration, invasion and EGF-induced signaling in CEACAM6-overexpressing cells. In conclusion, the complex N-glycosylation of CEACAM6 is critical for EGFR signaling of OSCC invasion and metastasis. Targeting glycosylated CEACAM6 with the TMU sdAb or TMU HCAb could be a feasible therapy for OSCC.	[Chiang, W-F; Cheng, T-M; Chang, C-C; Changou, C. A.; Tsui, W-L; Wu, M-H] Taipei Med Univ, Grad Inst Translat Med, Coll Med Sci & Technol, 250 Wuxing St, Taipei 11031, Taiwan; [Chiang, W-F] Chi Mei Med Ctr, Oral & Maxillofacial Sect, Tainan, Taiwan; [Chiang, W-F] Natl Yang Ming Univ, Sch Dent, Taipei, Taiwan; [Chang, C-C] Taipei Med Univ, Coll Pharm, PhD Program Biotechnol Res & Dev, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Coll Med, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, PhD Program Translat Med, Taipei, Taiwan; [Pan, S-H] Acad Sinica, Taipei, Taiwan; [Pan, S-H] Natl Taiwan Univ, Genome & Syst Biol Degree Program, Taipei, Taiwan; [Changou, C. A.; Lee, K-H] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan; [Chang, T-H; Wu, M-H] Taipei Med Univ, Grad Inst Biomed Informat, Coll Med Sci & Technol, Taipei, Taiwan; [Wu, S-Y] Taipei Med Univ, Wan Fang Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Wu, S-Y] Taipei Med Univ, Sch Med, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, Y-F] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan; [Chuang, K-H] Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei, Taiwan; [Shieh, D-B; Chen, Y-L] Natl Cheng Kung Univ & Hosp, Inst Basic Med Sci, Inst Oral Med, Tainan, Taiwan; [Shieh, D-B; Chen, Y-L] Natl Cheng Kung Univ & Hosp, Dept Stomatol, Coll Med, Tainan, Taiwan; [Shieh, D-B] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan, Taiwan; [Shieh, D-B] Natl Cheng Kung Univ, Ctr Micro Nano Sci & Technol, Tainan, Taiwan; [Tu, C-C] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Wu, M-H] Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan	Taipei Medical University; Chi Mei Hospital; National Yang Ming Chiao Tung University; Taipei Medical University; National Taiwan University; National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Kaohsiung Medical University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Taipei Medical University	Wu, MH (corresponding author), Taipei Med Univ, Grad Inst Translat Med, Coll Med Sci & Technol, 250 Wuxing St, Taipei 11031, Taiwan.	mhwu1015@tmu.edu.tw	Chiang, Wei-Fan/L-6537-2019; CHEN, YIH-FUNG/CAH-9367-2022; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; CHEN, YIH-FUNG/0000-0002-5595-1319; Wu, Szu-Yuan/0000-0001-5637-558X; Pan, Szu-Hua/0000-0002-0138-0434	National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology [MOST 104-2319-B-001-001]; Ministry of Science and Technology, Taiwan [MOST 103-2320-B-038-013-MY3, MOST 104-2321-B-038-007]; Taipei Medical University [TMU101-AE3-Y20, 103CM-TMU-01, CLFHR10222, TMU-T104-06]; Chi-Mei Medical Center, Taiwan; National Health Research Institutes, Taiwan [NHRI-EX105-10409BC]	National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University; Chi-Mei Medical Center, Taiwan; National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	RNAi reagents were obtained from the National Core Facility for Manipulation of Gene Function by RNAi, miRNA, miRNA sponges, and the CRISPR/Genomic Research Center, Academia Sinica, supported by the National Core Facility Program for Biotechnology Grants of the Ministry of Science and Technology (MOST 104-2319-B-001-001). The human samples were from the Human Tumor Tissue Bank, Chi-Mei Medical Center (Liouying, Tainan, Taiwan). We thank the Image and Bioinformatics Core Facility of Taipei Medical University which provided assistance with deconvolution microscopy and the microarray analysis. This work was supported by grants MOST 103-2320-B-038-013-MY3 and MOST 104-2321-B-038-007 from the Ministry of Science and Technology, Taiwan; grants TMU101-AE3-Y20, 103CM-TMU-01, CLFHR10222 and TMU-T104-06 from Taipei Medical University and Chi-Mei Medical Center, Taiwan; and grant NHRI-EX105-10409BC from the National Health Research Institutes, Taiwan.	Balk-Moller E, 2014, AM J PATHOL, V184, P1198, DOI 10.1016/j.ajpath.2013.12.013; Baral TN, 2011, J IMMUNOL METHODS, V371, P70, DOI 10.1016/j.jim.2011.06.017; Beauchemin N, 2013, CANCER METAST REV, V32, P643, DOI 10.1007/s10555-013-9444-6; Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420; Bonsor DA, 2015, P NATL ACAD SCI USA, V112, P13561, DOI 10.1073/pnas.1509511112; Camacho-Leal P, 2007, J CELL PHYSIOL, V211, P791, DOI 10.1002/jcp.20989; Cameron S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-74; Chan CHF, 2004, MOL THER, V9, P775, DOI 10.1016/j.ymthe.2004.03.009; Chen YF, 2009, CANCER RES, V69, P8585, DOI 10.1158/0008-5472.CAN-09-2284; Cheng TM, 2012, EUR J CANCER, V50, P713; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Duxbury MS, 2004, BRIT J CANCER, V91, P1384, DOI 10.1038/sj.bjc.6602113; Duxbury MS, 2004, ONCOGENE, V23, P5834, DOI 10.1038/sj.onc.1207775; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Gemei M, 2013, CANCER-AM CANCER SOC, V119, P729, DOI 10.1002/cncr.27794; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Khosroshahi SA, 2016, PROTEIN EXPRES PURIF, V120, P59, DOI 10.1016/j.pep.2015.12.005; Kobayashi M, 2012, BRIT J CANCER, V107, P1745, DOI 10.1038/bjc.2012.422; Kolla V, 2009, AM J PHYSIOL-LUNG C, V296, pL1019, DOI 10.1152/ajplung.90596.2008; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Lau KS, 2008, GLYCOBIOLOGY, V18, P750, DOI 10.1093/glycob/cwn071; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Monteiro LS, 2014, ORAL DIS, V20, P178, DOI 10.1111/odi.12087; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Riley CJ, 2009, CANCER RES, V69, P1933, DOI 10.1158/0008-5472.CAN-08-2707; Sato Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24823; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; Taniguchi N, 2015, ADV CANCER RES, V126, P11, DOI 10.1016/bs.acr.2014.11.001; van Gisbergen KPJM, 2005, CANCER RES, V65, P5935, DOI 10.1158/0008-5472.CAN-04-4140; WONG DYK, 1990, J ORAL MAXIL SURG, V48, P385, DOI 10.1016/0278-2391(90)90436-6; Wu MH, 2011, CLIN CANCER RES, V17, P1306, DOI 10.1158/1078-0432.CCR-10-1824; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Xu CC, 2015, NAT REV MOL CELL BIO, V16, P742, DOI 10.1038/nrm4073; Yang SC, 2003, J ORAL PATHOL MED, V32, P600, DOI 10.1034/j.1600-0714.2003.00199.x; Zang MD, 2015, BBA-MOL BASIS DIS, V1852, P1020, DOI 10.1016/j.bbadis.2015.02.005; Zang MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112908; Zhuo Y, 2016, J BIOL CHEM, V291, P20085, DOI 10.1074/jbc.M116.740050	40	22	23	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					116	127		10.1038/onc.2017.303	http://dx.doi.org/10.1038/onc.2017.303			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892050				2022-12-28	WOS:000422625000012
J	Chen, G; Zhang, B; Xu, H; Sun, Y; Shi, Y; Luo, Y; Jia, H; Wang, F				Chen, G.; Zhang, B.; Xu, H.; Sun, Y.; Shi, Y.; Luo, Y.; Jia, H.; Wang, F.			Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis	ONCOGENE			English	Article							STRAND BREAK REPAIR; MITOTIC CATASTROPHE; LYSINE ACETYLATION; ANTITUMOR-ACTIVITY; S-PHASE; KINASE; MK-1775; AZD1775; CYCLE; CHK1	Lung cancer treatment remains a challenge for clinical practice and new therapeutic approaches are urgently needed. Loss of functional WEE1 kinase causes DNA replication stress, DNA damage and unscheduled mitotic entry due to elevated CDK activity. The selective WEE1 inhibitor MK-1775 synergize with DNA-damaging agent to inhibit cancer cell growth. Here we report that inhibition of Sirt1 deacetylase through small interfering RNA or selective inhibitor Ex527 greatly enhances MK-1775-induced growth inhibition and apoptosis in human lung cancer cells. We further demonstrate that Sirt1 interacts and deacetylates homologous recombination (HR) repair machinery proteins, including NBS1 and Rad51. Inhibition of Sirt1 impairs HR repair activity, which causes unrepairable damage when combining MK-1775 and Ex527. Meanwhile, combination of MK-1775 and Ex527 induces cooperative antitumor activity in lung cancer xenograft model in vivo. Thus, our study provides a novel therapeutic strategy to optimize MK-1775 treatment efficiency in lung cancers.	[Chen, G.; Xu, H.; Sun, Y.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Zhang, B.] Xi An Jiao Tong Univ, Dept Physiol & Pathophysiol, Sch Med, Xian, Shaanxi, Peoples R China; [Shi, Y.; Wang, F.] Xidian Univ, Sch Life Sci & Technol, Engn Res Ctr Mol & Neuro Imaging, Minist Educ, Xian, Shaanxi, Peoples R China; [Luo, Y.] Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Jia, H.] Agr Univ Hebei, Dept Bioengn, Coll Food Sci & Technol, Baoding, Peoples R China	Emory University; Xi'an Jiaotong University; Xidian University; Naval Medical University; Hebei Agricultural University	Chen, G (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.; Wang, F (corresponding author), Xidian Univ, Sch Life Sci & Technol, Engn Res Ctr Mol & Neuro Imaging, Minist Educ, Xian, Shaanxi, Peoples R China.	guo.chen84@outlook.com; fwang@xidian.edu.cn	Xu, Haidong/Q-1095-2019; Chen, Guo/HGE-9902-2022; Sun, Youwei/I-1265-2018; Wang, Fu/S-7955-2017	Chen, Guo/0000-0001-8886-1873; Wang, Fu/0000-0001-9222-0833; Zhang, Beilei/0000-0003-1384-0175	National Natural Science Foundation of China [81772010, 81571721, 81301214]; National Basic Research and Development Program of China (973 Program) [2013CB733803]; Natural Science Basis Research Plan in Shaanxi Province of China [2016JM8016, 2013JQ4040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research and Development Program of China (973 Program)(National Basic Research Program of China); Natural Science Basis Research Plan in Shaanxi Province of China	This work was supported by National Natural Science Foundation of China (No. 81772010, 81571721 and 81301214), The National Basic Research and Development Program of China (973 Program; No. 2013CB733803) and Natural Science Basis Research Plan in Shaanxi Province of China (Program No. 2016JM8016 and 2013JQ4040).	Aarts M, 2015, MOL CANCER THER, V14, P865, DOI 10.1158/1535-7163.MCT-14-0845; Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Carrassa L, 2012, CELL CYCLE, V11, P2507, DOI 10.4161/cc.20899; Chaudhuri L, 2014, HAEMATOLOGICA, V99, P688, DOI 10.3324/haematol.2013.093187; Chen G, 2013, APPL MICROBIOL BIOT, V97, P4393, DOI 10.1007/s00253-012-4321-8; Chen G, 2012, INT J ONCOL, V40, P139, DOI 10.3892/ijo.2011.1210; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chu WK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6931; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Guertin AD, 2013, MOL CANCER THER, V12, P1442, DOI 10.1158/1535-7163.MCT-13-0025; Hamer PCD, 2011, CLIN CANCER RES, V17, P4200, DOI 10.1158/1078-0432.CCR-10-2537; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Jeggo PA, 2016, NAT REV CANCER, V16, P35, DOI 10.1038/nrc.2015.4; Jhuraney A, 2016, MOL CANCER THER, V15, P1669, DOI 10.1158/1535-7163.MCT-15-0182; Kreahling JM, 2012, MOL CANCER THER, V11, P174, DOI 10.1158/1535-7163.MCT-11-0529; KREAHLING JM, 2013, PLOS ONE, V8; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leijen S, 2016, J CLIN ONCOL, V34, P4371, DOI 10.1200/JCO.2016.67.5991; Magnussen GI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038254; Mak JPY, 2014, ONCOTARGET, V5, P10546, DOI 10.18632/oncotarget.2508; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osman AA, 2015, MOL CANCER THER, V14, P608, DOI 10.1158/1535-7163.MCT-14-0735-T; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Tomimatsu N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4561; Vassilopoulos A, 2015, ONCOGENE, V34, P3023, DOI 10.1038/onc.2014.239; Wang G, 2015, CANCER LETT, V356, P656, DOI 10.1016/j.canlet.2014.10.015; Wang LK, 2012, NUCLEIC ACIDS RES, V40, pW376, DOI 10.1093/nar/gks437; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhou L, 2015, LEUKEMIA, V29, P807, DOI 10.1038/leu.2014.296	40	37	39	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6863	6872		10.1038/onc.2017.297	http://dx.doi.org/10.1038/onc.2017.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28869605				2022-12-28	WOS:000418041800003
J	Yan, F; Shen, N; Pang, J; Zhao, N; Deng, B; Li, B; Yang, Y; Yang, P; Molina, JR; Liu, S				Yan, F.; Shen, N.; Pang, J.; Zhao, N.; Deng, B.; Li, B.; Yang, Y.; Yang, P.; Molina, J. R.; Liu, S.			A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness	ONCOGENE			English	Article							DE-NOVO METHYLATION; C-KIT; PHASE-I; CISPLATIN RESISTANCE; EXPRESSION; DNMT3A; HYPOMETHYLATION; TRANSCRIPTION; CHEMOTHERAPY; DECITABINE	Overexpression of DNMT1 and KIT is prevalent in lung cancer, yet the underlying molecular mechanisms are poorly understood. While the deregulated activation of DNMT1 or KIT has been implicated in lung cancer pathogenesis, whether and how DNMT1 and KIT orchestrate lung tumorigenesis are unclear. Here, using human lung cancer tissue microarrays and fresh frozen tissues, we found that the overexpression of DNMT1 is positively correlated with the upregulation of KIT in tumor tissues. We demonstrated that DNMT1 and KIT form a positive regulatory loop, in which ectopic DNMT1 expression increases, whereas targeted DNMT1 depletion abrogates KIT signaling cascade through Sp1/miR-29b network. Conversely, an increase of KIT levels augments, but a reduction of KIT expression ablates DNMT1 transcription by STAT3 pathway leading to in-parallel modification of the DNA methylation profiles. We provided evidence that KIT inactivation induces global DNA hypomethylation, restores the expression of tumor suppressor p15(INK4B) through promoter demethylation; in turn, DNMT1 dysfunction impairs KIT kinase signaling. Functionally, KIT and DNMT1 co-expression promotes, whereas dual inactivation of them suppresses, lung cancer cell proliferation and metastatic growth in vitro and in vivo, in a synergistic manner. These findings demonstrate the regulatory and functional interplay between DNA methylation and tyrosine kinase signaling in propelling tumorigenesis, providing a widely applicable approach for targeting lung cancer.	[Yan, F.; Shen, N.; Pang, J.; Zhao, N.; Liu, S.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Deng, B.; Yang, Y.; Yang, P.] Mayo Clin, Div Epidemiol, Rochester, MN USA; [Li, B.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA; [Molina, J. R.] Mayo Clin, Dept Med Oncol, Rochester, MN USA	University of Minnesota System; Mayo Clinic; University of Louisville; Mayo Clinic	Liu, S (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	sliu@umn.edu	Yan, Fei/G-4941-2016; , Bing/A-7536-2016	Yan, Fei/0000-0003-4750-1200; , Bing/0000-0001-5363-7070	Hormel Foundation; National Cancer Institute (Bethesda, MD, USA) [R01CA149623, R21CA155915]; NATIONAL CANCER INSTITUTE [R01CA149623, R21CA155915] Funding Source: NIH RePORTER	Hormel Foundation; National Cancer Institute (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Hormel Foundation (S. Liu) and National Cancer Institute (Bethesda, MD, USA) grants R01CA149623 (S. Liu) and R21CA155915 (S. Liu).	Abidin Aidalena Z, 2010, Ther Adv Med Oncol, V2, P25, DOI 10.1177/1758834009356014; Ansari J, 2009, ANTI-CANCER AGENT ME, V9, P569, DOI 10.2174/187152009788451879; Arand J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002750; Bauer C, 2015, J BIOL CHEM, V290, P4801, DOI 10.1074/jbc.M114.605881; Boldrini L, 2004, CLIN CANCER RES, V10, P4101, DOI 10.1158/1078-0432.CCR-03-0664; Carlomagno F, 2005, CURR MED CHEM, V12, P1773, DOI 10.2174/0929867054367266; Crivellari G, 2007, ONCOLOGIST, V12, P79, DOI 10.1634/theoncologist.12-1-79; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gauler TC, 2013, EUR J CANCER, V49, P2461, DOI 10.1016/j.ejca.2013.03.029; Gowher H, 2005, BIOCHEMISTRY-US, V44, P9899, DOI 10.1021/bi047634t; Itamochi H, 2014, INT J GYNECOL CANCER, V24, P61, DOI 10.1097/IGC.0000000000000014; Jafri Nazia F., 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P147, DOI 10.1615/JEnvPathToxOncol.v22.i3.10; Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Levina V, 2010, CANCER RES, V70, P338, DOI 10.1158/0008-5472.CAN-09-1102; Li W, 2012, ONCOGENE, V31, P2412, DOI 10.1038/onc.2011.426; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Litz J, 2006, MOL CANCER THER, V5, P1415, DOI 10.1158/1535-7163.MCT-05-0503; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; Miller AA, 2010, J THORAC ONCOL, V5, P380, DOI 10.1097/JTO.0b013e3181cee36e; Monnerat C, 2004, ANN ONCOL, V15, P316, DOI 10.1093/annonc/mdh052; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Poirier JT, 2015, ONCOGENE, V34, P5869, DOI 10.1038/onc.2015.38; Rossi Antonio, 2009, Curr Drug Discov Technol, V6, P91; Schneider BJ, 2010, CLIN LUNG CANCER, V11, P223, DOI 10.3816/CLC.2010.n.028; Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669; Tamborini E, 2004, CLIN CANCER RES, V10, P8214, DOI 10.1158/1078-0432.CCR-04-1013; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yan F, 2017, LEUKEMIA, V31, P1434, DOI 10.1038/leu.2016.349; Yan F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.380; Yan F, 2015, J BIOL CHEM, V290, P18480, DOI 10.1074/jbc.M114.633693; Yu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029450; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	42	19	19	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6919	6928		10.1038/onc.2017.305	http://dx.doi.org/10.1038/onc.2017.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28869603	Green Accepted			2022-12-28	WOS:000418041800008
J	Lee, SH; Yu, J; Hwang, GH; Kim, S; Kim, HS; Ye, S; Kim, K; Park, J; Park, DY; Cho, YK; Kim, JS; Bae, S				Lee, S. H.; Yu, J.; Hwang, G-H; Kim, S.; Kim, H. S.; Ye, S.; Kim, K.; Park, J.; Park, D. Y.; Cho, Y-K; Kim, J-S; Bae, S.			CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR	ONCOGENE			English	Article							CIRCULATING TUMOR DNA; LIQUID BIOPSY; RNA; MUTATIONS; CANCER; CAS9; BREAST; CELLS; QUANTIFICATION; ENDONUCLEASES	Circulating tumor DNA (ctDNA) has emerged as a tumor-specific biomarker for the early detection of various cancers. To date, several techniques have been devised to enrich the extremely small amounts of ctDNA present in plasma, but they are still insufficient for cancer diagnosis, especially at the early stage. Here, we developed a novel method, CUT (CRISPR-mediated, Ultrasensitive detection of Target DNA)-PCR, which uses CRISPR endonucleases to enrich and detect the extremely small amounts of tumor DNA fragments among the much more abundant wild-type DNA fragments by specifically eliminating the wild-type sequences. We computed that by using various orthologonal CRISPR endonucleases such as SpCas9 and FnCpf1, the CUT-PCR method would be applicable to 80% of known cancer-linked substitution mutations registered in the COSMIC database. We further verified that CUT-PCR together with targeted deep sequencing enables detection of a broad range of oncogenes with high sensitivity (<0.01%) and accuracy, which is superior to conventional targeted deep sequencing. In the end, we successfully applied CUT-PCR to detect sequences with oncogenic mutations in the ctDNA of colorectal cancer patients' blood, suggesting that our technique could be adopted for diagnosing various types of cancer at early stages.	[Lee, S. H.; Kim, S.; Kim, H. S.; Ye, S.; Kim, K.; Kim, J-S] Inst for Basic Sci Korea, Ctr Genome Engn, Seoul, South Korea; [Yu, J.] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea; [Hwang, G-H; Bae, S.] Hanyang Univ, Dept Chem, Room 36-316,222 Wangsimni Ro, Seoul 133791, South Korea; [Kim, H. S.; Kim, J-S] Seoul Natl Univ, Dept Chem, Seoul, South Korea; [Park, J.; Cho, Y-K] Inst Basic Sci, Ctr Soft & Living Matter, Ulsan, South Korea; [Park, D. Y.] Pusan Natl Univ, Sch Med, Dept Pathol, Busan, South Korea; [Park, D. Y.] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; [Cho, Y-K] Ulsan Natl Inst Sci & Technol, Dept Biomed Engn, Ulsan, South Korea; [Bae, S.] Hanyang Univ, Res Inst Convergence Basic Sci, Seoul, South Korea	Institute for Basic Science - Korea (IBS); Seoul National University (SNU); Hanyang University; Seoul National University (SNU); Institute for Basic Science - Korea (IBS); Pusan National University; Pusan National University; Pusan National University Hospital; Ulsan National Institute of Science & Technology (UNIST); Hanyang University	Bae, S (corresponding author), Hanyang Univ, Dept Chem, Room 36-316,222 Wangsimni Ro, Seoul 133791, South Korea.	sangsubae@hanyang.ac.kr	Park, Juhee/P-5219-2017; Kim, Kyoungmi/AAR-3964-2020; Yu, Jihyeon/U-4150-2019; KIM, Jin-Soo/M-6918-2013; Cho, Yoon-Kyoung/E-9082-2010; Cho, Yoon-Kyoung/ABF-9355-2021; Bae, Sangsu/E-5324-2017; Kim, Sang-Tae/U-9457-2018	Park, Juhee/0000-0002-8109-6387; Kim, Kyoungmi/0000-0003-0941-806X; Yu, Jihyeon/0000-0003-0247-7753; KIM, Jin-Soo/0000-0003-4847-1306; Cho, Yoon-Kyoung/0000-0001-6423-1834; Cho, Yoon-Kyoung/0000-0001-6423-1834; Bae, Sangsu/0000-0003-3615-8566; Kim, Sang-Tae/0000-0003-1645-6021	Ministry of Health and Welfare; Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs [HI16C1012, HI12C1845]; Institute for Basic Science [IBS-R021-D1]	Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs; Institute for Basic Science	We express our gratitude to all of the patients and healthy volunteers who contributed blood samples for this study. The biological specimens for this study were provided by the Pusan National University hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health and Welfare. All samples were obtained with informed consent according to the institutional review board-approved protocols. The deep-sequencing data are available at the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) under accession number SRX1970116. This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs (HI16C1012) to SB, (HI12C1845) to JP, DP and YC and Institute for Basic Science (IBS-R021-D1) to J-SK.	Alix-Panabieres C, 2012, ANNU REV MED, V63, P199, DOI 10.1146/annurev-med-062310-094219; Anders C, 2014, NATURE, V513, P569, DOI 10.1038/nature13579; Baek K, 2016, SCI REP-UK, V6, DOI 10.1038/srep30620; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014; Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45; Cheng FF, 2016, ONCOTARGET, V7, P48832, DOI 10.18632/oncotarget.9453; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2016, MOL ONCOL, V10, P464, DOI 10.1016/j.molonc.2015.12.001; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Freidin MB, 2015, CLIN CHEM, V61, P1299, DOI 10.1373/clinchem.2015.242453; Friedland AE, 2013, NAT METHODS, V10, P741, DOI 10.1038/nmeth.2532; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kim D, 2016, NAT BIOTECHNOL, V34, P863, DOI 10.1038/nbt.3609; Kim H, 2014, NAT REV GENET, V15, P321, DOI 10.1038/nrg3686; Kim JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4157; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Kleinstiver BP, 2015, NATURE, V523, P481, DOI 10.1038/nature14592; Kruglyak KM, 2014, EXPERT REV MOL DIAGN, V14, P635, DOI 10.1586/14737159.2014.916213; Lee SH, 2016, BMB REP, V49, P201, DOI 10.5483/BMBRep.2016.49.4.042; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; Narayan A, 2012, CANCER RES, V72, P3492, DOI 10.1158/0008-5472.CAN-11-4037; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Nishimasu H, 2014, CELL, V156, P935, DOI 10.1016/j.cell.2014.02.001; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Park JY, 2013, NAT BIOTECHNOL, V31, P990, DOI 10.1038/nbt.2743; Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Song C, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw650; Sorber L, 2017, LUNG CANCER, V107, P100, DOI 10.1016/j.lungcan.2016.04.026; Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu YX, 2013, CELL STEM CELL, V13, P659, DOI 10.1016/j.stem.2013.10.016; Xu XR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/623509; Yamano T, 2016, CELL, V165, P949, DOI 10.1016/j.cell.2016.04.003; Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038; Zhang YL, 2014, SCI REP-UK, V4, DOI 10.1038/srep05405	43	56	57	7	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6823	6829		10.1038/onc.2017.281	http://dx.doi.org/10.1038/onc.2017.281			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846115	hybrid, Green Published			2022-12-28	WOS:000417282500008
J	Chiodelli, P; Rezzola, S; Urbinati, C; Signori, FF; Monti, E; Ronca, R; Presta, M; Rusnati, M				Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Monti, E.; Ronca, R.; Presta, M.; Rusnati, M.			Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis	ONCOGENE			English	Article							CHORIOALLANTOIC MEMBRANE; ALPHA(V)BETA(3) INTEGRIN; LECTIN HISTOCHEMISTRY; CELL ADHESION; SIALIC ACIDS; EXPRESSION; SURFACE; GLYCOSYLATION; ACTIVATION; PROTEOGLYCAN	Vascular endothelial growth factor receptor-2 (VEGFR2) is the main pro-angiogenic receptor expressed by endothelial cells (ECs). Using surface plasmon resonance, immunoprecipitation, enzymatic digestion, immunofluorescence and cross-linking experiments with specific sugar-binding lectins, we demonstrated that VEGFR2 bears both alpha,1-fucose and alpha(2,6)-linked sialic acid (NeuAc). However, only the latter is required for VEGF binding to VEGFR2 and consequent VEGF-dependent VEGFR2 activation and motogenic response in ECs. Notably, downregulation of beta-galactoside alpha(2,6)-sialyltransferase expression by short hairpin RNA transduction inhibits VEGFR2 alpha(2,6) sialylation that is paralleled by an increase of beta-galactoside alpha(2,3)-sialyltransferase expression. This results in an ex-novo alpha(2,3)-NeuAc sialylation of the receptor that functionally replaces the lacking alpha(2,6)-NeuAc, thus allowing VEGF/VEGFR2 interaction. In keeping with the role of VEGFR2 sialylation in angiogenesis, the alpha(2,6)-NeuAc-binding lectin Sambucus nigra (SNA) prevents VEGF-dependent VEGFR2 autophosphorylation and EC motility, proliferation and motogenesis. In addition, SNA exerts a VEGF-antagonist activity in tridimensional angiogenesis models in vitro and in the chick-embryo chorioallantoic membrane neovascularization assay and mouse matrigel plug assay in vivo. In conclusion, VEGFR2-associated NeuAc plays an important role in modulating VEGF/VEGFR2 interaction, EC pro-angiogenic activation and neovessel formation. VEGFR2 sialylation may represent a target for the treatment of angiogenesis-dependent diseases.	[Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Ronca, R.; Presta, M.; Rusnati, M.] Univ Brescia, Unit Expt Oncol, Brescia, Italy; [Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Ronca, R.; Presta, M.; Rusnati, M.] Univ Brescia, Unit Immunol, Brescia, Italy; [Monti, E.] Univ Brescia, Unit Biotechnol, Dept Mol & Translat Med, Brescia, Italy	University of Brescia; University of Brescia; University of Brescia	Chiodelli, P; Rusnati, M (corresponding author), Dept Mol & Translat Med, Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	paola.chiodelli@unibs.it; marco.rusnati@unibs.it	Rezzola, Sara/AAE-8980-2020; Rezzola, Sara/AAA-2745-2019; Ronca, Roberto/AAC-6470-2022; Rusnati, Marco/F-1168-2010	Rezzola, Sara/0000-0003-1193-8929; Ronca, Roberto/0000-0001-8979-7068; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871	Ministero dell'Istruzione, Universita e Ricerca (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 18943, MFAG 18459]; AIRC	Ministero dell'Istruzione, Universita e Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grant from Ministero dell'Istruzione, Universita e Ricerca (MIUR) (ex 60%) to MR and by IG 18943 and MFAG 18459 grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to MP and RR, respectively. PC and SR were supported by AIRC Fellowships.	Abe Y, 1999, J IMMUNOL, V163, P2867; Antony P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-901; BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543; Brambilla A, 2015, INT J BIOCHEM CELL B, V69, P95, DOI 10.1016/j.biocel.2015.10.005; Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922; Bugatti A, 2013, J BIOL CHEM, V288, P1150, DOI 10.1074/jbc.M112.400077; Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084; Chandler KB, 2017, J PROTEOME RES, V16, P677, DOI 10.1021/acs.jproteome.6b00738; Chen JY, 2011, CANCER RES, V71, P473, DOI 10.1158/0008-5472.CAN-10-1303; Chiodelli P, 2012, J BIOL CHEM, V287, P20456, DOI 10.1074/jbc.M111.337139; Chiodelli P, 2011, ARTERIOSCL THROM VAS, V31, pE116, DOI 10.1161/ATVBAHA.111.235184; Chuang IC, 2015, LIFE SCI, V139, P52, DOI 10.1016/j.lfs.2015.08.002; Cioffi DL, 2012, AM J PHYSIOL-LUNG C, V302, pL1067, DOI 10.1152/ajplung.00190.2011; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Coltrini D, 2013, ANGIOGENESIS, V16, P469, DOI 10.1007/s10456-012-9324-7; Croci DO, 2014, GLYCOBIOLOGY, V24, P1283, DOI 10.1093/glycob/cwu083; Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043; DENG X, 2017, SCI REP UK, V7; Doiron AL, 2004, TECH PAPERS ISA, V449, P331; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Franklin MC, 2011, STRUCTURE, V19, P1097, DOI 10.1016/j.str.2011.01.019; Fuh G, 2000, J BIOL CHEM, V275, P26690; Garcia-Vallejo JJ, 2006, J CELL PHYSIOL, V206, P203, DOI 10.1002/jcp.20458; Cabral MG, 2010, IMMUNOL LETT, V131, P89, DOI 10.1016/j.imlet.2010.02.009; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Henry CBS, 1996, TISSUE CELL, V28, P449, DOI 10.1016/S0040-8166(96)80030-9; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Kitazume S, 2014, J BIOL CHEM, V289, P27604, DOI 10.1074/jbc.M114.563585; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lee C, 2014, J BIOL CHEM, V289, P9121, DOI 10.1074/jbc.M114.555888; Lee JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056211; Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Manning JC, 2004, HISTOL HISTOPATHOL, V19, P1043, DOI 10.14670/HH-19.1043; Marino K, 2010, NAT CHEM BIOL, V6, P713, DOI [10.1038/nchembio.437, 10.1038/NCHEMBIO.437]; Markowska AI, 2011, J BIOL CHEM, V286, P29913, DOI 10.1074/jbc.M111.226423; Mitola S, 2008, BLOOD, V112, P1154, DOI 10.1182/blood-2007-09-111450; Miyagawa S, 2010, XENOTRANSPLANTATION, V17, P61, DOI 10.1111/j.1399-3089.2009.00565.x; Monaco L, 1996, CYTOTECHNOLOGY, V22, P197, DOI 10.1007/BF00353939; Nacev BA, 2011, J BIOL CHEM, V286, P44045, DOI 10.1074/jbc.M111.278754; PEVERALI FA, 1994, J CELL PHYSIOL, V161, P1, DOI 10.1002/jcp.1041610102; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Rahimi N, 2015, PROTEOMICS, V15, P300, DOI 10.1002/pmic.201400183; Ravelli C, 2013, ANGIOGENESIS, V16, P235, DOI 10.1007/s10456-012-9309-6; Rezzola S, 2013, EXP EYE RES, V112, P51, DOI 10.1016/j.exer.2013.04.014; Ribatti D, 2012, METHODS MOL BIOL, V843, P47, DOI 10.1007/978-1-61779-523-7_5; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Safina G, 2012, ANAL CHIM ACTA, V712, P9, DOI 10.1016/j.aca.2011.11.016; Schauer R, 2009, CURR OPIN STRUC BIOL, V19, P507, DOI 10.1016/j.sbi.2009.06.003; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Stabile H, 2007, BLOOD, V109, P1834, DOI 10.1182/blood-2006-06-032276; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; Tatsuzuki A, 2009, ARCH HISTOL CYTOL, V72, P35, DOI 10.1679/aohc.72.35; Urbinati C, 2004, FEBS LETT, V568, P171, DOI 10.1016/j.febslet.2004.05.033; WANG WC, 1988, J BIOL CHEM, V263, P4576; Windwarder M, 2016, GLYCOCONJUGATE J, V33, P387, DOI 10.1007/s10719-015-9602-x	61	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6531	6541		10.1038/onc.2017.243	http://dx.doi.org/10.1038/onc.2017.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783175				2022-12-28	WOS:000416049200003
J	Zhou, Y; Huang, T; Zhang, J; Wong, CC; Zhang, B; Dong, Y; Wu, F; Tong, JHM; Wu, WKK; Cheng, ASL; Yu, J; Kang, W; To, KF				Zhou, Y.; Huang, T.; Zhang, J.; Wong, C. C.; Zhang, B.; Dong, Y.; Wu, F.; Tong, J. H. M.; Wu, W. K. K.; Cheng, A. S. L.; Yu, J.; Kang, W.; To, K. F.			TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis	ONCOGENE			English	Article							INHIBITS CELL-PROLIFERATION; GROWTH-FACTOR CTGF; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET; TUMOR-SUPPRESSOR; CANCER GENOMICS; BREAST-CANCER; EXPRESSION; CLASSIFICATION; YAP1	TEA domain (TEAD) transcription factors are key components of the Hippo-YAP1 signaling pathway, but their functional role and regulatory mechanisms remain unclear. This study aims to comprehensively explore the expression pattern and functional role of TEAD family in gastric carcinogenesis and investigate its regulation by microRNAs (miRNAs). The mRNA and protein expression of TEAD family were examined by quantitative reverse transcription-PCR (qRT-PCR) and western blot. Their functional roles were determined by in vitro and in vivo studies. The clinicopathological association of TEAD4 in gastric cancer (GC) was studied using immunohistochemistry on tissue microarray. The prediction of miRNAs, which potentially target TEAD1/4, was performed by TargetScan and miRDB. The regulation of TEAD1/4 by miRNAs was confirmed by qRT-PCR, western blot and luciferase assays. TEAD1/4 were overexpressed in GC cell lines and primary GC tissues. Knockdown of TEAD1/4 induced a significant anticancer effect in vitro and in vivo. TEAD1 was confirmed to be a direct target of miR-377-3p and miR-4269, while TEAD4 was negatively regulated by miR-1343-3p and miR-4269. Among them, miR-4269 was the most effective inhibitor of TEAD1/4. Ectopic expression of these miRNAs substantiated their tumor-suppressive effects. In primary GC tumors, downregulation of miR-4269 was associated with poor disease-specific survival and showed a negative correlation with TEAD4. TEAD1 and TEAD4 are oncogenic factors, whose aberrant activation are, in part, mediated by the silence of miR-377-3p, miR-1343-3p and miR-4269. For the first time, the nuclear accumulated TEAD4 and downregulated miR-4269 are proposed to serve as novel prognostic biomarkers in GC.	[Zhou, Y.; Huang, T.; Zhang, J.; Wu, F.; Tong, J. H. M.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Shatin, Hong Kong, Peoples R China; [Zhou, Y.; Huang, T.; Zhang, J.; Wong, C. C.; Dong, Y.; Wu, W. K. K.; Yu, J.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Inst Digest Dis, Partner State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Zhou, Y.; Huang, T.; Zhang, J.; Tong, J. H. M.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Huang, T.; Cheng, A. S. L.; Yu, J.; Kang, W.; To, K. F.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Zhang, B.] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Gastroenterol, Med Sch, Nanjing, Jiangsu, Peoples R China; [Wu, W. K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Cheng, A. S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen; Nanjing University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol South China, Shatin, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Cheng, Alfred SL/C-3327-2014; KANG, Wei/C-5451-2016; wu, william/HII-5817-2022; Wong, Chi Chun/C-4636-2016; Wu, William K.K./A-3277-2009; Jun, Yu/D-8569-2015	Cheng, Alfred SL/0000-0003-2345-6951; KANG, Wei/0000-0002-4651-677X; Wu, William K.K./0000-0002-5662-5240; Jun, Yu/0000-0001-5008-2153	General Research Fund (RGC) from Research Grants Council of Hong Kong [CUHK14114414, CUHK14110016]	General Research Fund (RGC) from Research Grants Council of Hong Kong	We acknowledge the TCGA research Network (http://cancergenome.nih.gov/), The UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu/) and NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/) for providing the gastric cancer data set and analysis. This study is supported by General Research Fund (RGC Reference No. CUHK14114414 and CUHK14110016) from The Research Grants Council of Hong Kong.	Bai N, 2013, CANCER BIOL THER, V14, P511, DOI 10.4161/cbt.24345; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117714; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; de la Cova C, 2006, SEMIN CANCER BIOL, V16, P303, DOI 10.1016/j.semcancer.2006.07.010; Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo C, 2015, INT J CLIN EXP PATHO, V8, P1690; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0281-3; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Li N, 2015, AM J CANCER RES, V5, P1158; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Mao B, 2014, ONCOGENE, V33, P1468, DOI 10.1038/onc.2013.88; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nowee ME, 2007, J PATHOL, V213, P46, DOI 10.1002/path.2217; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; Schutte U, 2014, TRANSL ONCOL, V7, P309, DOI 10.1016/j.tranon.2014.02.005; Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226; Skotheim RI, 2006, CELL ONCOL, V28, P315; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang CY, 2015, ONCOTARGET, V6, P17685, DOI 10.18632/oncotarget.3779; Wang RY, 2015, BIOMED PHARMACOTHER, V70, P64, DOI 10.1016/j.biopha.2015.01.012; Wanjin H, 2014, PLOS ONE, V9; Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030; Zehentmayr F, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0198-1; Zhang XT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116979; ZHOU YH, 2016, INT J MOL SCI, V17	48	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6518	6530		10.1038/onc.2017.257	http://dx.doi.org/10.1038/onc.2017.257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759040	Green Published, hybrid			2022-12-28	WOS:000416049200002
J	Velmurugan, KR; Varghese, RT; Fonville, NC; Garner, HR				Velmurugan, K. R.; Varghese, R. T.; Fonville, N. C.; Garner, H. R.			High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification	ONCOGENE			English	Article							BREAST-CANCER; INSTABILITY; VARIANTS; REVEALS; ACTIVATION; SIGNATURE; LYMPHOMA; PATTERNS; GAINS; GENES	There remains a large discrepancy between the known genetic contributions to cancer and that which can be explained by genomic variants, both inherited and somatic. Recently, understudied repetitive DNA regions called microsatellites have been identified as genetic risk markers for a number of diseases including various cancers (breast, ovarian and brain). In this study, we demonstrate an integrated process for identifying and further evaluating microsatellite-based risk markers for lung cancer using data from the cancer genome atlas and the 1000 genomes project. Comparing whole-exome germline sequencing data from 488 TCGA lung cancer samples to germline exome data from 390 control samples from the 1000 genomes project, we identified 119 potentially informative microsatellite loci. These loci were found to be able to distinguish between cancer and control samples with sensitivity and specificity ratios over 0.8. Then these loci, supplemented with additional loci from other cancers and controls, were evaluated using a target enrichment kit and sample-multiplexed nextgen sequencing. Thirteen of the 119 risk markers were found to be informative in a well powered study (40.99 for a 0.95 confidence interval) using high-depth (579x +/- 315) nextgen sequencing of 30 lung cancer and 89 control samples, resulting in sensitivity and specificity ratios of 0.90 and 0.94, respectively. When 8 loci harvested from the bioinformatic analysis of other cancers are added to the classifier, then the sensitivity and specificity rise to 0.93 and 0.97, respectively. Analysis of the genes harboring these loci revealed two genes (ARID1B and REL) and two significantly enriched pathways (chromatin organization and cellular stress response) suggesting that the process of lung carcinogenesis is linked to chromatin remodeling, inflammation, and tumor microenvironment restructuring. We illustrate that high-depth sequencing enables a high-precision microsatellite-based risk classifier analysis approach. This microsatellite-based platform confirms the potential to create clinically actionable diagnostics for lung cancer.	[Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Edward Via Coll Osteopath Med, Dept Biol Sci, Ctr Bioinformat & Genet, Blacksburg, VA 24060 USA; [Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Edward Via Coll Osteopath Med, Primary Care Res Network, 2265 Kraft Dr, Blacksburg, VA 24060 USA; [Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Gibbs Canc Ctr & Res Inst, Dept Biol Sci, Spartanburg, SC USA; [Fonville, N. C.] Riverside Law LLP, Glenhardie Corp Ctr, Dept Biol Sci, Wayne, PA USA		Garner, HR (corresponding author), Edward Via Coll Osteopath Med, Primary Care Res Network, 2265 Kraft Dr, Blacksburg, VA 24060 USA.; Garner, HR (corresponding author), Edward Via Coll Osteopath Med, Ctr Bioinformat & Genet, 2265 Kraft Dr, Blacksburg, VA 24060 USA.	skipgarner@gmail.com			Bradley Engineering Foundation; National Science Foundation [OCI-1124123]	Bradley Engineering Foundation; National Science Foundation(National Science Foundation (NSF))	This work was funded by a grant from the Bradley Engineering Foundation to the Edward Via College of Osteopathic Medicine, and computing was supported by a grant from the National Science Foundation (OCI-1124123). We wish to thank Zalman Vaksman and Lauren J. McIver for programming assistance. We also wish to thank Nicholas Kinney for assistance with statistical computations and manuscript preparation, and Ramu Anandakrishnan for manuscript review.	[Anonymous], 2016, CANC FACTS FIG 2016; Bavarva JH, 2014, ONCOTARGET, V5, P4788, DOI 10.18632/oncotarget.2033; Bavarva JH, 2014, AGING-US, V6, P511, DOI 10.18632/aging.100674; Biegel JA, 2014, AM J MED GENET C, V166, P350, DOI 10.1002/ajmg.c.31410; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Budworth Helen, 2013, Methods Mol Biol, V1010, P3, DOI 10.1007/978-1-62703-411-1_1; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fonville NC, 2015, ONCOTARGET, V6, P11407, DOI 10.18632/oncotarget.2933; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freimer NB, 1996, CIBA F SYMP, V197, P51; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geismann C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.417; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Guilmatre A, 2013, HUM MUTAT, V34, P1304, DOI 10.1002/humu.22359; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Hasnis E, 2007, J PHYSIOL PHARMACOL, V58, P275; Huang HT, 2015, ONCOL REP, V33, P283, DOI 10.3892/or.2014.3584; Hunter JE, 2016, BRIT J CANCER, V114, P1, DOI 10.1038/bjc.2015.410; Institute NC, 2016, SEER STAT FACT SHEET; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Karunasena E, 2015, ONCOTARGET, V6, P22038, DOI 10.18632/oncotarget.4194; Karunasena E, 2014, ONCOTARGET, V5, P6003, DOI 10.18632/oncotarget.2076; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Lian Y, 2005, BIOINFORMATICS, V21, P1358, DOI 10.1093/bioinformatics/bti180; Lu H, 2011, CANCER RES, V71, P6867, DOI 10.1158/0008-5472.CAN-11-2460; McIver LJ, 2014, BREAST CANCER RES TR, V145, P791, DOI 10.1007/s10549-014-2908-8; McIver LJ, 2013, GENE, V516, P328, DOI 10.1016/j.gene.2012.12.068; McIver LJ, 2011, GENOMICS, V97, P193, DOI 10.1016/j.ygeno.2011.01.001; Rivera GA, 2016, ADV EXP MED BIOL, V893, P43, DOI 10.1007/978-3-319-24223-1_3; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Society AC, 2016, NONSM CELL LUNG CANC; Society AC, 2016, WHAT IS NONSM CELL L; Team RDC, 2010, R LANG ENV STAT COMP; Vaksman Z, 2015, ONCOTARGET, V6, P5760, DOI 10.18632/oncotarget.3306; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56; Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Weniger MA, 2007, GENE CHROMOSOME CANC, V46, P406, DOI 10.1002/gcc.20420; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	49	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6383	6390		10.1038/onc.2017.256	http://dx.doi.org/10.1038/onc.2017.256			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759038	hybrid, Green Published			2022-12-28	WOS:000415622900003
J	Do, MT; Chai, TF; Casey, PJ; Wang, M				Do, M. T.; Chai, T. F.; Casey, P. J.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin beta 3 recycling, cell migration and cancer metastasis	ONCOGENE			English	Article							GDP DISSOCIATION INHIBITOR; PROSTATE-CANCER; TUMOR-GROWTH; RAB GTPASES; ALPHA-V-BETA-3 INTEGRIN; EPITHELIAL-CELLS; EARLY ENDOSOMES; BREAST-CANCER; PHASE-II; K-RAS	Isoprenylcysteine carboxylmethyltransferase (ICMT) catalyzes the post-translational modification of RAB GTPases that contain C-terminal CXC motifs. However, the functional impact of this modification on RAB proteins has not been actively explored. We found that inhibition of ICMT significantly reduced cell migration in vitro and cancer invasion and metastasis in vivo. This role of ICMT was found to be mediated by RAB4A, an essential regulator of the fast recycling of integrin beta 3. Integrin beta 3 regulates cell polarity and migration when localized appropriately to the plasma membrane, thereby having an essential role in cancer metastasis. ICMT catalyzed carboxylmethylation is critical for RAB4A activation and interaction with effectors, its localization to endosomes and recycling vesicles, and hence important for RAB4A-dependent integrin beta 3 recycling to plasma membrane. These findings bring attention to the effects of C-terminal carboxylmethylation on RAB GTPases and provide a rationale for targeting ICMT in the treatment of metastatic cancer.	[Do, M. T.; Chai, T. F.; Casey, P. J.; Wang, M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Casey, P. J.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore	National University of Singapore; Duke University; National University of Singapore	Wang, M (corresponding author), Duke NUS Med Sch, Program Canc Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg		Casey, Patrick/0000-0002-7366-9309; Do, Minh Truong/0000-0002-2319-0287	Ministry of Health through CSA scheme; Ministry of Health through Tier II scheme	Ministry of Health through CSA scheme; Ministry of Health through Tier II scheme	This work is supported by Singapore Ministries of Education and Ministry of Health for funding of this project through their Tier II and CSA schemes, respectively. We are grateful for the help on CAM assays by Dr Suhail Ahmed Kabeer Rasheed of Duke-NUS. The authors confirm that neither the submitted manuscript nor any similar manuscript, in whole or in part, is under consideration, in press, or reported elsewhere.	ARAKI S, 1990, J BIOL CHEM, V265, P13007; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Beekman KW, 2006, CLIN GENITOURIN CANC, V4, P299, DOI 10.3816/CGC.2006.n.012; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cushman I, 2011, CELL ADHES MIGR, V5, P11, DOI 10.4161/cam.5.1.13196; Cushman I, 2009, J BIOL CHEM, V284, P27964, DOI 10.1074/jbc.M109.025296; D'Souza RS, 2014, CURR BIOL, V24, P1187, DOI 10.1016/j.cub.2014.04.003; Deneka M, 2003, EMBO J, V22, P2645, DOI 10.1093/emboj/cdg257; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996; Frittoli E, 2014, J CELL BIOL, V206, P307, DOI 10.1083/jcb.201403127; Gruber G, 2005, BRIT J CANCER, V92, P41, DOI 10.1038/sj.bjc.6602278; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanker AB, 2010, ONCOGENE, V29, P380, DOI 10.1038/onc.2009.336; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Ignatev A, 2008, J BIOL CHEM, V283, P18377, DOI 10.1074/jbc.M709718200; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Legler DF, 2001, J CELL SCI, V114, P1545; Leung KF, 2007, J BIOL CHEM, V282, P1487, DOI 10.1074/jbc.M605557200; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; Manu KA, 2017, MOL CANCER THER, V16, P914, DOI 10.1158/1535-7163.MCT-16-0703; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; Ratajczak MZ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-95; Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510; Reynolds AR, 2009, NAT MED, V15, P392, DOI 10.1038/nm.1941; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990; Zijlstra A, 2002, CANCER RES, V62, P7083	52	18	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5757	5767		10.1038/onc.2017.183	http://dx.doi.org/10.1038/onc.2017.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604748	Green Published, hybrid			2022-12-28	WOS:000412843900009
J	Muppala, S; Xiao, R; Krukovets, I; Verbovetsky, D; Yendamuri, R; Habib, N; Raman, P; Plow, E; Stenina-Adognravi, O				Muppala, S.; Xiao, R.; Krukovets, I.; Verbovetsky, D.; Yendamuri, R.; Habib, N.; Raman, P.; Plow, E.; Stenina-Adognravi, O.			Thrombospondin-4 mediates TGF-beta-induced angiogenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; BREAST-CANCER; FIBROSIS; PATHWAY; TARGET; PROTEINS; CELLS	TGF-beta is a multifunctional cytokine affecting many cell types and implicated in tissue remodeling processes. Due to its many functions and cell-specific effects, the consequences of TGF-beta signaling are process-and stage-dependent, and it is not uncommon that TGF-beta exerts distinct and sometimes opposing effects on a disease progression depending on the stage and on the pathological changes associated with the stage. The mechanisms underlying cell-and process-specific effects of TGF-beta are poorly understood. We are describing a novel pathway that mediates induction of angiogenesis in response to TGF-beta 1. We found that in endothelial cells (EC) thrombospondin-4 (TSP-4), a secreted extracellular matrix (ECM) protein, is upregulated in response to TGF-beta 1 and mediates the effects of TGF-beta 1 on angiogenesis. Upregulation of TSP-4 does not require the synthesis of new protein, is not caused by decreased secretion of TSP-4, and is mediated by activation of SMAD3. Using Thbs4(-/-) mice and TSP-4 shRNA, we found that TSP-4 mediated pro-angiogenic functions in cultured EC and angiogenesis in vivo in response to TGF-beta 1. We observed similar to 3-fold increases in tumor mass and levels of angiogenesis markers in animals injected with TGF-beta 1, and these effects did not occur in Thbs4(-/-) animals. Injections of an inhibitor of TGF-beta 1 signaling SB-431542 also decreased the weights of tumors and cancer angiogenesis. Our results from in vivo angiogenesis models and cultured EC document that TSP-4 mediates upregulation of angiogenesis by TGF-beta 1. Upregulation of pro-angiogenic TSP-4 and selective effects of TSP-4 on EC may contribute to stimulation of tumor growth by TGF-beta despite the inhibition of cancer cell proliferation.	[Muppala, S.; Xiao, R.; Krukovets, I.; Verbovetsky, D.; Yendamuri, R.; Habib, N.; Plow, E.; Stenina-Adognravi, O.] Cleveland Clin, Dept Mol Cardiol, 9500 Euclid Ave NB50-66, Cleveland, OH 44195 USA; [Raman, P.] North Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH USA	Cleveland Clinic Foundation; Northeast Ohio Medical University (NEOMED)	Stenina-Adognravi, O (corresponding author), Cleveland Clin, Dept Mol Cardiol, 9500 Euclid Ave NB50-66, Cleveland, OH 44195 USA.	stenino@ccf.org	Xiao, Roy/AAZ-1915-2020; muppala, santoshi/AAK-2385-2020; Santoo/B-2423-2018; Muppala, Santoshi/K-6910-2019	Santoo/0000-0001-7830-9591; Muppala, Santoshi/0000-0001-7830-9591; Xiao, Roy/0000-0003-4459-0746	NIH [R01HL117216, CA177771]; National Center for Advancing Translational Sciences component of the National Institutes of Health [UL1TR000439]; National Institutes of Health Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA177771] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117216] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences component of the National Institutes of Health; National Institutes of Health Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by NIH R01HL117216 (OS-A and EP) and NIH CA177771 (OS-A). Isolation of HUVECs was supported by UL1TR000439. HUVECs were provided by a grant awarded to Clinical and Translational Science Collaborative of Cleveland, a grant from the National Center for Advancing Translational Sciences (UL1TR000439) component of the National Institutes of Health, and National Institutes of Health Roadmap for Medical Research.	Araujo-Jorge TC, 2012, CLIN PHARMACOL THER, V92, P613, DOI 10.1038/clpt.2012.102; Bhattacharyya S, 2008, J BIOL CHEM, V283, P5699, DOI 10.1074/jbc.M706435200; Bhattacharyya S, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.005967; Blahna MT, 2012, FEBS LETT, V586, P1906, DOI 10.1016/j.febslet.2012.01.041; Blanco FF, 2014, MOL CELL BIOL, V34, P180, DOI 10.1128/MCB.01020-13; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Cingolani OH, 2011, CIRC RES, V109, P1410, DOI 10.1161/CIRCRESAHA.111.256743; Congote LF, 2004, BIOCHEM BIOPH RES CO, V324, P673, DOI 10.1016/j.bbrc.2004.09.107; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dietz HC, 2010, J CLIN INVEST, V120, P403, DOI 10.1172/JCI42014; Eming SA, 2011, EXP DERMATOL, V20, P605, DOI 10.1111/j.1600-0625.2011.01309.x; Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW; Frolova EG, 2012, FASEB J, V26, P2363, DOI 10.1096/fj.11-190728; Frolova EG, 2010, CIRC RES, V107, P1313, DOI 10.1161/CIRCRESAHA.110.232371; Garcia R, 2015, BBA-MOL BASIS DIS, V1852, P1520, DOI 10.1016/j.bbadis.2015.04.006; Hoover LL, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.146pe48; Hubmacher D, 2013, CURR OPIN RHEUMATOL, V25, P65, DOI 10.1097/BOR.0b013e32835b137b; James D, 2010, NAT BIOTECHNOL, V28, P161, DOI 10.1038/nbt.1605; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Joseph JV, 2013, BIOCHEM PHARMACOL, V85, P478, DOI 10.1016/j.bcp.2012.11.005; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Kostourou V, 2014, BBA-GEN SUBJECTS, V1840, P2403, DOI 10.1016/j.bbagen.2014.02.018; Krishnan S, 2015, ONCOTARGET, V6, P22480, DOI 10.18632/oncotarget.4310; Lan HY, 2012, SEMIN NEPHROL, V32, P236, DOI 10.1016/j.semnephrol.2012.04.002; Loeys BL, 2013, PEDIATR ENDOCR REV P, V10, P417; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Lynch JM, 2012, CELL, V149, P1257, DOI 10.1016/j.cell.2012.03.050; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mahabeleshwar Ganapati H., 2006, V129, P197; Muppala S, 2015, ARTERIOSCL THROM VAS, V35, P1975, DOI 10.1161/ATVBAHA.115.305912; Mustonen E, 2012, ANN MED, V44, P793, DOI 10.3109/07853890.2011.614635; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Petroll WM, 1998, INVEST OPHTH VIS SCI, V39, P2018; Prendes MA, 2013, BRIT J OPHTHALMOL, V97, P680, DOI 10.1136/bjophthalmol-2011-301132; Samarakoon R, 2013, CELL SIGNAL, V25, P264, DOI 10.1016/j.cellsig.2012.10.003; Senger DR, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005090; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Soloviev Dmitry A., 2006, V129, P267; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Toma I, 2012, CELL TISSUE RES, V347, P155, DOI 10.1007/s00441-011-1189-3; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Weiss A, 2013, WIRES DEV BIOL, V2, P47, DOI 10.1002/wdev.86; Yanagita M, 2012, NEPHROL DIAL TRANSPL, V27, P3686, DOI 10.1093/ndt/gfs381; Yang SNY, 2010, J DIABETES, V2, P233, DOI 10.1111/j.1753-0407.2010.00089.x; Yang Y, 2009, J CELL BIOCHEM, V106, P1102, DOI 10.1002/jcb.22100; Yokoyama H, 1996, DIABETIC MED, V13, P313, DOI 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.3.CO;2-Z	49	72	77	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5189	5198		10.1038/onc.2017.140	http://dx.doi.org/10.1038/onc.2017.140			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481870	Green Accepted			2022-12-28	WOS:000409371100010
J	Wang, X; Haring, MF; Rathjen, T; Lockhart, SM; Sorensen, D; Ussar, S; Rasmussen, LM; Bertagnolli, MM; Kahn, CR; Rask-Madsen, C				Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Rasmussen, L. M.; Bertagnolli, M. M.; Kahn, C. R.; Rask-Madsen, C.			Insulin resistance in vascular endothelial cells promotes intestinal tumour formation	ONCOGENE			English	Article							BODY-MASS INDEX; GROWTH-FACTOR; BREAST-CANCER; COLORECTAL ADENOMAS; COLON-CANCER; RISK-FACTOR; OBESITY; INFLAMMATION; MECHANISMS; NEOPLASIA	The risk of several cancers, including colorectal cancer, is increased in patients with obesity and type 2 diabetes, conditions characterised by hyperinsulinaemia and insulin resistance. Because hyperinsulinaemia itself is an independent risk factor for cancer development, we examined tissue-specific insulin action in intestinal tumour formation. In vitro, insulin increased proliferation of intestinal tumour epithelial cells by almost two-fold in primary culture of tumour cells from Apc(Min/+) mice. Surprisingly, targeted deletion of insulin receptors in intestinal epithelial cells in Apc(Min/+) mice did not change intestinal tumour number or size distribution on either a low or high-fat diet. We therefore asked whether cells in the tumour stroma might explain the association between tumour formation and insulin resistance. To this end, we generated Apc(Min/+) mice with loss of insulin receptors in vascular endothelial cells. Strikingly, these mice had 42% more intestinal tumours than controls, no change in tumour angiogenesis, but increased expression of vascular cell adhesion molecule-1 (VCAM-1) in primary culture of tumour endothelial cells. Insulin decreased VCAM-1 expression and leukocyte adhesion in quiescent tumour endothelial cells with intact insulin receptors and partly prevented increases in VCAM-1 and leukocyte adhesion after treatment with tumour necrosis factor-a. Knockout of insulin receptors in endothelial cells also increased leukocyte adhesion in mesenteric venules and increased the frequency of neutrophils in tumours. We conclude that although insulin is mitogenic for intestinal tumour cells in vitro, impaired insulin action in the tumour microenvironment may be more important in conditions where hyperinsulinaemia is secondary to insulin resistance. Insulin resistance in tumour endothelial cells produces an activated, proinflammatory state that promotes tumorigenesis. Improvement of endothelial dysfunction may reduce colorectal cancer risk in patients with obesity and type 2 diabetes.	[Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Kahn, C. R.; Rask-Madsen, C.] Joslin Diabet Ctr, Boston, MA 02215 USA; [Wang, X.; Haering, M-F; Rathjen, T.; Lockhart, S. M.; Sorensen, D.; Ussar, S.; Bertagnolli, M. M.; Kahn, C. R.; Rask-Madsen, C.] Harvard Med Sch, One Joslin Pl, Boston, MA 02215 USA; [Wang, X.] Fudan Univ, Huashan Hosp, Shanghai, Peoples R China; [Haering, M-F] Univ Hosp Tuebingen, Dept Internal Med 4, Div Clin Chem & Pathobiochem, Tubingen, Germany; [Rathjen, T.] Novo Nordisk AS, Malov, Denmark; [Lockhart, S. M.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Sorensen, D.; Rasmussen, L. M.] Univ Southern Denmark, Odense Univ Hosp, Odense, Denmark; [Sorensen, D.] Danish Diabet Acad, Odense, Denmark; [Ussar, S.] Helmholtz Ctr Munich Neuherberg, Inst Diabet & Obes, JRG Adipocytes & Metab, Munich, Germany; [Ussar, S.] German Ctr Diabet Res DZD, Neuherberg, Germany; [Bertagnolli, M. M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Fudan University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Novo Nordisk; Queens University Belfast; University of Southern Denmark; Odense University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Brigham & Women's Hospital	Rask-Madsen, C (corresponding author), Harvard Med Sch, Joslin Diabet Ctr, Vasc Biol & Complicat, One Joslin Pl, Boston, MA 02215 USA.	christian.rask-madsen@joslin.harvard.edu	Lockhart, Sam/Q-2604-2015; Kahn, Ronald/AAY-2435-2021; Ussar, Siegfried/AAL-4331-2021	Lockhart, Sam/0000-0003-2092-4350; Kahn, Ronald/0000-0002-7583-9228; Ussar, Siegfried/0000-0001-7575-0920; Rasmussen, Lars Melholt/0000-0001-5795-4794; Rask-Madsen, Christian/0000-0002-8548-466X	NIH [R21 CA185196, DK031036, DK033201, 5P30DK036836]; National Natural Science Foundation of China [81370936]; Diabetes Research and Wellness Foundation; Danish Diabetes Academy - Novo Nordisk Foundation; Mary K. Iacocca Professorship; STAR Programme; NATIONAL CANCER INSTITUTE [R21CA185196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R37DK031036, R01DK033201, R01DK031036] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021740] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Diabetes Research and Wellness Foundation; Danish Diabetes Academy - Novo Nordisk Foundation; Mary K. Iacocca Professorship; STAR Programme; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant R21 CA185196 (to CRM), the National Natural Science Foundation of China grant 81370936 (XW), the Diabetes Research and Wellness Foundation (SML), the Danish Diabetes Academy which receives funding from the Novo Nordisk Foundation (DS), as well as NIH grants DK031036, DK033201 and the Mary K. Iacocca Professorship (CRK). TR was an employee of Novo Nordisk and was supported by the STAR Programme. Measurement of plasma insulin and flow cytometry was done using cores in the Diabetes Research Center, supported by NIH grant 5P30DK036836, at Joslin Diabetes Center. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Anderson JC, J CLIN GASTROENTEROL, DOI [10.1136/gutjnl-2016-312893, DOI 10.1136/GUTJNL-2016-312893]; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; Bickston SJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007571.pub2; Bruce WR, 2000, NUTR CANCER, V37, P19, DOI 10.1207/S15327914NC3701_2; Carothers AM, 2006, CANCER RES, V66, P6432, DOI 10.1158/0008-5472.CAN-06-0992; Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Davenport JR, 2018, GUT, V67, P456, DOI 10.1136/gutjnl-2016-312893; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Elmunzer BJ, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001352; Fischer A, 2016, GUT, V65, P1642, DOI 10.1136/gutjnl-2015-310022; Flores MBS, 2012, GASTROENTEROLOGY, V143, P741, DOI 10.1053/j.gastro.2012.05.045; FUKUMURA D, 1995, CANCER RES, V55, P4824; Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014; Gey GO, 1924, JAMA-J AM MED ASSOC, V82, P1609, DOI [DOI 10.1001/JAMA.1924.26520460003014D, 10.1001/jama.1924.26520460003014d]; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; IshShalom D, 1997, DIABETOLOGIA, V40, pS25, DOI 10.1007/s001250051393; Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Kim F, 2008, ARTERIOSCL THROM VAS, V28, P1982, DOI 10.1161/ATVBAHA.108.169722; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; LAAKSO M, 1992, DIABETES, V41, P1076, DOI 10.2337/diabetes.41.9.1076; Luck H, 2015, CELL METAB, V21, P527, DOI 10.1016/j.cmet.2015.03.001; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Makinen J, 2015, DIABETOLOGIA, V58, P1055, DOI 10.1007/s00125-015-3501-3; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Monteiro-Sepulveda M, 2015, CELL METAB, V22, P113, DOI 10.1016/j.cmet.2015.05.020; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Naruse K, 2006, DIABETES, V55, P691, DOI 10.2337/diabetes.55.03.06.db05-0771; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Okabayashi K, 2012, AM J GASTROENTEROL, V107, P1175, DOI 10.1038/ajg.2012.180; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; RAIZADA MK, 1976, J BIOL CHEM, V251, P6445; Rask-Madsen C, 2001, DIABETES, V50, P2611, DOI 10.2337/diabetes.50.11.2611; Rask-Madsen C, 2012, ARTERIOSCL THROM VAS, V32, P2052, DOI 10.1161/ATVBAHA.111.241919; Rask-Madsen C, 2010, CELL METAB, V11, P379, DOI 10.1016/j.cmet.2010.03.013; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Steyers CM, 2014, INT J MOL SCI, V15, P11324, DOI 10.3390/ijms150711324; Tabit CE, 2013, CIRCULATION, V127, P86, DOI 10.1161/CIRCULATIONAHA.112.127514; Targan SR, 2007, GASTROENTEROLOGY, V132, P1672, DOI 10.1053/j.gastro.2007.03.024; TEMIN HM, 1968, INT J CANCER, V3, P771, DOI 10.1002/ijc.2910030611; Treffers LW, 2016, IMMUNOL REV, V273, P312, DOI 10.1111/imr.12444; Vicent D, 2003, J CLIN INVEST, V111, P1373, DOI 10.1172/JCI200315211; Yoon YS, 2015, METABOLISM, V64, P1324, DOI 10.1016/j.metabol.2015.06.013; Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301; Zhao LN, 2015, CLIN SCI, V129, P1025, DOI 10.1042/CS20150143	58	19	22	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4987	4996		10.1038/onc.2017.107	http://dx.doi.org/10.1038/onc.2017.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459466	Green Submitted, Green Accepted			2022-12-28	WOS:000408768800004
J	Lau, HY; Tang, J; Casey, PJ; Wang, M				Lau, H. Y.; Tang, J.; Casey, P. J.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; CARBOXYL METHYLTRANSFERASE; CANCER-CELLS; PROTEIN PRENYLATION; EPITHELIAL-CELLS; K-RAS; DISEASE; ONCOGENESIS; APOPTOSIS; GROWTH	Despite extensive effort, there has been limited progress in the development of direct RAS inhibitors. Targeting isoprenylcysteine carboxylmethyltransferase (ICMT), a unique enzyme of RAS post-translational modification, represents a promising strategy to inhibit RAS function. However, there lacks direct genetic evidence on the role of ICMT in RAS-driven human cancer initiation and maintenance. Using CRISPR/Cas9 genome editing, we have created Icmt loss-of-function isogenic cell lines for both RAS-transformed human mammary epithelial cells (HME1) and human cancer cell lines MiaPaca-2 and MDA-MB-231 containing naturally occurring mutant KRAS. In both in vitro and in vivo tumorigenesis studies, Icmt loss-of-function abolishes the tumor initiation ability of all major isoforms of mutant RAS in HME1 cells, and the tumor maintenance capacity of MiaPaca-2 and MDA-MB-231 cells, establishing the critical role of ICMT in RAS-driven cancers.	[Lau, H. Y.; Tang, J.; Casey, P. J.; Wang, M.] Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore; [Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore	National University of Singapore; National University of Singapore	Wang, M (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg		Wang, Mei/0000-0001-6887-6840; Casey, Patrick/0000-0002-7366-9309	National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We would like to thank Dr Shang Li and Muhammad Khairul Ramlee for their invaluable technical assistance and advice, as well as Dr Mathijs Voorhoeve and Dr Shi Yun Yeo for the gift of retroviral expression vectors. This work was supported by the National Medical Research Council of Singapore.	Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Court H, 2013, J CLIN INVEST, V123, P4681, DOI 10.1172/JCI65764; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Davies BSJ, 2009, ANNU REV GENOM HUM G, V10, P153, DOI 10.1146/annurev-genom-082908-150150; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ibrahim MX, 2013, SCIENCE, V340, P1330, DOI 10.1126/science.1238880; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Ramlee MK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15587; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun WT, 2016, EXP HEMATOL, V44, P189, DOI 10.1016/j.exphem.2015.12.002; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wright LP, 2009, MOL CELL BIOL, V29, P1826, DOI 10.1128/MCB.01719-08	32	29	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3934	3942		10.1038/onc.2016.508	http://dx.doi.org/10.1038/onc.2016.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28192404	hybrid, Green Published			2022-12-28	WOS:000404848200013
J	Wu, MJ; Kim, MR; Chen, YS; Yang, JY; Chang, CJ				Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J			Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKC zeta pathway	ONCOGENE			English	Article							PROTEIN-KINASE-C; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL; PKC-ZETA; PROGRESSION; METASTASIS; TRIAL; FATE	The key molecular mechanism governing the cancer cell state (stem cell-like state vs differentiation state) to control the cancer stem cell (CSC) pool remains elusive. This study provides the first evidence showing that all-trans retinoic acid (ATRA) induces the interaction and chromatin recruitment of a novel RAR beta-TET2 complex to epigenetically activate a specific cohort of gene targets, including MiR-200c. TET2-activated miR-200c further targets and suppresses PKC zeta, a cell polarity protein that has a pivotal role in directing asymmetric division of mammalian stem cells to sustain the stem cell pool. Our data reveal that pharmacological concentration of ATRA effectively downregulates PKC zeta through activation of miR-200c, leading to a decrease of the stem cell-like populations from non-tumorigenic mammary epithelial cells and non-aggressive breast cancer cells. However, aggressive breast cancer cells that manifest TET2-miR-200c dysregulation sustain a CSC pool highly resistant to ATRA, where inhibition of PKC zeta directs the resistant CSCs to the luminal cell-like state and sensitization to tamoxifen, resulting in abrogation of mammary tumor growth and progression. Together, these findings elucidate a novel RAR beta-TET2-miR-200c-PKC zeta signaling pathway that directs cancer cell state changes and also provide previously unidentified therapeutic implications for PKC zeta inhibitors in diminishment of breast CSCs to eradicate breast cancer.	[Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA; [Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chang, CJ (corresponding author), Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	chunjuchang@purdue.edu	Wu, Meng-Ju/AAY-9406-2021; Wu, Meng-Ju/AAY-9410-2021	Wu, Meng-Ju/0000-0001-6847-7065; Chang, Chunju/0000-0003-2887-9603	Department of Defense Breast Cancer Breakthrough Award [W81XWH-15-1-0644]; V foundation for Cancer Research Grant [V2015-019];  [P30 CA023168]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER	Department of Defense Breast Cancer Breakthrough Award; V foundation for Cancer Research Grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the assistance of Dr Chao-Ching Chang as well as Dr Chi-Hong Chao with advice on animal and biochemical experiments, and Mr Chun-Chih Hsu with LC-MS/MS analysis. This study was supported by Department of Defense Breast Cancer Breakthrough Award (W81XWH-15-1-0644 to C-J Chang), V foundation for Cancer Research Grant (V2015-019 to C-J Chang), and P30 CA023168 to the Purdue University Center for Cancer Research in support of the use of facilities.	Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bryan M, 2011, INVEST NEW DRUG, V29, P1482, DOI 10.1007/s10637-010-9478-3; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Chang CC, 2015, CANCER RES, V75, P2375, DOI 10.1158/0008-5472.CAN-14-3076; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; Cuzick J, 2011, LANCET ONCOL, V12, P496, DOI 10.1016/S1470-2045(11)70030-4; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kumar BNP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-273; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Paul A, 2015, SCI REP-UK, V5, DOI 10.1038/srep12520; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Urtreger AJ, 2005, MOL CARCINOGEN, V42, P29, DOI 10.1002/mc.20066; Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Zhang F, 2010, CANCER RES, V70, P9360, DOI 10.1158/0008-5472.CAN-10-0207	32	26	27	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3193	3206		10.1038/onc.2016.467	http://dx.doi.org/10.1038/onc.2016.467			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28218902	Green Published, hybrid			2022-12-28	WOS:000402617900011
J	Sun, H; Peng, Z; Tang, H; Xie, D; Jia, Z; Zhong, L; Zhao, S; Ma, Z; Gao, Y; Zeng, L; Luo, R; Xie, K				Sun, H.; Peng, Z.; Tang, H.; Xie, D.; Jia, Z.; Zhong, L.; Zhao, S.; Ma, Z.; Gao, Y.; Zeng, L.; Luo, R.; Xie, K.			Loss of KLF4 and consequential downregulation of Smad7 exacerbate oncogenic TGF-beta signaling in and promote progression of hepatocellular carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; MESENCHYMAL TRANSITION; POOR-PROGNOSIS; CROSS-TALK; EXPRESSION; BLOCKS; TARGET; KRUPPEL-LIKE-FACTOR-4; HEPATOCARCINOGENESIS; METASTASIS	Hyperactivation of transforming growth factor-beta ( TGF-alpha) signaling pathway is a common feature of hepatocellular carcinoma (HCC) progression. However, the driver factors leading to enhanced TGF-beta activity are not well characterized. Here, we explore the mechanisms that loss of Kruppel-like factor 4 (KLF4) exacerbates oncogenic TGF-beta signaling in human HCC. The expression of KLF4 and TGF-beta signaling components in primary HCC and their clinicopathologic relevance and significance was evaluated by using tissue microarray and immunohistochemistry. Cellular and molecular impacts of altered KLF4 expression and TGF-beta signaling were determined using immunofluorescence, western blot, reverse-transcriptase PCR, chromatin immunoprecipitation and promoter reporter assays. Loss of KLF4 expression in primary HCC closely correlated with decreased Smad7 expression, increased p-Smad2/3 expression and independently predicts reduced overall and relapse-free survival after surgery. TGF-beta signaling components were expressed in most HCC cells, and activation of TGF-beta signaling promoted cell migration and invasion. Enforced KLF4 expression blocked TGF-beta signal transduction and inhibited cell migration and invasion via activation of Smad7 transcription, whereas deletion of its C-terminal zinc-finger domain diminished this effect. KLF4 protein physically interacts with the Smad7 promoter. Promoter deletion and point mutation analyses revealed that a region between nucleotides -15bp and -9bp of the Smad7 promoter was required for the induction of Smad7 promoter activity by KLF4. Our data indicate that KLF4 suppresses oncogenic TGF-beta signaling by activation of Smad7 transcription, and that loss of KLF4 expression in primary HCC may contribute to activation of oncogenic TGF-beta signaling and subsequent tumor progression.	[Sun, H.; Jia, Z.; Xie, K.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Sun, H.; Peng, Z.; Zhong, L.; Zhao, S.] Shanghai Gen Hosp, Dept Gen Surg, 85 Wujin Rd, Shanghai 200080, Peoples R China; [Tang, H.] Shanghai Jiao Tong Univ, Dept Pathol, Affiliated Shanghai Gen Hosp, Shanghai, Peoples R China; [Xie, D.; Gao, Y.] Tongji Univ, Sch Med, Dept Oncol, Shanghai East Hosp, Shanghai, Peoples R China; [Xie, D.; Gao, Y.] Tongji Univ, Sch Med, Tumor Inst, Shanghai East Hosp, Shanghai, Peoples R China; [Ma, Z.] Fudan Univ, Liver Transplantat Sect, Ctr Organ Transplantat, Shanghai, Peoples R China; [Zeng, L.; Luo, R.] Southern Med Univ, Tumor Hosp, Guangzhou, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Tongji University; Tongji University; Fudan University; Southern Medical University - China	Peng, Z (corresponding author), Shanghai Gen Hosp, Dept Gen Surg, 85 Wujin Rd, Shanghai 200080, Peoples R China.; Luo, R (corresponding author), Southern Med Univ, Tumor Hosp, Guangzhou, Guangdong, Peoples R China.; Xie, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Unit 1644, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xczmd@sjtu.edu.cn; luorc02@vip.163.com; kepxie@mdanderson.org			National Institutes of Health [R01-CA129956, R01-CA148954]; National Natural Science Foundation of China [81101623]; Science and Technology Commission of Shanghai Municipality [81101623, 81672846]; NATIONAL CANCER INSTITUTE [R01CA129956, R01CA148954, R01CA195651] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Don Norwood for editorial comments. The work is supported in part by grants R01-CA129956 and R01-CA148954 from the National Institutes of Health (K Xie), grant # 81101623 from the National Natural Science Foundation of China and grant # 81101623 and # 81672846 from Science and Technology Commission of Shanghai Municipality (H Sun).	Baek HJ, 2011, HEPATOLOGY, V53, P1676, DOI 10.1002/hep.24128; Chen YW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-181; Ding Bo, 2015, Asian Pac J Cancer Prev, V16, P3629; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Fransvea E, 2009, HEPATOLOGY, V49, P839, DOI 10.1002/hep.22731; Giannelli G, 2014, CANCER RES, V74, P1890, DOI 10.1158/0008-5472.CAN-14-0243; Hu B, 2007, AM J RESP CELL MOL, V36, P78, DOI 10.1165/rcmb.2006-0043OC; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Li Q, 2012, GASTROENTEROLOGY, V143, P799, DOI 10.1053/j.gastro.2012.05.043; Lin TH, 2015, CLIN CANCER RES, V21, P3678, DOI 10.1158/1078-0432.CCR-14-1954; Lin ZS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043593; Matsuzaki K, 2000, CANCER RES, V60, P1394; Mazzocca A, 2012, CURR PHARM DESIGN, V18, P4148, DOI 10.2174/138161212802430431; Mazzocca A, 2010, HEPATOLOGY, V51, P523, DOI 10.1002/hep.23285; Mazzocca A, 2009, HEPATOLOGY, V50, P1140, DOI 10.1002/hep.23118; Meindl-Beinker NM, 2012, DIGEST DIS, V30, P514, DOI 10.1159/000341704; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Reichl P, 2012, CURR PHARM DESIGN, V18, P4135, DOI 10.2174/138161212802430477; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Stolfi C, 2013, INT J MOL SCI, V14, P23774, DOI 10.3390/ijms141223774; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang J, 2013, J PATHOL, V230, P441, DOI 10.1002/path.4206; Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YD, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/705238; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396; Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587	36	48	49	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2957	2968		10.1038/onc.2016.447	http://dx.doi.org/10.1038/onc.2016.447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28192402	Green Accepted			2022-12-28	WOS:000402000400004
J	Li, Y; Zhao, M; Guo, C; Chu, H; Li, W; Chen, X; Wang, X; Li, Y; Jia, Y; Koussatidjoa, S; Zhu, F; Wang, J; Wang, X; Wang, Q; Zhao, W; Shi, Y; Chen, W; Zhang, L				Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Chen, W.; Zhang, L.			Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RHO GTPASES; HEPATOCELLULAR-CARCINOMA; INNATE INFLAMMATION; CYTOKINE PRODUCTION; POLYBASIC REGION; CANCER CELLS; LUNG-CANCER; IN-VIVO; INTERLEUKIN-37	IL-37, a newly found anti-inflammatory cytokine of the IL-1 family, has both extracellular and intracellular functions. Accumulating evidences indicate that it is also involved in tumor progression. However, the mechanism and its intracellular target are unclear. In this study, clinical data from 84 patients showed that loss or reduced expression of IL-37 in lung adenocarcinoma tissues was significantly associated with tumor metastasis. We further provided evidence that IL-37 inhibited effectively tumor metastasis in vitro and in vivo. Moreover, we uncovered a novel mechanism by which IL-37 suppressed tumor cell migration via its intracellular mature form (amino acids 46-218). Intracellular mature form of IL-37, but not its extracellular form, markedly inhibited migration of multiple kinds of tumor cells through inhibiting Rac1 activation. Mechanistically, intracellular mature IL-37 directly bound to the CAAX motif in the C-terminal hypervariable region of Rac1, and then inhibited Rac1 membrane translocation and subsequent downstream signaling. Our research identifies intracellular mature IL-37 as a novel endogenous inhibitor of Rac1. Given the crucial roles of Rac1 in tumor angiogenesis and metastasis, intracellular mature IL-37 might serve as a potential strategy for the control of Rac1 activity and tumor progression.	[Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Zhang, L.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, Y.; Zhao, M.; Guo, C.; Chu, H.; Li, W.; Chen, X.; Wang, X.; Li, Y.; Jia, Y.; Koussatidjoa, S.; Zhu, F.; Wang, J.; Wang, X.; Wang, Q.; Zhao, W.; Shi, Y.; Zhang, L.] Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Chen, W.] NIDCR, Mucosal Immunol Sect, NIH, Bethesda, MD USA	Shandong University; Shandong University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zhang, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhang, L (corresponding author), Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	zhanglining@sdu.edu.cn		Zhao, Wei/0000-0001-8440-2274	national key research and development plan of China [2016YFC1303405]; National Natural Science Foundation of China [31470856, 91439124]; Shandong Provincial Natural Science Foundation, China [2014GSF118076, ZR2011HZ003]; Fundamental Research Funds of Shandong University [2014QY004]; Major Project of Science and Technology of Shandong Province [2015ZDJS04001]; NIH, NIDCR, USA	national key research and development plan of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province); Fundamental Research Funds of Shandong University; Major Project of Science and Technology of Shandong Province; NIH, NIDCR, USA	This research is supported by the national key research and development plan of China (No. 2016YFC1303405), the National Natural Science Foundation of China (31470856 and 91439124), Shandong Provincial Natural Science Foundation, China (2014GSF118076, ZR2011HZ003), the Fundamental Research Funds of Shandong University (2014QY004) and Major Project of Science and Technology of Shandong Province (2015ZDJS04001). WC is supported by the Intramural Research Program of NIH, NIDCR, USA.	Abulkhir A, 2017, J LEUKOCYTE BIOL, V101, P395, DOI 10.1189/jlb.5RU0816-341R; Ballak DB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5711; Boraschi D, 2011, EUR CYTOKINE NETW, V22, P127, DOI 10.1684/ecn.2011.0288; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Bulau AM, 2011, THESCIENTIFICWORLDJO, V11, P2480, DOI 10.1100/2011/968479; Busfield SJ, 2000, GENOMICS, V66, P213, DOI 10.1006/geno.2000.6184; Cao XL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-149; Chai M, 2015, J INTERF CYTOK RES, V35, P530, DOI 10.1089/jir.2014.0212; Chen QY, 2011, INT J MOL MED, V28, P769, DOI 10.3892/ijmm.2011.775; Chen YH, 2016, ONCOL REP, V36, P2017, DOI 10.3892/or.2016.4995; Cherfils J, 2013, PHYSIOL REV, V93, P269, DOI 10.1152/physrev.00003.2012; Cherfils J, 2011, NAT CHEM BIOL, V7, P493, DOI 10.1038/nchembio.608; Coll-Miro M, 2016, P NATL ACAD SCI USA, V113, P1411, DOI 10.1073/pnas.1523212113; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Fang D, 2017, ONCOGENE, V36, P1546, DOI 10.1038/onc.2016.323; Gao JH, 2009, AM J TRANSL RES, V1, P312; Gao WT, 2003, J IMMUNOL, V170, P107, DOI 10.4049/jimmunol.170.1.107; Ge GQ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0293-3; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Kreis P, 2009, CELL SIGNAL, V21, P384, DOI 10.1016/j.cellsig.2008.11.001; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Kumar S, 2002, CYTOKINE, V18, P61, DOI 10.1006/cyto.2002.0873; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Li ZQ, 2016, ONCOTARGET, V7, P62224, DOI 10.18632/oncotarget.11406; Lin Y, 2015, EXPERT OPIN DRUG DIS, V10, P991, DOI 10.1517/17460441.2015.1058775; Liu R, 2016, ONCOTARGET, V7, P85079, DOI 10.18632/oncotarget.13196; Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240; Lunding L, 2015, ALLERGY, V70, P366, DOI 10.1111/all.12566; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; McNamee EN, 2011, P NATL ACAD SCI USA, V108, P16711, DOI 10.1073/pnas.1111982108; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Modha R, 2008, J BIOL CHEM, V283, P1492, DOI 10.1074/jbc.M706760200; Moretti S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004462; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; Quirk S, 2014, EXPERT REV CLIN IMMU, V10, P1703, DOI 10.1586/1744666X.2014.971014; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Schaefer Antje, 2014, Small GTPases, V5, P6, DOI 10.4161/21541248.2014.968004; Smithers CC, 2016, CELLS, V5, P2; Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047; Wang CQ, 2016, AM J CANCER RES, V6, P1873; Wang S, 2015, J CANCER, V6, P962, DOI 10.7150/jca.12266; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Wittinghofer A, 2011, ANNU REV BIOCHEM, V80, P943, DOI 10.1146/annurev-biochem-062708-134043; Wu B, 2014, CLIN EXP IMMUNOL, V176, P438, DOI 10.1111/cei.12284; Yan XF, 2017, ONCOTARGET, V8, P49064, DOI 10.18632/oncotarget.17093; Ye L, 2015, J IMMUNOL, V194, P5110, DOI 10.4049/jimmunol.1401810; Ye L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-69; Zhao JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05177; Zou T, 2017, CLIN GENET, V91, P520, DOI 10.1111/cge.12908	52	19	19	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1095	1106		10.1038/onc.2017.405	http://dx.doi.org/10.1038/onc.2017.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106392				2022-12-28	WOS:000425905700012
J	Gan, L; Meng, J; Xu, M; Liu, M; Qi, Y; Tan, C; Wang, Y; Zhang, P; Weng, W; Sheng, W; Huang, M; Wang, Z				Gan, L.; Meng, J.; Xu, M.; Liu, M.; Qi, Y.; Tan, C.; Wang, Y.; Zhang, P.; Weng, W.; Sheng, W.; Huang, M.; Wang, Z.			Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin beta 4/FAK/SOX2/HIF-1 alpha signaling pathway in gastric cancer	ONCOGENE			English	Article							STEM-CELLS; ECM1; OVEREXPRESSION; ACTIVATION; PHENOTYPE; MECHANISM; MIGRATION	Extracellular matrix protein 1 (ECM1) is related to strong invasiveness and poor prognosis in major malignancies, but the underlying mechanism remains unknown. Here we aimed to elucidate the function of ECM1 on cell metastasis and glucose metabolism in gastric cancer (GC). The level of ECM1 in sera and tissues of patient with GC were positively correlated with tumor invasion and recurrence. Genetic manipulation of ECM1 expression affected cell metastasis and glucose metabolism in GC cell lines. Enhanced ECM1 expression facilitated gene expression levels associated with epithelial-mesenchymal transition (EMT) and glucose metabolism. Interestingly, our results indicated that ECM1 directly interacted with integrin beta 4 (ITGB4) and activated ITGB4/focal adhesion kinase (FAK)/glycogen synthase kinase 3 beta signaling pathway, which further induced the expression of transcription factor SOX2. Aberrant expression of SOX2 altered gene expression of EMT factors and glucose metabolism enzymes. Furthermore, SOX2 enhanced hypoxia-inducible factor alpha (HIF-1 alpha) promoter activity to regulate glucose metabolism. The micro-positron emission tomography/computed tomography imaging of xenograft model showed that ECM1 substantially increased F-18-fluorodeoxyglucose uptake in xenograft tumors. Using in vivo mouse tail vein injection experiments, ECM1 was also found to increase in lung surface metastasis. These findings provide evidence that ECM1 regulates GC cell metastasis and glucose metabolism by inducing ITGB4/FAK/SOX2/HIF-1 alpha signal pathway and have important implications for the development of therapeutic target to prevent tumor metastasis and recurrence.	[Gan, L.; Meng, J.; Liu, M.; Zhang, P.; Wang, Z.] Fudan Univ, Canc Inst, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Gan, L.; Meng, J.; Qi, Y.; Huang, M.] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Gan, L.; Xu, M.; Qi, Y.; Tan, C.; Weng, W.; Sheng, W.; Huang, M.; Wang, Z.] Fudan Univ, Dept Oncol, Shanghai Med Coll, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Gan, L.] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China; [Xu, M.; Tan, C.; Weng, W.; Sheng, W.] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wang, Y.] Nanchang Univ, Nanchang Med Coll, Nanchang, Jiangxi, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Nanchang University	Wang, Z (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Huang, M; Wang, Z (corresponding author), Fudan Univ, Dept Oncol, Shanghai Med Coll, 270 Dongan Rd, Shanghai 200032, Peoples R China.	mingzhuhuang0718@163.com; huf_zlwang@126.com	xu, midie/AFS-3427-2022; Sheng, Weiqi/GXF-1216-2022	xu, midie/0000-0003-1775-6608; Sheng, Weiqi/0000-0002-8726-277X	National Nature Science Young Foundation of China [81502235, 81302096, 81602078]; Shanghai Natural Science Foundation [17ZR1406500]; Hospital Foundation of Fudan University Shanghai Cancer Center [YJ201504]; project of Shanghai Municipal Health Bureau [20114009]	National Nature Science Young Foundation of China; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Hospital Foundation of Fudan University Shanghai Cancer Center; project of Shanghai Municipal Health Bureau	This work was supported by the National Nature Science Young Foundation of China (81502235, 81302096 and 81602078), Shanghai Natural Science Foundation (17ZR1406500), Hospital Foundation of Fudan University Shanghai Cancer Center (YJ201504) and by the project of Shanghai Municipal Health Bureau (20114009).	Basan M, 2015, NATURE, V528, P99, DOI 10.1038/nature15765; Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552; Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278; Bianchini G, 2010, J CLIN ONCOL, V28, P4316, DOI 10.1200/JCO.2009.27.2419; Bugaj LJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7898; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Chamoto K, 2013, STEM CELL RES, V10, P267, DOI 10.1016/j.scr.2012.12.006; Chen H, 2011, MED ONCOL, V28, pS318, DOI 10.1007/s12032-010-9763-1; Chen HW, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661-016-0524-8; Ci YQ, 2016, MOLECULES, V21, DOI 10.3390/molecules21121634; Desrochers LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11958; Duan J, 2011, INT J BIOCHEM CELL B, V43, P1218, DOI 10.1016/j.biocel.2011.04.015; Fujimoto N, 2006, EXP DERMATOL, V15, P300, DOI 10.1111/j.0906-6705.2006.00409.x; Gao F, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0533-9; Gomez-Contreras P, 2016, CLIN EXP METASTASIS; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang PH, 2017, ONCOGENE, V36, P2202, DOI 10.1038/onc.2016.378; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Khurana S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13500; Lal G, 2009, ANN SURG ONCOL, V16, P2280, DOI 10.1245/s10434-009-0533-2; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Leask A, 2013, ADV WOUND CARE, V2, P160, DOI 10.1089/wound.2012.0365; Lee KM, 2015, ONCOGENE, V34, P6055, DOI 10.1038/onc.2015.54; Lee K, 2014, IEEE T MULTIMEDIA, V16, P1201, DOI 10.1109/TMM.2014.2311012; Lee KM, 2015, CELL SIGNAL, V27, P228, DOI 10.1016/j.cellsig.2014.11.004; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Massari F, 2016, CANCER TREAT REV, V45, P46, DOI 10.1016/j.ctrv.2016.03.005; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Nie W, 2015, LAB INVEST, V95, P56, DOI 10.1038/labinvest.2014.124; Qi P, 2015, INT J CANCER, V137, P1269, DOI 10.1002/ijc.29516; ROSZKOWSKI M, 1981, APPL RES MENT RETARD, V2, P359, DOI 10.1016/0270-3092(81)90030-8; Semenza G L, 2001, Novartis Found Symp, V240, P251; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Wang LP, 2003, CANCER LETT, V200, P57, DOI 10.1016/S0304-3835(03)00350-1; Wang ZL, 2015, ONCOTARGET, V6, P6670, DOI 10.18632/oncotarget.3118; Wang ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079117; Xiong GP, 2012, NEOPLASMA, V59, P409, DOI 10.4149/neo_2012_053; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Ye HQ, 2016, BIOMED PHARMACOTHER, V80, P109, DOI 10.1016/j.biopha.2016.02.019; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang W, 2016, ONCOTARGET, V7, P5800, DOI 10.18632/oncotarget.6807; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	47	75	77	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					744	755		10.1038/onc.2017.363	http://dx.doi.org/10.1038/onc.2017.363			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059156				2022-12-28	WOS:000424628100006
J	Bian, X; Gao, J; Luo, F; Rui, C; Zheng, T; Wang, D; Wang, Y; Roberts, TM; Liu, P; Zhao, JJ; Cheng, H				Bian, X.; Gao, J.; Luo, F.; Rui, C.; Zheng, T.; Wang, D.; Wang, Y.; Roberts, T. M.; Liu, P.; Zhao, J. J.; Cheng, H.			PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION REPAIR; OVARIAN-CANCER; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; PROSTATE-CANCER; PI3K INHIBITOR; NUCLEAR PTEN; MUTANT-CELLS; OLAPARIB	Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair. However, as HR-deficient tumors represent only a small fraction of endometrial cancers, the therapeutic utility of PARP inhibitors is limited in this disease. Somatic loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that counteracts phosphoinositide 3-kinase (PI3K) activity, is one of the most common genetic aberrations in endometrioid endometrial cancer. While previous works have identified the role of PTEN in DNA double-strand break repair, vulnerabilities of PTEN-deficient endometrioid endometrial cancers to PARP inhibition remain controversial. Here we find that PTENdeficient endometrioid endometrial cancer cells are not responsive to PARP inhibitor Olaparib alone, but instead show superior sensitivity to compound inhibition with PI3K inhibitor BKM120, as evidenced by reduced clonogenic cell growth and threedimensional (3D) spheroid disintegration. Mechanistically, PI3K blockade by BKM120 attenuated HR competency with.H2AX accumulation and reduced RAD51 and BRCA1 expression in Ishikawa, AN3CA and Nou-1 cells, but the same combination treatment led to enhanced phosphorylation of DNA-PK, a non-homologous end joining repair protein, in Hec-108 cells. Furthermore, we show that CRISPR/Cas9-mediated PTEN depletion rendered PTEN wild-type Hec-1A endometrioid endometrial cancer cells responsive to combined inhibition of PARP/PI3K, with concomitantly induced DNA damage accumulation and repair defects. The combination of BKM120 and Olaparib cooperated to inhibit tumor growth in a genetic mouse model of Pten-deficient endometrioid endometrial cancer. Together, these results suggest PI3K inhibition may be a plausible approach to expand the utility of PARP inhibitors to endometrioid endometrial cancers in a PTEN-deficient setting.	[Bian, X.; Gao, J.; Rui, C.; Wang, D.; Liu, P.; Cheng, H.] Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Canc Inst, Dalian, Peoples R China; [Luo, F.] Dalian Med Univ, Hosp 2, Dept Acute Abdomen Surg, Dalian, Peoples R China; [Zheng, T.] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China; [Wang, Y.] Dalian Med Univ, Dept Obstet & Gynecol, Hosp 2, Dalian, Peoples R China; [Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA; [Liu, P.] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Harvard University; Dana-Farber Cancer Institute; Dalian Medical University	Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA.; Cheng, H (corresponding author), Dalian Med Univ, Inst Canc, Hosp 2, Dalian 116023, Peoples R China.; Liu, P (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Peoples R China.	pixu_liu@dmu.edu.cn; jean_zhao@dfci.harvard.edu; hailingcheng_dmu@163.com			National Natural Science Foundation of China [81472447, 81672575, 81372853, 81572586, 81602274]; Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning [2014023002]; National Institutes of Health/National Cancer Institute (NIH/NCI) [P50 CA168504, CA187918, P50 CA165962, CA210057-01, CA172461-04]; Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE [R01CA172461, P50CA165962, R01CA187918, P50CA168504, R35CA210057] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning; National Institutes of Health/National Cancer Institute (NIH/NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Natural Science Foundation of China (No. 81472447 and No. 81672575 to H Cheng; No. 81372853 and No. 81572586 to P Liu; No. 81602274 to J Gao), Liaoning Provincial Climbing Scholars Supporting Program of China (H Cheng, P Liu), Liaoning Provincial Science and Technology Program for Oversea Talents (H Cheng), Provincial Natural Science Foundation of Liaoning (No. 2014023002 to P Liu), National Institutes of Health/National Cancer Institute (NIH/NCI) (P50 CA168504, CA187918, P50 CA165962, CA210057-01 and CA172461-04 to JJZ), and Breast Cancer Research Foundation and DFCI SSCWC Program Project Grant.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Cardillo TM, 2017, CLIN CANCER RES, V23, P3405, DOI 10.1158/1078-0432.CCR-16-2401; Cardnell RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152584; Chan SL, 2010, LANCET, V376, P211, DOI 10.1016/S0140-6736(10)61119-1; Cheng HL, 2014, CANCER RES, V74, P15, DOI 10.1158/0008-5472.CAN-13-0544; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Forster MD, 2011, NAT REV CLIN ONCOL, V8, P302, DOI 10.1038/nrclinonc.2011.42; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Billalabeitia E, 2014, CANCER DISCOV, V4, P896, DOI 10.1158/2159-8290.CD-13-0230; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Janzen DM, 2013, MOL CANCER THER, V12, P2917, DOI 10.1158/1535-7163.MCT-13-0572; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Martins FC, 2012, CANCER DISCOV, V2, P503, DOI 10.1158/2159-8290.CD-11-0325; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Miyasaka A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-179; Mo W, 2016, CLIN CANCER RES, V22, P1699, DOI 10.1158/1078-0432.CCR-15-1772; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Okkenhaug K, 2016, CANCER DISCOV, V6, P1090, DOI 10.1158/2159-8290.CD-16-0716; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang D, 2016, GYNECOL ONCOL, V142, P548, DOI 10.1016/j.ygyno.2016.07.092; Wang D, 2016, ONCOTARGET, V7, P13153, DOI 10.18632/oncotarget.7549; Weigelt B, 2013, CLIN CANCER RES, V19, P3533, DOI 10.1158/1078-0432.CCR-12-3815	47	70	72	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					341	351		10.1038/onc.2017.326	http://dx.doi.org/10.1038/onc.2017.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945226	Green Published, hybrid			2022-12-28	WOS:000422753900007
J	Liu, L; Wong, CC; Gong, B; Yu, J				Liu, L.; Wong, C. C.; Gong, B.; Yu, J.			Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer	ONCOGENE			English	Review							SCF-BETA-TRCP; UBIQUITIN-CONJUGATING ENZYME; WNT SIGNALING PATHWAY; CELL-CYCLE CONTROL; F-BOX PROTEINS; TUMOR-SUPPRESSOR; COLON-CANCER; NEDD8-ACTIVATING ENZYME; E-CADHERIN; KAPPA-B	Accumulative studies revealed that E3 ubiquitin ligases have important roles in colorectal carcinogenesis. The pathogenic mechanisms of colorectal cancer (CRC) initiation and progression are complex and heterogeneous, involving somatic mutations, abnormal gene fusion, deletion or amplification and epigenetic alteration, which may cause aberrant expression or altered function of E3 ligases in CRC. Defects of E3 ligases have been reported to be involved in the molecular etiology and pathogenesis of CRC. The aberrant expressed E3 ligases can function as either oncogenes or tumor suppressors depending on ubiquiting target substrates in CRC. Recently, considerable progress has been made in our understanding of the potential roles of E3 ligase-mediated ubiquitylation in colorectal carcinogenesis. There are mainly two subtypes of E3 ubiquitin ligases in humans, as defined by the presence of either a HECT domain or a RING finger domain on the basis of structural similitude. Most cancer-associated E3 ligases participate in regulating the cell cycle, apoptosis, gene transcription, cell signaling and DNA repair, the critical parts of CRC tumorigenesis. In this review, we have provided a comprehensive summary of abnormally expressed E3 ligases and their related pivotal mechanistic effects in CRC. In particular, we have highlighted the function of RING-type E3 ubiquitin enzymes in modulating cancer signaling pathways, immunity and tumor microenvironment in CRC development and progression; their mechanism(s) of action in CRC involving both ubiquitylation-dependent and ubiquitylation-independent effects; and the potential of RING E3 ligases as molecular biomarkers for predicting patient prognosis and as therapeutic targets in CRC. A better understanding of E3 ligase-mediated substrates' ubiquitylation involved in the development of CRC will provide new insights into the pathophysiology mechanisms of CRC, and unravel novel prognostic markers and therapeutic strategies for CRC.	[Liu, L.; Wong, C. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Inst Digest Dis,Dept Med &, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China; [Gong, B.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol,Digest Endoscopy Ctr, Shanghai, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Inst Digest Dis,Dept Med &, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-GRF Hong Kong [766613, 14106415, 14114615, 14111216]; HMRF Hong Kong [03140856]; National Key Technology RD Program [2014BAI09B05]; 135 program project [2016YFC1303200]	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; National Key Technology RD Program(National Key Technology R&D Program); 135 program project	This project was supported by RGC-GRF Hong Kong (766613, 14106415, 14114615, 14111216), HMRF Hong Kong (03140856), The National Key Technology R&D Program (2014BAI09B05) and 135 program project (2016YFC1303200).	Abdel-Fattah G, 2000, J GASTROINTEST SURG, V4, P109, DOI 10.1016/S1091-255X(00)80041-4; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Shamsi HO, 2016, J GASTROINTEST ONCOL, V7, P882, DOI 10.21037/jgo.2016.11.02; Baker R, 2013, NAT STRUCT MOL BIOL, V20, P46, DOI 10.1038/nsmb.2430; Bashir T, 2005, NAT CELL BIOL, V7, P779, DOI 10.1038/ncb0805-779; Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780; Bochis OV, 2015, J GASTROINTEST LIVER, V24, P225, DOI 10.15403/jgld.2014.1121.242.skp2; Buetow L, 2016, NAT REV MOL CELL BIO, V17, P626, DOI 10.1038/nrm.2016.91; Cantu C, 2013, EMBO REP, V14, P295, DOI 10.1038/embor.2013.21; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Ceccarelli DF, 2011, CELL, V145, P1075, DOI 10.1016/j.cell.2011.05.039; Chen HJ, 2014, MOL MED REP, V10, P1129, DOI 10.3892/mmr.2014.2308; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Coe GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30816; Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Davis H, 2014, GUT, V63, P792, DOI 10.1136/gutjnl-2013-304719; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Denuc A, 2010, BIOCHEM SOC T, V38, P34, DOI 10.1042/BST0380034; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dickson KM, 2004, DEV DYNAM, V231, P122, DOI 10.1002/dvdy.20110; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrenschwender M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.534; Fearon ER, 2012, CURR BIOL, V22, pR849, DOI 10.1016/j.cub.2012.08.002; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Glebov OK, 2006, CANCER EPIDEM BIOMAR, V15, P2253, DOI 10.1158/1055-9965.EPI-05-0694; Gonzalez-Prieto R, 2015, CELL CYCLE, V14, P1859, DOI 10.1080/15384101.2015.1040965; Grabbe C, 2011, NAT REV MOL CELL BIO, V12, P295, DOI 10.1038/nrm3099; Grim JE, 2012, MOL CELL BIOL, V32, P2160, DOI 10.1128/MCB.00305-12; Gu LB, 2016, CANCER CELL, V30, P623, DOI 10.1016/j.ccell.2016.08.015; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Hadjihannas MV, 2012, EMBO REP, V13, P347, DOI 10.1038/embor.2012.12; Hanson AJ, 2012, MOL CELL, V45, P619, DOI 10.1016/j.molcel.2011.12.032; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Inuzuka H, 2014, SPRING CANC RES, P1, DOI 10.1007/978-3-319-05026-3; Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kapanidou M, 2017, TRENDS BIOCHEM SCI, V42, P193, DOI 10.1016/j.tibs.2016.12.001; Kedrin D, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.12; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klampfer L, 2011, CURR CANCER DRUG TAR, V11, P451, DOI 10.2174/156800911795538066; Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Kotz J., 2011, SCIBX, V4, P1, DOI [10.1038/scibx.2011.559, DOI 10.1038/SCIBX.2011.559]; Kozuch PS, 2008, J CLIN ONCOL, V26, P2320, DOI 10.1200/JCO.2007.14.0152; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lee OH, 2015, BBA-MOL CELL RES, V1853, P409, DOI 10.1016/j.bbamcr.2014.11.007; Lee YY, 2009, DIS MARKERS, V26, P9, DOI [10.3233/DMA-2009-0598, 10.1155/2009/821543]; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365-2559.2007.02620.x; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Miyaki M, 2009, ONCOLOGY-BASEL, V76, P430, DOI 10.1159/000217811; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Paschall AV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-24; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Piao MY, 2016, SCAND J GASTROENTERO, V51, P572, DOI 10.3109/00365521.2015.1124285; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Ring A, 2014, STEM CELL REV REP, V10, P512, DOI 10.1007/s12015-014-9515-2; Sackton KL, 2014, NATURE, V514, P646, DOI 10.1038/nature13660; Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007; Sancho R, 2010, GASTROENTEROLOGY, V139, P929, DOI 10.1053/j.gastro.2010.05.078; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108; Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shukla S, 2014, NEOPLASIA, V16, P115, DOI 10.1593/neo.14184; Silke J, 2014, METHOD ENZYMOL, V545, P35, DOI 10.1016/B978-0-12-801430-1.00002-0; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Song E, 2001, BRIT J CANCER, V85, P1047, DOI 10.1038/sj.bjc.6692042; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Sriramachandran AM, 2014, BBA-MOL CELL RES, V1843, P75, DOI 10.1016/j.bbamcr.2013.08.022; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; Street I, 2012, EUR J CANCER, V48, pS250, DOI 10.1016/S0959-8049(12)71650-7; Sun H, 2013, CANCER RES, V73, P4950, DOI 10.1158/0008-5472.CAN-13-0370; Sun HY, 2012, J BIOL CHEM, V287, P42071, DOI 10.1074/jbc.M112.410985; Tan MJ, 2006, NEOPLASIA, V8, P1042, DOI 10.1593/neo.06568; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Thomas JJ, 2016, CELL REP, V16, P3388, DOI 10.1016/j.celrep.2016.08.024; Tong J, 2017, ONCOGENE, V36, P787, DOI 10.1038/onc.2016.247; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai WB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011171; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Uddin S, 2008, CANCER RES, V68, P3379, DOI 10.1158/0008-5472.CAN-07-6109; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wan JF, 2016, TECHNOL CANCER RES T, V15, P527, DOI 10.1177/1533034615588197; Wang XW, 2014, GUT LIVER, V8, P487, DOI 10.5009/gnl13133; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu BB, 2013, EMBO REP, V14, P347, DOI 10.1038/embor.2013.19; Wu WJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-142; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang T, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.23931; Zhang X, 2015, ONCOGENE, V34, P4412, DOI 10.1038/onc.2014.377; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	153	36	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					148	159		10.1038/onc.2017.313	http://dx.doi.org/10.1038/onc.2017.313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925398	hybrid, Green Published			2022-12-28	WOS:000422631700002
J	Yoo, JY; Yang, WS; Lee, JH; Kim, BG; Broaddus, RR; Lim, JM; Kim, TH; Jeong, JW				Yoo, J-Y; Yang, W. S.; Lee, J. H.; Kim, B. G.; Broaddus, R. R.; Lim, J. M.; Kim, T. H.; Jeong, J-W			MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; ENDOMETRIAL CANCER; CONSERVATIVE TREATMENT; SIGNAL TRANSDUCER; ACTIVATION; EXPRESSION; PROLIFERATION; HYPERPLASIA; LACTOFERRIN; INHIBITOR	Endometrial cancer is the most common malignancy of the female genital tract. Progesterone (P4) has been used for several decades in endometrial cancer treatment, especially in women who wish to retain fertility. However, it is unpredictable which patients will respond to P4 treatment and which may have a P4-resistant cancer. Therefore, identifying the mechanism of P4 resistance is essential to improve the therapies for endometrial cancer. Mitogen-inducible gene 6 (Mig-6) is a critical mediator of progesterone receptor (PGR) action in the uterus. In order to study the function of Mig-6 in P4 resistance, we generated a mouse model in which we specifically ablated Mig-6 in uterine epithelial cells using Sprr2f-cre mice (Sprr2f(cre+) Mig-6(f/f)). Female mutant mice develop endometrial hyperplasia due to aberrant phosphorylation of signal transducers and activators of transcription 3 (STAT3) and proliferation of the endometrial epithelial cells. The results from our immunoprecipitation and cell culture experiments showed that MIG-6 inhibited phosphorylation of STAT3 via protein interactions. Our previous study showed P4 resistance in mice with Mig-6 ablation in Pgr-positive cells (Pgr(cre/+) Mig-6(f/f)). However, Sprr2f(cre+) Mig-6(f/f) mice were P4-responsive. P4 treatment significantly decreased STAT3 phosphorylation and epithelial proliferation in the uterus of mutant mice. We showed that Mig-6 has an important function of tumor suppressor via inhibition of STAT3 phosphorylation in uterine epithelial cells, and the antitumor effects of P4 are mediated by the endometrial stroma. These data help to develop a new signaling pathway in the regulation of steroid hormones in the uterus, and to overcome P4 resistance in human reproductive diseases, such as endometrial cancer.	[Yoo, J-Y; Yang, W. S.; Lee, J. H.; Kim, B. G.; Kim, T. H.; Jeong, J-W] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA; [Yoo, J-Y] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; [Yang, W. S.; Lim, J. M.] Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lim, J. M.] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea; [Jeong, J-W] Spectrum Hlth Syst, Dept Womens Hlth, Grand Rapids, MI USA	Michigan State University; Michigan State University College of Human Medicine; Yonsei University; Yonsei University Health System; Seoul National University (SNU); University of Texas System; UTMD Anderson Cancer Center; Seoul National University (SNU)	Kim, TH; Jeong, JW (corresponding author), Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	TaeHoon.Kim@hc.msu.edu; JaeWook.Jeong@hc.msu.edu		Yoo, Jung-Yoon/0000-0001-9366-3863	America Cancer Society [RSG-12-084-01-TBG]; National Institutes of Health (NIH) [HD084478]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2016R1D1A1B03934346]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD084478] Funding Source: NIH RePORTER	America Cancer Society; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(National Research Foundation of Korea); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We would like to thank Dr Diego H Castrillon (University of Texas Southwestern Medical Center, Dallas, TX, USA) for Sprr2f-cre mice. We would also like to thank Hanna E Teasley and Paige Wells for manuscript preparation. This work was supported by America Cancer Society, RSG-12-084-01-TBG and National Institutes of Health (NIH, HD084478) to JWJ and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2016R1D1A1B03934346) to JYY.	Ambros RA, 2000, INT J GYNECOL PATHOL, V19, P206, DOI 10.1097/00004347-200007000-00002; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Bovicelli A, 2013, J CELL PHYSIOL, V228, P1154, DOI 10.1002/jcp.24292; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cheng JG, 2001, P NATL ACAD SCI USA, V98, P8680, DOI 10.1073/pnas.151180898; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Critchley HOD, 2009, REPROD SCI, V16, P191, DOI 10.1177/1933719108331121; Daikoku T, 2014, ENDOCRINOLOGY, V155, P2718, DOI 10.1210/en.2014-1265; Decruze SB, 2007, INT J GYNECOL CANCER, V17, P964, DOI 10.1111/j.1525-1438.2007.00897.x; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; Duncan CG, 2010, ONCOTARGET, V1, P265, DOI 10.18632/oncotarget.137; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Franco HL, 2012, FASEB J, V26, P1218, DOI 10.1096/fj.11-193334; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Hahn HS, 2009, INT J GYNECOL CANCER, V19, P1068, DOI 10.1111/IGC.0b013e3181aae1fb; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Kaunitz AM, 1998, INT J FERTIL WOMEN M, V43, P73; Kim BG, 2015, HUM REPROD, V30, P1069, DOI 10.1093/humrep/dev050; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Kim TH, 2013, CANCER RES, V73, P5090, DOI 10.1158/0008-5472.CAN-13-0241; Kurita T, 2000, BIOL REPROD, V62, P831, DOI 10.1095/biolreprod62.4.831; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Lee JH, 2013, FASEB J, V27, P2553, DOI 10.1096/fj.12-225664; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin CI, 2011, J CLIN ENDOCR METAB, V96, pE554, DOI 10.1210/jc.2010-1800; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; Reschke M, 2010, HEPATOLOGY, V51, P1383, DOI 10.1002/hep.23428; Rubel CA, 2010, SEMIN REPROD MED, V28, P27, DOI 10.1055/s-0029-1242990; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; van Laar T, 2001, MOL CARCINOGEN, V31, P63, DOI 10.1002/mc.1040; Wang XC, 2012, INT J ONCOL, V41, P1181, DOI 10.3892/ijo.2012.1568; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xiong AL, 2014, CANCERS, V6, P926, DOI 10.3390/cancers6020926; Yang S, 2011, TRENDS ENDOCRIN MET, V22, P145, DOI 10.1016/j.tem.2011.01.005; Ying HQ, 2010, P NATL ACAD SCI USA, V107, P6912, DOI 10.1073/pnas.0914930107; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790; Zhang YW, 2007, CELL CYCLE, V6, P507, DOI 10.4161/cc.6.5.3928	48	6	7	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					255	262		10.1038/onc.2017.335	http://dx.doi.org/10.1038/onc.2017.335			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925396	Green Submitted, Green Accepted			2022-12-28	WOS:000422631700011
J	Wang, Z; He, Y; Deng, W; Lang, L; Yang, H; Jin, B; Kolhe, R; Ding, HF; Zhang, J; Hai, T; Yan, C				Wang, Z.; He, Y.; Deng, W.; Lang, L.; Yang, H.; Jin, B.; Kolhe, R.; Ding, H-F; Zhang, J.; Hai, T.; Yan, C.			Atf3 deficiency promotes genome instability and spontaneous tumorigenesis in mice	ONCOGENE			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; DNA-DAMAGE RESPONSE; RADIATION-INDUCED APOPTOSIS; TUMOR SUPPRESSION; PROTEIN SUPPRESSES; P53-DEFICIENT MICE; CANCER DEVELOPMENT; ADAPTIVE-RESPONSE; P53 PROTEINS; LUNG-CANCER	Mice lacking genes involving in the DNA-damage response (DDR) are often tumor prone owing to genome instability caused by oncogenic challenges. Previous studies demonstrate that activating transcription factor 3 (ATF3), a common stress sensor, can activate the tumor suppressor p53 and regulate expression of p53 target genes upon DNA damage. However, whether ATF3 contributes to the maintenance of genome stability and tumor suppression remains unknown. Here we report that Atf3-deficient (Atf3(-/-)) mice developed spontaneous tumors, and died significantly earlier than wild-type (Atf3(+/+)) mice. Consistent with these results, Atf3(-/-) mouse embryonic fibroblasts (MEFs) had more aberrant chromosomes and micronuclei, and were genetically unstable. Whereas we demonstrated that ATF3 activated p53 and promoted its pro-apoptotic activity in mouse thymi and small intestines, the chromosomal instability caused by Atf3 deficiency was largely dependent on the regulation of p53 by ATF3. Interestingly, loss of Atf3 also promoted spontaneous tumorigenesis in Trp53(+/-) mice, but did not affect tumor formation in Trp53(-/-) mice. Our results thus provide the first genetic evidence linking ATF3 to the suppression of the early development of cancer, and underscore the importance of ATF3 in the maintenance of genome integrity.	[Wang, Z.; He, Y.; Lang, L.; Yang, H.; Ding, H-F; Yan, C.] Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA; [Deng, W.] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Jin, B.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Kolhe, R.; Ding, H-F] Augusta Univ, Dept Pathol, Med Coll Georgia, Augusta, GA USA; [Zhang, J.] Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA; [Hai, T.] Ohio State Univ, Dept Biol Chem & Pharmacol, Columbus, OH 43210 USA; [Yan, C.] Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA USA	University System of Georgia; Augusta University; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; University System of Georgia; Augusta University; Case Western Reserve University; University System of Ohio; Ohio State University; University System of Georgia; Augusta University	Yan, C (corresponding author), Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Blvd,CN2134, Augusta, GA 30912 USA.; Deng, W (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	dengwg@sysucc.org.cn; cyan@augusta.edu	Lang, Liwei/I-7744-2019; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Yan, Chunhong/0000-0002-3974-7991; KOLHE, RAVINDRA/0000-0002-8283-2403; Lang, Liwei/0000-0002-2374-645X; Ding, Han-Fei/0000-0001-5702-3439	NIH [R01CA139107]; National Science Foundation of China [81472178]; State 973 Program of China [2014CB542005]; NATIONAL CANCER INSTITUTE [R01CA139107, R01CA154625] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); State 973 Program of China(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH grant R01CA139107 to CY, and the grants from the National Science Foundation of China (81472178) and the State 973 Program of China (2014CB542005) to WD.	Armata HL, 2007, CANCER RES, V67, P11696, DOI 10.1158/0008-5472.CAN-07-1610; Bar J, 2016, NEOPLASIA, V18, P525, DOI 10.1016/j.neo.2016.07.004; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Beleza-Meireles A, 2008, EUR J ENDOCRINOL, V158, P729, DOI 10.1530/EJE-07-0793; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cui HM, 2016, J BIOL CHEM, V291, P10847, DOI 10.1074/jbc.M115.713099; Cui HM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7752; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gold ES, 2012, J EXP MED, V209, P807, DOI 10.1084/jem.20111202; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Ishiguro T, 1996, CANCER RES, V56, P875; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacquet K, 2016, MOL CELL, V62, P409, DOI 10.1016/j.molcel.2016.03.031; Jan YH, 2012, CANCER RES, V72, P5119, DOI 10.1158/0008-5472.CAN-12-1842; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; MERRITT AJ, 1994, CANCER RES, V54, P614; Mo PL, 2010, J BIOL CHEM, V285, P26908, DOI 10.1074/jbc.M110.132597; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Shin G, 2011, CANCER INFORM, V10, P149, DOI 10.4137/CIN.S7226; Sooraj D, 2016, MOL CANCER THER, V15, P1726, DOI 10.1158/1535-7163.MCT-15-0890; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Taketani K, 2012, ONCOGENE, V31, P2210, DOI 10.1038/onc.2011.397; Turchi L, 2008, CELL DEATH DIFFER, V15, P1472, DOI 10.1038/cdd.2008.74; Turchi L, 2009, CELL DEATH DIFFER, V16, P728, DOI 10.1038/cdd.2009.2; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang Z, 2016, ONCOGENE, V35, P3555, DOI 10.1038/onc.2015.417; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Wang ZY, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1010948; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Wei SS, 2014, J BIOL CHEM, V289, P8947, DOI 10.1074/jbc.M113.503755; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Xie JJ, 2014, ONCOTARGET, V5, P8569, DOI 10.18632/oncotarget.2322; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2005, MOL CANCER THER, V4, P233; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yoo YD, 2017, EMBO REP, V18, P150, DOI [10.15252/embr.201642360, 10.15252/embr.201744761]; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zhang C, 2002, BIOCHEM BIOPH RES CO, V297, P1302, DOI 10.1016/S0006-291X(02)02382-3; Zhao J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2664-8; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026744	69	22	22	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					18	27		10.1038/onc.2017.310	http://dx.doi.org/10.1038/onc.2017.310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869597	Green Accepted			2022-12-28	WOS:000422625000003
J	Leclerc, J; Ballotti, R; Bertolotto, C				Leclerc, J.; Ballotti, R.; Bertolotto, C.			Pathways from senescence to melanoma: focus on MITF sumoylation	ONCOGENE			English	Review							ONCOGENE-INDUCED SENESCENCE; MICROPHTHALMIA TRANSCRIPTION FACTOR; DNA-DAMAGE RESPONSE; CELLULAR SENESCENCE; BETA-CATENIN; GERMLINE MUTATION; BRAF MUTATIONS; TUMOR-SUPPRESSOR; ULTRAVIOLET-RADIATION; MELANOCYTIC NEVUS	Cutaneous melanoma is a deadly skin cancer that originates from melanocytes. The development of cutaneous melanoma involves a complex interaction between environmental factors, mainly ultraviolet radiation from sunlight, and genetic alterations. Melanoma can also occur from a pre-existing nevus, a benign lesion formed from melanocytes harboring oncogenic mutations that trigger proliferative arrest and senescence entry. Senescence is a potent barrier against tumor progression. As such, the acquisition of mutations that suppress senescence and promote cell division is mandatory for cancer development. This topic appears central to melanoma development because, in humans, several somatic and germline mutations are related to the control of cellular senescence and proliferative activity. Consequently, primary melanoma can be viewed as a paradigm of senescence evasion. In support of this notion, a sumoylation-defective germline mutation in microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte homeostasis, is associated with the development of melanoma. Interestingly, this MITF variant has also been recently reported to negatively impact the program of senescence. This article reviews the genetic alterations that have been shown to be involved in melanoma and that alter the process of senescence to favor melanoma development. Then, the transcription factor MITF and its sumoylation-defective mutant are described. How sumoylation misregulation can change MITF activity and impact the process of senescence is discussed. Finally, the contribution of such information to the development of anti-malignant melanoma strategies is evaluated.	[Leclerc, J.; Ballotti, R.; Bertolotto, C.] INSERM, U1065 Equipe 1, Equipe Labelisee ARC 2016, C3M, Ave St Antoine Ginestiere, F-06204 Nice, France; [Leclerc, J.; Ballotti, R.; Bertolotto, C.] Univ Cote Azur, INSERM, C3M, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bertolotto, C (corresponding author), INSERM, U1065 Equipe 1, Equipe Labelisee ARC 2016, C3M, Ave St Antoine Ginestiere, F-06204 Nice, France.	bertolot@unice.fr	BALLOTTI, Robert/F-8825-2013; Bertolotto, Corine/AAF-6634-2021; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Leclerc, Justine/0000-0003-3793-458X; BALLOTTI, Robert/0000-0002-7322-4908	INCa [INCa_10573, INCa_2013-070, ANR-13-BSV1-0025-01]; La ville de Nice	INCa(Institut National du Cancer (INCA) France); La ville de Nice	We are very grateful to Dr I Davidson (IGBMC, Strasbourg) for the analysis of the ChIP-sequencing data set by the MEME program and his helpful discussion. This work was funded by INCa grants INCa_10573 to CB and INCa_2013-070 to RB and ANR-13-BSV1-0025-01 to RB and from La ville de Nice.	Abdallah P, 2009, NAT CELL BIOL, V11, P988, DOI 10.1038/ncb1911; Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Andreou AM, 2010, ADV EXP MED BIOL, V694, P160; Andreou Artemisia M., 2009, Biotechnology Journal, V4, P1740, DOI 10.1002/biot.200900219; Aoude LG, 2015, PIGM CELL MELANOMA R, V28, P148, DOI 10.1111/pcmr.12333; Arafeh R, 2015, NAT GENET, V47, P1408, DOI 10.1038/ng.3427; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bastian BC, 2003, AM J DERMATOPATH, V25, P83, DOI 10.1097/00000372-200302000-00018; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Basu S, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026302; Bataille V, 2007, CANCER EPIDEM BIOMAR, V16, P1499, DOI 10.1158/1055-9965.EPI-07-0152; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bedogni B, 2006, CELL CYCLE, V5, P1258, DOI 10.4161/cc.5.12.2810; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bennett DC, 2016, PIGM CELL MELANOMA R, V29, P122, DOI 10.1111/pcmr.12422; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bonet C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw340; Bossis G, 2014, CELL REP, V7, P1815, DOI 10.1016/j.celrep.2014.05.016; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; de- Paillerets BB, 2013, EUR J CELL BIOL, V93, P71; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demenais F, 2010, JNCI-J NATL CANCER I, V102, P1568, DOI 10.1093/jnci/djq363; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fung C, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12062; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Ghiorzo P, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12047; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Haferkamp S, 2009, AGING-US, V1, P542, DOI 10.18632/aging.100051; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jafri M, 2015, CANCER DISCOV, V5, P723, DOI 10.1158/2159-8290.CD-14-1096; Jarrett SG, 2015, J INVEST DERMATOL, V135, P3086, DOI 10.1038/jid.2015.280; Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Kumar A, 2015, COMPUT STRUCT BIOTEC, V13, P204, DOI 10.1016/j.csbj.2015.03.001; Larribere L, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12369; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Levy C, 2003, MOL CELL BIOL, V23, P9073, DOI 10.1128/MCB.23.24.9073-9080.2003; Li A, 2012, J INVEST DERMATOL, V132, P2610, DOI 10.1038/jid.2012.186; Liu Y, 2013, EMBO MOL MED, V5, P149, DOI 10.1002/emmm.201201378; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Machesky LM, 2012, PIGM CELL MELANOMA R, V25, P762, DOI 10.1111/pcmr.12004; MacKenzie Ross AD, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12060; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mannava S, 2012, ONCOGENE, V31, P1484, DOI 10.1038/onc.2011.339; McNeal AS, 2015, CANCER DISCOV, V5, P1072, DOI 10.1158/2159-8290.CD-15-0196; Meierjohann S, 2014, EUR J CELL BIOL, V93, P36, DOI 10.1016/j.ejcb.2013.11.005; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Olumi AF, 1999, CANCER RES, V59, P5002; Pandiani C, 2017, GENE DEV, V31, P724, DOI 10.1101/gad.296962.117; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Potrony M, 2016, JAMA DERMATOL, V152, P405, DOI 10.1001/jamadermatol.2015.4356; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robles-Espinoza CD, 2015, MOL CANCER RES, V13, P211, DOI 10.1158/1541-7786.MCR-14-0305; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Scurr LL, 2017, ADV EXP MED BIOL, V963, P215, DOI 10.1007/978-3-319-50044-7_13; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sonnenblick A, 2004, MOL CELL BIOL, V24, P10584, DOI 10.1128/MCB.24.24.10584-10592.2004; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Sturm RA, 2014, J INVEST DERMATOL, V134, P141, DOI 10.1038/jid.2013.272; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Swope V, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12252; te Poele RH, 2002, CANCER RES, V62, P1876; Tentori L, 2013, TRENDS PHARMACOL SCI, V34, P656, DOI 10.1016/j.tips.2013.10.003; Terzian T, 2010, PIGM CELL MELANOMA R, V23, P781, DOI 10.1111/j.1755-148X.2010.00773.x; Tran S, 2013, AGING-US, V5, P98, DOI 10.18632/aging.100537; Tran Sieu L, 2013, Methods Mol Biol, V965, P313, DOI 10.1007/978-1-62703-239-1_21; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Xue Y, 2011, AM J PHYSIOL-HEART C, V300, pH2169, DOI 10.1152/ajpheart.00970.2010; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yu B, 2015, P NATL ACAD SCI USA, V112, pE1724, DOI 10.1073/pnas.1415569112; Zhang YQ, 2008, J CELL BIOL, V182, P35, DOI 10.1083/jcb.200712124; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017; Zhu ST, 2009, P NATL ACAD SCI USA, V106, P17025, DOI 10.1073/pnas.0909292106; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	150	13	13	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6659	6667		10.1038/onc.2017.292	http://dx.doi.org/10.1038/onc.2017.292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28825724	Green Submitted			2022-12-28	WOS:000416780800001
J	Fujishita, T; Kojima, Y; Kajino-Sakamoto, R; Taketo, MM; Aoki, M				Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; Taketo, M. M.; Aoki, M.			Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; APC(DELTA-716) MICE; ANTITUMOR-ACTIVITY; COLORECTAL-CANCER; KINASE INHIBITOR; POLYP FORMATION; BREAST-CANCER; AZD8055; THERAPY; GRB10	Mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is frequently activated in cancers and can be counteracted with the clinical mTORC1 inhibitors everolimus and temsirolimus. Although mTORC1 and dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication. Using the cis-Apc/Smad4 mouse model of locally invasive intestinal adenocarcinoma, we show that administration of everolimus or the dual mTORC1/2 inhibitor AZD8055 significantly reduces the growth of intestinal tumors. In contrast, although everolimus treatment at earlier phase of tumor progression delayed invasion of the tumors, both inhibitors exhibited little effect on blocking invasion of the tumors when administered later in their progression. Biochemical and immunohistochemical analyses revealed that treatment of cis-Apc/Smad4 mice with everolimus or AZD8055 induced marked increases in epidermal growth factor receptor (EGFR) and MEK/ERK signaling in tumor epithelial and stromal cells, respectively. Notably, co-administration of AZD8055 and the EGFR inhibitor erlotinib or the MEK inhibitor trametinib was sufficient to suppress tumor invasion in cis-Apc/Smad4 mice. These data indicate that mTOR inhibitor resistance in invasive intestinal tumors involves feedback signaling from both cancer epithelial and stromal cells, highlighting the role of tumor microenvironment in drug resistance, and support that simultaneous inhibition of mTOR and EGFR or MEK may be more effective in treating colon cancer.	[Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; Aoki, M.] Aichi Canc Ctr, Div Mol Pathol, Res Inst, Nagoya, Aichi, Japan; [Fujishita, T.; Taketo, M. M.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan; [Aoki, M.] Nagoya Univ, Grad Sch Med, Program Funct Construct Med, Dept Canc Genet, Nagoya, Aichi, Japan	Aichi Cancer Center; Kyoto University; Nagoya University	Aoki, M (corresponding author), Aichi Canc Ctr, Div Mol Pathol, Res Inst, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	msaoki@aichi-cc.jp	Aoki, Masahiro/A-5149-2016; Fujishita, Teruaki/O-1367-2019	Aoki, Masahiro/0000-0003-4316-9490; Fujishita, Teruaki/0000-0002-4397-2438	JSPS KAKENHI [24790382]; Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare; Yasuda Medical Foundation; Suzuken Memorial Foundation; Nagono Medical Foundation; Shimabara Science Promotion Foundation; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research [26111005] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare; Yasuda Medical Foundation; Suzuken Memorial Foundation; Nagono Medical Foundation; Shimabara Science Promotion Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank PM McSheehy for everolimus; M Oshima, T Kitamura, M Sonoshita, S Arimura, F Kakizaki, A Deguchi, K Sakuma and K Aoki for discussions; and R Mitsuya, M Tsuda, A Kojima, K Kobori and Y Goto for technical assistance. This work was supported by JSPS KAKENHI Grant Number 24790382 (to TF), Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare (to MA), The Yasuda Medical Foundation, Suzuken Memorial Foundation, Nagono Medical Foundation, The Shimabara Science Promotion Foundation (to TF), Takeda Science Foundation (to TF and MA), and Princess Takamatsu Cancer Research Fund (to MA).	Chen SM, 2014, INT J CANCER, V135, P2462, DOI 10.1002/ijc.28880; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Fujishita T, 2015, CANCER SCI, V106, P692, DOI 10.1111/cas.12670; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Herszenyi L, 2012, INT J MOL SCI, V13, P13240, DOI 10.3390/ijms131013240; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Jiang Q, 2011, CANCER RES, V71, P4074, DOI 10.1158/0008-5472.CAN-10-3968; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Metcalfe C, 2010, CANCER RES, V70, P6629, DOI 10.1158/0008-5472.CAN-10-1616; Mohamed A, 2013, AM J PATHOL, V183, P1096, DOI 10.1016/j.ajpath.2013.07.005; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Oshima H, 2012, J GASTROENTEROL, V47, P97, DOI 10.1007/s00535-011-0523-6; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wang Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066417, 10.1371/journal.pone.0068894]; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484	28	25	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6480	6489		10.1038/onc.2017.242	http://dx.doi.org/10.1038/onc.2017.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759045				2022-12-28	WOS:000415622900011
J	Zhong, Y; Yang, J; Xu, WW; Wang, Y; Zheng, CC; Li, B; He, QY				Zhong, Y.; Yang, J.; Xu, W. W.; Wang, Y.; Zheng, C-C; Li, B.; He, Q-Y			KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; CELL-CYCLE; ESOPHAGEAL CANCER; MITOTIC KINASES; AURORA-A; PROGRESSION; CDC25B; PHOSPHORYLATION; ACTIVATION; PROTEOMICS	Cell cycle dysregulation leads to uncontrolled cell proliferation and tumorigenesis. Understanding the molecular mechanisms underlying cell cycle progression can provide clues leading to the identification of key proteins involved in cancer development. In this study, we performed proteomics analysis to identify novel regulators of the cell cycle. We found that potassium channel tetramerization domain containing 12 (KCTD12) was significantly upregulated in M phase compared with S phase. We also found that KCTD12 overexpression not only facilitated the G2/M transition and induced cancer cell proliferation, but also promoted the growth of subcutaneous tumors and Ki-67 proliferation index in mice. Regarding the mechanism underlying these phenomena, cyclin-dependent kinase 1 (CDK1) was identified as an interacting partner of KCTD12 by immunoprecipitation and mass spectrometry analysis, which showed that KCTD12 activated CDK1 and Aurora kinase A (Aurora A) and that the effects of KCTD12 on CDK1 phosphorylation and cell proliferation were abrogated by cell division cycle 25B (CDC25B) silencing. In addition, Aurora A phosphorylated KCTD12 at serine 243, thereby initiating a positive feedback loop necessary for KCTD12 to exert its cancerpromoting effects. Furthermore, we analyzed the expression levels of various genes and the correlations between the expression of these genes and survival using tumor tissue microarray and Gene Expression Omnibus (GEO) data sets. The data showed that KCTD12 expression was significantly upregulated in cervical and lung cancers. More importantly, high KCTD12 expression was associated with larger tumor sizes, higher pathological stages and poor patient survival. Collectively, our study demonstrate that KCTD12 binds to CDC25B and activates CDK1 and Aurora A to facilitate the G2/M transition and promote tumorigenesis and that Aurora A phosphorylates KCTD12 at serine 243 to trigger a positive feedback loop, thereby potentiating the effects of KCTD12. Thus, the KCTD12-CDC25B-CDK1-Aurora A axis has important implications for cancer diagnoses and prognoses.	[Zhong, Y.; Yang, J.; Wang, Y.; Zheng, C-C; Li, B.; He, Q-Y] Jinan Univ, Inst Life & Hlth Engn, Coll Life Sci & Technol, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China; [Zhong, Y.] Jinan Univ, Dept Pathol, Coll Med, Guangzhou, Guangdong, Peoples R China; [Xu, W. W.] Jinan Univ, Inst Biomed, Natl Engn Res Ctr Genet Med, Guangdong Prov Key Lab Bioengn Med, Guangzhou, Guangdong, Peoples R China	Jinan University; Jinan University; Jinan University	Li, B; He, QY (corresponding author), Jinan Univ, Inst Life & Hlth Engn, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.	libin2015@jnu.edu.cn; tqyhe@jnu.edu.cn	Wang, Yang/GQH-2363-2022; He, Qing-Yu/H-7078-2014	Wang, Yang/0000-0001-6440-0204; He, Qing-Yu/0000-0003-0503-9492; Li, Bin/0000-0002-8979-610X	National Key Research and Development Program of China [2017YFA0505100]; National Natural Science Foundation of China [31770888, 31570828, 81672953, 81773085]; Guangdong Natural Science Research Grant [S2013030013315, 2016A030313838]; Fundamental Research Funds for the Central Universities [ZX20170413]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Research Grant; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Mr. Xing-Feng Yin and Mr. Zheng-Hua Sun for their technical assistance on mass spectrometry. This work was supported by the National Key Research and Development Program of China (No. 2017YFA0505100), the National Natural Science Foundation of China (31770888, 31570828, 81672953, 81773085), Guangdong Natural Science Research Grant (S2013030013315, 2016A030313838), and the Fundamental Research Funds for the Central Universities (ZX20170413).	Alexander RD, 2006, PROTEOMICS, V6, P1886, DOI 10.1002/pmic.200500548; Au FKC, 2017, DEV CELL, V40, P81, DOI 10.1016/j.devcel.2016.11.019; Booker SA, 2017, CEREB CORTEX, V27, P2318, DOI 10.1093/cercor/bhw090; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen XL, 2013, PROTEOMICS, V13, P3030, DOI 10.1002/pmic.201200448; Chen Y, 2013, METHODS MOL BIOL, V1077, P105, DOI 10.1007/978-1-62703-637-5_7; Correale S, 2013, J MOL RECOGNIT, V26, P488, DOI 10.1002/jmr.2291; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; de Freitas AC, 2015, CURR DRUG TARGETS, V16, P77, DOI 10.2174/1389450116666141205150942; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ivankova K, 2013, J BIOL CHEM, V288, P24848, DOI 10.1074/jbc.M113.476770; Jeong AL, 2013, BMB REP, V46, P289, DOI 10.5483/BMBRep.2013.46.6.041; Jullien D, 2011, CANCER RES, V71, P1968, DOI 10.1158/0008-5472.CAN-10-2453; Kang HJ, 2006, PROTEOMICS, V6, P1151, DOI 10.1002/pmic.200500372; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Li B, 2017, ONCOGENE, V36, P3986, DOI 10.1038/onc.2017.29; Li B, 2016, CLIN CANCER RES, V22, P1243, DOI 10.1158/1078-0432.CCR-15-1196; Li B, 2014, CLIN CANCER RES, V20, P2651, DOI 10.1158/1078-0432.CCR-13-2735; Li B, 2009, MOL CANCER THER, V8, P2635, DOI 10.1158/1535-7163.MCT-09-0162; Li LP, 2016, SCI REP-UK, V6, DOI 10.1038/srep20460; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Ma HT, 2017, METHODS MOL BIOL, V1524, P189, DOI 10.1007/978-1-4939-6603-5_12; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Milewski D, 2017, ONCOGENE, V36, P850, DOI 10.1038/onc.2016.254; Namiki T, 2015, CANCER RES, V75, P2708, DOI 10.1158/0008-5472.CAN-13-3209; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oh AY, 2016, CANCER RES, V76, P4791, DOI 10.1158/0008-5472.CAN-15-1025; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Resendes BL, 2004, JARO-J ASSOC RES OTO, V5, P185, DOI 10.1007/s10162-003-4042-x; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sobczyk GJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4319; Sprenger Adrian, 2013, Methods Mol Biol, V961, P179, DOI 10.1007/978-1-62703-227-8_10; Suehara Y, 2008, CLIN CANCER RES, V14, P1707, DOI 10.1158/1078-0432.CCR-07-1478; Taylor William R, 2004, Methods Mol Biol, V281, P293; Turecek R, 2014, NEURON, V82, P1032, DOI 10.1016/j.neuron.2014.04.015; Van Horn RD, 2010, J BIOL CHEM, V285, P21849, DOI 10.1074/jbc.M110.141010; Wang J, 2015, ONCOTARGET, V6, P1618, DOI 10.18632/oncotarget.2730; Wang Y, 2017, BIOCHEM PHARMACOL, V129, P43, DOI 10.1016/j.bcp.2017.01.006; Wang Y, 2016, APOPTOSIS, V21, P1438, DOI 10.1007/s10495-016-1300-z; Whalley HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8437; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zhang W, 2011, J BIOL CHEM, V286, P35899, DOI 10.1074/jbc.M111.267690	49	35	36	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6177	6189		10.1038/onc.2017.287	http://dx.doi.org/10.1038/onc.2017.287			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28869606	hybrid, Green Published			2022-12-28	WOS:000414249800011
J	Arslan, AD; Sassano, A; Saleiro, D; Lisowski, P; Kosciuczuk, EM; Fischietti, M; Eckerdt, F; Fish, EN; Platanias, LC				Arslan, A. D.; Sassano, A.; Saleiro, D.; Lisowski, P.; Kosciuczuk, E. M.; Fischietti, M.; Eckerdt, F.; Fish, E. N.; Platanias, L. C.			Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma	ONCOGENE			English	Article							GLIOMA; CELLS; CANCER; EXPRESSION; INVASION; FAMILY; GROWTH; BETA; DIFFERENTIATION; MAINTENANCE	We provide evidence that the IFN-regulated member of the Schlafen (SLFN) family of proteins, SLFN5, promotes the malignant phenotype in glioblastoma multiforme (GBM). Our studies indicate that SLFN5 expression promotes motility and invasiveness of GBM cells, and that high levels of SLFN5 expression correlate with high-grade gliomas and shorter overall survival in patients suffering from GBM. In efforts to uncover the mechanism by which SLFN5 promotes GBM tumorigenesis, we found that this protein is a transcriptional co-repressor of STAT1. Type-I IFN treatment triggers the interaction of STAT1 with SLFN5, and the resulting complex negatively controls STAT1-mediated gene transcription via interferon stimulated response elements. Thus, SLFN5 is both an IFN-stimulated response gene and a repressor of IFN-gene transcription, suggesting the existence of a negative-feedback regulatory loop that may account for suppression of antitumor immune responses in glioblastoma.	[Arslan, A. D.; Sassano, A.; Saleiro, D.; Kosciuczuk, E. M.; Fischietti, M.; Eckerdt, F.; Platanias, L. C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 303 East Super, Chicago, IL 60611 USA; [Arslan, A. D.; Sassano, A.; Saleiro, D.; Kosciuczuk, E. M.; Fischietti, M.; Platanias, L. C.] Northwestern Univ, Div Hematol Oncol, Dept Med, Feinberg Sch Med, Chicago, IL USA; [Lisowski, P.] Med Univ Warsaw, Dept Med Genet, Ctr Preclin Res & Technol CePT, Warsaw, Poland; [Lisowski, P.] Helmholtz Assoc, iPS Cell Based Dis Modeling Grp, Max Delbruck Ctr Mol Med MDC, Berlin, Germany; [Kosciuczuk, E. M.; Platanias, L. C.] Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL USA; [Fish, E. N.] Univ Hlth Network, Toronto Res Inst, Toronto, ON, Canada; [Fish, E. N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Medical University of Warsaw; Helmholtz Association; Max Delbruck Center for Molecular Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Platanias, LC (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 303 East Super, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Fischietti, Mariafausta/Y-6449-2019; Kosciuczuk, Ewa Maria/AAD-2815-2022		NIH [CA161196, CA77816, CA155566, T32CA070085, T32CA080621]; Department of Veterans Affairs [5I01CX000916]; National Science Centre, Poland [2016/22/M/NZ2/00548]; NATIONAL CANCER INSTITUTE [R01CA155566, R01CA077816, T32CA070085, R01CA161796, T32CA080621] Funding Source: NIH RePORTER; Veterans Affairs [I01CX000916] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); National Science Centre, Poland(National Science Centre, Poland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The work was supported in part by NIH grants CA161196, CA77816 and CA155566 and by grant 5I01CX000916 from the Department of Veterans Affairs. ADA was supported in part by NIH training grant T32CA070085, DS was supported in part by NIH training grant T32CA080621, and PL was supported in part by National Science Centre, Poland Grant 2016/22/M/NZ2/00548. We thank Dr John A. Kessler for providing the JK18 and JK46 GSC lines.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; BRADLEY NJ, 1983, BRIT J CANCER, V48, P819, DOI 10.1038/bjc.1983.272; Bustos O, 2009, GENE, V447, P1, DOI 10.1016/j.gene.2009.07.006; Desjardins A, 2005, FRONT BIOSCI-LANDMRK, V10, P2645, DOI 10.2741/1727; Eckerdt F, 2016, BIOTECHNIQUES, V60, P43, DOI 10.2144/000114372; Feng HZ, 2014, J CLIN INVEST, V124, P3741, DOI 10.1172/JCI73093; Fish EN, 2014, MOL CANCER RES, V12, P1691, DOI 10.1158/1541-7786.MCR-14-0450; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Geserick P, 2004, INT IMMUNOL, V16, P1535, DOI 10.1093/intimm/dxh155; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Ji F, 2013, INT J ONCOL, V42, P1578, DOI 10.3892/ijo.2013.1878; Katsoulidis E, 2010, J BIOL CHEM, V285, P40333, DOI 10.1074/jbc.M110.151076; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Li MQ, 2012, NATURE, V491, P125, DOI 10.1038/nature11433; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Mavrommatis E, 2013, J INTERF CYTOK RES, V33, P206, DOI 10.1089/jir.2012.0133; Motomura K, 2011, CANCER-AM CANCER SOC, V117, P1721, DOI 10.1002/cncr.25637; Nagato S, 2005, INT J CANCER, V117, P41, DOI 10.1002/ijc.21102; Napoles OC, 2017, J GASTROENTEROL, V52, P39, DOI 10.1007/s00535-016-1202-4; Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036; Neumann B, 2008, BIOCHEM BIOPH RES CO, V370, P62, DOI 10.1016/j.bbrc.2008.03.032; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platanias LC, 2013, J INTERF CYTOK RES, V33, P143, DOI 10.1089/jir.2013.0019; Porritt RA, 2015, TRENDS IMMUNOL, V36, P150, DOI 10.1016/j.it.2015.02.002; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Sassano A, 2015, MOL CELL BIOL, V35, P2684, DOI 10.1128/MCB.00019-15; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Srikanth M, 2013, NEURO-ONCOLOGY, V15, P319, DOI 10.1093/neuonc/nos316; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wakabayashi T, 2000, J NEURO-ONCOL, V49, P57, DOI 10.1023/A:1006405512579; Wang Z, 2015, ONCOTARGET, V6, P14191, DOI 10.18632/oncotarget.3691; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang ZF, 2013, GENOME MED, V5, DOI 10.1186/gm437; Zhu TZ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0727-2; Zoppoli G, 2012, P NATL ACAD SCI USA, V109, P15030, DOI 10.1073/pnas.1205943109	46	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6006	6019		10.1038/onc.2017.205	http://dx.doi.org/10.1038/onc.2017.205			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671669	Green Accepted			2022-12-28	WOS:000413841400009
J	Giebeler, N; Schonefuss, A; Landsberg, J; Tuting, T; Mauch, C; Zigrino, P				Giebeler, N.; Schoenefuss, A.; Landsberg, J.; Tuting, T.; Mauch, C.; Zigrino, P.			Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; INCREASED EXPRESSION; CELL-MIGRATION; CANCER-CELL; IN-VITRO; TUMOR; INVASION; METALLOPROTEINASES; PROLIFERATION; ABNORMALITIES	ADAM-9 is a metalloproteinase expressed in peritumoral areas by invading melanoma cells and by adjacent peritumoral stromal cells; however, its function in stromal and melanoma cells is not fully understood. To address this question in vivo in a spontaneous melanoma model, we deleted ADAM-9 in mice carrying the hepatocyte growth factor (Hgf) transgene and knock-in mutation Cdk4(R24C/R24C), demonstrated to spontaneously develop melanoma. Spontaneous melanoma arose less frequently in ADAM-9-deleted mice than in controls. Similarly reduced tumor numbers (although with faster growth kinetics) were detected upon induction of melanoma with 7,12-dimethylbenz[a]anthracene (DMBA). However, more lesions were induced at early time points in the absence of ADAM-9. Increased initial and decreased late tumor numbers were paralleled by altered tumor cell proliferation, but not apoptosis or inflammation. Importantly, significantly reduced lung metastases were detected upon ADAM-9 deletion. Using in vitro assays to address this effect mechanistically, we detected reduced adhesion and transmigration of ADAM-9-silenced melanoma cells to/through the endothelium. This implies that ADAM-9 functionally and cell autonomously mediates extravasation of melanoma cells. In vitro and in vivo we demonstrated that the basement membrane (BM) component laminin beta 3-chain is a direct substrate of ADAM-9, thus contributing to destabilization and disruption of the BM barrier during invasion. In in vitro invasion assays using human melanoma cells and skin equivalents, depletion of ADAM-9 resulted in decreased invasion of the BM, which remained almost completely intact, as shown by continuous staining for laminin beta 3-chain. Importantly, supplying soluble ADAM-9 to the system reversed this effect. Taken together, our data show that melanoma derived ADAM-9 autonomously contributes to melanoma progression by modulating cell adhesion to the endothelium and altering BM integrity by proteolytically processing the laminin-beta 3 chain. This newly described process and ADAM-9 itself may represent potential targets for anti-tumor therapies.	[Giebeler, N.; Schoenefuss, A.; Mauch, C.; Zigrino, P.] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; [Landsberg, J.] Univ Bonn, Dept Dermatol & Allergol, Bonn, Germany; [Tuting, T.] Univ Magdeburg, Dept Dermatol, Magdeburg, Germany	University of Cologne; University of Bonn; Otto von Guericke University	Zigrino, P (corresponding author), Univ Cologne, Dept Dermatol, NRW, Kerpener Str 62, D-50937 Cologne, Germany.	paola.zigrino@uni-koeln.de	Landsberg, Jennifer/AAF-5113-2019; Tüting, Thomas/AAJ-3610-2021; Landsberg, Jenny/AGI-0216-2022	Tüting, Thomas/0000-0001-7146-0934; Landsberg, Jenny/0000-0001-8029-3883; Zigrino, Paola/0000-0002-7470-0064	Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund); Deutsche Forschungsgemeinschaft [SFB829]; Koln Fortune Program of the University of Cologne	Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Koln Fortune Program of the University of Cologne	We thank Prof Manuel Koch, Department of Biochemistry, University of Cologne for kindly providing the laminin beta 3 antibody and recombinant laminin beta 3-chain. We thank Jan Zamek, Claudia Coerper-Ochsman and Nina Ruers for excellent technical assistance. This work was supported by the Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund), by the Deutsche Forschungsgemeinschaft through the SFB829 (B4) and by Koln Fortune Program of the University of Cologne.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Abety AN, 2012, J INVEST DERMATOL, V132, P2451, DOI 10.1038/jid.2012.153; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Chen CM, 2015, TUMOR BIOL, V36, P3407, DOI 10.1007/s13277-014-2975-9; Dennhofer R, 2003, INT J CANCER, V106, P316, DOI 10.1002/ijc.11255; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Felli N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056824; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-179; Guaiquil V, 2009, MOL CELL BIOL, V29, P2694, DOI 10.1128/MCB.01460-08; Landsberg J, 2010, PIGM CELL MELANOMA R, V23, P649, DOI 10.1111/j.1755-148X.2010.00744.x; Leiter U, 2004, J SURG ONCOL, V86, P172, DOI 10.1002/jso.20079; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Mammadova-Bach E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88245; McAteer MA, 2008, ARTERIOSCL THROM VAS, V28, P77, DOI 10.1161/ATVBAHA.107.145466; Micocci KC, 2016, BIOCHIMIE, V128, P174, DOI 10.1016/j.biochi.2016.08.006; Mongaret C, 2011, INT J CANCER, V129, P791, DOI 10.1002/ijc.25746; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Nath D, 2000, J CELL SCI, V113, P2319; Parry DA, 2009, AM J HUM GENET, V84, P683, DOI 10.1016/j.ajhg.2009.04.005; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Sarkar S, 2015, NEURO-ONCOLOGY, V17, P1095, DOI 10.1093/neuonc/nou362; SIKORSKI EE, 1993, J IMMUNOL, V151, P5239; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Strilic B, 2016, NATURE, V536, P215, DOI 10.1038/nature19076; Tao KS, 2010, JPN J CLIN ONCOL, V40, P645, DOI 10.1093/jjco/hyq030; Tormo D, 2006, AM J PATHOL, V169, P665, DOI 10.2353/ajpath.2006.060017; Tsuruta D, 2008, CURR MED CHEM, V15, P1968, DOI 10.2174/092986708785132834; Tzu J, 2008, INT J BIOCHEM CELL B, V40, P199, DOI 10.1016/j.biocel.2007.07.015; Udayakumar TS, 2003, CANCER RES, V63, P2292; Wan DW, 2016, ANTI-CANCER AGENT ME, V16, P414, DOI 10.2174/1871520615666150716105955; Wang CZ, 2015, INT J CLIN EXP PATHO, V8, P6547; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WILLIAMS RL, 1988, CELL, V52, P121; Xu Q, 2010, TUMOR BIOL, V31, P217, DOI 10.1007/s13277-010-0034-8; Yamada D, 2007, ANTICANCER RES, V27, P793; Zhang CZ, 2015, INVEST NEW DRUG, V33, P1, DOI 10.1007/s10637-014-0156-8; Zigrino P, 2005, INT J CANCER, V116, P853, DOI 10.1002/ijc.21087; Zigrino P, 2011, J BIOL CHEM, V286, P6801, DOI 10.1074/jbc.M110.168617	41	9	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5058	5067		10.1038/onc.2017.162	http://dx.doi.org/10.1038/onc.2017.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28553955				2022-12-28	WOS:000408768800010
J	Hsu, YL; Hung, JY; Chang, WA; Lin, YS; Pan, YC; Tsai, PH; Wu, CY; Kuo, PL				Hsu, Y-L; Hung, J-Y; Chang, W-A; Lin, Y-S; Pan, Y-C; Tsai, P-H; Wu, C-Y; Kuo, P-L			Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1	ONCOGENE			English	Article							FACTOR-1-ALPHA MESSENGER-RNA; PROSTATE-CANCER; UP-REGULATION; CELLS; HIF-1-ALPHA; METASTASIS; EXPRESSION; PHD2; TRANSCRIPTION; MICRORNAS	Hypoxia plays a critical role during the evolution of malignant cells and tumour microenvironment (TME). Tumour-derived exosomes contain informative microRNAs involved in the interaction of cancer and stromal cells, thus contributing to tissue remodelling of tumour microenvironment. This study aims to clarify how hypoxia affects tumour angiogenesis through exosomes shed from lung cancer cells. Lung cancer cells produce more exosomes under hypoxic conditions than do parental cells under normoxic conditions. miR-23a was significantly upregulated in exosomes from lung cancer under hypoxic conditions. Exosomal miR-23a directly suppressed its target prolyl hydroxylase 1 and 2 (PHD1 and 2), leading to the accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) in endothelial cells. Consequently, hypoxic lung cancer cells enhanced angiogenesis by exosomes derived from hypoxic cancer under both normoxic and hypoxic conditions. In addition, exosomal miR-23a also inhibits tight junction protein ZO-1, thereby increasing vascular permeability and cancer transendothelial migration. Inhibition of miR-23a by inhibitor administration decreased angiogenesis and tumour growth in a mouse model. Furthermore, elevated levels of circulating miR-23a are found in the sera of lung cancer patients, and miR-23a levels are positively correlated with proangiogenic activities. Taken together, our study reveals the clinical relevance and prognostic value of cancer-derived exosomal miR-23a under hypoxic conditions, and investigates a unique intercellular communication, mediated by cancer-derived exosomes, which modulates tumour vasculature.	[Hsu, Y-L] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Hung, J-Y; Chang, W-A] Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Hung, J-Y] Kaohsiung Med Univ, Sch Med, Coll Med, Kaohsiung, Taiwan; [Chang, W-A; Lin, Y-S; Pan, Y-C; Tsai, P-H; Wu, C-Y; Kuo, P-L] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan; [Kuo, P-L] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; National Sun Yat Sen University	Kuo, PL (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	kuopolin@seed.net.tw			Ministry of Science and Technology [MOST 104-2314-B-037-053-MY4, MOST 104-2320-B-037-014-MY3, MOST 103-2320-B-037-006-MY3]; Kaohsiung Medical University 'Aim for the Top Journals Grant' [KMU-DT106005]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University 'Aim for the Top Journals Grant'	This study was supported by grants from the Ministry of Science and Technology (MOST 104-2314-B-037-053-MY4; MOST 104-2320-B-037-014-MY3; MOST 103-2320-B-037-006-MY3), and the Kaohsiung Medical University 'Aim for the Top Journals Grant' (Grant No. KMU-DT106005).	Anderson JD, 2016, STEM CELLS, V34, P601, DOI 10.1002/stem.2298; Arjaans M, 2016, ONCOTARGET, V7, P21247, DOI 10.18632/oncotarget.6918; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Borges FT, 2013, J AM SOC NEPHROL, V24, P385, DOI 10.1681/ASN.2012101031; Branco-Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Cui H, 2015, ONCOGENE, V34, P3640, DOI 10.1038/onc.2014.300; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Ding GP, 2015, ONCOTARGET, V6, P29877, DOI 10.18632/oncotarget.4924; Foster JG, 2014, FUTURE ONCOL, V10, P2659, DOI 10.2217/fon.14.201; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hosseini-Beheshti E, 2016, ONCOTARGET, V7, P14639, DOI 10.18632/oncotarget.7052; Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Li XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11017; Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Pefanis E, 2015, CELL, V161, P774, DOI 10.1016/j.cell.2015.04.034; Pientka FK, 2012, J CELL SCI, V125, P5168, DOI 10.1242/jcs.109041; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rodriguez PL, 2014, INT J CANCER, V134, P1034, DOI 10.1002/ijc.28433; Sanchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song D, 2014, J BIOL CHEM, V289, P14656, DOI 10.1074/jbc.M113.541227; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140; Trikha P, 2016, ONCOGENE, V35, P3636, DOI 10.1038/onc.2015.429; Wang Q, 2014, GENE, V541, P69, DOI 10.1016/j.gene.2014.03.025; Wang SW, 2015, CARCINOGENESIS, V36, P104, DOI 10.1093/carcin/bgu218; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.240; Zhao HY, 2016, ELIFE, V5, DOI 10.7554/eLife.10250; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	42	339	357	11	110	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4929	4942		10.1038/onc.2017.105	http://dx.doi.org/10.1038/onc.2017.105			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436951				2022-12-28	WOS:000408234400009
J	Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B				Joseph, B.; Marchetti, P.; Formstecher, P.; Kroemer, G.; Lewensohn, R.; Zhivotovsky, B.			Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment (vol 21, pg 65, 2002)	ONCOGENE			English	Correction													Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4818	4818		10.1038/onc.2017.78	http://dx.doi.org/10.1038/onc.2017.78			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394341	Bronze			2022-12-28	WOS:000407702400015
J	Deguchi, S; Katsushima, K; Hatanaka, A; Shinjo, K; Ohka, F; Wakabayashi, T; Zong, H; Natsume, A; Kondo, Y				Deguchi, S.; Katsushima, K.; Hatanaka, A.; Shinjo, K.; Ohka, F.; Wakabayashi, T.; Zong, H.; Natsume, A.; Kondo, Y.			Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis	ONCOGENE			English	Article							TOPOISOMERASE-II; MOSAIC ANALYSIS; DOUBLE MARKERS; REVEALS; CELL; CANCER; GLIOMA; CERNA; TRANSCRIPTION; PLURIPOTENCY	Accumulating studies have demonstrated the importance of long noncoding RNAs (lncRNAs) during oncogenic transformation. However, because most lncRNAs are currently uncharacterized, the identification of novel oncogenic lncRNAs is difficult. Given that intergenic lncRNA have substantially less sequence conservation patterns than protein-coding genes across species, evolutionary conserved intergenic lncRNAs are likely to be functional. The current study identified a novel intergenic lncRNA, LINC00461 (ECONEXIN) using a combined approach consisting of searching lncRNAs by evolutionary conservation and validating their expression in a glioma mouse model. ECONEXIN was the most highly conserved intergenic lncRNA containing 83.0% homology with the mouse ortholog (C130071C03Rik) for a region over 2500 bp in length within its exon 3. Expressions of ECONEXIN and C130071C03Rik were significantly upregulated in both human and mouse glioma tissues. Moreover, the expression of C130071C03Rik was upregulated even in precancerous conditions and markedly increased during glioma progression. Functional analysis of ECONEXIN in glioma cell lines, U87 and U251, showed it was dominantly located in the cytoplasm and interacted with miR-411-5p via two binding sites within ECONEXIN. Inhibition of ECONEXIN upregulated miR-411-5p together with the downregulation of its target, Topoisomerase 2 alpha (TOP2A), in glioma cell lines, resulting in decreased cell proliferation. Our data demonstrated that ECONEXIN is a potential oncogene that regulates TOP2A by sponging miR-411-5p in glioma. In addition, our investigative approaches to identify conserved lncRNA and their molecular characterization by validation in mouse tumor models may be useful to functionally annotate novel lncRNAs, especially cancer-associated lncRNAs.	[Deguchi, S.; Katsushima, K.; Hatanaka, A.; Shinjo, K.; Kondo, Y.] Nagoya City Univ, Grad Sch Med Sci, Dept Epigenom, Nagoya, Aichi, Japan; [Deguchi, S.; Ohka, F.; Wakabayashi, T.; Natsume, A.] Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan; [Zong, H.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	Nagoya City University; Nagoya University; University of Virginia	Kondo, Y (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Epigenom, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	ykondo@med.nagoya-cu.ac.jp	katsushima, keisuke/AAD-5945-2019; katsushima, keisuke/AAV-5204-2020; Natsume, Atsushi/I-7364-2014; Ohka, Fumiharu/A-3420-2016	katsushima, keisuke/0000-0001-7770-432X; Natsume, Atsushi/0000-0002-9113-0470; Zong, Hui/0000-0002-4263-9633; Ohka, Fumiharu/0000-0002-5569-5626	Japan Society for the Promotion of Science [25290048]; Grants-in-Aid for Scientific Research [17K14995] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was performed as research programs of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan (YK), of the Project for Cancer Research And Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development, AMED (YK), of the PRESTO, JST (YK) and of the Grant-in-Aid for Scientific Research, the Japan Society for the Promotion of Science (25290048, YK).	Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen T, 2015, ONCOGENE, V34, P4019, DOI 10.1038/onc.2014.332; CLARK PI, 1994, J CLIN ONCOL, V12, P1427, DOI 10.1200/JCO.1994.12.7.1427; Denzler R, 2014, MOL CELL, V54, P766, DOI 10.1016/j.molcel.2014.03.045; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hezroni H, 2015, CELL REP, V11, P1110, DOI 10.1016/j.celrep.2015.04.023; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Ideue T, 2009, RNA, V15, P1578, DOI 10.1261/rna.1657609; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Ke J, 2015, ONCOTARGET, V6, P21934, DOI 10.18632/oncotarget.4290; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; Kutter C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002841; Labreche K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8207; Leonard A, 2013, ANTICANCER RES, V33, P3307; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lin NW, 2014, MOL CELL, V53, P1005, DOI 10.1016/j.molcel.2014.01.021; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Mistry AR, 2005, NEW ENGL J MED, V352, P1529, DOI 10.1056/NEJMoa042715; Mo CF, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt535; Moran I, 2012, CELL METAB, V16, P435, DOI 10.1016/j.cmet.2012.08.010; Oliver PL, 2015, CEREB CORTEX, V25, P3572, DOI 10.1093/cercor/bhu196; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Quinn JJ, 2016, GENE DEV, V30, P191, DOI 10.1101/gad.272187.115; Sauvageau M, 2013, ELIFE, V2, DOI 10.7554/eLife.01749; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Ulitsky I, 2016, NAT REV GENET, V17, P601, DOI 10.1038/nrg.2016.85; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wahlestedt C, 2013, NAT REV DRUG DISCOV, V12, P433, DOI 10.1038/nrd4018; Washietl S, 2014, GENOME RES, V24, P616, DOI 10.1101/gr.165035.113; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Zong H, 2005, CELL, V121, P479, DOI 10.1016/j.cell.2005.02.012	44	57	57	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4629	4640		10.1038/onc.2017.88	http://dx.doi.org/10.1038/onc.2017.88			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368417				2022-12-28	WOS:000407246200010
J	Frieling, JS; Shay, G; Izumi, V; Aherne, ST; Saul, RG; Budzevich, M; Koomen, J; Lynch, CC				Frieling, J. S.; Shay, G.; Izumi, V.; Aherne, S. T.; Saul, R. G.; Budzevich, M.; Koomen, J.; Lynch, C. C.			Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP(1-17)	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; STABLE-ISOTOPE STANDARDS; OSTEOBLAST-DERIVED PTHRP; PARATHYROID-HORMONE; PROSTATE-CANCER; BONE METASTASIS; PTH/PTHRP-RECEPTOR; ANTIPEPTIDE ANTIBODIES; SIGNALING PATHWAYS; MASS-SPECTROMETRY	Parathyroid hormone-related protein (PTHrP) is a critical regulator of bone resorption and augments osteolysis in skeletal malignancies. Here we report that the mature PTHrP(1-36) hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP(1-17). PTHrP(1-17) retains the ability to signal through PTH1R to induce calcium flux and ERK phosphorylation but not cyclic AMP production or CREB phosphorylation. Notably, PTHrP(1-17) promotes osteoblast migration and mineralization in vitro, and systemic administration of PTHrP(1-17) augments ectopic bone formation in vivo. Further, in contrast to PTHrP(1-36), PTHrP(1-17) does not affect osteoclast formation/function in vitro or in vivo. Finally, immunoprecipitation-mass spectrometry analyses using PTHrP(1-17)-specific antibodies establish that PTHrP(1-17) is indeed generated by cancer cells. Thus, matrix metalloproteinase-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote osteogenesis, indicating important roles for this circuit in bone remodelling in normal and disease contexts.	[Frieling, J. S.; Shay, G.; Aherne, S. T.; Lynch, C. C.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, SRB-3,12902,Magnolia Dr, Tampa, FL USA; [Izumi, V.; Koomen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA; [Saul, R. G.] Leidos Biomed Res, Antibody Characterizat Lab, Frederick, MD USA; [Budzevich, M.] H Lee Moffitt Canc Ctr & Res Inst, Canc Imaging & Metab, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); H Lee Moffitt Cancer Center & Research Institute	Lynch, CC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, SRB-3,12902,Magnolia Dr, Tampa, FL USA.	conor.lynch@moffitt.org		Shay, Gemma/0000-0001-6126-7049; Frieling, Jeremy/0000-0002-2181-1836	State of Florida Bankhead Coley Program [5BC-O1]; Miles for Moffitt Foundation Award; Moffitt Cancer Center Grant [P30-CA076292];  [R01-CA143094]	State of Florida Bankhead Coley Program; Miles for Moffitt Foundation Award; Moffitt Cancer Center Grant; 	This work was supported by R01-CA143094 (CCL), the State of Florida Bankhead Coley Program grant 5BC-O1 (CCL) and by a Miles for Moffitt Foundation Award. This work was also supported in part by the Core Facilities of the Moffitt Cancer Center Grant P30-CA076292. The authors thank Joe Johnson (Moffitt Analytical Microscopy), Robert Sprung (Moffitt Proteomics) and Gordon Whiteley (SAIC-Frederick, NCI-Frederick) for their helpful suggestions and expertise, and Drs John Cleveland and Srikumar Chellappan for critical review of this study.	Amizuka N, 2000, HISTOL HISTOPATHOL, V15, P957, DOI 10.14670/HH-15.957; Anderson NL, 2004, J PROTEOME RES, V3, P235, DOI 10.1021/pr034086h; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Bilezikian JP, 2015, PARATHYROIDBASIC C, P946; Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645; Cook LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29384; Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022-5347(01)65919-6; Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44; Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752; Cuthbertson RM, 1999, BBA-PROTEIN STRUCT M, V1432, P64, DOI 10.1016/S0167-4838(99)00078-3; Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328; Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002; Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114; Fukushima H, 2005, J DENT RES, V84, P329, DOI 10.1177/154405910508400407; Gallien S, 2012, MOL CELL PROTEOMICS, V11, P1709, DOI 10.1074/mcp.O112.019802; Garcia-Martin A, 2014, MOL ENDOCRINOL, V28, P925, DOI 10.1210/me.2013-1225; Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756-3282(02)00685-3; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Helfrich M.H., 2003, BONE RES PROTOCOLS; Hodde JP, 2004, J SURG RES, V120, P189, DOI 10.1016/j.jss.2003.10.022; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Ibaragi S, 2010, ANTICANCER RES, V30, P5029; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Katafuchi T, 2015, CELL METAB, V21, P898, DOI 10.1016/j.cmet.2015.05.004; Kawashima-Ohya Y, 1998, ENDOCRINOLOGY, V139, P2120, DOI 10.1210/en.139.4.2120; Krane SM, 2008, BONE, V43, P7, DOI 10.1016/j.bone.2008.03.020; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007; Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Mak IWY, 2013, BONE, V55, P198, DOI 10.1016/j.bone.2013.02.020; Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015; Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003-1695; Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918; Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978-1-59745-104-8_3; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; Park HJ, 2015, J CELL PHYSIOL, V230, P667, DOI 10.1002/jcp.24790; Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015; Pezzato E, 2004, INT J CANCER, V112, P787, DOI 10.1002/ijc.20460; Philbrick W, 2001, PARATHYROIDBASIC C, P881; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Remily-Wood ER, 2011, PROTEOM CLIN APPL, V5, P383, DOI 10.1002/prca.201000115; Ruchon AF, 2000, J BONE MINER RES, V15, P1266, DOI 10.1359/jbmr.2000.15.7.1266; Schluter KD, 2001, BRIT J PHARMACOL, V132, P427, DOI 10.1038/sj.bjp.0703830; Stewart AF, 1996, BONE, V19, P303, DOI 10.1016/S8756-3282(96)00221-9; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKUWA Y, 1989, AM J PHYSIOL, V257, pE797, DOI 10.1152/ajpendo.1989.257.6.E797; Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Washam CL, 2013, CANCER EPIDEM BIOMAR, V22, P972, DOI 10.1158/1055-9965.EPI-12-1318-T; Winding B, 2002, CLIN CANCER RES, V8, P1932; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406; Yoon H, 2013, BIOL CHEM, V394, P137, DOI 10.1515/hsz-2012-0249; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	63	6	7	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4498	4507		10.1038/onc.2017.70	http://dx.doi.org/10.1038/onc.2017.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368420	Green Accepted			2022-12-28	WOS:000406806000011
J	Jungnickel, C; Schmidt, LH; Bittigkoffer, L; Wolf, L; Wolf, A; Ritzmann, F; Kamyschnikow, A; Herr, C; Menger, MD; Spieker, T; Wiewrodt, R; Bals, R; Beisswenger, C				Jungnickel, C.; Schmidt, L. H.; Bittigkoffer, L.; Wolf, L.; Wolf, A.; Ritzmann, F.; Kamyschnikow, A.; Herr, C.; Menger, M. D.; Spieker, T.; Wiewrodt, R.; Bals, R.; Beisswenger, C.			IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth	ONCOGENE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; BREAST-CANCER; EPITHELIAL-CELLS; MYELOID CELLS; HOST-DEFENSE; KAPPA-B; INFLAMMATION; RECEPTOR; COPD; METASTASIS	Chronic obstructive pulmonary disease (COPD) is associated with an increased risk for lung cancer and an aberrant microbiota of the lung. Microbial colonization contributes to chronic neutrophilic inflammation in COPD. Nontypeable Haemophilus influenzae (NTHi) is frequently found in lungs of stable COPD patients and is the major pathogen triggering exacerbations. The epithelial cytokine interleukin-17C (IL-17C) promotes the recruitment of neutrophils into inflamed tissues. The purpose of this study was to investigate the function of IL-17C in the pulmonary tumor microenvironment. We subjected mice deficient for IL-17C (IL-17C(-/-)) and mice double deficient for Toll-like receptor 2 and 4 (TLR-2/4(-/-)) to a metastatic lung cancer model. Tumor proliferation and growth as well as the number of tumor-associated neutrophils was significantly decreased in IL-17C(-/-) and TLR-2/4(-/-) mice exposed to NTHi. The NTHi-induced pulmonary expression of IL-17C was dependent on TLR-2/4. In vitro, IL-17C increased the NTHi-and tumor necrosis factor-alpha-induced expression of the neutrophil chemokines keratinocyte-derived chemokine and macrophage inflammatory protein 2 in lung cancer cells but did not affect proliferation. Human lung cancer samples stained positive for IL-17C, and in non-small cell lung cancer patients with lymph node metastasis, IL-17C was identified as a negative prognostic factor. Our data indicate that epithelial IL-17C promotes neutrophilic inflammation in the tumor microenvironment and suggest that IL-17C links a pathologic microbiota, as present in COPD patients, with enhanced tumor growth.	[Jungnickel, C.; Bittigkoffer, L.; Wolf, L.; Wolf, A.; Ritzmann, F.; Kamyschnikow, A.; Herr, C.; Bals, R.; Beisswenger, C.] Saarland Univ, Dept Internal Med Pulmonol Allergol & Resp Crit C, D-66421 Homburg, Germany; [Schmidt, L. H.; Wiewrodt, R.] Univ Hosp Munster, Dept Med Hematol Oncol & Pulmonol A, Munster, Germany; [Menger, M. D.] Saarland Univ, Inst Clin & Expt Surg, Med Ctr, Homburg, Germany; [Spieker, T.] Univ Hosp Muenster, Gerhard Domagk Inst Pathol, Munster, Germany	Universitatsklinikum des Saarlandes; University of Munster; Universitatsklinikum des Saarlandes; University of Munster	Beisswenger, C (corresponding author), Saarland Univ, Dept Internal Med Pulmonol Allergol & Resp Crit C, D-66421 Homburg, Germany.	christoph.beisswenger@uks.eu	Herr, Christian/AAH-5291-2021; Beisswenger, Christoph/GRO-6580-2022	Herr, Christian/0000-0001-9422-6569	Wilhelm-Sander-Stiftung	Wilhelm-Sander-Stiftung	We thank Anja Honecker for excellent technical assistance. This study was supported by grants from the Wilhelm-Sander-Stiftung to Christoph Beisswenger and Robert Bals.	Adcock IM, 2011, RESPIRATION, V81, P265, DOI 10.1159/000324601; Bellocq A, 1998, AM J PATHOL, V152, P83; Chang SH, 2014, P NATL ACAD SCI USA, V111, P5664, DOI 10.1073/pnas.1319051111; Chang SH, 2011, IMMUNITY, V35, P611, DOI 10.1016/j.immuni.2011.09.010; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; El Rayes T, 2015, P NATL ACAD SCI USA, V112, P16000, DOI 10.1073/pnas.1507294112; Friedrich M, 2015, MUCOSAL IMMUNOL, V8, P943, DOI 10.1038/mi.2014.124; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hattar K, 2013, CANCER IMMUNOL IMMUN, V62, P309, DOI 10.1007/s00262-012-1341-2; Herr C, 2015, EXP TOXICOL PATHOL, V67, P261, DOI 10.1016/j.etp.2015.01.002; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Hoenderdos K, 2013, AM J RESP CELL MOL, V48, P531, DOI 10.1165/rcmb.2012-0492TR; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Johansen C, 2011, J BIOL CHEM, V286, P25487, DOI 10.1074/jbc.M111.240671; Jungnickel C, 2015, AM J PHYSIOL-LUNG C, V309, pL605, DOI 10.1152/ajplung.00116.2015; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Klein M, 2008, J INFECT DIS, V198, P1028, DOI 10.1086/591626; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kusagaya H, 2014, AM J RESP CELL MOL, V50, P30, DOI 10.1165/rcmb.2013-0130OC; Li D, 2014, ONCOGENE, V33, P2709, DOI 10.1038/onc.2013.248; Li D, 2014, ONCOGENE, V33, P1239, DOI 10.1038/onc.2013.75; Marsland BJ, 2014, NAT REV IMMUNOL, V14, P827, DOI 10.1038/nri3769; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfeifer P, 2013, AM J RESP CELL MOL, V48, P415, DOI 10.1165/rcmb.2012-0232OC; Rad R, 2009, GASTROENTEROLOGY, V136, P2247, DOI 10.1053/j.gastro.2009.02.066; Ramirez-Carrozzi V, 2011, NAT IMMUNOL, V12, P1159, DOI 10.1038/ni.2156; REMMELE W, 1987, PATHOLOGE, V8, P138; Roos AB, 2015, AM J RESP CRIT CARE, V192, P428, DOI 10.1164/rccm.201409-1689OC; Schmidt LH, 2014, J THORAC ONCOL, V9, P1294, DOI 10.1097/JTO.0000000000000243; Sethi S, 2010, EUR RESPIR J, V35, P1209, DOI 10.1183/09031936.00081409; Song XY, 2014, IMMUNITY, V40, P140, DOI 10.1016/j.immuni.2013.11.018; Song XY, 2011, NAT IMMUNOL, V12, P1151, DOI 10.1038/ni.2155; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Teramukai S, 2009, EUR J CANCER, V45, P1950, DOI 10.1016/j.ejca.2009.01.023; Voss M, 2015, AM J PHYSIOL-LUNG C, V309, pL188, DOI 10.1152/ajplung.00388.2014; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wolf L, 2016, AM J PHYSIOL-LUNG C, V311, pL1015, DOI 10.1152/ajplung.00158.2016; Yadava K, 2016, AM J RESP CRIT CARE, V193, P975, DOI 10.1164/rccm.201504-0779OC; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Zulueta JJ, 2012, CHEST, V141, P1216, DOI 10.1378/chest.11-0101	47	49	58	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4182	4190		10.1038/onc.2017.28	http://dx.doi.org/10.1038/onc.2017.28			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346430				2022-12-28	WOS:000405835800009
J	Zhang, H; Lu, Y; Chen, E; Li, X; Lv, B; Vikis, HG; Liu, P				Zhang, H.; Lu, Y.; Chen, E.; Li, X.; Lv, B.; Vikis, H. G.; Liu, P.			XRN2 promotes EMT and metastasis through regulating maturation of miR-10a	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; EXPRESSION ANALYSIS; REPRESSORS ZEB1; CANCER; MICRORNA-10A; PLASTICITY; ROLES; PHENOTYPE; MIGRATION	MicroRNAs (miRNAs) have been proposed as critical regulatory molecules in the epithelial-mesenchymal transition (EMT) program. However, the roles of mature miRNA biogenesis during EMT process needs to be defined. Here we determined that increased expression of XRN2 induced EMT and promoted metastasis in vitro and in vivo. Furthermore, we uncovered that XRN2 functions as pro-metastatic gene, which accelerates miR-10a maturation by binding pre-miR-10a in a DICER-independent manner. These findings suggest that XRN2 is a novel regulator of EMT that contributes to the metastatic processes in lung cancer through a novel miRNA regulatory mechanism.	[Zhang, H.] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Lu, Y.; Lv, B.] Zhejiang Univ, Affiliated Womens Hosp, Dept Gynecol Oncol, Hangzhou, Zhejiang, Peoples R China; [Lu, Y.; Lv, B.; Liu, P.] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Chen, E.; Li, X.; Liu, P.] Zhejiang Univ, Sir Run Run Shaw Hosp, Div Resp Med, Hangzhou, Zhejiang, Peoples R China; [Chen, E.; Li, X.; Liu, P.] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310058, Zhejiang, Peoples R China; [Vikis, H. G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Liu, P.] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Liu, P.] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Liu, P (corresponding author), Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310058, Zhejiang, Peoples R China.; Liu, P (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou 310058, Zhejiang, Peoples R China.	pyliu@zju.edu.cn			National Natural Science Foundation of China [81372514, 81472420, 81572256, 31401125]; National Key Research and Development program [2016YFA0501800, 2016YFC0902700]; Fundamental Research Funds for the Central Universities; 1000 talent Plan of China, Louisiana Hope Research Grant by Free to Breathe	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); 1000 talent Plan of China, Louisiana Hope Research Grant by Free to Breathe	This work has been support by National Natural Science Foundation of China (no. 81372514, 81472420, 81572256 and 31401125), National Key Research and Development program (2016YFA0501800 and 2016YFC0902700), the Fundamental Research Funds for the Central Universities and 1000 talent Plan of China, Louisiana Hope Research Grant provided by Free to Breathe. We thank Alison Kriegel for reading and commenting on the manuscript.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Chang CH, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0257-3; Chatterjee S, 2009, NATURE, V461, P546, DOI 10.1038/nature08349; Couvillion MT, 2012, MOL CELL, V48, P509, DOI 10.1016/j.molcel.2012.09.010; Dip N, 2012, J UROLOGY, V188, P1951, DOI 10.1016/j.juro.2012.07.004; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li HZ, 2004, BIOINFORMATICS, V20, P208, DOI 10.1093/bioinformatics/bth900; Li X, 2013, HAEMATOLOGICA, V98, P414, DOI 10.3324/haematol.2012.071753; Long MJ, 2012, CANCER LETT, V324, P186, DOI 10.1016/j.canlet.2012.05.022; Lu Y, 2010, ONCOGENE, V29, P1041, DOI 10.1038/onc.2009.396; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Lu Y, 2012, CARCINOGENESIS, V33, P1046, DOI 10.1093/carcin/bgs100; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Miki TS, 2014, NUCLEIC ACIDS RES, V42, P4056, DOI 10.1093/nar/gkt1418; Miki TS, 2013, BIOCHEM SOC T, V41, P825, DOI 10.1042/BST20130001; Ohuchida K, 2012, ANN SURG ONCOL, V19, P2394, DOI 10.1245/s10434-012-2252-3; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wagschal A, 2012, CELL, V150, P1147, DOI 10.1016/j.cell.2012.08.004; Wang MS, 2011, NUCLEIC ACIDS RES, V39, P1811, DOI 10.1093/nar/gkq1050; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Xiang S, 2009, NATURE, V458, P784, DOI 10.1038/nature07731; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yan Y, 2013, HEPATOLOGY, V57, P667, DOI 10.1002/hep.26071; Zakrzewska-Placzek M, 2010, NUCLEIC ACIDS RES, V38, P4487, DOI 10.1093/nar/gkq172; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11459	47	15	16	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3925	3933		10.1038/onc.2017.39	http://dx.doi.org/10.1038/onc.2017.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28319071				2022-12-28	WOS:000404848200012
